Images O +

Figure O +
1 O +

Figure O +
2 O +

Figure O +
3 O +

Figure O +
4 O +

Immunostaining O +
and O +
confocal O +
analysis O +

DNA O +
labelling O +
and O +
staining O +
with O +
5 O +
- O +
bromo O +
- O +
2 O +
' O +
- O +
deoxyuridine O +
( O +
BrdU O +
labelling O +
and O +
detection O +
kit O +
I O +
; O +
Boehringer O +
Mannheim O +
, O +
Germany O +
) O +
was O +
performed O +
according O +
to O +
the O +
manufacturer O +
' O +
s O +
instructions O +
. O +

The O +
nucleoli O +
were O +
detected O +
with O +
an O +
anti O +
- O +
nucleolin O +
antibody O +
( O +
clone O +
3G4B2 O +
; O +
Upstate O +
biotechnology O +
, O +
Lake O +
Placid O +
, O +
NY O +
) O +
on O +
cells O +
fixed O +
in O +
2 O +
% O +
formalin O +
for O +
10 O +
min O +
followed O +
by O +
permeabilization O +
with O +
ice O +
- O +
cold O +
methanol O +
for O +
30 O +
min O +
. O +

The O +
secondary O +
antibody O +
used O +
for O +
both O +
BrdU O +
and O +
nucleoli O +
staining O +
was O +
a O +
rhodamine O +
( O +
tetra O +
- O +
methyl O +
) O +
- O +
conjugated O +
goat O +
anti O +
- O +
mouse O +
antibody O +
( O +
T O +
- O +
2762 O +
) O +
from O +
Molecular O +
Probe O +
( O +
Eugene O +
, O +
OR O +
) O +
. O +

The O +
cells O +
were O +
examined O +
in O +
a O +
Zeiss O +
LSM O +
510 O +
laser O +
scanning O +
microscope O +
equipped O +
with O +
a O +
Plan O +
- O +
Apochromate O +
63x O +
/ O +
1 O +
. O +
4 O +
oil O +
immersion O +
objective O +
. O +

We O +
used O +
the O +
488 O +
nm O +
laser O +
line O +
for O +
excitation O +
of O +
EGFP O +
( O +
detected O +
at O +
505 O +
nm O +
< O +
lambdaEGFP O +
< O +
530 O +
nm O +
) O +
and O +
the O +
543 O +
nm O +
laser O +
line O +
for O +
rhodamine O +
( O +
tetra O +
- O +
methyl O +
) O +
( O +
detected O +
at O +
lambdaRhodamine O +
> O +
560 O +
nm O +
) O +
. O +

ECFP O +
fusion O +
protein O +
was O +
excited O +
with O +
a O +
458 O +
nm O +
laser O +
line O +
( O +
detected O +
at O +
480 O +
nm O +
< O +
lambdaECFP O +
< O +
520 O +
nm O +
) O +
, O +
EYFP O +
fusion O +
protein O +
was O +
excited O +
with O +
a O +
514 O +
nm O +
laser O +
line O +
( O +
lambdaEGFP O +
> O +
560 O +
nm O +
) O +
and O +
HcRed O +
fusion O +
protein O +
was O +
excited O +
with O +
a O +
543 O +
nm O +
laser O +
line O +
and O +
detected O +
at O +
> O +
585 O +
or O +
650 O +
nm O +
. O +

The O +
images O +
were O +
from O +
1 O +
mum O +
thick O +
slices O +
of O +
the O +
cells O +
. O +

The O +
images O +
were O +
exported O +
into O +
Adobe O +
Photoshop O +
( O +
Adobe O +
Systems O +
Inc O +
. O +
, O +
San O +
Jose O +
, O +
CA O +
) O +
. O +

( O +
a O +
) O +
Schematic O +
drawing O +
of O +
the O +
magnetic O +
tweezers O +
. O +

A O +
DNA O +
molecule O +
is O +
attached O +
at O +
one O +
end O +
to O +
the O +
bottom O +
of O +
the O +
flow O +
cell O +
and O +
at O +
the O +
other O +
end O +
to O +
a O +
magnetic O +
bead O +
. O +

This O +
molecule O +
can O +
be O +
pulled O +
and O +
twisted O +
using O +
small O +
magnets O +
placed O +
above O +
the O +
flow O +
cell O +
. O +

The O +
position O +
of O +
the O +
magnetic O +
bead O +
is O +
measured O +
using O +
an O +
inverted O +
microscope O +
placed O +
beneath O +
the O +
flow O +
cell O +
. O +

The O +
bead O +
position O +
and O +
thus O +
the O +
end O +
- O +
to O +
- O +
end O +
distance O +
of O +
the O +
DNA O +
molecule O +
is O +
determined O +
using O +
video O +
microscopy O +
and O +
image O +
analysis O +
. O +

( O +
b O +
) O +
Extension O +
of O +
a O +
DNA O +
molecule O +
versus O +
the O +
number O +
of O +
turns O +
applied O +
by O +
the O +
magnets O +
for O +
various O +
stretching O +
forces O +
. O +

At O +
low O +
force O +
, O +
contraction O +
of O +
the O +
molecule O +
is O +
symmetrical O +
under O +
positive O +
and O +
negative O +
applied O +
turns O +
. O +

At O +
higher O +
force O +
, O +
the O +
molecule O +
' O +
s O +
extension O +
initially O +
remains O +
constant O +
for O +
positive O +
applied O +
turns O +
. O +

The O +
induced O +
torque O +
increases O +
linearly O +
with O +
the O +
number O +
of O +
applied O +
turns O +
, O +
as O +
depicted O +
in O +
the O +
top O +
graph O +
until O +
a O +
buckling O +
transition O +
allows O +
the O +
system O +
to O +
saturate O +
its O +
torsional O +
constraint O +
through O +
the O +
formation O +
of O +
plectonemes O +
. O +

Effect O +
of O +
Trail O +
on O +
the O +
expression O +
of O +
endogenous O +
M2 O +
. O +

( O +
A O +
) O +
Effect O +
of O +
Trail O +
on O +
the O +
level O +
of O +
endogenous O +
M2 O +
protein O +
. O +

The O +
expression O +
level O +
of O +
endogenous O +
M2 O +
protein O +
in O +
HeLa B-CellLine +
cells O +
was O +
determined O +
using O +
western O +
blot O +
4 O +
h O +
following O +
Trail O +
( O +
250 O +
mug O +
/ O +
ml O +
) O +
treatment O +
. O +

( O +
B O +
) O +
Effect O +
of O +
Trail O +
on O +
the O +
endogenous O +
M2 O +
mRNA O +
. O +

The O +
expression O +
level O +
of O +
endogenous O +
M2 O +
mRNA O +
in O +
HeLa B-CellLine +
cells O +
was O +
detected O +
using O +
RNase O +
protection O +
assay O +
4 O +
h O +
following O +
Trail O +
( O +
250 O +
mug O +
/ O +
ml O +
) O +
treatment O +
. O +

( O +
C O +
) O +
Effect O +
of O +
Trail O +
on O +
the O +
synthesis O +
of O +
endogenous O +
M2 O +
protein O +
. O +

HeLa B-CellLine +
cells O +
were O +
first O +
treated O +
with O +
250 O +
mug O +
/ O +
ml O +
Trail O +
followed O +
by O +
pulse O +
labeling O +
of O +
newly O +
synthesized O +
proteins O +
with O +
[ O +
35S O +
] O +
methionine O +
. O +

M2 O +
protein O +
was O +
then O +
immunoprecipitated O +
and O +
separated O +
by O +
SDS O +
- O +
PAGE O +
for O +
autoradiography O +
as O +
described O +
in O +
Materials O +
and O +
Methods O +
. O +

The O +
most O +
highly O +
represented O +
gene O +
ontology O +
themes O +
in O +
the O +
neurosphere O +
vs O +
. O +
differentiated O +
cells O +
comparison O +
( O +
F O +
- O +
G O +
) O +
. O +

Planning O +
for O +
the O +
Future O +
: O +
Disaster O +
Preparedness O +
and O +
Mitigation O +

It O +
is O +
often O +
believed O +
that O +
casualties O +
from O +
natural O +
disasters O +
are O +
unavoidable O +
, O +
but O +
this O +
belief O +
is O +
false O +
[ O +
8 O +
] O +
. O +

There O +
are O +
many O +
measures O +
that O +
can O +
reduce O +
morbidity O +
and O +
mortality O +
following O +
large O +
and O +
potentially O +
catastrophic O +
flooding O +
events O +
[ O +
19 O +
] O +
. O +

Early O +
warning O +
of O +
impending O +
floods O +
and O +
natural O +
events O +
such O +
as O +
hurricanes O +
allows O +
sufficient O +
time O +
for O +
communities O +
to O +
be O +
evacuated O +
to O +
safe O +
areas O +
. O +

Although O +
Florida O +
experienced O +
one O +
of O +
the O +
worst O +
hurricane O +
seasons O +
on O +
record O +
in O +
2004 O +
, O +
the O +
number O +
of O +
fatalities O +
was O +
lower O +
than O +
expected O +
because O +
of O +
early O +
warning O +
and O +
evacuation O +
. O +

Early O +
warning O +
also O +
provides O +
sufficient O +
time O +
to O +
prepare O +
when O +
evacuation O +
is O +
not O +
possible O +
. O +

Hurricane O +
George O +
in O +
1998 O +
caused O +
widespread O +
damage O +
and O +
several O +
fatalities O +
in O +
the O +
Dominican O +
Republic O +
, O +
where O +
residents O +
were O +
not O +
warned O +
. O +

In O +
contrast O +
, O +
Cuba O +
and O +
Puerto O +
Rico O +
experienced O +
relatively O +
limited O +
damage O +
and O +
loss O +
of O +
life O +
, O +
because O +
preparations O +
were O +
made O +
in O +
the O +
hours O +
before O +
the O +
storm O +
. O +

Disaster O +
preparedness O +
can O +
also O +
be O +
developed O +
for O +
communities O +
that O +
are O +
regularly O +
exposed O +
to O +
flooding O +
disasters O +
. O +

Cyclone O +
shelters O +
built O +
by O +
the O +
Red O +
Cross O +
in O +
Orissa O +
, O +
India O +
, O +
saved O +
many O +
thousands O +
of O +
lives O +
in O +
1999 O +
when O +
two O +
cyclones O +
struck O +
. O +

In O +
the O +
region O +
of O +
the O +
Americas O +
, O +
the O +
Pan O +
American O +
Health O +
Organization O +
has O +
spent O +
many O +
years O +
promoting O +
and O +
integrating O +
disaster O +
preparedness O +
into O +
building O +
health O +
facilities O +
to O +
ensure O +
that O +
medical O +
services O +
needed O +
to O +
treat O +
victims O +
and O +
maintain O +
ongoing O +
care O +
for O +
patients O +
with O +
chronic O +
conditions O +
will O +
not O +
be O +
disrupted O +
by O +
disasters O +
. O +

A O +
recent O +
global O +
- O +
scale O +
review O +
of O +
health O +
risks O +
from O +
flooding O +
highlights O +
that O +
in O +
flood O +
- O +
prone O +
areas O +
, O +
disaster O +
preparedness O +
within O +
the O +
health O +
system O +
as O +
a O +
whole O +
is O +
particularly O +
important O +
[ O +
20 O +
] O +
. O +

In O +
addition O +
to O +
infrastructure O +
and O +
early O +
- O +
warning O +
systems O +
, O +
another O +
key O +
element O +
in O +
disaster O +
preparedness O +
is O +
education O +
and O +
raising O +
awareness O +
about O +
disaster O +
risks O +
and O +
response O +
plans O +
. O +

Had O +
there O +
been O +
greater O +
awareness O +
about O +
the O +
risk O +
of O +
tsunamis O +
, O +
perhaps O +
many O +
lives O +
could O +
have O +
been O +
saved O +
in O +
the O +
South O +
Asian O +
disaster O +
in O +
December O +
2004 O +
. O +

Discussion O +

Among O +
adolescent O +
boys O +
in O +
Chapaevsk O +
, O +
Russia O +
, O +
higher O +
serum O +
levels O +
of O +
sum O +
of O +
dioxin O +
- O +
like O +
compounds O +
and O +
sum O +
of O +
dioxin O +
TEQs O +
were O +
positively O +
associated O +
with O +
increased O +
age O +
, O +
consumption O +
of O +
fish O +
, O +
local O +
meats O +
other O +
than O +
chicken O +
, O +
and O +
inversely O +
with O +
weeks O +
of O +
gestation O +
. O +

The O +
age O +
association O +
was O +
found O +
despite O +
a O +
narrow O +
age O +
range O +
of O +
slightly O +
over O +
two O +
years O +
in O +
our O +
study O +
. O +

Although O +
not O +
statistically O +
significant O +
, O +
the O +
distance O +
the O +
boy O +
lived O +
from O +
the O +
Khimprom O +
factory O +
at O +
the O +
time O +
of O +
blood O +
draw O +
was O +
inversely O +
associated O +
with O +
serum O +
levels O +
of O +
sum O +
of O +
dioxin O +
- O +
like O +
compounds O +
and O +
sum O +
of O +
dioxin O +
TEQs O +
. O +

As O +
expected O +
, O +
serum O +
PCBs O +
, O +
specifically O +
PCB O +
118 O +
, O +
were O +
strongly O +
associated O +
with O +
both O +
sum O +
of O +
dioxin O +
- O +
like O +
compounds O +
and O +
sum O +
of O +
dioxin O +
TEQs O +
. O +

There O +
was O +
no O +
association O +
between O +
the O +
distance O +
of O +
the O +
residence O +
from O +
the O +
Khimprom O +
plant O +
during O +
the O +
pregnancy O +
and O +
subsequent O +
serum O +
dioxin O +
levels O +
. O +

One O +
potential O +
explanation O +
for O +
the O +
lack O +
of O +
association O +
may O +
include O +
misclassification O +
of O +
distance O +
since O +
the O +
mother O +
was O +
asked O +
to O +
recall O +
a O +
time O +
period O +
more O +
than O +
14 O +
years O +
prior O +
to O +
the O +
study O +
. O +

However O +
, O +
we O +
would O +
expect O +
that O +
the O +
mother O +
would O +
be O +
able O +
to O +
recall O +
residential O +
history O +
at O +
the O +
time O +
of O +
the O +
birth O +
of O +
their O +
son O +
. O +

Mother O +
' O +
s O +
self O +
- O +
reported O +
estimates O +
of O +
current O +
residential O +
distance O +
from O +
Khimprom O +
was O +
generally O +
accurate O +
; O +
twenty O +
- O +
one O +
of O +
twenty O +
- O +
nine O +
mothers O +
correctly O +
categorized O +
their O +
current O +
residential O +
distance O +
from O +
the O +
Khimprom O +
plants O +
based O +
on O +
cross O +
- O +
referencing O +
using O +
GIS O +
mapping O +
. O +

Other O +
explanations O +
include O +
that O +
prenatal O +
exposure O +
14 O +
or O +
more O +
years O +
prior O +
to O +
the O +
current O +
serum O +
sample O +
is O +
not O +
as O +
strong O +
a O +
predictor O +
as O +
are O +
exposures O +
resulting O +
from O +
present O +
residential O +
location O +
. O +

Although O +
there O +
was O +
no O +
association O +
of O +
case O +
status O +
( O +
cryptorchidism O +
or O +
hypospadias O +
) O +
with O +
dioxin O +
levels O +
, O +
we O +
did O +
not O +
have O +
sufficient O +
power O +
to O +
definitively O +
assess O +
this O +
relationship O +
. O +

Perinatal O +
history O +
( O +
e O +
. O +
g O +
. O +
weeks O +
of O +
breastfeeding O +
) O +
was O +
generally O +
not O +
associated O +
with O +
exposure O +
measures O +
in O +
this O +
population O +
; O +
this O +
may O +
be O +
a O +
function O +
of O +
older O +
age O +
of O +
the O +
children O +
. O +

However O +
, O +
there O +
are O +
limited O +
data O +
on O +
the O +
relationship O +
of O +
perinatal O +
factors O +
with O +
organochlorine O +
exposures O +
in O +
this O +
age O +
group O +
so O +
a O +
null O +
finding O +
is O +
of O +
interest O +
given O +
reports O +
that O +
differences O +
in O +
organochlorine O +
levels O +
among O +
breastfed O +
and O +
non O +
- O +
breastfed O +
are O +
generally O +
no O +
longer O +
discernable O +
by O +
early O +
school O +
age O +
[ O +
24 O +
, O +
25 O +
] O +
and O +
, O +
furthermore O +
, O +
that O +
dietary O +
intake O +
after O +
this O +
age O +
contributes O +
significantly O +
to O +
total O +
dioxin O +
intake O +
[ O +
26 O +
] O +
. O +

In O +
prior O +
studies O +
, O +
substantial O +
emphasis O +
has O +
been O +
placed O +
on O +
pre O +
- O +
and O +
early O +
postnatal O +
( O +
via O +
breastfeeding O +
) O +
exposures O +
because O +
of O +
particular O +
vulnerability O +
during O +
fetal O +
and O +
early O +
infant O +
development O +
. O +

The O +
exposure O +
risk O +
factors O +
during O +
peri O +
- O +
adolescence O +
, O +
another O +
period O +
of O +
potential O +
developmental O +
vulnerability O +
, O +
has O +
not O +
been O +
studied O +
in O +
- O +
detail O +
, O +
therefore O +
, O +
the O +
identification O +
of O +
exposure O +
risk O +
factors O +
specific O +
to O +
this O +
period O +
will O +
enhance O +
our O +
understanding O +
of O +
this O +
critical O +
period O +
. O +

Although O +
data O +
on O +
levels O +
of O +
PCDD O +
/ O +
PCDFs O +
in O +
children O +
is O +
limited O +
, O +
our O +
results O +
suggest O +
that O +
the O +
mean O +
total O +
TEQs O +
among O +
Chapaevsk O +
adolescents O +
were O +
higher O +
than O +
most O +
values O +
previously O +
reported O +
in O +
non O +
- O +
occupationally O +
exposed O +
populations O +
of O +
comparable O +
or O +
even O +
older O +
ages O +
. O +

Figure O +
2 O +
shows O +
a O +
comparison O +
of O +
the O +
mean O +
PCDD O +
/ O +
PCDFs O +
TEQ O +
levels O +
in O +
Chapaevsk O +
boys O +
with O +
other O +
populations O +
( O +
TEQ O +
from O +
dioxin O +
- O +
like O +
PCBs O +
was O +
not O +
included O +
, O +
since O +
some O +
of O +
these O +
studies O +
did O +
not O +
report O +
them O +
) O +
. O +

The O +
mean O +
TEQs O +
of O +
pooled O +
blood O +
samples O +
from O +
10 O +
year O +
- O +
old O +
German O +
boys O +
in O +
rural O +
and O +
urban O +
settings O +
was O +
8 O +
. O +
2 O +
pg O +
TEQ O +
/ O +
g O +
lipid O +
for O +
an O +
urban O +
industrial O +
area O +
, O +
9 O +
. O +
0 O +
pg O +
TEQ O +
/ O +
g O +
lipid O +
for O +
an O +
industrial O +
area O +
within O +
a O +
rural O +
setting O +
, O +
and O +
10 O +
. O +
1 O +
pg O +
TEQ O +
/ O +
g O +
lipid O +
for O +
a O +
rural O +
area O +
[ O +
27 O +
] O +
. O +

In O +
comparison O +
, O +
the O +
mean O +
TEQ O +
in O +
the O +
Chapevsk O +
boys O +
was O +
19 O +
. O +
3 O +
pg O +
TEQ O +
/ O +
g O +
lipid O +
. O +

With O +
the O +
exception O +
of O +
children O +
described O +
by O +
Wuthe O +
et O +
al O +
. O +

[ O +
27 O +
] O +
, O +
subjects O +
in O +
the O +
other O +
studies O +
in O +
Figure O +
2 O +
were O +
significantly O +
older O +
than O +
the O +
Chapaevsk O +
boys O +
. O +

Despite O +
age O +
differences O +
, O +
the O +
mean O +
TEQ O +
in O +
Chapaevsk O +
boys O +
was O +
comparable O +
to O +
or O +
even O +
higher O +
than O +
the O +
mean O +
TEQ O +
in O +
older O +
populations O +
from O +
other O +
countries O +
. O +

For O +
example O +
, O +
they O +
were O +
higher O +
than O +
mean O +
TEQs O +
of O +
18 O +
. O +
4 O +
pg O +
TEQ O +
/ O +
g O +
lipid O +
in O +
adults O +
( O +
40 O +
. O +
6 O +
years O +
old O +
average O +
) O +
from O +
South O +
Germany O +
[ O +
27 O +
] O +
or O +
16 O +
. O +
4 O +
pg O +
TEQ O +
/ O +
g O +
lipid O +
from O +
20 O +
year O +
old O +
Japanese O +
women O +
[ O +
28 O +
] O +
or O +
pooled O +
samples O +
from O +
randomly O +
selected O +
males O +
and O +
females O +
18 O +
- O +
69 O +
years O +
of O +
age O +
from O +
the O +
Spanish O +
city O +
of O +
Mataro O +
[ O +
29 O +
] O +
, O +
which O +
were O +
12 O +
. O +
5 O +
and O +
14 O +
. O +
7 O +
pg O +
TEQ O +
/ O +
g O +
lipid O +
respectively O +
. O +

The O +
mean O +
levels O +
in O +
adult O +
female O +
( O +
mean O +
age O +
41 O +
years O +
) O +
non O +
- O +
factory O +
workers O +
in O +
the O +
Russian O +
city O +
of O +
Shelekhovo O +
were O +
also O +
lower O +
at O +
14 O +
. O +
5 O +
pg O +
TEQ O +
/ O +
g O +
lipid O +
[ O +
30 O +
] O +
. O +

Mean O +
TEQs O +
for O +
the O +
general O +
population O +
( O +
mean O +
age O +
44 O +
. O +
2 O +
years O +
) O +
in O +
Germany O +
, O +
collected O +
in O +
1997 O +
- O +
98 O +
[ O +
31 O +
] O +
, O +
and O +
median O +
TEQs O +
for O +
long O +
- O +
term O +
workers O +
of O +
pulp O +
and O +
paper O +
mill O +
and O +
non O +
- O +
workers O +
in O +
the O +
U O +
. O +
S O +
. O +
in O +
1996 O +
[ O +
32 O +
] O +
were O +
similar O +
to O +
levels O +
found O +
in O +
the O +
Chapaevsk O +
boys O +
. O +

The O +
mean O +
levels O +
in O +
the O +
study O +
in O +
Germany O +
were O +
20 O +
. O +
71 O +
pg O +
TEQ O +
/ O +
g O +
lipid O +
and O +
in O +
the O +
U O +
. O +
S O +
. O +
the O +
median O +
levels O +
were O +
19 O +
. O +
1 O +
pg O +
TEQ O +
/ O +
g O +
lipid O +
for O +
community O +
residents O +
and O +
21 O +
. O +
2 O +
pg O +
TEQ O +
/ O +
g O +
lipid O +
for O +
low O +
exposure O +
workers O +
. O +

Figure O +
2 O +

Mean O +
PCDD O +
/ O +
PCDFs O +
TEQ O +
levels O +
in O +
Chapaevsk O +
boys O +
in O +
comparison O +
with O +
other O +
populations O +
. O +

Although O +
TCDD O +
was O +
largely O +
below O +
the O +
detection O +
limits O +
in O +
this O +
small O +
pilot O +
sample O +
, O +
the O +
two O +
boys O +
with O +
detectable O +
values O +
had O +
high O +
TCDD O +
levels O +
( O +
17 O +
. O +
9 O +
and O +
21 O +
. O +
7 O +
pg O +
/ O +
g O +
lipid O +
) O +
, O +
suggesting O +
that O +
exposure O +
for O +
at O +
least O +
some O +
portion O +
of O +
this O +
population O +
is O +
substantially O +
higher O +
than O +
typical O +
of O +
this O +
age O +
group O +
. O +

In O +
comparison O +
, O +
in O +
a O +
cohort O +
of O +
adult O +
( O +
mean O +
age O +
of O +
58 O +
years O +
) O +
fishermen O +
from O +
a O +
polluted O +
region O +
of O +
Finland O +
, O +
the O +
mean O +
TCDD O +
concentration O +
was O +
19 O +
pg O +
/ O +
g O +
lipid O +
[ O +
33 O +
] O +
. O +

In O +
adult O +
( O +
mean O +
age O +
of O +
53 O +
years O +
) O +
residents O +
from O +
Calcasieu O +
Parish O +
, O +
Louisiana O +
, O +
which O +
is O +
near O +
a O +
chemical O +
industrial O +
complex O +
, O +
the O +
mean O +
TCDD O +
level O +
was O +
7 O +
. O +
6 O +
pg O +
/ O +
g O +
lipid O +
[ O +
34 O +
] O +
. O +

Not O +
only O +
were O +
the O +
dioxin O +
levels O +
in O +
these O +
two O +
children O +
higher O +
than O +
those O +
found O +
in O +
these O +
studies O +
, O +
but O +
the O +
adults O +
in O +
the O +
previous O +
studies O +
were O +
several O +
decades O +
older O +
and O +
therefore O +
would O +
be O +
expected O +
to O +
have O +
higher O +
dioxin O +
body O +
burdens O +
than O +
younger O +
children O +
[ O +
35 O +
] O +
. O +

Potential O +
explanations O +
for O +
the O +
large O +
number O +
of O +
non O +
- O +
detectable O +
samples O +
for O +
TCDD O +
include O +
the O +
small O +
sample O +
volume O +
and O +
young O +
age O +
of O +
the O +
subjects O +
. O +

In O +
our O +
future O +
studies O +
in O +
this O +
population O +
, O +
we O +
will O +
collect O +
larger O +
volumes O +
of O +
serum O +
for O +
dioxin O +
analysis O +
. O +

In O +
one O +
of O +
the O +
few O +
studies O +
on O +
dioxin O +
- O +
like O +
compounds O +
in O +
which O +
children O +
were O +
included O +
, O +
Eskenazi O +
and O +
coworkers O +
[ O +
36 O +
] O +
evaluated O +
the O +
relationship O +
between O +
serum O +
TCDD O +
concentrations O +
and O +
age O +
at O +
exposure O +
of O +
female O +
residents O +
of O +
Seveso O +
, O +
Italy O +
. O +

Residents O +
near O +
the O +
ICMESA O +
chemical O +
plant O +
in O +
Seveso O +
were O +
exposed O +
to O +
some O +
of O +
the O +
highest O +
known O +
residential O +
levels O +
of O +
2 O +
, O +
3 O +
, O +
7 O +
, O +
8 O +
- O +
TCDD O +
as O +
a O +
result O +
of O +
an O +
explosion O +
at O +
the O +
plant O +
. O +

Archived O +
serum O +
collected O +
near O +
the O +
time O +
of O +
the O +
accident O +
was O +
used O +
to O +
measure O +
exposures O +
. O +

Residents O +
closest O +
to O +
the O +
plant O +
had O +
a O +
median O +
2 O +
, O +
3 O +
, O +
7 O +
, O +
8 O +
- O +
TCDD O +
level O +
of O +
272 O +
ppt O +
( O +
IQR O +
92 O +
- O +
883 O +
ppt O +
) O +
. O +

Residential O +
proximity O +
to O +
the O +
plant O +
and O +
younger O +
age O +
( O +
up O +
to O +
13 O +
years O +
old O +
) O +
were O +
the O +
strongest O +
predictors O +
of O +
an O +
individual O +
' O +
s O +
serum O +
2 O +
, O +
3 O +
, O +
7 O +
, O +
8 O +
- O +
TCDD O +
level O +
. O +

Other O +
predictors O +
included O +
being O +
outdoors O +
at O +
the O +
time O +
of O +
explosion O +
and O +
consumption O +
of O +
homegrown O +
food O +
. O +

The O +
higher O +
levels O +
found O +
in O +
children O +
were O +
most O +
likely O +
a O +
result O +
of O +
increased O +
exposure O +
as O +
a O +
result O +
of O +
activity O +
patterns O +
and O +
a O +
greater O +
proportionate O +
consumption O +
of O +
food O +
, O +
water O +
and O +
air O +
than O +
adults O +
[ O +
37 O +
] O +
. O +

Although O +
the O +
exposure O +
scenario O +
( O +
an O +
acute O +
high O +
exposure O +
event O +
) O +
is O +
different O +
than O +
the O +
chronic O +
low O +
/ O +
moderate O +
exposure O +
occurring O +
in O +
Chapaevsk O +
, O +
the O +
results O +
from O +
Seveso O +
suggest O +
that O +
children O +
may O +
be O +
at O +
increased O +
risk O +
for O +
high O +
dioxin O +
exposure O +
from O +
environmental O +
contamination O +
. O +

In O +
our O +
study O +
, O +
although O +
distance O +
from O +
the O +
Khimprom O +
plants O +
was O +
a O +
weak O +
predictor O +
of O +
serum O +
dioxin O +
- O +
like O +
compounds O +
, O +
consumption O +
of O +
local O +
foods O +
( O +
specifically O +
meat O +
and O +
fish O +
) O +
, O +
as O +
in O +
the O +
Seveso O +
study O +
, O +
was O +
a O +
strong O +
predictor O +
of O +
sum O +
of O +
dioxin O +
- O +
like O +
compounds O +
and O +
dioxin O +
TEQs O +
. O +

This O +
finding O +
is O +
notable O +
given O +
concerns O +
regarding O +
environmental O +
dioxin O +
contamination O +
in O +
the O +
community O +
and O +
suggests O +
that O +
food O +
may O +
be O +
one O +
of O +
the O +
more O +
, O +
if O +
not O +
most O +
, O +
important O +
routes O +
of O +
environmental O +
contaminant O +
exposure O +
for O +
residents O +
in O +
this O +
setting O +
. O +

In O +
other O +
settings O +
, O +
contaminated O +
food O +
generally O +
contributes O +
much O +
more O +
substantially O +
to O +
human O +
organochlorine O +
burden O +
than O +
air O +
or O +
soil O +
( O +
which O +
may O +
be O +
related O +
to O +
residential O +
proximity O +
to O +
pollutant O +
sources O +
) O +
[ O +
6 O +
] O +
. O +

We O +
will O +
investigate O +
this O +
issue O +
in O +
more O +
detail O +
in O +
our O +
ongoing O +
study O +
. O +

Figures O +
and O +
Tables O +

Figure O +
1 O +

Allergen O +
and O +
particle O +
dose O +
- O +
response O +
experiments O +
in O +
BALB O +
/ O +
cA O +
and O +
NIH O +
mice O +
Levels O +
of O +
serum O +
OVA O +
- O +
specific O +
IgE O +
( O +
A O +
, O +
D O +
) O +
, O +
IgG1 O +
( O +
B O +
, O +
E O +
) O +
and O +
IgG2a O +
( O +
C O +
, O +
F O +
) O +
on O +
day O +
26 O +
after O +
injection O +
into O +
one O +
hind O +
footpad O +
of O +
100 O +
( O +
open O +
columns O +
) O +
, O +
50 O +
( O +
gray O +
) O +
or O +
10 O +
( O +
black O +
) O +
mug O +
OVA O +
combined O +
with O +
100 O +
, O +
40 O +
, O +
10 O +
or O +
0 O +
mug O +
PSP O +
, O +
or O +
buffer O +
( O +
HBSS O +
( O +
hatched O +
) O +
) O +
, O +
in O +
BALB O +
/ O +
cA O +
( O +
A O +
, O +
B O +
, O +
C O +
) O +
and O +
NIH O +
( O +
D O +
, O +
E O +
, O +
F O +
) O +
mice O +
. O +

On O +
day O +
21 O +
the O +
mice O +
were O +
boostered O +
with O +
the O +
same O +
OVA O +
dose O +
in O +
the O +
footpad O +
. O +

The O +
PSP O +
- O +
control O +
( O +
" O +
PSP O +
ctr O +
" O +
) O +
group O +
was O +
given O +
100 O +
mug O +
PSP O +
on O +
day O +
0 O +
, O +
followed O +
by O +
HBSS O +
injection O +
on O +
day O +
21 O +
( O +
diamonds O +
) O +
. O +

Values O +
( O +
arbitrary O +
units O +
, O +
AU O +
) O +
for O +
individual O +
mice O +
( O +
circles O +
) O +
and O +
median O +
values O +
( O +
columns O +
) O +
for O +
groups O +
of O +
eight O +
mice O +
are O +
shown O +
. O +

Dotted O +
lines O +
indicate O +
the O +
lower O +
or O +
higher O +
detection O +
limits O +
for O +
the O +
ELISA O +
assays O +
. O +

Note O +
different O +
scales O +
for O +
the O +
two O +
strains O +
of O +
mice O +
. O +

Figure O +
2 O +

The O +
adjuvant O +
effect O +
of O +
PSP O +
on O +
OVA O +
- O +
specific O +
IgE O +
and O +
IgG2a O +
responses O +
in O +
different O +
strains O +
of O +
mice O +
Levels O +
of O +
serum O +
OVA O +
- O +
specific O +
IgE O +
( O +
A O +
) O +
and O +
IgG2a O +
( O +
B O +
) O +
on O +
day O +
26 O +
after O +
injection O +
into O +
one O +
hind O +
footpad O +
of O +
HBSS O +
( O +
open O +
columns O +
) O +
, O +
10 O +
mug O +
OVA O +
( O +
gray O +
) O +
, O +
40 O +
mug O +
PSP O +
( O +
hatched O +
) O +
or O +
10 O +
mug O +
OVA O +
+ O +
40 O +
mug O +
PSP O +
( O +
black O +
) O +
in O +
different O +
mouse O +
strains O +
. O +

On O +
day O +
21 O +
all O +
mice O +
were O +
boostered O +
with O +
10 O +
mug O +
OVA O +
in O +
the O +
footpad O +
. O +

Vertical O +
straight O +
lines O +
indicate O +
separate O +
experiments O +
. O +

Values O +
( O +
arbitrary O +
units O +
, O +
AU O +
) O +
for O +
individual O +
mice O +
( O +
circles O +
) O +
and O +
median O +
values O +
( O +
columns O +
) O +
for O +
groups O +
of O +
mice O +
are O +
shown O +
. O +

Dotted O +
lines O +
indicate O +
the O +
lower O +
detection O +
limits O +
for O +
the O +
ELISA O +
assays O +
. O +

Brackets O +
indicate O +
statistically O +
significant O +
differences O +
between O +
groups O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
. O +

All O +
experiments O +
were O +
performed O +
twice O +
with O +
similar O +
results O +
, O +
with O +
eight O +
mice O +
per O +
group O +
. O +

Figure O +
3 O +

The O +
primary O +
cellular O +
response O +
in O +
the O +
draining O +
lymph O +
node O +
The O +
primary O +
cellular O +
response O +
in O +
the O +
draining O +
PLN O +
was O +
determined O +
five O +
days O +
after O +
a O +
single O +
injection O +
of O +
HBSS O +
( O +
open O +
columns O +
) O +
, O +
10 O +
mug O +
OVA O +
( O +
gray O +
) O +
, O +
40 O +
mug O +
PSP O +
( O +
hatched O +
) O +
or O +
10 O +
mug O +
OVA O +
+ O +
40 O +
mug O +
PSP O +
( O +
black O +
) O +
into O +
both O +
hind O +
footpads O +
of O +
BALB O +
/ O +
cA O +
, O +
NIH O +
and O +
C3H O +
/ O +
HeN O +
mice O +
. O +

The O +
total O +
lymph O +
node O +
cell O +
numbers O +
( O +
A O +
) O +
and O +
IL O +
- O +
4 O +
( O +
B O +
) O +
, O +
IFN O +
- O +
gamma O +
( O +
C O +
) O +
and O +
IL O +
- O +
10 O +
( O +
D O +
) O +
secreted O +
from O +
the O +
PLN O +
cells O +
after O +
ex O +
vivo O +
stimulation O +
with O +
Con O +
A O +
were O +
determined O +
. O +

Values O +
for O +
individual O +
samples O +
( O +
circles O +
) O +
and O +
group O +
median O +
values O +
( O +
columns O +
) O +
are O +
shown O +
. O +

Dotted O +
lines O +
indicate O +
the O +
lower O +
detection O +
limits O +
for O +
the O +
cytokine O +
ELISA O +
assays O +
, O +
and O +
brackets O +
indicate O +
statistically O +
significant O +
differences O +
between O +
groups O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
. O +

Figures O +
and O +
Tables O +

Stages O +
in O +
the O +
life O +
cycle O +
of O +
Plasmodium O +
falciparum O +

( O +
Illustration O +
: O +
Coatney O +
GR O +
, O +
Collins O +
WE O +
, O +
Warren O +
M O +
, O +
Contacos O +
PG O +
( O +
1971 O +
) O +

The O +
primate O +
malarias O +
. O +
( O +
Bethesda O +
) O +
: O +
U O +
. O +
S O +
. O +
Department O +
of O +
Health O +
, O +
Education O +
and O +
Welfare O +
. O +
) O +

Transcripts O +
Upregulated O +
in O +
ST O +
- O +
HSC O +
Compared O +
to O +
LT O +
- O +
HSC O +

( O +
181 O +
KB O +
XLS O +
) O +

Results O +

OFTT O +
was O +
given O +
to O +
33 O +
men O +
with O +
MetS O +
( O +
defined O +
by O +
the O +
Adult O +
Treatment O +
Panel O +
III O +
) O +
, O +
17 O +
HTN O +
and O +
14 O +
healthy O +
men O +
. O +

The O +
MetS O +
group O +
was O +
further O +
divided O +
according O +
to O +
fasting O +
triglycerides O +
( O +
TG O +
) O +
into O +
TG O +
> O +
= O +
150 O +
[ O +
MetS O +
+ O +
TG O +
, O +
( O +
n O +
= O +
22 O +
) O +
] O +
or O +
< O +
150 O +
mg O +
/ O +
dl O +
[ O +
MetS O +
- O +
TG O +
( O +
n O +
= O +
11 O +
) O +
] O +
, O +
and O +
into O +
those O +
with O +
or O +
without O +
hypertension O +
[ O +
MetS O +
+ O +
HTN O +
( O +
n O +
= O +
24 O +
) O +
, O +
MetS O +
- O +
HTN O +
( O +
n O +
= O +
9 O +
) O +
, O +
respectively O +
] O +
. O +

TG O +
concentrations O +
were O +
measured O +
before O +
and O +
at O +
4 O +
, O +
6 O +
and O +
8 O +
h O +
after O +
OFTT O +
and O +
the O +
postprandial O +
response O +
was O +
quantified O +
using O +
the O +
area O +
under O +
the O +
curve O +
( O +
AUC O +
) O +
for O +
TG O +
. O +

The O +
postprandial O +
response O +
was O +
significantly O +
higher O +
in O +
MetS O +
compared O +
to O +
HTN O +
and O +
healthy O +
men O +
[ O +
AUC O +
( O +
SD O +
) O +
in O +
mg O +
/ O +
dl O +
/ O +
h O +
; O +
2534 O +
+ O +
/ O +
- O +
1016 O +
vs O +
. O +
1620 O +
+ O +
/ O +
- O +
494 O +
and O +
1019 O +
+ O +
/ O +
- O +
280 O +
, O +
respectively O +
, O +
p O +
< O +
= O +
0 O +
. O +
001 O +
] O +
. O +

The O +
TG O +
levels O +
were O +
increased O +
significantly O +
in O +
MetS O +
+ O +
TG O +
compared O +
to O +
MetS O +
- O +
TG O +
subjects O +
at O +
4 O +
( O +
p O +
= O +
0 O +
. O +
022 O +
) O +
, O +
6 O +
( O +
p O +
< O +
0 O +
. O +
001 O +
) O +
and O +
8 O +
hours O +
( O +
p O +
< O +
0 O +
. O +
001 O +
) O +
. O +

The O +
TG O +
were O +
increased O +
significantly O +
in O +
MetS O +
- O +
TG O +
compared O +
to O +
healthy O +
subjects O +
at O +
4 O +
( O +
p O +
= O +
0 O +
. O +
011 O +
) O +
, O +
6 O +
( O +
p O +
= O +
0 O +
. O +
001 O +
) O +
and O +
8 O +
hours O +
( O +
p O +
= O +
0 O +
. O +
015 O +
) O +
. O +

In O +
linear O +
regression O +
analysis O +
only O +
fasting O +
TG O +
levels O +
were O +
a O +
significant O +
predictor O +
of O +
the O +
AUC O +
( O +
Coefficient O +
B O +
= O +
8 O +
. O +
462 O +
, O +
p O +
< O +
0 O +
. O +
001 O +
) O +
. O +

Conclusions O +

Only O +
after O +
careful O +
consideration O +
of O +
the O +
biological O +
underpinnings O +
of O +
a O +
truly O +
beneficial O +
response O +
can O +
an O +
exposure O +
be O +
considered O +
for O +
the O +
general O +
population O +
, O +
such O +
as O +
the O +
addition O +
of O +
folic O +
acid O +
to O +
cereals O +
. O +

If O +
a O +
toxic O +
or O +
hazardous O +
pollutant O +
were O +
found O +
to O +
have O +
truly O +
beneficial O +
effects O +
at O +
low O +
dose O +
, O +
then O +
that O +
agent O +
should O +
be O +
tested O +
clinically O +
, O +
go O +
through O +
the O +
U O +
. O +
S O +
. O +

Food O +
and O +
Drug O +
Administration O +
( O +
FDA O +
) O +
approval O +
process O +
, O +
and O +
be O +
regulated O +
as O +
a O +
pharmaceutical O +
for O +
those O +
who O +
might O +
benefit O +
from O +
its O +
use O +
. O +

Certainly O +
, O +
the O +
general O +
population O +
should O +
not O +
be O +
exposed O +
to O +
chemotherapeutic O +
agents O +
that O +
benefit O +
cancer O +
patients O +
. O +

For O +
pharmaceuticals O +
, O +
it O +
is O +
understood O +
that O +
there O +
are O +
trade O +
offs O +
between O +
benefits O +
and O +
risks O +
. O +

For O +
example O +
, O +
although O +
aspirin O +
is O +
a O +
generally O +
well O +
- O +
tolerated O +
pain O +
reliever O +
and O +
is O +
increasingly O +
advocated O +
as O +
a O +
preventative O +
tool O +
for O +
heart O +
attacks O +
and O +
colorectal O +
cancer O +
( O +
Vainio O +
and O +
Miller O +
2003 O +
; O +
Werner O +
et O +
al O +
. O +
2004 O +
) O +
, O +
it O +
is O +
also O +
linked O +
to O +
increased O +
risk O +
of O +
gastrointestinal O +
bleeding O +
, O +
cerebral O +
hemorrhage O +
( O +
Werner O +
et O +
al O +
. O +
2004 O +
) O +
, O +
and O +
asthma O +
attacks O +
( O +
Jenkins O +
et O +
al O +
. O +
2004 O +
) O +
. O +

In O +
addition O +
, O +
aspirin O +
is O +
not O +
recommended O +
for O +
children O +
or O +
teenagers O +
who O +
have O +
or O +
are O +
recovering O +
from O +
chicken O +
pox O +
or O +
flulike O +
symptoms O +
because O +
it O +
can O +
cause O +
debilitating O +
and O +
sometimes O +
lethal O +
Reyes O +
syndrome O +
( O +
U O +
. O +
S O +
. O +
FDA O +
2003 O +
) O +
. O +

Individual O +
risks O +
to O +
pharmaceutical O +
agents O +
can O +
be O +
controlled O +
with O +
proper O +
usage O +
; O +
however O +
, O +
increased O +
exposure O +
to O +
environmental O +
toxins O +
presents O +
additional O +
involuntary O +
risks O +
for O +
the O +
general O +
population O +
. O +

Under O +
the O +
latter O +
condition O +
, O +
exposure O +
is O +
inadequately O +
controlled O +
, O +
and O +
there O +
is O +
no O +
mechanism O +
to O +
correct O +
for O +
individual O +
circumstances O +
( O +
e O +
. O +
g O +
. O +
, O +
medical O +
condition O +
or O +
age O +
) O +
that O +
may O +
result O +
in O +
harm O +
. O +

Although O +
hormetic O +
effects O +
may O +
occur O +
in O +
some O +
instances O +
, O +
it O +
is O +
indeed O +
rare O +
that O +
exposures O +
to O +
toxic O +
, O +
mutagenic O +
, O +
teratogenic O +
, O +
and O +
carcinogenic O +
chemicals O +
, O +
even O +
at O +
low O +
exposure O +
levels O +
, O +
would O +
be O +
risk O +
free O +
and O +
provide O +
health O +
benefits O +
for O +
the O +
general O +
public O +
. O +

Portraying O +
chemicals O +
with O +
numerous O +
adverse O +
effects O +
as O +
having O +
benefits O +
while O +
ignoring O +
their O +
hazards O +
is O +
irresponsible O +
and O +
does O +
not O +
provide O +
full O +
and O +
objective O +
disclosure O +
. O +

In O +
the O +
1950s O +
doctors O +
prescribed O +
DES O +
to O +
pregnant O +
women O +
to O +
prevent O +
miscarriage O +
and O +
premature O +
births O +
and O +
to O +
produce O +
" O +
bigger O +
and O +
stronger O +
babies O +
" O +
even O +
though O +
DES O +
had O +
been O +
shown O +
to O +
cause O +
damage O +
to O +
reproductive O +
tissues O +
in O +
animals O +
( O +
Dinusson O +
et O +
al O +
. O +
1948 O +
; O +
Dunn O +
and O +
Green O +
1963 O +
; O +
Takasugi O +
and O +
Bern O +
1964 O +
) O +
. O +

Human O +
use O +
of O +
DES O +
was O +
banned O +
in O +
the O +
United O +
States O +
in O +
1971 O +
after O +
the O +
discovery O +
of O +
high O +
rates O +
of O +
rare O +
, O +
clear O +
- O +
cell O +
adenocarcinomas O +
of O +
the O +
vagina O +
and O +
cervix O +
in O +
DES O +
- O +
exposed O +
daughters O +
( O +
Herbst O +
1981 O +
) O +
, O +
and O +
later O +
studies O +
showed O +
elevated O +
breast O +
cancer O +
risk O +
in O +
women O +
who O +
took O +
DES O +
during O +
pregnancy O +
( O +
Titus O +
- O +
Ernstoff O +
et O +
al O +
. O +
2001 O +
) O +
. O +

Certainly O +
, O +
health O +
policy O +
decisions O +
should O +
be O +
based O +
on O +
scientific O +
evidence O +
and O +
not O +
on O +
speculation O +
of O +
health O +
benefits O +
in O +
order O +
for O +
the O +
general O +
population O +
to O +
avoid O +
repeating O +
the O +
mistakes O +
of O +
the O +
past O +
similar O +
to O +
that O +
of O +
the O +
DES O +
tragedy O +
. O +

The O +
claims O +
and O +
projections O +
of O +
health O +
benefits O +
from O +
exposures O +
to O +
environmental O +
toxicants O +
and O +
carcinogens O +
are O +
based O +
on O +
untested O +
assumptions O +
and O +
disregard O +
numerous O +
well O +
- O +
established O +
scientific O +
principles O +
that O +
underpin O +
a O +
public O +
health O +
- O +
protective O +
approach O +
to O +
regulating O +
exposure O +
to O +
toxic O +
substances O +
. O +

If O +
hormesis O +
were O +
used O +
in O +
the O +
decision O +
- O +
making O +
process O +
to O +
allow O +
higher O +
exposures O +
to O +
toxic O +
and O +
carcinogenic O +
agents O +
, O +
this O +
would O +
substantially O +
increase O +
health O +
risks O +
for O +
many O +
, O +
if O +
not O +
most O +
, O +
segments O +
of O +
the O +
general O +
population O +
. O +

Measured O +
analytes O +
in O +
five O +
biologic O +
sample O +
matrices O +
. O +
a O +

Results O +

Competing O +
interests O +

None O +
declared O +
. O +

This O +
article O +
is O +
the O +
third O +
in O +
an O +
ongoing O +
, O +
educational O +
review O +
series O +
on O +
medical O +
statistics O +
in O +
critical O +
care O +
. O +

Previous O +
articles O +
have O +
covered O +
' O +
presenting O +
and O +
summarising O +
data O +
' O +
[ O +
3 O +
] O +
and O +
' O +
samples O +
and O +
populations O +
' O +
[ O +
4 O +
] O +
. O +

Future O +
topics O +
to O +
be O +
covered O +
include O +
power O +
calculations O +
, O +
comparison O +
of O +
means O +
, O +
comparison O +
of O +
proportions O +
, O +
and O +
analysis O +
of O +
survival O +
data O +
to O +
name O +
but O +
a O +
few O +
. O +

If O +
there O +
is O +
a O +
medical O +
statistics O +
topic O +
you O +
would O +
like O +
explained O +
contact O +
us O +
on O +
editorial O +
@ O +
ccforum O +
. O +
com O +
. O +

Results O +

The O +
set O +
of O +
E O +
. O +
coli O +
expression O +
vectors O +
, O +
encode O +
for O +
either O +
a O +
hexa O +
- O +
histidine O +
tag O +
or O +
the O +
three O +
most O +
commonly O +
used O +
solubility O +
tags O +
( O +
GST O +
, O +
MBP O +
, O +
NusA O +
) O +
and O +
all O +
with O +
an O +
N O +
- O +
terminal O +
hexa O +
- O +
histidine O +
sequence O +
. O +

The O +
result O +
is O +
two O +
- O +
fold O +
: O +
the O +
His O +
- O +
tag O +
facilitates O +
purification O +
by O +
immobilised O +
metal O +
affinity O +
chromatography O +
, O +
whilst O +
the O +
fusion O +
domains O +
act O +
primarily O +
as O +
solubility O +
aids O +
during O +
expression O +
, O +
in O +
addition O +
to O +
providing O +
an O +
optional O +
purification O +
step O +
. O +

We O +
have O +
also O +
incorporated O +
a O +
TEV O +
recognition O +
sequence O +
following O +
the O +
solubility O +
tag O +
domain O +
, O +
which O +
allows O +
for O +
highly O +
specific O +
cleavage O +
( O +
using O +
TEV O +
protease O +
) O +
of O +
the O +
fusion O +
protein O +
to O +
yield O +
native O +
protein O +
. O +

These O +
vectors O +
are O +
also O +
designed O +
for O +
ligation O +
- O +
independent O +
cloning O +
and O +
they O +
possess O +
a O +
high O +
- O +
level O +
expressing O +
T7 O +
promoter O +
, O +
which O +
is O +
suitable O +
for O +
auto O +
- O +
induction O +
. O +

To O +
validate O +
our O +
vector O +
system O +
, O +
we O +
have O +
cloned O +
four O +
different O +
genes O +
and O +
also O +
one O +
gene O +
into O +
all O +
four O +
vectors O +
and O +
used O +
small O +
- O +
scale O +
expression O +
and O +
purification O +
techniques O +
. O +

We O +
demonstrate O +
that O +
the O +
vectors O +
are O +
capable O +
of O +
high O +
levels O +
of O +
expression O +
and O +
that O +
efficient O +
screening O +
of O +
new O +
proteins O +
can O +
be O +
readily O +
achieved O +
at O +
the O +
laboratory O +
level O +
. O +

Images O +

FIGURE O +
2 O +
. O +

A O +

FIGURE O +
2 O +
. O +

B O +

FIGURE O +
3 O +
. O +

Images O +

FIGURE O +
2 O +
. O +

Inflammation O +
- O +
modulating O +
effect O +
of O +
antithrombin O +
on O +
the O +
endothelium O +
. O +

Ligation O +
of O +
heparan O +
sulfate O +
proteoglycans O +
( O +
HSPGs O +
) O +
of O +
endothelium O +
with O +
antithrombin O +
( O +
AT O +
) O +
induces O +
cellular O +
signalling O +
events O +
that O +
alter O +
the O +
cell O +
' O +
s O +
biochemical O +
and O +
functional O +
responses O +
to O +
inflammatory O +
stimuli O +
( O +
e O +
. O +
g O +
. O +
bacterial O +
lipopolysaccharide O +
[ O +
LPS O +
] O +
) O +
. O +

Changes O +
include O +
reduced O +
release O +
of O +
inflammatory O +
and O +
procoagulatory O +
mediators O +
( O +
e O +
. O +
g O +
. O +
interleukin O +
[ O +
IL O +
] O +
- O +
1 O +
, O +
IL O +
- O +
6 O +
, O +
tumour O +
necrosis O +
factor O +
- O +
alpha O +
[ O +
TNF O +
] O +
) O +
, O +
tissue O +
factor O +
( O +
TF O +
) O +
, O +
adenosine O +
diphosphate O +
( O +
ADP O +
) O +
and O +
cellular O +
adhesion O +
molecules O +
( O +
not O +
shown O +
) O +
, O +
as O +
well O +
as O +
increased O +
release O +
of O +
anticoagulatory O +
prostacyclin O +
( O +
prostaglandin O +
[ O +
PG O +
] O +
I O +
) O +
or O +
CD39 O +
/ O +
ATPDase O +
. O +

In O +
neuronal O +
tissue O +
, O +
protective O +
mechanisms O +
may O +
by O +
mediated O +
via O +
the O +
release O +
of O +
calcitonin O +
gene O +
- O +
related O +
peptide O +
and O +
nitric O +
oxide O +
with O +
the O +
potential O +
to O +
affect O +
prostacyclin O +
release O +
[ O +
55 O +
] O +
. O +

Background O +

Hallucinations O +
may O +
occur O +
in O +
any O +
sensory O +
modalities O +
. O +

Formed O +
musical O +
hallucinations O +
( O +
i O +
. O +
e O +
. O +
Perception O +
of O +
either O +
vocal O +
or O +
instrumental O +
melodies O +
) O +
reported O +
in O +
English O +
literature O +
to O +
date O +
have O +
typically O +
been O +
associated O +
with O +
marked O +
hearing O +
loss O +
, O +
advanced O +
age O +
, O +
female O +
sex O +
( O +
71 O +
% O +
) O +
, O +
lack O +
of O +
response O +
to O +
treatment O +
and O +
associated O +
psychopathology O +
[ O +
1 O +
] O +
but O +
has O +
been O +
concluded O +
that O +
hearing O +
loss O +
is O +
neither O +
a O +
necessary O +
nor O +
sufficient O +
condition O +
for O +
the O +
occurrence O +
of O +
musical O +
hallucinations O +
[ O +
1 O +
] O +
. O +

Tumor O +
like O +
Astrocytoma O +
, O +
Temporal O +
lobe O +
epilepsy O +
, O +
raised O +
intra O +
cranial O +
tension O +
, O +
drug O +
induced O +
( O +
tricyclics O +
, O +
Propronolol O +
etc O +
; O +
) O +
, O +
meningitis O +
and O +
psychotic O +
illness O +
were O +
shown O +
to O +
cause O +
palinacousis O +
and O +
musical O +
hallucinations O +
[ O +
2 O +
, O +
3 O +
] O +
. O +

Musical O +
hallucinations O +
are O +
pseudo O +
hallucinations O +
that O +
originate O +
in O +
memory O +
representations O +
and O +
they O +
may O +
undergo O +
a O +
transition O +
to O +
true O +
hallucination O +
. O +

In O +
musical O +
hallucination O +
spatial O +
projection O +
is O +
less O +
definite O +
. O +

Sometimes O +
they O +
are O +
perceived O +
like O +
the O +
tinnitus O +
in O +
patient O +
' O +
s O +
own O +
head O +
. O +

The O +
quality O +
is O +
usually O +
very O +
intense O +
and O +
distinct O +
often O +
very O +
loud O +
. O +

They O +
vary O +
from O +
elementary O +
sounds O +
to O +
instrumental O +
music O +
, O +
vocal O +
music O +
, O +
bird O +
songs O +
, O +
bells O +
, O +
pieces O +
of O +
melodies O +
or O +
sentences O +
, O +
religious O +
music O +
etc O +
: O +
- O +
We O +
report O +
an O +
unusual O +
presentation O +
of O +
an O +
elderly O +
lady O +
who O +
had O +
experienced O +
musical O +
hallucinations O +
whilst O +
being O +
treated O +
with O +
Electro O +
Convulsive O +
Therapy O +
. O +

Though O +
this O +
has O +
never O +
been O +
reported O +
earlier O +
, O +
there O +
seemed O +
to O +
have O +
a O +
good O +
association O +
between O +
the O +
initiation O +
of O +
Electro O +
convulsive O +
therapy O +
and O +
musical O +
hallucination O +
in O +
our O +
patient O +
. O +

Supporting O +
Information O +

Table O +
S1 O +

Supplementary O +
Information O +
on O +
Genes O +
in O +
the O +
Three O +
Gene O +
Sets O +

( O +
219 O +
KB O +
PDF O +
) O +

Click O +
here O +
for O +
additional O +
data O +
file O +
. O +

Table O +
S2 O +

UFW O +
Primers O +
for O +
Gene O +
Set O +
I O +

( O +
36 O +
KB O +
PDF O +
) O +

Click O +
here O +
for O +
additional O +
data O +
file O +
. O +

Table O +
S3 O +

UFW O +
Primers O +
for O +
Gene O +
Set O +
II O +

( O +
44 O +
KB O +
PDF O +
) O +

Click O +
here O +
for O +
additional O +
data O +
file O +
. O +

Table O +
S4 O +

UFW O +
Primers O +
for O +
Gene O +
Set O +
III O +

( O +
31 O +
KB O +
PDF O +
) O +

Click O +
here O +
for O +
additional O +
data O +
file O +
. O +

Table O +
S5 O +

Transposable O +
Element O +
- O +
Specific O +
Primers O +
for O +
Additional O +
Screens O +

( O +
80 O +
KB O +
PDF O +
) O +

Click O +
here O +
for O +
additional O +
data O +
file O +
. O +

Table O +
S6 O +

Primers O +
for O +
Intergenic O +
Regions O +

( O +
58 O +
KB O +
PDF O +
) O +

Click O +
here O +
for O +
additional O +
data O +
file O +
. O +

Table O +
S7 O +

P O +
Element O +
- O +
Specific O +
Primers O +
for O +
Orientation O +
and O +
Length O +
Determination O +

( O +
299 O +
KB O +
PDF O +
) O +

Click O +
here O +
for O +
additional O +
data O +
file O +
. O +

Correlation O +
between O +
sperm O +
morphology O +
and O +
seminal O +
plasma O +
NO O +
( O +
a O +
) O +
and O +
TBARS O +
( O +
b O +
) O +
levels O +
in O +
both O +
groups O +
. O +

Conclusion O +

The O +
survey O +
indicated O +
that O +
, O +
the O +
study O +
area O +
has O +
plenty O +
of O +
medicinal O +
plants O +
to O +
treat O +
a O +
wide O +
spectrum O +
of O +
human O +
ailments O +
. O +

Earlier O +
studies O +
on O +
traditional O +
medicinal O +
plants O +
also O +
revealed O +
that O +
the O +
economically O +
backward O +
local O +
and O +
tribal O +
people O +
of O +
Tamil O +
Nadu O +
prefer O +
folk O +
medicine O +
due O +
to O +
low O +
cost O +
and O +
sometimes O +
it O +
is O +
a O +
part O +
of O +
their O +
social O +
life O +
and O +
culture O +
[ O +
40 O +
- O +
45 O +
] O +
. O +

It O +
is O +
evident O +
from O +
the O +
interviews O +
conducted O +
in O +
different O +
villages O +
, O +
knowledge O +
of O +
medicinal O +
plants O +
is O +
limited O +
to O +
traditional O +
healers O +
, O +
herbalists O +
and O +
elderly O +
persons O +
who O +
are O +
living O +
in O +
rural O +
areas O +
. O +

This O +
study O +
also O +
points O +
out O +
that O +
certain O +
species O +
of O +
medicinal O +
plants O +
are O +
being O +
exploited O +
by O +
the O +
local O +
residents O +
who O +
are O +
unaware O +
of O +
the O +
importance O +
of O +
medicinal O +
plants O +
in O +
the O +
ecosystem O +
. O +

This O +
study O +
concluded O +
that O +
even O +
though O +
the O +
accessibility O +
of O +
Western O +
medicine O +
for O +
simple O +
and O +
complicated O +
diseases O +
is O +
available O +
, O +
many O +
people O +
in O +
the O +
studied O +
parts O +
of O +
Kancheepuram O +
district O +
is O +
still O +
continue O +
to O +
depend O +
on O +
medicinal O +
plants O +
, O +
at O +
least O +
for O +
the O +
treatment O +
of O +
some O +
simple O +
diseases O +
such O +
as O +
, O +
cold O +
, O +
cough O +
, O +
fever O +
, O +
headache O +
, O +
poison O +
bites O +
, O +
skin O +
diseases O +
and O +
tooth O +
infections O +
. O +

Well O +
- O +
knowledged O +
healers O +
have O +
good O +
interactions O +
with O +
patients O +
and O +
this O +
would O +
improve O +
the O +
quality O +
of O +
healthcare O +
delivery O +
. O +

The O +
present O +
- O +
day O +
traditional O +
healers O +
are O +
very O +
old O +
. O +

Due O +
to O +
lack O +
of O +
interest O +
among O +
the O +
younger O +
generation O +
as O +
well O +
as O +
their O +
tendency O +
to O +
migrate O +
to O +
cities O +
for O +
lucrative O +
jobs O +
, O +
there O +
is O +
a O +
possibility O +
of O +
losing O +
this O +
wealth O +
of O +
knowledge O +
in O +
the O +
near O +
future O +
. O +

It O +
thus O +
becomes O +
necessary O +
to O +
acquire O +
and O +
preserve O +
this O +
traditional O +
system O +
of O +
medicine O +
by O +
proper O +
documentation O +
and O +
identification O +
of O +
specimens O +
. O +

Nf O +
and O +
GA O +
- O +
1 O +
DNA O +
polymerases O +
couple O +
polymerization O +
to O +
strand O +
displacement O +
processively O +

The O +
results O +
presented O +
in O +
this O +
paper O +
clearly O +
indicate O +
that O +
Nf O +
and O +
GA O +
- O +
1 O +
DNA O +
polymerases O +
can O +
account O +
for O +
their O +
genome O +
replication O +
without O +
the O +
assistance O +
of O +
unwinding O +
and O +
processivity O +
factors O +
, O +
in O +
contrast O +
to O +
most O +
replicative O +
DNA O +
polymerases O +
which O +
require O +
their O +
physical O +
association O +
to O +
processivity O +
factors O +
and O +
DNA O +
unwinding O +
proteins O +
( O +
1 O +
, O +
70 O +
) O +
. O +

Strand O +
displacement O +
capacity O +
has O +
also O +
been O +
shown O +
for O +
other O +
protein O +
- O +
primed O +
DNA O +
polymerases O +
as O +
those O +
of O +
bacteriophages O +
phi29 O +
( O +
10 O +
) O +
, O +
Cp O +
- O +
1 O +
( O +
71 O +
) O +
and O +
PRD1 O +
( O +
72 O +
, O +
73 O +
) O +
. O +

On O +
the O +
contrary O +
, O +
adenovirus O +
DNA O +
polymerase O +
, O +
although O +
processive O +
, O +
can O -
not O +
couple O +
polymerization O +
to O +
strand O +
displacement O +
, O +
requiring O +
the O +
DNA O +
unwinding O +
activity O +
of O +
the O +
adenovirus O +
DBP O +
to O +
perform O +
strand O +
displacement O +
( O +
74 O +
, O +
75 O +
) O +
. O +

Whereas O +
it O +
was O +
possible O +
to O +
obtain O +
GA O +
- O +
1 O +
DNA O +
replication O +
by O +
using O +
exclusively O +
the O +
GA O +
- O +
1 O +
TP O +
and O +
DNA O +
polymerase O +
, O +
Nf O +
DNA O +
polymerase O +
, O +
although O +
provided O +
with O +
competent O +
strand O +
displacement O +
and O +
processivity O +
features O +
, O +
required O +
the O +
presence O +
of O +
Nf O +
DBP O +
for O +
an O +
effective O +
in O +
vitro O +
replication O +
of O +
Nf O +
TP O +
- O +
DNA O +
. O +

Results O +
presented O +
here O +
show O +
that O +
Nf O +
DBP O +
strongly O +
stimulates O +
the O +
formation O +
of O +
the O +
TP O +
- O +
dAMP O +
initiation O +
complex O +
by O +
decreasing O +
the O +
Km O +
for O +
dATP O +
and O +
facilitates O +
the O +
transition O +
from O +
initiation O +
to O +
elongation O +
, O +
as O +
it O +
occurs O +
in O +
phi29 O +
( O +
76 O +
) O +
. O +

These O +
results O +
point O +
to O +
either O +
a O +
specific O +
and O +
direct O +
contact O +
between O +
DBP O +
and O +
DNA O +
polymerase O +
that O +
promotes O +
conformational O +
changes O +
at O +
the O +
polymerization O +
active O +
site O +
or O +
to O +
an O +
effect O +
of O +
DBP O +
in O +
conferring O +
the O +
optimal O +
template O +
structure O +
to O +
direct O +
initiating O +
nucleotide O +
insertion O +
. O +

A O +
similar O +
role O +
has O +
been O +
proposed O +
for O +
adenovirus O +
DBP O +
, O +
a O +
DNA O +
unwinding O +
protein O +
( O +
77 O +
) O +
. O +

As O +
in O +
the O +
case O +
of O +
phi29 O +
and O +
Nf O +
DBP O +
, O +
this O +
protein O +
stimulates O +
the O +
rate O +
of O +
initiation O +
also O +
by O +
decreasing O +
the O +
Km O +
for O +
the O +
initiating O +
nucleotide O +
( O +
74 O +
) O +
. O +

The O +
fact O +
that O +
an O +
adenovirus O +
DBP O +
mutant O +
defective O +
in O +
unwinding O +
can O +
still O +
stimulate O +
initiation O +
precludes O +
the O +
unwinding O +
role O +
as O +
the O +
one O +
responsible O +
for O +
such O +
an O +
activation O +
( O +
77 O +
, O +
78 O +
) O +
. O +

In O +
this O +
case O +
, O +
contacts O +
between O +
DBP O +
and O +
pTP O +
/ O +
DNA O +
polymerase O +
complex O +
have O +
been O +
reported O +
( O +
77 O +
) O +
. O +

The O +
effect O +
of O +
Nf O +
DBP O +
in O +
promoting O +
elongation O +
of O +
the O +
initiation O +
products O +
could O +
be O +
due O +
to O +
a O +
decrease O +
of O +
the O +
Km O +
also O +
for O +
the O +
incorporation O +
of O +
the O +
dNMPs O +
during O +
the O +
transition O +
stage O +
from O +
initiation O +
to O +
elongation O +
, O +
to O +
a O +
different O +
type O +
of O +
contact O +
with O +
the O +
DNA O +
polymerase O +
that O +
helps O +
transition O +
to O +
elongation O +
, O +
or O +
both O +
. O +

The O +
similarity O +
in O +
replication O +
rates O +
when O +
comparing O +
M13 O +
DNA O +
replication O +
, O +
performed O +
in O +
the O +
absence O +
of O +
DBP O +
( O +
2400 O +
nt O +
/ O +
min O +
) O +
, O +
with O +
Nf O +
TP O +
- O +
DNA O +
replication O +
in O +
the O +
presence O +
of O +
DBP O +
( O +
2260 O +
nt O +
/ O +
min O +
) O +
, O +
suggests O +
that O +
the O +
DBP O +
stimulatory O +
role O +
is O +
restricted O +
to O +
the O +
first O +
phases O +
of O +
Nf O +
TP O +
- O +
DNA O +
replication O +
. O +

Figures O +
and O +
Tables O +

Figure O +
1 O +

Modular O +
crosstalking O +
in O +
synthetic O +
gene O +
networks O +
. O +

A O +
promoter O +
with O +
binding O +
sites O +
for O +
lambda O +
cI O +
dimers O +
( O +
OR1 O +
and O +
OR2 O +
) O +
and O +
for O +
the O +
lac O +
repressor O +
( O +
Olac O +
) O +
controls O +
the O +
production O +
of O +
the O +
lac O +
repressor O +
( O +
encoded O +
by O +
lacI O +
) O +
in O +
module O +
1 O +
and O +
lambda O +
cI O +
( O +
encoded O +
by O +
cI O +
) O +
in O +
module O +
2 O +
. O +

The O +
lac O +
repressor O +
and O +
lambda O +
cI O +
dimers O +
are O +
represented O +
by O +
blue O +
ellipsoids O +
and O +
red O +
circles O +
, O +
respectively O +
. O +

When O +
the O +
two O +
modules O +
are O +
put O +
together O +
, O +
two O +
pairs O +
of O +
lambda O +
cI O +
dimers O +
bound O +
at O +
different O +
operators O +
can O +
loop O +
DNA O +
and O +
octamerize O +
, O +
forming O +
a O +
tetramer O +
of O +
dimers O +
. O +

2 O +
- O +
Theory O +

Scanning O +
holography O +
is O +
a O +
two O +
- O +
pupil O +
interaction O +
method O +
[ O +
8 O +
] O +
by O +
which O +
incoherent O +
imaging O +
with O +
complex O +
point O +
- O +
spread O +
- O +
functions O +
( O +
PSF O +
) O +
is O +
possible O +
. O +

The O +
method O +
has O +
recently O +
been O +
applied O +
to O +
the O +
recording O +
of O +
high O +
resolution O +
holographic O +
images O +
of O +
incoherent O +
objects O +
and O +
fluorescent O +
biological O +
specimens O +
[ O +
6 O +
, O +
7 O +
] O +
. O +

A O +
single O +
- O +
sideband O +
in O +
- O +
line O +
Fresnel O +
hologram O +
is O +
obtained O +
by O +
a O +
2D O +
raster O +
scan O +
of O +
the O +
object O +
with O +
the O +
superposed O +
3D O +
diffraction O +
distributions O +
of O +
two O +
pupils O +
, O +
as O +
sketched O +
in O +
fig O +
. O +

1 O +
. O +

The O +
two O +
pupil O +
distributions O +
P O +
~ O +
1 O +
( O +
rho O +
- O +
- O +
> O +
) O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa O +
@ O +
3295 O +
@ O +
and O +
P O +
~ O +
2 O +
( O +
rho O +
- O +
- O +
> O +
) O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa O +
@ O +
3297 O +
@ O +
from O +
the O +
same O +
source O +
( O +
for O +
example O +
, O +
but O +
not O +
necessarily O +
, O +
a O +
laser O +
) O +
are O +
combined O +
by O +
a O +
beam O +
splitter O +
in O +
the O +
pupil O +
plane O +
of O +
the O +
objective O +
where O +
they O +
interfere O +
, O +
forming O +
a O +
Fresnel O +
pattern O +
with O +
a O +
depth O +
- O +
dependent O +
Fresnel O +
number O +
. O +

To O +
obtain O +
the O +
conventional O +
point O +
- O +
spread O +
function O +
of O +
wide O +
field O +
imaging O +
, O +
P1 O +
is O +
chosen O +
as O +
a O +
point O +
source O +
, O +
and O +
P2 O +
as O +
a O +
spherical O +
wave O +
with O +
appropriate O +
curvature O +
. O +

The O +
3D O +
specimen O +
is O +
placed O +
in O +
the O +
focal O +
region O +
of O +
the O +
objective O +
, O +
and O +
scattered O +
lights O +
( O +
transmitted O +
, O +
reflected O +
, O +
and O +
fluorescent O +
) O +
are O +
collected O +
by O +
non O +
- O +
imaging O +
detectors O +
. O +

The O +
hologram O +
data O +
can O +
be O +
obtained O +
by O +
heterodyne O +
detection O +
with O +
one O +
of O +
the O +
pupils O +
shifted O +
in O +
frequency O +
( O +
as O +
done O +
in O +
this O +
work O +
) O +
, O +
or O +
by O +
a O +
homodyne O +
method O +
requiring O +
the O +
capture O +
of O +
at O +
least O +
three O +
frames O +
with O +
different O +
relative O +
phases O +
between O +
the O +
two O +
pupils O +
[ O +
9 O +
] O +
. O +

The O +
amplitude O +
distribution O +
of O +
the O +
illuminating O +
beam O +
, O +
in O +
a O +
transverse O +
plane O +
at O +
an O +
axial O +
distance O +
z O +
from O +
the O +
focal O +
plane O +
of O +
the O +
objective O +
, O +
is O +
the O +
Fourier O +
transform O +
of O +
the O +
combined O +
pupil O +
distributions O +
[ O +
10 O +
] O +
. O +

Namely O +
: O +

Figure O +
1 O +

Experimental O +
set O +
up O +
of O +
a O +
scanning O +
holographic O +
microscope O +
. O +

Sketch O +
of O +
the O +
experimental O +
setup O +
. O +

M O +
' O +
s O +
are O +
mirrors O +
, O +
BS O +
' O +
s O +
are O +
beam O +
splitters O +
, O +
EO O +
is O +
an O +
electro O +
- O +
optic O +
phase O +
modulator O +
. O +

Lens O +
L1 O +
( O +
achromat O +
doublet O +
16 O +
cm O +
focal O +
length O +
) O +
produces O +
the O +
desired O +
Fresnel O +
pattern O +
in O +
the O +
focal O +
plane O +
of O +
L2 O +
( O +
achromat O +
doublet O +
16 O +
cm O +
focal O +
length O +
) O +
. O +

L2 O +
and O +
the O +
objective O +
form O +
a O +
4 O +
- O +
f O +
system O +
projecting O +
a O +
reduced O +
image O +
of O +
the O +
Fresnel O +
pattern O +
onto O +
the O +
specimen O +
. O +

L3 O +
( O +
achromat O +
doublet O +
12 O +
cm O +
focal O +
length O +
) O +
projects O +
the O +
images O +
of O +
the O +
pupils O +
on O +
the O +
pinhole O +
detector O +
. O +

( O +
Not O +
shown O +
are O +
the O +
beam O +
expanders O +
used O +
to O +
illuminate O +
the O +
pupils O +
) O +
. O +

S O +
( O +
r O +
- O +
- O +
> O +
, O +
z O +
) O +
= O +
F O +
- O +
1 O +
{ O +
[ O +
P O +
~ O +
1 O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
+ O +
P O +
~ O +
2 O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
exp O +
( O +
- O +
iOmegat O +
] O +
} O +
, O +
( O +
1a O +
) O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
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 O +
@ O +
5D95 O +
@ O +

where O +

P O +
~ O +
1 O +
, O +
2 O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
= O +
P O +
~ O +
1 O +
, O +
2 O +
( O +
rho O +
- O +
- O +
> O +
) O +
exp O +
( O +
ipilambdazrho2 O +
) O +
( O +
1b O +
) O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGH9aqpcuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCcqGGOaakcqWGPbqAcqWFapaCcqWF7oaBcqWG6bGEcqWFbpGCdaahaaWcbeqaaiabikdaYaaakiabcMcaPiaaxMaacaWLjaWaaeWaaeaacqaIXaqmcqqGIbGyaiaawIcacaGLPaaaaaa O +
@ O +
53A8 O +
@ O +

are O +
the O +
generalized O +
defocused O +
pupils O +
[ O +
11 O +
] O +
. O +

F O +
- O +
1 O +
stands O +
for O +
inverse O +
Fourier O +
transform O +
, O +
and O +
Omega O +
is O +
the O +
frequency O +
shift O +
of O +
one O +
of O +
the O +
pupils O +
. O +

The O +
transverse O +
spatial O +
frequency O +
vector O +
rho O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFbpGCgaWcaaaa O +
@ O +
2E85 O +
@ O +
= O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
P O +
/ O +
lambdaf0 O +
is O +
proportional O +
to O +
the O +
real O +
space O +
coordinate O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
P O +
in O +
the O +
pupil O +
plane O +
[ O +
10 O +
] O +
. O +
lambda O +
is O +
the O +
wavelength O +
of O +
the O +
illumination O +
, O +
and O +
f0 O +
is O +
the O +
focal O +
length O +
of O +
the O +
objective O +
. O +

The O +
two O +
pupils O +
used O +
to O +
obtain O +
an O +
in O +
- O +
line O +
Fresnel O +
hologram O +
are O +
, O +
respectively O +
, O +
a O +
spherical O +
wave O +
filling O +
the O +
pupil O +
of O +
the O +
objective O +
, O +
and O +
a O +
point O +
at O +
the O +
center O +
of O +
that O +
pupil O +
: O +

P O +
~ O +
1 O +
( O +
rho O +
- O +
- O +
> O +
) O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa O +
@ O +
3295 O +
@ O +
= O +
exp O +
( O +
ipilambdaz0rho2 O +
) O +
circ O +
( O +
rho O +
/ O +
rhoMAX O +
) O +

P O +
~ O +
2 O +
( O +
rho O +
- O +
- O +
> O +
) O +
= O +
delta O +
( O +
rho O +
- O +
- O +
> O +
) O +
. O +

( O +
2 O +
) O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpcqWF0oazcqGGOaakcuWFbpGCgaWcaiabcMcaPiabc6caUiaaxMaacaWLjaWaaeWaaeaacqaIYaGmaiaawIcacaGLPaaaaaa O +
@ O +
3D5F O +
@ O +

circ O +
( O +
x O +
) O +
is O +
a O +
disc O +
function O +
of O +
unit O +
radius O +
. O +

rhoMAX O +
= O +
sinalpha O +
/ O +
lambda O +
is O +
the O +
cutoff O +
frequency O +
of O +
the O +
objective O +
, O +
where O +
sinalpha O +
= O +
NA O +
is O +
its O +
numerical O +
aperture O +
. O +

The O +
Fresnel O +
pattern O +
projected O +
on O +
the O +
object O +
is O +
the O +
interference O +
of O +
the O +
Fourier O +
transforms O +
of O +
the O +
two O +
pupils O +
, O +
namely O +
a O +
spherical O +
wave O +
and O +
a O +
plane O +
wave O +
in O +
the O +
paraxial O +
approximation O +
. O +

The O +
Fresnel O +
number O +
of O +
this O +
pattern O +
is O +
determined O +
by O +
the O +
free O +
parameter O +
z0 O +
, O +
which O +
is O +
the O +
distance O +
from O +
the O +
objective O +
' O +
s O +
focal O +
plane O +
to O +
the O +
point O +
where O +
the O +
spherical O +
wave O +
comes O +
to O +
a O +
focus O +
. O +

There O +
are O +
two O +
possible O +
modes O +
of O +
operation O +
, O +
depending O +
on O +
the O +
detector O +
geometry O +
[ O +
5 O +
] O +
. O +

With O +
a O +
spatially O +
integrating O +
detector O +
, O +
the O +
resulting O +
data O +
is O +
a O +
convolution O +
of O +
the O +
object O +
' O +
s O +
intensity O +
distribution O +
with O +
the O +
desired O +
complex O +
PSF O +
( O +
namely O +
, O +
a O +
spherical O +
wave O +
with O +
a O +
radius O +
of O +
curvature O +
z0 O +
+ O +
z O +
, O +
and O +
a O +
radius O +
a O +
= O +
z0sinalpha O +
, O +
in O +
this O +
case O +
) O +
. O +

This O +
detection O +
mode O +
leads O +
to O +
a O +
hologram O +
from O +
which O +
the O +
three O +
- O +
dimensional O +
distribution O +
of O +
scattering O +
intensity O +
, O +
absorption O +
, O +
and O +
fluorescence O +
intensity O +
can O +
be O +
reconstructed O +
. O +

With O +
a O +
point O +
detector O +
at O +
the O +
center O +
of O +
a O +
conjugate O +
pupil O +
plane O +
, O +
the O +
resulting O +
data O +
is O +
a O +
convolution O +
of O +
the O +
object O +
' O +
s O +
complex O +
amplitude O +
distribution O +
with O +
the O +
same O +
complex O +
PSF O +
. O +

The O +
reconstruction O +
of O +
this O +
hologram O +
gives O +
the O +
three O +
- O +
dimensional O +
distribution O +
of O +
the O +
specimen O +
' O +
s O +
complex O +
amplitude O +
transmittance O +
. O +

In O +
particular O +
, O +
assuming O +
that O +
multiple O +
scattering O +
can O +
be O +
ignored O +
, O +
the O +
phase O +
of O +
the O +
reconstruction O +
is O +
a O +
quantitative O +
measure O +
of O +
the O +
integrated O +
optical O +
path O +
length O +
through O +
the O +
specimen O +
. O +

These O +
two O +
modes O +
of O +
operation O +
are O +
similar O +
to O +
the O +
usual O +
coherent O +
/ O +
incoherent O +
imaging O +
modes O +
of O +
a O +
conventional O +
system O +
, O +
which O +
are O +
obtained O +
by O +
using O +
, O +
respectively O +
, O +
a O +
point O +
source O +
, O +
or O +
a O +
large O +
spatially O +
incoherent O +
source O +
. O +

In O +
scanning O +
holography O +
, O +
the O +
detector O +
size O +
plays O +
a O +
similar O +
role O +
to O +
that O +
of O +
the O +
source O +
size O +
in O +
conventional O +
imaging O +
. O +

For O +
simplicity O +
, O +
let O +
' O +
s O +
assume O +
an O +
object O +
with O +
an O +
amplitude O +
transmittance O +
T O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
. O +

Note O +
that O +
for O +
an O +
incoherent O +
or O +
fluorescent O +
object O +
, O +
the O +
phase O +
of O +
the O +
transmitted O +
field O +
is O +
a O +
random O +
variable O +
, O +
and O +
only O +
the O +
intensity O +
I O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
= O +
| O +
T O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
| O +
2 O +
is O +
measurable O +
. O +

For O +
a O +
quasi O +
transparent O +
object O +
, O +
the O +
phase O +
is O +
equal O +
to O +
the O +
integrated O +
optical O +
thickness O +
of O +
the O +
object O +
: O +
Phi O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
) O +
= O +
( O +
2pi O +
/ O +
lambda O +
) O +
integraldzn O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
, O +
where O +
n O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
is O +
the O +
3D O +
distribution O +
of O +
refractive O +
index O +
. O +

The O +
amplitude O +
distribution O +
after O +
the O +
object O +
is O +
written O +
as O +

A O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
t O +
) O +
= O +
integraldzS O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
T O +
[ O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
- O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
S O +
( O +
t O +
) O +
, O +
z O +
] O +
, O +
( O +
3 O +
) O +

where O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
S O +
( O +
t O +
) O +
is O +
the O +
instantaneous O +
position O +
of O +
the O +
2D O +
raster O +
scan O +
. O +

The O +
incoherent O +
imaging O +
mode O +
is O +
obtained O +
with O +
a O +
spatially O +
integrating O +
detector O +
, O +
leading O +
to O +
a O +
temporal O +
signal O +
proportional O +
to O +
the O +
integrated O +
intensity O +
, O +
integrald2r O +
| O +
A O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
t O +
) O +
| O +
2 O +
, O +
which O +
is O +
stored O +
in O +
the O +
computer O +
. O +

The O +
data O +
corresponding O +
to O +
each O +
hologram O +
line O +
is O +
cut O +
from O +
the O +
signal O +
, O +
and O +
band O +
pass O +
filtered O +
to O +
extract O +
the O +
term O +
oscillating O +
at O +
Omega O +
. O +

The O +
lines O +
are O +
then O +
rearranged O +
in O +
a O +
2D O +
format O +
. O +

The O +
resulting O +
hologram O +
amplitude O +
is O +
found O +
to O +
be O +

HI O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
) O +
= O +
integraldzI O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
( O +
+ O +
) O +
[ O +
p1 O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
p O +
* O +
2 O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
] O +
, O +
( O +
4 O +
) O +

where O +
( O +
+ O +
) O +
symbolizes O +
a O +
convolution O +
integral O +
, O +
I O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
= O +
| O +
T O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
| O +
2 O +
, O +
and O +
p1 O +
, O +
2 O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
are O +
the O +
inverse O +
Fourier O +
transforms O +
of O +
the O +
defocused O +
pupil O +
distributions O +
( O +
eq O +
. O +
1b O +
) O +
. O +

The O +
superscript O +
* O +
stands O +
for O +
complex O +
conjugate O +
. O +

The O +
hologram O +
is O +
thus O +
the O +
convolution O +
of O +
the O +
object O +
intensity O +
with O +
a O +
spherical O +
wave O +
, O +
i O +
. O +
e O +
. O +
an O +
in O +
- O +
line O +
single O +
- O +
sideband O +
Gabor O +
hologram O +
. O +

In O +
Fourier O +
space O +
, O +
the O +
hologram O +
can O +
be O +
written O +
as O +

H O +
~ O +
I O +
( O +
rho O +
- O +
- O +
> O +
) O +
= O +
integraldzI O +
~ O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
[ O +
P O +
~ O +
1 O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
( O +
* O +
) O +
P O +
~ O +
2 O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
] O +
, O +
( O +
5 O +
) O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkdaWadaqaaiqbdcfaqzaaiaWaaSbaaSqaaiabigdaXaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPiabgEPielqbdcfaqzaaiaWaaSbaaSqaaiabikdaYaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPaGaay5waiaaw2faaiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI1aqnaiaawIcacaGLPaaaaaa O +
@ O +
58FF O +
@ O +

where O +
( O +
+ O +
) O +
symbolizes O +
a O +
correlation O +
integral O +
. O +

With O +
the O +
pupils O +
of O +
eq O +
. O +
2 O +
, O +
we O +
find O +
, O +
in O +
the O +
paraxial O +
approximation O +
, O +

H O +
~ O +
I O +
( O +
rho O +
- O +
- O +
> O +
) O +
= O +
integraldzI O +
~ O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
exp O +
[ O +
ipilambda O +
( O +
z0 O +
+ O +
z O +
) O +
rho2 O +
] O +
circ O +
( O +
rho O +
/ O +
rhoMAX O +
) O +
, O +
( O +
6 O +
) O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCdaWadaqaaiabdMgaPjab O +
= O +
b8aWjab O +
= O +
T7aSjabcIcaOiabdQha6naaBaaaleaacqaIWaamaeqaaOGaey4kaSIaemOEaONaeiykaKIae8xWdi3aaWbaaSqabeaacqaIYaGmaaaakiaawUfacaGLDbaacqWGJbWycqWGPbqAcqWGYbGCcqWGJbWycqGGOaakcqWFbpGCcqGGVaWlcqWFbpGCdaWgaaWcbaGaemyta0KaemyqaeKaemiwaGfabeaakiabcMcaPiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI2aGnaiaawIcacaGLPaaaaaa O +
@ O +
67E3 O +
@ O +

which O +
is O +
the O +
Fourier O +
transform O +
of O +
the O +
Fresnel O +
hologram O +
of O +
the O +
object O +
' O +
s O +
intensity O +
distribution O +
. O +

The O +
coherent O +
imaging O +
mode O +
is O +
obtained O +
by O +
using O +
a O +
pinhole O +
or O +
a O +
point O +
detector O +
at O +
the O +
center O +
of O +
a O +
conjugate O +
plane O +
of O +
the O +
pupil O +
of O +
the O +
objective O +
. O +

This O +
leads O +
to O +
the O +
hologram O +
amplitude O +

HC O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
) O +
= O +
integraldz O +
[ O +
T O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
( O +
+ O +
) O +
p1 O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
] O +
[ O +
T O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
( O +
+ O +
) O +
p2 O +
( O +
r O +
- O +
- O +
> O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa O +
@ O +
2E2B O +
@ O +
, O +
z O +
) O +
] O +
* O +
. O +

( O +
7 O +
) O +

Where O +
again O +
, O +
( O +
+ O +
) O +
symbolizes O +
a O +
convolution O +
product O +
, O +
and O +
the O +
superscript O +
* O +
stands O +
for O +
complex O +
conjugate O +
. O +

In O +
Fourier O +
space O +
, O +

H O +
~ O +
C O +
( O +
rho O +
- O +
- O +
> O +
) O +
= O +
integraldzT O +
~ O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
P O +
~ O +
1 O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
( O +
* O +
) O +
T O +
~ O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
P O +
~ O +
2 O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
. O +

( O +
8 O +
) O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGdbWqaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdsfauzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGHxkcXcuWGubavgaacaiabcIcaOiqb O +
= O +
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIafmiuaaLbaGaadaWgaaWcbaGaeGOmaidabeaakiabcIcaOiqb O +
= O +
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiIda4aGaayjkaiaawMcaaaaa O +
@ O +
5E5B O +
@ O +

With O +
the O +
pupils O +
of O +
eq O +
. O +
2 O +
, O +
we O +
find O +

H O +
~ O +
C O +
( O +
rho O +
- O +
- O +
> O +
) O +
= O +
integraldzT O +
~ O +
* O +
( O +
0 O +
; O +
z O +
) O +
T O +
~ O +
( O +
rho O +
- O +
- O +
> O +
; O +
z O +
) O +
exp O +
[ O +
ipilambda O +
( O +
z0 O +
+ O +
z O +
) O +
rho2 O +
] O +
circ O +
( O +
rho O +
/ O +
rhoMAX O +
) O +
. O +

( O +
9 O +
) O +
MathType O +
@ O +
MTEF O +
@ O +
5 O +
@ O +
5 O +
@ O +
+ O +
= O +
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O +
= O +
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O +
= O +
OqFfea0dXdd9vqai O +
= O +
hGuQ8kuc9pgc9s8qqaq O +
= O +
dirpe0xb9q8qiLsFr0 O +
= O +
vr0 O +
= O +
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 O +
= O +
f8aYjabc O +
+ O +
caViab O +
= O +
f8aYnaaBaaaleaacqWGnbqtcqWGbbqqcqWGybawaeqaaOGaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiMda5aGaayjkaiaawMcaaaaa O +
@ O +
6F41 O +
@ O +

Aside O +
from O +
an O +
inconsequential O +
complex O +
constant O +
( O +
the O +
first O +
term O +
under O +
the O +
integral O +
) O +
, O +
eq O +
. O +
9 O +
is O +
the O +
Fourier O +
transform O +
of O +
the O +
Fresnel O +
hologram O +
of O +
the O +
object O +
' O +
s O +
complex O +
amplitude O +
distribution O +
. O +

Thus O +
, O +
the O +
reconstruction O +
of O +
the O +
hologram O +
recorded O +
in O +
the O +
coherent O +
mode O +
carries O +
a O +
quantitative O +
measure O +
of O +
the O +
object O +
' O +
s O +
phase O +
distribution O +
. O +

Comparison O +
of O +
the O +
Predicted O +
Irr O +
Regulon O +
and O +
ICE O +
Motifs O +
with O +
the O +
Published O +
Expression O +
Microarray O +
Data O +
for O +
Iron O +
- O +
and O +
Irr O +
- O +
Affected O +
Genes O +
in O +
Bradyrhizobium O +
japonicum O +

Background O +

HIV O +
- O +
1 O +
infectivity O +
depends O +
on O +
free O +
cholesterol O +
incorporated O +
into O +
the O +
viral O +
envelope O +
. O +

Here O +
, O +
we O +
analyze O +
HIV O +
infectivity O +
in O +
the O +
presence O +
of O +
drugs O +
that O +
stimulate O +
cholesterol O +
efflux O +
. O +

Mass O +
casualty O +
estimation O +
on O +
a O +
geographic O +
basis O +

The O +
Defense O +
Threat O +
Reduction O +
Agency O +
( O +
DTRA O +
) O +
has O +
expended O +
considerable O +
effort O +
to O +
develop O +
models O +
for O +
calculating O +
mass O +
casualties O +
from O +
a O +
nuclear O +
detonation O +
. O +

In O +
order O +
to O +
specifically O +
evaluate O +
urban O +
medical O +
systems O +
vulnerability O +
we O +
are O +
employing O +
the O +
PC O +
based O +
Consequence O +
Assessment O +
Tool O +
Set O +
( O +
CATS O +
) O +
v6 O +
, O +
with O +
ESRI O +
' O +
s O +
ArcGIS9 O +
[ O +
14 O +
] O +
, O +
CATS O +
/ O +
JACE O +
( O +
Joint O +
Assessment O +
of O +
Catastrophic O +
Events O +
) O +
v5 O +
with O +
ESRI O +
' O +
s O +
ArcView O +
3 O +
. O +
3 O +
, O +
Hazard O +
Prediction O +
and O +
Assessment O +
Capability O +
( O +
HPAC O +
) O +
V4 O +
. O +
04SP3 O +
[ O +
15 O +
] O +
, O +
as O +
well O +
as O +
custom O +
GIS O +
and O +
database O +
software O +
applications O +
. O +

HPAC O +
does O +
excellent O +
Chemical O +
Biological O +
and O +
Nuclear O +
( O +
CBN O +
) O +
modeling O +
, O +
although O +
output O +
could O +
provide O +
more O +
flexibility O +
. O +

Additionally O +
, O +
results O +
can O +
be O +
exported O +
to O +
CATS O +
for O +
further O +
analysis O +
and O +
display O +
. O +

All O +
three O +
programs O +
can O +
access O +
the O +
current O +
weather O +
data O +
from O +
both O +
classified O +
and O +
unclassified O +
weather O +
servers O +
. O +

Examples O +
of O +
uses O +
of O +
CATS O +
/ O +
HPAC O +
are O +
hurricane O +
, O +
tidal O +
surge O +
and O +
earthquake O +
damage O +
, O +
prediction O +
of O +
the O +
results O +
from O +
nuclear O +
, O +
biological O +
and O +
chemical O +
releases O +
, O +
assessment O +
of O +
persons O +
and O +
infrastructure O +
affected O +
and O +
at O +
risk O +
( O +
e O +
. O +
g O +
. O +
which O +
hospitals O +
and O +
pharmacies O +
are O +
under O +
a O +
CBN O +
plume O +
and O +
are O +
thus O +
out O +
of O +
commission O +
) O +
, O +
and O +
mobilization O +
of O +
surviving O +
and O +
nearby O +
infrastructure O +
outside O +
the O +
plume O +
that O +
would O +
be O +
needed O +
to O +
address O +
healthcare O +
and O +
other O +
emergency O +
response O +
needs O +
of O +
the O +
community O +
. O +

These O +
models O +
have O +
been O +
, O +
and O +
continue O +
to O +
be O +
, O +
developed O +
with O +
a O +
view O +
to O +
better O +
estimating O +
the O +
impact O +
of O +
WMD O +
weapons O +
in O +
an O +
offensive O +
setting O +
. O +

However O +
, O +
recent O +
DTRA O +
enhancements O +
and O +
our O +
modifications O +
have O +
facilitated O +
their O +
use O +
in O +
helping O +
estimate O +
potential O +
casualties O +
from O +
a O +
WMD O +
terrorist O +
incident O +
. O +

One O +
area O +
of O +
intense O +
interest O +
, O +
and O +
somewhat O +
of O +
a O +
vacuum O +
in O +
public O +
health O +
planning O +
, O +
has O +
been O +
the O +
utility O +
of O +
this O +
approach O +
in O +
estimating O +
medical O +
care O +
vulnerabilities O +
in O +
such O +
an O +
attack O +
, O +
and O +
for O +
the O +
calculation O +
of O +
the O +
distribution O +
of O +
surviving O +
medical O +
care O +
resources O +
. O +

While O +
much O +
work O +
has O +
already O +
occurred O +
in O +
estimating O +
the O +
impact O +
of O +
chemical O +
weapons O +
( O +
due O +
to O +
the O +
dual O +
use O +
in O +
chemical O +
spill O +
management O +
from O +
transportation O +
and O +
industrial O +
accidents O +
) O +
, O +
or O +
in O +
nuclear O +
power O +
plant O +
accident O +
management O +
, O +
much O +
less O +
research O +
and O +
development O +
has O +
gone O +
into O +
estimating O +
the O +
impact O +
on O +
our O +
civilian O +
population O +
of O +
a O +
nuclear O +
weapon O +
detonation O +
from O +
a O +
terrorist O +
incident O +
in O +
a O +
large O +
urban O +
area O +
. O +

The O +
models O +
already O +
calculate O +
such O +
factors O +
as O +
the O +
impact O +
of O +
blast O +
, O +
thermal O +
effects O +
and O +
fallout O +
, O +
but O +
results O +
are O +
often O +
not O +
available O +
at O +
the O +
detail O +
level O +
needed O +
for O +
civil O +
defense O +
purposes O +
, O +
casualty O +
management O +
, O +
and O +
planning O +
the O +
use O +
of O +
scarce O +
health O +
resources O +
in O +
response O +
to O +
a O +
nuclear O +
weapon O +
detonation O +
. O +

Furthermore O +
, O +
the O +
models O +
do O +
not O +
readily O +
facilitate O +
the O +
calculation O +
of O +
injuries O +
from O +
multiple O +
effects O +
such O +
as O +
burns O +
and O +
blast O +
with O +
fallout O +
or O +
prompt O +
radiation O +
. O +

The O +
complexity O +
of O +
the O +
urban O +
three O +
- O +
dimensional O +
landscape O +
and O +
its O +
local O +
impact O +
on O +
thermal O +
, O +
blast O +
and O +
radiation O +
is O +
also O +
poorly O +
understood O +
. O +

Additionally O +
, O +
given O +
their O +
traditional O +
world O +
- O +
wide O +
focus O +
, O +
and O +
the O +
increased O +
sensitivity O +
to O +
providing O +
information O +
on O +
the O +
U O +
. O +
S O +
. O +
A O +
. O +
of O +
use O +
to O +
terrorists O +
, O +
the O +
models O +
do O +
not O +
provide O +
detailed O +
or O +
current O +
data O +
that O +
exists O +
for O +
the O +
United O +
States O +
that O +
would O +
help O +
provide O +
better O +
casualty O +
estimates O +
and O +
response O +
. O +

The O +
models O +
can O +
be O +
customized O +
locally O +
and O +
data O +
updated O +
if O +
the O +
user O +
has O +
sufficient O +
expertise O +
. O +

However O +
, O +
there O +
is O +
often O +
a O +
significant O +
duplication O +
of O +
effort O +
due O +
to O +
overlapping O +
jurisdictions O +
and O +
the O +
lack O +
of O +
data O +
sharing O +
due O +
to O +
security O +
and O +
other O +
considerations O +
. O +

CATS O +
and O +
HPAC O +
are O +
also O +
useful O +
for O +
creating O +
realistic O +
scenarios O +
for O +
training O +
and O +
planning O +
before O +
a O +
disaster O +
strikes O +
, O +
thus O +
enabling O +
responders O +
to O +
drill O +
and O +
exercise O +
so O +
they O +
know O +
roughly O +
what O +
to O +
expect O +
and O +
how O +
to O +
react O +
. O +

Contingency O +
plans O +
can O +
be O +
created O +
using O +
comprehensive O +
national O +
and O +
more O +
detailed O +
population O +
and O +
infrastructure O +
data O +
. O +

Should O +
disaster O +
strike O +
, O +
the O +
affected O +
population O +
and O +
the O +
impact O +
on O +
critical O +
facilities O +
can O +
be O +
quickly O +
assessed O +
, O +
although O +
efforts O +
frequently O +
need O +
to O +
be O +
expended O +
to O +
ensure O +
regional O +
and O +
local O +
databases O +
are O +
current O +
and O +
useful O +
. O +

Case O +
Presentation O +

The O +
patient O +
is O +
an O +
80 O +
year O +
old O +
male O +
with O +
diabetes O +
mellitus O +
and O +
hypertension O +
, O +
who O +
at O +
age O +
74 O +
( O +
March O +
2001 O +
) O +
had O +
received O +
a O +
living O +
non O +
- O +
related O +
donor O +
kidney O +
transplant O +
. O +

At O +
that O +
time O +
he O +
was O +
discharged O +
with O +
a O +
double O +
immunosuppressive O +
therapy O +
consisting O +
of O +
prednisone O +
20 O +
mg O +
/ O +
day O +
and O +
mophetil O +
mycophenolate O +
1 O +
. O +
5 O +
gr O +
/ O +
day O +
. O +

No O +
calcineurin O +
inhibitor O +
was O +
administered O +
. O +

His O +
prednisone O +
dose O +
was O +
further O +
decreased O +
to O +
5 O +
mg O +
/ O +
day O +
and O +
mophetil O +
mycophenolate O +
doses O +
sustained O +
. O +

In O +
November O +
2001 O +
he O +
developed O +
cutaneous O +
purple O +
elevated O +
lesions O +
in O +
his O +
lower O +
limbs O +
that O +
were O +
diagnosed O +
as O +
KS O +
by O +
skin O +
biopsy O +
. O +

He O +
received O +
19 O +
administrations O +
of O +
vincristine O +
( O +
1 O +
mg O +
) O +
and O +
bleomycin O +
( O +
15 O +
mg O +
) O +
weekly O +
that O +
resulted O +
in O +
flattening O +
and O +
fading O +
of O +
the O +
lesions O +
. O +

Treatment O +
was O +
discontinued O +
for O +
two O +
months O +
, O +
and O +
KS O +
recurred O +
, O +
with O +
pain O +
and O +
edema O +
in O +
both O +
legs O +
. O +

On O +
July O +
2002 O +
, O +
with O +
an O +
almost O +
100 O +
% O +
involvement O +
of O +
his O +
lower O +
limbs O +
skin O +
with O +
KS O +
but O +
no O +
visceral O +
involvement O +
he O +
received O +
50 O +
mg O +
of O +
liposomal O +
- O +
adriamycin O +
. O +

In O +
addition O +
, O +
he O +
was O +
then O +
prescribed O +
valganciclovir O +
450 O +
mg O +
BID O +
( O +
corrected O +
for O +
creatinine O +
clearance O +
) O +
[ O +
7 O +
] O +
and O +
three O +
additional O +
administrations O +
of O +
liposomal O +
- O +
adriamycin O +
, O +
up O +
to O +
December O +
2002 O +
. O +

He O +
showed O +
40 O +
% O +
response O +
again O +
with O +
early O +
relapse O +
. O +

On O +
January O +
2003 O +
the O +
patient O +
developed O +
disseminated O +
herpes O +
zoster O +
, O +
which O +
was O +
treated O +
with O +
IV O +
acyclovir O +
. O +

In O +
May O +
2003 O +
KS O +
progression O +
was O +
observed O +
and O +
received O +
radiotherapy O +
with O +
no O +
benefit O +
Figure O +
1 O +
. O +

In O +
August O +
2003 O +
he O +
started O +
oral O +
etoposide O +
at O +
50 O +
mg O +
QD O +
for O +
two O +
weeks O +
followed O +
by O +
two O +
weeks O +
off O +
until O +
May O +
2004 O +
achieving O +
a O +
very O +
slow O +
50 O +
% O +
response O +
. O +

Tolerance O +
was O +
good O +
and O +
serum O +
creatinine O +
remain O +
stable O +
at O +
around O +
1 O +
, O +
4 O +
mg O +
/ O +
dl O +
. O +

Mophetil O +
mycophenolate O +
dose O +
was O +
reduced O +
to O +
1 O +
g O +
/ O +
day O +
and O +
prednisone O +
to O +
2 O +
. O +
5 O +
mg O +
/ O +
day O +
. O +

Figure O +
1 O +

Kaposi O +
' O +
s O +
sarcoma O +
progressions O +
after O +
chemotherapy O +
withdrawal O +
, O +
both O +
lower O +
limbs O +
were O +
completely O +
covered O +
with O +
Kaposi O +
' O +
s O +
Sarcoma O +
( O +
June O +
2003 O +
) O +
. O +

On O +
May O +
2004 O +
the O +
patient O +
requested O +
a O +
second O +
opinion O +
and O +
was O +
prescribed O +
Imatinib O +
200 O +
mg O +
qd O +
for O +
two O +
weeks O +
followed O +
by O +
400 O +
mg O +
qd O +
. O +

After O +
four O +
weeks O +
of O +
Imatinib O +
, O +
his O +
health O +
deteriorated O +
rapidly O +
, O +
he O +
developed O +
anasarca O +
, O +
worsening O +
of O +
KS O +
, O +
his O +
serum O +
creatinine O +
increased O +
from O +
1 O +
. O +
4 O +
mg O +
/ O +
dl O +
to O +
2 O +
. O +
3 O +
mg O +
/ O +
dl O +
and O +
he O +
developed O +
grade O +
4 O +
granulocytopenia O +
( O +
Figure O +
2 O +
) O +
. O +

The O +
patient O +
was O +
hospitalized O +
with O +
fever O +
and O +
was O +
started O +
on O +
IV O +
antibiotics O +
and O +
daily O +
G O +
- O +
CSF O +
for O +
four O +
days O +
after O +
which O +
his O +
WBC O +
count O +
normalized O +
. O +

Two O +
weeks O +
later O +
the O +
creatinine O +
level O +
returned O +
to O +
1 O +
. O +
5 O +
mg O +
/ O +
dl O +
. O +

On O +
February O +
2005 O +
he O +
was O +
started O +
on O +
30 O +
mg O +
of O +
paclitaxel O +
IV O +
every O +
three O +
weeks O +
. O +

After O +
three O +
courses O +
with O +
no O +
clinical O +
benefit O +
he O +
developed O +
a O +
skin O +
rash O +
that O +
prompted O +
discontinuation O +
. O +

Figure O +
2 O +

Patient O +
developed O +
anasarca O +
with O +
rapid O +
progression O +
of O +
Kaposi O +
' O +
s O +
Sarcoma O +
after O +
four O +
weeks O +
of O +
taking O +
Imatinib O +
( O +
June O +
2004 O +
) O +
. O +

On O +
April O +
2005 O +
, O +
he O +
was O +
started O +
on O +
Sirolimus O +
2 O +
mg O +
a O +
day O +
, O +
and O +
after O +
8 O +
weeks O +
escalated O +
to O +
4 O +
mg O +
a O +
day O +
. O +

Three O +
weeks O +
later O +
mophetil O +
mycophenolate O +
and O +
prednisone O +
were O +
discontinued O +
. O +

Sustained O +
and O +
significant O +
KS O +
regression O +
was O +
evident O +
after O +
16 O +
weeks O +
, O +
but O +
he O +
developed O +
a O +
basal O +
cell O +
carcinoma O +
and O +
pneumonia O +
that O +
required O +
hospital O +
admission O +
; O +
Sirolimus O +
dose O +
was O +
lowered O +
to O +
2 O +
mg O +
a O +
day O +
. O +

Thereafter O +
his O +
clinical O +
course O +
has O +
been O +
satisfactory O +
with O +
continuous O +
and O +
progressive O +
regression O +
of O +
KS O +
lesions O +
( O +
Figure O +
3 O +
) O +
. O +

His O +
serum O +
creatinine O +
has O +
remained O +
under O +
1 O +
. O +
6 O +
mg O +
/ O +
dl O +
and O +
he O +
has O +
not O +
developed O +
new O +
infectious O +
episodes O +
. O +

Figure O +
3 O +

Extensive O +
regression O +
of O +
Kaposi O +
Sarcoma O +
after O +
immune O +
- O +
suppression O +
was O +
changed O +
to O +
Sirolimus O +
, O +
( O +
14 O +
months O +
later O +
) O +
, O +
he O +
only O +
has O +
hyperpigmented O +
areas O +
at O +
knee O +
levels O +
, O +
skin O +
looks O +
thin O +
and O +
delicate O +
and O +
easily O +
bruised O +
( O +
July O +
2006 O +
) O +
. O +

Step O +
- O +
wise O +
logistic O +
regression O +
( O +
STEPLOG O +
) O +

The O +
group O +
variable O +
was O +
considered O +
as O +
an O +
ordinal O +
( O +
or O +
binary O +
) O +
dependent O +
variable O +
and O +
the O +
feature O +
vector O +
( O +
multiple O +
marker O +
IBD O +
estimates O +
and O +
covariates O +
) O +
as O +
the O +
independent O +
variables O +
. O +

A O +
nonlinear O +
relationship O +
( O +
logit O +
) O +
between O +
the O +
dependent O +
and O +
independent O +
variables O +
was O +
taken O +
. O +

For O +
binary O +
data O +
( O +
collapsing O +
concordantly O +
affected O +
or O +
unaffected O +
sib O +
pair O +
into O +
one O +
group O +
) O +
, O +
a O +
conventional O +
logistic O +
regression O +
was O +
used O +
. O +

For O +
ordinal O +
data O +
, O +
the O +
SAS O +
LOGISTIC O +
[ O +
8 O +
] O +
procedure O +
fits O +
a O +
parallel O +
lines O +
regression O +
model O +
based O +
on O +
the O +
cumulative O +
distribution O +
probabilities O +
of O +
response O +
categories O +
, O +
rather O +
than O +
on O +
their O +
individual O +
probabilities O +
. O +

The O +
statistical O +
P O +
- O +
value O +
for O +
each O +
( O +
selected O +
) O +
independent O +
variable O +
was O +
obtained O +
from O +
the O +
final O +
model O +
fitting O +
with O +
only O +
selected O +
variables O +
included O +
via O +
an O +
asymptotic O +
chi O +
- O +
squared O +
statistic O +
. O +

Additional O +
File O +
1 O +

Appendix O +
1 O +
. O +

Indications O +
for O +
liver O +
function O +
tests O +
with O +
no O +
obvious O +
liver O +
disease O +
, O +
and O +
consequent O +
investigations O +

Hypothetical O +
distribution O +
patterns O +
of O +
the O +
meadow O +
brown O +
Maniola O +
jurtina O +
in O +
Europe O +
during O +
the O +
last O +
glacial O +
maximum O +
( O +
dark O +
hatched O +
areas O +
) O +
. O +

Postglacial O +
expansions O +
are O +
indicated O +
by O +
solid O +
arrows O +
. O +

The O +
postulated O +
actual O +
hybrid O +
zone O +
is O +
shown O +
by O +
the O +
hatched O +
area O +
. O +

Question O +
marks O +
indicate O +
lack O +
of O +
information O +
concerning O +
ancient O +
distribution O +
patterns O +
in O +
the O +
South O +
and O +
present O +
distribution O +
of O +
hybrid O +
populations O +
in O +
the O +
North O +
. O +

Redrawn O +
from O +
Schmitt O +
et O +
. O +

al O +
. O +

[ O +
36 O +
] O +
; O +
based O +
on O +
Thomson O +
[ O +
37 O +
] O +
and O +
Schmitt O +
et O +
al O +
. O +

[ O +
36 O +
] O +
. O +

Representative O +
PCR O +
/ O +
LDR O +
results O +
for O +
HPTs O +
in O +
fimX O +
, O +
BP0059 O +
, O +
BP0880 O +
, O +
sphB2 O +
, O +
ptxA O +
, O +
and O +
bhuR O +
. O +

Raw O +
capillary O +
electrophoresis O +
data O +
for O +
ligation O +
products O +
( O +
green O +
) O +
and O +
molecular O +
weight O +
standards O +
( O +
red O +
) O +
displayed O +
as O +
if O +
an O +
electrophoretic O +
gel O +
image O +
. O +

Assayed O +
locus O +
is O +
indicated O +
at O +
the O +
top O +
of O +
each O +
panel O +
; O +
strain O +
and O +
length O +
of O +
its O +
HPT O +
allele O +
are O +
noted O +
above O +
each O +
lane O +
. O +

Representative O +
LDR O +
results O +
are O +
depicted O +
here O +
; O +
for O +
complete O +
data O +
from O +
all O +
strains O +
see O +
Additional O +
files O +
8 O +
, O +
9 O +
, O +
10 O +
, O +
11 O +
, O +
12 O +
, O +
and O +
13 O +
. O +

BP0880 O +
, O +
BP0059 O +
, O +
fimX O +
, O +
and O +
sphB2 O +
HPTs O +
were O +
screened O +
by O +
uniplex O +
LDR O +
reactions O +
containing O +
only O +
the O +
discriminating O +
oligonucleotide O +
that O +
targets O +
the O +
Tohama O +
I O +
sequence O +
. O +

The O +
ptxA O +
and O +
bhuR O +
HPTs O +
were O +
screened O +
by O +
multiplex O +
reactions O +
that O +
contain O +
all O +
three O +
discriminating O +
oligonucleotides O +
. O +

Letters O +
in O +
teal O +
indicate O +
molecular O +
weight O +
standards O +
as O +
labeled O +
in O +
the O +
corresponding O +
supplementary O +
figures O +
. O +

Ligation O +
products O +
( O +
arrows O +
) O +
are O +
labeled O +
using O +
the O +
notation O +
described O +
in O +
the O +
legend O +
to O +
Figure O +
1 O +
. O +

The O +
open O +
arrowhead O +
indicates O +
a O +
synthesis O +
artifact O +
in O +
the O +
BP0059 O +
common O +
oligonucleotide O +
preparation O +
. O +

Supporting O +
Information O +

Alternate O +
Language O +
Article O +
S1 O +

Translation O +
of O +
the O +
manuscript O +
into O +
French O +
by O +
EL O +

( O +
201 O +
KB O +
DOC O +
) O +
. O +

Click O +
here O +
for O +
additional O +
data O +
file O +
. O +

Results O +

Here O +
we O +
include O +
data O +
obtained O +
from O +
active O +
, O +
oscillatory O +
brain O +
slices O +
as O +
well O +
as O +
from O +
recordings O +
during O +
cortical O +
slow O +
oscillations O +
in O +
anesthetized O +
animals O +
. O +

All O +
recordings O +
included O +
in O +
this O +
study O +
were O +
obtained O +
from O +
the O +
visual O +
cortex O +
of O +
the O +
ferret O +
( O +
in O +
vitro O +
) O +
, O +
cat O +
( O +
in O +
vivo O +
) O +
and O +
from O +
barrel O +
cortex O +
of O +
the O +
rat O +
( O +
in O +
vivo O +
) O +
. O +

Twenty O +
- O +
nine O +
neurons O +
recorded O +
from O +
ferret O +
cortical O +
slices O +
are O +
included O +
in O +
this O +
study O +
( O +
22 O +
regular O +
spiking O +
( O +
RS O +
) O +
; O +
5 O +
chattering O +
( O +
CH O +
) O +
and O +
2 O +
intrinsic O +
bursting O +
( O +
IB O +
) O +
) O +
, O +
27 O +
neurons O +
from O +
cat O +
visual O +
cortex O +
in O +
vivo O +
( O +
14 O +
RS O +
; O +
5 O +
CH O +
; O +
2 O +
IB O +
; O +
3 O +
fast O +
spiking O +
( O +
FS O +
) O +
; O +
plus O +
3 O +
non O +
classified O +
) O +
and O +
14 O +
neurons O +
from O +
rat O +
barrel O +
cortex O +
in O +
vivo O +
( O +
12 O +
RS O +
; O +
1 O +
CH O +
; O +
1 O +
IB O +
) O +
. O +

Synaptic O +
potentials O +
were O +
evoked O +
by O +
electric O +
shocks O +
( O +
intracortical O +
or O +
thalamocortical O +
connections O +
) O +
or O +
by O +
means O +
of O +
sensory O +
( O +
visual O +
or O +
whisker O +
) O +
stimulation O +
. O +

The O +
main O +
results O +
are O +
: O +
1 O +
) O +
Synaptic O +
potentials O +
show O +
more O +
paired O +
pulsed O +
facilitation O +
and O +
synaptic O +
augmentation O +
in O +
active O +
than O +
in O +
silent O +
cortical O +
networks O +
and O +
2 O +
) O +
Synaptic O +
potentials O +
occurring O +
during O +
up O +
or O +
activated O +
states O +
of O +
the O +
cortex O +
increased O +
their O +
amplitude O +
with O +
respect O +
to O +
those O +
occurring O +
during O +
down O +
states O +
. O +

INTRODUCTION O +

Comparing O +
genomic O +
sequences O +
across O +
related O +
species O +
is O +
a O +
fruitful O +
source O +
of O +
biological O +
insight O +
. O +

Functional O +
elements O +
such O +
as O +
exons O +
tend O +
to O +
exhibit O +
significant O +
sequence O +
similarity O +
due O +
to O +
purifying O +
selection O +
, O +
whereas O +
regions O +
that O +
are O +
not O +
functional O +
tend O +
to O +
be O +
neutrally O +
evolving O +
and O +
thus O +
less O +
conserved O +
. O +

The O +
first O +
step O +
in O +
comparing O +
genomic O +
sequences O +
is O +
to O +
align O +
them O +
- O +
- O +
to O +
map O +
the O +
letters O +
of O +
the O +
sequences O +
to O +
each O +
other O +
. O +

After O +
an O +
alignment O +
is O +
computed O +
, O +
visualization O +
frameworks O +
become O +
essential O +
to O +
enable O +
users O +
to O +
interact O +
with O +
the O +
sequence O +
and O +
conservation O +
data O +
, O +
especially O +
in O +
the O +
context O +
of O +
longer O +
DNA O +
sequences O +
or O +
whole O +
genomes O +
. O +

Visualization O +
frameworks O +
should O +
be O +
easy O +
to O +
understand O +
by O +
a O +
biologist O +
and O +
provide O +
insight O +
into O +
the O +
mutations O +
that O +
a O +
particular O +
genomic O +
locus O +
has O +
undergone O +
. O +

The O +
VISTA O +
portal O +
is O +
a O +
comprehensive O +
comparative O +
genomics O +
resource O +
that O +
provides O +
biomedical O +
scientists O +
with O +
a O +
single O +
unified O +
framework O +
to O +
generate O +
and O +
download O +
multiple O +
sequence O +
alignments O +
, O +
visualize O +
the O +
results O +
in O +
the O +
context O +
of O +
existing O +
annotations O +
and O +
analyze O +
comparative O +
results O +
in O +
search O +
for O +
important O +
sequence O +
signals O +
in O +
alignments O +
. O +

The O +
VISTA O +
suite O +
of O +
programs O +
has O +
been O +
in O +
development O +
and O +
continued O +
use O +
since O +
2000 O +
( O +
1 O +
- O +
4 O +
) O +
. O +

It O +
was O +
originally O +
developed O +
for O +
the O +
alignment O +
and O +
comparative O +
analysis O +
of O +
long O +
genomic O +
sequences O +
and O +
later O +
was O +
expanded O +
to O +
pair O +
- O +
wise O +
and O +
multiple O +
alignment O +
of O +
vertebrate O +
genomes O +
. O +

VISTA O +
has O +
popularized O +
the O +
visualization O +
of O +
the O +
level O +
of O +
conservation O +
in O +
the O +
format O +
of O +
a O +
continuous O +
curve O +
based O +
on O +
the O +
conservation O +
in O +
a O +
sliding O +
window O +
. O +

This O +
concept O +
proved O +
to O +
be O +
extremely O +
successful O +
due O +
to O +
the O +
easy O +
interpretation O +
of O +
the O +
resulting O +
plots O +
. O +

VISTA O +
was O +
built O +
through O +
a O +
close O +
collaboration O +
between O +
computational O +
and O +
biological O +
scientists O +
, O +
resulting O +
in O +
a O +
product O +
that O +
is O +
robust O +
, O +
efficient O +
and O +
powerful O +
, O +
yet O +
simple O +
to O +
use O +
for O +
a O +
person O +
without O +
extensive O +
computer O +
experience O +
, O +
as O +
is O +
illustrated O +
by O +
more O +
than O +
1000 O +
citations O +
to O +
the O +
various O +
VISTA O +
- O +
associated O +
tools O +
( O +
according O +
to O +
http O +
: O +
/ O +
/ O +
scholar O +
. O +
google O +
. O +
com O +
) O +
. O +

In O +
the O +
last O +
2 O +
years O +
the O +
VISTA O +
portal O +
has O +
seen O +
many O +
significant O +
improvements O +
. O +

In O +
addition O +
to O +
updating O +
the O +
whole O +
genome O +
alignments O +
, O +
computed O +
using O +
recent O +
assemblies O +
of O +
vertebrate O +
, O +
insect O +
, O +
plant O +
and O +
microbial O +
genomes O +
, O +
we O +
have O +
added O +
significant O +
new O +
functionality O +
and O +
resources O +
to O +
the O +
Genome O +
Browser O +
and O +
other O +
tools O +
, O +
including O +
: O +

A O +
novel O +
multiple O +
whole O +
genome O +
alignment O +
algorithm O +
. O +

A O +
new O +
server O +
for O +
whole O +
- O +
genome O +
alignment O +
of O +
bacterial O +
genomes O +
. O +

Base O +
- O +
pair O +
level O +
visualization O +
ability O +
within O +
the O +
VISTA O +
browser O +
. O +

Visual O +
access O +
to O +
the O +
results O +
of O +
the O +
prediction O +
of O +
potential O +
deleteriousness O +
of O +
non O +
- O +
synonymous O +
Single O +
Nucleotide O +
Polymorphisms O +
( O +
SNPs O +
) O +
by O +
the O +
algorithm O +
PolyPhen O +
( O +
5 O +
) O +
. O +

A O +
novel O +
conservation O +
track O +
, O +
Rank O +
- O +
VISTA O +
, O +
to O +
show O +
the O +
statistical O +
significance O +
of O +
conserved O +
regions O +
computed O +
by O +
the O +
Gumby O +
algorithm O +
( O +
6 O +
) O +
. O +

Whole O +
- O +
genome O +
rVISTA O +
, O +
that O +
allows O +
for O +
evaluation O +
of O +
which O +
conserved O +
transcription O +
factor O +
binding O +
sites O +
( O +
TFBS O +
) O +
are O +
over O +
- O +
represented O +
in O +
a O +
group O +
of O +
genes O +
. O +

Extrapyramidal O +
symptoms O +
based O +
on O +
Extrapyramidal O +
Symptoms O +
Rating O +
Scale O +

Images O +

Figure O +
5 O +

Etiology O +

Anorectal O +
malformations O +
( O +
ARM O +
) O +
represent O +
a O +
spectrum O +
of O +
abnormalities O +
ranging O +
from O +
mild O +
anal O +
anomalies O +
to O +
complex O +
cloacal O +
malformations O +
. O +

The O +
etiology O +
of O +
such O +
malformations O +
remains O +
unclear O +
and O +
is O +
likely O +
multifactorial O +
. O +

There O +
are O +
however O +
reasons O +
to O +
believe O +
there O +
is O +
a O +
genetic O +
componenet O +
. O +

As O +
early O +
as O +
the O +
1950s O +
, O +
it O +
was O +
recognized O +
that O +
there O +
was O +
an O +
increased O +
risk O +
for O +
a O +
sibling O +
of O +
a O +
patient O +
with O +
ARM O +
to O +
be O +
born O +
with O +
a O +
malformation O +
, O +
as O +
much O +
as O +
1 O +
in O +
100 O +
, O +
compared O +
with O +
the O +
incidence O +
of O +
about O +
1 O +
in O +
5000 O +
in O +
the O +
general O +
population O +
. O +

Since O +
that O +
time O +
there O +
have O +
been O +
reports O +
of O +
families O +
with O +
2 O +
or O +
more O +
affected O +
members O +
and O +
associations O +
of O +
ARMs O +
with O +
multisystem O +
syndromes O +
. O +

In O +
particular O +
, O +
mutations O +
in O +
specific O +
genes O +
encoding O +
transcription O +
factors O +
have O +
been O +
described O +
in O +
patients O +
having O +
Townes O +
- O +
Broks O +
syndrome O +
, O +
Currarino O +
' O +
s O +
syndrome O +
, O +
and O +
Pallister O +
- O +
Hall O +
syndrome O +
, O +
each O +
of O +
which O +
have O +
autosomal O +
dominant O +
modes O +
of O +
inheritance O +
. O +

In O +
addition O +
, O +
it O +
has O +
been O +
found O +
that O +
there O +
is O +
not O +
only O +
an O +
increased O +
incidence O +
of O +
ARM O +
in O +
patient O +
with O +
trisomy O +
21 O +
( O +
Down O +
' O +
s O +
syndrome O +
) O +
, O +
but O +
that O +
95 O +
% O +
of O +
patients O +
with O +
trisomy O +
21 O +
and O +
ARM O +
have O +
imperforate O +
anus O +
without O +
fistula O +
, O +
compared O +
with O +
only O +
5 O +
% O +
of O +
all O +
patients O +
with O +
ARM O +
. O +

Based O +
on O +
this O +
evidence O +
, O +
it O +
is O +
likely O +
that O +
the O +
mutation O +
of O +
a O +
variety O +
of O +
different O +
genes O +
can O +
result O +
in O +
ARM O +
, O +
or O +
that O +
the O +
etiology O +
of O +
ARM O +
is O +
multigenic O +
[ O +
13 O +
] O +
. O +

Images O +

Fig O +
. O +

1 O +

Fig O +
. O +

2 O +

Fig O +
. O +

3 O +

Miscellaneous O +
Proteins O +

Apart O +
from O +
the O +
above O +
- O +
described O +
proteins O +
, O +
several O +
other O +
molecules O +
are O +
also O +
associated O +
with O +
the O +
pathological O +
lesions O +
of O +
AD O +
, O +
and O +
some O +
of O +
these O +
can O +
be O +
regarded O +
as O +
amateur O +
chaperones O +
. O +

Acute O +
phase O +
proteins O +
, O +
such O +
as O +
alpha1 O +
- O +
antichymotrypsin O +
( O +
ACT O +
) O +
, O +
alpha2 O +
- O +
macroglobulin O +
( O +
alpha2 O -
M O +
) O +
, O +
and O +
SAP O +
, O +
are O +
all O +
associated O +
with O +
Abeta O +
deposition O +
[ O +
129 O +
- O +
132 O +
] O +
. O +

ACT O +
is O +
a O +
serine O +
protease O +
inhibitor O +
of O +
the O +
serpin O +
family O +
, O +
and O +
in O +
AD O +
, O +
ACT O +
levels O +
are O +
upregulated O +
, O +
and O +
binding O +
of O +
ACT O +
with O +
Abeta O +
induces O +
Abeta O +
fibrillogenesis O +
[ O +
133 O +
- O +
135 O +
] O +
. O +

Furthermore O +
, O +
when O +
ACT O +
is O +
overexpressed O +
in O +
transgenic O +
mice O +
, O +
an O +
increased O +
plaque O +
load O +
in O +
the O +
brains O +
of O +
these O +
mice O +
and O +
impaired O +
spatial O +
learning O +
is O +
observed O +
[ O +
134 O +
, O +
135 O +
] O +
. O +

alpha2 O -
M O +
also O +
binds O +
Abeta O +
, O +
although O +
in O +
contrast O +
to O +
ACT O +
, O +
this O +
binding O +
prevents O +
Abeta O +
fibril O +
formation O +
and O +
fibril O +
- O +
associated O +
neurotoxicity O +
[ O +
136 O +
, O +
137 O +
] O +
. O +

alpha2 O -
M O +
promotes O +
the O +
protease O +
- O +
mediated O +
degradation O +
of O +
alpha2 O -
M O +
/ O +
Abeta O +
complexes O +
and O +
contributes O +
to O +
clearance O +
of O +
Abeta O +
from O +
the O +
brain O +
( O +
discussed O +
in O +
paragraph O +
4 O +
) O +
[ O +
138 O +
, O +
139 O +
] O +
. O +

The O +
glycoprotein O +
SAP O +
belongs O +
to O +
the O +
pentraxin O +
family O +
and O +
is O +
a O +
common O +
component O +
of O +
all O +
known O +
types O +
of O +
amyloid O +
fibrils O +
. O +

SAP O +
is O +
upregulated O +
in O +
AD O +
and O +
protects O +
amyloid O +
fibrils O +
from O +
proteolysis O +
in O +
vitro O +
[ O +
140 O +
, O +
141 O +
] O +
. O +

SAP O +
not O +
only O +
colocalizes O +
with O +
SPs O +
and O +
interacts O +
with O +
aggregated O +
Abeta O +
; O +
SAP O +
oligomers O +
also O +
bind O +
and O +
activate O +
C1 O +
[ O +
142 O +
] O +
. O +

Both O +
C1 O +
and O +
SAP O +
may O +
bind O +
to O +
fibrillar O +
Abeta O +
deposits O +
in O +
vivo O +
and O +
induce O +
microglial O +
activation O +
, O +
as O +
cultured O +
human O +
microglial O +
cells O +
show O +
an O +
increase O +
in O +
cytokine O +
production O +
after O +
co O +
- O +
stimulation O +
of O +
Abeta O +
with O +
C1q O +
and O +
SAP O +
[ O +
104 O +
] O +
. O +

These O +
observations O +
further O +
strengthen O +
the O +
above O +
- O +
noted O +
suggestion O +
that O +
not O +
only O +
Abeta O +
, O +
but O +
also O +
several O +
Abeta O +
- O +
binding O +
proteins O +
, O +
are O +
capable O +
of O +
activating O +
the O +
complement O +
system O +
, O +
and O +
thus O +
, O +
contribute O +
to O +
neuroinflammation O +
in O +
AD O +
. O +

In O +
addition O +
, O +
both O +
alpha2 O -
M O +
and O +
ACT O +
, O +
in O +
contrast O +
to O +
SAP O +
, O +
can O +
be O +
regarded O +
as O +
amateur O +
chaperones O +
, O +
as O +
they O +
regulate O +
conformational O +
changes O +
of O +
Abeta O +
. O +

Tissue O +
- O +
type O +
plasminogen O +
activator O +
( O +
tPA O +
) O +
regulates O +
activation O +
of O +
plasminogen O +
into O +
plasmin O +
and O +
is O +
expressed O +
in O +
various O +
regions O +
of O +
the O +
brain O +
especially O +
in O +
the O +
hippocampus O +
[ O +
143 O +
] O +
. O +

Several O +
reports O +
suggested O +
an O +
important O +
role O +
for O +
tPA O +
in O +
AD O +
, O +
as O +
the O +
tPA O +
system O +
is O +
involved O +
in O +
Abeta O +
turnover O +
[ O +
144 O +
, O +
145 O +
] O +
. O +

Fibrillar O +
forms O +
of O +
Abeta O +
stimulate O +
tPA O +
activity O +
in O +
vitro O +
, O +
whereas O +
in O +
AD O +
patients O +
, O +
a O +
reduction O +
of O +
tPA O +
activity O +
is O +
observed O +
in O +
the O +
affected O +
areas O +
[ O +
144 O +
, O +
146 O +
] O +
. O +

Although O +
tPA O +
has O +
no O +
effect O +
on O +
conformational O +
changes O +
of O +
Abeta O +
, O +
it O +
might O +
play O +
a O +
role O +
in O +
the O +
clearance O +
of O +
Abeta O +
from O +
the O +
brain O +
( O +
paragraph O +
4 O +
] O +
. O +

The O +
actin O +
- O +
regulatory O +
protein O +
gelsolin O +
is O +
found O +
both O +
intracellularly O +
and O +
in O +
plasma O +
[ O +
147 O +
, O +
148 O +
] O +
. O +

Plasma O +
gelsolin O +
can O +
be O +
considered O +
an O +
amateur O +
chaperone O +
, O +
as O +
it O +
binds O +
Abeta O +
and O +
not O +
only O +
inhibits O +
its O +
Abeta O +
fibrillization O +
but O +
is O +
also O +
capable O +
of O +
degrading O +
preformed O +
Abeta O +
fibrils O +
[ O +
149 O +
, O +
150 O +
] O +
. O +

Furthermore O +
, O +
gelsolin O +
inhibits O +
Abeta O +
- O +
mediated O +
neurotoxicity O +
[ O +
151 O +
] O +
. O +

One O +
of O +
the O +
major O +
gangliosides O +
in O +
the O +
brain O +
is O +
GM1 O +
. O +

Soluble O +
Abeta O +
binds O +
GM1 O +
and O +
the O +
formed O +
complexes O +
accelerate O +
Abeta O +
fibrillogenesis O +
by O +
acting O +
as O +
a O +
seed O +
for O +
Abeta O +
[ O +
152 O +
] O +
. O +

In O +
the O +
presence O +
of O +
GM1 O +
, O +
Abeta O +
is O +
more O +
neurotoxic O +
than O +
Abeta O +
alone O +
, O +
and O +
cholesterol O +
- O +
rich O +
membranes O +
demonstrate O +
accelerated O +
Abeta O +
binding O +
due O +
to O +
the O +
formation O +
of O +
GM1 O +
clusters O +
[ O +
153 O +
, O +
154 O +
] O +
. O +

As O +
GM1 O +
is O +
a O +
major O +
component O +
of O +
lipid O +
rafts O +
and O +
recent O +
studies O +
suggest O +
that O +
Abeta O +
accumulation O +
in O +
these O +
lipid O +
rafts O +
is O +
an O +
early O +
event O +
in O +
AD O +
development O +
, O +
GM1 O +
might O +
play O +
an O +
important O +
role O +
in O +
the O +
early O +
steps O +
in O +
AD O +
pathogenesis O +
[ O +
155 O +
, O +
156 O +
] O +
. O +

In O +
summary O +
, O +
several O +
proteins O +
are O +
associated O +
with O +
Abeta O +
aggregates O +
in O +
the O +
AD O +
brain O +
and O +
contribute O +
to O +
the O +
aggregation O +
of O +
Abeta O +
and O +
should O +
, O +
therefore O +
, O +
be O +
considered O +
as O +
amateur O +
chaperones O +
. O +

In O +
addition O +
, O +
they O +
might O +
play O +
a O +
role O +
in O +
triggering O +
inflammation O +
. O +

Results O +

Images O +

Figure O +
1 O +

Results O +

The O +
observation O +
that O +
AP O +
- O +
3 O +
is O +
found O +
in O +
both O +
cytosolic O +
and O +
membrane O +
subcellular O +
fractions O +
, O +
and O +
that O +
membrane O +
- O +
associated O +
AP O +
- O +
3 O +
can O +
be O +
extracted O +
with O +
salts O +
( O +
Dell O +
' O +
Angelica O +
et O +
al O +
. O +
, O +
1997a O +
) O +
is O +
consistent O +
with O +
its O +
role O +
as O +
a O +
membrane O +
coat O +
that O +
can O +
be O +
recruited O +
from O +
a O +
cytosolic O +
pool O +
. O +

In O +
addition O +
, O +
the O +
punctate O +
staining O +
of O +
AP O +
- O +
3 O +
by O +
immunofluorescence O +
microscopy O +
, O +
its O +
redistribution O +
to O +
the O +
cytosol O +
by O +
BFA O +
, O +
and O +
the O +
reversibility O +
of O +
the O +
BFA O +
effect O +
( O +
Dell O +
' O +
Angelica O +
et O +
al O +
. O +
, O +
1997a O +
; O +
Simpson O +
et O +
al O +
. O +
, O +
1997 O +
) O +
also O +
indicate O +
that O +
AP O +
- O +
3 O +
can O +
cycle O +
between O +
the O +
cytosol O +
and O +
membranes O +
. O +

The O +
sensitivity O +
of O +
AP O +
- O +
3 O +
to O +
BFA O +
in O +
cells O +
suggests O +
that O +
its O +
membrane O +
association O +
may O +
be O +
regulated O +
by O +
ARF1 O +
, O +
since O +
BFA O +
inhibits O +
ARF1 O +
guanine O +
nucleotide O +
exchange O +
, O +
and O +
has O +
been O +
shown O +
to O +
prevent O +
ARF1 O +
membrane O +
binding O +
in O +
vitro O +
( O +
Donaldson O +
et O +
al O +
. O +
, O +
1992 O +
; O +
Helms O +
and O +
Rothman O +
, O +
1992 O +
; O +
Randazzo O +
et O +
al O +
. O +
, O +
1993 O +
) O +
. O +

Ca2 O +
+ O +
Dependence O +
of O +
Slob57 O +
Modulation O +
of O +
the O +
Voltage O +
Dependence O +
of O +
Activation O +
of O +
dSlo O +

Ca2 O +
+ O +
plays O +
a O +
fundamental O +
role O +
in O +
regulating O +
the O +
dSlo O +
response O +
to O +
membrane O +
depolarization O +
. O +

One O +
of O +
the O +
three O +
known O +
Ca2 O +
+ O +
binding O +
sites O +
( O +
Xia O +
et O +
al O +
. O +
, O +
2002 O +
; O +
Bao O +
et O +
al O +
. O +
, O +
2002 O +
; O +
Zeng O +
et O +
al O +
. O +
, O +
2005b O +
) O +
, O +
known O +
as O +
the O +
calcium O +
bowl O +
( O +
Schreiber O +
and O +
Salkoff O +
, O +
1997 O +
) O +
, O +
contributes O +
to O +
the O +
high O +
- O +
affinity O +
Ca2 O +
+ O +
sensitivity O +
of O +
the O +
channel O +
( O +
Schreiber O +
and O +
Salkoff O +
, O +
1997 O +
; O +
Schreiber O +
et O +
al O +
. O +
, O +
1999 O +
; O +
Braun O +
and O +
Sy O +
, O +
2001 O +
; O +
Bao O +
et O +
al O +
. O +
, O +
2002 O +
; O +
Niu O +
and O +
Magleby O +
, O +
2002 O +
; O +
Xia O +
et O +
al O +
. O +
, O +
2002 O +
; O +
Bao O +
et O +
al O +
. O +
, O +
2004 O +
; O +
Zeng O +
et O +
al O +
. O +
, O +
2005b O +
) O +
. O +

We O +
used O +
a O +
mutated O +
dSlo O +
channel O +
with O +
substitution O +
of O +
Asp966 O +
- O +
Asp970 O +
by O +
Asn966 O +
- O +
Asn970 O +
within O +
its O +
calcium O +
bowl O +
, O +
which O +
greatly O +
reduces O +
the O +
channel O +
' O +
s O +
calcium O +
sensitivity O +
( O +
Bian O +
et O +
al O +
. O +
, O +
2001 O +
) O +
, O +
to O +
determine O +
whether O +
Ca2 O +
+ O +
participates O +
in O +
Slob57 O +
modulation O +
of O +
dSlo O +
. O +

This O +
mutated O +
channel O +
, O +
dSloD5N5 O +
, O +
still O +
binds O +
to O +
full O +
- O +
length O +
and O +
truncated O +
Slobs O +
( O +
Fig O +
. O +
1 O +
B O +
, O +
lanes O +
4 O +
- O +
6 O +
) O +
. O +

During O +
a O +
350 O +
- O +
ms O +
test O +
pulse O +
( O +
Fig O +
. O +
7 O +
E O +
) O +
, O +
Slob57 O +
causes O +
dSloD5N5 O +
inactivation O +
( O +
Fig O +
. O +
7 O +
B O +
) O +
, O +
consistent O +
with O +
our O +
previous O +
finding O +
that O +
the O +
inactivation O +
caused O +
by O +
Slob57 O +
is O +
Ca2 O +
+ O +
independent O +
( O +
Zeng O +
et O +
al O +
. O +
, O +
2005a O +
) O +
. O +

After O +
deletion O +
of O +
the O +
amino O +
- O +
terminal O +
residues O +
2 O +
- O +
6 O +
of O +
Slob57 O +
, O +
the O +
inactivation O +
of O +
dSloD5N5 O +
is O +
eliminated O +
( O +
Fig O +
. O +
7 O +
C O +
) O +
, O +
and O +
further O +
truncation O +
of O +
Slob57 O +
to O +
Arg16 O +
also O +
eliminates O +
the O +
inactivation O +
( O +
Fig O +
. O +
7 O +
D O +
) O +
, O +
just O +
as O +
observed O +
with O +
wild O +
- O +
type O +
dSlo O +
( O +
Fig O +
. O +
2 O +
, O +
C O +
and O +
D O +
) O +
. O +

Figure O +
7 O +
. O +

Slob57 O +
causes O +
inactivation O +
of O +
dSloD5N5 O +
. O +

Same O +
as O +
Fig O +
. O +

2 O +
, O +
except O +
that O +
the O +
mutated O +
channel O +
dSloD5N5 O +
was O +
used O +
instead O +
of O +
wild O +
- O +
type O +
dSlo O +
. O +

( O +
A O +
) O +
dSloD5N5 O +
alone O +
, O +
( O +
B O +
) O +
dSloD5N5 O +
together O +
with O +
Slob57 O +
, O +
( O +
C O +
) O +
dSloD5N5 O +
together O +
with O +
Slob57DeltaN5 O +
, O +
( O +
D O +
) O +
dSloD5N5 O +
together O +
with O +
Slob57DeltaN15 O +
, O +
( O +
E O +
) O +
pulse O +
protocol O +
. O +

We O +
next O +
used O +
a O +
100 O +
- O +
ms O +
test O +
pulse O +
( O +
during O +
which O +
no O +
inactivation O +
occurs O +
) O +
to O +
measure O +
the O +
voltage O +
dependence O +
of O +
activation O +
of O +
dSloD5N5 O +
in O +
the O +
presence O +
of O +
110 O +
muM O +
free O +
Ca2 O +
+ O +
, O +
as O +
only O +
at O +
high O +
concentrations O +
of O +
free O +
Ca2 O +
+ O +
can O +
tail O +
current O +
saturation O +
be O +
achieved O +
with O +
the O +
mutant O +
channel O +
( O +
Fig O +
. O +
8 O +
) O +
. O +

As O +
shown O +
in O +
Fig O +
. O +

8 O +
, O +
Slob57 O +
does O +
not O +
rightward O +
shift O +
the O +
conductance O +
- O +
voltage O +
relationship O +
of O +
dSloD5N5 O +
. O +

Because O +
dSloD5N5 O +
can O +
still O +
respond O +
to O +
an O +
increment O +
of O +
free O +
Ca2 O +
+ O +
at O +
high O +
concentration O +
( O +
Bian O +
et O +
al O +
. O +
, O +
2001 O +
) O +
, O +
we O +
then O +
increased O +
the O +
concentration O +
of O +
free O +
Ca2 O +
+ O +
to O +
300 O +
muM O +
. O +

As O +
shown O +
in O +
Fig O +
. O +

8 O +
, O +
the O +
conductance O +
- O +
voltage O +
relationship O +
of O +
dSloD5N5 O +
shifts O +
to O +
less O +
depolarized O +
voltages O +
when O +
the O +
concentration O +
of O +
free O +
Ca2 O +
+ O +
is O +
increased O +
from O +
110 O +
to O +
300 O +
muM O +
, O +
but O +
again O +
the O +
V1 O +
/ O +
2 O +
is O +
not O +
modulated O +
by O +
Slob57 O +
. O +

Figure O +
8 O +
. O +

Conductance O +
- O +
voltage O +
relationships O +
for O +
dSloD5N5 O +
. O +

Same O +
protocol O +
as O +
Fig O +
. O +

6 O +
, O +
except O +
that O +
the O +
mutated O +
channel O +
dSloD5N5 O +
was O +
used O +
in O +
the O +
presence O +
( O +
circles O +
) O +
or O +
absence O +
( O +
squares O +
) O +
of O +
Slob57 O +
, O +
and O +
the O +
concentration O +
of O +
free O +
Ca2 O +
+ O +
was O +
either O +
110 O +
muM O +
( O +
filled O +
symbols O +
) O +
or O +
300 O +
muM O +
( O +
open O +
symbols O +
) O +
. O +

We O +
next O +
measured O +
the O +
voltage O +
dependence O +
of O +
activation O +
of O +
wild O +
- O +
type O +
dSlo O +
, O +
in O +
the O +
presence O +
or O +
absence O +
of O +
Slob57 O +
, O +
at O +
free O +
Ca2 O +
+ O +
concentrations O +
ranging O +
from O +
20 O +
to O +
300 O +
muM O +
. O +

As O +
shown O +
in O +
Fig O +
. O +

9 O +
A O +
( O +
and O +
by O +
many O +
previous O +
investigators O +
) O +
, O +
in O +
the O +
absence O +
of O +
Slob57 O +
, O +
the O +
voltage O +
- O +
conductance O +
relationship O +
of O +
dSlo O +
shifts O +
to O +
less O +
depolarized O +
voltages O +
as O +
the O +
free O +
Ca2 O +
+ O +
concentration O +
is O +
increased O +
in O +
this O +
range O +
. O +

The O +
V1 O +
/ O +
2 O +
decreases O +
from O +
85 O +
to O +
- O +
22 O +
mV O +
, O +
a O +
change O +
of O +
107 O +
mV O +
, O +
when O +
the O +
concentration O +
of O +
free O +
Ca2 O +
+ O +
is O +
increased O +
from O +
20 O +
to O +
300 O +
muM O +
. O +

In O +
contrast O +
, O +
when O +
dSlo O +
is O +
coexpressed O +
with O +
Slob57 O +
, O +
this O +
increment O +
of O +
free O +
Ca2 O +
+ O +
concentration O +
shifts O +
the O +
V1 O +
/ O +
2 O +
to O +
a O +
much O +
lesser O +
extent O +
( O +
Fig O +
. O +
9 O +
B O +
and O +
Fig O +
. O +
10 O +
A O +
) O +
. O +

Note O +
also O +
that O +
the O +
effect O +
of O +
Slob57 O +
on O +
the O +
V1 O +
/ O +
2 O +
is O +
more O +
apparent O +
at O +
higher O +
free O +
Ca2 O +
+ O +
concentrations O +
( O +
Fig O +
. O +
10 O +
A O +
) O +
. O +

To O +
illustrate O +
this O +
better O +
, O +
we O +
plotted O +
the O +
V1 O +
/ O +
2 O +
change O +
evoked O +
by O +
Slob57 O +
( O +
DeltaV1 O +
/ O +
2 O +
) O +
as O +
a O +
function O +
of O +
the O +
free O +
Ca2 O +
+ O +
concentration O +
( O +
Fig O +
. O +
10 O +
B O +
) O +
to O +
demonstrate O +
that O +
the O +
magnitude O +
of O +
the O +
modulatory O +
shift O +
in O +
V1 O +
/ O +
2 O +
evoked O +
by O +
Slob57 O +
itself O +
is O +
calcium O +
dependent O +
. O +

Figure O +
9 O +
. O +

Effect O +
of O +
calcium O +
on O +
dSlo O +
voltage O +
dependence O +
of O +
activation O +
in O +
the O +
absence O +
or O +
presence O +
of O +
Slob57 O +
. O +

Same O +
as O +
Fig O +
. O +

6 O +
, O +
except O +
that O +
the O +
measurements O +
of O +
dSlo O +
expressed O +
alone O +
( O +
A O +
) O +
or O +
together O +
with O +
Slob57 O +
( O +
B O +
) O +
were O +
performed O +
in O +
the O +
presence O +
of O +
different O +
concentrations O +
of O +
free O +
Ca2 O +
+ O +
: O +
20 O +
muM O +
( O +
diamonds O +
) O +
, O +
40 O +
muM O +
( O +
inverted O +
triangles O +
) O +
, O +
80 O +
muM O +
( O +
triangles O +
) O +
, O +
110 O +
muM O +
( O +
squares O +
) O +
, O +
and O +
300 O +
muM O +
( O +
circles O +
) O +
. O +

Figure O +
10 O +
. O +

Interaction O +
between O +
Slob57 O +
and O +
calcium O +
. O +

The O +
V1 O +
/ O +
2 O +
( O +
A O +
) O +
of O +
the O +
conductance O +
- O +
voltage O +
relationship O +
for O +
dSlo O +
expressed O +
alone O +
( O +
O O +
) O +
or O +
together O +
with O +
Slob57 O +
( O +
* O +
) O +
, O +
taken O +
from O +
Fig O +
. O +

9 O +
, O +
and O +
the O +
difference O +
in O +
V1 O +
/ O +
2 O +
( O +
DeltaV1 O +
/ O +
2 O +
) O +
evoked O +
by O +
Slob57 O +
( O +
B O +
) O +
are O +
plotted O +
as O +
a O +
function O +
of O +
the O +
concentration O +
of O +
free O +
Ca2 O +
+ O +
. O +

Immunocytochemistry O +

C2C12 B-CellLine +
cells O +
grown O +
in O +
8 O +
- O +
chamber O +
slides O +
( O +
Nunc O +
) O +
were O +
fixed O +
in O +
4 O +
% O +
PFA O +
/ O +
PBS O +
for O +
10 O +
min O +
and O +
permeabilized O +
in O +
0 O +
. O +
1 O +
% O +
Triton O +
X O +
- O +
100 O +
for O +
20 O +
min O +
. O +

In O +
some O +
cases O +
, O +
they O +
were O +
fixed O +
and O +
permeabilized O +
in O +
methanol O +
at O +
- O +
20degreesC O +
for O +
2 O +
min O +
. O +

The O +
fixed O +
and O +
permeabilized O +
cells O +
were O +
blocked O +
in O +
PBS O +
containing O +
3 O +
% O +
BSA O +
( O +
Jackson O +
ImmunoResearch O +
Laboratories O +
) O +
and O +
incubated O +
overnight O +
at O +
4degreesC O +
with O +
primary O +
antibodies O +
in O +
blocking O +
solution O +
. O +

Immunoreactivity O +
was O +
detected O +
with O +
either O +
Alexa O +
- O +
conjugated O +
secondary O +
antibody O +
( O +
Molecular O +
Probes O +
) O +
or O +
a O +
combination O +
of O +
biotin O +
- O +
conjugated O +
secondary O +
antibody O +
( O +
Vector O +
Laboratories O +
) O +
and O +
Alexa O +
- O +
conjugated O +
streptavidin O +
( O +
Molecular O +
Probes O +
) O +
. O +

Cytology O +
and O +
Histology O +

For O +
semithin O +
sections O +
, O +
embryoid O +
bodies O +
were O +
washed O +
twice O +
in O +
PBS O +
, O +
fixed O +
in O +
4 O +
% O +
paraformaldehyde O +
at O +
4degreesC O +
overnight O +
, O +
and O +
after O +
dehydration O +
in O +
ethanol O +
were O +
embedded O +
in O +
JB O +
- O +
4 O +
resin O +
( O +
Polysciences O +
, O +
Inc O +
. O +
) O +
. O +

1 O +
- O +
4 O +
- O +
mum O +
sections O +
were O +
cut O +
with O +
a O +
glass O +
knife O +
. O +

For O +
cytology O +
, O +
the O +
sections O +
were O +
stained O +
with O +
toluidine O +
blue O +
. O +

In O +
cell O +
mixing O +
experiments O +
, O +
the O +
embryoid O +
bodies O +
were O +
prefixed O +
and O +
stained O +
for O +
beta O +
- O +
galactosidase O +
and O +
the O +
sections O +
were O +
counterstained O +
with O +
neutral O +
red O +
. O +

Teratocarcinomas O +
were O +
fixed O +
in O +
Bouin O +
fixative O +
, O +
embedded O +
in O +
Paraplast O +
, O +
and O +
the O +
sections O +
were O +
stained O +
with O +
hematoxylin O +
and O +
eosin O +
. O +

Microphotography O +
was O +
with O +
a O +
ZEISS O +
Axiomat O +
microscope O +
. O +

Films O +
were O +
scanned O +
and O +
figures O +
were O +
prepared O +
with O +
Photoshop O +
5 O +
. O +
5 O +
software O +
. O +

Stimulation O +
/ O +
Inhibition O +
of O +
iDC O +
Functions O +
by O +
Activated O +
NK O +
Cells O +
. O +

Two O +
previous O +
studies O +
have O +
shown O +
that O +
both O +
resting O +
and O +
activated O +
NK O +
cells O +
partially O +
kill O +
autologous O +
DCs O +
, O +
as O +
measured O +
by O +
3 O +
- O +
4 O +
- O +
h O +
chromium O +
release O +
assays O +
using O +
high O +
NK O +
/ O +
DC O +
ratios O +
( O +
11 O +
, O +
12 O +
) O +
. O +

However O +
, O +
in O +
our O +
long O +
- O +
term O +
cultures O +
( O +
24 O +
- O +
48 O +
h O +
) O +
the O +
NK O +
cells O +
stimulated O +
the O +
iDCs O +
rather O +
than O +
lysing O +
them O +
. O +

Based O +
on O +
these O +
conflicting O +
results O +
, O +
we O +
examined O +
in O +
more O +
detail O +
the O +
apparent O +
stimulation O +
of O +
iDCs O +
after O +
contact O +
with O +
NK O +
cells O +
. O +

We O +
reasoned O +
that O +
activated O +
NK O +
cells O +
would O +
be O +
more O +
useful O +
for O +
these O +
experiments O +
because O +
( O +
i O +
) O +
an O +
encounter O +
in O +
vivo O +
between O +
NK O +
cells O +
that O +
normally O +
traffic O +
in O +
the O +
blood O +
( O +
4 O +
) O +
and O +
iDCs O +
which O +
reside O +
in O +
the O +
tissues O +
( O +
1 O +
, O +
3 O +
) O +
, O +
should O +
only O +
occur O +
when O +
both O +
cells O +
are O +
activated O +
; O +
( O +
ii O +
) O +
activated O +
NK O +
cells O +
mediate O +
more O +
potent O +
lysis O +
of O +
iDCs O +
( O +
11 O +
- O +
13 O +
) O +
, O +
thereby O +
allowing O +
for O +
a O +
more O +
rigorous O +
examination O +
of O +
a O +
potential O +
cytotoxic O +
effect O +
; O +
and O +
( O +
iii O +
) O +
the O +
number O +
of O +
NK O +
cells O +
obtained O +
after O +
short O +
- O +
term O +
in O +
vitro O +
culture O +
would O +
be O +
far O +
greater O +
providing O +
more O +
cells O +
for O +
analysis O +
( O +
9 O +
) O +
. O +

The O +
DC O +
maturation O +
induced O +
by O +
resting O +
NK O +
cells O +
we O +
observed O +
was O +
dependent O +
on O +
endogenous O +
TNF O +
- O +
alpha O +
production O +
. O +

Furthermore O +
, O +
TNF O +
- O +
alpha O +
and O +
other O +
proinflammatory O +
cytokines O +
are O +
important O +
amplifiers O +
of O +
immune O +
responses O +
( O +
14 O +
) O +
. O +

Therefore O +
, O +
we O +
used O +
TNF O +
- O +
alpha O +
production O +
as O +
a O +
readout O +
for O +
DC O +
stimulation O +
in O +
our O +
culture O +
system O +
. O +

Culturing O +
activated O +
NK O +
cells O +
with O +
DCs O +
at O +
low O +
NK O +
/ O +
DC O +
ratios O +
( O +
1 O +
: O +
5 O +
) O +
led O +
to O +
increases O +
in O +
TNF O +
- O +
alpha O +
production O +
, O +
which O +
were O +
augmented O +
dramatically O +
by O +
the O +
addition O +
of O +
suboptimal O +
doses O +
( O +
10 O +
ng O +
/ O +
ml O +
) O +
of O +
LPS O +
( O +
Fig O +
. O +
2 O +
A O +
) O +
. O +

The O +
increased O +
TNF O +
- O +
alpha O +
production O +
was O +
dependent O +
on O +
cell O +
- O +
to O +
- O +
cell O +
contact O +
because O +
when O +
the O +
two O +
cell O +
types O +
were O +
separated O +
in O +
trans O +
- O +
wells O +
, O +
no O +
stimulation O +
was O +
observed O +
( O +
Fig O +
. O +
2 O +
B O +
) O +
. O +

In O +
separate O +
experiments O +
we O +
observed O +
this O +
NK O +
- O +
stimulatory O +
effect O +
on O +
TNF O +
- O +
alpha O +
production O +
at O +
NK O +
/ O +
DC O +
ratios O +
as O +
low O +
as O +
1 O +
: O +
20 O +
and O +
1 O +
: O +
40 O +
( O +
data O +
not O +
shown O +
) O +
. O +

Raising O +
the O +
NK O +
/ O +
DC O +
ratio O +
to O +
5 O +
: O +
1 O +
changes O +
the O +
interaction O +
from O +
one O +
of O +
potent O +
DC O +
stimulation O +
to O +
that O +
of O +
complete O +
inhibition O +
in O +
the O +
presence O +
or O +
absence O +
of O +
LPS O +
( O +
Fig O +
. O +
2 O +
C O +
) O +
. O +

An O +
identical O +
pattern O +
is O +
seen O +
for O +
IL O +
- O +
12 O +
p40 O +
production O +
( O +
Fig O +
. O +
2 O +
D O +
) O +
. O +

No O +
IL O +
- O +
10 O +
production O +
in O +
the O +
cultures O +
was O +
detected O +
under O +
any O +
of O +
the O +
conditions O +
tested O +
( O +
data O +
not O +
shown O +
) O +
. O +

The O +
massive O +
production O +
of O +
TNF O +
- O +
alpha O +
in O +
the O +
cultures O +
at O +
the O +
lowest O +
ratios O +
was O +
mediated O +
primarily O +
by O +
DCs O +
in O +
the O +
culture O +
due O +
to O +
the O +
low O +
number O +
of O +
NK O +
cells O +
( O +
2 O +
x O +
104 O +
cells O +
per O +
well O +
) O +
used O +
in O +
these O +
experiments O +
. O +

In O +
addition O +
, O +
efforts O +
to O +
stimulate O +
NK O +
cells O +
directly O +
with O +
optimal O +
doses O +
of O +
anti O +
- O +
CD16 O +
, O +
rIL O +
- O +
2 O +
, O +
rIL O +
- O +
12 O +
, O +
and O +
PMA O +
/ O +
ionomycin O +
alone O +
or O +
in O +
combination O +
induced O +
only O +
moderate O +
( O +
< O +
500 O +
pg O +
/ O +
ml O +
) O +
TNF O +
- O +
alpha O +
production O +
by O +
the O +
NK O +
cells O +
alone O +
which O +
were O +
present O +
at O +
2 O +
x O +
105 O +
cells O +
per O +
well O +
( O +
data O +
not O +
shown O +
) O +
. O +

Figure O +
2 O +
. O +

Activated O +
/ O +
cultured O +
NK O +
cell O +
- O +
mediated O +
amplification O +
/ O +
inhibition O +
of O +
DC O +
cytokine O +
production O +
. O +

Results O +
are O +
presented O +
on O +
log O +
scales O +
. O +

Cultured O +
iDCs O +
were O +
incubated O +
alone O +
or O +
with O +
cultured O +
/ O +
purified O +
NK O +
cells O +
for O +
24 O +
h O +
( O +
A O +
and O +
B O +
) O +
or O +
48 O +
h O +
( O +
C O +
- O +
E O +
) O +
in O +
the O +
presence O +
or O +
absence O +
of O +
the O +
indicated O +
concentrations O +
of O +
LPS O +
. O +

After O +
culture O +
the O +
supernatants O +
were O +
removed O +
and O +
analyzed O +
by O +
ELISA O +
for O +
TNF O +
- O +
alpha O +
or O +
IL O +
- O +
12 O +
p40 O +
. O +

( O +
A O +
) O +
TNF O +
- O +
alpha O +
production O +
was O +
measured O +
in O +
the O +
supernatants O +
from O +
cultures O +
of O +
: O +
DCs O +
alone O +
( O +
gray O +
bars O +
) O +
; O +
NK O +
+ O +
DC O +
( O +
1 O +
: O +
5 O +
) O +
( O +
black O +
bars O +
) O +
. O +

LPS O +
concentrations O +
used O +
were O +
: O +
0 O +
, O +
10 O +
, O +
and O +
1 O +
, O +
000 O +
ng O +
/ O +
ml O +
( O +
DCs O +
alone O +
only O +
) O +
. O +

( O +
B O +
) O +
Contact O +
- O +
dependent O +
stimulation O +
of O +
iDC O +
TNF O +
- O +
alpha O +
production O +
by O +
NK O +
cells O +
was O +
tested O +
under O +
the O +
following O +
conditions O +
: O +
DCs O +
alone O +
( O +
gray O +
bars O +
) O +
; O +
NK O +
+ O +
DC O +
( O +
1 O +
: O +
5 O +
) O +
( O +
black O +
bars O +
) O +
; O +
NK O +
/ O +
DC O +
( O +
1 O +
: O +
5 O +
) O +
trans O +
- O +
wells O +
( O +
striped O +
bars O +
) O +
. O +

LPS O +
concentrations O +
used O +
were O +
: O +
10 O +
ng O +
/ O +
ml O +
( O +
donor O +
1 O +
) O +
and O +
20 O +
ng O +
/ O +
ml O +
( O +
donor O +
2 O +
) O +
. O +

( O +
C O +
and O +
D O +
) O +
Effect O +
of O +
increasing O +
the O +
NK O +
/ O +
DC O +
ratio O +
( O +
DCs O +
alone O +
; O +
NK O +
: O +
DC O +
- O +
1 O +
: O +
5 O +
; O +
1 O +
: O +
1 O +
; O +
5 O +
: O +
1 O +
) O +
on O +
( O +
C O +
) O +
TNF O +
- O +
alpha O +
and O +
( O +
D O +
) O +
IL O +
- O +
12 O +
p40 O +
production O +
. O +

LPS O +
concentrations O +
used O +
were O +
: O +
0 O +
ng O +
/ O +
ml O +
( O +
* O +
) O +
; O +
20 O +
ng O +
/ O +
ml O +
( O +
* O +
) O +
; O +
50 O +
ng O +
/ O +
ml O +
( O +
^ O +
) O +
; O +
and O +
1 O +
, O +
000 O +
ng O +
/ O +
ml O +
- O +
LPS O +
( O +
* O +
) O +
( O +
DCs O +
alone O +
only O +
) O +
. O +

( O +
E O +
) O +
The O +
effect O +
of O +
neutralizing O +
IFN O +
- O +
gamma O +
production O +
was O +
tested O +
under O +
the O +
following O +
conditions O +
: O +
DCs O +
alone O +
( O +
gray O +
bars O +
) O +
; O +
NK O +
+ O +
DC O +
( O +
1 O +
: O +
5 O +
) O +
( O +
black O +
bars O +
) O +
; O +
NK O +
+ O +
DC O +
( O +
1 O +
: O +
5 O +
) O +
and O +
10 O +
mug O +
/ O +
ml O +
of O +
blocking O +
anti O +
- O +
IFN O +
- O +
gamma O +
mAb O +
( O +
stippled O +
bars O +
) O +
. O +

LPS O +
concentrations O +
used O +
were O +
: O +
0 O +
ng O +
/ O +
ml O +
( O +
NO O +
LPS O +
) O +
and O +
20 O +
ng O +
/ O +
ml O +
( O +
LPS O +
20 O +
) O +
. O +

Blocking O +
reagents O +
for O +
CD80 O +
, O +
CD86 O +
, O +
CD154 O +
, O +
CD95 O +
, O +
CD11a O +
, O +
CD50 O +
, O +
or O +
IL O +
- O +
12 O +
, O +
had O +
no O +
effect O +
on O +
the O +
NK O +
cell O +
- O +
induced O +
TNF O +
- O +
alpha O +
or O +
IL O +
- O +
12 O +
p40 O +
production O +
, O +
whereas O +
a O +
neutralizing O +
antibody O +
for O +
IFN O +
- O +
gamma O +
while O +
not O +
affecting O +
TNF O +
- O +
alpha O +
production O +
partially O +
blocked O +
( O +
< O +
20 O +
% O +
) O +
IL O +
- O +
12 O +
p40 O +
production O +
induced O +
by O +
the O +
NK O +
cells O +
( O +
Fig O +
. O +
2 O +
E O +
) O +
. O +

This O +
partial O +
inhibition O +
is O +
consistent O +
with O +
numerous O +
previous O +
reports O +
demonstrating O +
a O +
central O +
role O +
for O +
an O +
IL O +
- O +
12 O +
/ O +
IFN O +
- O +
gamma O +
positive O +
feedback O +
loop O +
active O +
between O +
NK O +
cells O +
and O +
IL O +
- O +
12 O +
- O +
producing O +
cells O +
( O +
15 O +
- O +
17 O +
) O +
. O +

Clearly O +
, O +
however O +
, O +
this O +
well O +
- O +
described O +
cytokine O +
cross O +
- O +
talk O +
mechanism O +
is O +
secondary O +
to O +
the O +
contact O +
- O +
dependent O +
activation O +
of O +
DCs O +
by O +
NK O +
cells O +
described O +
here O +
. O +

Taken O +
together O +
these O +
results O +
indicate O +
that O +
novel O +
mechanisms O +
control O +
cognate O +
interactions O +
between O +
NK O +
cells O +
and O +
DCs O +
and O +
that O +
NK O +
- O +
DC O +
contact O +
has O +
the O +
potential O +
to O +
serve O +
as O +
an O +
important O +
control O +
switch O +
for O +
both O +
amplifying O +
and O +
attenuating O +
innate O +
immune O +
responses O +
in O +
vivo O +
. O +

We O +
next O +
tested O +
directly O +
whether O +
NK O +
cell O +
killing O +
was O +
active O +
in O +
our O +
system O +
using O +
both O +
short O +
- O +
term O +
( O +
4 O +
- O +
h O +
) O +
chromium O +
release O +
assays O +
( O +
data O +
not O +
shown O +
) O +
and O +
a O +
flow O +
cytometric O +
assay O +
which O +
allowed O +
us O +
to O +
follow O +
the O +
survival O +
of O +
the O +
autologous O +
iDCs O +
in O +
the O +
presence O +
of O +
NK O +
cells O +
over O +
longer O +
periods O +
( O +
Fig O +
. O +
3 O +
) O +
. O +

The O +
results O +
demonstrate O +
that O +
NK O +
cells O +
kill O +
autologous O +
iDCs O +
( O +
Fig O +
. O +
3 O +
A O +
) O +
at O +
all O +
NK O +
/ O +
DC O +
ratios O +
tested O +
after O +
4 O +
h O +
and O +
the O +
level O +
of O +
killing O +
is O +
similar O +
to O +
the O +
lysis O +
of O +
K562 B-CellLine +
cells O +
over O +
the O +
same O +
time O +
( O +
Fig O +
. O +
3 O +
B O +
) O +
. O +

After O +
24 O +
h O +
, O +
however O +
, O +
the O +
presence O +
of O +
NK O +
cells O +
led O +
to O +
completely O +
divergent O +
effects O +
on O +
the O +
DCs O +
. O +

At O +
the O +
5 O +
: O +
1 O +
( O +
NK O +
/ O +
DC O +
) O +
ratio O +
, O +
NK O +
cell O +
- O +
mediated O +
destruction O +
of O +
the O +
iDCs O +
was O +
the O +
dominant O +
feature O +
, O +
whereas O +
at O +
the O +
low O +
ratio O +
( O +
1 O +
: O +
5 O +
) O +
the O +
same O +
NK O +
cells O +
promoted O +
iDCs O +
survival O +
compared O +
with O +
iDCs O +
alone O +
over O +
the O +
same O +
period O +
( O +
Fig O +
. O +
3 O +
A O +
) O +
. O +

The O +
equal O +
ratio O +
of O +
NK O +
/ O +
DC O +
( O +
1 O +
: O +
1 O +
) O +
fell O +
between O +
these O +
two O +
extremes O +
. O +

The O +
NK O +
cell O +
- O +
mediated O +
lysis O +
of O +
the O +
K562 B-CellLine +
targets O +
increased O +
at O +
all O +
ratios O +
tested O +
after O +
the O +
24 O +
- O +
h O +
incubation O +
. O +

These O +
striking O +
differences O +
between O +
death O +
and O +
survival O +
of O +
DCs O +
upon O +
encountering O +
NK O +
cells O +
correlate O +
precisely O +
with O +
our O +
previous O +
results O +
on O +
TNF O +
- O +
alpha O +
and O +
IL O +
- O +
12 O +
p40 O +
production O +
where O +
increasing O +
numbers O +
of O +
NK O +
cells O +
in O +
the O +
culture O +
shifts O +
the O +
NK O +
effect O +
from O +
potent O +
stimulation O +
to O +
complete O +
inhibition O +
( O +
Fig O +
. O +
2 O +
) O +
. O +

Figure O +
3 O +
. O +

Activated O +
/ O +
cultured O +
NK O +
cell O +
- O +
mediated O +
death O +
/ O +
survival O +
of O +
DCs O +
and O +
NK O +
- O +
DC O +
conjugate O +
formation O +
. O +

NK O +
cell O +
mediated O +
killing O +
/ O +
survival O +
of O +
CFDA O +
. O +
SE O +
- O +
loaded O +
iDCs O +
( O +
A O +
) O +
and O +
K562 B-CellLine +
cells O +
( O +
B O +
) O +
was O +
measured O +
by O +
flow O +
cytometry O +
over O +
4 O +
h O +
( O +
* O +
) O +
or O +
24 O +
h O +
( O +
* O +
) O +
at O +
the O +
indicated O +
NK O +
/ O +
DC O +
ratios O +
as O +
described O +
in O +
Materials O +
and O +
Methods O +
. O +

Results O +
are O +
presented O +
as O +
percentage O +
of O +
specific O +
lysis O +
+ O +
/ O +
- O +
SEM O +
( O +
n O +
= O +
3 O +
independent O +
experiments O +
) O +
. O +

NK O +
- O +
DC O +
( O +
C O +
- O +
E O +
) O +
or O +
NK O +
- O +
K562 B-CellLine +
( O +
F O +
- O +
H O +
) O +
conjugate O +
formation O +
was O +
measured O +
by O +
flow O +
cytometry O +
, O +
at O +
the O +
following O +
ratios O +
( O +
NK O +
/ O +
DC O +
or O +
NK O +
/ O +
K562 B-CellLine +
) O +
: O +
1 O +
: O +
5 O +
( O +
C O +
and O +
F O +
) O +
; O +
1 O +
: O +
1 O +
( O +
D O +
and O +
G O +
) O +
; O +
and O +
5 O +
: O +
1 O +
( O +
E O +
and O +
H O +
) O +
. O +

Snarf O +
- O +
1 O +
( O +
FL3 O +
) O +
- O +
labeled O +
iDCs O +
or O +
K562 B-CellLine +
cells O +
were O +
incubated O +
( O +
30 O +
min O +
) O +
with O +
CFDA O +
. O +
SE O +
( O +
FL1 O +
) O +
- O +
labeled O +
NK O +
cells O +
at O +
the O +
different O +
ratios O +
. O +

The O +
percentage O +
of O +
conjugates O +
formed O +
( O +
top O +
right O +
quadrant O +
) O +
was O +
calculated O +
by O +
determining O +
the O +
percentage O +
of O +
FL3 O +
+ O +
( O +
Snarf O +
- O +
1 O +
) O +
events O +
which O +
were O +
also O +
positive O +
for O +
FL1 O +
( O +
CFDA O +
. O +
SE O +
) O +
. O +

The O +
results O +
are O +
representative O +
of O +
four O +
experiments O +
performed O +
with O +
activated O +
NK O +
cells O +
. O +

Resting O +
NK O +
cells O +
also O +
readily O +
formed O +
conjugates O +
with O +
autologous O +
iDCs O +
( O +
data O +
not O +
shown O +
) O +
. O +

NK O +
cells O +
can O +
both O +
efficiently O +
kill O +
and O +
potently O +
stimulate O +
DCs O +
in O +
our O +
model O +
system O +
and O +
each O +
of O +
these O +
opposing O +
effects O +
appear O +
dependent O +
on O +
cell O +
- O +
to O +
- O +
cell O +
contact O +
. O +

To O +
quantify O +
these O +
apparent O +
cognate O +
interactions O +
we O +
measured O +
the O +
formation O +
of O +
NK O +
- O +
DC O +
conjugates O +
and O +
compared O +
them O +
to O +
conjugates O +
formed O +
by O +
NK O +
cells O +
and O +
tumor O +
targets O +
. O +

Our O +
analysis O +
revealed O +
that O +
NK O +
cells O +
bound O +
DC O +
( O +
Fig O +
. O +
3 O +
C O +
- O +
E O +
) O +
with O +
an O +
efficiency O +
almost O +
equal O +
to O +
that O +
of O +
NK O +
cell O +
binding O +
to O +
the O +
classical O +
NK O +
- O +
target O +
, O +
K562 B-CellLine +
( O +
Fig O +
. O +
3 O +
F O +
- O +
H O +
) O +
. O +

Binding O +
was O +
detectable O +
even O +
at O +
the O +
lowest O +
NK O +
/ O +
DC O +
ratio O +
tested O +
( O +
1 O +
: O +
5 O +
) O +
indicating O +
that O +
NK O +
- O +
DC O +
conjugates O +
are O +
formed O +
in O +
our O +
other O +
experiments O +
measuring O +
cytokine O +
production O +
and O +
cell O +
killing O +
. O +

Our O +
initial O +
experiments O +
using O +
resting O +
NK O +
cells O +
( O +
Fig O +
. O +
1 O +
) O +
demonstrated O +
a O +
contact O +
- O +
dependent O +
NK O +
effect O +
driving O +
iDCs O +
to O +
mature O +
. O +

Therefore O +
, O +
we O +
tested O +
what O +
effects O +
activated O +
NK O +
cells O +
mediated O +
on O +
DC O +
maturation O +
( O +
Fig O +
. O +
4 O +
) O +
. O +

Similar O +
to O +
our O +
previous O +
results O +
with O +
activated O +
NK O +
cells O +
( O +
Figs O +
. O +
2 O +
and O +
3 O +
) O +
, O +
addition O +
of O +
NK O +
cells O +
to O +
the O +
culture O +
leads O +
to O +
opposing O +
effects O +
on O +
the O +
iDC O +
population O +
depending O +
on O +
the O +
NK O +
/ O +
DC O +
ratio O +
. O +

Compared O +
with O +
the O +
untreated O +
DCs O +
( O +
Fig O +
. O +
4 O +
A O +
- O +
C O +
) O +
, O +
low O +
NK O +
/ O +
DC O +
ratios O +
( O +
1 O +
: O +
5 O +
or O +
1 O +
: O +
1 O +
) O +
consistently O +
augmented O +
expression O +
of O +
the O +
maturation O +
markers O +
: O +
CD86 O +
( O +
Fig O +
. O +
4 O +
D O +
- O +
I O +
) O +
, O +
CD83 O +
, O +
and O +
HLA O +
- O +
DR O +
( O +
data O +
not O +
shown O +
) O +
. O +

At O +
a O +
5 O +
: O +
1 O +
ratio O +
( O +
NK O +
/ O +
DC O +
) O +
most O +
of O +
the O +
DCs O +
are O +
nonviable O +
( O +
Fig O +
. O +
4 O +
J O +
- O +
L O +
) O +
. O +

Addition O +
of O +
suboptimal O +
doses O +
of O +
LPS O +
( O +
Fig O +
. O +
4 O +
C O +
, O +
F O +
, O +
I O +
, O +
and O +
L O +
) O +
augmented O +
the O +
NK O +
- O +
induced O +
maturation O +
at O +
NK O +
/ O +
DC O +
ratios O +
of O +
1 O +
: O +
5 O +
and O +
1 O +
: O +
1 O +
, O +
but O +
had O +
no O +
effect O +
at O +
the O +
5 O +
: O +
1 O +
ratio O +
. O +

Again O +
, O +
DC O +
maturation O +
was O +
dependent O +
on O +
NK O +
cell O +
contact O +
and O +
endogenously O +
produced O +
TNF O +
- O +
alpha O +
, O +
because O +
it O +
did O +
not O +
occur O +
when O +
the O +
two O +
cell O +
types O +
were O +
separated O +
in O +
trans O +
- O +
wells O +
or O +
upon O +
the O +
addition O +
of O +
a O +
neutralizing O +
antibody O +
for O +
TNF O +
- O +
alpha O +
( O +
Fig O +
. O +
5 O +
) O +
. O +

Moreover O +
, O +
addition O +
of O +
blocking O +
reagents O +
for O +
CD80 O +
, O +
CD86 O +
, O +
CD154 O +
, O +
CD95 O +
, O +
CD11a O +
, O +
CD50 O +
, O +
IL O +
- O +
12 O +
, O +
IFN O +
- O +
gamma O +
, O +
IFN O +
- O +
alpha O +
, O +
or O +
IFN O +
- O +
beta O +
had O +
no O +
effect O +
on O +
the O +
NK O +
- O +
induced O +
maturation O +
( O +
data O +
not O +
shown O +
) O +
. O +

Figure O +
4 O +
. O +

Activated O +
/ O +
cultured O +
NK O +
cell O +
- O +
mediated O +
maturation O +
/ O +
death O +
of O +
DCs O +
. O +

Cultured O +
iDCs O +
were O +
incubated O +
for O +
48 O +
h O +
, O +
alone O +
( O +
A O +
- O +
C O +
) O +
, O +
or O +
with O +
NK O +
cells O +
at O +
the O +
following O +
ratios O +
( O +
NK O +
/ O +
DC O +
) O +
, O +
1 O +
: O +
5 O +
( O +
D O +
- O +
F O +
) O +
, O +
1 O +
: O +
1 O +
( O +
G O +
- O +
I O +
) O +
, O +
and O +
5 O +
: O +
1 O +
( O +
J O +
- O +
L O +
) O +
. O +

Forward O +
versus O +
side O +
scatter O +
plots O +
( O +
A O +
, O +
D O +
, O +
G O +
, O +
and O +
J O +
) O +
show O +
the O +
gating O +
on O +
the O +
DC O +
subset O +
and O +
demonstrate O +
its O +
disappearance O +
at O +
the O +
5 O +
: O +
1 O +
( O +
NK O +
/ O +
DC O +
) O +
ratio O +
( O +
J O +
) O +
. O +

Propidium O +
iodide O +
staining O +
of O +
the O +
NK O +
/ O +
DC O +
( O +
5 O +
: O +
1 O +
) O +
cultures O +
confirmed O +
the O +
almost O +
complete O +
absence O +
of O +
viable O +
DCs O +
( O +
data O +
not O +
shown O +
) O +
. O +

Staining O +
for O +
CD86 O +
expression O +
was O +
performed O +
as O +
described O +
in O +
Fig O +
. O +

1 O +
and O +
the O +
histograms O +
are O +
shown O +
for O +
DCs O +
cultured O +
in O +
the O +
presence O +
( O +
C O +
, O +
F O +
, O +
I O +
, O +
and O +
L O +
) O +
or O +
absence O +
( O +
B O +
, O +
E O +
, O +
H O +
, O +
and O +
K O +
) O +
of O +
1 O +
ng O +
/ O +
ml O +
of O +
LPS O +
. O +

Results O +
are O +
representative O +
of O +
six O +
experiments O +
performed O +
. O +

Figure O +
5 O +
. O +

Activated O +
/ O +
cultured O +
NK O +
cell O +
- O +
induced O +
DC O +
maturation O +
is O +
dependent O +
on O +
cell O +
- O +
to O +
- O +
cell O +
contact O +
and O +
endogenous O +
TNF O +
- O +
alpha O +
production O +
. O +

Cultured O +
iDCs O +
were O +
incubated O +
alone O +
( O +
A O +
, O +
D O +
, O +
and O +
G O +
) O +
; O +
with O +
activated O +
NK O +
cells O +
at O +
an O +
NK O +
/ O +
DC O +
ratio O +
of O +
1 O +
: O +
5 O +
( O +
B O +
, O +
E O +
, O +
and O +
H O +
) O +
; O +
with O +
activated O +
NK O +
cells O +
( O +
NK O +
/ O +
DC O +
; O +
1 O +
: O +
5 O +
) O +
separated O +
in O +
trans O +
- O +
wells O +
( O +
C O +
and O +
F O +
) O +
; O +
or O +
with O +
activated O +
NK O +
cells O +
and O +
10 O +
mug O +
/ O +
ml O +
of O +
a O +
neutralizing O +
antibody O +
for O +
TNF O +
- O +
alpha O +
( O +
I O +
) O +
. O +

LPS O +
concentrations O +
used O +
were O +
: O +
0 O +
ng O +
/ O +
ml O +
( O +
A O +
- O +
C O +
) O +
; O +
10 O +
ng O +
/ O +
ml O +
( O +
D O +
- O +
F O +
) O +
and O +
50 O +
ng O +
/ O +
ml O +
( O +
G O +
- O +
I O +
) O +
. O +

CD86 O +
staining O +
of O +
the O +
DC O +
subset O +
was O +
performed O +
as O +
in O +
Figs O +
. O +

1 O +
and O +
4 O +
. O +

Results O +
are O +
representative O +
of O +
four O +
experiments O +
performed O +
. O +

Acknowledgements O +

We O +
would O +
like O +
to O +
thank O +
our O +
colleague O +
Dr O +
. O +
Nikolaos O +
Papathanasiou O +
for O +
his O +
assistance O +
in O +
performing O +
the O +
statistical O +
analysis O +
. O +

Anion O +
to O +
cation O +
selectivity O +
ratio O +
determined O +
from O +
the O +
relative O +
rates O +
of O +
reaction O +
of O +
MTSES O +
- O +
and O +
MTSET O +
+ O +
with O +
the O +
water O +
exposed O +
residues O +
in O +
the O +
M6 O +
segment O +
. O +

The O +
anion O +
selectivity O +
ratio O +
is O +
calculated O +
as O +
described O +
in O +
Table O +
II O +
, O +
column O +
5 O +
. O +

Note O +
the O +
marked O +
increase O +
in O +
anion O +
selectivity O +
at O +
the O +
residues O +
T351C O +
and O +
Q353C O +
. O +

A O +
ratio O +
of O +
1 O +
indicates O +
no O +
selectivity O +
between O +
anions O +
and O +
cations O +
. O +

The O +
larger O +
the O +
ratio O +
the O +
greater O +
the O +
anion O +
selectivity O +
. O +

Mineralization O +
( O +
red O +
) O +
of O +
the O +
aorta O +
is O +
prevented O +
by O +
local O +
( O +
left O +
) O +
, O +
but O +
not O +
global O +
( O +
right O +
) O +
, O +
Mgp O +
expression O +
. O +

Loss O +
of O +
both O +
apical O +
pathways O +
( O +
bottom O +
) O +
allows O +
astral O +
microtubules O +
( O +
arrows O +
) O +
to O +
form O +
apically O +
and O +
basally O +
in O +
neuroblasts O +
. O +

Authors O +
' O +
contributions O +

All O +
authors O +
contributed O +
to O +
the O +
development O +
of O +
the O +
methodology O +
. O +

CY O +
and O +
NZ O +
led O +
method O +
conceptualization O +
and O +
prepared O +
the O +
original O +
draft O +
, O +
which O +
was O +
revised O +
by O +
JR O +
. O +

CY O +
and O +
VD O +
performed O +
most O +
implementations O +
. O +

All O +
authors O +
read O +
and O +
approved O +
the O +
final O +
manuscript O +
. O +

Determination O +
of O +
As O +
metabolites O +

We O +
assessed O +
As O +
metabolism O +
using O +
the O +
percentages O +
of O +
iAs O +
, O +
MMA O +
, O +
and O +
DMA O +
in O +
urine O +
, O +
as O +
well O +
as O +
two O +
methylation O +
indexes O +
[ O +
i O +
. O +
e O +
. O +
, O +
primary O +
methylation O +
index O +
( O +
PMI O +
) O +
, O +
defined O +
as O +
the O +
ratio O +
between O +
MMA O +
and O +
iAs O +
, O +
and O +
secondary O +
methylation O +
index O +
( O +
SMI O +
) O +
, O +
defined O +
as O +
the O +
ratio O +
between O +
DMA O +
and O +
MMA O +
. O +

We O +
used O +
total O +
urinary O +
As O +
[ O +
U O +
- O +
As O +
; O +
the O +
sum O +
of O +
As O +
metabolites O +
( O +
iAs O +
+ O +
MMA O +
+ O +
DMA O +
) O +
in O +
urine O +
] O +
as O +
the O +
measure O +
of O +
iAs O +
exposure O +
. O +

Concentrations O +
of O +
As O +
metabolites O +
in O +
urine O +
were O +
measured O +
with O +
an O +
Agilent O +
1100 O +
HPLC O +
system O +
( O +
Agilent O +
Technologies O +
, O +
Waldbronn O +
, O +
Germany O +
) O +
, O +
coupled O +
with O +
hydride O +
generation O +
( O +
HG O +
) O +
inductively O +
coupled O +
plasma O +
mass O +
spectrometry O +
( O +
ICPMS O +
) O +
( O +
Agilent O +
7500ce O +
series O +
; O +
Agilent O +
Technologies O +
, O +
Japan O +
) O +
. O +

The O +
method O +
measures O +
metabolites O +
of O +
iAs O +
[ O +
iAs O +
( O +
III O +
) O +
, O +
iAs O +
( O +
V O +
) O +
, O +
MMA O +
, O +
and O +
DMA O +
] O +
, O +
but O +
not O +
organic O +
As O +
species O +
( O +
e O +
. O +
g O +
. O +
, O +
arsenobetaine O +
, O +
arsenocholine O +
) O +
originating O +
from O +
the O +
diet O +
, O +
because O +
those O +
arsenicals O +
do O +
not O +
form O +
volatile O +
arsines O +
( O +
hydride O +
generation O +
) O +
like O +
iAs O +
and O +
its O +
metabolites O +
do O +
. O +

The O +
method O +
was O +
described O +
in O +
detail O +
by O +
Lindberg O +
et O +
al O +
. O +

( O +
2006 O +
) O +
. O +

Determination O +
limits O +
were O +
0 O +
. O +
1 O +
mug O +
/ O +
L O +
for O +
arsenite O +
[ O +
As O +
( O +
III O +
) O +
] O +
and O +
MMA O +
and O +
0 O +
. O +
2 O +
mug O +
/ O +
L O +
for O +
DMA O +
and O +
arsenate O +
[ O +
As O +
( O +
V O +
) O +
] O +
. O +

We O +
adjusted O +
As O +
concentrations O +
for O +
variations O +
in O +
dilution O +
by O +
specific O +
gravity O +
( O +
to O +
the O +
mean O +
value O +
of O +
1 O +
. O +
012 O +
g O +
/ O +
mL O +
) O +
; O +
U O +
- O +
Cre O +
, O +
which O +
is O +
commonly O +
used O +
for O +
dilution O +
adjustment O +
, O +
was O +
influenced O +
more O +
by O +
age O +
and O +
nutrition O +
than O +
was O +
specific O +
gravity O +
, O +
and O +
U O +
- O +
Cre O +
was O +
also O +
associated O +
with O +
urinary O +
As O +
( O +
Nermell O +
et O +
al O +
. O +
2007 O +
) O +
. O +

For O +
quality O +
control O +
purposes O +
, O +
we O +
analyzed O +
the O +
reference O +
material O +
( O +
CRM O +
No O +
. O +
18 O +
; O +
National O +
Institute O +
for O +
Environmental O +
Studies O +
, O +
Ibaraki O +
, O +
Japan O +
) O +
with O +
a O +
certified O +
DMA O +
concentration O +
of O +
36 O +
+ O +
/ O +
- O +
9 O +
mug O +
/ O +
L O +
together O +
with O +
the O +
collected O +
urine O +
samples O +
. O +

The O +
concentration O +
of O +
DMA O +
was O +
41 O +
+ O +
/ O +
- O +
3 O +
. O +
4 O +
mug O +
/ O +
L O +
( O +
mean O +
+ O +
/ O +
- O +
SD O +
; O +
n O +
= O +
18 O +
) O +
. O +

Urine O +
samples O +
were O +
also O +
analyzed O +
for O +
As O +
metabolites O +
by O +
atomic O +
fluorescence O +
spectrometry O +
( O +
AFS O +
) O +
and O +
for O +
the O +
sum O +
of O +
As O +
metabolites O +
by O +
atomic O +
absorption O +
spectrometry O +
( O +
AAS O +
) O +
, O +
as O +
reported O +
by O +
Lindberg O +
et O +
al O +
. O +

( O +
2007a O +
) O +
. O +

The O +
results O +
of O +
ICPMS O +
and O +
AFS O +
showed O +
good O +
agreement O +
for O +
all O +
metabolites O +
; O +
for O +
iAs O +
[ O +
As O +
( O +
III O +
) O +
+ O +
As O +
( O +
V O +
) O +
] O +
, O +
MMA O +
, O +
and O +
DMA O +
, O +
R2 O +
= O +
0 O +
. O +
91 O +
, O +
0 O +
. O +
91 O +
, O +
and O +
0 O +
. O +
97 O +
, O +
respectively O +
( O +
n O +
= O +
221 O +
) O +
. O +

Further O +
, O +
we O +
obtained O +
good O +
agreement O +
for O +
the O +
sum O +
of O +
As O +
metabolites O +
between O +
the O +
three O +
different O +
methods O +
( O +
for O +
ICPMS O +
vs O +
. O +
AFS O +
, O +
R2 O +
= O +
0 O +
. O +
97 O +
; O +
for O +
ICPMS O +
vs O +
. O +
AAS O +
, O +
R2 O +
= O +
0 O +
. O +
96 O +
( O +
n O +
= O +
221 O +
) O +
. O +

Background O +

Potato O +
late O +
blight O +
, O +
a O +
disease O +
caused O +
by O +
the O +
oomycete O +
pathogen O +
Phytophthora O +
infestans O +
, O +
is O +
one O +
of O +
the O +
world O +
' O +
s O +
most O +
devastating O +
crop O +
diseases O +
. O +

World O +
- O +
wide O +
losses O +
due O +
to O +
late O +
blight O +
exceed O +
several O +
billion O +
dollars O +
annually O +
[ O +
1 O +
] O +
. O +

Most O +
of O +
the O +
potato O +
cultivars O +
currently O +
grown O +
in O +
the O +
United O +
States O +
are O +
highly O +
susceptible O +
to O +
late O +
blight O +
and O +
control O +
of O +
this O +
disease O +
relies O +
almost O +
exclusively O +
on O +
fungicide O +
applications O +
. O +

The O +
most O +
effective O +
and O +
environmentally O +
sound O +
way O +
for O +
controlling O +
late O +
blight O +
is O +
to O +
incorporate O +
natural O +
resistance O +
into O +
potato O +
cultivars O +
. O +

The O +
pedigrees O +
of O +
many O +
potato O +
cultivars O +
currently O +
used O +
in O +
different O +
countries O +
include O +
late O +
blight O +
resistant O +
germplasm O +
derived O +
from O +
Solanum O +
demissum O +
, O +
Solanum O +
andigena O +
, O +
and O +
other O +
wild O +
species O +
. O +

However O +
, O +
most O +
of O +
the O +
resistance O +
derived O +
from O +
these O +
wild O +
species O +
is O +
controlled O +
by O +
single O +
dominant O +
resistance O +
genes O +
( O +
R O +
genes O +
) O +
. O +

These O +
R O +
genes O +
are O +
only O +
effective O +
in O +
preventing O +
the O +
development O +
of O +
late O +
blight O +
if O +
the O +
invading O +
P O +
. O +
infestans O +
race O +
contains O +
the O +
corresponding O +
avirulence O +
genes O +
. O +

This O +
R O +
gene O +
- O +
mediated O +
resistance O +
is O +
often O +
short O +
- O +
lived O +
and O +
is O +
rapidly O +
overcome O +
by O +
new O +
races O +
of O +
the O +
late O +
blight O +
pathogen O +
. O +

Solanum O +
bulbocastanum O +
( O +
2n O +
= O +
2x O +
= O +
24 O +
) O +
is O +
a O +
diploid O +
species O +
that O +
has O +
adapted O +
in O +
the O +
same O +
environment O +
as O +
the O +
late O +
blight O +
pathogen O +
. O +

This O +
wild O +
species O +
was O +
characterized O +
as O +
possessing O +
durable O +
resistance O +
against O +
P O +
. O +
infestans O +
, O +
even O +
under O +
high O +
disease O +
pressure O +
[ O +
2 O +
, O +
3 O +
] O +
. O +

Two O +
resistance O +
genes O +
, O +
RB O +
( O +
Rpi O +
- O +
blb1 O +
) O +
and O +
Rpi O +
- O +
blb2 O +
, O +
have O +
been O +
cloned O +
from O +
S O +
. O +
bulbocastanum O +
[ O +
4 O +
- O +
6 O +
] O +
. O +

Both O +
genes O +
confer O +
broad O +
- O +
spectrum O +
resistance O +
against O +
a O +
wide O +
range O +
of O +
known O +
P O +
. O +
infestans O +
races O +
. O +

Transgenic O +
potato O +
lines O +
containing O +
a O +
single O +
RB O +
gene O +
showed O +
a O +
high O +
- O +
level O +
resistance O +
in O +
the O +
Toluca O +
Valley O +
, O +
Mexico O +
, O +
where O +
the O +
potato O +
fields O +
are O +
naturally O +
intensively O +
infested O +
with O +
the O +
most O +
diversified O +
P O +
. O +
infestans O +
populations O +
[ O +
7 O +
] O +
. O +

Most O +
interestingly O +
, O +
transgenic O +
RB O +
plants O +
did O +
not O +
show O +
total O +
immunity O +
to O +
late O +
blight O +
, O +
but O +
instead O +
showed O +
a O +
marked O +
delay O +
in O +
both O +
onset O +
of O +
symptoms O +
and O +
development O +
of O +
lesions O +
. O +

Such O +
rate O +
- O +
limiting O +
resistance O +
may O +
put O +
less O +
selection O +
pressure O +
on O +
the O +
P O +
. O +
infestans O +
populations O +
and O +
protect O +
the O +
durability O +
of O +
this O +
resistance O +
gene O +
. O +

The O +
RB O +
gene O +
therefore O +
provides O +
an O +
excellent O +
model O +
to O +
study O +
the O +
mechanism O +
of O +
broad O +
- O +
spectrum O +
and O +
rate O +
- O +
limiting O +
disease O +
resistances O +
. O +

An O +
understanding O +
of O +
the O +
underlying O +
mechanism O +
of O +
this O +
type O +
of O +
resistance O +
is O +
important O +
for O +
developing O +
strategies O +
to O +
breed O +
durable O +
and O +
sustainable O +
disease O +
resistance O +
. O +

Several O +
genes O +
have O +
been O +
implicated O +
in O +
the O +
regulation O +
of O +
R O +
gene O +
function O +
. O +

Of O +
these O +
genes O +
, O +
Rar1 O +
and O +
Sgt1 O +
are O +
among O +
the O +
most O +
extensively O +
studied O +
genes O +
. O +

The O +
Rar1 O +
( O +
required O +
for O +
Mla12 O +
resistance O +
) O +
gene O +
was O +
first O +
identified O +
for O +
its O +
essential O +
role O +
in O +
the O +
function O +
of O +
a O +
subset O +
of O +
Mla O +
genes O +
that O +
confer O +
resistance O +
to O +
barley O +
powdery O +
mildew O +
[ O +
8 O +
] O +
. O +

The O +
RAR1 O +
protein O +
contains O +
two O +
highly O +
similar O +
but O +
distinct O +
cysteine O +
- O +
and O +
histidine O +
- O +
rich O +
( O +
CHORD O +
) O +
Zn2 O +
+ O +
- O +
binding O +
domains O +
and O +
was O +
proposed O +
to O +
play O +
a O +
role O +
in O +
stabilizing O +
R O +
proteins O +
in O +
a O +
confirmation O +
that O +
is O +
implicated O +
in O +
receiving O +
pathogen O +
signals O +
[ O +
9 O +
] O +
. O +

The O +
Sgt1 O +
gene O +
( O +
suppressor O +
of O +
the O +
G2 O +
allele O +
of O +
skp1 O +
) O +
is O +
an O +
essential O +
gene O +
with O +
multiple O +
functions O +
in O +
yeast O +
. O +

SGT1 O +
protein O +
was O +
initially O +
identified O +
as O +
a O +
RAR1 O +
- O +
interacting O +
partner O +
in O +
a O +
yeast O +
two O +
- O +
hybrid O +
screen O +
[ O +
10 O +
] O +
. O +

SGT1 O +
may O +
play O +
a O +
role O +
in O +
R O +
protein O +
accumulation O +
[ O +
11 O +
] O +
. O +

Rar1 O +
and O +
Sgt1 O +
genes O +
are O +
required O +
in O +
various O +
R O +
- O +
gene O +
mediated O +
resistance O +
against O +
viral O +
, O +
bacterial O +
, O +
oomycete O +
or O +
fungal O +
pathogens O +
[ O +
12 O +
] O +
. O +

However O +
, O +
none O +
of O +
the O +
previously O +
studied O +
R O +
genes O +
showed O +
a O +
race O +
- O +
non O +
- O +
specific O +
and O +
rate O +
- O +
limiting O +
resistance O +
phenotype O +
as O +
the O +
RB O +
gene O +
. O +

In O +
addition O +
, O +
the O +
role O +
the O +
Rar1 O +
and O +
Sgt1 O +
genes O +
are O +
not O +
universal O +
and O +
these O +
genes O +
are O +
not O +
essential O +
for O +
resistance O +
involving O +
some O +
R O +
genes O +
[ O +
12 O +
, O +
13 O +
] O +
. O +

Besides O +
the O +
two O +
broad O +
- O +
spectrum O +
resistance O +
genes O +
RB O +
and O +
Rpi O +
- O +
blb2 O +
, O +
several O +
race O +
- O +
specific O +
late O +
blight O +
resistance O +
genes O +
have O +
also O +
been O +
cloned O +
[ O +
14 O +
- O +
16 O +
] O +
. O +

Numerous O +
late O +
blight O +
resistance O +
genes O +
have O +
recently O +
been O +
mapped O +
in O +
various O +
potato O +
species O +
or O +
populations O +
[ O +
17 O +
- O +
25 O +
] O +
. O +

However O +
, O +
there O +
is O +
almost O +
no O +
information O +
available O +
about O +
the O +
resistance O +
pathways O +
mediated O +
by O +
any O +
of O +
these O +
genes O +
. O +

As O +
an O +
initial O +
effort O +
to O +
understand O +
the O +
RB O +
- O +
mediated O +
late O +
blight O +
resistance O +
pathway O +
, O +
we O +
silenced O +
the O +
Rar1 O +
and O +
Sgt1 O +
genes O +
using O +
an O +
RNAi O +
- O +
based O +
approach O +
in O +
a O +
potato O +
line O +
containing O +
the O +
RB O +
gene O +
. O +

We O +
demonstrated O +
that O +
SGT1 O +
, O +
but O +
not O +
RAR1 O +
, O +
is O +
essential O +
for O +
the O +
RB O +
- O +
mediated O +
broad O +
- O +
spectrum O +
resistance O +
to O +
potato O +
late O +
blight O +
. O +

Ovariectomy O +

Based O +
on O +
the O +
uterine O +
weight O +
, O +
we O +
determined O +
seven O +
unsuccessful O +
OVXs O +
. O +

The O +
rats O +
concerned O +
were O +
removed O +
from O +
further O +
analyses O +
, O +
which O +
left O +
nine O +
rats O +
in O +
the O +
control O +
group O +
, O +
five O +
in O +
the O +
OVX O +
group O +
, O +
seven O +
in O +
the O +
OVX O +
and O +
late O +
ZOL O +
group O +
, O +
and O +
eight O +
in O +
the O +
OVX O +
and O +
early O +
ZOL O +
group O +
. O +

For O +
each O +
animal O +
, O +
we O +
determined O +
the O +
percentage O +
change O +
in O +
structural O +
parameters O +
compared O +
to O +
the O +
values O +
at O +
week O +
0 O +
. O +

Figure O +
1 O +
shows O +
the O +
average O +
percentage O +
change O +
and O +
upper O +
standard O +
deviation O +
for O +
all O +
groups O +
for O +
BV O +
/ O +
TV O +
, O +
Conn O +
. O +
D O +
, O +
SMI O +
, O +
Tb O +
. O +
N O +
, O +
Tb O +
. O +
Th O +
, O +
and O +
Tb O +
. O +
Sp O +
. O +

The O +
OVX O +
group O +
without O +
treatment O +
showed O +
large O +
changes O +
in O +
structural O +
parameters O +
, O +
indicating O +
the O +
development O +
of O +
OVX O +
- O +
induced O +
bone O +
loss O +
( O +
Figs O +
. O +
1 O +
and O +
2 O +
) O +
. O +

Paired O +
Student O +
' O +
s O +
t O +
- O +
test O +
indicated O +
significant O +
changes O +
within O +
2 O +
weeks O +
after O +
OVX O +
for O +
all O +
structural O +
parameters O +
. O +

BV O +
/ O +
TV O +
, O +
Conn O +
. O +
D O +
, O +
and O +
Tb O +
. O +
N O +
decreased O +
during O +
the O +
experiment O +
and O +
SMI O +
and O +
Tb O +
. O +
Sp O +
increased O +
. O +

Both O +
Tb O +
. O +
Th O +
and O +
Tb O +
. O +
N O +
decreased O +
within O +
2 O +
weeks O +
, O +
indicating O +
that O +
both O +
thinning O +
and O +
complete O +
resorption O +
of O +
trabeculae O +
started O +
directly O +
after O +
OVX O +
. O +

The O +
initial O +
rapid O +
loss O +
of O +
bone O +
and O +
connectivity O +
was O +
largely O +
accompanied O +
by O +
trabecular O +
thinning O +
, O +
while O +
secondary O +
, O +
slower O +
loss O +
of O +
bone O +
was O +
concomitant O +
with O +
a O +
decrease O +
in O +
Tb O +
. O +
N O +
. O +

While O +
BV O +
/ O +
TV O +
, O +
Conn O +
. O +
D O +
, O +
SMI O +
, O +
Tb O +
. O +
N O +
, O +
and O +
Tb O +
. O +
Sp O +
showed O +
continuous O +
changes O +
in O +
the O +
same O +
direction O +
throughout O +
the O +
experiment O +
, O +
Tb O +
. O +
Th O +
initially O +
decreased O +
significantly O +
until O +
4 O +
weeks O +
after O +
OVX O +
and O +
then O +
increased O +
again O +
until O +
after O +
16 O +
weeks O +
Tb O +
. O +
Th O +
was O +
significantly O +
higher O +
than O +
in O +
the O +
control O +
group O +
. O +

Fig O +
. O +

1 O +

Average O +
percentage O +
change O +
in O +
structural O +
parameters O +
in O +
the O +
metaphyseal O +
proximal O +
tibia O +
and O +
upper O +
standard O +
deviation O +
for O +
all O +
groups O +
at O +
all O +
time O +
points O +
. O +

Brackets O +
indicate O +
P O +
< O +
0 O +
. O +
05 O +
at O +
week O +
16 O +

Fig O +
. O +

2 O +

Same O +
slice O +
of O +
an O +
unprocessed O +
CT O +
scan O +
of O +
the O +
same O +
rat O +
in O +
the O +
OVX O +
group O +
taken O +
at O +
weeks O +
0 O +
( O +
a O +
) O +
, O +
2 O +
( O +
b O +
) O +
, O +
4 O +
( O +
c O +
) O +
, O +
8 O +
( O +
d O +
) O +
, O +
12 O +
( O +
e O +
) O +
, O +
and O +
16 O +
( O +
f O +
) O +
. O +

Images O +
show O +
typical O +
trabecular O +
bone O +
loss O +
due O +
to O +
OVX O +
in O +
the O +
metaphysis O +
. O +

Green O +
line O +
shows O +
the O +
analyzed O +
metaphyseal O +
bone O +

The O +
absolute O +
average O +
values O +
and O +
standard O +
deviations O +
for O +
all O +
structural O +
parameters O +
of O +
all O +
measurements O +
are O +
shown O +
in O +
Table O +
1 O +
. O +

At O +
the O +
starting O +
point O +
, O +
some O +
differences O +
in O +
the O +
values O +
between O +
the O +
groups O +
were O +
present O +
. O +

This O +
was O +
due O +
to O +
the O +
fact O +
that O +
some O +
animals O +
, O +
which O +
mostly O +
had O +
a O +
relatively O +
low O +
BV O +
/ O +
TV O +
, O +
were O +
removed O +
from O +
the O +
study O +
because O +
they O +
did O +
not O +
respond O +
to O +
the O +
OVX O +
. O +

However O +
, O +
since O +
we O +
compared O +
the O +
relative O +
changes O +
in O +
each O +
animal O +
, O +
the O +
results O +
were O +
most O +
likely O +
not O +
affected O +
by O +
the O +
difference O +
in O +
absolute O +
values O +
. O +

Table O +
1 O +

Mean O +
values O +
and O +
standard O +
deviation O +
of O +
all O +
structural O +
parameters O +
of O +
all O +
groups O +
at O +
the O +
start O +
of O +
the O +
experiment O +

Group O +
BV O +
/ O +
TV O +
( O +
1 O +
) O +
Conn O +
. O +
D O +
( O +
1 O +
/ O +
mm O +
) O +
SMI O +
( O +
1 O +
) O +
Tb O +
. O +
N O +
( O +
1 O +
/ O +
mm O +
) O +
Tb O +
. O +
Th O +
( O +
mum O +
) O +
Tb O +
. O +
Sp O +
( O +
mum O +
) O +

Control O +
0 O +
. O +
17 O +
( O +
0 O +
. O +
056 O +
) O +
41 O +
( O +
47 O +
) O +
1 O +
. O +
52 O +
( O +
0 O +
. O +
53 O +
) O +
1 O +
. O +
89 O +
( O +
1 O +
. O +
38 O +
) O +
105 O +
( O +
49 O +
) O +
613 O +
( O +
368 O +
) O +

OVX O +
0 O +
. O +
26 O +
( O +
0 O +
. O +
055 O +
) O +
141 O +
( O +
76 O +
) O +
1 O +
. O +
22 O +
( O +
0 O +
. O +
39 O +
) O +
3 O +
. O +
77 O +
( O +
1 O +
. O +
66 O +
) O +
84 O +
( O +
10 O +
) O +
335 O +
( O +
174 O +
) O +

OVX O +
+ O +
late O +
ZOL O +
0 O +
. O +
23 O +
( O +
0 O +
. O +
062 O +
) O +
86 O +
( O +
66 O +
) O +
1 O +
. O +
23 O +
( O +
0 O +
. O +
34 O +
) O +
2 O +
. O +
77 O +
( O +
1 O +
. O +
55 O +
) O +
89 O +
( O +
13 O +
) O +
482 O +
( O +
227 O +
) O +

OVX O +
+ O +
early O +
ZOL O +
0 O +
. O +
17 O +
( O +
0 O +
. O +
056 O +
) O +
38 O +
( O +
21 O +
) O +
1 O +
. O +
70 O +
( O +
0 O +
. O +
39 O +
) O +
1 O +
. O +
86 O +
( O +
0 O +
. O +
80 O +
) O +
95 O +
( O +
7 O +
) O +
647 O +
( O +
207 O +
) O +

Basilar O +
papilla O +

The O +
basilar O +
papilla O +
is O +
found O +
in O +
a O +
recess O +
that O +
opens O +
into O +
the O +
saccular O +
space O +
at O +
one O +
end O +
, O +
and O +
is O +
limited O +
by O +
a O +
thin O +
contact O +
membrane O +
at O +
the O +
other O +
. O +

The O +
contact O +
membrane O +
separates O +
the O +
endolymphatic O +
fluid O +
in O +
the O +
papillar O +
recess O +
from O +
the O +
perilymphatic O +
fluid O +
at O +
the O +
round O +
window O +
( O +
Lewis O +
and O +
Narins O +
1999 O +
; O +
Wever O +
1985 O +
) O +
. O +

The O +
recess O +
perimeter O +
is O +
roughly O +
oval O +
in O +
shape O +
; O +
in O +
the O +
bullfrog O +
, O +
Rana O +
catesbeiana O +
, O +
its O +
major O +
axis O +
is O +
approximately O +
200 O +
mum O +
long O +
, O +
while O +
the O +
minor O +
axis O +
measures O +
approximately O +
150 O +
mum O +
( O +
Van O +
Bergeijk O +
1957 O +
) O +
. O +

In O +
the O +
leopard O +
frog O +
, O +
Rana O +
pipiens O +
pipiens O +
, O +
it O +
is O +
of O +
similar O +
size O +
( O +
personal O +
observation O +
, O +
RLMS O +
& O +
JMS O +
) O +
. O +

The O +
oval O +
perimeter O +
of O +
the O +
lumen O +
is O +
formed O +
from O +
limbic O +
tissue O +
; O +
a O +
substance O +
unique O +
to O +
the O +
inner O +
ear O +
, O +
and O +
similar O +
to O +
cartilage O +
( O +
Wever O +
1985 O +
) O +
. O +

The O +
sensory O +
epithelium O +
is O +
approximately O +
100 O +
mum O +
long O +
. O +

It O +
occupies O +
a O +
curved O +
area O +
that O +
is O +
symmetrical O +
in O +
the O +
major O +
axis O +
of O +
the O +
elliptical O +
lumen O +
. O +

It O +
contains O +
approximately O +
60 O +
hair O +
cells O +
( O +
measured O +
in O +
Rana O +
catesbeiana O +
) O +
, O +
from O +
which O +
the O +
stereovilli O +
protrude O +
into O +
the O +
lumen O +
and O +
connect O +
to O +
the O +
tectorial O +
membrane O +
( O +
Frishkopf O +
and O +
Flock O +
1974 O +
) O +
. O +

Typically O +
the O +
orientation O +
of O +
the O +
hair O +
cells O +
, O +
as O +
defined O +
by O +
the O +
direction O +
to O +
which O +
the O +
v O +
- O +
shape O +
of O +
the O +
stereovilli O +
bundle O +
points O +
( O +
Lewis O +
et O +
al O +
. O +
1985 O +
) O +
, O +
is O +
away O +
from O +
the O +
sacculus O +
in O +
Ranidae O +
. O +

The O +
tectorial O +
membrane O +
spans O +
the O +
lumen O +
of O +
the O +
papillar O +
recess O +
. O +

It O +
occludes O +
about O +
half O +
the O +
lumen O +
, O +
and O +
consequently O +
takes O +
an O +
approximately O +
semi O +
- O +
circular O +
shape O +
when O +
viewed O +
from O +
the O +
saccular O +
side O +
( O +
Frishkopf O +
and O +
Flock O +
1974 O +
; O +
Wever O +
1985 O +
) O +
. O +

The O +
membrane O +
has O +
pores O +
at O +
the O +
surface O +
closest O +
to O +
the O +
epithelium O +
, O +
into O +
which O +
the O +
tips O +
of O +
the O +
hair O +
bundles O +
project O +
( O +
Lewis O +
and O +
Narins O +
1999 O +
) O +
. O +
4 O +

3 O +
. O +

Results O +
and O +
discussion O +

AbsC O +
was O +
overexpressed O +
and O +
purified O +
with O +
a O +
final O +
yield O +
of O +
approximately O +
10 O +
mg O +
of O +
protein O +
from O +
1 O +
l O +
culture O +
and O +
was O +
judged O +
to O +
be O +
greater O +
than O +
98 O +
% O +
pure O +
by O +
SDS O +
- O +
PAGE O +
analysis O +
. O +

The O +
DLS O +
analysis O +
after O +
gel O +
filtration O +
showed O +
a O +
monomodal O +
distribution O +
, O +
with O +
a O +
polydispersity O +
value O +
of O +
18 O +
. O +
9 O +
% O +
and O +
a O +
molecular O +
- O +
size O +
estimate O +
of O +
39 O +
. O +
6 O +
kDa O +
. O +

This O +
was O +
comparable O +
to O +
the O +
value O +
of O +
36 O +
kDa O +
estimated O +
from O +
the O +
calibrated O +
gel O +
- O +
filtration O +
column O +
, O +
strongly O +
suggesting O +
that O +
AbsC O +
exists O +
as O +
a O +
homodimer O +
in O +
solution O +
( O +
calculated O +
molecular O +
weight O +
of O +
41 O +
. O +
0 O +
kDa O +
for O +
the O +
His O +
- O +
tagged O +
dimer O +
) O +
, O +
in O +
agreement O +
with O +
other O +
characterized O +
MarR O +
homologues O +
. O +

Preliminary O +
crystals O +
grew O +
within O +
24 O +
h O +
at O +
293 O +
K O +
from O +
several O +
different O +
crystallization O +
conditions O +
. O +

Improved O +
crystals O +
were O +
subsequently O +
obtained O +
with O +
a O +
precipitant O +
solution O +
consisting O +
of O +
1 O +
M O +
ammonium O +
sulfate O +
, O +
0 O +
. O +
55 O +
M O +
potassium O +
sodium O +
tartrate O +
in O +
100 O +
mM O +
citrate O +
pH O +
5 O +
. O +
6 O +
, O +
giving O +
crystals O +
with O +
approximate O +
dimensions O +
of O +
700 O +
x O +
50 O +
x O +
50 O +
microm O +
( O +
Fig O +
. O +
1 O +
> O +
) O +
. O +

Native O +
X O +
- O +
ray O +
data O +
were O +
collected O +
from O +
a O +
single O +
AbsC O +
crystal O +
: O +
a O +
total O +
of O +
214 O +
x O +
0 O +
. O +
4degrees O +
oscillation O +
images O +
were O +
recorded O +
in O +
a O +
continuous O +
sweep O +
to O +
a O +
maximum O +
resolution O +
of O +
2 O +
. O +
25 O +
A O +
. O +

Indexing O +
was O +
consistent O +
with O +
a O +
primitive O +
orthorhombic O +
lattice O +
, O +
with O +
unit O +
- O +
cell O +
parameters O +
a O +
= O +
43 O +
. O +
53 O +
, O +
b O +
= O +
121 O +
. O +
30 O +
, O +
c O +
= O +
143 O +
. O +
75 O +
A O +
. O +

After O +
processing O +
the O +
data O +
in O +
space O +
group O +
P222 O +
, O +
pseudo O +
- O +
precession O +
plots O +
were O +
analysed O +
using O +
HKLVIEW O +
( O +
Collaborative O +
Computational O +
Project O +
, O +
Number O +
4 O +
, O +
1994 O +
> O +
) O +
and O +
the O +
systematic O +
absences O +
were O +
indicative O +
of O +
space O +
group O +
P212121 O +
. O +

Reprocessing O +
in O +
this O +
space O +
group O +
yielded O +
a O +
data O +
set O +
that O +
was O +
95 O +
. O +
6 O +
% O +
complete O +
to O +
2 O +
. O +
25 O +
A O +
resolution O +
. O +

Data O +
- O +
collection O +
statistics O +
are O +
summarized O +
in O +
Table O +
1 O +
> O +
. O +

Estimation O +
of O +
the O +
content O +
of O +
the O +
asymmetric O +
unit O +
( O +
ASU O +
) O +
suggested O +
that O +
three O +
or O +
four O +
His O +
- O +
tagged O +
AbsC O +
subunits O +
were O +
most O +
likely O +
, O +
giving O +
solvent O +
contents O +
of O +
60 O +
. O +
3 O +
% O +
or O +
47 O +
. O +
0 O +
% O +
and O +
crystal O +
- O +
packing O +
parameters O +
( O +
V O +
M O +
) O +
of O +
3 O +
. O +
09 O +
or O +
2 O +
. O +
32 O +
A3 O +
Da O +
- O +
1 O +
, O +
respectively O +
. O +

Given O +
that O +
both O +
DLS O +
and O +
gel O +
filtration O +
suggest O +
that O +
AbsC O +
is O +
dimeric O +
and O +
that O +
MarR O +
homologues O +
exist O +
as O +
homodimers O +
( O +
Wilkinson O +
& O +
Grove O +
, O +
2006 O +
> O +
) O +
, O +
an O +
even O +
number O +
of O +
subunits O +
per O +
ASU O +
, O +
i O +
. O +
e O +
. O +
four O +
, O +
would O +
seem O +
to O +
be O +
the O +
most O +
probable O +
( O +
Matthews O +
, O +
1968 O +
> O +
) O +
. O +

A O +
Patterson O +
function O +
calculated O +
on O +
data O +
in O +
the O +
resolution O +
range O +
10 O +
. O +
0 O +
- O +
3 O +
. O +
0 O +
A O +
revealed O +
a O +
significant O +
peak O +
( O +
at O +
24 O +
% O +
of O +
the O +
origin O +
peak O +
) O +
with O +
a O +
vector O +
of O +
u O +
= O +
0 O +
. O +
0 O +
, O +
v O +
= O +
0 O +
. O +
5 O +
, O +
w O +
= O +
0 O +
. O +
014 O +
, O +
indicating O +
that O +
one O +
or O +
more O +
molecules O +
in O +
the O +
ASU O +
were O +
similarly O +
orientated O +
. O +

A O +
self O +
- O +
rotation O +
function O +
calculated O +
on O +
data O +
in O +
the O +
resolution O +
range O +
10 O +
. O +
0 O +
- O +
5 O +
. O +
0 O +
A O +
using O +
MOLREP O +
( O +
Vagin O +
& O +
Teplyakov O +
, O +
2000 O +
> O +
) O +
did O +
not O +
show O +
any O +
clear O +
noncrystallographic O +
symmetry O +
( O +
NCS O +
) O +
, O +
perhaps O +
suggesting O +
that O +
if O +
NCS O +
axes O +
were O +
present O +
they O +
were O +
parallel O +
( O +
or O +
almost O +
parallel O +
) O +
to O +
crystallographic O +
axes O +
. O +

Fold O +
prediction O +
, O +
based O +
on O +
the O +
amino O +
- O +
acid O +
sequence O +
of O +
AbsC O +
, O +
was O +
performed O +
using O +
the O +
FUGUE O +
server O +
( O +
http O +
: O +
/ O +
/ O +
www O +
- O +
cryst O +
. O +
bioc O +
. O +
cam O +
. O +
ac O +
. O +
uk O +
/ O +
~ O +
fugue O +
/ O +
prfsearch O +
. O +
html O +
; O +
Shi O +
et O +
al O +
. O +
, O +
2001 O +
> O +
) O +
. O +

This O +
found O +
eight O +
' O +
certain O +
' O +
hits O +
, O +
with O +
the O +
top O +
three O +
being O +
MarR O +
( O +
PDB O +
code O +
1jgs O +
; O +
Z O +
score O +
21 O +
. O +
4 O +
; O +
18 O +
% O +
sequence O +
identity O +
) O +
, O +
SlyA O +
( O +
PDB O +
code O +
1lj9 O +
; O +
Z O +
score O +
18 O +
. O +
4 O +
; O +
16 O +
% O +
sequence O +
identity O +
) O +
and O +
YusO O +
( O +
PDB O +
code O +
1s3j O +
; O +
Z O +
score O +
15 O +
. O +
7 O +
; O +
16 O +
% O +
sequence O +
identity O +
) O +
. O +

All O +
three O +
hits O +
were O +
used O +
as O +
search O +
models O +
for O +
molecular O +
replacement O +
in O +
the O +
program O +
AMoRe O +
( O +
Navaza O +
, O +
1994 O +
> O +
) O +
, O +
but O +
none O +
yielded O +
plausible O +
solutions O +
against O +
the O +
2 O +
. O +
25 O +
A O +
resolution O +
native O +
data O +
set O +
, O +
although O +
this O +
is O +
not O +
too O +
surprising O +
given O +
their O +
very O +
low O +
sequence O +
identities O +
. O +

Thus O +
, O +
we O +
will O +
need O +
to O +
solve O +
the O +
AbsC O +
structure O +
by O +
isomorphous O +
replacement O +
methods O +
. O +

To O +
this O +
end O +
, O +
we O +
are O +
preparing O +
selenomethionine O +
- O +
labelled O +
protein O +
; O +
there O +
are O +
a O +
total O +
of O +
seven O +
methionine O +
residues O +
present O +
in O +
the O +
158 O +
- O +
amino O +
- O +
acid O +
sequence O +
of O +
AbsC O +
. O +

Mean O +
differences O +
of O +
scores O +
with O +
baseline O +
of O +
the O +
22 O +
patients O +
who O +
competed O +
all O +
QLQ O +
- O +
C30 O +
questionnaires O +
- O +
symptoms O +
scores O +
. O +

Click O +
here O +
for O +
file O +

Aim O +

This O +
study O +
reports O +
the O +
results O +
of O +
a O +
large O +
prospective O +
single O +
- O +
blinded O +
clinical O +
trial O +
of O +
3 O +
SSRI O +
( O +
paroxetine O +
, O +
fluoxetine O +
and O +
escitalopram O +
) O +
in O +
PE O +
using O +
a O +
validated O +
questionnaire O +
. O +

Haplotype O +
block O +
structure O +
from O +
one O +
replicate O +
generated O +
by O +
the O +
block O +
method O +
( O +
ALS O +
) O +
. O +

CA O +
IX O +
and O +
response O +
to O +
PMRT O +

Kaplan O +
- O +
Meier O +
probability O +
plots O +
of O +
OS O +
after O +
PMRT O +
among O +
CA O +
IX O +
positive O +
and O +
CA O +
IX O +
negative O +
patients O +
revealed O +
improved O +
survival O +
after O +
PMRT O +
in O +
both O +
subgroups O +
of O +
patients O +
( O +
Figure O +
2 O +
) O +
. O +

Fifteen O +
- O +
year O +
OS O +
probabilities O +
were O +
improved O +
by O +
7 O +
% O +
and O +
9 O +
% O +
after O +
PMRT O +
for O +
the O +
subgroups O +
of O +
CA O +
IX O +
positive O +
and O +
CA O +
IX O +
negative O +
patients O +
, O +
respectively O +
. O +

The O +
HR O +
of O +
overall O +
mortality O +
after O +
PMRT O +
was O +
0 O +
. O +
87 O +
( O +
95 O +
% O +
CI O +
0 O +
. O +
60 O +
to O +
1 O +
. O +
27 O +
) O +
for O +
the O +
small O +
subgroup O +
of O +
151 O +
CA O +
IX O +
positive O +
patients O +
and O +
0 O +
. O +
82 O +
( O +
95 O +
% O +
CI O +
0 O +
. O +
69 O +
to O +
0 O +
. O +
97 O +
) O +
for O +
the O +
large O +
subgroup O +
of O +
813 O +
CA O +
IX O +
negative O +
patients O +
. O +

HRs O +
and O +
95 O +
% O +
CIs O +
after O +
PMRT O +
did O +
not O +
differ O +
significantly O +
between O +
CA O +
IX O +
positive O +
and O +
CA O +
IX O +
negative O +
patients O +
for O +
OS O +
, O +
DSS O +
, O +
DM O +
, O +
or O +
LRR O +
( O +
Table O +
4 O +
) O +
. O +

In O +
multivariate O +
analysis O +
by O +
Cox O +
regression O +
, O +
no O +
significant O +
interaction O +
was O +
found O +
between O +
CA O +
IX O +
and O +
randomization O +
status O +
for O +
any O +
of O +
the O +
four O +
end O +
- O +
points O +
. O +

Similar O +
tendencies O +
were O +
observed O +
when O +
the O +
women O +
were O +
separated O +
into O +
premenopausal O +
and O +
postmenopausal O +
women O +
, O +
and O +
into O +
women O +
with O +
one O +
to O +
three O +
positive O +
nodes O +
and O +
those O +
with O +
more O +
than O +
three O +
positive O +
nodes O +
. O +

Table O +
4 O +

Hazard O +
ratios O +

CA O +
IX O +
positive O +
( O +
n O +
= O +
151 O +
) O +
CA O +
IX O +
negative O +
( O +
n O +
= O +
794 O +
) O +

Overall O +
mortality O +
0 O +
. O +
87 O +
( O +
0 O +
. O +
60 O +
- O +
1 O +
. O +
27 O +
) O +
0 O +
. O +
82 O +
( O +
0 O +
. O +
69 O +
- O +
0 O +
. O +
97 O +
) O +

Disease O +
- O +
specific O +
mortality O +
0 O +
. O +
83 O +
( O +
0 O +
. O +
55 O +
- O +
1 O +
. O +
27 O +
) O +
0 O +
. O +
76 O +
( O +
0 O +
. O +
63 O +
- O +
0 O +
. O +
93 O +
) O +

Distant O +
metastases O +
0 O +
. O +
83 O +
( O +
0 O +
. O +
54 O +
- O +
1 O +
. O +
25 O +
) O +
0 O +
. O +
76 O +
( O +
0 O +
. O +
63 O +
- O +
0 O +
. O +
91 O +
) O +

Locoregional O +
recurrence O +
0 O +
. O +
23 O +
( O +
0 O +
. O +
08 O +
- O +
0 O +
. O +
61 O +
) O +
0 O +
. O +
16 O +
( O +
0 O +
. O +
09 O +
- O +
0 O +
. O +
28 O +
) O +

Presented O +
are O +
hazard O +
ratios O +
( O +
95 O +
% O +
confidence O +
intervals O +
) O +
of O +
overall O +
mortality O +
, O +
disease O +
- O +
specific O +
mortality O +
, O +
distant O +
metastases O +
and O +
loco O +
- O +
regional O +
recurrence O +
probabilities O +
after O +
postmastectomy O +
radiotherapy O +
in O +
carbonic O +
anhydrase O +
( O +
CA O +
) O +
IX O +
positive O +
and O +
in O +
CA O +
IX O +
negative O +
high O +
- O +
risk O +
breast O +
cancer O +
patients O +
. O +

Figure O +
2 O +

Overall O +
survival O +
in O +
high O +
- O +
risk O +
breast O +
cancer O +
patients O +
. O +

Shown O +
are O +
Kaplan O +
- O +
Meier O +
probability O +
plots O +
of O +
overall O +
survival O +
in O +
high O +
- O +
risk O +
breast O +
cancer O +
patients O +
as O +
a O +
function O +
of O +
randomization O +
to O +
postmastectomy O +
radiotherapy O +
( O +
RT O +
) O +
within O +
the O +
subgroups O +
of O +
carbonic O +
anhydrase O +
( O +
CA O +
) O +
IX O +
negative O +
and O +
CA O +
IX O +
positive O +
patients O +
. O +

The O +
values O +
given O +
in O +
parentheses O +
after O +
hazard O +
ratios O +
( O +
HRs O +
) O +
are O +
the O +
95 O +
% O +
confidence O +
intervals O +
. O +

Changing O +
the O +
cutpoints O +
to O +
at O +
least O +
one O +
tumour O +
cell O +
, O +
or O +
> O +
= O +
20 O +
% O +
or O +
> O +
= O +
30 O +
% O +
invasive O +
tumour O +
staining O +
did O +
not O +
improve O +
the O +
predictive O +
value O +
of O +
positive O +
CA O +
IX O +
staining O +
( O +
data O +
not O +
presented O +
) O +
. O +

Competing O +
interests O +

The O +
authors O +
declare O +
that O +
they O +
have O +
no O +
competing O +
interests O +
. O +

Analysis O +
of O +
furAII O +
- O +
katGII O +
region O +

The O +
cDNA O +
from O +
M O +
. O +
fortuitum O +
under O +
the O +
different O +
stresses O +
was O +
analysed O +
by O +
PCR O +
using O +
the O +
primers O +
furAII O +
- O +
Fo O +
and O +
P1 O +
. O +
1 O +
( O +
Table O +
2 O +
) O +
to O +
test O +
the O +
presence O +
of O +
furAII O +
and O +
katGII O +
cotranscripts O +
. O +

PCR O +
cycling O +
was O +
performed O +
as O +
follows O +
: O +
a O +
denaturizing O +
step O +
at O +
95degreesC O +
for O +
5 O +
minutes O +
; O +
36 O +
cycles O +
of O +
95degreesC O +
for O +
45 O +
seconds O +
, O +
54degreesC O +
for O +
45 O +
seconds O +
and O +
72degreesC O +
for O +
1 O +
minute O +
; O +
and O +
a O +
final O +
extension O +
at O +
72degreesC O +
for O +
10 O +
minutes O +
. O +

Background O +

Previous O +
publications O +
indicate O +
that O +
acupuncture O +
is O +
efficient O +
for O +
the O +
treatment O +
of O +
pelvic O +
girdle O +
pain O +
, O +
PGP O +
, O +
in O +
pregnant O +
women O +
. O +

However O +
, O +
the O +
use O +
of O +
acupuncture O +
for O +
PGP O +
is O +
rare O +
due O +
to O +
insufficient O +
documentation O +
of O +
adverse O +
effects O +
of O +
this O +
treatment O +
in O +
this O +
specific O +
condition O +
. O +

The O +
aim O +
of O +
the O +
present O +
work O +
was O +
to O +
assess O +
adverse O +
effects O +
of O +
acupuncture O +
on O +
the O +
pregnancy O +
, O +
mother O +
, O +
delivery O +
and O +
the O +
fetus O +
/ O +
neonate O +
in O +
comparison O +
with O +
women O +
that O +
received O +
stabilising O +
exercises O +
as O +
adjunct O +
to O +
standard O +
treatment O +
or O +
standard O +
treatment O +
alone O +
. O +

Summary O +
of O +
studies O +
reporting O +
comorbidities O +
with O +
diabetes O +
. O +

Authors O +
' O +
contributions O +

MP O +
prepared O +
the O +
first O +
draft O +
with O +
the O +
assistance O +
of O +
JLdR O +
. O +

Other O +
authors O +
reviewed O +
the O +
manuscript O +
, O +
provided O +
further O +
contributions O +
and O +
suggestions O +
. O +

All O +
of O +
the O +
authors O +
worked O +
collectively O +
to O +
develop O +
the O +
algorithms O +
and O +
methods O +
described O +
in O +
this O +
paper O +
. O +

Study O +
of O +
freeze O +
- O +
thaw O +
effects O +
and O +
CSF O +
pH O +
on O +
tissue O +
RNA O +
integrity O +

We O +
have O +
long O +
suspected O +
, O +
on O +
the O +
basis O +
of O +
our O +
tissue O +
banking O +
experience O +
, O +
that O +
most O +
of O +
the O +
molecular O +
degradation O +
that O +
occurs O +
in O +
banked O +
tissue O +
is O +
due O +
to O +
repeated O +
freeze O +
- O +
thaw O +
cycles O +
, O +
which O +
occur O +
due O +
to O +
improper O +
handling O +
during O +
dissection O +
for O +
tissue O +
retrieval O +
or O +
due O +
to O +
freezer O +
malfunctions O +
. O +

Our O +
freezers O +
are O +
currently O +
protected O +
by O +
temperature O +
- O +
sensitive O +
alarms O +
that O +
automatically O +
telephone O +
maintenance O +
and O +
tissue O +
banking O +
personnel O +
when O +
the O +
temperature O +
reaches O +
a O +
certain O +
level O +
. O +

More O +
protection O +
is O +
preferable O +
, O +
with O +
CO2 O +
tanks O +
for O +
backup O +
cooling O +
the O +
optimum O +
( O +
but O +
expensive O +
) O +
approach O +
. O +

We O +
plan O +
to O +
systematically O +
investigate O +
the O +
effects O +
of O +
thawing O +
and O +
refreezing O +
on O +
RNA O +
integrity O +
, O +
by O +
deliberately O +
thawing O +
and O +
freezing O +
small O +
samples O +
of O +
brain O +
tissue O +
over O +
varying O +
time O +
intervals O +
and O +
temperatures O +
. O +

Acknowledgements O +

The O +
authors O +
would O +
like O +
to O +
express O +
their O +
gratitude O +
to O +
Dr O +
. O +
Mahasti O +
Alizadeh O +
for O +
her O +
assistance O +
in O +
the O +
data O +
analysis O +
and O +
designing O +
the O +
questionnaire O +
. O +

Methods O +

Printing O +
solution O +

Several O +
transfection O +
reagents O +
were O +
tested O +
( O +
data O +
not O +
shown O +
) O +
, O +
and O +
we O +
found O +
that O +
the O +
X O +
- O +
tremeGENE O +
siRNA O +
transfection O +
reagent O +
( O +
Roche O +
) O +
gave O +
good O +
transfection O +
efficiencies O +
both O +
for O +
plasmids O +
and O +
siRNAs O +
, O +
and O +
chose O +
to O +
use O +
this O +
reagent O +
for O +
all O +
transfected O +
cell O +
microarray O +
experiments O +
in O +
the O +
present O +
study O +
. O +

For O +
printing O +
the O +
arrays O +
, O +
one O +
major O +
challenge O +
is O +
to O +
find O +
a O +
good O +
balance O +
between O +
high O +
transfection O +
efficiency O +
and O +
spatially O +
confined O +
spots O +
to O +
avoid O +
cross O +
- O +
contamination O +
between O +
the O +
spots O +
. O +

In O +
order O +
to O +
optimize O +
the O +
reverse O +
transfection O +
protocol O +
for O +
HEK O +
293ind O +
- O +
ICER O +
IIgamma O +
cells O +
( O +
see O +
below O +
) O +
and O +
X O +
- O +
tremeGENE O +
transfection O +
reagent O +
, O +
we O +
investigated O +
the O +
effect O +
of O +
varying O +
the O +
concentrations O +
of O +
gelatine O +
and O +
sucrose O +
in O +
the O +
printing O +
solution O +
. O +

These O +
reagents O +
have O +
been O +
reported O +
to O +
influence O +
both O +
the O +
transfection O +
efficiency O +
and O +
spot O +
integrity O +
( O +
6 O +
, O +
27 O +
) O +
. O +

Sucrose O +
was O +
observed O +
to O +
be O +
specifically O +
beneficial O +
for O +
obtaining O +
high O +
transfection O +
efficiency O +
when O +
storing O +
the O +
arrays O +
for O +
several O +
weeks O +
before O +
use O +
( O +
data O +
not O +
shown O +
) O +
. O +

Figure O +
1A O +
and O +
B O +
show O +
representative O +
images O +
of O +
the O +
observed O +
effects O +
of O +
varying O +
the O +
concentrations O +
of O +
gelatine O +
and O +
sucrose O +
. O +

We O +
observed O +
that O +
the O +
transfection O +
efficiency O +
increased O +
with O +
increasing O +
gelatine O +
concentration O +
( O +
tested O +
in O +
the O +
range O +
0 O +
. O +
01 O +
- O +
0 O +
. O +
40 O +
% O +
) O +
. O +

However O +
, O +
an O +
increased O +
disturbance O +
of O +
the O +
spatial O +
definition O +
of O +
the O +
spots O +
was O +
observed O +
with O +
increasing O +
concentrations O +
of O +
gelatine O +
or O +
sucrose O +
( O +
tested O +
in O +
the O +
range O +
0 O +
- O +
100 O +
mM O +
) O +
. O +

A O +
combined O +
effect O +
of O +
the O +
concentrations O +
of O +
gelatine O +
and O +
sucrose O +
was O +
also O +
observed O +
, O +
as O +
low O +
concentrations O +
of O +
gelatine O +
allowed O +
us O +
to O +
use O +
higher O +
concentrations O +
of O +
sucrose O +
than O +
with O +
higher O +
concentrations O +
of O +
gelatine O +
before O +
cells O +
spread O +
outside O +
the O +
spots O +
. O +

Based O +
on O +
several O +
optimizing O +
experiments O +
, O +
we O +
found O +
that O +
3 O +
microl O +
X O +
- O +
tremeGENE O +
solution O +
per O +
microgram O +
nucleic O +
acid O +
, O +
25 O +
mM O +
sucrose O +
and O +
0 O +
. O +
1 O +
% O +
gelatine O +
in O +
the O +
final O +
printing O +
solution O +
reproducibly O +
gave O +
spatial O +
restricted O +
transfection O +
with O +
high O +
transfection O +
efficiency O +
printing O +
the O +
arrays O +
with O +
both O +
a O +
pipette O +
tip O +
and O +
a O +
hand O +
- O +
held O +
arrayer O +
( O +
see O +
below O +
) O +
. O +

Figure O +
1 O +
. O +

Effects O +
of O +
sucrose O +
and O +
gelatine O +
concentrations O +
on O +
spot O +
integrity O +
and O +
transfection O +
efficiency O +
. O +

( O +
A O +
) O +
Array O +
printed O +
with O +
pDsRed O +
( O +
50 O +
ng O +
/ O +
microl O +
) O +
in O +
a O +
printing O +
solution O +
with O +
different O +
gelatine O +
and O +
sucrose O +
concentrations O +
. O +

Scanning O +
image O +
of O +
the O +
whole O +
array O +
and O +
magnifications O +
of O +
specific O +
spots O +
. O +

( O +
B O +
) O +
Array O +
printed O +
with O +
pEGFP O +
( O +
50 O +
ng O +
/ O +
microl O +
) O +
in O +
a O +
printing O +
solution O +
with O +
25 O +
mM O +
sucrose O +
and O +
four O +
different O +
concentrations O +
of O +
gelatine O +
. O +

Top O +
: O +
Box O +
plot O +
of O +
the O +
fluorescence O +
intensities O +
in O +
each O +
spot O +
( O +
n O +
= O +
32 O +
- O +
34 O +
) O +
. O +

Bottom O +
: O +
Scanning O +
image O +
showing O +
squares O +
of O +
seven O +
times O +
five O +
spots O +
for O +
the O +
four O +
gelatine O +
concentrations O +
. O +

From O +
left O +
to O +
right O +
: O +
0 O +
. O +
01 O +
, O +
0 O +
. O +
05 O +
, O +
0 O +
. O +
1 O +
and O +
0 O +
. O +
2 O +
% O +
gelatine O +
. O +

The O +
DNA O +
- O +
lipid O +
- O +
gelatine O +
- O +
sucrose O +
solutions O +
were O +
printed O +
manually O +
with O +
a O +
10 O +
microl O +
pipette O +
tip O +
( O +
A O +
) O +
or O +
by O +
MicroCasterTM O +
manual O +
arrayer O +
system O +
( O +
B O +
) O +
. O +

In O +
a O +
1 O +
. O +
5 O +
ml O +
microcentrifuge O +
tube O +
, O +
plasmid O +
( O +
1 O +
microg O +
/ O +
microl O +
) O +
and O +
siRNA O +
were O +
mixed O +
with O +
growth O +
medium O +
without O +
fetal O +
calf O +
serum O +
( O +
FCS O +
) O +
, O +
0 O +
. O +
5 O +
microl O +
1 O +
. O +
5 O +
M O +
sucrose O +
and O +
3 O +
microl O +
X O +
- O +
tremeGENE O +
per O +
microgram O +
nucleic O +
acid O +
to O +
a O +
final O +
volume O +
of O +
22 O +
. O +
5 O +
microl O +
. O +

After O +
15 O +
- O +
20 O +
min O +
of O +
incubation O +
, O +
7 O +
. O +
5 O +
microl O +
0 O +
. O +
4 O +
% O +
gelatine O +
( O +
Type O +
B O +
, O +
G9391 O +
, O +
Sigma O +
) O +
was O +
added O +
to O +
give O +
30 O +
microl O +
printing O +
solution O +
. O +

The O +
gelatine O +
solution O +
was O +
prepared O +
as O +
described O +
by O +
Ziauddin O +
and O +
Sabatini O +
( O +
1 O +
) O +
. O +

To O +
achieve O +
sufficient O +
level O +
of O +
expression O +
from O +
the O +
transfected O +
plasmids O +
, O +
25 O +
- O +
50 O +
ng O +
/ O +
microl O +
pEGFP O +
- O +
N1 O +
or O +
pDsRed O +
- O +
express O +
- O +
N1 O +
and O +
50 O +
- O +
75 O +
ng O +
/ O +
microl O +
of O +
CRE O +
or O +
NFkappaB O +
reporter O +
plasmids O +
was O +
used O +
. O +

For O +
siRNA O +
studies O +
, O +
2 O +
- O +
30 O +
ng O +
/ O +
microl O +
siRNA O +
in O +
the O +
final O +
printing O +
solution O +
was O +
used O +
. O +

Click O +
here O +
for O +
additional O +
data O +
file O +
. O +

Candle O +
wicks O +

Candles O +
with O +
a O +
lead O +
metal O +
core O +
contribute O +
to O +
lead O +
in O +
the O +
home O +
( O +
Nriagu O +
and O +
Kim O +
2000 O +
; O +
van O +
Alphen O +
1999 O +
) O +
. O +

Exposure O +
occurs O +
both O +
from O +
air O +
and O +
from O +
hand O +
- O +
to O +
- O +
mouth O +
activity O +
. O +

However O +
, O +
to O +
date O +
, O +
no O +
children O +
' O +
s O +
EBLs O +
traceable O +
to O +
candles O +
have O +
been O +
reported O +
. O +

In O +
2002 O +
, O +
the O +
CPSC O +
banned O +
candlewicks O +
containing O +
> O +
0 O +
. O +
06 O +
% O +
lead O +
( O +
CPSC O +
2003 O +
) O +
. O +

RESULTS O +

Forty O +
Caucasians O +
( O +
19 O +
females O +
) O +
with O +
essential O +
hypertension O +
were O +
enrolled O +
in O +
the O +
study O +
. O +

Their O +
mean O +
age O +
was O +
57 O +
years O +
. O +

Most O +
of O +
them O +
were O +
overweight O +
, O +
17 O +
had O +
metabolic O +
syndrome O +
according O +
to O +
the O +
updated O +
AHA O +
NHLBI O +
statement O +
( O +
defined O +
as O +
3 O +
or O +
more O +
of O +
the O +
following O +
: O +
waist O +
circumference O +
> O +
102 O +
cm O +
in O +
men O +
and O +
> O +
88 O +
cm O +
in O +
women O +
, O +
blood O +
pressure O +
> O +
= O +
130 O +
/ O +
85 O +
mmHg O +
, O +
triglycerides O +
> O +
150 O +
mg O +
/ O +
dl O +
, O +
HDL O +
- O +
C O +
< O +
40 O +
mg O +
/ O +
dl O +
in O +
men O +
and O +
< O +
50 O +
mg O +
/ O +
dl O +
in O +
women O +
, O +
and O +
fasting O +
glucose O +
> O +
= O +
100 O +
mg O +
/ O +
dl O +
) O +
, O +
8 O +
had O +
type O +
2 O +
diabetes O +
and O +
18 O +
were O +
smokers O +
( O +
Table O +
1 O +
) O +
. O +

Eprosartan O +
reduced O +
SBP O +
by O +
8 O +
% O +
( O +
p O +
< O +
0 O +
. O +
001 O +
) O +
and O +
DBP O +
by O +
13 O +
% O +
( O +
p O +
< O +
0 O +
. O +
001 O +
) O +
, O +
while O +
it O +
had O +
a O +
neutral O +
effect O +
on O +
the O +
lipid O +
profile O +
and O +
apolipoprotein O +
levels O +
( O +
Table2 O +
) O +
. O +

Eprosartan O +
did O +
not O +
affect O +
plasma O +
8 O +
- O +
epiPGF2a O +
levels O +
, O +
whereas O +
it O +
significantly O +
increased O +
by O +
24 O +
% O +
the O +
lag O +
time O +
of O +
total O +
serum O +
oxidation O +
( O +
145 O +
+ O +
/ O +
- O +
54 O +
min O +
vs O +
180 O +
+ O +
/ O +
- O +
58 O +
min O +
, O +
p O +
= O +
0 O +
. O +
001 O +
) O +
( O +
Table2 O +
) O +
. O +

Eprosartan O +
reduced O +
by O +
14 O +
% O +
the O +
aspartate O +
aminotransferase O +
( O +
form O +
21 O +
to O +
18 O +
U O +
/ O +
L O +
, O +
p O +
= O +
0 O +
. O +
04 O +
) O +
and O +
by O +
21 O +
% O +
the O +
alanine O +
aminotransferase O +
( O +
from O +
24 O +
to O +
19 O +
U O +
/ O +
L O +
, O +
p O +
= O +
0 O +
. O +
05 O +
) O +
activity O +
( O +
Table2 O +
) O +
. O +

The O +
administration O +
of O +
eprosartan O +
had O +
no O +
influence O +
on O +
glucose O +
homeostasis O +
, O +
as O +
well O +
as O +
on O +
creatinine O +
and O +
uric O +
acid O +
levels O +
( O +
Table2 O +
) O +
. O +

In O +
addition O +
, O +
eprosartan O +
did O +
not O +
affect O +
clotting O +
or O +
fibrinolytic O +
activity O +
as O +
this O +
was O +
estimated O +
by O +
PAI O +
- O +
1 O +
, O +
tPA O +
and O +
a2 O +
- O +
antiplasmin O +
( O +
Table2 O +
) O +
. O +

The O +
enzymatic O +
activity O +
of O +
Lp O +
- O +
PLA2 O +
and O +
PON1 O +
were O +
not O +
altered O +
significantly O +
following O +
eprosartan O +
treatment O +
( O +
Table2 O +
) O +
. O +

Comparison O +
of O +
the O +
number O +
of O +
known O +
complexes O +
matched O +
by O +
the O +
predicted O +
clusters O +
generated O +
by O +
IPCA O +
and O +
other O +
previous O +
algorithms O +

Images O +

Figure O +
1 O +

Figure O +
5 O +

Figure O +
6 O +

Characteristics O +
of O +
cases O +
with O +
childhood O +
leukaemia O +
( O +
n O +
= O +
162 O +
) O +
and O +
matched O +
controls O +
( O +
n O +
= O +
2125 O +
) O +
, O +
all O +
registered O +
within O +
3 O +
months O +
of O +
birth O +

Authors O +
' O +
contributions O +

OK O +
and O +
MG O +
analyzed O +
and O +
interpreted O +
the O +
patient O +
data O +
regarding O +
his O +
hospitalization O +
. O +

SP O +
and O +
PK O +
performed O +
the O +
coronary O +
angiography O +
, O +
and O +
were O +
the O +
major O +
contributors O +
in O +
writing O +
the O +
manuscript O +
. O +

All O +
authors O +
read O +
and O +
approved O +
the O +
final O +
manuscript O +
. O +

Appendix O +
Table O +

Detection O +
of O +
Nipah O +
virus O +
antibody O +
among O +
bat O +
serum O +
samples O +
collected O +
from O +
10 O +
provinces O +
in O +
China O +
, O +
2004 O +
- O +
2007 O +
* O +

Whole O +
- O +
Body O +
gamma O +
- O +
Irradiation O +

To O +
evaluate O +
differential O +
sensitivity O +
to O +
irradiation O +
, O +
mice O +
were O +
exposed O +
to O +
gamma O +
- O +
irradiation O +
( O +
4 O +
- O +
10 O +
Gy O +
, O +
single O +
dose O +
) O +
and O +
closely O +
monitored O +
throughout O +
the O +
experimentation O +
period O +
. O +

Animals O +
were O +
killed O +
at O +
the O +
first O +
appearance O +
of O +
signs O +
of O +
poor O +
health O +
. O +

Recipients O +
of O +
bone O +
marrow O +
transplants O +
were O +
pre O +
- O +
irradiated O +
with O +
a O +
total O +
dose O +
of O +
10 O +
. O +
2 O +
Gy O +
( O +
two O +
doses O +
of O +
5 O +
. O +
1 O +
Gy O +
, O +
3 O +
h O +
apart O +
) O +
. O +

For O +
in O +
vivo O +
DNA O +
damage O +
experiments O +
, O +
mice O +
were O +
irradiated O +
with O +
a O +
single O +
dose O +
of O +
5Gy O +
and O +
killed O +
after O +
1 O +
, O +
3 O +
or O +
6 O +
hours O +
. O +

All O +
irradiations O +
were O +
carried O +
out O +
in O +
a O +
Cesium O +
Mark1 O +
irradiator O +
( O +
Shepherd O +
Associates O +
) O +
. O +

Variables O +

Our O +
study O +
used O +
the O +
following O +
9 O +
HRQOL O +
questions O +
from O +
the O +
2004 O +
Rhode O +
Island O +
BRFSS O +
: O +
1 O +
) O +
self O +
- O +
rated O +
general O +
health O +
status O +
; O +
and O +
self O +
- O +
reported O +
number O +
of O +
healthy O +
and O +
unhealthy O +
days O +
in O +
the O +
previous O +
30 O +
days O +
for O +
2 O +
) O +
physical O +
health O +
, O +
3 O +
) O +
mental O +
health O +
, O +
4 O +
) O +
physical O +
or O +
mental O +
health O +
- O +
related O +
activity O +
limitation O +
, O +
5 O +
) O +
pain O +
- O +
related O +
activity O +
limitation O +
, O +
6 O +
) O +
sad O +
, O +
blue O +
, O +
or O +
depressed O +
, O +
7 O +
) O +
worried O +
, O +
tense O +
, O +
or O +
anxious O +
, O +
8 O +
) O +
lack O +
of O +
rest O +
or O +
sleep O +
, O +
and O +
9 O +
) O +
lack O +
of O +
energy O +
( O +
1 O +
, O +
2 O +
, O +
15 O +
) O +
. O +

We O +
created O +
9 O +
dichotomous O +
indicator O +
variables O +
. O +

The O +
responses O +
to O +
the O +
self O +
- O +
rated O +
general O +
health O +
status O +
question O +
were O +
dichotomized O +
into O +
" O +
poor O +
" O +
( O +
poor O +
or O +
fair O +
) O +
health O +
or O +
" O +
good O +
" O +
( O +
good O +
, O +
very O +
good O +
, O +
or O +
excellent O +
) O +
health O +
. O +

The O +
indicators O +
measured O +
in O +
days O +
were O +
dichotomized O +
at O +
a O +
cutoff O +
value O +
of O +
14 O +
or O +
more O +
days O +
of O +
poor O +
health O +
in O +
the O +
previous O +
month O +
compared O +
to O +
less O +
than O +
14 O +
days O +
( O +
3 O +
) O +
. O +

We O +
selected O +
the O +
14 O +
- O +
day O +
minimum O +
period O +
because O +
most O +
of O +
the O +
publications O +
we O +
reviewed O +
that O +
use O +
the O +
BRFSS O +
HRQOL O +
indicators O +
( O +
outcomes O +
) O +
use O +
the O +
cutoff O +
of O +
14 O +
or O +
more O +
days O +
compared O +
to O +
13 O +
or O +
fewer O +
days O +
( O +
3 O +
- O +
5 O +
, O +
7 O +
- O +
11 O +
, O +
16 O +
, O +
17 O +
) O +
. O +

Adopting O +
this O +
precedent O +
ensured O +
comparability O +
. O +

In O +
addition O +
, O +
clinicians O +
and O +
clinical O +
researchers O +
often O +
use O +
this O +
period O +
as O +
a O +
marker O +
for O +
clinical O +
depression O +
and O +
anxiety O +
disorders O +
, O +
and O +
long O +
symptomatic O +
durations O +
are O +
associated O +
with O +
high O +
levels O +
of O +
activity O +
limitation O +
( O +
2 O +
, O +
18 O +
) O +
. O +

Detailed O +
definitions O +
of O +
the O +
9 O +
indicators O +
are O +
available O +
in O +
our O +
previous O +
article O +
( O +
1 O +
) O +
or O +
are O +
accessible O +
through O +
the O +
Centers O +
for O +
Disease O +
Control O +
and O +
Prevention O +
' O +
s O +
HRQOL O +
Web O +
site O +
( O +
2 O +
) O +
. O +

We O +
chose O +
12 O +
predictors O +
for O +
the O +
analysis O +
: O +
5 O +
standard O +
demographic O +
measures O +
( O +
age O +
, O +
sex O +
, O +
race O +
/ O +
Hispanic O +
ethnicity O +
, O +
annual O +
income O +
, O +
and O +
employment O +
status O +
) O +
; O +
4 O +
health O +
conditions O +
( O +
asthma O +
, O +
diabetes O +
, O +
obesity O +
, O +
and O +
physical O +
disability O +
) O +
; O +
and O +
3 O +
health O +
risk O +
behaviors O +
( O +
smoking O +
, O +
chronic O +
alcohol O +
use O +
, O +
and O +
no O +
leisure O +
- O +
time O +
physical O +
activity O +
) O +
. O +

These O +
predictors O +
paralleled O +
the O +
results O +
of O +
other O +
studies O +
that O +
have O +
examined O +
relationships O +
between O +
a O +
specific O +
HRQOL O +
indicator O +
and O +
various O +
predictors O +
( O +
17 O +
, O +
19 O +
) O +
, O +
or O +
that O +
have O +
examined O +
multiple O +
HRQOL O +
indicators O +
in O +
relation O +
to O +
demographics O +
( O +
4 O +
, O +
20 O +
) O +
, O +
health O +
risks O +
( O +
5 O +
, O +
10 O +
, O +
21 O +
) O +
, O +
or O +
specific O +
health O +
conditions O +
( O +
6 O +
- O +
9 O +
, O +
12 O +
, O +
22 O +
) O +
. O +

We O +
dichotomized O +
some O +
predictors O +
for O +
the O +
analysis O +
( O +
ie O +
, O +
sex O +
, O +
current O +
smoking O +
, O +
alcohol O +
use O +
, O +
physical O +
activity O +
, O +
asthma O +
, O +
diabetes O +
, O +
obesity O +
, O +
and O +
disability O +
) O +
, O +
whereas O +
other O +
predictors O +
had O +
multiple O +
categories O +
( O +
ie O +
, O +
age O +
, O +
race O +
/ O +
Hispanic O +
ethnicity O +
, O +
income O +
, O +
and O +
employment O +
status O +
) O +
. O +

The O +
definitions O +
of O +
the O +
12 O +
predictors O +
are O +
available O +
in O +
our O +
previous O +
article O +
( O +
1 O +
) O +
. O +

Reference O +
groups O +
chosen O +
for O +
the O +
IRT O +
model O +
were O +
those O +
having O +
the O +
lowest O +
risk O +
for O +
poor O +
or O +
fair O +
general O +
health O +
and O +
usually O +
the O +
lowest O +
risk O +
for O +
the O +
other O +
HRQOL O +
variables O +
as O +
well O +
. O +

Background O +

Sealant O +
application O +
criteria O +
for O +
molar O +
fissures O +

Power O +
( O +
Y O +
- O +
axis O +
) O +
as O +
a O +
function O +
of O +
main O +
effects O +
( O +
x O +
- O +
axis O +
) O +
. O +

For O +
a O +
pure O +
main O +
- O +
effects O +
model O +
( O +
x O +
- O +
axis O +
= O +
a1 O +
> O +
0 O +
; O +
interaction O +
effects O +
a2 O +
= O +
a3 O +
= O +
0 O +
are O +
all O +
zero O +
) O +
, O +
Figure O +
1 O +
shows O +
that O +
pattern O +
( O +
solid O +
red O +
line O +
) O +
and O +
single O +
- O +
locus O +
( O +
broken O +
blue O +
line O +
) O +
approaches O +
have O +
virtually O +
the O +
same O +
power O +
. O +

Results O +

Peptide O +
- O +
BSA O +
conjugates O +
as O +
diagnostic O +
antigens O +

To O +
analyse O +
the O +
potential O +
of O +
the O +
peptides O +
to O +
behave O +
as O +
antigen O +
mimics O +
, O +
their O +
ability O +
to O +
react O +
with O +
IgM O +
antibodies O +
from O +
individuals O +
infected O +
with O +
EBV O +
was O +
assessed O +
. O +

In O +
our O +
previous O +
study O +
, O +
we O +
demonstrated O +
that O +
the O +
sensitivity O +
of O +
detection O +
was O +
greatly O +
improved O +
when O +
the O +
peptides O +
were O +
coupled O +
to O +
a O +
carrier O +
molecule O +
such O +
as O +
BSA O +
prior O +
to O +
immobilisation O +
onto O +
a O +
solid O +
surface O +
( O +
Casey O +
et O +
al O +
. O +
, O +
2006 O +
) O +
. O +

This O +
strategy O +
was O +
adopted O +
to O +
test O +
peptides O +
Eb1 O +
- O +
4 O +
and O +
H1 O +
. O +

A O +
set O +
of O +
40 O +
clinical O +
samples O +
that O +
were O +
classified O +
as O +
EBV O +
seropositive O +
( O +
n O +
= O +
16 O +
) O +
, O +
seronegative O +
( O +
n O +
= O +
16 O +
) O +
or O +
potentially O +
cross O +
- O +
reactive O +
sera O +
( O +
n O +
= O +
8 O +
) O +
were O +
assessed O +
for O +
reactivity O +
with O +
Eb1 O +
- O +
4 O +
and O +
H1 O +
peptides O +
individually O +
. O +

The O +
cut O +
- O +
off O +
level O +
was O +
defined O +
as O +
the O +
mean O +
optical O +
density O +
of O +
the O +
seronegative O +
samples O +
plus O +
3 O +
standard O +
deviations O +
shown O +
as O +
a O +
line O +
on O +
the O +
graphs O +
in O +
Fig O +
. O +

5 O +
. O +

Readings O +
above O +
this O +
level O +
were O +
defined O +
as O +
positive O +
and O +
below O +
this O +
level O +
negative O +
. O +

The O +
same O +
set O +
of O +
samples O +
were O +
analysed O +
on O +
BSA O +
alone O +
and O +
these O +
values O +
were O +
subtracted O +
from O +
the O +
peptide O +
- O +
BSA O +
conjugate O +
readings O +
and O +
the O +
corrected O +
absorbance O +
readings O +
were O +
plotted O +
individually O +
for O +
our O +
new O +
peptides O +
Eb1 O +
- O +
4 O +
and O +
H1 O +
in O +
Fig O +
. O +

5 O +
. O +

There O +
was O +
a O +
clear O +
difference O +
in O +
the O +
detection O +
of O +
seropositive O +
antibodies O +
by O +
all O +
the O +
peptides O +
( O +
Fig O +
. O +
5A O +
- O +
E O +
) O +
compared O +
with O +
the O +
analysis O +
of O +
BSA O +
alone O +
( O +
Fig O +
. O +
5F O +
) O +
, O +
with O +
the O +
majority O +
of O +
absorbance O +
readings O +
above O +
the O +
cut O +
- O +
off O +
level O +
. O +

We O +
compared O +
the O +
ability O +
of O +
our O +
panel O +
of O +
peptide O +
mimotopes O +
to O +
be O +
recognised O +
by O +
antibodies O +
in O +
the O +
same O +
set O +
of O +
seropositive O +
samples O +
in O +
Fig O +
. O +

6A O +
and O +
the O +
sensitivity O +
of O +
detection O +
is O +
shown O +
in O +
Fig O +
. O +

6B O +
. O +

We O +
also O +
included O +
F1 O +
and O +
Gp125 O +
mimotopes O +
specific O +
for O +
two O +
mAbs O +
in O +
our O +
previous O +
study O +
( O +
Casey O +
et O +
al O +
. O +
, O +
2006 O +
) O +
. O +

Of O +
the O +
peptides O +
identified O +
from O +
polyclonal O +
sera O +
Eb1 O +
, O +
Gp125 O +
and O +
F1 O +
had O +
the O +
highest O +
sensitivity O +
( O +
94 O +
% O +
) O +
. O +

Slightly O +
lower O +
sensitivity O +
was O +
observed O +
for O +
Eb2 O +
, O +
3 O +
and O +
4 O +
( O +
88 O +
% O +
) O +
and O +
H1 O +
peptide O +
had O +
the O +
lowest O +
sensitivity O +
( O +
81 O +
% O +
) O +
as O +
summarised O +
in O +
Fig O +
. O +

6B O +
. O +

The O +
sensitivity O +
of O +
F1 O +
and O +
Gp125 O +
was O +
similar O +
to O +
that O +
produced O +
by O +
the O +
mimotopes O +
selected O +
in O +
our O +
previous O +
study O +
, O +
95 O +
% O +
for O +
F1 O +
and O +
92 O +
% O +
for O +
Gp125 O +
. O +

Fig O +
. O +

5 O +

Evaluation O +
of O +
peptides O +
Eb1 O +
- O +
4 O +
and O +
H1 O +
coupled O +
to O +
BSA O +
as O +
EBV O +
diagnostic O +
reagents O +
. O +

Human O +
serum O +
( O +
n O +
= O +
40 O +
) O +
previously O +
analysed O +
using O +
a O +
diagnostic O +
test O +
for O +
VCA O +
IgM O +
was O +
allowed O +
to O +
react O +
with O +
the O +
peptides O +
and O +
the O +
bound O +
IgM O +
antibodies O +
were O +
detected O +
using O +
anti O +
- O +
human O +
IgM O +
HRP O +
. O +

The O +
absorbance O +
readings O +
for O +
1 O +
( O +
positive O +
) O +
, O +
2 O +
( O +
negative O +
) O +
and O +
putative O +
cross O +
- O +
reactive O +
sera O +
for O +
3 O +
( O +
Parvo O +
) O +
, O +
4 O +
( O +
HSV O +
) O +
, O +
5 O +
( O +
CMV O +
) O +
and O +
6 O +
( O +
RF O +
) O +
are O +
plotted O +
for O +
( O +
A O +
) O +
Eb1 O +
, O +
( O +
B O +
) O +
Eb2 O +
, O +
( O +
C O +
) O +
Eb3 O +
, O +
( O +
D O +
) O +
Eb4 O +
, O +
( O +
E O +
) O +
H1 O +
and O +
( O +
F O +
) O +
BSA O +
, O +
respectively O +
. O +

The O +
cut O +
- O +
off O +
value O +
is O +
defined O +
as O +
the O +
mean O +
of O +
the O +
negative O +
population O +
+ O +
3SD O +
indicated O +
by O +
a O +
solid O +
horizontal O +
line O +
; O +
since O +
there O +
were O +
no O +
false O +
positives O +
, O +
the O +
specificity O +
for O +
each O +
mimotope O +
was O +
100 O +
% O +
. O +

Fig O +
. O +

6 O +

Comparison O +
of O +
the O +
reactivities O +
of O +
our O +
panel O +
of O +
mimotopes O +
Eb1 O +
- O +
4 O +
, O +
H1 O +
, O +
F1 O +
and O +
Gp125 O +
conjugated O +
to O +
BSA O +
with O +
EBV O +
IgM O +
- O +
positive O +
sera O +
( O +
n O +
= O +
16 O +
) O +
absorbance O +
values O +
are O +
plotted O +
and O +
the O +
cut O +
- O +
off O +
levels O +
are O +
depicted O +
by O +
a O +
horizontal O +
line O +
in O +
( O +
A O +
) O +
. O +

( O +
B O +
) O +
Summary O +
of O +
the O +
false O +
- O +
negative O +
results O +
from O +
the O +
5 O +
/ O +
16 O +
serum O +
samples O +
seropositive O +
for O +
IgM O +
EBV O +
and O +
the O +
overall O +
sensitivity O +
for O +
each O +
mimotope O +
for O +
diagnosis O +
of O +
EBV O +
IgM O +
antibodies O +
. O +

We O +
also O +
considered O +
which O +
seropositive O +
EBV O +
samples O +
contained O +
antibodies O +
that O +
did O +
not O +
recognise O +
the O +
panel O +
of O +
peptides O +
, O +
i O +
. O +
e O +
. O +
false O +
- O +
negative O +
readings O +
, O +
listed O +
in O +
Fig O +
. O +

6B O +
. O +

The O +
antibodies O +
in O +
serum O +
1 O +
( O +
s1 O +
) O +
were O +
unreactive O +
with O +
all O +
of O +
the O +
peptides O +
identified O +
in O +
this O +
study O +
, O +
s2 O +
was O +
not O +
reactive O +
with O +
Eb3 O +
, O +
Eb4 O +
and O +
H1 O +
and O +
s3 O +
was O +
unreactive O +
with O +
H1 O +
. O +

Gp125 O +
and O +
F1 O +
that O +
were O +
selected O +
in O +
our O +
previous O +
study O +
were O +
recognised O +
by O +
s1 O +
, O +
2 O +
and O +
3 O +
; O +
however O +
, O +
two O +
different O +
serum O +
samples O +
( O +
s4 O +
and O +
5 O +
) O +
did O +
not O +
recognise O +
F1 O +
or O +
Gp125 O +
, O +
respectively O +
. O +

This O +
demonstrates O +
that O +
individual O +
peptides O +
are O +
not O +
recognised O +
by O +
all O +
EBV O +
antibodies O +
and O +
confirms O +
that O +
different O +
peptides O +
are O +
required O +
to O +
represent O +
different O +
epitopes O +
. O +

Therefore O +
, O +
a O +
combination O +
of O +
Eb1 O +
peptide O +
F1 O +
and O +
Gp125 O +
peptides O +
could O +
be O +
recognised O +
by O +
antibodies O +
present O +
in O +
all O +
this O +
set O +
of O +
EBV O +
clinical O +
samples O +
resulting O +
in O +
100 O +
% O +
sensitivity O +
. O +

For O +
the O +
samples O +
defined O +
as O +
EBV O +
- O +
seronegative O +
, O +
there O +
were O +
no O +
readings O +
above O +
the O +
cut O +
- O +
off O +
level O +
and O +
therefore O +
no O +
false O +
positives O +
, O +
resulting O +
in O +
100 O +
% O +
specificity O +
. O +

In O +
addition O +
, O +
there O +
were O +
no O +
absorbance O +
readings O +
above O +
the O +
cut O +
- O +
off O +
levels O +
for O +
the O +
potentially O +
cross O +
- O +
reactive O +
serum O +
samples O +
, O +
inferring O +
that O +
the O +
peptides O +
identified O +
in O +
this O +
study O +
have O +
high O +
specificity O +
for O +
EBV O +
antibodies O +
. O +

Additional O +
File O +
2 O +

Full O +
Model O +
Code O +
. O +

Full O +
model O +
code O +
plus O +
instructions O +
for O +
running O +
in O +
Berkeley O +
Madonna O +
( O +
TM O +
) O +
. O +

Fragmentation O +
of O +
the O +
parent O +
ion O +
/ O +
TCE O +
- O +
sulfate O +
moiety O +

The O +
mass O +
spectrum O +
of O +
compound O +
5 O +
displays O +
its O +
molecular O +
ion O +
5a O +
with O +
the O +
typical O +
isotope O +
pattern O +
[ O +
18 O +
] O +
of O +
a O +
pentachlorinated O +
compound O +
at O +
m O +
/ O +
z O +
448 O +
( O +
relative O +
abundance O +
, O +
15 O +
% O +
) O +
( O +
Figure O +
2 O +
) O +
. O +

Scheme O +
1 O +
illustrates O +
the O +
various O +
fragmentation O +
pathways O +
of O +
this O +
precursor O +
ion O +
. O +

The O +
molecular O +
ion O +
5a O +
loses O +
a O +
PCB O +
sulfate O +
( O +
ArOSO3 O +
- O +
) O +
group O +
, O +
thus O +
yielding O +
TCE O +
group O +
- O +
derived O +
fragment O +
ions O +
. O +

These O +
ions O +
, O +
[ O +
CH2CCl3 O +
] O +
+ O +
and O +
[ O +
CH O +
= O +
CCl2 O +
] O +
+ O +
, O +
are O +
observed O +
at O +
m O +
/ O +
z O +
131 O +
( O +
6 O +
% O +
) O +
and O +
95 O +
( O +
7 O +
% O +
) O +
, O +
respectively O +
. O +

Scheme O +
1 O +

Principal O +
EI O +
- O +
MS O +
fragmentation O +
pathways O +
of O +
sulfuric O +
acid O +
2 O +
' O +
, O +
5 O +
' O +
- O +
dichlorobiphenyl O +
- O +
4yl O +
ester O +
2 O +
, O +
2 O +
, O +
2 O +
- O +
trichloroethyl O +
ester O +
5 O +
. O +

More O +
complex O +
fragmentation O +
patterns O +
are O +
observed O +
for O +
the O +
fragmentation O +
of O +
the O +
- O +
OSO3 O +
- O +
TCE O +
group O +
. O +

The O +
abundant O +
fragment O +
ion O +
5 O -
g O +
( O +
m O +
/ O +
z O +
237 O +
, O +
28 O +
% O +
) O +
can O +
be O +
formed O +
by O +
two O +
fragmentation O +
pathways O +
from O +
precursor O +
ion O +
5a O +
. O +

One O +
pathway O +
involves O +
the O +
release O +
of O +
HCl O +
and O +
Cl O +
from O +
precursor O +
ion O +
5a O +
, O +
leading O +
to O +
an O +
unstable O +
cyclic O +
fragment O +
ion O +
5b O +
( O +
m O +
/ O +
z O +
377 O +
, O +
5 O +
% O +
) O +
. O +

In O +
turn O +
, O +
fragment O +
ion O +
5b O +
produces O +
the O +
fragment O +
ion O +
5 O -
g O +
after O +
releasing O +
chloroethyne O +
and O +
SO3 O +
. O +

The O +
other O +
pathway O +
resulting O +
in O +
the O +
formation O +
of O +
fragment O +
ion O +
5 O -
g O +
involves O +
the O +
removal O +
of O +
two O +
neutral O +
molecules O +
, O +
HCHO O +
and O +
SO2 O +
, O +
from O +
the O +
daughter O +
fragment O +
ion O +
5c O +
( O +
m O +
/ O +
z O +
331 O +
, O +
5 O +
% O +
) O +
, O +
which O +
is O +
formed O +
by O +
releasing O +
the O +
free O +
radical O +
group O +
CCl3 O +
from O +
fragment O +
ion O +
5a O +
. O +

Alternatively O +
, O +
the O +
fragment O +
ion O +
5c O +
can O +
also O +
produce O +
the O +
daughter O +
fragment O +
ion O +
5e O +
( O +
m O +
/ O +
z O +
183 O +
, O +
12 O +
% O +
) O +
by O +
losing O +
one O +
molecule O +
of O +
SO3 O +
. O +

In O +
addition O +
, O +
precursor O +
ion O +
5a O +
yields O +
the O +
daughter O +
ion O +
5d O +
by O +
losing O +
a O +
CHCCl3 O +
fragment O +
. O +

The O +
basic O +
fragment O +
ion O +
5f O +
at O +
m O +
/ O +
z O +
238 O +
is O +
produced O +
from O +
the O +
daughter O +
ion O +
5d O +
( O +
m O +
/ O +
z O +
318 O +
, O +
20 O +
% O +
) O +
by O +
releasing O +
one O +
molecule O +
of O +
SO3 O +
. O +

Fragment O +
ions O +
5f O +
and O +
5 O -
g O +
can O +
produce O +
the O +
important O +
fragment O +
ion O +
5h O +
at O +
m O +
/ O +
z O +
209 O +
with O +
a O +
relative O +
abundance O +
of O +
26 O +
% O +
by O +
losing O +
a O +
CHO O +
or O +
CO O +
fragment O +
, O +
respectively O +
. O +

The O +
same O +
fragmentation O +
pathways O +
are O +
observed O +
for O +
the O +
TCE O +
PCB O +
sulfates O +
diesters O +
1 O +
and O +
3 O +
- O +
10 O +
. O +

The O +
only O +
exception O +
is O +
compound O +
2 O +
, O +
which O +
has O +
the O +
TCE O +
sulfate O +
group O +
in O +
ortho O +
position O +
to O +
the O +
other O +
phenyl O +
ring O +
. O +

The O +
mass O +
spectrum O +
of O +
compounds O +
2 O +
is O +
distinctively O +
different O +
from O +
the O +
mass O +
spectrum O +
of O +
its O +
isomer O +
, O +
compound O +
3 O +
( O +
Figures O +
3 O +
and O +
4 O +
) O +
. O +

As O +
shown O +
in O +
Scheme O +
2 O +
, O +
the O +
basic O +
fragment O +
ion O +
of O +
compound O +
2 O +
is O +
the O +
stable O +
dibenzofuran O +
ion O +
2f O +
. O +

Fragment O +
ion O +
2f O +
is O +
formed O +
from O +
the O +
parent O +
ion O +
2a O +
( O +
m O +
/ O +
z O +
414 O +
; O +
relative O +
abundance O +
, O +
21 O +
% O +
) O +
by O +
sequential O +
loss O +
of O +
CHCCl3 O +
( O +
2d O +
, O +
m O +
/ O +
z O +
284 O +
; O +
relative O +
abundance O +
, O +
10 O +
% O +
) O +
, O +
SO3 O +
( O +
2e O +
, O +
m O +
/ O +
z O +
204 O +
; O +
relative O +
abundance O +
, O +
28 O +
% O +
) O +
and O +
HCl O +
( O +
2f O +
, O +
m O +
/ O +
z O +
168 O +
; O +
relative O +
abundance O +
, O +
100 O +
% O +
) O +
. O +

The O +
stable O +
dibenzofuran O +
cation O +
2f O +
is O +
also O +
formed O +
as O +
the O +
base O +
peak O +
ion O +
in O +
the O +
fragmentation O +
pathways O +
of O +
corresponding O +
methoxylated O +
PCB O +
11 O +
( O +
Table O +
1 O +
) O +
. O +

Similarly O +
, O +
other O +
2 O +
- O +
methoxy O +
PCB O +
derivatives O +
also O +
form O +
a O +
stable O +
dibenzofuran O +
cation O +
after O +
losing O +
chlorine O +
atom O +
and O +
methyl O +
group O +
[ O +
19 O +
] O +
. O +

Scheme O +
2 O +

Principal O +
EI O +
- O +
MS O +
fragmentation O +
pathways O +
of O +
sulfuric O +
acid O +
4 O +
' O +
- O +
dichlorobiphenyl O +
- O +
2 O +
- O +
yl O +
ester O +
2 O +
, O +
2 O +
, O +
2 O +
- O +
trichloroethyl O +
ester O +
2 O +
. O +

The O +
relative O +
abundance O +
of O +
several O +
fragment O +
ions O +
depends O +
on O +
the O +
position O +
of O +
the O +
- O +
OSO3 O +
- O +
TCE O +
group O +
and O +
the O +
chlorine O +
substitution O +
pattern O +
. O +

The O +
relative O +
abundance O +
of O +
the O +
[ O +
M O +
- O +
HCl2 O +
] O +
+ O +
and O +
[ O +
M O +
- O +
CCl3 O +
] O +
+ O +
fragment O +
ions O +
of O +
compound O +
2 O +
, O +
9 O +
and O +
10 O +
are O +
lower O +
compared O +
to O +
all O +
other O +
TCE O +
PCB O +
sulfate O +
diesters O +
( O +
Table O +
1 O +
) O +
. O +

This O +
lower O +
relative O +
abundance O +
is O +
due O +
to O +
steric O +
and O +
/ O +
or O +
electronic O +
effects O +
resulting O +
from O +
the O +
ortho O +
phenyl O +
substituent O +
in O +
compound O +
2 O +
or O +
the O +
two O +
ortho O +
chlorine O +
substituents O +
in O +
compounds O +
9 O +
and O +
10 O +
. O +

In O +
addition O +
, O +
the O +
relative O +
abundance O +
of O +
fragment O +
ion O +
[ O +
ArOSO3H O +
] O +
+ O +
of O +
the O +
TCE O +
PCB O +
sulfate O +
diesters O +
9 O +
and O +
10 O +
is O +
low O +
compared O +
to O +
the O +
corresponding O +
fragment O +
ion O +
of O +
the O +
other O +
TCE O +
PCB O +
sulfate O +
diesters O +
, O +
with O +
only O +
a O +
trace O +
of O +
the O +
respective O +
ions O +
being O +
observed O +
( O +
Table O +
1 O +
) O +
. O +

For O +
example O +
, O +
the O +
relative O +
abundance O +
of O +
[ O +
ArOSO3H O +
] O +
+ O +
5d O +
is O +
20 O +
% O +
, O +
whereas O +
the O +
abundance O +
of O +
the O +
corresponding O +
fragment O +
ions O +
of O +
compounds O +
9 O +
and O +
10 O +
is O +
< O +
< O +
1 O +
% O +
. O +

Since O +
compounds O +
9 O +
and O +
10 O +
have O +
two O +
chlorine O +
substituents O +
in O +
the O +
phenyl O +
ring O +
with O +
the O +
- O +
OSO3TCE O +
group O +
, O +
the O +
low O +
relative O +
abundance O +
of O +
fragment O +
ion O +
[ O +
ArOSO3H O +
] O +
+ O +
suggests O +
that O +
the O +
sulfate O +
group O +
of O +
both O +
compounds O +
is O +
less O +
stable O +
, O +
possibly O +
because O +
of O +
the O +
comparatively O +
high O +
pKa O +
value O +
of O +
the O +
Ar O +
- O +
OH O +
group O +
[ O +
20 O +
] O +
. O +

This O +
observation O +
is O +
in O +
agreement O +
with O +
the O +
decreasing O +
chemical O +
stability O +
of O +
aryl O +
sulfate O +
monoesters O +
with O +
increasing O +
acidity O +
of O +
the O +
phenolic O +
aryl O +
group O +
[ O +
21 O +
] O +
. O +

Authors O +
' O +
contributions O +

CM O +
, O +
JRH O +
, O +
HJP O +
, O +
and O +
JH O +
carried O +
animal O +
studies O +
. O +

CM O +
performed O +
the O +
statistical O +
analysis O +
. O +

JLK O +
conceived O +
of O +
the O +
study O +
, O +
participated O +
in O +
its O +
design O +
and O +
coordination O +
, O +
and O +
drafted O +
and O +
edited O +
the O +
manuscript O +
. O +

All O +
authors O +
read O +
and O +
approved O +
the O +
final O +
manuscript O +
. O +

Disk O +
preparation O +
phase O +

o O +
Adoption O +
of O +
a O +
two O +
- O +
stage O +
sampling O +
scheme O +
. O +

o O +
Careful O +
planning O +
and O +
choice O +
of O +
representative O +
sampling O +
groups O +
and O +
sites O +
according O +
to O +
the O +
adopted O +
network O +
sampling O +
technique O +
, O +
and O +
determining O +
certain O +
criteria O +
such O +
as O +
control O +
sites O +
where O +
major O +
sampling O +
groups O +
exist O +
( O +
i O +
. O +
e O +
. O +
surface O +
water O +
points O +
, O +
valleys O +
, O +
and O +
wells O +
) O +
, O +
impact O +
sites O +
where O +
contamination O +
is O +
expected O +
, O +
such O +
as O +
polygons O +
, O +
and O +
outlets O +
( O +
e O +
. O +
g O +
. O +
treated O +
water O +
discharges O +
site O +
) O +
to O +
maximise O +
understanding O +
the O +
quality O +
of O +
urban O +
water O +
sources O +
, O +
and O +
with O +
the O +
least O +
risk O +
of O +
missing O +
the O +
correct O +
representative O +
sampling O +
groups O +
and O +
sites O +
. O +

o O +
Attention O +
paid O +
to O +
ensure O +
inclusion O +
in O +
the O +
sampling O +
frame O +
of O +
all O +
groups O +
and O +
locations O +
( O +
sites O +
, O +
roads O +
, O +
venues O +
, O +
and O +
so O +
on O +
) O +
via O +
screening O +
, O +
browsing O +
, O +
and O +
delineation O +
from O +
a O +
satellite O +
digital O +
map O +
of O +
the O +
Khamis O +
Mushait O +
Governorate O +
zone O +
, O +
because O +
local O +
pre O +
- O +
knowledge O +
was O +
preferred O +
with O +
regard O +
to O +
accessibility O +
, O +
safety O +
, O +
and O +
permission O +
. O +

o O +
Approximation O +
of O +
the O +
number O +
of O +
the O +
target O +
study O +
population O +
in O +
each O +
group O +
and O +
sampling O +
location O +
. O +

o O +
Determination O +
of O +
the O +
proportional O +
allocation O +
of O +
samples O +
between O +
different O +
groups O +
and O +
locations O +
. O +

o O +
Training O +
of O +
interviewers O +
\ O +
sample O +
collectors O +
to O +
follow O +
and O +
to O +
use O +
the O +
sampling O +
strategy O +
and O +
procedures O +
. O +

o O +
Implementation O +
of O +
ways O +
to O +
boost O +
participation O +
rates O +
in O +
the O +
screening O +
and O +
core O +
interviews O +
and O +
sample O +
collection O +
. O +

o O +
Planning O +
of O +
logistic O +
needs O +
of O +
timing O +
, O +
gathering O +
, O +
handling O +
samples O +
, O +
and O +
laboratory O +
. O +

o O +
Producing O +
sampling O +
cards O +
to O +
be O +
completed O +
to O +
record O +
observations O +
at O +
scene O +
( O +
sample O +
ID O +
and O +
data O +
/ O +
information O +
: O +
date O +
, O +
time O +
, O +
temperature O +
, O +
group O +
, O +
locality O +
, O +
problems O +
in O +
the O +
area O +
, O +
sketch O +
map O +
) O +
. O +

o O +
Selection O +
of O +
an O +
appropriate O +
major O +
sampling O +
method O +
[ O +
52 O +
] O +
( O +
i O +
. O +
e O +
. O +
simple O +
random O +
sample O +
; O +
network O +
sampling O +
) O +
. O +

o O +
Planning O +
of O +
pilot O +
visits O +
to O +
samples O +
of O +
each O +
group O +
in O +
the O +
field O +
to O +
review O +
strategy O +
. O +

Secchi O +
depth O +
in O +
the O +
Baltic O +
Proper O +
, O +
June O +
- O +
August O +
, O +
1957 O +
- O +
1998 O +
. O +

Number O +
of O +
data O +
: O +
3 O +
, O +
452 O +
. O +

1 O +
. O +

Introduction O +

Phase O +
I O +
clinical O +
trials O +
of O +
new O +
anticancer O +
agents O +
have O +
been O +
commonly O +
conducted O +
using O +
the O +
method O +
of O +
modified O +
Fibonacci O +
[ O +
1 O +
] O +
. O +

In O +
brief O +
, O +
3 O +
patients O +
are O +
treated O +
at O +
a O +
starting O +
dose O +
which O +
is O +
typically O +
one O +
tenth O +
of O +
the O +
dose O +
that O +
is O +
lethal O +
to O +
10 O +
% O +
of O +
animals O +
defined O +
in O +
preclinical O +
studies O +
. O +

If O +
none O +
of O +
the O +
3 O +
patients O +
experiences O +
DLT O +
, O +
then O +
the O +
next O +
3 O +
patients O +
will O +
be O +
treated O +
at O +
the O +
next O +
higher O +
dose O +
. O +

If O +
DLT O +
is O +
observed O +
, O +
additional O +
patients O +
will O +
be O +
treated O +
at O +
the O +
same O +
or O +
lower O +
dose O +
level O +
to O +
determine O +
MTD O +
according O +
to O +
a O +
predetermined O +
schema O +
. O +

The O +
MTD O +
is O +
defined O +
as O +
the O +
highest O +
dose O +
reached O +
for O +
which O +
the O +
incidence O +
of O +
DLT O +
occurs O +
in O +
less O +
than O +
33 O +
% O +
of O +
the O +
subjects O +
. O +

Typically O +
, O +
intrapatient O +
dose O +
escalation O +
is O +
not O +
allowed O +
. O +

There O +
are O +
several O +
shortcomings O +
associated O +
with O +
the O +
modified O +
- O +
Fibonacci O +
design O +
. O +

It O +
has O +
long O +
been O +
recognized O +
that O +
a O +
substantial O +
number O +
of O +
patients O +
are O +
likely O +
to O +
be O +
treated O +
at O +
subtherapeutic O +
doses O +
[ O +
2 O +
, O +
3 O +
] O +
. O +

This O +
is O +
particularly O +
true O +
for O +
drugs O +
with O +
potential O +
anticancer O +
activity O +
. O +

Since O +
the O +
primary O +
purpose O +
of O +
phase O +
I O +
trials O +
is O +
to O +
determine O +
DLT O +
and O +
MTD O +
, O +
the O +
efficacy O +
of O +
the O +
drug O +
may O +
not O +
be O +
evident O +
for O +
certain O +
tumor O +
types O +
as O +
there O +
are O +
only O +
a O +
small O +
number O +
of O +
patients O +
enrolled O +
into O +
the O +
trial O +
. O +

Furthermore O +
, O +
the O +
modified O +
- O +
Fibonacci O +
design O +
does O +
not O +
take O +
into O +
account O +
individual O +
variations O +
in O +
therapeutic O +
and O +
toxicologic O +
responses O +
due O +
to O +
genomic O +
polymorphisms O +
[ O +
4 O +
, O +
5 O +
] O +
. O +

In O +
addition O +
, O +
since O +
there O +
is O +
a O +
limit O +
of O +
3 O +
subjects O +
allowed O +
for O +
each O +
cohort O +
, O +
a O +
waiting O +
period O +
of O +
up O +
to O +
four O +
weeks O +
is O +
commonly O +
required O +
before O +
enrollment O +
of O +
the O +
next O +
cohort O +
of O +
subjects O +
. O +

This O +
latter O +
requirement O +
creates O +
anxiety O +
of O +
waiting O +
for O +
eligible O +
patients O +
. O +

Several O +
alternative O +
phase O +
I O +
designs O +
have O +
been O +
proposed O +
which O +
limit O +
the O +
number O +
of O +
patients O +
accrued O +
at O +
each O +
dose O +
level O +
and O +
accelerate O +
the O +
dose O +
escalation O +
process O +
[ O +
1 O +
, O +
6 O +
] O +
. O +

There O +
has O +
also O +
been O +
an O +
increase O +
in O +
the O +
number O +
of O +
clinical O +
trials O +
that O +
include O +
a O +
component O +
of O +
intrapatient O +
dose O +
escalation O +
although O +
no O +
formal O +
validation O +
with O +
the O +
modified O +
- O +
Fibonacci O +
approach O +
has O +
been O +
reported O +
[ O +
7 O +
- O +
9 O +
] O +
. O +

We O +
have O +
pioneered O +
a O +
population O +
- O +
based O +
design O +
to O +
maximize O +
therapeutic O +
efficacy O +
, O +
to O +
provide O +
preliminary O +
efficacy O +
information O +
and O +
to O +
allow O +
derivation O +
of O +
a O +
pMTD O +
for O +
subsequent O +
phase O +
II O +
trials O +
. O +

Irinotecan O +
and O +
cisplatin O +
have O +
been O +
shown O +
to O +
have O +
promising O +
efficacy O +
in O +
patients O +
with O +
small O +
- O +
cell O +
lung O +
cancer O +
in O +
phase O +
III O +
trial O +
where O +
irinotecan O +
was O +
given O +
on O +
a O +
weekly O +
schedule O +
[ O +
10 O +
] O +
. O +

We O +
wished O +
to O +
perform O +
a O +
population O +
- O +
based O +
phase O +
I O +
trial O +
of O +
irinotecan O +
, O +
given O +
every O +
3 O +
weeks O +
, O +
and O +
carboplatin O +
, O +
a O +
platinated O +
anticancer O +
drug O +
which O +
is O +
generally O +
better O +
tolerated O +
than O +
its O +
cisplatin O +
analog O +
. O +

Nucleotide O +
features O +
of O +
free O +
- O +
standing O +
homing O +
- O +
endonucleases O +

Gene O +
control O +
elements O +
were O +
identified O +
for O +
several O +
members O +
of O +
each O +
type O +
of O +
intervening O +
homing O +
endonuclease O +
genes O +
described O +
in O +
this O +
study O +
. O +

In O +
15 O +
out O +
of O +
16 O +
, O +
5 O +
' O +
untranslated O +
regions O +
of O +
the O +
endonucleases O +
we O +
identified O +
RNA O +
hairpin O +
structures O +
upstream O +
of O +
initiation O +
codons O +
( O +
Figures O +
1 O +
and O +
4A O +
) O +
. O +

This O +
may O +
be O +
a O +
translational O +
regulatory O +
hairpin O +
structure O +
known O +
from O +
various O +
phage O +
genes O +
, O +
including O +
homing O +
endonucleases O +
( O +
22 O +
, O +
47 O +
- O +
49 O +
) O +
. O +

The O +
hairpins O +
we O +
found O +
are O +
in O +
fractured O +
gene O +
loci O +
with O +
different O +
protein O +
host O +
types O +
, O +
including O +
gp41 O +
, O +
IMPDH O +
, O +
DnaE O +
, O +
NrdJ O +
and O +
NrdA O +
. O +

Ten O +
of O +
these O +
hairpins O +
also O +
include O +
a O +
conserved O +
sequence O +
of O +
Aeh1 O +
phage O +
late O +
promoter O +
element O +
( O +
TATAAATA O +
) O +
, O +
which O +
was O +
recently O +
shown O +
to O +
inhibit O +
the O +
translation O +
of O +
a O +
gene O +
- O +
fracturing O +
endonuclease O +
gene O +
, O +
by O +
sequestering O +
its O +
ribosome O +
binding O +
site O +
( O +
22 O +
, O +
23 O +
) O +
. O +

Analysis O +
of O +
the O +
endonuclease O +
5 O +
' O +
untranslated O +
regions O +
revealed O +
two O +
conserved O +
motifs O +
( O +
Figures O +
4A O +
and O +
Supplementary O +
Figure O +
S4 O +
) O +
, O +
which O +
usually O +
complement O +
each O +
other O +
on O +
the O +
stem O +
of O +
the O +
conserved O +
hairpin O +
structures O +
. O +

Figure O +
4 O +
. O +

Nucleotide O +
features O +
of O +
endonuclease O +
genes O +
. O +

( O +
A O +
) O +
RNA O +
hairpin O +
structures O +
at O +
the O +
5 O +
' O +
untranslated O +
region O +
of O +
endonuclease O +
ORFs O +
in O +
the O +
gp41 O +
- O +
1 O +
( O +
representing O +
the O +
very O +
similar O +
sequences O +
of O +
gp41 O +
- O +
1 O +
- O +
7 O +
) O +
, O +
nrdA O +
- O +
5 O +
and O +
DnaE O +
- O +
1 O +
gene O +
loci O +
. O +

Initiator O +
codons O +
are O +
marked O +
by O +
arrows O +
, O +
conserved O +
putative O +
T4 O +
late O +
promoter O +
elements O +
are O +
boxed O +
, O +
and O +
conserved O +
sequence O +
motifs O +
( O +
Supplementary O +
Figure O +
S4 O +
) O +
are O +
highlighted O +
in O +
grey O +
. O +

The O +
expected O +
values O +
for O +
motifs O +
1 O +
and O +
2 O +
are O +
1 O +
. O +
7 O +
- O +
10 O +
and O +
9 O +
. O +
9 O +
- O +
3 O +
, O +
respectively O +
. O +

RNA O +
structures O +
were O +
calculated O +
using O +
the O +
Vienna O +
package O +
( O +
http O +
: O +
/ O +
/ O +
rna O +
. O +
tbi O +
. O +
univie O +
. O +
ac O +
. O +
at O +
/ O +
cgi O +
- O +
bin O +
/ O +
RNAfold O +
. O +
cgi O +
) O +
, O +
and O +
sequence O +
motifs O +
were O +
identified O +
using O +
the O +
MEME O +
program O +
. O +

( O +
B O +
) O +
Overlapping O +
# O +
protein O +
coding O +
regions O +
of O +
endonuclease O +
3 O +
' O +
termini O +
and O +
the O +
5 O +
' O +
termini O +
of O +
their O +
downstream O +
genes O +
. O +

Additionally O +
, O +
15 O +
loci O +
included O +
an O +
overlapping O +
region O +
of O +
6 O +
- O +
69 O +
bp O +
between O +
the O +
coding O +
regions O +
of O +
the O +
probable O +
endonuclease O +
C O +
- O +
termini O +
and O +
the O +
downstream O +
N O +
- O +
termini O +
of O +
the O +
split O +
- O +
intein O +
part O +
( O +
Figures O +
1 O +
and O +
4B O +
) O +
. O +

This O +
overlap O +
is O +
present O +
in O +
both O +
types O +
of O +
endonucleases O +
, O +
and O +
is O +
independent O +
on O +
the O +
presence O +
of O +
a O +
split O +
- O +
intein O +
part O +
in O +
the O +
fractured O +
gene O +
, O +
also O +
occurring O +
in O +
the O +
putative O +
sbcD O +
DNA O +
- O +
repair O +
gene O +
that O +
we O +
found O +
, O +
as O +
well O +
as O +
in O +
the O +
Aeh1 O +
fractured O +
nrdA O +
found O +
by O +
Gibb O +
and O +
Edgell O +
( O +
22 O +
) O +
. O +

Efficacy O +
of O +
MMF O +
in O +
current O +
immunosuppressive O +
regimens O +
after O +
kidney O +
transplantation O +

Current O +
established O +
immunosuppressive O +
strategies O +
in O +
kidney O +
transplantation O +
often O +
include O +
an O +
induction O +
agent O +
( O +
monoclonal O +
or O +
polyclonal O +
anti O +
- O +
T O +
- O +
cell O +
antibodies O +
) O +
based O +
on O +
the O +
immunologic O +
risk O +
of O +
the O +
recipient O +
, O +
followed O +
by O +
a O +
maintenance O +
regimen O +
combining O +
a O +
CNI O +
and O +
an O +
anti O +
- O +
proliferative O +
agent O +
, O +
with O +
or O +
without O +
corticosteroids O +
. O +
2 O +
- O +
4 O +
As O +
MMF O +
was O +
the O +
first O +
MPA O +
formulation O +
approved O +
in O +
clinical O +
kidney O +
transplantation O +
, O +
more O +
extensive O +
clinical O +
data O +
are O +
available O +
with O +
this O +
drug O +
in O +
comparison O +
to O +
EC O +
- O +
MPS O +
. O +

Results O +

In O +
the O +
established O +
adult O +
rat O +
NSC O +
culture O +
, O +
FGF O +
- O +
2 O +
promotes O +
self O +
- O +
renewal O +
by O +
increasing O +
proliferation O +
and O +
inhibiting O +
spontaneous O +
differentiation O +
of O +
adult O +
NSCs O +
, O +
accompanied O +
with O +
activation O +
of O +
MAPK O +
and O +
PLC O +
pathways O +
. O +

Using O +
a O +
molecular O +
genetic O +
approach O +
, O +
we O +
demonstrate O +
that O +
activation O +
of O +
FGF O +
receptor O +
1 O +
( O +
FGFR1 O +
) O +
, O +
largely O +
through O +
two O +
key O +
cytoplasmic O +
amino O +
acid O +
residues O +
that O +
are O +
linked O +
to O +
MAPK O +
and O +
PLC O +
activation O +
, O +
suffices O +
to O +
promote O +
adult O +
NSC B-CellLine +
self O +
- O +
renewal O +
. O +

The O +
canonical O +
MAPK O +
, O +
Erk1 O +
/ O +
2 O +
activation O +
, O +
is O +
both O +
required O +
and O +
sufficient O +
for O +
the O +
NSC B-CellLine +
expansion O +
and O +
anti O +
- O +
differentiation O +
effects O +
of O +
FGF O +
- O +
2 O +
. O +

In O +
contrast O +
, O +
PLC O +
activation O +
is O +
integral O +
to O +
the O +
maintenance O +
of O +
adult O +
NSC B-CellLine +
characteristics O +
, O +
including O +
the O +
full O +
capacity O +
for O +
neuronal O +
and O +
oligodendroglial O +
differentiation O +
. O +

2 O +
. O +
2 O +
. O +

Iris O +
and O +
Ciliary O +
Body O +

Serotonin O +
is O +
present O +
in O +
mammalian O +
iris O +
- O +
ciliary O +
body O +
complex O +
( O +
ICB O +
) O +
at O +
higher O +
concentration O +
that O +
in O +
non O +
- O +
mammalian O +
species O +
[ O +
5 O +
, O +
45 O +
, O +
73 O +
, O +
129 O +
, O +
137 O +
] O +
. O +

Moreover O +
, O +
the O +
presence O +
of O +
serotonergic O +
nerves O +
has O +
been O +
demonstrated O +
in O +
studies O +
conducted O +
on O +
the O +
ICB O +
of O +
various O +
species O +
[ O +
102 O +
, O +
137 O +
, O +
138 O +
] O +
. O +

Experimental O +
evidence O +
and O +
radioligand O +
analyses O +
have O +
defined O +
the O +
presence O +
at O +
this O +
level O +
of O +
three O +
different O +
types O +
of O +
serotonin O +
receptors O +
[ O +
10 O +
, O +
28 O +
, O +
85 O +
, O +
136 O +
, O +
137 O +
] O +
, O +
i O +
. O +
e O +
. O +
5 O +
- O +
HT1A O +
, O +
5 O +
- O +
HT2A O +
/ O +
2C O +
and O +
5 O +
- O +
HT7 O +
[ O +
98 O +
] O +
, O +
one O +
linked O +
to O +
a O +
stimulation O +
of O +
inositol O +
phosphates O +
( O +
5 O +
- O +
HT2 O +
subtype O +
) O +
, O +
while O +
the O +
others O +
two O +
are O +
linked O +
to O +
cAMP O +
activity O +
. O +

The O +
plausibility O +
of O +
the O +
existence O +
of O +
more O +
than O +
one O +
5 O +
- O +
HT O +
receptor O +
type O +
in O +
the O +
ciliary O +
body O +
is O +
confirmed O +
by O +
intraocular O +
pressure O +
( O +
IOP O +
) O +
experiments O +
. O +

Topical O +
application O +
of O +
serotonin O +
has O +
been O +
reported O +
to O +
both O +
elevate O +
[ O +
84 O +
] O +
and O +
lower O +
[ O +
88 O +
] O +
IOP O +
in O +
rabbit O +
. O +

A O +
large O +
number O +
of O +
reports O +
have O +
shown O +
that O +
serotonin O +
agonists O +
and O +
antagonists O +
can O +
produce O +
increases O +
and O +
decreases O +
in O +
IOP O +
when O +
given O +
orally O +
, O +
topically O +
to O +
the O +
eye O +
or O +
when O +
they O +
are O +
directly O +
injected O +
in O +
the O +
anterior O +
chamber O +
[ O +
10 O +
, O +
26 O +
, O +
34 O +
, O +
35 O +
, O +
64 O +
, O +
75 O +
, O +
84 O +
, O +
87 O +
, O +
88 O +
, O +
112 O +
, O +
113 O +
, O +
126 O +
, O +
136 O +
, O +
137 O +
] O +
. O +

A O +
rationale O +
for O +
such O +
apparently O +
contradictory O +
results O +
may O +
be O +
due O +
to O +
the O +
different O +
sites O +
of O +
action O +
, O +
i O +
. O +
e O +
. O +
which O +
class O +
of O +
serotonin O +
receptor O +
is O +
activated O +
. O +

In O +
fact O +
, O +
in O +
rabbit O +
the O +
administration O +
of O +
5 O +
- O +
methyl O +
- O +
urapidil O +
( O +
a O +
combined O +
5 O +
- O +
HT1A O +
agonist O +
/ O +
alpha1 O +
adrenoreceptor O +
antagonist O +
) O +
and O +
8 O +
- O +
OH O +
- O +
DPAT O +
( O +
8 O +
- O +
hydroxydypropylaminotetralin O +
, O +
a O +
5HT1A O +
agonist O +
) O +
reduces O +
IOP O +
, O +
while O +
the O +
administration O +
of O +
5 O +
- O +
CT O +
( O +
5 O +
- O +
carboxamidotryptamine O +
, O +
a O +
5 O +
- O +
HT1A O +
and O +
5 O +
- O +
HT7 O +
agonist O +
) O +
increases O +
IOP O +
[ O +
36 O +
, O +
84 O +
, O +
99 O +
] O +
. O +

Chidlow O +
, O +
Le O +
Corre O +
and O +
Osborne O +
[ O +
28 O +
] O +
have O +
recently O +
demonstrated O +
that O +
, O +
in O +
section O +
taken O +
through O +
the O +
whole O +
eye O +
and O +
ciliary O +
body O +
, O +
prominent O +
5 O +
- O +
HT1A O +
and O +
5 O +
- O +
HT7 O +
receptor O +
messenger O +
ribonucleic O +
acid O +
signals O +
were O +
obtained O +
. O +

These O +
signals O +
were O +
evident O +
in O +
both O +
the O +
pigmented O +
and O +
non O +
- O +
pigmented O +
epithelial O +
cell O +
layers O +
of O +
the O +
pars O +
plicata O +
region O +
of O +
the O +
ciliary O +
processes O +
, O +
but O +
not O +
in O +
the O +
pars O +
plana O +
or O +
in O +
the O +
ciliary O +
musculature O +
. O +

5 O +
- O +
HT1A O +
and O +
5 O +
- O +
HT7 O +
signals O +
were O +
apparent O +
in O +
the O +
posterior O +
processes O +
but O +
not O +
in O +
the O +
iris O +
processes O +
. O +

The O +
presence O +
of O +
both O +
receptors O +
in O +
the O +
ciliary O +
body O +
would O +
certainly O +
provide O +
an O +
explanation O +
for O +
the O +
shallow O +
displacement O +
curves O +
observed O +
in O +
[ O +
3H O +
] O +
5 O +
- O +
HT O +
binding O +
studies O +
with O +
the O +
tissue O +
[ O +
110 O +
] O +
, O +
since O +
this O +
ligand O +
can O +
be O +
used O +
to O +
label O +
both O +
receptors O +
. O +

Because O +
the O +
ciliary O +
epithelium O +
of O +
the O +
pars O +
plicata O +
is O +
responsible O +
for O +
the O +
secretion O +
of O +
aqueous O +
humor O +
, O +
an O +
obvious O +
function O +
for O +
these O +
two O +
receptors O +
would O +
be O +
an O +
involvement O +
in O +
the O +
control O +
of O +
aqueous O +
production O +
and O +
, O +
consequently O +
, O +
of O +
the O +
IOP O +
level O +
. O +

Further O +
, O +
the O +
almost O +
identical O +
distribution O +
of O +
the O +
5 O +
- O +
HT1A O +
and O +
5 O +
- O +
HT7 O +
messengers O +
ribonucleic O +
acid O +
indicate O +
that O +
the O +
receptors O +
may O +
be O +
co O +
- O +
localized O +
in O +
epithelial O +
cells O +
. O +

The O +
presence O +
of O +
two O +
serotonin O +
receptors O +
with O +
opposing O +
effects O +
on O +
cAMP O +
in O +
the O +
same O +
cell O +
layer O +
prompts O +
the O +
suggestion O +
that O +
they O +
could O +
act O +
antagonistically O +
. O +

The O +
agonism O +
of O +
5 O +
- O +
HT1A O +
receptors O +
, O +
negatively O +
coupled O +
to O +
cAMP O +
, O +
reduces O +
IOP O +
by O +
decreasing O +
the O +
production O +
of O +
aqueous O +
humor O +
, O +
like O +
beta O +
- O +
receptor O +
antagonists O +
which O +
, O +
diminishing O +
the O +
content O +
of O +
cAMP O +
at O +
the O +
postjunctional O +
site O +
, O +
lowers O +
the O +
aqueous O +
humor O +
secretion O +
with O +
a O +
consequent O +
decrease O +
in O +
IOP O +
[ O +
98 O +
] O +
. O +

On O +
the O +
contrary O +
, O +
the O +
administration O +
of O +
5 O +
- O +
CT O +
induces O +
a O +
rise O +
in O +
IOP O +
, O +
which O +
is O +
partly O +
or O +
entirely O +
caused O +
by O +
an O +
increase O +
in O +
aqueous O +
humor O +
secretion O +
mediated O +
by O +
5 O +
- O +
HT7 O +
receptors O +
[ O +
84 O +
] O +
. O +

The O +
other O +
type O +
of O +
serotonin O +
receptor O +
present O +
in O +
the O +
ICB O +
is O +
a O +
5 O +
- O +
HT2 O +
type O +
. O +

Serotonin O +
stimulates O +
the O +
accumulation O +
of O +
inositol O +
phosphates O +
in O +
the O +
ICB O +
and O +
this O +
effect O +
is O +
partially O +
counteracted O +
by O +
the O +
5 O +
- O +
HT2 O +
antagonists O +
ketanserin O +
, O +
methysergide O +
and O +
mianserin O +
[ O +
98 O +
] O +
. O +

Studies O +
with O +
ketanserin O +
have O +
demonstrated O +
that O +
, O +
when O +
orally O +
or O +
topically O +
applied O +
, O +
it O +
lowers O +
IOP O +
in O +
animals O +
, O +
healthy O +
volunteers O +
and O +
in O +
glaucomatous O +
patients O +
[ O +
26 O +
, O +
34 O +
, O +
37 O +
, O +
64 O +
, O +
75 O +
, O +
88 O +
, O +
113 O +
, O +
126 O +
] O +
. O +

It O +
has O +
been O +
emphasized O +
that O +
ketanserin O +
also O +
possesses O +
an O +
affinity O +
for O +
alpha1 O +
- O +
adrenoreceptors O +
[ O +
27 O +
, O +
36 O +
, O +
139 O +
] O +
, O +
and O +
for O +
this O +
reason O +
the O +
effects O +
of O +
ketanserin O +
on O +
IOP O +
may O +
not O +
be O +
entirely O +
caused O +
by O +
its O +
action O +
on O +
5 O +
- O +
HT2 O +
receptors O +
. O +

However O +
, O +
data O +
from O +
human O +
studies O +
conducted O +
after O +
oral O +
or O +
topical O +
administration O +
of O +
ketanserin O +
, O +
in O +
which O +
were O +
determined O +
the O +
variations O +
of O +
IOP O +
, O +
total O +
outflow O +
facility O +
and O +
pupil O +
diameter O +
, O +
demonstrated O +
that O +
the O +
alpha1 O +
- O +
adrenoreceptor O +
blocking O +
effect O +
exerted O +
by O +
ketanserin O +
should O +
represent O +
a O +
further O +
aspect O +
of O +
its O +
mechanism O +
of O +
action O +
, O +
probably O +
due O +
to O +
a O +
functional O +
sharing O +
of O +
these O +
receptors O +
[ O +
64 O +
, O +
87 O +
] O +
. O +

Lastly O +
, O +
already O +
in O +
1992 O +
Martin O +
and O +
co O +
- O +
workers O +
showed O +
the O +
occurrence O +
of O +
a O +
significant O +
correlation O +
between O +
the O +
content O +
of O +
serotonin O +
in O +
the O +
aqueous O +
humor O +
and O +
IOP O +
in O +
the O +
human O +
eye O +
[ O +
85 O +
] O +
. O +

In O +
1981 O +
, O +
Moro O +
and O +
his O +
collaborators O +
found O +
that O +
intravitreal O +
injection O +
of O +
5 O +
, O +
6 O +
- O +
dihydroxytryptamine O +
, O +
a O +
serotonergic O +
neurotoxin O +
, O +
causes O +
miosis O +
[ O +
91 O +
] O +
. O +

The O +
identification O +
of O +
5 O +
- O +
HT7 O +
, O +
but O +
not O +
of O +
5 O +
- O +
HT1 O +
receptors O +
in O +
the O +
rabbit O +
iris O +
, O +
suggests O +
that O +
this O +
population O +
of O +
serotonergic O +
receptors O +
is O +
involved O +
in O +
the O +
relaxation O +
of O +
the O +
sphincter O +
of O +
the O +
pupil O +
. O +

In O +
fact O +
, O +
one O +
of O +
the O +
function O +
correlate O +
to O +
5 O +
- O +
HT7 O +
receptor O +
activation O +
includes O +
smooth O +
muscle O +
relaxation O +
observed O +
in O +
a O +
variety O +
of O +
isolated O +
tissue O +
preparations O +
, O +
in O +
which O +
elevation O +
of O +
cAMP O +
concentration O +
was O +
also O +
detected O +
[ O +
3 O +
, O +
44 O +
] O +
. O +

Further O +
evidence O +
for O +
the O +
mediation O +
of O +
the O +
relaxant O +
response O +
via O +
the O +
5 O +
- O +
HT7 O +
receptor O +
is O +
provided O +
by O +
the O +
localization O +
of O +
messenger O +
ribonucleic O +
acid O +
transcripts O +
encoding O +
the O +
5 O +
- O +
HT7 O +
receptor O +
in O +
many O +
blood O +
vessels O +
[ O +
67 O +
] O +
. O +

This O +
hypothesized O +
mechanism O +
of O +
action O +
is O +
also O +
supported O +
by O +
the O +
fact O +
that O +
various O +
other O +
receptor O +
types O +
, O +
also O +
positively O +
coupled O +
to O +
cAMP O +
, O +
in O +
the O +
iris O +
cause O +
relaxation O +
of O +
the O +
sphincter O +
muscle O +
[ O +
1 O +
, O +
28 O +
] O +
. O +

Sex O +
and O +
age O +
distributions O +
of O +
confirmed O +
cases O +

Of O +
480 O +
confirmed O +
cases O +
, O +
56 O +
% O +
( O +
269 O +
/ O +
480 O +
) O +
were O +
male O +
patients O +
and O +
44 O +
% O +
( O +
211 O +
/ O +
480 O +
) O +
were O +
female O +
, O +
respectively O +
. O +

The O +
percentage O +
of O +
male O +
cases O +
was O +
higher O +
than O +
that O +
of O +
females O +
in O +
all O +
groups O +
except O +
for O +
the O +
group O +
aged O +
31 O +
- O +
40 O +
( O +
chi2 O +
= O +
42 O +
. O +
4 O +
, O +
P O +
< O +
0 O +
. O +
001 O +
) O +
. O +

278 O +
( O +
57 O +
. O +
9 O +
% O +
) O +
cases O +
were O +
in O +
the O +
group O +
aged O +
21 O +
- O +
50 O +
, O +
followed O +
by O +
102 O +
( O +
21 O +
. O +
3 O +
% O +
) O +
, O +
79 O +
( O +
16 O +
. O +
5 O +
% O +
) O +
and O +
21 O +
( O +
4 O +
. O +
4 O +
% O +
) O +
cases O +
in O +
the O +
group O +
aged O +
51 O +
- O +
70 O +
, O +
0 O +
- O +
20 O +
, O +
and O +
> O +
= O +
71 O +
, O +
respectively O +
. O +

The O +
youngest O +
and O +
oldest O +
cases O +
were O +
1 O +
. O +
5 O +
and O +
81 O +
years O +
old O +
, O +
respectively O +
( O +
Table O +
2 O +
) O +
. O +

Table O +
2 O +

Age O +
and O +
occupational O +
distributions O +
and O +
activities O +
( O +
1 O +
- O +
3 O +
weeks O +
prior O +
to O +
symptom O +
appearance O +
) O +
of O +
confirmed O +
cases O +

Cases O +
( O +
% O +
) O +
( O +
Male O +
: O +
Female O +
, O +
% O +
) O +

Age O +
( O +
Years O +
) O +

0 O +
- O +
10 O +
46 O +
( O +
9 O +
. O +
6 O +
) O +
( O +
76 O +
: O +
24 O +
) O +

11 O +
- O +
20 O +
33 O +
( O +
6 O +
. O +
9 O +
) O +
( O +
79 O +
: O +
21 O +
) O +

21 O +
- O +
30 O +
78 O +
( O +
16 O +
. O +
3 O +
) O +
( O +
51 O +
: O +
49 O +
) O +

31 O +
- O +
40 O +
99 O +
( O +
20 O +
. O +
6 O +
) O +
( O +
46 O +
: O +
54 O +
) O +

41 O +
- O +
50 O +
101 O +
( O +
21 O +
. O +
0 O +
) O +
( O +
56 O +
: O +
44 O +
) O +

51 O +
- O +
60 O +
47 O +
( O +
9 O +
. O +
8 O +
) O +
( O +
55 O +
: O +
45 O +
) O +

61 O +
- O +
70 O +
55 O +
( O +
11 O +
. O +
5 O +
) O +
( O +
53 O +
: O +
47 O +
) O +

> O +
= O +
71 O +
21 O +
( O +
4 O +
. O +
4 O +
) O +
( O +
52 O +
: O +
48 O +
) O +

Occupation O +

Children O +
at O +
preschool O +
age O +
20 O +
( O +
4 O +
. O +
2 O +
) O +
( O +
75 O +
: O +
25 O +
) O +

Pupils O +
50 O +
( O +
10 O +
. O +
4 O +
) O +
( O +
78 O +
: O +
22 O +
) O +

Farmers O +
408 O +
( O +
85 O +
. O +
0 O +
) O +
( O +
52 O +
: O +
48 O +
) O +

Others O +
2 O +
( O +
0 O +
. O +
4 O +
) O +
( O +
50 O +
: O +
50 O +
) O +

Activities O +

Farm O +
work O +
325 O +
( O +
67 O +
. O +
7 O +
) O +
( O +
53 O +
: O +
47 O +
) O +

Play O +
on O +
grassland O +
65 O +
( O +
13 O +
. O +
5 O +
) O +
( O +
75 O +
: O +
25 O +
) O +

Recreation O +
20 O +
( O +
4 O +
. O +
2 O +
) O +
( O +
65 O +
: O +
35 O +
) O +

Housework O +
25 O +
( O +
5 O +
. O +
2 O +
) O +
( O +
8 O +
: O +
92 O +
) O +

Unknown O +
45 O +
( O +
9 O +
. O +
4 O +
) O +
( O +
71 O +
: O +
29 O +
) O +

Stochastic O +
models O +

Stochasticity O +
inevitably O +
emerges O +
when O +
molecular O +
components O +
are O +
present O +
at O +
low O +
cellular O +
concentrations O +
( O +
McAdams O +
& O +
Arkin O +
, O +
1997 O +
; O +
Kierzek O +
et O +
al O +
. O +
, O +
2001 O +
) O +
. O +

This O +
physical O +
phenomenon O +
generates O +
noise O +
in O +
synthetic O +
and O +
natural O +
circuits O +
( O +
Paulsson O +
, O +
2004 O +
; O +
Mettetal O +
et O +
al O +
. O +
, O +
2006 O +
) O +
, O +
and O +
its O +
consequences O +
over O +
the O +
phenotype O +
are O +
starting O +
to O +
be O +
explored O +
( O +
Suel O +
et O +
al O +
. O +
, O +
2006 O +
) O +
. O +

For O +
example O +
, O +
noise O +
constitutes O +
the O +
driving O +
force O +
behind O +
differentiation O +
in O +
isogenetic O +
colonies O +
( O +
Colman O +
- O +
Lerner O +
et O +
al O +
. O +
, O +
2005 O +
) O +
. O +

Biological O +
and O +
theoretical O +
studies O +
have O +
aided O +
to O +
delineate O +
the O +
regulatory O +
mechanism O +
by O +
which O +
the O +
cell O +
handles O +
noise O +
efficiently O +
and O +
effectively O +
to O +
carry O +
out O +
its O +
biological O +
functions O +
( O +
Gardner O +
& O +
Collins O +
, O +
2000 O +
; O +
Orrell O +
& O +
Bolouri O +
, O +
2004 O +
; O +
Raser O +
& O +
O O +
' O +
Shea O +
, O +
2005 O +
) O +
. O +

From O +
a O +
theoretical O +
point O +
of O +
view O +
, O +
stochastic O +
models O +
are O +
the O +
most O +
challenging O +
but O +
also O +
the O +
most O +
realistic O +
ones O +
: O +
there O +
is O +
a O +
precise O +
counting O +
of O +
how O +
, O +
through O +
individual O +
chemical O +
reactions O +
, O +
the O +
populations O +
of O +
every O +
chemical O +
species O +
change O +
. O +

The O +
milestone O +
to O +
simulate O +
stochastic O +
processes O +
is O +
the O +
Gillespie O +
algorithm O +
( O +
Gillespie O +
, O +
1992 O +
) O +
. O +

Because O +
of O +
their O +
analytical O +
and O +
computational O +
complexity O +
, O +
the O +
present O +
models O +
do O +
not O +
surpass O +
a O +
handful O +
of O +
chemical O +
species O +
. O +

Two O +
immediate O +
problems O +
must O +
be O +
solved O +
to O +
model O +
systems O +
with O +
several O +
dozens O +
of O +
genetic O +
components O +
: O +
the O +
systematic O +
determination O +
of O +
kinetic O +
constants O +
and O +
the O +
efficient O +
computation O +
of O +
thousands O +
of O +
chemical O +
stochastic O +
equations O +
( O +
Kuwahara O +
et O +
al O +
. O +
, O +
2006 O +
; O +
Sanchez O +
& O +
Kondev O +
, O +
2008 O +
) O +
. O +

Luciferase O +
Assay O +

For O +
Fig O +
. O +

1 O +
, O +
10 O +
ng O +
of O +
TORC1 O +
, O +
5 O +
ng O +
of O +
TORC2 O +
, O +
and O +
15 O +
ng O +
of O +
PKAalpha O +
expression O +
plasmids O +
were O +
transfected O +
into O +
HEK293 B-CellLine +
cells O +
. O +

For O +
Fig O +
. O +

2 O +
, O +
800 O +
ng O +
of O +
total O +
DNA O +
consisted O +
of O +
200 O +
ng O +
of O +
the O +
pMLHoxb1ARE O +
luciferase O +
reporter O +
and O +
100 O +
ng O +
of O +
each O +
expression O +
plasmid O +
. O +

A O +
lacZ O +
reporter O +
was O +
co O +
- O +
transfected O +
to O +
normalize O +
transfection O +
efficiency O +
. O +

For O +
Fig O +
. O +

3A O +
, O +
the O +
amounts O +
of O +
pENTR O +
T2i O +
shRNA O +
( O +
TORC2 O +
shRNA O +
) O +
are O +
given O +
within O +
the O +
panel O +
. O +

For O +
Fig O +
. O +

3B O +
, O +
25 O +
, O +
000 O +
cells O +
per O +
well O +
were O +
plated O +
in O +
48 O +
- O +
well O +
plates O +
and O +
transfected O +
using O +
Lipofectamine O +
2000 O +
with O +
the O +
following O +
vectors O +
: O +
40 O +
ng O +
of O +
pML5xUAS O +
, O +
40 O +
ng O +
of O +
pGAL O +
- O +
DBD O +
or O +
pGAL O +
- O +
MEIS1A O +
( O +
335 O +
- O +
390 O +
) O +
, O +
40 O +
ng O +
of O +
pRSV O +
- O +
PBS O +
or O +
pRSV O +
- O +
PKA O +
, O +
40 O +
ng O +
of O +
pENTR O +
U6 O +
( O +
control O +
shRNA O +
) O +
or O +
pENTR O +
T2i O +
shRNA O +
( O +
TORC2 O +
shRNA O +
) O +
, O +
and O +
100 O +
ng O +
of O +
pRSV O +
- O +
beta O +
- O +
galactosidase O +
. O +

At O +
48 O +
h O +
post O +
- O +
transfection O +
, O +
cell O +
lysates O +
were O +
prepared O +
using O +
100 O +
mul O +
per O +
well O +
of O +
lysis O +
buffer O +
( O +
1 O +
% O +
Triton O +
X O +
- O +
100 O +
, O +
1 O +
mm O +
dithiothreitol O +
, O +
92 O +
. O +
8 O +
mm O +
K2HPO4 O +
, O +
pH O +
7 O +
. O +
8 O +
, O +
9 O +
. O +
2 O +
mm O +
KH2PO4 O +
, O +
pH O +
7 O +
. O +
8 O +
) O +
and O +
centrifuged O +
for O +
5 O +
min O +
at O +
4 O +
degreesC O +
. O +

A O +
20 O +
- O +
mul O +
aliquot O +
of O +
the O +
supernatant O +
was O +
added O +
to O +
12 O +
. O +
5 O +
mul O +
of O +
assay O +
buffer O +
( O +
20 O +
mm O +
ATP O +
, O +
40 O +
mm O +
MgCl2 O +
, O +
0 O +
. O +
4 O +
m O +
Tris O +
- O +
Cl O +
, O +
pH O +
7 O +
. O +
8 O +
) O +
. O +

The O +
mixture O +
was O +
immediately O +
quantified O +
for O +
luciferase O +
activity O +
using O +
a O +
Lumat O +
LB O +
9507 O +
luminometer O +
( O +
EG O +
& O +
G O +
Berthold O +
) O +
that O +
dispensed O +
100 O +
mul O +
per O +
reaction O +
of O +
luciferin O +
solution O +
, O +
which O +
contains O +
1 O +
mm O +
d O +
- O +
( O +
- O +
) O +
- O +
luciferin O +
( O +
catalogue O +
number O +
11626353001 O +
, O +
Roche O +
) O +
and O +
0 O +
. O +
1 O +
m O +
Tris O +
- O +
Cl O +
, O +
pH O +
7 O +
. O +
8 O +
. O +

Implications O +
for O +
Psychological O +
Models O +
of O +
Interval O +
Timing O +

Several O +
models O +
have O +
been O +
previously O +
applied O +
to O +
interpret O +
data O +
obtained O +
in O +
interval O +
- O +
timing O +
experiments O +
involving O +
gaps O +
( O +
retention O +
- O +
intervals O +
) O +
. O +

A O +
switch O +
model O +
, O +
assuming O +
that O +
during O +
the O +
gap O +
time O +
fails O +
to O +
accumulate O +
due O +
to O +
the O +
opening O +
of O +
a O +
stimulus O +
- O +
controlled O +
switch O +
, O +
predicts O +
that O +
, O +
irrespective O +
of O +
gap O +
and O +
criterion O +
durations O +
, O +
subjects O +
should O +
use O +
a O +
stop O +
rule O +
[ O +
14 O +
] O +
, O +
[ O +
15 O +
] O +
, O +
[ O +
30 O +
] O +
, O +
[ O +
31 O +
] O +
. O +

In O +
contrast O +
, O +
the O +
present O +
data O +
indicate O +
that O +
rats O +
flexibly O +
change O +
their O +
behavior O +
with O +
both O +
gap O +
and O +
criterion O +
duration O +
. O +

An O +
instructional O +
- O +
ambiguity O +
model O +
proposing O +
that O +
subjects O +
perceive O +
the O +
gap O +
as O +
an O +
ambiguous O +
, O +
ITI O +
- O +
like O +
event O +
, O +
predicts O +
that O +
manipulations O +
that O +
render O +
the O +
gap O +
similar O +
to O +
the O +
ITI O +
should O +
reset O +
the O +
clock O +
, O +
while O +
manipulations O +
that O +
render O +
the O +
gap O +
dissimilar O +
from O +
the O +
ITI O +
should O +
stop O +
the O +
clock O +
[ O +
37 O +
] O +
. O +

Because O +
in O +
our O +
experiment O +
the O +
gap O +
and O +
ITI O +
were O +
identical O +
( O +
dark O +
) O +
this O +
hypothesis O +
predicts O +
the O +
use O +
of O +
the O +
same O +
rule O +
( O +
reset O +
) O +
at O +
all O +
gap O +
and O +
criteria O +
durations O +
, O +
in O +
contrast O +
to O +
the O +
current O +
data O +
showing O +
the O +
use O +
of O +
different O +
rules O +
for O +
different O +
temporal O +
criteria O +
. O +

To O +
account O +
for O +
the O +
flexible O +
use O +
of O +
the O +
run O +
/ O +
stop O +
/ O +
reset O +
rules O +
by O +
rats O +
and O +
pigeons O +
, O +
Cabeza O +
de O +
Vaca O +
et O +
al O +
. O +

[ O +
38 O +
] O +
proposed O +
a O +
passive O +
memory O +
- O +
decay O +
model O +
which O +
assumes O +
that O +
subjective O +
time O +
- O +
- O +
stored O +
in O +
WM O +
- O +
- O +
decays O +
passively O +
during O +
the O +
gap O +
. O +

This O +
model O +
predicts O +
that O +
the O +
effect O +
of O +
a O +
gap O +
should O +
depend O +
solely O +
on O +
absolute O +
gap O +
duration O +
, O +
but O +
not O +
on O +
criterion O +
duration O +
, O +
as O +
found O +
here O +
( O +
Fig O +
. O +
1B O +
- O +
D O +
) O +
. O +

These O +
models O +
can O +
not O +
account O +
for O +
the O +
differential O +
effects O +
of O +
gaps O +
on O +
multiple O +
intervals O +
. O +

In O +
contrast O +
to O +
these O +
alternatives O +
, O +
the O +
present O +
resource O +
allocation O +
model O +
assumes O +
that O +
during O +
the O +
gaps O +
resources O +
are O +
re O +
- O +
allocated O +
( O +
diverted O +
away O +
from O +
timing O +
) O +
, O +
each O +
clock O +
is O +
unable O +
to O +
maintain O +
its O +
current O +
subjective O +
time O +
in O +
WM O +
, O +
and O +
the O +
response O +
is O +
delayed O +
[ O +
16 O +
] O +
, O +
[ O +
17 O +
] O +
, O +
[ O +
27 O +
] O +
in O +
proportion O +
to O +
the O +
perceived O +
salience O +
of O +
the O +
distracter O +
relative O +
to O +
the O +
times O +
signal O +
[ O +
34 O +
] O +
, O +
[ O +
35 O +
] O +
. O +

Indeed O +
, O +
the O +
effect O +
of O +
a O +
gap O +
is O +
affected O +
by O +
the O +
contrast O +
in O +
intensity O +
between O +
the O +
gap O +
and O +
the O +
timed O +
signal O +
[ O +
27 O +
] O +
, O +
[ O +
34 O +
] O +
, O +
[ O +
39 O +
] O +
and O +
by O +
the O +
perceptual O +
acuity O +
of O +
the O +
subjects O +
[ O +
27 O +
] O +
. O +

Importantly O +
, O +
the O +
predictions O +
of O +
this O +
resource O +
re O +
- O +
allocation O +
model O +
are O +
not O +
restricted O +
to O +
retention O +
- O +
intervals O +
( O +
i O +
. O +
e O +
. O +
, O +
gaps O +
) O +
, O +
but O +
extend O +
to O +
distracters O +
presented O +
during O +
the O +
continuous O +
presentation O +
of O +
a O +
timed O +
signal O +
. O +

Previous O +
data O +
were O +
quantitatively O +
accounted O +
for O +
by O +
assuming O +
that O +
during O +
a O +
gap O +
and O +
/ O +
or O +
distracter O +
the O +
accumulated O +
time O +
decays O +
at O +
a O +
rate O +
that O +
varies O +
with O +
the O +
relative O +
salience O +
of O +
the O +
distracter O +
to O +
the O +
timed O +
signal O +
[ O +
25 O +
] O +
, O +
[ O +
26 O +
] O +
, O +
[ O +
35 O +
] O +
. O +

Here O +
we O +
found O +
that O +
the O +
comparison O +
between O +
the O +
gap O +
and O +
the O +
( O +
multiple O +
) O +
timed O +
signal O +
( O +
s O +
) O +
extends O +
to O +
the O +
temporal O +
domain O +
. O +

Simulations O +
indicate O +
that O +
both O +
the O +
differential O +
effect O +
of O +
the O +
gap O +
on O +
multiple O +
durations O +
, O +
and O +
the O +
gradual O +
hierarchical O +
reset O +
due O +
to O +
increasing O +
gap O +
duration O +
can O +
be O +
quantitatively O +
accounted O +
for O +
assuming O +
that O +
the O +
three O +
clocks O +
have O +
separate O +
resources O +
re O +
- O +
allocated O +
independently O +
during O +
a O +
gap O +
at O +
a O +
rate O +
proportional O +
to O +
the O +
ratio O +
g O +
/ O +
Tk O +
between O +
the O +
duration O +
of O +
the O +
gap O +
and O +
each O +
criterion O +
duration O +
( O +
Fig O +
. O +
2A O +
: O +
D O +
- O +
Model O +
) O +
. O +

Discussion O +

Because O +
Netherton O +
syndrome O +
exhibits O +
allergic O +
phenotype O +
, O +
it O +
is O +
reasonable O +
to O +
speculate O +
that O +
SPINK5 O +
, O +
which O +
is O +
mutated O +
in O +
Netherton O +
syndrome O +
, O +
may O +
act O +
as O +
a O +
candidate O +
gene O +
for O +
asthma O +
and O +
other O +
allergic O +
diseases O +
[ O +
9 O +
] O +
. O +

An O +
extensive O +
search O +
for O +
single O +
nucleotide O +
polymorphisms O +
in O +
the O +
SPINK5 O +
led O +
to O +
the O +
identification O +
of O +
a O +
number O +
of O +
SNPs O +
, O +
including O +
six O +
nonsynonymous O +
SNPs O +
in O +
coding O +
region O +
that O +
might O +
perturb O +
its O +
immune O +
function O +
. O +

Subsequent O +
genotyping O +
of O +
three O +
nonsynonymous O +
SNPs O +
, O +
A1103 O -
G O +
, O +
G1156A O +
and O +
G1258A O +
in O +
two O +
independent O +
panels O +
of O +
British O +
families O +
showed O +
a O +
significant O +
association O +
between O +
SNP O +
G1258A O +
( O +
Glu420Lys O +
) O +
and O +
atopy O +
, O +
atopic O +
dermatitis O +
, O +
elevated O +
serum O +
IgE O +
levels O +
and O +
asthma O +
[ O +
10 O +
] O +
. O +

This O +
association O +
was O +
confirmed O +
in O +
a O +
large O +
German O +
population O +
and O +
two O +
Japanese O +
populations O +
[ O +
16 O +
- O +
18 O +
] O +
. O +

Kato O +
et O +
al O +
analyzed O +
eight O +
SNPs O +
in O +
exon O +
13 O +
and O +
14 O +
of O +
the O +
SPINK5 O +
including O +
G1258A O +
( O +
Glu420Lys O +
) O +
, O +
and O +
found O +
a O +
positive O +
association O +
of O +
seven O +
SNPs O +
with O +
atopic O +
dermatitis O +
in O +
a O +
Japanese O +
study O +
sample O +
using O +
a O +
case O +
- O +
control O +
study O +
design O +
[ O +
16 O +
] O +
. O +

Nishio O +
et O +
al O +
surveyed O +
five O +
of O +
six O +
previously O +
reported O +
nonsynonymous O +
SPINK5 O +
SNPs O +
in O +
Japanese O +
atopic O +
families O +
identified O +
through O +
asthmatic O +
children O +
or O +
subjects O +
with O +
atopic O +
dermatitis O +
and O +
found O +
that O +
SPINK5 O +
was O +
associated O +
with O +
development O +
of O +
atopic O +
dermatitis O +
but O +
not O +
asthma O +
[ O +
17 O +
] O +
. O +

Kabesch O +
M O +
et O +
al O +
. O +
analyzed O +
G1258A O +
( O +
Glu420Lys O +
) O +
in O +
a O +
German O +
population O +
of O +
school O +
children O +
, O +
and O +
found O +
its O +
association O +
with O +
asthma O +
as O +
well O +
as O +
a O +
concomitant O +
occurrence O +
of O +
asthma O +
and O +
atopic O +
dermatitis O +
[ O +
18 O +
] O +
. O +

However O +
, O +
two O +
subsequent O +
studies O +
failed O +
to O +
replicate O +
the O +
original O +
SPINK5 O +
findings O +
for O +
allergic O +
diseases O +
[ O +
19 O +
, O +
20 O +
] O +
. O +

Folster O +
- O +
Holst O +
et O +
al O +
genotyped O +
four O +
nonsynonymous O +
SNPs O +
( O +
Asp106Asn O +
, O +
Asn368Ser O +
, O +
Asp386Asn O +
, O +
and O +
Glu420Lys O +
) O +
, O +
and O +
detected O +
no O +
association O +
between O +
SPINK5 O +
and O +
atopic O +
dermatitis O +
in O +
populations O +
of O +
Northern O +
German O +
origin O +
[ O +
20 O +
] O +
. O +

Jongepier O +
H O +
et O +
al O +
. O +
failed O +
to O +
detect O +
any O +
association O +
between O +
SPINK5 O +
and O +
asthma O +
, O +
atopic O +
phenotypes O +
and O +
atopic O +
dermatitis O +
in O +
a O +
Dutch O +
population O +
[ O +
19 O +
] O +
. O +

These O +
discordant O +
findings O +
probably O +
reflect O +
different O +
genetic O +
and O +
environmental O +
backgrounds O +
in O +
various O +
populations O +
. O +

To O +
determine O +
whether O +
nonsynonymous O +
SNPs O +
of O +
the O +
SPINK5 O +
are O +
involved O +
in O +
the O +
pathogenesis O +
of O +
asthma O +
in O +
the O +
Chinese O +
Han O +
population O +
, O +
we O +
performed O +
a O +
case O +
- O +
control O +
study O +
by O +
genotyping O +
four O +
nonsynonymous O +
SNPs O +
in O +
the O +
SPINK5 O +
. O +

We O +
did O +
not O +
detect O +
any O +
significant O +
association O +
between O +
these O +
nonsynonymous O +
SNPs O +
and O +
asthma O +
in O +
our O +
Chinese O +
samples O +
. O +

With O +
our O +
sample O +
size O +
, O +
we O +
expected O +
a O +
power O +
of O +
at O +
least O +
80 O +
% O +
in O +
detecting O +
an O +
effect O +
of O +
OR O +
> O +
= O +
1 O +
. O +
3 O +
for O +
each O +
of O +
these O +
SNPs O +
. O +

Therefore O +
, O +
our O +
failure O +
to O +
detect O +
an O +
association O +
for O +
these O +
4 O +
SNPs O +
was O +
not O +
due O +
to O +
the O +
sample O +
size O +
. O +

These O +
results O +
suggest O +
that O +
the O +
polymorphisms O +
in O +
the O +
coding O +
region O +
of O +
the O +
SPINK5 O +
are O +
unlikely O +
to O +
contribute O +
to O +
asthma O +
risk O +
in O +
the O +
Chinese O +
Han O +
population O +
. O +

However O +
, O +
because O +
our O +
patients O +
were O +
ascertained O +
for O +
asthma O +
, O +
we O +
could O +
not O +
exclude O +
a O +
role O +
of O +
the O +
coding O +
SNPs O +
of O +
the O +
SPINK5 O +
in O +
atopic O +
dermatitis O +
in O +
our O +
population O +
. O +

The O +
variations O +
in O +
the O +
regulatory O +
sequences O +
of O +
genes O +
may O +
determine O +
risks O +
to O +
common O +
diseases O +
by O +
causing O +
different O +
levels O +
of O +
expression O +
. O +

Therefore O +
, O +
the O +
identification O +
and O +
functional O +
evaluation O +
of O +
polymorphisms O +
in O +
promoter O +
region O +
are O +
of O +
great O +
value O +
in O +
understanding O +
the O +
genetic O +
susceptibility O +
to O +
asthma O +
. O +

In O +
order O +
to O +
determine O +
the O +
role O +
of O +
the O +
SPINK5 O +
promoter O +
polymorphism O +
in O +
the O +
pathogenesis O +
of O +
asthma O +
, O +
we O +
genotyped O +
a O +
promoter O +
polymorphism O +
, O +
- O +
206 O -
G O +
> O +
A O +
, O +
in O +
422 O +
asthma O +
patients O +
and O +
410 O +
controls O +
, O +
and O +
found O +
a O +
marginal O +
association O +
. O +

The O +
frequency O +
of O +
allele O +
G O +
was O +
significantly O +
higher O +
in O +
asthmatic O +
patients O +
than O +
that O +
in O +
controls O +
( O +
p O +
= O +
0 O +
. O +
022 O +
) O +
. O +

To O +
confirm O +
the O +
association O +
, O +
additional O +
267 O +
asthma O +
patients O +
and O +
301 O +
controls O +
newly O +
recruited O +
from O +
the O +
same O +
hospital O +
were O +
genotyped O +
, O +
and O +
the O +
- O +
206 O -
G O +
> O +
A O +
polymorphism O +
remained O +
significantly O +
associated O +
with O +
asthma O +
( O +
P O +
= O +
0 O +
. O +
001 O +
) O +
, O +
even O +
after O +
Bonferroni O +
correction O +
( O +
adjusted O +
P O +
= O +
0 O +
. O +
01 O +
) O +
. O +

To O +
our O +
knowledge O +
, O +
this O +
is O +
the O +
first O +
report O +
of O +
an O +
association O +
of O +
- O +
206 O -
G O +
> O +
A O +
polymorphism O +
with O +
asthma O +
. O +

We O +
further O +
examined O +
the O +
potential O +
functional O +
role O +
of O +
this O +
promoter O +
polymorphism O +
, O +
and O +
found O +
that O +
the O +
G O +
to O +
A O +
substitution O +
at O +
- O +
206 O +
generated O +
a O +
GATA O +
- O +
3 O +
transcription O +
factor O +
binding O +
site O +
. O +

Major O +
transcription O +
factors O +
controlling O +
Th1 O +
and O +
Th2 O +
development O +
, O +
such O +
as O +
T O +
- O +
box O +
transcription O +
factor O +
and O +
GATA3 O +
, O +
are O +
possibly O +
involved O +
in O +
asthma O +
and O +
atopic O +
diseases O +
. O +

GATA O +
- O +
3 O +
, O +
a O +
transcription O +
factor O +
specifically O +
expressed O +
in O +
T O +
helper O +
2 O +
( O +
Th2 O +
) O +
cells O +
, O +
plays O +
a O +
critical O +
role O +
in O +
the O +
differentiation O +
of O +
Th2 O +
cells O +
from O +
uncommitted O +
CD4 O +
+ O +
lymphocytes O +
. O +

In O +
addition O +
, O +
GATA O +
- O +
3 O +
is O +
essential O +
for O +
the O +
expression O +
of O +
the O +
cytokines O +
IL O +
- O +
4 O +
, O +
IL O +
- O +
5 O +
and O +
IL O +
- O +
13 O +
that O +
mediate O +
allergic O +
inflammation O +
[ O +
23 O +
] O +
. O +

Our O +
luciferase O +
reporter O +
assay O +
confirmed O +
that O +
SNP O +
- O +
206 O -
G O +
> O +
A O +
is O +
associated O +
with O +
the O +
transcriptional O +
activity O +
of O +
SPINK5 O +
. O +

The O +
G O +
allele O +
was O +
associated O +
with O +
decreased O +
transcriptional O +
activity O +
of O +
the O +
SPINK5 O +
. O +

The O +
mechanism O +
by O +
which O +
the O +
- O +
206 O -
G O +
> O +
A O +
SNP O +
affects O +
SPINK5 O +
expression O +
may O +
be O +
explained O +
by O +
the O +
potential O +
differential O +
transcription O +
factor O +
binding O +
of O +
GATA O +
binding O +
factor O +
, O +
since O +
- O +
206 O -
G O +
> O +
A O +
is O +
located O +
at O +
the O +
core O +
sequence O +
of O +
GATA O +
binding O +
factor O +
binding O +
site O +
. O +

Electrophoretic O +
mobility O +
shift O +
assay O +
confirmed O +
that O +
the O +
A O +
to O +
G O +
substitution O +
at O +
- O +
206 O +
significantly O +
reduced O +
the O +
binding O +
efficiency O +
of O +
nuclear O +
proteins O +
to O +
this O +
element O +
. O +

Our O +
data O +
suggest O +
that O +
loss O +
of O +
GATA O +
transcription O +
factor O +
regulation O +
with O +
the O +
- O +
206 O -
G O +
may O +
decrease O +
the O +
SPINK5 O +
expression O +
and O +
thereby O +
potentially O +
perturb O +
the O +
immunosuppressive O +
function O +
of O +
LEKTI O +
. O +

SUMMARY O +

This O +
is O +
a O +
prospective O +
study O +
carried O +
out O +
to O +
determine O +
the O +
outcome O +
of O +
patients O +
who O +
refuse O +
cystectomy O +
after O +
receiving O +
neoadjuvant O +
chemotherapy O +
for O +
muscle O +
- O +
invasive O +
bladder O +
cancer O +
. O +

Sixty O +
- O +
three O +
patients O +
were O +
evaluated O +
between O +
1995 O +
and O +
2001 O +
who O +
declined O +
to O +
undergo O +
a O +
planned O +
cystectomy O +
because O +
they O +
achieved O +
a O +
complete O +
clinical O +
response O +
to O +
neoadjuvant O +
cisplatin O +
- O +
based O +
chemotherapy O +
. O +

Herr O +
assessed O +
patient O +
, O +
tumor O +
and O +
treatment O +
features O +
for O +
a O +
median O +
follow O +
- O +
up O +
of O +
86 O +
months O +
, O +
all O +
patients O +
being O +
followed O +
- O +
up O +
for O +
more O +
than O +
5 O +
years O +
. O +

Forty O +
patients O +
( O +
64 O +
% O +
) O +
survived O +
, O +
with O +
54 O +
% O +
of O +
them O +
having O +
an O +
intact O +
functioning O +
bladder O +
. O +

The O +
number O +
and O +
size O +
of O +
invasive O +
tumors O +
were O +
strongly O +
associated O +
with O +
the O +
overall O +
survival O +
. O +

The O +
most O +
significant O +
treatment O +
variable O +
predicting O +
better O +
survival O +
was O +
complete O +
resection O +
of O +
the O +
invasive O +
tumor O +
on O +
restaging O +
transurethral O +
resection O +
( O +
TUR O +
) O +
before O +
starting O +
chemotherapy O +
. O +

Of O +
23 O +
patients O +
( O +
36 O +
% O +
) O +
who O +
subsequently O +
died O +
of O +
disease O +
, O +
19 O +
( O +
30 O +
% O +
) O +
relapsed O +
with O +
invasive O +
cancer O +
in O +
the O +
bladder O +
. O +

Over O +
90 O +
% O +
of O +
the O +
surviving O +
patients O +
had O +
solitary O +
, O +
small O +
and O +
low O +
- O +
stage O +
invasive O +
tumors O +
completely O +
resected O +
and O +
83 O +
% O +
survived O +
without O +
relapses O +
in O +
the O +
bladder O +
. O +
[ O +
1 O +
] O +

Statistical O +
Analysis O +

Mitochondrial O +
DNA O +
haplogroup O +
frequencies O +
were O +
calculated O +
by O +
counting O +
from O +
the O +
observed O +
genotypes O +
. O +

The O +
Pearson O +
chi O +
- O +
square O +
test O +
and O +
the O +
chi O +
- O +
square O +
test O +
for O +
linear O +
- O +
by O +
- O +
linear O +
association O +
were O +
used O +
to O +
analyze O +
the O +
significances O +
between O +
the O +
prevalence O +
of O +
haplogroups O +
and O +
different O +
age O +
groups O +
. O +

SPSS O +
software O +
( O +
version O +
10 O +
. O +
0 O +
) O +
was O +
used O +
. O +

Duplicated O +
HGT O +
candidates O +
in O +
K O +
. O +
thermotolerans O +
. O +

( O +
A O +
) O +
Part O +
of O +
the O +
conserved O +
synteny O +
block O +
surrounding O +
KLTH0C07700 O -
g O +
and O +
KLTH0C07722 O -
g O +
tandem O +
genes O +
. O +

Same O +
legend O +
as O +
Figure O +
3A O +
. O +

( O +
B O +
) O +
Part O +
of O +
the O +
conserved O +
synteny O +
block O +
surrounding O +
KLTH0F12276 O -
g O +
gene O +
. O +

Same O +
legend O +
as O +
Figure O +
3A O +
. O +

( O +
C O +
) O +
Sequence O +
alignment O +
of O +
proteins O +
from O +
K O +
. O +
thermotolerans O +
and O +
K O +
. O +
waltii O +
. O +

( O +
D O +
) O +
Phylogenetic O +
tree O +
reconstructed O +
from O +
sequence O +
alignment O +
of O +
100 O +
sites O +
of O +
K O +
. O +
thermotolerans O +
protein O +
family O +
members O +
, O +
K O +
. O +
waltii O +
gene O +
, O +
bacterial O +
( O +
green O +
) O +
and O +
amoebal O +
( O +
blue O +
) O +
proteins O +
. O +

Bootstrap O +
values O +
are O +
indicated O +
next O +
to O +
the O +
nodes O +
and O +
branch O +
length O +
scale O +
is O +
shown O +
at O +
bottom O +
left O +
. O +

Quantitative O +
reverse O +
transcription O +
PCR O +

Reverse O +
transcription O +
was O +
performed O +
using O +
0 O +
. O +
2 O +
mug O +
of O +
total O +
RNA O +
from O +
muscle O +
of O +
10 O +
week O +
- O +
old O +
and O +
19 O +
month O +
- O +
old O +
C57Bl6 O +
mice O +
( O +
five O +
animals O +
per O +
group O +
) O +
, O +
a O +
Core O +
kit O +
( O +
RT O +
- O +
RTCK O +
- O +
03 O +
, O +
Eurogentec O +
) O +
according O +
to O +
manufacturer O +
' O +
s O +
instruction O +
and O +
a O +
mix O +
of O +
random O +
primers O +
( O +
9 O +
mers O +
) O +
and O +
oligodT O +
. O +

qPCR O +
was O +
performed O +
on O +
SDS7900HT O +
( O +
Applied O +
Biosystem O +
) O +
using O +
Mesagreen O +
qPCR O +
kit O +
for O +
SYBR O +
( O +
Eurogentec O +
) O +
and O +
the O +
following O +
primers O +
: O +

PPARbeta O +
: O +
5 O +
' O +
- O +
AGATGGTGGCAGAGCTATGACC O +
- O +
3 O +
' O +
; O +
5 O +
' O +
- O +
TCCTCCTGTGGCTGTTCC O +
- O +
3 O +
' O +
. O +

Catalase O +
: O +
5 O +
' O +
- O +
GGATCCTGACATGGTCTGGG O +
- O +
3 O +
' O +
; O +
5 O +
' O +
- O +
TGGAGAGACTCGGGACGAAG O +
- O +
3 O +
' O +
. O +

PDK4 O +
: O +
5 O +
' O +
- O +
GCATTTCTACTCGGATGCTCAATG O +
- O +
3 O +
' O +
; O +
5 O +
' O +
- O +
CCAATGTGGCTTGGGTTTCC O +
- O +
3 O +
' O +
. O +

36B4 O +
: O +
5 O +
' O +
- O +
TCCAGGCTTTGGGCATCA O +
- O +
3 O +
' O +
; O +
5 O +
' O +
- O +
CTTTATCAGCTGCACATCACTCAGA O +
- O +
3 O +
' O +
. O +

Data O +
were O +
all O +
normalised O +
using O +
36B4 O +
as O +
housekeeping O +
gene O +
. O +

Chicken O +
CCN3 O +
expression O +
in O +
embryonic O +
and O +
extraembryonic O +
tissues O +

Expression O +
of O +
CCN3 O +
in O +
axial O +
structure O +
becomes O +
visible O +
in O +
the O +
presegmentation O +
stage O +
and O +
reaches O +
to O +
the O +
highest O +
level O +
at O +
the O +
beginning O +
of O +
somitogenesis O +
( O +
HH O +
stage O +
7 O +
, O +
Fig O +
. O +
1a O +
) O +
. O +

Strong O +
similarity O +
between O +
CCN3 O +
and O +
Sonic O +
Hedgehog O +
was O +
observed O +
for O +
the O +
expression O +
pattern O +
in O +
axial O +
structure O +
( O +
notochord O +
and O +
floor O +
plate O +
) O +
, O +
in O +
which O +
the O +
left O +
- O +
right O +
asymmetrical O +
pattern O +
in O +
the O +
node O +
area O +
is O +
also O +
conserved O +
( O +
Fig O +
. O +
1b O +
) O +
. O +

However O +
, O +
Sonic O +
Hedgehog O +
expression O +
is O +
slightly O +
broader O +
than O +
that O +
of O +
CCN3 O +
. O +

Since O +
CCN3 O +
stimulates O +
Notch O +
signaling O +
( O +
Sakamoto O +
et O +
al O +
. O +
2002 O +
) O +
, O +
we O +
investigated O +
the O +
expression O +
of O +
Notch O +
signal O +
genes O +
. O +

Among O +
them O +
, O +
Serrate1 O +
, O +
a O +
ligand O +
of O +
Notch O +
is O +
unique O +
because O +
its O +
expression O +
is O +
apparently O +
a O +
right O +
deviated O +
pattern O +
in O +
the O +
node O +
area O +
( O +
Fig O +
. O +
1c O +
) O +
. O +

Another O +
Notch O +
ligand O +
, O +
Delta1 O +
shows O +
a O +
right O +
deviated O +
pattern O +
, O +
but O +
is O +
more O +
caudal O +
area O +
of O +
the O +
node O +
extending O +
to O +
the O +
primitive O +
streak O +
( O +
data O +
not O +
shown O +
) O +
. O +

The O +
expression O +
of O +
CCN3 O +
in O +
axial O +
structure O +
was O +
followed O +
by O +
the O +
presomitic O +
mesoderm O +
although O +
it O +
is O +
diminished O +
( O +
Sakamoto O +
et O +
al O +
. O +
2002 O +
) O +
. O +

Fig O +
. O +

1 O +

Expression O +
of O +
mRNA O +
in O +
early O +
stage O +
chicken O +
embryo O +
; O +
CCN3 O +
( O +
a O +
) O +
, O +
Sonic O +
Hedgehog O +
( O +
b O +
) O +
and O +
Serrate1 O +
( O +
c O +
) O +
at O +
the O +
beginning O +
stage O +
of O +
somitogenesis O +
( O +
Hamburger O +
and O +
Hamilton O +
( O +
HH O +
) O +
Stage O +
7 O +
) O +
. O +

Arrowheads O +
indicate O +
Hensen O +
' O +
s O +
node O +
. O +

Demonstrates O +
the O +
schematic O +
view O +
of O +
tissue O +
organization O +
at O +
this O +
stage O +
( O +
d O +
) O +
. O +

Expression O +
of O +
CCN3 O +
mRNA O +
in O +
blood O +
islands O +
of O +
chicken O +
extraembryonic O +
tissue O +
( O +
HH O +
stage O +
10 O +
) O +
( O +
e O +
) O +
. O +

Ventral O +
part O +
of O +
the O +
endothelial O +
precursor O +
cells O +
in O +
blood O +
islands O +
is O +
positive O +
for O +
CCN3 O +
expression O +
. O +

Coloration O +
was O +
stopped O +
before O +
the O +
background O +
staining O +
started O +
in O +
sense O +
probes O +
( O +
negative O +
control O +
) O +

There O +
is O +
accumulating O +
evidence O +
of O +
CCN3 O +
commitment O +
to O +
hematopoiesis O +
and O +
therefore O +
we O +
investigated O +
the O +
CCN3 O +
expression O +
in O +
extraembryonic O +
tissues O +
. O +

Blood O +
islands O +
are O +
formed O +
in O +
the O +
yolk O +
sac O +
mesodermal O +
area O +
just O +
between O +
the O +
visceral O +
endodermal O +
and O +
ectodermal O +
layers O +
, O +
which O +
supply O +
the O +
red O +
blood O +
cells O +
at O +
the O +
primary O +
stage O +
. O +

The O +
cells O +
in O +
blood O +
islands O +
are O +
called O +
hemangioblasts O +
since O +
they O +
also O +
differentiate O +
into O +
the O +
endothelial O +
cells O +
of O +
extraembryonic O +
blood O +
vessel O +
structure O +
. O +

In O +
chicken O +
embryo O +
, O +
differentiating O +
endothelial O +
cells O +
in O +
the O +
ventral O +
part O +
of O +
blood O +
islands O +
express O +
CCN3 O +
from O +
the O +
initial O +
stage O +
( O +
Fig O +
. O +
1e O +
) O +
. O +

Erythroblasts O +
in O +
the O +
center O +
of O +
blood O +
islands O +
( O +
spherical O +
cells O +
in O +
Fig O +
. O +
1e O +
) O +
weakly O +
express O +
CCN3 O +
and O +
their O +
expression O +
is O +
mildly O +
enhanced O +
in O +
later O +
stage O +
( O +
data O +
not O +
shown O +
) O +
. O +

COMMENTS O +

Recurrent O +
anterior O +
vaginal O +
wall O +
prolapse O +
can O +
develop O +
in O +
more O +
than O +
20 O +
% O +
of O +
patients O +
undergoing O +
traditional O +
anterior O +
colporrhaphy O +
. O +

In O +
light O +
of O +
this O +
high O +
recurrence O +
rate O +
many O +
surgeons O +
have O +
been O +
incorporating O +
synthetic O +
or O +
allograft O +
mesh O +
to O +
augment O +
the O +
repair O +
. O +

In O +
this O +
study O +
there O +
are O +
some O +
shortcomings O +
, O +
including O +
retrospective O +
design O +
, O +
short O +
follow O +
- O +
up O +
for O +
a O +
study O +
spanning O +
almost O +
six O +
years O +
and O +
a O +
lack O +
of O +
validated O +
questionnaires O +
. O +

Authors O +
report O +
a O +
negative O +
experience O +
with O +
porcine O +
dermis O +
, O +
both O +
in O +
terms O +
of O +
success O +
and O +
extrusion O +
rate O +
. O +

However O +
, O +
others O +
have O +
reported O +
better O +
outcome O +
[ O +
1 O +
] O +
which O +
may O +
be O +
due O +
to O +
different O +
follow O +
- O +
up O +
times O +
and O +
outcome O +
measures O +
. O +

Apart O +
from O +
this O +
, O +
biological O +
grafts O +
are O +
also O +
associated O +
with O +
allergic O +
reactions O +
and O +
disease O +
transmission O +
. O +

There O +
is O +
paucity O +
of O +
data O +
regarding O +
prospective O +
randomized O +
trials O +
on O +
the O +
use O +
of O +
these O +
biomaterials O +
prior O +
to O +
their O +
widespread O +
human O +
need O +
which O +
might O +
help O +
in O +
reducing O +
such O +
type O +
of O +
experiences O +
. O +

Unless O +
such O +
data O +
are O +
available O +
surgeons O +
should O +
give O +
serious O +
thought O +
prior O +
to O +
embarking O +
on O +
the O +
use O +
of O +
such O +
biological O +
materials O +
. O +
[ O +
2 O +
] O +

Background O +

Opioid O +
analgesics O +
are O +
generally O +
used O +
to O +
combat O +
the O +
pain O +
associated O +
with O +
cancerous O +
conditions O +
. O +

These O +
agents O +
not O +
only O +
inhibit O +
respiratory O +
function O +
and O +
cause O +
constipation O +
, O +
but O +
also O +
induce O +
other O +
significant O +
side O +
effects O +
such O +
as O +
addiction O +
and O +
tolerance O +
, O +
all O +
of O +
which O +
further O +
contribute O +
to O +
a O +
reduced O +
quality O +
of O +
life O +
for O +
cancer O +
patients O +
. O +

Thus O +
, O +
in O +
the O +
present O +
study O +
, O +
the O +
effects O +
of O +
electro O +
- O +
acupuncture O +
treatment O +
( O +
EA O +
) O +
on O +
mechanical O +
allodynia O +
were O +
examined O +
in O +
a O +
cancer O +
pain O +
mouse O +
model O +
. O +

2 O +
. O +
1 O +
. O +

Biological O +
samples O +

Placental O +
tissues O +
from O +
the O +
first O +
trimester O +
legally O +
induced O +
abortions O +
( O +
8 O +
- O +
12 O +
weeks O +
of O +
gestation O +
) O +
were O +
obtained O +
from O +
the O +
Department O +
of O +
Obstetrics O +
and O +
Gynecology O +
at O +
the O +
Broussais O +
, O +
Saint O +
Vincent O +
de O +
Paul O +
and O +
Cochin O +
Hospitals O +
. O +

Second O +
trimester O +
placental O +
tissues O +
were O +
collected O +
at O +
the O +
time O +
of O +
termination O +
of O +
pregnancy O +
at O +
15 O +
and O +
25 O +
weeks O +
of O +
gestation O +
( O +
in O +
weeks O +
of O +
amenorrhea O +
) O +
in O +
trisomy O +
21 O +
- O +
affected O +
pregnancies O +
. O +

Fetal O +
Down O +
syndrome O +
was O +
diagnosed O +
by O +
karyotyping O +
of O +
amniotic O +
fluid O +
cells O +
. O +

The O +
indication O +
of O +
amniocentesis O +
was O +
the O +
maternal O +
age O +
. O +

Term O +
placentas O +
were O +
obtained O +
after O +
elective O +
cesarean O +
section O +
from O +
healthy O +
mothers O +
near O +
term O +
with O +
uncomplicated O +
pregnancies O +
. O +

With O +
written O +
informed O +
consent O +
of O +
the O +
pregnant O +
woman O +
, O +
the O +
following O +
samples O +
were O +
collected O +
at O +
term O +
: O +
a O +
fragment O +
of O +
the O +
placenta O +
, O +
umbilical O +
cord O +
fetal O +
blood O +
and O +
maternal O +
blood O +
. O +

The O +
placenta O +
biopsy O +
sample O +
was O +
collected O +
at O +
a O +
depth O +
of O +
1 O +
cm O +
and O +
at O +
a O +
distance O +
of O +
8 O +
cm O +
from O +
the O +
edge O +
of O +
the O +
placenta O +
, O +
with O +
the O +
maternal O +
side O +
facing O +
upward O +
. O +

The O +
use O +
of O +
these O +
biological O +
samples O +
was O +
approved O +
by O +
local O +
ethical O +
committee O +
. O +

Villous O +
cytotrophoblastic O +
cells O +
were O +
isolated O +
by O +
sequential O +
enzymatic O +
digestion O +
of O +
chorionic O +
villi O +
from O +
the O +
first O +
trimester O +
, O +
second O +
trimester O +
and O +
term O +
placenta O +
and O +
purified O +
on O +
a O +
discontinuous O +
percoll O +
gradient O +
, O +
as O +
described O +
previously O +
. O +
47 O +
- O +
49 O +
These O +
cells O +
were O +
positively O +
stained O +
for O +
cytokeratin O +
7 O +
at O +
95 O +
% O +
, O +
indicating O +
the O +
cytotrophoblastic O +
origin O +
of O +
the O +
cells O +
. O +

Placental O +
fibroblasts O +
were O +
isolated O +
by O +
prolonged O +
enzymatic O +
digestion O +
from O +
first O +
trimester O +
chorionic O +
villi O +
as O +
in O +
Malassine O +
et O +
al O +
. O +
50 O +
Fibroblastic O +
cells O +
( O +
1 O +
. O +
25 O +
x O +
105 O +
cells O +
/ O +
mL O +
) O +
were O +
plated O +
on O +
35 O +
- O +
mm O +
plastic O +
dishes O +
( O +
TPP O +
, O +
Switzerland O +
) O +
and O +
cultured O +
for O +
48 O +
h O +
, O +
and O +
the O +
culture O +
medium O +
was O +
changed O +
daily O +
. O +

These O +
cultured O +
fibroblasts O +
were O +
characterized O +
using O +
immunocytochemistry O +
. O +

It O +
was O +
found O +
that O +
98 O +
% O +
of O +
the O +
cells O +
were O +
vimentin O +
positive O +
and O +
also O +
positive O +
for O +
a O +
monoclonal O +
antibody O +
against O +
specific O +
fibroblast O +
antigen O +
( O +
clone O +
ASO2 O +
, O +
Dianova O +
, O +
Hamburg O +
, O +
Germany O +
) O +
. O +

Owing O +
to O +
the O +
limited O +
amount O +
of O +
cells O +
, O +
only O +
DNA O +
was O +
extracted O +
. O +

Conclusions O +
and O +
policy O +
implications O +

Early O +
postnatal O +
home O +
visit O +
is O +
one O +
strategy O +
for O +
providing O +
critical O +
interventions O +
to O +
improve O +
newborn O +
survival O +
. O +

Given O +
the O +
compelling O +
data O +
in O +
this O +
study O +
, O +
we O +
recommend O +
that O +
in O +
developing O +
countries O +
, O +
especially O +
those O +
where O +
home O +
delivery O +
with O +
unskilled O +
attendants O +
is O +
the O +
norm O +
, O +
all O +
newborns O +
should O +
receive O +
a O +
home O +
visit O +
and O +
undergo O +
assessment O +
by O +
a O +
trained O +
worker O +
as O +
soon O +
as O +
possible O +
, O +
preferably O +
on O +
the O +
day O +
of O +
birth O +
but O +
no O +
later O +
than O +
48 O +
hours O +
after O +
birth O +
. O +

The O +
impact O +
of O +
this O +
approach O +
is O +
likely O +
to O +
be O +
dependent O +
on O +
the O +
content O +
, O +
quality O +
, O +
and O +
coverage O +
of O +
the O +
technical O +
interventions O +
included O +
. O +

Reaching O +
neonates O +
within O +
first O +
day O +
or O +
first O +
two O +
days O +
of O +
life O +
is O +
a O +
challenge O +
. O +

Given O +
that O +
the O +
community O +
health O +
workers O +
in O +
this O +
study O +
were O +
not O +
skilled O +
birth O +
attendants O +
and O +
attended O +
only O +
about O +
5 O +
% O +
of O +
deliveries O +
, O +
a O +
complementary O +
strategy O +
will O +
be O +
to O +
ensure O +
skilled O +
attendance O +
at O +
delivery O +
that O +
is O +
linked O +
to O +
essential O +
obstetric O +
care O +
. O +
31 O +
32 O +
Further O +
operational O +
research O +
will O +
be O +
needed O +
to O +
develop O +
context O +
specific O +
strategies O +
to O +
reach O +
all O +
newborns O +
as O +
soon O +
as O +
possible O +
after O +
birth O +
. O +

Model O +
of O +
how O +
estrogen O +
induces O +
DNA O +
damage O +
. O +

Estrogen O +
enters O +
the O +
cell O +
and O +
is O +
bound O +
by O +
the O +
ER O +
. O +

The O +
dimeric O +
ER O +
- O +
estrogen O +
complex O +
enters O +
the O +
nucleus O +
and O +
induces O +
AID O +
expression O +
. O +

This O +
leads O +
to O +
an O +
increase O +
in O +
mutations O +
and O +
translocations O +
, O +
and O +
potentially O +
cancer O +

Assessment O +
of O +
various O +
forms O +
of O +
bevavioural O +
addictions O +

A O +
first O +
approach O +
for O +
the O +
comprehensive O +
and O +
standardized O +
assessment O +
of O +
different O +
forms O +
of O +
behavioural O +
addictions O +
( O +
e O +
. O +
g O +
. O +
, O +
pathological O +
gambling O +
, O +
workaholism O +
, O +
compulsive O +
buying O +
) O +
is O +
the O +
German O +
self O +
- O +
assessment O +
questionnaire O +
" O +
Fragebogen O +
zur O +
Differenzierten O +
Anamnese O +
exzessiver O +
Verhaltensweisen O +
" O +
( O +
FDAV O +
, O +
Questionnaire O +
on O +
Differentiated O +
Assessment O +
of O +
Excessive O +
Behaviours O +
) O +
[ O +
96 O +
] O +
. O +

The O +
FDAV O +
is O +
based O +
on O +
the O +
criteria O +
of O +
substance O +
- O +
related O +
addictions O +
, O +
pathological O +
gambling O +
and O +
impulse O +
control O +
disorders O +
of O +
the O +
ICD O +
- O +
10 O +
[ O +
3 O +
] O +
and O +
the O +
DSM O +
- O +
IV O +
- O +
TR O +
[ O +
2 O +
] O +
. O +

The O +
FDAV O +
is O +
a O +
modified O +
version O +
of O +
the O +
" O +
Fragebogen O +
zur O +
Differenzierten O +
Drogenanamnese O +
" O +
( O +
FDDA O +
; O +
Questionnaire O +
on O +
Differentiated O +
Assessment O +
of O +
Addiction O +
, O +
QDAA O +
) O +
[ O +
97 O +
] O +
. O +

Its O +
seven O +
modules O +
obtain O +
" O +
sociodemographic O +
information O +
" O +
( O +
e O +
. O +
g O +
. O +
, O +
age O +
, O +
profession O +
, O +
marital O +
status O +
) O +
, O +
" O +
history O +
of O +
excessive O +
behaviour O +
" O +
( O +
e O +
. O +
g O +
. O +
, O +
diagnostic O +
criteria O +
for O +
addictions O +
and O +
impulse O +
control O +
disorder O +
, O +
individual O +
patterns O +
of O +
behaviour O +
, O +
craving O +
symptoms O +
) O +
, O +
" O +
critical O +
life O +
events O +
" O +
( O +
stress O +
caused O +
by O +
traumatic O +
events O +
) O +
, O +
" O +
legal O +
situation O +
" O +
, O +
" O +
medical O +
history O +
" O +
, O +
" O +
physical O +
and O +
psychological O +
complaints O +
" O +
, O +
and O +
" O +
emotional O +
state O +
" O +
( O +
triggering O +
psychological O +
conditions O +
, O +
or O +
consequences O +
of O +
the O +
addictive O +
behaviour O +
, O +
respectively O +
) O +
. O +

Every O +
module O +
can O +
be O +
administered O +
separately O +
according O +
to O +
the O +
suspected O +
behavioural O +
addiction O +
, O +
thereby O +
making O +
the O +
FDAV O +
an O +
economical O +
tool O +
in O +
assessing O +
behavioural O +
addictions O +
. O +

The O +
FDAV O +
is O +
suitable O +
for O +
diagnostics O +
, O +
evaluation O +
of O +
therapy O +
and O +
follow O +
- O +
up O +
in O +
clinical O +
practice O +
and O +
research O +
. O +

Currently O +
, O +
the O +
FDAV O +
is O +
being O +
validated O +
in O +
clinical O +
and O +
non O +
- O +
clinical O +
samples O +
. O +

Click O +
here O +
for O +
file O +

Authors O +
' O +
contributions O +

PM O +
carried O +
out O +
and O +
analyzed O +
molecular O +
assay O +
and O +
sequencing O +
data O +
and O +
drafted O +
the O +
manuscript O +
. O +

NS O +
participated O +
in O +
study O +
design O +
and O +
in O +
the O +
local O +
coordination O +
during O +
the O +
study O +
. O +

She O +
helped O +
to O +
draft O +
the O +
manuscript O +
. O +

MD O +
has O +
made O +
substantial O +
contributions O +
to O +
the O +
acquisition O +
and O +
analysis O +
of O +
data O +
. O +

He O +
participated O +
in O +
design O +
of O +
the O +
study O +
and O +
helped O +
to O +
draft O +
the O +
manuscript O +
. O +

MO O +
has O +
made O +
substantial O +
contributions O +
to O +
acquisition O +
and O +
analysis O +
of O +
data O +
. O +

GB O +
has O +
made O +
substantial O +
contributions O +
to O +
acquisition O +
and O +
analysis O +
of O +
data O +
. O +

GP O +
carried O +
out O +
microscopy O +
and O +
microbiology O +
analyses O +
in O +
Italy O +
and O +
contributed O +
in O +
drafting O +
the O +
manuscript O +
. O +

GBM O +
has O +
made O +
substantial O +
contributions O +
in O +
conceiving O +
, O +
analysing O +
and O +
writing O +
the O +
manuscript O +
. O +

AM O +
participated O +
in O +
the O +
design O +
of O +
the O +
study O +
and O +
helped O +
to O +
draft O +
the O +
manuscript O +
. O +

DMC O +
participated O +
in O +
the O +
design O +
of O +
the O +
study O +
and O +
conceived O +
, O +
and O +
analysed O +
the O +
manuscript O +
. O +

All O +
authors O +
read O +
and O +
approved O +
the O +
final O +
manuscript O +
. O +

Method O +

Results O +
: O +

All O +
fractures O +
united O +
. O +

Individual O +
movement O +
of O +
dorsiflexion O +
, O +
palmar O +
flexion O +
, O +
supination O +
, O +
pronation O +
and O +
radial O +
- O +
ulnar O +
deviation O +
were O +
all O +
significantly O +
better O +
in O +
the O +
dorsiflexed O +
- O +
immobilized O +
group O +
as O +
compared O +
with O +
the O +
palmar O +
flexed O +
immobilized O +
group O +
. O +

Grip O +
strength O +
recovery O +
with O +
subjective O +
assessment O +
was O +
better O +
in O +
the O +
dorsiflexed O +
group O +
( O +
77 O +
% O +
) O +
as O +
compared O +
to O +
the O +
palmar O +
flexed O +
group O +
( O +
23 O +
% O +
) O +
. O +

Radiological O +
parameters O +
were O +
markedly O +
better O +
in O +
the O +
dorsiflexed O +
group O +
. O +

Ninety O +
- O +
one O +
per O +
cent O +
of O +
patients O +
in O +
the O +
dorsiflexed O +
group O +
had O +
excellent O +
to O +
good O +
results O +
as O +
compared O +
to O +
66 O +
% O +
in O +
the O +
palmar O +
flexed O +
group O +
. O +

Methods O +

Therefore O +
, O +
we O +
developed O +
a O +
reciprocal O +
system O +
of O +
a O +
full O +
- O +
length O +
HIV O +
packaging O +
cell O +
line O +
and O +
a O +
shortened O +
HI O +
- O +
viral O +
shuttle O +
vector O +
. O +

The O +
Tat O +
- O +
deficient O +
packaging O +
construct O +
is O +
stably O +
integrated O +
in O +
a O +
VSVG O +
- O +
pseudotyped O +
cell O +
line O +
and O +
transactivated O +
by O +
the O +
shuttle O +
vector O +
by O +
expression O +
of O +
TATGFP O +
from O +
a O +
heterologous O +
promoter O +
which O +
also O +
indicates O +
positive O +
cells O +
. O +

Expression O +
of O +
the O +
HI O +
- O +
viral O +
structure O +
proteins O +
is O +
driven O +
by O +
a O +
natural O +
5 O +
' O +
LTR O +
promoter O +
and O +
a O +
3 O +
' O +
polyadenylation O +
signal O +
, O +
whereas O +
the O +
envelope O +
expression O +
out O +
of O +
the O +
shuttle O +
vector O +
is O +
achieved O +
by O +
an O +
IRES O +
. O +

This O +
system O +
of O +
two O +
vectors O +
is O +
tightly O +
controllable O +
and O +
bypasses O +
the O +
problem O +
of O +
limited O +
packaging O +
capacity O +
into O +
HIV O +
- O +
1 O +
virions O +
. O +

8 O +
. O +
2 O +
. O +

Species O +
Differences O +
in O +
PPARalpha O +
- O +
Associated O +
Signaling O +

The O +
PPARalpha O +
isotype O +
has O +
prime O +
importance O +
for O +
studies O +
with O +
animal O +
models O +
to O +
predict O +
the O +
effects O +
of O +
hepatic O +
PPs O +
in O +
humans O +
, O +
because O +
PPARalpha O +
agonists O +
induce O +
seemingly O +
quite O +
different O +
actions O +
in O +
rodents O +
and O +
humans O +
[ O +
53 O +
] O +
. O +

Originally O +
, O +
as O +
the O +
name O +
indicates O +
, O +
PPARs O +
were O +
studied O +
because O +
of O +
their O +
ability O +
to O +
bind O +
PPs O +
and O +
consequently O +
induce O +
PP O +
- O +
metabolizing O +
enzymes O +
. O +

In O +
rats O +
and O +
mice O +
, O +
but O +
not O +
in O +
humans O +
, O +
PPs O +
such O +
as O +
hypolipidemic O +
drugs O +
, O +
industrial O +
plasticizers O +
, O +
and O +
herbicides O +
are O +
non O +
- O +
genotoxic O +
carcinogens O +
that O +
cause O +
liver O +
tumors O +
[ O +
54 O +
] O +
. O +

In O +
humans O +
, O +
these O +
drugs O +
function O +
to O +
maintain O +
lipid O +
homeostasis O +
and O +
do O +
not O +
induce O +
peroxisome O +
proliferation O +
. O +

Thus O +
, O +
the O +
toxicity O +
and O +
carcinogenicity O +
of O +
PPs O +
are O +
highly O +
species O +
specific O +
[ O +
55 O +
] O +
. O +

The O +
species O +
differences O +
may O +
be O +
attributable O +
to O +
lower O +
PPAR O +
mRNA O +
expression O +
levels O +
in O +
h O +
- O +
hepatocytes O +
compared O +
with O +
rodent O +
cells O +
[ O +
56 O +
, O +
57 O +
] O +
. O +

Alternatively O +
, O +
or O +
additionally O +
, O +
species O +
differences O +
may O +
be O +
the O +
result O +
of O +
different O +
sensitivities O +
of O +
the O +
genes O +
associated O +
with O +
the O +
peroxisome O +
proliferation O +
response O +
to O +
low O +
levels O +
of O +
PPs O +
, O +
owing O +
to O +
structural O +
differences O +
in O +
PPARalpha O +
[ O +
54 O +
] O +
. O +

There O +
are O +
both O +
similarities O +
and O +
differences O +
in O +
responses O +
to O +
xenobiotics O +
among O +
not O +
only O +
different O +
species O +
( O +
interspecies O +
) O +
but O +
also O +
individuals O +
of O +
the O +
same O +
species O +
( O +
intraspecies O +
) O +
. O +

Interspecific O +
PPARalpha O +
diversity O +
between O +
rodents O +
and O +
humans O +
is O +
well O +
known O +
and O +
has O +
been O +
studied O +
with O +
respect O +
to O +
drug O +
metabolism O +
. O +

NR O +
subfamily O +
1 O +
members O +
have O +
at O +
least O +
two O +
functions O +
in O +
mammals O +
. O +

One O +
is O +
to O +
regulate O +
peroxisome O +
proliferation O +
through O +
binding O +
to O +
PPAR O +
response O +
elements O +
( O +
PPREs O +
) O +
in O +
the O +
promoters O +
of O +
genes O +
such O +
as O +
ACO O +
[ O +
58 O +
, O +
59 O +
] O +
, O +
bifunctional O +
dehydrogenase O +
/ O +
hydratase O +
( O +
BFE O +
) O +
[ O +
60 O +
] O +
, O +
and O +
microsomal O +
CYP4A1 O +
[ O +
61 O +
] O +
. O +

The O +
other O +
is O +
to O +
modulate O +
the O +
serum O +
cholesterol O +
level O +
by O +
targeting O +
genes O +
such O +
as O +
the O +
lipoprotein O +
lipase O +
gene O +
[ O +
62 O +
] O +
and O +
the O +
apolipoprotein O +
regulating O +
genes O +
AI O +
, O +
AII O +
, O +
and O +
CII O +
[ O +
63 O +
] O +
. O +

The O +
former O +
mechanism O +
appears O +
to O +
function O +
in O +
rodents O +
, O +
but O +
not O +
in O +
humans O +
, O +
and O +
is O +
responsible O +
for O +
the O +
induction O +
of O +
peroxisome O +
proliferation O +
and O +
hepatocarcinogenesis O +
, O +
whereas O +
the O +
latter O +
mechanism O +
controls O +
basic O +
lipid O +
metabolism O +
in O +
both O +
rodents O +
and O +
humans O +
[ O +
56 O +
] O +
. O +

This O +
species O +
difference O +
in O +
xenobiotic O +
receptor O +
/ O +
ligand O +
signaling O +
may O +
be O +
attributable O +
to O +
differences O +
in O +
the O +
expression O +
level O +
of O +
a O +
receptor O +
, O +
or O +
to O +
differences O +
in O +
receptor O +
/ O +
ligand O +
binding O +
affinity O +
, O +
and O +
causes O +
difficulty O +
in O +
determining O +
responses O +
in O +
humans O +
based O +
on O +
rodent O +
data O +
[ O +
56 O +
] O +
. O +

Results O +
: O +

In O +
the O +
total O +
population O +
( O +
N O +
= O +
95 O +
) O +
, O +
median O +
OS O +
was O +
significantly O +
longer O +
in O +
patients O +
with O +
baseline O +
CA O +
19 O +
- O +
9 O +
values O +
at O +
or O +
below O +
the O +
median O +
than O +
in O +
those O +
with O +
values O +
above O +
it O +
( O +
12 O +
. O +
2 O +
months O +
[ O +
95 O +
% O +
confidence O +
interval O +
( O +
CI O +
) O +
, O +
8 O +
. O +
6 O +
- O +
16 O +
. O +
6 O +
% O +
] O +
vs O +
5 O +
. O +
0 O +
months O +
[ O +
95 O +
% O +
CI O +
, O +
3 O +
. O +
9 O +
- O +
5 O +
. O +
7 O +
% O +
] O +
; O +
P O +
< O +
0 O +
. O +
0001 O +
) O +
. O +

This O +
also O +
reached O +
significance O +
in O +
the O +
Gem O +
+ O +
A O +
arm O +
( O +
median O +
OS O +
, O +
12 O +
. O +
5 O +
months O +
[ O +
95 O +
% O +
CI O +
, O +
8 O +
. O +
6 O +
- O +
16 O +
. O +
6 O +
% O +
] O +
vs O +
4 O +
. O +
9 O +
months O +
[ O +
95 O +
% O +
CI O +
, O +
3 O +
. O +
6 O +
- O +
5 O +
. O +
6 O +
% O +
] O +
; O +
P O +
< O +
0 O +
. O +
0001 O +
) O +
. O +

Patients O +
with O +
any O +
dBP O +
> O +
90 O +
mmHg O +
had O +
significantly O +
longer O +
OS O +
than O +
those O +
who O +
did O +
not O +
. O +

However O +
, O +
there O +
was O +
no O +
predictive O +
significance O +
of O +
CA O +
19 O +
- O +
9 O +
. O +

3 O +
. O +
2 O +
. O +

Cell O +
line O +
and O +
culture O +

DU145 B-CellLine +
( O +
prostate O +
cancer O +
) O +
cell O +
line O +
was O +
used O +
in O +
this O +
assay O +
. O +

DU145 B-CellLine +
was O +
grown O +
in O +
DMEM O +
/ O +
F O +
- O +
12 O +
medium O +
( O +
Gibco O +
BRL O +
Life O +
Technologies O +
, O +
San O +
Diego O +
, O +
CA O +
. O +
, O +
USA O +
) O +
supplemented O +
with O +
10 O +
% O +
fetal O +
calf O +
serum O +
and O +
kept O +
in O +
a O +
humidified O +
37 O +
degreesC O +
, O +
5 O +
% O +
CO2 O +
incubator O +
. O +

Reagents O +

CNQX O +
, O +
colchicine O +
, O +
forskolin O +
, O +
and O +
carbenoxolone O +
were O +
purchased O +
from O +
Sigma O +
. O +

DCG O +
- O +
IV O +
, O +
ZD7288 O +
, O +
CGP55845 O +
and O +
DPCPX O +
were O +
obtained O +
from O +
Tocris O +
Cookson O +
( O +
Ellisville O +
, O +
MO O +
) O +
. O +

Percutaneous O +
coronary O +
intervention O +
for O +
the O +
very O +
late O +
stent O +
thrombosis O +
in O +
right O +
coronary O +
artery O +
. O +

A O +
: O +
a O +
balloon O +
angioplasty O +
was O +
performed O +
to O +
treat O +
total O +
occlusion O +
of O +
the O +
stented O +
right O +
coronary O +
artery O +
. O +

B O +
: O +
final O +
coronary O +
angiogram O +
showed O +
good O +
distal O +
flow O +
without O +
residual O +
stenosis O +
. O +

Target O +
volumes O +
' O +
coverage O +

The O +
mean O +
PTV1 O +
and O +
PTV2 O +
volumes O +
were O +
452 O +
cm3 O +
( O +
range O +
276 O +
- O +
1074 O +
cm3 O +
) O +
and O +
300 O +
cm3 O +
( O +
range O +
137 O +
- O +
567 O +
cm3 O +
) O +
respectively O +
. O +

A O +
mean O +
of O +
> O +
98 O +
% O +
( O +
range O +
92 O +
- O +
100 O +
% O +
) O +
of O +
the O +
PTV1 O +
received O +
100 O +
% O +
of O +
the O +
prescribed O +
dose O +
in O +
all O +
planning O +
methods O +
. O +

A O +
mean O +
of O +
95 O +
. O +
5 O +
% O +
and O +
95 O +
. O +
7 O +
% O +
of O +
the O +
PTV2 O +
received O +
100 O +
% O +
of O +
the O +
prescribed O +
dose O +
with O +
TOMO O +
and O +
IMRT O +
plans O +
respectively O +
. O +

A O +
mean O +
of O +
94 O +
% O +
and O +
92 O +
% O +
of O +
the O +
PTV2 O +
received O +
100 O +
% O +
of O +
the O +
prescribed O +
dose O +
with O +
IB O +
and O +
3D O +
treatment O +
plans O +
, O +
respectively O +
. O +

The O +
mean O +
IB O +
and O +
3D O +
plans O +
PTV2 O +
coverage O +
was O +
significantly O +
inferior O +
then O +
the O +
IMRT O +
and O +
TOMO O +
plans O +
( O +
p O +
< O +
0 O +
. O +
02 O +
, O +
for O +
all O +
comparisons O +
) O +
. O +

The O +
mean O +
Inhomogeneity O +
Coefficient O +
( O +
IC O +
) O +
was O +
significantly O +
lower O +
( O +
better O +
) O +
with O +
the O +
TOMO O +
plans O +
, O +
compared O +
to O +
all O +
other O +
plans O +
for O +
both O +
PTV1 O +
and O +
PTV2 O +
( O +
p O +
< O +
0 O +
. O +
0003 O +
for O +
all O +
comparisons O +
) O +
( O +
figure O +
3 O +
) O +
. O +

The O +
mean O +
IC O +
of O +
the O +
IMRT O +
plans O +
was O +
significantly O +
higher O +
( O +
worse O +
) O +
than O +
the O +
mean O +
IC O +
of O +
the O +
3D O +
plans O +
regarding O +
PTV O +
1 O +
( O +
p O +
< O +
0 O +
. O +
02 O +
) O +
and O +
higher O +
( O +
worse O +
) O +
then O +
the O +
mean O +
IC O +
of O +
the O +
IB O +
plans O +
regarding O +
PTV2 O +
( O +
p O +
< O +
0 O +
. O +
03 O +
) O +
( O +
figure O +
3 O +
) O +
. O +

No O +
significant O +
difference O +
was O +
found O +
between O +
the O +
means O +
of O +
the O +
IC O +
of O +
the O +
3D O +
and O +
IB O +
plans O +
. O +

Figure O +
3 O +

The O +
mean O +
Inhomogeneity O +
Coefficient O +
( O +
IC O +
) O +
achieved O +
by O +
the O +
different O +
planning O +
methods O +
. O +

The O +
mean O +
of O +
the O +
Inhomogeneity O +
Coefficient O +
is O +
a O +
measure O +
of O +
dose O +
inhomogeneity O +
in O +
the O +
target O +
volumes O +
. O +

The O +
closer O +
the O +
IC O +
to O +
zero O +
, O +
the O +
more O +
homogenous O +
the O +
dose O +
is O +
. O +

All O +
- O +
cause O +
mortality O +
in O +
RALES O +
and O +
EPHESUS O +
( O +
adapted O +
from O +
[ O +
4 O +
] O +
and O +
[ O +
5 O +
] O +
) O +
. O +

Mean O +
follow O +
- O +
up O +
period O +
is O +
24 O +
months O +
in O +
RALES O +
and O +
16 O +
months O +
in O +
EPHESUS O +

Pre O +
- O +
publication O +
history O +

The O +
pre O +
- O +
publication O +
history O +
for O +
this O +
paper O +
can O +
be O +
accessed O +
here O +
: O +

http O +
: O +
/ O +
/ O +
www O +
. O +
biomedcentral O +
. O +
com O +
/ O +
1471 O +
- O +
2377 O +
/ O +
9 O +
/ O +
57 O +
/ O +
prepub O +

RESEARCH O +
DESIGN O +
AND O +
METHODS O +

For O +
this O +
study O +
, O +
20 O +
individuals O +
( O +
mean O +
age O +
39 O +
. O +
5 O +
+ O +
/ O +
- O +
11 O +
. O +
1 O +
years O +
) O +
with O +
long O +
- O +
standing O +
type O +
1 O +
diabetes O +
( O +
21 O +
. O +
3 O +
+ O +
/ O +
- O +
10 O +
. O +
7 O +
years O +
) O +
were O +
enrolled O +
in O +
this O +
prospective O +
open O +
- O +
label O +
crossover O +
trial O +
. O +

After O +
achieving O +
optimal O +
blood O +
glucose O +
control O +
, O +
16 O +
subjects O +
were O +
randomized O +
to O +
exenatide O +
with O +
or O +
without O +
daclizumab O +
. O +

Endogenous O +
insulin O +
production O +
was O +
determined O +
by O +
repeatedly O +
measuring O +
serum O +
C O +
- O +
peptide O +
. O +

Subjects O +
and O +
Methods O +

ABPM O +
was O +
conducted O +
for O +
60 O +
selected O +
patients O +
who O +
had O +
visited O +
Sunlin O +
Hospital O +
between O +
January O +
2008 O +
and O +
August O +
2008 O +
. O +

Patients O +
were O +
classified O +
into O +
3 O +
groups O +
; O +
an O +
obese O +
group O +
whose O +
body O +
mass O +
index O +
( O +
BMI O +
) O +
was O +
> O +
the O +
95th O +
percentile O +
, O +
an O +
overweight O +
group O +
whose O +
BMI O +
was O +
> O +
the O +
85th O +
percentile O +
but O +
less O +
than O +
the O +
95th O +
percentile O +
, O +
and O +
a O +
normal O +
group O +
whose O +
BMI O +
was O +
below O +
the O +
85th O +
percentile O +
. O +

Overall O +
mean O +
BP O +
, O +
day O +
and O +
night O +
BP O +
and O +
BP O +
load O +
were O +
measured O +
by O +
ABPM O +
. O +

Results O +

Contrary O +
to O +
previous O +
reports O +
that O +
PON1 O +
activities O +
plateau O +
by O +
2 O +
years O +
of O +
age O +
, O +
we O +
observed O +
an O +
age O +
- O +
dependent O +
increase O +
in O +
all O +
three O +
PON1 O +
measures O +
from O +
birth O +
through O +
7 O +
years O +
of O +
age O +
( O +
p O +
< O +
0 O +
. O +
0001 O +
) O +
. O +

The O +
PON1192 O +
genotype O +
significantly O +
modified O +
the O +
effect O +
of O +
age O +
on O +
paraoxonase O +
( O +
POase O +
) O +
activity O +
( O +
p O +
< O +
0 O +
. O +
0001 O +
) O +
such O +
that O +
increases O +
in O +
enzyme O +
activity O +
with O +
age O +
were O +
influenced O +
by O +
the O +
number O +
of O +
R O +
alleles O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
. O +

Children O +
with O +
the O +
PON1 O +
- O +
108CC192RR O +
diplotype O +
had O +
significantly O +
higher O +
mean O +
PON1 O +
activities O +
and O +
also O +
experienced O +
steeper O +
increases O +
of O +
POase O +
activity O +
over O +
time O +
compared O +
with O +
children O +
with O +
the O +
PON1 O +
- O +
108TT192QQ O +
diplotype O +
. O +

Surgery O +

Trabeculectomy O +
should O +
be O +
considered O +
in O +
all O +
patients O +
, O +
when O +
the O +
' O +
target O +
IOP O +
' O +
is O +
not O +
achieved O +
with O +
glaucoma O +
medications O +
and O +
if O +
the O +
expected O +
rate O +
of O +
visual O +
loss O +
could O +
affect O +
the O +
patient O +
during O +
their O +
lifetime O +
. O +

In O +
this O +
procedure O +
, O +
an O +
opening O +
is O +
made O +
in O +
the O +
trabecular O +
meshwork O +
, O +
so O +
that O +
aqueous O +
humor O +
can O +
drain O +
into O +
the O +
sclera O +
. O +

Many O +
patients O +
can O +
discontinue O +
glaucoma O +
medications O +
after O +
surgery O +
. O +

Approximately O +
one O +
- O +
third O +
of O +
the O +
trabeculectomy O +
patients O +
develop O +
cataract O +
within O +
five O +
years O +
. O +

If O +
trabeculectomy O +
fails O +
, O +
another O +
type O +
of O +
surgery O +
places O +
a O +
drainage O +
tube O +
( O +
Molteno O +
tube O +
) O +
in O +
the O +
eye O +
, O +
between O +
the O +
cornea O +
and O +
iris O +
, O +
which O +
exits O +
at O +
the O +
junction O +
of O +
the O +
cornea O +
and O +
sclera O +
. O +

Cyclodestructive O +
procedures O +
, O +
which O +
lower O +
IOP O +
by O +
destroying O +
the O +
ciliary O +
body O +
, O +
are O +
typically O +
reserved O +
for O +
eyes O +
, O +
which O +
are O +
refractory O +
to O +
all O +
other O +
forms O +
of O +
therapy O +
. O +

These O +
procedures O +
include O +
cyclocryotherapy O +
, O +
cylcodiathermy O +
and O +
laser O +
cyclophotocoagulation O +
. O +
[ O +
91 O +
- O +
93 O +
] O +

Follow O +
- O +
up O +

Patients O +
were O +
followed O +
up O +
at O +
the O +
outpatient O +
clinic O +
at O +
1 O +
, O +
4 O +
, O +
and O +
7 O +
months O +
after O +
the O +
ablation O +
procedure O +
and O +
every O +
6 O +
months O +
thereafter O +
. O +

Routine O +
24 O +
or O +
48 O +
h O +
Holter O +
monitoring O +
was O +
performed O +
before O +
each O +
appointment O +
, O +
and O +
a O +
12 O +
- O +
lead O +
electrocardiogram O +
was O +
obtained O +
at O +
each O +
visit O +
. O +

Patients O +
were O +
asked O +
to O +
report O +
to O +
the O +
emergency O +
room O +
or O +
our O +
arrhythmia O +
unit O +
for O +
an O +
ECG O +
if O +
any O +
symptom O +
suggestive O +
of O +
recurrence O +
occurred O +
between O +
scheduled O +
visits O +
. O +

After O +
the O +
ablation O +
procedure O +
, O +
all O +
patients O +
received O +
anti O +
- O +
arrhythmic O +
treatment O +
for O +
at O +
least O +
1 O +
month O +
to O +
protect O +
against O +
early O +
recurrences O +
and O +
continued O +
oral O +
anticoagulation O +
for O +
a O +
minimum O +
of O +
2 O +
months O +
to O +
maintain O +
an O +
international O +
normalized O +
ratio O +
between O +
2 O +
. O +
0 O +
and O +
3 O +
. O +
0 O +
. O +

Additionally O +
, O +
magnetic O +
resonance O +
angiography O +
was O +
repeated O +
at O +
3 O +
- O +
6 O +
months O +
after O +
the O +
procedure O +
to O +
evaluate O +
the O +
presence O +
of O +
PV O +
stenosis O +
. O +

Arrhythmia O +
recurrence O +
was O +
defined O +
as O +
a O +
documented O +
AF O +
or O +
atrial O +
flutter O +
episode O +
of O +
> O +
30 O +
s O +
. O +

Arrhythmic O +
episodes O +
within O +
the O +
first O +
3 O +
months O +
after O +
the O +
CPVA O +
( O +
healing O +
period O +
) O +
were O +
not O +
considered O +
in O +
the O +
evaluation O +
of O +
final O +
success O +
rates O +
because O +
they O +
are O +
often O +
described O +
as O +
transient O +
recurrences O +
related O +
to O +
atrial O +
inflammatory O +
processes O +
following O +
RF O +
lesions O +
. O +
26 O +

The O +
endpoint O +
of O +
the O +
study O +
was O +
freedom O +
from O +
arrhythmia O +
recurrence O +
after O +
a O +
single O +
CPVA O +
procedure O +
, O +
without O +
anti O +
- O +
arrhythmic O +
medication O +
. O +

A O +
minimum O +
follow O +
- O +
up O +
of O +
3 O +
months O +
was O +
required O +
. O +

Background O +

Refractive O +
outcomes O +
have O +
become O +
an O +
increasingly O +
important O +
part O +
of O +
cataract O +
surgery O +
and O +
the O +
limbal O +
relaxing O +
incision O +
( O +
LRI O +
) O +
has O +
been O +
shown O +
to O +
be O +
a O +
safe O +
and O +
effective O +
procedure O +
to O +
reduce O +
astigmatism O +
[ O +
1 O +
- O +
4 O +
] O +
. O +

Currently O +
, O +
ophthalmic O +
surgeons O +
have O +
only O +
two O +
material O +
choices O +
for O +
knives O +
to O +
perform O +
limbal O +
relaxing O +
incision O +
, O +
diamond O +
and O +
metal O +
. O +

BD O +
( O +
Becton O +
, O +
Dickinson O +
and O +
Company O +
) O +
, O +
Franklin O +
Lakes O +
, O +
NJ O +
has O +
developed O +
a O +
safety O +
engineered O +
, O +
single O +
use O +
, O +
uni O +
- O +
directional O +
cutting O +
silicon O +
knife O +
for O +
these O +
incisions O +
. O +

Previous O +
research O +
has O +
suggested O +
that O +
the O +
silicon O +
BD O +
Atomic O +
Edge O +
( O +
TM O +
) O +
knife O +
has O +
superior O +
performance O +
characteristics O +
when O +
compared O +
to O +
a O +
metal O +
knife O +
and O +
performance O +
similar O +
to O +
diamond O +
knife O +
when O +
making O +
various O +
incisions O +
[ O +
5 O +
, O +
6 O +
] O +
. O +

This O +
study O +
was O +
designed O +
to O +
determine O +
the O +
performance O +
characteristics O +
of O +
silicon O +
accurate O +
depth O +
knives O +
in O +
comparison O +
to O +
diamond O +
LRI O +
knives O +
and O +
steel O +
accurate O +
depth O +
knives O +
in O +
five O +
performance O +
characteristics O +
. O +

Electrostatic O +
interaction O +
energies O +
between O +
the O +
SNARE O +
complex O +
and O +
fusing O +
membranes O +
. O +

( O +
A O +
) O +
Schematic O +
diagram O +
and O +
definitions O +
of O +
intermolecular O +
interaction O +
energies O +
presented O +
in O +
( O +
B O +
) O +
and O +
( O +
C O +
) O +
. O +

In O +
( O +
A O +
) O +
through O +
( O +
C O +
) O +
, O +
only O +
the O +
SNARE O +
core O +
complex O +
is O +
considered O +
. O +

Interaction O +
free O +
energies O +
are O +
calculated O +
for O +
( O +
B O +
) O +
a O +
series O +
of O +
SNARE O +
/ O +
membrane O +
distances O +
and O +
( O +
C O +
) O +
different O +
membrane O +
lipid O +
compositions O +
. O +

Arrow O +
in O +
( O +
B O +
) O +
indicates O +
the O +
most O +
physiologically O +
relevant O +
distance O +
when O +
the O +
closest O +
points O +
between O +
SNARE O +
and O +
membranes O +
are O +
3 O +
A O +
, O +
the O +
thickness O +
of O +
a O +
layer O +
of O +
water O +
. O +
[ O +
19 O +
] O +
In O +
( O +
D O +
) O +
through O +
( O +
F O +
) O +
, O +
TMDs O +
of O +
VAMP O +
and O +
syntaxin O +
are O +
present O +
and O +
embedded O +
in O +
membranes O +
. O +

Furthermore O +
, O +
the O +
C O +
- O +
terminus O +
of O +
the O +
SNARE O +
motif O +
is O +
partially O +
unraveled O +
into O +
individual O +
alpha O +
- O +
helices O +
by O +
molecular O +
dynamics O +
simulations O +
to O +
represent O +
trans O +
- O +
SNARE O +
complex O +
. O +

Interaction O +
free O +
energies O +
are O +
then O +
calculated O +
for O +
( O +
E O +
) O +
a O +
series O +
of O +
SNARE O +
motif O +
C O +
- O +
terminus O +
separation O +
distances O +
and O +
( O +
F O +
) O +
different O +
lipid O +
compositions O +
of O +
the O +
membranes O +
. O +

Conclusions O +
drawn O +
from O +
both O +
groups O +
of O +
studies O +
are O +
essentially O +
the O +
same O +
. O +

V O +
( O +
circles O +
) O +
: O +
Interaction O +
energies O +
between O +
the O +
SNARE O +
complex O +
and O +
the O +
v O +
- O +
membrane O +
. O +

T O +
( O +
squares O +
) O +
: O +
Interaction O +
energies O +
between O +
SNARE O +
and O +
the O +
t O +
- O +
membrane O +
. O +

VT O +
( O +
triangles O +
) O +
: O +
Interaction O +
energies O +
between O +
the O +
v O +
- O +
and O +
the O +
t O +
- O +
membranes O +
if O +
the O +
SNARE O +
complex O +
were O +
extracted O +
. O +

Percentage O +
reported O +
purchasing O +
intentions O +
, O +
comparing O +
ITN O +
- O +
owning O +
to O +
non O +
- O +
owning O +
households O +

Demographic O +
data O +
of O +
subjects O +

School O +
environment O +

At O +
the O +
majority O +
of O +
the O +
schools O +
a O +
soft O +
drink O +
vending O +
machine O +
( O +
91 O +
% O +
, O +
n O +
= O +
446 O +
) O +
and O +
/ O +
or O +
a O +
vending O +
machine O +
containing O +
sweets O +
and O +
candy O +
bars O +
( O +
81 O +
% O +
, O +
n O +
= O +
413 O +
) O +
is O +
present O +
( O +
Table O +
2 O +
) O +
. O +

At O +
78 O +
% O +
( O +
n O +
= O +
393 O +
) O +
of O +
the O +
schools O +
there O +
is O +
a O +
supermarket O +
, O +
gas O +
station O +
or O +
a O +
fast O +
food O +
restaurant O +
in O +
the O +
neighbourhood O +
( O +
within O +
1 O +
km O +
of O +
the O +
school O +
) O +
. O +

At O +
68 O +
% O +
( O +
n O +
= O +
345 O +
) O +
of O +
the O +
schools O +
there O +
are O +
facilities O +
at O +
or O +
around O +
the O +
school O +
property O +
where O +
the O +
students O +
can O +
be O +
physically O +
active O +
, O +
for O +
example O +
a O +
soccer O +
field O +
or O +
a O +
basketball O +
field O +
. O +

Table O +
2 O +

The O +
school O +
environment O +

Total O +
School O +
level O +

Vocational O +
education O +
schools O +
Mixed O +
schools O +
Higher O +
education O +
schools O +
Vocational O +
education O +
schools O +
versus O +
higher O +
education O +
schools O +
# O +
Mixed O +
schools O +
versus O +
higher O +
education O +
schools O +
# O +

n O +
= O +
515 O +
n O +
= O +
216 O +
n O +
= O +
232 O +
n O +
= O +
67 O +

% O +
( O +
n O +
) O +
% O +
( O +
n O +
) O +
% O +
( O +
n O +
) O +
% O +
( O +
n O +
) O +
OR O +
( O +
95 O +
% O +
CI O +
) O +
OR O +
( O +
95 O +
% O +
CI O +
) O +

Soft O +
drink O +
vending O +
machine O +
present O +
at O +
school O +
91 O +
. O +
4 O +
( O +
466 O +
) O +
90 O +
. O +
2 O +
( O +
194 O +
) O +
91 O +
. O +
3 O +
( O +
209 O +
) O +
95 O +
. O +
5 O +
( O +
63 O +
) O +
1 O +
. O +
0 O +
( O +
0 O +
. O +
9 O +
; O +
1 O +
. O +
1 O +
) O +
1 O +
. O +
0 O +
( O +
0 O +
. O +
9 O +
; O +
1 O +
. O +
0 O +
) O +

Percentage O +
of O +
soft O +
drink O +
vending O +
machines O +
present O +
at O +
school O +
that O +
contain O +
light O +
soft O +
drinks O +
79 O +
. O +
8 O +
( O +
372 O +
) O +
75 O +
. O +
4 O +
( O +
147 O +
) O +
82 O +
. O +
2 O +
( O +
171 O +
) O +
85 O +
. O +
7 O +
( O +
54 O +
) O +
0 O +
. O +
9 O +
( O +
0 O +
. O +
8 O +
; O +
1 O +
. O +
0 O +
) O +
1 O +
. O +
0 O +
( O +
0 O +
. O +
9 O +
; O +
1 O +
. O +
1 O +
) O +

Soft O +
drink O +
vending O +
machines O +
contain O +
more O +
unhealthy O +
drinks O +
than O +
healthy O +
drinks O +
57 O +
. O +
9 O +
( O +
268 O +
) O +
61 O +
. O +
9 O +
( O +
120 O +
) O +
58 O +
. O +
5 O +
( O +
121 O +
) O +
43 O +
. O +
6 O +
( O +
27 O +
) O +
1 O +
. O +
4 O +
( O +
1 O +
. O +
0 O +
; O +
1 O +
. O +
9 O +
) O +
1 O +
. O +
4 O +
( O +
1 O +
. O +
0 O +
; O +
1 O +
. O +
9 O +
) O +
* O +

Vending O +
machine O +
present O +
at O +
school O +
that O +
contains O +
sweets O +
/ O +
candy O +
bars O +
80 O +
. O +
7 O +
( O +
413 O +
) O +
75 O +
. O +
6 O +
( O +
161 O +
) O +
84 O +
. O +
9 O +
( O +
197 O +
) O +
82 O +
. O +
1 O +
( O +
55 O +
) O +
1 O +
. O +
1 O +
( O +
0 O +
. O +
9 O +
; O +
1 O +
. O +
2 O +
) O +
1 O +
. O +
1 O +
( O +
1 O +
. O +
0 O +
; O +
1 O +
. O +
2 O +
) O +

Sweets O +
/ O +
candy O +
bars O +
vending O +
machines O +
contain O +
more O +
unhealthy O +
than O +
healthy O +
foods O +
63 O +
. O +
7 O +
( O +
260 O +
) O +
70 O +
. O +
6 O +
( O +
113 O +
) O +
64 O +
. O +
4 O +
( O +
125 O +
) O +
40 O +
. O +
7 O +
( O +
22 O +
) O +
1 O +
. O +
7 O +
( O +
1 O +
. O +
2 O +
; O +
2 O +
. O +
4 O +
) O +
* O +
1 O +
. O +
6 O +
( O +
1 O +
. O +
1 O +
; O +
2 O +
. O +
3 O +
) O +
* O +

There O +
is O +
a O +
supermarket O +
, O +
gas O +
station O +
, O +
or O +
fast O +
food O +
restaurant O +
in O +
the O +
neighbourhood O +
of O +
the O +
school O +
78 O +
. O +
3 O +
( O +
393 O +
) O +
76 O +
. O +
7 O +
( O +
161 O +
) O +
79 O +
. O +
7 O +
( O +
181 O +
) O +
78 O +
. O +
5 O +
( O +
51 O +
) O +
1 O +
. O +
1 O +
( O +
0 O +
. O +
9 O +
; O +
1 O +
. O +
2 O +
) O +
1 O +
. O +
1 O +
( O +
0 O +
. O +
9 O +
; O +
1 O +
. O +
2 O +
) O +

The O +
students O +
are O +
allowed O +
to O +
leave O +
the O +
school O +
property O +
during O +
school O +
hours O +
57 O +
. O +
4 O +
( O +
295 O +
) O +
42 O +
. O +
6 O +
( O +
92 O +
) O +
65 O +
. O +
8 O +
( O +
152 O +
) O +
76 O +
. O +
1 O +
( O +
51 O +
) O +
0 O +
. O +
6 O +
( O +
0 O +
. O +
5 O +
; O +
0 O +
. O +
8 O +
) O +
* O +
0 O +
. O +
9 O +
( O +
0 O +
. O +
8 O +
; O +
1 O +
. O +
0 O +
) O +

There O +
are O +
facilities O +
at O +
and O +
around O +
the O +
school O +
property O +
where O +
the O +
students O +
can O +
be O +
physically O +
active O +
68 O +
. O +
1 O +
( O +
345 O +
) O +
63 O +
. O +
1 O +
( O +
135 O +
) O +
70 O +
. O +
3 O +
( O +
161 O +
) O +
76 O +
. O +
6 O +
( O +
49 O +
) O +
0 O +
. O +
8 O +
( O +
0 O +
. O +
7 O +
; O +
1 O +
. O +
0 O +
) O +
0 O +
. O +
9 O +
( O +
0 O +
. O +
8 O +
; O +
1 O +
. O +
1 O +
) O +

# O +
Associations O +
are O +
adjusted O +
for O +
school O +
size O +

* O +
p O +
< O +
0 O +
. O +
05 O +

The O +
vocational O +
education O +
schools O +
did O +
not O +
differ O +
from O +
the O +
higher O +
education O +
schools O +
with O +
regard O +
to O +
the O +
presence O +
of O +
vending O +
machines O +
and O +
a O +
canteen O +
, O +
but O +
the O +
vending O +
machines O +
and O +
the O +
canteen O +
contained O +
a O +
less O +
favourable O +
selection O +
of O +
foods O +
and O +
drinks O +
. O +

The O +
vocational O +
education O +
schools O +
indicated O +
more O +
often O +
that O +
the O +
vending O +
machines O +
and O +
the O +
canteen O +
contained O +
more O +
unhealthy O +
foods O +
and O +
drinks O +
than O +
healthy O +
foods O +
and O +
drinks O +
. O +

Vocational O +
education O +
schools O +
had O +
fewer O +
facilities O +
at O +
and O +
around O +
the O +
school O +
property O +
to O +
be O +
physical O +
than O +
the O +
higher O +
education O +
schools O +
. O +

Most O +
associations O +
were O +
attenuated O +
after O +
adjustment O +
for O +
school O +
size O +
. O +

For O +
example O +
, O +
the O +
association O +
between O +
school O +
level O +
and O +
content O +
of O +
the O +
soft O +
drink O +
vending O +
machines O +
was O +
OR O +
= O +
1 O +
. O +
42 O +
, O +
95 O +
% O +
CI O +
: O +
1 O +
. O +
05 O +
- O +
1 O +
. O +
93 O +
in O +
the O +
crude O +
analysis O +
and O +
OR O +
= O +
1 O +
. O +
35 O +
, O +
95 O +
% O +
CI O +
: O +
0 O +
. O +
99 O +
- O +
1 O +
. O +
85 O +
in O +
the O +
adjusted O +
analysis O +
. O +

Behavior O +

Across O +
all O +
participants O +
, O +
50 O +
% O +
+ O +
/ O +
- O +
13 O +
of O +
studied O +
high O +
- O +
complexity O +
scene O +
were O +
later O +
recognized O +
as O +
" O +
old O +
" O +
( O +
hit O +
rate O +
) O +
, O +
and O +
52 O +
% O +
+ O +
/ O +
- O +
18 O +
of O +
studied O +
low O +
- O +
complexity O +
scenes O +
were O +
later O +
recognized O +
as O +
" O +
old O +
" O +
. O +

For O +
new O +
scenes O +
presented O +
at O +
test O +
( O +
foils O +
) O +
, O +
22 O +
% O +
+ O +
/ O +
- O +
16 O +
of O +
high O +
- O +
complexity O +
scenes O +
were O +
falsely O +
categorized O +
as O +
" O +
old O +
" O +
( O +
false O +
alarm O +
rate O +
) O +
, O +
and O +
22 O +
% O +
+ O +
/ O +
- O +
14 O +
of O +
low O +
- O +
complexity O +
scenes O +
were O +
falsely O +
categorized O +
as O +
" O +
old O +
" O +
. O +

Across O +
all O +
participants O +
, O +
adjusted O +
hit O +
rate O +
( O +
hit O +
rate O +
- O +
false O +
alarm O +
rate O +
) O +
for O +
high O +
- O +
complexity O +
scenes O +
( O +
28 O +
% O +
+ O +
/ O +
- O +
13 O +
) O +
did O +
not O +
differ O +
from O +
that O +
for O +
low O +
- O +
complexity O +
scenes O +
( O +
30 O +
% O +
+ O +
/ O +
- O +
14 O +
) O +
( O +
t O +
( O +
45 O +
) O +
= O +
1 O +
. O +
02 O +
, O +
p O +
= O +
0 O +
. O +
31 O +
) O +
. O +

Critically O +
, O +
the O +
adjusted O +
hit O +
rate O +
increased O +
with O +
age O +
for O +
high O +
- O +
complexity O +
( O +
r O +
= O +
0 O +
. O +
40 O +
, O +
p O +
= O +
0 O +
. O +
006 O +
) O +
, O +
but O +
not O +
for O +
low O +
- O +
complexity O +
( O +
r O +
= O +
0 O +
. O +
11 O +
, O +
p O +
= O +
0 O +
. O +
46 O +
) O +
scenes O +
. O +

Thus O +
, O +
overall O +
participants O +
had O +
similar O +
memory O +
accuracy O +
for O +
high O +
- O +
and O +
low O +
- O +
complexity O +
scenes O +
, O +
but O +
memory O +
accuracy O +
improved O +
with O +
age O +
only O +
for O +
high O +
- O +
complexity O +
scenes O +
. O +

Participants O +
categorized O +
as O +
" O +
remembered O +
" O +
( O +
RHIT O +
) O +
, O +
28 O +
% O +
+ O +
/ O +
- O +
12 O +
of O +
the O +
studied O +
high O +
- O +
complexity O +
scenes O +
, O +
and O +
29 O +
% O +
+ O +
/ O +
- O +
15 O +
of O +
the O +
studied O +
low O +
- O +
complexity O +
scenes O +
. O +

Participants O +
had O +
similar O +
rates O +
of O +
falsely O +
categorizing O +
as O +
" O +
remembered O +
" O +
( O +
RFA O +
) O +
high O +
( O +
5 O +
% O +
+ O +
/ O +
- O +
6 O +
) O +
and O +
low O +
( O +
5 O +
% O +
+ O +
/ O +
- O +
6 O +
) O +
complexity O +
foils O +
. O +

Across O +
all O +
participants O +
, O +
adjusted O +
R O +
rates O +
( O +
RHIT O +
- O +
RFA O +
) O +
for O +
high O +
- O +
complexity O +
scenes O +
did O +
not O +
differ O +
from O +
that O +
for O +
low O +
- O +
complexity O +
scenes O +
( O +
t O +
( O +
45 O +
) O +
= O +
1 O +
. O +
41 O +
, O +
p O +
= O +
0 O +
. O +
17 O +
) O +
. O +

Adjusted O +
R O +
rates O +
increased O +
with O +
age O +
for O +
high O +
- O +
complexity O +
( O +
r O +
= O +
0 O +
. O +
38 O +
, O +
p O +
= O +
0 O +
. O +
009 O +
) O +
, O +
but O +
not O +
for O +
low O +
- O +
complexity O +
( O +
r O +
= O +
0 O +
. O +
16 O +
, O +
p O +
= O +
0 O +
. O +
30 O +
) O +
, O +
scenes O +
( O +
Figures O +
1C O +
, O +
D O +
) O +
. O +

The O +
difference O +
between O +
the O +
adjusted O +
R O +
rates O +
of O +
high O +
- O +
and O +
low O +
- O +
complexity O +
scenes O +
increased O +
with O +
age O +
( O +
r O +
= O +
0 O +
. O +
27 O +
, O +
p O +
= O +
0 O +
. O +
03 O +
; O +
1 O +
- O +
tailed O +
) O +
, O +
suggesting O +
that O +
the O +
age O +
- O +
related O +
improvements O +
in O +
memory O +
performance O +
were O +
more O +
robust O +
for O +
recollected O +
high O +
- O +
complexity O +
scenes O +
. O +

Thus O +
, O +
overall O +
, O +
participants O +
had O +
similar O +
memory O +
accuracy O +
for O +
recollected O +
high O +
- O +
and O +
low O +
- O +
complexity O +
scenes O +
, O +
but O +
accuracy O +
for O +
recollected O +
high O +
- O +
complexity O +
scenes O +
improved O +
with O +
age O +
, O +
whereas O +
accuracy O +
for O +
recollected O +
low O +
- O +
complexity O +
scenes O +
did O +
not O +
change O +
with O +
age O +
. O +

Participants O +
categorized O +
as O +
" O +
familiar O +
" O +
( O +
KHIT O +
) O +
, O +
22 O +
% O +
+ O +
/ O +
- O +
9 O +
of O +
studied O +
high O +
- O +
complexity O +
scenes O +
, O +
and O +
22 O +
% O +
+ O +
/ O +
- O +
10 O +
of O +
studied O +
low O +
- O +
complexity O +
scenes O +
. O +

Participants O +
falsely O +
categorized O +
as O +
" O +
familiar O +
" O +
( O +
KFA O +
) O +
17 O +
% O +
+ O +
/ O +
- O +
11 O +
of O +
high O +
- O +
complexity O +
, O +
and O +
17 O +
% O +
+ O +
/ O +
- O +
12 O +
of O +
low O +
- O +
complexity O +
foils O +
. O +

Across O +
all O +
participants O +
, O +
adjusted O +
K O +
rates O +
( O +
KHIT O +
- O +
KFA O +
) O +
for O +
high O +
- O +
complexity O +
scenes O +
did O +
not O +
differ O +
from O +
that O +
for O +
low O +
- O +
complexity O +
scenes O +
( O +
t O +
( O +
45 O +
) O +
= O +
0 O +
. O +
06 O +
, O +
p O +
= O +
0 O +
. O +
95 O +
) O +
. O +

Adjusted O +
K O +
rates O +
did O +
not O +
change O +
with O +
age O +
for O +
either O +
high O +
- O +
complexity O +
or O +
low O +
- O +
complexity O +
scenes O +
( O +
| O +
r O +
| O +
s O +
< O +
0 O +
. O +
09 O +
, O +
ps O +
> O +
0 O +
. O +
56 O +
) O +
( O +
Figures O +
1C O +
, O +
D O +
) O +
. O +

During O +
the O +
encoding O +
task O +
, O +
participants O +
were O +
overall O +
faster O +
to O +
respond O +
to O +
low O +
- O +
complexity O +
scenes O +
( O +
1072 O +
+ O +
/ O +
- O +
275 O +
ms O +
) O +
than O +
to O +
high O +
- O +
complexity O +
scenes O +
( O +
1093 O +
+ O +
/ O +
- O +
287 O +
ms O +
) O +
( O +
t O +
( O +
45 O +
) O +
= O +
2 O +
. O +
31 O +
, O +
p O +
= O +
0 O +
. O +
03 O +
) O +
. O +

Response O +
times O +
decreased O +
with O +
age O +
for O +
low O +
- O +
( O +
r O +
= O +
- O +
0 O +
. O +
37 O +
, O +
p O +
= O +
0 O +
. O +
01 O +
) O +
and O +
high O +
- O +
( O +
r O +
= O +
- O +
0 O +
. O +
33 O +
, O +
p O +
= O +
0 O +
. O +
03 O +
) O +
complexity O +
scenes O +
. O +

The O +
difference O +
between O +
the O +
response O +
times O +
for O +
high O +
- O +
and O +
low O +
- O +
complexity O +
scenes O +
, O +
however O +
, O +
did O +
not O +
change O +
with O +
age O +
( O +
r O +
= O +
0 O +
. O +
14 O +
, O +
p O +
= O +
0 O +
. O +
35 O +
) O +
. O +

Response O +
times O +
decreased O +
with O +
age O +
for O +
R O +
, O +
K O +
and O +
F O +
trial O +
types O +
for O +
both O +
high O +
- O +
and O +
low O +
- O +
complexity O +
scenes O +
( O +
- O +
0 O +
. O +
36 O +
< O +
r O +
< O +
- O +
0 O +
. O +
30 O +
, O +
ps O +
< O +
0 O +
. O +
04 O +
) O +
. O +

The O +
difference O +
between O +
response O +
times O +
for O +
R O +
and O +
F O +
trial O +
types O +
, O +
however O +
, O +
did O +
not O +
change O +
with O +
age O +
for O +
either O +
high O +
( O +
r O +
= O +
0 O +
. O +
12 O +
, O +
p O +
= O +
0 O +
. O +
43 O +
) O +
or O +
low O +
complexity O +
scenes O +
( O +
r O +
= O +
0 O +
. O +
08 O +
, O +
p O +
= O +
0 O +
. O +
60 O +
) O +
. O +

1 O +
. O +

Background O +

The O +
United O +
Republic O +
of O +
Tanzania O +
, O +
is O +
among O +
the O +
many O +
countries O +
in O +
sub O +
- O +
Saharan O +
Africa O +
facing O +
a O +
human O +
resources O +
crisis O +
in O +
its O +
health O +
sector O +
, O +
with O +
a O +
small O +
and O +
inequitably O +
distributed O +
health O +
workforce O +
[ O +
1 O +
] O +
that O +
shoulders O +
a O +
disproportionately O +
high O +
burden O +
of O +
disease O +
[ O +
2 O +
] O +
. O +

Although O +
all O +
poor O +
countries O +
in O +
the O +
world O +
face O +
a O +
severe O +
human O +
resource O +
crisis O +
in O +
their O +
health O +
sectors O +
[ O +
3 O +
, O +
4 O +
] O +
, O +
the O +
problem O +
is O +
most O +
acute O +
in O +
Sub O +
- O +
Saharan O +
Africa O +
, O +
in O +
which O +
an O +
estimated O +
workforce O +
of O +
750 O +
000 O +
health O +
workers O +
in O +
the O +
region O +
serves O +
682 O +
million O +
people O +
[ O +
2 O +
] O +
. O +

By O +
comparison O +
, O +
the O +
ratio O +
is O +
10 O +
to O +
15 O +
times O +
higher O +
in O +
developed O +
countries O +
. O +

Moreover O +
, O +
this O +
estimated O +
workforce O +
of O +
doctors O +
, O +
nurses O +
and O +
allied O +
health O +
workers O +
in O +
Sub O +
- O +
Saharan O +
Africa O +
constitutes O +
1 O +
. O +
3 O +
% O +
of O +
the O +
world O +
' O +
s O +
health O +
workforce O +
, O +
while O +
Africa O +
suffers O +
from O +
25 O +
% O +
of O +
the O +
world O +
' O +
s O +
burden O +
of O +
disease O +
[ O +
2 O +
] O +
. O +

A O +
minimum O +
level O +
of O +
a O +
health O +
workforce O +
of O +
2 O +
. O +
5 O +
health O +
workers O +
per O +
1000 O +
people O +
is O +
required O +
to O +
achieve O +
the O +
Millennium O +
Development O +
Goals O +
[ O +
5 O +
] O +
. O +

Africa O +
is O +
far O +
from O +
this O +
level O +
with O +
a O +
health O +
workforce O +
density O +
that O +
only O +
averages O +
0 O +
. O +
8 O +
worker O +
per O +
1000 O +
people O +
, O +
while O +
the O +
world O +
median O +
density O +
of O +
health O +
personnel O +
is O +
5 O +
per O +
1000 O +
people O +
[ O +
5 O +
] O +
. O +

There O +
is O +
a O +
positive O +
correlation O +
between O +
health O +
worker O +
density O +
and O +
various O +
health O +
indices O +
, O +
most O +
notably O +
infant O +
mortality O +
rate O +
, O +
maternal O +
mortality O +
rates O +
, O +
and O +
various O +
disease O +
specific O +
mortality O +
and O +
morbidity O +
rates O +
[ O +
6 O +
, O +
7 O +
] O +
. O +

An O +
increase O +
in O +
the O +
number O +
of O +
health O +
workers O +
per O +
capita O +
is O +
associated O +
with O +
a O +
notable O +
decline O +
in O +
the O +
rates O +
mentioned O +
above O +
. O +

As O +
a O +
consequence O +
, O +
it O +
has O +
been O +
argued O +
that O +
health O +
worker O +
shortages O +
have O +
impeded O +
the O +
implementation O +
of O +
development O +
goals O +
in O +
many O +
poor O +
countries O +
[ O +
8 O +
] O +
. O +

CASE O +
: O +

Here O +
for O +
the O +
first O +
time O +
a O +
case O +
of O +
CDLS O +
from O +
Iran O +
, O +
a O +
15 O +
- O +
week O +
- O +
old O +
male O +
infant O +
who O +
was O +
refereed O +
as O +
a O +
case O +
of O +
multiple O +
congenital O +
anomalies O +
. O +

Clinical O +
investigation O +
showed O +
that O +
the O +
child O +
was O +
a O +
case O +
of O +
CDLS O +
. O +

NSPCs O +
protect O +
against O +
30 O +
minute O +
MCAO O +
. O +

( O +
A O +
- O +
D O +
) O +
Coronal O +
histological O +
sections O +
through O +
the O +
ischemic O +
striatum O +
3 O +
days O +
following O +
MCAO O +
, O +
stained O +
for O +
TUNEL O +
( O +
A O +
, O +
B O +
) O +
or O +
NeuN O +
( O +
C O +
, O +
D O +
) O +
. O +

Mice O +
received O +
intrastriatal O +
injections O +
of O +
exogenous O +
PBS O +
( O +
A O +
, O +
C O +
) O +
or O +
EGFP O +
+ O +
NSPCs O +
( O +
B O +
, O +
D O +
, O +
E O +
) O +
72 O +
hr O +
prior O +
to O +
MCAO O +
. O +

Inset O +
in O +
( O +
B O +
) O +
shows O +
40x O +
magnified O +
view O +
of O +
the O +
injection O +
site O +
. O +

( O +
E O +
) O +
Monochrome O +
conversion O +
of O +
image O +
shown O +
in O +
B O +
to O +
demonstrate O +
concentric O +
ring O +
structures O +
used O +
for O +
Sholl O +
analysis O +
. O +

( O +
F O +
) O +
Quantification O +
of O +
TUNEL O +
+ O +
cells O +
using O +
Sholl O +
analysis O +
performed O +
on O +
fluorescent O +
images O +
. O +

* O +
p O +
< O +
0 O +
. O +
05 O +
, O +
n O +
= O +
5 O +
mice O +
per O +
group O +
. O +

Scale O +
bar O +
: O +
A O +
, O +
B O +
= O +
20 O +
microm O +
; O +
C O +
, O +
D O +
= O +
10 O +
microm O +
. O +

Magnetic O +
resonance O +
imaging O +
of O +
axial O +
plan O +
with O +
intravenous O +
contrast O +
gadolinium O +
- O +
BOPTA O +
demonstrating O +
a O +
mass O +
adherent O +
to O +
the O +
right O +
ventricular O +
wall O +
. O +

Applying O +
A1C O +
cut O +
offs O +
to O +
the O +
AusDiab O +
population O +
( O +
4 O +
. O +
6 O +
% O +
undiagnosed O +
diabetes O +
) O +

Applying O +
the O +
same O +
cut O +
offs O +
, O +
a O +
total O +
75 O +
. O +
9 O +
% O +
of O +
the O +
AusDiab O +
population O +
had O +
diabetes O +
ruled O +
in O +
or O +
ruled O +
out O +
( O +
Fig O +
. O +
1B O +
) O +
, O +
while O +
the O +
remaining O +
24 O +
. O +
1 O +
% O +
had O +
impaired O +
A1C O +
. O +

From O +
those O +
with O +
impaired O +
A1C O +
, O +
69 O +
. O +
3 O +
% O +
had O +
abnormal O +
glucose O +
status O +
. O +

For O +
diabetes O +
, O +
A1C O +
at O +
5 O +
. O +
5 O +
% O +
provided O +
moderate O +
sensitivity O +
( O +
83 O +
. O +
5 O +
% O +
) O +
but O +
high O +
NPV O +
( O +
99 O +
. O +
0 O +
% O +
) O +
, O +
since O +
diabetes O +
prevalence O +
was O +
lower O +
in O +
the O +
AusDiab O +
than O +
in O +
the O +
MP O +
population O +
. O +

A1C O +
at O +
7 O +
. O +
0 O +
% O +
gave O +
100 O +
% O +
specificity O +
and O +
100 O +
% O +
PPV O +
. O +

By O +
dropping O +
the O +
cut O +
off O +
to O +
6 O +
. O +
5 O +
% O +
, O +
specificity O +
remained O +
99 O +
. O +
9 O +
% O +
, O +
with O +
PPV O +
near O +
100 O +
% O +
. O +

Background O +

Over O +
the O +
past O +
decades O +
, O +
extensive O +
comparative O +
mapping O +
research O +
has O +
been O +
performed O +
in O +
the O +
plant O +
family O +
Solanaceae O +
. O +

The O +
recent O +
identification O +
of O +
a O +
large O +
set O +
of O +
single O +
- O +
copy O +
conserved O +
orthologous O +
( O +
COSII O +
) O +
markers O +
has O +
greatly O +
accelerated O +
comparative O +
mapping O +
studies O +
among O +
major O +
solanaceous O +
species O +
including O +
tomato O +
, O +
potato O +
, O +
eggplant O +
, O +
pepper O +
and O +
diploid O +
Nicotiana O +
species O +
( O +
as O +
well O +
as O +
tetraploid O +
tobacco O +
) O +
. O +

The O +
large O +
amount O +
of O +
comparative O +
data O +
now O +
available O +
for O +
these O +
species O +
provides O +
the O +
opportunity O +
to O +
describe O +
the O +
overall O +
patterns O +
of O +
chromosomal O +
evolution O +
in O +
this O +
important O +
plant O +
family O +
. O +

The O +
results O +
of O +
this O +
investigation O +
are O +
described O +
herein O +
. O +

Calcium O +
intake O +
and O +
effects O +
on O +
QUS O +
T O +
- O +
score O +

Figure O +
5 O +
shows O +
the O +
amounts O +
of O +
dietary O +
calcium O +
intake O +
according O +
to O +
menopausal O +
status O +
. O +

Calcium O +
consumption O +
in O +
most O +
groups O +
, O +
like O +
that O +
in O +
the O +
study O +
population O +
as O +
a O +
whole O +
, O +
was O +
inadequate O +
. O +

Fewer O +
than O +
one O +
third O +
of O +
premenopausal O +
and O +
postmenopausal O +
women O +
received O +
more O +
than O +
800 O +
mg O +
calcium O +
daily O +
, O +
and O +
fewer O +
than O +
16 O +
% O +
of O +
premenopausal O +
women O +
in O +
the O +
50 O +
- O +
59 O +
age O +
decade O +
( O +
n O +
= O +
38 O +
) O +
consumed O +
more O +
than O +
800 O +
mg O +
calcium O +
daily O +
. O +

Figure O +
5 O +

Daily O +
calcium O +
intake O +
in O +
premenopausal O +
and O +
postmenopausal O +
women O +
. O +

This O +
figure O +
depicts O +
the O +
daily O +
amounts O +
of O +
dietary O +
calcium O +
intake O +
( O +
and O +
percent O +
) O +
according O +
to O +
menopausal O +
status O +
using O +
800 O +
mg O +
daily O +
as O +
cut O +
off O +
point O +
. O +

QUS O +
T O +
- O +
score O +
were O +
then O +
calculated O +
according O +
to O +
daily O +
calcium O +
intake O +
in O +
all O +
premenopausal O +
and O +
postmenopausal O +
activity O +
groups O +
using O +
800 O +
mg O +
daily O +
calcium O +
as O +
cutoff O +
point O +
. O +

As O +
shown O +
in O +
Tables O +
3 O +
and O +
4 O +
and O +
Figure O +
6 O +
, O +
premenopausal O +
women O +
who O +
were O +
systematically O +
active O +
and O +
consumed O +
more O +
than O +
800 O +
mg O +
calcium O +
daily O +
had O +
significantly O +
higher O +
QUS O +
T O +
- O +
scores O +
compared O +
with O +
all O +
other O +
activity O +
groups O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
. O +

Among O +
systematically O +
active O +
premenopausal O +
women O +
who O +
received O +
more O +
than O +
800 O +
mg O +
calcium O +
per O +
day O +
, O +
this O +
difference O +
was O +
separately O +
significant O +
verses O +
sedentary O +
( O +
p O +
= O +
0 O +
. O +
028 O +
) O +
and O +
moderately O +
active O +
( O +
p O +
= O +
0 O +
. O +
04 O +
) O +
women O +
. O +

In O +
contrast O +
, O +
postmenopausal O +
women O +
showed O +
no O +
difference O +
in O +
QUS O +
T O +
- O +
scores O +
regardless O +
of O +
the O +
amount O +
of O +
daily O +
calcium O +
intake O +
. O +

Figure O +
6 O +

Synergy O +
between O +
physical O +
activity O +
and O +
dietary O +
calcium O +
intake O +
in O +
women O +
consuming O +
calcium O +
amounts O +
greater O +
than O +
800 O +
mg O +
/ O +
day O +
. O +

This O +
graphic O +
depicts O +
mean O +
QUS O +
T O +
- O +
score O +
values O +
calculated O +
according O +
to O +
daily O +
calcium O +
intake O +
in O +
all O +
premenopausal O +
and O +
postmenopausal O +
activity O +
groups O +
using O +
800 O +
mg O +
daily O +
as O +
cut O +
off O +
point O +
( O +
for O +
statistical O +
significant O +
values O +
see O +
text O +
) O +
. O +

CONCLUSIONS O +

The O +
lack O +
of O +
association O +
between O +
depression O +
and O +
glycemic O +
control O +
is O +
not O +
due O +
to O +
the O +
use O +
of O +
a O +
binary O +
measure O +
of O +
depression O +
. O +

Findings O +
further O +
clarify O +
the O +
significant O +
association O +
between O +
distress O +
and O +
A1C O +
. O +

Additional O +
file O +
3 O +

Primers O +
used O +
in O +
this O +
study O +
. O +

All O +
of O +
the O +
primers O +
used O +
for O +
generating O +
PCR O +
products O +
for O +
microinjection O +
and O +
site O +
- O +
direct O +
mutagenesis O +
are O +
listed O +
. O +

Discussion O +

This O +
is O +
the O +
first O +
study O +
to O +
employ O +
such O +
a O +
large O +
number O +
of O +
replicated O +
samples O +
in O +
order O +
to O +
assess O +
the O +
bacterial O +
communities O +
of O +
healthy O +
and O +
diseased O +
corals O +
, O +
and O +
the O +
first O +
culture O +
- O +
independent O +
assessment O +
of O +
bacterial O +
communities O +
on O +
Acroporid O +
WS O +
corals O +
on O +
the O +
GBR O +
. O +

Despite O +
the O +
potential O +
of O +
not O +
capturing O +
rare O +
or O +
very O +
low O +
abundance O +
bacterial O +
ribotypes O +
, O +
the O +
DGGE O +
analysis O +
used O +
in O +
this O +
study O +
indicated O +
similar O +
results O +
of O +
captured O +
bacterial O +
ribotypes O +
and O +
tentative O +
bacterial O +
species O +
replacement O +
in O +
unhealthy O +
corals O +
to O +
that O +
of O +
less O +
replicated O +
studies O +
using O +
other O +
non O +
- O +
culture O +
based O +
techniques O +
( O +
e O +
. O +
g O +
. O +
[ O +
3 O +
] O +
, O +
[ O +
54 O +
] O +
, O +
[ O +
69 O +
] O +
; O +
Figure O +
4 O +
) O +
. O +

The O +
results O +
from O +
this O +
research O +
reinforce O +
, O +
with O +
statistically O +
relevant O +
data O +
, O +
that O +
corals O +
harbour O +
bacterial O +
communities O +
different O +
to O +
the O +
water O +
column O +
[ O +
7 O +
] O +
, O +
[ O +
9 O +
] O +
, O +
[ O +
42 O +
] O +
, O +
corroborate O +
findings O +
that O +
corals O +
associate O +
only O +
with O +
certain O +
specific O +
bacterial O +
groups O +
, O +
and O +
that O +
these O +
coral O +
- O +
associated O +
bacterial O +
communities O +
are O +
' O +
host O +
' O +
species O +
- O +
specific O +
[ O +
2 O +
] O +
. O +

The O +
data O +
presented O +
here O +
highlight O +
a O +
cluster O +
of O +
bacterial O +
ribotypes O +
frequently O +
associated O +
with O +
corals O +
, O +
and O +
the O +
distribution O +
of O +
these O +
bacterial O +
ribotypes O +
on O +
healthy O +
and O +
diseased O +
corals O +
, O +
which O +
allows O +
for O +
further O +
targeted O +
research O +
into O +
a O +
tentative O +
link O +
between O +
these O +
common O +
coral O +
associates O +
and O +
coral O +
health O +
. O +

This O +
study O +
indicates O +
that O +
coral O +
bacterial O +
community O +
assessments O +
require O +
a O +
number O +
of O +
replicates O +
per O +
coral O +
species O +
and O +
site O +
to O +
accurately O +
describe O +
the O +
diversity O +
present O +
across O +
the O +
population O +
and O +
in O +
order O +
to O +
draw O +
inferences O +
on O +
health O +
- O +
related O +
changes O +
in O +
the O +
community O +
composition O +
. O +

In O +
addition O +
, O +
the O +
comparisons O +
of O +
healthy O +
and O +
diseased O +
Acropora O +
hyacinthus O +
samples O +
showed O +
that O +
bacterial O +
communities O +
can O +
change O +
dramatically O +
in O +
diseased O +
individuals O +
. O +

The O +
DGGE O +
profiles O +
observed O +
for O +
corals O +
displaying O +
signs O +
of O +
White O +
Syndrome O +
comprised O +
a O +
range O +
of O +
bacterial O +
ribotypes O +
not O +
generally O +
found O +
on O +
healthy O +
corals O +
, O +
including O +
close O +
relatives O +
of O +
bacteria O +
previously O +
found O +
on O +
Black O +
Band O +
Diseased O +
corals O +
. O +

However O +
the O +
community O +
profiles O +
across O +
the O +
samples O +
taken O +
from O +
diseased O +
coral O +
colonies O +
were O +
inconsistent O +
and O +
not O +
indicative O +
of O +
a O +
single O +
bacterial O +
causative O +
agent O +
. O +

2 O +
. O +

Methods O +

We O +
conducted O +
a O +
systematic O +
study O +
of O +
patients O +
hospitalized O +
from O +
August O +
2006 O +
until O +
September O +
2007 O +
at O +
the O +
Yerevan O +
City O +
and O +
the O +
Republican O +
Dispensaries O +
, O +
the O +
two O +
reference O +
TB O +
hospitals O +
in O +
Armenia O +
. O +

Following O +
focus O +
group O +
discussions O +
and O +
pilot O +
testing O +
to O +
refine O +
the O +
survey O +
instrument O +
, O +
patient O +
interviews O +
began O +
in O +
the O +
fall O +
of O +
2006 O +
and O +
were O +
conducted O +
by O +
trained O +
students O +
in O +
the O +
public O +
health O +
program O +
of O +
the O +
American O +
University O +
of O +
Armenia O +
. O +

Students O +
received O +
training O +
by O +
the O +
study O +
designer O +
( O +
SO O +
) O +
on O +
principles O +
of O +
interview O +
ethics O +
and O +
interviewing O +
processes O +
. O +

Most O +
patient O +
interviews O +
were O +
conducted O +
at O +
the O +
Republican O +
Dispensary O +
in O +
Abovian O +
Marz O +
, O +
the O +
national O +
TB O +
diagnostic O +
and O +
treatment O +
facility O +
to O +
which O +
all O +
suspected O +
cases O +
throughout O +
the O +
country O +
are O +
referred O +
for O +
diagnostic O +
confirmation O +
. O +

In O +
the O +
past O +
several O +
years O +
, O +
strong O +
financial O +
support O +
has O +
been O +
provided O +
to O +
Armenia O +
by O +
a O +
number O +
of O +
international O +
organizations O +
, O +
such O +
as O +
the O +
German O +
Gesellschaft O +
fur O +
Technische O +
Zusammenarbeit O +
( O +
GTZ O +
) O +
, O +
the O +
Global O +
Fund O +
to O +
Fight O +
AIDS O +
, O +
Tuberculosis O +
and O +
Malaria O +
, O +
and O +
the O +
Red O +
Cross O +
, O +
which O +
has O +
enabled O +
both O +
microscopic O +
and O +
culture O +
examinations O +
for O +
each O +
TB O +
case O +
to O +
be O +
performed O +
at O +
the O +
National O +
Reference O +
Laboratory O +
located O +
at O +
the O +
Republican O +
TB O +
Dispensary O +
. O +

All O +
culture O +
- O +
confirmed O +
TB O +
cases O +
are O +
admitted O +
as O +
in O +
- O +
patients O +
while O +
undergoing O +
the O +
initial O +
phase O +
of O +
therapy O +
. O +

Because O +
all O +
confirmed O +
TB O +
patients O +
in O +
Armenia O +
are O +
referred O +
to O +
one O +
of O +
these O +
dispensaries O +
for O +
treatment O +
, O +
this O +
population O +
represents O +
all O +
known O +
TB O +
cases O +
in O +
the O +
country O +
. O +

Therefore O +
, O +
all O +
culture O +
- O +
confirmed O +
TB O +
in O +
- O +
patients O +
present O +
at O +
the O +
time O +
of O +
the O +
interviewer O +
visits O +
were O +
eligible O +
for O +
inclusion O +
in O +
the O +
study O +
( O +
the O +
study O +
group O +
included O +
both O +
new O +
and O +
relapsed O +
patients O +
) O +
. O +

Our O +
systematic O +
sample O +
of O +
the O +
inpatient O +
TB O +
population O +
- O +
- O +
in O +
which O +
interviewers O +
visited O +
every O +
hospital O +
room O +
to O +
identify O +
patients O +
willing O +
to O +
participate O +
- O +
- O +
yielded O +
a O +
participation O +
rate O +
of O +
approximately O +
80 O +
% O +
( O +
a O +
total O +
of O +
240 O +
patients O +
) O +
. O +

Interviewers O +
collected O +
demographic O +
information O +
and O +
asked O +
each O +
patient O +
to O +
recall O +
when O +
they O +
first O +
began O +
to O +
feel O +
ill O +
, O +
what O +
symptoms O +
they O +
experienced O +
, O +
how O +
long O +
after O +
symptom O +
onset O +
they O +
waited O +
to O +
see O +
a O +
doctor O +
, O +
their O +
reasons O +
for O +
delaying O +
medical O +
evaluation O +
, O +
the O +
type O +
of O +
facility O +
at O +
which O +
they O +
first O +
sought O +
care O +
, O +
the O +
initial O +
diagnosis O +
, O +
if O +
they O +
had O +
been O +
referred O +
for O +
further O +
evaluation O +
, O +
and O +
their O +
adherence O +
to O +
treatment O +
once O +
diagnosed O +
with O +
TB O +
. O +

In O +
2006 O +
, O +
129 O +
of O +
the O +
planned O +
250 O +
surveys O +
were O +
completed O +
. O +

Data O +
collection O +
resumed O +
in O +
the O +
fall O +
of O +
2007 O +
and O +
a O +
total O +
of O +
240 O +
interviews O +
were O +
conducted O +
. O +

Summary O +

Kindt O +
et O +
al O +
. O +
1 O +
published O +
a O +
report O +
entitled O +
" O +
Intestinal O +
immune O +
activation O +
in O +
presumed O +
post O +
- O +
infectious O +
functional O +
syspepsia O +
" O +
in O +
the O +
August O +
issue O +
of O +
Neurogastroenterology O +
and O +
Motility O +
in O +
2009 O +
. O +

By O +
comparing O +
the O +
signs O +
of O +
inflammation O +
and O +
the O +
degree O +
of O +
hyperplasia O +
of O +
the O +
enterochromaffin O +
cells O +
( O +
EC O +
) O +
in O +
duodenal O +
biopsies O +
obtained O +
from O +
patients O +
with O +
presumed O +
post O +
- O +
infectious O +
functional O +
dyspepsia O +
( O +
PI O +
- O +
FD O +
) O +
and O +
unspecified O +
- O +
onset O +
functional O +
dyspepsia O +
( O +
U O +
- O +
FD O +
) O +
, O +
they O +
showed O +
that O +
PI O +
- O +
FD O +
is O +
associated O +
with O +
persistence O +
of O +
focal O +
T O +
- O +
cell O +
aggregates O +
, O +
decrease O +
in O +
CD4 O +
+ O +
cells O +
and O +
increased O +
macrophage O +
counts O +
surrounding O +
the O +
crypts O +
, O +
without O +
any O +
significant O +
differences O +
in O +
the O +
numbers O +
of O +
EC O +
or O +
chromogranin O +
A O +
( O +
CA O +
) O +
- O +
positive O +
cells O +
( O +
mast O +
cells O +
) O +
. O +

This O +
finding O +
may O +
indicate O +
impaired O +
ability O +
of O +
the O +
immune O +
system O +
in O +
these O +
cases O +
to O +
terminate O +
the O +
inflammatory O +
response O +
after O +
an O +
acute O +
insult O +
. O +

Temporary O +
migration O +
module O +

A O +
temporary O +
migration O +
census O +
module O +
was O +
conducted O +
in O +
2002 O +
and O +
2007 O +
. O +

People O +
who O +
were O +
identified O +
as O +
temporary O +
migrants O +
were O +
entered O +
into O +
the O +
module O +
, O +
and O +
a O +
household O +
respondent O +
answered O +
questions O +
about O +
the O +
migration O +
. O +

Key O +
areas O +
included O +
the O +
duration O +
of O +
migration O +
, O +
destination O +
, O +
reasons O +
for O +
migration O +
, O +
return O +
pattern O +
, O +
communication O +
pattern O +
, O +
remittances O +
, O +
linked O +
moves O +
and O +
child O +
care O +
arrangements O +
. O +

Introduction O +

Tea O +
( O +
Camellia O +
sinensis O +
L O +
. O +
) O +
is O +
one O +
of O +
the O +
most O +
widely O +
consumed O +
beverages O +
in O +
the O +
world O +
. O +

( O +
- O +
) O +
- O +
Epigallocatechin O +
- O +
3 O +
- O +
O O +
- O +
gallate O +
( O +
EGCG O +
) O +
, O +
which O +
is O +
the O +
major O +
green O +
tea O +
catechin O +
present O +
in O +
the O +
leaves O +
, O +
is O +
believed O +
to O +
the O +
compound O +
most O +
responsible O +
for O +
the O +
health O +
benefits O +
attributed O +
to O +
tea O +
. O +

EGCG O +
was O +
reported O +
to O +
have O +
antioxidative O +
[ O +
1 O +
] O +
, O +
[ O +
2 O +
] O +
, O +
antimutagenic O +
[ O +
3 O +
] O +
, O +
anti O +
- O +
inflammatory O +
[ O +
4 O +
] O +
, O +
and O +
anticarcinogenic O +
activities O +
[ O +
5 O +
] O +
. O +

Although O +
the O +
EGCG O +
concentrations O +
required O +
to O +
elicit O +
the O +
anticancer O +
activity O +
have O +
been O +
shown O +
to O +
be O +
more O +
than O +
1 O +
microM O +
, O +
the O +
blood O +
level O +
of O +
EGCG O +
after O +
consuming O +
the O +
equivalent O +
of O +
2 O +
- O +
3 O +
cups O +
of O +
green O +
tea O +
was O +
0 O +
. O +
1 O +
- O +
0 O +
. O +
6 O +
microM O +
and O +
for O +
an O +
equivalent O +
of O +
7 O +
- O +
9 O +
cups O +
was O +
still O +
lower O +
than O +
1 O +
microM O +
[ O +
6 O +
] O +
, O +
[ O +
7 O +
] O +
. O +

In O +
a O +
cohort O +
study O +
, O +
daily O +
consumption O +
of O +
ten O +
cups O +
of O +
green O +
tea O +
was O +
required O +
for O +
the O +
cancer O +
preventive O +
effect O +
[ O +
8 O +
] O +
. O +

Moreover O +
, O +
adverse O +
effects O +
of O +
green O +
tea O +
, O +
mainly O +
hepatitis O +
, O +
by O +
consumption O +
of O +
high O +
doses O +
of O +
green O +
tea O +
have O +
been O +
reported O +
[ O +
9 O +
] O +
. O +

Therefore O +
, O +
it O +
is O +
important O +
to O +
enhance O +
the O +
pharmacologic O +
effect O +
of O +
EGCG O +
to O +
obtain O +
the O +
health O +
benefit O +
in O +
reasonable O +
concentration O +
in O +
daily O +
life O +
. O +

We O +
have O +
reported O +
that O +
the O +
cell O +
- O +
surface O +
binding O +
of O +
EGCG O +
and O +
its O +
derivatives O +
is O +
involved O +
in O +
their O +
biological O +
activities O +
[ O +
10 O +
] O +
- O +
[ O +
15 O +
] O +
. O +

We O +
have O +
identified O +
the O +
67 O +
- O +
kDa O +
laminin O +
receptor O +
( O +
67LR O +
) O +
as O +
a O +
cell O +
surface O +
receptor O +
for O +
EGCG O +
that O +
mediates O +
the O +
anticancer O +
activity O +
of O +
EGCG O +
[ O +
16 O +
] O +
. O +

67LR O +
has O +
been O +
shown O +
to O +
be O +
overexpressed O +
on O +
the O +
cell O +
surface O +
of O +
various O +
tumor O +
cells O +
[ O +
17 O +
] O +
. O +

It O +
was O +
postulated O +
that O +
67LR O +
plays O +
a O +
significant O +
role O +
in O +
the O +
tumor O +
progression O +
and O +
speculated O +
that O +
studies O +
conducted O +
to O +
define O +
the O +
function O +
of O +
67LR O +
could O +
provide O +
a O +
new O +
approach O +
to O +
cancer O +
prevention O +
. O +

Indeed O +
, O +
expression O +
of O +
67 O +
LR O +
confers O +
EGCG O +
responsiveness O +
to O +
tumor O +
cells O +
in O +
vivo O +
[ O +
18 O +
] O +
. O +

Vitamin O +
A O +
, O +
also O +
known O +
as O +
retinol O +
, O +
participates O +
in O +
physiological O +
activities O +
related O +
to O +
the O +
immune O +
system O +
, O +
maintenance O +
of O +
epithelial O +
and O +
mucosa O +
tissues O +
, O +
growth O +
, O +
reproduction O +
, O +
and O +
bone O +
development O +
. O +

It O +
comes O +
from O +
animal O +
sources O +
, O +
such O +
as O +
eggs O +
, O +
meat O +
, O +
milk O +
, O +
cheese O +
, O +
cream O +
, O +
liver O +
, O +
kidney O +
, O +
cod O +
and O +
halibut O +
fish O +
oil O +
. O +

In O +
vitro O +
and O +
in O +
animal O +
models O +
, O +
it O +
has O +
been O +
demonstrated O +
that O +
vitamin O +
A O +
is O +
involved O +
in O +
the O +
regulation O +
and O +
promotion O +
of O +
growth O +
and O +
differentiation O +
of O +
many O +
cells O +
[ O +
19 O +
] O +
. O +

The O +
visual O +
function O +
of O +
vitamin O +
A O +
depends O +
on O +
its O +
natural O +
and O +
synthetic O +
derivatives O +
, O +
retinoids O +
[ O +
20 O +
] O +
. O +

All O +
- O +
trans O +
- O +
retinoic O +
acid O +
( O +
ATRA O +
) O +
, O +
the O +
active O +
derivative O +
of O +
vitamin O +
A O +
, O +
has O +
been O +
well O +
documented O +
as O +
a O +
growth O +
and O +
differentiation O +
factor O +
in O +
many O +
tissues O +
and O +
cells O +
, O +
and O +
proved O +
to O +
be O +
an O +
effective O +
treatment O +
to O +
many O +
diseases O +
including O +
cancers O +
[ O +
21 O +
] O +
, O +
[ O +
22 O +
] O +
. O +

Retinoids O +
exert O +
their O +
physiological O +
activities O +
through O +
retinoid O +
receptor O +
nuclear O +
proteins O +
that O +
belong O +
to O +
the O +
superfamily O +
of O +
steroid O +
/ O +
thyroid O +
hormone O +
receptors O +
, O +
of O +
which O +
there O +
are O +
two O +
classes O +
, O +
retinoic O +
acid O +
receptors O +
( O +
RARs O +
) O +
and O +
the O +
retinoic O +
- O +
X O +
receptors O +
( O +
RXRs O +
) O +
, O +
each O +
of O +
which O +
has O +
three O +
subtypes O +
, O +
alpha O +
, O +
beta O +
, O +
and O +
gamma O +
[ O +
23 O +
] O +
, O +
[ O +
24 O +
] O +
. O +

The O +
natural O +
ligands O +
for O +
the O +
RARs O +
are O +
ATRA O +
and O +
its O +
stereoisomers O +
9 O +
- O +
cis O +
- O +
RA O +
and O +
13 O +
- O +
cis O +
- O +
RA O +
, O +
whereas O +
RXRs O +
are O +
activated O +
by O +
9 O +
- O +
cis O +
- O +
RA O +
only O +
. O +

ATRA O +
acts O +
through O +
RAR O +
to O +
transcriptionally O +
activate O +
target O +
genes O +
, O +
such O +
as O +
cytochrome O +
P450 O +
and O +
CRABI O +
[ O +
24 O +
] O +
. O +

This O +
study O +
was O +
designed O +
to O +
identify O +
a O +
food O +
component O +
that O +
could O +
be O +
effectively O +
used O +
in O +
combination O +
with O +
EGCG O +
and O +
to O +
investigate O +
the O +
mechanism O +
of O +
action O +
of O +
this O +
combination O +
. O +

By O +
using O +
in O +
vitro O +
and O +
in O +
vivo O +
systems O +
involving O +
a O +
highly O +
metastatic O +
mouse O +
B16 B-CellLine +
melanoma O +
cell O +
line O +
[ O +
25 O +
] O +
, O +
we O +
found O +
that O +
ATRA O +
enhances O +
the O +
antitumor O +
activity O +
of O +
EGCG O +
by O +
upregulating O +
the O +
67 O +
LR O +
expression O +
through O +
RAR O +
. O +

Comparison O +
of O +
the O +
molecular O +
organisation O +
of O +
the O +
tra O +
- O +
2 O +
of O +
A O +
. O +
obliqua O +
( O +
A O +
) O +
, O +
C O +
. O +
capitata O +
( O +
B O +
) O +
and O +
D O +
. O +
melanogaster O +
( O +
C O +
) O +
and O +
their O +
proteins O +
. O +

Exons O +
( O +
boxes O +
) O +
and O +
introns O +
( O +
dashed O +
lines O +
) O +
are O +
not O +
drawn O +
to O +
scale O +
. O +

The O +
numbers O +
inside O +
the O +
boxes O +
indicate O +
the O +
number O +
of O +
the O +
exon O +
. O +

The O +
beginning O +
and O +
the O +
end O +
of O +
the O +
ORF O +
are O +
indicated O +
by O +
ATG O +
and O +
TAA O +
respectively O +
. O +

AAA O +
stands O +
for O +
poly O +
- O +
A O +
( O +
+ O +
) O +
. O +

( O +
D O +
) O +
Expression O +
of O +
gene O +
tra O +
- O +
2 O +
of O +
A O +
. O +
obliqua O +
. O +

RT O +
- O +
PCR O +
analyses O +
of O +
total O +
RNA O +
from O +
ovaries O +
( O +
O O +
) O +
, O +
embryos O +
( O +
E O +
) O +
, O +
from O +
male O +
and O +
female O +
larvae O +
( O +
L O +
) O +
, O +
male O +
soma O +
( O +
head O +
plus O +
thorax O +
, O +
MS O +
) O +
and O +
female O +
soma O +
( O +
head O +
plus O +
thorax O +
, O +
FS O +
) O +
. O +

( O +
E O +
) O +
Expression O +
of O +
gene O +
tra O +
- O +
2 O +
of O +
A O +
. O +
obliqua O +
. O +

RT O +
- O +
PCR O +
analysis O +
of O +
total O +
RNA O +
from O +
A O +
. O +
obliqua O +
testis O +
. O +

Lane O +
1 O +
corresponds O +
to O +
PCR O +
with O +
primers O +
PM1 O +
and O +
P2 O +
; O +
lane O +
2 O +
corresponds O +
to O +
PCR O +
with O +
primers O +
P1 O +
and O +
P2 O +
( O +
see O +
location O +
of O +
primers O +
in O +
Figure O +
1A O +
) O +
. O +

( O +
F O +
) O +
Southern O +
- O +
blot O +
corresponding O +
to O +
the O +
gel O +
shown O +
in O +
( O +
E O +
) O +
and O +
hybridisation O +
with O +
a O +
probe O +
specific O +
for O +
intron O +
3 O +
of O +
A O +
. O +
obliqua O +
. O +

The O +
arrow O +
marks O +
the O +
hybridisation O +
to O +
the O +
higher O +
band O +
in O +
lane O +
1 O +
of O +
Figure O +
1E O +
. O +

The O +
size O +
of O +
the O +
mRNAs O +
encoding O +
the O +
proteins O +
shown O +
in O +
this O +
figure O +
are O +
: O +
1923 O +
bp O +
for O +
A O +
. O +
obliqua O +
mRNA O +
, O +
1113 O +
bp O +
for O +
C O +
. O +
capitata O +
mRNA O +
, O +
and O +
960 O +
, O +
1583 O +
and O +
1391 O +
bp O +
for O +
D O +
. O +
melanogaster O +
mRNAs O +
tra2 O +
- O +
179 O +
, O +
tra2 O +
- O +
226 O +
and O +
tra2 O +
- O +
264 O +
, O +
respectively O +
. O +

The O +
eukaryotic O +
parasite O +
Trypanosoma O +
brucei O +
is O +
able O +
to O +
import O +
inositol O +
from O +
the O +
environment O +
or O +
synthesize O +
it O +
de O +
novo O +
. O +

However O +
, O +
according O +
to O +
the O +
current O +
model O +
, O +
inositol O +
imported O +
from O +
the O +
environment O +
is O +
utilized O +
primarily O +
in O +
bulk O +
phosphatidylinositol O +
( O +
red O +
and O +
yellow O +
phospholipid O +
) O +
production O +
via O +
a O +
phosphatidylinositol O +
synthase O +
( O +
PIS O +
) O +
localized O +
to O +
the O +
Golgi O +
complex O +
. O +

Inositol O +
synthesized O +
de O +
novo O +
is O +
primarily O +
used O +
to O +
generate O +
phosphatidylinositol O +
that O +
is O +
used O +
for O +
production O +
of O +
glycosylphosphatidylinositols O +
( O +
GPIs O +
) O +
. O +

The O +
de O +
novo O +
- O +
synthesized O +
inositol O +
is O +
believed O +
to O +
be O +
utilized O +
mostly O +
for O +
GPI O +
production O +
because O +
the O +
IMPase O +
that O +
dephosphorylates O +
inositol O +
3 O +
- O +
phosphate O +
to O +
inositol O +
is O +
localized O +
to O +
the O +
ER O +
, O +
where O +
GPI O +
synthesis O +
occurs O +
. O +

Mutants O +
lacking O +
TbINO1 O +
are O +
inviable O +
because O +
of O +
diminished O +
GPI O +
production O +
. O +

2 O +
. O +

CLINICAL O +
PROTEOMICS O +
AT O +
THE O +
BEDSIDE O +

Clinically O +
- O +
based O +
proteomics O +
has O +
a O +
large O +
potential O +
for O +
the O +
development O +
of O +
strategies O +
which O +
aim O +
to O +
alleviate O +
risk O +
associated O +
with O +
cardiac O +
disease O +
. O +

Biomarkers O +
that O +
are O +
used O +
in O +
clinical O +
practice O +
are O +
highly O +
useful O +
in O +
that O +
they O +
support O +
medical O +
decision O +
making O +
, O +
by O +
complementing O +
other O +
diagnostic O +
tests O +
, O +
such O +
as O +
the O +
medical O +
history O +
, O +
physical O +
examination O +
, O +
and O +
various O +
other O +
special O +
tests O +
. O +

Theoretically O +
, O +
there O +
are O +
three O +
criteria O +
that O +
, O +
if O +
satisfied O +
, O +
would O +
provide O +
an O +
optimal O +
biomarker O +
of O +
the O +
disease O +
state O +
. O +

First O +
, O +
the O +
potential O +
biomarkers O +
must O +
be O +
easily O +
measurable O +
in O +
a O +
short O +
time O +
period O +
at O +
a O +
cost O +
that O +
is O +
practical O +
. O +

Second O +
, O +
elevation O +
of O +
this O +
protein O +
would O +
offer O +
diagnostic O +
information O +
that O +
was O +
not O +
previously O +
present O +
in O +
the O +
absence O +
of O +
the O +
protein O +
. O +

Third O +
, O +
the O +
information O +
obtained O +
would O +
aid O +
in O +
the O +
medical O +
decision O +
making O +
process O +
performed O +
by O +
the O +
clinician O +
[ O +
11 O +
] O +
. O +

Fulfillment O +
of O +
such O +
criteria O +
encourages O +
follow O +
- O +
up O +
of O +
such O +
a O +
biomarker O +
in O +
other O +
model O +
systems O +
or O +
patient O +
cohort O +
samples O +
. O +

For O +
instance O +
, O +
cardiac O +
troponin O +
I O +
has O +
been O +
previously O +
shown O +
to O +
fulfill O +
such O +
criteria O +
, O +
and O +
further O +
follow O +
- O +
up O +
in O +
patient O +
cohorts O +
is O +
underway O +
. O +

Recently O +
, O +
this O +
approach O +
was O +
utilized O +
to O +
ascertain O +
whether O +
Cardiac O +
Troponin O +
I O +
( O +
CTN O +
I O +
) O +
or O +
Creatine O +
Kinase O +
- O +
Myoglobin O +
( O +
CK O +
- O +
MB O +
) O +
could O +
be O +
used O +
as O +
short O +
- O +
term O +
or O +
long O +
- O +
term O +
markers O +
of O +
risk O +
associated O +
with O +
cardiac O +
surgery O +
[ O +
12 O +
] O +
. O +

In O +
this O +
study O +
, O +
a O +
patient O +
cohort O +
of O +
252 O +
individuals O +
who O +
had O +
undergone O +
cardiac O +
surgery O +
was O +
used O +
to O +
analyze O +
levels O +
of O +
these O +
two O +
proteins O +
in O +
blood O +
. O +

Not O +
only O +
was O +
CTN O +
- O +
I O +
shown O +
to O +
be O +
a O +
strong O +
predictor O +
of O +
mortality O +
, O +
but O +
increases O +
in O +
the O +
levels O +
of O +
this O +
protein O +
also O +
correlated O +
well O +
with O +
increases O +
in O +
mortality O +
. O +

Findings O +
from O +
this O +
study O +
support O +
the O +
utilization O +
of O +
patient O +
cohorts O +
as O +
a O +
means O +
to O +
ease O +
the O +
transition O +
from O +
bench O +
to O +
bedside O +
. O +

Titration O +
of O +
Ab O +
- O +
01 O +
inhibition O +
of O +
ex O +
vivo O +
response O +
to O +
rhIL21 O +

Samples O +
from O +
4 O +
individual O +
healthy O +
human O +
donors O +
were O +
pre O +
- O +
incubated O +
for O +
2 O +
hours O +
at O +
the O +
indicated O +
concentration O +
of O +
Ab O +
- O +
01 O +
or O +
the O +
control O +
IgG1TM O +
prior O +
to O +
addition O +
of O +
10 O +
ng O +
/ O +
mL O +
rhIL21 O +
and O +
2 O +
hr O +
incubation O +
, O +
and O +
the O +
effect O +
on O +
the O +
6 O +
biomarkers O +
was O +
then O +
assessed O +
( O +
Figures O +
4 O +
and O +
5 O +
) O +
. O +

For O +
the O +
first O +
2 O +
donors O +
tested O +
, O +
even O +
the O +
lowest O +
concentration O +
of O +
Ab O +
- O +
01 O +
( O +
0 O +
. O +
1 O +
mug O +
/ O +
mL O +
, O +
0 O +
. O +
66 O +
nM O +
) O +
resulted O +
in O +
complete O +
inhibition O +
of O +
the O +
rhIL21 O +
response O +
, O +
therefore O +
the O +
two O +
subsequent O +
donors O +
were O +
tested O +
at O +
increasing O +
concentrations O +
of O +
Ab O +
- O +
01 O +
starting O +
at O +
0 O +
. O +
003 O +
mug O +
/ O +
mL O +
. O +

Ab O +
- O +
01 O +
inhibited O +
the O +
response O +
of O +
all O +
6 O +
genes O +
in O +
all O +
4 O +
donors O +
. O +

IC50 O +
values O +
ranged O +
between O +
0 O +
. O +
003 O +
and O +
0 O +
. O +
015 O +
mug O +
/ O +
mL O +
Ab O +
- O +
01 O +
( O +
Figure O +
5 O +
) O +
. O +

Control O +
IgG1TM O +
had O +
no O +
significant O +
effect O +
on O +
rhIL21 O +
response O +
( O +
Figure4B O +
) O +
. O +

Figure O +
4 O +

Average O +
percent O +
inhibition O +
of O +
the O +
expression O +
level O +
of O +
6 O +
IL21 O +
- O +
responsive O +
genes O +
. O +

Percent O +
inhibition O +
values O +
were O +
calculated O +
based O +
on O +
RQ O +
( O +
relative O +
quantification O +
) O +
values O +
of O +
untreated O +
control O +
and O +
rhIL21 O +
- O +
treated O +
samples O +
for O +
each O +
of O +
the O +
4 O +
donors O +
, O +
and O +
subsequently O +
the O +
mean O +
and O +
standard O +
deviation O +
were O +
determined O +
for O +
each O +
gene O +
shown O +
. O +

A O +
: O +
Percent O +
inhibition O +
in O +
presence O +
of O +
Ab O +
- O +
01 O +
. O +

B O +
: O +
Percent O +
inhibition O +
in O +
presence O +
of O +
control O +
IgG1TM O +
. O +

Data O +
for O +
the O +
0 O +
. O +
1 O +
mug O +
/ O +
mL O +
, O +
0 O +
. O +
3 O +
mug O +
/ O +
mL O +
and O +
1 O +
mug O +
/ O +
mL O +
concentrations O +
were O +
generated O +
using O +
4 O +
donors O +
. O +

Data O +
for O +
the O +
higher O +
and O +
the O +
lower O +
concentrations O +
were O +
generated O +
using O +
2 O +
donors O +
. O +

Figure O +
5 O +

Inhibition O +
by O +
Ab O +
- O +
01 O +
at O +
the O +
indicated O +
concentration O +
is O +
shown O +
for O +
6 O +
IL21 O +
- O +
responsive O +
genes O +
. O +

IC50 O +
values O +
of O +
inhibition O +
curves O +
shown O +
in O +
Figure O +
4A O +
were O +
calculated O +
using O +
curve O +
fit O +
( O +
XLfit O +
) O +
program O +
for O +
each O +
of O +
the O +
referred O +
biomarker O +
genes O +
. O +

Values O +
for O +
the O +
0 O +
. O +
1 O +
mug O +
/ O +
mL O +
, O +
0 O +
. O +
3 O +
mug O +
/ O +
mL O +
and O +
1 O +
mug O +
/ O +
mL O +
concentrations O +
were O +
generated O +
using O +
4 O +
donors O +
. O +

Data O +
for O +
the O +
higher O +
and O +
the O +
lower O +
concentrations O +
were O +
generated O +
using O +
2 O +
donors O +
each O +
. O +

Large O +
nodular O +
hepatic O +
flexure O +
lesions O +
as O +
seen O +
on O +
Colonoscopy O +
. O +

MOR1 O -
K O +
expression O +
and O +
binding O +
pattern O +
. O +

( O +
A O +
) O +
The O +
schematic O +
diagram O +
illustrates O +
the O +
exonic O +
composition O +
and O +
relative O +
positions O +
of O +
PCR O +
primers O +
designed O +
to O +
amplify O +
the O +
major O +
MOR1 O +
isoform O +
and O +
the O +
newly O +
identified O +
alternative O +
MOR1 O -
K O +
isoform O +
. O +

The O +
relative O +
positions O +
of O +
translation O +
initiation O +
start O +
and O +
stop O +
codons O +
are O +
designated O +
by O +
ATG O +
and O +
TGA O +
, O +
respectively O +
. O +

The O +
predicted O +
protein O +
structure O +
of O +
MOR1 O +
and O +
MOR1 O -
K O +
isoforms O +
is O +
schematically O +
presented O +
. O +

Translation O +
of O +
the O +
MOR1 O -
K O +
variant O +
results O +
in O +
a O +
6TM O +
receptor O +
, O +
truncated O +
at O +
the O +
N O +
- O +
terminus O +
. O +

( O +
B O +
) O +
Real O +
- O +
time O +
PCR O +
was O +
performed O +
on O +
total O +
RNA O +
samples O +
from O +
the O +
human O +
brain O +
regions O +
known O +
to O +
express O +
MOR1 O +
. O +

Primers O +
specific O +
for O +
exons O +
1 O +
and O +
2 O +
were O +
used O +
to O +
measure O +
MOR1 O +
and O +
primers O +
specific O +
for O +
exons O +
13 O +
and O +
exon O +
2 O +
were O +
used O +
to O +
measure O +
MOR1 O -
K O +
[ O +
32 O +
] O +
. O +

GAP3DH O +
was O +
used O +
as O +
a O +
control O +
for O +
cDNA O +
loading O +
and O +
PCR O +
efficiency O +
. O +

( O +
C O +
) O +
Confocal O +
images O +
of O +
C O +
- O +
terminally O +
MYC O +
- O +
tagged O +
MOR1 O +
or O +
FLAG O +
- O +
tagged O +
MOR1 O -
K O +
overexpressed O +
in O +
HEK293 B-CellLine +
cells O +
and O +
stained O +
with O +
either O +
Anti O +
- O +
MYC O +
- O +
Tag O +
Antibody O +
( O +
Alexa O +
Fluor O +
647 O +
Conjugate O +
) O +
or O +
Anti O +
- O +
DYKDDDDK O +
Tag O +
Antibody O +
( O +
Alexa O +
Fluor O +
555 O +
conjugate O +
) O +
. O +

Cells O +
transfected O +
with O +
MOR1 O +
showed O +
membrane O +
expression O +
of O +
receptor O +
, O +
while O +
cell O +
transfected O +
with O +
MOR1 O -
K O +
express O +
receptor O +
only O +
intracellular O +
. O +

( O +
D O +
) O +
Confocal O +
images O +
of O +
C O +
- O +
terminally O +
FLAG O +
- O +
tagged O +
MOR1 O -
K O +
overexpressed O +
in O +
Be2C B-CellLine +
cells O +
and O +
stained O +
with O +
either O +
Anti O +
- O +
FLAG O +
M2 O +
Antibody O +
Alexa O +
Fluor O +
Conjugate O +
or O +
fluorescent O +
- O +
labeled O +
naloxone O +
( O +
FNAL O +
) O +
. O +

Cells O +
transfected O +
with O +
MOR1 O -
K O +
showed O +
intracellular O +
retention O +
of O +
FNAL O +
that O +
co O +
- O +
localized O +
with O +
antibody O +
- O +
labeled O +
receptor O +
. O +

( O +
E O +
) O +
The O +
binding O +
of O +
naloxone O +
to O +
MOR1 O -
K O +
was O +
assessed O +
using O +
flow O +
cytometry O +
to O +
measure O +
FNAL O +
retention O +
. O +

Be2C B-CellLine +
cells O +
transfected O +
with O +
either O +
MOR1 O +
or O +
MOR1 O -
K O +
isoforms O +
showed O +
increased O +
retention O +
of O +
FNAL O +
at O +
concentrations O +
of O +
0 O +
. O +
1 O +
and O +
1 O +
muM O +
. O +

FNAL O +
retention O +
was O +
abolished O +
in O +
the O +
presence O +
of O +
10 O +
muM O +
unlabelled O +
naloxone O +
( O +
Nal O +
) O +
. O +

In O +
panel O +
E O +
, O +
data O +
are O +
presented O +
as O +
mean O +
+ O +
SEM O +
. O +

* O +
P O +
< O +
0 O +
. O +
05 O +
different O +
from O +
controls O +
) O +
. O +

Water O +
emerging O +
from O +
the O +
yoke O +
adapter O +
of O +
the O +
nitrous O +
oxide O +
hose O +

Treatment O +
for O +
patients O +
with O +
diabetes O +

It O +
is O +
notable O +
that O +
treatment O +
of O +
diabetes O +
has O +
not O +
been O +
directly O +
monitored O +
by O +
OECD O +
indicators O +
, O +
largely O +
due O +
to O +
complexity O +
in O +
data O +
collection O +
. O +

Treatment O +
is O +
tailored O +
for O +
individuals O +
depending O +
on O +
the O +
patient O +
' O +
s O +
disease O +
status O +
, O +
and O +
plays O +
a O +
crucial O +
role O +
in O +
diabetes O +
management O +
. O +

Clinical O +
trials O +
have O +
found O +
that O +
a O +
one O +
percentage O +
point O +
reduction O +
in O +
HbA1c O +
levels O +
would O +
reduce O +
micro O +
- O +
vascular O +
complications O +
by O +
25 O +
% O +
to O +
30 O +
% O +
[ O +
49 O +
, O +
50 O +
] O +
and O +
a O +
10 O +
mmHg O +
reduction O +
in O +
blood O +
pressure O +
would O +
decrease O +
macro O +
- O +
and O +
micro O +
- O +
vascular O +
complications O +
and O +
death O +
rates O +
by O +
32 O +
% O +
[ O +
51 O +
] O +
. O +

Improved O +
control O +
of O +
blood O +
lipids O +
can O +
reduce O +
risk O +
of O +
coronary O +
heart O +
disease O +
by O +
39 O +
% O +
and O +
risk O +
of O +
death O +
by O +
43 O +
% O +
[ O +
52 O +
] O +
. O +

RAND O +
' O +
s O +
Quality O +
Assessment O +
Tools O +
System O +
offers O +
indicators O +
relating O +
to O +
diabetes O +
treatment O +
[ O +
53 O +
] O +
, O +
and O +
application O +
of O +
these O +
indicators O +
in O +
a O +
national O +
study O +
in O +
the O +
US O +
has O +
provided O +
insight O +
into O +
adherence O +
to O +
recommended O +
treatment O +
regimens O +
. O +

For O +
people O +
with O +
newly O +
diagnosed O +
diabetes O +
56 O +
% O +
received O +
dietary O +
and O +
exercise O +
counselling O +
. O +

In O +
type O +
2 O +
diabetes O +
patients O +
, O +
use O +
of O +
oral O +
hypoglycaemic O +
agents O +
for O +
those O +
inadequately O +
controlled O +
on O +
dietary O +
therapy O +
was O +
38 O +
% O +
and O +
use O +
of O +
insulin O +
for O +
those O +
inadequately O +
controlled O +
on O +
oral O +
hypoglycaemics O +
was O +
39 O +
% O +
. O +

Fifty O +
- O +
five O +
percent O +
of O +
diabetics O +
were O +
offered O +
an O +
ACE O +
inhibitor O +
within O +
3 O +
months O +
of O +
the O +
notation O +
of O +
proteinuria O +
unless O +
contraindicated O +
. O +

The O +
AusDiab O +
study O +
reported O +
the O +
treatment O +
pattern O +
among O +
Australian O +
adults O +
with O +
type O +
2 O +
diabetes O +
[ O +
37 O +
] O +
. O +

While O +
32 O +
% O +
of O +
diabetes O +
patients O +
were O +
on O +
diet O +
regimen O +
only O +
, O +
58 O +
% O +
used O +
oral O +
hypoglycaemic O +
agents O +
and O +
diet O +
only O +
, O +
and O +
another O +
10 O +
% O +
took O +
insulin O +
. O +

Bailie O +
and O +
colleagues O +
reported O +
pharmaceutical O +
interventions O +
for O +
diabetes O +
patients O +
in O +
remote O +
Aboriginal O +
communities O +
in O +
the O +
Northern O +
Territory O +
[ O +
54 O +
] O +
. O +

During O +
the O +
3 O +
- O +
years O +
study O +
period O +
, O +
75 O +
- O +
79 O +
% O +
of O +
Aboriginal O +
patients O +
took O +
oral O +
hypoglycaemic O +
agents O +
, O +
and O +
4 O +
- O +
7 O +
% O +
used O +
insulin O +
. O +

The O +
pedigree O +
of O +
a O +
Korean O +
family O +
with O +
macular O +
dystrophy O +
demonstrating O +
the O +
characteristics O +
of O +
an O +
autosomal O +
dominant O +
inheritance O +
trait O +
. O +

Histological O +
analysis O +

A O +
cross O +
- O +
section O +
of O +
the O +
distal O +
colon O +
( O +
2 O +
cm O +
) O +
was O +
fixed O +
in O +
10 O +
% O +
paraformaldehyde O +
solution O +
. O +

Afterwards O +
, O +
it O +
was O +
cut O +
into O +
small O +
fragments O +
, O +
dehydrated O +
through O +
an O +
ethanol O +
series O +
( O +
70 O +
% O +
- O +
100 O +
% O +
) O +
, O +
cleared O +
in O +
xylol O +
and O +
embedded O +
in O +
paraffin O +
. O +

The O +
fragments O +
were O +
sliced O +
into O +
5 O +
mum O +
thick O +
sections O +
and O +
stained O +
with O +
hematoxylin O +
- O +
eosin O +
. O +

Histological O +
evaluation O +
was O +
done O +
by O +
a O +
pathologist O +
who O +
was O +
blinded O +
to O +
the O +
experimental O +
groups O +
, O +
and O +
it O +
was O +
based O +
on O +
the O +
intensity O +
of O +
mononuclear O +
and O +
polymorphonuclear O +
infiltrates O +
in O +
the O +
lamina O +
propria O +
, O +
crypt O +
dilation O +
, O +
cellular O +
destruction O +
and O +
mucosal O +
ulceration O +
. O +

Histopathological O +
changes O +
were O +
graded O +
according O +
to O +
the O +
degree O +
of O +
inflammation O +
using O +
the O +
following O +
scale O +
: O +
absent O +
( O +
0 O +
) O +
, O +
light O +
( O +
1 O +
) O +
, O +
moderate O +
( O +
2 O +
) O +
and O +
intense O +
( O +
3 O +
) O +
, O +
and O +
the O +
numbers O +
represented O +
the O +
inflammation O +
score O +
( O +
IS O +
) O +
. O +

Results O +
were O +
expressed O +
as O +
mean O +
values O +
of O +
IS O +
+ O +
/ O +
- O +
standard O +
error O +
of O +
the O +
mean O +
( O +
SEM O +
) O +
for O +
each O +
experimental O +
group O +
. O +

Authors O +
' O +
contributions O +

MBH O +
made O +
the O +
pathological O +
diagnosis O +
and O +
was O +
responsible O +
for O +
conception O +
and O +
final O +
approval O +
of O +
the O +
manuscript O +
. O +

MB O +
carried O +
out O +
the O +
literature O +
search O +
and O +
drafted O +
the O +
manuscript O +
. O +

IC O +
carried O +
out O +
the O +
surgical O +
procedure O +
and O +
reviewed O +
the O +
manuscript O +
. O +

RM O +
carried O +
out O +
the O +
surgical O +
procedure O +
, O +
provided O +
clinical O +
details O +
, O +
followed O +
up O +
our O +
patient O +
and O +
obtained O +
her O +
consent O +
to O +
publish O +
this O +
case O +
report O +
. O +

All O +
authors O +
read O +
and O +
approved O +
the O +
final O +
manuscript O +
. O +

The O +
effect O +
of O +
PCL O +
elevation O +

Our O +
hypothesis O +
that O +
the O +
dynamics O +
of O +
the O +
flexion O +
gap O +
depend O +
on O +
the O +
orientation O +
of O +
the O +
PCL O +
was O +
confirmed O +
. O +

Distraction O +
of O +
the O +
knee O +
with O +
a O +
low O +
PCL O +
elevation O +
angle O +
( O +
i O +
. O +
e O +
. O +
a O +
flat O +
PCL O +
) O +
resulted O +
in O +
greater O +
increase O +
in O +
gap O +
height O +
than O +
distraction O +
of O +
a O +
knee O +
with O +
a O +
steep O +
PCL O +
. O +

This O +
result O +
was O +
to O +
be O +
expected O +
; O +
when O +
the O +
gap O +
between O +
the O +
tibia O +
and O +
femur O +
was O +
increased O +
, O +
the O +
increase O +
in O +
PCL O +
tension O +
resulted O +
in O +
the O +
tibia O +
pivoting O +
around O +
the O +
femoral O +
insertion O +
of O +
the O +
PCL O +
. O +

Thus O +
, O +
the O +
greatest O +
increase O +
in O +
gap O +
height O +
will O +
occur O +
when O +
the O +
PCL O +
is O +
flat O +
. O +

Taking O +
this O +
finding O +
into O +
consideration O +
, O +
the O +
surgeon O +
should O +
be O +
aware O +
of O +
the O +
strong O +
effect O +
of O +
PCL O +
elevation O +
on O +
the O +
relationship O +
between O +
gap O +
height O +
increase O +
and O +
tibial O +
translation O +
. O +

A O +
flat O +
PCL O +
will O +
lead O +
to O +
a O +
mean O +
anterior O +
tibial O +
translation O +
of O +
1 O +
. O +
7 O +
mm O +
when O +
the O +
gap O +
is O +
distracted O +
1 O +
mm O +
. O +

A O +
knee O +
with O +
a O +
steep O +
PCL O +
will O +
even O +
translate O +
2 O +
. O +
3 O +
mm O +
on O +
average O +
with O +
1 O +
mm O +
of O +
gap O +
distraction O +
. O +

If O +
the O +
PCL O +
were O +
the O +
only O +
structure O +
that O +
was O +
tensioned O +
with O +
distraction O +
of O +
the O +
flexion O +
gap O +
, O +
then O +
at O +
100 O +
N O +
it O +
would O +
be O +
oriented O +
vertically O +
. O +

This O +
is O +
not O +
the O +
case O +
, O +
and O +
therefore O +
other O +
structures O +
such O +
as O +
the O +
collateral O +
ligaments O +
must O +
have O +
restrained O +
the O +
translation O +
. O +

From O +
an O +
anatomical O +
point O +
of O +
view O +
, O +
the O +
collateral O +
structures O +
are O +
the O +
only O +
structures O +
that O +
could O +
have O +
had O +
a O +
restraining O +
function O +
on O +
vertical O +
movements O +
. O +

For O +
obvious O +
reasons O +
, O +
in O +
this O +
in O +
vivo O +
study O +
we O +
could O +
not O +
test O +
what O +
would O +
have O +
happened O +
to O +
the O +
orientation O +
of O +
the O +
PCL O +
when O +
the O +
collateral O +
structures O +
were O +
resected O +
. O +

In O +
addition O +
, O +
the O +
PCL O +
elevation O +
angle O +
at O +
100 O +
N O +
influenced O +
the O +
increase O +
in O +
PCL O +
elevation O +
angle O +
between O +
100 O +
N O +
and O +
200 O +
N O +
( O +
DeltaPCLe O +
) O +
. O +

This O +
seems O +
logical O +
: O +
a O +
flat O +
PCL O +
can O +
be O +
recruited O +
more O +
easily O +
whereas O +
knees O +
with O +
a O +
steep O +
PCL O +
might O +
already O +
be O +
tensioned O +
at O +
100 O +
N O +
so O +
that O +
a O +
further O +
increase O +
in O +
PCL O +
elevation O +
angle O +
would O +
be O +
hard O +
to O +
achieve O +
. O +

However O +
, O +
steep O +
PCLs O +
are O +
not O +
necessarily O +
recruited O +
more O +
than O +
flat O +
PCLs O +
. O +

Furthermore O +
, O +
the O +
situation O +
during O +
implantation O +
of O +
a O +
TKR O +
is O +
quite O +
unnatural O +
: O +
we O +
investigated O +
the O +
PCL O +
elevation O +
after O +
the O +
tibia O +
was O +
cut O +
. O +

Breast O +
cancer O +

The O +
incidence O +
of O +
breast O +
cancer O +
is O +
no O +
higher O +
than O +
in O +
the O +
rest O +
of O +
the O +
population O +
. O +

Tamoxifen O +
should O +
not O +
be O +
used O +
as O +
it O +
may O +
worsen O +
symptoms O +
[ O +
43 O +
] O +
. O +

Women O +
need O +
also O +
specific O +
management O +
for O +
treatment O +
of O +
HAE O +
. O +

Short O +
term O +
prophylaxis O +
: O +
three O +
options O +
are O +
available O +
: O +
attenuated O +
androgens O +
, O +
tranexamic O +
acid O +
or O +
C1Inh O +
concentrate O +
. O +

There O +
is O +
no O +
specific O +
problem O +
for O +
the O +
use O +
of O +
theses O +
drugs O +
for O +
short O +
course O +
in O +
female O +
patients O +
. O +

In O +
case O +
of O +
short O +
term O +
prophylaxis O +
with O +
attenuated O +
androgens O +
, O +
no O +
virilisation O +
has O +
been O +
observed O +
[ O +
44 O +
, O +
45 O +
] O +
. O +

Acute O +
attack O +
treatment O +
: O +
there O +
is O +
no O +
specific O +
problem O +
for O +
the O +
use O +
of O +
C1inh O +
concentrate O +
, O +
tranexamic O +
acid O +
, O +
icatibant O +
; O +
or O +
ecallantide O +
in O +
female O +
patients O +
. O +

Pteris O +
vittata O +

RNA O +
extraction O +
and O +
reverse O +
transcription O +

Total O +
RNA O +
were O +
extracted O +
from O +
cells O +
using O +
either O +
Trizol O +
reagent O +
( O +
Invitrogen O +
) O +
or O +
RNeasy O +
kit O +
( O +
Qiagen O +
) O +
and O +
treated O +
with O +
DNaseI O +
reagent O +
( O +
Macherey O +
- O +
Nagel O +
) O +
for O +
30 O +
min O +
at O +
room O +
temperature O +
. O +

Reverse O +
transcriptions O +
were O +
performed O +
using O +
1microg O +
total O +
RNA O +
and O +
the O +
High O +
capacity O +
cDNA O +
reverse O +
transcription O +
kit O +
with O +
RNase O +
Inhibitor O +
( O +
Applied O +
Biosystems O +
) O +
. O +

Intervention O +

Patients O +
' O +
initial O +
introduction O +
to O +
the O +
Wrist O +
Extension O +
Dynasplint O +
( O +
WED O +
) O +
system O +
, O +
[ O +
Dynasplint O +
Systems O +
, O +
Inc O +
. O +
, O +
Severna O +
Park O +
, O +
MD O +
, O +
USA O +
] O +
included O +
customized O +
fitting O +
( O +
wrist O +
length O +
, O +
width O +
, O +
and O +
girth O +
so O +
that O +
the O +
force O +
and O +
counter O +
force O +
straps O +
could O +
be O +
properly O +
aligned O +
) O +
and O +
training O +
on O +
donning O +
and O +
doffing O +
of O +
the O +
device O +
. O +

( O +
See O +
figure O +
1 O +
. O +
) O +
Verbal O +
and O +
written O +
instructions O +
were O +
provided O +
throughout O +
the O +
duration O +
of O +
treatment O +
for O +
safety O +
, O +
general O +
wear O +
and O +
care O +
, O +
and O +
tension O +
setting O +
goals O +
based O +
on O +
patient O +
tolerance O +
. O +

Figure O +
1 O +

Wrist O +
Extension O +
Dynasplint O +
. O +

Each O +
patient O +
initially O +
wore O +
the O +
WED O +
for O +
4 O +
- O +
6 O +
continuous O +
hours O +
at O +
an O +
initial O +
tension O +
setting O +
of O +
# O +
2 O +
( O +
0 O +
. O +
1 O +
foot O +
pounds O +
of O +
torque O +
) O +
. O +

This O +
duration O +
was O +
for O +
acclimatization O +
to O +
the O +
system O +
; O +
then O +
patients O +
were O +
instructed O +
to O +
wear O +
the O +
WED O +
system O +
at O +
night O +
while O +
sleeping O +
for O +
6 O +
- O +
8 O +
hours O +
of O +
continuous O +
wear O +
. O +

After O +
each O +
patient O +
was O +
comfortable O +
wearing O +
the O +
unit O +
for O +
one O +
week O +
at O +
tension O +
level O +
# O +
2 O +
, O +
they O +
were O +
instructed O +
to O +
increase O +
the O +
tension O +
level O +
to O +
# O +
3 O +
( O +
0 O +
. O +
3 O +
ft O +
lbs O +
. O +
) O +
and O +
make O +
continual O +
increases O +
every O +
two O +
weeks O +
. O +

If O +
prolonged O +
soreness O +
followed O +
a O +
session O +
( O +
soreness O +
for O +
more O +
than O +
15 O +
minutes O +
) O +
the O +
patient O +
was O +
instructed O +
to O +
decrease O +
the O +
tension O +
one O +
half O +
a O +
setting O +
for O +
two O +
days O +
until O +
they O +
were O +
comfortable O +
wearing O +
it O +
for O +
6 O +
- O +
8 O +
hours O +
at O +
the O +
new O +
tension O +
setting O +
. O +

The O +
majority O +
of O +
all O +
patients O +
reached O +
level O +
# O +
5 O +
( O +
0 O +
. O +
8 O +
foot O +
pounds O +
of O +
torque O +
) O +
by O +
the O +
end O +
of O +
two O +
months O +
. O +

All O +
range O +
of O +
motion O +
measurements O +
were O +
recorded O +
by O +
the O +
prescribing O +
clinician O +
. O +

Differential O +
expression O +
of O +
drug O +
- O +
induced O +
drug O +
targets O +

Integrating O +
4849 O +
CMap O +
arrays O +
with O +
40 O +
, O +
656 O +
drug O +
target O +
relations O +
from O +
STITCH O +
resulted O +
in O +
a O +
set O +
of O +
1 O +
, O +
290 O +
drug O +
- O +
target O +
relations O +
for O +
which O +
a O +
genome O +
- O +
wide O +
cellular O +
response O +
is O +
available O +
. O +

We O +
found O +
that O +
thirteen O +
out O +
of O +
167 O +
distinct O +
drug O +
targets O +
in O +
this O +
set O +
( O +
8 O +
% O +
; O +
86 O +
drug O +
target O +
relations O +
) O +
are O +
subjected O +
to O +
significant O +
differential O +
expression O +
upon O +
drug O +
treatment O +
( O +
Figure O +
3 O +
) O +
by O +
comparing O +
the O +
drug O +
- O +
induced O +
expression O +
changes O +
of O +
the O +
drug O +
target O +
against O +
all O +
other O +
treatments O +
present O +
in O +
CMap O +
( O +
see O +
methods O +
) O +
. O +

We O +
found O +
supporting O +
evidence O +
in O +
the O +
literature O +
for O +
seven O +
out O +
of O +
thirteen O +
( O +
q O +
- O +
value O +
< O +
0 O +
. O +
05 O +
) O +
significant O +
differential O +
regulations O +
of O +
drug O +
targets O +
shown O +
in O +
Figure O +
3 O +
, O +
confirming O +
the O +
rationale O +
and O +
predictive O +
power O +
of O +
our O +
systematic O +
approach O +
. O +

For O +
the O +
remaining O +
six O +
targets O +
we O +
can O +
predict O +
a O +
hitherto O +
unknown O +
drug O +
- O +
induced O +
differential O +
regulation O +
. O +

10 O +
. O +
1371 O +
/ O +
journal O +
. O +
pcbi O +
. O +
1000925 O +
. O +
g003 O +
Figure O +
3 O +

Drug O +
- O +
induced O +
differentially O +
regulated O +
drug O +
targets O +
. O +

Anova O +
is O +
used O +
to O +
assess O +
the O +
significance O +
of O +
the O +
differential O +
expression O +
of O +
drug O +
- O +
induced O +
drug O +
targets O +
against O +
the O +
mRNA O +
changes O +
of O +
the O +
same O +
gene O +
in O +
the O +
population O +
of O +
heterogeneous O +
drug O +
treatments O +
from O +
CMap O +
. O +

The O +
genes O +
are O +
mainly O +
ordered O +
based O +
on O +
their O +
q O +
- O +
values O +
as O +
provided O +
in O +
Table O +
S1 O +
. O +

In O +
the O +
scatter O +
plots O +
, O +
inhibitors O +
/ O +
activators O +
are O +
labeled O +
in O +
red O +
/ O +
green O +
respectively O +
and O +
grey O +
represents O +
all O +
other O +
treatments O +
present O +
in O +
CMap O +
. O +

The O +
identified O +
, O +
differentially O +
regulated O +
drug O +
targets O +
are O +
enriched O +
in O +
G O +
- O +
protein O +
coupled O +
receptors O +
( O +
GPCRs O +
) O +
( O +
Figure O +
S4 O +
) O +
, O +
in O +
agreement O +
with O +
previous O +
reports O +
that O +
members O +
of O +
the O +
GPCR O +
family O +
are O +
generally O +
regulated O +
by O +
several O +
mechanisms O +
including O +
receptor O +
desensitization O +
, O +
endocytosis O +
at O +
the O +
protein O +
level O +
and O +
regulation O +
of O +
the O +
cellular O +
receptor O +
content O +
[ O +
18 O +
] O +
, O +
[ O +
19 O +
] O +
. O +

In O +
the O +
three O +
cancer O +
cell O +
lines O +
used O +
, O +
we O +
observe O +
agonist O +
- O +
induced O +
down O +
- O +
regulation O +
of O +
GPCR O +
mRNAs O +
for O +
beta O +
- O +
2 O +
adrenergic O +
receptor O +
( O +
ADRB2 O +
) O +
, O +
prostaglandin O +
E2 O +
receptor O +
subtype O +
EP2 O +
and O +
prostaglandin O +
E4 O +
receptor O +
subtype O +
EP4 O +
( O +
Figure O +
3 O +
, O +
Genes O +
3 O +
, O +
4 O +
, O +
12 O +
) O +
, O +
which O +
were O +
previously O +
reported O +
in O +
DDT1 B-CellLine +
MF I-CellLine +
- I-CellLine +
2 I-CellLine +
smooth O +
muscle O +
cells O +
( O +
ADRB2 O +
) O +
and O +
293 B-CellLine +
- I-CellLine +
EBNA I-CellLine +
human O +
embryonic O +
kidney O +
cells O +
( O +
prostaglandin O +
E2 O +
/ O +
E4 O +
receptor O +
subtypes O +
EP2 O +
/ O +
EP4 O +
) O +
[ O +
20 O +
] O +
, O +
[ O +
21 O +
] O +
. O +

This O +
indicates O +
that O +
drugs O +
can O +
induce O +
similar O +
feedback O +
loops O +
in O +
a O +
wide O +
variety O +
of O +
cell O +
types O +
. O +

However O +
, O +
we O +
can O -
not O +
rule O +
out O +
that O +
cross O +
- O +
regulation O +
among O +
signaling O +
pathways O +
may O +
be O +
responsible O +
for O +
the O +
regulation O +
of O +
GPCR O +
mRNAs O +
as O +
it O +
has O +
been O +
described O +
before O +
[ O +
22 O +
] O +
. O +

For O +
example O +
, O +
it O +
has O +
been O +
shown O +
that O +
a O +
beta O +
adrenergic O +
mRNA O +
- O +
binding O +
protein O +
, O +
ELAV O +
- O +
like O +
protein O +
1 O +
( O +
ELAVL1 O +
) O +
can O +
be O +
induced O +
by O +
ADRB2 O +
agonist O +
or O +
elevated O +
levels O +
of O +
cyclic O +
adenosine O +
monophosphate O +
( O +
cAMP O +
) O +
[ O +
22 O +
] O +
, O +
[ O +
23 O +
] O +
and O +
destabilizes O +
ADRB2 O +
mRNA O +
. O +

The O +
ELAVL1 O +
protein O +
binds O +
to O +
GPCR O +
mRNAs O +
and O +
recognizes O +
a O +
cognate O +
sequence O +
located O +
at O +
the O +
3 O +
' O +
- O +
UTR O +
of O +
ADRB2 O +
, O +
proteinase O +
- O +
activated O +
receptor O +
and O +
M2 O +
, O +
M3 O +
muscarinic O +
acetylcholine O +
receptor O +
mRNAs O +
[ O +
24 O +
] O +
, O +
[ O +
25 O +
] O +
. O +

Therefore O +
cAMP O +
provides O +
cross O +
- O +
talk O +
among O +
GPCR O +
regulatory O +
networks O +
. O +

However O +
, O +
it O +
is O +
shown O +
that O +
intracellular O +
cAMP O +
accumulation O +
is O +
not O +
the O +
only O +
factor O +
contributing O +
to O +
the O +
reduction O +
of O +
ADRB2 O +
mRNA O +
levels O +
[ O +
20 O +
] O +
. O +

Moreover O +
, O +
we O +
find O +
that O +
GPCR O +
- O +
targeting O +
drugs O +
regulate O +
the O +
transcription O +
of O +
their O +
specific O +
targets O +
( O +
Figure O +
S5 O +
) O +
. O +

We O +
conclude O +
that O +
in O +
addition O +
to O +
the O +
cross O +
- O +
regulation O +
of O +
G O +
- O +
protein O +
signaling O +
pathways O +
drug O +
target O +
- O +
specific O +
feedback O +
loops O +
are O +
also O +
responsible O +
for O +
the O +
regulation O +
of O +
drug O +
target O +
mRNAs O +
. O +

In O +
addition O +
to O +
cross O +
- O +
regulation O +
of O +
multiple O +
drugs O +
through O +
the O +
same O +
signaling O +
pathways O +
, O +
promiscuous O +
drugs O +
targeting O +
multiple O +
proteins O +
may O +
cause O +
complex O +
regulatory O +
networks O +
. O +

In O +
order O +
to O +
explore O +
the O +
cross O +
- O +
regulation O +
of O +
drug O +
targets O +
induced O +
by O +
a O +
promiscuous O +
drug O +
, O +
we O +
searched O +
and O +
found O +
that O +
259 O +
out O +
of O +
466 O +
total O +
drugs O +
are O +
multi O +
- O +
target O +
drugs O +
and O +
4 O +
of O +
these O +
drugs O +
act O +
on O +
multiple O +
differentially O +
regulated O +
drug O +
targets O +
upon O +
drug O +
treatment O +
. O +

For O +
example O +
, O +
Podophyllotoxin O +
used O +
in O +
various O +
chemotherapies O +
is O +
known O +
to O +
target O +
both O +
tubulin O +
beta O +
2C O +
and O +
DNA O +
topoisomerase O +
2 O +
- O +
alpha O +
. O +

The O +
tubulin O +
beta O +
2C O +
and O +
DNA O +
topoisomerase O +
2 O +
- O +
alpha O +
mRNAs O +
are O +
both O +
down O +
- O +
regulated O +
upon O +
drug O +
treatment O +
in O +
three O +
cell O +
lines O +
( O +
Figure O +
3 O +
, O +
Genes O +
8 O +
, O +
13 O +
) O +
. O +

Tubulin O +
beta O +
2C O +
inhibitors O +
induce O +
microtubule O +
depolymerization O +
that O +
leads O +
to O +
the O +
specific O +
down O +
- O +
regulation O +
of O +
tubulin O +
beta O +
2C O +
mRNAs O +
preventing O +
the O +
translational O +
synthesis O +
and O +
thus O +
the O +
further O +
accumulation O +
of O +
abundant O +
tubulin O +
monomers O +
[ O +
26 O +
] O +
. O +

Moreover O +
, O +
we O +
found O +
that O +
DNA O +
topoisomerase O +
2 O +
- O +
alpha O +
mRNAs O +
are O +
not O +
down O +
- O +
regulated O +
upon O +
treatment O +
of O +
other O +
tubulin O +
inhibitors O +
( O +
Figure O +
S5 O +
) O +
. O +

Therefore O +
, O +
we O +
conclude O +
that O +
feedback O +
loops O +
of O +
tubulin O +
beta O +
2C O +
and O +
DNA O +
topoisomerase O +
2 O +
- O +
alpha O +
are O +
not O +
cross O +
- O +
regulated O +
. O +

Two O +
other O +
examples O +
of O +
multi O +
- O +
target O +
drugs O +
are O +
vorinostat O +
used O +
for O +
the O +
treatment O +
of O +
cutaneous O +
T O +
cell O +
lymphoma O +
and O +
trichostatin O +
A O +
that O +
serves O +
as O +
an O +
antifungal O +
antibiotic O +
. O +

Vorinostat O +
and O +
trichostatin O +
A O +
are O +
considered O +
to O +
be O +
nonspecific O +
histone O +
deacetylase O +
inhibitors O +
. O +

These O +
drugs O +
lead O +
to O +
the O +
up O +
- O +
regulation O +
of O +
histone O +
deacetylase O +
3 O +
( O +
HDAC3 O +
) O +
and O +
down O +
- O +
regulation O +
of O +
histone O +
deacetylase O +
7 O +
( O +
HDAC7 O +
) O +
( O +
Figure O +
3 O +
, O +
Genes O +
1 O +
, O +
5 O +
) O +
. O +

In O +
this O +
case O +
it O +
is O +
unclear O +
whether O +
there O +
is O +
cross O +
- O +
regulation O +
, O +
although O +
HDAC7 O +
siRNA O +
experiments O +
failed O +
to O +
induce O +
the O +
up O +
- O +
regulation O +
of O +
HDAC3 O +
mRNAs O +
[ O +
27 O +
] O +
, O +
a O +
result O +
that O +
is O +
disfavoring O +
the O +
cross O +
- O +
regulation O +
. O +

While O +
the O +
above O +
cases O +
only O +
confirm O +
literature O +
reports O +
in O +
other O +
cell O +
lines O +
or O +
tissues O +
, O +
we O +
also O +
identified O +
new O +
cases O +
of O +
drug O +
- O +
induced O +
expression O +
regulation O +
of O +
drug O +
targets O +
. O +

The O +
significant O +
novel O +
findings O +
are O +
the O +
inhibitor O +
- O +
induced O +
down O +
- O +
regulation O +
of O +
calmodulin O +
1 O +
, O +
DNA O +
topoisomerase O +
2 O +
- O +
alpha O +
and O +
up O +
- O +
regulation O +
of O +
endoplasmin O +
, O +
lanosterol O +
14 O +
- O +
alpha O +
demethylase O +
and O +
cAMP O +
- O +
specific O +
phosphodiesterase O +
4D O +
( O +
Figure O +
3 O +
, O +
Genes O +
9 O +
, O +
8 O +
, O +
2 O +
, O +
7 O +
, O +
10 O +
) O +
. O +

Lanosterol O +
14 O +
- O +
alpha O +
demethylase O +
is O +
actually O +
an O +
off O +
- O +
target O +
of O +
antifungal O +
drugs O +
that O +
bind O +
the O +
mammalian O +
version O +
with O +
lower O +
affinity O +
than O +
the O +
fungal O +
lanosterol O +
14 O +
- O +
alpha O +
demethylase O +
. O +

Probably O +
, O +
the O +
up O +
- O +
regulation O +
of O +
the O +
mammalian O +
lanosterol O +
14 O +
- O +
alpha O +
demethylase O +
compensates O +
for O +
the O +
undesired O +
inhibition O +
and O +
modulates O +
the O +
adverse O +
effects O +
. O +

On O +
the O +
contrary O +
, O +
we O +
observed O +
a O +
feedback O +
loop O +
that O +
accelerates O +
the O +
down O +
regulation O +
of O +
calmodulin O +
1 O +
mRNA O +
induced O +
by O +
calmodulin O +
inhibitors O +
. O +

Calmodulin O +
targeting O +
drugs O +
can O +
provide O +
a O +
rapid O +
and O +
effective O +
therapeutic O +
effect O +
, O +
while O +
at O +
the O +
same O +
time O +
small O +
variations O +
of O +
drug O +
concentrations O +
can O +
increase O +
adverse O +
effects O +
. O +

Therefore O +
, O +
it O +
would O +
be O +
interesting O +
to O +
study O +
further O +
the O +
functional O +
effects O +
upon O +
target O +
inhibition O +
of O +
lanosterol O +
14 O +
- O +
alpha O +
demethylase O +
, O +
endoplasmin O +
and O +
calmodulin O +
1 O +
to O +
elucidate O +
the O +
roles O +
of O +
feedback O +
loops O +
in O +
drug O +
mode O +
of O +
action O +
and O +
adverse O +
effects O +
. O +

Drug O +
- O +
induced O +
target O +
regulation O +
might O +
be O +
implicated O +
in O +
tolerance O +
development O +
and O +
thus O +
identifying O +
potential O +
target O +
regulation O +
should O +
be O +
an O +
integral O +
part O +
of O +
drug O +
discovery O +
to O +
prevent O +
failures O +
in O +
later O +
stages O +
of O +
clinical O +
trials O +
. O +

For O +
example O +
, O +
we O +
have O +
observed O +
the O +
inhibitor O +
- O +
induced O +
up O +
- O +
regulation O +
of O +
ADRB2 O +
and O +
thymidylate O +
synthetase O +
( O +
TYMS O +
) O +
( O +
Figure O +
3 O +
, O +
Genes O +
3 O +
, O +
11 O +
) O +
[ O +
28 O +
] O +
. O +

TYMS O +
is O +
an O +
essential O +
enzyme O +
for O +
DNA O +
replication O +
/ O +
repair O +
and O +
an O +
important O +
drug O +
target O +
in O +
cancerous O +
cells O +
. O +

Indeed O +
, O +
it O +
has O +
been O +
shown O +
that O +
inhibitor O +
- O +
induced O +
TYMS O +
over O +
- O +
expression O +
obstructs O +
the O +
clinical O +
efficiency O +
by O +
inducing O +
tumor O +
drug O +
resistance O +
[ O +
29 O +
] O +
. O +

In O +
addition O +
to O +
over O +
- O +
expression O +
, O +
down O +
- O +
regulation O +
of O +
drug O +
targets O +
upon O +
agonist O +
treatment O +
may O +
also O +
cause O +
treatment O +
tolerance O +
as O +
observed O +
for O +
ADRB2 O +
long O +
- O +
acting O +
agonist O +
treatment O +
. O +

ADRB2 O +
is O +
a O +
therapeutic O +
target O +
activated O +
to O +
treat O +
the O +
symptoms O +
of O +
asthma O +
. O +

We O +
observe O +
the O +
agonist O +
- O +
induced O +
up O +
- O +
regulation O +
of O +
ADRB2 O +
and O +
already O +
in O +
2005 O +
, O +
the O +
FDA O +
warned O +
patients O +
that O +
ADRB2 O +
might O +
be O +
down O +
- O +
regulated O +
( O +
desensitization O +
) O +
and O +
be O +
unresponsive O +
for O +
asthma O +
treatment O +
due O +
to O +
long O +
- O +
acting O +
agonist O +
exposure O +
[ O +
20 O +
] O +
, O +
[ O +
30 O +
] O +
. O +

Thus O +
, O +
robustness O +
in O +
biological O +
systems O +
could O +
prevent O +
the O +
applicability O +
of O +
the O +
long O +
- O +
term O +
treatments O +
via O +
positive O +
/ O +
negative O +
feedback O +
loops O +
of O +
the O +
drug O +
target O +
affecting O +
the O +
clinical O +
efficiency O +
of O +
drugs O +
in O +
trial O +
and O +
on O +
the O +
market O +
. O +

Drug O +
- O +
induced O +
regulation O +
of O +
drug O +
targets O +
can O +
thus O +
be O +
linked O +
to O +
tolerance O +
development O +
, O +
which O +
restricts O +
the O +
efficiency O +
of O +
clinical O +
treatments O +
where O +
the O +
drug O +
concentration O +
is O +
limited O +
to O +
avoid O +
an O +
excess O +
of O +
adverse O +
drug O +
reactions O +
. O +

Taken O +
together O +
, O +
we O +
have O +
identified O +
drug O +
- O +
induced O +
differential O +
regulation O +
of O +
drug O +
targets O +
. O +

Due O +
to O +
the O +
limited O +
signal O +
to O +
noise O +
ratio O +
in O +
the O +
data O +
at O +
hand O +
, O +
the O +
identified O +
8 O +
% O +
of O +
all O +
drug O +
targets O +
that O +
show O +
feedback O +
loops O +
has O +
to O +
be O +
seen O +
as O +
a O +
lower O +
limit O +
, O +
i O +
. O +
e O +
. O +
target O +
- O +
regulation O +
appears O +
as O +
a O +
wide O +
- O +
spread O +
biological O +
phenomenon O +
that O +
has O +
to O +
be O +
taken O +
into O +
account O +
during O +
drug O +
development O +
. O +

Study O +
Population O +

This O +
prospective O +
longitudinal O +
study O +
was O +
conducted O +
at O +
the O +
University O +
of O +
British O +
Columbia O +
and O +
was O +
approved O +
by O +
the O +
human O +
research O +
ethics O +
board O +
at O +
that O +
institution O +
. O +

All O +
subjects O +
who O +
received O +
a O +
renal O +
transplant O +
from O +
January O +
2005 O +
to O +
December O +
2007 O +
were O +
invited O +
to O +
participate O +
, O +
and O +
those O +
who O +
agreed O +
and O +
signed O +
consent O +
forms O +
were O +
enrolled O +
in O +
the O +
study O +
. O +

Patients O +
were O +
followed O +
routinely O +
at O +
the O +
transplant O +
center O +
, O +
and O +
blood O +
and O +
urine O +
samples O +
were O +
obtained O +
prior O +
to O +
and O +
serially O +
post O +
- O +
transplant O +
at O +
0 O +
. O +
5 O +
, O +
1 O +
, O +
2 O +
, O +
3 O +
, O +
4 O +
, O +
8 O +
, O +
12 O +
, O +
and O +
26 O +
weeks O +
; O +
then O +
every O +
6 O +
months O +
through O +
year O +
3 O +
; O +
and O +
also O +
at O +
the O +
time O +
of O +
suspected O +
rejection O +
. O +

Graft O +
biopsy O +
tissue O +
was O +
obtained O +
pretransplant O +
and O +
at O +
the O +
time O +
of O +
all O +
biopsies O +
performed O +
post O +
- O +
transplant O +
. O +

Blood O +
samples O +
from O +
normal O +
healthy O +
controls O +
served O +
as O +
reference O +
samples O +
. O +

Samples O +
from O +
cases O +
, O +
controls O +
, O +
and O +
comparators O +
were O +
treated O +
identically O +
. O +

All O +
rejection O +
episodes O +
were O +
diagnosed O +
by O +
conventional O +
clinical O +
and O +
laboratory O +
parameters O +
, O +
confirmed O +
by O +
biopsy O +
, O +
and O +
graded O +
according O +
to O +
the O +
Banff O +
97 O +
working O +
classification O +
of O +
renal O +
allograft O +
pathology O +
( O +
28 O +
) O +
. O +

Banff O +
categories O +
2 O +
and O +
4 O +
( O +
antibody O +
- O +
mediated O +
or O +
acute O +
/ O +
active O +
cellular O +
rejection O +
) O +
were O +
considered O +
significant O +
. O +

Category O +
3 O +
( O +
borderline O +
change O +
) O +
was O +
only O +
considered O +
significant O +
if O +
associated O +
with O +
graft O +
dysfunction O +
and O +
treated O +
for O +
rejection O +
. O +

All O +
baseline O +
demographic O +
and O +
follow O +
- O +
up O +
data O +
were O +
recorded O +
in O +
the O +
transplant O +
program O +
electronic O +
database O +
, O +
and O +
there O +
was O +
no O +
loss O +
to O +
follow O +
- O +
up O +
during O +
the O +
period O +
of O +
study O +
. O +

Statistical O +
results O +
showing O +
significant O +
differences O +
between O +
habitats O +
. O +

Animals O +

STOP O +
null O +
mice O +
and O +
their O +
WT O +
littermates O +
were O +
generated O +
on O +
a O +
mixed O +
BALBc O +
/ O +
129 O +
SvPas O +
and O +
on O +
a O +
pure O +
129 O +
SvPas O +
background O +
as O +
previously O +
reported O +
by O +
Andrieux O +
et O +
al O +
. O +

[ O +
4 O +
] O +
. O +

All O +
animals O +
used O +
in O +
the O +
study O +
underwent O +
immunohistochemistry O +
for O +
the O +
detection O +
of O +
STOP O +
protein O +
, O +
resulting O +
in O +
no O +
staining O +
in O +
STOP O +
null O +
mice O +
, O +
and O +
genotyping O +
by O +
PCR O +
as O +
described O +
by O +
Andrieux O +
et O +
al O +
. O +

[ O +
4 O +
] O +
. O +

All O +
mice O +
were O +
kept O +
under O +
standard O +
housing O +
conditions O +
with O +
a O +
12 O +
- O +
hour O +
/ O +
12 O +
- O +
hour O +
dark O +
- O +
light O +
cycle O +
. O +

The O +
experiments O +
were O +
carried O +
out O +
in O +
accordance O +
with O +
the O +
European O +
Communities O +
Council O +
Directive O +
of O +
24 O +
November O +
1986 O +
( O +
86 O +
/ O +
609 O +
/ O +
EEC O +
) O +
, O +
and O +
the O +
French O +
Department O +
of O +
Agriculture O +
( O +
License O +
Ndegrees O +
67 O +
- O +
95 O +
) O +
. O +

The O +
protocol O +
was O +
approved O +
by O +
the O +
ethical O +
Animal O +
Research O +
Committee O +
of O +
Louis O +
Pasteur O +
University O +
( O +
CREMEAS O +
# O +
AL O +
/ O +
01 O +
/ O +
19 O +
/ O +
10 O +
/ O +
07 O +
) O +
. O +

In O +
a O +
first O +
experiment O +
, O +
we O +
searched O +
for O +
differences O +
in O +
glomerular O +
ultrastructure O +
and O +
peripheral O +
neurogenesis O +
between O +
WT O +
and O +
STOP O +
null O +
mice O +
: O +
a O +
first O +
group O +
of O +
24 O +
mice O +
, O +
3 O +
- O +
to O +
6 O +
- O +
month O +
- O +
old O +
, O +
was O +
used O +
for O +
ultrastructural O +
study O +
of O +
the O +
OBs O +
; O +
a O +
second O +
group O +
of O +
13 O +
animals O +
was O +
used O +
to O +
analyse O +
proliferation O +
and O +
apoptosis O +
in O +
the O +
OE O +
and O +
VNE O +
on O +
paraffin O +
sections O +
in O +
3 O +
- O +
month O +
- O +
old O +
mice O +
. O +

In O +
a O +
second O +
experiment O +
we O +
analysed O +
, O +
in O +
WT O +
and O +
STOP O +
null O +
mice O +
, O +
the O +
effect O +
of O +
OE O +
regeneration O +
on O +
glomeruli O +
structure O +
and O +
ultrastructure O +
and O +
on O +
peripheral O +
neurogenesis O +
at O +
two O +
age O +
times O +
( O +
3 O +
and O +
10 O +
months O +
) O +
. O +

INTRODUCTION O +

For O +
several O +
years O +
now O +
, O +
virtual O +
microscopy O +
has O +
been O +
utilized O +
in O +
medical O +
teaching O +
, O +
research O +
, O +
proficiency O +
testing O +
, O +
American O +
Board O +
of O +
Pathology O +
examinations O +
, O +
pathology O +
meetings O +
and O +
conferences O +
, O +
and O +
quality O +
assurance O +
programs O +
. O +

In O +
diagnostic O +
practice O +
, O +
it O +
is O +
most O +
widely O +
and O +
routinely O +
used O +
in O +
image O +
analysis O +
. O +

Some O +
practices O +
are O +
beginning O +
to O +
use O +
it O +
internally O +
( O +
within O +
their O +
group O +
) O +
for O +
frozen O +
section O +
intraoperative O +
consultations O +
and O +
subspecialty O +
consultations O +
due O +
to O +
geographic O +
and O +
time O +
constrains O +
. O +

Although O +
diagnostic O +
consultation O +
for O +
expert O +
second O +
opinion O +
is O +
a O +
well O +
- O +
established O +
practice O +
in O +
pathology O +
for O +
glass O +
slides O +
, O +
similar O +
consultation O +
via O +
virtual O +
microscopy O +
poses O +
multiple O +
controversial O +
issues O +
such O +
as O +
licensing O +
, O +
liability O +
, O +
security O +
, O +
reimbursement O +
, O +
and O +
scanning O +
quality O +
and O +
its O +
validation O +
. O +

Regulations O +
and O +
standardization O +
are O +
not O +
yet O +
in O +
place O +
that O +
pathologists O +
can O +
use O +
to O +
allay O +
these O +
fears O +
. O +

Nevertheless O +
, O +
if O +
the O +
virtual O +
microscopy O +
scans O +
are O +
of O +
optimal O +
quality O +
, O +
these O +
can O +
be O +
simply O +
substituted O +
for O +
glass O +
slides O +
and O +
a O +
microscope O +
while O +
maintaining O +
all O +
other O +
practice O +
guidelines O +
for O +
second O +
opinion O +
consultation O +
. O +

Additionally O +
, O +
the O +
cost O +
and O +
maintenance O +
of O +
scanning O +
equipment O +
is O +
not O +
currently O +
affordable O +
to O +
most O +
practitioners O +
and O +
consultants O +
. O +

A O +
practice O +
model O +
that O +
offers O +
tertiary O +
consultation O +
in O +
gastrointestinal O +
( O +
GI O +
) O +
and O +
liver O +
pathology O +
is O +
presented O +
that O +
eliminates O +
the O +
cost O +
and O +
maintenance O +
of O +
scanners O +
by O +
the O +
consultants O +
and O +
clients O +
, O +
minimizes O +
the O +
need O +
for O +
review O +
of O +
glass O +
slides O +
, O +
facilitates O +
clinicopathological O +
and O +
radiological O +
correlation O +
and O +
serves O +
the O +
need O +
of O +
clients O +
who O +
need O +
timely O +
help O +
with O +
challenging O +
liver O +
and O +
GI O +
cases O +
and O +
to O +
obtain O +
expert O +
opinion O +
for O +
dysplasia O +
in O +
Barrett O +
' O +
s O +
and O +
ulcerative O +
colitis O +
surveillance O +
biopsies O +
required O +
by O +
the O +
American O +
Gastroenterology O +
Association O +
( O +
AGA O +
) O +
. O +

This O +
model O +
has O +
been O +
practiced O +
for O +
3 O +
years O +
and O +
applied O +
to O +
over O +
2000 O +
cases O +
by O +
small O +
pathology O +
practices O +
in O +
the O +
50 O +
United O +
States O +
and O +
a O +
single O +
consultant O +
GI O +
and O +
liver O +
pathologist O +
. O +

Definition O +
of O +
pathogens O +

It O +
remains O +
difficult O +
to O +
determine O +
whether O +
the O +
organisms O +
detected O +
by O +
the O +
DNA O +
Detection O +
Kit O +
are O +
true O +
pathogens O +
. O +

This O +
also O +
applies O +
, O +
although O +
to O +
a O +
much O +
lesser O +
degree O +
, O +
to O +
conventional O +
blood O +
culture O +
analysis O +
. O +

However O +
, O +
detected O +
organisms O +
were O +
considered O +
to O +
be O +
pathogens O +
if O +
the O +
results O +
of O +
culture O +
tests O +
from O +
samples O +
of O +
the O +
suspected O +
infectious O +
sites O +
coincided O +
with O +
the O +
results O +
of O +
DNA O +
Detection O +
Kit O +
or O +
blood O +
culture O +
analysis O +
. O +

The O +
culture O +
data O +
of O +
sputum O +
, O +
urine O +
, O +
pus O +
and O +
drainage O +
fluid O +
were O +
used O +
to O +
define O +
the O +
pathogens O +
. O +

A O +
decision O +
as O +
to O +
whether O +
an O +
identified O +
organism O +
was O +
a O +
pathogen O +
was O +
taken O +
based O +
on O +
the O +
decision O +
tree O +
shown O +
in O +
Figure O +
1 O +
. O +

Thus O +
, O +
when O +
the O +
same O +
organism O +
was O +
detected O +
by O +
both O +
DNA O +
Detection O +
Kit O +
and O +
blood O +
culture O +
analysis O +
, O +
the O +
detected O +
organism O +
was O +
considered O +
an O +
infectious O +
pathogen O +
. O +

If O +
there O +
was O +
a O +
discrepancy O +
between O +
the O +
organism O +
that O +
was O +
detected O +
by O +
SeptiFast O +
analysis O +
and O +
that O +
detected O +
by O +
blood O +
culture O +
analysis O +
, O +
or O +
if O +
an O +
organism O +
was O +
only O +
detected O +
in O +
one O +
of O +
these O +
tests O +
, O +
then O +
other O +
samples O +
taken O +
from O +
the O +
infection O +
site O +
were O +
analyzed O +
. O +

If O +
this O +
second O +
culture O +
test O +
of O +
the O +
suspected O +
infectious O +
site O +
revealed O +
the O +
presence O +
of O +
the O +
same O +
organism O +
, O +
this O +
organism O +
was O +
considered O +
to O +
be O +
a O +
pathogen O +
. O +

If O +
the O +
microbial O +
strain O +
was O +
only O +
detected O +
once O +
for O +
a O +
sample O +
, O +
we O +
then O +
checked O +
the O +
second O +
culture O +
results O +
in O +
the O +
suspected O +
infectious O +
sites O +
. O +

If O +
this O +
result O +
identified O +
the O +
same O +
strain O +
as O +
that O +
identified O +
by O +
SeptiFast O +
analysis O +
then O +
it O +
was O +
decided O +
that O +
this O +
strain O +
was O +
a O +
pathogen O +
. O +

However O +
, O +
if O +
the O +
strain O +
was O +
still O +
only O +
detected O +
in O +
some O +
of O +
the O +
assays O +
, O +
we O +
next O +
determined O +
if O +
the O +
patient O +
involved O +
suffered O +
from O +
sepsis O +
. O +

Sepsis O +
is O +
defined O +
as O +
SIRS O +
caused O +
by O +
infection O +
. O +

The O +
definition O +
of O +
sepsis O +
that O +
we O +
used O +
was O +
based O +
on O +
the O +
International O +
Sepsis O +
Forum O +
Definition O +
of O +
Infection O +
at O +
the O +
ICU O +
Consensus O +
Conference O +
[ O +
7 O +
] O +
. O +

However O +
, O +
if O +
the O +
underlying O +
disease O +
is O +
acute O +
lymphoma O +
leukemia O +
( O +
ALL O +
) O +
, O +
malignant O +
lymphoma O +
( O +
ML O +
) O +
, O +
or O +
acute O +
myelogenous O +
leukemia O +
( O +
AML O +
) O +
, O +
the O +
definition O +
of O +
infection O +
is O +
defined O +
as O +
the O +
ability O +
to O +
detect O +
infectious O +
organisms O +
by O +
blood O +
culture O +
analysis O +
. O +

If O +
the O +
patient O +
was O +
not O +
defined O +
as O +
having O +
sepsis O +
when O +
whole O +
blood O +
was O +
administered O +
to O +
the O +
patient O +
, O +
we O +
decided O +
that O +
the O +
strain O +
detected O +
by O +
subsequent O +
DNA O +
Detection O +
Kit O +
or O +
blood O +
culture O +
analysis O +
was O +
not O +
a O +
pathogen O +
. O +

Figure O +
1 O +

Flowchart O +
for O +
pathogen O +
decision O +
. O +

Samples O +
were O +
defined O +
as O +
negative O +
for O +
pathogens O +
if O +
a O +
pathogen O +
could O +
not O +
be O +
detected O +
by O +
any O +
method O +
of O +
analysis O +
within O +
seven O +
days O +
, O +
and O +
if O +
another O +
type O +
of O +
culture O +
test O +
did O +
not O +
detect O +
this O +
pathogen O +
but O +
could O +
detect O +
other O +
organisms O +
. O +

CoNS O +
bacteria O +
, O +
which O +
are O +
represented O +
by O +
the O +
Staphylococcus O +
epidermidis O +
( O +
S O +
. O +
epidermidis O +
) O +
and O +
Streptococcus O +
spp O +
. O +
are O +
indigenous O +
bacteria O +
and O +
often O +
cause O +
contamination O +
in O +
assays O +
of O +
pathogens O +
. O +

Therefore O +
, O +
when O +
CoNS O +
or O +
Streptococcus O +
spp O +
. O +
were O +
detected O +
by O +
blood O +
culture O +
and O +
SeptiFast O +
analysis O +
, O +
the O +
following O +
criteria O +
were O +
applied O +
to O +
define O +
whether O +
these O +
strains O +
represented O +
a O +
pathogenic O +
infection O +
: O +
( O +
1 O +
) O +
Tests O +
were O +
performed O +
at O +
least O +
twice O +
within O +
48 O +
hours O +
before O +
and O +
after O +
CoNS O +
were O +
detected O +
by O +
blood O +
culture O +
or O +
SeptiFast O +
analysis O +
; O +
( O +
2 O +
) O +
CoNS O +
or O +
Streptococcus O +
spp O +
. O +
were O +
detected O +
in O +
two O +
different O +
blood O +
culture O +
tests O +
that O +
were O +
separately O +
performed O +
twice O +
within O +
48 O +
hours O +
; O +
and O +
, O +
( O +
3 O +
) O +
CoNS O +
or O +
Streptococcus O +
spp O +
. O +
were O +
detected O +
twice O +
or O +
more O +
in O +
tests O +
that O +
were O +
performed O +
three O +
times O +
[ O +
11 O +
- O +
15 O +
] O +
. O +

If O +
a O +
sample O +
' O +
s O +
results O +
met O +
any O +
of O +
these O +
three O +
criteria O +
, O +
then O +
the O +
sample O +
was O +
evaluated O +
as O +
a O +
pathogen O +
. O +

The O +
distinction O +
between O +
pathogen O +
and O +
contamination O +
was O +
also O +
determined O +
for O +
CoNS O +
or O +
Streptococcus O +
spp O +
. O +
from O +
the O +
crossing O +
point O +
( O +
Cp O +
) O +
obtained O +
using O +
the O +
LightCycler O +
analysis O +
software O +
v4 O +
. O +
05 O +
. O +

The O +
Cp O +
represents O +
the O +
point O +
in O +
the O +
amplification O +
cycle O +
where O +
the O +
amplification O +
curve O +
crosses O +
the O +
detection O +
threshold O +
. O +

When O +
CoNS O +
or O +
Streptococcus O +
spp O +
. O +
were O +
detected O +
using O +
the O +
LightCycler O +
analysis O +
software O +
v4 O +
. O +
05 O +
, O +
a O +
Cp O +
of O +
less O +
than O +
20 O +
was O +
defined O +
as O +
indicating O +
a O +
pathogen O +
and O +
a O +
Cp O +
of O +
over O +
20 O +
was O +
defined O +
as O +
contamination O +
by O +
checking O +
the O +
amplification O +
curve O +
. O +

Effect O +
of O +
the O +
deletion O +
of O +
IRE1alpha O +
on O +
the O +
liver O +
. O +

( O +
A O +
) O +
HE O +
- O +
stained O +
sections O +
of O +
the O +
liver O +
tissue O +
( O +
scale O +
bar O +
: O +
50 O +
mum O +
) O +
. O +

( O +
B O +
) O +
Comparison O +
of O +
the O +
serum O +
AST O +
and O +
ALT O +
levels O +
between O +
the O +
IRE1alpha O +
CKO O +
mice O +
and O +
the O +
control O +
mice O +
. O +

Data O +
are O +
expressed O +
as O +
mean O +
+ O +
/ O +
- O +
S O +
. O +
E O +
. O +
M O +
( O +
n O +
= O +
5 O +
) O +
. O +

( O +
C O +
) O +
Quantitative O +
PCR O +
analysis O +
of O +
lipid O +
synthesis O +
genes O +
in O +
the O +
liver O +
of O +
mice O +
fed O +
normal O +
or O +
high O +
- O +
fructose O +
feed O +
. O +

Columns O +
indicate O +
mean O +
and O +
error O +
bars O +
denote O +
S O +
. O +
E O +
. O +
M O +
( O +
n O +
= O +
3 O +
) O +
. O +

All O +
the O +
data O +
were O +
obtained O +
from O +
20 O +
weeks O +
old O +
male O +
mice O +
. O +

2 O +
. O +

Methods O +

Conclusion O +
: O +

This O +
study O +
demonstrates O +
that O +
surgery O +
plus O +
chemotherapy O +
and O +
radiation O +
therapy O +
is O +
helpful O +
for O +
treating O +
patients O +
with O +
pelvic O +
Ewing O +
' O +
s O +
sarcoma O +
, O +
particularly O +
in O +
achieving O +
local O +
control O +
. O +

Historical O +
Background O +
of O +
PTSD O +

PTSD O +
gained O +
acceptance O +
in O +
the O +
medical O +
and O +
psychiatric O +
community O +
after O +
a O +
number O +
of O +
studies O +
appeared O +
in O +
prominent O +
medical O +
and O +
psychiatric O +
journals O +
describing O +
the O +
psychiatric O +
symptoms O +
of O +
soldiers O +
who O +
had O +
served O +
and O +
fought O +
in O +
the O +
Vietnam O +
War O +
( O +
Fox O +
1972 O +
; O +
Goldsmith O +
and O +
Cretekos O +
1969 O +
) O +
. O +

Subsequent O +
publications O +
described O +
the O +
profound O +
psychological O +
and O +
emotional O +
sequelae O +
secondary O +
to O +
being O +
exposed O +
to O +
extremely O +
traumatic O +
events O +
such O +
as O +
fires O +
, O +
explosions O +
, O +
floods O +
, O +
torture O +
, O +
serious O +
motor O +
vehicle O +
accidents O +
( O +
MVAs O +
) O +
, O +
violent O +
crimes O +
, O +
and O +
sexual O +
assault O +
( O +
e O +
. O +
g O +
. O +
, O +
Horowitz O +
1976 O +
) O +
. O +

These O +
publications O +
posited O +
that O +
individuals O +
with O +
PTSD O +
no O +
longer O +
felt O +
in O +
control O +
of O +
their O +
lives O +
, O +
viewed O +
the O +
world O +
as O +
an O +
unpredictable O +
and O +
dangerous O +
place O +
, O +
lived O +
in O +
fear O +
, O +
and O +
reported O +
a O +
loss O +
of O +
trust O +
in O +
a O +
" O +
just O +
world O +
. O +
" O +
These O +
studies O +
also O +
reported O +
that O +
individuals O +
with O +
PTSD O +
avoided O +
thoughts O +
or O +
situations O +
that O +
might O +
trigger O +
traumatic O +
memories O +
, O +
complained O +
of O +
feelings O +
of O +
emotional O +
numbness O +
, O +
and O +
exhibited O +
symptoms O +
of O +
blunted O +
affect O +
. O +

The O +
conceptual O +
refinements O +
coupled O +
with O +
the O +
empirical O +
information O +
generated O +
by O +
these O +
studies O +
significantly O +
advanced O +
our O +
understanding O +
of O +
individuals O +
who O +
have O +
been O +
exposed O +
to O +
a O +
traumatic O +
stressor O +
. O +

This O +
led O +
in O +
1980 O +
to O +
the O +
inclusion O +
of O +
the O +
diagnostic O +
criteria O +
for O +
PTSD O +
in O +
the O +
Diagnostic O +
and O +
Statistical O +
Manual O +
of O +
Mental O +
Disorders O +
III O +
( O +
DSM O +
- O +
III O +
; O +
American O +
Psychiatric O +
Association O +
1980 O +
) O +
. O +

At O +
that O +
time O +
, O +
PTSD O +
was O +
defined O +
as O +
a O +
syndrome O +
that O +
developed O +
in O +
response O +
to O +
a O +
" O +
stressor O +
that O +
would O +
evoke O +
significant O +
symptoms O +
of O +
distress O +
in O +
almost O +
everyone O +
" O +
( O +
p O +
. O +
238 O +
) O +
. O +

The O +
DSM O +
- O +
III O +
criteria O +
also O +
required O +
that O +
the O +
individual O +
who O +
developed O +
PTSD O +
had O +
to O +
have O +
been O +
directly O +
exposed O +
to O +
a O +
traumatic O +
event O +
. O +

The O +
DSM O +
- O +
IV O +
criteria O +
( O +
APA O +
1994 O +
) O +
significantly O +
broadened O +
the O +
definition O +
of O +
PTSD O +
to O +
include O +
( O +
a O +
) O +
a O +
" O +
personal O +
experience O +
of O +
an O +
event O +
that O +
involves O +
actual O +
or O +
threatened O +
death O +
or O +
serious O +
injury O +
, O +
or O +
other O +
threat O +
to O +
one O +
' O +
s O +
physical O +
integrity O +
" O +
( O +
p O +
. O +
463 O +
) O +
or O +
( O +
b O +
) O +
witnessing O +
a O +
comparable O +
traumatic O +
event O +
or O +
even O +
" O +
learning O +
about O +
unexpected O +
or O +
violent O +
death O +
, O +
serious O +
harm O +
, O +
or O +
threat O +
of O +
death O +
or O +
injury O +
experienced O +
by O +
a O +
family O +
member O +
or O +
a O +
close O +
associate O +
" O +
( O +
p O +
. O +
462 O +
) O +
. O +

As O +
a O +
consequence O +
of O +
these O +
modifications O +
, O +
the O +
DSM O +
- O +
IV O +
diagnostic O +
criteria O +
for O +
PTSD O +
have O +
been O +
criticized O +
for O +
failing O +
to O +
discriminate O +
between O +
symptoms O +
of O +
PTSD O +
and O +
normal O +
stress O +
reactions O +
( O +
e O +
. O +
g O +
. O +
, O +
learning O +
about O +
the O +
9 O +
/ O +
11 O +
disaster O +
; O +
Wakefield O +
and O +
Spitzer O +
2002 O +
) O +
. O +

Summary O +
of O +
instrument O +
characteristics O +

Click O +
here O +
for O +
file O +

The O +
right O +
eye O +
of O +
a O +
50 O +
- O +
year O +
- O +
old O +
patient O +
with O +
severe O +
hypertension O +
at O +
the O +
first O +
visit O +
. O +

( O +
a O +
) O +
Fundus O +
photograph O +
shows O +
serous O +
retinal O +
detachment O +
. O +

The O +
optic O +
disc O +
is O +
pale O +
at O +
the O +
temporal O +
side O +
. O +

( O +
b O +
) O +
Optical O +
coherence O +
tomography O +
( O +
OCT O +
) O +
shows O +
retinal O +
detachment O +
involving O +
the O +
fovea O +
and O +
cystic O +
change O +
of O +
inner O +
retina O +
. O +

( O +
c O +
) O +
Early O +
phase O +
images O +
of O +
fluorescein O +
angiography O +
( O +
FA O +
) O +
( O +
left O +
) O +
and O +
indocyanine O +
green O +
angiography O +
( O +
IA O +
) O +
( O +
right O +
) O +
. O +

( O +
d O +
) O +
Late O +
phase O +
images O +
of O +
FA O +
( O +
left O +
) O +
and O +
IA O +
( O +
right O +
) O +
. O +

FA O +
shows O +
window O +
defect O +
associated O +
with O +
macular O +
cystic O +
change O +
. O +

Note O +
that O +
no O +
active O +
leakage O +
is O +
observed O +
in O +
the O +
area O +
with O +
serous O +
retinal O +
detachment O +
or O +
cystoid O +
edema O +
. O +

IA O +
shows O +
decreased O +
perfusion O +
of O +
the O +
choroid O +
at O +
the O +
macula O +
and O +
window O +
defect O +
with O +
the O +
damaged O +
RPE O +
. O +

Hypofluorescence O +
( O +
arrow O +
) O +
along O +
the O +
retinal O +
artery O +
are O +
observed O +
. O +

These O +
are O +
unique O +
findings O +
. O +

Additional O +
file O +
2 O +

Video O +
S2 O +
TTE O +
apical O +
4 O +
- O +
chamber O +
view O +
. O +

The O +
vegetation O +
seems O +
located O +
just O +
above O +
the O +
tricuspid O +
septal O +
valve O +
without O +
causing O +
obstruction O +
on O +
it O +
. O +

Histology O +
of O +
the O +
lung O +

The O +
left O +
lung O +
was O +
fixed O +
by O +
gentle O +
infusion O +
of O +
fixative O +
( O +
4 O +
% O +
paraformaldehyde O +
) O +
through O +
the O +
tracheal O +
cannula O +
[ O +
24 O +
] O +
. O +

After O +
excision O +
, O +
the O +
lung O +
was O +
immersed O +
in O +
a O +
fresh O +
fixative O +
for O +
2 O +
h O +
. O +

The O +
lung O +
lobe O +
was O +
embedded O +
in O +
paraffin O +
and O +
cut O +
into O +
3 O +
mum O +
transverse O +
sections O +
, O +
followed O +
by O +
immunohistochemical O +
and O +
chemical O +
staining O +
. O +

Photomicrographs O +
were O +
captured O +
using O +
KS400 O +
image O +
analyze O +
platform O +
( O +
Zeiss O +
, O +
Oberkochen O +
, O +
Germany O +
) O +
and O +
analyzed O +
quantitatively O +
. O +

Fractional O +
atomic O +
coordinates O +
and O +
isotropic O +
or O +
equivalent O +
isotropic O +
displacement O +
parameters O +
( O +
A2 O +
) O +

x O +
y O +
z O +
Uiso O +
* O +
/ O +
Ueq O +

C1 O +
0 O +
. O +
3043 O +
( O +
3 O +
) O +
0 O +
. O +
1779 O +
( O +
4 O +
) O +
0 O +
. O +
79280 O +
( O +
13 O +
) O +
0 O +
. O +
0445 O +
( O +
6 O +
) O +

C2 O +
0 O +
. O +
4358 O +
( O +
4 O +
) O +
0 O +
. O +
1697 O +
( O +
5 O +
) O +
0 O +
. O +
84058 O +
( O +
17 O +
) O +
0 O +
. O +
0604 O +
( O +
8 O +
) O +

H2 O +
0 O +
. O +
4201 O +
0 O +
. O +
1476 O +
0 O +
. O +
8809 O +
0 O +
. O +
072 O +
* O +

C3 O +
0 O +
. O +
5911 O +
( O +
4 O +
) O +
0 O +
. O +
1953 O +
( O +
6 O +
) O +
0 O +
. O +
8269 O +
( O +
2 O +
) O +
0 O +
. O +
0783 O +
( O +
12 O +
) O +

H3 O +
0 O +
. O +
6811 O +
0 O +
. O +
1914 O +
0 O +
. O +
8584 O +
0 O +
. O +
094 O +
* O +

C4 O +
0 O +
. O +
6130 O +
( O +
4 O +
) O +
0 O +
. O +
2267 O +
( O +
6 O +
) O +
0 O +
. O +
7670 O +
( O +
2 O +
) O +
0 O +
. O +
0773 O +
( O +
11 O +
) O +

H4 O +
0 O +
. O +
7180 O +
0 O +
. O +
2427 O +
0 O +
. O +
7582 O +
0 O +
. O +
093 O +
* O +

C5 O +
0 O +
. O +
4818 O +
( O +
5 O +
) O +
0 O +
. O +
2344 O +
( O +
5 O +
) O +
0 O +
. O +
7202 O +
( O +
2 O +
) O +
0 O +
. O +
0746 O +
( O +
10 O +
) O +

H5 O +
0 O +
. O +
4980 O +
0 O +
. O +
2547 O +
0 O +
. O +
6798 O +
0 O +
. O +
090 O +
* O +

C6 O +
0 O +
. O +
3257 O +
( O +
4 O +
) O +
0 O +
. O +
2121 O +
( O +
4 O +
) O +
0 O +
. O +
73293 O +
( O +
15 O +
) O +
0 O +
. O +
0562 O +
( O +
7 O +
) O +

H6 O +
0 O +
. O +
2360 O +
0 O +
. O +
2200 O +
0 O +
. O +
7015 O +
0 O +
. O +
067 O +
* O +

C7 O +
0 O +
. O +
1252 O +
( O +
3 O +
) O +
0 O +
. O +
3838 O +
( O +
4 O +
) O +
0 O +
. O +
90059 O +
( O +
11 O +
) O +
0 O +
. O +
0400 O +
( O +
6 O +
) O +

C8 O +
0 O +
. O +
2051 O +
( O +
4 O +
) O +
0 O +
. O +
5522 O +
( O +
4 O +
) O +
0 O +
. O +
90920 O +
( O +
13 O +
) O +
0 O +
. O +
0484 O +
( O +
6 O +
) O +

H8 O +
0 O +
. O +
2132 O +
0 O +
. O +
6288 O +
0 O +
. O +
8758 O +
0 O +
. O +
058 O +
* O +

C9 O +
0 O +
. O +
2725 O +
( O +
4 O +
) O +
0 O +
. O +
6041 O +
( O +
4 O +
) O +
0 O +
. O +
96827 O +
( O +
15 O +
) O +
0 O +
. O +
0558 O +
( O +
7 O +
) O +

C10 O +
0 O +
. O +
2645 O +
( O +
4 O +
) O +
0 O +
. O +
4935 O +
( O +
4 O +
) O +
1 O +
. O +
01861 O +
( O +
14 O +
) O +
0 O +
. O +
0590 O +
( O +
8 O +
) O +

H10 O +
0 O +
. O +
3122 O +
0 O +
. O +
5293 O +
1 O +
. O +
0582 O +
0 O +
. O +
071 O +
* O +

C11 O +
0 O +
. O +
1830 O +
( O +
4 O +
) O +
0 O +
. O +
3278 O +
( O +
4 O +
) O +
1 O +
. O +
00819 O +
( O +
13 O +
) O +
0 O +
. O +
0534 O +
( O +
7 O +
) O +

C12 O +
0 O +
. O +
1118 O +
( O +
3 O +
) O +
0 O +
. O +
2699 O +
( O +
4 O +
) O +
0 O +
. O +
95062 O +
( O +
12 O +
) O +
0 O +
. O +
0480 O +
( O +
6 O +
) O +

H12 O +
0 O +
. O +
0561 O +
0 O +
. O +
1577 O +
0 O +
. O +
9451 O +
0 O +
. O +
058 O +
* O +

N1 O +
0 O +
. O +
0494 O +
( O +
3 O +
) O +
0 O +
. O +
3297 O +
( O +
3 O +
) O +
0 O +
. O +
84009 O +
( O +
10 O +
) O +
0 O +
. O +
0441 O +
( O +
5 O +
) O +

H1N O +
0 O +
. O +
038 O +
( O +
4 O +
) O +
0 O +
. O +
418 O +
( O +
3 O +
) O +
0 O +
. O +
8138 O +
( O +
12 O +
) O +
0 O +
. O +
053 O +
* O +

O1 O +
- O +
0 O +
. O +
0021 O +
( O +
3 O +
) O +
0 O +
. O +
1298 O +
( O +
3 O +
) O +
0 O +
. O +
74998 O +
( O +
9 O +
) O +
0 O +
. O +
0527 O +
( O +
5 O +
) O +

O2 O +
0 O +
. O +
1112 O +
( O +
3 O +
) O +
- O +
0 O +
. O +
0066 O +
( O +
3 O +
) O +
0 O +
. O +
85135 O +
( O +
10 O +
) O +
0 O +
. O +
0574 O +
( O +
6 O +
) O +

Cl1 O +
0 O +
. O +
37237 O +
( O +
16 O +
) O +
0 O +
. O +
81541 O +
( O +
13 O +
) O +
0 O +
. O +
97944 O +
( O +
5 O +
) O +
0 O +
. O +
0927 O +
( O +
4 O +
) O +

Cl2 O +
0 O +
. O +
16462 O +
( O +
15 O +
) O +
0 O +
. O +
18752 O +
( O +
15 O +
) O +
1 O +
. O +
07089 O +
( O +
4 O +
) O +
0 O +
. O +
0834 O +
( O +
4 O +
) O +

S1 O +
0 O +
. O +
10584 O +
( O +
7 O +
) O +
0 O +
. O +
14095 O +
( O +
9 O +
) O +
0 O +
. O +
80800 O +
( O +
3 O +
) O +
0 O +
. O +
0412 O +
( O +
3 O +
) O +

Data O +
collection O +
: O +
CrystalClear O +
( O +
Rigaku O +
/ O +
MSC O +
, O +
2005 O +
> O +
) O +
; O +
cell O +
refinement O +
: O +
CrystalClear O +
; O +
data O +
reduction O +
: O +
CrystalClear O +
; O +
program O +
( O +
s O +
) O +
used O +
to O +
solve O +
structure O +
: O +
SHELXS97 O +
( O +
Sheldrick O +
, O +
2008 O +
> O +
) O +
; O +
program O +
( O +
s O +
) O +
used O +
to O +
refine O +
structure O +
: O +
SHELXL97 O +
( O +
Sheldrick O +
, O +
2008 O +
> O +
) O +
; O +
molecular O +
graphics O +
: O +
ORTEPII O +
( O +
Johnson O +
, O +
1976 O +
> O +
) O +
; O +
software O +
used O +
to O +
prepare O +
material O +
for O +
publication O +
: O +
SHELXL97 O +
. O +

Experimental O +

The O +
molecular O +
structure O +
of O +
( O +
I O +
) O +
, O +
showing O +
displacement O +
ellipsoids O +
at O +
the O +
30 O +
% O +
probability O +
level O +
for O +
non O +
- O +
H O +
atoms O +
. O +

Crystal O +
data O +

C16H20N4 O +

M O +
r O +
= O +
268 O +
. O +
36 O +

Monoclinic O +
, O +

a O +
= O +
12 O +
. O +
819 O +
( O +
4 O +
) O +
A O +

b O +
= O +
8 O +
. O +
441 O +
( O +
3 O +
) O +
A O +

c O +
= O +
13 O +
. O +
310 O +
( O +
4 O +
) O +
A O +

beta O +
= O +
95 O +
. O +
462 O +
( O +
5 O +
) O +
degrees O +

V O +
= O +
1433 O +
. O +
7 O +
( O +
8 O +
) O +
A3 O +

Z O +
= O +
4 O +

Mo O +
Kalpha O +
radiation O +

mu O +
= O +
0 O +
. O +
08 O +
mm O +
- O +
1 O +

T O +
= O +
298 O +
( O +
2 O +
) O +
K O +

0 O +
. O +
33 O +
x O +
0 O +
. O +
28 O +
x O +
0 O +
. O +
21 O +
mm O +

Crystal O +
data O +

C15H12ClN3O2S2 O +
F O +
( O +
000 O +
) O +
= O +
752 O +

Mr O +
= O +
365 O +
. O +
85 O +
Dx O +
= O +
1 O +
. O +
507 O +
Mg O +
m O +
- O +
3 O +

Monoclinic O +
, O +
P21 O +
/ O +
n O +
Mo O +
Kalpha O +
radiation O +
, O +
lambda O +
= O +
0 O +
. O +
71073 O +
A O +

Hall O +
symbol O +
: O +
- O +
P O +
2yn O +
Cell O +
parameters O +
from O +
25 O +
reflections O +

a O +
= O +
10 O +
. O +
175 O +
( O +
2 O +
) O +
A O +
theta O +
= O +
9 O +
- O +
12degrees O +

b O +
= O +
8 O +
. O +
4958 O +
( O +
17 O +
) O +
A O +
micro O +
= O +
0 O +
. O +
51 O +
mm O +
- O +
1 O +

c O +
= O +
19 O +
. O +
318 O +
( O +
4 O +
) O +
A O +
T O +
= O +
293 O +
K O +

beta O +
= O +
105 O +
. O +
01 O +
( O +
3 O +
) O +
degrees O +
Block O +
, O +
yellow O +

V O +
= O +
1613 O +
. O +
0 O +
( O +
6 O +
) O +
A3 O +
0 O +
. O +
25 O +
x O +
0 O +
. O +
15 O +
x O +
0 O +
. O +
15 O +
mm O +

Z O +
= O +
4 O +

Discussion O +

Our O +
results O +
indicate O +
beneficial O +
effects O +
of O +
motivational O +
incentives O +
on O +
cognitive O +
performance O +
and O +
alleviating O +
effects O +
on O +
cognitive O +
decline O +
. O +

These O +
beneficial O +
effects O +
were O +
evident O +
in O +
healthy O +
young O +
and O +
older O +
adults O +
and O +
in O +
patients O +
with O +
Parkinson O +
' O +
s O +
disease O +
. O +

Young O +
adults O +
showed O +
improved O +
antisaccade O +
preparation O +
when O +
a O +
reward O +
was O +
at O +
stake O +
; O +
older O +
adults O +
and O +
PD O +
patients O +
could O +
utilize O +
reward O +
prospect O +
to O +
improve O +
their O +
impaired O +
antisaccade O +
preparation O +
. O +

Elderly O +
participants O +
and O +
PD O +
patients O +
were O +
not O +
only O +
better O +
prepared O +
by O +
means O +
of O +
commonly O +
used O +
preparatory O +
aids O +
( O +
i O +
. O +
e O +
. O +
, O +
more O +
preparation O +
time O +
and O +
advance O +
information O +
on O +
the O +
upcoming O +
response O +
) O +
but O +
also O +
by O +
means O +
of O +
motivational O +
incentives O +
. O +

These O +
beneficial O +
effects O +
of O +
motivational O +
incentives O +
on O +
cognitive O +
action O +
preparation O +
in O +
healthy O +
and O +
pathological O +
aging O +
further O +
support O +
views O +
that O +
question O +
the O +
notion O +
of O +
monotonic O +
deterioration O +
of O +
cognitive O +
function O +
with O +
age O +
( O +
Allen O +
et O +
al O +
. O +
, O +
2001 O +
) O +
. O +

They O +
indicate O +
that O +
age O +
- O +
related O +
declines O +
can O +
be O +
modulated O +
by O +
emotion O +
- O +
cognition O +
interactions O +
. O +

In O +
line O +
with O +
the O +
predominant O +
view O +
that O +
cognitive O +
control O +
deteriorates O +
in O +
aging O +
and O +
Parkinson O +
' O +
s O +
disease O +
, O +
and O +
in O +
line O +
with O +
previous O +
findings O +
on O +
age O +
- O +
related O +
changes O +
in O +
antisaccade O +
control O +
specifically O +
( O +
Eenshuistra O +
et O +
al O +
. O +
, O +
2004 O +
; O +
Chan O +
et O +
al O +
. O +
, O +
2005 O +
; O +
Amador O +
et O +
al O +
. O +
, O +
2006 O +
; O +
Abel O +
and O +
Douglas O +
, O +
2007 O +
) O +
, O +
the O +
current O +
results O +
showed O +
decline O +
in O +
antisaccade O +
preparation O +
in O +
PD O +
patients O +
with O +
severe O +
motor O +
symptoms O +
as O +
compared O +
to O +
healthy O +
seniors O +
. O +

Mild O +
- O +
symptom O +
patients O +
and O +
healthy O +
elderly O +
did O +
not O +
differ O +
in O +
antisaccade O +
preparation O +
. O +

Healthy O +
seniors O +
showed O +
declining O +
antisaccade O +
preparation O +
as O +
compared O +
to O +
young O +
adults O +
. O +

Decline O +
was O +
evident O +
on O +
several O +
oculomotor O +
parameters O +
and O +
most O +
pronounced O +
on O +
antisaccade O +
onset O +
latencies O +
. O +

In O +
line O +
with O +
the O +
notion O +
that O +
in O +
general O +
, O +
elderly O +
tend O +
to O +
prefer O +
accuracy O +
over O +
speed O +
, O +
elderly O +
showed O +
no O +
decreased O +
antisaccade O +
accuracy O +
as O +
compared O +
to O +
young O +
adults O +
. O +

As O +
compared O +
to O +
the O +
young O +
group O +
, O +
elderly O +
and O +
PD O +
patients O +
exhibited O +
slightly O +
, O +
but O +
not O +
significantly O +
more O +
premature O +
eye O +
movements O +
. O +

Premature O +
eye O +
movements O +
, O +
however O +
significantly O +
increased O +
in O +
elderly O +
and O +
PD O +
patients O +
but O +
only O +
slightly O +
in O +
the O +
young O +
, O +
when O +
more O +
specific O +
information O +
on O +
the O +
upcoming O +
movement O +
was O +
available O +
in O +
advance O +
. O +

Presumably O +
, O +
this O +
increase O +
in O +
premature O +
eye O +
movements O +
reflects O +
difficulties O +
with O +
the O +
inhibition O +
of O +
externally O +
guided O +
movement O +
and O +
/ O +
or O +
the O +
suppression O +
of O +
strongly O +
activated O +
prepotent O +
action O +
plans O +
. O +

On O +
the O +
one O +
hand O +
, O +
the O +
choice O +
for O +
medicated O +
PD O +
patients O +
represents O +
a O +
limitation O +
of O +
the O +
current O +
study O +
as O +
we O +
can O -
not O +
exclude O +
differential O +
effects O +
of O +
medication O +
on O +
behavior O +
. O +

On O +
the O +
other O +
hand O +
, O +
PD O +
patients O +
generally O +
take O +
medication O +
in O +
their O +
daily O +
routine O +
, O +
such O +
that O +
the O +
results O +
can O +
be O +
generalized O +
to O +
clinical O +
practice O +
. O +

Exploratory O +
analysis O +
within O +
the O +
PD O +
patient O +
group O +
revealed O +
that O +
patients O +
with O +
more O +
severe O +
motoric O +
symptoms O +
( O +
as O +
indexed O +
by O +
their O +
motoric O +
subscore O +
on O +
the O +
UPDRS O +
) O +
displayed O +
more O +
signs O +
of O +
antisaccade O +
decline O +
, O +
such O +
as O +
longer O +
antisaccade O +
latencies O +
and O +
lower O +
accuracy O +
compared O +
to O +
mildly O +
affected O +
patients O +
, O +
who O +
initiated O +
saccades O +
equally O +
fast O +
as O +
healthy O +
adults O +
. O +

This O +
suggests O +
that O +
dopaminergic O +
medication O +
was O +
not O +
sufficient O +
to O +
raise O +
the O +
patient O +
' O +
s O +
antisaccadic O +
preparation O +
up O +
to O +
the O +
level O +
of O +
the O +
healthy O +
older O +
adults O +
. O +

One O +
intriguing O +
observation O +
was O +
that O +
despite O +
the O +
different O +
extents O +
of O +
observed O +
antisaccade O +
performance O +
decline O +
in O +
elderly O +
and O +
PD O +
patients O +
, O +
reward O +
prospect O +
led O +
to O +
beneficial O +
effects O +
on O +
antisaccade O +
latency O +
and O +
accuracy O +
in O +
young O +
, O +
elderly O +
, O +
and O +
PD O +
patients O +
alike O +
. O +

Young O +
, O +
elderly O +
and O +
PD O +
patients O +
benefited O +
from O +
reward O +
prospect O +
to O +
the O +
same O +
extent O +
, O +
confirming O +
that O +
the O +
expectancy O +
of O +
reward O +
is O +
a O +
powerful O +
mediator O +
of O +
cognitive O +
control O +
, O +
even O +
if O +
cognitive O +
control O +
suffers O +
from O +
decline O +
. O +

The O +
expectation O +
of O +
rewarding O +
incentives O +
thus O +
seems O +
to O +
support O +
older O +
adults O +
' O +
and O +
PD O +
patients O +
' O +
ability O +
to O +
anticipate O +
, O +
prepare O +
and O +
initiate O +
goal O +
- O +
directed O +
behavior O +
. O +

These O +
findings O +
imply O +
that O +
despite O +
a O +
general O +
decline O +
in O +
the O +
action O +
preparation O +
system O +
as O +
indexed O +
by O +
increased O +
antisaccade O +
latency O +
, O +
action O +
preparation O +
processes O +
remain O +
susceptible O +
to O +
the O +
prospect O +
of O +
future O +
reward O +
. O +

It O +
could O +
thus O +
be O +
argued O +
that O +
the O +
neural O +
representations O +
of O +
upcoming O +
rewards O +
influence O +
neural O +
systems O +
concerned O +
with O +
action O +
preparation O +
and O +
oculomotor O +
control O +
. O +

Although O +
the O +
current O +
behavioral O +
results O +
can O -
not O +
exclude O +
or O +
confirm O +
neural O +
links O +
between O +
reward O +
anticipation O +
and O +
action O +
preparation O +
systems O +
in O +
the O +
brain O +
, O +
they O +
suggest O +
intact O +
cross O +
- O +
talk O +
among O +
subcortical O +
circuits O +
that O +
allow O +
goal O +
- O +
directed O +
action O +
to O +
be O +
modified O +
by O +
motivational O +
factors O +
. O +

The O +
motivational O +
neural O +
reward O +
anticipation O +
signal O +
presumably O +
activates O +
the O +
reward O +
network O +
including O +
the O +
amygdala O +
, O +
orbitofrontal O +
cortex O +
, O +
the O +
more O +
ventral O +
and O +
dorsal O +
striatum O +
( O +
nucleus O +
accumbens O +
, O +
putamen O +
, O +
and O +
caudate O +
) O +
, O +
leading O +
to O +
an O +
release O +
of O +
caudate O +
/ O +
SNr O +
inhibition O +
on O +
the O +
executive O +
oculomotor O +
structure O +
superior O +
colliculus O +
. O +

This O +
transiently O +
decreased O +
inhibitory O +
force O +
on O +
superior O +
colliculus O +
may O +
improve O +
goal O +
- O +
directed O +
oculomotor O +
control O +
. O +

Thus O +
reward O +
anticipation O +
might O +
compensate O +
for O +
the O +
age O +
- O +
and O +
disease O +
- O +
related O +
dopaminergic O +
loss O +
in O +
the O +
SNc O +
projections O +
to O +
the O +
caudate O +
/ O +
SNr O +
and O +
may O +
thus O +
play O +
a O +
compensatory O +
role O +
in O +
" O +
boosting O +
" O +
the O +
efficiency O +
of O +
interactions O +
between O +
motivational O +
and O +
impaired O +
cognitive O +
control O +
processes O +
. O +

However O +
the O +
reward O +
- O +
related O +
modulation O +
of O +
the O +
oculomotor O +
control O +
system O +
may O +
not O +
only O +
apply O +
to O +
the O +
basal O +
ganglia O +
part O +
of O +
the O +
oculomotor O +
network O +
. O +

Although O +
speculative O +
, O +
it O +
could O +
extend O +
to O +
the O +
cortical O +
eyefields O +
( O +
frontal O +
, O +
supplementary O +
, O +
and O +
parietal O +
eyefields O +
) O +
and O +
to O +
parts O +
of O +
the O +
visual O +
cortex O +
. O +

Human O +
research O +
shows O +
that O +
more O +
preparatory O +
activation O +
in O +
the O +
frontal O +
eyefields O +
leads O +
to O +
a O +
faster O +
antisaccade O +
latency O +
( O +
Connolly O +
et O +
al O +
. O +
, O +
2002 O +
, O +
2005 O +
) O +
. O +

The O +
compensatory O +
effect O +
on O +
the O +
antisaccade O +
latency O +
, O +
therefore O +
, O +
could O +
theoretically O +
stem O +
from O +
a O +
propagation O +
of O +
reward O +
anticipation O +
signal O +
in O +
the O +
caudate O +
to O +
the O +
frontal O +
eyefields O +
. O +

Complex O +
structural O +
connections O +
enable O +
the O +
striatum O +
to O +
exert O +
a O +
controlling O +
influence O +
over O +
the O +
cerebral O +
cortex O +
via O +
a O +
series O +
of O +
reentrant O +
corticobasal O +
ganglia O +
circuits O +
. O +

Thus O +
reward O +
anticipation O +
may O +
increase O +
the O +
level O +
of O +
preparation O +
in O +
the O +
intact O +
cortical O +
eyefields O +
and O +
thereby O +
compensate O +
for O +
age O +
- O +
and O +
disease O +
- O +
related O +
subcortical O +
decrements O +
in O +
the O +
oculomotor O +
network O +
. O +

Taken O +
together O +
, O +
it O +
seems O +
plausible O +
that O +
motivational O +
reward O +
processes O +
in O +
the O +
caudate O +
enhance O +
preparatory O +
activation O +
in O +
subcortical O +
as O +
well O +
as O +
in O +
cortical O +
nodes O +
of O +
the O +
oculomotor O +
network O +
. O +

Several O +
neurotransmission O +
mechanisms O +
may O +
underlie O +
the O +
remedial O +
effect O +
of O +
positive O +
incentives O +
on O +
declining O +
antisaccadic O +
control O +
. O +

Given O +
the O +
convergence O +
of O +
dopamine O +
and O +
glutamate O +
inputs O +
at O +
the O +
spiny O +
projection O +
neurons O +
in O +
the O +
striatum O +
( O +
Burns O +
et O +
al O +
. O +
, O +
1994 O +
) O +
, O +
an O +
interaction O +
between O +
dopamine O +
and O +
glutamate O +
might O +
underlie O +
striatal O +
processes O +
of O +
reward O +
anticipation O +
and O +
action O +
preparation O +
. O +

However O +
, O +
it O +
can O -
not O +
be O +
fully O +
excluded O +
that O +
alterations O +
in O +
other O +
neurotransmitter O +
systems O +
may O +
also O +
have O +
an O +
effect O +
on O +
declining O +
oculomotor O +
control O +
and O +
on O +
remediating O +
incentive O +
effects O +
. O +

Non O +
- O +
dopaminergic O +
changes O +
such O +
as O +
noradrenergic O +
, O +
serotonergic O +
, O +
and O +
cholinergic O +
deafferentation O +
of O +
the O +
cortex O +
also O +
occur O +
in O +
PD O +
and O +
can O +
inflict O +
cognitive O +
deficits O +
( O +
Agid O +
et O +
al O +
. O +
, O +
1987 O +
) O +
. O +

Evidence O +
from O +
non O +
- O +
human O +
primates O +
suggests O +
that O +
basal O +
ganglia O +
dopamine O +
acts O +
to O +
speed O +
motor O +
responding O +
in O +
response O +
to O +
rewarding O +
cues O +
( O +
Niv O +
, O +
2007 O +
; O +
Niv O +
et O +
al O +
. O +
, O +
2007 O +
) O +
. O +

Among O +
at O +
least O +
five O +
types O +
of O +
DA O +
receptors O +
, O +
mainly O +
D1 O +
and O +
D2 O +
receptors O +
are O +
expressed O +
in O +
caudate O +
projection O +
neurons O +
( O +
Nakamura O +
and O +
Hikosaka O +
, O +
2006 O +
) O +
. O +

Tendencies O +
to O +
speed O +
responses O +
to O +
obtain O +
large O +
rewards O +
have O +
been O +
found O +
to O +
be O +
dependent O +
on O +
striatal O +
D1 O +
receptors O +
( O +
Dalley O +
et O +
al O +
. O +
, O +
2005 O +
; O +
Berridge O +
, O +
2007 O +
) O +
. O +

In O +
contrast O +
to O +
this O +
D1 O +
modulated O +
speeding O +
in O +
reward O +
- O +
motor O +
tasks O +
, O +
evidence O +
from O +
saccade O +
tasks O +
in O +
non O +
- O +
human O +
primates O +
suggests O +
D2 O +
receptor O +
modulation O +
of O +
reward O +
dependent O +
improvements O +
of O +
performance O +
( O +
Nakamura O +
and O +
Hikosaka O +
, O +
2006 O +
) O +
. O +

Injections O +
of O +
a O +
D1 O +
antagonist O +
and O +
a O +
D2 O +
antagonist O +
into O +
the O +
region O +
of O +
the O +
caudate O +
where O +
saccade O +
- O +
related O +
neurons O +
are O +
clustered O +
while O +
the O +
monkey O +
performed O +
a O +
reward O +
- O +
biased O +
saccade O +
task O +
showed O +
that O +
D1 O +
antagonists O +
attenuate O +
the O +
reward O +
modulation O +
of O +
saccade O +
behavior O +
whereas O +
D2 O +
antagonists O +
into O +
the O +
same O +
region O +
enhanced O +
the O +
reward O +
- O +
dependent O +
changes O +
. O +

Future O +
studies O +
of O +
Parkinson O +
patients O +
on O +
versus O +
off O +
medication O +
, O +
could O +
provide O +
some O +
information O +
on O +
the O +
role O +
of O +
dopaminergic O +
mechanisms O +
in O +
the O +
remedial O +
effects O +
on O +
antisaccadic O +
performance O +
. O +

A O +
recent O +
study O +
of O +
reward O +
learning O +
in O +
Parkinson O +
patients O +
on O +
/ O +
off O +
dopaminergic O +
medication O +
showed O +
that O +
patients O +
adapted O +
their O +
behavior O +
to O +
maximize O +
expected O +
reward O +
value O +
dependent O +
on O +
their O +
medication O +
status O +
( O +
Moustafa O +
et O +
al O +
. O +
, O +
2008 O +
) O +
. O +

Whilst O +
off O +
dopaminergic O +
medication O +
, O +
patients O +
slowed O +
their O +
responses O +
to O +
avoid O +
low O +
expected O +
values O +
, O +
but O +
succeeded O +
less O +
well O +
in O +
speeding O +
responses O +
when O +
a O +
reward O +
was O +
at O +
stake O +
. O +

The O +
opposite O +
pattern O +
emerged O +
when O +
the O +
same O +
patients O +
were O +
on O +
medication O +
; O +
patients O +
showed O +
better O +
response O +
speeding O +
, O +
and O +
worse O +
response O +
slowing O +
, O +
to O +
maximize O +
expected O +
value O +
. O +

The O +
current O +
behavioral O +
findings O +
are O +
in O +
line O +
with O +
neuroimaging O +
research O +
showing O +
intact O +
neural O +
representations O +
of O +
future O +
reward O +
in O +
the O +
aging O +
striatum O +
( O +
Samanez O +
- O +
Larkin O +
et O +
al O +
. O +
, O +
2007 O +
) O +
. O +

The O +
observation O +
however O +
that O +
older O +
adults O +
and O +
PD O +
patients O +
can O +
use O +
this O +
intact O +
neural O +
representation O +
of O +
reward O +
anticipation O +
( O +
a O +
positive O +
motivational O +
incentive O +
) O +
to O +
optimize O +
their O +
preparatory O +
processes O +
, O +
can O -
not O +
necessarily O +
be O +
generalized O +
to O +
cognitive O +
contexts O +
with O +
negative O +
motivational O +
incentives O +
. O +

Samanez O +
- O +
Larkin O +
et O +
al O +
. O +
( O +
2010 O +
) O +
recently O +
showed O +
that O +
older O +
adults O +
were O +
not O +
able O +
to O +
optimally O +
use O +
their O +
intact O +
neural O +
reward O +
anticipation O +
system O +
in O +
risky O +
financial O +
decision O +
making O +
. O +

Elderly O +
made O +
more O +
suboptimal O +
choices O +
when O +
they O +
were O +
to O +
choose O +
risky O +
assets O +
. O +

The O +
authors O +
deemed O +
it O +
likely O +
that O +
these O +
decrements O +
in O +
value O +
- O +
based O +
decision O +
making O +
are O +
explained O +
by O +
the O +
fact O +
that O +
value O +
- O +
based O +
decision O +
making O +
requires O +
the O +
weighting O +
of O +
behavioral O +
alternatives O +
, O +
that O +
may O +
lead O +
to O +
either O +
gain O +
or O +
loss O +
. O +

During O +
anticipation O +
of O +
rewards O +
older O +
adults O +
show O +
similar O +
neural O +
responses O +
as O +
young O +
adults O +
but O +
they O +
show O +
reduced O +
neural O +
activation O +
during O +
the O +
anticipation O +
of O +
losses O +
( O +
Samanez O +
- O +
Larkin O +
et O +
al O +
. O +
, O +
2007 O +
) O +
. O +

The O +
latter O +
, O +
together O +
with O +
the O +
observation O +
that O +
older O +
adults O +
tend O +
to O +
shift O +
their O +
attention O +
away O +
from O +
negative O +
stimuli O +
and O +
attend O +
to O +
positive O +
information O +
instead O +
( O +
Mather O +
and O +
Carstensen O +
, O +
2003 O +
, O +
2005 O +
) O +
, O +
may O +
have O +
led O +
to O +
the O +
underestimation O +
of O +
loss O +
and O +
therefore O +
to O +
more O +
risky O +
and O +
suboptimal O +
decisions O +
. O +

In O +
this O +
respect O +
, O +
one O +
limitation O +
of O +
the O +
current O +
task O +
is O +
that O +
it O +
built O +
solely O +
on O +
reward O +
prospect O +
and O +
not O +
on O +
the O +
prospect O +
of O +
loss O +
, O +
such O +
that O +
the O +
question O +
of O +
how O +
the O +
anticipation O +
of O +
loss O +
influences O +
action O +
preparation O +
was O +
not O +
tested O +
. O +

The O +
impact O +
of O +
negative O +
incentives O +
might O +
be O +
an O +
intriguing O +
question O +
for O +
future O +
research O +
, O +
as O +
due O +
to O +
the O +
decreased O +
activation O +
of O +
the O +
neural O +
loss O +
anticipation O +
system O +
( O +
Samanez O +
- O +
Larkin O +
et O +
al O +
. O +
, O +
2007 O +
) O +
together O +
with O +
the O +
observed O +
differential O +
attentional O +
bias O +
for O +
negative O +
and O +
positive O +
information O +
( O +
Mather O +
and O +
Carstensen O +
, O +
2003 O +
) O +
, O +
it O +
seems O +
likely O +
that O +
negative O +
motivational O +
incentives O +
, O +
i O +
. O +
e O +
. O +
, O +
the O +
prospect O +
of O +
loss O +
, O +
might O +
have O +
a O +
different O +
impact O +
on O +
action O +
preparation O +
in O +
older O +
adults O +
than O +
in O +
the O +
young O +
. O +

Future O +
approaches O +
to O +
the O +
effect O +
of O +
loss O +
anticipation O +
on O +
declining O +
antisaccade O +
control O +
may O +
ideally O +
contain O +
a O +
sequence O +
of O +
experiments O +
, O +
starting O +
with O +
a O +
separate O +
( O +
punishment O +
only O +
) O +
approach O +
before O +
moving O +
to O +
combined O +
reward O +
- O +
punishment O +
designs O +
. O +

This O +
might O +
be O +
necessary O +
as O +
previous O +
evidence O +
( O +
from O +
healthy O +
young O +
adults O +
) O +
suggests O +
that O +
the O +
reward O +
effect O +
on O +
oculomotor O +
control O +
disappears O +
in O +
the O +
presence O +
of O +
punishment O +
trials O +
. O +

The O +
authors O +
deemed O +
it O +
likely O +
that O +
the O +
participants O +
increased O +
caution O +
to O +
all O +
incentive O +
( O +
reward O +
and O +
punishment O +
) O +
trials O +
( O +
Blaukopf O +
and O +
DiGirolamo O +
, O +
2006 O +
) O +
. O +

As O +
of O +
yet O +
, O +
age O +
- O +
related O +
changes O +
in O +
neural O +
reward O +
anticipation O +
have O +
mainly O +
been O +
studied O +
in O +
isolation O +
. O +

Recently O +
however O +
, O +
the O +
interaction O +
of O +
neural O +
reward O +
processing O +
with O +
other O +
cognitive O +
functions O +
and O +
their O +
underlying O +
neural O +
systems O +
, O +
such O +
as O +
the O +
action O +
control O +
system O +
, O +
has O +
gained O +
increasing O +
interest O +
( O +
Haber O +
and O +
Knutson O +
, O +
2010 O +
) O +
. O +

Initial O +
evidence O +
suggests O +
coordinated O +
activity O +
between O +
distant O +
brain O +
regions O +
responsible O +
for O +
reward O +
processing O +
( O +
Cohen O +
et O +
al O +
. O +
, O +
2009 O +
) O +
. O +

The O +
current O +
results O +
encourage O +
further O +
neural O +
network O +
investigations O +
on O +
the O +
role O +
of O +
coordinated O +
brain O +
network O +
activity O +
in O +
motivated O +
behavior O +
. O +

Behavioral O +
benefits O +
from O +
motivation O +
might O +
be O +
associated O +
with O +
changes O +
in O +
functional O +
brain O +
connectivity O +
on O +
a O +
larger O +
scale O +
, O +
e O +
. O +
g O +
. O +
, O +
between O +
frontostriatal O +
reward O +
and O +
action O +
preparation O +
structures O +
. O +

Another O +
important O +
factor O +
that O +
emerges O +
from O +
the O +
present O +
and O +
previous O +
results O +
, O +
is O +
the O +
importance O +
of O +
the O +
training O +
of O +
the O +
motivational O +
aspects O +
of O +
the O +
instructions O +
that O +
need O +
to O +
be O +
kept O +
in O +
working O +
memory O +
when O +
performing O +
a O +
cognitive O +
task O +
. O +

Samanez O +
- O +
Larkin O +
et O +
al O +
. O +

( O +
2007 O +
) O +
found O +
intact O +
neural O +
reward O +
anticipation O +
processes O +
specifically O +
in O +
the O +
absence O +
of O +
learning O +
( O +
after O +
the O +
learning O +
process O +
of O +
reward O +
cue O +
- O +
reward O +
associations O +
was O +
completed O +
) O +
. O +

Therefore O +
it O +
might O +
be O +
important O +
for O +
researchers O +
doing O +
experiments O +
with O +
motivation O +
based O +
instructions O +
to O +
keep O +
in O +
mind O +
that O +
, O +
compared O +
to O +
young O +
adults O +
, O +
elderly O +
and O +
PD O +
patients O +
are O +
generally O +
hampered O +
on O +
stimulus O +
- O +
response O +
learning O +
( O +
Shohamy O +
et O +
al O +
. O +
, O +
2004 O +
; O +
Marschner O +
et O +
al O +
. O +
, O +
2005 O +
) O +
. O +

Reward O +
instruction O +
cues O +
, O +
as O +
they O +
were O +
used O +
in O +
the O +
current O +
study O +
require O +
participants O +
to O +
form O +
reward O +
cue O +
- O +
reward O +
associations O +
. O +

Impairments O +
in O +
the O +
learning O +
of O +
associations O +
between O +
the O +
cue O +
signaling O +
reward O +
and O +
the O +
actual O +
reward O +
might O +
conceal O +
intact O +
reward O +
anticipation O +
processes O +
. O +

When O +
the O +
formation O +
of O +
associations O +
is O +
weakened O +
, O +
it O +
could O +
appear O +
as O +
a O +
failure O +
to O +
capitalize O +
on O +
the O +
neural O +
reward O +
anticipation O +
system O +
, O +
whereas O +
it O +
represents O +
an O +
indirect O +
effect O +
of O +
non O +
- O +
available O +
reward O +
associations O +
in O +
working O +
memory O +
when O +
preparing O +
the O +
response O +
. O +

Hence O +
, O +
one O +
might O +
circumvent O +
the O +
effect O +
of O +
potential O +
learning O +
impairments O +
on O +
reward O +
anticipation O +
processes O +
by O +
the O +
training O +
of O +
abstract O +
reward O +
cues O +
( O +
as O +
in O +
the O +
current O +
and O +
in O +
Samanez O +
- O +
Larkin O +
' O +
s O +
study O +
) O +
or O +
by O +
using O +
explicit O +
and O +
concrete O +
rewards O +
. O +

Once O +
the O +
learning O +
of O +
reward O +
cues O +
is O +
accomplished O +
the O +
intact O +
reward O +
anticipation O +
processes O +
might O +
become O +
evident O +
. O +

In O +
sum O +
, O +
the O +
results O +
confirmed O +
that O +
the O +
preparation O +
of O +
goal O +
- O +
directed O +
actions O +
declined O +
in O +
PD O +
patients O +
compared O +
to O +
healthy O +
seniors O +
, O +
and O +
in O +
healthy O +
seniors O +
compared O +
to O +
young O +
adults O +
. O +

Due O +
perhaps O +
to O +
deterioration O +
in O +
dopaminergic O +
striatal O +
circuitry O +
, O +
antisaccade O +
performance O +
is O +
subject O +
to O +
decline O +
in O +
healthy O +
seniors O +
, O +
and O +
even O +
more O +
in O +
individuals O +
with O +
Parkinson O +
' O +
s O +
disease O +
. O +

The O +
prospect O +
of O +
future O +
reward O +
however O +
provided O +
a O +
motivational O +
incentive O +
for O +
optimizing O +
oculomotor O +
preparation O +
in O +
all O +
groups O +
alike O +
. O +

These O +
results O +
suggest O +
that O +
reward O +
- O +
processing O +
networks O +
and O +
oculomotor O +
- O +
control O +
networks O +
in O +
the O +
brain O +
are O +
connected O +
in O +
such O +
a O +
way O +
( O +
presumably O +
with O +
the O +
dorsal O +
striatum O +
as O +
a O +
common O +
nexus O +
) O +
that O +
reward O +
anticipation O +
can O +
facilitate O +
oculomotor O +
control O +
and O +
alleviate O +
the O +
deficiencies O +
experienced O +
by O +
healthy O +
seniors O +
and O +
PD O +
patients O +
. O +

Future O +
investigations O +
should O +
examine O +
whether O +
the O +
observed O +
effects O +
are O +
specific O +
for O +
the O +
current O +
task O +
or O +
generalize O +
to O +
other O +
tasks O +
that O +
show O +
age O +
- O +
and O +
PD O +
- O +
related O +
cognitive O +
decrements O +
( O +
e O +
. O +
g O +
. O +
, O +
in O +
task O +
switching O +
) O +
and O +
have O +
been O +
related O +
to O +
dopaminergic O +
denervation O +
in O +
the O +
caudate O +
( O +
e O +
. O +
g O +
. O +
, O +
impaired O +
verbal O +
episodic O +
memory O +
, O +
attention O +
, O +
and O +
response O +
inhibition O +
; O +
Rinne O +
et O +
al O +
. O +
, O +
2000 O +
; O +
Bruck O +
et O +
al O +
. O +
, O +
2005 O +
) O +
. O +

Future O +
studies O +
on O +
network O +
processes O +
may O +
help O +
to O +
localize O +
the O +
neural O +
link O +
between O +
reward O +
prospect O +
and O +
action O +
preparation O +
that O +
enables O +
alleviating O +
effects O +
of O +
motivational O +
incentives O +
on O +
cognitive O +
decline O +
. O +

Atomic O +
displacement O +
parameters O +
( O +
A2 O +
) O +

U11 O +
U22 O +
U33 O +
U12 O +
U13 O +
U23 O +

Br O +
0 O +
. O +
03555 O +
( O +
15 O +
) O +
0 O +
. O +
05091 O +
( O +
17 O +
) O +
0 O +
. O +
03161 O +
( O +
14 O +
) O +
- O +
0 O +
. O +
01198 O +
( O +
11 O +
) O +
0 O +
. O +
01077 O +
( O +
10 O +
) O +
- O +
0 O +
. O +
00502 O +
( O +
11 O +
) O +

S O +
0 O +
. O +
0273 O +
( O +
3 O +
) O +
0 O +
. O +
0176 O +
( O +
2 O +
) O +
0 O +
. O +
0338 O +
( O +
3 O +
) O +
0 O +
. O +
0016 O +
( O +
2 O +
) O +
- O +
0 O +
. O +
0020 O +
( O +
2 O +
) O +
0 O +
. O +
0026 O +
( O +
2 O +
) O +

F O +
0 O +
. O +
0514 O +
( O +
10 O +
) O +
0 O +
. O +
0486 O +
( O +
9 O +
) O +
0 O +
. O +
0464 O +
( O +
9 O +
) O +
0 O +
. O +
0068 O +
( O +
8 O +
) O +
0 O +
. O +
0279 O +
( O +
8 O +
) O +
- O +
0 O +
. O +
0001 O +
( O +
7 O +
) O +

O1 O +
0 O +
. O +
0293 O +
( O +
8 O +
) O +
0 O +
. O +
0186 O +
( O +
7 O +
) O +
0 O +
. O +
0251 O +
( O +
7 O +
) O +
- O +
0 O +
. O +
0030 O +
( O +
6 O +
) O +
0 O +
. O +
0028 O +
( O +
6 O +
) O +
0 O +
. O +
0004 O +
( O +
6 O +
) O +

O2A O +
0 O +
. O +
0417 O +
( O +
12 O +
) O +
0 O +
. O +
0238 O +
( O +
9 O +
) O +
0 O +
. O +
0326 O +
( O +
10 O +
) O +
- O +
0 O +
. O +
0001 O +
( O +
8 O +
) O +
- O +
0 O +
. O +
0051 O +
( O +
8 O +
) O +
0 O +
. O +
0102 O +
( O +
7 O +
) O +

O2B O +
0 O +
. O +
036 O +
( O +
11 O +
) O +
0 O +
. O +
010 O +
( O +
7 O +
) O +
0 O +
. O +
025 O +
( O +
9 O +
) O +
- O +
0 O +
. O +
003 O +
( O +
7 O +
) O +
0 O +
. O +
003 O +
( O +
7 O +
) O +
0 O +
. O +
007 O +
( O +
6 O +
) O +

C1 O +
0 O +
. O +
0228 O +
( O +
11 O +
) O +
0 O +
. O +
0192 O +
( O +
9 O +
) O +
0 O +
. O +
0233 O +
( O +
10 O +
) O +
0 O +
. O +
0001 O +
( O +
8 O +
) O +
- O +
0 O +
. O +
0023 O +
( O +
8 O +
) O +
0 O +
. O +
0019 O +
( O +
8 O +
) O +

C2 O +
0 O +
. O +
0258 O +
( O +
11 O +
) O +
0 O +
. O +
0199 O +
( O +
10 O +
) O +
0 O +
. O +
0193 O +
( O +
9 O +
) O +
0 O +
. O +
0000 O +
( O +
8 O +
) O +
- O +
0 O +
. O +
0033 O +
( O +
8 O +
) O +
0 O +
. O +
0016 O +
( O +
7 O +
) O +

C3 O +
0 O +
. O +
0263 O +
( O +
11 O +
) O +
0 O +
. O +
0229 O +
( O +
10 O +
) O +
0 O +
. O +
0177 O +
( O +
9 O +
) O +
- O +
0 O +
. O +
0020 O +
( O +
8 O +
) O +
- O +
0 O +
. O +
0031 O +
( O +
8 O +
) O +
0 O +
. O +
0008 O +
( O +
8 O +
) O +

C4 O +
0 O +
. O +
0294 O +
( O +
12 O +
) O +
0 O +
. O +
0228 O +
( O +
10 O +
) O +
0 O +
. O +
0277 O +
( O +
11 O +
) O +
- O +
0 O +
. O +
0014 O +
( O +
9 O +
) O +
- O +
0 O +
. O +
0008 O +
( O +
9 O +
) O +
0 O +
. O +
0027 O +
( O +
8 O +
) O +

C5 O +
0 O +
. O +
0323 O +
( O +
13 O +
) O +
0 O +
. O +
0297 O +
( O +
11 O +
) O +
0 O +
. O +
0285 O +
( O +
11 O +
) O +
- O +
0 O +
. O +
0081 O +
( O +
10 O +
) O +
- O +
0 O +
. O +
0003 O +
( O +
9 O +
) O +
0 O +
. O +
0042 O +
( O +
9 O +
) O +

C6 O +
0 O +
. O +
0257 O +
( O +
12 O +
) O +
0 O +
. O +
0389 O +
( O +
13 O +
) O +
0 O +
. O +
0207 O +
( O +
10 O +
) O +
- O +
0 O +
. O +
0049 O +
( O +
10 O +
) O +
0 O +
. O +
0013 O +
( O +
8 O +
) O +
0 O +
. O +
0001 O +
( O +
9 O +
) O +

C7 O +
0 O +
. O +
0320 O +
( O +
13 O +
) O +
0 O +
. O +
0304 O +
( O +
11 O +
) O +
0 O +
. O +
0218 O +
( O +
10 O +
) O +
0 O +
. O +
0015 O +
( O +
9 O +
) O +
0 O +
. O +
0009 O +
( O +
9 O +
) O +
- O +
0 O +
. O +
0005 O +
( O +
9 O +
) O +

C8 O +
0 O +
. O +
0298 O +
( O +
12 O +
) O +
0 O +
. O +
0257 O +
( O +
10 O +
) O +
0 O +
. O +
0178 O +
( O +
9 O +
) O +
0 O +
. O +
0006 O +
( O +
9 O +
) O +
- O +
0 O +
. O +
0012 O +
( O +
8 O +
) O +
0 O +
. O +
0001 O +
( O +
8 O +
) O +

C9 O +
0 O +
. O +
0392 O +
( O +
14 O +
) O +
0 O +
. O +
0205 O +
( O +
10 O +
) O +
0 O +
. O +
0219 O +
( O +
10 O +
) O +
0 O +
. O +
0034 O +
( O +
9 O +
) O +
0 O +
. O +
0031 O +
( O +
9 O +
) O +
- O +
0 O +
. O +
0010 O +
( O +
8 O +
) O +

C10 O +
0 O +
. O +
0378 O +
( O +
13 O +
) O +
0 O +
. O +
0184 O +
( O +
10 O +
) O +
0 O +
. O +
0234 O +
( O +
10 O +
) O +
- O +
0 O +
. O +
0017 O +
( O +
9 O +
) O +
0 O +
. O +
0014 O +
( O +
9 O +
) O +
0 O +
. O +
0006 O +
( O +
8 O +
) O +

C11 O +
0 O +
. O +
0254 O +
( O +
11 O +
) O +
0 O +
. O +
0227 O +
( O +
10 O +
) O +
0 O +
. O +
0198 O +
( O +
10 O +
) O +
- O +
0 O +
. O +
0024 O +
( O +
8 O +
) O +
0 O +
. O +
0004 O +
( O +
8 O +
) O +
0 O +
. O +
0006 O +
( O +
8 O +
) O +

C12 O +
0 O +
. O +
0254 O +
( O +
11 O +
) O +
0 O +
. O +
0187 O +
( O +
10 O +
) O +
0 O +
. O +
0222 O +
( O +
10 O +
) O +
- O +
0 O +
. O +
0003 O +
( O +
8 O +
) O +
- O +
0 O +
. O +
0032 O +
( O +
8 O +
) O +
- O +
0 O +
. O +
0007 O +
( O +
7 O +
) O +

C13 O +
0 O +
. O +
0237 O +
( O +
11 O +
) O +
0 O +
. O +
0220 O +
( O +
10 O +
) O +
0 O +
. O +
0222 O +
( O +
10 O +
) O +
0 O +
. O +
0012 O +
( O +
8 O +
) O +
- O +
0 O +
. O +
0008 O +
( O +
8 O +
) O +
0 O +
. O +
0030 O +
( O +
8 O +
) O +

C14 O +
0 O +
. O +
0298 O +
( O +
12 O +
) O +
0 O +
. O +
0241 O +
( O +
10 O +
) O +
0 O +
. O +
0286 O +
( O +
11 O +
) O +
- O +
0 O +
. O +
0009 O +
( O +
9 O +
) O +
- O +
0 O +
. O +
0007 O +
( O +
9 O +
) O +
- O +
0 O +
. O +
0006 O +
( O +
9 O +
) O +

C15 O +
0 O +
. O +
0408 O +
( O +
14 O +
) O +
0 O +
. O +
0267 O +
( O +
11 O +
) O +
0 O +
. O +
0269 O +
( O +
11 O +
) O +
0 O +
. O +
0049 O +
( O +
10 O +
) O +
0 O +
. O +
0028 O +
( O +
10 O +
) O +
- O +
0 O +
. O +
0031 O +
( O +
9 O +
) O +

C16 O +
0 O +
. O +
0353 O +
( O +
14 O +
) O +
0 O +
. O +
0326 O +
( O +
12 O +
) O +
0 O +
. O +
0294 O +
( O +
12 O +
) O +
0 O +
. O +
0094 O +
( O +
10 O +
) O +
0 O +
. O +
0094 O +
( O +
10 O +
) O +
0 O +
. O +
0058 O +
( O +
9 O +
) O +

C17 O +
0 O +
. O +
0255 O +
( O +
12 O +
) O +
0 O +
. O +
0281 O +
( O +
11 O +
) O +
0 O +
. O +
0349 O +
( O +
12 O +
) O +
- O +
0 O +
. O +
0001 O +
( O +
9 O +
) O +
0 O +
. O +
0015 O +
( O +
9 O +
) O +
0 O +
. O +
0082 O +
( O +
9 O +
) O +

C18 O +
0 O +
. O +
0271 O +
( O +
12 O +
) O +
0 O +
. O +
0231 O +
( O +
10 O +
) O +
0 O +
. O +
0250 O +
( O +
11 O +
) O +
0 O +
. O +
0002 O +
( O +
9 O +
) O +
- O +
0 O +
. O +
0032 O +
( O +
9 O +
) O +
0 O +
. O +
0011 O +
( O +
8 O +
) O +

C19 O +
0 O +
. O +
0353 O +
( O +
14 O +
) O +
0 O +
. O +
0251 O +
( O +
11 O +
) O +
0 O +
. O +
0375 O +
( O +
13 O +
) O +
- O +
0 O +
. O +
0045 O +
( O +
10 O +
) O +
- O +
0 O +
. O +
0070 O +
( O +
10 O +
) O +
- O +
0 O +
. O +
0012 O +
( O +
9 O +
) O +

Different O +
ROC O +
analysis O +

When O +
the O +
true O +
positive O +
peptides O +
are O +
not O +
known O +
a O +
priori O +
, O +
there O +
exist O +
various O +
strategies O +
in O +
classifying O +
hits O +
into O +
true O +
or O +
false O +
positives O +
when O +
making O +
a O +
ROC O +
plot O +
. O +

These O +
strategies O +
, O +
unfortunately O +
, O +
will O +
make O +
a O +
notable O +
difference O +
in O +
retrieval O +
assessment O +
. O +

For O +
example O +
, O +
in O +
a O +
cell O +
lysate O +
experiment O +
of O +
a O +
certain O +
organism O +
, O +
it O +
is O +
customary O +
to O +
estimate O +
the O +
number O +
of O +
false O +
positive O +
hits O +
by O +
introducing O +
a O +
decoy O +
database O +
during O +
the O +
data O +
analysis O +
. O +

The O +
main O +
idea O +
there O +
is O +
to O +
first O +
sort O +
the O +
peptide O +
hits O +
according O +
to O +
their O +
scores O +
. O +

Then O +
for O +
each O +
decoy O +
hit O +
, O +
one O +
assumes O +
that O +
there O +
is O +
just O +
one O +
corresponding O +
false O +
hit O +
in O +
the O +
target O +
database O +
. O +

This O +
strategy O +
has O +
been O +
used O +
extensively O +
[ O +
24 O +
] O +
. O +

ROC O +
analyses O +
done O +
this O +
way O +
generally O +
count O +
false O +
positives O +
, O +
which O +
are O +
highly O +
homologous O +
to O +
the O +
target O +
peptides O +
, O +
towards O +
true O +
positives O +
. O +

This O +
has O +
two O +
effects O +
: O +
an O +
overcount O +
of O +
true O +
positives O +
and O +
a O +
undercount O +
of O +
false O +
positives O +
. O +

As O +
a O +
consequence O +
, O +
the O +
ROC O +
curves O +
will O +
appear O +
more O +
impressive O +
. O +

To O +
mimick O +
this O +
situation O +
, O +
we O +
used O +
BLAST O +
to O +
find O +
in O +
the O +
NCBI O +
' O +
s O +
nr O +
database O +
highly O +
homologous O +
proteins O +
to O +
the O +
target O +
proteins O +
used O +
in O +
the O +
experiment O +
and O +
include O +
those O +
proteins O +
in O +
our O +
true O +
positive O +
set O +
. O +

This O +
strategy O +
produces O +
ROC O +
curves O +
shown O +
as O +
the O +
solid O +
curves O +
of O +
Figure O +
S8 O +
. O +

When O +
compared O +
to O +
Figure O +
6 O +
and O +
Figure O +
S6 O +
, O +
the O +
ROC O +
curves O +
produced O +
by O +
this O +
strategy O +
seem O +
much O +
more O +
impressive O +
. O +

Not O +
counting O +
highly O +
homologous O +
proteins O +
as O +
false O +
positives O +
would O +
probably O +
be O +
agreeable O +
. O +

However O +
, O +
counting O +
those O +
peptides O +
/ O +
proteins O +
as O +
true O +
positives O +
could O +
be O +
exaggerating O +
. O +

Therefore O +
one O +
may O +
use O +
a O +
slightly O +
different O +
strategy O +
: O +
removing O +
from O +
consideration O +
proteins O +
homologous O +
to O +
the O +
target O +
proteins O +
, O +
which O +
is O +
called O +
the O +
cluster O +
removal O +
strategy O +
[ O +
11 O +
] O +
. O +

The O +
dashed O +
curves O +
of O +
Figure O +
S9 O +
are O +
ROC O +
curves O +
obtained O +
this O +
way O +
. O +

This O +
strategy O +
also O +
produces O +
slightly O +
more O +
impressive O +
ROC O +
curves O +
than O +
in O +
Figure O +
6 O +
and O +
Figure O +
S6 O +
. O +

Apparently O +
, O +
this O +
indicates O +
the O +
highly O +
homologous O +
false O +
positive O +
hits O +
are O +
the O +
ones O +
that O +
degrade O +
the O +
retrieval O +
performance O +
. O +

Thus O +
, O +
it O +
can O +
be O +
useful O +
to O +
remove O +
those O +
false O +
positives O +
from O +
consideration O +
. O +

Keeping O +
only O +
the O +
best O +
hit O +
per O +
spectrum O +
turns O +
out O +
to O +
be O +
one O +
way O +
to O +
achieve O +
this O +
goal O +
. O +

Crystal O +
data O +

C24H21ClN4O2S O +

M O +
r O +
= O +
464 O +
. O +
96 O +

Triclinic O +
, O +

a O +
= O +
8 O +
. O +
6798 O +
( O +
18 O +
) O +
A O +

b O +
= O +
11 O +
. O +
078 O +
( O +
2 O +
) O +
A O +

c O +
= O +
11 O +
. O +
372 O +
( O +
2 O +
) O +
A O +

alpha O +
= O +
78 O +
. O +
984 O +
( O +
7 O +
) O +
degrees O +

beta O +
= O +
81 O +
. O +
867 O +
( O +
10 O +
) O +
degrees O +

gamma O +
= O +
81 O +
. O +
718 O +
( O +
11 O +
) O +
degrees O +

V O +
= O +
1054 O +
. O +
8 O +
( O +
4 O +
) O +
A3 O +

Z O +
= O +
2 O +

Cu O +
Kalpha O +
radiation O +

mu O +
= O +
2 O +
. O +
78 O +
mm O +
- O +
1 O +

T O +
= O +
113 O +
K O +

0 O +
. O +
28 O +
x O +
0 O +
. O +
24 O +
x O +
0 O +
. O +
20 O +
mm O +

Characteristics O +
of O +
fistula O +
lesions O +

Selective O +
SMA O +
angiography O +
was O +
performed O +
5 O +
h O +
from O +
onset O +
. O +

Before O +
therapy O +
, O +
the O +
SMA O +
was O +
completely O +
occluded O +
by O +
an O +
embolus O +
at O +
the O +
proximal O +
portion O +
( O +
a O +
) O +
, O +
and O +
after O +
the O +
bolus O +
infusion O +
of O +
urokinase O +
( O +
600 O +
, O +
000 O +
IU O +
) O +
into O +
the O +
SMA O +
, O +
peripheral O +
blood O +
flow O +
was O +
improved O +
. O +

However O +
, O +
the O +
thrombus O +
decreased O +
in O +
size O +
, O +
but O +
remained O +
( O +
b O +
) O +
. O +

Asterisks O +
indicate O +
thrombus O +
. O +

Measurement O +
of O +
IgA1 O +
content O +

IgA1 O +
content O +
in O +
the O +
supernatant O +
from O +
each O +
culture O +
well O +
was O +
measured O +
in O +
duplicate O +
using O +
enzyme O +
- O +
linked O +
immunosorbent O +
assay O +
( O +
ELISA O +
) O +
. O +

All O +
incubations O +
were O +
performed O +
at O +
room O +
temperature O +
except O +
for O +
capture O +
antibody O +
coating O +
. O +

Briefly O +
, O +
96 O +
- O +
well O +
immunoplates O +
( O +
Thermo O +
Fisher O +
Scientific O +
, O +
Waltham O +
, O +
MA O +
, O +
USA O +
) O +
were O +
coated O +
with O +
5 O +
microg O +
/ O +
mL O +
of O +
F O +
( O +
ab O +
' O +
) O +
2 O +
fragment O +
goat O +
anti O +
- O +
human O +
IgA O +
antibody O +
( O +
Jackson O +
ImmunoResearch O +
Laboratories O +
, O +
West O +
Grove O +
, O +
PA O +
, O +
USA O +
) O +
, O +
in O +
phosphate O +
- O +
buffered O +
saline O +
( O +
PBS O +
) O +
at O +
4degreesC O +
overnight O +
. O +

After O +
three O +
washes O +
with O +
PBS O +
containing O +
0 O +
. O +
05 O +
% O +
Tween O +
- O +
20 O +
( O +
PBST O +
) O +
, O +
plates O +
were O +
blocked O +
by O +
adding O +
PBS O +
containing O +
1 O +
% O +
bovine O +
serum O +
albumin O +
( O +
BSA O +
) O +
to O +
the O +
wells O +
for O +
90 O +
min O +
. O +

Next O +
, O +
50 O +
microL O +
of O +
supernatant O +
sample O +
or O +
standard O +
human O +
IgA1 O +
( O +
CALBIOCHEM O +
, O +
La O +
Jolla O +
, O +
CA O +
, O +
USA O +
) O +
was O +
added O +
to O +
the O +
reaction O +
wells O +
and O +
then O +
incubated O +
for O +
90 O +
min O +
. O +

After O +
three O +
washes O +
, O +
0 O +
. O +
75 O +
microg O +
/ O +
mL O +
alkaline O +
phosphatase O +
conjugated O +
goat O +
anti O +
- O +
human O +
IgA O +
( O +
Southern O +
Biotechnology O +
Associates O +
, O +
Birmingham O +
, O +
AL O +
, O +
USA O +
) O +
in O +
1 O +
% O +
BSA O +
/ O +
PBS O +
was O +
added O +
to O +
the O +
reaction O +
wells O +
and O +
then O +
incubated O +
for O +
90 O +
min O +
. O +

Plates O +
were O +
washed O +
three O +
times O +
and O +
developed O +
with O +
a O +
substrate O +
solution O +
of O +
1 O +
mg O +
/ O +
mL O +
p O +
- O +
nitrophenyl O +
phosphate O +
disodium O +
salt O +
( O +
SIGMA O +
, O +
St O +
. O +
Louis O +
, O +
MO O +
, O +
USA O +
) O +
in O +
0 O +
. O +
1 O +
M O +
glycine O +
buffer O +
containing O +
1 O +
mM O +
MgCl2 O +
, O +
1 O +
mM O +
ZnCl2 O +
, O +
pH O +
10 O +
. O +
4 O +
. O +

The O +
optical O +
density O +
at O +
405 O +
nm O +
was O +
determined O +
in O +
a O +
microplate O +
reader O +
( O +
Benchmark O +
PlusTM O +
Bio O +
- O +
Rad O +
Laboratories O +
, O +
Hercules O +
, O +
CA O +
, O +
USA O +
) O +
. O +

IgA1 O +
concentration O +
in O +
unknown O +
duplicate O +
samples O +
was O +
determined O +
by O +
interpolation O +
of O +
the O +
respective O +
optical O +
density O +
into O +
the O +
appropriate O +
standard O +
curve O +
. O +

IgG O +
and O +
IgM O +
contents O +
in O +
the O +
supernatant O +
were O +
measured O +
using O +
sandwich O +
ELISA O +
( O +
IMMUNOtek O +
( O +
R O +
) O +
, O +
ZeptoMetrix O +
Corporation O +
, O +
Buffalo O +
, O +
NY O +
, O +
USA O +
) O +
according O +
to O +
the O +
manufacturer O +
' O +
s O +
instructions O +
. O +

Results O +
and O +
Discussion O +

Figure O +
4 O +
shows O +
the O +
frequency O +
response O +
of O +
the O +
device O +
before O +
and O +
after O +
plating O +
cells O +
. O +

In O +
the O +
frequency O +
range O +
measured O +
( O +
4 O +
- O +
600 O +
Hz O +
) O +
, O +
only O +
two O +
clear O +
peaks O +
can O +
be O +
seen O +
in O +
the O +
bare O +
device O +
. O +

After O +
cells O +
had O +
adhered O +
to O +
the O +
surface O +
, O +
there O +
is O +
a O +
shift O +
in O +
both O +
the O +
resonant O +
frequency O +
and O +
the O +
height O +
of O +
these O +
peaks O +
. O +

Table O +
1 O +
shows O +
the O +
results O +
for O +
this O +
trial O +
and O +
a O +
second O +
trial O +
where O +
the O +
experiment O +
was O +
repeated O +
to O +
confirm O +
the O +
initial O +
results O +
. O +

At O +
a O +
plating O +
density O +
of O +
1300 O +
cells O +
/ O +
mm2 O +
, O +
there O +
were O +
approximately O +
140 O +
cells O +
on O +
the O +
portion O +
of O +
the O +
cantilever O +
free O +
to O +
vibrate O +
( O +
dimensions O +
shown O +
in O +
Figure O +
1 O +
) O +
. O +

Table O +
1 O +

Cantilever O +
response O +
data O +
from O +
two O +
trials O +

Experiment O +
# O +
1 O +
Experiment O +
# O +
2 O +

Freq O +
. O +

1 O +
( O +
kHz O +
) O +
Amp O +
. O +

1 O +
( O +
deg O +
) O +
Freq O +
. O +

2 O +
( O +
kHz O +
) O +
Amp O +
. O +

2 O +
( O +
deg O +
) O +
Freq O +
. O +

1 O +
( O +
kHz O +
) O +
Amp O +
. O +

1 O +
( O +
deg O +
) O +
Freq O +
. O +

2 O +
( O +
kHz O +
) O +
Amp O +
. O +

2 O +
( O +
deg O +
) O +

Initial O +
313 O +
. O +
0 O +
. O +
086 O +
375 O +
. O +
5 O +
. O +
055 O +
313 O +
. O +
9 O +
. O +
091 O +
376 O +
. O +
5 O +
. O +
071 O +

With O +
cells O +
307 O +
. O +
5 O +
. O +
031 O +
371 O +
. O +
0 O +
. O +
018 O +
308 O +
. O +
052 O +
370 O +
. O +
5 O +
. O +
043 O +

Change O +
5 O +
. O +
5 O +
. O +
055 O +
4 O +
. O +
5 O +
. O +
037 O +
5 O +
. O +
9 O +
. O +
039 O +
6 O +
. O +
0 O +
. O +
028 O +

Figure O +
4 O +

Phase O +
angle O +
vs O +
. O +
frequency O +
. O +

( O +
left O +
) O +
Phase O +
angle O +
of O +
impedance O +
with O +
linear O +
regression O +
line O +
. O +

( O +
right O +
) O +
To O +
provide O +
an O +
easier O +
comparison O +
, O +
phase O +
angles O +
have O +
been O +
levelled O +
with O +
respect O +
to O +
the O +
linear O +
regression O +
line O +
that O +
passes O +
through O +
each O +
set O +
of O +
data O +
. O +

The O +
addition O +
of O +
cells O +
causes O +
the O +
peaks O +
to O +
shift O +
to O +
lower O +
frequencies O +
and O +
decrease O +
in O +
amplitude O +
. O +

The O +
two O +
peaks O +
shown O +
were O +
the O +
only O +
detectable O +
resonances O +
despite O +
the O +
relatively O +
wide O +
frequency O +
range O +
measured O +
. O +

The O +
electrical O +
detection O +
of O +
resonances O +
is O +
critically O +
compromised O +
by O +
the O +
strong O +
damping O +
imposed O +
by O +
the O +
cell O +
media O +
, O +
making O +
these O +
measurements O +
more O +
challenging O +
than O +
those O +
carried O +
out O +
in O +
air O +
or O +
in O +
a O +
vacuum O +
where O +
resonance O +
peaks O +
show O +
much O +
larger O +
amplitude O +
[ O +
18 O +
] O +
. O +

In O +
the O +
desired O +
in O +
vivo O +
application O +
for O +
this O +
work O +
, O +
as O +
a O +
sensor O +
for O +
stent O +
healing O +
, O +
it O +
can O +
be O +
expected O +
that O +
in O +
the O +
course O +
of O +
normal O +
healing O +
the O +
stent O +
will O +
be O +
fully O +
populated O +
with O +
a O +
significantly O +
thicker O +
layer O +
of O +
endothelial O +
cells O +
. O +

In O +
the O +
case O +
of O +
restenosis O +
, O +
this O +
lining O +
would O +
be O +
even O +
thicker O +
. O +

This O +
may O +
hamper O +
any O +
movement O +
of O +
the O +
cantilever O +
and O +
cause O +
the O +
peaks O +
to O +
eventually O +
become O +
undetectable O +
. O +

Frequent O +
measurements O +
of O +
the O +
resonant O +
frequencies O +
will O +
differentiate O +
this O +
end O +
state O +
with O +
the O +
possibility O +
of O +
device O +
failure O +
. O +

The O +
noninvasive O +
nature O +
of O +
these O +
measurements O +
that O +
can O +
be O +
transmitted O +
wirelessly O +
to O +
an O +
external O +
device O +
make O +
this O +
an O +
attractive O +
and O +
low O +
risk O +
option O +
for O +
monitoring O +
healing O +
. O +

The O +
thickness O +
of O +
the O +
inner O +
retina O +
was O +
established O +
as O +
the O +
distance O +
between O +
retinal O +
nerve O +
fiber O +
layer O +
and O +
inner O +
nuclear O +
layer O +
and O +
was O +
measured O +
using O +
the O +
1 O +
, O +
000 O +
mum O +
caliper O +
available O +
in O +
the O +
OCT O +
- O +
SLO O +
Spectralis O +
. O +

Ten O +
age O +
- O +
matched O +
normal O +
eyes O +
were O +
used O +
as O +
controls O +
. O +

Observe O +
the O +
decrease O +
in O +
the O +
nasal O +
and O +
temporal O +
inner O +
retinal O +
thickness O +
in O +
the O +
right O +
eye O +
in O +
comparison O +
to O +
the O +
left O +
and O +
normal O +
control O +
eyes O +
. O +

2 O +
. O +
1 O +
. O +

Genome O +
sequencing O +
, O +
assembly O +
and O +
validation O +

DNA O +
shotgun O +
libraries O +
with O +
average O +
insert O +
sizes O +
of O +
1 O +
. O +
6 O +
and O +
6 O +
. O +
5 O +
kb O +
were O +
constructed O +
in O +
pUC118 O +
( O +
TaKaRa O +
) O +
, O +
whereas O +
a O +
fosmid O +
library O +
with O +
average O +
insert O +
size O +
of O +
37 O +
kb O +
was O +
constructed O +
in O +
pCC1FOS O +
( O +
EPICENTRE O +
) O +
as O +
described O +
previously O +
. O +
18 O +
, O +
19 O +
A O +
total O +
of O +
50 O +
400 O +
clones O +
( O +
34 O +
560 O +
, O +
10 O +
752 O +
and O +
5088 O +
clones O +
from O +
libraries O +
with O +
1 O +
. O +
6 O +
, O +
6 O +
. O +
5 O +
and O +
37 O +
kb O +
inserts O +
, O +
respectively O +
) O +
were O +
subjected O +
to O +
sequencing O +
from O +
both O +
ends O +
of O +
the O +
inserts O +
on O +
either O +
ABI O +
3730xl O +
DNA O +
Analyzer O +
( O +
Applied O +
Biosystems O +
) O +
or O +
Base O +
Station O +
DNA O +
Fragment O +
Analyzer O +
BST O +
- O +
0100 O +
( O +
MJ O +
Research O +
, O +
Inc O +
. O +
) O +
. O +

Sequence O +
reads O +
were O +
trimmed O +
at O +
a O +
threshold O +
quality O +
value O +
of O +
20 O +
by O +
Phred O +
and O +
assembled O +
by O +
Phrap O +
and O +
CONSED O +
assembly O +
tools O +
. O +
20 O +
, O +
21 O +
For O +
alignment O +
and O +
validation O +
of O +
contigs O +
, O +
Optical O +
Mapping O +
( O +
OpGen O +
) O +
was O +
used O +
. O +

Gaps O +
between O +
contigs O +
were O +
closed O +
by O +
sequencing O +
PCR O +
products O +
, O +
which O +
bridge O +
two O +
neighboring O +
contigs O +
. O +

Finally O +
, O +
each O +
base O +
of O +
K O +
. O +
setae O +
NBRC O +
14216 O -
T O +
genome O +
was O +
ensured O +
to O +
be O +
sequenced O +
from O +
multiple O +
clones O +
and O +
from O +
both O +
directions O +
with O +
Phrap O +
quality O +
score O +
> O +
= O +
70 O +
or O +
from O +
one O +
direction O +
with O +
Phrap O +
quality O +
score O +
> O +
= O +
40 O +
. O +

Chromosomal O +
terminus O +
was O +
determined O +
after O +
attaching O +
adenine O +
and O +
thymine O +
homopolymers O +
to O +
the O +
naked O +
3 O +
' O +
ends O +
of O +
the O +
chromosome O +
as O +
described O +
previously O +
. O +
5 O +

Sensitivity O +
of O +
intervention O +
cost O +
- O +
effectiveness O +
to O +
rates O +
of O +
decay O +
in O +
intervention O +
effectiveness O +
between O +
0 O +
% O +
( O +
life O +
- O +
long O +
health O +
benefits O +
from O +
one O +
- O +
off O +
intervention O +
) O +
and O +
100 O +
% O +
( O +
no O +
health O +
benefits O +
beyond O +
the O +
end O +
of O +
intervention O +
) O +
. O +

Real O +
time O +
RT O +
- O +
PCR O +

RNA O +
extraction O +
and O +
real O +
- O +
time O +
RT O +
- O +
PCR O +
were O +
performed O +
as O +
we O +
described O +
previously O +
[ O +
22 O +
] O +
. O +

The O +
sequences O +
of O +
ABCG2 O +
primers O +
are O +
5 O +
' O +
- O +
GGCTTTCTACCTGCACGAAAACCAGTTGAG O +
- O +
3 O +
' O +
( O +
forward O +
) O +
and O +
5 O +
' O +
- O +
ATGGCGTTGAGACCAG O +
- O +
3 O +
' O +
( O +
reverse O +
) O +
. O +

The O +
sequences O +
of O +
GAPDH O +
primers O +
are O +
5 O +
' O +
- O +
AAGGACTCATGACCACAGTCCAT O +
- O +
3 O +
' O +
( O +
forward O +
) O +
and O +
5 O +
' O +
- O +
CCATCACGCCACAGTTTCC O +
- O +
3 O +
' O +
( O +
reverse O +
) O +
. O +

The O +
relative O +
ABCG2 O +
RNA O +
level O +
( O +
2DeltaCT O +
) O +
treated O +
with O +
inhibitors O +
was O +
expressed O +
as O +
percentage O +
of O +
the O +
control O +
( O +
in O +
the O +
presence O +
of O +
0 O +
. O +
1 O +
% O +
DMSO O +
) O +
where O +
DeltaCT O +
( O +
threshold O +
cycle O +
) O +
= O +
( O +
CTABCG2 O +
- O +
CTGAPDH O +
) O +
. O +

Introduction O +

Adipose O +
tissue O +
, O +
once O +
viewed O +
as O +
simply O +
a O +
storage O +
and O +
release O +
depot O +
for O +
lipids O +
, O +
is O +
now O +
considered O +
an O +
endocrine O +
tissue O +
[ O +
1 O +
, O +
2 O +
] O +
that O +
secretes O +
various O +
substances O +
( O +
adipokines O +
) O +
, O +
including O +
tumor O +
necrosis O +
factor O +
- O +
alpha O +
( O +
TNF O +
- O +
alpha O +
) O +
, O +
interleukin O +
( O +
IL O +
) O +
- O +
6 O +
, O +
leptin O +
, O +
adiponectin O +
, O +
resistin O +
, O +
visfatin O +
, O +
and O +
omenetin O +
[ O +
3 O +
, O +
4 O +
] O +
. O +

Among O +
these O +
adipokines O +
, O +
much O +
attention O +
has O +
been O +
paid O +
to O +
adiponectin O +
' O +
s O +
relationship O +
with O +
insulin O +
sensitivity O +
and O +
glucose O +
and O +
lipid O +
metabolism O +
in O +
the O +
past O +
10 O +
years O +
. O +

In O +
addition O +
, O +
adiponectin O +
is O +
known O +
to O +
exhibit O +
potent O +
anti O +
- O +
inflammatory O +
[ O +
5 O +
] O +
, O +
atheroprotective O +
[ O +
6 O +
] O +
, O +
and O +
antidiabetic O +
[ O +
7 O +
] O +
effects O +
. O +

Recent O +
findings O +
suggest O +
that O +
adiponectin O +
may O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
rheumatoid O +
arthritis O +
( O +
RA O +
) O +
. O +

Levels O +
of O +
adiponectin O +
in O +
synovial O +
fluid O +
and O +
sera O +
were O +
elevated O +
in O +
patients O +
with O +
RA O +
[ O +
8 O +
, O +
9 O +
] O +
. O +

Adiponectin O +
also O +
induces O +
the O +
production O +
of O +
proinflammatory O +
cytokines O +
, O +
IL O +
- O +
6 O +
, O +
matrix O +
metalloproteinase O +
( O +
MMP O +
) O +
- O +
1 O +
, O +
and O +
IL O +
- O +
8 O +
from O +
RA O +
synovial O +
fibroblasts O +
in O +
vitro O +
[ O +
10 O +
, O +
11 O +
] O +
. O +

Thus O +
, O +
it O +
was O +
suggested O +
that O +
adiponectin O +
can O +
also O +
exert O +
significant O +
proinflammatory O +
and O +
matrix O +
- O +
degrading O +
effects O +
. O +

However O +
, O +
the O +
role O +
of O +
adiponectin O +
in O +
the O +
pathogenesis O +
of O +
RA O +
is O +
still O +
controversial O +
because O +
of O +
conflicting O +
reports O +
about O +
its O +
function O +
[ O +
10 O +
, O +
12 O +
- O +
15 O +
] O +
. O +

In O +
particular O +
, O +
adiponectin O +
seems O +
to O +
play O +
an O +
anti O +
- O +
inflammatory O +
role O +
because O +
it O +
significantly O +
inhibited O +
IL O +
- O +
1beta O +
- O +
stimulated O +
synovial O +
cell O +
proliferation O +
in O +
collagen O +
- O +
induced O +
arthritic O +
mice O +
, O +
despite O +
increased O +
IL O +
- O +
6 O +
expression O +
[ O +
16 O +
] O +
. O +

In O +
contrast O +
, O +
high O +
- O +
grade O +
inflammation O +
in O +
RA O +
patients O +
was O +
negatively O +
correlated O +
with O +
circulating O +
adiponectin O +
concentrations O +
[ O +
17 O +
] O +
. O +

Rather O +
, O +
it O +
was O +
suggested O +
that O +
circulating O +
adiponectin O +
may O +
be O +
involved O +
in O +
cardiovascular O +
disease O +
in O +
RA O +
patients O +
. O +

Although O +
this O +
contradiction O +
was O +
partly O +
explained O +
by O +
the O +
induction O +
of O +
tolerance O +
to O +
inflammatory O +
stimuli O +
by O +
adiponectin O +
[ O +
18 O +
] O +
, O +
the O +
pro O +
- O +
or O +
anti O +
- O +
inflammatory O +
effects O +
of O +
adiponectin O +
on O +
the O +
pathogenesis O +
of O +
RA O +
remain O +
unknown O +
. O +

With O +
regard O +
to O +
adiponectin O +
' O +
s O +
proinflammatory O +
effects O +
, O +
we O +
wondered O +
whether O +
adiponectin O +
might O +
stimulate O +
the O +
production O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
and O +
MMPs O +
as O +
well O +
as O +
proinflammatory O +
mediators O +
like O +
IL O +
- O +
1beta O +
and O +
TNF O +
- O +
alpha O +
do O +
. O +

In O +
this O +
study O +
, O +
we O +
investigated O +
the O +
stimulatory O +
effect O +
of O +
adiponectin O +
on O +
the O +
production O +
of O +
IL O +
- O +
6 O +
, O +
IL O +
- O +
8 O +
, O +
prostaglandin O +
E2 O +
( O +
PGE2 O +
) O +
, O +
VEGF O +
, O +
and O +
MMPs O +
. O +

In O +
addition O +
, O +
the O +
correlation O +
between O +
adiponectin O +
and O +
VEGF O +
or O +
MMPs O +
was O +
investigated O +
by O +
measuring O +
the O +
levels O +
of O +
these O +
three O +
proteins O +
in O +
the O +
joint O +
fluid O +
of O +
patients O +
with O +
RA O +
or O +
osteoarthritis O +
( O +
OA O +
) O +
. O +

Correlation O +
matrix O +
for O +
ear O +
( O +
E O +
) O +
traits O +
in O +
2006 O +
; O +
data O +
from O +
water O +
stress O +
plots O +
( O +
lower O +
left O +
) O +
and O +
well O +
- O +
watered O +
plots O +
( O +
upper O +
right O +
) O +
of O +
350 O +
maize O +
inbreds O +

Refinement O +

The O +
H O +
- O +
atoms O +
were O +
positioned O +
geometrically O +
( O +
O O +
- O +
H O +
= O +
0 O +
. O +
82 O +
, O +
C O +
- O +
H O +
= O +
0 O +
. O +
93 O +
A O +
) O +
and O +
were O +
included O +
in O +
the O +
refinement O +
in O +
the O +
riding O +
model O +
approximation O +
, O +
with O +
Uiso O +
( O +
H O +
) O +
= O +
xUeq O +
( O +
C O +
, O +
O O +
) O +
, O +
where O +
x O +
= O +
1 O +
. O +
2 O +
for O +
all O +
H O +
- O +
atoms O +
. O +

Reagents O +
and O +
antibodies O +

Maxisorp O +
strips O +
( O +
NunC O +
, O +
Roskilde O +
, O +
Denmark O +
) O +
, O +
GST O +
- O +
PNMA2 O +
recombinant O +
protein O +
( O +
Abnova O +
, O +
Taipei O +
, O +
Taiwan O +
) O +
; O +
3 O +
, O +
3 O +
' O +
, O +
5 O +
, O +
5 O +
- O +
tetramethylbenzidine O +
( O +
TMB O +
) O +
+ O +
substrate O +
( O +
Dako O +
, O +
Glostrup O +
, O +
Denmark O +
) O +
, O +
Peroxidase O +
with O +
dakocytomation O +
peroxidase O +
block O +
( O +
Dako O +
) O +
, O +
Dakocytomation O +
envision O +
( O +
R O +
) O +
system O +
labeled O +
polymer O +
- O +
HRP O +
anti O +
- O +
rabbit O +
kit O +
and O +
3 O +
- O +
3 O +
' O +
- O +
diaminobenzidine O +
( O +
Dako O +
) O +
, O +
Mayer O +
' O +
s O +
hematoxylin O +
( O +
Histolab O +
Product O +
AB O +
, O +
Gothenburg O +
, O +
Sweden O +
) O +
, O +
Graded O +
alcohol O +
( O +
Kemetyl O +
, O +
Vestby O +
, O +
Norway O +
) O +
, O +
Xylen O +
( O +
Solveco O +
, O +
Rosersberg O +
, O +
Sweden O +
) O +
, O +
Pertex O +
( O +
R O +
) O +
( O +
Histolab O +
, O +
Gothenburg O +
, O +
Sweden O +
) O +
, O +
Tris O +
- O +
Glycine O +
blotting O +
buffer O +
( O +
Amresco O +
, O +
Solon O +
, O +
OH O +
) O +
, O +
Western O +
blotting O +
( O +
WB O +
) O +
reagent O +
and O +
Lumi O +
- O +
Light O +
WB O +
substrate O +
( O +
Roche O +
, O +
Basel O +
, O +
Switzerland O +
) O +
, O +
EasyTag O +
Methionine O +
- O +
L O +
- O +
35S O +
, O +
NEG709A005MC O +
( O +
PerkinElmer O +
, O +
Waltham O +
, O +
MA O +
) O +
, O +
Full O +
- O +
length O +
cDNA O +
clone O +
for O +
human O +
PNMA2 O +
, O +
ID6580976 O +
( O +
BioScience O +
Geneservice O +
, O +
Cambridge O +
, O +
UK O +
) O +
, O +
TnT O +
( O +
R O +
) O +
SP6 O +
Quick O +
Coupled O +
Transcription O +
/ O +
Translation O +
System O +
( O +
Promega O +
, O +
Madison O +
, O +
WI O +
) O +
, O +
Protein O +
G O +
- O +
Sepharose O +
beads O +
( O +
GE O +
Healthcare O +
, O +
Little O +
Chalfont O +
, O +
Buckinghamshire O +
, O +
UK O +
) O +
, O +
Peroxidase O +
( O +
HRP O +
) O +
- O +
conjugated O +
rabbit O +
anti O +
human O +
IgG O +
( O +
anti O +
- O +
IgG O +
) O +
( O +
Dako O +
) O +
, O +
rabbit O +
polyclonal O +
antibody O +
anti O +
- O +
PNMA2 O +
( O +
Atlas O +
Antibodies O +
, O +
Stockholm O +
, O +
Sweden O +
) O +
, O +
monoclonal O +
mouse O +
anti O +
- O +
GST O +
, O +
sc O +
- O +
138 O +
, O +
polyclonal O +
goat O +
anti O +
- O +
human O +
Ma2 O +
, O +
sc O +
- O +
68099 O +
, O +
HRP O +
- O +
donkey O +
anti O +
- O +
goat O +
, O +
sc O +
- O +
2020 O +
, O +
( O +
Santa O +
Cruz O +
Biotechnology O +
, O +
Santa O +
Cruz O +
, O +
CA O +
) O +
, O +
HRP O +
- O +
goat O +
anti O +
- O +
rabbit O +
, O +
P0448 O +
, O +
( O +
Dako O +
) O +
and O +
Ravo O +
PNS O +
- O +
Blot O +
, O +
( O +
Ravo O +
Diagnostika O +
GmbH O +
, O +
Freiburg O +
, O +
Germany O +
) O +
. O +

FUNDING O +

National O +
Institutes O +
of O +
Health O +
grants O +
, O +
National O +
Institute O +
of O +
Environmental O +
Health O +
Sciences O +
and O +
the O +
National O +
Library O +
of O +
Medicine O +
( O +
R01 O +
ES014065 O +
and O +
R01 O +
ES014065 O +
- O +
04S1 O +
to O +
CTD O +
) O +
; O +
INBRE O +
program O +
of O +
the O +
National O +
Center O +
for O +
Research O +
Resources O +
( O +
P20 O +
RR016463 O +
) O +
. O +

Funding O +
for O +
open O +
access O +
charge O +
: O +
NIEHS O +
grant O +
( O +
R01 O +
ES014065 O +
) O +
. O +

Conflict O +
of O +
interest O +
statement O +
. O +

None O +
declared O +
. O +

Tarsoconjunctival O +
flap O +
after O +
division O +

Statistical O +
analysis O +

All O +
statistical O +
analyses O +
were O +
performed O +
using O +
SPSS13 O +
. O +
0 O +
software O +
. O +

The O +
differences O +
between O +
groups O +
were O +
compared O +
using O +
Student O +
' O +
s O +
t O +
- O +
test O +
, O +
and O +
data O +
were O +
expressed O +
as O +
mean O +
+ O +
/ O +
- O +
SD O +
. O +

Statistical O +
difference O +
was O +
accepted O +
at O +
P O +
< O +
0 O +
. O +
05 O +
. O +

The O +
importance O +
in O +
identifying O +
genes O +
involved O +
in O +
spinal O +
curvature O +

Spinal O +
curvature O +
is O +
a O +
prevalent O +
and O +
costly O +
deformity O +
among O +
humans O +
and O +
teleosts O +
. O +

The O +
estimated O +
annual O +
cost O +
of O +
treating O +
children O +
hospitalized O +
with O +
idiopathic O +
scoliosis O +
( O +
IS O +
) O +
in O +
the O +
United O +
States O +
alone O +
is O +
over O +
$ O +
3 O +
billion O +
. O +

This O +
cost O +
estimate O +
does O +
not O +
consider O +
Scheuermann O +
kyphosis O +
, O +
or O +
adults O +
with O +
idiopathic O +
- O +
type O +
spinal O +
curvature O +
who O +
suffer O +
from O +
chronic O +
back O +
pain O +
, O +
contributing O +
to O +
the O +
estimated O +
$ O +
849 O +
billion O +
cost O +
of O +
treatment O +
and O +
lost O +
wages O +
associated O +
with O +
musculoskeletal O +
disease O +
[ O +
24 O +
] O +
. O +

Among O +
teleosts O +
, O +
spinal O +
column O +
deformities O +
reduce O +
total O +
production O +
in O +
the O +
aquaculture O +
industry O +
substantially O +
[ O +
12 O +
] O +
. O +

In O +
contrast O +
to O +
humans O +
, O +
teleost O +
curve O +
phenotypes O +
are O +
less O +
well O +
characterized O +
; O +
although O +
heritable O +
curves O +
are O +
acknowledged O +
to O +
account O +
for O +
many O +
cases O +
among O +
cultured O +
stocks O +
, O +
whether O +
these O +
cases O +
are O +
from O +
congenital O +
defects O +
or O +
are O +
idiopathic O +
- O +
type O +
is O +
often O +
not O +
known O +
. O +

Despite O +
the O +
prevalence O +
and O +
impact O +
of O +
this O +
type O +
of O +
deformity O +
, O +
the O +
genetic O +
architecture O +
and O +
specific O +
genes O +
involved O +
are O +
unknown O +
. O +

The O +
current O +
view O +
is O +
that O +
human O +
idiopathic O +
- O +
type O +
scoliosis O +
is O +
a O +
complex O +
genetic O +
disorder O +
with O +
multiple O +
genes O +
segregating O +
in O +
the O +
population O +
exhibiting O +
complex O +
genotype O +
by O +
environment O +
interactions O +
[ O +
25 O +
- O +
30 O +
] O +
. O +

In O +
aquaculture O +
stocks O +
, O +
inheritance O +
for O +
spinal O +
curvature O +
has O +
been O +
described O +
as O +
Mendelian O +
recessive O +
or O +
dominant O +
, O +
as O +
well O +
as O +
polygenic O +
, O +
depending O +
on O +
how O +
well O +
the O +
phenotype O +
is O +
characterized O +
and O +
what O +
stock O +
is O +
considered O +
( O +
reviewed O +
in O +
[ O +
13 O +
] O +
, O +
[ O +
16 O +
] O +
) O +
. O +

The O +
guppy O +
curveback O +
phenotype O +
has O +
been O +
extensively O +
characterized O +
so O +
that O +
the O +
lineage O +
can O +
be O +
applied O +
as O +
a O +
model O +
for O +
understanding O +
the O +
biological O +
context O +
of O +
heritable O +
spinal O +
curvature O +
[ O +
1 O +
, O +
7 O +
- O +
9 O +
] O +
. O +

Future O +
studies O +
can O +
use O +
approaches O +
to O +
map O +
QTL O +
affecting O +
shape O +
based O +
on O +
digital O +
photos O +
[ O +
31 O +
, O +
32 O +
] O +
, O +
rather O +
than O +
the O +
qualitative O +
scale O +
used O +
in O +
the O +
present O +
study O +
. O +

The O +
identification O +
of O +
QTL O +
in O +
this O +
study O +
is O +
a O +
first O +
step O +
in O +
understanding O +
the O +
genetics O +
of O +
this O +
type O +
of O +
deformity O +
and O +
will O +
lead O +
to O +
the O +
identification O +
of O +
biological O +
pathways O +
associated O +
with O +
spinal O +
integrity O +
. O +

MoClo O +
cloning O +
protocol O +

Restriction O +
- O +
ligations O +
were O +
set O +
up O +
by O +
pipetting O +
in O +
one O +
tube O +
approximately O +
40 O +
fmol O +
( O +
~ O +
100 O +
ng O +
of O +
DNA O +
for O +
a O +
4 O +
kb O +
plasmid O +
) O +
of O +
each O +
DNA O +
component O +
( O +
PCR O +
product O +
or O +
plasmid O +
) O +
, O +
10 O +
U O +
of O +
the O +
required O +
restriction O +
enzyme O +
( O +
BsaI O +
or O +
BpiI O +
) O +
and O +
10 O +
U O +
T4 O +
DNA O +
ligase O +
( O +
using O +
high O +
concentration O +
ligase O +
, O +
20 O +
U O +
/ O +
microl O +
) O +
in O +
Promega O +
ligation O +
buffer O +
in O +
a O +
final O +
reaction O +
volume O +
of O +
20 O +
microl O +
. O +

The O +
reaction O +
was O +
incubated O +
in O +
a O +
thermocycler O +
for O +
5 O +
hours O +
at O +
37degreesC O +
, O +
5 O +
min O +
at O +
50degreesC O +
and O +
10 O +
min O +
at O +
80degreesC O +
. O +

The O +
reaction O +
mix O +
was O +
then O +
added O +
to O +
100 O +
microl O +
chemically O +
competent O +
DH10b B-CellLine +
cells O +
, O +
incubated O +
for O +
15 O +
- O +
30 O +
min O +
on O +
ice O +
and O +
transformed O +
by O +
heat O +
shock O +
. O +

800 O +
microl O +
of O +
liquid O +
LB O +
was O +
then O +
added O +
to O +
the O +
transformation O +
, O +
and O +
the O +
cells O +
were O +
let O +
to O +
recover O +
45 O +
min O +
at O +
37degreesC O +
. O +

Different O +
aliquots O +
of O +
the O +
transformation O +
were O +
plated O +
on O +
LB O +
plates O +
containing O +
the O +
appropriate O +
antibiotic O +
. O +

The O +
number O +
of O +
colonies O +
was O +
counted O +
for O +
one O +
or O +
two O +
selected O +
plates O +
( O +
containing O +
countable O +
number O +
of O +
colonies O +
) O +
, O +
or O +
from O +
a O +
section O +
of O +
the O +
plates O +
when O +
very O +
high O +
number O +
of O +
colonies O +
were O +
obtained O +
even O +
for O +
the O +
lowest O +
volume O +
plated O +
. O +

The O +
number O +
of O +
colonies O +
was O +
then O +
extrapolated O +
for O +
the O +
entire O +
transformation O +
. O +

For O +
level O +
2 O +
- O +
2 O +
cloning O +
, O +
two O +
type O +
IIS O +
enzymes O +
were O +
required O +
, O +
BpiI O +
and O +
BsaI O +
. O +

The O +
same O +
protocol O +
was O +
used O +
as O +
described O +
above O +
except O +
that O +
10 O +
U O +
and O +
2 O +
. O +
5 O +
U O +
were O +
used O +
for O +
the O +
enzymes O +
BpiI O +
and O +
BsaI O +
, O +
respectively O +
. O +

To O +
optimize O +
efficiency O +
of O +
the O +
restriction O +
- O +
ligation O +
for O +
the O +
final O +
construct O +
containing O +
11 O +
transcription O +
units O +
( O +
cL2 O +
- O +
13 O +
* O +
) O +
, O +
a O +
variation O +
of O +
this O +
protocol O +
was O +
used O +
as O +
follows O +
. O +

The O +
reaction O +
mix O +
was O +
set O +
up O +
containing O +
20 O +
U O +
ligase O +
, O +
5 O +
U O +
BpiI O +
and O +
5 O +
U O +
BsaI O +
, O +
in O +
a O +
total O +
reaction O +
volume O +
of O +
20 O +
microl O +
. O +

The O +
mix O +
was O +
incubated O +
in O +
a O +
thermocycler O +
with O +
the O +
following O +
parameters O +
: O +
incubation O +
for O +
2 O +
minutes O +
at O +
37degreesC O +
, O +
5 O +
minutes O +
at O +
16degreesC O +
, O +
both O +
steps O +
repeated O +
45 O +
times O +
, O +
followed O +
by O +
incubation O +
for O +
5 O +
minutes O +
at O +
50degreesC O +
and O +
10 O +
minutes O +
at O +
80degreesC O +
. O +

The O +
reaction O +
mix O +
was O +
transformed O +
in O +
E O +
. O +
coli O +
chemically O +
competent O +
cells O +
as O +
described O +
above O +
. O +

Intact O +
mass O +
analysis O +
of O +
a O +
mixed O +
population O +
of O +
proteins O +
. O +

A O +
mixture O +
of O +
the O +
membrane O +
protein O +
KCNJ12 O +
, O +
the O +
soluble O +
TEV O +
protease O +
used O +
to O +
cleave O +
the O +
fusion O +
tag O +
, O +
and O +
the O +
membrane O +
protein O +
HVCN1 O +
, O +
which O +
occurred O +
as O +
a O +
contaminant O +
from O +
an O +
earlier O +
analysis O +
on O +
the O +
same O +
LC O +
column O +
. O +

Observed O +
type O +
I O +
error O +
for O +
datasets O +
simulated O +
under O +
the O +
null O +
hypothesis O +

DNA O +
isolation O +

All O +
solutions O +
used O +
for O +
DNA O +
isolation O +
are O +
purged O +
with O +
nitrogen O +
( O +
immediately O +
prior O +
to O +
use O +
) O +
and O +
supplemented O +
with O +
50 O +
muM O +
phenyl O +
- O +
tert O +
- O +
butyl O +
nitrone O +
to O +
minimise O +
oxidative O +
damage O +
to O +
DNA O +
[ O +
31 O +
] O +
. O +

Qiagen O +
DNAeasy O +
Kit O +
( O +
# O +
69506 O +
) O +

includes O +
: O +
Proteinase O +
K O +
, O +
AW1 O +
, O +
AW2 O +
, O +
AE O +
and O +
Spin O +
- O +
columns O +

Dithiothreitol O +
( O +
DTT O +
; O +
Sigma O +
) O +

Ethanol O +
( O +
Ajax O +
Finechem O +
# O +
214 O +
- O +
2 O +
. O +
5L O +
) O +

Nitrogen O +
( O +
for O +
purging O +
of O +
buffers O +
) O +

Genes O +
related O +
to O +
signal O +
transduction O +

On O +
day O +
7 O +
, O +
the O +
up O +
- O +
regulated O +
genes O +
related O +
to O +
signal O +
transduction O +
were O +
PDE1A O +
, O +
MYO10 O +
, O +
APOB O +
, O +
and O +
so O +
on O +
, O +
and O +
down O +
- O +
regulated O +
genes O +
were O +
CYTL1 O +
and O +
IL6 O +
. O +

On O +
day O +
14 O +
, O +
the O +
up O +
- O +
regulated O +
genes O +
were O +
ANGPTL4 O +
, O +
EPHA3 O +
, O +
RASL10B O +
, O +
etc O +
. O +
, O +
and O +
the O +
down O +
- O +
regulated O +
genes O +
were O +
CXCL12 O +
, O +
CCL8 O +
and O +
VLDLR O +
. O +

The O +
genes O +
up O +
- O +
regulated O +
on O +
both O +
days O +
were O +
LEP O +
, O +
RAC3 O +
, O +
and O +
RASL11B O +
, O +
and O +
those O +
down O +
- O +
regulated O +
both O +
days O +
were O +
MX1 O +
and O +
WISP2 O +
. O +

Notably O +
, O +
up O +
- O +
and O +
down O +
- O +
regulated O +
genes O +
PDE1A O +
, O +
APOB O +
, O +
ALCAM O +
, O +
PSCD4 O +
, O +
CYTL1 O +
, O +
and O +
IL6 O +
were O +
more O +
strongly O +
expressed O +
on O +
day O +
7 O +
than O +
on O +
day O +
14 O +
, O +
while O +
ANGPTL4 O +
, O +
EPHA3 O +
, O +
RAB12 O +
, O +
CXCL12 O +
, O +
CCL8 O +
, O +
and O +
VLDLR O +
were O +
more O +
strongly O +
expressed O +
on O +
day O +
14 O +
than O +
on O +
day O +
7 O +
. O +

The O +
asymmetric O +
unit O +
of O +
the O +
title O +
compound O +
with O +
the O +
atomic O +
labelling O +
scheme O +
. O +
Displacement O +
are O +
drawn O +
at O +
the O +
50 O +
% O +
probability O +
level O +
. O +

H O +
atoms O +
are O +
represented O +
as O +
small O +
spheres O +
of O +
arbitrary O +
radii O +
. O +

Hydrogen O +
bonds O +
are O +
shown O +
as O +
dashed O +
lines O +
. O +

Modified O +
radiology O +
- O +
guided O +
percutaneous O +
gastrostomy O +
technique O +
. O +

A O +
. O +

21 O -
G O +
fine O +
needle O +
punctured O +
localized O +
collection O +
of O +
air O +
, O +
which O +
was O +
visible O +
in O +
collapsed O +
stomach O +
under O +
fluoroscopy O +
- O +
guided O +
gastrostomy O +
. O +

Needle O +
tip O +
is O +
then O +
gradually O +
withdrawn O +
while O +
injecting O +
small O +
amounts O +
of O +
water O +
- O +
soluble O +
contrast O +
medium O +
. O +

Location O +
of O +
stomach O +
is O +
confirmed O +
by O +
visualization O +
of O +
opacified O +
gastric O +
rugae O +
. O +

B O +
. O +

Stomach O +
was O +
inflated O +
with O +
approximately O +
600 O +
- O +
800 O +
mL O +
of O +
room O +
air O +
through O +
21 O -
G O +
fine O +
needle O +
. O +

C O +
. O +

100 O +
- O +
cm O +
stainless O +
steel O +
guide O +
wire O +
is O +
inserted O +
through O +
needle O +
, O +
and O +
gastro O +
- O +
percutaneous O +
tract O +
is O +
gradually O +
dilated O +
. O +

D O +
. O +

Insertion O +
of O +
14 O +
- O +
Fr O +
pigtail O +
gastrostomy O +
catheter O +
and O +
injection O +
of O +
small O +
amount O +
of O +
water O +
- O +
soluble O +
contrast O +
medium O +
via O +
pigtail O +
catheter O +
confirmed O +
that O +
gastrostomy O +
catheter O +
is O +
correctly O +
placed O +
within O +
stomach O +
. O +

SUMMARY O +

Both O +
the O +
innate O +
and O +
adaptive O +
immune O +
subsystems O +
are O +
necessary O +
to O +
provide O +
an O +
effective O +
immune O +
response O +
whether O +
to O +
an O +
actual O +
pathogenic O +
agent O +
or O +
to O +
an O +
immunization O +
. O +

Further O +
, O +
effective O +
immunizations O +
must O +
induce O +
long O +
- O +
term O +
stimulation O +
of O +
both O +
the O +
humoral O +
and O +
cell O +
- O +
mediated O +
arms O +
of O +
the O +
adaptive O +
system O +
by O +
the O +
production O +
of O +
effector O +
cells O +
for O +
the O +
current O +
infection O +
and O +
memory O +
cells O +
for O +
future O +
infections O +
with O +
the O +
pathogenic O +
agent O +
. O +

At O +
least O +
seven O +
different O +
types O +
of O +
vaccines O +
are O +
currently O +
in O +
use O +
or O +
in O +
development O +
that O +
produce O +
this O +
effective O +
immunity O +
and O +
have O +
contributed O +
greatly O +
to O +
the O +
prevention O +
of O +
infectious O +
disease O +
around O +
the O +
world O +
. O +

Encoding O +
methods O +
of O +
SOLiDzipper O +
. O +

Notes O +
: O +
A O +
) O +
The O +
quality O +
value O +
in O +
QV O +
files O +
from O +
ABI O +
SOLiD O +
system O +
ranges O +
from O +
- O +
1 O +
to O +
40 O +
, O +
which O +
requires O +
6 O +
bit O +
space O +
. O +

The O +
remaining O +
2 O +
bit O +
space O +
out O +
of O +
1 O +
byte O +
can O +
be O +
used O +
for O +
storing O +
another O +
quality O +
value O +
in O +
part O +
. O +

B O +
) O +
Csfasta O +
files O +
contain O +
the O +
sequence O +
information O +
in O +
four O +
digits O +
, O +
' O +
0123 O +
' O +
, O +
which O +
require O +
2 O +
bit O +
space O +
. O +

Provided O +
that O +
' O +
0 O +
' O +
, O +
1 O +
byte O +
character O +
in O +
csfasta O +
files O +
, O +
is O +
mapped O +
as O +
binary O +
data O +
' O +
00 O +
' O +
, O +
' O +
1 O +
' O +
as O +
' O +
01 O +
' O +
, O +
' O +
2 O +
' O +
as O +
' O +
10 O +
' O +
, O +
' O +
3 O +
' O +
as O +
' O +
11 O +
' O +
, O +
4 O +
byte O +
data O +
' O +
0113 O +
' O +
can O +
be O +
encoded O +
into O +
1 O +
byte O +
character O +
0x17 O +
( O +
00010111 O +
) O +
through O +
shift O +
operation O +
. O +

C O +
) O +
Sequence O +
IDs O +
are O +
extracted O +
from O +
QV O +
and O +
csfasta O +
files O +
, O +
combined O +
, O +
and O +
compressed O +
using O +
the O +
general O +
purpose O +
compression O +
methods O +
. O +

D O +
) O +
Encoded O +
data O +
are O +
stored O +
as O +
data O +
blocks O +
of O +
fixed O +
size O +
. O +

This O +
allows O +
for O +
selective O +
decoding O +
. O +

Western O +
blots O +
showing O +
C O +
/ O +
EBPalpha O +
( O +
top O +
) O +
, O +
adiponectin O +
( O +
middle O +
) O +
, O +
and O +
GAPDH O +
( O +
bottom O +
) O +
protein O +
bands O +
in O +
confluent O +
GO O +
orbital O +
fibroblast O +
cultures O +
exposed O +
throughout O +
10 O +
days O +
in O +
culture O +
to O +
the O +
indicated O +
treatments O +
. O +

Lane O +
1 O +
) O +
no O +
treatment O +
; O +
2 O +
) O +
LY294002 O +
( O +
10 O +
muM O +
) O +
; O +
3 O +
) O +
M22 O +
( O +
10 O +
ng O +
/ O +
ml O +
) O +
; O +
4 O +
) O +
M22 O +
plus O +
LY294002 O +
. O +

Loss O +
of O +
body O +
weight O +
after O +
challenge O +
- O +
infection O +
with O +
WNV O +
. O +

Mice O +
( O +
n O +
= O +
8 O +
) O +
were O +
vaccinated O +
intranasally O +
with O +
Flu O +
- O +
NA O +
- O +
DIII O +
( O +
* O +
) O +
or O +
Flu O +
- O +
NA O +
- O +
GFP O +
( O +
o O +
) O +
or O +
by O +
the O +
subcutaneous O +
route O +
( O +
^ O +
and O +
^ O +
, O +
respectively O +
) O +
. O +

The O +
daily O +
weights O +
of O +
each O +
animal O +
were O +
calculated O +
compared O +
to O +
their O +
respective O +
weight O +
on O +
the O +
day O +
of O +
challenge O +
, O +
and O +
data O +
are O +
shown O +
as O +
the O +
average O +
percentage O +
of O +
initial O +
weight O +
for O +
each O +
group O +
. O +

Error O +
bars O +
represent O +
the O +
standard O +
error O +
for O +
all O +
samples O +
available O +
at O +
that O +
time O +
point O +
. O +

Subsequently O +
, O +
the O +
mice O +
were O +
challenged O +
subcutaneously O +
with O +
106 O +
TCID50 O +
WNV O +
- O +
NY99 O +
and O +
weighed O +
daily O +
. O +

The O +
mean O +
body O +
weight O +
is O +
expressed O +
as O +
the O +
percentage O +
of O +
the O +
body O +
weight O +
before O +
challenge O +
infection O +
( O +
A O +
) O +
. O +

The O +
survival O +
rates O +
of O +
mice O +
after O +
challenge O +
infection O +
with O +
WNV O +
- O +
NY99 O +
are O +
depicted O +
as O +
Kaplan O +
- O +
Meier O +
survival O +
curves O +
( O +
B O +
) O +
. O +

The O +
difference O +
in O +
survival O +
rate O +
between O +
Flu O +
- O +
NA O +
- O +
DIII O +
and O +
Flu O +
- O +
NA O +
- O +
GFP O +
vaccinated O +
mice O +
was O +
statistically O +
significant O +
as O +
determined O +
by O +
the O +
logrank O +
test O +
. O +

The O +
symbols O +
for O +
the O +
respective O +
groups O +
are O +
the O +
same O +
as O +
in O +
panel O +
A O +
. O +

CONCLUSION O +

Intra O +
- O +
operative O +
monitoring O +
of O +
partial O +
pressure O +
of O +
tissue O +
oxygen O +
( O +
PtiO2 O +
) O +
is O +
a O +
very O +
sensitive O +
method O +
of O +
detecting O +
the O +
decrease O +
of O +
oxygen O +
for O +
cell O +
utilization O +
, O +
due O +
to O +
decreased O +
blood O +
flow O +
, O +
during O +
temporary O +
clipping O +
and O +
after O +
definitive O +
clipping O +
, O +
in O +
middle O +
cerebral O +
artery O +
incidental O +
unruptured O +
aneurysm O +
surgery O +
. O +

" O +
Basal O +
values O +
" O +
, O +
obtained O +
without O +
the O +
influence O +
of O +
subarachnoid O +
blood O +
, O +
were O +
lower O +
than O +
expected O +
in O +
" O +
uninjured O +
" O +
brain O +
, O +
and O +
this O +
fact O +
, O +
although O +
unexplained O +
, O +
should O +
be O +
kept O +
in O +
mind O +
in O +
future O +
investigation O +
in O +
this O +
field O +
. O +

Although O +
values O +
that O +
could O +
be O +
predictive O +
of O +
brain O +
ischemia O +
could O +
not O +
be O +
established O +
, O +
an O +
incomplete O +
recovery O +
or O +
continuous O +
decrease O +
in O +
PtiO2 O +
values O +
after O +
definitive O +
clipping O +
should O +
be O +
considered O +
an O +
indicator O +
of O +
high O +
risk O +
for O +
the O +
development O +
of O +
post O +
- O +
operative O +
brain O +
infarction O +
, O +
and O +
, O +
therefore O +
, O +
an O +
indication O +
for O +
verification O +
of O +
the O +
position O +
of O +
the O +
clip O +
. O +

Representative O +
time O +
histories O +
of O +
the O +
estimated O +
SatO2 O +
levels O +
of O +
normal O +
cortex O +
( O +
black O +
) O +
and O +
tumor O +
( O +
grey O +
) O +
from O +
all O +
six O +
patients O +
. O +

Etymology O +
. O +

Professor O +
Stephen O +
Lane O +
Wood O +
worked O +
extensively O +
on O +
collections O +
of O +
Scolytinae O +
preserved O +
in O +
Indian O +
museums O +
, O +
and O +
described O +
a O +
number O +
of O +
new O +
Scolytinae O +
species O +
from O +
India O +
. O +

In O +
this O +
paper O +
we O +
describe O +
one O +
more O +
new O +
bark O +
- O +
beetle O +
species O +
from O +
India O +
kept O +
in O +
the O +
Natural O +
History O +
Museum O +
in O +
Vienna O +
( O +
NHMW O +
) O +
and O +
dedicate O +
this O +
species O +
to O +
the O +
late O +
Professor O +
Stephen O +
Lane O +
Wood O +
. O +

View O +
of O +
the O +
structure O +
of O +
the O +
title O +
compound O +
along O +
the O +
a O +
axis O +
displaying O +
chains O +
alternating O +
with O +
amine O +
groups O +
. O +

Results O +

Statistics O +

The O +
survival O +
of O +
mice O +
was O +
analyzed O +
using O +
Kaplan O +
- O +
Meier O +
survival O +
analysis O +
. O +

All O +
other O +
data O +
were O +
analyzed O +
by O +
one O +
- O +
way O +
ANOVA O +
, O +
followed O +
by O +
the O +
Student O +
- O +
Newman O +
- O +
Keuls O +
test O +
for O +
all O +
pairwise O +
comparisons O +
. O +

Prior O +
to O +
ANOVA O +
, O +
Levene O +
' O +
s O +
Test O +
for O +
Equality O +
of O +
Variances O +
was O +
performed O +
. O +

All O +
statistical O +
analyses O +
were O +
performed O +
using O +
MedCalc O +
software O +
, O +
version O +
11 O +
. O +
2 O +
. O +
1 O +
. O +
0 O +
. O +

5 O +
. O +

Conclusion O +

RLs O +
are O +
new O +
actors O +
in O +
animal O +
and O +
plant O +
defense O +
and O +
their O +
low O +
toxicity O +
and O +
biodegradability O +
make O +
them O +
promising O +
molecules O +
to O +
be O +
used O +
against O +
pathogens O +
. O +

In O +
this O +
respect O +
, O +
there O +
are O +
some O +
clues O +
now O +
available O +
for O +
the O +
success O +
of O +
RL O +
applications O +
in O +
greenhouses O +
to O +
fight O +
phytopathogens O +
. O +

A O +
better O +
understanding O +
of O +
RL O +
mode O +
of O +
action O +
, O +
especially O +
their O +
perception O +
and O +
the O +
signaling O +
pathways O +
activated O +
, O +
will O +
be O +
very O +
important O +
to O +
potentiate O +
their O +
beneficial O +
effects O +
in O +
plants O +
. O +

RLs O +
have O +
a O +
dual O +
mode O +
of O +
action O +
: O +
they O +
are O +
antimicrobial O +
and O +
also O +
stimulate O +
plant O +
defense O +
responses O +
. O +

This O +
dual O +
property O +
is O +
probably O +
very O +
important O +
for O +
the O +
efficiency O +
of O +
new O +
biopesticides O +
. O +

In O +
animals O +
, O +
the O +
use O +
of O +
RLs O +
is O +
also O +
at O +
an O +
advanced O +
stage O +
. O +

RLs O +
are O +
successfully O +
used O +
as O +
antimicrobial O +
agents O +
, O +
especially O +
for O +
skin O +
disease O +
treatment O +
. O +

Deep O +
insight O +
into O +
the O +
physiochemical O +
effects O +
of O +
RLs O +
and O +
their O +
biological O +
importance O +
would O +
reveal O +
new O +
dimensions O +
in O +
the O +
fields O +
of O +
research O +
like O +
agriculture O +
and O +
medicine O +
, O +
precisely O +
in O +
plant O +
defense O +
, O +
disease O +
control O +
and O +
pathogenesis O +
. O +

An O +
understanding O +
of O +
bacterial O +
genera O +
producing O +
RLs O +
that O +
are O +
not O +
yet O +
well O +
studied O +
would O +
provide O +
light O +
on O +
these O +
fascinating O +
aspects O +
. O +

( O +
a O +
) O +
Sequence O +
alignment O +
of O +
PY O +
- O +
NLSs O +
. O +

The O +
homologous O +
regions O +
of O +
C O +
- O +
NLS O +
of O +
the O +
EWS O +
protein O +
, O +
NLS O +
of O +
Sam68 O +
and O +
FUS O +
/ O +
TLS O +
protein O +
and O +
M9 O +
NLS O +
of O +
hnRNP O +
A1 O +
and O +
hnRNP O +
M O +
, O +
classified O +
as O +
PY O +
- O +
NLS O +
are O +
in O +
yellow O +
boxes O +
. O +

Phosphorylated O +
Y656 O +
of O +
the O +
EWS O +
protein O +
and O +
Y440 O +
of O +
Sam68 O +
are O +
indicated O +
( O +
in O +
red O +
) O +
. O +

Positions O +
of O +
identical O +
residues O +
in O +
SAM68 O +
and O +
EWS O +
C O +
- O +
NLS O +
are O +
indicated O +
in O +
bold O +
and O +
residues O +
with O +
identical O +
charges O +
are O +
underlined O +
. O +

Known O +
positions O +
of O +
the O +
FUS O +
/ O +
TLS O +
mutations O +
in O +
ALS O +
are O +
in O +
bold O +
. O +

( O +
b O +
) O +
Subcellular O +
localization O +
of O +
YFP O +
, O +
the O +
C O +
- O +
terminally O +
tagged O +
EWS O +
- O +
YFP O +
, O +
EWS O +
( O +
Y656A O +
) O +
- O +
YFP O +
, O +
EWS O +
( O +
Y656F O +
) O +
- O +
YFP O +
, O +
and O +
EWS O +
( O +
Y656D O +
) O +
- O +
YFP O +
( O +
in O +
green O +
) O +
. O +

Nuclei O +
are O +
shown O +
by O +
DAPI O +
staining O +
( O +
in O +
blue O +
) O +
. O +

Bars O +
, O +
15 O +
mum O +
. O +

Background O +

Inflammation O +
plays O +
a O +
critical O +
role O +
in O +
plaque O +
initiation O +
, O +
progression O +
, O +
and O +
disruption O +
. O +

As O +
such O +
, O +
inflammation O +
represents O +
an O +
emerging O +
target O +
for O +
the O +
treatment O +
of O +
atherosclerosis O +
. O +

Conclusions O +

Myocardial O +
ischaemia O +
during O +
DCMR O +
is O +
independently O +
predictive O +
of O +
cardiac O +
events O +
among O +
patients O +
with O +
previous O +
myocardial O +
revascularisation O +
. O +

Acknowledgements O +

The O +
authors O +
gratefully O +
acknowledge O +
the O +
support O +
of O +
DRUID O +
study O +
participants O +
, O +
study O +
staff O +
, O +
members O +
of O +
the O +
Indigenous O +
Steering O +
Group O +
, O +
and O +
partner O +
organisations O +
. O +

The O +
DRUID O +
Study O +
was O +
funded O +
by O +
the O +
National O +
Health O +
and O +
Medical O +
Research O +
Council O +
( O +
NHMRC O +
Project O +
Grant O +
# O +
236207 O +
) O +
, O +
with O +
additional O +
support O +
from O +
the O +
Australian O +
Government O +
Department O +
of O +
Employment O +
and O +
Workplace O +
Relations O +
, O +
the O +
Clive O +
and O +
Vera O +
Ramaciotti O +
Foundation O +
, O +
the O +
Vincent O +
Fairfax O +
Family O +
Foundation O +
, O +
the O +
International O +
Diabetes O +
Institute O +
( O +
AusDiab O +
Partnership O +
) O +
, O +
and O +
Bayer O +
HealthCare O +
. O +

The O +
DRUID O +
Study O +
is O +
an O +
in O +
- O +
kind O +
project O +
of O +
the O +
Cooperative O +
Research O +
Centre O +
for O +
Aboriginal O +
Health O +
. O +

LMB O +
had O +
a O +
NHMRC O +
Scholarship O +
2003 O +
- O +
5 O +
and O +
is O +
supported O +
by O +
NHMRC O +
Training O +
Fellowship O +
( O +
# O +
605837 O +
) O +
, O +
NHMRC O +
# O +
320860 O +
and O +
the O +
Centre O +
of O +
Clinical O +
Research O +
Excellence O +
in O +
Clinical O +
Science O +
in O +
Diabetes O +
, O +
University O +
of O +
Melbourne O +
. O +

JC O +
was O +
supported O +
by O +
a O +
NHMRC O +
Career O +
Development O +
Award O +
( O +
# O +
283310 O +
) O +
and O +
a O +
NHMRC O +
Research O +
Fellowship O +
( O +
# O +
545200 O +
) O +
. O +

AH O +
is O +
supported O +
by O +
NHMRC O +
Fellowship O +
( O +
# O +
520316 O +
) O +
. O +

Thank O +
you O +
to O +
Dr O +
Jaquelyne O +
Hughes O +
for O +
comments O +
on O +
the O +
manuscript O +
. O +

Funding O +
sources O +
played O +
no O +
role O +
in O +
the O +
study O +
design O +
, O +
in O +
the O +
collection O +
, O +
analysis O +
and O +
interpretation O +
of O +
the O +
data O +
, O +
in O +
the O +
writing O +
of O +
the O +
manuscript O +
, O +
or O +
in O +
the O +
decision O +
to O +
submit O +
the O +
manuscript O +
for O +
publication O +
. O +

Importing O +
citations O +
in O +
different O +
formats O +
using O +
Google O +
Scholar O +

Acknowledgements O +

We O +
thank O +
Dr O +
. O +
Neva O +
Meyer O +
for O +
confocal O +
imaging O +
and O +
generation O +
of O +
Z O +
- O +
stack O +
projection O +
, O +
and O +
the O +
following O +
members O +
of O +
the O +
Seaver O +
lab O +
for O +
their O +
continued O +
support O +
of O +
this O +
project O +
: O +
Dr O +
. O +
Neva O +
Meyer O +
, O +
Dr O +
. O +
Aldine O +
Amiel O +
, O +
and O +
Tyler O +
Smith O +
. O +

This O +
work O +
was O +
supported O +
by O +
the O +
National O +
Science O +
Foundation O +
( O +
REU O +
Supplement O +
of O +
10B05 O +
- O +
44869 O +
to O +
E O +
. O +
C O +
. O +
S O +
. O +
) O +
. O +

Concurrent O +
disease O +
in O +
33 O +
cows O +
with O +
LDA O +
. O +

Subject O +
disposition O +
. O +

Data O +
from O +
110 O +
enrolled O +
subjects O +
were O +
eligible O +
for O +
analysis O +
. O +

The O +
demographics O +
of O +
the O +
study O +
subjects O +
, O +
by O +
site O +
, O +
are O +
recorded O +
in O +
Table O +
1 O +
. O +

The O +
population O +
studied O +
was O +
predominantly O +
not O +
HIV O +
infected O +
( O +
92 O +
% O +
) O +
, O +
and O +
by O +
the O +
study O +
entry O +
criteria O +
, O +
their O +
probability O +
of O +
infection O +
was O +
considered O +
to O +
be O +
low O +
. O +

The O +
risk O +
categories O +
assigned O +
at O +
the O +
time O +
of O +
study O +
entry O +
were O +
combined O +
into O +
groups O +
for O +
analysis O +
, O +
based O +
on O +
the O +
predisposition O +
for O +
PCP O +
. O +

The O +
analysis O +
groups O +
were O +
as O +
follows O +
: O +
( O +
i O +
) O +
HIV O +
/ O +
AIDS O +
, O +
( O +
ii O +
) O +
lung O +
transplant O +
( O +
one O +
subject O +
with O +
a O +
dual O +
organ O +
transplant O +
[ O +
lung O +
/ O +
kidney O +
] O +
was O +
included O +
in O +
this O +
category O +
) O +
, O +
( O +
iii O +
) O +
all O +
other O +
organ O +
transplants O +
and O +
allogeneic O +
hematopoietic O +
stem O +
cell O +
transplants O +
( O +
HSCT O +
) O +
, O +
( O +
iv O +
) O +
leukemia O +
, O +
other O +
hematological O +
disorders O +
, O +
and O +
autologous O +
HSCT O +
, O +
( O +
v O +
) O +
other O +
solid O +
tumors O +
, O +
and O +
( O +
vi O +
) O +
other O +
nonmalignant O +
conditions O +
. O +

Table O +
1 O +
. O +

Subject O +
enrollment O +
, O +
disposition O +
, O +
and O +
demographics O +
by O +
sitea O +

Characteristic O +
Valueb O +

Site O +
1 O +
Site O +
2 O +
Site O +
3 O +
Site O +
4 O +

Enrollment O +

Unique O +
subjects O +
18 O +
29 O +
22 O +
62 O +

Subjects O +
entering O +
into O +
primary O +
analysisc O +
18 O +
22 O +
22 O +
48 O +

Subjects O +
with O +
repeat O +
visits O +
0 O +
0 O +
0 O +
16 O +

No O +
. O +
of O +
samples O +
assayed O +
18 O +
22 O +
22 O +
70 O +

Gender O +

Male O +
7 O +
10 O +
13 O +
29 O +

Female O +
11 O +
12 O +
9 O +
19 O +

Race O +

Caucasian O +
12 O +
4 O +
0 O +
48 O +

Black O +
6 O +
13 O +
0 O +
0 O +

Other O +
( O +
nonwhite O +
) O +
0 O +
5 O +
0 O +
0 O +

No O +
data O +
0 O +
0 O +
22 O +
0 O +

Mean O +
( O +
range O +
) O +
age O +
( O +
yr O +
) O +
57 O +
( O +
26 O +
- O +
78 O +
) O +
54 O +
( O +
21 O +
- O +
75 O +
) O +
52 O +
( O +
26 O +
- O +
74 O +
) O +
56 O +
( O +
23 O +
- O +
73 O +
) O +

Pretest O +
probability O +
of O +
PCP O +

Moderate O +
0 O +
3 O +
4 O +
0 O +

Low O +
18 O +
19 O +
18 O +
48 O +

Sample O +
type O +

BAL O +
18 O +
20 O +
20 O +
43 O +

Sputum O +
0 O +
1 O +
1 O +
0 O +

Other O +
LRT O +
0 O +
1 O +
1 O +
5 O +

At O +
- O +
risk O +
group O +

HIV O +
/ O +
AIDS O +
0 O +
3 O +
6 O +
0 O +

Lung O +
transplant O +
8 O +
0 O +
1 O +
31 O +

Other O +
transplants O +
1 O +
7 O +
3 O +
0 O +

Leukemia O +
1 O +
1 O +
7 O +
0 O +

Other O +
solid O +
tumors O +
2 O +
1 O +
1 O +
7 O +

Other O +
nonmalignant O +
conditions O +
6 O +
10 O +
4 O +
10 O +

a O +

The O +
testing O +
and O +
enrollment O +
sites O +
for O +
the O +
study O +
were O +
Duke O +
University O +
School O +
of O +
Medicine O +
, O +
Durham O +
, O +
NC O +
; O +
Albert O +
Einstein O +
College O +
of O +
Medicine O +
and O +
Montefiore O +
Medical O +
Center O +
, O +
Bronx O +
, O +
NY O +
; O +
Centre O +
Hospitalier O +
Universitaire O +
Vaudois O +
and O +
University O +
of O +
Lausanne O +
, O +
Lausanne O +
, O +
Switzerland O +
; O +
and O +
Medizinische O +
Universitat O +
and O +
Landeskrankenhaus O +
Natters O +
, O +
Innsbruck O +
, O +
Austria O +
. O +

b O +

Except O +
where O +
otherwise O +
indicated O +
, O +
values O +
are O +
numbers O +
of O +
patients O +
. O +

c O +

Subjects O +
were O +
excluded O +
from O +
analysis O +
if O +
they O +
withdrew O +
consent O +
or O +
if O +
there O +
was O +
inadequate O +
sample O +
left O +
for O +
PCR O +
testing O +
. O +

Parkin O +
regulates O +
the O +
proteasomal O +
degradation O +
of O +
PARIS O +
and O +
PGC O +
- O +
1alpha O +
- O +
dependent O +
mitochondrial O +
biogenesis O +
. O +

( O +
A O +
) O +
Normal O +
physiological O +
conditions O +
that O +
maintain O +
mitochondrial O +
homeostasis O +
: O +
PINK1 O +
recruits O +
parkin O +
to O +
the O +
mitochondria O +
, O +
where O +
these O +
two O +
proteins O +
interact O +
to O +
eliminate O +
abnormal O +
mitochondria O +
through O +
mitophagy O +
. O +

Alterations O +
in O +
mitochondrial O +
membrane O +
potential O +
( O +
DeltaPsim O +
; O +
a O +
key O +
indicator O +
of O +
mitochondrial O +
physiology O +
and O +
cell O +
viability O +
) O +
initiate O +
the O +
PINK1 O +
- O +
parkin O +
cascade O +
of O +
events O +
that O +
lead O +
to O +
mitophagy O +
. O +

Furthermore O +
, O +
parkin O +
ubiquitylates O +
and O +
thereby O +
promotes O +
proteasomal O +
degradation O +
of O +
PARIS O +
. O +

Because O +
PARIS O +
represses O +
the O +
expression O +
of O +
PGC O +
- O +
1alpha O +
, O +
degradation O +
of O +
PARIS O +
by O +
parkin O +
allows O +
PGC O +
- O +
1alpha O +
- O +
dependent O +
gene O +
expression O +
and O +
enables O +
mitochondrial O +
biogenesis O +
. O +

Parkin O +
seems O +
to O +
be O +
an O +
integral O +
regulator O +
of O +
mitochondrial O +
homeostasis O +
, O +
controlling O +
both O +
degradation O +
and O +
biogenesis O +
. O +

( O +
B O +
) O +
Loss O +
of O +
parkin O +
function O +
as O +
a O +
result O +
of O +
familial O +
mutations O +
( O +
in O +
the O +
case O +
of O +
AR O +
- O +
PD O +
) O +
or O +
aging O +
, O +
environmental O +
or O +
cellular O +
stress O +
( O +
in O +
the O +
case O +
of O +
sporadic O +
PD O +
) O +
leads O +
to O +
the O +
accumulation O +
of O +
abnormal O +
mitochondria O +
, O +
owing O +
to O +
faulty O +
mitophagy O +
. O +

In O +
addition O +
, O +
PARIS O +
accumulates O +
and O +
represses O +
PGC O +
- O +
1alpha O +
, O +
preventing O +
mitochondrial O +
biogenesis O +
. O +

Loss O +
of O +
parkin O +
function O +
does O +
not O +
tip O +
the O +
balance O +
between O +
mitochondrial O +
biogenesis O +
and O +
degradation O +
to O +
either O +
side O +
, O +
but O +
leads O +
to O +
a O +
general O +
breakdown O +
of O +
mitochondrial O +
homeostasis O +
that O +
can O +
ultimately O +
lead O +
to O +
PD O +
. O +

Acknowledgments O +
and O +
Funding O +

The O +
authors O +
thank O +
CRB O +
GADIE O +
( O +
Diane O +
Esquerre O +
) O +
for O +
BAC O +
clones O +
handling O +
and O +
Brian O +
Smith O +
, O +
Renee O +
Fincham O +
and O +
Kristy O +
Shewbridge O +
for O +
microsatellites O +
genotyping O +
. O +

We O +
are O +
grateful O +
to O +
Yann O +
Guiguen O +
for O +
help O +
and O +
precious O +
contribution O +
to O +
fund O +
raising O +
for O +
this O +
study O +
. O +

This O +
work O +
was O +
made O +
possible O +
by O +
financial O +
support O +
of O +
Genoscope O +
. O +

We O +
acknowledge O +
Rene O +
Guyomard O +
for O +
his O +
initial O +
contribution O +
in O +
BAC O +
library O +
procurement O +
. O +

The O +
microsatellites O +
genotyping O +
was O +
supported O +
by O +
NRI O +
Grant O +
No O +
. O +
2007 O +
- O +
35616 O +
- O +
17875 O +
from O +
the O +
USDA O +
National O +
Institute O +
of O +
Food O +
and O +
Agriculture O +
. O +

Confocal O +
and O +
scanning O +
microscopic O +
images O +
of O +
mammoth O +
' O +
s O +
and O +
human O +
hair O +
. O +

Taphonomic O +
changes O +
, O +
indicated O +
by O +
arrow O +
- O +
heads O +
and O +
straight O +
white O +
arrow O +
in O +
the O +
confocal O +
image O +
. O +

Bacterial O +
- O +
fungal O +
colonies O +
are O +
shown O +
by O +
broken O +
arrows O +
. O +

Red O +
arrow O +
indicates O +
space O +
between O +
cuticle O +
and O +
hair O +
shaft O +
due O +
to O +
shrinkage O +
. O +

Extensive O +
taphonomic O +
changes O +
in O +
YUK O +
are O +
evident O +
. O +

Note O +
the O +
preservation O +
of O +
the O +
cuticle O +
in O +
the O +
human O +
hair O +
in O +
contrast O +
to O +
the O +
craters O +
in O +
the O +
cuticles O +
of O +
the O +
mammoth O +
' O +
s O +
hair O +
. O +

Bacterial O +
biofilms O +
are O +
a O +
feature O +
of O +
human O +
hair O +
; O +
mammoth O +
' O +
s O +
hair O +
was O +
protected O +
from O +
bacterial O +
invasion O +
in O +
permafrost O +
. O +

Scheme O +
of O +
the O +
activity O +
of O +
5 O +
- O +
HT O +
( O +
A O +
) O +
and O +
norepinephrine O +
( O +
NE O +
) O +
( O +
B O +
) O +
neurotransmission O +
during O +
treatment O +
with O +
milnacipran O +
. O +

A O +
) O +
5 O +
- O +
HT O +
system O +
. O +

Acute O +
treatment O +
with O +
milnacipran O +
results O +
in O +
a O +
decreased O +
firing O +
of O +
5 O +
- O +
HT O +
neurons O +
from O +
the O +
raphe O +
nucleus O +
possibly O +
due O +
in O +
part O +
to O +
increased O +
stimulation O +
of O +
somatodendritic O +
autoreceptors O +
. O +

Long O +
- O +
term O +
treatment O +
with O +
milnacipran O +
results O +
in O +
a O +
full O +
recovery O +
in O +
the O +
firing O +
rate O +
of O +
5 O +
- O +
HT O +
neurons O +
in O +
the O +
presence O +
of O +
milnacipran O +
thereby O +
leading O +
to O +
a O +
net O +
increase O +
in O +
5 O +
- O +
HT O +
neurotransmission O +
. O +

Contributing O +
to O +
this O +
enhancement O +
are O +
: O +
1 O +
) O +
the O +
normalized O +
firing O +
rate O +
of O +
5 O +
- O +
HT O +
neurons O +
in O +
the O +
presence O +
of O +
milnacipran O +
2 O +
) O +
the O +
desensitization O +
of O +
the O +
terminal O +
5 O +
- O +
HT1B O +
autoreceptor O +
, O +
and O +
3 O +
) O +
the O +
desensitization O +
of O +
the O +
alpha2 O +
- O +
adrenergic O +
heteroreceptors O +
on O +
5 O +
- O +
HT O +
terminals O +
. O +

B O +
) O +
NE O +
system O +
. O +

Acute O +
treatment O +
with O +
milnacipran O +
results O +
in O +
increased O +
synaptic O +
concentrations O +
of O +
NE O +
but O +
decreased O +
firing O +
of O +
the O +
NE O +
neurons O +
of O +
the O +
locus O +
coeruleus O +
due O +
to O +
increased O +
stimulation O +
of O +
the O +
somatodendritic O +
alpha2 O +
- O +
adrenergic O +
autoreceptors O +
. O +

Long O +
- O +
term O +
treatment O +
with O +
milnacipran O +
results O +
in O +
a O +
further O +
increase O +
in O +
synaptic O +
concentrations O +
of O +
NE O +
due O +
to O +
desensitization O +
of O +
presynaptic O +
autoreceptors O +
. O +

The O +
somatodendritic O +
alpha2 O +
- O +
adrenergic O +
autoreceptors O +
do O +
not O +
desensitize O +
. O +

3 O +
. O +
1 O +
. O +

Glucose O +
Tolerance O +
Test O +
at O +
Various O +
Times O +
following O +
Dosing O +

DIO O +
mice O +
were O +
treated O +
with O +
a O +
single O +
IV O +
dose O +
of O +
CNTO O +
530 O +
( O +
0 O +
. O +
3 O +
mg O +
/ O +
kg O +
) O +
, O +
and O +
glucose O +
metabolism O +
was O +
monitored O +
using O +
an O +
intraperitoneal O +
glucose O +
tolerance O +
test O +
( O +
IPGTT O +
) O +
at O +
various O +
times O +
following O +
dosing O +
( O +
day O +
1 O +
to O +
35 O +
) O +
. O +

CNTO O +
530 O +
did O +
not O +
influence O +
glucose O +
tolerance O +
24 O +
hours O +
after O +
dosing O +
. O +

However O +
, O +
a O +
significant O +
improvement O +
was O +
observed O +
in O +
both O +
fasting O +
glucose O +
( O +
179 O +
+ O +
/ O +
- O +
29 O +
versus O +
133 O +
+ O +
/ O +
- O +
19 O +
mg O +
/ O +
dL O +
for O +
untreated O +
versus O +
treated O +
) O +
and O +
overall O +
glucose O +
tolerance O +
seven O +
days O +
after O +
a O +
single O +
dose O +
of O +
CNTO O +
530 O +
( O +
Figure O +
2 O +
( O +
b O +
) O +
) O +
. O +

In O +
a O +
separate O +
study O +
, O +
the O +
activity O +
of O +
CNTO O +
530 O +
was O +
compared O +
to O +
a O +
control O +
protein O +
that O +
lacked O +
the O +
EMP O +
- O +
1 O +
peptides O +
to O +
ensure O +
that O +
the O +
observed O +
effects O +
were O +
due O +
to O +
the O +
peptide O +
and O +
not O +
the O +
Fc O +
. O +

The O +
glucose O +
lowering O +
effect O +
was O +
not O +
observed O +
in O +
the O +
mice O +
treated O +
with O +
the O +
protein O +
lacking O +
the O +
EMP O +
- O +
1 O +
peptides O +
( O +
data O +
not O +
shown O +
) O +
. O +

Fasting O +
blood O +
glucose O +
remained O +
improved O +
in O +
the O +
treated O +
animals O +
14 O +
and O +
21 O +
days O +
after O +
CNTO530 O +
treatment O +
, O +
but O +
was O +
similar O +
to O +
the O +
untreated O +
group O +
after O +
35 O +
days O +
( O +
data O +
not O +
shown O +
) O +
. O +

The O +
area O +
under O +
the O +
curve O +
( O +
AUC O +
) O +
for O +
the O +
glucose O +
tolerance O +
tests O +
showed O +
a O +
significant O +
improvement O +
with O +
CNTO O +
530 O +
treatment O +
on O +
days O +
7 O +
, O +
14 O +
, O +
20 O +
, O +
and O +
28 O +
( O +
Figure O +
2 O +
( O +
b O +
) O +
) O +
. O +

The O +
most O +
dramatic O +
effect O +
on O +
glucose O +
tolerance O +
following O +
CNTO O +
530 O +
- O +
treatment O +
was O +
observed O +
on O +
day O +
14 O +
where O +
glucose O +
was O +
cleared O +
from O +
circulation O +
by O +
the O +
15 O +
- O +
minute O +
time O +
point O +
( O +
Figure O +
2 O +
( O +
a O +
) O +
) O +
. O +

CNTO O +
530 O +
- O +
mediated O +
acceleration O +
of O +
glucose O +
utilization O +
was O +
diminished O +
but O +
still O +
significant O +
by O +
day O +
28 O +
and O +
not O +
seen O +
by O +
day O +
35 O +
( O +
Figure O +
2 O +
( O +
b O +
) O +
) O +
. O +

Hemoglobin O +
levels O +
followed O +
a O +
similar O +
time O +
- O +
dependent O +
change O +
, O +
showing O +
an O +
increase O +
that O +
peaked O +
on O +
day O +
22 O +
and O +
returned O +
to O +
normal O +
levels O +
by O +
day O +
29 O +
( O +
Figure O +
2 O +
( O +
c O +
) O +
) O +
. O +

Similar O +
studies O +
were O +
completed O +
in O +
lean O +
littermate O +
mice O +
fed O +
a O +
normal O +
chow O +
diet O +
. O +

Mice O +
( O +
n O +
= O +
7 O +
) O +
were O +
given O +
a O +
single O +
administration O +
of O +
CNTO O +
530 O +
( O +
0 O +
. O +
01 O +
- O +
0 O +
. O +
3 O +
mg O +
/ O +
kg O +
) O +
, O +
and O +
glucose O +
tolerance O +
tests O +
were O +
completed O +
after O +
1 O +
and O +
14 O +
days O +
. O +

As O +
we O +
observed O +
in O +
the O +
diabetic O +
rodents O +
, O +
no O +
significant O +
changes O +
were O +
seen O +
in O +
glucose O +
clearance O +
24 O +
hours O +
after O +
dosing O +
. O +

However O +
, O +
there O +
were O +
significant O +
improvements O +
in O +
the O +
area O +
under O +
the O +
curve O +
in O +
the O +
glucose O +
tolerance O +
test O +
in O +
animals O +
dosed O +
with O +
0 O +
. O +
3 O +
and O +
0 O +
. O +
1 O +
mg O +
/ O +
kg O +
CNTO O +
530 O +
as O +
compared O +
to O +
PBS O +
( O +
22865 O +
. O +
4 O +
+ O +
/ O +
- O +
1900 O +
. O +
2 O +
, O +
24478 O +
. O +
9 O +
+ O +
/ O +
- O +
1093 O +
. O +
4 O +
, O +
and O +
28773 O +
. O +
2 O +
+ O +
/ O +
- O +
1368 O +
. O +
3 O +
, O +
resp O +
. O +
, O +
mean O +
+ O +
/ O +
- O +
SEM O +
) O +
. O +

There O +
were O +
no O +
dose O +
- O +
dependent O +
changes O +
in O +
the O +
fasting O +
blood O +
glucose O +
. O +

Cone O +
beam O +
geometry O +

Calculation O +
of O +
male O +
mating O +
success O +

In O +
order O +
to O +
compare O +
whether O +
males O +
' O +
access O +
to O +
receptive O +
females O +
followed O +
the O +
predictions O +
of O +
the O +
PoA O +
model O +
, O +
we O +
calculated O +
mating O +
success O +
as O +
follows O +
. O +

For O +
all O +
the O +
mating O +
partners O +
a O +
female O +
had O +
during O +
the O +
receptive O +
period O +
of O +
her O +
conceptive O +
cycle O +
, O +
mating O +
success O +
of O +
each O +
mating O +
partner O +
was O +
calculated O +
as O +
the O +
number O +
of O +
mating O +
series O +
a O +
male O +
was O +
involved O +
in O +
divided O +
by O +
the O +
total O +
number O +
of O +
mating O +
series O +
the O +
female O +
was O +
involved O +
in O +
. O +

Overall O +
mating O +
success O +
of O +
each O +
male O +
was O +
calculated O +
as O +
the O +
sum O +
of O +
all O +
mating O +
successes O +
calculated O +
for O +
this O +
male O +
as O +
described O +
above O +
. O +

4 O +
. O +
2 O +
. O +

Histological O +
Findings O +

Microscopy O +
revealed O +
features O +
of O +
a O +
diffusely O +
growing O +
discohesive O +
carcinoma O +
, O +
exclusively O +
growing O +
in O +
the O +
alveolar O +
interstitium O +
, O +
thus O +
expanding O +
it O +
, O +
while O +
leaving O +
the O +
original O +
alveolar O +
architecture O +
intact O +
( O +
Figure O +
2 O +
) O +
. O +

There O +
was O +
local O +
ulceration O +
of O +
the O +
pleura O +
, O +
while O +
, O +
beyond O +
this O +
ulcer O +
, O +
the O +
tumor O +
formed O +
a O +
thick O +
cake O +
of O +
discohesive O +
tumor O +
cells O +
lining O +
the O +
pleural O +
membrane O +
( O +
Figure O +
2 O +
( O +
c O +
) O +
) O +
, O +
with O +
only O +
focal O +
, O +
microscopic O +
invasion O +
into O +
the O +
fatty O +
tissue O +
of O +
the O +
parietal O +
pleura O +
. O +

The O +
tumor O +
consisted O +
of O +
atypical O +
, O +
moderately O +
polymorphous O +
, O +
and O +
irregularly O +
shaped O +
tumor O +
cells O +
with O +
marked O +
discohesiveness O +
. O +

They O +
featured O +
scant O +
eosinophilic O +
cytoplasm O +
and O +
irregularly O +
contoured O +
and O +
hyperchromatic O +
nuclei O +
, O +
often O +
containing O +
one O +
or O +
more O +
prominent O +
nucleoli O +
( O +
Figure O +
2 O +
( O +
b O +
) O +
) O +
. O +

There O +
were O +
many O +
mitoses O +
and O +
apoptoses O +
present O +
, O +
but O +
necrosis O +
was O +
not O +
observed O +
. O +

No O +
squamous O +
or O +
glandular O +
differentiation O +
was O +
observed O +
, O +
and O +
mucin O +
stains O +
( O +
PAS O +
- O +
D O +
and O +
alcian O +
blue O +
) O +
were O +
negative O +
. O +

Within O +
the O +
tumor O +
, O +
there O +
were O +
multiple O +
small O +
blood O +
- O +
filled O +
clefts O +
and O +
blood O +
lakes O +
. O +

Angioinvasion O +
in O +
medium O +
- O +
sized O +
vessels O +
, O +
including O +
an O +
artery O +
, O +
was O +
demonstrated O +
( O +
Figure O +
2 O +
( O +
d O +
) O +
) O +
. O +

Of O +
note O +
, O +
the O +
broadened O +
alveolar O +
septa O +
were O +
lined O +
by O +
markedly O +
atypical O +
epithelial O +
cells O +
, O +
yet O +
less O +
atypical O +
than O +
the O +
interstitial O +
carcinoma O +
( O +
Figures O +
2 O +
( O +
a O +
) O +
and O +
2 O +
( O +
b O +
) O +
) O +
. O +

The O +
atypia O +
of O +
the O +
lining O +
cells O +
extended O +
beyond O +
the O +
tumor O +
front O +
, O +
showing O +
a O +
sharp O +
demarcation O +
with O +
normal O +
type O +
I O +
pneumocytes O +
( O +
Figure O +
2 O +
( O +
a O +
) O +
) O +
, O +
a O +
feature O +
characteristic O +
to O +
nonmucinous O +
adenocarcinoma O +
in O +
situ O +
with O +
lepidic O +
growth O +
pattern O +
( O +
former O +
bronchioloalveolar O +
carcinoma O +
, O +
BAC O +
) O +
[ O +
3 O +
] O +
. O +

Tail O +
flick O +
test O +

CSLE O +
did O +
not O +
show O +
any O +
difference O +
compared O +
with O +
control O +
, O +
at O +
all O +
the O +
tested O +
doses O +
[ O +
Figure O +
4 O +
] O +
. O +

Morphine O +
showed O +
a O +
significant O +
increase O +
of O +
latency O +
time O +
at O +
45 O +
, O +
60 O +
and O +
75 O +
min O +
. O +

Figure O +
4 O +

Effect O +
of O +
CSLE O +
( O +
100 O +
, O +
200 O +
and O +
500 O +
mg O +
/ O +
kg O +
) O +
and O +
morphine O +
on O +
the O +
latency O +
response O +
of O +
mice O +
in O +
the O +
tail O +
flick O +
test O +
. O +

Values O +
are O +
presented O +
as O +
the O +
mean O +
+ O +
/ O +
- O +
SEM O +
( O +
n O +
= O +
5 O +
) O +
* O +
P O +
< O +
0 O +
. O +
05 O +
, O +
significant O +
increase O +
from O +
control O +

Details O +
of O +
treatment O +
programs O +
A O +
and O +
B O +
in O +
respect O +
to O +
visits O +
to O +
different O +
health O +
care O +
professionals O +
and O +
treatment O +
activities O +

Paederus O +
dermatitis O +
involving O +
the O +
neck O +

Genes O +
associated O +
with O +
nonsegmental O +
vitiligo O +
. O +

a O +
, O +
b O +
Radiographs O +
of O +
the O +
left O +
elbow O +
and O +
forearm O +
5 O +
months O +
after O +
the O +
surgery O +

Introduction O +

During O +
the O +
weaning O +
period O +
and O +
transition O +
to O +
solid O +
foods O +
in O +
the O +
first O +
year O +
of O +
life O +
, O +
infants O +
take O +
a O +
critical O +
step O +
in O +
their O +
eating O +
behavior O +
and O +
need O +
to O +
meet O +
high O +
nutrient O +
requirements O +
[ O +
1 O +
, O +
2 O +
] O +
. O +

They O +
are O +
exposed O +
to O +
new O +
foods O +
and O +
food O +
combinations O +
, O +
which O +
should O +
ensure O +
a O +
smooth O +
transition O +
to O +
the O +
family O +
diet O +
later O +
in O +
life O +
. O +

At O +
this O +
stage O +
, O +
either O +
homemade O +
or O +
commercially O +
prepared O +
foods O +
may O +
be O +
fed O +
. O +

It O +
is O +
worth O +
noting O +
that O +
in O +
prosperous O +
countries O +
the O +
modern O +
diet O +
differs O +
considerably O +
from O +
that O +
of O +
previous O +
generations O +
, O +
now O +
dominated O +
by O +
products O +
that O +
have O +
been O +
processed O +
, O +
stored O +
, O +
and O +
transported O +
over O +
great O +
distances O +
. O +

Traditional O +
, O +
cold O +
- O +
pressed O +
vegetable O +
oils O +
of O +
the O +
highest O +
nutritional O +
quality O +
, O +
e O +
. O +
g O +
. O +
extra O +
virgin O +
olive O +
oil O +
, O +
may O +
therefore O +
constitute O +
an O +
important O +
part O +
of O +
the O +
modern O +
diet O +
[ O +
3 O +
, O +
4 O +
] O +
. O +

In O +
Poland O +
, O +
many O +
infants O +
do O +
not O +
receive O +
any O +
traditional O +
homemade O +
foods O +
and O +
even O +
fruits O +
come O +
from O +
purchased O +
jars O +
. O +

Commercial O +
baby O +
foods O +
are O +
regarded O +
by O +
some O +
parents O +
and O +
medical O +
professionals O +
to O +
be O +
more O +
appropriate O +
for O +
several O +
reasons O +
: O +
they O +
undergo O +
intense O +
screening O +
for O +
contaminants O +
in O +
comparison O +
to O +
foods O +
sold O +
for O +
the O +
general O +
population O +
, O +
contain O +
no O +
additives O +
of O +
certain O +
types O +
, O +
and O +
are O +
thought O +
to O +
be O +
designed O +
to O +
help O +
infants O +
meet O +
nutrient O +
requirements O +
[ O +
5 O +
] O +
. O +

The O +
process O +
of O +
peeling O +
, O +
however O +
, O +
was O +
identified O +
as O +
the O +
most O +
effective O +
, O +
and O +
simple O +
, O +
procedure O +
in O +
reducing O +
residues O +
, O +
e O +
. O +
g O +
. O +
pesticides O +
, O +
in O +
fruits O +
and O +
vegetables O +
[ O +
6 O +
] O +
. O +

Moreover O +
, O +
contrary O +
to O +
homemade O +
food O +
, O +
which O +
does O +
not O +
contain O +
furan O +
, O +
the O +
highest O +
average O +
content O +
of O +
this O +
chemical O +
was O +
found O +
in O +
ready O +
- O +
to O +
- O +
eat O +
baby O +
foods O +
with O +
pasta O +
meals O +
, O +
followed O +
by O +
vegetable O +
meals O +
and O +
meals O +
with O +
meat O +
[ O +
7 O +
] O +
. O +

Furan O +
is O +
considered O +
to O +
be O +
potentially O +
hazardous O +
chemical O +
and O +
is O +
classified O +
as O +
a O +
possible O +
carcinogen O +
. O +

The O +
problem O +
of O +
this O +
chemical O +
in O +
homemade O +
food O +
may O +
only O +
arise O +
if O +
meals O +
with O +
potatoes O +
are O +
stored O +
and O +
then O +
hardly O +
re O +
- O +
heated O +
[ O +
7 O +
] O +
. O +

There O +
is O +
a O +
growing O +
body O +
of O +
evidence O +
that O +
flavor O +
experiences O +
and O +
dietary O +
patterns O +
in O +
childhood O +
influence O +
these O +
patterns O +
later O +
in O +
life O +
[ O +
1 O +
, O +
8 O +
, O +
9 O +
] O +
. O +

It O +
is O +
most O +
likely O +
early O +
in O +
life O +
that O +
culture O +
- O +
specific O +
flavor O +
preferences O +
are O +
initiated O +
[ O +
10 O +
, O +
11 O +
] O +
. O +

Consequently O +
, O +
exposure O +
to O +
flavors O +
and O +
smells O +
of O +
transitory O +
foods O +
may O +
serve O +
to O +
heighten O +
preferences O +
for O +
" O +
known O +
tastes O +
" O +
in O +
the O +
family O +
diet O +
later O +
in O +
adulthood O +
. O +

Moreover O +
, O +
adopting O +
elements O +
of O +
childhood O +
dinner O +
patterns O +
was O +
recognized O +
to O +
be O +
an O +
important O +
part O +
of O +
the O +
social O +
reproduction O +
of O +
family O +
identities O +
across O +
generations O +
[ O +
12 O +
] O +
. O +

Processing O +
industries O +
have O +
been O +
successful O +
in O +
manufacturing O +
and O +
marketing O +
jarred O +
baby O +
foods O +
on O +
a O +
commercial O +
scale O +
. O +

Available O +
products O +
contain O +
different O +
ingredients O +
and O +
depend O +
on O +
the O +
manufacturer O +
, O +
country O +
, O +
traditional O +
cuisine O +
, O +
income O +
rate O +
, O +
and O +
lastly O +
, O +
personal O +
beliefs O +
and O +
values O +
of O +
parents O +
[ O +
9 O +
, O +
11 O +
] O +
. O +

Jarred O +
foods O +
with O +
vegetables O +
, O +
meats O +
, O +
and O +
desserts O +
may O +
contain O +
added O +
fat O +
from O +
a O +
variety O +
of O +
sources O +
: O +
vegetable O +
oils O +
, O +
cow O +
milk O +
butter O +
, O +
or O +
cream O +
. O +

Manufacturer O +
advertising O +
makes O +
the O +
majority O +
of O +
consumers O +
feel O +
safe O +
, O +
causing O +
them O +
to O +
believe O +
that O +
they O +
are O +
doing O +
the O +
best O +
possible O +
in O +
buying O +
given O +
products O +
[ O +
11 O +
] O +
. O +

A O +
noteworthy O +
fact O +
is O +
that O +
many O +
types O +
of O +
baby O +
foods O +
produced O +
by O +
international O +
manufacturers O +
are O +
, O +
in O +
essence O +
, O +
the O +
same O +
mixtures O +
with O +
different O +
names O +
; O +
this O +
procedure O +
aims O +
to O +
exploit O +
the O +
specifics O +
of O +
local O +
markets O +
without O +
delivering O +
any O +
new O +
, O +
real O +
value O +
[ O +
11 O +
] O +
. O +

In O +
the O +
book O +
, O +
How O +
to O +
Eat O +
Well O +
and O +
Stay O +
Well O +
the O +
Mediterranean O +
Way O +
by O +
Keys O +
[ O +
13 O +
] O +
first O +
used O +
the O +
term O +
" O +
good O +
Mediterranean O +
diet O +
" O +
to O +
describe O +
the O +
eating O +
patterns O +
of O +
populations O +
dwelling O +
in O +
southern O +
Europe O +
, O +
where O +
the O +
olive O +
tree O +
( O +
Olea O +
europaea O +
) O +
is O +
an O +
emblematic O +
species O +
[ O +
4 O +
, O +
14 O +
] O +
. O +

There O +
is O +
variation O +
between O +
the O +
exact O +
diet O +
in O +
different O +
parts O +
of O +
the O +
Mediterranean O +
region O +
. O +

However O +
, O +
generalized O +
and O +
distinctive O +
dietary O +
patterns O +
do O +
exist O +
, O +
including O +
olive O +
oil O +
as O +
the O +
main O +
source O +
of O +
visible O +
fat O +
, O +
employed O +
both O +
in O +
cooking O +
and O +
as O +
a O +
dressing O +
, O +
moderate O +
fish O +
and O +
poultry O +
but O +
low O +
red O +
meat O +
consumption O +
, O +
high O +
intake O +
of O +
vegetables O +
, O +
fruits O +
, O +
legumes O +
, O +
nuts O +
, O +
and O +
whole O +
- O +
grain O +
cereals O +
[ O +
4 O +
, O +
14 O +
- O +
16 O +
] O +
. O +

When O +
dietary O +
fats O +
are O +
added O +
, O +
in O +
accordance O +
with O +
the O +
traditional O +
Mediterranean O +
diet O +
, O +
olive O +
oil O +
is O +
the O +
choice O +
for O +
children O +
[ O +
17 O +
] O +
. O +

It O +
has O +
been O +
repeatedly O +
observed O +
that O +
individuals O +
applying O +
the O +
Mediterranean O +
diet O +
have O +
reduced O +
risks O +
of O +
type O +
2 O +
diabetes O +
and O +
other O +
diseases O +
associated O +
with O +
the O +
metabolic O +
syndrome O +
, O +
autoimmunological O +
diseases O +
, O +
and O +
certain O +
forms O +
of O +
cancer O +
[ O +
18 O +
] O +
. O +

Moreover O +
, O +
considerable O +
evidence O +
exists O +
that O +
the O +
Mediterranean O +
diet O +
increases O +
quality O +
of O +
life O +
in O +
the O +
course O +
of O +
ageing O +
, O +
as O +
well O +
as O +
longevity O +
[ O +
13 O +
, O +
19 O +
] O +
. O +

The O +
health O +
benefits O +
of O +
olive O +
oil O +
have O +
been O +
attributed O +
to O +
two O +
main O +
constituents O +
: O +
a O +
high O +
oleic O +
acid O +
( O +
monounsaturated O +
fatty O +
acid O +
, O +
18 O +
: O +
1n O +
- O +
9 O +
) O +
content O +
( O +
70 O +
- O +
85 O +
% O +
) O +
and O +
a O +
large O +
amount O +
of O +
antioxidant O +
compounds O +
, O +
which O +
also O +
possess O +
antiviral O +
, O +
antibacterial O +
, O +
and O +
immunomodulating O +
effects O +
[ O +
3 O +
, O +
4 O +
, O +
14 O +
, O +
16 O +
] O +
. O +

Polyphenols O +
found O +
in O +
virgin O +
olive O +
oil O +
are O +
linked O +
to O +
both O +
its O +
flavor O +
and O +
its O +
remarkable O +
stability O +
[ O +
3 O +
] O +
. O +

The O +
introduction O +
of O +
solid O +
foods O +
in O +
infancy O +
is O +
one O +
of O +
the O +
primary O +
matters O +
often O +
discussed O +
by O +
parents O +
with O +
their O +
child O +
' O +
s O +
pediatrician O +
. O +

However O +
, O +
many O +
parents O +
do O +
not O +
feel O +
that O +
the O +
diet O +
of O +
their O +
child O +
may O +
be O +
linked O +
to O +
poor O +
health O +
outcomes O +
in O +
the O +
future O +
. O +

Parents O +
should O +
be O +
educated O +
about O +
the O +
interplay O +
of O +
environmental O +
and O +
genetic O +
influences O +
on O +
children O +
, O +
specifically O +
during O +
the O +
early O +
years O +
of O +
development O +
when O +
the O +
child O +
is O +
maturing O +
and O +
taking O +
control O +
of O +
its O +
own O +
diet O +
[ O +
11 O +
] O +
. O +

Nutrition O +
educators O +
should O +
increase O +
the O +
critical O +
awareness O +
of O +
parents O +
in O +
relation O +
to O +
their O +
child O +
' O +
s O +
solid O +
food O +
choices O +
. O +

It O +
is O +
important O +
to O +
emphasize O +
to O +
parents O +
the O +
fundamental O +
role O +
that O +
the O +
Mediterranean O +
diet O +
and O +
consumption O +
of O +
foods O +
with O +
olive O +
oil O +
play O +
in O +
a O +
healthy O +
life O +
style O +
[ O +
14 O +
, O +
20 O +
] O +
. O +

Parental O +
management O +
of O +
the O +
family O +
food O +
environment O +
may O +
be O +
complicated O +
by O +
numerous O +
mitigating O +
factors O +
, O +
e O +
. O +
g O +
. O +
health O +
literacy O +
, O +
time O +
availability O +
, O +
and O +
financial O +
resources O +
. O +

Considering O +
the O +
role O +
baby O +
food O +
manufacturers O +
play O +
in O +
the O +
infant O +
' O +
s O +
contextual O +
environment O +
, O +
their O +
products O +
, O +
as O +
well O +
as O +
the O +
manufacturers O +
themselves O +
, O +
should O +
also O +
be O +
viewed O +
as O +
key O +
players O +
and O +
central O +
agents O +
in O +
establishing O +
dietary O +
habits O +
. O +

Consequently O +
, O +
we O +
attempted O +
to O +
survey O +
manufacturer O +
claims O +
concerning O +
added O +
fat O +
in O +
jarred O +
infant O +
foods O +
supplied O +
to O +
the O +
Polish O +
market O +
. O +

Materials O +
and O +
Methods O +

Discussion O +

The O +
two O +
most O +
important O +
factors O +
leading O +
to O +
the O +
development O +
of O +
hypoxia O +
are O +
biological O +
processes O +
that O +
determine O +
the O +
amount O +
of O +
organic O +
matter O +
available O +
to O +
be O +
degraded O +
and O +
physical O +
factors O +
creating O +
stratification O +
. O +

Stratification O +
in O +
most O +
areas O +
of O +
the O +
coastal O +
zone O +
of O +
the O +
Baltic O +
Sea O +
is O +
due O +
to O +
seasonal O +
temperature O +
changes O +
, O +
although O +
stratification O +
by O +
occasional O +
inflowing O +
saltier O +
water O +
does O +
occur O +
in O +
some O +
estuaries O +
. O +
( O +
14 O +
) O +
Hypoxia O +
is O +
common O +
in O +
estuaries O +
located O +
in O +
the O +
Danish O +
Straits O +
due O +
to O +
the O +
large O +
load O +
of O +
nutrients O +
sustaining O +
algal O +
production O +
and O +
the O +
strong O +
stratification O +
caused O +
by O +
large O +
differences O +
in O +
surface O +
and O +
bottom O +
water O +
salinity O +
. O +
( O +
5 O +
) O +
Hypoxia O +
in O +
the O +
Swedish O +
and O +
Finnish O +
archipelagos O +
are O +
influenced O +
by O +
phytoplankton O +
growth O +
stimulated O +
by O +
nutrient O +
loads O +
from O +
urban O +
and O +
agricultural O +
sources O +
, O +
but O +
also O +
by O +
restricted O +
water O +
circulation O +
. O +

The O +
Finnish O +
Archipelago O +
Sea O +
is O +
impacted O +
by O +
drifting O +
algal O +
mats O +
that O +
consume O +
oxygen O +
during O +
their O +
decomposition O +
when O +
they O +
sink O +
to O +
the O +
bottom O +
. O +
( O +
15 O +
) O +
By O +
contrast O +
, O +
hypoxia O +
is O +
rare O +
in O +
the O +
northern O +
Baltic O +
Sea O +
estuaries O +
located O +
in O +
the O +
Bothnian O +
Sea O +
coastal O +
zone O +
where O +
nutrient O +
loads O +
are O +
lower O +
. O +

Hypoxia O +
is O +
uncommon O +
along O +
the O +
eastern O +
shore O +
from O +
Estonia O +
to O +
Poland O +
due O +
to O +
enhanced O +
circulation O +
of O +
water O +
in O +
open O +
areas O +
along O +
the O +
coastline O +
( O +
Figure O +
1 O +
) O +
. O +

There O +
are O +
very O +
limited O +
data O +
available O +
to O +
examine O +
how O +
far O +
back O +
in O +
time O +
hypoxia O +
has O +
occurred O +
. O +

A O +
key O +
question O +
in O +
this O +
ecosystem O +
affected O +
daily O +
by O +
over O +
85 O +
million O +
people O +
could O +
be O +
" O +
Is O +
hypoxia O +
a O +
natural O +
phenomenon O +
? O +
" O +
. O +
( O +
16 O +
) O +
The O +
large O +
numbers O +
of O +
enclosed O +
areas O +
, O +
in O +
many O +
cases O +
with O +
shallow O +
sills O +
that O +
restrict O +
the O +
exchange O +
of O +
bottom O +
water O +
and O +
often O +
in O +
combination O +
with O +
large O +
irregular O +
changes O +
in O +
salinity O +
, O +
might O +
mean O +
that O +
hypoxia O +
has O +
always O +
been O +
present O +
in O +
the O +
coastal O +
zone O +
. O +

However O +
, O +
sediment O +
laminations O +
from O +
Stockholm O +
Archipelago O +
, O +
an O +
indicator O +
of O +
past O +
hypoxia O +
, O +
( O +
17 O +
) O +
have O +
been O +
shown O +
to O +
be O +
a O +
recent O +
phenomenon O +
with O +
very O +
few O +
areas O +
with O +
laminated O +
sediments O +
prior O +
to O +
1900 O +
. O +
17 O +
, O +
18 O +
The O +
long O +
- O +
term O +
millennial O +
trends O +
in O +
coastal O +
hypoxia O +
remain O +
unknown O +
, O +
although O +
hypoxia O +
has O +
occurred O +
intermittently O +
throughout O +
the O +
last O +
8000 O +
years O +
in O +
offshore O +
deep O +
waters O +
of O +
the O +
Baltic O +
Sea O +
. O +
( O +
10 O +
) O +
Further O +
sediment O +
studies O +
are O +
necessary O +
, O +
similar O +
to O +
those O +
carried O +
out O +
in O +
the O +
open O +
Baltic O +
Sea O +
, O +
( O +
10 O +
) O +
to O +
ascertain O +
how O +
far O +
back O +
in O +
time O +
hypoxia O +
was O +
observed O +
in O +
the O +
coastal O +
zone O +
. O +

Key O +
uncertainties O +
remain O +
including O +
how O +
have O +
the O +
driving O +
forces O +
for O +
hypoxia O +
, O +
e O +
. O +
g O +
. O +
, O +
climate O +
( O +
19 O +
) O +
and O +
nutrient O +
loading O +
, O +
changed O +
through O +
time O +
in O +
the O +
Baltic O +
Sea O +
coastal O +
zone O +
, O +
and O +
do O +
they O +
vary O +
during O +
the O +
same O +
time O +
periods O +
that O +
hypoxia O +
varies O +
in O +
the O +
open O +
waters O +
? O +
( O +
16 O +
) O +

An O +
important O +
consideration O +
in O +
determining O +
the O +
number O +
of O +
ecosystems O +
experiencing O +
hypoxia O +
is O +
the O +
size O +
of O +
the O +
assessment O +
unit O +
. O +

We O +
combined O +
numerous O +
monitoring O +
points O +
and O +
sites O +
to O +
form O +
a O +
coherent O +
coastal O +
unit O +
when O +
bottom O +
waters O +
were O +
physically O +
connected O +
to O +
each O +
other O +
. O +

This O +
means O +
that O +
assessment O +
units O +
considered O +
hypoxic O +
might O +
occur O +
in O +
the O +
same O +
geographical O +
region O +
and O +
could O +
be O +
in O +
close O +
proximately O +
to O +
each O +
other O +
, O +
if O +
their O +
bottom O +
waters O +
were O +
physically O +
disconnected O +
. O +

The O +
Baltic O +
Sea O +
archipelagos O +
have O +
a O +
complex O +
topography O +
with O +
many O +
basins O +
disjoined O +
by O +
shallow O +
sills O +
resulting O +
in O +
many O +
distinct O +
sites O +
, O +
although O +
they O +
are O +
all O +
affected O +
by O +
similar O +
mechanisms O +
. O +

In O +
fact O +
, O +
the O +
Stockholm O +
and O +
Finnish O +
archipelagos O +
contributed O +
21 O +
% O +
of O +
the O +
total O +
assessment O +
units O +
, O +
a O +
relatively O +
large O +
share O +
compared O +
to O +
the O +
total O +
Baltic O +
Sea O +
coastal O +
zone O +
, O +
but O +
> O +
40 O +
% O +
of O +
the O +
hypoxic O +
sites O +
. O +

The O +
coastal O +
stretches O +
of O +
the O +
Western O +
Gotland O +
Basin O +
and O +
Gulf O +
of O +
Finland O +
that O +
have O +
a O +
substantial O +
number O +
of O +
hypoxic O +
sites O +
are O +
also O +
archipelagos O +
, O +
which O +
are O +
more O +
prone O +
to O +
hypoxia O +
because O +
of O +
the O +
complex O +
topography O +
, O +
proximity O +
to O +
development O +
, O +
and O +
consequently O +
more O +
sensitive O +
to O +
enhanced O +
nutrient O +
inputs O +
from O +
land O +
. O +

Surprisingly O +
only O +
4 O +
. O +
0 O +
% O +
of O +
all O +
sites O +
were O +
classified O +
as O +
seasonally O +
hypoxic O +
according O +
to O +
our O +
definition O +
when O +
> O +
50 O +
% O +
and O +
< O +
80 O +
% O +
of O +
profiles O +
during O +
the O +
stratified O +
period O +
have O +
oxygen O +
concentrations O +
less O +
than O +
2 O +
mg O +
L O +
- O +
1 O +
. O +

A O +
statistically O +
rigorous O +
definition O +
of O +
what O +
constitutes O +
seasonal O +
hypoxia O +
does O +
not O +
currently O +
exist O +
and O +
in O +
fact O +
should O +
be O +
linked O +
to O +
ecological O +
consequences O +
for O +
it O +
to O +
be O +
ecologically O +
relevant O +
and O +
not O +
just O +
connected O +
to O +
absolute O +
concentrations O +
. O +
( O +
3 O +
) O +
Currently O +
coastal O +
marine O +
ecosystems O +
that O +
experience O +
hypoxia O +
for O +
a O +
period O +
of O +
days O +
to O +
months O +
every O +
year O +
are O +
often O +
considered O +
to O +
be O +
seasonally O +
hypoxic O +
, O +
although O +
we O +
have O +
categorized O +
them O +
here O +
as O +
being O +
episodic O +
, O +
because O +
we O +
required O +
the O +
monitoring O +
units O +
to O +
be O +
hypoxic O +
for O +
most O +
of O +
the O +
stratified O +
period O +
. O +

However O +
, O +
in O +
Limfjorden O +
, O +
Denmark O +
, O +
bottom O +
water O +
oxygen O +
concentrations O +
can O +
vary O +
greatly O +
between O +
weekly O +
samplings O +
( O +
SI O +
Figure O +
S6 O +
) O +
, O +
although O +
nearly O +
every O +
year O +
hypoxic O +
conditions O +
are O +
observed O +
somewhere O +
in O +
the O +
Limfjorden O +
. O +

Our O +
statistical O +
estimation O +
is O +
that O +
Limfjorden O +
is O +
episodically O +
hypoxic O +
. O +

Diaz O +
and O +
Rosenberg O +
( O +
1 O +
) O +
would O +
classify O +
Limfjorden O +
as O +
periodically O +
hypoxic O +
, O +
although O +
we O +
have O +
found O +
it O +
difficult O +
to O +
create O +
a O +
statistically O +
robust O +
indicator O +
that O +
would O +
classify O +
systems O +
as O +
periodically O +
hypoxic O +
. O +

Periodic O +
hypoxia O +
is O +
problematic O +
because O +
it O +
never O +
allows O +
for O +
re O +
- O +
establishment O +
of O +
benthic O +
communities O +
. O +
( O +
20 O +
) O +

Currently O +
, O +
there O +
are O +
416 O +
areas O +
in O +
the O +
world O +
with O +
reported O +
coastal O +
hypoxia O +
with O +
about O +
30 O +
previously O +
reported O +
sites O +
in O +
the O +
Baltic O +
Sea O +
region O +
, O +
which O +
includes O +
both O +
coastal O +
zone O +
hypoxia O +
and O +
deep O +
water O +
sites O +
in O +
the O +
Baltic O +
Sea O +
. O +
( O +
1 O +
) O +
We O +
have O +
identified O +
an O +
additional O +
96 O +
sites O +
that O +
have O +
experienced O +
hypoxia O +
, O +
increasing O +
the O +
global O +
total O +
to O +
nearly O +
500 O +
sites O +
. O +

Of O +
all O +
the O +
known O +
sites O +
around O +
the O +
world O +
, O +
around O +
20 O +
% O +
of O +
the O +
sites O +
are O +
found O +
in O +
the O +
Baltic O +
Sea O +
region O +
. O +

Most O +
sites O +
experienced O +
episodic O +
hypoxia O +
, O +
which O +
is O +
a O +
precursor O +
to O +
development O +
of O +
seasonal O +
hypoxia O +
. O +
( O +
20 O +
) O +
The O +
large O +
number O +
of O +
sites O +
partially O +
reflects O +
the O +
fact O +
that O +
the O +
Baltic O +
Sea O +
is O +
one O +
of O +
the O +
most O +
data O +
rich O +
regions O +
of O +
the O +
world O +
with O +
no O +
tidal O +
mixing O +
and O +
complex O +
bottom O +
topography O +
creating O +
conditions O +
favorable O +
for O +
hypoxia O +
, O +
although O +
these O +
are O +
only O +
the O +
" O +
monitored O +
areas O +
" O +
and O +
many O +
more O +
hypoxic O +
sites O +
probably O +
exist O +
in O +
the O +
Baltic O +
Sea O +
coastal O +
zone O +
. O +

In O +
contrast O +
, O +
there O +
was O +
no O +
evidence O +
of O +
hypoxia O +
at O +
95 O +
stations O +
in O +
estuarine O +
and O +
coastal O +
waters O +
around O +
Ireland O +
due O +
to O +
sufficient O +
tidal O +
mixing O +
. O +
( O +
21 O +
) O +
If O +
such O +
detailed O +
data O +
existed O +
for O +
other O +
coastal O +
regions O +
around O +
the O +
world O +
, O +
it O +
is O +
likely O +
that O +
the O +
number O +
of O +
areas O +
would O +
increase O +
globally O +
. O +

Oxygen O +
is O +
an O +
important O +
parameter O +
in O +
water O +
quality O +
assessments O +
since O +
sufficient O +
oxygen O +
is O +
essential O +
to O +
aquatic O +
life O +
and O +
is O +
necessary O +
to O +
support O +
healthy O +
biological O +
communities O +
. O +
( O +
3 O +
) O +
For O +
example O +
, O +
oxygen O +
concentration O +
is O +
a O +
supporting O +
element O +
to O +
the O +
biological O +
quality O +
elements O +
in O +
the O +
European O +
Water O +
Framework O +
Directive O +
, O +
( O +
21 O +
) O +
is O +
one O +
of O +
the O +
ecological O +
objectives O +
in O +
the O +
Helsinki O +
Commission O +
' O +
s O +
( O +
HELCOM O +
) O +
eutrophication O +
assessment O +
of O +
the O +
Baltic O +
Sea O +
, O +
and O +
is O +
included O +
in O +
the O +
European O +
Marine O +
Strategy O +
Framework O +
Directive O +
as O +
an O +
effect O +
parameter O +
of O +
eutrophication O +
. O +

Accurate O +
data O +
for O +
the O +
concentration O +
of O +
dissolved O +
oxygen O +
are O +
essential O +
for O +
documenting O +
environmental O +
changes O +
in O +
water O +
resources O +
resulting O +
from O +
natural O +
phenomena O +
and O +
human O +
activities O +
. O +

Reports O +
of O +
hypoxia O +
globally O +
are O +
increasing1 O +
, O +
22 O +
both O +
due O +
to O +
the O +
recognition O +
of O +
the O +
seriousness O +
of O +
hypoxia O +
on O +
ecosystem O +
functioning O +
and O +
as O +
decades O +
- O +
long O +
monitoring O +
records O +
become O +
available O +
in O +
databases O +
. O +

How O +
the O +
large O +
number O +
of O +
newly O +
identified O +
hypoxic O +
areas O +
influences O +
nutrient O +
biogeochemical O +
cycles O +
and O +
ecosystem O +
services O +
in O +
the O +
coastal O +
zone O +
in O +
the O +
Baltic O +
Sea O +
is O +
currently O +
unknown O +
, O +
although O +
the O +
functioning O +
of O +
the O +
coastal O +
filter O +
certainly O +
plays O +
an O +
important O +
role O +
in O +
how O +
adjacent O +
marine O +
systems O +
respond O +
to O +
changes O +
in O +
nutrient O +
loading O +
. O +

Presently O +
about O +
40 O +
% O +
of O +
the O +
world O +
' O +
s O +
population O +
lives O +
within O +
100 O +
km O +
of O +
the O +
coastal O +
zone O +
strongly O +
impacting O +
ocean O +
health O +
, O +
( O +
24 O +
) O +
including O +
increasing O +
the O +
occurrence O +
of O +
hypoxic O +
areas O +
. O +
1 O +
, O +
2 O +
What O +
is O +
currently O +
lacking O +
is O +
the O +
link O +
to O +
the O +
driving O +
factors O +
of O +
hypoxia O +
including O +
nutrient O +
enrichment O +
, O +
organic O +
carbon O +
loading O +
and O +
climate O +
change O +
, O +
( O +
25 O +
) O +
and O +
a O +
determination O +
of O +
appropriate O +
nutrient O +
loading O +
targets O +
for O +
guidance O +
to O +
managers O +
to O +
ameliorate O +
the O +
devastating O +
impact O +
of O +
hypoxia O +
. O +
( O +
24 O +
) O +

2 O +
. O +
1 O +
. O +
3 O +

Pixel O +
Classification O +

The O +
feature O +
vector O +
of O +
a O +
grid O +
, O +
which O +
consists O +
of O +
nine O +
features O +
, O +
is O +
normalized O +
to O +
[ O +
0 O +
, O +
1 O +
] O +
, O +
and O +
the O +
position O +
features O +
are O +
scaled O +
by O +
the O +
weighting O +
coefficient O +
wpos O +
. O +

Then O +
, O +
taking O +
the O +
nine O +
dimensional O +
vector O +
of O +
each O +
grid O +
as O +
the O +
input O +
of O +
the O +
classifier O +
, O +
the O +
ROI O +
and O +
non O +
- O +
ROI O +
background O +
in O +
ultrasonic O +
breast O +
tumor O +
images O +
can O +
be O +
distinguished O +
. O +

In O +
this O +
section O +
, O +
the O +
self O +
- O +
organizing O +
feature O +
map O +
neural O +
network O +
( O +
SOMNN O +
) O +
[ O +
25 O +
] O +
, O +
proposed O +
by O +
Kohonen O +
according O +
to O +
characteristics O +
of O +
the O +
nervous O +
system O +
, O +
is O +
used O +
for O +
the O +
classification O +
of O +
these O +
grids O +
to O +
detect O +
the O +
ROI O +
automatically O +
. O +

The O +
SOM O +
is O +
trained O +
by O +
the O +
unsupervised O +
learning O +
to O +
produce O +
a O +
low O +
- O +
dimensional O +
discretized O +
representation O +
of O +
the O +
input O +
space O +
of O +
the O +
training O +
samples O +
, O +
and O +
it O +
uses O +
a O +
neighborhood O +
function O +
to O +
preserve O +
the O +
topological O +
properties O +
of O +
the O +
input O +
space O +
, O +
which O +
makes O +
it O +
different O +
from O +
other O +
artificial O +
neural O +
networks O +
. O +

In O +
this O +
way O +
, O +
the O +
SOM O +
is O +
able O +
to O +
classify O +
the O +
sub O +
- O +
blocks O +
into O +
n O +
clusters O +
only O +
by O +
the O +
unsupervised O +
learning O +
. O +

In O +
our O +
study O +
, O +
the O +
output O +
layer O +
number O +
n O +
is O +
set O +
to O +
2 O +
( O +
ROI O +
and O +
non O +
- O +
ROI O +
output O +
) O +
and O +
the O +
feature O +
vector O +
extracted O +
from O +
each O +
grid O +
is O +
taken O +
as O +
the O +
input O +
. O +

To O +
map O +
the O +
sorted O +
sub O +
- O +
blocks O +
back O +
to O +
the O +
size O +
of O +
the O +
original O +
ultrasonic O +
images O +
, O +
the O +
initial O +
result O +
of O +
ROI O +
detection O +
can O +
be O +
represented O +
by O +
a O +
binary O +
image O +
as O +
shown O +
in O +
Fig O +
. O +

( O +
2d O +
) O +
, O +
where O +
white O +
areas O +
indicate O +
the O +
ROI O +
candidates O +
while O +
black O +
areas O +
the O +
non O +
- O +
ROIs O +
. O +

Materials O +
and O +
Methods O +
: O +

A O +
total O +
of O +
75 O +
brain O +
abscess O +
pus O +
specimens O +
were O +
collected O +
during O +
neurosurgery O +
, O +
either O +
by O +
burr O +
hole O +
or O +
by O +
craniotomy O +
. O +

These O +
specimens O +
were O +
further O +
subjected O +
to O +
Gram O +
stain O +
, O +
Ziehl O +
- O +
Neelsen O +
( O +
ZN O +
) O +
stain O +
, O +
and O +
conventional O +
microbiological O +
culture O +
. O +

Only O +
those O +
cases O +
which O +
showed O +
presence O +
of O +
AFB O +
on O +
ZN O +
stain O +
along O +
with O +
the O +
growth O +
of O +
Mycobacterium O +
tuberculosis O +
were O +
considered O +
as O +
TBAs O +
. O +

Such O +
TBA O +
cases O +
were O +
further O +
presented O +
along O +
with O +
their O +
In O +
vitro O +
Proton O +
Magnetic O +
Resonance O +
( O +
MR O +
) O +
Spectroscopic O +
findings O +
. O +

Rate O +
of O +
distraction O +
calculation O +
( O +
Figs O +
. O +
6 O +
, O +
7 O +
and O +
8 O +
) O +

Ideal O +
rate O +
for O +
new O +
bone O +
formation O +
by O +
distraction O +
osteogenesis O +
is O +
known O +
as O +
1 O +
mm O +
/ O +
day O +
. O +
5 O +
, O +
6 O +
The O +
slower O +
rates O +
may O +
lead O +
to O +
premature O +
consolidation O +
, O +
whereas O +
the O +
faster O +
rates O +
may O +
result O +
in O +
poor O +
regenerate O +
bone O +
formation O +
. O +

In O +
simple O +
longitudinal O +
lengthening O +
, O +
the O +
rate O +
of O +
distraction O +
is O +
equal O +
at O +
any O +
point O +
of O +
the O +
corticotomy O +
, O +
however O +
, O +
the O +
rate O +
of O +
distraction O +
at O +
any O +
given O +
portion O +
of O +
the O +
corticotomy O +
varies O +
during O +
angular O +
correction O +
. O +

Usually O +
, O +
the O +
gap O +
between O +
corticotomized O +
bone O +
ends O +
is O +
larger O +
on O +
the O +
concave O +
side O +
, O +
therefore O +
, O +
the O +
rate O +
of O +
angular O +
correction O +
should O +
be O +
adjusted O +
so O +
that O +
the O +
rate O +
of O +
distraction O +
of O +
the O +
concave O +
side O +
is O +
closer O +
to O +
1 O +
mm O +
/ O +
day O +
. O +

In O +
cases O +
with O +
passive O +
hinge O +
system O +
, O +
the O +
amount O +
of O +
daily O +
angular O +
correction O +
can O +
easily O +
be O +
calculated O +
by O +
the O +
geometric O +
methods O +
using O +
the O +
rule O +
of O +
similar O +
triangles O +
and O +
the O +
rule O +
of O +
concentric O +
circles O +
, O +
and O +
can O +
be O +
expressed O +
as O +
the O +
amount O +
of O +
daily O +
lengthening O +
of O +
motor O +
system O +
. O +

In O +
passive O +
hinge O +
system O +
, O +
the O +
ACA O +
is O +
fixed O +
on O +
the O +
frame O +
in O +
Ilizarov O +
system O +
or O +
on O +
the O +
convex O +
side O +
of O +
corticotomy O +
in O +
unilateral O +
fixator O +
system O +
, O +
and O +
angular O +
correction O +
is O +
achieved O +
by O +
changing O +
the O +
length O +
of O +
the O +
motor O +
( O +
Ilizarov O +
system O +
) O +
or O +
the O +
lengthener O +
( O +
unilateral O +
fixator O +
) O +
which O +
rotates O +
the O +
passive O +
hinge O +
. O +

However O +
, O +
in O +
active O +
hinge O +
system O +
, O +
angulator O +
directly O +
corrects O +
angular O +
deformity O +
, O +
and O +
the O +
lengthener O +
and O +
translator O +
adjust O +
secondary O +
displacement O +
. O +

Therefore O +
, O +
the O +
rate O +
of O +
angular O +
correction O +
can O -
not O +
be O +
determined O +
by O +
the O +
simple O +
geometric O +
methods O +
used O +
for O +
passive O +
hinge O +
system O +
. O +

Regardless O +
of O +
types O +
of O +
fixators O +
, O +
the O +
gap O +
opens O +
larger O +
on O +
the O +
concave O +
side O +
of O +
the O +
deformity O +
after O +
realignment O +
. O +

The O +
rate O +
of O +
angular O +
correction O +
also O +
should O +
be O +
adjusted O +
so O +
that O +
the O +
rate O +
of O +
distraction O +
of O +
concave O +
side O +
is O +
1 O +
mm O +
/ O +
day O +
. O +

Theoretically O +
, O +
after O +
realignment O +
by O +
Dyna O +
- O +
ATC O +
with O +
adjustment O +
of O +
secondary O +
displacement O +
, O +
the O +
convex O +
side O +
of O +
the O +
corticotomy O +
does O +
not O +
change O +
in O +
length O +
, O +
but O +
the O +
cocave O +
side O +
opens O +
to O +
correct O +
angular O +
deformity O +
. O +

The O +
amount O +
of O +
lengthening O +
on O +
the O +
concave O +
side O +
can O +
be O +
calculated O +
with O +
the O +
thickness O +
of O +
the O +
bone O +
at O +
the O +
corticotomy O +
site O +
and O +
the O +
amount O +
of O +
angular O +
deformity O +
( O +
Fig O +
. O +
6 O +
) O +
. O +

If O +
the O +
corticotomy O +
is O +
performed O +
on O +
the O +
CORA O +
, O +
no O +
translation O +
deformity O +
happens O +
, O +
however O +
, O +
if O +
not O +
, O +
translation O +
results O +
at O +
the O +
corticotomy O +
site O +
after O +
realignment O +
is O +
achieved O +
. O +

The O +
amount O +
of O +
translation O +
can O +
be O +
calculated O +
with O +
the O +
distance O +
from O +
the O +
CORA O +
to O +
the O +
corticotomy O +
over O +
the O +
longitudinal O +
bisecting O +
line O +
( O +
lBL O +
) O +
( O +
Fig O +
. O +
6 O +
) O +
. O +

On O +
the O +
immediate O +
post O +
- O +
operative O +
radiographs O +
, O +
the O +
gap O +
distance O +
of O +
concave O +
side O +
after O +
realignment O +
can O +
be O +
calculated O +
with O +
the O +
expected O +
change O +
in O +
length O +
and O +
translation O +
on O +
the O +
concave O +
side O +
of O +
the O +
corticotomy O +
using O +
the O +
Pythaorean O +
theorem O +
. O +

The O +
rate O +
of O +
angular O +
correction O +
should O +
be O +
given O +
as O +
the O +
amount O +
of O +
daily O +
correction O +
angle O +
, O +
but O +
not O +
as O +
the O +
amount O +
of O +
length O +
change O +
of O +
the O +
fixator O +
. O +

The O +
angular O +
change O +
of O +
angulator O +
determines O +
the O +
secondary O +
change O +
of O +
length O +
and O +
translation O +
of O +
the O +
corticotomy O +
site O +
. O +

The O +
amount O +
of O +
secondary O +
deformity O +
during O +
angular O +
correction O +
can O +
be O +
calculated O +
with O +
the O +
thickness O +
of O +
bone O +
at O +
the O +
corticotomy O +
site O +
, O +
the O +
distance O +
between O +
the O +
ACA O +
and O +
the O +
corticotomy O +
, O +
and O +
tan O +
( O +
a O +
/ O +
2 O +
) O +
( O +
a O +
is O +
the O +
amount O +
of O +
angular O +
correction O +
) O +
( O +
Fig O +
. O +
6 O +
) O +
. O +

The O +
thickness O +
of O +
the O +
bone O +
at O +
the O +
corticotomy O +
site O +
and O +
the O +
distance O +
between O +
the O +
ACA O +
and O +
the O +
corticotomy O +
do O +
not O +
change O +
, O +
once O +
the O +
corticotomy O +
is O +
performed O +
after O +
Dyna O +
- O +
ATC O +
is O +
applied O +
. O +

Therefore O +
, O +
the O +
amount O +
of O +
secondary O +
deformities O +
changes O +
only O +
with O +
tan O +
( O +
a O +
/ O +
2 O +
) O +
value O +
. O +

If O +
tangent O +
value O +
varies O +
proportionally O +
with O +
changes O +
of O +
angle O +
, O +
the O +
gap O +
distance O +
increases O +
constantly O +
with O +
the O +
given O +
amount O +
of O +
daily O +
correction O +
angle O +
during O +
angular O +
correction O +
. O +

If O +
not O +
, O +
the O +
gap O +
distance O +
varies O +
continuously O +
with O +
changes O +
of O +
the O +
angle O +
, O +
therefore O +
, O +
the O +
amount O +
of O +
correction O +
angle O +
should O +
be O +
readjusted O +
everyday O +
to O +
maintain O +
1 O +
mm O +
/ O +
day O +
of O +
distraction O +
rate O +
on O +
the O +
concave O +
side O +
of O +
the O +
corticotomy O +
. O +

Fortunately O +
, O +
while O +
the O +
value O +
of O +
tangent O +
angle O +
increases O +
exponentially O +
especially O +
over O +
45 O +
degrees O +
, O +
tangent O +
function O +
curve O +
is O +
nearly O +
straight O +
, O +
less O +
than O +
30 O +
degrees O +
( O +
Fig O +
. O +
7 O +
) O +
. O +

Therefore O +
, O +
in O +
cases O +
with O +
less O +
than O +
60 O +
degrees O +
of O +
angular O +
deformity O +
, O +
the O +
amount O +
of O +
daily O +
correction O +
angle O +
which O +
permits O +
1 O +
mm O +
/ O +
day O +
of O +
distraction O +
rate O +
on O +
the O +
concave O +
side O +
of O +
the O +
corticotomy O +
can O +
be O +
obtained O +
as O +
the O +
rate O +
of O +
angular O +
correction O +
without O +
daily O +
adjustment O +
during O +
angular O +
correction O +
. O +

Once O +
the O +
amount O +
of O +
daily O +
angular O +
correction O +
is O +
determined O +
, O +
the O +
amount O +
of O +
daily O +
length O +
and O +
translation O +
compensation O +
can O +
also O +
be O +
calculated O +
with O +
the O +
amount O +
of O +
daily O +
angular O +
correction O +
. O +

Exact O +
adjustment O +
of O +
secondary O +
changes O +
in O +
length O +
and O +
translation O +
at O +
each O +
angular O +
correction O +
opens O +
the O +
concave O +
side O +
of O +
the O +
corticotomy O +
1 O +
mm O +
per O +
day O +
, O +
but O +
allows O +
minimal O +
gap O +
on O +
the O +
corticotomy O +
of O +
convex O +
side O +
especially O +
in O +
the O +
early O +
stage O +
of O +
angular O +
correction O +
. O +

Therefore O +
, O +
it O +
is O +
possible O +
that O +
the O +
corticotomized O +
bone O +
ends O +
of O +
convex O +
side O +
, O +
may O +
abut O +
each O +
other O +
and O +
prevent O +
angular O +
correction O +
or O +
adjustment O +
of O +
secondary O +
translation O +
. O +

For O +
the O +
cases O +
where O +
the O +
concomitant O +
lengthening O +
is O +
required O +
, O +
longitudinal O +
lengthening O +
prior O +
to O +
angular O +
correction O +
is O +
recommended O +
. O +

Otherwise O +
, O +
about O +
5 O +
mm O +
pre O +
- O +
lengthening O +
and O +
re O +
- O +
shortening O +
after O +
angular O +
correction O +
could O +
be O +
helpful O +
in O +
avoiding O +
abutment O +
on O +
the O +
convex O +
side O +
of O +
the O +
corticotomy O +
site O +
. O +

Inappropriate O +
sequence O +
of O +
angular O +
correction O +
and O +
adjustment O +
of O +
secondary O +
deformities O +
could O +
be O +
one O +
of O +
the O +
causes O +
of O +
the O +
impingement O +
. O +

Appropriate O +
sequence O +
of O +
correction O +
is O +
lengthening O +
- O +
translation O +
- O +
angulation O +
with O +
Dyna O +
- O +
ATC O +
on O +
the O +
concave O +
side O +
and O +
angulation O +
- O +
translation O +
- O +
shortening O +
with O +
Dyna O +
- O +
ATC O +
on O +
the O +
convex O +
side O +
. O +

Pharmacokinetic O +
- O +
pharmacodynamic O +
analysis O +
. O +

The O +
mean O +
( O +
90 O +
% O +
CI O +
) O +
slope O +
estimate O +
from O +
the O +
linezolid O +
concentration O +
- O +
R O +
- O +
R O +
interval O +
analysis O +
was O +
- O +
0 O +
. O +
0017 O +
( O +
- O +
0 O +
. O +
0022 O +
to O +
- O +
0 O +
. O +
0011 O +
) O +
ms O +
/ O +
ng O +
/ O +
ml O +
. O +

This O +
translates O +
to O +
mean O +
( O +
90 O +
% O +
CI O +
) O +
predicted O +
decreases O +
in O +
heart O +
rate O +
of O +
approximately O +
1 O +
. O +
5 O +
( O +
1 O +
. O +
0 O +
to O +
2 O +
. O +
0 O +
) O +
and O +
3 O +
. O +
0 O +
( O +
2 O +
. O +
1 O +
to O +
4 O +
. O +
1 O +
) O +
beats O +
/ O +
min O +
at O +
the O +
mean O +
Cmax O +
following O +
the O +
administration O +
of O +
600 O +
- O +
and O +
1 O +
, O +
200 O +
- O +
mg O +
linezolid O +
doses O +
, O +
respectively O +
. O +

The O +
study O +
- O +
specific O +
mean O +
correction O +
factor O +
estimated O +
from O +
baseline O +
data O +
was O +
0 O +
. O +
278 O +
, O +
which O +
is O +
slightly O +
less O +
than O +
Fridericia O +
' O +
s O +
correction O +
( O +
0 O +
. O +
333 O +
) O +
. O +

Evaluation O +
of O +
the O +
various O +
correction O +
factors O +
showed O +
that O +
QTcF O +
most O +
appropriately O +
resolves O +
the O +
relationship O +
between O +
the O +
QT O +
interval O +
and O +
the O +
heart O +
rate O +
in O +
the O +
baseline O +
data O +
from O +
the O +
present O +
study O +
. O +

This O +
is O +
evident O +
upon O +
inspection O +
of O +
Fig O +
. O +

4 O +
, O +
since O +
the O +
slope O +
between O +
the O +
QTcF O +
interval O +
and O +
the O +
R O +
- O +
R O +
interval O +
is O +
closest O +
to O +
zero O +
when O +
this O +
correction O +
is O +
applied O +
. O +

Fig O +
. O +

4 O +
. O +

Evaluation O +
of O +
various O +
heart O +
rate O +
correction O +
factors O +
for O +
the O +
QT O +
interval O +
versus O +
the O +
R O +
- O +
R O +
interval O +
. O +

The O +
predicted O +
line O +
in O +
each O +
figure O +
represents O +
the O +
fit O +
from O +
a O +
linear O +
mixed O +
- O +
effect O +
model O +
with O +
R O +
- O +
R O +
interval O +
as O +
a O +
fixed O +
effect O +
and O +
subject O +
- O +
specific O +
random O +
effects O +
for O +
intercept O +
and O +
slope O +
. O +

The O +
results O +
from O +
the O +
concentration O +
- O +
QTcF O +
analysis O +
are O +
graphically O +
depicted O +
in O +
Fig O +
. O +

5 O +
. O +

The O +
mean O +
( O +
90 O +
% O +
CI O +
) O +
slope O +
estimate O +
from O +
the O +
linezolid O +
concentration O +
- O +
QTcF O +
analysis O +
was O +
- O +
0 O +
. O +
0145 O +
( O +
- O +
0 O +
. O +
0768 O +
to O +
0 O +
. O +
0477 O +
) O +
ms O +
/ O +
mug O +
/ O +
ml O +
. O +

At O +
the O +
geometric O +
mean O +
Cmax O +
following O +
the O +
infusion O +
of O +
linezolid O +
at O +
600 O +
mg O +
( O +
14 O +
. O +
9 O +
mug O +
/ O +
ml O +
) O +
and O +
1 O +
, O +
200 O +
mg O +
( O +
30 O +
. O +
5 O +
mug O +
/ O +
ml O +
) O +
, O +
the O +
mean O +
( O +
90 O +
% O +
CI O +
) O +
predicted O +
placebo O +
- O +
adjusted O +
changes O +
from O +
the O +
baseline O +
QTcF O +
were O +
- O +
0 O +
. O +
217 O +
( O +
- O +
1 O +
. O +
14 O +
to O +
0 O +
. O +
710 O +
) O +
and O +
- O +
0 O +
. O +
444 O +
( O +
- O +
2 O +
. O +
34 O +
to O +
1 O +
. O +
45 O +
) O +
ms O +
, O +
respectively O +
, O +
thus O +
confirming O +
a O +
lack O +
of O +
a O +
relationship O +
between O +
linezolid O +
concentrations O +
and O +
QTc O +
interval O +
. O +

Fig O +
. O +

5 O +
. O +

QTcF O +
interval O +
versus O +
plasma O +
linezolid O +
concentrations O +
. O +

Results O +

primary O +
pancreatic O +
sarcomas O +
are O +
extremely O +
rare O +
. O +

Pancreatic O +
sarcomas O +
are O +
more O +
aggressive O +
than O +
other O +
pancreatic O +
neoplasms O +
. O +

Challenges O +
to O +
creating O +
and O +
implementing O +
a O +
perioperative O +
glycemic O +
control O +
protocol O +
. O +

Introduction O +

Hip O +
fractures O +
in O +
the O +
aged O +
constitute O +
a O +
major O +
health O +
problem O +
with O +
substantial O +
morbidity O +
[ O +
1 O +
] O +
, O +
mortality O +
[ O +
2 O +
, O +
3 O +
] O +
, O +
and O +
, O +
as O +
the O +
ageing O +
population O +
increases O +
, O +
an O +
increasing O +
burden O +
on O +
the O +
health O +
care O +
system O +
[ O +
4 O +
] O +
. O +

Fracture O +
risk O +
varies O +
markedly O +
between O +
countries O +
[ O +
5 O +
] O +
. O +

In O +
a O +
study O +
by O +
Kanis O +
et O +
al O +
. O +

[ O +
6 O +
] O +
, O +
comparing O +
10 O +
- O +
year O +
probability O +
of O +
hip O +
fracture O +
, O +
all O +
countries O +
except O +
Norway O +
had O +
lower O +
risk O +
than O +
Sweden O +
. O +

Other O +
countries O +
categorized O +
at O +
very O +
high O +
risk O +
( O +
> O +
75 O +
% O +
of O +
the O +
risk O +
of O +
Sweden O +
) O +
were O +
Iceland O +
, O +
Denmark O +
and O +
the O +
US O +
. O +

At O +
the O +
age O +
of O +
80 O +
, O +
the O +
estimated O +
probability O +
of O +
sustaining O +
a O +
hip O +
fracture O +
the O +
next O +
10 O +
years O +
is O +
8 O +
. O +
6 O +
% O +
and O +
17 O +
. O +
7 O +
% O +
in O +
Norwegian O +
men O +
and O +
women O +
, O +
respectively O +
[ O +
7 O +
] O +
, O +
and O +
a O +
report O +
from O +
the O +
Norwegian O +
capital O +
Oslo O +
calculated O +
an O +
overall O +
annual O +
fracture O +
rate O +
of O +
118 O +
. O +
0 O +
in O +
women O +
and O +
44 O +
. O +
0 O +
in O +
men O +
per O +
10 O +
, O +
000 O +
[ O +
8 O +
] O +
. O +

Several O +
recent O +
studies O +
are O +
reporting O +
declining O +
fracture O +
incidence O +
[ O +
9 O +
- O +
14 O +
] O +
. O +

Although O +
the O +
Norwegian O +
hip O +
fracture O +
rates O +
remain O +
the O +
highest O +
reported O +
in O +
the O +
world O +
, O +
data O +
from O +
Oslo O +
in O +
1996 O +
- O +
1997 O +
indicated O +
no O +
increasing O +
incidence O +
rates O +
compared O +
to O +
the O +
1988 O +
- O +
1989 O +
[ O +
8 O +
] O +
. O +
Within O +
Norway O +
, O +
considerable O +
geographic O +
differences O +
have O +
been O +
reported O +
, O +
with O +
substantially O +
lower O +
rates O +
in O +
smaller O +
cities O +
and O +
rural O +
areas O +
compared O +
to O +
Oslo O +
[ O +
7 O +
, O +
15 O +
] O +
. O +

However O +
, O +
these O +
are O +
reports O +
based O +
on O +
sporadic O +
studies O +
in O +
few O +
regions O +
and O +
in O +
limited O +
time O +
periods O +
[ O +
16 O +
, O +
17 O +
] O +
. O +

From O +
1985 O +
to O +
2003 O +
, O +
the O +
Norwegian O +
Institute O +
of O +
Public O +
Health O +
commissioned O +
four O +
Norwegian O +
hospitals O +
, O +
representing O +
10 O +
% O +
of O +
the O +
population O +
, O +
to O +
run O +
a O +
national O +
injury O +
registry O +
[ O +
18 O +
] O +
. O +

The O +
registry O +
collected O +
a O +
variety O +
of O +
data O +
connected O +
to O +
the O +
actual O +
injury O +
itself O +
and O +
the O +
event O +
leading O +
to O +
the O +
injury O +
. O +

In O +
the O +
city O +
of O +
Harstad O +
in O +
Northern O +
Norway O +
, O +
the O +
registration O +
continued O +
and O +
has O +
been O +
running O +
for O +
more O +
than O +
23 O +
years O +
. O +

Throughout O +
the O +
years O +
of O +
the O +
National O +
Injury O +
Registry O +
, O +
the O +
injury O +
rates O +
in O +
Harstad O +
closely O +
resembled O +
the O +
rates O +
of O +
the O +
national O +
registry O +
[ O +
18 O +
] O +
. O +

With O +
reference O +
to O +
the O +
recent O +
reports O +
suggesting O +
stabilizing O +
hip O +
fracture O +
incidence O +
internationally O +
as O +
well O +
as O +
nationally O +
, O +
and O +
regional O +
differences O +
within O +
Norway O +
, O +
we O +
have O +
used O +
the O +
hip O +
fracture O +
data O +
in O +
the O +
Harstad O +
Injury O +
Registry O +
to O +
: O +

Describe O +
age O +
- O +
and O +
sex O +
- O +
specific O +
incidence O +
of O +
hip O +
fractures O +
in O +
Harstad O +
, O +
Northern O +
Norway O +
and O +
make O +
comparison O +
with O +
rates O +
from O +
the O +
Norwegian O +
capital O +
Oslo O +

Describe O +
time O +
trends O +
in O +
hip O +
fracture O +
incidence O +
in O +
Harstad O +
from O +
1994 O +
to O +
2008 O +

Describe O +
place O +
of O +
injury O +
and O +
seasonal O +
variations O +
in O +
hip O +
fracture O +
incidence O +
in O +
Harstad O +

Compare O +
3 O +
- O +
month O +
, O +
6 O +
- O +
month O +
, O +
and O +
1 O +
- O +
year O +
mortality O +
after O +
hip O +
fracture O +
between O +
women O +
and O +
men O +
in O +
Harstad O +

( O +
a O +
) O +
The O +
Tn6087 O +
target O +
site O +
within O +
S O +
. O +
oralis O +
F O +
. O +
MI O +
. O +
5 O +
. O +

( O +
b O +
) O +
The O +
left O +
end O +
and O +
( O +
c O +
) O +
right O +
end O +
of O +
Tn6087 O +
are O +
shown O +
in O +
bold O +
. O +

( O +
d O +
) O +
The O +
joint O +
of O +
the O +
circular O +
intermediate O +
of O +
Tn6087 O +
is O +
shown O +
. O +

The O +
transposon O +
' O +
s O +
coupling O +
sequences O +
are O +
shown O +
in O +
bold O +
italics O +
. O +

As O +
can O +
be O +
seen O +
in O +
( O +
d O +
) O +
, O +
the O +
coupling O +
sequence O +
at O +
the O +
joint O +
of O +
the O +
circular O +
form O +
is O +
a O +
heteroduplex O +
. O +

Parameters O +
derived O +
from O +
normalized O +
averaged O +
data O +
across O +
participants O +

Results O +

Table O +
1 O +
shows O +
the O +
predicted O +
new O +
case O +
detection O +
rates O +
at O +
25 O +
years O +
after O +
the O +
initiation O +
of O +
the O +
interventions O +
. O +

Under O +
the O +
baseline O +
control O +
program O +
, O +
the O +
different O +
mechanisms O +
that O +
determined O +
susceptibility O +
showed O +
up O +
to O +
three O +
- O +
fold O +
differences O +
in O +
the O +
predicted O +
number O +
of O +
cases O +
per O +
100 O +
, O +
000 O +
people O +
. O +

In O +
Figure O +
1 O +
, O +
the O +
trends O +
in O +
the O +
new O +
case O +
detection O +
rates O +
over O +
50 O +
years O +
are O +
shown O +
for O +
all O +
seven O +
interventions O +
. O +

All O +
susceptibility O +
mechanisms O +
give O +
qualitatively O +
comparable O +
trends O +
. O +

When O +
the O +
intervention O +
scenarios O +
were O +
ordered O +
after O +
50 O +
years O +
by O +
the O +
amount O +
of O +
reduction O +
in O +
new O +
case O +
detection O +
rates O +
, O +
the O +
order O +
was O +
as O +
good O +
as O +
identical O +
for O +
all O +
mechanisms O +
; O +
i O +
. O +
e O +
. O +
early O +
diagnosis O +
lowest O +
; O +
then O +
no O +
BCG O +
& O +
early O +
diagnosis O +
; O +
then O +
chemoprophylaxis O +
; O +
then O +
baseline O +
; O +
then O +
no O +
BCG O +
& O +
chemoprophylaxis O +
together O +
with O +
no O +
contact O +
tracing O +
; O +
and O +
finally O +
no O +
BCG O +
had O +
the O +
highest O +
new O +
case O +
detection O +
rate O +
. O +

10 O +
. O +
1371 O +
/ O +
journal O +
. O +
pntd O +
. O +
0001330 O +
. O +
g001 O +
Figure O +
1 O +

Predicted O +
decline O +
of O +
the O +
new O +
case O +
detection O +
rate O +
with O +
seven O +
intervention O +
scenarios O +
and O +
six O +
mechanisms O +
of O +
leprosy O +
susceptiblity O +
since O +
start O +
of O +
intervention O +
strategy O +
. O +

The O +
baseline O +
program O +
( O +
black O +
line O +
) O +
included O +
passive O +
detection O +
, O +
multidrug O +
therapy O +
, O +
contact O +
tracing O +
, O +
and O +
an O +
infant O +
leprosy O +
- O +
preventative O +
BCG O +
vaccination O +
given O +
at O +
the O +
population O +
level O +
. O +

The O +
other O +
six O +
intervention O +
strategies O +
included O +
the O +
baseline O +
program O +
and O +
, O +
introduction O +
of O +
a O +
new O +
tuberculosis O +
vaccine O +
ineffective O +
against O +
leprosy O +
replacing O +
BCG O +
( O +
red O +
) O +
; O +
no O +
tracing O +
of O +
household O +
contacts O +
( O +
orange O +
) O +
; O +
a O +
single O +
chemoprophylactic O +
dose O +
of O +
rifampicin O +
that O +
cured O +
50 O +
% O +
of O +
subclinically O +
infected O +
contacts O +
( O +
yellow O +
) O +
; O +
early O +
diagnosis O +
of O +
70 O +
% O +
of O +
subclinically O +
infected O +
contacts O +
in O +
each O +
of O +
3 O +
consecutive O +
annual O +
examinations O +
( O +
green O +
) O +
; O +
chemoprophylaxis O +
plus O +
introduction O +
of O +
a O +
tuberculosis O +
vaccine O +
ineffective O +
against O +
leprosy O +
( O +
blue O +
) O +
; O +
and O +
detection O +
of O +
subclinically O +
infected O +
contacts O +
plus O +
introduction O +
of O +
a O +
tuberculosis O +
vaccine O +
ineffective O +
against O +
le O +
- O +
pro O +
- O +
sy O +
( O +
purple O +
) O +
. O +

Results O +
are O +
the O +
average O +
of O +
100 O +
runs O +
of O +
the O +
simulation O +
model O +
for O +
each O +
scenario O +
and O +
susceptibilty O +
mechanism O +
. O +

10 O +
. O +
1371 O +
/ O +
journal O +
. O +
pntd O +
. O +
0001330 O +
. O +
t001 O +
Table O +
1 O +

Predicted O +
new O +
case O +
detection O +
rates O +
( O +
per O +
100 O +
, O +
000 O +
) O +
at O +
25 O +
years O +
after O +
the O +
introduction O +
of O +
the O +
indicated O +
intervention O +
scenario O +
for O +
six O +
mechanisms O +
of O +
leprosy O +
susceptibility O +
as O +
described O +
in O +
[ O +
9 O +
] O +
. O +

Intervention O +
Mechanism O +
determining O +
susceptibilty O +

Random O +
Household O +
Dominant O +
Recessive O +
Household O +
& O +
dominant O +
Household O +
& O +
recessive O +

Baseline O +
control O +
3 O +
. O +
4 O +
4 O +
. O +
0 O +
10 O +
. O +
4 O +
8 O +
. O +
2 O +
5 O +
. O +
6 O +
4 O +
. O +
6 O +

No O +
BCG O +
4 O +
. O +
6 O +
5 O +
. O +
5 O +
15 O +
. O +
0 O +
11 O +
. O +
9 O +
7 O +
. O +
6 O +
6 O +
. O +
4 O +

No O +
contact O +
tracing O +
3 O +
. O +
8 O +
4 O +
. O +
1 O +
10 O +
. O +
5 O +
8 O +
. O +
5 O +
5 O +
. O +
5 O +
4 O +
. O +
8 O +

Chemoprophylaxis O +
2 O +
. O +
8 O +
3 O +
. O +
2 O +
6 O +
. O +
9 O +
5 O +
. O +
9 O +
4 O +
. O +
1 O +
3 O +
. O +
4 O +

Early O +
diagnosis O +
1 O +
. O +
1 O +
2 O +
. O +
1 O +
2 O +
. O +
7 O +
2 O +
. O +
6 O +
2 O +
. O +
1 O +
2 O +
. O +
0 O +

No O +
BCG O +
& O +
chemoprophylaxis O +
3 O +
. O +
6 O +
4 O +
. O +
0 O +
10 O +
. O +
5 O +
8 O +
. O +
5 O +
5 O +
. O +
9 O +
5 O +
. O +
1 O +

No O +
BCG O +
& O +
early O +
diagnosis O +
1 O +
. O +
2 O +
2 O +
. O +
5 O +
3 O +
. O +
7 O +
3 O +
. O +
7 O +
2 O +
. O +
9 O +
2 O +
. O +
8 O +

The O +
results O +
are O +
average O +
of O +
100 O +
runs O +
of O +
the O +
simulation O +
model O +
. O +

Both O +
the O +
cessation O +
of O +
contact O +
tracing O +
and O +
the O +
replacement O +
of O +
BCG O +
vaccine O +
by O +
a O +
tuberculosis O +
vaccine O +
ineffective O +
for O +
leprosy O +
( O +
no O +
BCG O +
) O +
would O +
have O +
detrimental O +
effects O +
on O +
the O +
rate O +
of O +
decline O +
in O +
leprosy O +
( O +
Figure O +
2 O +
) O +
. O +

Twenty O +
- O +
five O +
years O +
after O +
introduction O +
of O +
the O +
ineffective O +
vaccine O +
( O +
no O +
BCG O +
) O +
, O +
the O +
new O +
case O +
detection O +
of O +
leprosy O +
was O +
approximately O +
1 O +
. O +
5 O +
times O +
higher O +
than O +
the O +
baseline O +
( O +
Table O +
1 O +
) O +
. O +

The O +
cessation O +
of O +
contact O +
tracing O +
was O +
predicted O +
to O +
have O +
a O +
smaller O +
impact O +
, O +
with O +
a O +
marked O +
drop O +
in O +
detection O +
of O +
new O +
leprosy O +
cases O +
during O +
the O +
first O +
few O +
years O +
. O +

This O +
sudden O +
drop O +
was O +
due O +
to O +
the O +
reduced O +
number O +
of O +
examinations O +
of O +
people O +
in O +
contact O +
with O +
patients O +
; O +
thus O +
, O +
these O +
cases O +
would O +
not O +
be O +
detected O +
until O +
later O +
, O +
through O +
passive O +
detection O +
( O +
self O +
- O +
reporting O +
) O +
. O +

10 O +
. O +
1371 O +
/ O +
journal O +
. O +
pntd O +
. O +
0001330 O +
. O +
g002 O +
Figure O +
2 O +

Predicted O +
new O +
case O +
detection O +
rates O +
for O +
six O +
intervention O +
scenarios O +
relative O +
to O +
the O +
baseline O +
control O +
program O +
. O +

For O +
each O +
intervention O +
scenario O +
simulations O +
with O +
different O +
mechanisms O +
of O +
susceptibility O +
to O +
leprosy O +
, O +
as O +
defined O +
in O +
our O +
previous O +
paper O +
[ O +
9 O +
] O +
are O +
performed O +
. O +

For O +
each O +
intervention O +
scenario O +
, O +
the O +
two O +
dotted O +
lines O +
show O +
the O +
smallest O +
and O +
largest O +
deviations O +
from O +
the O +
baseline O +
control O +
program O +
. O +

The O +
solid O +
line O +
shows O +
the O +
median O +
of O +
all O +
susceptibility O +
mechanisms O +
. O +

Results O +
are O +
the O +
average O +
of O +
100 O +
runs O +
of O +
the O +
simulation O +
model O +
. O +

Both O +
chemoprophylaxis O +
and O +
early O +
diagnosis O +
were O +
predicted O +
to O +
have O +
substantial O +
effects O +
on O +
the O +
new O +
case O +
detection O +
of O +
leprosy O +
( O +
Figure O +
2 O +
) O +
. O +

With O +
no O +
BCG O +
, O +
chemoprophylaxis O +
would O +
partially O +
compensate O +
for O +
the O +
predicted O +
increase O +
in O +
new O +
case O +
detection O +
rates O +
. O +

Furthermore O +
, O +
early O +
diagnosis O +
was O +
predicted O +
to O +
more O +
than O +
compensate O +
for O +
the O +
adverse O +
effects O +
of O +
a O +
leprosy O +
- O +
ineffective O +
tuberculosis O +
vaccine O +
, O +
and O +
reduce O +
the O +
rate O +
of O +
new O +
case O +
detection O +
compared O +
to O +
the O +
baseline O +
. O +

The O +
effects O +
were O +
more O +
promising O +
with O +
the O +
ongoing O +
presence O +
of O +
the O +
BCG O +
vaccine O +
. O +

Under O +
those O +
conditions O +
, O +
at O +
25 O +
years O +
after O +
the O +
introduction O +
of O +
chemoprophylaxis O +
, O +
the O +
new O +
case O +
detection O +
rate O +
was O +
predicted O +
to O +
be O +
25 O +
% O +
lower O +
than O +
baseline O +
control O +
. O +

Moreover O +
, O +
with O +
the O +
introduction O +
of O +
early O +
diagnosis O +
, O +
the O +
new O +
case O +
detection O +
rate O +
was O +
predicted O +
to O +
halve O +
the O +
baseline O +
incidence O +
after O +
25 O +
years O +
( O +
Table O +
1 O +
) O +
. O +

Early O +
diagnosis O +
of O +
infection O +
allows O +
the O +
detection O +
of O +
subclinical O +
cases O +
, O +
of O +
which O +
part O +
would O +
be O +
detected O +
later O +
or O +
never O +
at O +
all O +
. O +

These O +
subclinical O +
cases O +
are O +
added O +
to O +
the O +
number O +
of O +
detected O +
cases O +
. O +

This O +
is O +
seen O +
in O +
the O +
results O +
of O +
this O +
intervention O +
. O +

The O +
introduction O +
of O +
early O +
diagnosis O +
would O +
increase O +
the O +
total O +
number O +
of O +
detected O +
cases O +
in O +
the O +
first O +
18 O +
years O +
, O +
simply O +
because O +
of O +
the O +
detection O +
of O +
previously O +
undetectable O +
subclinical O +
cases O +
. O +

Over O +
time O +
however O +
, O +
the O +
total O +
number O +
of O +
new O +
cases O +
( O +
subclinical O +
and O +
clinical O +
) O +
would O +
finally O +
drop O +
below O +
the O +
number O +
detected O +
in O +
the O +
baseline O +
control O +
program O +
( O +
Figure O +
3 O +
) O +
. O +

In O +
Figure O +
3 O +
, O +
we O +
show O +
that O +
the O +
new O +
cases O +
detected O +
under O +
the O +
chemoprophylaxis O +
intervention O +
strategy O +
drop O +
immediately O +
below O +
the O +
level O +
of O +
the O +
baseline O +
control O +
program O +
. O +

The O +
additional O +
effect O +
of O +
chemoprophylaxis O +
is O +
that O +
additional O +
new O +
infections O +
are O +
prevented O +
on O +
top O +
of O +
the O +
cure O +
of O +
subclinical O +
infections O +
. O +

These O +
additional O +
prevented O +
infections O +
are O +
due O +
to O +
a O +
shorter O +
infectious O +
period O +
of O +
the O +
cured O +
subclinical O +
infections O +
. O +

To O +
illustrate O +
this O +
effect O +
we O +
show O +
in O +
Figure O +
3 O +
the O +
clinical O +
and O +
the O +
subclinical O +
cases O +
that O +
were O +
cured O +
by O +
the O +
chemoprophylactic O +
intervention O +
. O +

During O +
the O +
first O +
10 O +
years O +
, O +
this O +
total O +
number O +
of O +
newly O +
detected O +
cases O +
plus O +
cured O +
cases O +
is O +
equal O +
to O +
the O +
number O +
of O +
newly O +
detected O +
cases O +
under O +
the O +
baseline O +
control O +
program O +
, O +
but O +
afterwards O +
the O +
number O +
of O +
cases O +
plus O +
cured O +
subclinical O +
cases O +
in O +
the O +
chemoprophylaxis O +
intervention O +
group O +
drops O +
under O +
the O +
baseline O +
control O +
program O +
, O +
indicating O +
the O +
prevention O +
of O +
new O +
infections O +
. O +

10 O +
. O +
1371 O +
/ O +
journal O +
. O +
pntd O +
. O +
0001330 O +
. O +
g003 O +
Figure O +
3 O +

Cumulative O +
New O +
cases O +
detected O +
of O +
leprosy O +
per O +
person O +
- O +
year O +
since O +
start O +
of O +
the O +
interventions O +
. O +

Results O +
are O +
the O +
average O +
of O +
100 O +
runs O +
of O +
the O +
simulation O +
model O +
. O +

Breeding O +
of O +
p53 O +
mice O +
with O +
BCCIP O +
conditional O +
knockdown O +
mice O +

The O +
heterozygous O +
p53 O +
knockout O +
mice O +
[ O +
36 O +
] O +
were O +
crossed O +
with O +
LoxPshBCCIP O +
+ O +
/ O +
+ O +
- O +
4 O +
mouse O +
and O +
EIIaCre O +
+ O +
/ O +
+ O +
mouse O +
respectively O +
to O +
generate O +
p53 O +
+ O +
/ O +
- O +
; O +
LoxPshBCCIP O +
+ O +
/ O +
- O +
, O +
and O +
p53 O +
+ O +
/ O +
- O +
; O +
EIIaCre O +
+ O +
/ O +
- O +
mice O +
. O +

The O +
PCR O +
primers O +
used O +
to O +
genotype O +
p53 O +
are O +
: O +
p53ex6F O +
: O +
5 O +
' O +
- O +
GTATCCCGAGTATCTGGAAGACAG O +
- O +
3 O +
' O +
, O +
p53neoF O +
: O +
5 O +
' O +
- O +
GCCTTCTATCGCCTTCTTGACG O +
- O +
3 O +
' O +
, O +
p53ex7RN O +
: O +
5 O +
' O +
- O +
AAGGATAGGTCGGCGGTTCATGC O +
- O +
3 O +
' O +
. O +

The O +
same O +
PCR O +
primer O +
pairs O +
as O +
described O +
earlier O +
in O +
this O +
report O +
were O +
used O +
for O +
BCCIPshRNA O +
and O +
EIIaCre O +
genotyping O +
. O +

The O +
p53 O +
+ O +
/ O +
- O +
; O +
LoxPshBCCIP O +
+ O +
/ O +
+ O +
mice O +
were O +
obtained O +
by O +
crossing O +
p53 O +
+ O +
/ O +
- O +
; O +
LoxPshBCCIP O +
+ O +
/ O +
- O +
females O +
with O +
p53 O +
+ O +
/ O +
- O +
; O +
LoxPshBCCIP O +
+ O +
/ O +
- O +
males O +
. O +

The O +
p53 O +
+ O +
/ O +
- O +
; O +
LoxPshBCCIP O +
+ O +
/ O +
+ O +
or O +
p53 O +
+ O +
/ O +
- O +
; O +
LoxPshBCCIP O +
+ O +
/ O +
- O +
mice O +
were O +
crossed O +
with O +
p53 O +
+ O +
/ O +
- O +
; O +
EIIaCre O +
+ O +
/ O +
- O +
mice O +
respectively O +
. O +

ACKNOWLEDGEMENTS O +

The O +
authors O +
thank O +
Mr O +
. O +
C O +
. O +

Roberto O +
for O +
providing O +
animal O +
care O +
. O +

This O +
research O +
was O +
supported O +
by O +
the O +
State O +
of O +
Rio O +
de O +
Janeiro O +
Carlos O +
Chagas O +
Filho O +
Research O +
Foundation O +
( O +
FAPERJ O +
) O +
and O +
the O +
Coordination O +
for O +
the O +
Enhancement O +
of O +
Higher O +
Education O +
Personnel O +
( O +
CAPES O +
) O +
. O +

Absolute O +
responder O +
rates O +
for O +
medical O +
management O +
recommendations O +
. O +

Biochemical O +
traits O +

ERK O +
signaling O +
is O +
involved O +
in O +
decreasing O +
BDNF O +
- O +
induced O +
gene O +
activity O +
via O +
Eph O +
receptors O +

Data O +
provided O +
so O +
far O +
suggest O +
that O +
ephrin O +
- O +
A5 O +
might O +
counteract O +
BDNF O +
- O +
mediated O +
gene O +
expression O +
and O +
growth O +
cone O +
responses O +
via O +
decreasing O +
ERK O +
activity O +
and O +
nuclear O +
localization O +
( O +
Figs O +
. O +
2 O +
and O +
3 O +
) O +
. O +

To O +
test O +
this O +
hypothesis O +
more O +
directly O +
, O +
we O +
analyzed O +
whether O +
Eph O +
forward O +
signaling O +
can O +
still O +
suppress O +
BDNF O +
- O +
stimulated O +
IEG O +
induction O +
and O +
growth O +
cone O +
collapse O +
when O +
ERK O +
kinase O +
activity O +
was O +
experimentally O +
raised O +
. O +

For O +
this O +
, O +
ERK O +
activity O +
was O +
elevated O +
by O +
expressing O +
constitutively O +
- O +
active O +
MEK1 O +
( O +
CA O +
- O +
MEK1 O +
) O +
, O +
an O +
ERK O +
upstream O +
activator O +
, O +
in O +
cortical O +
neurons O +
( O +
Fig O +
. O +
S3 O +
) O +
. O +

Subsequently O +
, O +
neurons O +
were O +
subjected O +
to O +
either O +
an O +
ephrin O +
- O +
A5 O +
mediated O +
growth O +
cone O +
collapse O +
assay O +
( O +
Fig O +
. O +
5 O +
) O +
or O +
stimulated O +
with O +
guidance O +
cues O +
for O +
20 O +
minutes O +
and O +
IEG O +
mRNA O +
levels O +
were O +
quantified O +
via O +
qRT O +
- O +
PCR O +
( O +
Fig O +
. O +
6 O +
) O +
. O +

10 O +
. O +
1371 O +
/ O +
journal O +
. O +
pone O +
. O +
0026089 O +
. O +
g005 O +
Figure O +
5 O +

Constitutively O +
- O +
active O +
MEK1 O +
blocks O +
ephrin O +
- O +
A5 O +
mediated O +
growth O +
cone O +
collapse O +
. O +

Wild O +
- O +
type O +
neurons O +
were O +
electroporated O +
with O +
vectors O +
expressing O +
GFP O +
( O +
control O +
; O +
A O +
, O +
C O +
, O +
E O +
) O +
or O +
expressing O +
a O +
FLAG O +
- O +
tagged O +
constitutively O +
- O +
active O +
MEK1 O +
( O +
CA O +
- O +
MEK1 O +
; O +
B O +
, O +
D O +
, O +
F O +
) O +
. O +

Neurons O +
were O +
treated O +
with O +
ephrin O +
- O +
A5 O +
- O +
Fc O +
for O +
30 O +
min O +
followed O +
by O +
visualization O +
of O +
GFP O +
( O +
A O +
, O +
C O +
, O +
E O +
) O +
or O +
CA O +
- O +
MEK O +
- O +
1 O +
( O +
green O +
in O +
B O +
, O +
D O +
, O +
F O +
) O +
, O +
F O +
- O +
actin O +
and O +
betaIII O +
tubulin O +
. O +

( O +
A O +
, O +
B O +
) O +
Overexpression O +
of O +
CA O +
- O +
MEK1 O +
( O +
B O +
) O +
reduces O +
mean O +
neurite O +
length O +
compared O +
to O +
a O +
control O +
GFP O +
- O +
expressing O +
neuron O +
( O +
A O +
) O +
. O +

( O +
C O +
- O +
F O +
) O +
A O +
control O +
growth O +
cone O +
without O +
ephrin O +
- O +
A5 O +
application O +
( O +
C O +
) O +
typically O +
protrudes O +
multiple O +
filopodia O +
( O +
arrow O +
) O +
. O +

CA O +
- O +
MEK O +
- O +
1 O +
expressing O +
growth O +
cones O +
( O +
D O +
) O +
were O +
indistinguishable O +
from O +
a O +
GFP O +
- O +
expressing O +
growth O +
cone O +
. O +

Note O +
that O +
CA O +
- O +
MEK1 O +
was O +
expressed O +
in O +
a O +
dot O +
- O +
like O +
pattern O +
in O +
the O +
growth O +
cone O +
( O +
arrowheads O +
in O +
D O +
and O +
F O +
) O +
. O +

Upon O +
ephrin O +
- O +
A5 O +
application O +
, O +
a O +
control O +
growth O +
cone O +
( O +
E O +
) O +
collapsed O +
resulting O +
in O +
only O +
few O +
filopodia O +
. O +

In O +
contrast O +
, O +
a O +
CA O +
- O +
MEK1 O +
expressing O +
growth O +
cone O +
( O +
F O +
) O +
was O +
only O +
partially O +
collapsed O +
and O +
many O +
filopodia O +
structures O +
were O +
preserved O +
after O +
ephrin O +
- O +
A5 O +
induction O +
. O +

( O +
G O +
) O +
Quantification O +
of O +
average O +
neurite O +
length O +
. O +

( O +
H O +
, O +
I O +
) O +
Quantification O +
of O +
growth O +
cone O +
area O +
( O +
H O +
) O +
and O +
filopodia O +
number O +
/ O +
growth O +
cone O +
( O +
I O +
) O +
in O +
the O +
four O +
conditions O +
. O +

Ephrin O +
- O +
A5 O +
induces O +
a O +
growth O +
cone O +
collapse O +
, O +
resulting O +
in O +
reduced O +
growth O +
cone O +
area O +
and O +
filopodia O +
number O +
in O +
GFP O +
but O +
not O +
CA O +
- O +
MEK1 O +
expressing O +
neurons O +
. O +

Scale O +
- O +
bar O +
( O +
A O +
, O +
B O +
) O +
= O +
10 O +
microm O +
; O +
( O +
C O +
- O +
F O +
) O +
= O +
2 O +
microm O +
. O +

10 O +
. O +
1371 O +
/ O +
journal O +
. O +
pone O +
. O +
0026089 O +
. O +
g006 O +
Figure O +
6 O +

Ephrin O +
- O +
A5 O +
suppresses O +
BDNF O +
- O +
induced O +
IEG O +
responses O +
via O +
MAP O +
kinase O +
signaling O +
. O +

Wild O +
- O +
type O +
cortical O +
neurons O +
, O +
mock O +
- O +
electroporated O +
( O +
black O +
bars O +
) O +
or O +
with O +
a O +
vector O +
expressing O +
constitutively O +
- O +
active O +
MEK1 O +
( O +
white O +
bars O +
) O +
, O +
were O +
treated O +
with O +
guidance O +
cues O +
for O +
20 O +
minutes O +
as O +
depicted O +
, O +
followed O +
by O +
mRNA O +
quantification O +
. O +

In O +
mock O +
- O +
electroporated O +
neurons O +
, O +
BDNF O +
induced O +
an O +
IEG O +
response O +
of O +
c O +
- O +
fos O +
( O +
A O +
) O +
, O +
Egr1 O +
( O +
B O +
) O +
, O +
Egr2 O +
( O +
C O +
) O +
and O +
Arc O +
( O +
D O +
) O +
. O +

Co O +
- O +
application O +
of O +
ephrin O +
- O +
A5 O +
and O +
BDNF O +
reduced O +
mRNA O +
levels O +
of O +
all O +
four O +
IEGs O +
in O +
mock O +
- O +
electroporated O +
neurons O +
( O +
A O +
- O +
D O +
) O +
. O +

In O +
contrast O +
, O +
expression O +
of O +
constitutively O +
- O +
active O +
MEK1 O +
prevented O +
Eph O +
forward O +
signaling O +
from O +
suppressing O +
BDNF O +
- O +
evoked O +
IEG O +
responses O +
. O +

This O +
was O +
most O +
evident O +
for O +
the O +
IEGs O +
Egr1 O +
( O +
B O +
) O +
and O +
Egr2 O +
( O +
C O +
) O +
. O +

First O +
of O +
all O +
, O +
we O +
analyzed O +
the O +
impact O +
of O +
CA O +
- O +
MEK1 O +
on O +
neurite O +
outgrowth O +
and O +
ephrin O +
- O +
A5 O +
mediated O +
growth O +
cone O +
responses O +
( O +
Fig O +
. O +
5 O +
) O +
. O +

The O +
average O +
neurite O +
length O +
of O +
neurons O +
overexpressing O +
CA O +
- O +
MEK1 O +
( O +
Fig O +
. O +
5B O +
) O +
was O +
clearly O +
reduced O +
compared O +
to O +
control O +
GFP O +
expressing O +
neurons O +
( O +
Fig O +
. O +
5A O +
; O +
see O +
quantification O +
in O +
( O +
G O +
) O +
) O +
. O +

Growth O +
cones O +
of O +
GFP O +
( O +
C O +
) O +
and O +
CA O +
- O +
MEK1 O +
expressing O +
neurons O +
were O +
similar O +
and O +
protruded O +
many O +
filopodia O +
( O +
arrows O +
in O +
Fig O +
. O +
5C O +
- O +
F O +
) O +
. O +

CA O +
- O +
MEK1 O +
expression O +
in O +
growth O +
cones O +
was O +
confined O +
to O +
individual O +
dot O +
- O +
like O +
structures O +
( O +
arrowheads O +
in O +
Fig O +
. O +
5D O +
, O +
F O +
) O +
. O +

Ephrin O +
- O +
A5 O +
application O +
on O +
a O +
GFP O +
expressing O +
control O +
growth O +
cone O +
( O +
Fig O +
. O +
5E O +
) O +
resulted O +
in O +
a O +
growth O +
cone O +
collapse O +
as O +
revealed O +
by O +
reduced O +
overall O +
growth O +
cone O +
area O +
and O +
filopodia O +
number O +
( O +
quantified O +
in O +
Fig O +
. O +
5H O +
, O +
I O +
) O +
. O +

In O +
contrast O +
, O +
in O +
neurons O +
overexpressing O +
CA O +
- O +
MEK1 O +
( O +
Fig O +
. O +
5F O +
) O +
, O +
ephrin O +
- O +
A5 O +
induced O +
only O +
a O +
partial O +
growth O +
cone O +
collapse O +
. O +

Thus O +
, O +
growth O +
cone O +
area O +
and O +
filopodia O +
number O +
were O +
not O +
reduced O +
( O +
see O +
Fig O +
. O +
5H O +
, O +
I O +
) O +
. O +

This O +
result O +
suggests O +
that O +
an O +
ephrin O +
- O +
A5 O +
induced O +
signaling O +
cascade O +
targets O +
MAP O +
kinase O +
signaling O +
to O +
exert O +
a O +
full O +
growth O +
cone O +
collapse O +
. O +

This O +
result O +
is O +
in O +
contrast O +
to O +
a O +
recent O +
report O +
[ O +
46 O +
] O +
which O +
excluded O +
ERK O +
signaling O +
downstream O +
of O +
an O +
ephrin O +
- O +
A5 O +
mediated O +
growth O +
cone O +
collapse O +
. O +

Next O +
, O +
we O +
tested O +
whether O +
ephrin O +
- O +
A5 O +
signaling O +
suppresses O +
ERK O +
kinase O +
signaling O +
also O +
to O +
interfere O +
with O +
BDNF O +
- O +
mediated O +
gene O +
expression O +
( O +
Fig O +
. O +
6 O +
) O +
. O +

In O +
agreement O +
with O +
previous O +
results O +
( O +
Fig O +
. O +
4 O +
) O +
, O +
in O +
mock O +
- O +
electroporated O +
neurons O +
, O +
ephrin O +
- O +
A5 O +
incubation O +
reduced O +
the O +
BDNF O +
- O +
mediated O +
up O +
- O +
regulation O +
of O +
c O +
- O +
fos O +
( O +
Fig O +
. O +
6A O +
) O +
, O +
Egr1 O +
( O +
Fig O +
. O +
6B O +
) O +
, O +
Egr2 O +
( O +
Fig O +
. O +
6C O +
) O +
and O +
Arc O +
( O +
Fig O +
. O +
6D O +
) O +
mRNA O +
. O +

In O +
contrast O +
, O +
in O +
neurons O +
over O +
- O +
expressing O +
CA O +
- O +
MEK1 O +
, O +
ephrin O +
- O +
A5 O +
could O +
not O +
suppress O +
BDNF O +
- O +
induced O +
IEG O +
responses O +
to O +
the O +
same O +
degree O +
. O +

Particularly O +
Egr1 O +
( O +
Fig O +
. O +
6B O +
) O +
and O +
Egr2 O +
( O +
Fig O +
. O +
6C O +
) O +
mRNA O +
levels O +
were O +
almost O +
identical O +
when O +
comparing O +
neurons O +
treated O +
with O +
BDNF O +
alone O +
and O +
neurons O +
with O +
BDNF O +
and O +
ephrin O +
- O +
A5 O +
together O +
. O +

Thus O +
, O +
ephrin O +
- O +
A5 O +
represses O +
gene O +
activity O +
elicited O +
by O +
BDNF O +
at O +
least O +
in O +
part O +
via O +
MAP O +
kinases O +
. O +

Besides O +
IEGs O +
, O +
we O +
inspected O +
the O +
influence O +
of O +
both O +
guidance O +
cues O +
on O +
cytoskeletal O +
genes O +
, O +
whose O +
gene O +
products O +
might O +
modulate O +
cytoskeletal O +
dynamics O +
evoked O +
by O +
ephrin O +
- O +
As O +
and O +
/ O +
or O +
neurotrophins O +
( O +
Fig O +
. O +
S4 O +
) O +
. O +

Therefore O +
, O +
the O +
filamentous O +
actin O +
( O +
F O +
- O +
actin O +
) O +
stabilizing O +
tropomyosins O +
( O +
Tpm1 O +
and O +
Tpm2 O +
) O +
, O +
the O +
F O +
- O +
actin O +
cross O +
- O +
linker O +
alpha O +
- O +
actinin O +
1 O +
( O +
Actn1 O +
) O +
and O +
the O +
motor O +
protein O +
dynein O +
light O +
chain O +
1 O +
( O +
Dnal1 O +
) O +
were O +
analyzed O +
. O +

mRNA O +
levels O +
of O +
other O +
cytoskeletal O +
genes O +
were O +
not O +
altered O +
by O +
any O +
of O +
the O +
guidance O +
cues O +
( O +
i O +
. O +
e O +
. O +
cofilin O +
, O +
filamin O +
A O +
, O +
mena O +
, O +
vinculin O +
and O +
smooth O +
muscle O +
actin O +
; O +
data O +
not O +
shown O +
) O +
. O +

Short O +
- O +
term O +
stimulation O +
with O +
guidance O +
cues O +
did O +
not O +
result O +
in O +
major O +
alterations O +
of O +
cytoskeletal O +
mRNA O +
levels O +
except O +
for O +
upregulation O +
of O +
Tpm1 O +
by O +
ephrin O +
- O +
A5 O +
( O +
Fig O +
. O +
S4A O +
) O +
. O +

At O +
16h O +
of O +
incubation O +
, O +
both O +
tropomyosin O +
genes O +
were O +
induced O +
by O +
BDNF O +
and O +
ephrin O +
- O +
A5 O +
alone O +
and O +
both O +
together O +
( O +
Fig O +
. O +
S4B O +
, O +
D O +
) O +
. O +

Actn1 O +
levels O +
were O +
induced O +
by O +
individual O +
application O +
of O +
ephrin O +
- O +
A5 O +
and O +
BDNF O +
and O +
by O +
co O +
- O +
application O +
of O +
both O +
( O +
Fig O +
. O +
S4F O +
) O +
. O +

A O +
similar O +
profile O +
was O +
observed O +
for O +
the O +
dynein O +
light O +
chain O +
( O +
Fig O +
. O +
S4H O +
) O +
. O +

Taken O +
together O +
, O +
cytoskeletal O +
gene O +
expression O +
was O +
modulated O +
by O +
ephrin O +
- O +
A5 O +
and O +
BDNF O +
. O +

In O +
contrast O +
to O +
the O +
antagonistic O +
impact O +
on O +
the O +
IEG O +
gene O +
response O +
( O +
Figs O +
. O +
4 O +
and O +
6 O +
) O +
, O +
ephrin O +
- O +
A5 O +
and O +
BDNF O +
resulted O +
in O +
rather O +
synergistic O +
action O +
on O +
cytoskeletal O +
gene O +
expression O +
. O +

This O +
difference O +
might O +
be O +
due O +
to O +
short O +
- O +
term O +
( O +
i O +
. O +
e O +
. O +
20 O +
minutes O +
) O +
vs O +
. O +
long O +
- O +
term O +
( O +
i O +
. O +
e O +
. O +
16h O +
) O +
exposure O +
of O +
both O +
guidance O +
cues O +
in O +
the O +
IEG O +
and O +
cytoskeletal O +
gene O +
response O +
, O +
respectively O +
. O +

Introduction O +

Yeast O +
infections O +
cause O +
significant O +
mortality O +
in O +
critically O +
ill O +
and O +
immunocompromised O +
patients O +
. O +

In O +
particular O +
, O +
Candida O +
species O +
are O +
the O +
4th O +
most O +
common O +
cause O +
of O +
nosocomial O +
bloodstream O +
infections O +
in O +
the O +
United O +
States O +
, O +
and O +
Cryptococcus O +
neoformans O +
, O +
the O +
commonest O +
cause O +
of O +
fungal O +
meningitis O +
worldwide O +
[ O +
1 O +
] O +
, O +
[ O +
2 O +
] O +
. O +

Whilst O +
Candida O +
albicans O +
remains O +
the O +
leading O +
pathogenic O +
yeast O +
, O +
infections O +
due O +
to O +
non O +
- O +
C O +
. O +
albicans O +
species O +
such O +
as O +
Candida O +
glabrata O +
, O +
as O +
well O +
as O +
previously O +
rare O +
opportunists O +
such O +
as O +
Trichosporon O +
and O +
Geotrichum O +
species O +
, O +
are O +
increasingly O +
reported O +
[ O +
1 O +
] O +
, O +
[ O +
3 O +
] O +
- O +
[ O +
6 O +
] O +
. O +

Novel O +
pathogenic O +
Candida O +
species O +
such O +
as O +
Candida O +
nivariensis O +
and O +
Candida O +
bracarensis O +
have O +
also O +
been O +
described O +
[ O +
7 O +
] O +
. O +

Since O +
many O +
non O +
- O +
C O +
. O +
albicans O +
Candida O +
and O +
non O +
- O +
Candida O +
yeasts O +
are O +
resistant O +
or O +
less O +
susceptible O +
to O +
antifungal O +
agents O +
, O +
rapid O +
accurate O +
species O +
identification O +
is O +
central O +
to O +
timely O +
, O +
effective O +
antifungal O +
therapy O +
[ O +
3 O +
] O +
- O +
[ O +
6 O +
] O +
, O +
[ O +
8 O +
] O +
, O +
[ O +
9 O +
] O +
. O +

Conventional O +
phenotypic O +
- O +
based O +
methods O +
for O +
yeast O +
identification O +
, O +
however O +
, O +
are O +
slow O +
( O +
24 O +
- O +
72 O +
h O +
) O +
, O +
insensitive O +
and O +
often O +
unable O +
to O +
identify O +
more O +
unusual O +
species O +
. O +

Various O +
molecular O +
techniques O +
including O +
real O +
- O +
time O +
PCR O +
, O +
DNA O +
sequence O +
analysis O +
, O +
microarray O +
analysis O +
, O +
and O +
fluorescence O +
in O +
- O +
situ O +
hybridization O +
provide O +
accurate O +
identification O +
[ O +
10 O +
] O +
, O +
[ O +
11 O +
] O +
but O +
are O +
expensive O +
, O +
require O +
substantial O +
specimen O +
processing O +
time O +
( O +
hours O +
to O +
a O +
day O +
) O +
and O +
are O +
not O +
easily O +
implemented O +
as O +
routine O +
techniques O +
in O +
the O +
clinical O +
laboratory O +
. O +

Matrix O +
- O +
assisted O +
laser O +
desorption O +
ionization O +
- O +
time O +
of O +
flight O +
mass O +
spectrometry O +
( O +
MALDI O +
- O +
TOF O +
MS O +
) O +
has O +
emerged O +
as O +
a O +
powerful O +
and O +
rapid O +
tool O +
for O +
the O +
identification O +
of O +
bacterial O +
and O +
yeast O +
pathogens O +
[ O +
12 O +
] O +
- O +
[ O +
17 O +
] O +
. O +

Using O +
MALDI O +
- O +
TOF O +
MS O +
, O +
the O +
protein O +
spectral O +
" O +
fingerprint O +
" O +
of O +
an O +
isolate O +
is O +
compared O +
to O +
a O +
reference O +
spectral O +
database O +
for O +
identification O +
[ O +
18 O +
] O +
. O +

Previous O +
studies O +
have O +
reported O +
species O +
identification O +
rates O +
of O +
92 O +
- O +
99 O +
% O +
amongst O +
collections O +
of O +
yeasts O +
and O +
yeast O +
- O +
like O +
organisms O +
[ O +
14 O +
] O +
- O +
[ O +
17 O +
] O +
, O +
[ O +
19 O +
] O +
, O +
[ O +
20 O +
] O +
. O +

However O +
, O +
taken O +
collectively O +
, O +
the O +
results O +
may O +
not O +
be O +
directly O +
comparable O +
since O +
these O +
studies O +
have O +
used O +
different O +
approaches O +
to O +
assign O +
species O +
- O +
from O +
comparing O +
spectra O +
from O +
test O +
organisms O +
to O +
reference O +
spectra O +
in O +
MALDI O +
- O +
TOF O +
MS O +
databases O +
[ O +
16 O +
] O +
, O +
[ O +
20 O +
] O +
, O +
to O +
enhancing O +
these O +
databases O +
, O +
and O +
in O +
some O +
instances O +
developing O +
study O +
- O +
specific O +
databases O +
, O +
with O +
" O +
in O +
- O +
house O +
" O +
spectral O +
signatures O +
[ O +
14 O +
] O +
, O +
[ O +
15 O +
] O +
. O +

There O +
also O +
is O +
a O +
continuing O +
need O +
to O +
extend O +
the O +
repository O +
of O +
reference O +
spectra O +
in O +
MALDI O +
- O +
TOF O +
MS O +
databases O +
. O +

We O +
therefore O +
undertook O +
the O +
present O +
study O +
to O +
evaluate O +
the O +
utility O +
of O +
the O +
MALDI O +
Biotyper O +
2 O +
. O +
0 O +
Microflex O +
LT O +
spectrometer O +
( O +
Bruker O +
Daltonik O +
GmbH O +
; O +
Bremen O +
, O +
Germany O +
) O +
with O +
its O +
current O +
spectral O +
database O +
in O +
comparison O +
with O +
phenotypic O +
- O +
based O +
methods O +
for O +
the O +
identification O +
of O +
a O +
broad O +
range O +
of O +
yeasts O +
in O +
a O +
diagnostic O +
laboratory O +
. O +

The O +
first O +
part O +
of O +
the O +
study O +
comprised O +
testing O +
of O +
reference O +
and O +
clinical O +
strains O +
from O +
our O +
culture O +
collection O +
. O +

The O +
second O +
was O +
a O +
blinded O +
prospective O +
analysis O +
of O +
freshly O +
- O +
collected O +
yeast O +
isolates O +
recovered O +
during O +
routine O +
laboratory O +
work O +
flow O +
; O +
discrepant O +
results O +
between O +
MALDI O +
TOF O +
MS O +
and O +
phenotypic O +
methods O +
were O +
resolved O +
using O +
sequence O +
analysis O +
of O +
the O +
fungal O +
internal O +
transcribed O +
spacer O +
( O +
ITS O +
) O +
regions O +
[ O +
21 O +
] O +
, O +
[ O +
22 O +
] O +
. O +

Results O +
obtained O +
by O +
preparation O +
of O +
yeasts O +
by O +
extraction O +
of O +
fungal O +
proteins O +
and O +
by O +
direct O +
application O +
of O +
yeast O +
colonies O +
onto O +
the O +
MALDI O +
TOF O +
MS O +
plate O +
were O +
also O +
compared O +
. O +

Conclusions O +

This O +
is O +
the O +
first O +
prospective O +
evaluation O +
of O +
parents O +
' O +
preferences O +
in O +
newly O +
diagnosed O +
juvenile O +
idiopathic O +
arthritis O +
patients O +
participating O +
in O +
the O +
BeSt O +
for O +
Kids O +
trial O +
. O +

Within O +
the O +
limitations O +
of O +
the O +
small O +
amounts O +
, O +
patients O +
clearly O +
preferred O +
initial O +
combination O +
therapy O +
with O +
etanercept O +
and O +
disliked O +
taking O +
prednisone O +
. O +

After O +
actual O +
exposure O +
and O +
follow O +
up O +
, O +
this O +
questionnaire O +
will O +
be O +
repeated O +
to O +
see O +
if O +
preferences O +
remain O +
the O +
same O +
. O +

Classification O +
result O +
. O +

Effects O +
of O +
rule O +
- O +
breakers O +
on O +
intermediary O +
- O +
based O +
networks O +
. O +

Individuals O +
using O +
rule O +
- O +
breaking O +
strategy O +
primarily O +
affected O +
( O +
A O +
) O +
their O +
own O +
social O +
position O +
( O +
H O +
( O +
2 O +
) O +
= O +
213 O +
. O +
18 O +
, O +
p O +
< O +
0 O +
. O +
0001 O +
) O +
, O +
but O +
also O +
made O +
an O +
impact O +
on O +
the O +
other O +
aspects O +
of O +
the O +
social O +
system O +
, O +
affecting O +
( O +
B O +
) O +
the O +
social O +
position O +
of O +
others O +
( O +
H O +
( O +
2 O +
) O +
= O +
6 O +
. O +
79 O +
, O +
p O +
= O +
0 O +
. O +
034 O +
) O +
and O +
( O +
C O +
) O +
group O +
organization O +
( O +
H O +
( O +
2 O +
) O +
= O +
125 O +
. O +
3 O +
, O +
p O +
< O +
0 O +
. O +
0001 O +
) O +
as O +
their O +
frequency O +
in O +
a O +
population O +
increased O +
. O +

The O +
boxes O +
show O +
medians O +
, O +
quartiles O +
, O +
minima O +
and O +
maxima O +
. O +

Results O +
significantly O +
different O +
from O +
a O +
relevant O +
uniform O +
network O +
with O +
no O +
rule O +
- O +
breaking O +
behavior O +
( O +
p O +
< O +
0 O +
. O +
05 O +
in O +
Dunn O +
' O +
s O +
multiple O +
comparison O +
test O +
for O +
comparing O +
each O +
group O +
with O +
control O +
) O +
are O +
designated O +
with O +
* O +
. O +

Patients O +
and O +
Study O +
Design O +

A O +
prospective O +
evaluation O +
of O +
the O +
different O +
CMR O +
parameters O +
for O +
predicting O +
LV O +
segmental O +
and O +
global O +
functional O +
recovery O +
was O +
performed O +
in O +
46 O +
patients O +
( O +
63 O +
+ O +
/ O +
- O +
10 O +
years O +
old O +
, O +
3 O +
with O +
previous O +
CABG O +
, O +
35 O +
with O +
three O +
- O +
vessel O +
disease O +
, O +
3 O +
with O +
one O +
- O +
vessel O +
disease O +
) O +
with O +
LV O +
systolic O +
dysfunction O +
( O +
LVEF O +
35 O +
+ O +
/ O +
- O +
8 O +
% O +
) O +
before O +
they O +
underwent O +
surgical O +
( O +
n O +
= O +
34 O +
) O +
or O +
percutaneous O +
( O +
n O +
= O +
12 O +
) O +
revascularisation O +
. O +

Sixty O +
patients O +
without O +
contraindications O +
for O +
CMR O +
were O +
screened O +
for O +
the O +
following O +
inclusion O +
criteria O +
: O +
( O +
1 O +
) O +
CAD O +
( O +
> O +
70 O +
% O +
stenosis O +
in O +
one O +
or O +
more O +
major O +
epicardial O +
vessels O +
) O +
, O +
scheduled O +
for O +
a O +
revascularisation O +
procedure O +
; O +
( O +
2 O +
) O +
LVEF O +
< O +
= O +
45 O +
% O +
; O +
( O +
3 O +
) O +
at O +
least O +
two O +
adjacent O +
segments O +
with O +
wall O +
motion O +
abnormalities O +
at O +
rest O +
; O +
and O +
( O +
4 O +
) O +
no O +
infarction O +
or O +
revascularisation O +
within O +
the O +
last O +
two O +
months O +
. O +

Patients O +
were O +
included O +
in O +
the O +
study O +
only O +
after O +
a O +
successful O +
and O +
complete O +
coronary O +
revascularisation O +
. O +

Of O +
the O +
14 O +
patients O +
who O +
did O +
not O +
complete O +
the O +
study O +
, O +
3 O +
decided O +
not O +
to O +
undergo O +
the O +
repeated O +
CMR O +
scan O +
or O +
were O +
lost O +
during O +
follow O +
- O +
up O +
; O +
7 O +
had O +
significant O +
periprocedural O +
injury O +
( O +
new O +
LGE O +
zones O +
on O +
repeated O +
CMR O +
scans O +
and O +
clinically O +
proven O +
periprocedural O +
myocardial O +
infarction O +
( O +
MI O +
) O +
or O +
MI O +
between O +
both O +
scans O +
) O +
; O +
3 O +
had O +
pacemakers O +
or O +
defibrillators O +
implanted O +
in O +
the O +
period O +
between O +
the O +
MR O +
scans O +
; O +
and O +
1 O +
was O +
excluded O +
because O +
of O +
dilated O +
cardiomyopathy O +
with O +
secondary O +
CAD O +
. O +

None O +
of O +
the O +
patients O +
were O +
excluded O +
from O +
the O +
study O +
for O +
technical O +
reasons O +
or O +
image O +
quality O +
. O +

The O +
mean O +
interval O +
between O +
CMR O +
and O +
revascularisation O +
was O +
12 O +
+ O +
/ O +
- O +
13 O +
days O +
, O +
and O +
none O +
of O +
the O +
patients O +
presented O +
clinical O +
evidence O +
of O +
infarction O +
during O +
this O +
period O +
. O +

The O +
mean O +
interval O +
between O +
MI O +
and O +
the O +
first O +
CMR O +
was O +
3 O +
. O +
6 O +
years O +
. O +

In O +
46 O +
patients O +
, O +
the O +
extent O +
of O +
regional O +
contractility O +
and O +
LGE O +
were O +
determined O +
repeatedly O +
by O +
CMR O +
28 O +
+ O +
/ O +
- O +
4 O +
weeks O +
( O +
6 O +
months O +
) O +
after O +
revascularisation O +
. O +

The O +
study O +
was O +
approved O +
by O +
the O +
Lithuanian O +
Bioethics O +
Committee O +
( O +
Nr O +
. O +
17 O +
) O +
, O +
and O +
informed O +
written O +
consent O +
was O +
obtained O +
from O +
each O +
patient O +
prior O +
to O +
inclusion O +
in O +
the O +
study O +
. O +

3 O +
. O +
2 O +
. O +

Molecular O +
Mechanisms O +
Mediating O +
the O +
Perinatal O +
Beta O +
- O +
Cell O +
Adaptive O +
Response O +
to O +
Early O +
- O +
Life O +
Stressors O +

Molecular O +
mechanisms O +
responsible O +
for O +
impaired O +
beta O +
- O +
cell O +
mass O +
formation O +
after O +
IUCR O +
or O +
IUPR O +
have O +
come O +
under O +
investigation O +
. O +

First O +
, O +
it O +
has O +
been O +
proposed O +
that O +
IUCR O +
can O +
result O +
in O +
a O +
reduction O +
of O +
the O +
embryonic O +
beta O +
- O +
cell O +
progenitor O +
pool O +
leading O +
to O +
inappropriate O +
postnatal O +
beta O +
- O +
cell O +
formation O +
. O +

Stanger O +
et O +
al O +
. O +

[ O +
108 O +
] O +
demonstrated O +
that O +
selective O +
genetic O +
reduction O +
in O +
the O +
size O +
of O +
PDX O +
- O +
1 O +
+ O +
pancreatic O +
progenitors O +
during O +
the O +
fetal O +
period O +
results O +
in O +
impaired O +
beta O +
- O +
cell O +
formation O +
during O +
the O +
postnatal O +
period O +
with O +
consequent O +
development O +
of O +
glucose O +
intolerance O +
during O +
adulthood O +
. O +

Consistent O +
with O +
this O +
, O +
maternal O +
food O +
restriction O +
leads O +
to O +
significant O +
reduction O +
in O +
PDX O +
- O +
1 O +
+ O +
and O +
neurogenin O +
- O +
3 O +
+ O +
pancreatic O +
precursors O +
during O +
embryonic O +
development O +
in O +
rats O +
, O +
diminished O +
postnatal O +
beta O +
- O +
cell O +
formation O +
, O +
and O +
inability O +
to O +
expand O +
beta O +
- O +
cell O +
mass O +
in O +
response O +
to O +
pregnancy O +
[ O +
47 O +
, O +
94 O +
] O +
. O +

The O +
UPI O +
model O +
is O +
also O +
characterized O +
by O +
a O +
permanent O +
decrease O +
in O +
islet O +
PDX O +
- O +
1 O +
mRNA O +
expression O +
. O +

This O +
decrease O +
has O +
recently O +
been O +
shown O +
to O +
be O +
due O +
to O +
progressive O +
epigenetic O +
silencing O +
of O +
the O +
Pdx1 O +
gene O +
locus O +
secondary O +
to O +
proximal O +
promoter O +
methylation O +
[ O +
69 O +
, O +
109 O +
] O +
, O +
and O +
it O +
may O +
be O +
responsible O +
for O +
the O +
decreased O +
rate O +
of O +
beta O +
- O +
cell O +
replication O +
and O +
inappropriate O +
postnatal O +
beta O +
- O +
cell O +
mass O +
development O +
[ O +
69 O +
, O +
110 O +
] O +
. O +

In O +
the O +
same O +
way O +
of O +
thinking O +
, O +
studies O +
have O +
demonstrated O +
that O +
the O +
maintenance O +
of O +
methylated O +
histone O +
H3 O +
Lys4 O +
by O +
Set7 O +
/ O +
9 O +
, O +
a O +
member O +
of O +
the O +
SET O +
methyltransferase O +
family O +
, O +
is O +
crucial O +
to O +
Pdx1 O +
activity O +
in O +
beta O +
- O +
cell O +
lines O +
[ O +
111 O +
- O +
113 O +
] O +
. O +

This O +
led O +
to O +
the O +
hypothesis O +
that O +
Set7 O +
/ O +
9 O +
may O +
represent O +
a O +
novel O +
chromatin O +
- O +
modifying O +
protein O +
that O +
functions O +
in O +
part O +
through O +
its O +
recruitment O +
to O +
target O +
genes O +
by O +
cell O +
- O +
specific O +
transcription O +
factors O +
such O +
as O +
Pdx1 O +
. O +

Since O +
then O +
, O +
a O +
role O +
of O +
histone O +
methyl O +
transferases O +
, O +
particularly O +
set7 O +
, O +
has O +
also O +
been O +
demonstrated O +
in O +
the O +
sustained O +
deleterious O +
effects O +
of O +
chronic O +
hyperglycemia O +
on O +
human O +
microvascular O +
endothelial O +
cells O +
[ O +
114 O +
] O +
. O +

Such O +
an O +
epigenetic O +
change O +
could O +
potentially O +
be O +
involved O +
in O +
the O +
deleterious O +
effect O +
of O +
high O +
glucose O +
upon O +
the O +
fetal O +
pancreas O +
in O +
the O +
IUED O +
models O +
. O +

Another O +
mechanism O +
proposed O +
to O +
explain O +
reduced O +
beta O +
- O +
cell O +
formation O +
after O +
IUCR O +
is O +
related O +
to O +
prenatal O +
glucocorticoid O +
exposure O +
. O +

Administration O +
of O +
either O +
dexamethasone O +
or O +
carbenoxolone O +
( O +
to O +
inhibit O +
11 O +
beta O +
- O +
hydroxysteroid O +
dehydrogenase O +
type O +
2 O +
) O +
to O +
normal O +
pregnant O +
rats O +
also O +
causes O +
fetal O +
growth O +
retardation O +
and O +
the O +
adult O +
offspring O +
are O +
hypertensive O +
and O +
hyperglycemic O +
, O +
with O +
hyperactive O +
hypothalamic O +
- O +
pituitary O +
- O +
adrenal O +
axis O +
[ O +
115 O +
] O +
. O +

Maternal O +
undernutrition O +
significantly O +
increased O +
both O +
fetal O +
and O +
maternal O +
corticosterone O +
concentrations O +
in O +
rats O +
[ O +
116 O +
] O +
. O +

Subsequently O +
, O +
maternal O +
and O +
/ O +
or O +
fetal O +
overexposure O +
to O +
glucocorticoids O +
( O +
via O +
administration O +
of O +
dexamethasone O +
) O +
impairs O +
both O +
fetal O +
and O +
postnatal O +
beta O +
- O +
cell O +
formation O +
in O +
rodents O +
and O +
nonhuman O +
primates O +
[ O +
94 O +
, O +
117 O +
- O +
119 O +
] O +
. O +

Seckl O +
et O +
al O +
. O +

[ O +
115 O +
] O +
have O +
shown O +
that O +
fetal O +
corticosterone O +
concentrations O +
are O +
inversely O +
correlated O +
with O +
fetal O +
insulin O +
content O +
and O +
postnatal O +
beta O +
- O +
cell O +
formation O +
in O +
rats O +
. O +

Evidence O +
suggests O +
that O +
glucocorticoids O +
can O +
exert O +
a O +
direct O +
effect O +
on O +
the O +
developing O +
fetal O +
pancreas O +
via O +
transcriptional O +
modulation O +
of O +
transcription O +
factors O +
involved O +
in O +
beta O +
- O +
cell O +
formation O +
and O +
differentiation O +
[ O +
117 O +
] O +
. O +

Glucocorticoid O +
receptors O +
are O +
present O +
in O +
the O +
pancreas O +
during O +
embryonic O +
development O +
of O +
rodents O +
and O +
humans O +
[ O +
117 O +
] O +
, O +
and O +
glucocorticoids O +
can O +
bind O +
to O +
the O +
Pdx1 O +
promoter O +
and O +
thus O +
suppress O +
fetal O +
endocrine O +
cell O +
differentiation O +
[ O +
117 O +
] O +
. O +

Glucocorticoid O +
treatment O +
has O +
been O +
shown O +
to O +
significantly O +
reduce O +
fetal O +
expression O +
of O +
key O +
endocrine O +
transcription O +
factors O +
such O +
as O +
Pdx1 O +
and O +
Pax6 O +
but O +
simultaneously O +
increase O +
expression O +
of O +
transcription O +
factors O +
that O +
regulate O +
development O +
of O +
the O +
exocrine O +
pancreas O +
[ O +
119 O +
] O +
. O +

It O +
has O +
also O +
been O +
demonstrated O +
that O +
the O +
UPI O +
or O +
the O +
low O +
- O +
protein O +
IUPR O +
offspring O +
experience O +
increased O +
oxidative O +
stress O +
and O +
impaired O +
mitochondrial O +
function O +
[ O +
96 O +
, O +
120 O +
] O +
. O +

The O +
mitochondrial O +
dysfunction O +
was O +
not O +
limited O +
to O +
just O +
the O +
beta O +
cell O +
, O +
as O +
mitochondria O +
from O +
both O +
the O +
liver O +
and O +
skeletal O +
muscle O +
exhibit O +
decreased O +
oxidation O +
of O +
pyruvate O +
, O +
subsequently O +
leading O +
to O +
the O +
development O +
of O +
features O +
commonly O +
found O +
in O +
T2D O +
[ O +
100 O +
, O +
121 O +
] O +
. O +

Also O +
exposure O +
to O +
a O +
Western O +
- O +
style O +
diet O +
before O +
and O +
during O +
pregnancy O +
( O +
an O +
IUEO O +
model O +
) O +
alters O +
the O +
redox O +
state O +
as O +
early O +
as O +
preimplantation O +
development O +
, O +
leading O +
to O +
mild O +
oxidative O +
stress O +
associated O +
with O +
inflammation O +
. O +

The O +
finding O +
that O +
administration O +
of O +
antioxidants O +
to O +
the O +
dam O +
reverses O +
oxidative O +
stress O +
and O +
completely O +
prevents O +
the O +
development O +
of O +
glucose O +
intolerance O +
and O +
increased O +
adiposity O +
in O +
the O +
adult O +
offspring O +
suggests O +
that O +
oxidative O +
stress O +
plays O +
an O +
important O +
role O +
in O +
the O +
development O +
of O +
adiposity O +
in O +
this O +
case O +
[ O +
122 O +
] O +
. O +

Some O +
studies O +
in O +
the O +
low O +
- O +
protein O +
IUPR O +
model O +
have O +
demonstrated O +
that O +
oxidative O +
stress O +
is O +
not O +
limited O +
to O +
just O +
mitochondrial O +
DNA O +
damage O +
, O +
but O +
also O +
to O +
genomic O +
DNA O +
, O +
impacting O +
cell O +
- O +
cycle O +
regulation O +
and O +
gene O +
expression O +
[ O +
123 O +
] O +
. O +

While O +
DNA O +
is O +
being O +
targeted O +
throughout O +
by O +
ROS O +
, O +
there O +
are O +
particular O +
regions O +
that O +
are O +
known O +
to O +
be O +
more O +
sensitive O +
to O +
ROS O +
- O +
mediated O +
damage O +
, O +
for O +
example O +
, O +
telomeres O +
. O +

Telomeres O +
comprise O +
GC O +
- O +
rich O +
repeats O +
and O +
are O +
found O +
at O +
the O +
ends O +
of O +
each O +
chromosome O +
. O +

They O +
are O +
known O +
to O +
shorten O +
with O +
each O +
cellular O +
division O +
and O +
, O +
hence O +
, O +
can O +
act O +
as O +
a O +
mitotic O +
clock O +
, O +
registering O +
the O +
number O +
of O +
replicative O +
divisions O +
to O +
have O +
taken O +
place O +
within O +
the O +
cell O +
. O +

Investigations O +
using O +
an O +
IUPR O +
model O +
have O +
indeed O +
reported O +
a O +
decrease O +
in O +
longevity O +
in O +
the O +
offspring O +
[ O +
123 O +
, O +
124 O +
] O +
accompanied O +
by O +
reduction O +
in O +
mitochondrial O +
antioxidant O +
defences O +
[ O +
96 O +
, O +
125 O +
] O +
and O +
telomere O +
length O +
in O +
islets O +
[ O +
125 O +
] O +
. O +

Pancreatic O +
islet O +
development O +
has O +
been O +
shown O +
to O +
be O +
influenced O +
by O +
a O +
number O +
of O +
growth O +
factors O +
including O +
the O +
insulin O +
- O +
like O +
growth O +
factors O +
, O +
IGF O +
- O +
I O +
and O +
IGF O +
- O +
II O +
whose O +
expression O +
in O +
utero O +
is O +
regulated O +
by O +
nutrient O +
and O +
hormone O +
concentrations O +
. O +

IUPR O +
modifies O +
expression O +
of O +
both O +
IGF O +
genes O +
in O +
a O +
variety O +
of O +
fetal O +
tissues O +
. O +

In O +
an O +
IUPR O +
rat O +
model O +
with O +
a O +
decreased O +
beta O +
- O +
cell O +
mass O +
and O +
beta O +
- O +
cell O +
replication O +
and O +
an O +
increased O +
rate O +
of O +
beta O +
- O +
cell O +
apoptosis O +
, O +
gene O +
expression O +
for O +
IGF O +
- O +
II O +
but O +
not O +
IGF O +
- O +
I O +
was O +
found O +
reduced O +
in O +
the O +
fetal O +
pancreas O +
[ O +
126 O +
] O +
. O +

In O +
a O +
different O +
IUPR O +
model O +
with O +
more O +
severe O +
global O +
food O +
restriction O +
which O +
induced O +
hyperinsulinemia O +
and O +
an O +
increase O +
in O +
beta O +
- O +
cell O +
mass O +
in O +
their O +
fetuses O +
[ O +
90 O +
] O +
, O +
the O +
fetal O +
phenotype O +
was O +
unexpectedly O +
associated O +
with O +
an O +
increase O +
in O +
pancreatic O +
IGF O +
- O +
I O +
expression O +
, O +
islet O +
IGF O +
- O +
1R O +
[ O +
91 O +
] O +
, O +
and O +
IRS O +
- O +
2 O +
[ O +
92 O +
] O +
. O +

In O +
the O +
fetal O +
GK O +
/ O +
Par O +
rat O +
exposed O +
to O +
mild O +
hyperglycemia O +
during O +
gestation O +
( O +
a O +
model O +
of O +
IUED O +
) O +
, O +
data O +
from O +
our O +
group O +
suggest O +
that O +
the O +
beta O +
- O +
cell O +
deficit O +
( O +
reduced O +
by O +
more O +
than O +
50 O +
% O +
) O +
starts O +
as O +
early O +
as O +
fetal O +
age O +
E16 O +
and O +
reflects O +
decreased O +
beta O +
- O +
cell O +
proliferation O +
, O +
a O +
limitation O +
of O +
beta O +
- O +
cell O +
neogenesis O +
from O +
precursors O +
, O +
and O +
increased O +
apoptosis O +
of O +
both O +
beta O +
cells O +
and O +
their O +
precursors O +
[ O +
86 O +
] O +
. O +

Notably O +
, O +
Pdx1 O +
and O +
Neurogenin3 O +
expression O +
were O +
decreased O +
on O +
E18 O +
but O +
normally O +
expressed O +
on O +
E13 O +
[ O +
86 O +
] O +
. O +

Defective O +
signalling O +
through O +
the O +
Igf2 O +
/ O +
Igf1 O +
- O +
R O +
pathway O +
may O +
represent O +
the O +
primary O +
instrumental O +
anomaly O +
since O +
Igf2 O +
and O +
Igf1 O +
- O +
R O +
protein O +
expressions O +
are O +
already O +
decreased O +
within O +
the O +
GK O +
/ O +
Par O +
pancreatic O +
rudiment O +
at O +
E13 O +
, O +
at O +
a O +
time O +
when O +
beta O +
- O +
cell O +
mass O +
( O +
first O +
wave O +
of O +
beta O +
- O +
cell O +
expansion O +
) O +
is O +
in O +
fact O +
normal O +
[ O +
31 O +
] O +
. O +

Low O +
levels O +
of O +
pancreatic O +
Igf2 O +
associated O +
with O +
beta O +
- O +
cell O +
mass O +
deficiency O +
are O +
maintained O +
thereafter O +
within O +
the O +
fetal O +
pancreas O +
[ O +
87 O +
] O +
. O +

Crossbreeding O +
protocols O +
between O +
nondiabetic O +
W O +
and O +
diabetic O +
GK O +
rats O +
showed O +
that O +
, O +
in O +
late O +
gestation O +
( O +
E18 O +
) O +
, O +
pancreatic O +
Igf2 O +
protein O +
expression O +
was O +
as O +
low O +
in O +
GKmother O +
/ O +
GKfather O +
and O +
Wmother O +
/ O +
GKfather O +
crosses O +
as O +
in O +
GKmother O +
/ O +
GKfather O +
crosses O +
[ O +
87 O +
] O +
. O +

These O +
findings O +
rather O +
support O +
the O +
hypothesis O +
that O +
the O +
pancreatic O +
Igf2 O +
anomaly O +
in O +
the O +
GK O +
diabetic O +
model O +
is O +
linked O +
to O +
a O +
genetic O +
determinism O +
. O +

This O +
view O +
is O +
also O +
consistent O +
with O +
the O +
results O +
of O +
genetic O +
analyses O +
that O +
linked O +
a O +
locus O +
containing O +
the O +
gene O +
encoding O +
Igf2 O +
to O +
diabetes O +
in O +
the O +
GK O +
rat O +
[ O +
127 O +
] O +
. O +

The O +
Igf2 O +
gene O +
is O +
subjected O +
to O +
paternal O +
genomic O +
imprinting O +
. O +

However O +
, O +
because O +
the O +
Igf2 O +
expression O +
is O +
similarly O +
affected O +
in O +
fetuses O +
, O +
regardless O +
of O +
whether O +
the O +
father O +
is O +
W O +
or O +
GK O +
[ O +
87 O +
] O +
, O +
we O +
can O -
not O +
conclude O +
with O +
a O +
simple O +
change O +
of O +
Igf2 O +
gene O +
imprinting O +
in O +
the O +
GK O +
rat O +
. O +

Finally O +
, O +
our O +
understanding O +
of O +
the O +
underlying O +
mechanisms O +
for O +
reduced O +
BCM O +
in O +
response O +
to O +
inappropriate O +
perinatal O +
nutrition O +
is O +
growing O +
rapidly O +
. O +

However O +
, O +
the O +
relative O +
contribution O +
of O +
the O +
many O +
intrinsic O +
and O +
extrinsic O +
factors O +
which O +
contribute O +
to O +
the O +
adaptive O +
response O +
of O +
the O +
developing O +
endocrine O +
pancreas O +
is O +
still O +
to O +
be O +
established O +
. O +

4 O +
. O +

The O +
kinetochore O +

The O +
arguments O +
built O +
in O +
the O +
previous O +
section O +
lead O +
to O +
the O +
conclusion O +
that O +
it O +
is O +
essential O +
to O +
understand O +
error O +
correction O +
and O +
spindle O +
checkpoint O +
signalling O +
in O +
the O +
context O +
of O +
the O +
complex O +
structural O +
organization O +
of O +
the O +
kinetochore O +
. O +

A O +
complete O +
account O +
of O +
kinetochore O +
organization O +
is O +
beyond O +
the O +
scope O +
of O +
this O +
review O +
and O +
several O +
reviews O +
on O +
this O +
topic O +
have O +
been O +
made O +
available O +
recently O +
[ O +
21 O +
, O +
22 O +
] O +
. O +

Suffice O +
to O +
say O +
that O +
kinetochores O +
are O +
thought O +
to O +
consist O +
of O +
an O +
inner O +
plate O +
hosting O +
an O +
interface O +
between O +
the O +
15 O +
- O +
subunit O +
constitutive O +
centromere O +
- O +
associated O +
network O +
( O +
CCAN O +
) O +
and O +
specialized O +
centromeric O +
chromatin O +
; O +
and O +
an O +
outer O +
plate O +
containing O +
the O +
10 O +
- O +
subunit O +
KMN O +
network O +
( O +
from O +
the O +
initials O +
of O +
its O +
Knl1 O +
, O +
Mis12 O +
and O +
Ndc80 O +
subcomplexes O +
) O +
implicated O +
in O +
microtubule O +
binding O +
. O +

The O +
CCAN O +
and O +
KMN O +
networks O +
are O +
tightly O +
connected O +
. O +

An O +
interaction O +
between O +
CENP O +
- O +
C O +
( O +
CCAN O +
) O +
and O +
the O +
Mis12 O +
complex O +
( O +
KMN O +
network O +
) O +
provides O +
an O +
important O +
point O +
of O +
contact O +
[ O +
81 O +
- O +
83 O +
] O +
. O +

The O +
existence O +
of O +
additional O +
points O +
of O +
contact O +
, O +
including O +
one O +
between O +
CENP O +
- O +
T O +
( O +
CCAN O +
) O +
and O +
the O +
Ndc80 O +
subcomplex O +
( O +
KMN O +
network O +
) O +
[ O +
83 O +
, O +
84 O +
] O +
, O +
is O +
supported O +
by O +
extensive O +
analyses O +
of O +
localization O +
dependencies O +
of O +
kinetochore O +
proteins O +
and O +
from O +
initial O +
experiments O +
of O +
biochemical O +
reconstitution O +
. O +

Biochemical O +
and O +
structural O +
studies O +
, O +
including O +
super O +
- O +
resolution O +
investigations O +
of O +
kinetochore O +
organization O +
by O +
fluorescence O +
microscopy O +
, O +
have O +
finally O +
resulted O +
in O +
rather O +
precise O +
maps O +
of O +
the O +
relative O +
position O +
of O +
many O +
structural O +
kinetochore O +
proteins O +
and O +
of O +
several O +
checkpoint O +
components O +
[ O +
85 O +
- O +
88 O +
] O +
. O +

For O +
instance O +
, O +
these O +
studies O +
clarified O +
that O +
the O +
highly O +
elongated O +
4 O +
- O +
subunit O +
Ndc80 O +
complex O +
, O +
conserved O +
in O +
all O +
eukaryotes O +
, O +
orients O +
its O +
approximately O +
60 O +
nm O +
long O +
axis O +
at O +
a O +
relatively O +
small O +
angle O +
with O +
the O +
inter O +
- O +
kinetochore O +
axis O +
[ O +
85 O +
- O +
87 O +
] O +
. O +

The O +
kinetochore O +
- O +
binding O +
end O +
of O +
the O +
Ndc80 O +
complex O +
was O +
predicted O +
to O +
be O +
positioned O +
near O +
the O +
Mis12 O +
and O +
Knl1 O +
complexes O +
[ O +
87 O +
, O +
88 O +
] O +
, O +
and O +
this O +
prediction O +
was O +
fully O +
confirmed O +
in O +
experiments O +
of O +
biochemical O +
reconstitution O +
[ O +
89 O +
] O +
. O +

In O +
prophase O +
Drosophila O +
melanogaster O +
S2 B-CellLine +
cells O +
, O +
the O +
C O +
- O +
terminal O +
region O +
of O +
the O +
Ndc80 O +
subunit O +
is O +
located O +
approximately O +
65 O +
nm O +
outward O +
( O +
i O +
. O +
e O +
. O +
towards O +
the O +
microtubule O +
) O +
relative O +
to O +
CENP O +
- O +
A O +
, O +
the O +
histone O +
H3 O +
variant O +
that O +
marks O +
centromeres O +
from O +
yeast O +
to O +
humans O +
[ O +
40 O +
] O +
. O +

Remarkably O +
, O +
it O +
was O +
shown O +
that O +
this O +
distance O +
increases O +
to O +
approximately O +
100 O +
nm O +
when O +
kinetochores O +
experience O +
microtubule O +
- O +
dependent O +
tension O +
at O +
metaphase O +
[ O +
40 O +
] O +
. O +

This O +
phenomenon O +
is O +
now O +
known O +
as O +
intra O +
- O +
kinetochore O +
stretch O +
or O +
tension O +
[ O +
40 O +
, O +
90 O +
] O +
. O +

A O +
major O +
task O +
for O +
the O +
future O +
is O +
to O +
understand O +
how O +
intra O +
- O +
kinetochore O +
stretch O +
is O +
generated O +
when O +
microtubules O +
bind O +
the O +
kinetochore O +
. O +

At O +
one O +
extreme O +
, O +
intra O +
- O +
kinetochore O +
stretching O +
might O +
be O +
the O +
result O +
of O +
a O +
discreet O +
conformational O +
change O +
in O +
the O +
kinetochore O +
caused O +
by O +
microtubule O +
binding O +
[ O +
22 O +
, O +
91 O +
] O +
. O +

While O +
this O +
is O +
possible O +
, O +
it O +
seems O +
unlikely O +
when O +
considering O +
the O +
great O +
structural O +
complexity O +
of O +
kinetochores O +
. O +

Each O +
microtubule O +
- O +
binding O +
site O +
contains O +
six O +
to O +
eight O +
copies O +
of O +
the O +
approximately O +
30 O +
structural O +
kinetochore O +
components O +
[ O +
85 O +
] O +
. O +

Furthermore O +
, O +
in O +
most O +
species O +
, O +
kinetochores O +
are O +
designed O +
to O +
bind O +
multiple O +
microtubules O +
. O +

Plausibly O +
, O +
each O +
microtubule O +
- O +
binding O +
site O +
becomes O +
engaged O +
at O +
a O +
different O +
time O +
. O +

Thus O +
, O +
it O +
may O +
be O +
more O +
sensible O +
to O +
interpret O +
intra O +
- O +
kinetochore O +
stretching O +
as O +
a O +
progressive O +
, O +
continuous O +
distortion O +
of O +
the O +
kinetochore O +
when O +
microtubules O +
are O +
added O +
. O +

In O +
agreement O +
with O +
this O +
idea O +
, O +
intermediate O +
levels O +
of O +
stretching O +
are O +
observed O +
when O +
microtubule O +
end O +
dynamics O +
are O +
inhibited O +
through O +
addition O +
of O +
taxol O +
[ O +
40 O +
] O +
. O +

Importantly O +
, O +
intra O +
- O +
kinetochore O +
stretch O +
was O +
shown O +
to O +
correlate O +
with O +
the O +
status O +
of O +
checkpoint O +
activation O +
, O +
with O +
high O +
stretch O +
being O +
correlated O +
with O +
checkpoint O +
satisfaction O +
. O +

This O +
idea O +
of O +
checkpoint O +
control O +
is O +
alternative O +
to O +
a O +
previous O +
idea O +
that O +
tension O +
might O +
be O +
monitored O +
at O +
the O +
centromere O +
, O +
i O +
. O +
e O +
. O +
between O +
sister O +
kinetochores O +
( O +
inter O +
- O +
kinetochore O +
tension O +
) O +
[ O +
46 O +
] O +
. O +

A O +
significant O +
theoretical O +
limitation O +
of O +
the O +
idea O +
that O +
the O +
checkpoint O +
sensor O +
monitors O +
tension O +
between O +
sister O +
kinetochores O +
is O +
that O +
it O +
is O +
not O +
applicable O +
to O +
meiosis O +
I O +
, O +
when O +
the O +
sisters O +
co O +
- O +
orient O +
and O +
the O +
homologues O +
pair O +
through O +
the O +
chiasmata O +
. O +

Conversely O +
, O +
the O +
intra O +
- O +
kinetochore O +
tension O +
idea O +
is O +
also O +
applicable O +
to O +
checkpoint O +
control O +
in O +
meiosis O +
I O +
. O +

Discussion O +

In O +
our O +
previous O +
work O +
, O +
we O +
considered O +
in O +
CD O +
families O +
the O +
risk O +
to O +
develop O +
the O +
disease O +
according O +
to O +
a O +
specific O +
HLA O +
haplotypes O +
, O +
obtaining O +
a O +
risk O +
range O +
from O +
0 O +
. O +
01 O +
to O +
> O +
= O +
0 O +
. O +
20 O +
[ O +
1 O +
] O +
. O +

In O +
the O +
present O +
study O +
we O +
evaluated O +
the O +
role O +
of O +
3 O +
non O +
- O +
HLA O +
genetic O +
markers O +
to O +
influence O +
the O +
CD O +
risk O +
in O +
first O +
relatives O +
of O +
CD O +
affected O +
children O +
. O +

We O +
collected O +
data O +
on O +
families O +
with O +
at O +
least O +
one O +
CD O +
- O +
affected O +
among O +
offspring O +
. O +

This O +
family O +
set O +
helped O +
to O +
evaluate O +
the O +
association O +
between O +
SNPs O +
and O +
CD O +
( O +
TDT O +
on O +
parents O +
- O +
offspring O +
trios O +
) O +
and O +
to O +
estimate O +
the O +
risk O +
of O +
CD O +
in O +
the O +
other O +
sibs O +
. O +

The O +
TDT O +
design O +
provides O +
robustness O +
to O +
population O +
stratification O +
and O +
mitigation O +
of O +
the O +
possible O +
confounding O +
effect O +
of O +
environmental O +
factors O +
, O +
because O +
all O +
family O +
members O +
share O +
the O +
same O +
environment O +
[ O +
16 O +
] O +
. O +

Ten O +
SNPs O +
, O +
selected O +
from O +
those O +
previously O +
found O +
to O +
be O +
associated O +
with O +
CD O +
by O +
GWAS O +
[ O +
13 O +
] O +
, O +
were O +
successfully O +
genotyped O +
. O +

In O +
our O +
population O +
three O +
SNPs O +
resulted O +
significantly O +
associated O +
with O +
CD O +
( O +
those O +
in O +
LPP O +
, O +
RGS1 O +
and O +
REL O +
genes O +
) O +
and O +
the O +
other O +
seven O +
investigated O +
SNPs O +
, O +
even O +
if O +
not O +
statistically O +
associated O +
with O +
CD O +
, O +
showed O +
always O +
an O +
higher O +
frequency O +
of O +
the O +
previously O +
reported O +
risk O +
alleles O +
[ O +
13 O +
] O +
in O +
affected O +
subjects O +
than O +
in O +
controls O +
. O +

The O +
three O +
genes O +
selected O +
appear O +
to O +
be O +
appealing O +
for O +
the O +
pathogenesis O +
of O +
CD O +
. O +

LPP O +
( O +
OR O +
= O +
2 O +
. O +
36 O +
; O +
p O +
< O +
0 O +
. O +
001 O +
) O +
was O +
reported O +
to O +
be O +
highly O +
expressed O +
in O +
small O +
intestinal O +
mucosa O +
and O +
may O +
have O +
a O +
structural O +
role O +
at O +
sites O +
of O +
cell O +
adhesion O +
in O +
maintaining O +
cell O +
shape O +
and O +
motility O +
[ O +
7 O +
] O +
. O +

RGS1 O +
( O +
OR O +
= O +
1 O +
. O +
75 O +
; O +
p O +
= O +
0 O +
. O +
025 O +
) O +
belongs O +
to O +
a O +
family O +
of O +
RGS O +
genes O +
. O +

It O +
attenuates O +
the O +
signaling O +
activity O +
of O +
G O +
- O +
proteins O +
, O +
blocking O +
the O +
homing O +
of O +
Intra O +
Epithelial O +
Lymphocytes O +
( O +
IELs O +
) O +
, O +
and O +
it O +
is O +
specifically O +
expressed O +
both O +
in O +
human O +
small O +
intestinal O +
mucosa O +
and O +
in O +
murine O +
IELs O +
, O +
key O +
players O +
in O +
the O +
development O +
of O +
human O +
CD O +
villous O +
atrophy O +
[ O +
7 O +
] O +
, O +
[ O +
17 O +
] O +
. O +

REL O +
( O +
OR O +
= O +
1 O +
. O +
66 O +
; O +
p O +
= O +
0 O +
. O +
034 O +
) O +
is O +
a O +
subunit O +
of O +
NF O +
- O +
kB O +
complex O +
, O +
implicated O +
in O +
T O +
cell O +
differentiation O +
[ O +
18 O +
] O +
and O +
it O +
appears O +
to O +
be O +
a O +
key O +
molecule O +
regulating O +
inflammation O +
and O +
the O +
switch O +
from O +
tolerance O +
to O +
autoimmunity O +
[ O +
19 O +
] O +
. O +

It O +
is O +
interesting O +
to O +
note O +
that O +
our O +
data O +
confirm O +
previous O +
pathogenetic O +
implications O +
reported O +
in O +
literature O +
of O +
these O +
SNPs O +
with O +
CD O +
as O +
well O +
as O +
with O +
other O +
autoimmune O +
diseases O +
[ O +
20 O +
] O +
. O +

By O +
the O +
Bayesian O +
approach O +
we O +
calculated O +
a O +
ranking O +
score O +
( O +
BS O +
) O +
among O +
the O +
sibs O +
. O +

However O +
, O +
it O +
should O +
be O +
considered O +
that O +
BS O +
is O +
not O +
a O +
plain O +
disease O +
risk O +
, O +
rather O +
a O +
method O +
to O +
rank O +
different O +
genotypes O +
according O +
to O +
their O +
contribution O +
to O +
make O +
an O +
individual O +
susceptible O +
to O +
CD O +
. O +

For O +
instance O +
, O +
some O +
of O +
our O +
BS O +
are O +
very O +
near O +
to O +
1 O +
, O +
nevertheless O +
none O +
of O +
the O +
considered O +
genotypes O +
could O +
give O +
a O +
100 O +
% O +
risk O +
to O +
develop O +
the O +
disease O +
. O +

In O +
other O +
terms O +
, O +
we O +
considered O +
the O +
BS O +
as O +
a O +
ranking O +
measure O +
, O +
only O +
stating O +
that O +
a O +
given O +
genotype O +
could O +
assign O +
a O +
higher O +
risk O +
than O +
another O +
genotype O +
but O +
does O +
not O +
allow O +
a O +
quantitative O +
measure O +
of O +
the O +
risk O +
difference O +
( O +
2 O +
- O +
fold O +
, O +
3 O +
- O +
fold O +
, O +
etc O +
) O +
. O +

However O +
, O +
even O +
if O +
the O +
addition O +
of O +
only O +
3 O +
SNPs O +
to O +
HLA O +
could O +
be O +
considered O +
at O +
" O +
minor O +
effect O +
" O +
[ O +
13 O +
] O +
, O +
we O +
demonstrated O +
that O +
they O +
could O +
significantly O +
improve O +
the O +
prediction O +
of O +
CD O +
risk O +
in O +
sibs O +
, O +
in O +
terms O +
of O +
diagnostic O +
sensitivity O +
and O +
negative O +
predictive O +
value O +
. O +

So O +
, O +
in O +
a O +
cohort O +
of O +
CD O +
families O +
, O +
our O +
data O +
confirm O +
that O +
non O +
- O +
HLA O +
SNPs O +
evaluation O +
is O +
an O +
usefull O +
diagnostic O +
tool O +
in O +
CD O +
risk O +
evaluation O +
as O +
a O +
previous O +
study O +
showed O +
in O +
CD O +
unrelated O +
subjects O +
[ O +
14 O +
] O +
. O +

CD O +
, O +
on O +
the O +
basis O +
of O +
the O +
actual O +
knowledge O +
, O +
can O -
not O +
be O +
exactly O +
predicted O +
by O +
genetic O +
testing O +
, O +
but O +
a O +
reliable O +
probabilistic O +
method O +
might O +
be O +
associated O +
to O +
careful O +
surveillance O +
of O +
infants O +
carrying O +
the O +
higher O +
risk O +
. O +

This O +
will O +
help O +
to O +
significantly O +
reduce O +
the O +
heavy O +
load O +
of O +
anxiety O +
and O +
pain O +
associated O +
with O +
the O +
appearance O +
of O +
symptoms O +
of O +
CD O +
, O +
by O +
anticipating O +
, O +
with O +
simple O +
serological O +
tests O +
, O +
the O +
clinical O +
appearance O +
of O +
the O +
disease O +
. O +

To O +
improve O +
the O +
possibility O +
to O +
identify O +
high O +
risk O +
patients O +
in O +
CD O +
families O +
we O +
propose O +
in O +
alternative O +
to O +
the O +
classical O +
HLA O +
classification O +
( O +
Fig O +
. O +
4 O +
, O +
panel O +
A O +
) O +
a O +
slight O +
improved O +
flow O +
- O +
chart O +
( O +
Fig O +
. O +
4 O +
, O +
panel O +
B O +
) O +
: O +
1 O +
) O +
HLA O +
genotyping O +
: O +
subjects O +
belonging O +
to O +
the O +
HLA O +
risk O +
groups O +
1 O +
and O +
2 O +
will O +
be O +
classified O +
as O +
at O +
high O +
CD O +
risk O +
; O +
2 O +
) O +
subjects O +
belonging O +
to O +
the O +
HLA O +
risk O +
groups O +
3 O +
and O +
4 O +
, O +
will O +
be O +
further O +
investigated O +
for O +
our O +
SNPs O +
combination O +
( O +
LPP O +
, O +
REL O +
, O +
RGS1 O +
) O +
in O +
order O +
to O +
calculate O +
their O +
BS O +
( O +
Fig O +
. O +
4 O +
, O +
panel O +
B O +
) O +
. O +

Among O +
these O +
latter O +
subjects O +
those O +
with O +
a O +
BS O +
> O +
= O +
the O +
median O +
value O +
will O +
be O +
classified O +
at O +
high O +
risk O +
; O +
3 O +
) O +
subjects O +
belonging O +
to O +
the O +
HLA O +
risk O +
group O +
5 O +
will O +
be O +
considered O +
at O +
low O +
CD O +
risk O +
. O +

All O +
CD O +
familials O +
belonging O +
to O +
the O +
above O +
high O +
risk O +
groups O +
( O +
HLA O +
group O +
1 O +
- O +
2 O +
and O +
HLA O +
group O +
3 O +
- O +
4 O +
with O +
BS O +
> O +
= O +
median O +
) O +
will O +
be O +
undergo O +
a O +
strict O +
surveillance O +
. O +

10 O +
. O +
1371 O +
/ O +
journal O +
. O +
pone O +
. O +
0026920 O +
. O +
g004 O +
Figure O +
4 O +

Classification O +
flow O +
- O +
chart O +
. O +

In O +
panel O +
A O +
the O +
classical O +
HLA O +
- O +
based O +
classification O +
. O +

In O +
panel O +
B O +
the O +
proposed O +
BS O +
- O +
based O +
classification O +
considering O +
the O +
genotypes O +
of O +
HLA O +
plus O +
LPP O +
, O +
RGS1 O +
and O +
REL O +
SNPs O +
. O +

One O +
of O +
the O +
limitation O +
of O +
our O +
cohort O +
family O +
study O +
could O +
be O +
the O +
sample O +
size O +
, O +
which O +
may O +
have O +
not O +
allowed O +
to O +
explore O +
genes O +
at O +
smaller O +
effect O +
, O +
so O +
explaining O +
the O +
lack O +
of O +
association O +
between O +
SNPs O +
in O +
TAGAP O +
, O +
IL2 O +
/ O +
IL21 O +
, O +
OLIG3 O +
, O +
CCR O +
, O +
SH2B3 O +
, O +
IL12A O +
and O +
IL12A O +
/ O +
SCHIP1 O +
genes O +
with O +
CD O +
although O +
the O +
trend O +
observed O +
in O +
previous O +
studies O +
in O +
unrelated O +
CD O +
patients O +
was O +
confirmed O +
[ O +
13 O +
] O +
. O +

In O +
the O +
main O +
time O +
the O +
homogeneity O +
of O +
the O +
genetic O +
and O +
environmental O +
domains O +
in O +
the O +
tested O +
families O +
allows O +
to O +
explore O +
risk O +
factors O +
within O +
a O +
controlled O +
cohort O +
. O +

A O +
second O +
limit O +
of O +
the O +
study O +
is O +
the O +
relatively O +
short O +
( O +
6 O +
years O +
) O +
follow O +
up O +
of O +
the O +
sibship O +
, O +
which O +
could O +
cause O +
an O +
underestimation O +
of O +
the O +
disease O +
development O +
at O +
later O +
ages O +
. O +

Our O +
aim O +
is O +
to O +
go O +
on O +
with O +
the O +
monitoring O +
of O +
these O +
families O +
in O +
the O +
next O +
years O +
. O +

In O +
conclusion O +
, O +
the O +
estimate O +
of O +
the O +
CD O +
risk O +
by O +
HLA O +
+ O +
SNPs O +
approach O +
, O +
even O +
if O +
not O +
applicable O +
to O +
prevention O +
, O +
could O +
be O +
a O +
precious O +
tool O +
improving O +
CD O +
diagnosis O +
respect O +
to O +
the O +
only O +
HLA O +
( O +
NPV O +
: O +
95 O +
% O +
vs O +
91 O +
% O +
, O +
and O +
DS O +
: O +
79 O +
% O +
vs O +
45 O +
% O +
) O +
, O +
in O +
the O +
cohort O +
of O +
first O +
degree O +
relatives O +
. O +

In O +
fact O +
in O +
clinical O +
practice O +
the O +
absence O +
of O +
HLA O +
risk O +
groups O +
1 O +
or O +
2 O +
, O +
allows O +
to O +
exclude O +
the O +
disease O +
with O +
high O +
probability O +
, O +
while O +
testing O +
the O +
three O +
SNPs O +
in O +
HLA O +
groups O +
3 O +
or O +
4 O +
could O +
represent O +
a O +
further O +
tool O +
to O +
identify O +
less O +
frequent O +
CD O +
cases O +
. O +

So O +
, O +
an O +
infant O +
with O +
high O +
HLA O +
+ O +
SNPs O +
score O +
even O +
if O +
belonging O +
to O +
HLA O +
low O +
risk O +
groups O +
, O +
shall O +
undergo O +
a O +
simple O +
surveillance O +
system O +
to O +
allow O +
proper O +
diagnosis O +
and O +
treatment O +
before O +
the O +
full O +
blow O +
disease O +
appears O +
. O +

Refinement O +

R O +
[ O +
F O +
2 O +
> O +
2sigma O +
( O +
F O +
2 O +
) O +
] O +
= O +
0 O +
. O +
052 O +

wR O +
( O +
F O +
2 O +
) O +
= O +
0 O +
. O +
132 O +

S O +
= O +
1 O +
. O +
02 O +

3804 O +
reflections O +

229 O +
parameters O +

67 O +
restraints O +

H O +
- O +
atom O +
parameters O +
constrained O +

Deltarhomax O +
= O +
0 O +
. O +
56 O +
e O +
A O +
- O +
3 O +

Deltarhomin O +
= O +
- O +
0 O +
. O +
38 O +
e O +
A O +
- O +
3 O +

Objectives O +

Evaluate O +
relationships O +
between O +
MRI O +
and O +
clinical O +
/ O +
laboratory O +
/ O +
radiographic O +
findings O +
in O +
rheumatoid O +
arthritis O +
( O +
RA O +
) O +
. O +

Authors O +
' O +
contributions O +

EEKN O +
was O +
responsible O +
for O +
data O +
collection O +
, O +
statistical O +
analysis O +
and O +
drafting O +
the O +
manuscript O +
. O +

SAGN O +
and O +
YW O +
involved O +
in O +
data O +
collection O +
and O +
helped O +
with O +
the O +
data O +
analysis O +
. O +

AS O +
helped O +
in O +
data O +
analysis O +
. O +

EST O +
and O +
JL O +
directed O +
the O +
study O +
and O +
helped O +
in O +
revising O +
the O +
manuscript O +
. O +

RMVD O +
helped O +
in O +
data O +
analysis O +
, O +
interpretation O +
of O +
the O +
results O +
and O +
led O +
writing O +
of O +
the O +
manuscript O +
. O +

All O +
authors O +
read O +
and O +
approved O +
the O +
final O +
manuscript O +
. O +

Outcomes O +

The O +
primary O +
outcomes O +
of O +
this O +
study O +
are O +
smoking O +
abstinence O +
rates O +
post O +
release O +
as O +
well O +
as O +
number O +
of O +
days O +
to O +
first O +
cigarette O +
after O +
release O +
. O +

Seven O +
day O +
point O +
- O +
prevalence O +
abstinence O +
will O +
be O +
determined O +
by O +
combining O +
self O +
- O +
reported O +
tobacco O +
use O +
over O +
the O +
prior O +
seven O +
days O +
and O +
urine O +
cotinine O +
assays O +
( O +
below O +
200 O +
ng O +
/ O +
ml O +
versus O +
200 O +
or O +
above O +
) O +
. O +

Participants O +
with O +
self O +
- O +
reported O +
abstinence O +
and O +
cotinine O +
levels O +
below O +
the O +
cut O +
- O +
off O +
will O +
be O +
classified O +
as O +
abstinent O +
. O +

Participants O +
lost O +
to O +
follow O +
- O +
up O +
will O +
be O +
considered O +
non O +
- O +
abstinent O +
. O +

A O +
secondary O +
analysis O +
will O +
examine O +
the O +
effect O +
of O +
length O +
of O +
forced O +
abstinence O +
on O +
quit O +
rates O +
. O +

Abbreviations O +

ARDS O +
: O +
acute O +
respiratory O +
distress O +
syndrome O +
; O +
CMV O +
: O +
conventional O +
mechanical O +
ventilation O +
; O +
HFOV O +
: O +
high O +
- O +
frequency O +
oscillation O +
ventilation O +
; O +
LPS O +
: O +
lipopolysaccharide O +
; O +
PEEP O +
: O +
positive O +
end O +
- O +
expiratory O +
pressure O +
; O +
VILI O +
: O +
ventilator O +
- O +
induced O +
lung O +
injury O +
. O +

TxA2 O +
, O +
generated O +
from O +
arachidonic O +
acid O +
by O +
cyclooxygenase O +
1 O +
( O +
COX O +
- O +
1 O +
) O +
and O +
Tx O +
synthase O +
, O +
further O +
amplifies O +
platelet O +
activation O +
. O +

COX O +
- O +
1 O +
converts O +
arachidonic O +
acid O +
into O +
prostaglandin O +
endoperoxides O +
PGG2 O +
and O +
PGH2 O +
, O +
the O +
latter O +
being O +
, O +
in O +
turn O +
, O +
transformed O +
by O +
Tx O +
synthase O +
into O +
TxA2 O +
, O +
a O +
potent O +
amplifier O +
of O +
platelet O +
aggregation O +
with O +
vasoconstrictive O +
properties O +
. O +

At O +
the O +
site O +
of O +
the O +
atheroma O +
rupture O +
, O +
platelet O +
- O +
released O +
TxA2 O +
leads O +
to O +
downstream O +
micro O +
- O +
vessel O +
contraction O +
and O +
thrombus O +
propagation O +
( O +
7 O +
) O +
. O +

In O +
addition O +
to O +
its O +
role O +
in O +
coagulation O +
, O +
thrombin O +
at O +
extremely O +
low O +
concentrations O +
is O +
one O +
of O +
the O +
major O +
platelet O +
activators O +
( O +
8 O +
) O +
. O +

Human O +
platelets O +
express O +
two O +
cell O +
surface O +
G O +
- O +
protein O +
- O +
coupled O +
protease O +
- O +
activated O +
receptors O +
( O +
PARs O +
) O +
for O +
thrombin O +
: O +
PAR O +
- O +
1 O +
and O +
PAR O +
- O +
4 O +
. O +

By O +
binding O +
the O +
hirudin O +
- O +
like O +
extracellular O +
amino O +
terminal O +
domain O +
( O +
the O +
so O +
- O +
called O +
thrombin O +
receptor O +
) O +
, O +
thrombin O +
activates O +
platelets O +
and O +
smooth O +
muscle O +
cells O +
, O +
thus O +
promoting O +
platelet O +
pro O +
- O +
coagulant O +
activity O +
, O +
shape O +
change O +
, O +
secretion O +
and O +
release O +
of O +
agonists O +
( O +
ADP O +
and O +
TxA2 O +
) O +
, O +
expression O +
of O +
P O +
- O +
selectin O +
, O +
activation O +
of O +
the O +
alphaIIbbeta3 O +
integrin O +
receptor O +
, O +
and O +
aggregation O +
. O +

Thrombin O +
also O +
binds O +
to O +
GpIbalpha O +
on O +
the O +
surface O +
of O +
platelets O +
, O +
thought O +
to O +
act O +
as O +
a O +
co O +
- O +
factor O +
that O +
localizes O +
the O +
enzyme O +
on O +
the O +
platelet O +
surface O +
and O +
accelerates O +
the O +
hydrolysis O +
of O +
PAR O +
- O +
1 O +
( O +
9 O +
) O +
. O +

PAR O +
- O +
1 O +
and O +
P2Y12 O +
cross O +
- O +
react O +
in O +
platelet O +
activation O +
, O +
and O +
Galphaq O +
and O +
Galphai O +
- O +
coupled O +
receptors O +
are O +
involved O +
in O +
this O +
process O +
. O +

Thrombin O +
- O +
dependent O +
platelet O +
aggregation O +
is O +
mediated O +
in O +
part O +
by O +
secreted O +
ADP O +
, O +
acting O +
on O +
the O +
Galphai O +
- O +
linked O +
ADP O +
receptor O +
. O +

By O +
blocking O +
Galphaq O +
via O +
PAR O +
- O +
1 O +
and O +
Gbetai O +
via O +
P2Y12 O +
, O +
combined O +
inhibition O +
of O +
thrombin O +
and O +
P2Y12 O +
receptors O +
leads O +
to O +
a O +
synergistic O +
inhibitory O +
effect O +
on O +
thrombin O +
- O +
induced O +
platelet O +
aggregation O +
( O +
10 O +
) O +
. O +

5 O +
- O +
HT O +
is O +
a O +
vasoconstrictor O +
agent O +
that O +
binds O +
to O +
5HT O +
- O +
2A O +
receptors O +
and O +
amplifies O +
the O +
platelet O +
response O +
by O +
stimulating O +
shape O +
change O +
and O +
enhancing O +
platelet O +
recruitment O +
at O +
sites O +
of O +
injury O +
( O +
3 O +
) O +
. O +

It O +
may O +
also O +
play O +
a O +
pro O +
- O +
coagulant O +
role O +
by O +
promoting O +
the O +
retention O +
of O +
fibrinogen O +
and O +
thrombospondin O +
on O +
the O +
platelet O +
surface O +
. O +

Intraplatelet O +
5 O +
- O +
HT O +
stores O +
are O +
implicated O +
in O +
shear O +
- O +
induced O +
platelet O +
aggregation O +
and O +
thrombus O +
propagation O +
( O +
3 O +
) O +
. O +

Assessment O +
instruments O +

The O +
SCID O +
- O +
I O +
/ O +
P O +
was O +
administered O +
by O +
psychiatrists O +
trained O +
and O +
certified O +
in O +
the O +
use O +
of O +
all O +
instruments O +
in O +
this O +
study O +
. O +

The O +
ICG O +
is O +
a O +
self O +
- O +
report O +
instrument O +
that O +
can O +
be O +
used O +
to O +
identify O +
CG O +
when O +
the O +
total O +
score O +
is O +
> O +
25 O +
, O +
that O +
demonstrated O +
high O +
internal O +
consistency O +
( O +
Cronbach O +
' O +
s O +
alpha O +
= O +
0 O +
. O +
94 O +
) O +
, O +
and O +
convergent O +
and O +
criterion O +
validity O +
[ O +
27 O +
] O +
. O +

The O +
ICG O +
total O +
score O +
also O +
showed O +
a O +
fairly O +
high O +
association O +
with O +
the O +
Beck O +
Depression O +
Inventory O +
( O +
BDI O +
) O +
[ O +
32 O +
] O +
total O +
score O +
( O +
r O +
= O +
0 O +
. O +
67 O +
, O +
P O +
< O +
0 O +
. O +
001 O +
) O +
, O +
the O +
Texas O +
Revised O +
Inventory O +
of O +
Grief O +
( O +
TRIG O +
) O +
[ O +
33 O +
] O +
score O +
( O +
r O +
= O +
0 O +
. O +
87 O +
, O +
P O +
< O +
0 O +
. O +
001 O +
) O +
, O +
and O +
the O +
Grief O +
Measurement O +
Scale O +
( O +
GMS O +
) O +
[ O +
34 O +
] O +
score O +
( O +
r O +
= O +
0 O +
. O +
70 O +
, O +
P O +
< O +
0 O +
. O +
001 O +
) O +
. O +

The O +
ASA O +
- O +
27 O +
is O +
a O +
self O +
- O +
report O +
measure O +
developed O +
to O +
rate O +
separation O +
anxiety O +
symptoms O +
in O +
adult O +
life O +
( O +
from O +
18 O +
years O +
of O +
age O +
) O +
. O +

Principal O +
components O +
analysis O +
revealed O +
a O +
coherent O +
construct O +
of O +
adult O +
separation O +
anxiety O +
with O +
high O +
internal O +
consistency O +
( O +
Cronbach O +
' O +
s O +
alpha O +
= O +
0 O +
. O +
95 O +
) O +
and O +
sound O +
test O +
- O +
retest O +
reliability O +
( O +
r O +
= O +
0 O +
. O +
86 O +
; O +
P O +
< O +
0 O +
. O +
001 O +
) O +
. O +

Further O +
, O +
a O +
receiver O +
operation O +
characteristic O +
( O +
ROC O +
) O +
analysis O +
against O +
the O +
semistructured O +
interview O +
yielded O +
a O +
high O +
area O +
under O +
the O +
curve O +
( O +
AUC O +
) O +
index O +
of O +
0 O +
. O +
9 O +
, O +
suggesting O +
that O +
the O +
questionnaire O +
is O +
an O +
adequate O +
alternative O +
measure O +
of O +
adult O +
separation O +
anxiety O +
[ O +
29 O +
] O +
. O +

The O +
WSAS O +
is O +
a O +
self O +
- O +
report O +
scale O +
of O +
functional O +
impairment O +
that O +
includes O +
five O +
questions O +
rating O +
interference O +
of O +
psychiatric O +
symptoms O +
in O +
work O +
, O +
home O +
management O +
, O +
social O +
or O +
private O +
leisure O +
activities O +
, O +
and O +
ability O +
to O +
form O +
and O +
maintain O +
close O +
relationships O +
with O +
others O +
. O +

Each O +
question O +
is O +
rated O +
on O +
a O +
0 O +
to O +
8 O +
scale O +
with O +
0 O +
indicating O +
no O +
impairment O +
at O +
all O +
and O +
8 O +
indicating O +
very O +
severe O +
impairment O +
. O +

The O +
Cronbach O +
' O +
s O +
alpha O +
measure O +
of O +
internal O +
scale O +
consistency O +
ranged O +
from O +
0 O +
. O +
70 O +
to O +
0 O +
. O +
94 O +
, O +
the O +
test O +
- O +
retest O +
correlation O +
was O +
0 O +
. O +
73 O +
, O +
and O +
the O +
WSAS O +
interactive O +
voice O +
response O +
administrations O +
gave O +
correlations O +
of O +
0 O +
. O +
81 O +
and O +
0 O +
. O +
86 O +
with O +
clinician O +
interviews O +
[ O +
30 O +
] O +
. O +

Correlations O +
of O +
WSAS O +
with O +
severity O +
of O +
depression O +
and O +
obsessive O +
- O +
compulsive O +
disorder O +
symptoms O +
were O +
0 O +
. O +
76 O +
and O +
0 O +
. O +
61 O +
, O +
respectively O +
, O +
and O +
the O +
scores O +
were O +
sensitive O +
to O +
patient O +
differences O +
in O +
disorder O +
severity O +
and O +
treatment O +
- O +
related O +
change O +
[ O +
30 O +
] O +
. O +

The O +
MOODS O +
- O +
SR O +
is O +
an O +
instrument O +
developed O +
and O +
validated O +
to O +
assess O +
lifetime O +
mood O +
spectrum O +
symptoms O +
[ O +
35 O +
] O +
, O +
including O +
manic O +
and O +
depressive O +
features O +
, O +
rhythmicity O +
and O +
vegetative O +
functions O +
. O +

The O +
manic O +
and O +
depressive O +
components O +
are O +
subtyped O +
into O +
mood O +
, O +
energy O +
and O +
cognition O +
domains O +
, O +
focusing O +
on O +
manic O +
or O +
depressive O +
symptoms O +
, O +
respectively O +
. O +

The O +
rhythmicity O +
and O +
vegetative O +
functions O +
domain O +
include O +
changes O +
in O +
energy O +
, O +
physical O +
wellbeing O +
, O +
mental O +
and O +
physical O +
efficiency O +
, O +
related O +
to O +
the O +
weather O +
and O +
season O +
, O +
and O +
changes O +
in O +
appetite O +
, O +
sleep O +
and O +
sexual O +
activities O +
. O +

The O +
sum O +
of O +
the O +
scores O +
on O +
the O +
3 O +
manic O +
domains O +
( O +
mood O +
, O +
energy O +
, O +
cognition O +
) O +
constitutes O +
the O +
' O +
manic O +
component O +
' O +
( O +
62 O +
items O +
) O +
and O +
that O +
of O +
the O +
3 O +
depressive O +
domains O +
the O +
' O +
depressive O +
component O +
' O +
( O +
63 O +
items O +
) O +
. O +

The O +
rhythmicity O +
and O +
vegetative O +
functions O +
domain O +
includes O +
29 O +
items O +
. O +

The O +
instrument O +
can O +
be O +
downloaded O +
from O +
http O +
: O +
/ O +
/ O +
www O +
. O +
spectrum O +
- O +
project O +
. O +
org O +
. O +

Figures O +

Fig O +
. O +

1 O +
. O +

A O +
view O +
of O +
( O +
I O +
) O +
with O +
displacement O +
ellipsoids O +
drawn O +
at O +
the O +
30 O +
% O +
probability O +
level O +
. O +

Fig O +
. O +

2 O +
. O +

Stereoview O +
of O +
the O +
sheet O +
formed O +
by O +
C O +
- O +
- O +
H O +
. O +
. O +
. O +
pi O +
interactions O +
. O +

Hydrogen O +
atoms O +
not O +
involved O +
in O +
the O +
motifs O +
are O +
not O +
included O +
. O +

Background O +

Eucalyptus O +
globulus O +
is O +
the O +
most O +
widely O +
planted O +
species O +
for O +
pulpwood O +
production O +
in O +
temperate O +
regions O +
of O +
the O +
world O +
and O +
there O +
are O +
breeding O +
programs O +
in O +
numerous O +
countries O +
. O +

There O +
is O +
interest O +
in O +
molecular O +
approaches O +
to O +
breeding O +
, O +
particularly O +
marker O +
assisted O +
selection O +
of O +
wood O +
properties O +
. O +

QTL O +
analysis O +
has O +
an O +
important O +
role O +
in O +
identifying O +
positional O +
candidate O +
genes O +
responsible O +
for O +
variation O +
in O +
wood O +
properties O +
. O +

This O +
is O +
one O +
approach O +
to O +
targeting O +
genes O +
which O +
may O +
harbour O +
functional O +
allelic O +
variants O +
( O +
SNPs O +
) O +
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
detect O +
and O +
validate O +
QTL O +
across O +
multiple O +
sites O +
and O +
pedigrees O +
, O +
in O +
order O +
to O +
identify O +
genomic O +
regions O +
and O +
genes O +
affecting O +
growth O +
and O +
wood O +
properties O +
with O +
wide O +
applicability O +
in O +
the O +
species O +
. O +

We O +
also O +
aimed O +
to O +
determine O +
the O +
proportion O +
of O +
QTL O +
which O +
were O +
stable O +
in O +
their O +
expression O +
across O +
sites O +
of O +
contrasting O +
productivity O +
. O +

Such O +
information O +
will O +
be O +
important O +
to O +
exploit O +
the O +
full O +
potential O +
of O +
the O +
impending O +
Eucalyptus O +
genome O +
sequences O +
. O +

Methods O +

We O +
studied O +
3 O +
, O +
574 O +
Canadian O +
children O +
, O +
aged O +
7 O +
- O +
8 O +
yr O +
, O +
enrolled O +
in O +
a O +
population O +
- O +
based O +
birth O +
cohort O +
. O +

Standardized O +
questionnaires O +
were O +
completed O +
by O +
the O +
children O +
' O +
s O +
parents O +
, O +
and O +
data O +
were O +
analyzed O +
by O +
multivariate O +
logistic O +
regression O +
. O +

The O +
growth O +
in O +
the O +
number O +
of O +
database O +
publications O +
per O +
year O +
. O +

Each O +
bar O +
shows O +
the O +
number O +
of O +
research O +
articles O +
with O +
the O +
keyword O +
' O +
database O +
' O +
appearing O +
in O +
the O +
article O +
title O +
in O +
the O +
given O +
year O +
. O +

The O +
count O +
only O +
covers O +
articles O +
indexed O +
in O +
PubMed O +
. O +

The O +
increase O +
shows O +
an O +
exponential O +
trend O +
that O +
will O +
produce O +
nearly O +
2000 O +
database O +
publications O +
per O +
year O +
by O +
2015 O +
. O +

( O +
iii O +
) O +
HIV O +
testing O +
response O +
rate O +
by O +
educational O +
attainment O +
and O +
gender O +
. O +

Cation O +
binding O +
to O +
yolk O +
platelet O +
phosvitin O +

In O +
addition O +
to O +
non O +
- O +
heme O +
iron O +
[ O +
23 O +
] O +
, O +
yolk O +
phosvitin O +
also O +
contains O +
Ca2 O +
+ O +
, O +
Mg2 O +
+ O +
, O +
Na O +
+ O +
and O +
K O +
+ O +
[ O +
11 O +
] O +
. O +

Partially O +
relaxed O +
23Na O +
Fourier O +
transform O +
NMR O +
spectra O +
revealed O +
the O +
existence O +
of O +
at O +
least O +
two O +
major O +
intracellular O +
compartments O +
of O +
NMR O +
- O +
visible O +
Na O +
+ O +
[ O +
35 O +
] O +
. O +

A O +
large O +
fraction O +
of O +
the O +
Rana O +
oocyte O +
Na O +
+ O +
was O +
NMR O +
- O +
invisible O +
and O +
could O +
be O +
recovered O +
in O +
the O +
yolk O +
platelets O +
[ O +
35 O +
] O +
. O +

During O +
the O +
first O +
meiotic O +
division O +
there O +
is O +
a O +
net O +
increase O +
in O +
NMR O +
- O +
visible O +
Na O +
+ O +
; O +
by O +
completion O +
of O +
the O +
second O +
meiotic O +
division O +
( O +
following O +
fertilization O +
) O +
, O +
about O +
70 O +
% O +
of O +
the O +
total O +
Na O +
+ O +
becomes O +
NMR O +
- O +
visible O +
. O +

Thus O +
, O +
phosvitin O +
not O +
only O +
serves O +
as O +
a O +
site O +
for O +
energy O +
storage O +
, O +
but O +
also O +
as O +
a O +
storage O +
site O +
for O +
iron O +
and O +
other O +
ions O +
essential O +
for O +
embryonic O +
development O +
in O +
ponds O +
and O +
streams O +
that O +
contain O +
little O +
dissolved O +
salts O +
and O +
minerals O +
. O +

Predicted O +
methylation O +
level O +
of O +
C O +
. O +
gigas O +
genes O +
categorized O +
by O +
biological O +
processes O +
compared O +
to O +
measured O +
level O +
of O +
DNA O +
methylation O +
. O +

Mean O +
CpG O +
O O +
/ O +
E O +
for O +
10 O +
, O +
699 O +
C O +
. O +
gigas O +
genes O +
categorized O +
according O +
to O +
Biological O +
Process O +
Gene O +
Ontology O +
( O +
GO O +
) O +
Slim O +
terms O +
are O +
plotted O +
on O +
the O +
x O +
- O +
axis O +
( O +
modified O +
from O +
Gavery O +
and O +
Roberts O +
, O +
2010 O +
) O +
. O +

DNA O +
methylation O +
was O +
empirically O +
measured O +
by O +
performing O +
MBD O +
- O +
seq O +
on O +
the O +
SOLiD O +
4 O +
platform O +
( O +
Applied O +
Biosystems O +
) O +
. O +

Genes O +
identified O +
in O +
the O +
MBD O +
- O +
library O +
were O +
associated O +
with O +
respective O +
GO O +
terms O +
and O +
enrichment O +
analysis O +
was O +
performed O +
based O +
on O +
the O +
entire O +
transcriptome O +
( O +
Fleury O +
et O +
al O +
. O +
, O +
2009 O +
) O +
using O +
DAVID O +
( O +
Huang O +
et O +
al O +
. O +
, O +
2009a O +
, O +
b O +
) O +
. O +

Results O +
indicate O +
the O +
most O +
underrepresented O +
genes O +
in O +
the O +
library O +
are O +
involved O +
in O +
cell O +
adhesion O +
and O +
genes O +
involved O +
in O +
DNA O +
and O +
protein O +
metabolism O +
were O +
most O +
prevalent O +
in O +
the O +
MBD O +
- O +
library O +
. O +

Methods O +

Thirteen O +
focus O +
group O +
discussions O +
with O +
first O +
- O +
time O +
parents O +
and O +
female O +
and O +
male O +
informal O +
supporters O +
were O +
analysed O +
by O +
discourse O +
analysis O +
. O +

Mitochondria O +
in O +
Cardiac O +
Myocyte O +
Apoptosis O +

It O +
has O +
been O +
suggested O +
that O +
activation O +
of O +
the O +
mitochondrial O +
apoptotic O +
pathway O +
leading O +
to O +
executioner O +
casp O +
activation O +
is O +
relevant O +
in O +
heart O +
injury O +
. O +
1 O +
The O +
notion O +
of O +
participation O +
of O +
casp O +
activation O +
in O +
adult O +
cardiac O +
myocyte O +
apoptosis O +
emerged O +
from O +
studies O +
using O +
immunofluorescence O +
microscopy16 O +
and O +
casp O +
inhibitors O +
. O +
37 O +
Bahi O +
et O +
al O +
. O +
38 O +
demonstrated O +
that O +
cardiomyocyte O +
levels O +
of O +
all O +
casps O +
decrease O +
with O +
age O +
, O +
and O +
they O +
are O +
very O +
low O +
in O +
adult O +
cardiac O +
cells O +
. O +

Recently O +
, O +
Bae O +
et O +
al O +
. O +
39 O +
reported O +
that O +
apoptosis O +
can O +
be O +
induced O +
in O +
the O +
heart O +
lacking O +
casp O +
activation O +
via O +
casp O +
- O +
independent O +
pathways O +
, O +
probably O +
through O +
apoptosis O +
- O +
inducing O +
factor O +
( O +
AIF O +
) O +
. O +

Both O +
the O +
intrinsic O +
and O +
extrinsic O +
pathways O +
can O +
be O +
inhibited O +
by O +
the O +
cytoprotective O +
protein O +
apoptosis O +
repressor O +
with O +
caspase O +
recruitment O +
domain O +
( O +
ARC O +
) O +
. O +

ARC O +
inhibits O +
the O +
extrinsic O +
pathway O +
by O +
interacting O +
with O +
casp O +
8 O +
and O +
components O +
of O +
the O +
death O +
- O +
inducing O +
signaling O +
complex O +
, O +
such O +
as O +
FADD O +
, O +
whereas O +
inhibition O +
of O +
the O +
intrinsic O +
pathway O +
is O +
mediated O +
by O +
blocking O +
BAX O +
activation O +
and O +
mitochondria O +
translocation O +
. O +
40 O +

AIF O +
is O +
anchored O +
by O +
its O +
N O +
terminus O +
to O +
the O +
mitochondrial O +
inner O +
membrane O +
, O +
with O +
its O +
C O +
terminus O +
oriented O +
toward O +
the O +
intermembrane O +
space O +
. O +

AIF O +
is O +
required O +
for O +
oxidative O +
phosphorylation O +
and O +
for O +
the O +
assembly O +
and O +
/ O +
or O +
stabilization O +
of O +
respiratory O +
complex O +
I O +
. O +
41 O +
Upon O +
induction O +
of O +
apoptosis O +
, O +
AIF O +
is O +
cleaved O +
and O +
released O +
into O +
the O +
cytosol O +
, O +
where O +
it O +
translocates O +
to O +
the O +
nucleus O +
and O +
mediates O +
chromatin O +
condensation O +
and O +
large O +
- O +
scale O +
DNA O +
fragmentation O +
. O +
41 O +
However O +
, O +
this O +
well O +
- O +
known O +
pro O +
- O +
apoptotic O +
action O +
of O +
AIF O +
is O +
in O +
conflict O +
with O +
the O +
observation O +
that O +
AIF O +
is O +
essential O +
for O +
the O +
maintenance O +
of O +
normal O +
heart O +
function O +
and O +
its O +
inactivation O +
results O +
in O +
dilated O +
C O +
. O +
42 O +
Moreover O +
, O +
cardiac O +
myocytes O +
isolated O +
from O +
a O +
mouse O +
model O +
with O +
80 O +
% O +
reduction O +
in O +
AIF O +
levels O +
manifested O +
increased O +
cell O +
death O +
induced O +
by O +
oxidative O +
stress O +
, O +
and O +
the O +
hearts O +
of O +
these O +
mice O +
displayed O +
enhanced O +
ischemic O +
damage O +
after O +
in O +
vivo O +
I O +
/ O +
R O +
. O +
43 O +
Although O +
it O +
has O +
been O +
described O +
that O +
AIF O +
is O +
released O +
from O +
cardiac O +
myocyte O +
mitochondria O +
during O +
I O +
/ O +
R O +
, O +
its O +
contribution O +
to O +
I O +
/ O +
R O +
- O +
induced O +
apoptosis O +
was O +
discounted O +
. O +
38 O +
However O +
, O +
AIF O +
has O +
been O +
implicated O +
in O +
cardiac O +
myocyte O +
death O +
induced O +
by O +
oxidative O +
stress O +
and O +
HF O +
. O +
44 O +

Endonuclease O +
G O +
( O +
Endo O +
G O +
) O +
is O +
a O +
nuclear O +
- O +
encoded O +
endonuclease O +
localized O +
to O +
the O +
intermembrane O +
space O +
of O +
mitochondria O +
. O +

In O +
cardiac O +
myocyte O +
apoptosis O +
, O +
Endo O +
G O +
translocates O +
to O +
the O +
nucleus O +
, O +
where O +
it O +
cleaves O +
DNA O +
. O +

In O +
heart O +
and O +
cultured O +
cardiac O +
myocytes O +
, O +
Endo O +
G O +
has O +
a O +
role O +
in O +
I O +
/ O +
R O +
- O +
mediated O +
cell O +
death O +
. O +
38 O +
Activation O +
of O +
the O +
intrinsic O +
pathway O +
by O +
the O +
extrinsic O +
apoptotic O +
pathway O +
can O +
take O +
place O +
through O +
casp O +
- O +
8 O +
- O +
dependent O +
cleavage O +
of O +
BCL2 O +
- O +
interacting O +
protein O +
( O +
BID O +
) O +
to O +
truncated O +
BID O +
( O +
t O +
- O +
BID O +
) O +
. O +

The O +
C O +
- O +
terminal O +
fragment O +
of O +
t O +
- O +
BID O +
subsequently O +
translocates O +
to O +
the O +
mitochondrial O +
outer O +
membrane O +
, O +
where O +
it O +
presumably O +
activates O +
the O +
intrinsic O +
pathway O +
. O +

This O +
pathway O +
is O +
operative O +
in O +
the O +
heart O +
. O +
1 O +

Discussion O +

We O +
estimated O +
the O +
future O +
acceptability O +
of O +
PrEP O +
, O +
examining O +
the O +
attitudes O +
and O +
preferences O +
of O +
potential O +
user O +
groups O +
from O +
different O +
countries O +
towards O +
hypothetical O +
and O +
known O +
PrEP O +
attributes O +
. O +

Our O +
results O +
show O +
that O +
participants O +
were O +
generally O +
willing O +
to O +
accept O +
PrEP O +
and O +
adopt O +
it O +
as O +
soon O +
as O +
it O +
becomes O +
available O +
. O +

Surprisingly O +
, O +
participants O +
were O +
also O +
willing O +
to O +
take O +
PrEP O +
even O +
when O +
reminded O +
of O +
potential O +
side O +
effects O +
, O +
cost O +
, O +
condom O +
use O +
, O +
and O +
frequent O +
HIV O +
testing O +
. O +

These O +
findings O +
indicate O +
participants O +
' O +
motivation O +
to O +
overcome O +
barriers O +
which O +
can O +
have O +
a O +
considerable O +
impact O +
on O +
uptake O +
. O +

In O +
contrast O +
, O +
participants O +
mentioned O +
that O +
the O +
thought O +
of O +
taking O +
PrEP O +
made O +
them O +
feel O +
anxious O +
, O +
although O +
they O +
also O +
indicated O +
that O +
taking O +
PrEP O +
would O +
not O +
be O +
embarrassing O +
and O +
they O +
would O +
want O +
their O +
partner O +
or O +
partners O +
to O +
know O +
. O +

Participants O +
' O +
anxiety O +
may O +
be O +
explained O +
by O +
the O +
hypothetical O +
nature O +
of O +
most O +
of O +
the O +
presented O +
PrEP O +
characteristics O +
, O +
the O +
stigma O +
associated O +
with O +
HIV O +
[ O +
34 O +
] O +
, O +
and O +
in O +
some O +
settings O +
, O +
the O +
criminalization O +
of O +
sex O +
work O +
, O +
injected O +
drug O +
use O +
and O +
homosexuality O +
[ O +
35 O +
] O +
. O +

Most O +
participants O +
, O +
nonetheless O +
, O +
subsequently O +
indicated O +
that O +
PrEP O +
would O +
give O +
them O +
hope O +
, O +
which O +
suggests O +
that O +
their O +
initial O +
willingness O +
to O +
take O +
it O +
remained O +
largely O +
unscathed O +
. O +

Female O +
participants O +
indicated O +
a O +
higher O +
level O +
of O +
willingness O +
to O +
take O +
PrEP O +
than O +
male O +
participants O +
, O +
which O +
may O +
be O +
explained O +
by O +
women O +
' O +
s O +
difficulty O +
negotiating O +
the O +
use O +
of O +
condoms O +
and O +
awareness O +
of O +
their O +
and O +
/ O +
or O +
their O +
partners O +
' O +
risk O +
of O +
becoming O +
infected O +
with O +
HIV O +
[ O +
36 O +
] O +
. O +

We O +
also O +
found O +
that O +
younger O +
participants O +
and O +
those O +
with O +
fewer O +
children O +
, O +
those O +
who O +
reported O +
adherence O +
to O +
past O +
medication O +
, O +
more O +
frequent O +
condom O +
usage O +
, O +
having O +
been O +
tested O +
for O +
HIV O +
in O +
the O +
past O +
and O +
never O +
injecting O +
drugs O +
, O +
reported O +
greater O +
willingness O +
to O +
take O +
PrEP O +
. O +

These O +
promising O +
findings O +
suggest O +
that O +
those O +
who O +
are O +
currently O +
bearing O +
the O +
brunt O +
of O +
HIV O +
[ O +
1 O +
] O +
, O +
have O +
higher O +
perceived O +
risk O +
, O +
and O +
are O +
most O +
likely O +
to O +
adhere O +
to O +
a O +
comprehensive O +
PrEP O +
program O +
, O +
are O +
also O +
the O +
most O +
motivated O +
to O +
enroll O +
. O +

Yet O +
, O +
while O +
participants O +
stated O +
not O +
being O +
interested O +
in O +
selling O +
PrEP O +
, O +
the O +
majority O +
reported O +
intentions O +
to O +
share O +
it O +
. O +

Therefore O +
, O +
information O +
and O +
counseling O +
about O +
the O +
risks O +
of O +
sharing O +
PrEP O +
should O +
be O +
readily O +
available O +
as O +
part O +
of O +
any O +
implementation O +
program O +
. O +

Results O +
from O +
the O +
conjoint O +
analysis O +
reveal O +
trends O +
in O +
participants O +
' O +
preferences O +
which O +
deserve O +
consideration O +
. O +

PrEP O +
route O +
of O +
administration O +
was O +
the O +
most O +
important O +
attribute O +
, O +
and O +
bi O +
- O +
monthly O +
and O +
monthly O +
injections O +
were O +
the O +
preferred O +
alternatives O +
. O +

This O +
finding O +
is O +
encouraging O +
from O +
a O +
policy O +
perspective O +
if O +
such O +
modalities O +
become O +
available O +
; O +
since O +
it O +
may O +
reduce O +
users O +
' O +
likelihood O +
of O +
sharing O +
, O +
selling O +
or O +
forgetting O +
to O +
take O +
PrEP O +
, O +
but O +
it O +
also O +
raises O +
questions O +
regarding O +
participants O +
' O +
willingness O +
to O +
take O +
oral O +
PrEP O +
. O +

HIV O +
testing O +
was O +
the O +
second O +
most O +
important O +
attribute O +
, O +
and O +
a O +
test O +
every O +
six O +
months O +
was O +
, O +
as O +
expected O +
, O +
the O +
preferred O +
alternative O +
. O +

Interestingly O +
, O +
dispensing O +
sites O +
were O +
more O +
important O +
than O +
any O +
other O +
attribute O +
for O +
some O +
groups O +
, O +
particularly O +
in O +
Africa O +
. O +

This O +
may O +
indicate O +
concerns O +
about O +
social O +
stigma O +
and O +
access O +
[ O +
37 O +
] O +
. O +

However O +
, O +
it O +
is O +
encouraging O +
that O +
most O +
participants O +
were O +
willing O +
to O +
receive O +
PrEP O +
at O +
a O +
healthcare O +
facility O +
, O +
which O +
can O +
facilitate O +
synergies O +
between O +
PrEP O +
and O +
other O +
existing O +
prevention O +
services O +
. O +

Time O +
spent O +
obtaining O +
PrEP O +
and O +
frequency O +
of O +
pick O +
up O +
, O +
which O +
we O +
used O +
as O +
a O +
proxy O +
measure O +
for O +
cost O +
- O +
opportunity O +
, O +
were O +
generally O +
less O +
important O +
, O +
consistent O +
with O +
participants O +
' O +
willingness O +
to O +
pay O +
for O +
PrEP O +
. O +

Our O +
findings O +
are O +
broadly O +
consistent O +
with O +
the O +
work O +
of O +
Guest O +
et O +
al O +
. O +
and O +
Galea O +
et O +
al O +
[ O +
18 O +
] O +
, O +
[ O +
19 O +
] O +
. O +

However O +
, O +
specific O +
comparisons O +
are O +
not O +
advisable O +
as O +
the O +
composition O +
and O +
size O +
of O +
the O +
samples O +
, O +
recruitment O +
methods O +
, O +
measures O +
and O +
statistical O +
analyses O +
differ O +
greatly O +
. O +

Previous O +
work O +
on O +
PrEP O +
implementation O +
suggests O +
that O +
delivery O +
programs O +
will O +
need O +
to O +
meet O +
a O +
number O +
of O +
requirements O +
in O +
order O +
to O +
be O +
effective O +
, O +
including O +
: O +
prioritization O +
of O +
groups O +
at O +
higher O +
risk O +
of O +
infection O +
; O +
delivery O +
of O +
PrEP O +
in O +
combination O +
with O +
other O +
prevention O +
services O +
, O +
including O +
risk O +
reduction O +
and O +
medication O +
adherence O +
counseling O +
, O +
condoms O +
provision O +
, O +
diagnosis O +
and O +
treatment O +
of O +
other O +
sexually O +
transmitted O +
infections O +
, O +
and O +
frequent O +
HIV O +
testing O +
; O +
and O +
monitoring O +
of O +
side O +
effects O +
, O +
adherence O +
and O +
risk O +
behaviors O +
[ O +
8 O +
] O +
, O +
[ O +
38 O +
] O +
, O +
[ O +
39 O +
] O +
, O +
[ O +
40 O +
] O +
, O +
[ O +
41 O +
] O +
, O +
[ O +
42 O +
] O +
. O +

Our O +
results O +
provide O +
valuable O +
clues O +
that O +
can O +
help O +
countries O +
to O +
deliver O +
PrEP O +
more O +
effectively O +
, O +
should O +
they O +
decide O +
to O +
implement O +
it O +
, O +
by O +
focusing O +
their O +
efforts O +
on O +
the O +
aspects O +
that O +
need O +
more O +
attention O +
. O +

This O +
is O +
the O +
first O +
multinational O +
study O +
, O +
to O +
our O +
knowledge O +
, O +
that O +
integrates O +
different O +
disciplines O +
to O +
shed O +
light O +
on O +
a O +
question O +
that O +
we O +
believe O +
is O +
of O +
global O +
importance O +
. O +

Our O +
study O +
complements O +
previous O +
work O +
on O +
PrEP O +
by O +
examining O +
potential O +
users O +
' O +
perspective O +
and O +
offering O +
insights O +
into O +
their O +
attitudes O +
and O +
preferences O +
. O +

We O +
note O +
that O +
it O +
may O +
not O +
be O +
possible O +
to O +
generalize O +
the O +
observed O +
PrEP O +
acceptability O +
to O +
other O +
settings O +
and O +
our O +
results O +
should O +
be O +
considered O +
within O +
the O +
context O +
of O +
this O +
study O +
' O +
s O +
limitations O +
. O +

Given O +
the O +
sensitive O +
nature O +
of O +
the O +
addressed O +
questions O +
, O +
and O +
despite O +
all O +
our O +
efforts O +
to O +
reduce O +
social O +
desirability O +
bias O +
, O +
there O +
is O +
an O +
unavoidable O +
risk O +
that O +
participants O +
may O +
have O +
felt O +
at O +
times O +
compelled O +
to O +
provide O +
what O +
they O +
felt O +
was O +
the O +
" O +
right O +
" O +
answer O +
. O +

Additionally O +
, O +
our O +
data O +
collection O +
took O +
place O +
in O +
urban O +
areas O +
, O +
where O +
HIV O +
incidence O +
is O +
normally O +
higher O +
, O +
thus O +
current O +
findings O +
may O +
not O +
be O +
generalizable O +
to O +
rural O +
settings O +
. O +

Finally O +
, O +
examining O +
acceptability O +
among O +
users O +
enrolled O +
in O +
pilot O +
programs O +
is O +
much O +
deserving O +
, O +
as O +
actual O +
acceptability O +
may O +
differ O +
from O +
potential O +
willingness O +
to O +
take O +
PrEP O +
, O +
especially O +
if O +
relevant O +
attributes O +
of O +
a O +
product O +
or O +
program O +
are O +
modified O +
, O +
as O +
observed O +
in O +
other O +
comparable O +
interventions O +
[ O +
43 O +
] O +
. O +

Origins O +
of O +
Acquired O +
Antibiotic O +
Resistance O +
Mechanisms O +

Recently O +
, O +
D O +
' O +
Costa O +
et O +
al O +
. O +

( O +
2011 O +
) O +
have O +
reported O +
a O +
metagenomic O +
analysis O +
of O +
the O +
Beringian O +
permafrost O +
, O +
which O +
is O +
30 O +
, O +
000 O +
years O +
old O +
. O +

They O +
showed O +
molecular O +
evidences O +
of O +
the O +
ancient O +
origins O +
of O +
antibiotic O +
resistances O +
, O +
detecting O +
beta O +
- O +
lactamases O +
genes O +
, O +
vanX O +
- O +
like O +
, O +
component O +
of O +
the O +
vancomycin O +
resistance O +
operon O +
, O +
and O +
tetM O +
, O +
coding O +
for O +
a O +
protein O +
protecting O +
the O +
ribosomal O +
target O +
from O +
tetracycline O +
. O +

Sequence O +
analysis O +
revealed O +
that O +
the O +
beta O +
- O +
lactamases O +
genes O +
recovered O +
from O +
the O +
permafrost O +
demonstrated O +
an O +
amino O +
- O +
acid O +
homology O +
( O +
53 O +
- O +
84 O +
% O +
) O +
to O +
known O +
beta O +
- O +
lactamases O +
from O +
beta O +
- O +
lactams O +
producing O +
Streptomyces O +
. O +

The O +
tetM O +
sequences O +
revealed O +
a O +
high O +
similarity O +
to O +
the O +
genes O +
coding O +
for O +
the O +
ribosomal O +
protection O +
protein O +
of O +
actinomycetes O +
. O +

The O +
vanX O +
sequence O +
showed O +
a O +
similarity O +
to O +
the O +
vanX O +
gene O +
recovered O +
in O +
pathogenic O +
vancomycin O +
resistant O +
enterococci O +
( O +
VRE O +
) O +
and O +
to O +
the O +
vanX O +
gene O +
from O +
Amycolatopsis O +
orientalis O +
. O +

This O +
environmental O +
species O +
, O +
belonging O +
to O +
the O +
actinobacteria O +
phylum O +
, O +
is O +
a O +
natural O +
producer O +
of O +
vancomycin O +
, O +
and O +
very O +
likely O +
the O +
progenitor O +
of O +
the O +
van O +
genes O +
operons O +
, O +
responsible O +
for O +
resistance O +
to O +
vancomycin O +
. O +

The O +
integration O +
of O +
the O +
van O +
operons O +
on O +
transposons O +
and O +
on O +
conjugative O +
plasmids O +
has O +
enhanced O +
their O +
spread O +
( O +
Courvalin O +
, O +
2006 O +
) O +
. O +

Reports O +
of O +
VRE O +
in O +
freshwater O +
have O +
been O +
provided O +
by O +
several O +
authors O +
( O +
Talebi O +
et O +
al O +
. O +
, O +
2008 O +
; O +
Lata O +
et O +
al O +
. O +
, O +
2009 O +
; O +
Luczkiewicz O +
et O +
al O +
. O +
, O +
2010 O +
) O +
. O +

Interestingly O +
, O +
Schwartz O +
et O +
al O +
. O +

( O +
2003 O +
) O +
detected O +
vanA O +
genes O +
in O +
the O +
biofilm O +
of O +
drinking O +
water O +
supplies O +
, O +
in O +
the O +
absence O +
of O +
enterococci O +
, O +
demonstrating O +
the O +
lateral O +
transfer O +
of O +
this O +
gene O +
. O +

Notably O +
, O +
the O +
progenitors O +
of O +
these O +
resistance O +
genes O +
are O +
soil O +
bacteria O +
thus O +
most O +
likely O +
, O +
a O +
shuttle O +
has O +
been O +
responsible O +
for O +
the O +
introduction O +
of O +
these O +
genes O +
into O +
the O +
commensal O +
bacterial O +
community O +
and O +
afterward O +
into O +
the O +
pathogenic O +
species O +
. O +

Results O +

Supplementary O +
Material O +

Crystal O +
structure O +
: O +
contains O +
datablock O +
( O +
s O +
) O +
global O +
, O +
I O +
. O +

DOI O +
: O +
10 O +
. O +
1107 O +
/ O +
S1600536812002796 O +
/ O +
hg5166sup1 O +
. O +
cif O +

Structure O +
factors O +
: O +
contains O +
datablock O +
( O +
s O +
) O +
I O +
. O +

DOI O +
: O +
10 O +
. O +
1107 O +
/ O +
S1600536812002796 O +
/ O +
hg5166Isup2 O +
. O +
hkl O +

Additional O +
supplementary O +
materials O +
: O +
crystallographic O +
information O +
; O +
3D O +
view O +
; O +
checkCIF O +
report O +

Relative O +
phage O +
haplotype O +
frequencies O +
in O +
PAO1 O +
samples O +
, O +
( O +
A O +
) O +
planktonic O +
, O +
( O +
B O +
) O +
biofilm O +
4 O +
days O +
, O +
( O +
C O +
) O +
biofilm O +
11 O +
days O +
. O +

Collaxa O +
BPEL O +
Server O +
Screenshot O +
of O +
Collaxa O +
' O +
s O +
bpelz O +
design O +
tool O +
, O +
building O +
a O +
choreography O +
of O +
GetHAPI O +
and O +
GetUMLS O +
web O +
services O +

Abbreviations O +

Ac O +
- O +
DEVD O +
- O +
AMC O +
= O +
N O +
- O +
acetyl O +
- O +
Asp O +
- O +
Glu O +
- O +
Val O +
- O +
Asp O +
- O +
7 O +
- O +
amino O +
- O +
4 O +
- O +
methylcoumarin O +
; O +
Ac O +
- O +
DEVD O +
- O +
CHO O +
= O +
N O +
- O +
acetyl O +
- O +
Asp O +
- O +
Glu O +
- O +
Val O +
- O +
Asp O +
- O +
aldehyde O +
; O +
COX O +
= O +
cyclooxygenase O +
; O +
Deltapsim O +
= O +
mitochondrial O +
membrane O +
potential O +
; O +
DAPI O +
= O +
4 O +
' O +
, O +
6 O +
- O +
diamidino O +
- O +
2 O +
- O +
phenylindole O +
; O +
DMEM O +
= O +
Dulbecco O +
' O +
s O +
modified O +
Eagle O +
' O +
s O +
medium O +
; O +
ELISA O +
= O +
enzyme O +
- O +
linked O +
immunosorbent O +
assay O +
; O +
FCS O +
= O +
fetal O +
calf O +
serum O +
; O +
FLS O +
= O +
fibroblast O +
- O +
like O +
synoviocytes O +
; O +
IL O +
= O +
interleukin O +
; O +
JC O +
- O +
1 O +
= O +
5 O +
, O +
5 O +
' O +
, O +
6 O +
, O +
6 O +
' O +
- O +
tetrachloro O +
- O +
1 O +
, O +
1 O +
' O +
, O +
3 O +
, O +
3 O +
' O +
- O +
tetraethylbenzimidazole O +
carbocyanide O +
iodide O +
; O +
MTT O +
= O +
3 O +
- O +
( O +
4 O +
, O +
5 O +
- O +
dimethylthiazol O +
- O +
2 O +
- O +
yl O +
) O +
- O +
2 O +
, O +
5 O +
- O +
diphenyltetrazolium O +
bromide O +
; O +
PBS O +
= O +
phosphate O +
- O +
buffered O +
saline O +
; O +
PGE2 O +
= O +
prostaglandin O +
E2 O +
; O +
RA O +
= O +
rheumatoid O +
arthritis O +
. O +

Results O +

Authors O +
' O +
contributions O +

FR O +
initiated O +
and O +
designed O +
the O +
research O +
, O +
collected O +
and O +
analyzed O +
the O +
data O +
and O +
wrote O +
the O +
paper O +
. O +

FO O +
was O +
the O +
main O +
supervisor O +
, O +
helped O +
in O +
analysis O +
, O +
and O +
revised O +
and O +
edited O +
the O +
drafts O +
. O +

MN O +
was O +
co O +
- O +
supervisor O +
and O +
revised O +
the O +
drafts O +
. O +

Conclusion O +

Artificial O +
addition O +
of O +
siderophores O +
and O +
HSLs O +
may O +
be O +
a O +
possible O +
method O +
to O +
aid O +
in O +
the O +
identification O +
and O +
isolation O +
of O +
marine O +
bacterial O +
species O +
which O +
are O +
thought O +
to O +
be O +
unknown O +
. O +

Ventricular O +
fibrillation O +
due O +
to O +
long O +
QT O +
syndrome O +
probably O +
caused O +
by O +
clindamycin O +
. O +

Prolongation O +
of O +
QT O +
time O +
interval O +
may O +
be O +
provoked O +
by O +
a O +
limited O +
number O +
of O +
drugs O +
, O +
especially O +
macrolide O +
antibiotics O +
. O +

We O +
describe O +
a O +
case O +
of O +
QT O +
time O +
interval O +
prolongation O +
induced O +
by O +
clindamycin O +
with O +
subsequent O +
repeated O +
ventricular O +
fibrillation O +
and O +
resuscitation O +
; O +
there O +
is O +
no O +
previous O +
report O +
in O +
the O +
literature O +
of O +
QT O +
time O +
prolongation O +
caused O +
by O +
lincosamides O +
. O +

[ O +
Epidemiology O +
of O +
respiratory O +
allergy O +
in O +
children O +
] O +
. O +

Epidemiology O +
of O +
paediatric O +
respiratory O +
allergic O +
disorders O +
allows O +
the O +
approach O +
to O +
causal O +
and O +
preventive O +
risk O +
factors O +
by O +
studying O +
groups O +
or O +
sub O +
groups O +
of O +
children O +
in O +
different O +
locations O +
and O +
under O +
different O +
conditions O +
. O +

This O +
is O +
, O +
however O +
, O +
complicated O +
by O +
the O +
lack O +
of O +
consensus O +
on O +
disease O +
definitions O +
, O +
which O +
renders O +
comparisons O +
between O +
studies O +
difficult O +
. O +

Atopy O +
is O +
usually O +
defined O +
by O +
the O +
presence O +
of O +
positive O +
skin O +
tests O +
( O +
wheal O +
size O +
of O +
at O +
least O +
a O +
mean O +
diameter O +
> O +
or O +
= O +
3 O +
mm O +
) O +
, O +
by O +
the O +
presence O +
of O +
specific O +
IgE O +
, O +
or O +
by O +
the O +
presence O +
of O +
increased O +
total O +
IgE O +
( O +
> O +
or O +
= O +
100 O +
UI O +
/ O +
mL O +
) O +
. O +

Infantile O +
asthma O +
is O +
not O +
well O +
defined O +
, O +
complicated O +
by O +
the O +
high O +
prevalence O +
of O +
bronchiolitis O +
; O +
one O +
thus O +
questions O +
between O +
wheezing O +
or O +
wheezy O +
bronchitis O +
. O +

Prevalence O +
is O +
high O +
: O +
among O +
early O +
wheezers O +
, O +
two O +
populations O +
will O +
be O +
defined O +
by O +
the O +
medium O +
term O +
evolution O +
: O +
transient O +
wheezers O +
and O +
persistent O +
wheezers O +
. O +

Risk O +
factors O +
for O +
these O +
two O +
conditions O +
are O +
different O +
. O +

Childhood O +
asthma O +
may O +
be O +
defined O +
by O +
the O +
diagnosis O +
of O +
asthma O +
( O +
specific O +
but O +
fairly O +
non O +
- O +
sensitive O +
) O +
, O +
by O +
asthmatic O +
symptoms O +
( O +
wheezing O +
, O +
waking O +
by O +
an O +
attack O +
of O +
shortness O +
of O +
breath O +
) O +
( O +
sensitive O +
but O +
not O +
very O +
specific O +
) O +
, O +
or O +
by O +
the O +
combination O +
of O +
symptoms O +
and O +
airway O +
hyperresponsiveness O +
. O +

The O +
ISAAC O +
study O +
has O +
standardised O +
a O +
questionnaire O +
to O +
assess O +
the O +
prevalence O +
of O +
asthma O +
. O +

The O +
preliminary O +
results O +
show O +
that O +
there O +
are O +
wide O +
variations O +
across O +
the O +
world O +
. O +

The O +
prevalence O +
is O +
low O +
in O +
Africa O +
and O +
Asia O +
, O +
intermediate O +
in O +
Europe O +
, O +
and O +
high O +
in O +
Anglo O +
- O +
Saxon O +
countries O +
. O +

The O +
prevalence O +
of O +
asthma O +
has O +
gradually O +
increased O +
over O +
the O +
past O +
20 O +
years O +
in O +
developed O +
countries O +
. O +

Asthma O +
and O +
atopy O +
are O +
closely O +
associated O +
in O +
children O +
. O +

Risk O +
factors O +
are O +
genetic O +
, O +
associated O +
with O +
sex O +
and O +
environmental O +
factors O +
. O +

Among O +
these O +
, O +
allergic O +
sensitisation O +
is O +
associated O +
with O +
the O +
degree O +
of O +
exposure O +
to O +
allergens O +
. O +

Westernization O +
of O +
way O +
of O +
life O +
is O +
associated O +
with O +
increased O +
prevalence O +
of O +
atopy O +
, O +
allergic O +
rhinitis O +
and O +
asthma O +
. O +

Atopy O +
seems O +
inversely O +
correlated O +
to O +
certain O +
infections O +
. O +

Passive O +
smoking O +
is O +
clearly O +
associated O +
with O +
early O +
wheezing O +
. O +

This O +
and O +
atmospheric O +
pollution O +
aggravate O +
childhood O +
asthma O +
. O +

However O +
, O +
the O +
inducing O +
role O +
of O +
pollution O +
on O +
asthma O +
is O +
still O +
controversial O +
. O +

The O +
TGF O +
- O +
beta O +
type O +
II O +
receptor O +
in O +
chronic O +
myeloid O +
leukemia O +
: O +
analysis O +
of O +
microsatellite O +
regions O +
and O +
gene O +
expression O +
. O +

Genomic O +
instability O +
is O +
one O +
mechanism O +
proposed O +
to O +
play O +
a O +
role O +
in O +
the O +
disease O +
progression O +
of O +
chronic O +
myeloid O +
leukemia O +
( O +
CML O +
) O +
. O +

Microsatellite O +
regions O +
in O +
the O +
type O +
II O +
transforming O +
growth O +
factor O +
- O +
beta O +
receptor O +
( O +
TGF O +
- O +
beta O +
RII O +
) O +
gene O +
appear O +
to O +
be O +
targets O +
for O +
mutation O +
in O +
some O +
cancers O +
displaying O +
microsatellite O +
instability O +
( O +
replication O +
error O +
phenotype O +
, O +
RER O +
+ O +
) O +
. O +

Furthermore O +
, O +
TGF O +
- O +
beta O +
RII O +
mutations O +
in O +
RER O +
+ O +
tumors O +
have O +
been O +
associated O +
with O +
decreased O +
TGF O +
- O +
beta O +
RII O +
mRNA O +
levels O +
. O +

As O +
TGF O +
- O +
beta O +
is O +
a O +
potent O +
negative O +
growth O +
regulator O +
of O +
hematopoietic O +
cells O +
, O +
investigations O +
were O +
undertaken O +
to O +
determine O +
whether O +
inactivation O +
of O +
the O +
receptor O +
by O +
microsatellite O +
alteration O +
might O +
be O +
involved O +
in O +
the O +
progression O +
of O +
CML O +
. O +

Analysis O +
of O +
TGF O +
- O +
beta O +
RII O +
mRNA O +
expression O +
by O +
RNase O +
protection O +
, O +
with O +
comparison O +
of O +
cells O +
from O +
the O +
chronic O +
, O +
accelerated O +
and O +
blast O +
phases O +
of O +
CML O +
, O +
showed O +
no O +
change O +
in O +
TGF O +
- O +
beta O +
RII O +
transcript O +
levels O +
during O +
disease O +
progression O +
. O +

However O +
, O +
during O +
each O +
phase O +
of O +
the O +
disease O +
, O +
low O +
levels O +
of O +
TGF O +
- O +
beta O +
RII O +
were O +
detected O +
when O +
compared O +
with O +
the O +
hematopoietic O +
cells O +
of O +
normal O +
donors O +
. O +

Furthermore O +
, O +
this O +
decreased O +
expression O +
was O +
also O +
observed O +
in O +
the O +
other O +
myeloproliferative O +
disorders O +
, O +
polycythemia O +
rubra O +
vera O +
( O +
PRV O +
) O +
and O +
essential O +
thrombocythemia O +
( O +
ET O +
) O +
. O +

The O +
leukemia O +
cell O +
lines O +
K562 B-CellLine +
and O +
HL B-CellLine +
- I-CellLine +
60 I-CellLine +
had O +
no O +
detectable O +
TGF O +
- O +
beta O +
RII O +
mRNA O +
. O +

Two O +
microsatellite O +
regions O +
found O +
altered O +
in O +
RER O +
+ O +
colon O +
cancers O +
were O +
analyzed O +
to O +
establish O +
if O +
these O +
sequences O +
were O +
aberrant O +
in O +
CML O +
. O +

No O +
alteration O +
was O +
detected O +
in O +
either O +
of O +
these O +
regions O +
in O +
any O +
phase O +
of O +
the O +
disease O +
. O +

These O +
results O +
suggest O +
that O +
alterations O +
of O +
the O +
microsatellite O +
regions O +
in O +
the O +
TGF O +
- O +
beta O +
RII O +
gene O +
are O +
not O +
involved O +
in O +
the O +
progression O +
of O +
CML O +
. O +

Decreased O +
expression O +
of O +
TGF O +
- O +
beta O +
RII O +
in O +
CML O +
cells O +
and O +
leukemia O +
cell O +
lines O +
raises O +
the O +
possibility O +
that O +
altered O +
expression O +
of O +
the O +
receptor O +
may O +
play O +
a O +
role O +
in O +
the O +
initiation O +
and O +
/ O +
or O +
maintenance O +
of O +
the O +
disease O +
state O +
. O +

N O +
- O +
glycosylation O +
of O +
glucose O +
transporter O +
- O +
1 O +
( O +
Glut O +
- O +
1 O +
) O +
is O +
associated O +
with O +
increased O +
transporter O +
affinity O +
for O +
glucose O +
in O +
human O +
leukemic O +
cells O +
. O +

To O +
elucidate O +
the O +
role O +
of O +
N O +
- O +
glycosylation O +
in O +
the O +
functional O +
activity O +
of O +
the O +
universal O +
glucose O +
transporter O +
, O +
Glut O +
- O +
1 O +
, O +
we O +
investigated O +
effects O +
of O +
the O +
N O +
- O +
glycosylation O +
inhibitor O +
, O +
tunicamycin O +
, O +
on O +
glucose O +
transport O +
by O +
human O +
leukemic O +
cell O +
lines O +
K562 B-CellLine +
, O +
U937 B-CellLine +
and O +
HL60 B-CellLine +
. O +

Treatment O +
with O +
tunicamycin O +
produced O +
a O +
40 O +
- O +
50 O +
% O +
inhibition O +
of O +
2 O +
- O +
deoxyglucose O +
uptake O +
and O +
this O +
was O +
associated O +
with O +
a O +
2 O +
- O +
2 O +
. O +
5 O +
- O +
fold O +
decrease O +
in O +
transporter O +
affinity O +
for O +
glucose O +
( O +
Km O +
) O +
without O +
a O +
change O +
in O +
Vmax O +
. O +

Leukemic O +
K562 B-CellLine +
, O +
U937 B-CellLine +
and O +
HL60 B-CellLine +
cells O +
expressed O +
Glut O +
- O +
1 O +
transporter O +
protein O +
. O +

With O +
K562 B-CellLine +
cells O +
Glut O +
- O +
1 O +
appeared O +
as O +
a O +
broad O +
band O +
of O +
50 O +
- O +
60 O +
kDa O +
, O +
whereas O +
with O +
U937 B-CellLine +
and O +
HL60 B-CellLine +
cells O +
a O +
diffuse O +
band O +
was O +
observed O +
at O +
approximately O +
55 O +
kDa O +
. O +

Treatment O +
of O +
K562 B-CellLine +
cells O +
with O +
tunicamycin O +
for O +
18 O +
h O +
, O +
resulted O +
in O +
extensive O +
loss O +
of O +
the O +
50 O +
- O +
60 O +
kDa O +
glycoprotein O +
, O +
appearance O +
of O +
a O +
30 O +
- O +
40 O +
kDa O +
band O +
and O +
increased O +
staining O +
of O +
a O +
45 O +
kDa O +
band O +
. O +

With O +
U937 B-CellLine +
cells O +
, O +
tunicamycin O +
treatment O +
resulted O +
in O +
the O +
appearance O +
of O +
a O +
30 O +
- O +
40 O +
kDa O +
band O +
and O +
increased O +
staining O +
of O +
a O +
45 O +
kDa O +
band O +
. O +

With O +
HL60 B-CellLine +
cells O +
loss O +
of O +
the O +
55 O +
kDa O +
Glut O +
- O +
1 O +
band O +
was O +
observed O +
and O +
a O +
band O +
of O +
45 O +
kDa O +
appeared O +
. O +

Tunicamycin O +
- O +
treatment O +
resulted O +
in O +
75 O +
- O +
90 O +
% O +
inhibition O +
in O +
[ O +
3H O +
] O +
mannose O +
incorporation O +
but O +
only O +
20 O +
- O +
25 O +
% O +
inhibition O +
in O +
[ O +
3H O +
] O +
thymidine O +
and O +
[ O +
3H O +
] O +
leucine O +
incorporation O +
. O +

In O +
contrast O +
, O +
tunicamycin O +
had O +
little O +
effect O +
on O +
the O +
viability O +
and O +
MTT O +
responses O +
of O +
the O +
cells O +
used O +
. O +

These O +
results O +
suggest O +
that O +
in O +
leukemic O +
cells O +
N O +
- O +
glycosylation O +
of O +
Glut O +
- O +
1 O +
plays O +
an O +
important O +
role O +
in O +
maintaining O +
its O +
structure O +
and O +
functional O +
integration O +
. O +

Decontamination O +
of O +
medical O +
equipment O +
- O +
- O +
manufacturer O +
' O +
s O +
problems O +
. O +

1 O +
. O +

Small O +
items O +
sent O +
via O +
the O +
post O +
present O +
a O +
much O +
greater O +
hidden O +
hazard O +
and O +
a O +
higher O +
potential O +
for O +
catching O +
people O +
unawares O +
. O +

2 O +
. O +

Large O +
items O +
accompanied O +
by O +
a O +
Decontamination O +
Certificate O +
need O +
to O +
be O +
treated O +
with O +
caution O +
because O +
only O +
those O +
surfaces O +
which O +
are O +
accessible O +
will O +
have O +
been O +
cleaned O +
; O +
as O +
soon O +
as O +
engineers O +
start O +
dismantling O +
equipment O +
, O +
areas O +
which O +
are O +
still O +
soiled O +
become O +
exposed O +
. O +

3 O +
. O +

Total O +
co O +
- O +
operation O +
between O +
hospital O +
staff O +
and O +
service O +
engineers O +
is O +
necessary O +
to O +
resolve O +
these O +
problems O +
- O +
neither O +
can O +
work O +
safely O +
without O +
the O +
assistance O +
of O +
the O +
other O +
. O +

4 O +
. O +

Many O +
products O +
in O +
use O +
in O +
hospitals O +
may O +
be O +
up O +
to O +
20 O +
years O +
old O +
and O +
clearly O +
were O +
not O +
designed O +
to O +
facilitate O +
decontamination O +
and O +
therefore O +
present O +
far O +
greater O +
risk O +
to O +
all O +
concerned O +
. O +

5 O +
. O +

For O +
the O +
future O +
there O +
a O +
clearly O +
a O +
responsibility O +
with O +
manufacturers O +
to O +
give O +
more O +
thought O +
to O +
the O +
design O +
of O +
their O +
equipment O +
so O +
that O +
decontamination O +
can O +
be O +
achieved O +
more O +
effectively O +
. O +

Positron O +
emission O +
tomography O +
in O +
a O +
case O +
of O +
intracranial O +
hemangiopericytoma O +
. O +

Due O +
to O +
the O +
low O +
prevalence O +
of O +
hemangiopericytomas O +
( O +
HPCs O +
) O +
, O +
data O +
on O +
the O +
biophysiological O +
characteristics O +
of O +
this O +
tumor O +
are O +
rare O +
. O +

Positron O +
emission O +
tomography O +
( O +
PET O +
) O +
demonstrated O +
a O +
sixfold O +
increased O +
uptake O +
of O +
[ O +
11C O +
] O +
methionine O +
and O +
hyperperfusion O +
in O +
the O +
HPC O +
, O +
whereas O +
glucose O +
utilization O +
was O +
decreased O +
in O +
this O +
area O +
. O +

This O +
low O +
glucose O +
utilization O +
is O +
in O +
contrast O +
to O +
the O +
high O +
[ O +
11C O +
] O +
methionine O +
uptake O +
and O +
the O +
malignancy O +
of O +
these O +
tumors O +
. O +

The O +
characteristics O +
of O +
HPCs O +
in O +
PET O +
described O +
herein O +
for O +
the O +
first O +
time O +
offer O +
additional O +
diagnostic O +
criteria O +
and O +
may O +
help O +
especially O +
to O +
differentiate O +
these O +
tumors O +
from O +
meningiomas O +
. O +

Novel O +
mechanism O +
for O +
the O +
impairment O +
of O +
cell O +
proliferation O +
in O +
HIV O +
- O +
1 O +
infection O +
. O +

The O +
synthesis O +
of O +
ribonucleotides O +
is O +
essential O +
to O +
cell O +
proliferation O +
. O +

Defects O +
in O +
the O +
relevant O +
metabolic O +
pathways O +
have O +
been O +
demonstrated O +
in O +
stimulated O +
T O +
cells O +
from O +
AIDS O +
patients O +
and O +
are O +
associated O +
with O +
lymphocyte O +
necrotic O +
death O +
. O +

Here O +
, O +
Margarita O +
Bofill O +
and O +
colleagues O +
discuss O +
the O +
possibility O +
that O +
an O +
impaired O +
ribonucleotide O +
metabolism O +
might O +
be O +
common O +
to O +
all O +
rapidly O +
dividing O +
cells O +
and O +
thus O +
contribute O +
to O +
other O +
recognized O +
symptoms O +
of O +
HIV O +
- O +
1 O +
infection O +
. O +

Enterococci O +
at O +
the O +
crossroads O +
of O +
food O +
safety O +
? O +

Enterococci O +
are O +
gram O +
- O +
positive O +
bacteria O +
and O +
fit O +
within O +
the O +
general O +
definition O +
of O +
lactic O +
acid O +
bacteria O +
. O +

Modern O +
classification O +
techniques O +
resulted O +
in O +
the O +
transfer O +
of O +
some O +
members O +
of O +
the O +
genus O +
Streptococcus O +
, O +
notably O +
some O +
of O +
the O +
Lancefield O +
' O +
s O +
group O +
D O +
streptococci O +
, O +
to O +
the O +
new O +
genus O +
Enterococcus O +
. O +

Enterococci O +
can O +
be O +
used O +
as O +
indicators O +
of O +
faecal O +
contamination O +
. O +

They O +
have O +
been O +
implicated O +
in O +
outbreaks O +
of O +
foodborne O +
illness O +
, O +
and O +
they O +
have O +
been O +
ascribed O +
a O +
beneficial O +
or O +
detrimental O +
role O +
in O +
foods O +
. O +

In O +
processed O +
meats O +
, O +
enterococci O +
may O +
survive O +
heat O +
processing O +
and O +
cause O +
spoilage O +
, O +
though O +
in O +
certain O +
cheeses O +
the O +
growth O +
of O +
enterococci O +
contributes O +
to O +
ripening O +
and O +
development O +
of O +
product O +
flavour O +
. O +

Some O +
enterococci O +
of O +
food O +
origin O +
produce O +
bacteriocins O +
that O +
exert O +
anti O +
- O +
Listeria O +
activity O +
. O +

Enterococci O +
are O +
used O +
as O +
probiotics O +
to O +
improve O +
the O +
microbial O +
balance O +
of O +
the O +
intestine O +
, O +
or O +
as O +
a O +
treatment O +
for O +
gastroenteritis O +
in O +
humans O +
and O +
animals O +
. O +

On O +
the O +
other O +
hand O +
, O +
enterococci O +
have O +
become O +
recognised O +
as O +
serious O +
nosocomial O +
pathogens O +
causing O +
bacteraemia O +
, O +
endocarditis O +
, O +
urinary O +
tract O +
and O +
other O +
infections O +
. O +

This O +
is O +
in O +
part O +
explained O +
by O +
the O +
resistance O +
of O +
some O +
of O +
these O +
bacteria O +
to O +
most O +
antibiotics O +
that O +
are O +
currently O +
in O +
use O +
. O +

Resistance O +
is O +
acquired O +
by O +
gene O +
transfer O +
systems O +
, O +
such O +
as O +
conjugative O +
or O +
nonconjugative O +
plasmids O +
or O +
transposons O +
. O +

Virulence O +
of O +
enterococci O +
is O +
not O +
well O +
understood O +
but O +
adhesins O +
, O +
haemolysin O +
, O +
hyaluronidase O +
, O +
aggregation O +
substance O +
and O +
gelatinase O +
are O +
putative O +
virulence O +
factors O +
. O +

It O +
appears O +
that O +
foods O +
could O +
be O +
a O +
source O +
of O +
vancomycin O +
- O +
resistant O +
enterococci O +
. O +

This O +
review O +
addresses O +
the O +
issue O +
of O +
the O +
health O +
risk O +
of O +
foods O +
containing O +
enterococci O +
. O +

Thyrotropin O +
receptor O +
: O +
a O +
role O +
for O +
thyroid O +
tumourigenesis O +
? O +

Human O +
thyroid O +
tumours O +
represent O +
an O +
example O +
of O +
the O +
interplay O +
of O +
genetic O +
and O +
non O +
genetic O +
carcinogenesis O +
. O +

Recently O +
, O +
genetic O +
abnormalities O +
in O +
the O +
elements O +
of O +
the O +
Thyrotropin O +
receptor O +
( O +
TSH O +
- O +
R O +
) O +
dependent O +
cAMP O +
regulatory O +
cascade O +
have O +
been O +
found O +
to O +
be O +
involved O +
both O +
in O +
benign O +
and O +
malignant O +
thyroid O +
tumours O +
. O +

The O +
presence O +
of O +
activating O +
mutations O +
has O +
been O +
demonstrated O +
in O +
the O +
TSH O +
- O +
R O +
gene O +
as O +
well O +
as O +
in O +
the O +
Gs O +
alpha O +
protein O +
gene O +
in O +
thyroid O +
toxic O +
adenoma O +
resulting O +
in O +
the O +
constitutive O +
activation O +
of O +
the O +
cAMP O +
pathway O +
and O +
it O +
has O +
been O +
hypothesised O +
that O +
these O +
genetic O +
alterations O +
may O +
play O +
a O +
causative O +
role O +
in O +
the O +
disease O +
. O +

However O +
, O +
recent O +
observations O +
suggest O +
more O +
caution O +
in O +
accepting O +
such O +
a O +
hypothesis O +
. O +

The O +
presence O +
of O +
activating O +
TSH O +
- O +
R O +
mutations O +
has O +
also O +
been O +
demonstrated O +
in O +
differentiated O +
thyroid O +
carcinomas O +
. O +

At O +
present O +
, O +
the O +
percentage O +
of O +
such O +
a O +
modification O +
is O +
low O +
, O +
unless O +
referred O +
to O +
selected O +
series O +
of O +
tumours O +
. O +

Activating O +
mutations O +
of O +
the O +
TSH O +
- O +
R O +
gene O +
have O +
been O +
detected O +
in O +
a O +
group O +
of O +
differentiated O +
carcinomas O +
with O +
high O +
basal O +
adenylyl O +
cyclase O +
activity O +
, O +
and O +
in O +
a O +
few O +
cases O +
of O +
hyperfunctioning O +
thyroid O +
carcinoma O +
. O +

However O +
, O +
the O +
role O +
of O +
the O +
TSH O +
- O +
R O +
- O +
related O +
cAMP O +
pathway O +
alterations O +
in O +
thyroid O +
transformation O +
remains O +
to O +
be O +
elucidated O +
. O +

In O +
this O +
review O +
, O +
the O +
role O +
of O +
TSH O +
- O +
R O +
gene O +
alterations O +
in O +
benign O +
and O +
malignant O +
thyroid O +
neoplasia O +
is O +
examined O +
. O +

Immunohistochemical O +
analysis O +
of O +
nm23 O +
- O +
H1 O +
gene O +
product O +
in O +
node O +
- O +
positive O +
lung O +
cancer O +
and O +
lymph O +
nodes O +
. O +

The O +
nm23 O +
- O +
H1 O +
gene O +
product O +
has O +
been O +
considered O +
as O +
an O +
anti O +
- O +
metastatic O +
protein O +
and O +
the O +
level O +
of O +
its O +
expression O +
has O +
been O +
reported O +
to O +
correlate O +
inversely O +
with O +
metastatic O +
potential O +
in O +
some O +
cancers O +
. O +

However O +
, O +
the O +
expression O +
of O +
nm23 O +
- O +
H1 O +
gene O +
product O +
in O +
the O +
metastatic O +
sites O +
have O +
not O +
been O +
studied O +
in O +
detail O +
. O +

We O +
examined O +
the O +
expression O +
of O +
nm23 O +
- O +
H1 O +
gene O +
product O +
in O +
surgically O +
resected O +
46 O +
pairs O +
of O +
primary O +
lung O +
cancers O +
and O +
metastatic O +
lymph O +
nodes O +
by O +
immunohistochemistry O +
. O +

The O +
positive O +
staining O +
of O +
nm23 O +
- O +
H1 O +
gene O +
product O +
in O +
primary O +
cancers O +
and O +
metastatic O +
lymph O +
nodes O +
were O +
observed O +
in O +
56 O +
. O +
5 O +
and O +
67 O +
. O +
4 O +
% O +
, O +
respectively O +
. O +

The O +
heterogeneity O +
of O +
nm23 O +
- O +
H1 O +
gene O +
product O +
expression O +
between O +
primary O +
cancers O +
and O +
metastatic O +
lymph O +
nodes O +
was O +
observed O +
in O +
41 O +
. O +
3 O +
% O +
. O +

No O +
correlations O +
were O +
found O +
between O +
the O +
nm23 O +
- O +
H1 O +
gene O +
product O +
expression O +
in O +
lung O +
cancers O +
and O +
the O +
patients O +
survival O +
. O +

No O +
significant O +
association O +
was O +
also O +
observed O +
between O +
nm23 O +
- O +
H1 O +
gene O +
product O +
expression O +
in O +
lymph O +
nodes O +
and O +
the O +
patients O +
survival O +
. O +

There O +
was O +
, O +
furthermore O +
, O +
no O +
correlation O +
between O +
the O +
heterogeneity O +
of O +
nm23 O +
- O +
H1 O +
gene O +
product O +
expression O +
and O +
the O +
patients O +
survival O +
. O +

In O +
conclusion O +
, O +
the O +
level O +
of O +
nm23 O +
- O +
H1 O +
gene O +
product O +
expression O +
does O +
not O +
significantly O +
reveal O +
prognostic O +
value O +
in O +
node O +
- O +
positive O +
lung O +
cancers O +
. O +

Expression O +
of O +
nm23 O +
- O +
H1 O +
gene O +
product O +
in O +
metastatic O +
lymph O +
nodes O +
was O +
also O +
unrelated O +
to O +
patients O +
survival O +
. O +

Bradycardia O +
- O +
induced O +
coronary O +
angiogenesis O +
is O +
dependent O +
on O +
vascular O +
endothelial O +
growth O +
factor O +
. O +

A O +
marked O +
coronary O +
angiogenesis O +
is O +
known O +
to O +
occur O +
with O +
chronic O +
bradycardia O +
. O +

We O +
tested O +
the O +
hypothesis O +
that O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
, O +
an O +
endothelial O +
cell O +
mitogen O +
and O +
a O +
major O +
regulator O +
of O +
angiogenesis O +
, O +
is O +
upregulated O +
in O +
response O +
to O +
low O +
heart O +
rate O +
and O +
consequential O +
increased O +
stroke O +
volume O +
. O +

Bradycardia O +
was O +
induced O +
in O +
rats O +
by O +
administering O +
the O +
bradycardic O +
drug O +
alinidine O +
( O +
3 O +
mg O +
/ O +
kg O +
body O +
weight O +
) O +
twice O +
daily O +
. O +

Heart O +
rate O +
decreased O +
by O +
32 O +
% O +
for O +
20 O +
to O +
40 O +
minutes O +
after O +
injection O +
and O +
was O +
chronically O +
reduced O +
by O +
10 O +
% O +
, O +
14 O +
% O +
, O +
and O +
18 O +
. O +
5 O +
% O +
after O +
1 O +
, O +
2 O +
, O +
and O +
3 O +
weeks O +
of O +
treatment O +
, O +
respectively O +
. O +

Arterial O +
pressure O +
and O +
cardiac O +
output O +
were O +
unchanged O +
. O +

Left O +
ventricular O +
capillary O +
length O +
density O +
( O +
mm O +
/ O +
mm O +
( O +
3 O +
) O +
) O +
increased O +
gradually O +
with O +
alinidine O +
administration O +
; O +
a O +
15 O +
% O +
increase O +
after O +
2 O +
weeks O +
and O +
a O +
40 O +
% O +
increase O +
after O +
3 O +
weeks O +
of O +
alinidine O +
treatment O +
were O +
documented O +
. O +

Left O +
ventricular O +
weight O +
, O +
body O +
weight O +
, O +
and O +
their O +
ratio O +
were O +
not O +
significantly O +
altered O +
by O +
alinidine O +
treatment O +
. O +

After O +
1 O +
week O +
of O +
treatment O +
, O +
before O +
an O +
increase O +
in O +
capillary O +
length O +
density O +
, O +
VEGF O +
mRNA O +
increased O +
greater O +
than O +
2 O +
- O +
fold O +
and O +
then O +
declined O +
to O +
control O +
levels O +
after O +
3 O +
weeks O +
of O +
treatment O +
. O +

VEGF O +
protein O +
was O +
higher O +
in O +
alinidine O +
- O +
treated O +
rats O +
than O +
in O +
controls O +
after O +
2 O +
weeks O +
and O +
increased O +
further O +
after O +
3 O +
weeks O +
of O +
treatment O +
. O +

Injection O +
of O +
VEGF O +
- O +
neutralizing O +
antibodies O +
over O +
a O +
2 O +
- O +
week O +
period O +
completely O +
blocked O +
alinidine O +
- O +
stimulated O +
angiogenesis O +
. O +

In O +
contrast O +
, O +
bFGF O +
mRNA O +
was O +
not O +
altered O +
by O +
alinidine O +
treatment O +
. O +

These O +
data O +
suggest O +
that O +
VEGF O +
plays O +
a O +
key O +
role O +
in O +
the O +
angiogenic O +
response O +
that O +
occurs O +
with O +
chronic O +
bradycardia O +
. O +

The O +
mechanism O +
underlying O +
this O +
VEGF O +
- O +
associated O +
angiogenesis O +
may O +
be O +
an O +
increase O +
in O +
stretch O +
due O +
to O +
enhanced O +
diastolic O +
filling O +
. O +

[ O +
Histopathologic O +
examination O +
of O +
rectal O +
carcinoma O +
] O +
. O +

In O +
patients O +
with O +
rectal O +
carcinoma O +
, O +
the O +
histopathological O +
evaluation O +
of O +
the O +
surgical O +
specimen O +
provides O +
pivotal O +
prognostic O +
and O +
therapeutic O +
information O +
. O +

Important O +
parameters O +
are O +
tumor O +
site O +
, O +
depth O +
of O +
invasion O +
, O +
histological O +
type O +
and O +
grade O +
, O +
pattern O +
of O +
invasion O +
( O +
diffusely O +
infiltrating O +
versus O +
expanding O +
margin O +
) O +
, O +
degree O +
of O +
peritumoral O +
lymphocytic O +
infiltration O +
, O +
and O +
tumor O +
involvement O +
of O +
surgical O +
margins O +
and O +
lymph O +
nodes O +
. O +

Evaluation O +
of O +
the O +
circumferential O +
( O +
deep O +
, O +
lateral O +
) O +
margin O +
is O +
of O +
utmost O +
importance O +
. O +

It O +
should O +
be O +
labeled O +
with O +
ink O +
in O +
the O +
gross O +
specimen O +
and O +
should O +
be O +
examined O +
histologically O +
using O +
several O +
tissue O +
blocks O +
. O +

The O +
number O +
of O +
lymph O +
node O +
metastases O +
and O +
the O +
total O +
number O +
of O +
lymph O +
nodes O +
examined O +
should O +
be O +
reported O +
. O +

A O +
histological O +
evaluation O +
of O +
the O +
distal O +
mesorectum O +
in O +
its O +
entirety O +
is O +
recommended O +
to O +
detect O +
discontinuous O +
distal O +
mesorectal O +
tumor O +
spread O +
. O +

The O +
histopathological O +
findings O +
should O +
be O +
summarized O +
using O +
the O +
TNM O +
- O +
classification O +
. O +

Cooccurrence O +
of O +
reduced O +
expression O +
of O +
alpha O +
- O +
catenin O +
and O +
overexpression O +
of O +
p53 O +
is O +
a O +
predictor O +
of O +
lymph O +
node O +
metastasis O +
in O +
early O +
gastric O +
cancer O +
. O +

BACKGROUND O +
AND O +
OBJECTIVES O +
: O +
Even O +
though O +
the O +
pathological O +
background O +
contributes O +
to O +
lymph O +
node O +
metastasis O +
, O +
the O +
biological O +
characteristics O +
of O +
tumors O +
have O +
also O +
gained O +
wide O +
attention O +
. O +

In O +
this O +
study O +
, O +
the O +
expression O +
of O +
the O +
cadherin O +
- O +
catenin O +
complex O +
and O +
p53 O +
was O +
studied O +
in O +
early O +
gastric O +
cancer O +
. O +

Their O +
correlation O +
with O +
lymph O +
node O +
metastasis O +
and O +
the O +
predictability O +
of O +
lymph O +
node O +
metastases O +
, O +
by O +
combining O +
these O +
factors O +
, O +
were O +
also O +
discussed O +
. O +

METHODS O +
: O +
One O +
hundred O +
and O +
one O +
specimens O +
obtained O +
from O +
surgery O +
were O +
studied O +
by O +
immunohistochemistry O +
using O +
monoclonal O +
anti O +
- O +
E O +
- O +
cadherin O +
, O +
anti O +
- O +
alpha O +
- O +
catenin O +
and O +
anti O +
- O +
p53 O +
antibodies O +
. O +

RESULTS O +
: O +
Expression O +
of O +
E O +
- O +
cadherin O +
and O +
alpha O +
- O +
catenin O +
was O +
reduced O +
in O +
50 O +
. O +
5 O +
and O +
64 O +
. O +
4 O +
% O +
, O +
respectively O +
. O +

p53 O +
protein O +
staining O +
was O +
positive O +
in O +
29 O +
. O +
7 O +
% O +
. O +

There O +
was O +
a O +
significant O +
correlation O +
between O +
E O +
- O +
cadherin O +
and O +
alpha O +
- O +
catenin O +
expression O +
, O +
but O +
no O +
correlation O +
was O +
found O +
between O +
p53 O +
expression O +
and O +
E O +
- O +
cadherin O +
or O +
alpha O +
- O +
catenin O +
expression O +
. O +

A O +
reduction O +
in O +
alpha O +
- O +
catenin O +
expression O +
and O +
p53 O +
overexpression O +
correlated O +
to O +
lymph O +
node O +
metastases O +
, O +
respectively O +
. O +

Multivariate O +
analysis O +
showed O +
that O +
cooccurrence O +
of O +
reduced O +
expression O +
of O +
alpha O +
- O +
catenin O +
and O +
overexpression O +
of O +
p53 O +
was O +
an O +
independent O +
factor O +
indicating O +
lymph O +
node O +
metastases O +
. O +

CONCLUSION O +
: O +
A O +
study O +
of O +
both O +
alpha O +
- O +
catenin O +
and O +
p53 O +
expression O +
may O +
be O +
helpful O +
to O +
predict O +
lymph O +
node O +
metastases O +
in O +
early O +
gastric O +
cancer O +
. O +

Antisense O +
technologies O +
have O +
a O +
future O +
fighting O +
neurodegenerative O +
diseases O +
. O +

Our O +
growing O +
understanding O +
of O +
the O +
role O +
that O +
unfavorable O +
patterns O +
of O +
gene O +
expression O +
play O +
in O +
the O +
etiology O +
of O +
neurodegenerative O +
disease O +
emphasizes O +
the O +
need O +
for O +
strategies O +
to O +
selectively O +
block O +
the O +
biosynthesis O +
of O +
harmful O +
proteins O +
in O +
the O +
brain O +
. O +

Antisense O +
technologies O +
are O +
ideally O +
suited O +
to O +
this O +
purpose O +
. O +

Tailor O +
- O +
designed O +
to O +
target O +
specific O +
RNA O +
, O +
antisense O +
oligonucleotides O +
and O +
ribozymes O +
offer O +
tools O +
to O +
suppress O +
the O +
production O +
of O +
proteins O +
mediating O +
neurodegeneration O +
. O +

Although O +
technical O +
limitations O +
must O +
still O +
be O +
overcome O +
, O +
the O +
antisense O +
approach O +
represents O +
a O +
novel O +
and O +
exciting O +
strategy O +
for O +
intervention O +
in O +
diseases O +
of O +
the O +
central O +
nervous O +
system O +
. O +

Proto O +
- O +
oncogene O +
N O +
- O +
myc O +
promoter O +
is O +
down O +
regulated O +
by O +
the O +
Wilms O +
' O +
tumor O +
suppressor O +
gene O +
WT1 O +
. O +

The O +
Wilms O +
' O +
tumor O +
1 O +
( O +
WT1 O +
) O +
gene O +
is O +
a O +
tumor O +
suppressor O +
gene O +
that O +
encodes O +
a O +
zinc O +
- O +
finger O +
transcription O +
factor O +
. O +

WT1 O +
represses O +
transcription O +
of O +
several O +
growth O +
factors O +
and O +
growth O +
factor O +
receptors O +
. O +

The O +
N O +
- O +
myc O +
proto O +
- O +
oncogene O +
encodes O +
a O +
transcription O +
factor O +
which O +
regulates O +
cell O +
growth O +
and O +
differentiation O +
. O +

N O +
- O +
myc O +
is O +
coexpressed O +
with O +
WT1 O +
in O +
the O +
developing O +
kidney O +
and O +
is O +
overexpressed O +
in O +
many O +
Wilms O +
' O +
tumors O +
. O +

Here O +
, O +
we O +
show O +
that O +
the O +
proto O +
- O +
oncogene O +
N O +
- O +
myc O +
promoter O +
was O +
down O +
- O +
regulated O +
by O +
WT1 O +
in O +
transient O +
transfection O +
assays O +
. O +

However O +
, O +
mutant O +
WT1 O +
( O +
R394W O +
) O +
which O +
has O +
a O +
mutation O +
in O +
the O +
DNA O +
binding O +
domain O +
could O +
not O +
repress O +
the O +
N O +
- O +
myc O +
promoter O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
showed O +
that O +
the O +
oligonucleotides O +
containing O +
the O +
WT1 O +
motifs O +
could O +
bind O +
recombinant O +
WT1 O +
proteins O +
. O +

This O +
suggests O +
that O +
the O +
repression O +
of O +
the O +
N O +
- O +
myc O +
promoter O +
is O +
mediated O +
through O +
the O +
WT1 O +
binding O +
sites O +
. O +

This O +
finding O +
may O +
help O +
to O +
elucidate O +
the O +
relationship O +
of O +
WT1 O +
and O +
N O +
- O +
myc O +
in O +
tumorigenesis O +
and O +
renal O +
development O +
. O +

UFT O +
and O +
its O +
metabolites O +
inhibit O +
the O +
angiogenesis O +
induced O +
by O +
murine O +
renal O +
cell O +
carcinoma O +
, O +
as O +
determined O +
by O +
a O +
dorsal O +
air O +
sac O +
assay O +
in O +
mice O +
. O +

UFT O +
, O +
an O +
anticancer O +
agent O +
that O +
is O +
composed O +
of O +
tegafur O +
( O +
FT O +
) O +
and O +
uracil O +
at O +
a O +
molar O +
ratio O +
of O +
1 O +
: O +
4 O +
, O +
is O +
widely O +
used O +
in O +
clinical O +
practice O +
in O +
Japan O +
to O +
treat O +
cancer O +
patients O +
requiring O +
a O +
long O +
- O +
term O +
chemotherapy O +
, O +
and O +
it O +
is O +
associated O +
with O +
few O +
side O +
effects O +
, O +
if O +
any O +
. O +

In O +
this O +
study O +
, O +
we O +
have O +
evaluated O +
the O +
inhibitory O +
effect O +
of O +
UFT O +
against O +
RENCA B-CellLine +
cell O +
- O +
induced O +
angiogenesis O +
by O +
a O +
dorsal O +
air O +
sac O +
assay O +
. O +

Marked O +
angiogenesis O +
is O +
induced O +
by O +
implantation O +
of O +
a O +
chamber O +
containing O +
RENCA B-CellLine +
cells O +
into O +
mice O +
. O +

In O +
this O +
model O +
, O +
UFT O +
showed O +
a O +
strong O +
angiogenesis O +
- O +
inhibitory O +
effect O +
, O +
whereas O +
5 O +
- O +
fluorouracil O +
( O +
5 O +
- O +
FU O +
) O +
and O +
doxifluridine O +
were O +
less O +
effective O +
. O +

Additional O +
experiments O +
revealed O +
FT O +
to O +
be O +
effective O +
component O +
of O +
UFT O +
; O +
uracil O +
remained O +
ineffective O +
in O +
the O +
inhibition O +
of O +
angiogenesis O +
. O +

Moreover O +
, O +
we O +
have O +
found O +
that O +
gamma O +
- O +
hydroxybutyric O +
acid O +
and O +
gamma O +
- O +
butyrolactone O +
, O +
the O +
metabolites O +
of O +
FT O +
, O +
possess O +
a O +
potent O +
angiogenesis O +
inhibitory O +
effect O +
that O +
is O +
amplified O +
when O +
the O +
compounds O +
are O +
administered O +
by O +
a O +
continuous O +
infusion O +
. O +

This O +
may O +
reflect O +
a O +
transition O +
in O +
blood O +
concentration O +
of O +
each O +
metabolite O +
resulting O +
from O +
the O +
administration O +
of O +
UFT O +
. O +

Similar O +
results O +
were O +
also O +
obtained O +
with O +
respect O +
to O +
5 O +
- O +
FU O +
. O +

It O +
was O +
suggested O +
that O +
UFT O +
has O +
a O +
stronger O +
angiogenesis O +
- O +
inhibitory O +
effect O +
than O +
did O +
other O +
fluorinated O +
pyrimidines O +
, O +
partly O +
due O +
to O +
its O +
pharmacokinetic O +
properties O +
characterized O +
by O +
maintaining O +
of O +
higher O +
and O +
long O +
- O +
lasting O +
blood O +
levels O +
of O +
5 O +
- O +
FU O +
and O +
partly O +
due O +
the O +
inhibitory O +
effects O +
derived O +
from O +
gamma O +
- O +
hydroxybutyric O +
acid O +
and O +
gamma O +
- O +
butyrolactone O +
, O +
UFT O +
- O +
specific O +
metabolites O +
. O +

External O +
beam O +
radiotherapy O +
for O +
subretinal O +
neovascularization O +
in O +
age O +
- O +
related O +
macular O +
degeneration O +
: O +
is O +
this O +
treatment O +
efficient O +
? O +

PURPOSE O +
: O +
Control O +
of O +
the O +
natural O +
course O +
of O +
subretinal O +
neovascularization O +
( O +
SRNV O +
) O +
in O +
age O +
- O +
related O +
macular O +
degeneration O +
( O +
AMD O +
) O +
is O +
difficult O +
. O +

Only O +
a O +
subset O +
of O +
patients O +
is O +
suitable O +
for O +
laser O +
coagulation O +
. O +

This O +
prospective O +
study O +
aimed O +
to O +
determine O +
the O +
efficacy O +
and O +
individual O +
benefit O +
of O +
external O +
beam O +
radiotherapy O +
( O +
EBRT O +
) O +
. O +

METHODS O +
AND O +
MATERIALS O +
: O +
The O +
prospective O +
trial O +
included O +
287 O +
patients O +
with O +
subfoveal O +
neovascularization O +
due O +
to O +
AMD O +
which O +
was O +
verified O +
by O +
fluorescein O +
angiography O +
. O +

Patients O +
have O +
been O +
treated O +
between O +
January O +
1996 O +
and O +
October O +
1997 O +
. O +

All O +
patients O +
received O +
a O +
total O +
dose O +
of O +
16 O +
Gy O +
in O +
2 O +
- O +
Gy O +
daily O +
fractions O +
with O +
5 O +
- O +
6 O +
MeV O +
photons O +
based O +
on O +
computerized O +
treatment O +
planning O +
in O +
individual O +
head O +
mask O +
fixation O +
. O +

This O +
first O +
analysis O +
is O +
based O +
on O +
73 O +
patients O +
( O +
50 O +
women O +
, O +
23 O +
men O +
, O +
median O +
age O +
74 O +
. O +
3 O +
years O +
) O +
, O +
with O +
a O +
median O +
follow O +
- O +
up O +
of O +
13 O +
. O +
3 O +
months O +
and O +
a O +
minimum O +
follow O +
- O +
up O +
of O +
11 O +
months O +
. O +

RESULTS O +
: O +
All O +
patients O +
completed O +
therapy O +
and O +
tolerability O +
was O +
good O +
. O +

First O +
clinical O +
control O +
with O +
second O +
angiography O +
was O +
performed O +
6 O +
weeks O +
after O +
irradiation O +
, O +
then O +
in O +
3 O +
- O +
month O +
intervals O +
. O +

Eighteen O +
patients O +
with O +
SRNV O +
refusing O +
radiotherapy O +
served O +
as O +
a O +
control O +
group O +
and O +
were O +
matched O +
with O +
18 O +
irradiated O +
patients O +
. O +

After O +
7 O +
months O +
median O +
visual O +
acuity O +
( O +
VA O +
) O +
was O +
20 O +
/ O +
160 O +
for O +
the O +
irradiated O +
and O +
20 O +
/ O +
400 O +
for O +
the O +
untreated O +
patients O +
. O +

One O +
year O +
after O +
radiotherapy O +
final O +
median O +
VA O +
was O +
20 O +
/ O +
400 O +
in O +
both O +
groups O +
. O +

CONCLUSION O +
: O +
These O +
results O +
suggest O +
that O +
16 O +
Gy O +
of O +
conventionally O +
fractionated O +
external O +
beam O +
irradiation O +
slows O +
down O +
the O +
visual O +
loss O +
in O +
exudative O +
AMD O +
for O +
only O +
a O +
few O +
months O +
. O +

Patients O +
' O +
reading O +
vision O +
could O +
not O +
be O +
saved O +
for O +
a O +
long O +
- O +
term O +
run O +
. O +

Increased O +
serum O +
levels O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
in O +
patients O +
with O +
renal O +
cell O +
carcinoma O +
. O +

Neovascularization O +
, O +
an O +
essential O +
event O +
for O +
the O +
growth O +
of O +
solid O +
tumors O +
, O +
is O +
regulated O +
by O +
a O +
number O +
of O +
angiogenic O +
factors O +
. O +

One O +
such O +
factor O +
, O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
, O +
is O +
considered O +
to O +
exert O +
a O +
potent O +
angiogenic O +
activity O +
, O +
as O +
indicated O +
by O +
immunohistochemical O +
and O +
molecular O +
evidence O +
. O +

In O +
this O +
study O +
we O +
investigated O +
the O +
serum O +
VEGF O +
level O +
( O +
s O +
- O +
VEGF O +
) O +
in O +
patients O +
with O +
renal O +
cell O +
carcinoma O +
( O +
RCC O +
) O +
. O +

s O +
- O +
VEGF O +
in O +
peripheral O +
blood O +
samples O +
was O +
analyzed O +
in O +
40 O +
RCC O +
patients O +
and O +
40 O +
patients O +
without O +
cancer O +
( O +
controls O +
) O +
using O +
a O +
sandwich O +
enzyme O +
- O +
linked O +
immunoassay O +
. O +

In O +
20 O +
RCC O +
patients O +
, O +
serum O +
samples O +
were O +
obtained O +
separately O +
from O +
the O +
bilateral O +
renal O +
veins O +
. O +

s O +
- O +
VEGF O +
was O +
also O +
measured O +
before O +
, O +
4 O +
and O +
8 O +
weeks O +
after O +
nephrectomy O +
in O +
11 O +
patients O +
. O +

There O +
were O +
significant O +
differences O +
in O +
s O +
- O +
VEGF O +
between O +
the O +
RCC O +
patients O +
and O +
the O +
controls O +
( O +
207 O +
. O +
3 O +
+ O +
/ O +
- O +
32 O +
. O +
9 O +
vs O +
. O +
71 O +
. O +
5 O +
+ O +
/ O +
- O +
9 O +
. O +
1 O +
pg O +
/ O +
ml O +
, O +
mean O +
+ O +
/ O +
- O +
SE O +
) O +
( O +
P O +
less O +
than O +
0 O +
. O +
005 O +
) O +
, O +
between O +
the O +
tumor O +
- O +
bearing O +
renal O +
veins O +
and O +
the O +
contralateral O +
ones O +
( O +
P O +
less O +
than O +
0 O +
. O +
01 O +
) O +
, O +
between O +
the O +
pre O +
- O +
and O +
post O +
- O +
nephrectomy O +
situations O +
( O +
P O +
less O +
than O +
0 O +
. O +
01 O +
) O +
and O +
among O +
the O +
various O +
parameters O +
of O +
tumor O +
status O +
such O +
as O +
tumor O +
extent O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
and O +
existence O +
of O +
metastasis O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
. O +

s O +
- O +
VEGF O +
significantly O +
correlated O +
with O +
the O +
tumor O +
volume O +
obtained O +
by O +
a O +
three O +
- O +
dimensional O +
measurement O +
( O +
r O +
= O +
0 O +
. O +
802 O +
, O +
P O +
less O +
than O +
0 O +
. O +
0001 O +
) O +
. O +

The O +
sensitivity O +
and O +
specificity O +
of O +
s O +
- O +
VEGF O +
at O +
the O +
cut O +
- O +
off O +
level O +
of O +
100 O +
pg O +
/ O +
ml O +
, O +
as O +
determined O +
by O +
the O +
receiver O +
- O +
operating O +
- O +
characteristics O +
curve O +
, O +
were O +
80 O +
. O +
0 O +
% O +
and O +
72 O +
. O +
5 O +
% O +
, O +
respectively O +
. O +

The O +
results O +
indicate O +
that O +
tumor O +
tissue O +
of O +
RCC O +
liberates O +
VEGF O +
into O +
the O +
systemic O +
blood O +
flow O +
and O +
that O +
s O +
- O +
VEGF O +
is O +
a O +
possible O +
marker O +
for O +
RCC O +
. O +

Insulin O +
- O +
induced O +
vascular O +
endothelial O +
growth O +
factor O +
expression O +
in O +
retina O +
. O +

PURPOSE O +
: O +
Clinical O +
studies O +
have O +
demonstrated O +
that O +
intensive O +
insulin O +
therapy O +
causes O +
a O +
transient O +
worsening O +
of O +
retinopathy O +
. O +

The O +
mechanisms O +
underlying O +
the O +
initial O +
insulin O +
- O +
induced O +
deterioration O +
of O +
retinal O +
status O +
in O +
patients O +
with O +
diabetes O +
remain O +
unknown O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
is O +
known O +
to O +
be O +
operative O +
in O +
the O +
pathogenesis O +
of O +
diabetic O +
retinopathy O +
. O +

The O +
current O +
study O +
was O +
conducted O +
to O +
characterize O +
the O +
effect O +
of O +
insulin O +
on O +
retinal O +
VEGF O +
gene O +
expression O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

METHODS O +
: O +
The O +
effect O +
of O +
insulin O +
on O +
VEGF O +
expression O +
in O +
vivo O +
was O +
examined O +
by O +
in O +
situ O +
hybridization O +
studies O +
of O +
rat O +
retinal O +
VEGF O +
transcripts O +
. O +

To O +
examine O +
the O +
mechanisms O +
by O +
which O +
insulin O +
regulates O +
VEGF O +
expression O +
, O +
human O +
retinal O +
pigment O +
epithelial O +
( O +
RPE O +
) O +
cells O +
were O +
exposed O +
to O +
insulin O +
, O +
and O +
VEGF O +
mRNA O +
levels O +
were O +
quantified O +
with O +
RNase O +
protection O +
assays O +
( O +
RPAs O +
) O +
. O +

Conditioned O +
media O +
from O +
insulin O +
- O +
treated O +
RPE O +
cells O +
were O +
assayed O +
for O +
VEGF O +
protein O +
and O +
capillary O +
endothelial O +
cell O +
proliferation O +
. O +

The O +
capacity O +
of O +
insulin O +
to O +
stimulate O +
the O +
VEGF O +
promoter O +
linked O +
to O +
a O +
luciferase O +
reporter O +
gene O +
was O +
characterized O +
in O +
transient O +
transfection O +
assays O +
. O +

RESULTS O +
: O +
Insulin O +
increased O +
VEGF O +
mRNA O +
levels O +
in O +
the O +
ganglion O +
, O +
inner O +
nuclear O +
, O +
and O +
RPE O +
cell O +
layers O +
. O +

In O +
vitro O +
, O +
insulin O +
increased O +
VEGF O +
mRNA O +
levels O +
in O +
human O +
RPE O +
cells O +
and O +
enhanced O +
VEGF O +
promoter O +
activity O +
without O +
affecting O +
transcript O +
stability O +
. O +

Insulin O +
treatment O +
also O +
increased O +
VEGF O +
protein O +
levels O +
in O +
conditioned O +
RPE O +
cell O +
media O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
with O +
a O +
median O +
effective O +
concentration O +
of O +
5 O +
nM O +
. O +

The O +
insulin O +
- O +
conditioned O +
RPE O +
cell O +
media O +
stimulated O +
capillary O +
endothelial O +
cell O +
proliferation O +
, O +
an O +
effect O +
that O +
was O +
completely O +
blocked O +
by O +
anti O +
- O +
VEGF O +
neutralizing O +
antibody O +
. O +

CONCLUSIONS O +
: O +
Insulin O +
increases O +
VEGF O +
mRNA O +
and O +
secreted O +
protein O +
levels O +
in O +
RPE O +
cells O +
through O +
enhanced O +
transcription O +
of O +
the O +
VEGF O +
gene O +
. O +

Intensive O +
insulin O +
therapy O +
may O +
cause O +
a O +
transient O +
worsening O +
of O +
retinopathy O +
in O +
patients O +
with O +
diabetes O +
through O +
increased O +
retinal O +
VEGF O +
gene O +
expression O +
. O +

The O +
antiangiogenic O +
agent O +
linomide O +
inhibits O +
the O +
growth O +
rate O +
of O +
von O +
Hippel O +
- O +
Lindau O +
paraganglioma O +
xenografts O +
to O +
mice O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
ascertain O +
the O +
potential O +
usefulness O +
of O +
the O +
antiangiogenic O +
compound O +
linomide O +
for O +
treatment O +
of O +
von O +
Hippel O +
- O +
Lindau O +
( O +
VHL O +
) O +
- O +
related O +
tumors O +
. O +

Paraganglioma O +
tissue O +
fragments O +
obtained O +
at O +
surgery O +
from O +
a O +
VHL O +
type O +
2a O +
patient O +
were O +
transplanted O +
s O +
. O +
c O +
. O +
to O +
male O +
BALB O +
/ O +
c O +
nu O +
/ O +
nu O +
( O +
nude O +
) O +
mice O +
: O +
( O +
a O +
) O +
2 O +
- O +
3 O +
- O +
mm O +
fragments O +
for O +
" O +
prevention O +
" O +
experiments O +
; O +
and O +
( O +
b O +
) O +
2 O +
- O +
3 O +
- O +
mm O +
fragments O +
allowed O +
to O +
grow O +
to O +
1 O +
cm O +
for O +
" O +
intervention O +
" O +
studies O +
. O +

Both O +
groups O +
received O +
either O +
0 O +
. O +
5 O +
mg O +
/ O +
ml O +
linomide O +
in O +
drinking O +
water O +
or O +
acidified O +
water O +
and O +
were O +
followed O +
until O +
tumor O +
diameter O +
reached O +
3 O +
cm O +
or O +
for O +
4 O +
weeks O +
. O +

In O +
both O +
the O +
prevention O +
and O +
intervention O +
experiments O +
, O +
a O +
significant O +
diminution O +
of O +
tumor O +
size O +
and O +
weight O +
was O +
observed O +
in O +
the O +
drug O +
- O +
treated O +
animals O +
. O +

In O +
vivo O +
nuclear O +
magnetic O +
resonance O +
analysis O +
of O +
tumor O +
blood O +
flow O +
in O +
linomide O +
- O +
treated O +
animals O +
showed O +
localization O +
of O +
blood O +
vessels O +
almost O +
exclusively O +
to O +
the O +
periphery O +
of O +
the O +
poorly O +
vascularized O +
tumors O +
with O +
a O +
significant O +
reduction O +
of O +
both O +
vascular O +
functionality O +
and O +
vasodilation O +
. O +

Histological O +
examination O +
of O +
tumors O +
from O +
linomide O +
- O +
treated O +
animals O +
revealed O +
marked O +
avascularity O +
. O +

Treated O +
animals O +
also O +
displayed O +
a O +
2 O +
. O +
4 O +
- O +
fold O +
reduction O +
of O +
tumor O +
vascular O +
endothelial O +
growth O +
factor O +
mRNA O +
levels O +
. O +

Taken O +
together O +
, O +
our O +
data O +
indicate O +
that O +
in O +
VHL O +
disease O +
, O +
therapy O +
directed O +
at O +
inhibition O +
of O +
constitutively O +
expressed O +
VEGF O +
induction O +
of O +
angiogenesis O +
by O +
VHL O +
tumors O +
may O +
constitute O +
an O +
effective O +
medical O +
treatment O +
. O +

Spacing O +
effects O +
on O +
the O +
memory O +
for O +
faces O +
. O +

25 O +
undergraduate O +
women O +
studied O +
12 O +
stimulus O +
pictures O +
of O +
female O +
faces O +
successively O +
presented O +
in O +
spaced O +
or O +
massed O +
conditions O +
and O +
made O +
affective O +
judgments O +
for O +
the O +
pictures O +
along O +
a O +
dimension O +
of O +
like O +
to O +
dislike O +
. O +

One O +
week O +
after O +
the O +
exposure O +
( O +
study O +
) O +
period O +
, O +
subjects O +
were O +
given O +
an O +
identification O +
test O +
comprised O +
of O +
photographs O +
of O +
the O +
same O +
female O +
faces O +
with O +
different O +
expressions O +
. O +

Analysis O +
showed O +
that O +
the O +
pictures O +
presented O +
in O +
the O +
spaced O +
condition O +
were O +
more O +
frequently O +
and O +
accurately O +
identified O +
than O +
those O +
presented O +
under O +
the O +
massed O +
condition O +
and O +
that O +
affective O +
judgment O +
was O +
unrelated O +
to O +
conditions O +
of O +
presentation O +
. O +

Phosphatidyl O +
serine O +
exposure O +
during O +
apoptosis O +
precedes O +
release O +
of O +
cytochrome O +
c O +
and O +
decrease O +
in O +
mitochondrial O +
transmembrane O +
potential O +
. O +

Time O +
kinetics O +
of O +
phosphatidyl O +
serine O +
( O +
PS O +
) O +
exposure O +
were O +
compared O +
to O +
other O +
apoptotic O +
parameters O +
following O +
different O +
apoptotic O +
stimuli O +
. O +

Our O +
data O +
indicate O +
that O +
anti O +
- O +
Fas O +
treatment O +
of O +
L929sAhFas B-CellLine +
cells O +
results O +
in O +
rapid O +
exposure O +
of O +
PS O +
, O +
which O +
precedes O +
decrease O +
in O +
mitochondrial O +
transmembrane O +
potential O +
( O +
DeltaPsi O +
( O +
m O +
) O +
) O +
and O +
release O +
of O +
cytochrome O +
c O +
, O +
indicating O +
that O +
PS O +
exposure O +
occurs O +
independently O +
of O +
these O +
mitochondrial O +
events O +
. O +

Also O +
during O +
TNF O +
- O +
, O +
etoposide O +
- O +
or O +
staurosporine O +
- O +
mediated O +
apoptosis O +
in O +
PC60 B-CellLine +
RI O +
/ O +
RII O +
cells O +
, O +
PS O +
- O +
positive O +
cells O +
were O +
observed O +
before O +
they O +
had O +
a O +
decreased O +
DeltaPsi O +
( O +
m O +
) O +
. O +

However O +
, O +
during O +
growth O +
factor O +
depletion O +
- O +
induced O +
death O +
of O +
32D B-CellLine +
cells O +
, O +
both O +
phenomena O +
seemed O +
to O +
occur O +
at O +
the O +
same O +
time O +
. O +

LMP1 O +
of O +
Epstein O +
- O +
Barr O +
virus O +
induces O +
proliferation O +
of O +
primary O +
mouse O +
embryonic O +
fibroblasts O +
and O +
cooperatively O +
transforms O +
the O +
cells O +
with O +
a O +
p16 O +
- O +
insensitive O +
CDK4 O +
oncogene O +
. O +

The O +
latent O +
membrane O +
protein O +
LMP1 O +
of O +
Epstein O +
- O +
Barr O +
virus O +
( O +
EBV O +
) O +
is O +
often O +
present O +
in O +
EBV O +
- O +
associated O +
malignancies O +
including O +
nasopharyngeal O +
carcinoma O +
and O +
Hodgkin O +
' O +
s O +
lymphoma O +
. O +

Previous O +
work O +
demonstrates O +
that O +
the O +
LMP1 O +
gene O +
of O +
EBV O +
is O +
sufficient O +
to O +
transform O +
certain O +
established O +
rodent O +
fibroblast O +
cell O +
lines O +
and O +
to O +
induce O +
the O +
tumorigenicity O +
of O +
some O +
human O +
epithelial O +
cell O +
lines O +
. O +

In O +
addition O +
, O +
LMP1 O +
plays O +
pleiotropic O +
roles O +
in O +
cell O +
growth O +
arrest O +
, O +
differentiation O +
, O +
and O +
apoptosis O +
, O +
depending O +
on O +
the O +
background O +
of O +
the O +
target O +
cells O +
. O +

To O +
examine O +
the O +
roles O +
of O +
LMP1 O +
in O +
cell O +
proliferation O +
and O +
growth O +
regulation O +
in O +
primary O +
culture O +
cells O +
, O +
we O +
constructed O +
a O +
recombinant O +
retrovirus O +
containing O +
an O +
LMP1 O +
gene O +
. O +

With O +
this O +
retrovirus O +
, O +
LMP1 O +
was O +
shown O +
to O +
stimulate O +
the O +
proliferation O +
of O +
primary O +
mouse O +
embryonic O +
fibroblasts O +
( O +
MEF O +
cells O +
) O +
. O +

It O +
has O +
a O +
mitogenic O +
activity O +
for O +
MEF O +
cells O +
, O +
as O +
demonstrated O +
by O +
an O +
immediate O +
induction O +
of O +
cell O +
doubling O +
time O +
. O +

In O +
addition O +
, O +
it O +
significantly O +
extends O +
the O +
passage O +
number O +
of O +
MEF O +
cells O +
to O +
more O +
than O +
30 O +
after O +
retroviral O +
infection O +
, O +
compared O +
with O +
less O +
than O +
5 O +
for O +
uninfected O +
MEF O +
cells O +
. O +

Furthermore O +
, O +
LMP1 O +
cooperates O +
with O +
a O +
p16 O +
- O +
insensitive O +
CDK4 O +
( O +
R24C O +
) O +
oncogene O +
in O +
transforming O +
MEF O +
cells O +
. O +

Our O +
results O +
provide O +
the O +
first O +
evidence O +
of O +
the O +
abilities O +
of O +
the O +
LMP1 O +
gene O +
, O +
acting O +
alone O +
, O +
to O +
effectively O +
induce O +
the O +
proliferation O +
of O +
primary O +
MEF O +
cells O +
and O +
of O +
its O +
cooperativity O +
with O +
another O +
cellular O +
oncogene O +
in O +
transforming O +
primary O +
cells O +
. O +

Obstructive O +
nephropathy O +
: O +
lessons O +
from O +
cystic O +
kidney O +
disease O +
. O +

Obstructive O +
nephropathy O +
is O +
one O +
of O +
the O +
most O +
important O +
causes O +
of O +
renal O +
failure O +
in O +
infants O +
and O +
children O +
, O +
while O +
polycystic O +
kidney O +
disease O +
( O +
PKD O +
) O +
is O +
a O +
major O +
cause O +
of O +
renal O +
failure O +
in O +
the O +
adult O +
population O +
. O +

This O +
review O +
summarizes O +
the O +
evidence O +
that O +
there O +
may O +
be O +
a O +
number O +
of O +
mechanisms O +
common O +
to O +
the O +
pathophysiology O +
of O +
both O +
conditions O +
. O +

In O +
animal O +
models O +
of O +
obstructive O +
nephropathy O +
and O +
PKD O +
, O +
the O +
renal O +
tubular O +
expression O +
of O +
epidermal O +
growth O +
factor O +
is O +
suppressed O +
, O +
and O +
expression O +
of O +
clusterin O +
is O +
increased O +
, O +
both O +
of O +
which O +
suggest O +
arrested O +
maturation O +
or O +
dedifferentiation O +
of O +
the O +
tubular O +
cell O +
. O +

There O +
is O +
a O +
marked O +
increase O +
in O +
apoptosis O +
of O +
epithelial O +
cells O +
in O +
dilated O +
tubules O +
, O +
associated O +
with O +
an O +
increase O +
in O +
apoptotic O +
stimuli O +
. O +

The O +
renin O +
- O +
angiotensin O +
system O +
is O +
activated O +
in O +
both O +
obstructive O +
nephropathy O +
and O +
PKD O +
, O +
which O +
may O +
contribute O +
to O +
tubular O +
atrophy O +
and O +
interstitial O +
fibrosis O +
, O +
which O +
characterize O +
the O +
progression O +
of O +
both O +
conditions O +
. O +

Focal O +
cystic O +
dilatation O +
of O +
the O +
tubule O +
is O +
found O +
in O +
obstructive O +
nephropathy O +
, O +
while O +
tubular O +
obstruction O +
is O +
present O +
in O +
cystic O +
kidney O +
disease O +
. O +

It O +
is O +
therefore O +
likely O +
that O +
elucidation O +
of O +
the O +
effects O +
of O +
mechanical O +
stretch O +
on O +
renal O +
tubular O +
epithelial O +
cells O +
will O +
contribute O +
to O +
our O +
understanding O +
of O +
both O +
conditions O +
. O +

Autotaxin O +
( O +
ATX O +
) O +
, O +
a O +
potent O +
tumor O +
motogen O +
, O +
augments O +
invasive O +
and O +
metastatic O +
potential O +
of O +
ras O +
- O +
transformed O +
cells O +
. O +

Autotaxin O +
( O +
ATX O +
) O +
, O +
an O +
exo O +
- O +
nucleotide O +
pyrophosphatase O +
and O +
phosphodiesterase O +
, O +
was O +
originally O +
isolated O +
as O +
a O +
potent O +
stimulator O +
of O +
tumor O +
cell O +
motility O +
. O +

In O +
order O +
to O +
study O +
whether O +
ATX O +
expression O +
affects O +
motility O +
- O +
dependent O +
processes O +
such O +
as O +
invasion O +
and O +
metastasis O +
, O +
we O +
stably O +
transfected O +
full O +
- O +
length O +
ATX O +
cDNA O +
into O +
two O +
non O +
- O +
expressing O +
cell O +
lines O +
, O +
parental O +
and O +
ras O +
- O +
transformed O +
NIH3T3 B-CellLine +
( O +
clone7 O +
) O +
cells O +
. O +

The O +
effect O +
of O +
ATX O +
secretion O +
on O +
in O +
vitro O +
cell O +
motility O +
was O +
variable O +
. O +

The O +
ras O +
- O +
transformed O +
, O +
ATX O +
- O +
secreting O +
subclones O +
had O +
enhanced O +
motility O +
to O +
ATX O +
as O +
chemoattractant O +
, O +
but O +
there O +
was O +
little O +
difference O +
in O +
the O +
motility O +
responses O +
of O +
NIH3T3 B-CellLine +
cells O +
transfected O +
with O +
atx O +
, O +
an O +
inactive O +
mutant O +
gene O +
, O +
or O +
empty O +
vector O +
. O +

In O +
MatrigelTM O +
invasion O +
assays O +
, O +
all O +
subclones O +
, O +
which O +
secreted O +
enzymatically O +
active O +
ATX O +
, O +
demonstrated O +
greater O +
spontaneous O +
and O +
ATX O +
- O +
stimulated O +
invasion O +
than O +
appropriate O +
controls O +
. O +

This O +
difference O +
in O +
invasiveness O +
was O +
not O +
caused O +
by O +
differences O +
in O +
gelatinase O +
production O +
, O +
which O +
was O +
constant O +
within O +
each O +
group O +
of O +
transfectants O +
. O +

In O +
vivo O +
studies O +
with O +
athymic O +
nude O +
mice O +
demonstrated O +
that O +
injection O +
of O +
atx O +
- O +
transfected O +
NIH3T3 B-CellLine +
cells O +
resulted O +
in O +
a O +
weak O +
tumorigenic O +
capacity O +
with O +
few O +
experimental O +
metastases O +
. O +

Combination O +
of O +
ATX O +
expression O +
with O +
ras O +
transformation O +
produced O +
cells O +
with O +
greatly O +
amplified O +
tumorigenesis O +
and O +
metastatic O +
potential O +
compared O +
to O +
ras O +
- O +
transformed O +
controls O +
. O +

Thus O +
, O +
ATX O +
appears O +
to O +
augment O +
cellular O +
characteristics O +
necessary O +
for O +
tumor O +
aggressiveness O +
. O +

Tumour O +
- O +
specific O +
distribution O +
of O +
BRCA1 O +
promoter O +
region O +
methylation O +
supports O +
a O +
pathogenetic O +
role O +
in O +
breast O +
and O +
ovarian O +
cancer O +
. O +

The O +
role O +
of O +
BRCA1 O +
in O +
sporadic O +
breast O +
and O +
ovarian O +
cancers O +
remains O +
elusive O +
. O +

Direct O +
involvement O +
of O +
BRCA1 O +
in O +
the O +
development O +
of O +
breast O +
and O +
ovarian O +
cancer O +
is O +
suggested O +
by O +
the O +
finding O +
that O +
the O +
BRCA1 O +
promoter O +
region O +
CpG O +
island O +
is O +
methylated O +
in O +
a O +
proportion O +
of O +
breast O +
and O +
ovarian O +
cancers O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
compare O +
the O +
incidence O +
of O +
BRCA1 O +
promoter O +
region O +
methylation O +
in O +
tumours O +
in O +
which O +
loss O +
of O +
BRCA1 O +
has O +
been O +
shown O +
to O +
play O +
a O +
role O +
in O +
pathogenesis O +
( O +
breast O +
and O +
ovarian O +
carcinomas O +
) O +
with O +
the O +
incidence O +
in O +
tumours O +
in O +
which O +
BRCA1 O +
is O +
unlikely O +
to O +
play O +
a O +
role O +
in O +
pathogenesis O +
. O +

Promoter O +
region O +
hypermethylation O +
was O +
significantly O +
more O +
common O +
( O +
P O +
< O +
0 O +
. O +
008 O +
) O +
in O +
breast O +
and O +
ovarian O +
cancer O +
( O +
6 O +
/ O +
38 O +
tumours O +
methylated O +
) O +
than O +
in O +
colon O +
cancer O +
( O +
0 O +
/ O +
35 O +
tumours O +
methylated O +
) O +
or O +
in O +
leukaemias O +
( O +
0 O +
/ O +
19 O +
samples O +
methylated O +
) O +
. O +

The O +
restriction O +
of O +
BRCA1 O +
promoter O +
region O +
hypermethylation O +
to O +
breast O +
and O +
ovarian O +
cancer O +
is O +
consistent O +
with O +
a O +
pathogenetic O +
role O +
of O +
BRCA1 O +
promoter O +
methylation O +
in O +
these O +
tumours O +
. O +

We O +
suggest O +
that O +
the O +
rarity O +
of O +
observed O +
BRCA1 O +
mutations O +
in O +
sporadic O +
breast O +
and O +
ovarian O +
cancer O +
is O +
due O +
to O +
the O +
greater O +
likelihood O +
of O +
BRCA1 O +
inactivation O +
by O +
non O +
- O +
mutational O +
mechanisms O +
such O +
as O +
methylation O +
. O +

Regulation O +
of O +
the O +
resident O +
chromosomal O +
copy O +
of O +
c O +
- O +
myc O +
by O +
c O +
- O +
Myb O +
is O +
involved O +
in O +
myeloid O +
leukemogenesis O +
. O +

c O +
- O +
myb O +
is O +
a O +
frequent O +
target O +
of O +
retroviral O +
insertional O +
mutagenesis O +
in O +
murine O +
leukemia O +
virus O +
- O +
induced O +
myeloid O +
leukemia O +
. O +

Induction O +
of O +
the O +
leukemogenic O +
phenotype O +
is O +
generally O +
associated O +
with O +
inappropriate O +
expression O +
of O +
this O +
transcriptional O +
regulator O +
. O +

Despite O +
intensive O +
investigations O +
, O +
the O +
target O +
genes O +
of O +
c O +
- O +
myb O +
that O +
are O +
specifically O +
involved O +
in O +
development O +
of O +
these O +
myeloid O +
lineage O +
neoplasms O +
are O +
still O +
unknown O +
. O +

In O +
vitro O +
assays O +
have O +
indicated O +
that O +
c O +
- O +
myc O +
may O +
be O +
a O +
target O +
gene O +
of O +
c O +
- O +
Myb O +
; O +
however O +
, O +
regulation O +
of O +
the O +
resident O +
chromosomal O +
gene O +
has O +
not O +
yet O +
been O +
demonstrated O +
. O +

To O +
address O +
this O +
question O +
further O +
, O +
we O +
analyzed O +
the O +
expression O +
of O +
c O +
- O +
myc O +
in O +
a O +
myeloblastic O +
cell O +
line O +
, O +
M1 B-CellLine +
, O +
expressing O +
a O +
conditionally O +
active O +
c O +
- O +
Myb O +
- O +
estrogen O +
receptor O +
fusion O +
protein O +
( O +
MybER O +
) O +
. O +

Activation O +
of O +
MybER O +
both O +
prevented O +
the O +
growth O +
arrest O +
induced O +
by O +
interleukin O +
- O +
6 O +
( O +
IL O +
- O +
6 O +
) O +
and O +
rapidly O +
restored O +
c O +
- O +
myc O +
expression O +
in O +
nearly O +
terminal O +
differentiated O +
cells O +
that O +
had O +
been O +
exposed O +
to O +
IL O +
- O +
6 O +
for O +
3 O +
days O +
. O +

Restoration O +
occurred O +
in O +
the O +
presence O +
of O +
a O +
protein O +
synthesis O +
inhibitor O +
but O +
not O +
after O +
a O +
transcriptional O +
block O +
, O +
indicating O +
that O +
c O +
- O +
myc O +
is O +
a O +
direct O +
, O +
transcriptionally O +
regulated O +
target O +
of O +
c O +
- O +
Myb O +
. O +

c O +
- O +
myc O +
is O +
a O +
major O +
target O +
that O +
transduces O +
Myb O +
' O +
s O +
proliferative O +
signal O +
, O +
as O +
shown O +
by O +
the O +
ability O +
of O +
a O +
c O +
- O +
Myc O +
- O +
estrogen O +
receptor O +
fusion O +
protein O +
alone O +
to O +
also O +
reverse O +
growth O +
arrest O +
in O +
this O +
system O +
. O +

To O +
investigate O +
the O +
possibility O +
that O +
this O +
regulatory O +
connection O +
contributes O +
to O +
Myb O +
' O +
s O +
oncogenicity O +
, O +
we O +
expressed O +
a O +
dominant O +
negative O +
Myb O +
in O +
the O +
myeloid O +
leukemic O +
cell O +
line O +
RI B-CellLine +
- I-CellLine +
4 I-CellLine +
- I-CellLine +
11 I-CellLine +
. O +

In O +
this O +
cell O +
line O +
, O +
c O +
- O +
myb O +
is O +
activated O +
by O +
insertional O +
mutagenesis O +
and O +
can O -
not O +
be O +
effectively O +
down O +
regulated O +
by O +
cytokine O +
. O +

Myb O +
' O +
s O +
ability O +
to O +
regulate O +
c O +
- O +
myc O +
' O +
s O +
expression O +
was O +
also O +
demonstrated O +
in O +
these O +
cells O +
, O +
showing O +
a O +
mechanism O +
through O +
which O +
the O +
proto O +
- O +
oncogene O +
c O +
- O +
myb O +
can O +
exert O +
its O +
oncogenic O +
potential O +
in O +
myeloid O +
lineage O +
hematopoietic O +
cells O +
. O +

Oncogenic O +
epidermal O +
growth O +
factor O +
receptor O +
mutants O +
with O +
tandem O +
duplication O +
: O +
gene O +
structure O +
and O +
effects O +
on O +
receptor O +
function O +
. O +

A O +
number O +
of O +
epidermal O +
growth O +
factor O +
receptor O +
( O +
EGFR O +
) O +
deletion O +
mutants O +
have O +
been O +
identified O +
in O +
gliomas O +
, O +
in O +
which O +
the O +
EGFR O +
gene O +
is O +
frequently O +
amplified O +
and O +
rearranged O +
. O +

We O +
have O +
previously O +
characterized O +
the O +
structure O +
of O +
a O +
gene O +
in O +
A B-CellLine +
- I-CellLine +
172 I-CellLine +
human O +
glioma O +
cells O +
that O +
encodes O +
a O +
190 O +
- O +
kDa O +
EGFR O +
mutant O +
with O +
tandem O +
duplication O +
of O +
the O +
tyrosine O +
kinase O +
( O +
TK O +
) O +
and O +
calcium O +
- O +
mediated O +
internalization O +
( O +
CAIN O +
) O +
domains O +
. O +

Here O +
we O +
describe O +
a O +
185 O +
- O +
kDa O +
tandem O +
duplication O +
mutant O +
( O +
TDM O +
) O +
that O +
is O +
expressed O +
in O +
KE O +
and O +
A B-CellLine +
- I-CellLine +
1235 I-CellLine +
glioma O +
cells O +
, O +
along O +
with O +
certain O +
functional O +
characteristics O +
of O +
the O +
mutants O +
. O +

The O +
corresponding O +
transcripts O +
in O +
KE O +
and O +
A B-CellLine +
- I-CellLine +
1235 I-CellLine +
cells O +
contain O +
1053 O +
additional O +
nucleotides O +
representing O +
an O +
in O +
- O +
frame O +
duplication O +
of O +
exons O +
18 O +
through O +
25 O +
which O +
encode O +
the O +
entire O +
TK O +
region O +
and O +
a O +
portion O +
of O +
the O +
CAIN O +
domain O +
. O +

As O +
with O +
duplication O +
of O +
the O +
entire O +
TK O +
/ O +
CAIN O +
region O +
( O +
exons O +
18 O +
- O +
26 O +
) O +
in O +
A B-CellLine +
- I-CellLine +
172 I-CellLine +
cells O +
, O +
duplication O +
of O +
exons O +
18 O +
- O +
25 O +
is O +
associated O +
with O +
a O +
specific O +
genomic O +
rearrangement O +
between O +
flanking O +
introns O +
. O +

Involved O +
introns O +
contain O +
homology O +
to O +
recombination O +
signal O +
sequence O +
( O +
RSS O +
) O +
heptamers O +
present O +
in O +
the O +
V O +
( O +
D O +
) O +
J O +
region O +
of O +
the O +
T O +
lymphocyte O +
receptor O +
gene O +
. O +

In O +
defined O +
medium O +
, O +
both O +
oncogenic O +
TDM O +
are O +
constitutively O +
autophosphorylated O +
and O +
inefficiently O +
downregulated O +
. O +

High O +
- O +
affinity O +
binding O +
is O +
reduced O +
in O +
EGFR O +
. O +
TDM O +
/ O +
18 O +
- O +
26 O +
, O +
although O +
the O +
t1 O +
/ O +
2 O +
of O +
receptor O +
internalization O +
is O +
not O +
prolonged O +
. O +

Ciprofloxacin O +
mediated O +
cell O +
growth O +
inhibition O +
, O +
S O +
/ O +
G2 O +
- O +
M O +
cell O +
cycle O +
arrest O +
, O +
and O +
apoptosis O +
in O +
a O +
human O +
transitional O +
cell O +
carcinoma O +
of O +
the O +
bladder O +
cell O +
line O +
. O +

The O +
second O +
most O +
prevalent O +
urological O +
malignancy O +
in O +
middle O +
aged O +
and O +
elderly O +
men O +
is O +
bladder O +
cancer O +
, O +
with O +
90 O +
% O +
of O +
the O +
cases O +
being O +
transitional O +
cell O +
carcinomas O +
. O +

The O +
success O +
of O +
current O +
systemic O +
and O +
intravesical O +
therapeutic O +
agents O +
, O +
such O +
as O +
cisplatin O +
, O +
thiotepa O +
, O +
Adriamycin O +
, O +
mitomycin O +
C O +
, O +
and O +
bacillus O +
Calmette O +
- O +
Guerin O +
, O +
is O +
limited O +
with O +
recurrence O +
rates O +
reduced O +
to O +
17 O +
- O +
44 O +
% O +
. O +

In O +
addition O +
, O +
most O +
of O +
these O +
agents O +
require O +
instrumentation O +
of O +
the O +
urinary O +
tract O +
and O +
are O +
delivered O +
at O +
a O +
significant O +
cost O +
and O +
potential O +
morbidity O +
to O +
the O +
patient O +
. O +

Fluroquinolone O +
antibiotics O +
such O +
as O +
ciprofloxacin O +
, O +
which O +
can O +
be O +
administered O +
p O +
. O +
o O +
. O +
, O +
may O +
have O +
a O +
profound O +
effect O +
in O +
bladder O +
cancer O +
management O +
. O +

This O +
is O +
primarily O +
based O +
on O +
limited O +
in O +
vitro O +
studies O +
on O +
tumor O +
cells O +
derived O +
from O +
transitional O +
cell O +
carcinoma O +
of O +
the O +
bladder O +
that O +
revealed O +
a O +
dose O +
- O +
and O +
time O +
- O +
dependent O +
inhibition O +
of O +
cell O +
growth O +
by O +
ciprofloxacin O +
at O +
concentrations O +
that O +
are O +
easily O +
attainable O +
in O +
the O +
urine O +
of O +
patients O +
. O +

However O +
, O +
the O +
mechanism O +
( O +
s O +
) O +
by O +
which O +
ciprofloxacin O +
elicits O +
its O +
biological O +
effects O +
on O +
bladder O +
cancer O +
cells O +
is O +
not O +
well O +
documented O +
. O +

Our O +
experimental O +
data O +
confirm O +
previous O +
studies O +
showing O +
the O +
in O +
vitro O +
cell O +
growth O +
inhibition O +
of O +
the O +
transitional O +
cell O +
carcinoma O +
of O +
the O +
bladder O +
cell O +
line O +
HTB9 B-CellLine +
and O +
further O +
showed O +
the O +
induction O +
of O +
cell O +
cycle O +
arrest O +
at O +
the O +
S O +
/ O +
G2 O +
- O +
M O +
checkpoints O +
. O +

In O +
addition O +
, O +
we O +
found O +
down O +
- O +
regulation O +
of O +
cyclin O +
B O +
, O +
cyclin O +
E O +
, O +
and O +
dephosphorylation O +
of O +
cdk2 O +
in O +
ciprofloxacin O +
- O +
treated O +
bladder O +
tumor O +
cells O +
. O +

There O +
was O +
also O +
an O +
up O +
- O +
regulation O +
of O +
Bax O +
, O +
which O +
altered O +
the O +
Bax O +
: O +
Bcl O +
- O +
2 O +
ratio O +
, O +
which O +
may O +
be O +
responsible O +
for O +
mitochondrial O +
depolarization O +
reported O +
to O +
be O +
involved O +
prior O +
to O +
the O +
induction O +
of O +
apoptosis O +
. O +

The O +
cyclin O +
- O +
dependent O +
kinase O +
inhibitor O +
p21WAF1 O +
level O +
was O +
found O +
to O +
be O +
decreased O +
within O +
12 O +
h O +
of O +
ciprofloxacin O +
treatment O +
and O +
disappeared O +
completely O +
when O +
HTB9 B-CellLine +
cells O +
were O +
treated O +
with O +
200 O +
microg O +
/ O +
ml O +
ciprofloxacin O +
for O +
24 O +
h O +
. O +

The O +
down O +
- O +
regulation O +
of O +
p21WAF1 O +
closely O +
correlated O +
with O +
poly O +
( O +
ADP O +
- O +
ribose O +
) O +
polymerase O +
cleavage O +
and O +
CPP32 O +
activation O +
. O +

Recent O +
studies O +
revealed O +
that O +
p21WAF1 O +
protects O +
cells O +
from O +
apoptosis O +
by O +
arresting O +
them O +
in O +
G1 O +
and O +
further O +
binds O +
to O +
pro O +
- O +
caspase O +
- O +
3 O +
, O +
preventing O +
its O +
activation O +
and O +
thus O +
, O +
inhibiting O +
the O +
apoptotic O +
cascade O +
. O +

Hence O +
, O +
the O +
down O +
- O +
regulation O +
of O +
p21WAF1 O +
, O +
together O +
with O +
the O +
alterations O +
in O +
Bax O +
and O +
cdk2 O +
as O +
observed O +
in O +
our O +
studies O +
, O +
may O +
define O +
a O +
novel O +
mechanism O +
by O +
which O +
ciprofloxacin O +
inhibits O +
tumor O +
cell O +
growth O +
and O +
induces O +
apoptotic O +
cell O +
death O +
. O +

The O +
results O +
of O +
our O +
current O +
studies O +
provide O +
strong O +
experimental O +
evidence O +
for O +
the O +
use O +
of O +
ciprofloxacin O +
as O +
a O +
potential O +
preventive O +
and O +
/ O +
or O +
therapeutic O +
agent O +
for O +
the O +
management O +
of O +
transitional O +
cell O +
carcinoma O +
of O +
the O +
bladder O +
. O +

Genuine O +
monovalent O +
ligands O +
of O +
TrkA O +
nerve O +
growth O +
factor O +
receptors O +
reveal O +
a O +
novel O +
pharmacological O +
mechanism O +
of O +
action O +
. O +

Developing O +
small O +
molecule O +
agonistic O +
ligands O +
for O +
tyrosine O +
kinase O +
receptors O +
has O +
been O +
difficult O +
, O +
and O +
it O +
is O +
generally O +
thought O +
that O +
such O +
ligands O +
require O +
bivalency O +
. O +

Moreover O +
, O +
multisubunit O +
receptors O +
are O +
difficult O +
to O +
target O +
, O +
because O +
each O +
subunit O +
contributes O +
to O +
ligand O +
affinity O +
, O +
and O +
each O +
subunit O +
may O +
have O +
distinct O +
and O +
sometimes O +
opposing O +
functions O +
. O +

Here O +
, O +
the O +
nerve O +
growth O +
factor O +
receptor O +
subunits O +
p75 O +
and O +
the O +
tyrosine O +
kinase O +
TrkA O +
were O +
studied O +
using O +
artificial O +
ligands O +
that O +
bind O +
specifically O +
to O +
their O +
extracellular O +
domain O +
. O +

Bivalent O +
TrkA O +
ligands O +
afford O +
robust O +
signals O +
. O +

However O +
, O +
genuine O +
monomeric O +
and O +
monovalent O +
TrkA O +
ligands O +
afford O +
partial O +
agonism O +
, O +
activate O +
the O +
tyrosine O +
kinase O +
activity O +
, O +
cause O +
receptor O +
internalization O +
, O +
and O +
induce O +
survival O +
and O +
differentiation O +
in O +
cell O +
lines O +
and O +
primary O +
neurons O +
. O +

Monomeric O +
and O +
monovalent O +
TrkA O +
ligands O +
can O +
synergize O +
with O +
ligands O +
that O +
bind O +
the O +
p75 O +
subunit O +
. O +

However O +
, O +
the O +
p75 O +
ligands O +
used O +
in O +
this O +
study O +
must O +
be O +
bivalent O +
, O +
and O +
monovalent O +
p75 O +
ligands O +
have O +
no O +
effect O +
. O +

These O +
findings O +
will O +
be O +
useful O +
in O +
designing O +
and O +
developing O +
screens O +
of O +
small O +
molecules O +
selective O +
for O +
tyrosine O +
kinase O +
receptors O +
and O +
indicate O +
that O +
strategies O +
for O +
designing O +
agonists O +
of O +
multisubunit O +
receptors O +
require O +
consideration O +
of O +
the O +
role O +
of O +
each O +
subunit O +
. O +

Last O +
, O +
the O +
strategy O +
of O +
using O +
anti O +
- O +
receptor O +
mAbs O +
and O +
small O +
molecule O +
hormone O +
mimics O +
as O +
receptor O +
ligands O +
could O +
be O +
applied O +
to O +
the O +
study O +
of O +
many O +
other O +
heteromeric O +
cell O +
surface O +
receptors O +
. O +

Vascular O +
proliferation O +
and O +
enhanced O +
expression O +
of O +
endothelial O +
nitric O +
oxide O +
synthase O +
in O +
human O +
peritoneum O +
exposed O +
to O +
long O +
- O +
term O +
peritoneal O +
dialysis O +
. O +

Long O +
- O +
term O +
peritoneal O +
dialysis O +
( O +
PD O +
) O +
is O +
associated O +
with O +
alterations O +
in O +
peritoneal O +
permeability O +
and O +
loss O +
of O +
ultrafiltration O +
. O +

These O +
changes O +
originate O +
from O +
increased O +
peritoneal O +
surface O +
area O +
, O +
but O +
the O +
morphologic O +
and O +
molecular O +
mechanisms O +
involved O +
remain O +
unknown O +
. O +

The O +
hypothesis O +
that O +
modifications O +
of O +
activity O +
and O +
/ O +
or O +
expression O +
of O +
nitric O +
oxide O +
synthase O +
( O +
NOS O +
) O +
isozymes O +
might O +
play O +
a O +
role O +
in O +
these O +
modifications O +
, O +
via O +
enhanced O +
local O +
production O +
of O +
nitric O +
oxide O +
, O +
was O +
tested O +
in O +
this O +
study O +
. O +

NOS O +
activities O +
were O +
measured O +
by O +
the O +
L O +
- O +
citrulline O +
assay O +
in O +
peritoneal O +
biopsies O +
from O +
seven O +
control O +
subjects O +
, O +
eight O +
uremic O +
patients O +
immediately O +
before O +
the O +
onset O +
of O +
PD O +
, O +
and O +
13 O +
uremic O +
patients O +
on O +
short O +
- O +
term O +
( O +
less O +
than O +
18 O +
mo O +
, O +
n O +
= O +
6 O +
) O +
or O +
long O +
- O +
term O +
( O +
greater O +
than O +
18 O +
mo O +
, O +
n O +
= O +
7 O +
) O +
PD O +
. O +

Peritoneal O +
NOS O +
activity O +
is O +
increased O +
fivefold O +
in O +
long O +
- O +
term O +
PD O +
patients O +
compared O +
with O +
control O +
subjects O +
. O +

In O +
uremic O +
patients O +
, O +
NOS O +
activity O +
is O +
positively O +
correlated O +
with O +
the O +
duration O +
of O +
PD O +
. O +

Increased O +
NOS O +
activity O +
is O +
mediated O +
solely O +
by O +
Ca O +
( O +
2 O +
+ O +
) O +
- O +
dependent O +
NOS O +
and O +
, O +
as O +
shown O +
by O +
immunoblotting O +
, O +
an O +
upregulation O +
of O +
endothelial O +
NOS O +
. O +

The O +
biologic O +
relevance O +
of O +
increased O +
NOS O +
in O +
long O +
- O +
term O +
PD O +
was O +
demonstrated O +
by O +
enhanced O +
nitrotyrosine O +
immunoreactivity O +
and O +
a O +
significant O +
increase O +
in O +
vascular O +
density O +
and O +
endothelial O +
area O +
in O +
the O +
peritoneum O +
. O +

Immunoblotting O +
and O +
immunostaining O +
studies O +
demonstrated O +
an O +
upregulation O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
mostly O +
along O +
the O +
endothelium O +
lining O +
peritoneal O +
blood O +
vessels O +
in O +
long O +
- O +
term O +
PD O +
patients O +
. O +

In O +
the O +
latter O +
, O +
VEGF O +
colocalized O +
with O +
the O +
advanced O +
glycation O +
end O +
product O +
pentosidine O +
deposits O +
. O +

These O +
data O +
provide O +
a O +
morphologic O +
( O +
angiogenesis O +
and O +
increased O +
endothelial O +
area O +
) O +
and O +
molecular O +
( O +
enhanced O +
NOS O +
activity O +
and O +
endothelial O +
NOS O +
upregulation O +
) O +
basis O +
for O +
explaining O +
the O +
permeability O +
changes O +
observed O +
in O +
long O +
- O +
term O +
PD O +
. O +

They O +
also O +
support O +
the O +
implication O +
of O +
local O +
advanced O +
glycation O +
end O +
product O +
deposits O +
and O +
liberation O +
of O +
VEGF O +
in O +
that O +
process O +
. O +

Adenovirus O +
- O +
mediated O +
gene O +
transfer O +
of O +
endostatin O +
in O +
vivo O +
results O +
in O +
high O +
level O +
of O +
transgene O +
expression O +
and O +
inhibition O +
of O +
tumor O +
growth O +
and O +
metastases O +
. O +

Inhibition O +
of O +
angiogenesis O +
has O +
been O +
shown O +
to O +
be O +
an O +
effective O +
strategy O +
in O +
cancer O +
therapy O +
in O +
mice O +
. O +

However O +
, O +
its O +
widespread O +
application O +
has O +
been O +
hampered O +
by O +
difficulties O +
in O +
the O +
large O +
- O +
scale O +
production O +
of O +
the O +
antiangiogenic O +
proteins O +
. O +

This O +
limitation O +
may O +
be O +
resolved O +
by O +
in O +
vivo O +
delivery O +
and O +
expression O +
of O +
the O +
antiangiogenic O +
genes O +
. O +

We O +
have O +
constructed O +
a O +
recombinant O +
adenovirus O +
that O +
expresses O +
murine O +
endostatin O +
that O +
is O +
biologically O +
active O +
both O +
in O +
vitro O +
, O +
as O +
determined O +
in O +
endothelial O +
cell O +
proliferation O +
assays O +
, O +
and O +
in O +
vivo O +
, O +
by O +
suppression O +
of O +
angiogenesis O +
induced O +
by O +
vascular O +
endothelial O +
growth O +
factor O +
165 O +
. O +

Persistent O +
high O +
serum O +
levels O +
of O +
endostatin O +
( O +
605 O +
- O +
1740 O +
ng O +
/ O +
ml O +
; O +
mean O +
, O +
936 O +
ng O +
/ O +
ml O +
) O +
were O +
achieved O +
after O +
systemic O +
administration O +
of O +
the O +
vector O +
to O +
nude O +
mice O +
, O +
which O +
resulted O +
in O +
significant O +
reduction O +
of O +
the O +
growth O +
rates O +
and O +
the O +
volumes O +
of O +
JC O +
breast O +
carcinoma O +
and O +
Lewis O +
lung O +
carcinoma O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
and O +
P O +
less O +
than O +
0 O +
. O +
05 O +
, O +
respectively O +
) O +
. O +

In O +
addition O +
, O +
the O +
endostatin O +
vector O +
treatment O +
completely O +
prevented O +
the O +
formation O +
of O +
pulmonary O +
micrometastases O +
in O +
Lewis O +
lung O +
carcinoma O +
( O +
P O +
= O +
0 O +
. O +
0001 O +
) O +
. O +

Immunohistochemical O +
staining O +
of O +
the O +
tumors O +
demonstrated O +
a O +
decreased O +
number O +
of O +
blood O +
vessels O +
in O +
the O +
treatment O +
group O +
versus O +
the O +
controls O +
. O +

In O +
conclusion O +
, O +
the O +
present O +
study O +
clearly O +
demonstrates O +
the O +
potential O +
of O +
vector O +
- O +
mediated O +
antiangiogenic O +
gene O +
therapy O +
as O +
a O +
component O +
in O +
cancer O +
therapy O +
. O +

Active O +
hair O +
growth O +
( O +
anagen O +
) O +
is O +
associated O +
with O +
angiogenesis O +
. O +

After O +
the O +
completion O +
of O +
skin O +
development O +
, O +
angiogenesis O +
, O +
i O +
. O +
e O +
. O +
, O +
the O +
growth O +
of O +
new O +
capillaries O +
from O +
pre O +
- O +
existing O +
blood O +
vessels O +
, O +
is O +
held O +
to O +
occur O +
in O +
the O +
skin O +
only O +
under O +
pathologic O +
conditions O +
. O +

It O +
has O +
long O +
been O +
noted O +
, O +
however O +
, O +
that O +
hair O +
follicle O +
cycling O +
is O +
associated O +
with O +
prominent O +
changes O +
in O +
skin O +
perfusion O +
, O +
that O +
the O +
epithelial O +
hair O +
bulbs O +
of O +
anagen O +
follicles O +
display O +
angiogenic O +
properties O +
, O +
and O +
that O +
the O +
follicular O +
dermal O +
papilla O +
can O +
produce O +
angiogenic O +
factors O +
. O +

Despite O +
these O +
suggestive O +
observations O +
, O +
no O +
formal O +
proof O +
is O +
as O +
yet O +
available O +
for O +
the O +
concept O +
that O +
angiogenesis O +
is O +
a O +
physiologic O +
event O +
that O +
occurs O +
all O +
over O +
the O +
mature O +
mammalian O +
integument O +
whenever O +
hair O +
follicles O +
switch O +
from O +
resting O +
( O +
telogen O +
) O +
to O +
active O +
growth O +
( O +
anagen O +
) O +
. O +

This O +
study O +
uses O +
quantitative O +
histomorphometry O +
and O +
double O +
- O +
immunohistologic O +
detection O +
techniques O +
for O +
the O +
demarcation O +
of O +
proliferating O +
endothelial O +
cells O +
, O +
to O +
show O +
that O +
synchronized O +
hair O +
follicle O +
cycling O +
in O +
adolescent O +
C57BL O +
/ O +
6 O +
mice O +
is O +
associated O +
with O +
substantial O +
angiogenesis O +
, O +
and O +
that O +
inhibiting O +
angiogenesis O +
in O +
vivo O +
by O +
the O +
intraperitoneal O +
application O +
of O +
a O +
fumagillin O +
derivative O +
retards O +
experimentally O +
induced O +
anagen O +
development O +
in O +
these O +
mice O +
. O +

Thus O +
, O +
angiogenesis O +
is O +
a O +
physiologic O +
event O +
in O +
normal O +
postnatal O +
murine O +
skin O +
, O +
apparently O +
is O +
dictated O +
by O +
the O +
hair O +
follicle O +
, O +
and O +
appears O +
to O +
be O +
required O +
for O +
normal O +
anagen O +
development O +
. O +

Anagen O +
- O +
associated O +
angiogenesis O +
offers O +
an O +
attractive O +
model O +
for O +
identifying O +
the O +
physiologic O +
controls O +
of O +
cutaneous O +
angiogenesis O +
, O +
and O +
an O +
interesting O +
system O +
for O +
screening O +
the O +
effects O +
of O +
potential O +
antiangiogenic O +
drugs O +
in O +
vivo O +
. O +

Abdominal O +
approach O +
for O +
the O +
ligation O +
of O +
bleeding O +
oesophageal O +
varices O +
. O +

The O +
conventional O +
surgical O +
treatment O +
of O +
bleeding O +
oesophageal O +
varices O +
in O +
the O +
emergency O +
situation O +
is O +
based O +
upon O +
the O +
Boerema O +
- O +
Crile O +
operation O +
of O +
transthoracic O +
oesophagotomy O +
and O +
ligation O +
of O +
the O +
varices O +
. O +

This O +
and O +
the O +
other O +
methods O +
of O +
treatment O +
of O +
this O +
condition O +
in O +
current O +
practice O +
are O +
discussed O +
. O +

Two O +
cases O +
are O +
reported O +
in O +
which O +
a O +
transabdominal O +
oesophagogastrotomy O +
was O +
used O +
to O +
approach O +
the O +
site O +
of O +
bleeding O +
. O +

This O +
operation O +
is O +
described O +
and O +
the O +
theoretical O +
and O +
practical O +
advantages O +
it O +
appears O +
to O +
offer O +
over O +
the O +
standard O +
approach O +
are O +
considered O +
. O +

Neuroblastoma O +
and O +
hepatocyte O +
coculture O +
conditioned O +
media O +
alter O +
apoptosis O +
. O +

BACKGROUND O +
: O +
Neuroblastoma O +
is O +
a O +
childhood O +
tumor O +
that O +
often O +
displays O +
unusual O +
biological O +
behavior O +
. O +

The O +
tumor O +
may O +
present O +
with O +
widespread O +
metastases O +
that O +
are O +
unresponsive O +
to O +
aggressive O +
treatment O +
. O +

At O +
other O +
times O +
, O +
both O +
the O +
metastases O +
and O +
the O +
primary O +
tumor O +
may O +
spontaneously O +
regress O +
without O +
treatment O +
. O +

Apoptosis O +
, O +
or O +
programmed O +
cell O +
death O +
, O +
is O +
thought O +
to O +
play O +
a O +
role O +
in O +
the O +
dichotomous O +
behavior O +
of O +
neuroblastoma O +
. O +

We O +
hypothesize O +
that O +
neuroblastoma O +
cells O +
will O +
interact O +
with O +
host O +
tissues O +
to O +
release O +
mediators O +
that O +
affect O +
apoptosis O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +
Human O +
neuroblastoma O +
cells O +
and O +
human O +
Chang O +
hepatocytes O +
are O +
grown O +
in O +
a O +
noncontact O +
, O +
coculture O +
system O +
. O +

After O +
incubation O +
for O +
4 O +
days O +
, O +
the O +
medium O +
from O +
the O +
coculture O +
system O +
is O +
collected O +
. O +

Neuroblastoma O +
cells O +
and O +
Chang O +
hepatocytes O +
are O +
then O +
plated O +
separately O +
with O +
the O +
conditioned O +
medium O +
and O +
their O +
own O +
standard O +
growth O +
medium O +
as O +
controls O +
. O +

After O +
4 O +
days O +
, O +
these O +
cells O +
are O +
harvested O +
and O +
cytospins O +
made O +
for O +
immunostaining O +
. O +

Tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O +
- O +
alpha O +
) O +
, O +
Fas O +
ligand O +
, O +
and O +
Bcl O +
- O +
2 O +
, O +
are O +
measured O +
with O +
immunohistochemistry O +
. O +

Apoptosis O +
is O +
detected O +
with O +
the O +
TUNEL O +
method O +
. O +

Immunostaining O +
data O +
are O +
interpreted O +
with O +
computer O +
image O +
analysis O +
and O +
reported O +
as O +
stain O +
index O +
. O +

TUNEL O +
data O +
are O +
reported O +
as O +
percentage O +
apoptotic O +
cells O +
. O +

All O +
data O +
are O +
reported O +
as O +
means O +
+ O +
/ O +
- O +
SEM O +
. O +

Statistical O +
analysis O +
is O +
performed O +
and O +
P O +
< O +
0 O +
. O +
05 O +
considered O +
significant O +
. O +

RESULTS O +
: O +
Chang O +
hepatocytes O +
grown O +
in O +
the O +
coculture O +
conditioned O +
media O +
have O +
an O +
increase O +
in O +
TNF O +
- O +
alpha O +
and O +
Fas O +
ligand O +
. O +

The O +
neuroblastoma O +
cells O +
have O +
a O +
significant O +
decrease O +
in O +
Fas O +
ligand O +
. O +

There O +
is O +
a O +
significant O +
increase O +
in O +
the O +
number O +
of O +
apoptotic O +
hepatocytes O +
when O +
they O +
are O +
cultured O +
in O +
the O +
conditioned O +
media O +
. O +

In O +
contrast O +
, O +
the O +
neuroblastoma O +
cells O +
grown O +
in O +
the O +
coculture O +
conditioned O +
media O +
show O +
no O +
increase O +
in O +
apoptosis O +
. O +

Finally O +
, O +
Bcl O +
- O +
2 O +
is O +
significantly O +
increased O +
in O +
the O +
neuroblastoma O +
cells O +
cultured O +
in O +
the O +
conditioned O +
media O +
. O +

CONCLUSIONS O +
: O +
Neuroblastoma O +
cells O +
grown O +
in O +
coculture O +
conditioned O +
media O +
show O +
increased O +
expression O +
of O +
Bcl O +
- O +
2 O +
and O +
decreased O +
Fas O +
ligand O +
levels O +
. O +

These O +
changes O +
should O +
diminish O +
apoptosis O +
activity O +
in O +
the O +
tumor O +
cells O +
. O +

In O +
contrast O +
, O +
the O +
conditioned O +
media O +
induce O +
elevated O +
levels O +
of O +
proapoptotic O +
mediators O +
in O +
the O +
Chang O +
hepatocytes O +
. O +

A O +
tumor O +
' O +
s O +
ability O +
to O +
successfully O +
metastasize O +
may O +
be O +
dependent O +
on O +
mediators O +
generated O +
in O +
the O +
tumor O +
- O +
host O +
interaction O +
, O +
and O +
may O +
not O +
be O +
just O +
an O +
independent O +
characteristic O +
of O +
the O +
tumor O +
itself O +
. O +

Neoplastic O +
transformation O +
by O +
Notch O +
requires O +
nuclear O +
localization O +
. O +

Notch O +
proteins O +
are O +
plasma O +
membrane O +
- O +
spanning O +
receptors O +
that O +
mediate O +
important O +
cell O +
fate O +
decisions O +
such O +
as O +
differentiation O +
, O +
proliferation O +
, O +
and O +
apoptosis O +
. O +

The O +
mechanism O +
of O +
Notch O +
signaling O +
remains O +
poorly O +
understood O +
. O +

However O +
, O +
it O +
is O +
clear O +
that O +
the O +
Notch O +
signaling O +
pathway O +
mediates O +
its O +
effects O +
through O +
intercellular O +
contact O +
between O +
neighboring O +
cells O +
. O +

The O +
prevailing O +
model O +
for O +
Notch O +
signaling O +
suggests O +
that O +
ligand O +
, O +
presented O +
on O +
a O +
neighboring O +
cell O +
, O +
triggers O +
proteolytic O +
processing O +
of O +
Notch O +
. O +

Following O +
proteolysis O +
, O +
it O +
is O +
thought O +
that O +
the O +
intracellular O +
portion O +
of O +
Notch O +
( O +
N O +
( O +
ic O +
) O +
) O +
translocates O +
to O +
the O +
nucleus O +
, O +
where O +
it O +
is O +
involved O +
in O +
regulating O +
gene O +
expression O +
. O +

There O +
is O +
considerable O +
debate O +
concerning O +
where O +
in O +
the O +
cell O +
Notch O +
functions O +
and O +
what O +
proteins O +
serve O +
as O +
effectors O +
of O +
the O +
Notch O +
signal O +
. O +

Several O +
Notch O +
genes O +
have O +
clearly O +
been O +
shown O +
to O +
be O +
proto O +
- O +
oncogenes O +
in O +
mammalian O +
cells O +
. O +

Activation O +
of O +
Notch O +
proto O +
- O +
oncogenes O +
has O +
been O +
associated O +
with O +
tumorigenesis O +
in O +
several O +
human O +
and O +
other O +
mammalian O +
cancers O +
. O +

Transforming O +
alleles O +
of O +
Notch O +
direct O +
the O +
expression O +
of O +
truncated O +
proteins O +
that O +
primarily O +
consist O +
of O +
N O +
( O +
ic O +
) O +
and O +
are O +
not O +
tethered O +
to O +
the O +
plasma O +
membrane O +
. O +

However O +
, O +
the O +
mechanism O +
by O +
which O +
Notch O +
oncoproteins O +
( O +
generically O +
termed O +
here O +
as O +
N O +
( O +
ic O +
) O +
) O +
induce O +
neoplastic O +
transformation O +
is O +
not O +
known O +
. O +

Previously O +
we O +
demonstrated O +
that O +
N1 O +
( O +
ic O +
) O +
and O +
N2 O +
( O +
ic O +
) O +
could O +
transform O +
E1A O +
immortalized O +
baby O +
rat O +
kidney O +
cells O +
( O +
RKE O +
) O +
in O +
vitro O +
. O +

We O +
now O +
report O +
direct O +
evidence O +
that O +
N1 O +
( O +
ic O +
) O +
must O +
accumulate O +
in O +
the O +
nucleus O +
to O +
induce O +
transformation O +
of O +
RKE O +
cells O +
. O +

In O +
addition O +
, O +
we O +
define O +
the O +
minimal O +
domain O +
of O +
N1 O +
( O +
ic O +
) O +
required O +
to O +
induce O +
transformation O +
and O +
present O +
evidence O +
that O +
transformation O +
of O +
RKE O +
cells O +
by O +
N1 O +
( O +
ic O +
) O +
is O +
likely O +
to O +
be O +
through O +
a O +
CBF1 O +
- O +
independent O +
pathway O +
. O +

High O +
frequency O +
of O +
hypermethylation O +
at O +
the O +
14 O +
- O +
3 O +
- O +
3 O +
sigma O +
locus O +
leads O +
to O +
gene O +
silencing O +
in O +
breast O +
cancer O +
. O +

Expression O +
of O +
14 O +
- O +
3 O +
- O +
3 O +
final O +
sigma O +
( O +
final O +
sigma O +
) O +
is O +
induced O +
in O +
response O +
to O +
DNA O +
damage O +
, O +
and O +
causes O +
cells O +
to O +
arrest O +
in O +
G O +
( O +
2 O +
) O +
. O +

By O +
SAGE O +
( O +
serial O +
analysis O +
of O +
gene O +
expression O +
) O +
analysis O +
, O +
we O +
identified O +
final O +
sigma O +
as O +
a O +
gene O +
whose O +
expression O +
is O +
7 O +
- O +
fold O +
lower O +
in O +
breast O +
carcinoma O +
cells O +
than O +
in O +
normal O +
breast O +
epithelium O +
. O +

We O +
verified O +
this O +
finding O +
by O +
Northern O +
blot O +
analysis O +
. O +

Remarkably O +
, O +
final O +
sigma O +
mRNA O +
was O +
undetectable O +
in O +
45 O +
of O +
48 O +
primary O +
breast O +
carcinomas O +
. O +

Genetic O +
alterations O +
at O +
final O +
sigma O +
such O +
as O +
loss O +
of O +
heterozygosity O +
were O +
rare O +
( O +
1 O +
/ O +
20 O +
informative O +
cases O +
) O +
, O +
and O +
no O +
mutations O +
were O +
detected O +
( O +
0 O +
/ O +
34 O +
) O +
. O +

On O +
the O +
other O +
hand O +
, O +
hypermethylation O +
of O +
CpG O +
islands O +
in O +
the O +
final O +
sigma O +
gene O +
was O +
detected O +
in O +
91 O +
% O +
( O +
75 O +
/ O +
82 O +
) O +
of O +
breast O +
tumors O +
and O +
was O +
associated O +
with O +
lack O +
of O +
gene O +
expression O +
. O +

Hypermethylation O +
of O +
final O +
sigma O +
is O +
functionally O +
important O +
, O +
because O +
treatment O +
of O +
final O +
sigma O +
- O +
non O +
- O +
expressing O +
breast O +
cancer O +
cell O +
lines O +
with O +
the O +
drug O +
5 O +
- O +
aza O +
- O +
2 O +
' O +
- O +
deoxycytidine O +
resulted O +
in O +
demethylation O +
of O +
the O +
gene O +
and O +
synthesis O +
of O +
final O +
sigma O +
mRNA O +
. O +

Breast O +
cancer O +
cells O +
lacking O +
final O +
sigma O +
expression O +
showed O +
increased O +
number O +
of O +
chromosomal O +
breaks O +
and O +
gaps O +
when O +
exposed O +
to O +
gamma O +
- O +
irradiation O +
. O +

Therefore O +
, O +
it O +
is O +
possible O +
that O +
loss O +
of O +
final O +
sigma O +
expression O +
contributes O +
to O +
malignant O +
transformation O +
by O +
impairing O +
the O +
G O +
( O +
2 O +
) O +
cell O +
cycle O +
checkpoint O +
function O +
, O +
thus O +
allowing O +
an O +
accumulation O +
of O +
genetic O +
defects O +
. O +

Hypermethylation O +
and O +
loss O +
of O +
final O +
sigma O +
expression O +
are O +
the O +
most O +
consistent O +
molecular O +
alterations O +
in O +
breast O +
cancer O +
identified O +
so O +
far O +
. O +

Alpha O +
- O +
melanocyte O +
- O +
stimulating O +
hormone O +
modulates O +
activation O +
of O +
NF O +
- O +
kappa O +
B O +
and O +
AP O +
- O +
1 O +
and O +
secretion O +
of O +
interleukin O +
- O +
8 O +
in O +
human O +
dermal O +
fibroblasts O +
. O +

Alpha O +
- O +
melanocyte O +
- O +
stimulating O +
hormone O +
( O +
alpha O +
- O +
MSH O +
) O +
has O +
evolved O +
as O +
a O +
mediator O +
of O +
diverse O +
biological O +
activities O +
in O +
an O +
ever O +
- O +
growing O +
number O +
of O +
non O +
- O +
melanocytic O +
cell O +
types O +
. O +

One O +
mechanism O +
by O +
which O +
alpha O +
- O +
MSH O +
exerts O +
its O +
effects O +
is O +
modulation O +
of O +
AP O +
- O +
1 O +
and O +
NF O +
- O +
kappa O +
B O +
. O +

These O +
two O +
transcription O +
factors O +
also O +
play O +
an O +
important O +
role O +
in O +
fibroblasts O +
, O +
in O +
extracellular O +
matrix O +
composition O +
, O +
and O +
in O +
cytokine O +
expression O +
. O +

By O +
use O +
of O +
electric O +
mobility O +
shift O +
assays O +
, O +
we O +
demonstrate O +
that O +
alpha O +
- O +
MSH O +
( O +
10 O +
( O +
- O +
6 O +
) O +
to O +
10 O +
( O +
- O +
14 O +
) O +
M O +
) O +
activates O +
AP O +
- O +
1 O +
in O +
human O +
dermal O +
fibroblasts O +
, O +
whereas O +
coincubation O +
with O +
interleukin O +
- O +
1 O +
beta O +
( O +
IL O +
- O +
1 O +
beta O +
) O +
results O +
in O +
suppression O +
of O +
its O +
activation O +
. O +

alpha O +
- O +
MSH O +
also O +
induces O +
activation O +
of O +
NF O +
- O +
kappa O +
B O +
but O +
does O +
not O +
modulate O +
DNA O +
binding O +
on O +
costimulation O +
with O +
IL O +
- O +
1 O +
beta O +
. O +

Since O +
AP O +
- O +
1 O +
and O +
NF O +
- O +
kappa O +
B O +
are O +
key O +
elements O +
in O +
controlling O +
interleukin O +
- O +
8 O +
( O +
IL O +
- O +
8 O +
) O +
transcription O +
, O +
human O +
fibroblasts O +
were O +
treated O +
with O +
alpha O +
- O +
MSH O +
and O +
IL O +
- O +
1 O +
beta O +
for O +
24 O +
hours O +
, O +
and O +
cytokine O +
levels O +
in O +
the O +
supernatants O +
were O +
measured O +
by O +
ELISA O +
. O +

alpha O +
- O +
MSH O +
alone O +
had O +
little O +
effect O +
, O +
whereas O +
coincubation O +
with O +
IL O +
- O +
1 O +
beta O +
led O +
to O +
marked O +
downregulation O +
of O +
IL O +
- O +
8 O +
secretion O +
( O +
at O +
most O +
288 O +
+ O +
/ O +
- O +
152 O +
ng O +
/ O +
mL O +
) O +
when O +
compared O +
to O +
treatment O +
with O +
IL O +
- O +
1 O +
beta O +
alone O +
( O +
919 O +
+ O +
/ O +
- O +
157 O +
ng O +
/ O +
mL O +
) O +
. O +

Our O +
results O +
indicate O +
that O +
alpha O +
- O +
MSH O +
exerts O +
modulatory O +
effects O +
on O +
the O +
activation O +
of O +
NF O +
- O +
kappa O +
B O +
and O +
AP O +
- O +
1 O +
, O +
and O +
that O +
it O +
can O +
regulate O +
chemokine O +
secretion O +
in O +
human O +
dermal O +
fibroblasts O +
. O +

These O +
effects O +
of O +
alpha O +
- O +
MSH O +
may O +
have O +
important O +
regulatory O +
functions O +
in O +
extracellular O +
matrix O +
composition O +
, O +
wound O +
healing O +
, O +
or O +
angiogenesis O +
. O +

Application O +
of O +
microsatellite O +
PCR O +
techniques O +
in O +
the O +
identification O +
of O +
mixed O +
up O +
tissue O +
specimens O +
in O +
surgical O +
pathology O +
. O +

A O +
fragment O +
of O +
tumour O +
was O +
erroneously O +
mixed O +
up O +
with O +
an O +
endometrial O +
biopsy O +
. O +

Micro O +
- O +
satellite O +
polymerase O +
chain O +
reaction O +
( O +
PCR O +
) O +
clearly O +
demonstrated O +
the O +
extraneous O +
nature O +
of O +
the O +
fragment O +
. O +

Micro O +
- O +
satellite O +
PCR O +
may O +
be O +
useful O +
for O +
the O +
identification O +
of O +
mis O +
- O +
labelled O +
or O +
mismatched O +
tissue O +
fragments O +
in O +
surgical O +
pathology O +
specimens O +
. O +

CD40 O +
expression O +
on O +
human O +
lung O +
cancer O +
correlates O +
with O +
metastatic O +
spread O +
. O +

PURPOSE O +
: O +
The O +
poor O +
prognosis O +
associated O +
with O +
lung O +
cancer O +
is O +
related O +
to O +
the O +
high O +
incidence O +
of O +
regional O +
and O +
distant O +
metastasis O +
. O +

There O +
is O +
a O +
crucial O +
need O +
to O +
identify O +
parameters O +
that O +
can O +
predict O +
a O +
tendancy O +
to O +
metastatic O +
spread O +
to O +
allow O +
better O +
prognostic O +
evaluation O +
and O +
therapeutic O +
approach O +
. O +

METHODS O +
: O +
Using O +
flow O +
cytometry O +
we O +
evaluated O +
18 O +
human O +
lung O +
cancer O +
cell O +
lines O +
for O +
the O +
expression O +
of O +
different O +
surface O +
markers O +
on O +
lung O +
cancers O +
suggested O +
to O +
be O +
possible O +
prognostic O +
parameters O +
, O +
including O +
epidermal O +
growth O +
factor O +
receptor O +
( O +
EGFR O +
) O +
, O +
intercellular O +
adhesion O +
molecule O +
1 O +
( O +
ICAM O +
- O +
1 O +
) O +
, O +
Fas O +
and O +
CD40 O +
. O +

RESULTS O +
: O +
No O +
correlation O +
was O +
found O +
between O +
tumor O +
prognosis O +
and O +
EGFR O +
, O +
ICAM O +
- O +
1 O +
or O +
Fas O +
. O +

However O +
, O +
a O +
statistically O +
significant O +
correlation O +
was O +
found O +
between O +
the O +
surface O +
expression O +
of O +
CD40 O +
and O +
the O +
metastatic O +
spread O +
of O +
the O +
tumor O +
. O +

In O +
this O +
study O +
, O +
14 O +
of O +
18 O +
lung O +
cancer O +
cell O +
lines O +
( O +
78 O +
% O +
) O +
expressed O +
CD40 O +
on O +
their O +
surface O +
. O +

All O +
of O +
the O +
4 O +
tumors O +
that O +
were O +
CD40 O +
- O +
negative O +
, O +
were O +
stage O +
I O +
tumors O +
, O +
without O +
any O +
evidence O +
of O +
regional O +
or O +
distant O +
metastasis O +
. O +

Of O +
the O +
14 O +
tumors O +
that O +
expressed O +
CD40 O +
, O +
all O +
but O +
1 O +
( O +
93 O +
% O +
) O +
had O +
either O +
nodal O +
or O +
systemic O +
metastasis O +
at O +
the O +
time O +
of O +
diagnosis O +
. O +

Patients O +
whose O +
tumors O +
were O +
CD40 O +
- O +
negative O +
showed O +
a O +
significantly O +
better O +
N O +
stage O +
, O +
overall O +
stage O +
at O +
presentation O +
and O +
survival O +
than O +
those O +
patients O +
with O +
CD40 O +
- O +
positive O +
patients O +
. O +

No O +
significant O +
differences O +
between O +
the O +
two O +
groups O +
were O +
observed O +
in O +
tumor O +
size O +
, O +
gender O +
, O +
age O +
, O +
histology O +
, O +
differentiation O +
or O +
preoperative O +
therapy O +
. O +

CONCLUSIONS O +
: O +
These O +
results O +
suggest O +
that O +
CD40 O +
expression O +
on O +
lung O +
cancer O +
may O +
play O +
a O +
role O +
in O +
metastatic O +
spread O +
, O +
and O +
also O +
may O +
serve O +
as O +
a O +
prognostic O +
marker O +
and O +
an O +
indicator O +
of O +
advanced O +
disease O +
. O +

Specific O +
subgroup O +
B O +
adenovirus O +
diagnosis O +
by O +
PCR O +
of O +
the O +
fibre O +
gene O +
. O +

OBJECTIVE O +
: O +

A O +
highly O +
sensitive O +
and O +
specific O +
PCR O +
assay O +
targeting O +
regions O +
of O +
the O +
fibre O +
gene O +
was O +
developed O +
for O +
the O +
identification O +
of O +
subgroup O +
B O +
adenovirus O +
strains O +
. O +

This O +
is O +
critical O +
, O +
since O +
these O +
adenovirus O +
strains O +
are O +
frequently O +
associated O +
with O +
severe O +
respiratory O +
infections O +
in O +
infants O +
and O +
new O +
- O +
borns O +
. O +

METHODS O +
: O +

Clinical O +
samples O +
from O +
nasopharyngeal O +
aspirates O +
were O +
analysed O +
by O +
PCR O +
using O +
several O +
sets O +
of O +
primers O +
corresponding O +
to O +
sequences O +
of O +
the O +
gene O +
coding O +
for O +
the O +
fibre O +
protein O +
. O +

RESULTS O +
: O +

The O +
assay O +
allowed O +
the O +
detection O +
and O +
identification O +
of O +
all O +
the O +
genotypes O +
of O +
adenovirus O +
subgroup O +
B O +
, O +
based O +
on O +
the O +
size O +
of O +
the O +
amplified O +
product O +
when O +
analysed O +
on O +
polyacrilamide O +
gel O +
electrophoresis O +
. O +

Specifically O +
, O +
one O +
set O +
of O +
primers O +
was O +
able O +
to O +
amplify O +
DNA O +
of O +
subgroup O +
B O +
but O +
not O +
subgroup O +
C O +
and O +
E O +
viruses O +
. O +

CONCLUSION O +
: O +

The O +
detection O +
of O +
adenovirus O +
and O +
the O +
genotyping O +
can O +
be O +
done O +
on O +
a O +
routine O +
basis O +
by O +
a O +
PCR O +
assay O +
using O +
the O +
fibre O +
gene O +
as O +
a O +
target O +
. O +

The O +
assay O +
allows O +
the O +
identification O +
of O +
ADV O +
subgroup O +
B O +
, O +
including O +
genotype O +
7h O +
, O +
which O +
is O +
the O +
single O +
most O +
important O +
viral O +
pathogen O +
associated O +
with O +
respiratory O +
diseases O +
in O +
infants O +
and O +
young O +
children O +
in O +
the O +
southern O +
part O +
of O +
South O +
America O +
. O +

Stimulation O +
of O +
the O +
sodium O +
pump O +
by O +
azide O +
and O +
high O +
internal O +
sodium O +
: O +
changes O +
in O +
the O +
number O +
of O +
pumping O +
sites O +
and O +
turnover O +
rate O +
. O +

1 O +
. O +

The O +
effects O +
of O +
5 O +
mM O +
azide O +
on O +
[ O +
3H O +
] O +
ouabain O +
uptake O +
and O +
22Na O +
efflux O +
were O +
determined O +
. O +

Both O +
glycoside O +
uptake O +
and O +
22Na O +
efflux O +
were O +
enhanced O +
by O +
azide O +
. O +

2 O +
. O +

Azide O +
stimulated O +
the O +
Na O +
pump O +
in O +
muscles O +
whose O +
pumping O +
sites O +
had O +
been O +
inhibited O +
by O +
ouabain O +
and O +
then O +
transferred O +
to O +
a O +
glycoside O +
- O +
free O +
solution O +
. O +

This O +
stimulation O +
was O +
observed O +
before O +
detecting O +
any O +
recovery O +
of O +
the O +
initial O +
pumping O +
activity O +
. O +

3 O +
. O +

When O +
both O +
the O +
resting O +
and O +
the O +
azide O +
- O +
stimulated O +
22Na O +
efflux O +
had O +
been O +
blocked O +
by O +
ouabain O +
, O +
an O +
additional O +
exposure O +
to O +
azide O +
, O +
in O +
a O +
ouabain O +
- O +
free O +
solution O +
, O +
had O +
no O +
further O +
effects O +
on O +
22Na O +
efflux O +
. O +

4 O +
. O +

It O +
is O +
concluded O +
that O +
the O +
increase O +
in O +
Na O +
pumping O +
caused O +
by O +
azide O +
is O +
due O +
in O +
part O +
to O +
an O +
increase O +
in O +
the O +
number O +
of O +
pumping O +
sites O +
. O +

5 O +
. O +

[ O +
3H O +
] O +
ouabain O +
binding O +
was O +
measured O +
in O +
muscles O +
with O +
different O +
intracellular O +
alkali O +
cation O +
concentrations O +
. O +

Variations O +
in O +
[ O +
Na O +
] O +
i O +
from O +
15 O +
up O +
to O +
50 O +
mM O +
did O +
not O +
significantly O +
affect O +
the O +
amount O +
of O +
glycoside O +
bound O +
. O +

A O +
substantial O +
increase O +
in O +
binding O +
occurred O +
when O +
[ O +
Na O +
] O +
i O +
reached O +
70 O +
mM O +
. O +

6 O +
. O +

It O +
is O +
proposed O +
that O +
the O +
increase O +
in O +
Na O +
extrusion O +
that O +
occurs O +
during O +
the O +
recovery O +
of O +
Na O +
loaded O +
muscles O +
mostly O +
results O +
from O +
an O +
increased O +
turnover O +
rate O +
of O +
the O +
pump O +
rather O +
than O +
from O +
an O +
increase O +
in O +
number O +
of O +
pumping O +
sites O +
. O +

The O +
value O +
of O +
serum O +
S O +
- O +
100beta O +
and O +
interleukins O +
as O +
tumour O +
markers O +
in O +
advanced O +
melanoma O +
. O +

Recently O +
serum O +
S O +
- O +
100beta O +
has O +
shown O +
promise O +
as O +
a O +
tumour O +
marker O +
in O +
melanoma O +
; O +
however O +
, O +
its O +
use O +
as O +
a O +
prognostic O +
marker O +
in O +
the O +
advanced O +
stage O +
needs O +
to O +
be O +
confirmed O +
. O +

Interleukins O +
( O +
ILs O +
) O +
may O +
mediate O +
regression O +
or O +
progression O +
of O +
cancer O +
. O +

In O +
order O +
to O +
study O +
their O +
relation O +
to O +
the O +
metastatic O +
profile O +
and O +
survival O +
, O +
we O +
evaluated O +
the O +
association O +
between O +
pretreatment O +
serum O +
levels O +
of O +
S O +
- O +
100beta O +
, O +
IL O +
- O +
6 O +
, O +
IL O +
- O +
10 O +
and O +
IL O +
- O +
12 O +
and O +
metastatic O +
site O +
and O +
survival O +
in O +
50 O +
patients O +
with O +
advanced O +
melanoma O +
who O +
were O +
to O +
receive O +
chemoimmunotherapy O +
. O +

Patients O +
with O +
liver O +
and O +
/ O +
or O +
bone O +
metastases O +
had O +
significantly O +
higher O +
median O +
concentrations O +
of O +
S O +
- O +
100beta O +
, O +
IL O +
- O +
6 O +
and O +
IL O +
- O +
10 O +
than O +
those O +
with O +
only O +
skin O +
, O +
nodal O +
and O +
/ O +
or O +
lung O +
involvement O +
. O +

The O +
differences O +
in O +
IL O +
- O +
12 O +
levels O +
were O +
unremarkable O +
. O +

Using O +
univariate O +
analysis O +
, O +
the O +
S O +
- O +
100beta O +
level O +
and O +
metastatic O +
profile O +
were O +
found O +
to O +
be O +
statistically O +
significant O +
prognostic O +
factors O +
for O +
survival O +
. O +

Using O +
multivariate O +
analysis O +
the O +
S O +
- O +
100beta O +
level O +
was O +
the O +
most O +
powerful O +
prognostic O +
indicator O +
, O +
while O +
the O +
metastatic O +
profile O +
was O +
found O +
to O +
be O +
significant O +
after O +
exclusion O +
of O +
S O +
- O +
100beta O +
. O +

The O +
findings O +
suggest O +
that O +
elevated O +
serum O +
levels O +
of O +
S O +
- O +
100beta O +
, O +
IL O +
- O +
6 O +
and O +
IL O +
- O +
10 O +
reflect O +
concurrent O +
liver O +
or O +
bone O +
metastases O +
in O +
melanoma O +
. O +

S O +
- O +
100beta O +
is O +
also O +
an O +
independent O +
prognostic O +
marker O +
. O +

Pretreatment O +
IL O +
levels O +
were O +
not O +
associated O +
with O +
outcome O +
. O +

TEL O +
, O +
a O +
putative O +
tumor O +
suppressor O +
, O +
modulates O +
cell O +
growth O +
and O +
cell O +
morphology O +
of O +
ras O +
- O +
transformed O +
cells O +
while O +
repressing O +
the O +
transcription O +
of O +
stromelysin O +
- O +
1 O +
. O +

TEL O +
is O +
a O +
member O +
of O +
the O +
ETS O +
family O +
of O +
transcription O +
factors O +
that O +
interacts O +
with O +
the O +
mSin3 O +
and O +
SMRT O +
corepressors O +
to O +
regulate O +
transcription O +
. O +

TEL O +
is O +
biallelically O +
disrupted O +
in O +
acute O +
leukemia O +
, O +
and O +
loss O +
of O +
heterozygosity O +
at O +
the O +
TEL O +
locus O +
has O +
been O +
observed O +
in O +
various O +
cancers O +
. O +

Here O +
we O +
show O +
that O +
expression O +
of O +
TEL O +
in O +
Ras O +
- O +
transformed O +
NIH B-CellLine +
3T3 I-CellLine +
cells O +
inhibits O +
cell O +
growth O +
in O +
soft O +
agar O +
and O +
in O +
normal O +
cultures O +
. O +

Unexpectedly O +
, O +
cells O +
expressing O +
both O +
Ras O +
and O +
TEL O +
grew O +
as O +
aggregates O +
. O +

To O +
begin O +
to O +
explain O +
the O +
morphology O +
of O +
Ras O +
- O +
plus O +
TEL O +
- O +
expressing O +
cells O +
, O +
we O +
demonstrated O +
that O +
the O +
endogenous O +
matrix O +
metalloproteinase O +
stromelysin O +
- O +
1 O +
was O +
repressed O +
by O +
TEL O +
. O +

TEL O +
bound O +
sequences O +
in O +
the O +
stromelysin O +
- O +
1 O +
promoter O +
and O +
repressed O +
the O +
promoter O +
in O +
transient O +
- O +
expression O +
assays O +
, O +
suggesting O +
that O +
it O +
is O +
a O +
direct O +
target O +
for O +
TEL O +
- O +
mediated O +
regulation O +
. O +

Mutants O +
of O +
TEL O +
that O +
removed O +
a O +
binding O +
site O +
for O +
the O +
mSin3A O +
corepressor O +
but O +
retained O +
the O +
ETS O +
domain O +
failed O +
to O +
repress O +
stromelysin O +
- O +
1 O +
. O +

When O +
BB O +
- O +
94 O +
, O +
a O +
matrix O +
metalloproteinase O +
inhibitor O +
, O +
was O +
added O +
to O +
the O +
culture O +
medium O +
of O +
Ras O +
- O +
expressing O +
cells O +
, O +
it O +
caused O +
a O +
cell O +
aggregation O +
phenotype O +
similar O +
to O +
that O +
caused O +
by O +
TEL O +
expression O +
. O +

In O +
addition O +
, O +
TEL O +
inhibited O +
the O +
invasiveness O +
of O +
Ras O +
- O +
transformed O +
cells O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

Our O +
results O +
suggest O +
that O +
TEL O +
acts O +
as O +
a O +
tumor O +
suppressor O +
, O +
in O +
part O +
, O +
by O +
transcriptional O +
repression O +
of O +
stromelysin O +
- O +
1 O +
. O +

Caspase O +
- O +
3 O +
is O +
essential O +
for O +
procaspase O +
- O +
9 O +
processing O +
and O +
cisplatin O +
- O +
induced O +
apoptosis O +
of O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
breast O +
cancer O +
cells O +
. O +

In O +
this O +
study O +
, O +
we O +
sought O +
to O +
investigate O +
in O +
more O +
detail O +
the O +
role O +
of O +
caspase O +
- O +
3 O +
in O +
apoptotic O +
processes O +
in O +
cultured O +
cells O +
and O +
in O +
cell O +
- O +
free O +
extracts O +
of O +
breast O +
cancer O +
cells O +
. O +

We O +
present O +
evidence O +
that O +
apoptosis O +
of O +
caspase O +
- O +
3 O +
- O +
deficient O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
breast O +
cancer O +
cells O +
is O +
defective O +
in O +
response O +
to O +
cisplatin O +
treatment O +
, O +
as O +
determined O +
by O +
chromatin O +
condensation O +
, O +
nuclear O +
fragmentation O +
, O +
DNA O +
fragmentation O +
, O +
and O +
release O +
of O +
cytochrome O +
c O +
from O +
the O +
mitochondria O +
. O +

Reconstitution O +
of O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
cells O +
by O +
stable O +
transfection O +
of O +
CASP O +
- O +
3 O +
cDNA O +
restores O +
all O +
these O +
defects O +
and O +
results O +
in O +
an O +
extensive O +
apoptosis O +
after O +
cisplatin O +
treatment O +
. O +

We O +
further O +
show O +
that O +
in O +
extracts O +
from O +
caspase O +
- O +
3 O +
- O +
deficient O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
cells O +
, O +
procaspase O +
- O +
9 O +
processing O +
is O +
strongly O +
impaired O +
after O +
stimulation O +
with O +
either O +
cytochrome O +
c O +
or O +
recombinant O +
caspase O +
- O +
8 O +
. O +

Reconstitution O +
of O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
cell O +
extracts O +
with O +
procaspase O +
- O +
3 O +
corrects O +
this O +
defect O +
, O +
resulting O +
in O +
an O +
efficient O +
and O +
complete O +
processing O +
of O +
procaspase O +
- O +
9 O +
. O +

Together O +
, O +
our O +
data O +
define O +
caspase O +
- O +
3 O +
as O +
an O +
important O +
integrator O +
of O +
the O +
apoptotic O +
process O +
in O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
breast O +
cancer O +
cells O +
and O +
reveal O +
an O +
essential O +
function O +
of O +
caspase O +
- O +
3 O +
for O +
procaspase O +
- O +
9 O +
processing O +
. O +

Vasodilator O +
- O +
stimulated O +
phosphoprotein O +
is O +
involved O +
in O +
stress O +
- O +
fiber O +
and O +
membrane O +
ruffle O +
formation O +
in O +
endothelial O +
cells O +
. O +

Vasodilator O +
- O +
stimulated O +
phosphoprotein O +
( O +
VASP O +
) O +
is O +
highly O +
expressed O +
in O +
vascular O +
endothelial O +
cells O +
, O +
where O +
it O +
has O +
been O +
implicated O +
in O +
cellular O +
reorganization O +
during O +
angiogenesis O +
, O +
as O +
well O +
as O +
in O +
endothelial O +
retraction O +
and O +
changes O +
in O +
vessel O +
permeability O +
. O +

However O +
, O +
the O +
cellular O +
functions O +
of O +
VASP O +
are O +
not O +
known O +
. O +

In O +
this O +
study O +
, O +
we O +
have O +
expressed O +
wild O +
- O +
type O +
and O +
mutant O +
forms O +
of O +
VASP O +
in O +
endothelial O +
cells O +
to O +
determine O +
in O +
what O +
aspects O +
of O +
cytoskeletal O +
behavior O +
this O +
protein O +
participates O +
. O +

Expression O +
of O +
wild O +
- O +
type O +
VASP O +
induces O +
marked O +
membrane O +
ruffling O +
and O +
formation O +
of O +
prominent O +
stress O +
fibers O +
in O +
bovine O +
aortic O +
endothelial O +
cells O +
. O +

Deletion O +
of O +
the O +
proline O +
- O +
rich O +
domain O +
of O +
VASP O +
abolishes O +
its O +
ability O +
to O +
bind O +
profilin O +
but O +
does O +
not O +
affect O +
ruffling O +
or O +
stress O +
fiber O +
formation O +
. O +

Further O +
deletions O +
reveal O +
a O +
sequence O +
within O +
the O +
carboxy O +
- O +
terminal O +
domain O +
that O +
is O +
responsible O +
for O +
in O +
vivo O +
bundle O +
formation O +
. O +

Ruffling O +
occurs O +
only O +
on O +
the O +
expression O +
of O +
forms O +
of O +
VASP O +
that O +
possess O +
bundling O +
activity O +
and O +
the O +
capacity O +
to O +
bind O +
zyxin O +
/ O +
vinculin O +
- O +
derived O +
peptide O +
. O +

The O +
ability O +
of O +
distinct O +
subdomains O +
within O +
VASP O +
to O +
bind O +
adhesion O +
proteins O +
and O +
induce O +
F O +
- O +
actin O +
bundling O +
in O +
vivo O +
suggests O +
that O +
this O +
protein O +
could O +
function O +
in O +
the O +
aggregation O +
and O +
tethering O +
of O +
actin O +
filaments O +
during O +
the O +
formation O +
of O +
endothelial O +
cell O +
- O +
substrate O +
and O +
cell O +
- O +
cell O +
contacts O +
. O +

These O +
data O +
provide O +
a O +
mechanism O +
whereby O +
VASP O +
can O +
influence O +
endothelial O +
migration O +
and O +
organization O +
during O +
capillary O +
formation O +
and O +
modulate O +
vascular O +
permeability O +
via O +
effects O +
on O +
endothelial O +
cell O +
contractility O +
. O +

Urokinase O +
receptor O +
: O +
a O +
molecular O +
organizer O +
in O +
cellular O +
communication O +
. O +

In O +
a O +
variety O +
of O +
cell O +
types O +
, O +
the O +
glycolipid O +
- O +
anchored O +
urokinase O +
receptor O +
( O +
uPAR O +
) O +
is O +
colocalized O +
pericellularly O +
with O +
components O +
of O +
the O +
plasminogen O +
activation O +
system O +
and O +
endocytosis O +
receptors O +
. O +

uPAR O +
is O +
also O +
coexpressed O +
with O +
caveolin O +
and O +
members O +
of O +
the O +
integrin O +
adhesion O +
receptor O +
superfamily O +
. O +

The O +
formation O +
of O +
functional O +
units O +
with O +
these O +
various O +
proteins O +
allows O +
the O +
uPAR O +
to O +
mediate O +
the O +
focused O +
proteolysis O +
required O +
for O +
cell O +
migration O +
and O +
invasion O +
and O +
to O +
contribute O +
both O +
directly O +
and O +
indirectly O +
to O +
cell O +
adhesive O +
processes O +
in O +
a O +
non O +
- O +
proteolytic O +
fashion O +
. O +

This O +
dual O +
activity O +
, O +
together O +
with O +
the O +
initiation O +
of O +
signal O +
transduction O +
pathways O +
by O +
uPAR O +
, O +
is O +
believed O +
to O +
influence O +
cellular O +
behaviour O +
in O +
angiogenesis O +
, O +
inflammation O +
, O +
wound O +
repair O +
and O +
tumor O +
progression O +
/ O +
metastasis O +
and O +
open O +
up O +
the O +
way O +
for O +
uPAR O +
- O +
based O +
therapeutic O +
approaches O +
. O +

Reduced O +
oncogenicity O +
of O +
p190 O +
Bcr O +
/ O +
Abl O +
F O +
- O +
actin O +
- O +
binding O +
domain O +
mutants O +
. O +

The O +
deregulated O +
Bcr O +
/ O +
Abl O +
tyrosine O +
kinase O +
is O +
responsible O +
for O +
the O +
development O +
of O +
Philadelphia O +
( O +
Ph O +
) O +
- O +
positive O +
leukemia O +
in O +
humans O +
. O +

To O +
investigate O +
the O +
significance O +
of O +
the O +
C O +
- O +
terminal O +
Abl O +
actin O +
- O +
binding O +
domain O +
within O +
Bcr O +
/ O +
Abl O +
p190 O +
in O +
the O +
development O +
of O +
leukemia O +
/ O +
lymphoma O +
in O +
vivo O +
, O +
mutant O +
p190 O +
DNA O +
constructs O +
were O +
used O +
to O +
generate O +
transgenic O +
mice O +
. O +

Eight O +
founder O +
and O +
progeny O +
mice O +
of O +
5 O +
different O +
lines O +
were O +
monitored O +
for O +
leukemogenesis O +
. O +

Latency O +
was O +
markedly O +
increased O +
and O +
occurrence O +
decreased O +
in O +
the O +
p190 O +
del O +
C O +
lines O +
as O +
compared O +
with O +
nonmutated O +
p190 O +
BCR O +
/ O +
ABL O +
transgenics O +
. O +

Western O +
blot O +
analysis O +
of O +
involved O +
hematologic O +
tissues O +
of O +
the O +
p190 O +
del O +
C O +
transgenics O +
with O +
end O +
- O +
stage O +
disease O +
showed O +
high O +
- O +
level O +
expression O +
of O +
the O +
transgene O +
and O +
tyrosine O +
phosphorylation O +
of O +
Cbl O +
and O +
Hef1 O +
/ O +
Cas O +
, O +
proteins O +
previously O +
shown O +
to O +
be O +
affected O +
by O +
Bcr O +
/ O +
Abl O +
. O +

These O +
results O +
show O +
that O +
the O +
actin O +
- O +
binding O +
domain O +
of O +
Abl O +
enhances O +
leukemia O +
development O +
but O +
does O +
not O +
appear O +
to O +
be O +
an O +
absolute O +
requirement O +
for O +
leukemogenesis O +
. O +

Building O +
the O +
vertebrate O +
vasculature O +
: O +
research O +
is O +
going O +
swimmingly O +
. O +

The O +
vertebrate O +
vasculature O +
develops O +
in O +
remarkably O +
similar O +
fashion O +
in O +
all O +
vertebrates O +
. O +

A O +
cohort O +
of O +
unspecified O +
mesodermal O +
cells O +
differentiates O +
into O +
primitive O +
endothelial O +
cells O +
, O +
which O +
migrate O +
to O +
and O +
occupy O +
positions O +
within O +
the O +
stereotypical O +
blueprint O +
of O +
the O +
primitive O +
vasculature O +
. O +

Once O +
in O +
position O +
, O +
these O +
cells O +
coalesce O +
and O +
form O +
cords O +
, O +
which O +
lumenize O +
and O +
become O +
ensheathed O +
by O +
supporting O +
pericytes O +
and O +
smooth O +
muscle O +
cells O +
. O +

This O +
primitive O +
vascular O +
network O +
is O +
extensively O +
remodeled O +
in O +
some O +
places O +
, O +
and O +
expanded O +
by O +
sprouting O +
in O +
others O +
. O +

Various O +
studies O +
using O +
the O +
mouse O +
, O +
quail O +
/ O +
chick O +
, O +
and O +
frog O +
have O +
uncovered O +
a O +
number O +
of O +
signals O +
that O +
guide O +
these O +
complex O +
processes O +
but O +
many O +
gaps O +
still O +
exist O +
in O +
our O +
understanding O +
of O +
the O +
mechanisms O +
by O +
which O +
the O +
embryonic O +
vasculature O +
is O +
built O +
. O +

Because O +
many O +
questions O +
will O +
require O +
in O +
vivo O +
studies O +
to O +
be O +
properly O +
addressed O +
, O +
the O +
zebrafish O +
, O +
with O +
its O +
unique O +
accessibility O +
to O +
analysis O +
by O +
combined O +
embryological O +
, O +
molecular O +
, O +
and O +
genetic O +
methods O +
, O +
should O +
prove O +
invaluable O +
in O +
identifying O +
new O +
molecules O +
involved O +
in O +
blood O +
vessel O +
development O +
and O +
integrating O +
pathways O +
that O +
influence O +
embryonic O +
blood O +
vessel O +
formation O +
. O +

Nitric O +
oxide O +
synthase O +
inhibition O +
results O +
in O +
synergistic O +
anti O +
- O +
tumour O +
activity O +
with O +
melphalan O +
and O +
tumour O +
necrosis O +
factor O +
alpha O +
- O +
based O +
isolated O +
limb O +
perfusions O +
. O +

Nitric O +
oxide O +
( O +
NO O +
) O +
is O +
an O +
important O +
molecule O +
in O +
regulating O +
tumour O +
blood O +
flow O +
and O +
stimulating O +
tumour O +
angiogenesis O +
. O +

Inhibition O +
of O +
NO O +
synthase O +
by O +
L O +
- O +
NAME O +
might O +
induce O +
an O +
anti O +
- O +
tumour O +
effect O +
by O +
limiting O +
nutrients O +
and O +
oxygen O +
to O +
reach O +
tumour O +
tissue O +
or O +
affecting O +
vascular O +
growth O +
. O +

The O +
anti O +
- O +
tumour O +
effect O +
of O +
L O +
- O +
NAME O +
after O +
systemic O +
administration O +
was O +
studied O +
in O +
a O +
renal O +
subcapsular O +
CC531 B-CellLine +
adenocarcinoma O +
model O +
in O +
rats O +
. O +

Moreover O +
, O +
regional O +
administration O +
of O +
L O +
- O +
NAME O +
, O +
in O +
combination O +
with O +
TNF O +
and O +
melphalan O +
, O +
was O +
studied O +
in O +
an O +
isolated O +
limb O +
perfusion O +
( O +
ILP O +
) O +
model O +
using O +
BN175 O +
soft O +
- O +
tissue O +
sarcomas O +
. O +

Systemic O +
treatment O +
with O +
L O +
- O +
NAME O +
inhibited O +
growth O +
of O +
adenocarcinoma O +
significantly O +
but O +
was O +
accompanied O +
by O +
impaired O +
renal O +
function O +
. O +

In O +
ILP O +
, O +
reduced O +
tumour O +
growth O +
was O +
observed O +
when O +
L O +
- O +
NAME O +
was O +
used O +
alone O +
. O +

In O +
combination O +
with O +
TNF O +
or O +
melphalan O +
, O +
L O +
- O +
NAME O +
increased O +
response O +
rates O +
significantly O +
compared O +
to O +
perfusions O +
without O +
L O +
- O +
NAME O +
( O +
0 O +
- O +
64 O +
% O +
and O +
0 O +
- O +
63 O +
% O +
respectively O +
) O +
. O +

An O +
additional O +
anti O +
- O +
tumour O +
effect O +
was O +
demonstrated O +
when O +
L O +
- O +
NAME O +
was O +
added O +
to O +
the O +
synergistic O +
combination O +
of O +
melphalan O +
and O +
TNF O +
( O +
responses O +
increased O +
from O +
70 O +
to O +
100 O +
% O +
) O +
. O +

Inhibition O +
of O +
NO O +
synthase O +
reduces O +
tumour O +
growth O +
both O +
after O +
systemic O +
and O +
regional O +
( O +
ILP O +
) O +
treatment O +
. O +

A O +
synergistic O +
anti O +
- O +
tumour O +
effect O +
of O +
L O +
- O +
NAME O +
is O +
observed O +
in O +
combination O +
with O +
melphalan O +
and O +
/ O +
or O +
TNF O +
using O +
ILP O +
. O +

These O +
results O +
indicate O +
a O +
possible O +
role O +
of O +
L O +
- O +
NAME O +
for O +
the O +
treatment O +
of O +
solid O +
tumours O +
in O +
a O +
systemic O +
or O +
regional O +
setting O +
. O +

p75 O +
mediated O +
apoptosis O +
in O +
neuroblastoma O +
cells O +
is O +
inhibited O +
by O +
expression O +
of O +
TrkA O +
. O +

BACKGROUND O +
: O +
Neurotrophins O +
mediate O +
their O +
effects O +
by O +
binding O +
to O +
members O +
of O +
the O +
Trk O +
family O +
of O +
receptor O +
tyrosine O +
kinases O +
and O +
to O +
the O +
low O +
- O +
affinity O +
nerve O +
growth O +
factor O +
receptor O +
p75 O +
. O +

Nerve O +
growth O +
factor O +
( O +
NGF O +
) O +
has O +
been O +
demonstrated O +
to O +
support O +
survival O +
and O +
differentiation O +
of O +
neuroblastoma O +
( O +
NB O +
) O +
cells O +
by O +
activation O +
of O +
the O +
TrkA O +
receptor O +
. O +

The O +
p75 O +
receptor O +
belongs O +
to O +
the O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
family O +
of O +
death O +
receptors O +
and O +
has O +
been O +
suggested O +
as O +
a O +
receptor O +
that O +
mediates O +
apoptosis O +
in O +
neuronal O +
and O +
NB O +
cells O +
. O +

PROCEDURE O +
: O +
To O +
investigate O +
the O +
effect O +
of O +
p75 O +
expression O +
in O +
NB O +
, O +
we O +
transfected O +
the O +
p75 O +
cDNA O +
into O +
SH B-CellLine +
- I-CellLine +
SY5Y I-CellLine +
cells O +
, O +
an O +
NB O +
cell O +
line O +
lacking O +
expression O +
of O +
both O +
p75 O +
and O +
TrkA O +
. O +

RESULTS O +
: O +
Cell O +
clones O +
expressing O +
elevated O +
levels O +
of O +
p75 O +
showed O +
a O +
high O +
degree O +
of O +
apoptosis O +
even O +
in O +
10 O +
% O +
serum O +
- O +
supplemented O +
medium O +
. O +

Apoptotic O +
signaling O +
by O +
p75 O +
was O +
ligand O +
- O +
independent O +
and O +
only O +
partly O +
caspase O +
- O +
dependent O +
. O +

The O +
level O +
of O +
apoptosis O +
correlated O +
directly O +
with O +
the O +
expression O +
level O +
of O +
the O +
receptor O +
, O +
indicating O +
that O +
p75 O +
may O +
activate O +
the O +
cell O +
death O +
program O +
directly O +
. O +

However O +
, O +
additional O +
transfection O +
of O +
TrkA O +
into O +
SY5Y B-CellLine +
- O +
p75 O +
cells O +
resulted O +
in O +
a O +
significantly O +
reduced O +
rate O +
of O +
apoptosis O +
even O +
in O +
the O +
absence O +
of O +
NGF O +
. O +

CONCLUSIONS O +
: O +
Thus O +
, O +
expression O +
of O +
the O +
TrkA O +
receptor O +
itself O +
inhibits O +
p75 O +
mediated O +
apoptosis O +
in O +
NB O +
cells O +
. O +

[ O +
Interleukin O +
- O +
18 O +
and O +
new O +
drugs O +
. O +
Protective O +
effect O +
against O +
tumor O +
growth O +
and O +
infections O +
] O +
. O +

IL O +
- O +
18 O +
, O +
originally O +
identified O +
as O +
interferon O +
- O +
gamma O +
inducing O +
factor O +
( O +
IGIF O +
) O +
, O +
is O +
related O +
to O +
the O +
IL O +
- O +
1 O +
family O +
in O +
terms O +
of O +
its O +
structure O +
as O +
well O +
as O +
its O +
processing O +
, O +
receptor O +
, O +
signal O +
transduction O +
pathway O +
and O +
pro O +
- O +
inflammatory O +
properties O +
. O +

IL O +
- O +
18 O +
is O +
also O +
functionally O +
related O +
to O +
IL O +
- O +
12 O +
, O +
as O +
it O +
induces O +
the O +
production O +
of O +
Th1 O +
cytokines O +
and O +
participates O +
in O +
cell O +
- O +
mediated O +
immune O +
cytotoxicity O +
. O +

A O +
summary O +
is O +
made O +
of O +
recent O +
advances O +
in O +
the O +
understanding O +
of O +
IL O +
- O +
18 O +
structure O +
, O +
processing O +
, O +
receptor O +
expression O +
and O +
immunoregulatory O +
functions O +
. O +

It O +
focuses O +
on O +
the O +
role O +
of O +
IL O +
- O +
18 O +
modulation O +
in O +
tumours O +
, O +
infections O +
and O +
autoimmune O +
and O +
inflammatory O +
diseases O +
. O +

RNA O +
damage O +
and O +
inhibition O +
of O +
neoplastic O +
endothelial O +
cell O +
growth O +
: O +
effects O +
of O +
human O +
and O +
amphibian O +
ribonucleases O +
. O +

Angiogenesis O +
defines O +
the O +
many O +
steps O +
involved O +
in O +
the O +
growth O +
and O +
migration O +
of O +
endothelial O +
cell O +
- O +
derived O +
blood O +
vessels O +
. O +

This O +
process O +
is O +
necessary O +
for O +
the O +
growth O +
and O +
metastasis O +
of O +
tumors O +
, O +
and O +
considerable O +
effort O +
is O +
being O +
expended O +
to O +
find O +
inhibitors O +
of O +
tumor O +
angiogenesis O +
. O +

This O +
usually O +
involves O +
screening O +
of O +
potential O +
anti O +
- O +
angiogenic O +
compounds O +
on O +
endothelial O +
cells O +
. O +

To O +
this O +
end O +
, O +
two O +
candidate O +
anti O +
- O +
angiogenic O +
RNA O +
- O +
damaging O +
agents O +
, O +
onconase O +
and O +
( O +
- O +
4 O +
) O +
rhEDN O +
, O +
were O +
screened O +
for O +
their O +
effects O +
on O +
endothelial O +
cell O +
proliferation O +
using O +
three O +
distinct O +
types O +
of O +
endothelial O +
cells O +
in O +
culture O +
: O +
HPV O +
- O +
16 O +
E6 O +
/ O +
E7 O +
- O +
immortalized O +
human B-CellLine +
umbilical I-CellLine +
vein I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
( O +
HUVECs B-CellLine +
) O +
, O +
a O +
Kras O +
- O +
transformed O +
HPV O +
- O +
16 O +
E6 O +
/ O +
E7 O +
HUVEC B-CellLine +
( O +
Rhim O +
et O +
al O +
. O +
, O +
Carcinogenesis O +
4 O +
, O +
673 O +
- O +
681 O +
, O +
1998 O +
) O +
, O +
and O +
primary O +
HUVECs O +
. O +

Onconase O +
similarly O +
inhibited O +
proliferation O +
in O +
all O +
three O +
cell O +
lines O +
( O +
IC O +
( O +
50 O +
) O +
= O +
0 O +
. O +
3 O +
- O +
1 O +
. O +
0 O +
microM O +
) O +
while O +
( O +
- O +
4 O +
) O +
rhEDN O +
was O +
more O +
effective O +
on O +
immortalized O +
HUVEC B-CellLine +
cell O +
lines O +
( O +
IC O +
( O +
50 O +
) O +
= O +
0 O +
. O +
02 O +
- O +
0 O +
. O +
06 O +
microM O +
) O +
than O +
on O +
primary O +
HUVECs O +
( O +
IC O +
( O +
50 O +
) O +
> O +
0 O +
. O +
1 O +
microM O +
) O +
. O +

Differential O +
sensitivity O +
to O +
these O +
agents O +
implies O +
that O +
more O +
than O +
one O +
endothelial O +
cell O +
type O +
must O +
be O +
used O +
in O +
proliferation O +
assays O +
to O +
screen O +
for O +
novel O +
anti O +
- O +
angiogenic O +
compounds O +
. O +

Apoptosis O +
induced O +
by O +
1 O +
' O +
- O +
acetoxychavicol O +
acetate O +
in O +
Ehrlich O +
ascites O +
tumor O +
cells O +
is O +
associated O +
with O +
modulation O +
of O +
polyamine O +
metabolism O +
and O +
caspase O +
- O +
3 O +
activation O +
. O +

The O +
efficacy O +
of O +
the O +
antitumor O +
activity O +
of O +
1 O +
' O +
- O +
acetoxychavicol O +
acetate O +
( O +
ACA O +
) O +
, O +
reported O +
to O +
be O +
a O +
suppressor O +
of O +
chemically O +
induced O +
carcinogenesis O +
, O +
was O +
evaluated O +
in O +
Ehrlich O +
ascites O +
tumor O +
cells O +
. O +

ACA O +
treatment O +
resulted O +
in O +
changes O +
in O +
morphology O +
and O +
a O +
dose O +
- O +
dependent O +
suppression O +
of O +
cell O +
viability O +
. O +

Apoptosis O +
, O +
characterized O +
by O +
nuclear O +
condensation O +
, O +
membrane O +
blebbing O +
, O +
cell O +
shrinkage O +
and O +
a O +
significant O +
induction O +
of O +
caspase O +
- O +
3 O +
- O +
like O +
protease O +
activity O +
at O +
8 O +
h O +
in O +
a O +
time O +
- O +
course O +
study O +
were O +
observed O +
. O +

Formation O +
of O +
apoptotic O +
bodies O +
was O +
preceded O +
by O +
lowering O +
of O +
intracellular O +
polyamines O +
, O +
particularly O +
putrescine O +
, O +
and O +
both O +
dose O +
- O +
and O +
time O +
- O +
dependent O +
inhibitory O +
and O +
activation O +
effect O +
by O +
ACA O +
on O +
ornithine O +
decarboxylase O +
( O +
ODC O +
) O +
and O +
spermidine O +
/ O +
spermine O +
N O +
( O +
1 O +
) O +
- O +
acetyltransferase O +
( O +
SSAT O +
) O +
, O +
respectively O +
. O +

Administration O +
of O +
exogenous O +
polyamines O +
prevented O +
ACA O +
- O +
induced O +
apoptosis O +
represented O +
by O +
a O +
reduction O +
in O +
the O +
number O +
of O +
apoptotic O +
bodies O +
and O +
also O +
caused O +
reduction O +
in O +
the O +
induced O +
caspase O +
- O +
3 O +
- O +
like O +
protease O +
activity O +
at O +
8 O +
h O +
. O +

These O +
findings O +
suggest O +
that O +
the O +
anticarcinogenic O +
effects O +
of O +
ACA O +
might O +
be O +
partly O +
due O +
to O +
perturbation O +
of O +
the O +
polyamine O +
metabolic O +
pathway O +
and O +
triggering O +
of O +
caspase O +
- O +
3 O +
- O +
like O +
activity O +
, O +
which O +
result O +
in O +
apoptosis O +
. O +

Focal O +
congenital O +
alveolar O +
proteinosis O +
associated O +
with O +
abnormal O +
surfactant O +
protein O +
B O +
messenger O +
RNA O +
. O +

Two O +
siblings O +
presented O +
with O +
typical O +
clinical O +
features O +
of O +
congenital O +
pulmonary O +
alveolar O +
proteinosis O +
( O +
PAP O +
) O +
. O +

Necropsy O +
of O +
one O +
sibling O +
revealed O +
scattered O +
foci O +
of O +
the O +
diagnostic O +
histologic O +
changes O +
in O +
the O +
lung O +
tissue O +
. O +

In O +
contrast O +
to O +
infantile O +
and O +
adult O +
PAP O +
, O +
focal O +
distribution O +
is O +
uncommon O +
in O +
congenital O +
PAP O +
. O +

Defective O +
expression O +
of O +
the O +
granulocyte O +
- O +
macrophage O +
colony O +
- O +
stimulating O +
factor O +
receptor O +
was O +
ruled O +
out O +
. O +

The O +
surfactant O +
protein O +
B O +
( O +
SP O +
- O +
B O +
) O +
content O +
in O +
the O +
lung O +
tissue O +
of O +
the O +
autopsied O +
patient O +
was O +
low O +
, O +
and O +
a O +
deletion O +
in O +
the O +
SP O +
- O +
B O +
messenger O +
RNA O +
was O +
detected O +
. O +

We O +
speculate O +
that O +
the O +
PAP O +
in O +
our O +
patients O +
was O +
related O +
to O +
the O +
reduced O +
quantity O +
and O +
/ O +
or O +
to O +
the O +
altered O +
quality O +
of O +
SP O +
- O +
B O +
. O +

TRADD O +
domain O +
of O +
Epstein O +
- O +
Barr O +
virus O +
transforming O +
protein O +
LMP1 O +
is O +
essential O +
for O +
inducing O +
immortalization O +
and O +
suppressing O +
senescence O +
of O +
primary O +
rodent O +
fibroblasts O +
. O +

Mutation O +
analysis O +
of O +
latent O +
membrane O +
protein O +
1 O +
( O +
LMP1 O +
) O +
in O +
Epstein O +
- O +
Barr O +
virus O +
( O +
EBV O +
) O +
- O +
induced O +
B O +
- O +
cell O +
immortalization O +
revealed O +
two O +
transformation O +
effector O +
sites O +
, O +
TES1 O +
and O +
TES2 O +
. O +

TES2 O +
mediates O +
the O +
interaction O +
with O +
tumor O +
necrosis O +
factor O +
receptor O +
- O +
associated O +
death O +
domain O +
protein O +
( O +
TRADD O +
) O +
and O +
plays O +
a O +
key O +
role O +
in O +
transactivating O +
NF O +
- O +
kappa O +
B O +
and O +
AP O +
- O +
1 O +
. O +

Recombinant O +
EBV O +
containing O +
LMP1 O +
with O +
TES2 O +
deleted O +
induces O +
a O +
limited O +
proliferation O +
of O +
B O +
cells O +
. O +

The O +
present O +
study O +
shows O +
that O +
a O +
mutant O +
with O +
an O +
LMP1 O +
site O +
- O +
specific O +
mutation O +
at O +
TES2 O +
, O +
LMP1 O +
( O +
TRADD O +
) O +
, O +
initially O +
stimulates O +
cell O +
growth O +
and O +
significantly O +
extends O +
the O +
life O +
span O +
of O +
MEF O +
. O +

However O +
, O +
it O +
is O +
not O +
sufficient O +
for O +
the O +
immortalization O +
of O +
MEF O +
, O +
and O +
MEF O +
- O +
LMP1 O +
( O +
TRADD O +
) O +
cells O +
eventually O +
enter O +
growth O +
arrest O +
. O +

Further O +
analysis O +
reveals O +
that O +
although O +
LMP1 O +
( O +
TRADD O +
) O +
promotes O +
cell O +
growth O +
, O +
it O +
does O +
not O +
prevent O +
the O +
eventual O +
onset O +
of O +
senescence O +
and O +
the O +
expression O +
of O +
tumor O +
suppressor O +
p16 O +
( O +
Ink4a O +
) O +
. O +

IL O +
- O +
12 O +
inhibition O +
of O +
endothelial O +
cell O +
functions O +
and O +
angiogenesis O +
depends O +
on O +
lymphocyte O +
- O +
endothelial O +
cell O +
cross O +
- O +
talk O +
. O +

In O +
vivo O +
IL O +
- O +
12 O +
- O +
dependent O +
tumor O +
inhibition O +
rests O +
on O +
the O +
ability O +
of O +
IL O +
- O +
12 O +
to O +
activate O +
a O +
CD8 O +
- O +
mediated O +
cytotoxicity O +
, O +
inhibit O +
angiogenesis O +
, O +
and O +
cause O +
vascular O +
injury O +
. O +

Although O +
in O +
vivo O +
studies O +
have O +
shown O +
that O +
such O +
inhibition O +
stems O +
from O +
complex O +
interactions O +
of O +
immune O +
cells O +
and O +
the O +
production O +
of O +
IFN O +
- O +
gamma O +
and O +
other O +
downstream O +
angiostatic O +
chemokines O +
, O +
the O +
mechanisms O +
involved O +
are O +
still O +
poorly O +
defined O +
. O +

Here O +
we O +
show O +
that O +
IL O +
- O +
12 O +
activates O +
an O +
anti O +
- O +
angiogenic O +
program O +
in O +
Con O +
A O +
- O +
activated O +
mouse O +
spleen O +
cells O +
( O +
activated O +
spc O +
) O +
or O +
human O +
PBMC O +
( O +
activated O +
PBMC O +
) O +
. O +

The O +
soluble O +
factors O +
they O +
release O +
in O +
its O +
presence O +
arrest O +
the O +
cycle O +
of O +
endothelial O +
cells O +
( O +
EC O +
) O +
, O +
inhibit O +
in O +
vitro O +
angiogenesis O +
, O +
negatively O +
modulate O +
the O +
production O +
of O +
matrix O +
metalloproteinase O +
- O +
9 O +
, O +
and O +
the O +
ability O +
of O +
EC O +
to O +
adhere O +
to O +
vitronectin O +
and O +
up O +
- O +
regulate O +
ICAM O +
- O +
1 O +
and O +
VCAM O +
- O +
1 O +
expression O +
. O +

These O +
effects O +
do O +
not O +
require O +
direct O +
cell O +
- O +
cell O +
contact O +
, O +
yet O +
result O +
from O +
continuous O +
interaction O +
between O +
activated O +
lymphoid O +
cells O +
and O +
EC O +
. O +

We O +
used O +
neutralizing O +
Abs O +
to O +
show O +
that O +
the O +
IFN O +
- O +
inducible O +
protein O +
- O +
10 O +
and O +
monokine O +
- O +
induced O +
by O +
IFN O +
- O +
gamma O +
chemokines O +
are O +
pivotal O +
in O +
inducing O +
these O +
effects O +
. O +

Experiments O +
with O +
nu O +
/ O +
nu O +
mice O +
, O +
nonobese O +
diabetic O +
- O +
SCID O +
mice O +
, O +
or O +
activated O +
spc O +
enriched O +
in O +
specific O +
cell O +
subpopulations O +
demonstrated O +
that O +
CD4 O +
( O +
+ O +
) O +
, O +
CD8 O +
( O +
+ O +
) O +
, O +
and O +
NK O +
cells O +
are O +
all O +
needed O +
to O +
mediate O +
the O +
full O +
anti O +
- O +
angiogenetic O +
effect O +
of O +
IL O +
- O +
12 O +
. O +

[ O +
Study O +
of O +
fungus O +
polysaccharides O +
compounds O +
( O +
FPC O +
) O +
in O +
inducing O +
the O +
apoptosis O +
of O +
liver O +
cancer O +
cell O +
Bel B-CellLine +
- I-CellLine +
7402 I-CellLine +
] O +
. O +

To O +
observe O +
the O +
influence O +
of O +
fungus O +
polysaccharides O +
compounds O +
( O +
FPC O +
) O +
in O +
inducing O +
human O +
liver O +
cancer O +
cell O +
Bel B-CellLine +
- I-CellLine +
7402 I-CellLine +
apoptosis O +
in O +
cell O +
cultivating O +
in O +
vitro O +
, O +
the O +
authors O +
analyzed O +
tumor O +
inhibitive O +
gene O +
P53 O +
expression O +
in O +
Bel B-CellLine +
- I-CellLine +
7402 I-CellLine +
apoptosis O +
by O +
applying O +
double O +
immuno O +
- O +
marker O +
. O +

The O +
result O +
showed O +
that O +
the O +
multilevel O +
of O +
FPC O +
could O +
all O +
apparently O +
induce O +
Bel B-CellLine +
- I-CellLine +
7402 I-CellLine +
apoptosis O +
. O +

With O +
the O +
enhancement O +
of O +
FPC O +
concentration O +
, O +
the O +
authors O +
observed O +
chromatin O +
condensation O +
in O +
some O +
phases O +
companying O +
with O +
the O +
characteristic O +
apoptosis O +
. O +

In O +
the O +
meantime O +
, O +
it O +
could O +
also O +
greatly O +
reduce O +
the O +
G1 O +
and O +
S O +
, O +
with O +
obviously O +
dose O +
- O +
response O +
relationship O +
. O +

The O +
percentage O +
of O +
cell O +
apoptosis O +
increased O +
with O +
the O +
enhancing O +
of O +
concentration O +
. O +

In O +
the O +
high O +
- O +
level O +
group O +
the O +
authors O +
found O +
typical O +
DNA O +
ladder O +
eletrophoresis O +
stripe O +
. O +

The O +
result O +
showed O +
that O +
the O +
mechanism O +
of O +
the O +
FPC O +
antineoplastic O +
effect O +
had O +
an O +
intimate O +
relation O +
with O +
its O +
induction O +
to O +
apoptosis O +
and O +
that O +
the O +
result O +
of O +
FPC O +
inducing O +
tumor O +
cell O +
apoptosis O +
had O +
the O +
character O +
of O +
P53 O +
independence O +
. O +

Tonometry O +
in O +
normal O +
and O +
scarred O +
corneas O +
, O +
and O +
in O +
postkeratoplasty O +
eyes O +
: O +
a O +
comparative O +
study O +
of O +
the O +
Goldmann O +
, O +
the O +
ProTon O +
and O +
the O +
Schiotz O +
tonometers O +
. O +

PURPOSE O +
: O +

Clinical O +
comparison O +
of O +
intraocular O +
pressure O +
( O +
IOP O +
) O +
measured O +
with O +
the O +
Goldmann O +
applanation O +
tonometer O +
( O +
GAT O +
) O +
, O +
the O +
ProTon O +
tonometer O +
( O +
PT O +
) O +
, O +
and O +
the O +
Schiotz O +
tonometer O +
( O +
ST O +
) O +
, O +
in O +
normal O +
eyes O +
, O +
eyes O +
with O +
scarred O +
corneas O +
and O +
postkeratoplasty O +
eyes O +
. O +

MATERIAL O +
AND O +
METHODS O +
: O +

The O +
IOP O +
readings O +
with O +
GAT O +
, O +
PT O +
, O +
and O +
ST O +
were O +
compared O +
in O +
125 O +
eyes O +
with O +
normal O +
corneas O +
( O +
Group O +
A O +
) O +
, O +
17 O +
eyes O +
with O +
scarred O +
corneas O +
( O +
Group O +
B O +
) O +
, O +
and O +
in O +
21 O +
postkeratoplasty O +
eyes O +
( O +
Group O +
C O +
) O +
. O +

The O +
data O +
were O +
statistically O +
analysed O +
at O +
95 O +
% O +
confidence O +
interval O +
; O +
linear O +
regression O +
analysis O +
and O +
paired O +
t O +
- O +
test O +
were O +
done O +
. O +

RESULTS O +
: O +

The O +
mean O +
differences O +
and O +
their O +
standard O +
deviation O +
[ O +
SD O +
] O +
between O +
GAT O +
and O +
PT O +
readings O +
, O +
and O +
GAT O +
and O +
ST O +
readings O +
respectively O +
were O +
: O +
[ O +
1 O +
] O +
in O +
Group O +
A O +
: O +
- O +
0 O +
. O +
23 O +
[ O +
SD O +
2 O +
. O +
75 O +
] O +
mmHg O +
and O +
+ O +
0 O +
. O +
24 O +
[ O +
SD O +
3 O +
. O +
18 O +
] O +
mmHg O +
respectively O +
; O +
[ O +
2 O +
] O +
in O +
Group O +
B O +
: O +
- O +
1 O +
. O +
8 O +
[ O +
SD O +
12 O +
. O +
67 O +
] O +
mmHg O +
and O +
- O +
4 O +
. O +
5 O +
[ O +
SD O +
9 O +
. O +
95 O +
mmHg O +
; O +
and O +
[ O +
3 O +
] O +
in O +
Group O +
C O +
: O +
+ O +
0 O +
. O +
24 O +
[ O +
SD O +
8 O +
. O +
72 O +
] O +
mmHg O +
and O +
- O +
0 O +
. O +
12 O +
[ O +
SD O +
8 O +
. O +
7 O +
] O +
mmHg O +
. O +

They O +
were O +
not O +
statistically O +
significant O +
. O +

In O +
Group O +
A O +
the O +
95 O +
% O +
confidence O +
interval O +
between O +
GAT O +
and O +
PT O +
readings O +
was O +
- O +
5 O +
. O +
27 O +
mmHg O +
to O +
5 O +
. O +
73 O +
mmHg O +
, O +
and O +
between O +
GAT O +
and O +
ST O +
readings O +
, O +
- O +
6 O +
. O +
12 O +
mmHg O +
to O +
6 O +
. O +
59 O +
mmHg O +
. O +

Ninety O +
six O +
[ O +
77 O +
% O +
] O +
eyes O +
with O +
the O +
PT O +
and O +
84 O +
[ O +
69 O +
% O +
] O +
eyes O +
with O +
ST O +
measurements O +
were O +
within O +
3 O +
mmHg O +
of O +
GAT O +
pressure O +
. O +

The O +
correlation O +
coefficients O +
[ O +
r O +
] O +
for O +
PT O +
and O +
ST O +
were O +
0 O +
. O +
93 O +
[ O +
P O +
= O +
0 O +
. O +
0000 O +
] O +
and O +
0 O +
. O +
88 O +
[ O +
P O +
= O +
0 O +
. O +
0000 O +
] O +
respectively O +
. O +

In O +
Group O +
B O +
95 O +
% O +
confidence O +
interval O +
between O +
GAT O +
and O +
PT O +
readings O +
was O +
- O +
27 O +
. O +
17 O +
mmHg O +
to O +
23 O +
. O +
51 O +
mmHg O +
, O +
and O +
between O +
GAT O +
and O +
ST O +
measurement O +
, O +
- O +
24 O +
. O +
37 O +
mmHg O +
to O +
15 O +
. O +
44 O +
mmHg O +
. O +

The O +
correlation O +
coefficients O +
[ O +
r O +
] O +
for O +
the O +
PT O +
and O +
ST O +
were O +
0 O +
. O +
112 O +
[ O +
P O +
= O +
0 O +
. O +
660 O +
] O +
and O +
0 O +
. O +
630 O +
[ O +
P O +
= O +
0 O +
. O +
006 O +
] O +
respectively O +
. O +

In O +
group O +
C O +
, O +
the O +
95 O +
% O +
confidence O +
interval O +
between O +
GAT O +
and O +
PT O +
measurements O +
was O +
- O +
17 O +
. O +
20 O +
mmHg O +
to O +
17 O +
. O +
67 O +
mmHg O +
, O +
and O +
between O +
GAT O +
and O +
ST O +
measurements O +
, O +
- O +
17 O +
. O +
51 O +
mmHg O +
to O +
17 O +
. O +
27 O +
mmHg O +
. O +

The O +
correlation O +
coefficients O +
[ O +
r O +
] O +
for O +
the O +
PT O +
and O +
the O +
ST O +
were O +
0 O +
. O +
780 O +
[ O +
P O +
= O +
0 O +
. O +
0000 O +
] O +
and O +
0 O +
. O +
740 O +
[ O +
P O +
= O +
0 O +
. O +
0001 O +
] O +
respectively O +
. O +

CONCLUSIONS O +
: O +

In O +
clinical O +
practice O +
PT O +
appears O +
to O +
have O +
a O +
higher O +
level O +
of O +
accuracy O +
than O +
ST O +
in O +
normal O +
corneas O +
. O +

In O +
scarred O +
corneas O +
and O +
post O +
- O +
penetrating O +
keratoplasty O +
eyes O +
, O +
because O +
of O +
high O +
SD O +
for O +
mean O +
differences O +
and O +
wide O +
confidence O +
interval O +
of O +
95 O +
% O +
, O +
both O +
PT O +
and O +
ST O +
are O +
inaccurate O +
in O +
measuring O +
IOP O +
as O +
compared O +
to O +
GAT O +
in O +
such O +
eyes O +
. O +

A O +
pancreatic O +
beta O +
- O +
cell O +
- O +
specific O +
enhancer O +
in O +
the O +
human O +
PDX O +
- O +
1 O +
gene O +
is O +
regulated O +
by O +
hepatocyte O +
nuclear O +
factor O +
3beta O +
( O +
HNF O +
- O +
3beta O +
) O +
, O +
HNF O +
- O +
1alpha O +
, O +
and O +
SPs O +
transcription O +
factors O +
. O +

The O +
PDX O +
- O +
1 O +
transcription O +
factor O +
plays O +
a O +
key O +
role O +
in O +
pancreas O +
development O +
. O +

Although O +
expressed O +
in O +
all O +
cells O +
at O +
the O +
early O +
stages O +
, O +
in O +
the O +
adult O +
it O +
is O +
mainly O +
restricted O +
to O +
the O +
beta O +
- O +
cell O +
. O +

To O +
characterize O +
the O +
regulatory O +
elements O +
and O +
potential O +
transcription O +
factors O +
necessary O +
for O +
human O +
PDX O +
- O +
1 O +
gene O +
expression O +
in O +
beta O +
- O +
cells O +
, O +
we O +
constructed O +
a O +
series O +
of O +
5 O +
' O +
and O +
3 O +
' O +
deletion O +
fragments O +
of O +
the O +
5 O +
' O +
- O +
flanking O +
region O +
of O +
the O +
gene O +
, O +
fused O +
to O +
the O +
luciferase O +
reporter O +
gene O +
. O +

In O +
this O +
report O +
, O +
we O +
identify O +
by O +
transient O +
transfections O +
in O +
beta O +
- O +
and O +
non O +
- O +
beta O +
- O +
cells O +
a O +
novel O +
beta O +
- O +
cell O +
- O +
specific O +
distal O +
enhancer O +
element O +
located O +
between O +
- O +
3 O +
. O +
7 O +
and O +
- O +
3 O +
. O +
45 O +
kilobases O +
. O +

DNase O +
I O +
footprinting O +
analysis O +
revealed O +
two O +
protected O +
regions O +
, O +
one O +
binding O +
the O +
transcription O +
factors O +
SP1 O +
and O +
SP3 O +
and O +
the O +
other O +
hepatocyte O +
nuclear O +
factor O +
3beta O +
( O +
HNF O +
- O +
3beta O +
) O +
and O +
HNF O +
- O +
1alpha O +
. O +

Cotransfection O +
experiments O +
suggest O +
that O +
HNF O +
- O +
3beta O +
, O +
HNF O +
- O +
1alpha O +
, O +
and O +
SP1 O +
are O +
positive O +
regulators O +
of O +
the O +
herein O +
- O +
described O +
human O +
PDX O +
- O +
1 O +
enhancer O +
element O +
. O +

Furthermore O +
, O +
mutations O +
within O +
each O +
motif O +
abolished O +
the O +
binding O +
of O +
the O +
corresponding O +
factor O +
( O +
s O +
) O +
and O +
dramatically O +
impaired O +
the O +
enhancer O +
activity O +
, O +
therefore O +
suggesting O +
cooperativity O +
between O +
these O +
factors O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
- O +
B O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
- O +
C O +
expression O +
in O +
renal O +
cell O +
carcinomas O +
: O +
regulation O +
by O +
the O +
von O +
Hippel O +
- O +
Lindau O +
gene O +
and O +
hypoxia O +
. O +

Angiogenesis O +
is O +
essential O +
for O +
tumor O +
growth O +
and O +
metastasis O +
. O +

It O +
is O +
regulated O +
by O +
numerous O +
angiogenic O +
factors O +
, O +
one O +
of O +
the O +
most O +
important O +
being O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
. O +

Recently O +
VEGF O +
- O +
B O +
and O +
VEGF O +
- O +
C O +
, O +
two O +
new O +
VEGF O +
family O +
members O +
, O +
have O +
been O +
identified O +
that O +
bind O +
to O +
the O +
tyrosine O +
kinase O +
receptors O +
flt O +
- O +
1 O +
( O +
VEGFR1 O +
) O +
, O +
KDR O +
( O +
VEGFR2 O +
) O +
, O +
and O +
flt O +
- O +
4 O +
( O +
VEGFR3 O +
) O +
. O +

Although O +
the O +
importance O +
of O +
VEGF O +
- O +
A O +
has O +
been O +
shown O +
in O +
renal O +
carcinomas O +
, O +
the O +
contribution O +
of O +
these O +
new O +
ligands O +
in O +
kidney O +
tumors O +
is O +
not O +
clear O +
. O +

We O +
have O +
, O +
therefore O +
, O +
measured O +
the O +
mRNA O +
level O +
of O +
VEGF O +
- O +
B O +
and O +
VEGF O +
- O +
C O +
together O +
with O +
their O +
receptors O +
by O +
RNase O +
protection O +
assay O +
( O +
RPA O +
) O +
in O +
26 O +
normal O +
kidney O +
samples O +
and O +
45 O +
renal O +
cell O +
cancers O +
. O +

We O +
observed O +
a O +
significant O +
up O +
- O +
regulation O +
of O +
VEGF O +
- O +
B O +
( O +
P O +
= O +
0 O +
. O +
002 O +
) O +
but O +
not O +
VEGF O +
- O +
C O +
( O +
P O +
= O +
0 O +
. O +
3 O +
) O +
in O +
neoplastic O +
kidney O +
compared O +
with O +
normal O +
tissues O +
. O +

In O +
addition O +
, O +
although O +
VEGF O +
receptors O +
were O +
higher O +
in O +
tumors O +
than O +
normal O +
kidney O +
, O +
there O +
was O +
a O +
significant O +
up O +
- O +
regulation O +
of O +
only O +
flt O +
- O +
1 O +
( O +
P O +
= O +
0 O +
. O +
003 O +
) O +
but O +
not O +
KDR O +
( O +
P O +
= O +
0 O +
. O +
12 O +
) O +
or O +
flt O +
- O +
4 O +
( O +
P O +
= O +
0 O +
. O +
09 O +
) O +
. O +

There O +
was O +
also O +
a O +
significant O +
correlation O +
between O +
VEGF O +
- O +
C O +
and O +
both O +
of O +
its O +
receptors O +
flt O +
- O +
4 O +
( O +
P O +
= O +
0 O +
. O +
006 O +
) O +
and O +
KDR O +
( O +
P O +
= O +
0 O +
. O +
03 O +
) O +
but O +
no O +
association O +
between O +
VEGF O +
- O +
B O +
and O +
its O +
receptor O +
flt O +
- O +
1 O +
( O +
P O +
= O +
0 O +
. O +
23 O +
) O +
. O +

A O +
significant O +
increase O +
was O +
observed O +
in O +
flt O +
- O +
1 O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
, O +
KDR O +
( O +
P O +
= O +
0 O +
. O +
02 O +
) O +
, O +
and O +
flt O +
- O +
4 O +
( O +
P O +
= O +
0 O +
. O +
01 O +
) O +
but O +
not O +
VEGF O +
- O +
B O +
( O +
P O +
= O +
0 O +
. O +
82 O +
) O +
or O +
VEGF O +
- O +
C O +
( O +
P O +
= O +
0 O +
. O +
52 O +
) O +
expression O +
in O +
clear O +
cell O +
compared O +
with O +
chromophil O +
( O +
papillary O +
) O +
carcinomas O +
. O +

No O +
significant O +
association O +
was O +
demonstrated O +
between O +
VEGF O +
- O +
B O +
, O +
VEGF O +
- O +
C O +
, O +
flt O +
- O +
1 O +
, O +
KDR O +
, O +
and O +
flt O +
- O +
4 O +
with O +
patient O +
sex O +
, O +
patient O +
age O +
, O +
or O +
tumor O +
size O +
( O +
P O +
greater O +
than O +
0 O +
. O +
05 O +
) O +
. O +

The O +
effect O +
of O +
von O +
Hippel O +
- O +
Lindau O +
( O +
VHL O +
) O +
gene O +
and O +
hypoxia O +
on O +
VEGF O +
- O +
B O +
and O +
VEGF O +
- O +
C O +
expression O +
in O +
the O +
renal O +
carcinoma O +
cell O +
line O +
786 B-CellLine +
- I-CellLine +
0 I-CellLine +
transfected O +
with O +
wild O +
- O +
type O +
and O +
mutant O +
VHL O +
was O +
determined O +
by O +
growing O +
cells O +
under O +
21 O +
% O +
O2 O +
- O +
and O +
0 O +
. O +
1 O +
% O +
O2 O +
. O +

In O +
wild O +
- O +
type O +
VHL O +
cells O +
, O +
whereas O +
VEGF O +
- O +
A O +
was O +
significantly O +
up O +
- O +
regulated O +
under O +
hypoxic O +
compared O +
with O +
normoxic O +
conditions O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
, O +
expression O +
of O +
VEGF O +
- O +
C O +
was O +
reduced O +
( O +
P O +
less O +
than O +
0 O +
. O +
002 O +
) O +
. O +

Nevertheless O +
, O +
the O +
repression O +
of O +
VEGF O +
- O +
C O +
was O +
lost O +
in O +
mutant O +
VHL O +
cell O +
lines O +
under O +
hypoxia O +
. O +

In O +
contrast O +
VEGF O +
- O +
B O +
was O +
not O +
regulated O +
by O +
VHL O +
despite O +
clear O +
up O +
- O +
regulation O +
in O +
vivo O +
. O +

These O +
findings O +
strongly O +
support O +
an O +
enhanced O +
role O +
for O +
this O +
pathway O +
in O +
clear O +
cell O +
carcinomas O +
by O +
regulating O +
angiogenesis O +
and O +
/ O +
or O +
lymphangiogenesis O +
. O +

The O +
study O +
shows O +
that O +
clear O +
cell O +
tumors O +
are O +
able O +
to O +
up O +
- O +
regulate O +
angiogenic O +
growth O +
factor O +
receptors O +
more O +
efficiently O +
than O +
chromophil O +
( O +
papillary O +
) O +
, O +
that O +
clear O +
cell O +
tumors O +
can O +
use O +
pathways O +
independent O +
of O +
VHL O +
to O +
regulate O +
angiogenesis O +
, O +
and O +
that O +
this O +
combined O +
regulation O +
may O +
account O +
for O +
their O +
more O +
aggressive O +
phenotype O +
, O +
which O +
suggests O +
that O +
targeting O +
VEGFR1 O +
( O +
flt O +
- O +
l O +
) O +
may O +
be O +
particularly O +
effective O +
in O +
these O +
tumor O +
types O +
. O +

A O +
small O +
peptide O +
derived O +
from O +
Flt O +
- O +
1 O +
( O +
VEGFR O +
- O +
1 O +
) O +
functions O +
as O +
an O +
angiogenic O +
inhibitor O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
is O +
an O +
angiogenic O +
stimulator O +
which O +
functions O +
through O +
two O +
endothelial O +
specific O +
tyrosine O +
kinase O +
receptors O +
, O +
Flt O +
- O +
1 O +
and O +
Flk O +
- O +
1 O +
. O +

In O +
this O +
work O +
, O +
we O +
show O +
that O +
an O +
11 O +
- O +
amino O +
acid O +
peptide O +
derived O +
from O +
the O +
second O +
immunoglobulin O +
- O +
like O +
domain O +
of O +
Flt O +
- O +
1 O +
functions O +
as O +
an O +
angiogenic O +
inhibitor O +
in O +
chick O +
chorioallantoic O +
membrane O +
and O +
inhibited O +
VEGF O +
- O +
induced O +
vascular O +
permeability O +
in O +
Miles O +
' O +
assay O +
without O +
binding O +
to O +
VEGF O +
directly O +
. O +

Circular O +
dichroism O +
and O +
nuclear O +
magnetic O +
resonance O +
analyses O +
indicate O +
that O +
this O +
peptide O +
forms O +
a O +
stable O +
extended O +
structure O +
in O +
solution O +
, O +
presumably O +
beta O +
- O +
sheet O +
structure O +
and O +
is O +
most O +
likely O +
existing O +
as O +
a O +
dimer O +
. O +

Our O +
results O +
suggest O +
that O +
this O +
small O +
peptide O +
functions O +
as O +
an O +
angiogenic O +
inhibitor O +
by O +
inhibiting O +
VEGF O +
function O +
through O +
a O +
non O +
- O +
VEGF O +
binding O +
mechanism O +
. O +

[ O +
H O +
. O +
pylori O +
infection O +
. O +
Our O +
experience O +
with O +
the O +
quadruple O +
and O +
triple O +
therapy O +
as O +
first O +
pharmacologic O +
approach O +
] O +
. O +

For O +
now O +
the O +
most O +
used O +
pharmacological O +
treatment O +
of O +
first O +
instance O +
to O +
eradication O +
of O +
Hp O +
foresees O +
utilization O +
of O +
triple O +
therapy O +
( O +
PPI O +
+ O +
two O +
antibiotics O +
) O +
. O +

In O +
our O +
study O +
we O +
have O +
compared O +
this O +
kind O +
of O +
treatment O +
with O +
the O +
quadruple O +
therapy O +
( O +
PPI O +
+ O +
three O +
antibiotics O +
) O +
, O +
that O +
have O +
showed O +
a O +
taller O +
percentage O +
of O +
eradication O +
at O +
the O +
end O +
of O +
first O +
therapeutical O +
cycle O +
with O +
a O +
shorter O +
time O +
and O +
lower O +
price O +
of O +
treatment O +
. O +

Effects O +
of O +
morphological O +
patterning O +
on O +
endothelial O +
cell O +
migration O +
. O +

The O +
migration O +
of O +
vascular O +
endothelial O +
cells O +
( O +
ECs O +
) O +
plays O +
an O +
important O +
role O +
in O +
vascular O +
remodeling O +
. O +

Here O +
we O +
studied O +
the O +
effects O +
of O +
cell O +
morphology O +
on O +
the O +
migration O +
of O +
bovine O +
aortic O +
ECs O +
by O +
culturing O +
cells O +
on O +
micropatterned O +
strips O +
of O +
collagen O +
matrix O +
( O +
60 O +
- O +
, O +
30 O +
- O +
, O +
and O +
15 O +
- O +
microm O +
wide O +
) O +
. O +

The O +
spreading O +
areas O +
of O +
the O +
cells O +
on O +
15 O +
- O +
and O +
30 O +
- O +
microm O +
wide O +
strips O +
were O +
30 O +
% O +
lower O +
than O +
those O +
on O +
60 O +
- O +
microm O +
wide O +
strips O +
and O +
unpatterned O +
collagen O +
. O +

The O +
cells O +
on O +
15 O +
- O +
microm O +
wide O +
strips O +
completely O +
aligned O +
in O +
the O +
direction O +
of O +
the O +
strip O +
, O +
and O +
had O +
significantly O +
lower O +
shape O +
index O +
than O +
those O +
in O +
all O +
other O +
groups O +
. O +

On O +
strips O +
of O +
all O +
widths O +
, O +
ECs O +
tended O +
to O +
migrate O +
in O +
the O +
direction O +
of O +
strips O +
. O +

ECs O +
on O +
15 O +
- O +
microm O +
wide O +
strips O +
had O +
highest O +
speed O +
, O +
particularly O +
in O +
the O +
direction O +
of O +
the O +
strip O +
. O +

Vinculin O +
staining O +
showed O +
that O +
the O +
leading O +
edge O +
of O +
ECs O +
on O +
15 O +
- O +
microm O +
wide O +
strips O +
had O +
focal O +
adhesions O +
that O +
were O +
oriented O +
with O +
their O +
lamellipodial O +
protrusion O +
and O +
the O +
direction O +
of O +
cell O +
migration O +
; O +
this O +
arrangement O +
of O +
the O +
focal O +
adhesions O +
may O +
promote O +
EC O +
migration O +
. O +

The O +
present O +
study O +
provides O +
direct O +
evidence O +
on O +
the O +
role O +
of O +
cell O +
morphology O +
in O +
EC O +
migration O +
, O +
and O +
will O +
help O +
us O +
to O +
understand O +
the O +
mechanisms O +
of O +
EC O +
migration O +
during O +
angiogenesis O +
and O +
wound O +
healing O +
. O +

Thrombospondin O +
- O +
2 O +
plays O +
a O +
protective O +
role O +
in O +
multistep O +
carcinogenesis O +
: O +
a O +
novel O +
host O +
anti O +
- O +
tumor O +
defense O +
mechanism O +
. O +

The O +
angiogenic O +
switch O +
during O +
tumorigenesis O +
is O +
thought O +
to O +
be O +
induced O +
by O +
a O +
change O +
in O +
the O +
balance O +
of O +
pro O +
- O +
angiogenic O +
and O +
anti O +
- O +
angiogenic O +
factors O +
. O +

To O +
elucidate O +
the O +
biological O +
role O +
of O +
the O +
endogenous O +
angiogenesis O +
inhibitor O +
thrombospondin O +
- O +
2 O +
( O +
TSP O +
- O +
2 O +
) O +
during O +
multistep O +
carcinogenesis O +
, O +
we O +
subjected O +
TSP O +
- O +
2 O +
- O +
deficient O +
and O +
wild O +
- O +
type O +
mice O +
to O +
a O +
chemical O +
skin O +
carcinogenesis O +
regimen O +
. O +

Surprisingly O +
, O +
TSP O +
- O +
2 O +
expression O +
was O +
strongly O +
upregulated O +
in O +
the O +
mesenchymal O +
stroma O +
of O +
wild O +
- O +
type O +
mice O +
throughout O +
the O +
consecutive O +
stages O +
of O +
tumorigenesis O +
whereas O +
the O +
angiogenesis O +
factor O +
, O +
vascular O +
endothelial O +
growth O +
factor O +
, O +
was O +
induced O +
predominantly O +
in O +
tumor O +
cells O +
. O +

TSP O +
- O +
2 O +
deficiency O +
dramatically O +
enhanced O +
susceptibility O +
to O +
skin O +
carcinogenesis O +
and O +
resulted O +
in O +
accelerated O +
and O +
increased O +
tumor O +
formation O +
. O +

The O +
angiogenic O +
switch O +
occurred O +
in O +
early O +
stages O +
of O +
pre O +
- O +
malignant O +
tumor O +
formation O +
, O +
and O +
tumor O +
angiogenesis O +
was O +
significantly O +
enhanced O +
in O +
TSP O +
- O +
2 O +
- O +
deficient O +
mice O +
. O +

While O +
TSP O +
- O +
2 O +
deficiency O +
did O +
not O +
affect O +
tumor O +
differentiation O +
or O +
proliferation O +
, O +
tumor O +
cell O +
apoptosis O +
was O +
significantly O +
reduced O +
. O +

These O +
results O +
reveal O +
upregulation O +
of O +
an O +
endogenous O +
angiogenesis O +
inhibitor O +
during O +
multi O +
step O +
tumorigenesis O +
and O +
identify O +
enhanced O +
stromal O +
TSP O +
- O +
2 O +
expression O +
as O +
a O +
novel O +
host O +
anti O +
- O +
tumor O +
defense O +
mechanism O +
. O +

Relationship O +
of O +
p53 O +
and O +
Helicobacter O +
pylori O +
to O +
clinicopathological O +
features O +
of O +
human O +
remnant O +
stomach O +
cancer O +
after O +
gastric O +
surgery O +
for O +
primary O +
gastric O +
cancer O +
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
the O +
biological O +
features O +
of O +
gastric O +
cancer O +
of O +
the O +
remnant O +
stomach O +
( O +
RSC O +
) O +
. O +

Twenty O +
- O +
one O +
patients O +
underwent O +
resection O +
of O +
the O +
remnant O +
stomach O +
for O +
RSC O +
and O +
were O +
divided O +
into O +
two O +
groups O +
: O +
the O +
RSCB O +
group O +
consisted O +
of O +
11 O +
patients O +
who O +
underwent O +
distal O +
gastrectomy O +
for O +
benign O +
disease O +
and O +
the O +
RSCM O +
group O +
consisted O +
of O +
10 O +
patients O +
who O +
underwent O +
gastrectomy O +
for O +
primary O +
gastric O +
cancer O +
. O +

The O +
interval O +
between O +
primary O +
surgery O +
and O +
the O +
appearance O +
of O +
gastric O +
cancer O +
in O +
the O +
remnant O +
stomach O +
was O +
significantly O +
shorter O +
in O +
the O +
RSCM O +
group O +
than O +
in O +
the O +
RSCB O +
group O +
. O +

Invasion O +
of O +
adjacent O +
organs O +
was O +
more O +
frequent O +
in O +
the O +
RSCM O +
group O +
than O +
in O +
the O +
RSCB O +
group O +
and O +
the O +
Ki O +
- O +
67 O +
labeling O +
index O +
of O +
the O +
tumors O +
was O +
significantly O +
higher O +
in O +
the O +
former O +
group O +
. O +

Furthermore O +
, O +
p53 O +
overexpression O +
by O +
tumors O +
was O +
almost O +
twice O +
as O +
common O +
in O +
the O +
RSCM O +
group O +
as O +
in O +
the O +
RSCB O +
group O +
. O +

Although O +
there O +
was O +
no O +
significant O +
difference O +
of O +
the O +
H O +
. O +
pylori O +
positivity O +
between O +
the O +
two O +
groups O +
, O +
the O +
rate O +
for O +
both O +
groups O +
was O +
higher O +
than O +
reported O +
in O +
previous O +
studies O +
. O +

Mutation O +
of O +
p53 O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
high O +
proliferative O +
activity O +
of O +
tumors O +
in O +
the O +
RSCM O +
group O +
and O +
H O +
. O +
pylori O +
infection O +
may O +
be O +
closely O +
related O +
to O +
carcinogenesis O +
in O +
patients O +
with O +
RSC O +
. O +

Coexpression O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
p53 O +
protein O +
in O +
squamous O +
cell O +
carcinoma O +
of O +
the O +
esophagus O +
. O +

OBJECTIVE O +
: O +
p53 O +
plays O +
a O +
role O +
in O +
tumor O +
angiogenesis O +
, O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
plays O +
a O +
key O +
role O +
in O +
tumor O +
angiogenesis O +
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
clarify O +
how O +
expression O +
of O +
p53 O +
protein O +
participates O +
in O +
angiogenesis O +
, O +
and O +
whether O +
the O +
coexpression O +
of O +
VEGF O +
and O +
p53 O +
protein O +
has O +
a O +
significance O +
for O +
angiogenesis O +
and O +
the O +
clinicopathological O +
features O +
in O +
esophageal O +
squamous O +
cell O +
carcinoma O +
( O +
SCC O +
) O +
. O +

METHODS O +
: O +
Tissues O +
samples O +
were O +
taken O +
from O +
60 O +
patients O +
with O +
esophageal O +
SCC O +
after O +
surgery O +
. O +

The O +
expression O +
of O +
VEGF O +
and O +
p53 O +
protein O +
in O +
these O +
SCC O +
was O +
examined O +
immunohistochemically O +
. O +

Microvessel O +
density O +
( O +
MVD O +
) O +
was O +
determined O +
by O +
counting O +
microvessels O +
in O +
tumor O +
sections O +
stained O +
for O +
Factor O +
VIII O +
- O +
related O +
antigen O +
. O +

Ki O +
- O +
67 O +
labeling O +
index O +
( O +
LI O +
) O +
was O +
calculated O +
, O +
based O +
on O +
Ki O +
- O +
67 O +
antigen O +
immunostaining O +
, O +
as O +
a O +
proliferative O +
marker O +
. O +

Apoptotic O +
index O +
( O +
AI O +
) O +
was O +
calculated O +
, O +
based O +
on O +
the O +
terminal O +
deoxynucleotidyl O +
transferase O +
- O +
mediated O +
deoxyuridine O +
triphosphate O +
biotin O +
nick O +
end O +
labeling O +
, O +
to O +
evaluate O +
apoptosis O +
. O +

RESULTS O +
: O +
VEGF O +
expression O +
was O +
observed O +
in O +
58 O +
. O +
3 O +
% O +
, O +
and O +
p53 O +
protein O +
expression O +
was O +
observed O +
in O +
61 O +
. O +
7 O +
% O +
of O +
the O +
60 O +
patients O +
. O +

VEGF O +
and O +
p53 O +
protein O +
were O +
significantly O +
coexpressed O +
in O +
26 O +
( O +
43 O +
. O +
4 O +
% O +
) O +
. O +

Histological O +
venous O +
invasion O +
( O +
p O +
less O +
than O +
0 O +
. O +
01 O +
) O +
and O +
distant O +
metastasis O +
( O +
p O +
less O +
than O +
0 O +
. O +
05 O +
) O +
were O +
significantly O +
correlated O +
with O +
p53 O +
protein O +
expression O +
. O +

The O +
two O +
parameters O +
were O +
more O +
frequently O +
observed O +
in O +
the O +
SCC O +
with O +
VEGF O +
/ O +
p53 O +
coexpression O +
than O +
in O +
those O +
without O +
the O +
coexpression O +
. O +

The O +
MVD O +
and O +
Ki O +
- O +
67 O +
LI O +
were O +
significantly O +
higher O +
( O +
p O +
less O +
than O +
0 O +
. O +
01 O +
and O +
p O +
less O +
than O +
0 O +
. O +
001 O +
) O +
, O +
and O +
the O +
AI O +
was O +
significantly O +
lower O +
( O +
p O +
less O +
than O +
0 O +
. O +
001 O +
) O +
in O +
the O +
SCC O +
with O +
p53 O +
protein O +
expression O +
than O +
in O +
the O +
SCC O +
without O +
it O +
. O +

The O +
MVD O +
and O +
Ki O +
- O +
67 O +
LI O +
were O +
higher O +
, O +
and O +
the O +
AI O +
was O +
lower O +
in O +
the O +
SCC O +
with O +
VEGF O +
/ O +
p53 O +
coexpression O +
than O +
in O +
those O +
without O +
the O +
coexpression O +
. O +

The O +
5 O +
- O +
yr O +
survival O +
rate O +
in O +
patients O +
with O +
the O +
coexpression O +
was O +
poorer O +
than O +
in O +
the O +
other O +
patients O +
. O +

CONCLUSION O +
: O +
These O +
results O +
suggest O +
that O +
mutant O +
p53 O +
expression O +
is O +
associated O +
with O +
angiogenesis O +
and O +
distant O +
metastasis O +
in O +
esophageal O +
SCC O +
, O +
and O +
that O +
the O +
coexpression O +
of O +
p53 O +
and O +
VEGF O +
may O +
play O +
an O +
important O +
role O +
in O +
angiogenesis O +
, O +
and O +
have O +
important O +
clinical O +
significance O +
. O +

Current O +
prospects O +
for O +
controlling O +
cancer O +
growth O +
with O +
non O +
- O +
cytotoxic O +
agents O +
- O +
- O +
nutrients O +
, O +
phytochemicals O +
, O +
herbal O +
extracts O +
, O +
and O +
available O +
drugs O +
. O +

In O +
animal O +
or O +
cell O +
culture O +
studies O +
, O +
the O +
growth O +
and O +
spread O +
of O +
cancer O +
can O +
be O +
slowed O +
by O +
many O +
nutrients O +
, O +
food O +
factors O +
, O +
herbal O +
extracts O +
, O +
and O +
well O +
- O +
tolerated O +
, O +
available O +
drugs O +
that O +
are O +
still O +
rarely O +
used O +
in O +
the O +
clinical O +
management O +
of O +
cancer O +
, O +
in O +
part O +
because O +
they O +
seem O +
unlikely O +
to O +
constitute O +
definitive O +
therapies O +
in O +
themselves O +
. O +

However O +
, O +
it O +
is O +
reasonable O +
to O +
expect O +
that O +
mechanistically O +
complementary O +
combinations O +
of O +
these O +
measures O +
could O +
have O +
a O +
worthwhile O +
impact O +
on O +
survival O +
times O +
and O +
, O +
when O +
used O +
as O +
adjuvants O +
, O +
could O +
improve O +
the O +
cure O +
rates O +
achievable O +
with O +
standard O +
therapies O +
. O +

The O +
therapeutic O +
options O +
available O +
in O +
this O +
regard O +
include O +
measures O +
that O +
: O +
down O +
- O +
regulate O +
serum O +
free O +
IGF O +
- O +
I O +
; O +
suppress O +
the O +
synthesis O +
of O +
mevalonic O +
acid O +
and O +
/ O +
or O +
certain O +
derivatives O +
thereof O +
; O +
modulate O +
arachidonate O +
metabolism O +
by O +
inhibiting O +
5 O +
- O +
lipoxygenase O +
, O +
12 O +
- O +
lipoxygenase O +
, O +
or O +
COX O +
- O +
2 O +
; O +
antagonize O +
the O +
activation O +
of O +
AP O +
- O +
1 O +
transcription O +
factors O +
; O +
promote O +
the O +
activation O +
of O +
PPAR O +
- O +
gamma O +
transcription O +
factors O +
; O +
and O +
that O +
suppress O +
angiogenesis O +
by O +
additional O +
mechanisms O +
. O +

Many O +
of O +
these O +
measures O +
appear O +
suitable O +
for O +
use O +
in O +
cancer O +
prevention O +
. O +

[ O +
mRNA O +
expression O +
of O +
metastasis O +
- O +
suppressor O +
gene O +
nm23 O +
in O +
carcinoma O +
of O +
buccal O +
mucosa O +
. O +
II O +
. O +
Quantitative O +
reverse O +
transcription O +
PCR O +
amplification O +
] O +
. O +

The O +
nm23 O +
gene O +
is O +
a O +
conspicuous O +
metastasis O +
- O +
suppressor O +
gene O +
. O +

The O +
authors O +
detected O +
both O +
nm23 O +
- O +
H1 O +
and O +
nm23 O +
- O +
H2 O +
mRNA O +
levels O +
in O +
47 O +
tissues O +
samples O +
of O +
patients O +
with O +
carcinoma O +
of O +
buccal O +
mucosa O +
( O +
CBM O +
) O +
by O +
quantitative O +
reverse O +
transcription O +
PCR O +
amplification O +
. O +

The O +
results O +
showed O +
that O +
expression O +
levels O +
of O +
both O +
nm23 O +
- O +
H1 O +
and O +
nm23 O +
- O +
H2 O +
mRNA O +
varied O +
in O +
normal O +
buccal O +
mucosa O +
, O +
leukoplakia O +
, O +
adjacent O +
nontumorous O +
mucosa O +
, O +
submandibular O +
gland O +
, O +
CBM O +
and O +
lymph O +
nodes O +
with O +
or O +
without O +
metastasis O +
. O +

The O +
nm23 O +
- O +
H1 O +
mRNA O +
expression O +
levels O +
in O +
CBM O +
with O +
lymph O +
nodes O +
metastases O +
were O +
lower O +
than O +
those O +
in O +
CBM O +
without O +
metastases O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
, O +
while O +
no O +
significance O +
of O +
nm23 O +
- O +
H2 O +
mRNA O +
expression O +
levels O +
was O +
found O +
between O +
CBM O +
with O +
and O +
CBM O +
without O +
metastasis O +
( O +
P O +
> O +
0 O +
. O +
05 O +
) O +
. O +

The O +
results O +
were O +
comparative O +
to O +
those O +
of O +
Northern O +
blotting O +
of O +
the O +
same O +
cases O +
. O +

The O +
authors O +
concluded O +
that O +
, O +
as O +
also O +
in O +
the O +
study O +
of O +
Northern O +
blotting O +
, O +
the O +
expression O +
of O +
nm23 O +
- O +
H1 O +
mRNA O +
significantly O +
correlated O +
inversely O +
with O +
lymph O +
node O +
metastasis O +
in O +
CBM O +
, O +
while O +
the O +
expression O +
of O +
nm23 O +
- O +
H2 O +
mRNA O +
not O +
. O +

Q O +
- O +
RT O +
- O +
PCR O +
was O +
a O +
useful O +
method O +
to O +
detect O +
the O +
mRNA O +
levels O +
of O +
nm23 O +
gene O +
in O +
buccal O +
carcinoma O +
. O +

Glucose O +
catabolism O +
in O +
cancer O +
cells O +
: O +
identification O +
and O +
characterization O +
of O +
a O +
marked O +
activation O +
response O +
of O +
the O +
type O +
II O +
hexokinase O +
gene O +
to O +
hypoxic O +
conditions O +
. O +

One O +
of O +
the O +
most O +
common O +
signatures O +
of O +
highly O +
malignant O +
tumors O +
is O +
their O +
capacity O +
to O +
metabolize O +
more O +
glucose O +
to O +
lactic O +
acid O +
than O +
their O +
tissues O +
of O +
origin O +
. O +

Hepatomas O +
exhibiting O +
this O +
phenotype O +
are O +
dependent O +
on O +
the O +
high O +
expression O +
of O +
type O +
II O +
hexokinase O +
, O +
which O +
supplies O +
such O +
tumors O +
with O +
abundant O +
amounts O +
of O +
glucose O +
6 O +
- O +
phosphate O +
, O +
a O +
significant O +
carbon O +
and O +
energy O +
source O +
especially O +
under O +
hypoxic O +
conditions O +
. O +

Here O +
we O +
report O +
that O +
the O +
distal O +
region O +
of O +
the O +
hepatoma O +
type O +
II O +
hexokinase O +
promoter O +
displays O +
consensus O +
motifs O +
for O +
hypoxia O +
- O +
inducible O +
factor O +
( O +
HIF O +
- O +
1 O +
) O +
that O +
overlap O +
E O +
- O +
box O +
sequences O +
known O +
to O +
be O +
related O +
in O +
other O +
gene O +
promoters O +
to O +
glucose O +
response O +
. O +

Moreover O +
, O +
we O +
show O +
that O +
subjecting O +
transfected O +
hepatoma O +
cells O +
to O +
hypoxic O +
conditions O +
activates O +
the O +
type O +
II O +
hexokinase O +
promoter O +
almost O +
3 O +
- O +
fold O +
, O +
a O +
value O +
that O +
approaches O +
7 O +
- O +
fold O +
in O +
the O +
presence O +
of O +
glucose O +
. O +

Consistent O +
with O +
these O +
findings O +
is O +
the O +
induction O +
under O +
hypoxic O +
conditions O +
of O +
the O +
HIF O +
- O +
1 O +
protein O +
. O +

Reporter O +
gene O +
analyses O +
with O +
a O +
series O +
of O +
nested O +
deletion O +
mutants O +
of O +
the O +
hepatoma O +
type O +
II O +
hexokinase O +
promoter O +
show O +
that O +
a O +
significant O +
fraction O +
of O +
the O +
total O +
activation O +
observed O +
under O +
hypoxic O +
conditions O +
localizes O +
to O +
the O +
distal O +
region O +
where O +
the O +
overlapping O +
HIF O +
- O +
1 O +
/ O +
E O +
- O +
box O +
sequences O +
are O +
located O +
. O +

Finally O +
, O +
DNase O +
I O +
footprint O +
analysis O +
with O +
a O +
segment O +
of O +
the O +
promoter O +
containing O +
these O +
elements O +
reveals O +
the O +
binding O +
of O +
several O +
nuclear O +
proteins O +
. O +

In O +
summary O +
, O +
these O +
novel O +
studies O +
identify O +
and O +
characterize O +
a O +
marked O +
glucose O +
- O +
modulated O +
activation O +
response O +
of O +
the O +
type O +
II O +
hexokinase O +
gene O +
to O +
hypoxic O +
conditions O +
within O +
highly O +
glycolytic O +
hepatoma O +
cells O +
, O +
a O +
property O +
that O +
may O +
help O +
assure O +
that O +
such O +
cells O +
exhibit O +
a O +
growth O +
and O +
survival O +
advantage O +
over O +
their O +
parental O +
cells O +
of O +
origin O +
. O +

Neoplastic O +
transformation O +
and O +
tumorigenesis O +
associated O +
with O +
overexpression O +
of O +
phospholipase O +
D O +
isozymes O +
in O +
cultured O +
murine O +
fibroblasts O +
. O +

Phospholipase O +
D O +
( O +
PLD O +
) O +
has O +
been O +
suggested O +
to O +
play O +
an O +
important O +
role O +
in O +
a O +
variety O +
of O +
cellular O +
functions O +
. O +

PLD O +
activity O +
has O +
been O +
shown O +
to O +
be O +
significantly O +
elevated O +
in O +
many O +
tumours O +
and O +
transformed O +
cells O +
, O +
suggesting O +
the O +
possibility O +
that O +
PLD O +
might O +
be O +
involved O +
in O +
tumorigenesis O +
. O +

In O +
this O +
study O +
, O +
we O +
have O +
established O +
stable O +
cell O +
lines O +
overexpressing O +
PLD1 O +
and O +
PLD2 O +
from O +
fibroblast O +
cells O +
. O +

These O +
cells O +
, O +
but O +
not O +
control O +
cells O +
, O +
showed O +
altered O +
growth O +
properties O +
and O +
anchorage O +
- O +
independent O +
growth O +
in O +
soft O +
agar O +
. O +

Both O +
PLD1 O +
and O +
PLD2 O +
also O +
induced O +
an O +
up O +
- O +
regulation O +
of O +
the O +
activity O +
of O +
matrix O +
metalloprotease O +
- O +
9 O +
as O +
detected O +
by O +
zymograms O +
. O +

Furthermore O +
, O +
both O +
PLD1 O +
and O +
PLD2 O +
transformants O +
, O +
but O +
not O +
vector O +
- O +
transfectants O +
, O +
induced O +
undifferentiated O +
sarcoma O +
when O +
transplanted O +
into O +
nude O +
mice O +
. O +

Both O +
PLD1 O +
- O +
and O +
PLD2 O +
- O +
mediated O +
cell O +
cycle O +
distributions O +
in O +
stable O +
cell O +
lines O +
revealed O +
an O +
increased O +
fraction O +
of O +
cells O +
in O +
the O +
S O +
phase O +
compared O +
with O +
control O +
cells O +
. O +

Interestingly O +
, O +
the O +
level O +
of O +
cyclin O +
D3 O +
protein O +
, O +
known O +
as O +
an O +
activator O +
of O +
G O +
( O +
1 O +
) O +
to O +
S O +
phase O +
transition O +
in O +
the O +
cell O +
cycle O +
, O +
was O +
aberrantly O +
high O +
in O +
cells O +
overexpressing O +
PLD1 O +
and O +
PLD2 O +
compared O +
with O +
control O +
cells O +
. O +

These O +
results O +
suggest O +
that O +
overexpression O +
of O +
PLD O +
isozymes O +
may O +
play O +
an O +
important O +
role O +
in O +
neoplastic O +
transformation O +
. O +

Oncogenic O +
mechanisms O +
of O +
Evi O +
- O +
1 O +
protein O +
. O +

Although O +
Evi O +
- O +
1 O +
is O +
thought O +
to O +
promote O +
growth O +
or O +
block O +
differentiation O +
in O +
some O +
cell O +
types O +
, O +
its O +
biological O +
functions O +
have O +
not O +
been O +
elucidated O +
. O +

To O +
explore O +
the O +
mechanisms O +
underlying O +
Evi O +
- O +
1 O +
- O +
induced O +
oncogenesis O +
, O +
we O +
investigated O +
whether O +
Evi O +
- O +
1 O +
affects O +
the O +
signaling O +
of O +
transforming O +
growth O +
factor O +
beta O +
( O +
TGF O +
- O +
beta O +
) O +
, O +
which O +
inhibits O +
proliferation O +
of O +
a O +
wide O +
range O +
of O +
cell O +
types O +
and O +
is O +
one O +
of O +
the O +
most O +
studied O +
growth O +
regulatory O +
factors O +
. O +

We O +
demonstrated O +
that O +
Evi O +
- O +
1 O +
represses O +
TGF O +
- O +
beta O +
signaling O +
and O +
antagonizes O +
its O +
growth O +
- O +
inhibitory O +
effects O +
. O +

Two O +
separate O +
regions O +
of O +
Evi O +
- O +
1 O +
are O +
responsible O +
for O +
this O +
repression O +
, O +
one O +
of O +
which O +
is O +
the O +
first O +
zinc O +
- O +
finger O +
domain O +
. O +

Through O +
this O +
domain O +
, O +
Evi O +
- O +
1 O +
physically O +
interacts O +
with O +
Smad3 O +
, O +
an O +
intracellular O +
mediator O +
of O +
TGF O +
- O +
beta O +
signaling O +
, O +
thereby O +
suppressing O +
the O +
transcriptional O +
activity O +
of O +
Smad3 O +
. O +

These O +
results O +
define O +
a O +
novel O +
function O +
of O +
Evi O +
- O +
1 O +
as O +
a O +
repressor O +
of O +
signaling O +
components O +
of O +
TGF O +
- O +
beta O +
. O +

We O +
also O +
demonstrated O +
that O +
Evi O +
- O +
1 O +
represses O +
Smad O +
- O +
induced O +
transcriptional O +
activation O +
by O +
recruiting O +
CtBP O +
as O +
a O +
corepressor O +
. O +

Evi O +
- O +
1 O +
associates O +
with O +
CtBP1 O +
through O +
one O +
of O +
the O +
CtBP O +
- O +
binding O +
consensus O +
motifs O +
within O +
the O +
region O +
from O +
amino O +
acid O +
544 O +
to O +
607 O +
, O +
and O +
this O +
association O +
is O +
required O +
for O +
the O +
efficient O +
inhibition O +
of O +
TGF O +
- O +
beta O +
signaling O +
. O +

A O +
specific O +
histone O +
deacetylase O +
( O +
HDAc O +
) O +
inhibitor O +
, O +
trichostatin O +
A O +
( O +
TSA O +
) O +
, O +
alleviates O +
Evi O +
- O +
1 O +
- O +
mediated O +
repression O +
of O +
TGF O +
- O +
beta O +
signaling O +
, O +
suggesting O +
that O +
HDAc O +
is O +
involved O +
in O +
transcriptional O +
repression O +
by O +
Evi O +
- O +
1 O +
. O +

This O +
identifies O +
a O +
novel O +
function O +
of O +
Evi O +
- O +
1 O +
as O +
a O +
member O +
of O +
corepressor O +
complexes O +
and O +
suggests O +
that O +
aberrant O +
recruitment O +
of O +
corepressors O +
is O +
one O +
of O +
the O +
mechanisms O +
involved O +
in O +
Evi O +
- O +
1 O +
- O +
induced O +
leukemogenesis O +
. O +

These O +
results O +
indicate O +
that O +
specific O +
HDAc O +
inhibitors O +
may O +
be O +
useful O +
in O +
the O +
treatment O +
of O +
Evi O +
- O +
1 O +
- O +
induced O +
neoplastic O +
tumors O +
, O +
including O +
myeloid O +
leukemias O +
. O +

Antibodies O +
to O +
PAI O +
- O +
1 O +
alter O +
the O +
invasive O +
and O +
migratory O +
properties O +
of O +
human O +
tumour O +
cells O +
in O +
vitro O +
. O +

Recent O +
reports O +
suggest O +
that O +
elevated O +
levels O +
of O +
plasminogen O +
activator O +
inhibitor O +
- O +
1 O +
( O +
PAI O +
- O +
1 O +
) O +
may O +
contribute O +
to O +
tumour O +
progression O +
. O +

The O +
studies O +
reported O +
here O +
were O +
designed O +
to O +
help O +
elucidate O +
PAI O +
- O +
1 O +
' O +
s O +
contribution O +
to O +
the O +
invasive O +
and O +
migratory O +
phenotype O +
. O +

Antibodies O +
to O +
PA O +
- O +
1 O +
dose O +
- O +
dependently O +
, O +
and O +
significantly O +
, O +
inhibited O +
the O +
invasive O +
and O +
migratory O +
potential O +
of O +
human O +
HT1080 B-CellLine +
fibrosarcoma O +
cells O +
, O +
as O +
did O +
an O +
antibody O +
to O +
uPA O +
and O +
the O +
plasmin O +
inhibitor O +
aprotinin O +
. O +

Invasion O +
of O +
the O +
human O +
melanoma O +
cell O +
line O +
, O +
BLM B-CellLine +
, O +
was O +
also O +
attenuated O +
by O +
the O +
anti O +
- O +
PAI O +
- O +
1 O +
monoclonal O +
antibody O +
MAI O +
- O +
12 O +
. O +

The O +
non O +
- O +
invasive O +
human O +
melanoma O +
cell O +
line O +
, O +
IF6 B-CellLine +
, O +
which O +
does O +
not O +
express O +
uPA O +
, O +
provided O +
further O +
confirmation O +
of O +
PAI O +
- O +
1 O +
and O +
uPA O +
' O +
s O +
role O +
as O +
, O +
upon O +
transfection O +
with O +
uPA O +
, O +
this O +
cell O +
line O +
attained O +
an O +
invasive O +
phenotype O +
, O +
which O +
was O +
again O +
attenuated O +
by O +
MAI O +
- O +
12 O +
. O +

Although O +
antibodies O +
to O +
PAI O +
- O +
1 O +
did O +
not O +
affect O +
the O +
adhesion O +
of O +
HT1080 B-CellLine +
cells O +
to O +
vitronectin O +
, O +
the O +
antibody O +
to O +
uPA O +
reduced O +
their O +
attachment O +
. O +

Addition O +
of O +
exogenous O +
PAI O +
- O +
1 O +
, O +
however O +
, O +
prevented O +
HT1080 B-CellLine +
cell O +
adhesion O +
( O +
IC50 O +
180 O +
nM O +
) O +
and O +
promoted O +
cell O +
detachment O +
from O +
vitronectin O +
. O +

Furthermore O +
melanoma O +
cells O +
transfected O +
with O +
a O +
uPA O +
variant O +
, O +
which O +
had O +
an O +
impaired O +
interaction O +
with O +
PAI O +
- O +
1 O +
, O +
were O +
not O +
invasive O +
and O +
had O +
impaired O +
binding O +
to O +
vitronectin O +
. O +

These O +
data O +
highlight O +
the O +
importance O +
of O +
a O +
balanced O +
proteolysis O +
and O +
suggest O +
an O +
additional O +
role O +
for O +
PAI O +
- O +
1 O +
distinct O +
from O +
its O +
role O +
in O +
proteolysis O +
. O +

These O +
data O +
also O +
suggest O +
that O +
uPA O +
and O +
PAI O +
- O +
1 O +
may O +
co O +
- O +
operate O +
in O +
the O +
migratory O +
process O +
by O +
respectively O +
facilitating O +
the O +
attachment O +
to O +
, O +
and O +
subsequent O +
detachment O +
from O +
, O +
vitronectin O +
in O +
the O +
extracellular O +
matrix O +
. O +

These O +
results O +
support O +
the O +
clinical O +
findings O +
and O +
indicate O +
that O +
modulation O +
of O +
PAI O +
- O +
1 O +
activity O +
may O +
be O +
of O +
therapeutic O +
benefit O +
for O +
the O +
treatment O +
of O +
cancer O +
. O +

[ O +
Anesthetic O +
management O +
of O +
a O +
patient O +
with O +
Dyggve O +
- O +
Melchior O +
- O +
Clausen O +
syndrome O +
] O +
. O +

The O +
Dyggve O +
- O +
Melchior O +
- O +
Clausen O +
syndrome O +
( O +
DMCS O +
) O +
is O +
a O +
rare O +
autosomal O +
recessive O +
skeletal O +
dysplasia O +
characterized O +
by O +
short O +
- O +
trunk O +
dwarfism O +
and O +
mental O +
retardation O +
. O +

A O +
49 O +
- O +
year O +
- O +
old O +
male O +
with O +
DMCS O +
underwent O +
resection O +
arthroplasty O +
for O +
contracture O +
of O +
the O +
right O +
hip O +
joint O +
under O +
general O +
anesthesia O +
using O +
thiamylal O +
, O +
nitrous O +
oxide O +
, O +
sevoflurane O +
, O +
and O +
vecuronium O +
. O +

Although O +
he O +
was O +
assumed O +
to O +
have O +
difficult O +
airway O +
due O +
to O +
short O +
neck O +
, O +
macroglossia O +
, O +
and O +
disturbance O +
of O +
neck O +
flexion O +
, O +
tracheal O +
intubation O +
was O +
not O +
difficult O +
. O +

No O +
complications O +
including O +
malignant O +
hyperthermia O +
were O +
observed O +
during O +
the O +
95 O +
min O +
of O +
the O +
operation O +
. O +

Assembly O +
strategies O +
and O +
GTPase O +
regulation O +
of O +
the O +
eukaryotic O +
and O +
Escherichia O +
coil O +
translocons O +
. O +

The O +
translocation O +
of O +
most O +
proteins O +
across O +
the O +
endoplasmic O +
reticulum O +
or O +
bacterial O +
inner O +
membrane O +
occurs O +
through O +
an O +
aqueous O +
pore O +
that O +
spans O +
the O +
membrane O +
. O +

Substrates O +
that O +
are O +
translocated O +
co O +
- O +
translationally O +
across O +
the O +
membrane O +
are O +
directed O +
to O +
the O +
translocation O +
pore O +
via O +
an O +
interaction O +
between O +
the O +
cytosolic O +
signal O +
recognition O +
particle O +
and O +
its O +
membrane O +
- O +
bound O +
receptor O +
. O +

Together O +
the O +
translocation O +
pore O +
and O +
the O +
receptor O +
are O +
referred O +
to O +
as O +
a O +
translocon O +
. O +

By O +
studying O +
the O +
biogenesis O +
of O +
the O +
translocon O +
a O +
number O +
of O +
alternate O +
targeting O +
and O +
membrane O +
- O +
integration O +
pathways O +
have O +
been O +
discovered O +
that O +
operate O +
independently O +
of O +
the O +
signal O +
recognition O +
particle O +
( O +
SRP O +
) O +
pathway O +
. O +

The O +
novel O +
assembly O +
strategies O +
of O +
the O +
translocon O +
and O +
the O +
ways O +
in O +
which O +
these O +
components O +
interact O +
to O +
ensure O +
the O +
fidelity O +
and O +
unidirectionality O +
of O +
the O +
targeting O +
and O +
translocation O +
process O +
are O +
reviewed O +
here O +
. O +

[ O +
Decreased O +
stimulation O +
of O +
glycosaminoglycan O +
synthesis O +
by O +
human O +
skin O +
fibroblasts O +
by O +
interleukin O +
6 O +
within O +
the O +
scope O +
of O +
in O +
vitro O +
aging O +
] O +
. O +

Addition O +
of O +
human O +
recombinant O +
interleukin O +
6 O +
( O +
IL O +
- O +
6 O +
) O +
to O +
culture O +
medium O +
( O +
supplemented O +
MEM O +
without O +
or O +
with O +
10 O +
% O +
fetal O +
calf O +
serum O +
( O +
FCS O +
) O +
) O +
of O +
human O +
skin O +
fibroblasts O +
exerted O +
a O +
stimulating O +
effect O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
on O +
glycosaminoglycan O +
( O +
GAG O +
) O +
synthesis O +
, O +
including O +
hyaluronic O +
acid O +
( O +
hyaluronan O +
) O +
synthesis O +
, O +
of O +
young O +
( O +
phase O +
- O +
II O +
) O +
skin O +
fibroblasts O +
in O +
concentrations O +
of O +
1 O +
ng O +
/ O +
ml O +
and O +
10 O +
ng O +
/ O +
ml O +
. O +

Stimulation O +
was O +
mainly O +
due O +
to O +
an O +
increase O +
in O +
extracellular O +
GAGs O +
( O +
secreted O +
into O +
culture O +
medium O +
) O +
, O +
and O +
to O +
a O +
lesser O +
extent O +
to O +
an O +
increase O +
in O +
peri O +
- O +
and O +
intracellular O +
GAGs O +
. O +

Stimulation O +
with O +
1 O +
ng O +
/ O +
ml O +
and O +
10 O +
ng O +
/ O +
ml O +
IL O +
- O +
6 O +
led O +
to O +
an O +
increase O +
in O +
hyaluronic O +
acid O +
from O +
48 O +
% O +
to O +
61 O +
% O +
( O +
- O +
FCS O +
) O +
and O +
from O +
77 O +
% O +
to O +
90 O +
% O +
( O +
+ O +
10 O +
% O +
FCS O +
) O +
, O +
respectively O +
. O +

Maximum O +
stimulation O +
, O +
with O +
and O +
without O +
FCS O +
, O +
was O +
achieved O +
by O +
10 O +
ng O +
/ O +
ml O +
IL O +
- O +
6 O +
. O +

Compared O +
to O +
young O +
( O +
phase O +
- O +
II O +
) O +
cells O +
, O +
senescent O +
( O +
phase O +
- O +
III O +
) O +
cells O +
, O +
showed O +
no O +
significant O +
stimulation O +
of O +
total O +
GAG O +
( O +
including O +
hyaluronic O +
acid O +
) O +
synthesis O +
by O +
IL O +
- O +
6 O +
. O +

The O +
diminished O +
response O +
of O +
GAG O +
- O +
and O +
hyaluronic O +
acid O +
synthesis O +
during O +
aging O +
of O +
these O +
in O +
vitro O +
cultured O +
fibroblasts O +
should O +
motivate O +
further O +
research O +
if O +
similar O +
processes O +
occur O +
during O +
aging O +
in O +
an O +
organism O +
. O +

Renormalization O +
group O +
analysis O +
of O +
autoregressive O +
processes O +
and O +
fractional O +
noise O +
. O +

A O +
renormalization O +
group O +
analysis O +
is O +
applied O +
to O +
autoregressive O +
processes O +
with O +
an O +
infinite O +
series O +
of O +
coefficients O +
. O +

A O +
simple O +
fixed O +
point O +
is O +
given O +
by O +
a O +
random O +
walk O +
, O +
and O +
a O +
second O +
class O +
is O +
found O +
that O +
is O +
proportional O +
to O +
the O +
high O +
order O +
coefficients O +
of O +
fractional O +
autoregressive O +
integrated O +
moving O +
average O +
( O +
ARIMA O +
) O +
processes O +
. O +

The O +
approach O +
might O +
be O +
useful O +
to O +
detect O +
nonstationarity O +
in O +
autoregressive O +
processes O +
. O +

Troponin O +
I O +
inhibits O +
capillary O +
endothelial O +
cell O +
proliferation O +
by O +
interaction O +
with O +
the O +
cell O +
' O +
s O +
bFGF O +
receptor O +
. O +

Troponin O +
I O +
( O +
TnI O +
) O +
is O +
a O +
novel O +
cartilage O +
- O +
derived O +
angiogenesis O +
inhibitor O +
, O +
first O +
demonstrated O +
by O +
Moses O +
et O +
al O +
. O +

( O +
1999 O +
, O +
Proc O +
. O +
Natl O +
. O +
Acad O +
. O +
Sci O +
. O +
USA O +
2645 O +
- O +
2650 O +
) O +
to O +
inhibit O +
endothelial O +
cell O +
proliferation O +
and O +
angiogenesis O +
, O +
both O +
in O +
vivo O +
and O +
in O +
vitro O +
, O +
and O +
to O +
inhibit O +
metastasis O +
of O +
a O +
wide O +
variety O +
of O +
tumors O +
in O +
vivo O +
. O +

Despite O +
convincing O +
evidence O +
of O +
its O +
efficacy O +
, O +
little O +
is O +
known O +
about O +
the O +
mechanism O +
of O +
action O +
of O +
TnI O +
as O +
an O +
anti O +
- O +
proliferative O +
and O +
anti O +
- O +
angiogenic O +
agent O +
. O +

In O +
the O +
current O +
article O +
we O +
demonstrate O +
that O +
TnI O +
inhibits O +
both O +
bFGF O +
- O +
stimulated O +
and O +
basal O +
levels O +
of O +
endothelial O +
cell O +
proliferation O +
, O +
and O +
we O +
hypothesize O +
that O +
this O +
inhibition O +
is O +
occurring O +
, O +
at O +
least O +
in O +
part O +
, O +
via O +
an O +
interaction O +
of O +
TnI O +
with O +
the O +
cell O +
- O +
surface O +
bFGF O +
receptor O +
on O +
capillary O +
endothelial O +
cells O +
. O +

We O +
further O +
support O +
this O +
hypothesis O +
by O +
providing O +
the O +
first O +
evidence O +
that O +
TnI O +
can O +
act O +
on O +
nonendothelial O +
as O +
well O +
as O +
endothelial O +
cells O +
and O +
by O +
demonstrating O +
that O +
this O +
inhibitory O +
action O +
is O +
specific O +
for O +
the O +
bFGF O +
receptor O +
on O +
the O +
target O +
cells O +
. O +

Preliminary O +
data O +
suggest O +
that O +
TnI O +
may O +
be O +
competing O +
with O +
bFGF O +
for O +
interaction O +
with O +
the O +
bFGF O +
receptor O +
on O +
responsive O +
cells O +
. O +

RhoA O +
activation O +
promotes O +
transformation O +
and O +
loss O +
of O +
thyroid O +
cell O +
differentiation O +
interfering O +
with O +
thyroid O +
transcription O +
factor O +
- O +
1 O +
activity O +
. O +

Highly O +
specialized O +
cells O +
, O +
the O +
thyrocytes O +
, O +
express O +
a O +
thyroid O +
- O +
specific O +
set O +
of O +
genes O +
for O +
thyroglobulin O +
( O +
Tg O +
) O +
, O +
thyroperoxidase O +
, O +
and O +
the O +
transcription O +
factors O +
TTF O +
- O +
1 O +
, O +
TTF O +
- O +
2 O +
, O +
and O +
Pax O +
- O +
8 O +
. O +

The O +
implication O +
of O +
the O +
small O +
GTPase O +
RhoA O +
in O +
TSH O +
- O +
mediated O +
proliferation O +
of O +
FRTL B-CellLine +
- I-CellLine +
5 I-CellLine +
rat O +
thyroid O +
cells O +
has O +
been O +
previously O +
demonstrated O +
. O +

To O +
further O +
analyze O +
RhoA O +
function O +
in O +
thyroid O +
cell O +
proliferation O +
and O +
differentiation O +
patterns O +
, O +
we O +
combined O +
transient O +
and O +
stable O +
transfection O +
assays O +
to O +
express O +
different O +
mutant O +
RhoA O +
forms O +
in O +
FRTL B-CellLine +
- I-CellLine +
5 I-CellLine +
cells O +
. O +

Constitutively O +
active O +
RhoA O +
( O +
FRTL B-CellLine +
- I-CellLine +
5 I-CellLine +
- O +
RhoA O +
QL O +
cells O +
) O +
exhibited O +
a O +
fibroblast O +
- O +
like O +
phenotype O +
with O +
organized O +
actin O +
fibers O +
, O +
whereas O +
cells O +
expressing O +
the O +
RhoA O +
negative O +
dominant O +
phenotype O +
( O +
FRTL B-CellLine +
- I-CellLine +
5 I-CellLine +
- O +
RhoA O +
N19 O +
cells O +
) O +
present O +
a O +
rounded O +
morphology O +
and O +
lose O +
normal O +
cytoskeletal O +
architecture O +
. O +

In O +
addition O +
, O +
expression O +
of O +
the O +
constitutively O +
active O +
form O +
of O +
RhoA O +
results O +
in O +
TSH O +
- O +
independent O +
proliferation O +
and O +
anchorage O +
- O +
independent O +
growth O +
and O +
induces O +
tumors O +
when O +
inoculated O +
in O +
nude O +
mice O +
. O +

Interestingly O +
, O +
FRTL B-CellLine +
- I-CellLine +
5 I-CellLine +
- O +
RhoA O +
QL O +
cells O +
express O +
less O +
Tg O +
and O +
TTF O +
- O +
1 O +
than O +
wild O +
- O +
type O +
FRTL B-CellLine +
- I-CellLine +
5 I-CellLine +
( O +
FRTL B-CellLine +
- I-CellLine +
5 I-CellLine +
- O +
vector O +
) O +
or O +
FRTL B-CellLine +
- I-CellLine +
5 I-CellLine +
- O +
RhoA O +
N19 O +
, O +
suggesting O +
a O +
loss O +
at O +
the O +
differentiation O +
stage O +
. O +

This O +
effect O +
is O +
mediated O +
, O +
at O +
least O +
in O +
part O +
, O +
by O +
a O +
decrease O +
in O +
TTF O +
- O +
1 O +
activity O +
, O +
since O +
transient O +
or O +
stable O +
expression O +
of O +
RhoA O +
QL O +
results O +
in O +
a O +
reduction O +
in O +
the O +
activity O +
of O +
the O +
wild O +
- O +
type O +
Tg O +
promoter O +
as O +
well O +
as O +
an O +
artificial O +
promoter O +
the O +
activation O +
of O +
which O +
depends O +
exclusively O +
on O +
TTF O +
- O +
1 O +
. O +

The O +
similarity O +
between O +
RhoA O +
effects O +
and O +
thyroid O +
transformation O +
by O +
Ras O +
suggests O +
that O +
RhoA O +
may O +
act O +
as O +
a O +
downstream O +
effector O +
of O +
Ras O +
; O +
in O +
fact O +
, O +
the O +
dominant O +
negative O +
RhoA O +
N19 O +
abolished O +
the O +
down O +
- O +
regulatory O +
effect O +
of O +
Ras O +
V12 O +
over O +
the O +
Tg O +
promoter O +
. O +

Taken O +
together O +
, O +
these O +
results O +
show O +
for O +
the O +
first O +
time O +
that O +
active O +
RhoA O +
is O +
able O +
to O +
transform O +
FRTL B-CellLine +
- I-CellLine +
5 I-CellLine +
cells O +
and O +
that O +
this O +
effect O +
is O +
coupled O +
to O +
a O +
loss O +
of O +
thyroid O +
differentiation O +
due O +
to O +
impaired O +
TTF O +
- O +
1 O +
activity O +
. O +

Phonology O +
: O +
a O +
review O +
and O +
proposals O +
from O +
a O +
connectionist O +
perspective O +
. O +

A O +
parallel O +
distributed O +
processing O +
( O +
PDP O +
) O +
model O +
of O +
phonological O +
processing O +
is O +
developed O +
, O +
including O +
components O +
to O +
support O +
repetition O +
, O +
auditory O +
processing O +
, O +
comprehension O +
, O +
and O +
language O +
production O +
. O +

From O +
the O +
performance O +
of O +
the O +
PDP O +
reading O +
model O +
of O +
Plaut O +
, O +
McClelland O +
, O +
Seidenberg O +
, O +
and O +
Patterson O +
( O +
1996 O +
) O +
, O +
it O +
is O +
inferred O +
that O +
the O +
acoustic O +
- O +
articulatory O +
motor O +
pattern O +
associator O +
that O +
supports O +
repetition O +
provides O +
the O +
basis O +
for O +
phonological O +
sequence O +
knowledge O +
. O +

From O +
the O +
observation O +
that O +
many O +
patients O +
make O +
phonemic O +
paraphasic O +
errors O +
in O +
language O +
production O +
, O +
as O +
in O +
repetition O +
, O +
it O +
is O +
argued O +
that O +
there O +
must O +
be O +
a O +
direct O +
link O +
between O +
distributed O +
concept O +
representations O +
( O +
lexical O +
semantic O +
knowledge O +
) O +
and O +
this O +
network O +
representation O +
of O +
sequence O +
knowledge O +
. O +

In O +
this O +
way O +
, O +
both O +
lexical O +
semantic O +
and O +
phonotactic O +
constraints O +
are O +
brought O +
to O +
bear O +
on O +
language O +
production O +
. O +

The O +
literature O +
on O +
phonological O +
function O +
in O +
normal O +
subjects O +
( O +
slip O +
- O +
of O +
- O +
the O +
- O +
tongue O +
corpora O +
) O +
and O +
in O +
patients O +
with O +
aphasia O +
is O +
critically O +
reviewed O +
from O +
this O +
perspective O +
. O +

The O +
relationship O +
between O +
acoustic O +
and O +
articulatory O +
motor O +
representations O +
in O +
the O +
process O +
of O +
phonetic O +
perception O +
is O +
considered O +
. O +

Repetition O +
and O +
reproduction O +
conduction O +
aphasia O +
are O +
reviewed O +
in O +
detail O +
and O +
extended O +
consideration O +
is O +
given O +
to O +
the O +
representation O +
of O +
auditory O +
verbal O +
short O +
- O +
term O +
memory O +
in O +
the O +
model O +
. O +

Finally O +
, O +
the O +
PDP O +
model O +
is O +
reconciled O +
with O +
information O +
processing O +
models O +
of O +
phonological O +
processing O +
, O +
including O +
that O +
of O +
Lichtheim O +
, O +
and O +
with O +
current O +
knowledge O +
of O +
the O +
anatomic O +
localization O +
of O +
phonological O +
processing O +
. O +

Although O +
no O +
simulations O +
of O +
the O +
model O +
were O +
run O +
, O +
a O +
number O +
of O +
simulation O +
studies O +
are O +
proposed O +
. O +

Clinical O +
significance O +
of O +
plasma O +
endostatin O +
in O +
acute O +
myeloid O +
leukemia O +
/ O +
myelodysplastic O +
syndrome O +
. O +

BACKGROUND O +
: O +
Endostatin O +
, O +
a O +
C O +
- O +
terminal O +
fragment O +
of O +
collagen O +
XVIII O +
, O +
is O +
an O +
endogenous O +
angiogenesis O +
inhibitor O +
. O +

While O +
endostatin O +
is O +
being O +
investigated O +
for O +
its O +
usefulness O +
in O +
treating O +
solid O +
tumors O +
, O +
its O +
significance O +
in O +
hematologic O +
malignancies O +
is O +
unknown O +
. O +

METHODS O +
: O +
The O +
authors O +
evaluated O +
plasma O +
endostatin O +
( O +
PE O +
) O +
levels O +
using O +
an O +
enzyme O +
linked O +
immunoassay O +
in O +
71 O +
patients O +
with O +
acute O +
myeloid O +
leukemia O +
( O +
AML O +
) O +
and O +
43 O +
patients O +
with O +
myelodysplastic O +
syndrome O +
( O +
MDS O +
) O +
, O +
and O +
correlated O +
PE O +
with O +
various O +
clinical O +
parameters O +
. O +

RESULTS O +
: O +
There O +
was O +
no O +
significant O +
difference O +
in O +
the O +
median O +
PE O +
level O +
between O +
AML O +
/ O +
MDS O +
patients O +
and O +
the O +
normal O +
controls O +
. O +

Nevertheless O +
, O +
patients O +
who O +
achieved O +
complete O +
remission O +
( O +
CR O +
) O +
had O +
a O +
significantly O +
lower O +
median O +
PE O +
level O +
compared O +
to O +
those O +
who O +
did O +
not O +
. O +

In O +
multivariate O +
analysis O +
, O +
PE O +
was O +
found O +
to O +
be O +
a O +
significant O +
( O +
P O +
= O +
0 O +
. O +
03 O +
) O +
predictor O +
of O +
overall O +
survival O +
( O +
OS O +
) O +
with O +
adjustment O +
of O +
the O +
other O +
baseline O +
covariates O +
, O +
including O +
patient O +
age O +
, O +
history O +
of O +
antecedent O +
hematologic O +
disorders O +
, O +
and O +
the O +
use O +
of O +
protective O +
environments O +
. O +

The O +
prognostic O +
value O +
of O +
PE O +
was O +
also O +
evaluated O +
by O +
dividing O +
MDS O +
/ O +
AML O +
patients O +
into O +
high O +
and O +
low O +
PE O +
groups O +
using O +
the O +
median O +
PE O +
level O +
of O +
normal O +
controls O +
as O +
the O +
cut O +
- O +
off O +
. O +

The O +
authors O +
found O +
that O +
patients O +
in O +
the O +
high O +
PE O +
group O +
survived O +
for O +
a O +
significantly O +
shorter O +
time O +
than O +
those O +
patients O +
in O +
the O +
low O +
PE O +
group O +
. O +

CONCLUSIONS O +
: O +
PE O +
is O +
a O +
useful O +
prognostic O +
predictor O +
of O +
CR O +
and O +
OS O +
for O +
AML O +
/ O +
MDS O +
patients O +
. O +

The O +
mechanism O +
underlying O +
the O +
association O +
between O +
high O +
PE O +
and O +
poor O +
clinical O +
outcome O +
is O +
unclear O +
, O +
although O +
it O +
may O +
be O +
related O +
to O +
the O +
possible O +
PE O +
reflection O +
of O +
tumor O +
burden O +
. O +

Modulation O +
of O +
angiogenesis O +
and O +
progelatinase O +
a O +
by O +
thrombin O +
receptor O +
mimetics O +
and O +
antagonists O +
. O +

The O +
angiogenic O +
action O +
of O +
thrombin O +
has O +
been O +
shown O +
to O +
be O +
mediated O +
by O +
activation O +
of O +
the O +
thrombin O +
receptor O +
. O +

In O +
this O +
report O +
we O +
studied O +
the O +
effects O +
of O +
SFLLR O +
, O +
an O +
agonist O +
of O +
the O +
activated O +
thrombin O +
receptor O +
and O +
thrombin O +
receptor O +
peptide O +
and O +
non O +
peptide O +
antagonists O +
on O +
angiogenesis O +
in O +
the O +
chick O +
chorioallantoic O +
membrane O +
( O +
CAM O +
) O +
system O +
. O +

As O +
antagonists O +
were O +
used O +
the O +
tripeptide O +
FPR O +
and O +
non O +
- O +
peptide O +
1 O +
, O +
4 O +
- O +
disubstituted O +
piperazine O +
derivatives O +
. O +

The O +
pentapeptide O +
SFLLR O +
, O +
like O +
thrombin O +
, O +
caused O +
a O +
marked O +
stimulation O +
of O +
angiogenesis O +
in O +
the O +
CAM O +
. O +

FPR O +
and O +
the O +
piperazine O +
derivatives O +
caused O +
suppression O +
of O +
angiogenesis O +
and O +
in O +
combination O +
with O +
thrombin O +
antagonized O +
its O +
angiogenic O +
effect O +
. O +

Thrombin O +
and O +
SFLLR O +
activated O +
progelatinase O +
A O +
( O +
MMP O +
- O +
2 O +
) O +
in O +
the O +
culture O +
medium O +
of O +
human O +
umbilical O +
cord O +
endothelial O +
cells O +
( O +
HUVECs O +
) O +
. O +

MMP O +
- O +
2 O +
is O +
involved O +
in O +
the O +
early O +
steps O +
of O +
angiogenesis O +
leading O +
to O +
local O +
dissolution O +
of O +
basement O +
membrane O +
collagen O +
and O +
migration O +
of O +
the O +
activated O +
endothelial O +
cells O +
. O +

FPR O +
and O +
the O +
piperazine O +
derivatives O +
inhibited O +
the O +
activation O +
of O +
this O +
enzyme O +
. O +

They O +
also O +
antagonised O +
the O +
effects O +
of O +
both O +
thrombin O +
and O +
SFLLR O +
on O +
MMP O +
- O +
2 O +
activation O +
. O +

These O +
results O +
suggest O +
that O +
non O +
- O +
thrombogenic O +
agonists O +
or O +
antagonists O +
of O +
the O +
activated O +
thrombin O +
receptor O +
can O +
be O +
used O +
as O +
modulators O +
of O +
angiogenesis O +
. O +

Inhibition O +
of O +
PDGF O +
- O +
stimulated O +
and O +
matrix O +
- O +
mediated O +
proliferation O +
of O +
human O +
vascular O +
smooth O +
muscle O +
cells O +
by O +
SPARC O +
is O +
independent O +
of O +
changes O +
in O +
cell O +
shape O +
or O +
cyclin O +
- O +
dependent O +
kinase O +
inhibitors O +
. O +

Interactions O +
among O +
growth O +
factors O +
, O +
cells O +
, O +
and O +
extracellular O +
matrix O +
regulate O +
proliferation O +
during O +
normal O +
development O +
and O +
in O +
pathologies O +
such O +
as O +
atherosclerosis O +
. O +

SPARC O +
( O +
secreted O +
protein O +
, O +
acidic O +
, O +
and O +
rich O +
in O +
cysteine O +
) O +
is O +
a O +
matrix O +
- O +
associated O +
glycoprotein O +
that O +
modulates O +
the O +
adhesion O +
and O +
proliferation O +
of O +
vascular O +
cells O +
. O +

In O +
this O +
study O +
, O +
we O +
demonstrate O +
that O +
SPARC O +
inhibits O +
human O +
arterial O +
smooth O +
muscle O +
cell O +
proliferation O +
stimulated O +
by O +
platelet O +
- O +
derived O +
growth O +
factor O +
or O +
by O +
adhesion O +
to O +
monomeric O +
type O +
I O +
collagen O +
. O +

Binding O +
studies O +
with O +
SPARC O +
and O +
SPARC O +
peptides O +
indicate O +
specific O +
and O +
saturable O +
interaction O +
with O +
smooth O +
muscle O +
cells O +
that O +
involves O +
the O +
C O +
- O +
terminal O +
Ca2 O +
+ O +
- O +
binding O +
region O +
of O +
the O +
protein O +
. O +

We O +
also O +
report O +
that O +
SPARC O +
arrests O +
monomeric O +
collagen O +
- O +
supported O +
smooth O +
muscle O +
cell O +
proliferation O +
in O +
the O +
late O +
G1 O +
- O +
phase O +
of O +
the O +
cell O +
cycle O +
in O +
the O +
absence O +
of O +
an O +
effect O +
on O +
cell O +
shape O +
or O +
on O +
levels O +
of O +
cyclin O +
- O +
dependent O +
kinase O +
inhibitors O +
. O +

Cyclin O +
- O +
dependent O +
kinase O +
- O +
2 O +
activity O +
, O +
p107 O +
and O +
cyclin O +
A O +
levels O +
, O +
and O +
retinoblastoma O +
protein O +
phosphorylation O +
are O +
markedly O +
reduced O +
in O +
response O +
to O +
the O +
addition O +
of O +
exogenous O +
SPARC O +
and O +
/ O +
or O +
peptides O +
derived O +
from O +
specific O +
domains O +
of O +
SPARC O +
. O +

Thus O +
, O +
SPARC O +
, O +
previously O +
characterized O +
as O +
an O +
inhibitor O +
of O +
platelet O +
- O +
derived O +
growth O +
factor O +
binding O +
to O +
its O +
receptor O +
, O +
also O +
antagonizes O +
smooth O +
muscle O +
cell O +
proliferation O +
mediated O +
by O +
monomeric O +
collagen O +
at O +
the O +
level O +
of O +
cyclin O +
- O +
dependent O +
kinase O +
- O +
2 O +
activity O +
. O +

Prognostic O +
significance O +
of O +
heat O +
shock O +
protein O +
27 O +
( O +
HSP27 O +
) O +
in O +
patients O +
with O +
oral O +
squamous O +
cell O +
carcinoma O +
. O +

Heat O +
shock O +
proteins O +
( O +
HSPs O +
) O +
have O +
been O +
defined O +
as O +
proteins O +
induced O +
by O +
heat O +
shock O +
and O +
other O +
environmental O +
and O +
pathophysiologic O +
stress O +
. O +

Heat O +
shock O +
protein O +
27 O +
( O +
HSP27 O +
) O +
is O +
one O +
of O +
the O +
small O +
heat O +
shock O +
proteins O +
. O +

HSP27 O +
is O +
implicated O +
in O +
protein O +
- O +
protein O +
interactions O +
such O +
as O +
folding O +
, O +
translocation O +
, O +
and O +
prevention O +
of O +
inappropriate O +
protein O +
aggregation O +
. O +

Many O +
of O +
their O +
functions O +
suggest O +
that O +
they O +
play O +
important O +
roles O +
in O +
cancers O +
. O +

Archival O +
tissues O +
from O +
40 O +
patients O +
with O +
oral O +
squamous O +
cell O +
carcinoma O +
who O +
received O +
primary O +
surgical O +
resection O +
were O +
examined O +
for O +
HSP27 O +
by O +
immunohistochemistry O +
and O +
correlated O +
with O +
clinical O +
stage O +
, O +
lymph O +
node O +
metastasis O +
, O +
histological O +
grade O +
and O +
survival O +
period O +
. O +

HSP27 O +
expression O +
was O +
positive O +
staining O +
( O +
+ O +
) O +
in O +
20 O +
( O +
50 O +
% O +
) O +
, O +
weak O +
or O +
negative O +
staining O +
( O +
- O +
) O +
in O +
20 O +
( O +
50 O +
% O +
) O +
of O +
total O +
40 O +
cases O +
. O +

There O +
was O +
no O +
correlation O +
between O +
HSP27 O +
expression O +
and O +
clinical O +
stage O +
, O +
lymph O +
node O +
metastasis O +
and O +
histological O +
grade O +
. O +

However O +
, O +
when O +
compared O +
with O +
clinicopathological O +
features O +
, O +
the O +
expression O +
of O +
HSP27 O +
correlated O +
inversely O +
with O +
survival O +
period O +
. O +

This O +
study O +
suggests O +
that O +
the O +
expression O +
of O +
HSP27 O +
is O +
frequently O +
promoted O +
in O +
patients O +
with O +
oral O +
squamous O +
cell O +
carcinoma O +
and O +
should O +
be O +
considered O +
an O +
independent O +
prognostic O +
factor O +
of O +
oral O +
squamous O +
cell O +
carcinoma O +
patients O +
. O +

Abnormal O +
expression O +
of O +
E O +
- O +
cadherin O +
and O +
beta O +
- O +
catenin O +
may O +
be O +
a O +
molecular O +
marker O +
of O +
submucosal O +
invasion O +
and O +
lymph O +
node O +
metastasis O +
in O +
early O +
gastric O +
cancer O +
. O +

BACKGROUND O +
: O +
Impaired O +
expression O +
of O +
E O +
- O +
cadherin O +
and O +
alpha O +
- O +
and O +
beta O +
- O +
catenin O +
is O +
frequently O +
observed O +
in O +
several O +
human O +
cancers O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
examine O +
immunohistochemical O +
expression O +
of O +
these O +
adhesion O +
molecules O +
, O +
focusing O +
on O +
early O +
gastric O +
carcinomas O +
, O +
and O +
to O +
investigate O +
differences O +
between O +
differentiated O +
and O +
undifferentiated O +
gastric O +
cancer O +
at O +
the O +
early O +
phase O +
of O +
carcinogenesis O +
. O +

METHODS O +
: O +
Immunohistochemical O +
staining O +
of O +
E O +
- O +
cadherin O +
and O +
alpha O +
- O +
and O +
beta O +
- O +
catenin O +
was O +
performed O +
using O +
specimens O +
from O +
143 O +
patients O +
with O +
early O +
gastric O +
cancer O +
. O +

RESULTS O +
: O +
Abnormal O +
E O +
- O +
cadherin O +
and O +
beta O +
- O +
catenin O +
staining O +
correlated O +
with O +
depth O +
of O +
tumour O +
invasion O +
in O +
differentiated O +
- O +
type O +
tumours O +
. O +

In O +
contrast O +
, O +
abnormal O +
staining O +
was O +
frequently O +
found O +
even O +
in O +
intramucosal O +
carcinoma O +
of O +
undifferentiated O +
- O +
type O +
tumours O +
, O +
suggesting O +
an O +
apparent O +
difference O +
in O +
the O +
onset O +
of O +
E O +
- O +
cadherin O +
- O +
catenin O +
complex O +
abnormality O +
between O +
the O +
two O +
cancer O +
types O +
. O +

Absent O +
staining O +
of O +
beta O +
- O +
catenin O +
was O +
associated O +
with O +
lymph O +
node O +
metastasis O +
. O +

Multivariate O +
analysis O +
revealed O +
abnormal O +
E O +
- O +
cadherin O +
expression O +
as O +
an O +
independent O +
factor O +
that O +
correlated O +
with O +
submucosal O +
invasion O +
in O +
early O +
gastric O +
cancer O +
. O +

CONCLUSION O +
: O +
Abnormal O +
E O +
- O +
cadherin O +
expression O +
is O +
a O +
possible O +
marker O +
of O +
submucosal O +
invasion O +
in O +
differentiated O +
- O +
type O +
early O +
gastric O +
cancer O +
and O +
absent O +
beta O +
- O +
catenin O +
staining O +
could O +
be O +
used O +
as O +
a O +
predictor O +
of O +
lymph O +
node O +
metastasis O +
in O +
both O +
types O +
. O +

Dominant O +
negative O +
interference O +
of O +
transcription O +
factor O +
AP O +
- O +
2 O +
causes O +
inhibition O +
of O +
ErbB O +
- O +
3 O +
expression O +
and O +
suppresses O +
malignant O +
cell O +
growth O +
. O +

ErbB O +
- O +
3 O +
( O +
HER3 O +
) O +
is O +
a O +
member O +
of O +
the O +
epidermal O +
growth O +
factor O +
receptor O +
family O +
. O +

Increasing O +
evidence O +
suggests O +
that O +
elevated O +
expression O +
of O +
ErbB O +
- O +
3 O +
is O +
important O +
for O +
malignancy O +
. O +

In O +
this O +
study O +
, O +
we O +
found O +
that O +
elevated O +
levels O +
of O +
ErbB O +
- O +
3 O +
expression O +
did O +
not O +
occur O +
in O +
the O +
absence O +
of O +
AP O +
- O +
2gamma O +
in O +
a O +
panel O +
of O +
human O +
mammary O +
epithelial O +
and O +
fibroblasts O +
cell O +
lines O +
. O +

In O +
contrast O +
, O +
there O +
was O +
no O +
association O +
between O +
the O +
expression O +
of O +
AP O +
- O +
2alpha O +
or O +
AP O +
- O +
2beta O +
and O +
the O +
level O +
of O +
ErbB O +
- O +
3 O +
, O +
or O +
between O +
AP O +
- O +
2alpha O +
and O +
AP O +
- O +
2gamma O +
double O +
positivity O +
and O +
ErbB O +
- O +
3 O +
expression O +
. O +

In O +
co O +
- O +
transfection O +
experiments O +
, O +
exogenous O +
expression O +
of O +
AP O +
- O +
2gamma O +
robustly O +
activated O +
ErbB O +
- O +
3 O +
promoter O +
activity O +
. O +

Moreover O +
, O +
expression O +
of O +
a O +
dominant O +
negative O +
AP O +
- O +
2 O +
protein O +
, O +
AP O +
- O +
2delta O +
( O +
deleted O +
residues O +
31 O +
- O +
117 O +
) O +
, O +
not O +
only O +
repressed O +
the O +
ErbB O +
- O +
3 O +
promoter O +
activity O +
but O +
also O +
suppressed O +
endogenous O +
ErbB O +
- O +
3 O +
transcription O +
in O +
the O +
ErbB O +
- O +
3 O +
overexpressing O +
cell O +
line O +
MRC B-CellLine +
- I-CellLine +
5VA I-CellLine +
. O +

Overexpression O +
of O +
AP O +
- O +
2A O +
resulted O +
in O +
a O +
decreased O +
proliferation O +
rate O +
and O +
inhibitin O +
of O +
colony O +
formation O +
. O +

Taken O +
together O +
, O +
these O +
data O +
strongly O +
support O +
a O +
role O +
for O +
the O +
AP O +
- O +
2 O +
gene O +
family O +
, O +
in O +
particular O +
, O +
AP O +
- O +
2gamma O +
, O +
in O +
the O +
control O +
of O +
ErbB O +
- O +
3 O +
expression O +
. O +

Interference O +
with O +
the O +
function O +
of O +
transcription O +
factor O +
AP O +
- O +
2 O +
might O +
provide O +
a O +
potential O +
strategy O +
for O +
modulation O +
of O +
the O +
malignant O +
phenotype O +
. O +

Membrane O +
- O +
anchored O +
Cbl O +
suppresses O +
Hck O +
protein O +
- O +
tyrosine O +
kinase O +
mediated O +
cellular O +
transformation O +
. O +

The O +
mammalian O +
proto O +
- O +
oncogene O +
Cbl O +
and O +
its O +
cellular O +
homologues O +
in O +
Caenorhabditis O +
elegans O +
( O +
Sli O +
- O +
1 O +
) O +
and O +
Drosophila O +
( O +
D O +
- O +
Cbl O +
) O +
are O +
negative O +
regulators O +
of O +
some O +
growth O +
factor O +
receptor O +
signaling O +
pathways O +
. O +

Herein O +
we O +
show O +
that O +
Cbl O +
can O +
negatively O +
regulate O +
another O +
signaling O +
molecule O +
, O +
namely O +
theSrc O +
- O +
family O +
kinase O +
Hck O +
by O +
targeting O +
it O +
for O +
degradation O +
. O +

Hck O +
- O +
mediated O +
cellular O +
transformation O +
of O +
murine O +
fibroblasts O +
is O +
reverted O +
by O +
ectopic O +
expression O +
of O +
a O +
membrane O +
- O +
anchored O +
allele O +
of O +
Cbl O +
as O +
assessed O +
by O +
the O +
cellular O +
morphology O +
, O +
suppression O +
of O +
anchorage O +
independent O +
growth O +
, O +
and O +
an O +
overall O +
reduction O +
in O +
the O +
total O +
tyrosine O +
phosphorylation O +
levels O +
within O +
the O +
cells O +
. O +

The O +
expression O +
of O +
Cbl O +
at O +
the O +
plasma O +
membrane O +
targets O +
both O +
Hck O +
and O +
itself O +
for O +
ubiquitination O +
and O +
degradation O +
, O +
requiring O +
an O +
intact O +
RING O +
finger O +
. O +

Pharmacological O +
inhibition O +
of O +
the O +
proteasome O +
prevents O +
the O +
degradation O +
of O +
Hck O +
correlating O +
with O +
an O +
increase O +
in O +
the O +
phosphotyrosine O +
levels O +
within O +
the O +
cells O +
. O +

Activated O +
Hck O +
and O +
membrane O +
- O +
anchored O +
Cbl O +
are O +
present O +
in O +
similar O +
subcellular O +
localizations O +
and O +
co O +
- O +
immunoprecipitate O +
, O +
suggesting O +
that O +
their O +
interaction O +
is O +
required O +
for O +
subsequent O +
ubiquitination O +
and O +
degradation O +
. O +

Interestingly O +
, O +
both O +
constitutively O +
active O +
and O +
kinase O +
- O +
inactive O +
Hck O +
interact O +
with O +
and O +
are O +
targeted O +
for O +
degradation O +
by O +
Cbl O +
. O +

This O +
work O +
illustrates O +
alternate O +
means O +
to O +
regulate O +
Src O +
- O +
family O +
kinases O +
, O +
and O +
suggests O +
that O +
Cbl O +
may O +
be O +
able O +
to O +
suppress O +
many O +
signaling O +
pathways O +
that O +
are O +
activated O +
in O +
various O +
proliferative O +
syndromes O +
including O +
cancer O +
. O +

Novel O +
method O +
for O +
multiturn O +
extraction O +
: O +
trapping O +
charged O +
particles O +
in O +
islands O +
of O +
phase O +
space O +
. O +

A O +
novel O +
method O +
for O +
multiturn O +
extraction O +
from O +
a O +
circular O +
particle O +
accelerator O +
is O +
presented O +
, O +
based O +
on O +
trapping O +
particles O +
into O +
islands O +
of O +
phase O +
space O +
generated O +
by O +
nonlinear O +
resonances O +
. O +

By O +
appropriate O +
use O +
of O +
sextupoles O +
and O +
octupoles O +
, O +
stable O +
islands O +
can O +
be O +
created O +
at O +
small O +
amplitude O +
in O +
phase O +
space O +
. O +

By O +
varying O +
the O +
linear O +
tune O +
, O +
particles O +
can O +
be O +
trapped O +
inside O +
these O +
islands O +
and O +
then O +
transported O +
towards O +
higher O +
amplitudes O +
for O +
extraction O +
. O +

Results O +
of O +
numerical O +
simulations O +
are O +
discussed O +
. O +

Upregulation O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
receptors O +
is O +
associated O +
with O +
advanced O +
neuroblastoma O +
. O +

BACKGROUND O +
: O +
Angiogenesis O +
is O +
essential O +
for O +
tumor O +
growth O +
and O +
relies O +
on O +
the O +
production O +
of O +
angiogenic O +
factors O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
is O +
a O +
major O +
regulator O +
of O +
angiogenesis O +
that O +
binds O +
to O +
tyrosine O +
kinase O +
receptors O +
Flt O +
- O +
1 O +
and O +
KDR O +
. O +

The O +
interaction O +
of O +
VEGF O +
and O +
its O +
receptors O +
at O +
gene O +
and O +
protein O +
levels O +
in O +
neuroblastoma O +
remains O +
widely O +
unknown O +
. O +

METHODS O +
: O +
Tumor O +
biopsy O +
specimens O +
and O +
serum O +
were O +
obtained O +
from O +
37 O +
neuroblastoma O +
patients O +
; O +
adrenal O +
biopsy O +
sections O +
and O +
sera O +
of O +
7 O +
normal O +
children O +
served O +
as O +
controls O +
. O +

Biopsy O +
specimens O +
were O +
examined O +
by O +
real O +
- O +
time O +
reverse O +
transcription O +
polymerase O +
chain O +
reaction O +
( O +
RT O +
- O +
PCR O +
) O +
and O +
Western O +
blotting O +
; O +
serum O +
was O +
analyzed O +
by O +
enzyme O +
- O +
linked O +
immunosorbent O +
assay O +
( O +
ELISA O +
) O +
. O +

VEGF O +
- O +
A O +
( O +
165 O +
) O +
, O +
B O +
, O +
C O +
, O +
Flt O +
- O +
1 O +
, O +
and O +
KDR O +
were O +
analyzed O +
. O +

RESULTS O +
: O +
VEGF O +
isoforms O +
and O +
its O +
receptors O +
' O +
mRNA O +
were O +
expressed O +
in O +
neuroblastoma O +
and O +
control O +
tissues O +
. O +

Whereas O +
the O +
ligands O +
were O +
increased O +
in O +
stages O +
III O +
and O +
IV O +
, O +
the O +
receptors O +
were O +
upregulated O +
in O +
stage O +
III O +
only O +
. O +

At O +
protein O +
level O +
, O +
VEGF O +
- O +
B O +
and O +
C O +
, O +
Flt O +
- O +
1 O +
, O +
and O +
KDR O +
were O +
not O +
detectable O +
in O +
tissue O +
lysates O +
, O +
whereas O +
VEGF O +
- O +
A O +
was O +
increased O +
in O +
stages O +
III O +
and O +
IV O +
. O +

Serum O +
VEGF O +
protein O +
levels O +
were O +
upregulated O +
in O +
stage O +
III O +
. O +

CONCLUSIONS O +
: O +
VEGF O +
- O +
A O +
( O +
165 O +
) O +
is O +
one O +
of O +
the O +
major O +
angiogenesis O +
regulators O +
among O +
the O +
ligands O +
' O +
family O +
of O +
VEGF O +
, O +
whereas O +
its O +
receptors O +
KDR O +
, O +
and O +
most O +
probably O +
Flt O +
- O +
1 O +
, O +
may O +
contribute O +
to O +
a O +
poor O +
prognosis O +
( O +
angiogenic O +
) O +
phenotype O +
, O +
as O +
indicated O +
by O +
their O +
upregulated O +
MRNA O +
levels O +
in O +
stage O +
III O +
neuroblastoma O +
. O +

VEGF O +
- O +
A O +
( O +
165 O +
) O +
mainly O +
contributes O +
to O +
increased O +
serum O +
VEGF O +
levels O +
and O +
may O +
serve O +
as O +
a O +
diagnostic O +
tool O +
in O +
advanced O +
- O +
stage O +
neuroblastoma O +
. O +

Hypoxia O +
- O +
inducible O +
factor O +
1 O +
activation O +
by O +
aerobic O +
glycolysis O +
implicates O +
the O +
Warburg O +
effect O +
in O +
carcinogenesis O +
. O +

Cancer O +
cells O +
display O +
high O +
rates O +
of O +
aerobic O +
glycolysis O +
, O +
a O +
phenomenon O +
known O +
historically O +
as O +
the O +
Warburg O +
effect O +
. O +

Lactate O +
and O +
pyruvate O +
, O +
the O +
end O +
products O +
of O +
glycolysis O +
, O +
are O +
highly O +
produced O +
by O +
cancer O +
cells O +
even O +
in O +
the O +
presence O +
of O +
oxygen O +
. O +

Hypoxia O +
- O +
induced O +
gene O +
expression O +
in O +
cancer O +
cells O +
has O +
been O +
linked O +
to O +
malignant O +
transformation O +
. O +

Here O +
we O +
provide O +
evidence O +
that O +
lactate O +
and O +
pyruvate O +
regulate O +
hypoxia O +
- O +
inducible O +
gene O +
expression O +
independently O +
of O +
hypoxia O +
by O +
stimulating O +
the O +
accumulation O +
of O +
hypoxia O +
- O +
inducible O +
Factor O +
1alpha O +
( O +
HIF O +
- O +
1alpha O +
) O +
. O +

In O +
human O +
gliomas O +
and O +
other O +
cancer O +
cell O +
lines O +
, O +
the O +
accumulation O +
of O +
HIF O +
- O +
1alpha O +
protein O +
under O +
aerobic O +
conditions O +
requires O +
the O +
metabolism O +
of O +
glucose O +
to O +
pyruvate O +
that O +
prevents O +
the O +
aerobic O +
degradation O +
of O +
HIF O +
- O +
1alpha O +
protein O +
, O +
activates O +
HIF O +
- O +
1 O +
DNA O +
binding O +
activity O +
, O +
and O +
enhances O +
the O +
expression O +
of O +
several O +
HIF O +
- O +
1 O +
- O +
activated O +
genes O +
including O +
erythropoietin O +
, O +
vascular O +
endothelial O +
growth O +
factor O +
, O +
glucose O +
transporter O +
3 O +
, O +
and O +
aldolase O +
A O +
. O +

Our O +
findings O +
support O +
a O +
novel O +
role O +
for O +
pyruvate O +
in O +
metabolic O +
signaling O +
and O +
suggest O +
a O +
mechanism O +
by O +
which O +
high O +
rates O +
of O +
aerobic O +
glycolysis O +
can O +
promote O +
the O +
malignant O +
transformation O +
and O +
survival O +
of O +
cancer O +
cells O +
. O +

VEGF165 O +
mediates O +
formation O +
of O +
complexes O +
containing O +
VEGFR O +
- O +
2 O +
and O +
neuropilin O +
- O +
1 O +
that O +
enhance O +
VEGF165 O +
- O +
receptor O +
binding O +
. O +

Co O +
- O +
expression O +
of O +
NRP1 O +
and O +
( O +
VEGFR O +
- O +
2 O +
) O +
KDR O +
on O +
the O +
surface O +
of O +
endothelial O +
cells O +
( O +
EC O +
) O +
enhances O +
VEGF165 O +
binding O +
to O +
KDR O +
and O +
EC O +
chemotaxis O +
in O +
response O +
to O +
VEGF165 O +
. O +

Overexpression O +
of O +
NRP1 O +
by O +
prostate O +
tumor O +
cells O +
in O +
vivo O +
results O +
in O +
increased O +
tumor O +
angiogenesis O +
and O +
growth O +
. O +

We O +
investigated O +
the O +
molecular O +
mechanisms O +
underlying O +
NRP1 O +
- O +
mediated O +
angiogenesis O +
by O +
analyzing O +
the O +
association O +
of O +
NRP1 O +
and O +
KDR O +
. O +

An O +
intracellular O +
complex O +
containing O +
NRP1 O +
and O +
KDR O +
was O +
immunoprecipitated O +
from O +
EC O +
by O +
anti O +
- O +
NRP1 O +
antibodies O +
only O +
in O +
the O +
presence O +
of O +
VEGF165 O +
. O +

In O +
contrast O +
, O +
VEGF121 O +
, O +
which O +
does O +
not O +
bind O +
to O +
NRP1 O +
, O +
did O +
not O +
support O +
complex O +
formation O +
. O +

Complexes O +
containing O +
VEGF165 O +
, O +
NRP1 O +
, O +
and O +
KDR O +
were O +
also O +
formed O +
in O +
an O +
intercellular O +
fashion O +
by O +
co O +
- O +
culture O +
of O +
EC O +
expressing O +
KDR O +
only O +
, O +
with O +
cells O +
expressing O +
NRP1 O +
only O +
, O +
for O +
example O +
, O +
breast O +
carcinoma O +
cells O +
. O +

VEGF165 O +
also O +
mediated O +
the O +
binding O +
of O +
a O +
soluble O +
NRP1 O +
dimer O +
to O +
cells O +
expressing O +
KDR O +
only O +
, O +
confirming O +
the O +
formation O +
of O +
such O +
complexes O +
. O +

Furthermore O +
, O +
the O +
formation O +
of O +
complexes O +
containing O +
KDR O +
and O +
NRP1 O +
markedly O +
increased O +
125I O +
- O +
VEGF165 O +
binding O +
to O +
KDR O +
. O +

Our O +
results O +
suggest O +
that O +
formation O +
of O +
a O +
ternary O +
complex O +
of O +
VEGF165 O +
, O +
KDR O +
, O +
and O +
NRP1 O +
potentiates O +
VEGF165 O +
binding O +
to O +
KDR O +
. O +

These O +
complexes O +
are O +
formed O +
on O +
the O +
surface O +
of O +
EC O +
and O +
in O +
a O +
juxtacrine O +
manner O +
via O +
association O +
of O +
tumor O +
cell O +
NRP1 O +
and O +
EC O +
KDR O +
. O +

Risk O +
of O +
myelodysplastic O +
syndrome O +
and O +
acute O +
myeloid O +
leukemia O +
in O +
congenital O +
neutropenias O +
. O +

Granulocyte O +
colony O +
- O +
stimulating O +
factor O +
( O +
G O +
- O +
CSF O +
) O +
has O +
had O +
a O +
major O +
impact O +
on O +
the O +
management O +
of O +
" O +
severe O +
chronic O +
neutropenia O +
" O +
( O +
SCN O +
) O +
, O +
a O +
collective O +
term O +
referring O +
to O +
congenital O +
, O +
idiopathic O +
, O +
or O +
cyclic O +
neutropenia O +
. O +

Almost O +
all O +
patients O +
respond O +
to O +
G O +
- O +
CSF O +
with O +
increased O +
neutrophils O +
, O +
reduced O +
infections O +
, O +
and O +
improved O +
survival O +
. O +

Some O +
responders O +
with O +
congenital O +
neutropenia O +
and O +
Shwachman O +
- O +
Diamond O +
syndrome O +
( O +
SDS O +
) O +
have O +
developed O +
myelodysplastic O +
syndrome O +
and O +
acute O +
myeloid O +
leukemia O +
( O +
MDS O +
/ O +
AML O +
) O +
, O +
which O +
raises O +
the O +
question O +
of O +
the O +
role O +
of O +
G O +
- O +
CSF O +
in O +
pathogenesis O +
. O +

The O +
issue O +
is O +
complicated O +
because O +
both O +
disorders O +
have O +
a O +
propensity O +
for O +
MDS O +
or O +
AML O +
as O +
part O +
of O +
their O +
natural O +
history O +
. O +

To O +
address O +
this O +
, O +
the O +
Severe O +
Chronic O +
Neutropenia O +
International O +
Registry O +
( O +
SCNIR O +
) O +
used O +
its O +
large O +
database O +
of O +
chronic O +
neutropenia O +
patients O +
treated O +
with O +
G O +
- O +
CSF O +
to O +
determine O +
the O +
incidence O +
of O +
malignant O +
myeloid O +
transformation O +
in O +
the O +
two O +
disorders O +
, O +
and O +
its O +
relationship O +
to O +
treatment O +
and O +
to O +
other O +
patient O +
characteristics O +
. O +

No O +
statistically O +
significant O +
relationships O +
were O +
found O +
between O +
age O +
at O +
onset O +
of O +
MDS O +
or O +
AML O +
and O +
patient O +
gender O +
, O +
G O +
- O +
CSF O +
dose O +
, O +
or O +
duration O +
of O +
G O +
- O +
CSF O +
therapy O +
. O +

What O +
was O +
observed O +
, O +
however O +
, O +
was O +
the O +
multistep O +
acquisition O +
of O +
aberrant O +
cellular O +
genetic O +
changes O +
in O +
marrow O +
cells O +
from O +
patients O +
who O +
transformed O +
, O +
including O +
activating O +
ras O +
oncogene O +
mutations O +
, O +
clonal O +
cytogenetic O +
abnormalities O +
, O +
and O +
G O +
- O +
CSF O +
receptor O +
mutations O +
. O +

In O +
murine O +
models O +
, O +
the O +
latter O +
produces O +
a O +
hyperproliferative O +
response O +
to O +
G O +
- O +
CSF O +
, O +
confers O +
resistance O +
to O +
apoptosis O +
, O +
and O +
enhances O +
cell O +
survival O +
. O +

Since O +
congenital O +
neutropenia O +
and O +
SDS O +
are O +
inherited O +
forms O +
of O +
bone O +
marrow O +
failure O +
, O +
G O +
- O +
CSF O +
may O +
accelerate O +
the O +
propensity O +
for O +
MDS O +
/ O +
AML O +
in O +
the O +
genetically O +
altered O +
stem O +
and O +
progenitor O +
cells O +
, O +
especially O +
in O +
those O +
with O +
G O +
- O +
CSF O +
receptor O +
and O +
ras O +
mutations O +
( O +
82 O +
% O +
and O +
50 O +
% O +
of O +
patients O +
who O +
transform O +
, O +
respectively O +
) O +
. O +

Alternatively O +
, O +
and O +
equally O +
plausible O +
, O +
G O +
- O +
CSF O +
may O +
simply O +
be O +
an O +
" O +
innocent O +
bystander O +
" O +
that O +
corrects O +
neutropenia O +
, O +
prolongs O +
patient O +
survival O +
, O +
and O +
allows O +
time O +
for O +
the O +
malignant O +
predisposition O +
to O +
declare O +
itself O +
. O +

In O +
patients O +
who O +
transform O +
to O +
overt O +
MDS O +
or O +
AML O +
, O +
hematopoietic O +
stem O +
cell O +
transplantation O +
is O +
the O +
only O +
chance O +
for O +
cure O +
. O +

In O +
those O +
with O +
" O +
soft O +
" O +
signs O +
of O +
MDS O +
, O +
such O +
as O +
an O +
isolated O +
clonal O +
cytogenetic O +
change O +
but O +
without O +
other O +
evidence O +
of O +
MDS O +
, O +
or O +
with O +
an O +
isolated O +
G O +
- O +
CSF O +
receptor O +
mutation O +
, O +
there O +
is O +
room O +
for O +
conservative O +
management O +
. O +

One O +
option O +
is O +
to O +
reduce O +
the O +
G O +
- O +
CSF O +
dosage O +
as O +
much O +
as O +
possible O +
, O +
and O +
observe O +
the O +
tempo O +
of O +
progression O +
, O +
if O +
any O +
, O +
to O +
more O +
overt O +
signs O +
of O +
malignancy O +
. O +

Stimulation O +
of O +
beta O +
- O +
adrenergic O +
receptors O +
in O +
the O +
pineal O +
gland O +
increases O +
the O +
noradrenaline O +
stores O +
of O +
its O +
sympathetic O +
nerves O +
. O +

The O +
administration O +
of O +
isoproterenol O +
decreases O +
the O +
level O +
of O +
serotonin O +
in O +
the O +
rat O +
pineal O +
gland O +
and O +
at O +
the O +
same O +
time O +
it O +
increases O +
pineal O +
noradrenaline O +
. O +

These O +
effects O +
depend O +
on O +
the O +
stimulation O +
of O +
a O +
beta O +
- O +
adrenergic O +
receptor O +
because O +
they O +
are O +
blocked O +
by O +
pretreatment O +
of O +
the O +
animals O +
with O +
propranolol O +
; O +
this O +
drug O +
by O +
itself O +
does O +
not O +
modify O +
either O +
serotonin O +
or O +
noradrenaline O +
levels O +
in O +
the O +
pineal O +
. O +

The O +
elevation O +
of O +
noradrenaline O +
produced O +
by O +
isoproterenol O +
is O +
selective O +
for O +
the O +
pineal O +
because O +
it O +
is O +
not O +
observed O +
in O +
the O +
salivary O +
gland O +
innervated O +
by O +
postganglionic O +
adrenergic O +
fibers O +
from O +
the O +
same O +
origin O +
as O +
pineal O +
nerves O +
. O +

Pineal O +
serotonin O +
is O +
stored O +
in O +
equilibrium O +
in O +
two O +
compartments O +
, O +
i O +
. O +
e O +
. O +
, O +
the O +
parenchymal O +
cells O +
and O +
the O +
adrenergic O +
nerves O +
and O +
thus O +
is O +
most O +
probably O +
reduced O +
in O +
both O +
sites O +
. O +

Since O +
noradrenaline O +
and O +
serotonin O +
are O +
detected O +
in O +
pineal O +
nerve O +
vesicles O +
and O +
may O +
coexist O +
in O +
them O +
, O +
the O +
diminution O +
of O +
intravesicular O +
serotonin O +
, O +
by O +
making O +
more O +
storage O +
sites O +
available O +
, O +
probably O +
determines O +
the O +
selective O +
increase O +
of O +
pineal O +
noradrenaline O +
. O +

A O +
similar O +
modification O +
in O +
the O +
ratio O +
of O +
intravesicular O +
amines O +
as O +
a O +
result O +
of O +
the O +
physiological O +
stimulation O +
of O +
pineal O +
beta O +
- O +
adrenergic O +
receptors O +
by O +
the O +
adrenergic O +
neurotransmitter O +
may O +
explain O +
some O +
of O +
the O +
changes O +
observed O +
in O +
the O +
content O +
of O +
pineal O +
amines O +
. O +

Hypoxic O +
induction O +
of O +
HIF O +
- O +
1alpha O +
and O +
VEGF O +
expression O +
in O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O +
lines O +
is O +
mediated O +
by O +
stress O +
activated O +
protein O +
kinases O +
. O +

Solid O +
tumors O +
must O +
establish O +
a O +
blood O +
supply O +
in O +
order O +
to O +
proliferate O +
and O +
grow O +
. O +

Cancer O +
cells O +
secrete O +
soluble O +
factors O +
which O +
can O +
induce O +
proliferation O +
and O +
migration O +
of O +
capillary O +
endothelial O +
cells O +
. O +

Among O +
the O +
most O +
potent O +
of O +
the O +
angiogenic O +
factors O +
is O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
. O +

Increased O +
VEGF O +
expression O +
by O +
malignant O +
tumors O +
has O +
been O +
associated O +
with O +
high O +
vascularity O +
, O +
increased O +
cancer O +
cell O +
growth O +
, O +
and O +
lymph O +
node O +
metastasis O +
. O +

Reduced O +
oxygen O +
tension O +
has O +
been O +
shown O +
to O +
increase O +
VEGF O +
production O +
by O +
induction O +
of O +
the O +
transcription O +
factor O +
hypoxia O +
inducible O +
factor O +
1 O +
alpha O +
( O +
HIF O +
- O +
1alpha O +
) O +
. O +

The O +
mechanisms O +
by O +
which O +
hypoxic O +
tumor O +
environments O +
induce O +
HIF O +
- O +
1alpha O +
and O +
VEGF O +
expression O +
are O +
largely O +
unknown O +
. O +

Jun O +
N O +
terminal O +
kinase O +
( O +
JNK1 O +
) O +
and O +
p38 O +
kinase O +
are O +
activated O +
by O +
a O +
variety O +
of O +
stress O +
stimuli O +
. O +

To O +
determine O +
if O +
hypoxic O +
activation O +
of O +
these O +
stress O +
activated O +
protein O +
kinases O +
regulated O +
HIF O +
- O +
1alpha O +
and O +
VEGF O +
expression O +
, O +
we O +
assayed O +
JNK1 O +
and O +
p38 O +
activity O +
in O +
squamous O +
cell O +
carcinoma O +
( O +
SCC O +
) O +
lines O +
grown O +
under O +
normoxic O +
or O +
hypoxic O +
conditions O +
. O +

Hypoxia O +
rapidly O +
induced O +
both O +
JNK1 O +
and O +
p38 O +
activity O +
in O +
these O +
cells O +
. O +

This O +
activation O +
correlated O +
with O +
induction O +
of O +
HIF O +
- O +
1alpha O +
expression O +
and O +
DNA O +
binding O +
activity O +
which O +
was O +
blocked O +
by O +
the O +
p38 O +
inhibitor O +
SB203580 O +
. O +

Hypoxia O +
also O +
increased O +
VEGF O +
production O +
by O +
SCC O +
lines O +
, O +
which O +
was O +
inhibited O +
by O +
treatment O +
with O +
SB203580 O +
. O +

Overexpression O +
of O +
JNK1 O +
or O +
p38 O +
was O +
sufficient O +
to O +
induce O +
HIF O +
- O +
1alpha O +
and O +
VEGF O +
expression O +
. O +

These O +
results O +
indicate O +
that O +
induction O +
of O +
SAPKs O +
by O +
hypoxia O +
regulates O +
HIF O +
- O +
1alpha O +
and O +
VEGF O +
expression O +
in O +
head O +
and O +
neck O +
carcinoma O +
cell O +
lines O +
. O +

In O +
vitro O +
cytotoxic O +
potential O +
and O +
mechanism O +
of O +
action O +
of O +
selected O +
coumarins O +
, O +
using O +
human O +
renal O +
cell O +
lines O +
. O +

This O +
study O +
determined O +
the O +
selective O +
cytotoxicity O +
of O +
eight O +
coumarin O +
compounds O +
to O +
human O +
renal O +
carcinoma O +
cells O +
, O +
relative O +
to O +
non O +
- O +
carcinoma O +
proximal O +
tubular O +
cells O +
. O +

Selectivity O +
cytotoxicity O +
was O +
observed O +
following O +
exposure O +
to O +
6 O +
- O +
nitro O +
- O +
7 O +
- O +
hydroxycoumarin O +
( O +
6 O +
- O +
NO O +
( O +
2 O +
) O +
- O +
7 O +
- O +
OHC O +
) O +
and O +
7 O +
, O +
8 O +
- O +
dihydroxycoumarin O +
( O +
7 O +
, O +
8 O +
- O +
OHC O +
) O +
. O +

6 O +
- O +
NO O +
( O +
2 O +
) O +
- O +
7 O +
- O +
OHC O +
induced O +
cytotoxicity O +
was O +
irreversible O +
in O +
both O +
cell O +
lines O +
, O +
unlike O +
7 O +
, O +
8 O +
- O +
OHC O +
, O +
which O +
was O +
reversible O +
in O +
the O +
carcinoma O +
cells O +
only O +
. O +

Mobility O +
shift O +
and O +
BrdU O +
incorporation O +
assays O +
showed O +
that O +
both O +
compounds O +
did O +
not O +
intercalate O +
DNA O +
but O +
had O +
a O +
concentration O +
- O +
dependent O +
inhibitory O +
effect O +
on O +
its O +
synthesis O +
. O +

All O +
coumarins O +
studied O +
were O +
found O +
to O +
be O +
non O +
- O +
mutagenic O +
using O +
the O +
standard O +
Ames O +
test O +
. O +

These O +
results O +
would O +
suggest O +
that O +
6 O +
- O +
NO O +
( O +
2 O +
) O +
- O +
7 O +
- O +
OHC O +
and O +
7 O +
, O +
8 O +
- O +
OHC O +
might O +
have O +
a O +
therapeutic O +
role O +
to O +
play O +
in O +
the O +
treatment O +
of O +
renal O +
cell O +
carcinoma O +
. O +

[ O +
Radiologic O +
- O +
pathologic O +
correlations O +
in O +
breast O +
diseases O +
] O +

The O +
objective O +
of O +
this O +
article O +
is O +
to O +
explain O +
radiologic O +
patterns O +
of O +
benign O +
and O +
malignant O +
breast O +
lesions O +
( O +
masses O +
, O +
microcalcifications O +
) O +
based O +
on O +
histological O +
correlations O +
. O +

The O +
stromal O +
fibrous O +
reaction O +
associated O +
to O +
infiltrating O +
carcinomas O +
is O +
responsible O +
of O +
focal O +
increased O +
density O +
, O +
and O +
architectural O +
distorsion O +
, O +
ultrasound O +
acoustic O +
shadowing O +
; O +
abnormal O +
neoangiogenesis O +
can O +
be O +
detected O +
by O +
Doppler O +
, O +
CT O +
or O +
MR O +
imaging O +
. O +

Invasive O +
carcinomas O +
without O +
spiculated O +
margins O +
are O +
poorly O +
differentiated O +
tumors O +
. O +

Mammographic O +
patterns O +
of O +
microcalcifications O +
depend O +
on O +
their O +
physiopathological O +
process O +
( O +
necrosis O +
, O +
secretion O +
) O +
, O +
and O +
the O +
shape O +
of O +
clusters O +
( O +
round O +
, O +
triangular O +
) O +
typifies O +
their O +
anatomical O +
site O +
of O +
origin O +
( O +
lobular O +
, O +
ductal O +
) O +
. O +

Less O +
frequent O +
lesions O +
( O +
invasive O +
lobular O +
, O +
mucinous O +
, O +
and O +
medullary O +
carcinomas O +
, O +
radial O +
scar O +
) O +
will O +
be O +
also O +
explained O +
based O +
on O +
radiopathological O +
correlations O +
. O +

Knowledge O +
of O +
radiopathological O +
correlations O +
in O +
breast O +
diseases O +
helps O +
the O +
radiologists O +
to O +
analyze O +
and O +
characterize O +
breast O +
lesions O +
. O +

Multiple O +
stages O +
of O +
malignant O +
transformation O +
of O +
human O +
endothelial O +
cells O +
modelled O +
by O +
co O +
- O +
expression O +
of O +
telomerase O +
reverse O +
transcriptase O +
, O +
SV40 O +
T O +
antigen O +
and O +
oncogenic O +
N O +
- O +
ras O +
. O +

We O +
have O +
modelled O +
multiple O +
stages O +
of O +
malignant O +
transformation O +
of O +
human O +
endothelial O +
cells O +
( O +
ECs O +
) O +
by O +
overexpressing O +
the O +
catalytic O +
subunit O +
of O +
human O +
telomerase O +
( O +
hTERT O +
) O +
, O +
together O +
with O +
SV40 O +
T O +
antigen O +
( O +
SV40 O -
T O +
) O +
and O +
oncogenic O +
N O +
- O +
ras O +
. O +

Transfection O +
with O +
hTERT O +
alone O +
, O +
led O +
to O +
the O +
immortalization O +
of O +
two O +
out O +
of O +
three O +
cultures O +
of O +
bone O +
marrow O +
- O +
derived O +
ECs O +
( O +
BMECs O +
) O +
. O +

One O +
hTERT O +
transduced O +
BMEC O +
culture O +
underwent O +
a O +
long O +
proliferative O +
lag O +
before O +
resuming O +
proliferation O +
. O +

BMECs O +
transfected O +
with O +
hTERT O +
alone O +
were O +
functionally O +
and O +
phenotypically O +
normal O +
. O +

BMECs O +
transfected O +
with O +
SV40 O -
T O +
( O +
BMSVTs O +
) O +
had O +
an O +
extended O +
lifespan O +
, O +
but O +
eventually O +
succumbed O +
to O +
crisis O +
. O +

BMSVTs O +
exhibited O +
a O +
partially O +
transformed O +
phenotype O +
, O +
demonstrating O +
growth O +
factor O +
independence O +
, O +
altered O +
antigen O +
expression O +
and O +
forming O +
tiny O +
, O +
infrequent O +
colonies O +
in O +
vitro O +
. O +

Transduction O +
of O +
BMSVTs O +
with O +
hTERT O +
resulted O +
in O +
immortalization O +
of O +
4 O +
out O +
of O +
4 O +
cultures O +
. O +

BMSVTs O +
immortalized O +
with O +
hTERT O +
formed O +
large O +
colonies O +
in O +
vitro O +
and O +
small O +
transient O +
tumours O +
in O +
vivo O +
. O +

BMECs O +
co O +
- O +
expressing O +
SV40 O -
T O +
, O +
hTERT O +
and O +
N O +
- O +
ras O +
exhibited O +
an O +
overtly O +
transformed O +
phenotype O +
; O +
forming O +
very O +
large O +
colonies O +
with O +
an O +
altered O +
morphology O +
and O +
generating O +
rapidly O +
growing O +
tumours O +
in O +
vivo O +
. O +

These O +
investigations O +
demonstrate O +
transformation O +
of O +
human O +
ECs O +
to O +
an O +
overtly O +
malignant O +
phenotype O +
. O +

This O +
model O +
will O +
be O +
useful O +
for O +
understanding O +
mechanisms O +
underlying O +
vascular O +
and O +
angiogenic O +
neoplasias O +
, O +
as O +
well O +
as O +
for O +
testing O +
drugs O +
designed O +
to O +
curtail O +
aberrant O +
EC O +
growth O +
. O +

Pten O +
signaling O +
in O +
gliomas O +
. O +

In O +
1997 O +
, O +
the O +
PTEN O +
gene O +
( O +
phosphatase O +
and O +
tensin O +
homolog O +
deleted O +
on O +
chromosome O +
10 O +
) O +
was O +
identified O +
as O +
a O +
tumor O +
suppressor O +
gene O +
on O +
the O +
long O +
arm O +
of O +
chromosome O +
10 O +
. O +

Since O +
then O +
, O +
important O +
progress O +
has O +
been O +
made O +
with O +
respect O +
to O +
the O +
understanding O +
of O +
the O +
role O +
of O +
the O +
Pten O +
protein O +
in O +
the O +
normal O +
development O +
of O +
the O +
brain O +
as O +
well O +
as O +
in O +
the O +
molecular O +
pathogenesis O +
of O +
human O +
gliomas O +
. O +

This O +
review O +
summarizes O +
the O +
current O +
state O +
of O +
the O +
art O +
concerning O +
the O +
involvement O +
of O +
aberrant O +
Pten O +
function O +
in O +
the O +
development O +
of O +
different O +
biologic O +
features O +
of O +
malignant O +
gliomas O +
, O +
such O +
as O +
loss O +
of O +
cell O +
- O +
cycle O +
control O +
and O +
uncontrolled O +
cell O +
proliferation O +
, O +
escape O +
from O +
apoptosis O +
, O +
brain O +
invasion O +
, O +
and O +
aberrant O +
neoangiogenesis O +
. O +

Most O +
of O +
the O +
tumor O +
- O +
suppressive O +
properties O +
of O +
Pten O +
are O +
dependent O +
on O +
its O +
lipid O +
phosphatase O +
activity O +
, O +
which O +
inhibits O +
the O +
phosphatidylinositol O +
- O +
3 O +
' O +
- O +
kinase O +
( O +
PI3 O -
K O +
) O +
/ O +
Akt O +
signaling O +
pathway O +
through O +
dephosphorylation O +
of O +
phosphatidylinositol O +
- O +
( O +
3 O +
, O +
4 O +
, O +
5 O +
) O +
- O +
triphosphate O +
. O +

The O +
additional O +
function O +
of O +
Pten O +
as O +
a O +
dual O +
- O +
specificity O +
protein O +
phosphatase O +
may O +
also O +
play O +
a O +
role O +
in O +
glioma O +
pathogenesis O +
. O +

Besides O +
the O +
wealth O +
of O +
data O +
elucidating O +
the O +
functional O +
roles O +
of O +
Pten O +
, O +
recent O +
studies O +
suggest O +
a O +
diagnostic O +
significance O +
of O +
PTEN O +
gene O +
alterations O +
as O +
a O +
molecular O +
marker O +
for O +
poor O +
prognosis O +
in O +
anaplastic O +
astrocytomas O +
and O +
anaplastic O +
oligodendrogliomas O +
. O +

Furthermore O +
, O +
the O +
possibility O +
of O +
selective O +
targeting O +
of O +
PTEN O +
mutant O +
tumor O +
cells O +
by O +
specific O +
pharmacologic O +
inhibitors O +
of O +
members O +
of O +
the O +
Pten O +
/ O +
PI3 O -
K O +
/ O +
Akt O +
pathway O +
opens O +
up O +
new O +
perspectives O +
for O +
a O +
targeted O +
molecular O +
therapy O +
of O +
malignant O +
gliomas O +
. O +

[ O +
A O +
case O +
report O +
of O +
advanced O +
gastric O +
cancer O +
responding O +
to O +
TS O +
- O +
1 O +
, O +
a O +
novel O +
oral O +
fluorouracil O +
derivative O +
] O +
. O +

TS O +
- O +
1 O +
is O +
a O +
new O +
, O +
oral O +
anticancer O +
agent O +
composed O +
of O +
two O +
modulators O +
, O +
gimeracil O +
( O +
CDHP O +
) O +
and O +
oteracil O +
potassium O +
( O +
Oxo O +
) O +
are O +
mixed O +
with O +
tegafur O +
in O +
a O +
ratio O +
of O +
1 O +
: O +
0 O +
. O +
4 O +
: O +
1 O +
. O +

We O +
report O +
one O +
case O +
of O +
advanced O +
gastric O +
cancer O +
with O +
lung O +
and O +
lymph O +
node O +
metastases O +
that O +
completely O +
responded O +
to O +
TS O +
- O +
1 O +
. O +

A O +
71 O +
- O +
year O +
- O +
old O +
woman O +
was O +
admitted O +
to O +
our O +
hospital O +
because O +
of O +
breathlessness O +
. O +

A O +
diagnosis O +
of O +
advanced O +
gastric O +
cancer O +
with O +
extensive O +
lymph O +
node O +
metastases O +
and O +
multiple O +
pulmonary O +
metastases O +
was O +
made O +
. O +

One O +
hundred O +
mg O +
/ O +
body O +
/ O +
day O +
of O +
TS O +
- O +
1 O +
was O +
orally O +
administrated O +
for O +
4 O +
weeks O +
. O +

A O +
partial O +
response O +
( O +
PR O +
) O +
was O +
obtained O +
after O +
the O +
first O +
course O +
with O +
regression O +
of O +
multiple O +
pulmonary O +
metastases O +
. O +

After O +
1 O +
drug O +
- O +
free O +
week O +
, O +
the O +
second O +
course O +
was O +
administered O +
with O +
120 O +
mg O +
/ O +
body O +
/ O +
day O +
of O +
TS O +
- O +
1 O +
for O +
4 O +
weeks O +
. O +

After O +
two O +
courses O +
, O +
the O +
primary O +
tumor O +
was O +
reduced O +
to O +
an O +
ulcer O +
scar O +
with O +
pathological O +
confirmation O +
of O +
a O +
complete O +
disappearance O +
of O +
the O +
cancer O +
tissue O +
. O +

Moreover O +
, O +
computed O +
tomography O +
( O +
CT O +
) O +
showed O +
a O +
complete O +
regression O +
of O +
the O +
extensive O +
lymph O +
node O +
and O +
diffuse O +
lung O +
metastases O +
, O +
for O +
a O +
complete O +
response O +
( O +
CR O +
) O +
. O +

The O +
serum O +
level O +
of O +
CEA O +
was O +
reduced O +
from O +
172 O +
. O +
7 O +
ng O +
/ O +
ml O +
to O +
8 O +
. O +
1 O +
ng O +
/ O +
ml O +
after O +
TS O +
- O +
1 O +
treatment O +
. O +

As O +
for O +
adverse O +
events O +
, O +
only O +
pigmentation O +
of O +
the O +
skin O +
and O +
Grade O +
2 O +
oral O +
aphta O +
were O +
observed O +
. O +

Systemic O +
regulation O +
of O +
distraction O +
osteogenesis O +
: O +
a O +
cascade O +
of O +
biochemical O +
factors O +
. O +

This O +
study O +
investigates O +
the O +
systemic O +
biochemical O +
regulation O +
of O +
fracture O +
healing O +
in O +
distraction O +
osteogenesis O +
compared O +
with O +
rigid O +
osteotomy O +
in O +
a O +
prospective O +
in O +
vivo O +
study O +
in O +
humans O +
. O +

To O +
further O +
clarify O +
the O +
influence O +
of O +
mechanical O +
strain O +
on O +
the O +
regulation O +
of O +
bone O +
formation O +
, O +
bone O +
growth O +
factors O +
( O +
insulin O +
- O +
like O +
growth O +
factor O +
[ O +
IGF O +
] O +
I O +
, O +
IGF O +
binding O +
protein O +
[ O +
IGFBP O +
] O +
3 O +
, O +
transforming O +
growth O +
factor O +
[ O +
TGF O +
] O +
beta1 O +
, O +
and O +
basic O +
FGF O +
[ O +
bFGF O +
] O +
) O +
, O +
bone O +
matrix O +
degrading O +
enzymes O +
( O +
matrix O +
- O +
metalloproteinases O +
[ O +
MMPs O +
] O +
1 O +
, O +
2 O +
, O +
and O +
3 O +
) O +
, O +
human O +
growth O +
hormone O +
( O +
hGH O +
) O +
, O +
and O +
bone O +
formation O +
markers O +
( O +
ALP O +
, O +
bone O +
- O +
specific O +
ALP O +
[ O +
BAP O +
] O +
, O +
and O +
osteocalcin O +
[ O +
OC O +
] O +
) O +
have O +
been O +
analyzed O +
in O +
serum O +
samples O +
from O +
10 O +
patients O +
in O +
each O +
group O +
pre O +
- O +
and O +
postoperatively O +
. O +

In O +
the O +
distraction O +
group O +
, O +
a O +
significant O +
postoperative O +
increase O +
in O +
MMP O +
- O +
1 O +
, O +
bFGF O +
, O +
ALP O +
, O +
and O +
BAP O +
could O +
be O +
observed O +
during O +
the O +
lengthening O +
and O +
the O +
consolidation O +
period O +
when O +
compared O +
with O +
the O +
baseline O +
levels O +
. O +

Osteotomy O +
fracture O +
healing O +
without O +
the O +
traction O +
stimulus O +
failed O +
to O +
induce O +
a O +
corresponding O +
increase O +
in O +
these O +
factors O +
. O +

In O +
addition O +
, O +
comparison O +
of O +
both O +
groups O +
revealed O +
a O +
significantly O +
higher O +
increase O +
in O +
TGF O +
- O +
beta1 O +
, O +
IGF O +
- O +
I O +
, O +
IGFBP O +
- O +
3 O +
, O +
and O +
hGH O +
in O +
the O +
lengthening O +
group O +
during O +
the O +
distraction O +
period O +
, O +
indicating O +
key O +
regulatory O +
functions O +
in O +
mechanotransduction O +
. O +

The O +
time O +
courses O +
of O +
changes O +
in O +
MMP O +
- O +
1 O +
, O +
bone O +
growth O +
factors O +
( O +
TGF O +
- O +
beta1 O +
and O +
bFGF O +
) O +
, O +
and O +
hGH O +
, O +
respectively O +
, O +
correlated O +
significantly O +
during O +
the O +
lengthening O +
phase O +
, O +
indicating O +
common O +
regulatory O +
pathways O +
for O +
these O +
factors O +
in O +
distraction O +
osteogenesis O +
. O +

Significant O +
correlation O +
between O +
the O +
osteoblastic O +
marker O +
BAP O +
, O +
TGF O +
- O +
beta1 O +
, O +
and O +
bFGF O +
suggests O +
strain O +
- O +
activated O +
osteoblastic O +
cells O +
as O +
a O +
major O +
source O +
of O +
systemically O +
increased O +
bone O +
growth O +
factors O +
during O +
callus O +
distraction O +
. O +

The O +
systemic O +
increase O +
in O +
bFGF O +
and O +
MMP O +
- O +
1 O +
might O +
reflect O +
an O +
increased O +
local O +
stimulation O +
of O +
angiogenesis O +
during O +
distraction O +
osteogenesis O +
. O +

Simian O +
virus O +
40 O +
large O +
T O +
antigen O +
and O +
two O +
independent O +
T O +
- O +
antigen O +
segments O +
sensitize O +
cells O +
to O +
apoptosis O +
following O +
genotoxic O +
damage O +
. O +

The O +
simian O +
virus O +
40 O +
( O +
SV40 O +
) O +
large O +
tumor O +
( O +
T O +
) O +
antigen O +
is O +
sufficient O +
to O +
transform O +
cells O +
in O +
cultures O +
and O +
induce O +
tumors O +
in O +
experimental O +
animals O +
. O +

Transformation O +
of O +
primary O +
cells O +
in O +
cultures O +
requires O +
both O +
overcoming O +
growth O +
arrest O +
by O +
stimulating O +
the O +
cell O +
cycle O +
and O +
blocking O +
cell O +
death O +
activities O +
presumably O +
activated O +
by O +
oncogene O +
- O +
mediated O +
hyperproliferation O +
signals O +
. O +

The O +
study O +
presented O +
here O +
examined O +
the O +
ability O +
of O +
specific O +
regions O +
and O +
activities O +
of O +
T O +
antigen O +
to O +
modulate O +
apoptosis O +
in O +
cells O +
treated O +
with O +
the O +
genotoxic O +
agent O +
5 O +
- O +
fluorouracil O +
( O +
5 O +
- O +
FU O +
) O +
. O +

The O +
results O +
showed O +
that O +
the O +
expression O +
of O +
full O +
- O +
length O +
T O +
antigen O +
rendered O +
rat O +
embryo O +
fibroblasts O +
( O +
REF O +
) O +
sensitive O +
to O +
5 O +
- O +
FU O +
- O +
induced O +
apoptosis O +
. O +

Thus O +
, O +
neither O +
the O +
p53 O +
- O +
binding O +
region O +
nor O +
the O +
Bcl O +
- O +
2 O +
homology O +
region O +
of O +
T O +
antigen O +
was O +
sufficient O +
to O +
prevent O +
cell O +
death O +
induced O +
by O +
the O +
DNA O +
- O +
damaging O +
agent O +
. O +

T O +
- O +
antigen O +
- O +
mediated O +
sensitization O +
occurred O +
independently O +
of O +
retinoblastoma O +
protein O +
or O +
p53 O +
and O +
p300 O +
binding O +
. O +

An O +
N O +
- O +
terminal O +
segment O +
containing O +
the O +
first O +
127 O +
T O +
- O +
antigen O +
amino O +
acids O +
( O +
T1 O +
- O +
127 O +
) O +
was O +
sufficient O +
to O +
sensitize O +
cells O +
. O +

A O +
C O +
- O +
terminal O +
segment O +
consisting O +
of O +
T O +
- O +
antigen O +
amino O +
acids O +
251 O +
to O +
708 O +
( O +
T251 O +
- O +
708 O +
) O +
also O +
sensitized O +
cells O +
to O +
5 O +
- O +
FU O +
- O +
induced O +
apoptosis O +
. O +

This O +
sensitization O +
did O +
not O +
occur O +
when O +
T251 O +
- O +
708 O +
was O +
targeted O +
to O +
the O +
nucleus O +
by O +
inclusion O +
of O +
the O +
SV40 O +
nuclear O +
localization O +
signal O +
. O +

The O +
introduction O +
of O +
mutations O +
into O +
the O +
T O +
- O +
antigen O +
J O +
domain O +
resulted O +
in O +
mutation O +
- O +
specific O +
and O +
variable O +
inhibition O +
of O +
apoptosis O +
. O +

This O +
result O +
suggested O +
that O +
either O +
the O +
structural O +
or O +
the O +
functional O +
integrity O +
of O +
the O +
J O +
domain O +
is O +
required O +
to O +
sensitize O +
cells O +
to O +
apoptosis O +
. O +

Treatment O +
of O +
REF O +
or O +
REF O +
expressing O +
full O +
- O +
length O +
T O +
antigen O +
, O +
an O +
N O +
- O +
terminal O +
segment O +
, O +
or O +
T251 O +
- O +
708 O +
resulted O +
in O +
increased O +
expression O +
of O +
the O +
p53 O +
- O +
responsive O +
MDM2 O +
gene O +
; O +
apoptosis O +
occurred O +
through O +
a O +
p53 O +
- O +
dependent O +
pathway O +
, O +
as O +
p53 O +
- O +
null O +
cells O +
expressing O +
these O +
T O +
antigens O +
were O +
resistant O +
to O +
5 O +
- O +
FU O +
- O +
induced O +
apoptosis O +
. O +

Possible O +
mechanisms O +
involved O +
in O +
sensitizing O +
cells O +
to O +
a O +
p53 O +
- O +
dependent O +
apoptosis O +
pathway O +
in O +
spite O +
of O +
the O +
ability O +
of O +
T O +
antigen O +
to O +
bind O +
and O +
inactivate O +
the O +
transcriptional O +
transactivating O +
activity O +
of O +
p53 O +
are O +
discussed O +
. O +

Human O +
papillomavirus O +
oncoprotein O +
E6 O +
inactivates O +
the O +
transcriptional O +
coactivator O +
human O +
ADA3 O +
. O +

High O +
- O +
risk O +
human O +
papillomaviruses O +
( O +
HPVs O +
) O +
are O +
associated O +
with O +
carcinomas O +
of O +
the O +
cervix O +
and O +
other O +
genital O +
tumors O +
. O +

The O +
HPV O +
oncoprotein O +
E6 O +
is O +
essential O +
for O +
oncogenic O +
transformation O +
. O +

We O +
identify O +
here O +
hADA3 O +
, O +
human O +
homologue O +
of O +
the O +
yeast O +
transcriptional O +
coactivator O +
yADA3 O +
, O +
as O +
a O +
novel O +
E6 O +
- O +
interacting O +
protein O +
and O +
a O +
target O +
of O +
E6 O +
- O +
induced O +
degradation O +
. O +

hADA3 O +
binds O +
selectively O +
to O +
the O +
high O +
- O +
risk O +
HPV O +
E6 O +
proteins O +
and O +
only O +
to O +
immortalization O +
- O +
competent O +
E6 O +
mutants O +
. O +

hADA3 O +
functions O +
as O +
a O +
coactivator O +
for O +
p53 O +
- O +
mediated O +
transactivation O +
by O +
stabilizing O +
p53 O +
protein O +
. O +

Notably O +
, O +
three O +
immortalizing O +
E6 O +
mutants O +
that O +
do O +
not O +
induce O +
direct O +
p53 O +
degradation O +
but O +
do O +
interact O +
with O +
hADA3 O +
induced O +
the O +
abrogation O +
of O +
p53 O +
- O +
mediated O +
transactivation O +
and O +
G O +
( O +
1 O +
) O +
cell O +
cycle O +
arrest O +
after O +
DNA O +
damage O +
, O +
comparable O +
to O +
wild O +
- O +
type O +
E6 O +
. O +

These O +
findings O +
reveal O +
a O +
novel O +
strategy O +
of O +
HPV O +
E6 O +
- O +
induced O +
loss O +
of O +
p53 O +
function O +
that O +
is O +
independent O +
of O +
direct O +
p53 O +
degradation O +
. O +

Given O +
the O +
likely O +
role O +
of O +
the O +
evolutionarily O +
conserved O +
hADA3 O +
in O +
multiple O +
coactivator O +
complexes O +
, O +
inactivation O +
of O +
its O +
function O +
may O +
allow O +
E6 O +
to O +
perturb O +
numerous O +
cellular O +
pathways O +
during O +
HPV O +
oncogenesis O +
. O +

Optimizing O +
treatment O +
of O +
choroidal O +
neovascularization O +
feeder O +
vessels O +
associated O +
with O +
age O +
- O +
related O +
macular O +
degeneration O +
. O +

PURPOSE O +
: O +
To O +
optimize O +
the O +
method O +
of O +
treating O +
choroidal O +
neovascularization O +
( O +
CNV O +
) O +
associated O +
with O +
age O +
- O +
related O +
macular O +
degeneration O +
( O +
AMD O +
) O +
. O +

DESIGN O +
: O +
Experimental O +
study O +
and O +
interventional O +
case O +
series O +
. O +

METHODS O +
: O +
The O +
parameters O +
associated O +
with O +
locating O +
and O +
then O +
photocoagulating O +
CNV O +
feeder O +
vessels O +
were O +
identified O +
and O +
optimized O +
using O +
published O +
data O +
and O +
data O +
derived O +
from O +
modeling O +
the O +
choroidal O +
vasculature O +
. O +

Based O +
on O +
these O +
optimized O +
parameters O +
, O +
a O +
prototype O +
diagnostic O +
/ O +
treatment O +
system O +
was O +
designed O +
that O +
captures O +
high O +
- O +
speed O +
indocyanine O +
green O +
( O +
ICG O +
) O +
angiogram O +
images O +
and O +
facilitates O +
analysis O +
of O +
the O +
images O +
by O +
enhancing O +
visualization O +
of O +
dye O +
movement O +
through O +
CNV O +
feeder O +
vessels O +
( O +
FVs O +
) O +
. O +

The O +
system O +
also O +
permits O +
precise O +
aiming O +
and O +
delivery O +
of O +
810 O +
- O +
nm O +
wavelength O +
photocoagulation O +
laser O +
energy O +
to O +
target O +
FVs O +
on O +
a O +
real O +
- O +
time O +
ICG O +
angiogram O +
image O +
of O +
the O +
choroidal O +
vasculature O +
. O +

Target O +
FVs O +
are O +
tracked O +
by O +
a O +
joy O +
- O +
stick O +
controlled O +
laser O +
aiming O +
beam O +
until O +
an O +
intravenously O +
- O +
injected O +
high O +
- O +
concentration O +
ICG O +
dye O +
bolus O +
is O +
observed O +
to O +
enter O +
the O +
target O +
vessel O +
, O +
at O +
which O +
time O +
the O +
laser O +
is O +
fired O +
. O +

Proof O +
of O +
principle O +
of O +
the O +
combined O +
diagnosis O +
/ O +
treatment O +
system O +
design O +
for O +
performing O +
dye O +
- O +
enhanced O +
photocoagulation O +
( O +
DEP O +
) O +
in O +
the O +
clinical O +
setting O +
and O +
determination O +
of O +
the O +
minimum O +
DEP O +
laser O +
energy O +
needed O +
to O +
close O +
CNV O +
FVs O +
was O +
made O +
in O +
11 O +
AMD O +
patients O +
requiring O +
treatment O +
of O +
CNV O +
, O +
but O +
for O +
whom O +
other O +
treatment O +
was O +
not O +
appropriate O +
. O +

RESULTS O +
: O +
Using O +
ICG O +
- O +
DEP O +
, O +
CNV O +
feeder O +
vessels O +
were O +
closed O +
with O +
single O +
pulse O +
laser O +
energy O +
, O +
delivering O +
as O +
little O +
as O +
0 O +
. O +
6 O +
to O +
1 O +
. O +
8 O +
J O +
of O +
energy O +
to O +
the O +
fundus O +
, O +
producing O +
no O +
visible O +
change O +
in O +
the O +
fundus O +
. O +

Successful O +
FV O +
closure O +
was O +
usually O +
indicated O +
immediately O +
by O +
presence O +
of O +
incarcerated O +
ICG O +
dye O +
in O +
the O +
vessel O +
adjacent O +
to O +
the O +
burn O +
site O +
. O +

The O +
prototype O +
system O +
proved O +
relatively O +
easy O +
to O +
operate O +
. O +

After O +
acquiring O +
and O +
interpreting O +
diagnostic O +
angiograms O +
and O +
repositioning O +
a O +
patient O +
in O +
front O +
of O +
the O +
device O +
, O +
feeder O +
vessel O +
DEP O +
and O +
treatment O +
evaluation O +
required O +
15 O +
to O +
20 O +
minutes O +
. O +

CONCLUSIONS O +
: O +
Indocyanine O +
green O +
dye O +
- O +
enhanced O +
photocoagulation O +
of O +
CNV O +
feeder O +
vessels O +
, O +
facilitated O +
by O +
use O +
of O +
a O +
device O +
that O +
permits O +
real O +
- O +
time O +
visualization O +
of O +
the O +
choroidal O +
circulation O +
while O +
aiming O +
the O +
treatment O +
laser O +
beam O +
, O +
appears O +
to O +
minimize O +
the O +
amount O +
of O +
energy O +
applied O +
to O +
the O +
fundus O +
and O +
the O +
volume O +
of O +
fundus O +
tissue O +
affected O +
by O +
treatment O +
, O +
compared O +
with O +
other O +
treatment O +
modalities O +
. O +

The O +
combination O +
diagnosis O +
/ O +
treatment O +
device O +
should O +
be O +
useful O +
in O +
optimizing O +
FV O +
treatment O +
and O +
in O +
refining O +
and O +
evaluating O +
the O +
efficacy O +
of O +
DEP O +
in O +
future O +
clinical O +
trials O +
. O +

Immunohistochemical O +
staining O +
for O +
thyroid O +
transcription O +
factor O +
- O +
1 O +
: O +
a O +
helpful O +
aid O +
in O +
discerning O +
primary O +
site O +
of O +
tumor O +
origin O +
in O +
patients O +
with O +
brain O +
metastases O +
. O +

Metastatic O +
carcinoma O +
of O +
unknown O +
primary O +
origin O +
is O +
a O +
perplexing O +
but O +
common O +
problem O +
, O +
accounting O +
for O +
up O +
to O +
10 O +
% O +
to O +
15 O +
% O +
of O +
all O +
solid O +
tumors O +
at O +
presentation O +
. O +

Many O +
of O +
these O +
metastases O +
presumably O +
arise O +
from O +
primary O +
lung O +
carcinomas O +
, O +
but O +
the O +
morphologic O +
features O +
and O +
immunohistochemical O +
profile O +
of O +
lung O +
cancer O +
is O +
often O +
too O +
nonspecific O +
to O +
permit O +
unequivocal O +
confirmation O +
. O +

Thyroid O +
transcription O +
factor O +
- O +
1 O +
( O +
TTF O +
- O +
1 O +
) O +
is O +
expressed O +
in O +
lung O +
adenocarcinomas O +
and O +
thyroid O +
carcinomas O +
but O +
not O +
in O +
adenocarcinomas O +
arising O +
from O +
other O +
sites O +
. O +

For O +
patients O +
with O +
adenocarcinomas O +
in O +
the O +
lung O +
, O +
TTF O +
- O +
1 O +
staining O +
is O +
now O +
routinely O +
used O +
to O +
distinguish O +
a O +
primary O +
lung O +
cancer O +
from O +
a O +
lung O +
metastasis O +
. O +

Along O +
these O +
same O +
lines O +
, O +
TTF O +
- O +
1 O +
staining O +
might O +
prove O +
useful O +
in O +
localizing O +
the O +
tumor O +
origin O +
of O +
adenocarcinomas O +
encountered O +
outside O +
of O +
the O +
lung O +
. O +

The O +
archival O +
surgical O +
pathology O +
files O +
of O +
The O +
Johns O +
Hopkins O +
Hospital O +
were O +
searched O +
for O +
cases O +
of O +
brain O +
metastases O +
biopsied O +
between O +
1990 O +
and O +
2000 O +
. O +

Tissue O +
blocks O +
were O +
obtained O +
and O +
immunoperoxidase O +
staining O +
was O +
performed O +
using O +
the O +
TTF O +
- O +
1 O +
antibody O +
. O +

The O +
medical O +
records O +
were O +
reviewed O +
independent O +
of O +
the O +
staining O +
results O +
to O +
determine O +
site O +
of O +
tumor O +
origin O +
. O +

Seventy O +
- O +
five O +
patients O +
underwent O +
biopsies O +
of O +
carcinomas O +
metastatic O +
to O +
the O +
brain O +
. O +

At O +
the O +
time O +
of O +
brain O +
biopsy O +
, O +
the O +
primary O +
site O +
of O +
tumor O +
origin O +
was O +
known O +
in O +
45 O +
cases O +
and O +
unknown O +
in O +
30 O +
cases O +
. O +

Ultimately O +
, O +
the O +
primary O +
site O +
was O +
established O +
on O +
clinical O +
and O +
radiographic O +
grounds O +
in O +
71 O +
cases O +
( O +
95 O +
% O +
) O +
. O +

These O +
included O +
40 O +
( O +
56 O +
% O +
) O +
metastases O +
from O +
a O +
primary O +
lung O +
carcinoma O +
and O +
31 O +
( O +
44 O +
% O +
) O +
metastases O +
from O +
some O +
nonpulmonary O +
carcinoma O +
. O +

TTF O +
- O +
1 O +
staining O +
was O +
present O +
in O +
31 O +
of O +
the O +
40 O +
( O +
78 O +
% O +
) O +
metastatic O +
lung O +
carcinomas O +
, O +
but O +
in O +
only O +
1 O +
of O +
the O +
31 O +
( O +
3 O +
% O +
) O +
metastatic O +
nonpulmonary O +
carcinomas O +
( O +
a O +
small O +
- O +
cell O +
carcinoma O +
of O +
the O +
sinonasal O +
tract O +
) O +
. O +

When O +
the O +
metastatic O +
lung O +
carcinomas O +
were O +
subtyped O +
, O +
TTF O +
- O +
1 O +
staining O +
was O +
noted O +
in O +
11 O +
of O +
11 O +
( O +
100 O +
% O +
) O +
adenocarcinomas O +
, O +
in O +
6 O +
of O +
7 O +
( O +
86 O +
% O +
) O +
small O +
- O +
cell O +
carcinomas O +
, O +
in O +
15 O +
of O +
19 O +
( O +
79 O +
% O +
) O +
large O +
- O +
cell O +
carcinomas O +
, O +
and O +
in O +
none O +
of O +
3 O +
( O +
0 O +
% O +
) O +
squamous O +
cell O +
carcinomas O +
. O +

TTF O +
- O +
1 O +
staining O +
is O +
very O +
reliable O +
in O +
discerning O +
whether O +
a O +
brain O +
metastasis O +
has O +
arisen O +
from O +
a O +
pulmonary O +
or O +
nonpulmonary O +
site O +
, O +
particularly O +
when O +
dealing O +
with O +
adenocarcinomas O +
and O +
large O +
- O +
cell O +
carcinomas O +
. O +

TTF O +
- O +
1 O +
immunohistochemistry O +
could O +
focus O +
the O +
search O +
for O +
the O +
primary O +
tumor O +
for O +
patients O +
presenting O +
with O +
brain O +
metastasis O +
as O +
the O +
initial O +
manifestation O +
. O +

Inhibition O +
of O +
angiogenesis O +
by O +
the O +
cancer O +
chemopreventive O +
agent O +
conjugated O +
linoleic O +
acid O +
. O +

Dietary O +
conjugated O +
linoleic O +
acid O +
( O +
CLA O +
) O +
has O +
been O +
shown O +
previously O +
to O +
inhibit O +
rat O +
mammary O +
carcinogenesis O +
. O +

In O +
addition O +
to O +
direct O +
effects O +
on O +
mammary O +
epithelial O +
cells O +
, O +
including O +
decreased O +
proliferation O +
and O +
induction O +
of O +
apoptosis O +
, O +
CLA O +
may O +
exert O +
its O +
effects O +
indirectly O +
by O +
inhibiting O +
the O +
differentiation O +
of O +
mammary O +
stromal O +
cells O +
to O +
an O +
endothelial O +
cell O +
type O +
. O +

Specifically O +
, O +
CLA O +
was O +
found O +
to O +
decrease O +
the O +
ability O +
of O +
mammary O +
stromal O +
cells O +
to O +
form O +
complex O +
anastomosing O +
microcapillary O +
networks O +
in O +
vitro O +
on O +
Engelbreth O +
- O +
Holm O +
- O +
Swarm O +
- O +
derived O +
reconstituted O +
basement O +
membrane O +
. O +

This O +
suggested O +
that O +
CLA O +
might O +
inhibit O +
angiogenesis O +
in O +
vivo O +
. O +

To O +
test O +
this O +
possibility O +
, O +
CD2 O +
/ O +
F O +
( O +
1 O +
) O +
mice O +
were O +
placed O +
on O +
synthetic O +
diets O +
containing O +
0 O +
, O +
1 O +
, O +
or O +
2 O +
% O +
CLA O +
for O +
6 O +
weeks O +
, O +
before O +
angiogenic O +
challenge O +
by O +
s O +
. O +
c O +
. O +
injection O +
with O +
an O +
angiogenic O +
gel O +
substrate O +
( O +
Matrigel O +
pellet O +
assay O +
) O +
. O +

After O +
7 O +
days O +
, O +
the O +
pellets O +
from O +
animals O +
fed O +
the O +
control O +
diet O +
were O +
infiltrated O +
by O +
abundant O +
branching O +
networks O +
of O +
blood O +
vessels O +
with O +
patent O +
lumen O +
- O +
containing O +
RBCs O +
. O +

In O +
contrast O +
, O +
pellets O +
from O +
the O +
CLA O +
- O +
fed O +
animals O +
contained O +
fewer O +
infiltrating O +
cells O +
, O +
which O +
formed O +
limited O +
branching O +
cellular O +
networks O +
, O +
the O +
majority O +
of O +
which O +
had O +
collapsed O +
lumen O +
and O +
no O +
RBCs O +
. O +

Both O +
levels O +
of O +
dietary O +
CLA O +
showed O +
similar O +
effects O +
, O +
with O +
the O +
number O +
of O +
RBC O +
- O +
containing O +
vessels O +
per O +
20x O +
field O +
decreased O +
to O +
a O +
third O +
of O +
that O +
seen O +
in O +
control O +
. O +

Dietary O +
CLA O +
decreased O +
serum O +
levels O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
and O +
whole O +
mammary O +
gland O +
levels O +
of O +
VEGF O +
and O +
its O +
receptor O +
Flk O +
- O +
1 O +
. O +

Both O +
cis O +
- O +
9 O +
, O +
trans O +
- O +
11 O +
and O +
trans O +
- O +
10 O +
, O +
cis O +
- O +
12 O +
CLA O +
isomers O +
were O +
effective O +
in O +
inhibiting O +
angiogenesis O +
in O +
vitro O +
in O +
a O +
dose O +
- O +
dependent O +
fashion O +
. O +

The O +
ability O +
of O +
CLA O +
to O +
inhibit O +
angiogenesis O +
may O +
contribute O +
to O +
its O +
efficacy O +
as O +
a O +
chemopreventive O +
agent O +
. O +

Molecular O +
characterization O +
of O +
angiogenic O +
properties O +
of O +
human O +
oral O +
squamous O +
cell O +
carcinoma O +
cells O +
. O +

Little O +
is O +
known O +
about O +
the O +
specificity O +
of O +
angiogenic O +
properties O +
of O +
oral O +
cancer O +
cells O +
and O +
the O +
possible O +
mechanisms O +
. O +

Stimulatory O +
effects O +
on O +
proliferation O +
and O +
migration O +
of O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
( O +
HUVEC O +
) O +
characterized O +
the O +
angiogenic O +
properties O +
of O +
oral O +
cancer O +
cells O +
but O +
not O +
normal O +
oral O +
keratinocytes O +
( O +
NOK O +
) O +
. O +

ELISA O +
found O +
the O +
presence O +
of O +
vascular O +
endothelial O +
growth O +
factors O +
( O +
VEGF O +
) O +
both O +
in O +
the O +
tested O +
oral O +
cancer O +
cells O +
and O +
NOK O +
. O +

Attenuation O +
of O +
the O +
proangiogenic O +
effects O +
by O +
neutralizing O +
VEGF O +
antibodies O +
suggests O +
VEGF O +
play O +
a O +
key O +
role O +
in O +
the O +
acquisition O +
of O +
the O +
angiogenic O +
phenotype O +
in O +
oral O +
cancer O +
cells O +
. O +

Western O +
blotting O +
of O +
p53 O +
and O +
murine O +
double O +
mutant O +
2 O +
( O +
Mdm2 O +
) O +
together O +
with O +
p53 O +
DNA O +
sequencing O +
analysis O +
indicate O +
that O +
p53 O +
function O +
loss O +
by O +
mutation O +
or O +
overexpression O +
of O +
Mdm2 O +
occurred O +
in O +
all O +
tested O +
oral O +
cancer O +
cells O +
regardless O +
of O +
their O +
etiology O +
. O +

In O +
summary O +
, O +
the O +
angiogenic O +
property O +
of O +
oral O +
cancer O +
cells O +
is O +
mediated O +
by O +
many O +
factors O +
in O +
addition O +
to O +
VEGF O +
and O +
the O +
functional O +
status O +
of O +
p53 O +
. O +

Prenatal O +
hypoxia O +
decreases O +
lung O +
extracellular O +
superoxide O +
dismutase O +
expression O +
and O +
activity O +
. O +

Extracellular O +
superoxide O +
dismutase O +
( O +
EC O +
- O +
SOD O +
) O +
, O +
which O +
scavenges O +
extracellular O +
superoxide O +
( O +
O O +
. O +
) O +
, O +
is O +
highly O +
regulated O +
in O +
the O +
developing O +
lung O +
. O +

In O +
the O +
prenatal O +
rabbit O +
, O +
EC O +
- O +
SOD O +
is O +
predominantly O +
intracellular O +
and O +
inactive O +
, O +
and O +
postnatally O +
, O +
active O +
EC O +
- O +
SOD O +
is O +
secreted O +
. O +

We O +
hypothesized O +
that O +
prenatal O +
hypoxia O +
would O +
delay O +
the O +
normal O +
postnatal O +
secretion O +
of O +
active O +
EC O +
- O +
SOD O +
in O +
the O +
lung O +
. O +

Pregnant O +
New O +
Zealand O +
White O +
rabbits O +
were O +
exposed O +
to O +
hypobaric O +
hypoxia O +
( O +
15 O +
, O +
000 O +
ft O +
x O +
36 O +
h O +
) O +
to O +
alter O +
fetal O +
O O +
( O +
2 O +
) O +
tension O +
or O +
were O +
maintained O +
in O +
room O +
air O +
. O +

Lungs O +
were O +
harvested O +
from O +
preterm O +
( O +
28 O +
days O +
) O +
, O +
term O +
( O +
30 O +
+ O +
/ O +
- O +
1 O +
day O +
) O +
, O +
and O +
1 O +
- O +
wk O +
- O +
old O +
kits O +
. O +

After O +
prenatal O +
hypobaric O +
hypoxia O +
, O +
EC O +
- O +
SOD O +
mRNA O +
expression O +
was O +
significantly O +
decreased O +
in O +
lungs O +
of O +
full O +
- O +
term O +
kits O +
, O +
whereas O +
EC O +
- O +
SOD O +
protein O +
decreased O +
at O +
all O +
ages O +
. O +

Immunohistochemical O +
staining O +
for O +
EC O +
- O +
SOD O +
showed O +
that O +
hypoxia O +
delayed O +
secretion O +
of O +
the O +
isoenzyme O +
in O +
the O +
airways O +
and O +
pulmonary O +
vasculature O +
. O +

Furthermore O +
, O +
pulmonary O +
EC O +
- O +
SOD O +
enzyme O +
activity O +
was O +
significantly O +
decreased O +
in O +
the O +
1 O +
- O +
wk O +
- O +
old O +
kits O +
exposed O +
to O +
prenatal O +
hypoxia O +
. O +

We O +
conclude O +
that O +
prenatal O +
hypoxia O +
downregulates O +
EC O +
- O +
SOD O +
expression O +
at O +
both O +
the O +
transcriptional O +
and O +
posttranslational O +
levels O +
. O +

Furthermore O +
, O +
prenatal O +
hypoxia O +
delays O +
secretion O +
of O +
active O +
EC O +
- O +
SOD O +
enzyme O +
. O +

These O +
findings O +
have O +
important O +
implications O +
for O +
the O +
effects O +
of O +
prenatal O +
asphyxia O +
on O +
postnatal O +
response O +
to O +
oxidant O +
stress O +
. O +

Impacts O +
of O +
water O +
management O +
options O +
on O +
flows O +
in O +
the O +
Condamine O +
River O +
in O +
Southern O +
Queensland O +
. O +

This O +
paper O +
examines O +
the O +
implications O +
for O +
river O +
flows O +
of O +
a O +
number O +
of O +
water O +
practices O +
and O +
potential O +
management O +
options O +
in O +
the O +
alluvial O +
plains O +
of O +
the O +
Upper O +
Condamine O +
River O +
. O +

It O +
is O +
an O +
intensively O +
cultivated O +
area O +
where O +
irrigation O +
is O +
limited O +
by O +
the O +
availability O +
of O +
water O +
resources O +
. O +

The O +
practice O +
of O +
capturing O +
overland O +
flows O +
was O +
investigated O +
by O +
the O +
development O +
of O +
a O +
model O +
that O +
simulates O +
the O +
performance O +
of O +
clusters O +
of O +
offstream O +
storages O +
up O +
to O +
sub O +
- O +
catchment O +
scale O +
. O +

Management O +
options O +
examined O +
included O +
improvement O +
to O +
on O +
- O +
farm O +
water O +
use O +
efficiency O +
, O +
the O +
suppression O +
of O +
evaporation O +
from O +
open O +
water O +
storages O +
, O +
increasing O +
the O +
depth O +
of O +
those O +
storages O +
, O +
decreasing O +
their O +
number O +
, O +
and O +
improved O +
tailwater O +
return O +
from O +
irrigated O +
land O +
. O +

Impacts O +
of O +
management O +
options O +
were O +
analysed O +
using O +
a O +
catchment O +
scale O +
water O +
allocation O +
model O +
. O +

Retinal O +
microangiopathies O +
overlying O +
pigment O +
epithelial O +
detachment O +
in O +
age O +
- O +
related O +
macular O +
degeneration O +
. O +

PURPOSE O +
: O +
To O +
evaluate O +
alterations O +
in O +
the O +
retinal O +
vasculature O +
overlying O +
pigment O +
epithelial O +
detachments O +
( O +
PED O +
) O +
in O +
exudative O +
age O +
- O +
related O +
macular O +
degeneration O +
( O +
ARMD O +
) O +
using O +
indocyanine O +
green O +
and O +
fluorescein O +
angiography O +
. O +

METHODS O +
: O +
Forty O +
- O +
one O +
patients O +
( O +
41 O +
eyes O +
) O +
with O +
a O +
clinical O +
diagnosis O +
of O +
exudative O +
ARMD O +
with O +
PED O +
underwent O +
simultaneous O +
fluorescein O +
and O +
indocyanine O +
green O +
angiography O +
, O +
also O +
under O +
high O +
( O +
10 O +
degrees O +
) O +
magnification O +
. O +

Vascular O +
abnormalities O +
in O +
the O +
retina O +
were O +
compared O +
between O +
patients O +
with O +
vascularized O +
( O +
n O +
= O +
34 O +
, O +
group O +
1 O +
) O +
and O +
nonvascularized O +
( O +
n O +
= O +
7 O +
, O +
group O +
2 O +
) O +
PED O +
on O +
indocyanine O +
green O +
angiography O +
and O +
correlated O +
with O +
the O +
size O +
of O +
the O +
PED O +
and O +
the O +
presence O +
of O +
serous O +
retinal O +
detachment O +
. O +

RESULTS O +
: O +
In O +
all O +
, O +
67 O +
vascular O +
abnormalities O +
were O +
found O +
by O +
indocyanine O +
green O +
angiography O +
and O +
only O +
22 O +
by O +
fluorescein O +
angiography O +
; O +
this O +
finding O +
was O +
statistically O +
significant O +
( O +
P O +
less O +
than O +
0 O +
. O +
0001 O +
) O +
. O +

The O +
finding O +
of O +
retinal O +
vasculopathy O +
( O +
32 O +
patients O +
in O +
group O +
1 O +
and O +
two O +
patients O +
in O +
group O +
2 O +
) O +
was O +
directly O +
correlated O +
with O +
the O +
presence O +
of O +
choroidal O +
neovascularizations O +
( O +
P O +
= O +
0 O +
. O +
002 O +
) O +
. O +

There O +
was O +
also O +
a O +
direct O +
correlation O +
between O +
the O +
presence O +
of O +
choroidal O +
neovascularization O +
and O +
size O +
of O +
the O +
PED O +
( O +
P O +
= O +
0 O +
. O +
03 O +
) O +
. O +

The O +
number O +
of O +
retinal O +
vascular O +
findings O +
was O +
not O +
significantly O +
correlated O +
with O +
serous O +
elevation O +
of O +
the O +
retina O +
. O +

CONCLUSIONS O +
: O +
Retinal O +
vasculopathies O +
may O +
be O +
observed O +
in O +
eyes O +
with O +
PED O +
and O +
are O +
detectable O +
by O +
indocyanine O +
green O +
and O +
fluorescein O +
angiography O +
. O +

Protein O +
expression O +
profile O +
of O +
primary O +
human O +
squamous O +
cell O +
lung O +
carcinomas O +
indicative O +
of O +
the O +
incidence O +
of O +
metastases O +
. O +

The O +
purpose O +
of O +
this O +
investigation O +
was O +
to O +
evaluate O +
firstly O +
whether O +
different O +
protein O +
expression O +
patterns O +
exist O +
in O +
primary O +
squamous O +
cell O +
lung O +
carcinomas O +
of O +
patients O +
with O +
and O +
without O +
lymph O +
node O +
involvement O +
and O +
secondly O +
, O +
whether O +
or O +
not O +
different O +
patterns O +
exist O +
in O +
tumours O +
with O +
positive O +
lymph O +
nodes O +
. O +

For O +
this O +
reason O +
, O +
formalin O +
- O +
fixed O +
, O +
paraffin O +
- O +
embedded O +
specimens O +
from O +
130 O +
patients O +
with O +
squamous O +
cell O +
lung O +
carcinomas O +
were O +
analyzed O +
by O +
immunohistochemistry O +
. O +

In O +
a O +
first O +
step O +
, O +
proteins O +
were O +
selected O +
which O +
showed O +
a O +
relationship O +
to O +
lymph O +
node O +
involvement O +
. O +

The O +
expression O +
of O +
JUN O +
, O +
ERBB2 O +
, O +
MYC O +
, O +
cyclin O +
D O +
, O +
PCNA O +
, O +
bFGF O +
, O +
VEGF O +
and O +
Hsp70 O +
proteins O +
revealed O +
a O +
positive O +
correlation O +
to O +
lymph O +
node O +
involvement O +
. O +

In O +
contrast O +
, O +
caspase O +
- O +
3 O +
, O +
Fas O +
ligand O +
, O +
Fas O +
/ O +
CD95 O +
, O +
and O +
PAI O +
showed O +
an O +
inverse O +
correlation O +
to O +
lymph O +
node O +
involvement O +
. O +

In O +
a O +
second O +
step O +
, O +
these O +
parameters O +
were O +
further O +
analyzed O +
by O +
hierarchical O +
cluster O +
analyses O +
. O +

The O +
resulting O +
clusters O +
were O +
correlated O +
to O +
patients O +
with O +
or O +
without O +
lymph O +
node O +
involvement O +
. O +

The O +
data O +
show O +
that O +
different O +
protein O +
expression O +
patterns O +
exist O +
between O +
primary O +
squamous O +
cell O +
lung O +
carcinomas O +
with O +
and O +
without O +
lymph O +
node O +
involvement O +
and O +
within O +
carcinomas O +
with O +
lymph O +
node O +
involvement O +
. O +

The O +
data O +
suggest O +
that O +
various O +
metastasis O +
profiles O +
exist O +
. O +

Antiangiogenic O +
and O +
antitumor O +
effects O +
of O +
a O +
protein O +
kinase O +
Cbeta O +
inhibitor O +
in O +
human O +
breast O +
cancer O +
and O +
ovarian O +
cancer O +
xenografts O +
. O +

In O +
cell O +
culture O +
, O +
the O +
compound O +
317615 O +
2HCl O +
, O +
a O +
potent O +
inhibitor O +
of O +
VEGF O +
- O +
stimulated O +
HUVEC O +
proliferation O +
, O +
was O +
not O +
very O +
effective O +
against O +
MX B-CellLine +
- I-CellLine +
1 I-CellLine +
breast O +
cancer O +
cells O +
( O +
IC50 O +
= O +
8 O +
. O +
1 O +
microM O +
) O +
or O +
SKOV B-CellLine +
- I-CellLine +
3 I-CellLine +
ovarian O +
carcinoma O +
cells O +
( O +
IC50 O +
= O +
9 O +
. O +
5 O +
microM O +
) O +
. O +

Exposure O +
to O +
combinations O +
of O +
paclitaxel O +
or O +
carboplatin O +
and O +
317615 O +
x O +
2HCl O +
with O +
MX B-CellLine +
- I-CellLine +
1 I-CellLine +
cells O +
in O +
culture O +
resulted O +
in O +
cell O +
survival O +
that O +
reflected O +
primarily O +
additivity O +
of O +
the O +
two O +
agents O +
. O +

Exposure O +
of O +
SKOV B-CellLine +
- I-CellLine +
3 I-CellLine +
cells O +
to O +
paclitaxel O +
or O +
carboplatin O +
along O +
with O +
317615 O +
2HCl O +
resulted O +
in O +
cell O +
survivals O +
that O +
reflected O +
additivity O +
of O +
317615 O +
x O +
2HCl O +
with O +
paclitaxel O +
and O +
greater O +
- O +
than O +
- O +
additive O +
cytotoxicity O +
with O +
carboplatin O +
. O +

Administration O +
of O +
317615 O +
x O +
2HCI O +
orally O +
twice O +
daily O +
to O +
nude O +
mice O +
bearing O +
subcutaneous O +
MX B-CellLine +
- I-CellLine +
1 I-CellLine +
tumors O +
or O +
SKOV B-CellLine +
- I-CellLine +
3 I-CellLine +
tumors O +
resulted O +
in O +
a O +
decreased O +
number O +
of O +
intratumoral O +
vessels O +
as O +
determined O +
by O +
CD31 O +
and O +
CD105 O +
staining O +
with O +
decreases O +
of O +
35 O +
% O +
and O +
43 O +
% O +
in O +
MX B-CellLine +
- I-CellLine +
1 I-CellLine +
tumors O +
and O +
60 O +
% O +
and O +
75 O +
% O +
in O +
SKOV B-CellLine +
- I-CellLine +
3 I-CellLine +
tumors O +
, O +
respectively O +
. O +

317615 O +
x O +
2HCl O +
was O +
an O +
active O +
antitumor O +
agent O +
against O +
the O +
MX B-CellLine +
- I-CellLine +
1 I-CellLine +
xenograft O +
and O +
increased O +
the O +
tumor O +
growth O +
delay O +
produced O +
by O +
paclitaxel O +
by O +
1 O +
. O +
7 O +
- O +
fold O +
and O +
the O +
tumor O +
growth O +
delay O +
produced O +
by O +
carboplatin O +
by O +
3 O +
. O +
8 O +
- O +
fold O +
. O +

Administration O +
of O +
317615 O +
x O +
2HCl O +
also O +
increased O +
the O +
tumor O +
growth O +
delay O +
produced O +
by O +
fractionated O +
radiation O +
therapy O +
in O +
the O +
MX B-CellLine +
- I-CellLine +
1 I-CellLine +
tumor O +
. O +

Treatment O +
with O +
317615 O +
x O +
2HCl O +
alone O +
increased O +
the O +
lifespan O +
of O +
animals O +
bearing O +
intraperitoneal O +
SKOV B-CellLine +
- I-CellLine +
3 I-CellLine +
xenografts O +
by O +
1 O +
. O +
9 O +
fold O +
compared O +
with O +
untreated O +
control O +
animals O +
. O +

The O +
combination O +
of O +
paclitaxel O +
and O +
317615 O +
x O +
2HCl O +
resulted O +
in O +
100 O +
% O +
120 O +
- O +
day O +
survival O +
of O +
SKOV B-CellLine +
- I-CellLine +
3 I-CellLine +
bearing O +
animals O +
. O +

Administration O +
of O +
317615 O +
x O +
2HCl O +
along O +
with O +
carboplatin O +
to O +
animals O +
bearing O +
the O +
SKOV B-CellLine +
- I-CellLine +
3 I-CellLine +
tumor O +
produced O +
a O +
1 O +
. O +
8 O +
- O +
fold O +
increase O +
in O +
lifespan O +
compared O +
with O +
carboplatin O +
alone O +
. O +

317615 O +
x O +
2HCl O +
is O +
a O +
promising O +
new O +
antiangiogenic O +
agent O +
that O +
is O +
in O +
early O +
phase O +
clinical O +
testing O +
. O +

Expression O +
of O +
CD154 O +
on O +
renal O +
cell O +
carcinomas O +
and O +
effect O +
on O +
cell O +
proliferation O +
, O +
motility O +
and O +
platelet O +
- O +
activating O +
factor O +
synthesis O +
. O +

CD40 O +
activation O +
by O +
CD154 O +
may O +
trigger O +
diverse O +
cellular O +
responses O +
, O +
ranging O +
from O +
proliferation O +
and O +
differentiation O +
to O +
growth O +
suppression O +
and O +
cell O +
death O +
, O +
in O +
normal O +
and O +
malignant O +
cells O +
. O +

However O +
, O +
the O +
pathophysiologic O +
role O +
of O +
CD154 O +
expressed O +
by O +
tumor O +
cells O +
remains O +
unclear O +
. O +

We O +
have O +
investigated O +
the O +
expression O +
of O +
the O +
CD40 O +
- O +
CD154 O +
system O +
in O +
24 O +
primary O +
cultures O +
derived O +
from O +
renal O +
cell O +
carcinomas O +
, O +
its O +
correlation O +
with O +
tumor O +
stage O +
and O +
its O +
potential O +
functional O +
significance O +
. O +

We O +
found O +
coexpression O +
of O +
CD40 O +
and O +
CD154 O +
in O +
most O +
of O +
the O +
renal O +
carcinoma O +
cell O +
lines O +
. O +

CD154 O +
, O +
but O +
not O +
CD40 O +
expression O +
, O +
significantly O +
correlated O +
with O +
tumor O +
stage O +
. O +

Moreover O +
, O +
renal O +
carcinoma O +
cell O +
lines O +
also O +
released O +
the O +
soluble O +
form O +
of O +
CD154 O +
into O +
the O +
supernatant O +
. O +

CD40 O +
engagement O +
by O +
CD154 O +
did O +
not O +
affect O +
apoptosis O +
or O +
survival O +
. O +

On O +
the O +
contrary O +
, O +
CD154 O +
stimulated O +
cell O +
proliferation O +
, O +
motility O +
and O +
production O +
of O +
PAF O +
, O +
a O +
phospholipid O +
mediator O +
of O +
inflammation O +
with O +
angiogenic O +
properties O +
. O +

Furthermore O +
, O +
the O +
renal O +
carcinoma O +
cell O +
lines O +
expressed O +
PAF O +
- O +
R O +
. O +

Blockade O +
of O +
PAF O +
- O +
R O +
by O +
WEB O +
- O +
2170 O +
, O +
a O +
PAF O +
- O +
R O +
antagonist O +
, O +
abolished O +
the O +
CD154 O +
- O +
dependent O +
motility O +
, O +
indicating O +
a O +
role O +
for O +
PAF O +
synthesized O +
after O +
CD154 O +
stimulation O +
in O +
renal O +
carcinoma O +
cell O +
motility O +
. O +

In O +
conclusion O +
, O +
this O +
study O +
identifies O +
new O +
functional O +
properties O +
for O +
CD154 O +
, O +
which O +
are O +
potentially O +
relevant O +
for O +
the O +
growth O +
and O +
dissemination O +
of O +
renal O +
carcinoma O +
cells O +
. O +

Fas O +
- O +
Fas O +
ligand O +
signaling O +
pathway O +
mediates O +
an O +
interleukin O +
- O +
12 O +
- O +
induced O +
rejection O +
of O +
a O +
murine O +
prostate O +
tumor O +
system O +
. O +

BACKGROUND O +
: O +
Recent O +
data O +
suggest O +
that O +
anti O +
- O +
tumor O +
activities O +
of O +
interleukin O +
- O +
12 O +
( O +
IL O +
- O +
12 O +
) O +
involve O +
the O +
induction O +
of O +
apoptosis O +
. O +

Fas O +
( O +
APO O +
- O +
1 O +
/ O +
CD95 O +
) O +
is O +
a O +
type O +
I O +
membrane O +
protein O +
that O +
is O +
capable O +
of O +
initiating O +
an O +
apoptosis O +
signaling O +
pathway O +
when O +
bound O +
to O +
its O +
ligand O +
( O +
FasL O +
) O +
. O +

We O +
undertook O +
this O +
study O +
to O +
test O +
the O +
hypothesis O +
that O +
Fas O +
- O +
FasL O +
- O +
mediated O +
apoptosis O +
plays O +
a O +
role O +
in O +
IL O +
- O +
12 O +
- O +
induced O +
tumor O +
regression O +
. O +

METHODS O +
: O +
An O +
mIL O +
- O +
12 O +
expression O +
vector O +
driven O +
by O +
cytomegalovirus O +
promoter O +
was O +
used O +
to O +
express O +
murine O +
IL O +
- O +
12 O +
cDNA O +
in O +
the O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
murine O +
prostate O +
carcinoma O +
cell O +
line O +
. O +

Control O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
cells O +
and O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
cells O +
stably O +
transfected O +
with O +
IL O +
- O +
12 O +
gene O +
( O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
- O +
IL12 O +
) O +
were O +
inoculated O +
subcutaneously O +
in O +
4 O +
- O +
to O +
6 O +
- O +
week O +
- O +
old O +
male O +
C57BL O +
/ O +
J6 O +
mice O +
. O +

Tumor O +
size O +
was O +
measured O +
every O +
3 O +
days O +
. O +

Western O +
blot O +
and O +
immunohistochemical O +
assays O +
were O +
used O +
to O +
evaluate O +
Fas O +
and O +
FasL O +
protein O +
expression O +
. O +

In O +
situ O +
fluorescent O +
end O +
labeling O +
was O +
used O +
to O +
label O +
apoptotic O +
cells O +
. O +

RESULTS O +
: O +
IL O +
- O +
12 O +
- O +
expressing O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
prostate O +
carcinoma O +
cells O +
transplanted O +
into O +
C57BL O +
/ O +
J6 O +
mice O +
grew O +
more O +
slowly O +
than O +
control O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
cells O +
and O +
vector O +
control O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
- O +
Luc O +
cells O +
. O +

The O +
average O +
survival O +
time O +
of O +
the O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
- O +
IL12 O +
mice O +
was O +
longer O +
than O +
53 O +
days O +
, O +
whereas O +
the O +
mean O +
survival O +
for O +
mice O +
transplanted O +
with O +
control O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
cells O +
was O +
only O +
16 O +
days O +
. O +

Apoptotic O +
cells O +
were O +
more O +
numerous O +
in O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
- O +
IL12 O +
tumors O +
: O +
10 O +
. O +
3 O +
% O +
vs O +
. O +
1 O +
. O +
5 O +
% O +
in O +
control O +
( O +
P O +
= O +
0 O +
. O +
001 O +
) O +
. O +

Fas O +
and O +
FasL O +
proteins O +
were O +
increased O +
approximately O +
twofold O +
in O +
the O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
- O +
IL12 O +
tumors O +
compared O +
with O +
the O +
RM B-CellLine +
- I-CellLine +
9 I-CellLine +
control O +
tumors O +
as O +
determined O +
by O +
Western O +
blot O +
and O +
immunohistochemical O +
analyses O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

CONCLUSION O +
: O +
The O +
Fas O +
- O +
FasL O +
- O +
mediated O +
apoptosis O +
pathway O +
may O +
contribute O +
to O +
the O +
IL O +
- O +
12 O +
- O +
induced O +
rejection O +
of O +
prostate O +
carcinoma O +
. O +

DNA O +
damage O +
induces O +
a O +
novel O +
p53 O +
- O +
survivin O +
signaling O +
pathway O +
regulating O +
cell O +
cycle O +
and O +
apoptosis O +
in O +
acute O +
lymphoblastic O +
leukemia O +
cells O +
. O +

Survivin O +
is O +
a O +
novel O +
member O +
of O +
the O +
inhibitor O +
of O +
apoptosis O +
protein O +
( O +
IAP O +
) O +
family O +
. O +

Here O +
we O +
report O +
that O +
the O +
chemotherapeutic O +
drug O +
doxorubicin O +
, O +
a O +
DNA O +
- O +
damaging O +
agent O +
, O +
activates O +
a O +
p53 O +
- O +
survivin O +
signaling O +
pathway O +
inducing O +
cell O +
cycle O +
arrest O +
and O +
apoptosis O +
in O +
childhood O +
acute O +
lymphoblastic O +
leukemia O +
( O +
ALL O +
) O +
. O +

Treatment O +
of O +
wild O +
- O +
type O +
( O +
wt O +
) O +
p53 O +
ALL O +
cells O +
( O +
EU B-CellLine +
- I-CellLine +
3 I-CellLine +
cell O +
line O +
) O +
with O +
doxorubicin O +
caused O +
accumulation O +
of O +
p53 O +
, O +
resulting O +
in O +
dramatic O +
down O +
- O +
regulation O +
of O +
survivin O +
, O +
depletion O +
of O +
cells O +
in O +
G O +
( O +
2 O +
) O +
/ O +
M O +
, O +
and O +
apoptosis O +
( O +
increased O +
sub O +
- O +
G O +
( O +
1 O +
) O +
compartment O +
) O +
. O +

In O +
contrast O +
, O +
doxorubicin O +
treatment O +
of O +
mutant O +
( O +
mut O +
) O +
p53 O +
cells O +
( O +
EU B-CellLine +
- I-CellLine +
6 I-CellLine +
/ O +
ALL O +
line O +
) O +
up O +
- O +
regulated O +
survivin O +
and O +
induced O +
G O +
( O +
2 O +
) O +
/ O +
M O +
arrest O +
without O +
inducing O +
apoptosis O +
. O +

However O +
, O +
treating O +
EU B-CellLine +
- I-CellLine +
6 I-CellLine +
with O +
anti O +
- O +
survivin O +
antisense O +
resensitized O +
these O +
cells O +
to O +
doxorubicin O +
, O +
resulting O +
in O +
apoptosis O +
. O +

With O +
a O +
p53 O +
- O +
null O +
cell O +
line O +
( O +
EU B-CellLine +
- I-CellLine +
4 I-CellLine +
) O +
, O +
although O +
doxorubicin O +
treatment O +
arrested O +
cells O +
in O +
G O +
( O +
2 O +
) O +
/ O +
M O +
, O +
survivin O +
expression O +
was O +
unchanged O +
, O +
and O +
cells O +
underwent O +
only O +
limited O +
apoptosis O +
. O +

However O +
, O +
re O +
- O +
expression O +
of O +
wt O +
- O +
p53 O +
in O +
EU B-CellLine +
- I-CellLine +
4 I-CellLine +
cells O +
could O +
restore O +
the O +
doxorubicin O +
- O +
p53 O +
- O +
survivin O +
pathway O +
, O +
resulting O +
in O +
significantly O +
decreased O +
survivin O +
expression O +
and O +
increased O +
apoptosis O +
in O +
these O +
cells O +
after O +
doxorubicin O +
treatment O +
. O +

Following O +
cotransfection O +
of O +
p53 O +
- O +
null O +
EU B-CellLine +
- I-CellLine +
4 I-CellLine +
cells O +
with O +
survivin O +
promoter O +
- O +
luciferase O +
constructs O +
and O +
either O +
wt O +
- O +
p53 O +
or O +
different O +
mut O +
- O +
p53 O +
expression O +
vectors O +
, O +
wt O +
- O +
p53 O +
inhibited O +
survivin O +
promoter O +
activity O +
; O +
p53 O +
- O +
mediated O +
inhibition O +
could O +
be O +
abrogated O +
by O +
overexpression O +
of O +
murine O +
double O +
minute2 O +
( O +
MDM2 O +
) O +
protein O +
. O +

Together O +
, O +
these O +
studies O +
define O +
a O +
novel O +
p53 O +
- O +
survivin O +
signaling O +
pathway O +
activated O +
by O +
DNA O +
damage O +
that O +
results O +
in O +
down O +
- O +
regulation O +
of O +
survivin O +
, O +
cell O +
cycle O +
arrest O +
, O +
and O +
apoptosis O +
. O +

Furthermore O +
, O +
our O +
data O +
indicate O +
that O +
loss O +
of O +
wt O +
- O +
p53 O +
function O +
in O +
tumor O +
cells O +
may O +
contribute O +
to O +
up O +
- O +
regulation O +
of O +
survivin O +
and O +
resistance O +
to O +
DNA O +
- O +
damaging O +
agents O +
. O +

Male O +
role O +
in O +
fertility O +
decisions O +
in O +
Robertsport O +
, O +
Liberia O +
: O +
an O +
experimental O +
exercise O +
for O +
policy O +
formulation O +
. O +

There O +
is O +
a O +
tendency O +
to O +
believe O +
that O +
in O +
African O +
societies O +
men O +
are O +
the O +
dominant O +
decision O +
makers O +
in O +
the O +
family O +
. O +

In O +
Robertsport O +
, O +
Liberia O +
, O +
there O +
are O +
indications O +
that O +
, O +
with O +
respect O +
to O +
fertility O +
regulation O +
, O +
the O +
dominance O +
of O +
the O +
husband O +
in O +
fertility O +
decisions O +
exists O +
, O +
but O +
it O +
is O +
also O +
apparent O +
that O +
many O +
of O +
these O +
decisions O +
are O +
made O +
jointly O +
by O +
both O +
husband O +
and O +
wife O +
. O +

Education O +
is O +
particularly O +
influential O +
in O +
the O +
joint O +
fertility O +
decision O +
- O +
making O +
process O +
. O +

The O +
100 O +
husbands O +
sampled O +
in O +
1982 O +
desired O +
a O +
large O +
number O +
of O +
children O +
and O +
had O +
experience O +
with O +
infant O +
and O +
child O +
mortality O +
. O +

If O +
family O +
planning O +
programs O +
should O +
attain O +
their O +
goals O +
, O +
men O +
should O +
be O +
more O +
involved O +
, O +
than O +
at O +
present O +
, O +
in O +
every O +
aspect O +
of O +
the O +
programs O +
. O +

Equally O +
important O +
is O +
the O +
urgency O +
for O +
studies O +
related O +
to O +
the O +
role O +
of O +
men O +
in O +
fertility O +
regulation O +
, O +
using O +
adequately O +
large O +
samples O +
. O +

Genetic O +
differences O +
in O +
susceptibility O +
to O +
ulcerative O +
enteritis O +
in O +
Japanese O +
quail O +
. O +

Six O +
lines O +
of O +
Japanese O +
quail O +
were O +
derived O +
from O +
a O +
single O +
foundation O +
population O +
. O +

Four O +
of O +
the O +
lines O +
were O +
selected O +
on O +
the O +
basis O +
of O +
family O +
mean O +
three O +
week O +
body O +
weight O +
, O +
two O +
were O +
unselected O +
and O +
all O +
lines O +
were O +
randomly O +
mated O +
. O +

Quail O +
were O +
housed O +
in O +
wire O +
batteries O +
during O +
the O +
brooding O +
, O +
rearing O +
and O +
laying O +
periods O +
. O +

During O +
the O +
brooding O +
period O +
, O +
hover O +
temperature O +
and O +
floor O +
space O +
per O +
chick O +
were O +
similar O +
from O +
line O +
to O +
line O +
. O +

For O +
the O +
rearing O +
and O +
laying O +
periods O +
, O +
floor O +
space O +
per O +
chick O +
was O +
approximately O +
the O +
same O +
from O +
line O +
to O +
line O +
. O +

During O +
an O +
outbreak O +
of O +
ulcerative O +
enteritis O +
( O +
diagnosed O +
on O +
the O +
basis O +
of O +
gross O +
and O +
histopathology O +
) O +
in O +
generation O +
31 O +
and O +
again O +
in O +
generation O +
34 O +
, O +
mortality O +
ranged O +
from O +
zero O +
for O +
males O +
of O +
one O +
control O +
line O +
to O +
approximately O +
50 O +
percent O +
for O +
females O +
of O +
one O +
selected O +
line O +
. O +

Analysis O +
of O +
variance O +
showed O +
that O +
incidence O +
of O +
mortality O +
differed O +
significantly O +
among O +
lines O +
and O +
between O +
sexes O +
. O +

Mortality O +
was O +
generally O +
higher O +
in O +
selected O +
than O +
in O +
control O +
lines O +
and O +
in O +
females O +
than O +
in O +
males O +
. O +

It O +
is O +
suggested O +
that O +
susceptibility O +
to O +
ulcerative O +
enteritis O +
in O +
quail O +
may O +
be O +
a O +
polygenically O +
inherited O +
trait O +
and O +
that O +
the O +
breeding O +
which O +
accompanied O +
selection O +
for O +
body O +
size O +
may O +
have O +
made O +
some O +
loci O +
homozygous O +
for O +
susceptibility O +
alleles O +
. O +

[ O +
A O +
decline O +
in O +
the O +
French O +
demographic O +
situation O +
in O +
the O +
context O +
of O +
a O +
Europe O +
also O +
in O +
demographic O +
decline O +
] O +
. O +

The O +
author O +
analyzes O +
the O +
decline O +
in O +
French O +
fertility O +
which O +
has O +
occurred O +
over O +
the O +
past O +
two O +
years O +
using O +
data O +
from O +
official O +
sources O +
. O +

Some O +
comparisons O +
are O +
made O +
with O +
fertility O +
trends O +
in O +
other O +
European O +
countries O +
. O +

On O +
the O +
relationship O +
between O +
the O +
population O +
structure O +
and O +
national O +
economic O +
development O +
in O +
China O +
. O +

The O +
authors O +
examine O +
the O +
relationship O +
between O +
population O +
reproduction O +
and O +
the O +
production O +
of O +
material O +
goods O +
, O +
with O +
particular O +
reference O +
to O +
the O +
effect O +
of O +
changes O +
in O +
the O +
age O +
composition O +
of O +
the O +
population O +
on O +
the O +
national O +
economy O +
and O +
national O +
income O +
. O +

An O +
analysis O +
of O +
the O +
population O +
structure O +
of O +
China O +
is O +
presented O +
, O +
with O +
consideration O +
given O +
to O +
age O +
characteristics O +
, O +
occupation O +
, O +
and O +
urban O +
and O +
rural O +
population O +
. O +

Suggestions O +
for O +
improving O +
the O +
population O +
structure O +
to O +
achieve O +
maximum O +
rates O +
of O +
economic O +
development O +
are O +
presented O +
. O +

Regional O +
differences O +
in O +
population O +
structure O +
are O +
also O +
discussed O +
. O +

The O +
patterns O +
of O +
internal O +
migration O +
in O +
Maharashtra O +
: O +
an O +
analysis O +
of O +
1971 O +
census O +
data O +
. O +

Patterns O +
of O +
internal O +
migration O +
in O +
the O +
state O +
of O +
Maharashtra O +
, O +
India O +
, O +
for O +
the O +
period O +
1961 O +
- O +
1971 O +
are O +
analyzed O +
using O +
1971 O +
census O +
data O +
. O +

The O +
nature O +
, O +
volume O +
, O +
and O +
direction O +
of O +
migration O +
are O +
examined O +
. O +

Migrants O +
are O +
characterized O +
according O +
to O +
factors O +
including O +
age O +
, O +
sex O +
, O +
marital O +
status O +
, O +
occupation O +
, O +
and O +
areas O +
of O +
origin O +
and O +
destination O +
. O +

Act O +
No O +
. O +
16 O +
. O +
045 O +
of O +
2 O +
June O +
1989 O +
prohibiting O +
all O +
discrimination O +
that O +
violates O +
the O +
principle O +
of O +
equality O +
of O +
treatment O +
and O +
opportunities O +
for O +
both O +
sexes O +
in O +
all O +
sectors O +
of O +
labor O +
activity O +
. O +

This O +
Uruguayan O +
Act O +
prohibits O +
discrimination O +
in O +
employment O +
with O +
respect O +
to O +
the O +
following O +
areas O +
, O +
among O +
others O +
: O +
1 O +
) O +
advertising O +
for O +
the O +
provision O +
of O +
positions O +
; O +
2 O +
) O +
selection O +
criteria O +
; O +
3 O +
) O +
recruitment O +
and O +
hiring O +
; O +
4 O +
) O +
evaluation O +
of O +
performance O +
criteria O +
; O +
5 O +
) O +
the O +
right O +
to O +
advancement O +
and O +
promotion O +
; O +
6 O +
) O +
labour O +
stability O +
; O +
7 O +
) O +
social O +
benefits O +
; O +
8 O +
) O +
suspension O +
and O +
dismissal O +
, O +
particularly O +
in O +
cases O +
involving O +
a O +
change O +
of O +
civil O +
status O +
, O +
pregnancy O +
, O +
or O +
nursing O +
; O +
9 O +
) O +
possibilities O +
for O +
professional O +
and O +
technical O +
education O +
or O +
retraining O +
; O +
and O +
10 O +
) O +
remuneration O +
criteria O +
. O +

Reserving O +
places O +
for O +
one O +
sex O +
because O +
of O +
the O +
presence O +
of O +
activities O +
in O +
which O +
the O +
sex O +
of O +
the O +
employee O +
is O +
essential O +
for O +
performance O +
or O +
to O +
comply O +
with O +
international O +
labor O +
treaties O +
does O +
not O +
constitute O +
discrimination O +
. O +

Nor O +
do O +
compensatory O +
acts O +
designed O +
to O +
promote O +
equality O +
of O +
opportunities O +
and O +
treatment O +
of O +
both O +
sexes O +
in O +
concrete O +
situations O +
. O +

In O +
cases O +
where O +
the O +
provisions O +
of O +
this O +
Act O +
have O +
been O +
violated O +
, O +
specially O +
designated O +
judges O +
will O +
call O +
the O +
parties O +
together O +
and O +
may O +
adopt O +
measures O +
designed O +
to O +
end O +
the O +
situation O +
complained O +
of O +
. O +

If O +
they O +
deem O +
it O +
necessary O +
, O +
the O +
judges O +
may O +
institute O +
more O +
formal O +
proceedings O +
. O +

If O +
the O +
measures O +
adopted O +
are O +
not O +
carried O +
out O +
, O +
the O +
person O +
violating O +
the O +
law O +
is O +
subject O +
to O +
a O +
daily O +
fine O +
, O +
as O +
well O +
as O +
administrative O +
penalties O +
set O +
out O +
in O +
Act O +
15 O +
. O +
903 O +
of O +
10 O +
November O +
1987 O +
. O +

Adverse O +
decisions O +
may O +
be O +
appealed O +
. O +

The O +
state O +
is O +
also O +
to O +
undertake O +
educative O +
campaigns O +
to O +
create O +
interest O +
in O +
and O +
understanding O +
of O +
the O +
problems O +
affecting O +
women O +
workers O +
, O +
thus O +
promoting O +
awareness O +
in O +
such O +
workers O +
and O +
their O +
employers O +
of O +
their O +
situation O +
. O +

No O +
evidence O +
for O +
an O +
influence O +
of O +
the O +
human O +
platelet O +
antigen O +
- O +
1 O +
polymorphism O +
on O +
the O +
antiplatelet O +
effects O +
of O +
glycoprotein O +
IIb O +
/ O +
IIIa O +
inhibitors O +
. O +

This O +
study O +
investigated O +
the O +
hypothesis O +
that O +
the O +
human O +
platelet O +
antigen O +
- O +
1 O +
( O +
HPA O +
- O +
1 O +
) O +
polymorphism O +
may O +
influence O +
the O +
antiplatelet O +
effects O +
of O +
glycoprotein O +
( O +
GP O +
) O +
IIb O +
/ O +
IIIa O +
inhibitors O +
. O +

Adenosine O +
diphosphate O +
( O +
30 O +
micro O +
mol O +
) O +
- O +
induced O +
fibrinogen O +
binding O +
was O +
measured O +
by O +
flow O +
cytometry O +
. O +

Abciximab O +
( O +
0 O +
. O +
03 O +
- O +
3 O +
micro O +
g O +
/ O +
ml O +
) O +
, O +
tirofiban O +
( O +
0 O +
. O +
3 O +
- O +
30 O +
nmol O +
/ O +
l O +
) O +
or O +
eptifibatide O +
( O +
0 O +
. O +
01 O +
- O +
1 O +
micro O +
g O +
/ O +
ml O +
) O +
were O +
incubated O +
for O +
15 O +
min O +
with O +
the O +
samples O +
prior O +
to O +
stimulation O +
. O +

IC O +
( O +
50 O +
) O +
values O +
for O +
the O +
inhibition O +
of O +
fibrinogen O +
binding O +
were O +
determined O +
from O +
each O +
experiment O +
. O +

All O +
subjects O +
were O +
genotyped O +
by O +
GALIOS O +
and O +
automated O +
fluorescence O +
correlation O +
spectroscopy O +
. O +

Although O +
a O +
marked O +
variability O +
in O +
the O +
inhibitory O +
effects O +
of O +
all O +
three O +
GPIIb O +
/ O +
IIIa O +
inhibitors O +
was O +
confirmed O +
, O +
there O +
were O +
no O +
significant O +
differences O +
between O +
the O +
genotypes O +
with O +
respect O +
to O +
the O +
inhibition O +
of O +
fibrinogen O +
binding O +
. O +

Thus O +
, O +
the O +
present O +
study O +
does O +
not O +
provide O +
evidence O +
for O +
an O +
effect O +
of O +
HPA O +
- O +
1 O +
polymorphism O +
on O +
the O +
inter O +
- O +
individual O +
variability O +
in O +
the O +
platelet O +
inhibitory O +
effects O +
of O +
the O +
three O +
GPIIb O +
/ O +
IIIa O +
inhibitors O +
approved O +
for O +
clinical O +
use O +
. O +

Effects O +
of O +
4 O +
- O +
alkylmorpholine O +
N O +
- O +
oxides O +
on O +
ATP O +
- O +
producing O +
processes O +
in O +
Ehrlich O +
ascites O +
and O +
L1210 B-CellLine +
leukaemia O +
cells O +
. O +

The O +
main O +
purpose O +
of O +
the O +
present O +
investigation O +
was O +
to O +
study O +
the O +
effect O +
of O +
the O +
homologous O +
series O +
of O +
4 O +
- O +
alkylmorpholine O +
N O +
- O +
oxides O +
on O +
ATP O +
- O +
producing O +
processes O +
in O +
Ehrlich O +
ascites O +
and O +
L1210 B-CellLine +
murine O +
leukaemia O +
cells O +
. O +

The O +
effects O +
on O +
aerobic O +
glucose O +
consumption O +
, O +
lactic O +
acid O +
formation O +
, O +
content O +
of O +
total O +
( O +
T O +
- O +
SH O +
) O +
and O +
non O +
- O +
protein O +
thiol O +
groups O +
( O +
NP O +
- O +
SH O +
) O +
, O +
endogenous O +
and O +
exogenous O +
respiration O +
and O +
the O +
level O +
of O +
ATP O +
in O +
tumour O +
cells O +
incubated O +
in O +
vitro O +
were O +
investigated O +
. O +

4 O +
- O +
Dodecylmorpholine O +
N O +
- O +
oxide O +
( O +
DMNO O +
) O +
, O +
one O +
of O +
the O +
most O +
active O +
compounds O +
, O +
decreased O +
the O +
level O +
of O +
ATP O +
immediately O +
after O +
addition O +
to O +
the O +
suspension O +
of O +
Ehrlich O +
cells O +
in O +
an O +
ice O +
bath O +
. O +

After O +
2 O +
h O +
incubation O +
at O +
37 O +
degrees O +
C O +
the O +
drop O +
in O +
the O +
ATP O +
level O +
was O +
much O +
lower O +
. O +

A O +
possible O +
explanation O +
for O +
the O +
decrease O +
in O +
the O +
ATP O +
level O +
might O +
be O +
interaction O +
of O +
the O +
amine O +
oxide O +
with O +
the O +
cell O +
membrane O +
. O +

The O +
Acute O +
Dialysis O +
Quality O +
Initiative O +
- O +
- O +
part O +
IV O +
: O +
membranes O +
for O +
CRRT O +
. O +

The O +
extracorporeal O +
membrane O +
used O +
in O +
a O +
continuous O +
renal O +
replacement O +
therapy O +
( O +
CRRT O +
) O +
for O +
the O +
treatment O +
of O +
a O +
critically O +
ill O +
patient O +
with O +
acute O +
renal O +
failure O +
( O +
ARF O +
) O +
is O +
vitally O +
important O +
for O +
several O +
reasons O +
, O +
including O +
its O +
influence O +
on O +
biocompatibility O +
and O +
filter O +
performance O +
. O +

The O +
clinical O +
relevance O +
of O +
membrane O +
- O +
related O +
biocompatibility O +
markers O +
traditionally O +
used O +
in O +
chronic O +
hemodialysis O +
remains O +
unclear O +
in O +
CRRT O +
. O +

Numerous O +
approaches O +
may O +
be O +
used O +
to O +
assess O +
membrane O +
and O +
filter O +
performance O +
in O +
CRRT O +
, O +
but O +
no O +
specific O +
methodology O +
is O +
accepted O +
widely O +
at O +
present O +
. O +

Although O +
a O +
potential O +
benefit O +
of O +
certain O +
membranes O +
used O +
for O +
CRRT O +
is O +
adsorptive O +
removal O +
of O +
inflammatory O +
mediators O +
, O +
this O +
issue O +
has O +
not O +
been O +
assessed O +
carefully O +
in O +
well O +
- O +
designed O +
clinical O +
trials O +
. O +

These O +
and O +
other O +
issues O +
should O +
be O +
the O +
subject O +
of O +
future O +
clinical O +
research O +
efforts O +
. O +

Enforced O +
expression O +
of O +
tissue O +
inhibitor O +
of O +
matrix O +
metalloproteinase O +
- O +
3 O +
affects O +
functional O +
capillary O +
morphogenesis O +
and O +
inhibits O +
tumor O +
growth O +
in O +
a O +
murine O +
tumor O +
model O +
. O +

Homeostasis O +
of O +
the O +
extracellular O +
matrix O +
is O +
a O +
delicate O +
balance O +
between O +
degradation O +
and O +
remodeling O +
, O +
the O +
balance O +
being O +
maintained O +
by O +
the O +
interaction O +
of O +
activated O +
matrix O +
metalloproteinases O +
( O +
MMPs O +
) O +
and O +
specific O +
tissue O +
inhibitors O +
of O +
matrix O +
metalloproteinases O +
( O +
TIMPs O +
) O +
. O +

Up O +
- O +
regulation O +
of O +
MMP O +
activity O +
, O +
favoring O +
proteolytic O +
degradation O +
of O +
the O +
basement O +
membrane O +
and O +
extracellular O +
matrix O +
, O +
has O +
been O +
linked O +
to O +
tumor O +
growth O +
and O +
metastasis O +
, O +
as O +
well O +
as O +
tumor O +
- O +
associated O +
angiogenesis O +
, O +
whereas O +
inhibition O +
of O +
MMP O +
activity O +
appears O +
to O +
restrict O +
these O +
processes O +
. O +

We O +
have O +
used O +
retroviral O +
- O +
mediated O +
gene O +
delivery O +
to O +
effect O +
sustained O +
autocrine O +
expression O +
of O +
TIMP O +
- O +
3 O +
in O +
murine O +
neuroblastoma O +
and O +
melanoma O +
tumor O +
cells O +
in O +
order O +
to O +
further O +
examine O +
the O +
ability O +
of O +
TIMPs O +
to O +
inhibit O +
angiogenesis O +
in O +
vivo O +
. O +

Growth O +
of O +
both O +
histologic O +
types O +
of O +
gene O +
- O +
modified O +
tumor O +
cells O +
in O +
severe O +
combined O +
immunodeficiency O +
( O +
SCID O +
) O +
mice O +
was O +
significantly O +
restricted O +
when O +
compared O +
with O +
controls O +
. O +

Grossly O +
, O +
these O +
tumors O +
were O +
small O +
and O +
had O +
few O +
feeding O +
vessels O +
. O +

Histologic O +
evaluation O +
revealed O +
that O +
although O +
tumors O +
overexpressing O +
TIMP O +
- O +
3 O +
had O +
an O +
increased O +
number O +
of O +
CD31 O +
( O +
+ O +
) O +
endothelial O +
cells O +
, O +
these O +
endothelial O +
cells O +
had O +
not O +
formed O +
functional O +
tubules O +
, O +
as O +
evidenced O +
by O +
decreased O +
vessel O +
continuity O +
and O +
minimal O +
pericyte O +
recruitment O +
. O +

This O +
effect O +
appears O +
to O +
be O +
mediated O +
, O +
in O +
part O +
, O +
by O +
decreased O +
expression O +
of O +
vascular O +
endothelial O +
( O +
VE O +
) O +
- O +
cadherin O +
by O +
endothelial O +
cells O +
in O +
the O +
presence O +
of O +
TIMP O +
- O +
3 O +
as O +
seen O +
both O +
in O +
an O +
in O +
vitro O +
assay O +
and O +
in O +
TIMP O +
- O +
3 O +
- O +
overexpressing O +
tumors O +
. O +

Taken O +
together O +
, O +
these O +
results O +
demonstrate O +
that O +
overexpression O +
of O +
TIMP O +
- O +
3 O +
can O +
inhibit O +
angiogenesis O +
and O +
associated O +
tumor O +
growth O +
, O +
and O +
that O +
the O +
antiangiogenic O +
effects O +
of O +
TIMP O +
- O +
3 O +
appear O +
to O +
be O +
mediated O +
through O +
the O +
inhibition O +
of O +
functional O +
capillary O +
morphogenesis O +
. O +

Fibroblast O +
growth O +
factor O +
2 O +
promotes O +
microvessel O +
formation O +
from O +
mouse O +
embryonic O +
aorta O +
. O +

To O +
delineate O +
the O +
roles O +
that O +
oxygen O +
and O +
fibroblast O +
growth O +
factors O +
( O +
FGFs O +
) O +
play O +
in O +
the O +
process O +
of O +
angiogenesis O +
from O +
the O +
embryonic O +
aorta O +
, O +
we O +
cultured O +
mouse O +
embryonic O +
aorta O +
explants O +
( O +
thoracic O +
level O +
to O +
lateral O +
vessels O +
supplying O +
the O +
mesonephros O +
and O +
metanephros O +
) O +
in O +
a O +
three O +
- O +
dimensional O +
type O +
I O +
collagen O +
gel O +
matrix O +
. O +

During O +
8 O +
days O +
of O +
culture O +
under O +
5 O +
% O +
O O +
( O +
2 O +
) O +
, O +
but O +
not O +
room O +
air O +
, O +
the O +
addition O +
of O +
FGF2 O +
to O +
explants O +
stimulated O +
the O +
formation O +
of O +
Gs O +
- O +
IB O +
( O +
4 O +
- O +
) O +
positive O +
, O +
CD31 O +
- O +
positive O +
, O +
and O +
Flk O +
- O +
1 O +
- O +
positive O +
microvessels O +
in O +
a O +
concentration O +
- O +
dependent O +
manner O +
. O +

FGF2 O +
- O +
stimulated O +
microvessel O +
formation O +
was O +
inhibited O +
by O +
sequestration O +
of O +
FGF2 O +
via O +
addition O +
of O +
soluble O +
FGF O +
receptor O +
( O +
FGFR O +
) O +
chimera O +
protein O +
or O +
anti O +
- O +
FGF2 O +
antibodies O +
. O +

FGFR1 O +
and O +
FGFR2 O +
were O +
present O +
on O +
explants O +
. O +

Levels O +
of O +
FGFR1 O +
, O +
but O +
not O +
FGFR2 O +
, O +
were O +
increased O +
in O +
embryonic O +
aorta O +
cultured O +
under O +
5 O +
% O +
O O +
( O +
2 O +
) O +
relative O +
to O +
room O +
air O +
. O +

Our O +
data O +
suggest O +
that O +
low O +
oxygen O +
upregulates O +
FGFR1 O +
expression O +
in O +
embryonic O +
aorta O +
in O +
vitro O +
and O +
renders O +
it O +
more O +
responsive O +
to O +
FGF2 O +
. O +

Brn O +
- O +
3a O +
, O +
a O +
neuronal O +
transcription O +
factor O +
of O +
the O +
POU O +
gene O +
family O +
: O +
indications O +
for O +
its O +
involvement O +
in O +
cancer O +
and O +
angiogenesis O +
. O +

Brn O +
- O +
3a O +
, O +
a O +
member O +
of O +
the O +
POU O +
gene O +
family O +
( O +
so O +
- O +
called O +
because O +
of O +
the O +
similarity O +
with O +
the O +
group O +
of O +
transcription O +
factors O +
Pit O +
, O +
Oct O +
, O +
and O +
Unc O +
) O +
, O +
was O +
found O +
in O +
neuronal O +
cells O +
engaged O +
in O +
the O +
transcription O +
activity O +
of O +
the O +
p1 O +
and O +
p2 O +
promoters O +
of O +
the O +
most O +
powerful O +
antiapoptotic O +
gene O +
, O +
namely O +
, O +
Bcl O +
- O +
2 O +
. O +

The O +
alternative O +
splicing O +
of O +
Brn O +
- O +
3a O +
mRNA O +
produces O +
two O +
molecular O +
forms O +
: O +
a O +
longer O +
, O +
Bcl O +
- O +
2 O +
transactivating O +
form O +
, O +
and O +
a O +
shorter O +
inactive O +
form O +
, O +
lacking O +
84 O +
AA O +
in O +
the O +
aminoterminus O +
. O +

In O +
neuronal O +
cells O +
, O +
following O +
Brn O +
- O +
3a O +
gene O +
transfection O +
and O +
superexpression O +
, O +
an O +
increase O +
of O +
30 O +
fold O +
of O +
the O +
Bcl O +
- O +
2 O +
protein O +
occurs O +
, O +
leading O +
to O +
apoptosis O +
protection O +
. O +

However O +
, O +
recent O +
works O +
demonstrate O +
that O +
Brn O +
- O +
3a O +
expression O +
is O +
not O +
restricted O +
to O +
neuronal O +
cells O +
, O +
as O +
its O +
activity O +
was O +
detected O +
also O +
in O +
cancer O +
cells O +
of O +
non O +
- O +
neuronal O +
nature O +
. O +

Looking O +
for O +
mechanisms O +
linking O +
Brn O +
- O +
3a O +
to O +
carcinogenesis O +
, O +
we O +
discuss O +
the O +
role O +
of O +
this O +
transcription O +
factor O +
in O +
influencing O +
Bcl O +
- O +
2 O +
/ O +
p53 O +
antagonism O +
and O +
Bcl O +
- O +
2 O +
/ O +
VEGF O +
induction O +
of O +
tumor O +
angiogenesis O +
, O +
concluding O +
this O +
review O +
with O +
a O +
proposal O +
for O +
the O +
oncogenic O +
nature O +
of O +
Brn O +
- O +
3a O +
. O +

Roles O +
of O +
cell O +
adhesion O +
molecules O +
in O +
tumor O +
angiogenesis O +
induced O +
by O +
cotransplantation O +
of O +
cancer O +
and O +
endothelial O +
cells O +
to O +
nude O +
rats O +
. O +

Roles O +
of O +
cell O +
adhesion O +
molecules O +
mediating O +
the O +
interaction O +
of O +
cancer O +
and O +
endothelial O +
cells O +
in O +
tumor O +
angiogenesis O +
were O +
investigated O +
using O +
new O +
in O +
vitro O +
and O +
in O +
vivo O +
model O +
systems O +
with O +
a O +
cultured O +
murine O +
endothelial O +
cell O +
line O +
( O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
) O +
and O +
human O +
cultured O +
epidermoid O +
cancer O +
cells O +
( O +
A431 B-CellLine +
) O +
. O +

The O +
A431 B-CellLine +
cells O +
exhibited O +
typical O +
in O +
vitro O +
cell O +
adhesion O +
to O +
the O +
endothelial O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
. O +

The O +
initial O +
step O +
of O +
adhesion O +
was O +
mediated O +
by O +
sialyl O +
Lewis O +
( O +
x O +
) O +
( O +
Le O +
( O +
x O +
) O +
) O +
and O +
sialyl O +
Le O +
( O +
a O +
) O +
, O +
the O +
carbohydrate O +
determinants O +
expressed O +
on O +
the O +
cancer O +
cells O +
, O +
and O +
E O +
- O +
selectin O +
expressed O +
constitutively O +
on O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
. O +

Prolonged O +
culture O +
led O +
to O +
the O +
implantation O +
of O +
cancer O +
cells O +
into O +
the O +
monolayer O +
of O +
the O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
, O +
which O +
was O +
mediated O +
mainly O +
by O +
alpha O +
( O +
3 O +
) O +
beta O +
( O +
1 O +
) O +
- O +
integrin O +
. O +

F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
cultured O +
on O +
Matrigel O +
showed O +
evident O +
tube O +
formation O +
, O +
and O +
coculture O +
of O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
with O +
A431 B-CellLine +
cells O +
led O +
to O +
the O +
formation O +
of O +
A431 B-CellLine +
cell O +
nests O +
constantly O +
surrounded O +
by O +
tube O +
- O +
like O +
networks O +
consisting O +
of O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
. O +

This O +
in O +
vitro O +
morphogenesis O +
was O +
inhibited O +
by O +
the O +
addition O +
of O +
anti O +
- O +
sialyl O +
Le O +
( O +
x O +
) O +
/ O +
Le O +
( O +
a O +
) O +
or O +
anti O +
- O +
beta O +
( O +
1 O +
) O +
- O +
integrin O +
antibodies O +
, O +
which O +
led O +
to O +
the O +
formation O +
of O +
cancer O +
cell O +
aggregates O +
that O +
were O +
independent O +
from O +
the O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cell O +
networks O +
. O +

This O +
in O +
vitro O +
morphological O +
appearance O +
was O +
exactly O +
reproduced O +
in O +
the O +
in O +
vivo O +
tumors O +
, O +
which O +
were O +
formed O +
when O +
the O +
mixture O +
of O +
A431 B-CellLine +
and O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
at O +
the O +
ratio O +
of O +
10 O +
: O +
1 O +
were O +
cotransplanted O +
s O +
. O +
c O +
. O +
into O +
the O +
back O +
of O +
nude O +
rats O +
. O +

The O +
tumors O +
of O +
A431 B-CellLine +
supplemented O +
with O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
were O +
profoundly O +
vascularized O +
throughout O +
by O +
the O +
tubular O +
structures O +
formed O +
by O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
, O +
the O +
lumen O +
of O +
which O +
contained O +
the O +
host O +
rat O +
blood O +
cells O +
. O +

The O +
tumor O +
mass O +
thus O +
formed O +
was O +
an O +
average O +
5 O +
. O +
8 O +
- O +
fold O +
as O +
large O +
as O +
control O +
A431 B-CellLine +
tumors O +
that O +
were O +
grown O +
without O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
. O +

The O +
co O +
- O +
injection O +
of O +
anti O +
- O +
Le O +
( O +
x O +
) O +
/ O +
Le O +
( O +
a O +
) O +
or O +
anti O +
- O +
beta O +
( O +
1 O +
) O +
- O +
integrin O +
antibodies O +
produced O +
a O +
marked O +
reduction O +
in O +
the O +
size O +
of O +
A431 B-CellLine +
tumors O +
, O +
which O +
were O +
not O +
vascularized O +
and O +
accompanied O +
an O +
independent O +
tiny O +
remnant O +
clump O +
of O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
. O +

The O +
size O +
of O +
these O +
A431 B-CellLine +
tumors O +
did O +
not O +
differ O +
significantly O +
from O +
those O +
of O +
control O +
A431 B-CellLine +
tumors O +
raised O +
without O +
F B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
. O +

These O +
results O +
indicate O +
that O +
the O +
interaction O +
of O +
tumor O +
cells O +
and O +
endothelial O +
cells O +
in O +
orderly O +
tumor O +
angiomorphogenesis O +
is O +
highly O +
dependent O +
on O +
the O +
action O +
of O +
cell O +
adhesion O +
molecules O +
mediating O +
the O +
adhesion O +
of O +
cancer O +
cells O +
to O +
endothelial O +
cells O +
, O +
inhibition O +
of O +
which O +
remarkably O +
retards O +
tumor O +
growth O +
and O +
angiogenesis O +
. O +

Identification O +
of O +
Dss1 O +
as O +
a O +
12 O +
- O +
O O +
- O +
tetradecanoylphorbol O +
- O +
13 O +
- O +
acetate O +
- O +
responsive O +
gene O +
expressed O +
in O +
keratinocyte O +
progenitor O +
cells O +
, O +
with O +
possible O +
involvement O +
in O +
early O +
skin O +
tumorigenesis O +
. O +

This O +
study O +
identifies O +
genes O +
expressed O +
early O +
in O +
12 O +
- O +
O O +
- O +
tetradecanoylphorbol O +
- O +
13 O +
- O +
acetate O +
( O +
TPA O +
) O +
- O +
induced O +
skin O +
carcinogenesis O +
in O +
genetically O +
initiated O +
Tg O +
. O +
AC O +
v O +
- O +
Ha O +
- O +
ras O +
transgenic O +
mice O +
. O +

Keratinocyte O +
progenitor O +
cells O +
from O +
TPA O +
- O +
treated O +
Tg O +
. O +
AC O +
mice O +
were O +
isolated O +
with O +
fluorescence O +
- O +
activated O +
cell O +
sorting O +
and O +
expression O +
was O +
analyzed O +
using O +
cDNA O +
microarray O +
technology O +
. O +

Eleven O +
genes O +
were O +
identified O +
whose O +
expression O +
changed O +
significantly O +
in O +
response O +
to O +
carcinogen O +
treatment O +
. O +

Deleted O +
in O +
split O +
hand O +
/ O +
split O +
foot O +
1 O +
( O +
Dss1 O +
) O +
is O +
a O +
gene O +
associated O +
with O +
a O +
heterogeneous O +
limb O +
developmental O +
disorder O +
called O +
split O +
hand O +
/ O +
split O +
foot O +
malformation O +
. O +

cDNA O +
microarray O +
expression O +
analysis O +
showed O +
that O +
the O +
mouse O +
homologue O +
of O +
Dss1 O +
is O +
induced O +
by O +
TPA O +
. O +

Dss1 O +
overexpression O +
was O +
detected O +
by O +
Northern O +
blot O +
analysis O +
in O +
early O +
TPA O +
- O +
treated O +
hyperplastic O +
skins O +
and O +
in O +
JB6 O +
Cl O +
41 O +
- O +
5a O +
epidermal O +
cells O +
. O +

Interestingly O +
, O +
Dss1 O +
expression O +
was O +
also O +
shown O +
to O +
be O +
elevated O +
in O +
skin O +
papillomas O +
relative O +
to O +
normal O +
skins O +
, O +
and O +
further O +
increased O +
in O +
squamous O +
cell O +
malignancies O +
. O +

Functional O +
studies O +
by O +
ectopically O +
constitutive O +
expression O +
of O +
Dss1 O +
in O +
JB6 O +
Cl O +
41 O +
- O +
5a O +
preneoplastic O +
cells O +
strongly O +
increased O +
focus O +
formation O +
and O +
proliferation O +
of O +
these O +
cells O +
and O +
enhanced O +
efficiency O +
of O +
neoplastic O +
transformation O +
of O +
the O +
cells O +
in O +
soft O +
agar O +
. O +

These O +
results O +
strongly O +
suggest O +
that O +
Dss1 O +
is O +
a O +
TPA O +
- O +
inducible O +
gene O +
that O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
early O +
stages O +
of O +
skin O +
carcinogenesis O +
. O +

Downregulation O +
of O +
c O +
- O +
FLIP O +
sensitizes O +
DU145 B-CellLine +
prostate O +
cancer O +
cells O +
to O +
Fas O +
- O +
mediated O +
apoptosis O +
. O +

Although O +
DU145 B-CellLine +
prostate O +
cancer O +
cells O +
are O +
resistant O +
to O +
exogenously O +
applied O +
Fas O +
agonist O +
CH O +
- O +
11 O +
( O +
anti O +
- O +
Fas O +
monoclonal O +
antibody O +
) O +
, O +
Fas O +
- O +
resistance O +
can O +
be O +
overcome O +
using O +
a O +
FasL O +
expressing O +
adenovirus O +
( O +
AdGFPFasL O +
( O +
TET O +
) O +
) O +
[ O +
Hyer O +
et O +
al O +
. O +
, O +
Molecular O +
Therapy O +
, O +
2000 O +
; O +
2 O +
: O +
348 O +
- O +
58 O +
( O +
ref O +
. O +
12 O +
) O +
] O +
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
try O +
to O +
understand O +
why O +
DU145 B-CellLine +
cells O +
are O +
resistant O +
to O +
CH O +
- O +
11 O +
and O +
determine O +
the O +
signaling O +
pathway O +
utilized O +
by O +
AdGFPFasL O +
( O +
TET O +
) O +
to O +
induce O +
apoptosis O +
in O +
these O +
Fas O +
- O +
resistant O +
cells O +
. O +

Using O +
immunoblot O +
analysis O +
, O +
we O +
show O +
that O +
AdGFPFasL O +
( O +
TET O +
) O +
is O +
capable O +
of O +
initiating O +
the O +
classic O +
Fas O +
- O +
mediated O +
apoptotic O +
pathway O +
in O +
DU145 B-CellLine +
cells O +
, O +
which O +
includes O +
activation O +
of O +
caspases O +
- O +
8 O +
, O +
- O +
3 O +
, O +
- O +
7 O +
, O +
and O +
- O +
9 O +
, O +
BID O +
cleavage O +
, O +
cytochrome O +
c O +
release O +
from O +
mitochondria O +
, O +
and O +
PARP O +
cleavage O +
. O +

In O +
contrast O +
, O +
CH O +
- O +
11 O +
binds O +
to O +
Fas O +
, O +
but O +
is O +
unable O +
to O +
transmit O +
the O +
death O +
signal O +
beyond O +
the O +
plasma O +
membrane O +
suggesting O +
a O +
block O +
at O +
the O +
DISC O +
( O +
death O +
inducing O +
signaling O +
complex O +
) O +
. O +

The O +
anti O +
- O +
apoptotic O +
protein O +
c O +
- O +
FLIP O +
( O +
cellular O +
Flice O +
- O +
like O +
inhibitory O +
protein O +
) O +
, O +
which O +
has O +
been O +
shown O +
to O +
inhibit O +
Fas O +
- O +
mediated O +
apoptosis O +
at O +
the O +
DISC O +
, O +
was O +
down O +
- O +
regulated O +
following O +
AdGFPFasL O +
( O +
TET O +
) O +
treatment O +
prompting O +
us O +
to O +
investigate O +
its O +
role O +
in O +
inhibiting O +
CH O +
- O +
11 O +
- O +
induced O +
cell O +
death O +
. O +

Using O +
c O +
- O +
FLIP O +
anti O +
- O +
sense O +
oligonucleotides O +
to O +
down O +
- O +
regulate O +
c O +
- O +
FLIP O +
we O +
sensitized O +
DU145 B-CellLine +
cells O +
to O +
CH O +
- O +
11 O +
- O +
induced O +
apoptosis O +
. O +

These O +
data O +
suggest O +
that O +
c O +
- O +
FLIP O +
may O +
play O +
a O +
critical O +
role O +
in O +
regulating O +
Fas O +
- O +
mediated O +
apoptosis O +
in O +
prostate O +
cancer O +
cells O +
and O +
that O +
modulation O +
of O +
c O +
- O +
FLIP O +
may O +
enhance O +
Fas O +
signaling O +
based O +
therapies O +
. O +

Topoisomerase O +
I O +
protein O +
expression O +
in O +
primary O +
colorectal O +
cancer O +
and O +
lymph O +
node O +
metastases O +
. O +

Topoisomerase O +
I O +
( O +
topo O +
I O +
) O +
is O +
an O +
important O +
target O +
for O +
the O +
treatment O +
of O +
malignant O +
disease O +
, O +
especially O +
colorectal O +
cancer O +
. O +

Because O +
there O +
is O +
little O +
information O +
on O +
the O +
expression O +
of O +
topo O +
I O +
in O +
colorectal O +
tumors O +
, O +
this O +
study O +
evaluated O +
and O +
characterized O +
topo O +
I O +
protein O +
expression O +
in O +
primary O +
colorectal O +
cancer O +
and O +
lymph O +
node O +
metastases O +
and O +
studied O +
the O +
association O +
between O +
topo O +
I O +
protein O +
expression O +
and O +
clinicopathologic O +
data O +
, O +
p53 O +
status O +
, O +
and O +
proliferating O +
cell O +
nuclear O +
antigen O +
( O +
PCNA O +
) O +
status O +
. O +

Immunohistochemistry O +
assay O +
was O +
performed O +
for O +
topo O +
I O +
protein O +
expression O +
in O +
249 O +
primary O +
human O +
colorectal O +
cancer O +
and O +
42 O +
paired O +
lymph O +
node O +
metastasis O +
samples O +
. O +

Topo O +
I O +
expression O +
was O +
described O +
as O +
the O +
percentage O +
of O +
cells O +
staining O +
positive O +
for O +
topo O +
I O +
, O +
along O +
with O +
the O +
intensity O +
and O +
localization O +
of O +
the O +
staining O +
. O +

Clinicopathologic O +
data O +
( O +
sex O +
, O +
age O +
, O +
Dukes O +
' O +
stage O +
, O +
differentiation O +
grade O +
, O +
survival O +
status O +
) O +
, O +
p53 O +
status O +
, O +
and O +
PCNA O +
status O +
were O +
statistically O +
analyzed O +
for O +
association O +
with O +
topo O +
I O +
protein O +
expression O +
. O +

Topo O +
I O +
expression O +
in O +
paired O +
primary O +
lymph O +
node O +
metastases O +
were O +
studied O +
for O +
concordance O +
. O +

Topo O +
I O +
protein O +
expression O +
was O +
detected O +
in O +
127 O +
( O +
51 O +
% O +
) O +
samples O +
, O +
including O +
24 O +
. O +
4 O +
% O +
with O +
> O +
50 O +
% O +
positive O +
tumor O +
cells O +
. O +

The O +
majority O +
had O +
nuclear O +
( O +
70 O +
. O +
1 O +
% O +
) O +
or O +
nuclear O +
and O +
cytoplasmic O +
staining O +
( O +
17 O +
. O +
3 O +
% O +
) O +
. O +

A O +
higher O +
percentage O +
of O +
cells O +
expressing O +
topo O +
I O +
in O +
primary O +
colorectal O +
cancer O +
was O +
significantly O +
associated O +
with O +
advanced O +
age O +
( O +
P O +
= O +
. O +
040 O +
) O +
. O +

Patients O +
with O +
rectal O +
cancer O +
had O +
greater O +
topo O +
I O +
expression O +
than O +
those O +
with O +
colon O +
tumors O +
( O +
P O +
= O +
. O +
029 O +
) O +
. O +

No O +
significant O +
correlation O +
was O +
found O +
between O +
topo O +
I O +
protein O +
expression O +
and O +
sex O +
, O +
Dukes O +
' O +
stage O +
, O +
differentiation O +
grade O +
, O +
survival O +
status O +
, O +
p53 O +
status O +
, O +
and O +
PCNA O +
status O +
. O +

Concordance O +
in O +
topo O +
I O +
staining O +
between O +
primary O +
and O +
lymph O +
node O +
metastases O +
was O +
observed O +
in O +
33 O +
of O +
42 O +
cases O +
( O +
P O +
= O +
. O +
029 O +
) O +
. O +

This O +
suggests O +
that O +
the O +
activity O +
of O +
topo O +
I O +
inhibitors O +
will O +
not O +
differ O +
across O +
various O +
tumor O +
stages O +
, O +
pathology O +
, O +
and O +
patient O +
gender O +
. O +

p53 O +
and O +
PCNA O +
status O +
do O +
not O +
appear O +
to O +
influence O +
topo O +
I O +
expression O +
, O +
and O +
topo O +
I O +
has O +
no O +
apparent O +
association O +
with O +
the O +
acquisition O +
of O +
a O +
metastatic O +
phenotype O +
. O +

Topo O +
I O +
expression O +
now O +
needs O +
to O +
be O +
evaluated O +
in O +
patients O +
undergoing O +
topo O +
I O +
- O +
inhibitor O +
therapy O +
, O +
to O +
better O +
define O +
the O +
role O +
of O +
this O +
protein O +
as O +
a O +
predictive O +
marker O +
. O +

Adaptor O +
protein O +
Crk O +
is O +
required O +
for O +
ephrin O +
- O +
B1 O +
- O +
induced O +
membrane O +
ruffling O +
and O +
focal O +
complex O +
assembly O +
of O +
human O +
aortic O +
endothelial O +
cells O +
. O +

Endothelial O +
cell O +
migration O +
is O +
an O +
essential O +
step O +
in O +
vasculogenesis O +
and O +
angiogenesis O +
, O +
in O +
which O +
receptor O +
tyrosine O +
kinases O +
play O +
a O +
pivotal O +
role O +
. O +

We O +
investigated O +
the O +
mechanism O +
by O +
which O +
ephrin O +
- O +
B1 O +
promotes O +
membrane O +
ruffling O +
in O +
human O +
aortic O +
endothelial O +
cells O +
, O +
because O +
membrane O +
ruffling O +
heralds O +
cell O +
body O +
migration O +
. O +

We O +
especially O +
focused O +
on O +
the O +
role O +
of O +
Crk O +
adaptor O +
protein O +
in O +
EphB O +
- O +
mediated O +
signaling O +
. O +

Using O +
DsRed O +
- O +
tagged O +
Crk O +
and O +
a O +
fluorescent O +
time O +
- O +
lapse O +
microscope O +
, O +
we O +
showed O +
that O +
Crk O +
was O +
recruited O +
to O +
the O +
nascent O +
focal O +
complex O +
after O +
ephrin O +
- O +
B1 O +
stimulation O +
. O +

Furthermore O +
, O +
we O +
found O +
that O +
p130 O +
( O +
Cas O +
) O +
, O +
but O +
not O +
paxillin O +
, O +
recruited O +
Crk O +
to O +
the O +
nascent O +
focal O +
complex O +
. O +

The O +
necessity O +
of O +
Crk O +
in O +
ephrin O +
- O +
B1 O +
- O +
induced O +
membrane O +
ruffling O +
was O +
shown O +
both O +
by O +
the O +
overexpression O +
of O +
dominant O +
negative O +
Crk O +
mutants O +
and O +
by O +
the O +
depletion O +
of O +
Crk O +
by O +
using O +
RNA O +
interference O +
. O +

Then O +
, O +
we O +
examined O +
the O +
role O +
of O +
two O +
major O +
downstream O +
molecules O +
of O +
Crk O +
, O +
Rac1 O +
and O +
Rap1 O +
. O +

The O +
dominant O +
negative O +
mutant O +
of O +
Rac1 O +
completely O +
inhibited O +
ephrin O +
- O +
B1 O +
- O +
induced O +
membrane O +
ruffling O +
and O +
focal O +
complex O +
assembly O +
. O +

In O +
contrast O +
, O +
rap1GAPII O +
, O +
a O +
negative O +
regulator O +
of O +
Rap1 O +
, O +
did O +
not O +
inhibit O +
ephrin O +
- O +
B1 O +
- O +
induced O +
membrane O +
ruffling O +
. O +

However O +
, O +
in O +
rap1GAPII O +
- O +
expressing O +
cells O +
, O +
ephrin O +
- O +
B1 O +
did O +
not O +
induce O +
membrane O +
spreading O +
, O +
probably O +
due O +
to O +
instability O +
of O +
the O +
focal O +
complex O +
. O +

These O +
results O +
indicated O +
that O +
Crk O +
plays O +
a O +
critical O +
role O +
in O +
Rac1 O +
- O +
induced O +
membrane O +
ruffling O +
and O +
Rap1 O +
- O +
mediated O +
nascent O +
focal O +
complex O +
stabilization O +
contributing O +
to O +
ephrin O +
- O +
B1 O +
- O +
induced O +
human O +
aortic O +
endothelial O +
cells O +
migration O +
. O +

CXC O +
chemokine O +
receptors O +
in O +
the O +
central O +
nervous O +
system O +
: O +
Role O +
in O +
cerebellar O +
neuromodulation O +
and O +
development O +
. O +

Chemokines O +
and O +
their O +
receptors O +
are O +
constitutively O +
present O +
in O +
the O +
central O +
nervous O +
system O +
( O +
CNS O +
) O +
, O +
expressed O +
in O +
neurons O +
and O +
glial O +
cells O +
. O +

Much O +
evidence O +
suggests O +
that O +
, O +
beyond O +
their O +
involvement O +
in O +
neuroinflammation O +
, O +
these O +
proteins O +
play O +
a O +
role O +
in O +
neurodevelopment O +
and O +
neurophysiological O +
signaling O +
. O +

The O +
goal O +
of O +
this O +
review O +
is O +
to O +
summarize O +
recent O +
information O +
concerning O +
expression O +
, O +
signaling O +
, O +
and O +
function O +
of O +
CXC O +
chemokine O +
receptor O +
in O +
the O +
CNS O +
, O +
with O +
the O +
main O +
focus O +
on O +
the O +
developmental O +
and O +
neuromodulatory O +
actions O +
of O +
chemokines O +
in O +
the O +
cerebellum O +
. O +

Combined O +
tracheal O +
and O +
esophageal O +
stenting O +
for O +
palliation O +
of O +
tracheoesophageal O +
symptoms O +
from O +
mediastinal O +
lymphoma O +
. O +

Mediastinal O +
lymphoma O +
as O +
a O +
cause O +
of O +
tracheobronchial O +
obstruction O +
is O +
uncommon O +
, O +
and O +
a O +
malignant O +
tracheoesophageal O +
fistula O +
in O +
the O +
setting O +
of O +
mediastinal O +
lymphoma O +
is O +
rare O +
. O +

Malignant O +
tracheoesophageal O +
fistulas O +
are O +
associated O +
with O +
pronounced O +
morbidity O +
and O +
mortality O +
. O +

We O +
describe O +
a O +
patient O +
with O +
mediastinal O +
lymphomatous O +
infiltration O +
resulting O +
in O +
tracheal O +
obstruction O +
, O +
esophageal O +
obstruction O +
, O +
and O +
tracheoesophageal O +
fistula O +
that O +
were O +
successfully O +
palliated O +
with O +
combined O +
airway O +
and O +
esophageal O +
stent O +
placement O +
. O +

Regulation O +
of O +
transforming O +
growth O +
factor O +
- O +
beta O +
signaling O +
and O +
vascular O +
diseases O +
. O +

PURPOSE O +
: O +
Members O +
of O +
the O +
transforming O +
growth O +
factor O +
( O +
TGF O +
) O +
- O +
beta O +
superfamily O +
play O +
critical O +
roles O +
in O +
regulation O +
of O +
various O +
cellular O +
functions O +
. O +

Dysregulation O +
of O +
the O +
signaling O +
mechanisms O +
of O +
the O +
TGF O +
- O +
beta O +
superfamily O +
proteins O +
is O +
associated O +
with O +
clinical O +
diseases O +
such O +
as O +
cancer O +
, O +
fibrotic O +
diseases O +
, O +
and O +
vascular O +
disorders O +
. O +

Therefore O +
, O +
understanding O +
these O +
signaling O +
mechanisms O +
may O +
provide O +
us O +
with O +
novel O +
ways O +
to O +
develop O +
strategies O +
for O +
treating O +
clinical O +
diseases O +
induced O +
by O +
these O +
cytokines O +
. O +

METHODS O +
: O +
This O +
review O +
discusses O +
our O +
current O +
understanding O +
of O +
the O +
mechanisms O +
of O +
TGF O +
- O +
beta O +
signaling O +
, O +
focusing O +
on O +
the O +
roles O +
of O +
TGF O +
- O +
beta O +
in O +
regulation O +
of O +
vascular O +
wall O +
cells O +
and O +
on O +
the O +
regulation O +
of O +
TGF O +
- O +
beta O +
superfamily O +
signals O +
by O +
inhibitory O +
Smads O +
. O +

[ O +
Expression O +
and O +
mutation O +
of O +
c O +
- O +
kit O +
gene O +
in O +
gastrointestinal O +
stromal O +
tumor O +
] O +
. O +

OBJECTIVE O +
: O +
To O +
investigate O +
the O +
effect O +
of O +
the O +
expression O +
and O +
mutation O +
of O +
c O +
- O +
kit O +
gene O +
and O +
its O +
relationship O +
with O +
clinical O +
pathology O +
and O +
prognosis O +
of O +
gastrointestinal O +
stromal O +
tumor O +
( O +
GIST O +
) O +
. O +

METHODS O +
: O +
Immunohistochemical O +
and O +
PCR O +
- O +
SSCP O +
techniques O +
were O +
used O +
to O +
detect O +
c O +
- O +
kit O +
protein O +
expression O +
and O +
c O +
- O +
kit O +
gene O +
exon O +
11 O +
mutation O +
in O +
82 O +
patients O +
with O +
GIST O +
. O +

RESULTS O +
: O +
The O +
positive O +
c O +
- O +
kit O +
protein O +
expression O +
and O +
c O +
- O +
kit O +
gene O +
mutation O +
rates O +
were O +
97 O +
. O +
6 O +
% O +
( O +
80 O +
/ O +
82 O +
) O +
and O +
41 O +
. O +
5 O +
% O +
( O +
34 O +
/ O +
82 O +
) O +
. O +

Correlating O +
the O +
results O +
of O +
these O +
two O +
methods O +
and O +
clinicopathological O +
factors O +
, O +
the O +
c O +
- O +
kit O +
expression O +
and O +
c O +
- O +
kit O +
gene O +
mutation O +
rates O +
were O +
95 O +
. O +
0 O +
% O +
( O +
19 O +
/ O +
20 O +
) O +
and O +
0 O +
in O +
benign O +
GIST O +
, O +
and O +
were O +
98 O +
. O +
4 O +
% O +
( O +
61 O +
/ O +
62 O +
) O +
, O +
54 O +
. O +
8 O +
% O +
( O +
34 O +
/ O +
62 O +
) O +
in O +
malignant O +
GIST O +
. O +

Mutation O +
positive O +
GIST O +
showed O +
higher O +
frequency O +
of O +
adjacent O +
tissue O +
invasion O +
, O +
metastasis O +
and O +
recurrence O +
as O +
compared O +
with O +
mutation O +
negative O +
ones O +
. O +

CONCLUSION O +
: O +
c O +
- O +
kit O +
protein O +
is O +
an O +
important O +
diagnostic O +
marker O +
of O +
gastrointestinal O +
stromal O +
tumor O +
. O +

c O +
- O +
kit O +
gene O +
mutation O +
may O +
play O +
a O +
significant O +
role O +
in O +
the O +
pathogenesis O +
of O +
GIST O +
and O +
also O +
may O +
be O +
a O +
prognostic O +
marker O +
. O +

Insulin O +
- O +
like O +
growth O +
factor O +
- O +
I O +
receptor O +
- O +
mediated O +
vasculogenesis O +
/ O +
angiogenesis O +
in O +
human O +
lung O +
development O +
. O +

The O +
structural O +
and O +
functional O +
development O +
of O +
the O +
pulmonary O +
system O +
is O +
dependent O +
upon O +
appropriate O +
early O +
vascularization O +
of O +
the O +
embryonic O +
lung O +
. O +

Our O +
previous O +
in O +
vitro O +
studies O +
in O +
a O +
rat O +
model O +
indicated O +
that O +
insulin O +
- O +
like O +
growth O +
factor O +
- O +
I O +
( O +
IGF O +
- O +
I O +
) O +
is O +
a O +
potent O +
angiogenic O +
agent O +
for O +
fetal O +
lung O +
endothelial O +
cells O +
. O +

To O +
assess O +
its O +
role O +
on O +
human O +
vascular O +
lung O +
development O +
, O +
we O +
first O +
examined O +
the O +
expression O +
of O +
IGF O +
- O +
I O +
/ O +
II O +
and O +
IGF O +
receptor O +
type O +
I O +
( O +
IGF O +
- O +
IR O +
) O +
in O +
human O +
embryonic O +
and O +
fetal O +
lung O +
tissues O +
at O +
4 O +
- O +
12 O +
wk O +
of O +
gestation O +
. O +

Immunohistochemical O +
and O +
in O +
situ O +
hybridization O +
studies O +
revealed O +
the O +
presence O +
of O +
IGF O +
- O +
I O +
/ O +
II O +
- O +
IGF O +
- O +
IR O +
ligands O +
and O +
mRNA O +
transcripts O +
in O +
embryonic O +
lungs O +
as O +
early O +
as O +
4 O +
wk O +
gestation O +
. O +

Immunotargeting O +
using O +
an O +
anti O +
- O +
IGF O +
- O +
IR O +
neutralizing O +
antibody O +
on O +
human O +
fetal O +
lung O +
explants O +
demonstrated O +
a O +
significant O +
blockade O +
of O +
IGF O +
- O +
IR O +
signaling O +
. O +

Inactivation O +
of O +
IGF O +
- O +
IR O +
resulted O +
in O +
a O +
loss O +
of O +
endothelial O +
cells O +
, O +
accompanied O +
by O +
dramatic O +
changes O +
in O +
fetal O +
lung O +
explant O +
morphology O +
. O +

Terminal O +
transferase O +
dUTP O +
end O +
- O +
labeling O +
assay O +
and O +
TEM O +
studies O +
of O +
anti O +
- O +
IGF O +
- O +
IR O +
- O +
treated O +
lungs O +
demonstrated O +
numerous O +
apoptotic O +
mesenchymal O +
cells O +
. O +

Rat O +
embryonic O +
lung O +
explant O +
studies O +
further O +
validated O +
the O +
importance O +
of O +
the O +
IGF O +
- O +
IGF O +
- O +
IR O +
system O +
for O +
lung O +
vascular O +
development O +
. O +

These O +
data O +
provide O +
the O +
first O +
demonstration O +
of O +
IGF O +
- O +
I O +
/ O +
II O +
expression O +
in O +
the O +
human O +
lung O +
in O +
early O +
gestation O +
and O +
indicate O +
that O +
the O +
IGF O +
family O +
of O +
growth O +
factors O +
, O +
acting O +
through O +
the O +
IGF O +
- O +
IR O +
, O +
is O +
required O +
as O +
a O +
survival O +
factor O +
during O +
normal O +
human O +
lung O +
vascularization O +
. O +

Inhibition O +
of O +
glucose O +
metabolism O +
sensitizes O +
tumor O +
cells O +
to O +
death O +
receptor O +
- O +
triggered O +
apoptosis O +
through O +
enhancement O +
of O +
death O +
- O +
inducing O +
signaling O +
complex O +
formation O +
and O +
apical O +
procaspase O +
- O +
8 O +
processing O +
. O +

Tumors O +
display O +
a O +
high O +
rate O +
of O +
glucose O +
uptake O +
and O +
glycolysis O +
. O +

We O +
investigated O +
how O +
inhibition O +
of O +
glucose O +
metabolism O +
could O +
affect O +
death O +
receptor O +
- O +
mediated O +
apoptosis O +
in O +
human O +
tumor O +
cells O +
of O +
diverse O +
origin O +
. O +

We O +
show O +
that O +
both O +
substitution O +
of O +
glucose O +
for O +
pyruvate O +
and O +
treatment O +
with O +
2 O +
- O +
deoxyglucose O +
enhanced O +
apoptosis O +
induced O +
by O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
- O +
alpha O +
, O +
CD95 O +
agonistic O +
antibody O +
, O +
and O +
TNF O +
- O +
related O +
apoptosis O +
- O +
inducing O +
ligand O +
( O +
TRAIL O +
) O +
. O +

Inhibition O +
of O +
glucose O +
metabolism O +
enhanced O +
killing O +
of O +
myeloid O +
leukemia O +
U937 B-CellLine +
, O +
cervical O +
carcinoma O +
HeLa B-CellLine +
, O +
and O +
breast O +
carcinoma O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
cells O +
upon O +
death O +
receptor O +
ligation O +
. O +

Caspase O +
activation O +
, O +
mitochondrial O +
depolarization O +
, O +
and O +
cytochrome O +
c O +
release O +
were O +
increased O +
under O +
these O +
conditions O +
. O +

Glucose O +
deprivation O +
- O +
mediated O +
sensitization O +
to O +
apoptosis O +
was O +
prevented O +
in O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
cells O +
overexpressing O +
BCL O +
- O +
2 O +
. O +

Interestingly O +
, O +
the O +
human O +
B O +
- O +
lymphoblastoid O +
cell O +
line B-CellLine +
SKW6 I-CellLine +
. I-CellLine +
4 I-CellLine +
, O +
a O +
prototype O +
for O +
mitochondria O +
- O +
independent O +
death O +
receptor O +
- O +
induced O +
apoptosis O +
, O +
was O +
also O +
sensitized O +
to O +
anti O +
- O +
CD95 O +
and O +
TRAIL O +
- O +
induced O +
apoptosis O +
under O +
glucose O +
- O +
free O +
conditions O +
. O +

Changes O +
in O +
c O +
- O +
FLIP O +
( O +
L O +
) O +
and O +
cFLIPs O +
levels O +
were O +
observed O +
in O +
some O +
but O +
not O +
all O +
the O +
cell O +
lines O +
studied O +
following O +
glucose O +
deprivation O +
. O +

Glucose O +
deprivation O +
enhanced O +
death O +
receptor O +
- O +
triggered O +
formation O +
of O +
death O +
- O +
inducing O +
signaling O +
complex O +
and O +
early O +
processing O +
of O +
procaspase O +
- O +
8 O +
. O +

Altogether O +
, O +
these O +
results O +
suggest O +
that O +
the O +
glycolytic O +
pathway O +
may O +
be O +
an O +
important O +
target O +
for O +
therapeutic O +
intervention O +
to O +
sensitize O +
tumor O +
cells O +
to O +
selectively O +
toxic O +
soluble O +
death O +
ligands O +
or O +
death O +
ligand O +
- O +
expressing O +
cells O +
of O +
the O +
immune O +
system O +
by O +
facilitating O +
the O +
activation O +
of O +
initiator O +
caspase O +
- O +
8 O +
. O +

Enhanced O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
by O +
periodontal O +
pathogens O +
in O +
gingival O +
fibroblasts O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
has O +
recently O +
attracted O +
attention O +
as O +
a O +
potent O +
inducer O +
of O +
vascular O +
permeability O +
and O +
angiogenesis O +
. O +

Aberrant O +
angiogenesis O +
is O +
often O +
associated O +
with O +
lesion O +
formation O +
in O +
chronic O +
periodontitis O +
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
properties O +
of O +
VEGF O +
expression O +
in O +
human O +
gingival O +
fibroblasts O +
( O +
HGF O +
) O +
culture O +
. O +

HGF O +
were O +
stimulated O +
with O +
lipopolysaccharide O +
( O +
LPS O +
) O +
, O +
vesicle O +
( O +
Ve O +
) O +
and O +
outer O +
membrane O +
protein O +
( O +
OMP O +
) O +
from O +
Actinobacillus O +
actinomycetemcomitans O +
and O +
Porphyromonas O +
gingivalis O +
. O +

HGF O +
constitutively O +
produced O +
VEGF O +
and O +
levels O +
were O +
significantly O +
enhanced O +
( O +
P O +
less O +
than O +
0 O +
. O +
01 O +
) O +
by O +
stimulation O +
with O +
Ve O +
and O +
OMP O +
from O +
A O +
. O +
actinomycetemcomitans O +
and O +
P O +
. O +
gingivalis O +
at O +
concentrations O +
of O +
10 O +
microg O +
/ O +
ml O +
or O +
higher O +
. O +

On O +
the O +
other O +
hand O +
, O +
VEGF O +
levels O +
were O +
not O +
increased O +
by O +
LPS O +
stimulation O +
. O +

VEGF O +
mRNA O +
expression O +
was O +
also O +
observed O +
in O +
Ve O +
- O +
and O +
OMP O +
- O +
stimulated O +
HGF O +
. O +

A O +
vascular O +
permeability O +
enhancement O +
( O +
VPE O +
) O +
assay O +
was O +
performed O +
using O +
guinea O +
pigs O +
to O +
ascertain O +
whether O +
supernatant O +
from O +
cultures O +
of O +
Ve O +
- O +
and O +
OMP O +
- O +
stimulated O +
HGF O +
enhance O +
vascular O +
permeability O +
in O +
vivo O +
. O +

Supernatant O +
from O +
cultures O +
of O +
Ve O +
- O +
and O +
OMP O +
- O +
stimulated O +
HGF O +
strongly O +
induced O +
VPE O +
. O +

This O +
was O +
markedly O +
suppressed O +
upon O +
simultaneous O +
injection O +
of O +
anti O +
- O +
VEGF O +
polyclonal O +
antibodies O +
with O +
the O +
supernatant O +
. O +

Heating O +
and O +
protease O +
treatment O +
of O +
the O +
stimulants O +
reduced O +
the O +
VEGF O +
enhancing O +
levels O +
in O +
Ve O +
and O +
OMP O +
in O +
vitro O +
. O +

These O +
results O +
suggest O +
that O +
Ve O +
and O +
OMP O +
may O +
be O +
crucial O +
heat O +
- O +
labile O +
and O +
protease O +
- O +
sensitive O +
components O +
of O +
periodontal O +
pathogens O +
that O +
enhance O +
VEGF O +
expression O +
. O +

In O +
addition O +
, O +
VEGF O +
might O +
be O +
associated O +
with O +
the O +
etiology O +
of O +
periodontitis O +
in O +
its O +
early O +
stages O +
according O +
to O +
neovascularization O +
stimulated O +
by O +
periodontal O +
pathogens O +
causing O +
swelling O +
and O +
edema O +
. O +

Postoperative O +
progression O +
of O +
pulmonary O +
metastasis O +
in O +
osteosarcoma O +
. O +

Early O +
relapse O +
with O +
distant O +
metastasis O +
often O +
is O +
observed O +
in O +
patients O +
with O +
cancer O +
after O +
resection O +
of O +
the O +
primary O +
tumor O +
. O +

It O +
is O +
considered O +
that O +
resection O +
of O +
the O +
primary O +
tumor O +
induces O +
activation O +
of O +
systemic O +
angiogenesis O +
and O +
enhances O +
progression O +
of O +
remote O +
metastasis O +
. O +

The O +
authors O +
show O +
that O +
resection O +
of O +
the O +
primary O +
osteosarcoma O +
tumor O +
enhances O +
progression O +
of O +
pulmonary O +
metastasis O +
in O +
animal O +
osteosarcoma O +
models O +
. O +

Matrigel O +
plug O +
neovascularization O +
assay O +
revealed O +
that O +
systemic O +
angiogenic O +
activity O +
was O +
elevated O +
after O +
primary O +
tumor O +
removal O +
( O +
tumor O +
intact O +
group O +
, O +
1 O +
. O +
61 O +
+ O +
/ O +
- O +
0 O +
. O +
21 O +
g O +
/ O +
dL O +
; O +
tumor O +
removed O +
group O +
, O +
4 O +
. O +
92 O +
+ O +
/ O +
- O +
0 O +
. O +
35 O +
g O +
/ O +
dL O +
) O +
. O +

In O +
addition O +
, O +
serum O +
concentration O +
of O +
the O +
angiogenesis O +
inhibitor O +
, O +
endostatin O +
, O +
decreased O +
significantly O +
after O +
primary O +
tumor O +
removal O +
. O +

Treatment O +
with O +
the O +
antiangiogenic O +
reagent O +
TNP O +
- O +
470 O +
suppressed O +
postoperative O +
progression O +
of O +
pulmonary O +
metastasis O +
. O +

These O +
results O +
indicate O +
the O +
possibility O +
that O +
activation O +
of O +
angiogenic O +
activity O +
after O +
resection O +
of O +
osteosarcoma O +
tumors O +
enhances O +
progression O +
of O +
pulmonary O +
metastasis O +
. O +

The O +
current O +
data O +
also O +
suggest O +
that O +
administration O +
of O +
antiangiogenic O +
reagents O +
can O +
prevent O +
progression O +
of O +
pulmonary O +
metastasis O +
in O +
osteosarcoma O +
postoperatively O +
. O +

Rural O +
/ O +
urban O +
differences O +
in O +
access O +
to O +
and O +
utilization O +
of O +
services O +
among O +
people O +
in O +
Alabama O +
with O +
sickle O +
cell O +
disease O +
. O +

OBJECTIVE O +
: O +

This O +
study O +
examined O +
relationships O +
between O +
socioeconomic O +
factors O +
and O +
the O +
geographic O +
distribution O +
of O +
662 O +
cases O +
of O +
sickle O +
cell O +
disease O +
in O +
Alabama O +
in O +
1999 O +
- O +
2001 O +
. O +

METHODS O +
: O +

Measures O +
of O +
community O +
distress O +
, O +
physical O +
functioning O +
, O +
and O +
medical O +
problems O +
were O +
used O +
in O +
analyzing O +
utilization O +
differences O +
between O +
individuals O +
with O +
sickle O +
cell O +
disease O +
living O +
in O +
urban O +
and O +
rural O +
areas O +
. O +

RESULTS O +
: O +

Utilization O +
of O +
comprehensive O +
sickle O +
cells O +
disease O +
services O +
was O +
lower O +
for O +
individuals O +
with O +
sickle O +
cell O +
disease O +
living O +
in O +
rural O +
areas O +
than O +
for O +
those O +
living O +
in O +
urban O +
areas O +
. O +

Rural O +
clients O +
reported O +
significantly O +
more O +
limitations O +
than O +
urban O +
clients O +
on O +
several O +
measures O +
of O +
physical O +
functioning O +
. O +

The O +
results O +
also O +
suggest O +
that O +
utilization O +
of O +
services O +
was O +
higher O +
for O +
those O +
with O +
more O +
medical O +
problems O +
and O +
those O +
who O +
lived O +
in O +
high O +
distress O +
areas O +
, O +
although O +
these O +
findings O +
did O +
not O +
meet O +
the O +
criterion O +
for O +
statistical O +
significance O +
. O +

CONCLUSIONS O +
: O +

Conclusions O +
based O +
on O +
statistical O +
evidence O +
that O +
geographic O +
location O +
and O +
socioeconomic O +
factors O +
relate O +
to O +
significantly O +
different O +
health O +
care O +
service O +
experience O +
bear O +
important O +
implications O +
for O +
medical O +
and O +
health O +
care O +
support O +
systems O +
, O +
especially O +
on O +
the O +
community O +
level O +
. O +

Arteriogenesis O +
: O +
the O +
development O +
and O +
growth O +
of O +
collateral O +
arteries O +
. O +

In O +
patients O +
with O +
atherosclerotic O +
vascular O +
diseases O +
, O +
collateral O +
vessels O +
bypassing O +
major O +
arterial O +
obstructions O +
have O +
frequently O +
been O +
observed O +
. O +

This O +
may O +
explain O +
why O +
some O +
patients O +
remain O +
without O +
symptoms O +
or O +
signs O +
of O +
ischemia O +
. O +

The O +
term O +
" O +
arteriogenesis O +
" O +
was O +
introduced O +
to O +
differentiate O +
the O +
formation O +
of O +
collateral O +
arteries O +
from O +
angiogenesis O +
, O +
which O +
mainly O +
occurs O +
in O +
the O +
ischemic O +
, O +
collateral O +
flow O +
- O +
dependent O +
tissue O +
. O +

Many O +
observations O +
in O +
various O +
animal O +
models O +
and O +
humans O +
support O +
that O +
the O +
remodeling O +
of O +
preexisting O +
collateral O +
vessels O +
is O +
the O +
mechanism O +
of O +
collateral O +
artery O +
formation O +
. O +

This O +
remodeling O +
process O +
seems O +
to O +
be O +
mainly O +
flow O +
- O +
mediated O +
. O +

It O +
involves O +
endothelial O +
cell O +
activation O +
, O +
basal O +
membrane O +
degradation O +
, O +
leukocyte O +
invasion O +
, O +
proliferation O +
of O +
vascular O +
cells O +
, O +
neointima O +
formation O +
( O +
in O +
most O +
species O +
studied O +
) O +
, O +
and O +
changes O +
of O +
the O +
extracellular O +
matrix O +
. O +

The O +
contribution O +
of O +
ischemia O +
to O +
arteriogenesis O +
is O +
still O +
unclear O +
, O +
but O +
arteriogenesis O +
clearly O +
can O +
occur O +
in O +
the O +
absence O +
of O +
any O +
significant O +
ischemia O +
. O +

It O +
is O +
questionable O +
, O +
whether O +
collateral O +
arteries O +
also O +
form O +
de O +
novo O +
in O +
ischemic O +
vascular O +
diseases O +
. O +

A O +
better O +
understanding O +
of O +
the O +
mechanisms O +
of O +
arteriogenesis O +
will O +
be O +
important O +
for O +
the O +
design O +
of O +
more O +
effective O +
strategies O +
for O +
the O +
treatment O +
of O +
patients O +
with O +
ischemic O +
vascular O +
diseases O +
. O +

NF O +
- O +
kappaB O +
/ O +
Rel O +
transcriptional O +
pathway O +
: O +
implications O +
in O +
pancreatic O +
cancer O +
. O +

Despite O +
considerable O +
efforts O +
in O +
understanding O +
the O +
cellular O +
mechanisms O +
contributing O +
to O +
pancreatic O +
cancer O +
, O +
the O +
prognosis O +
of O +
this O +
malignant O +
disease O +
is O +
still O +
extremely O +
poor O +
. O +

Although O +
pancreatic O +
cancer O +
is O +
the O +
fifth O +
common O +
cause O +
of O +
cancer O +
death O +
in O +
Western O +
countries O +
, O +
current O +
options O +
in O +
treatment O +
enable O +
a O +
5 O +
- O +
yr O +
survival O +
rate O +
for O +
all O +
stages O +
of O +
less O +
than O +
5 O +
% O +
. O +

In O +
the O +
face O +
fo O +
the O +
fatal O +
outcome O +
, O +
new O +
approaches O +
to O +
the O +
therapy O +
have O +
been O +
established O +
. O +

Based O +
on O +
its O +
role O +
in O +
malignant O +
transformation O +
, O +
apoptosis O +
, O +
and O +
cell O +
proliferation O +
, O +
the O +
transcription O +
factor O +
NF O +
- O +
kappaB O +
/ O +
Rel O +
has O +
gained O +
the O +
attention O +
of O +
many O +
laboratories O +
. O +

This O +
review O +
provides O +
basic O +
information O +
for O +
the O +
understanding O +
of O +
the O +
biology O +
of O +
NF O +
- O +
kappaB O +
and O +
aims O +
at O +
presenting O +
experimental O +
data O +
illustrating O +
the O +
involvement O +
of O +
NF O +
- O +
kappaB O +
/ O +
Rel O +
in O +
pancreatic O +
cancer O +
. O +

Sickle O +
cell O +
disease O +
: O +
continuous O +
arterial O +
spin O +
- O +
labeling O +
perfusion O +
MR O +
imaging O +
in O +
children O +
. O +

Cerebral O +
blood O +
flow O +
( O +
CBF O +
) O +
was O +
measured O +
with O +
continuous O +
arterial O +
spin O +
- O +
labeling O +
perfusion O +
magnetic O +
resonance O +
( O +
MR O +
) O +
imaging O +
in O +
14 O +
children O +
with O +
sickle O +
cell O +
disease O +
and O +
seven O +
control O +
subjects O +
. O +

Mean O +
CBF O +
values O +
were O +
higher O +
in O +
patients O +
( O +
P O +
< O +
. O +
005 O +
) O +
than O +
in O +
control O +
subjects O +
in O +
all O +
cerebral O +
artery O +
territories O +
. O +

Three O +
patients O +
had O +
decreased O +
CBF O +
in O +
right O +
anterior O +
and O +
middle O +
cerebral O +
artery O +
territories O +
compared O +
with O +
CBF O +
on O +
the O +
left O +
, O +
and O +
one O +
patient O +
had O +
a O +
profound O +
decrease O +
in O +
CBF O +
in O +
all O +
three O +
territories O +
in O +
the O +
right O +
hemisphere O +
. O +

Baseline O +
CBF O +
was O +
significantly O +
decreased O +
in O +
territories O +
seen O +
as O +
unaffected O +
on O +
conventional O +
MR O +
images O +
and O +
MR O +
angiograms O +
in O +
four O +
children O +
with O +
sickle O +
cell O +
disease O +
. O +

Bee O +
venom O +
induces O +
apoptosis O +
and O +
inhibits O +
expression O +
of O +
cyclooxygenase O +
- O +
2 O +
mRNA O +
in O +
human O +
lung O +
cancer O +
cell O +
line O +
NCI B-CellLine +
- I-CellLine +
H1299 I-CellLine +
. O +

To O +
investigate O +
whether O +
bee O +
venom O +
( O +
BV O +
) O +
induces O +
apoptosis O +
, O +
the O +
3 O +
- O +
( O +
4 O +
, O +
5 O +
- O +
dimethylthiazol O +
- O +
2 O +
- O +
yl O +
) O +
- O +
2 O +
, O +
5 O +
- O +
diphenyltetrazolium O +
bromide O +
assay O +
, O +
terminal O +
deoxynucleotidyl O +
transferase O +
- O +
mediated O +
dUTP O +
nick O +
end O +
- O +
labeling O +
assay O +
, O +
4 O +
, O +
6 O +
- O +
diamidino O +
- O +
2 O +
- O +
phenylindole O +
staining O +
, O +
flow O +
cytometric O +
analysis O +
, O +
and O +
DNA O +
fragmentation O +
assay O +
were O +
performed O +
on O +
NCI B-CellLine +
- I-CellLine +
H1299 I-CellLine +
lung O +
cancer O +
cells O +
treated O +
with O +
BV O +
. O +

Through O +
morphological O +
and O +
biochemical O +
analyses O +
, O +
it O +
was O +
demonstrated O +
that O +
NCI B-CellLine +
- I-CellLine +
H1299 I-CellLine +
cells O +
treated O +
with O +
BV O +
exhibit O +
several O +
features O +
of O +
apoptosis O +
. O +

In O +
addition O +
, O +
reverse O +
transcription O +
- O +
polymerase O +
chain O +
reaction O +
and O +
prostaglandin O +
E O +
( O +
2 O +
) O +
( O +
PGE O +
( O +
2 O +
) O +
) O +
immunoassay O +
were O +
performed O +
to O +
verify O +
whether O +
BV O +
possesses O +
an O +
inhibitory O +
effect O +
on O +
the O +
expression O +
of O +
cyclooxygenase O +
( O +
COX O +
) O +
and O +
PGE O +
( O +
2 O +
) O +
synthesis O +
. O +

Expression O +
of O +
COX O +
- O +
2 O +
mRNA O +
and O +
synthesis O +
of O +
PGE O +
( O +
2 O +
) O +
were O +
inhibited O +
by O +
BV O +
. O +

These O +
results O +
suggest O +
the O +
possibility O +
that O +
BV O +
may O +
exert O +
an O +
anti O +
- O +
tumor O +
effect O +
on O +
human O +
lung O +
cancer O +
. O +

Prenatal O +
aspects O +
of O +
ascorbic O +
acid O +
metabolism O +
in O +
the O +
albino O +
rat O +
. O +

Transfer O +
of O +
ascorbic O +
acid O +
and O +
/ O +
or O +
its O +
derivatives O +
from O +
maternal O +
blood O +
into O +
the O +
fetus O +
was O +
studied O +
during O +
the O +
last O +
week O +
of O +
gestation O +
in O +
the O +
rat O +
. O +

Rats O +
were O +
injected O +
intravenously O +
with O +
[ O +
1 O +
- O +
14C O +
] O +
- O +
ascorbic O +
acid O +
and O +
the O +
rate O +
of O +
transfer O +
estimated O +
by O +
the O +
concentration O +
and O +
content O +
of O +
label O +
present O +
in O +
placentas O +
and O +
fetuses O +
. O +

At O +
all O +
times O +
studied O +
the O +
concentration O +
of O +
label O +
in O +
the O +
placenta O +
was O +
greater O +
than O +
in O +
the O +
fetus O +
. O +

The O +
highest O +
capacity O +
of O +
the O +
placenta O +
to O +
concentrate O +
label O +
was O +
found O +
on O +
day O +
15 O +
decreasing O +
to O +
a O +
low O +
at O +
day O +
19 O +
and O +
again O +
increasing O +
up O +
to O +
day O +
21 O +
. O +

While O +
in O +
the O +
fetuses O +
, O +
the O +
concentration O +
of O +
label O +
per O +
gram O +
of O +
tissue O +
remained O +
remarkably O +
constant O +
throughout O +
the O +
study O +
. O +

The O +
quantity O +
of O +
labeled O +
compounds O +
transferred O +
into O +
the O +
fetus O +
per O +
gram O +
of O +
placental O +
tissue O +
increased O +
between O +
day O +
15 O +
and O +
day O +
21 O +
of O +
gestation O +
. O +

Possible O +
role O +
of O +
cyclooxygenase O +
II O +
in O +
the O +
acquisition O +
of O +
ovarian O +
luteal O +
function O +
in O +
rodents O +
. O +

The O +
development O +
of O +
the O +
corpus O +
luteum O +
( O +
CL O +
) O +
, O +
which O +
involves O +
angiogenesis O +
, O +
is O +
essential O +
for O +
the O +
establishment O +
of O +
early O +
pregnancy O +
. O +

We O +
investigated O +
the O +
roles O +
of O +
the O +
prostaglandin O +
synthases O +
cyclooxygenase O +
( O +
COX O +
) O +
I O +
and O +
COX O +
- O +
II O +
in O +
angiogenesis O +
and O +
progesterone O +
production O +
in O +
the O +
newly O +
formed O +
CL O +
, O +
using O +
inhibitors O +
of O +
the O +
COX O +
enzymes O +
and O +
the O +
gonadotropin O +
- O +
induced O +
pseudopregnant O +
rat O +
as O +
a O +
model O +
. O +

Injection O +
of O +
indomethacin O +
, O +
a O +
nonselective O +
COX O +
inhibitor O +
, O +
on O +
the O +
day O +
of O +
ovulation O +
and O +
the O +
following O +
day O +
decreased O +
serum O +
levels O +
of O +
progesterone O +
, O +
as O +
did O +
injection O +
of O +
the O +
selective O +
COX O +
- O +
II O +
inhibitor O +
NS O +
- O +
398 O +
. O +

In O +
contrast O +
, O +
a O +
selective O +
COX O +
- O +
I O +
inhibitor O +
, O +
SC O +
- O +
560 O +
, O +
had O +
no O +
effect O +
on O +
serum O +
progesterone O +
concentrations O +
. O +

None O +
of O +
the O +
inhibitors O +
had O +
any O +
effect O +
on O +
the O +
weight O +
of O +
the O +
superovulated O +
ovaries O +
or O +
on O +
the O +
synthesis O +
of O +
progesterone O +
by O +
cultured O +
luteal O +
cells O +
. O +

To O +
determine O +
whether O +
changes O +
in O +
angiogenesis O +
are O +
responsible O +
for O +
the O +
decrease O +
in O +
progesterone O +
synthesis O +
, O +
we O +
measured O +
hemoglobin O +
and O +
CD34 O +
levels O +
in O +
luteinized O +
ovaries O +
following O +
injection O +
of O +
COX O +
inhibitors O +
and O +
measured O +
the O +
relative O +
frequency O +
of O +
cells O +
positive O +
for O +
platelet O +
- O +
endothelial O +
cell O +
adhesion O +
molecule O +
as O +
a O +
specific O +
marker O +
for O +
endothelial O +
cells O +
. O +

All O +
of O +
these O +
parameters O +
were O +
reduced O +
by O +
the O +
COX O +
- O +
II O +
inhibitors O +
, O +
suggesting O +
that O +
changes O +
in O +
the O +
vasculature O +
are O +
responsible O +
for O +
the O +
decrease O +
in O +
serum O +
progesterone O +
. O +

Histological O +
examination O +
of O +
ovarian O +
corrosion O +
casts O +
indicated O +
that O +
NS O +
- O +
398 O +
inhibited O +
the O +
establishment O +
of O +
luteal O +
capillary O +
vessels O +
following O +
the O +
injection O +
of O +
hCG O +
. O +

The O +
results O +
are O +
consistent O +
with O +
the O +
hypothesis O +
that O +
the O +
activity O +
of O +
COX O +
- O +
II O +
is O +
associated O +
with O +
the O +
formation O +
of O +
functional O +
CL O +
via O +
its O +
stimulation O +
of O +
angiogenesis O +
. O +

Tumor O +
angiogenesis O +
modulates O +
leukocyte O +
- O +
vessel O +
wall O +
interactions O +
in O +
vivo O +
by O +
reducing O +
endothelial O +
adhesion O +
molecule O +
expression O +
. O +

The O +
expression O +
of O +
endothelial O +
cell O +
( O +
EC O +
) O +
adhesion O +
molecules O +
involved O +
in O +
leukocyte O +
- O +
vessel O +
wall O +
interactions O +
is O +
suppressed O +
in O +
malignancies O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
investigated O +
in O +
vivo O +
the O +
regulation O +
of O +
leukocyte O +
- O +
vessel O +
wall O +
interactions O +
by O +
the O +
presence O +
of O +
a O +
tumor O +
. O +

By O +
means O +
of O +
intravital O +
microscopy O +
, O +
tumor O +
necrosis O +
factor O +
alpha O +
- O +
stimulated O +
leukocyte O +
- O +
vessel O +
wall O +
interactions O +
were O +
studied O +
in O +
ear O +
skin O +
microvessels O +
of O +
nude O +
mice O +
bearing O +
small O +
human O +
LS174 B-CellLine -
T I-CellLine +
colon O +
carcinomas O +
and O +
in O +
C57Bl O +
/ O +
6 O +
mice O +
bearing O +
murine O +
B16F10 B-CellLine +
melanomas O +
. O +

Leukocyte O +
- O +
vessel O +
wall O +
interactions O +
were O +
studied O +
both O +
within O +
and O +
outside O +
small O +
tumors O +
growing O +
in O +
the O +
ear O +
, O +
and O +
in O +
ear O +
microvessels O +
of O +
mice O +
with O +
a O +
large O +
tumor O +
growing O +
on O +
their O +
flank O +
. O +

Tumor O +
- O +
free O +
mice O +
were O +
used O +
as O +
controls O +
. O +

Compared O +
with O +
values O +
measured O +
at O +
the O +
edge O +
of O +
the O +
ear O +
and O +
in O +
the O +
contralateral O +
ear O +
, O +
leukocyte O +
adhesion O +
was O +
found O +
to O +
be O +
diminished O +
significantly O +
in O +
vessels O +
inside O +
the O +
ear O +
tumor O +
in O +
both O +
mouse O +
models O +
. O +

This O +
reduction O +
disappeared O +
with O +
increasing O +
distance O +
from O +
the O +
tumor O +
. O +

Surprisingly O +
, O +
the O +
level O +
of O +
leukocyte O +
adhesion O +
in O +
ear O +
venules O +
of O +
mice O +
with O +
a O +
large O +
flank O +
tumor O +
was O +
also O +
reduced O +
significantly O +
. O +

Leukocyte O +
rolling O +
, O +
i O +
. O +
e O +
. O +
, O +
the O +
step O +
preceding O +
adhesion O +
, O +
was O +
not O +
influenced O +
by O +
the O +
presence O +
of O +
a O +
tumor O +
in O +
nude O +
mice O +
, O +
but O +
was O +
down O +
- O +
regulated O +
in O +
immune O +
- O +
competent O +
C57Bl O +
/ O +
6 O +
mice O +
. O +

Treatment O +
of O +
mice O +
bearing O +
a O +
small O +
ear O +
tumor O +
with O +
a O +
humanized O +
antivascular O +
endothelial O +
growth O +
factor O +
antibody O +
prevented O +
the O +
down O +
- O +
regulation O +
of O +
leukocyte O +
- O +
vessel O +
wall O +
interactions O +
inside O +
the O +
tumor O +
vessels O +
compared O +
with O +
the O +
nontreated O +
group O +
. O +

Fluorescence O +
- O +
activated O +
cell O +
sorter O +
analysis O +
showed O +
that O +
isolated O +
tumor O +
ECs O +
have O +
suppressed O +
levels O +
of O +
intercellular O +
adhesion O +
molecule O +
1 O +
as O +
compared O +
with O +
ECs O +
from O +
normal O +
mouse O +
tissues O +
. O +

In O +
cultured O +
b B-CellLine +
. I-CellLine +
END5 I-CellLine +
cells I-CellLine +
the O +
tumor O +
necrosis O +
factor O +
alpha O +
- O +
induced O +
up O +
- O +
regulation O +
of O +
intercellular O +
adhesion O +
molecule O +
1 O +
and O +
vascular O +
cell O +
adhesion O +
molecule O +
1 O +
was O +
reduced O +
in O +
ECs O +
that O +
were O +
preincubated O +
with O +
basic O +
fibroblast O +
growth O +
factor O +
or O +
vascular O +
endothelial O +
growth O +
factor O +
. O +

The O +
current O +
results O +
may O +
have O +
an O +
impact O +
on O +
the O +
effectiveness O +
of O +
clinical O +
immunotherapeutic O +
treatment O +
protocols O +
, O +
because O +
immune O +
effector O +
cells O +
may O +
not O +
be O +
able O +
to O +
enter O +
tumor O +
tissue O +
. O +

Antiapoptotic O +
effect O +
of O +
coagulation O +
factor O +
VIIa O +
. O +

Binding O +
of O +
factor O +
VIIa O +
( O +
FVIIa O +
) O +
to O +
its O +
cellular O +
receptor O +
tissue O +
factor O +
( O +
TF O +
) O +
was O +
previously O +
shown O +
to O +
induce O +
various O +
intracellular O +
signaling O +
events O +
, O +
which O +
were O +
thought O +
to O +
be O +
responsible O +
for O +
TF O +
- O +
mediated O +
biologic O +
effects O +
, O +
including O +
angiogenesis O +
, O +
tumor O +
metastasis O +
, O +
and O +
restenosis O +
. O +

To O +
understand O +
the O +
mechanisms O +
behind O +
these O +
processes O +
, O +
we O +
have O +
examined O +
the O +
effect O +
of O +
FVIIa O +
on O +
apoptosis O +
. O +

Serum O +
deprivation O +
- O +
induced O +
apoptosis O +
of O +
BHK B-CellLine +
( O +
+ O +
TF O +
) O +
cells O +
was O +
characterized O +
by O +
apoptotic O +
blebs O +
, O +
nuclei O +
with O +
chromatin O +
- O +
condensed O +
bodies O +
, O +
DNA O +
degradation O +
, O +
and O +
activation O +
of O +
caspase O +
3 O +
. O +

FVIIa O +
markedly O +
decreased O +
the O +
number O +
of O +
cells O +
with O +
apoptotic O +
morphology O +
and O +
prevented O +
the O +
DNA O +
degradation O +
as O +
measured O +
by O +
means O +
of O +
TdT O +
- O +
mediated O +
dUTP O +
nick O +
end O +
labeling O +
( O +
TUNEL O +
) O +
. O +

The O +
antiapoptotic O +
effect O +
of O +
FVIIa O +
was O +
confirmed O +
by O +
the O +
observation O +
that O +
FVIIa O +
attenuated O +
caspase O +
3 O +
activation O +
. O +

FVIIa O +
- O +
induced O +
antiapoptotic O +
effect O +
was O +
dependent O +
on O +
its O +
proteolytic O +
activity O +
and O +
TF O +
but O +
independent O +
of O +
factor O +
Xa O +
and O +
thrombin O +
. O +

FVIIa O +
- O +
induced O +
cell O +
survival O +
correlated O +
with O +
the O +
activation O +
of O +
Akt O +
and O +
was O +
inhibited O +
markedly O +
by O +
the O +
specific O +
PI3 O +
- O +
kinase O +
inhibitor O +
, O +
LY294002 O +
. O +

Blocking O +
the O +
activation O +
of O +
p44 O +
/ O +
42 O +
mitogen O +
- O +
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
by O +
the O +
specific O +
mitogen O +
- O +
induced O +
extracellular O +
kinase O +
( O +
MEK O +
) O +
inhibitor O +
, O +
U0126 O +
, O +
impaired O +
modestly O +
the O +
ability O +
of O +
FVIIa O +
to O +
promote O +
cell O +
survival O +
. O +

In O +
conclusion O +
, O +
FVIIa O +
binding O +
to O +
TF O +
provided O +
protection O +
against O +
apoptosis O +
induced O +
by O +
growth O +
factor O +
deprivation O +
, O +
primarily O +
through O +
activation O +
of O +
PI3 O +
- O +
kinase O +
/ O +
Akt O +
pathway O +
, O +
and O +
to O +
a O +
lesser O +
extent O +
, O +
p44 O +
/ O +
42 O +
MAPK O +
pathway O +
. O +

Impact O +
of O +
technology O +
on O +
the O +
utilisation O +
of O +
positron O +
emission O +
tomography O +
in O +
lymphoma O +
: O +
current O +
and O +
future O +
perspectives O +
. O +

Positron O +
emission O +
tomography O +
( O +
PET O +
) O +
has O +
now O +
gained O +
a O +
place O +
in O +
the O +
management O +
of O +
patients O +
with O +
cancer O +
, O +
including O +
those O +
with O +
Hodgkin O +
' O +
s O +
disease O +
and O +
non O +
- O +
Hodgkin O +
' O +
s O +
lymphoma O +
. O +

Restaging O +
studies O +
and O +
those O +
addressing O +
the O +
monitoring O +
of O +
response O +
to O +
treatment O +
are O +
especially O +
in O +
focus O +
. O +

Most O +
of O +
the O +
knowledge O +
gained O +
has O +
been O +
achieved O +
with O +
dedicated O +
BGO O +
- O +
based O +
PET O +
technology O +
, O +
but O +
there O +
are O +
a O +
number O +
of O +
developments O +
that O +
will O +
impact O +
on O +
the O +
use O +
of O +
this O +
metabolic O +
imaging O +
technique O +
in O +
the O +
investigation O +
of O +
patients O +
with O +
lymphoma O +
. O +

The O +
challenges O +
ahead O +
are O +
determined O +
by O +
the O +
need O +
for O +
high O +
- O +
quality O +
whole O +
- O +
body O +
imaging O +
associated O +
with O +
increased O +
patient O +
throughput O +
and O +
the O +
need O +
to O +
investigate O +
the O +
role O +
of O +
new O +
labelled O +
ligands O +
. O +

The O +
latter O +
are O +
likely O +
to O +
yield O +
new O +
insights O +
into O +
tumour O +
cell O +
characterisation O +
, O +
tumour O +
behaviour O +
and O +
tumour O +
outcome O +
assessment O +
. O +

The O +
study O +
of O +
new O +
radiolabelled O +
ligands O +
will O +
impose O +
further O +
demands O +
for O +
rapid O +
dynamic O +
data O +
acquisition O +
and O +
accurate O +
tracer O +
quantification O +
. O +

Current O +
and O +
future O +
developments O +
in O +
PET O +
technology O +
range O +
from O +
the O +
use O +
of O +
new O +
detector O +
materials O +
to O +
different O +
detector O +
geometries O +
and O +
data O +
acquisition O +
modes O +
. O +

The O +
search O +
for O +
alternatives O +
to O +
BGO O +
scintillation O +
materials O +
for O +
PET O +
has O +
led O +
to O +
the O +
development O +
of O +
PET O +
instruments O +
utilising O +
new O +
crystals O +
such O +
as O +
LSO O +
and O +
GSO O +
. O +

The O +
use O +
of O +
these O +
new O +
detectors O +
and O +
the O +
increased O +
sensitivity O +
achieved O +
with O +
3D O +
data O +
acquisitions O +
represent O +
the O +
most O +
significant O +
current O +
developments O +
in O +
the O +
field O +
. O +

With O +
the O +
increasing O +
demands O +
imposed O +
on O +
the O +
clinical O +
utilisation O +
of O +
PET O +
, O +
issues O +
such O +
as O +
study O +
cost O +
and O +
patient O +
throughput O +
will O +
emerge O +
as O +
significant O +
future O +
factors O +
. O +

As O +
a O +
consequence O +
, O +
low O +
- O +
cost O +
units O +
are O +
being O +
offered O +
by O +
the O +
manufacturers O +
through O +
the O +
utilisation O +
of O +
gamma O +
camera O +
- O +
based O +
SPET O +
systems O +
for O +
PET O +
coincidence O +
imaging O +
. O +

Unfortunately O +
, O +
clinical O +
studies O +
in O +
lymphoma O +
and O +
other O +
cancers O +
have O +
already O +
demonstrated O +
the O +
limitations O +
of O +
this O +
technology O +
, O +
with O +
20 O +
% O +
of O +
lesions O +
< O +
15 O +
mm O +
in O +
size O +
escaping O +
detection O +
. O +

On O +
the O +
other O +
hand O +
, O +
the O +
recent O +
development O +
of O +
combined O +
PET O +
/ O +
CT O +
devices O +
attempts O +
to O +
address O +
the O +
lack O +
of O +
anatomical O +
information O +
inherent O +
with O +
PET O +
images O +
, O +
taking O +
advantage O +
of O +
further O +
improvement O +
in O +
patient O +
throughput O +
and O +
hence O +
cost O +
- O +
effectiveness O +
. O +

Preliminary O +
studies O +
using O +
this O +
multimodality O +
imaging O +
approach O +
have O +
already O +
demonstrated O +
the O +
potential O +
of O +
the O +
technique O +
. O +

Although O +
the O +
potential O +
exists O +
, O +
certain O +
technical O +
issues O +
with O +
PET O +
/ O +
CT O +
require O +
refinement O +
of O +
the O +
methodology O +
. O +

Such O +
issues O +
include O +
organ O +
movement O +
( O +
such O +
as O +
respiratory O +
motion O +
) O +
, O +
which O +
strongly O +
influences O +
the O +
image O +
fusion O +
of O +
a O +
rapidly O +
acquired O +
CT O +
scan O +
with O +
the O +
slower O +
acquisition O +
of O +
a O +
PET O +
dataset O +
, O +
and O +
the O +
derivation O +
of O +
CT O +
- O +
based O +
attenuation O +
coefficients O +
in O +
the O +
presence O +
of O +
contrast O +
agents O +
or O +
metallic O +
implants O +
. O +

The O +
application O +
of O +
the O +
technology O +
for O +
radiotherapy O +
planning O +
also O +
poses O +
a O +
number O +
of O +
associated O +
challenges O +
. O +

Finally O +
, O +
the O +
development O +
of O +
dedicated O +
PET O +
systems O +
based O +
on O +
planar O +
detector O +
arrangements O +
with O +
new O +
detector O +
components O +
has O +
the O +
potential O +
to O +
improve O +
clinical O +
throughput O +
by O +
over O +
100 O +
% O +
, O +
but O +
clinical O +
trials O +
using O +
such O +
systems O +
have O +
still O +
to O +
be O +
carried O +
out O +
in O +
order O +
to O +
establish O +
the O +
associated O +
whole O +
- O +
body O +
image O +
quality O +
. O +

[ O +
Effects O +
of O +
Epstein O +
- O +
Barr O +
virus O +
latent O +
membrane O +
protein O +
1 O +
( O +
EBV O +
- O +
LMP1 O +
) O +
on O +
related O +
factors O +
of O +
metastasis O +
of O +
nasopharyngeal O +
carcinoma O +
cell O +
line O +
CNE1 B-CellLine +
] O +
. O +

BACKGROUND O +
& O +
# O +
38 O +
; O +
OBJECTIVE O +
: O +
It O +
has O +
been O +
proved O +
that O +
Epstein O +
- O +
Barr O +
virus O +
( O +
EBV O +
) O +
latent O +
membrane O +
protein O +
1 O +
( O +
EBV O +
- O +
LMP1 O +
) O +
can O +
induce O +
the O +
expression O +
of O +
matrix O +
metalloproteinase O +
- O +
9 O +
( O +
MMP O +
- O +
9 O +
) O +
. O +

This O +
study O +
was O +
designed O +
to O +
investigate O +
the O +
effect O +
of O +
EBV O +
- O +
LMP1 O +
on O +
related O +
factors O +
of O +
metastasis O +
of O +
nasopharyngeal O +
carcinoma O +
cell O +
line O +
CNE1 B-CellLine +
. O +

METHODS O +
: O +
Expression O +
of O +
MMP O +
- O +
9 O +
was O +
studied O +
in O +
human O +
NPC O +
cell O +
lines O +
cultured O +
in O +
vitro O +
: O +
CNE1 B-CellLine +
( O +
well O +
differentiated O +
cell O +
line O +
of O +
NPC O +
) O +
and O +
CNE1 B-CellLine +
- O +
GL O +
( O +
CNE1 B-CellLine +
cell O +
line O +
transfected O +
with O +
an O +
eukaryotic O +
LMP1 O +
- O +
expression O +
plasmid O +
) O +
by O +
SP O +
immunohistochemistry O +
and O +
Western O +
blot O +
analysis O +
. O +

Cell O +
- O +
matrix O +
adhesion O +
assay O +
was O +
used O +
to O +
study O +
the O +
adhesive O +
ability O +
of O +
CNE1 B-CellLine +
- O +
GL O +
cells O +
. O +

The O +
effects O +
of O +
LMP1 O +
on O +
the O +
invasion O +
and O +
migration O +
of O +
CNE1 B-CellLine +
cells O +
were O +
investigated O +
by O +
transwell O +
methods O +
. O +

RESULTS O +
: O +
MMP O +
- O +
9 O +
was O +
expressed O +
in O +
both O +
cell O +
lines O +
but O +
the O +
intensity O +
of O +
the O +
staining O +
was O +
different O +
. O +

The O +
positive O +
rates O +
of O +
expression O +
of O +
MMP O +
- O +
9 O +
in O +
CNE1 B-CellLine +
and O +
CNE1 B-CellLine +
- O +
GL O +
cells O +
were O +
30 O +
. O +
2 O +
% O +
and O +
98 O +
. O +
2 O +
% O +
, O +
respectively O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

The O +
increased O +
expression O +
of O +
MMP O +
- O +
9 O +
was O +
also O +
shown O +
in O +
CNE1 B-CellLine +
- O +
GL O +
cells O +
by O +
Western O +
blot O +
analysis O +
. O +

Cell O +
- O +
matrix O +
adhesion O +
assay O +
showed O +
that O +
the O +
adhesive O +
ability O +
of O +
CNE1 B-CellLine +
- O +
GL O +
with O +
the O +
matrix O +
( O +
mean O +
A O +
value O +
: O +
1 O +
. O +
2508 O +
+ O +
/ O +
- O +
0 O +
. O +
0711 O +
) O +
was O +
higher O +
than O +
that O +
of O +
CNE1 B-CellLine +
cell O +
( O +
mean O +
A O +
value O +
: O +
0 O +
. O +
9519 O +
+ O +
/ O +
- O +
0 O +
. O +
068 O +
) O +
( O +
P O +
< O +
0 O +
. O +
001 O +
) O +
. O +

Invasion O +
assay O +
and O +
migration O +
assay O +
showed O +
that O +
the O +
invasion O +
and O +
migration O +
of O +
CNE1 B-CellLine +
- O +
GL O +
cell O +
were O +
higher O +
than O +
those O +
of O +
CNE1 B-CellLine +
cells O +
( O +
P O +
< O +
0 O +
. O +
01 O +
) O +
. O +

CONCLUSION O +
: O +
The O +
transfection O +
of O +
LMP1 O +
can O +
increase O +
the O +
expression O +
of O +
MMP O +
- O +
9 O +
in O +
CNE1 B-CellLine +
cells O +
. O +

Abilities O +
of O +
adhesion O +
, O +
migration O +
, O +
and O +
invasion O +
of O +
CNE1 B-CellLine +
cell O +
were O +
induced O +
by O +
LMP1 O +
. O +

It O +
is O +
suggested O +
that O +
MMP O +
- O +
9 O +
may O +
have O +
a O +
role O +
in O +
the O +
LMP1 O +
- O +
induced O +
acceleration O +
of O +
invasion O +
and O +
metastasis O +
of O +
NPC O +
cells O +
. O +

Combined O +
topical O +
fluconazole O +
and O +
corticosteroid O +
treatment O +
for O +
experimental O +
Candida O +
albicans O +
keratomycosis O +
. O +

PURPOSE O +
: O +
To O +
determine O +
the O +
most O +
efficient O +
time O +
point O +
and O +
concentration O +
of O +
topical O +
corticosteroids O +
in O +
Candida O +
albicans O +
keratitis O +
treated O +
with O +
fluconazole O +
. O +

METHODS O +
: O +
Corneas O +
of O +
105 O +
rabbits O +
were O +
infected O +
with O +
viable O +
yeast O +
cells O +
of O +
C O +
. O +
albicans O +
( O +
2 O +
. O +
5 O +
x O +
10 O +
( O +
5 O +
) O +
) O +
. O +

After O +
a O +
48 O +
- O +
hour O +
incubation O +
period O +
, O +
seven O +
groups O +
of O +
animals O +
were O +
treated O +
for O +
21 O +
days O +
with O +
fluconazole O +
, O +
with O +
group O +
I O +
acting O +
as O +
a O +
control O +
, O +
and O +
groups O +
II O +
to O +
VII O +
receiving O +
adjunct O +
therapy O +
with O +
the O +
corticosteroid O +
prednisolone O +
( O +
5 O +
or O +
10 O +
times O +
daily O +
; O +
3 O +
, O +
9 O +
, O +
or O +
15 O +
days O +
after O +
infection O +
) O +
. O +

The O +
degree O +
of O +
corneal O +
infiltration O +
, O +
ulceration O +
, O +
corneal O +
clouding O +
, O +
hypopyon O +
, O +
conjunctivitis O +
, O +
neovascularization O +
, O +
and O +
corneal O +
perforation O +
was O +
monitored O +
over O +
a O +
24 O +
- O +
day O +
period O +
, O +
as O +
well O +
as O +
recultivation O +
and O +
resistance O +
to O +
fluconazole O +
of O +
the O +
C O +
. O +
albicans O +
pathogen O +
. O +

RESULTS O +
: O +
The O +
control O +
group O +
showed O +
the O +
highest O +
level O +
of O +
corneal O +
clouding O +
and O +
neovascularization O +
. O +

In O +
comparison O +
, O +
by O +
day O +
24 O +
, O +
the O +
majority O +
of O +
groups O +
also O +
treated O +
with O +
prednisolone O +
displayed O +
significantly O +
less O +
corneal O +
clouding O +
and O +
neovascularization O +
. O +

An O +
immediate O +
decrease O +
in O +
corneal O +
clouding O +
was O +
observed O +
in O +
groups O +
treated O +
with O +
additional O +
low O +
- O +
or O +
high O +
- O +
dose O +
prednisolone O +
from O +
day O +
9 O +
after O +
inoculation O +
. O +

After O +
additional O +
prednisolone O +
treatment O +
from O +
day O +
9 O +
or O +
15 O +
after O +
inoculation O +
, O +
no O +
significant O +
difference O +
was O +
detected O +
in O +
the O +
recultivation O +
rate O +
of O +
C O +
. O +
albicans O +
compared O +
with O +
the O +
control O +
. O +

Early O +
administration O +
of O +
prednisolone O +
( O +
day O +
3 O +
, O +
low O +
and O +
high O +
dose O +
) O +
resulted O +
in O +
the O +
recultivation O +
of O +
significantly O +
more O +
C O +
. O +
albicans O +
. O +

CONCLUSIONS O +
: O +
Fluconazole O +
plus O +
adjunct O +
high O +
- O +
dose O +
prednisolone O +
treatment O +
was O +
most O +
effective O +
when O +
administered O +
9 O +
days O +
after O +
infection O +
. O +

The O +
delayed O +
application O +
of O +
corticosteroids O +
after O +
treatment O +
with O +
antimycotic O +
drugs O +
in O +
cases O +
of O +
fungal O +
keratitis O +
is O +
therefore O +
not O +
contraindicated O +
and O +
may O +
be O +
beneficial O +
in O +
patients O +
. O +

Solid O +
tumor O +
therapy O +
: O +
manipulation O +
of O +
the O +
vasculature O +
with O +
TNF O +
. O +

Drug O +
delivery O +
to O +
solid O +
tumors O +
is O +
one O +
of O +
the O +
most O +
challenging O +
aspects O +
in O +
cancer O +
therapy O +
. O +

Whereas O +
agents O +
seem O +
promising O +
in O +
the O +
test O +
tube O +
, O +
clinical O +
trials O +
often O +
fail O +
due O +
to O +
unfavorable O +
pharmacokinetics O +
, O +
poor O +
delivery O +
, O +
low O +
local O +
concentrations O +
, O +
and O +
limited O +
accumulation O +
in O +
the O +
target O +
cell O +
. O +

A O +
major O +
step O +
forwards O +
in O +
the O +
treatment O +
of O +
solid O +
tumors O +
is O +
the O +
recognition O +
of O +
the O +
tumor O +
- O +
associated O +
vasculature O +
as O +
an O +
important O +
target O +
for O +
therapy O +
. O +

Inhibition O +
of O +
tumor O +
vascular O +
development O +
has O +
a O +
direct O +
effect O +
on O +
the O +
growth O +
and O +
progression O +
of O +
the O +
tumor O +
. O +

Destruction O +
of O +
an O +
existing O +
vasculature O +
also O +
directly O +
inflicts O +
serious O +
damage O +
to O +
the O +
tumor O +
cell O +
. O +

Moreover O +
, O +
the O +
tumor O +
vascular O +
bed O +
can O +
be O +
manipulated O +
facilitating O +
enhanced O +
permissiveness O +
of O +
the O +
tumor O +
for O +
administered O +
chemotherapeutics O +
. O +

In O +
this O +
review O +
, O +
we O +
focus O +
on O +
the O +
use O +
of O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O +
) O +
in O +
local O +
and O +
systemic O +
therapy O +
in O +
conjunction O +
with O +
chemotherapy O +
. O +

In O +
these O +
settings O +
TNF O +
demonstrates O +
potent O +
and O +
selective O +
activity O +
on O +
the O +
tumor O +
vascular O +
bed O +
, O +
which O +
strongly O +
improves O +
tumor O +
response O +
. O +

Truncated O +
galectin O +
- O +
3 O +
inhibits O +
tumor O +
growth O +
and O +
metastasis O +
in O +
orthotopic O +
nude O +
mouse O +
model O +
of O +
human O +
breast O +
cancer O +
. O +

PURPOSE O +
: O +
The O +
goal O +
of O +
this O +
research O +
was O +
to O +
evaluate O +
a O +
potential O +
therapeutic O +
agent O +
for O +
breast O +
cancer O +
based O +
on O +
galectin O +
- O +
3 O +
that O +
has O +
been O +
implicated O +
in O +
tumorigenicity O +
and O +
metastasis O +
of O +
breast O +
cancer O +
. O +

The O +
hypothesis O +
was O +
that O +
therapy O +
with O +
NH O +
( O +
2 O +
) O +
- O +
terminally O +
truncated O +
form O +
of O +
galectin O +
- O +
3 O +
( O +
galectin O +
- O +
3C O +
) O +
will O +
be O +
efficacious O +
for O +
reduction O +
in O +
tumor O +
growth O +
and O +
for O +
inhibition O +
of O +
metastases O +
. O +

EXPERIMENTAL O +
DESIGN O +
: O +
Recombinant O +
human O +
galectin O +
- O +
3 O +
was O +
produced O +
in O +
Escherichia O +
coli O +
from O +
which O +
galectin O +
- O +
3C O +
was O +
derived O +
by O +
collagenase O +
enzyme O +
digestion O +
. O +

Toxicity O +
, O +
pharmacokinetic O +
, O +
and O +
organ O +
biodistribution O +
studies O +
were O +
performed O +
in O +
nude O +
mice O +
. O +

For O +
efficacy O +
studies O +
, O +
nude O +
mice O +
bearing O +
orthotopically O +
implanted O +
tumors O +
derived O +
from O +
breast O +
cancer O +
cell O +
line O +
MDA B-CellLine +
- I-CellLine +
MB I-CellLine +
- I-CellLine +
435 I-CellLine +
were O +
treated O +
with O +
galectin O +
- O +
3C O +
or O +
a O +
vehicle O +
control O +
i O +
. O +
m O +
. O +
twice O +
daily O +
for O +
90 O +
days O +
. O +

RESULTS O +
: O +
The O +
maximum O +
tolerated O +
dose O +
of O +
galectin O +
- O +
3C O +
in O +
nude O +
mice O +
was O +
determined O +
to O +
be O +
> O +
125 O +
mg O +
/ O +
kg O +
without O +
overt O +
adverse O +
effects O +
. O +

The O +
elimination O +
half O +
- O +
life O +
when O +
administered O +
i O +
. O +
m O +
. O +
was O +
found O +
to O +
be O +
3 O +
. O +
0 O +
h O +
in O +
the O +
serum O +
and O +
4 O +
. O +
3 O +
h O +
in O +
the O +
cellular O +
fraction O +
of O +
the O +
blood O +
. O +

Organ O +
biodistribution O +
studies O +
revealed O +
that O +
galectin O +
- O +
3C O +
localized O +
in O +
the O +
liver O +
, O +
kidneys O +
, O +
and O +
spleen O +
but O +
not O +
in O +
the O +
heart O +
or O +
lungs O +
. O +

We O +
found O +
that O +
the O +
mean O +
tumor O +
volumes O +
and O +
weights O +
were O +
statistically O +
significantly O +
less O +
in O +
mice O +
treated O +
with O +
galectin O +
- O +
3C O +
compared O +
with O +
control O +
mice O +
, O +
and O +
that O +
fewer O +
numbers O +
of O +
mice O +
exhibited O +
lymph O +
node O +
metastases O +
in O +
the O +
treated O +
group O +
compared O +
with O +
the O +
control O +
group O +
. O +

CONCLUSIONS O +
: O +
Galectin O +
- O +
3C O +
is O +
not O +
overtly O +
toxic O +
, O +
and O +
is O +
efficacious O +
in O +
reducing O +
metastases O +
and O +
tumor O +
volumes O +
and O +
weights O +
in O +
primary O +
tumors O +
in O +
an O +
orthotopic O +
nude O +
mouse O +
model O +
of O +
human O +
breast O +
cancer O +
. O +

[ O +
Screening O +
and O +
identification O +
of O +
novel O +
genes O +
involved O +
in O +
biosynthesis O +
of O +
ginsenoside O +
in O +
Panax O +
ginseng O +
plant O +
] O +
. O +

The O +
root O +
of O +
Panax O +
ginseng O +
plant O +
undergoes O +
a O +
specific O +
developmental O +
process O +
to O +
become O +
a O +
biosynthesis O +
and O +
accumulation O +
organ O +
for O +
ginsenosides O +
. O +

To O +
identify O +
and O +
analyze O +
genes O +
involved O +
in O +
the O +
biosynthesis O +
of O +
ginsenoside O +
, O +
suppression O +
subtractive O +
hybridization O +
( O +
SSH O +
) O +
between O +
mRNAs O +
of O +
4 O +
- O +
and O +
1 O +
- O +
year O +
- O +
old O +
root O +
tissues O +
was O +
performed O +
, O +
and O +
a O +
subtracted O +
cDNA O +
library O +
specific O +
to O +
4 O +
- O +
year O +
- O +
old O +
roots O +
was O +
constructed O +
. O +

Forty O +
cDNA O +
clones O +
selected O +
randomly O +
from O +
the O +
subtracted O +
cDNA O +
library O +
were O +
sequenced O +
. O +

Sequence O +
information O +
of O +
all O +
clones O +
was O +
evaluated O +
by O +
Nucleotide O +
Blast O +
analysis O +
in O +
GenBank O +
/ O +
DDBJ O +
/ O +
EMBL O +
. O +

The O +
results O +
showed O +
that O +
six O +
subtracted O +
cDNA O +
clones O +
represented O +
the O +
novel O +
genes O +
( O +
ESTs O +
) O +
, O +
because O +
no O +
sequence O +
homology O +
with O +
any O +
known O +
sequences O +
was O +
found O +
in O +
the O +
database O +
. O +

Expression O +
in O +
4 O +
- O +
year O +
- O +
old O +
P O +
. O +
ginseng O +
root O +
tissues O +
was O +
verified O +
by O +
reverse O +
Northern O +
dot O +
hybridization O +
for O +
the O +
six O +
clones O +
. O +

These O +
six O +
novel O +
genes O +
were O +
named O +
GBR1 O +
, O +
GBR2 O +
, O +
GBR3 O +
, O +
GBR4 O +
, O +
GBR5 O +
, O +
and O +
GBR6 O +
, O +
and O +
their O +
Accession O +
numbers O +
of O +
GenBank O +
are O +
AF485334 O +
, O +
AF485335 O +
, O +
AF485336 O +
, O +
AF485337 O +
, O +
AF485332 O +
, O +
and O +
AF485333 O +
, O +
respectively O +
. O +

Finally O +
, O +
Northern O +
blot O +
analysis O +
and O +
semi O +
- O +
quantitative O +
reverse O +
transcription O +
polymerase O +
chain O +
reaction O +
( O +
RT O +
- O +
PCR O +
) O +
confirmed O +
that O +
these O +
six O +
novel O +
genes O +
were O +
differentially O +
expressed O +
in O +
the O +
defined O +
development O +
stage O +
of O +
P O +
. O +
ginseng O +
plant O +
roots O +
. O +

It O +
is O +
possible O +
that O +
their O +
overexpression O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
ginsenoside O +
biosynthesis O +
. O +

In O +
addition O +
, O +
most O +
of O +
transcripts O +
of O +
all O +
genes O +
could O +
also O +
be O +
detected O +
in O +
other O +
P O +
. O +
ginseng O +
plant O +
tissues O +
such O +
as O +
stem O +
, O +
leaf O +
and O +
seed O +
. O +

Our O +
results O +
provided O +
a O +
basis O +
for O +
obtaining O +
the O +
full O +
- O +
length O +
cDNA O +
sequences O +
of O +
such O +
six O +
novel O +
genes O +
, O +
and O +
for O +
identifying O +
their O +
function O +
involved O +
in O +
the O +
biosynthesis O +
of O +
ginsenoside O +
. O +

The O +
septic O +
abscess O +
wall O +
: O +
a O +
cytokine O +
- O +
generating O +
organ O +
associated O +
with O +
portal O +
venous O +
cytokinemia O +
, O +
hepatic O +
outflow O +
fibrosis O +
, O +
sinusoidal O +
congestion O +
, O +
inflammatory O +
cell O +
sequestration O +
, O +
hepatocellular O +
lipid O +
deposition O +
, O +
and O +
focal O +
cell O +
death O +
. O +

An O +
acute O +
septic O +
inflammatory O +
response O +
with O +
access O +
to O +
the O +
portal O +
circulation O +
was O +
created O +
in O +
a O +
rat O +
model O +
using O +
an O +
intra O +
- O +
abdominal O +
abscess O +
composed O +
of O +
a O +
sterile O +
agar O +
pellet O +
, O +
or O +
one O +
contaminated O +
with O +
102 O +
Escherichia O +
coli O +
( O +
E O +
. O +
coli O +
) O +
and O +
109 O +
Bacteriodes O +
fragilis O +
( O +
B O +
. O +
fragilis O +
) O +
. O +

After O +
3 O +
days O +
postimplantation O +
, O +
a O +
well O +
- O +
formed O +
intra O +
- O +
abdominal O +
abscess O +
occurred O +
whose O +
wall O +
showed O +
IL O +
- O +
6 O +
DNA O +
by O +
PCR O +
and O +
IL O +
- O +
6 O +
mRNA O +
by O +
in O +
situ O +
hybridization O +
. O +

Portal O +
venous O +
blood O +
draining O +
into O +
the O +
liver O +
from O +
the O +
intra O +
- O +
abdominal O +
abscess O +
had O +
increased O +
levels O +
of O +
TNF O +
- O +
alpha O +
, O +
IL O +
- O +
1beta O +
, O +
and O +
IL O +
- O +
6 O +
in O +
both O +
sterile O +
and O +
septic O +
groups O +
compared O +
with O +
a O +
control O +
normal O +
animal O +
group O +
. O +

Increased O +
levels O +
of O +
these O +
cytokines O +
were O +
also O +
found O +
in O +
suprahepatic O +
inferior O +
vena O +
caval O +
blood O +
, O +
but O +
were O +
correlated O +
with O +
the O +
higher O +
portal O +
vein O +
levels O +
, O +
suggesting O +
a O +
gradient O +
from O +
abscess O +
wall O +
to O +
portal O +
vein O +
into O +
the O +
systemic O +
circulation O +
via O +
the O +
liver O +
. O +

Liver O +
histology O +
demonstrated O +
sinusoidal O +
congestion O +
centering O +
on O +
the O +
central O +
vein O +
, O +
growing O +
worse O +
with O +
progression O +
from O +
normal O +
in O +
control O +
, O +
to O +
sterile O +
, O +
to O +
septic O +
. O +

Similarly O +
, O +
the O +
degree O +
of O +
intrahepatic O +
myeloperoxidase O +
- O +
positive O +
inflammatory O +
cell O +
infiltration O +
and O +
hepatocellular O +
lipid O +
deposition O +
and O +
apoptosis O +
also O +
increased O +
from O +
control O +
, O +
to O +
sterile O +
, O +
to O +
septic O +
. O +

Gene O +
expression O +
by O +
in O +
situ O +
hybridization O +
demonstrated O +
a O +
significant O +
increase O +
in O +
IL O +
- O +
6 O +
and O +
fibrinogen O +
mRNAs O +
in O +
cells O +
surrounding O +
the O +
central O +
vein O +
in O +
sterile O +
and O +
septic O +
animals O +
, O +
being O +
greatest O +
in O +
animals O +
with O +
sepsis O +
, O +
associated O +
with O +
an O +
increased O +
deposition O +
of O +
collagen O +
in O +
the O +
central O +
vein O +
area O +
, O +
most O +
prominent O +
in O +
the O +
septic O +
liver O +
. O +

The O +
pericentral O +
vein O +
cells O +
with O +
IL O +
- O +
6 O +
and O +
fibrinogen O +
mRNA O +
increases O +
paralleled O +
the O +
increases O +
in O +
cells O +
containing O +
IL O +
- O +
6 O +
and O +
fibrinogen O +
mRNAs O +
in O +
the O +
abscess O +
walls O +
of O +
sterile O +
and O +
septic O +
animals O +
, O +
respectively O +
. O +

The O +
data O +
suggest O +
that O +
an O +
intra O +
- O +
abdominal O +
abscess O +
, O +
especially O +
when O +
contaminated O +
with O +
gram O +
- O +
negative O +
bacteria O +
, O +
induces O +
mRNA O +
- O +
generated O +
cytokine O +
responses O +
in O +
the O +
abscess O +
wall O +
that O +
are O +
related O +
to O +
increased O +
portal O +
venous O +
levels O +
of O +
the O +
inflammatory O +
cytokines O +
TNF O +
- O +
alpha O +
, O +
IL O +
- O +
1beta O +
, O +
and O +
IL O +
- O +
6 O +
perfusing O +
the O +
liver O +
. O +

These O +
, O +
in O +
turn O +
, O +
induce O +
localized O +
production O +
of O +
IL O +
- O +
6 O +
and O +
fibrinogen O +
mRNAs O +
in O +
cells O +
at O +
the O +
central O +
vein O +
area O +
with O +
resultant O +
outflow O +
fibrosis O +
and O +
increased O +
inflammatory O +
cell O +
sequestration O +
within O +
the O +
liver O +
lobular O +
sinuses O +
. O +

This O +
is O +
associated O +
with O +
a O +
generalized O +
inflammatory O +
response O +
and O +
intrahepatic O +
portal O +
sinusoid O +
congestion O +
. O +

There O +
is O +
also O +
increased O +
hepatocellular O +
lipid O +
deposition O +
and O +
apoptosis O +
. O +

Thus O +
, O +
the O +
cytokine O +
production O +
of O +
the O +
abscess O +
wall O +
itself O +
appears O +
to O +
be O +
a O +
major O +
mediator O +
of O +
the O +
septic O +
hepatic O +
response O +
. O +

Prognostic O +
value O +
of O +
p53 O +
protein O +
expression O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
expression O +
in O +
resected O +
squamous O +
cell O +
carcinoma O +
of O +
the O +
esophagus O +
. O +

The O +
most O +
common O +
genetic O +
alterations O +
found O +
in O +
a O +
wide O +
variety O +
of O +
cancers O +
are O +
p53 O +
tumor O +
suppressor O +
gene O +
mutations O +
. O +

p53 O +
appears O +
to O +
be O +
a O +
nuclear O +
transcription O +
factor O +
that O +
plays O +
a O +
role O +
in O +
the O +
control O +
of O +
cell O +
proliferation O +
, O +
apoptosis O +
, O +
and O +
the O +
maintenance O +
of O +
genetic O +
stability O +
. O +

Angiogenesis O +
is O +
a O +
critical O +
process O +
in O +
solid O +
tumor O +
growth O +
and O +
metastasis O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
, O +
a O +
recently O +
identified O +
growth O +
factor O +
with O +
significant O +
angiogenic O +
properties O +
, O +
may O +
be O +
a O +
major O +
tumor O +
angiogenesis O +
regulator O +
. O +

Few O +
studies O +
have O +
investigated O +
the O +
association O +
between O +
p53 O +
and O +
VEGF O +
expressions O +
and O +
prognosis O +
in O +
esophageal O +
carcinoma O +
. O +

Forty O +
- O +
seven O +
specimens O +
resected O +
from O +
patients O +
with O +
stage O +
II O +
and O +
III O +
squamous O +
cell O +
carcinoma O +
( O +
SCC O +
) O +
of O +
the O +
esophagus O +
were O +
studied O +
using O +
immunohistochemical O +
staining O +
. O +

VEGF O +
and O +
p53 O +
expressions O +
were O +
observed O +
in O +
40 O +
% O +
and O +
53 O +
% O +
of O +
the O +
tumors O +
, O +
respectively O +
. O +

The O +
p53 O +
and O +
VEGF O +
staining O +
statuses O +
were O +
coincident O +
in O +
only O +
21 O +
% O +
of O +
the O +
tumors O +
, O +
and O +
no O +
significant O +
correlation O +
was O +
found O +
between O +
p53 O +
and O +
VEGF O +
statuses O +
. O +

No O +
clinicopathologic O +
factors O +
were O +
significantly O +
correlated O +
with O +
p53 O +
or O +
VEGF O +
expression O +
. O +

No O +
significant O +
association O +
between O +
p53 O +
and O +
VEGF O +
expressions O +
and O +
poor O +
prognosis O +
was O +
found O +
. O +

In O +
conclusion O +
, O +
p53 O +
and O +
VEGF O +
were O +
not O +
correlated O +
with O +
prognosis O +
in O +
patients O +
with O +
stage O +
II O +
and O +
III O +
SCC O +
of O +
the O +
esophagus O +
. O +

Comparison O +
of O +
tissue O +
integration O +
between O +
polyester O +
and O +
polypropylene O +
prostheses O +
in O +
the O +
preperitoneal O +
space O +
. O +

Tissue O +
integration O +
and O +
implant O +
characteristics O +
of O +
various O +
biomaterials O +
commonly O +
used O +
for O +
inguinal O +
hernia O +
repair O +
have O +
not O +
been O +
studied O +
extensively O +
. O +

The O +
aim O +
of O +
this O +
study O +
is O +
to O +
compare O +
behavior O +
and O +
tissue O +
response O +
between O +
two O +
new O +
polyester O +
prostheses O +
and O +
a O +
commonly O +
used O +
polypropylene O +
( O +
PP O +
) O +
mesh O +
. O +

The O +
polyester O +
prostheses O +
utilized O +
were O +
polyester O +
flat O +
( O +
PF O +
) O +
and O +
polyester O +
soft O +
three O +
- O +
dimensional O +
( O +
PS O +
) O +
; O +
the O +
PP O +
mesh O +
utilized O +
was O +
Marlex O +
. O +

Eight O +
randomly O +
assigned O +
4 O +
x O +
4 O +
- O +
cm2 O +
pieces O +
of O +
two O +
different O +
meshes O +
were O +
fixed O +
in O +
the O +
preperitoneal O +
space O +
with O +
a O +
centrally O +
placed O +
single O +
suture O +
. O +

Gross O +
evaluation O +
included O +
shrinkage O +
and O +
stiffness O +
. O +

Histological O +
evaluation O +
included O +
amount O +
of O +
fibrous O +
and O +
fat O +
encapsulation O +
, O +
connective O +
tissue O +
, O +
foreign O +
- O +
body O +
reaction O +
, O +
neovascularization O +
, O +
hemorrhage O +
, O +
necrosis O +
, O +
and O +
exudate O +
. O +

Evaluations O +
were O +
graded O +
on O +
a O +
zero O +
to O +
four O +
scale O +
. O +

The O +
area O +
and O +
the O +
area O +
ratio O +
were O +
measured O +
using O +
a O +
calibrated O +
micrometer O +
. O +

PP O +
mesh O +
resulted O +
in O +
more O +
fibrous O +
encapsulation O +
and O +
stiffness O +
than O +
PF O +
and O +
PS O +
prostheses O +
. O +

PP O +
also O +
resulted O +
in O +
less O +
connective O +
tissue O +
formation O +
and O +
foreign O +
- O +
body O +
reaction O +
than O +
PF O +
and O +
PS O +
prostheses O +
. O +

There O +
was O +
no O +
difference O +
in O +
fat O +
encapsulation O +
, O +
necrosis O +
, O +
hemorrhage O +
, O +
or O +
exudate O +
between O +
prostheses O +
. O +

Both O +
polyester O +
prostheses O +
( O +
PF O +
and O +
PS O +
) O +
have O +
better O +
tissue O +
integration O +
than O +
the O +
PP O +
mesh O +
, O +
as O +
evidenced O +
by O +
the O +
higher O +
amount O +
of O +
connective O +
tissue O +
and O +
lower O +
extent O +
of O +
fibrous O +
encapsulation O +
. O +

Therapeutic O +
targeting O +
of O +
the O +
survivin O +
pathway O +
in O +
cancer O +
: O +
initiation O +
of O +
mitochondrial O +
apoptosis O +
and O +
suppression O +
of O +
tumor O +
- O +
associated O +
angiogenesis O +
. O +

PURPOSE O +
: O +
Molecular O +
antagonists O +
of O +
the O +
inhibitor O +
of O +
apoptosis O +
protein O +
survivin O +
have O +
shown O +
promise O +
as O +
novel O +
anticancer O +
strategies O +
for O +
triggering O +
tumor O +
cell O +
apoptosis O +
, O +
dysregulating O +
mitotic O +
progression O +
, O +
and O +
inhibiting O +
tumor O +
growth O +
in O +
preclinical O +
models O +
. O +

However O +
, O +
how O +
survivin O +
couples O +
to O +
the O +
cell O +
death O +
machinery O +
has O +
remained O +
elusive O +
, O +
and O +
the O +
relevant O +
cellular O +
targets O +
of O +
survivin O +
antagonists O +
have O +
not O +
been O +
completely O +
elucidated O +
. O +

Experimental O +
Design O +
: O +
Human O +
umbilical O +
vein O +
and O +
dermal O +
microvascular O +
endothelial O +
cells O +
were O +
infected O +
with O +
replication O +
- O +
deficient O +
adenoviruses O +
encoding O +
survivin O +
( O +
pAd O +
- O +
Survivin O +
) O +
, O +
green O +
fluorescent O +
protein O +
( O +
pAd O +
- O +
GFP O +
) O +
, O +
or O +
a O +
phosphorylation O +
- O +
defective O +
survivin O +
Thr O +
( O +
34 O +
) O +
- O +
- O +
> O +
Ala O +
( O +
pAd O +
- O +
T34A O +
) O +
dominant O +
negative O +
mutant O +
. O +

The O +
effect O +
of O +
wild O +
- O +
type O +
or O +
mutant O +
survivin O +
was O +
investigated O +
on O +
capillary O +
network O +
stability O +
, O +
endothelial O +
cell O +
viability O +
, O +
and O +
caspase O +
activation O +
in O +
vitro O +
and O +
on O +
kinetics O +
of O +
tumor O +
growth O +
and O +
development O +
of O +
angiogenesis O +
in O +
a O +
breast O +
cancer O +
xenograft O +
model O +
in O +
vivo O +
. O +

The O +
cell O +
death O +
pathway O +
initiated O +
by O +
survivin O +
targeting O +
was O +
mapped O +
with O +
respect O +
to O +
cytochrome O +
c O +
release O +
, O +
changes O +
in O +
mitochondrial O +
transmembrane O +
potential O +
, O +
and O +
apoptosome O +
requirements O +
using O +
mouse O +
embryonic O +
fibroblasts O +
deficient O +
in O +
Apaf O +
- O +
1 O +
or O +
caspase O +
- O +
9 O +
. O +

RESULTS O +
: O +
Adenoviral O +
transduction O +
of O +
endothelial O +
cells O +
with O +
pAd O +
- O +
Survivin O +
inhibited O +
growth O +
factor O +
deprivation O +
- O +
or O +
ceramide O +
- O +
induced O +
apoptosis O +
, O +
reduced O +
caspase O +
- O +
3 O +
and O +
- O +
7 O +
generation O +
, O +
and O +
stabilized O +
three O +
- O +
dimensional O +
capillary O +
networks O +
in O +
vitro O +
. O +

Conversely O +
, O +
expression O +
of O +
pAd O +
- O +
T34A O +
caused O +
apoptosis O +
in O +
umbilical O +
vein O +
and O +
dermal O +
microvascular O +
endothelial O +
cells O +
and O +
resulted O +
in O +
caspase O +
- O +
3 O +
activity O +
. O +

Cell O +
death O +
induced O +
by O +
survivin O +
targeting O +
exhibited O +
the O +
hallmarks O +
of O +
mitochondrial O +
- O +
dependent O +
apoptosis O +
with O +
release O +
of O +
cytochrome O +
c O +
and O +
loss O +
of O +
mitochondrial O +
transmembrane O +
potential O +
and O +
was O +
suppressed O +
in O +
Apaf O +
- O +
1 O +
or O +
caspase O +
- O +
9 O +
knockout O +
mouse O +
embryonic O +
fibroblasts O +
. O +

When O +
injected O +
in O +
human O +
breast O +
cancer O +
xenografts O +
, O +
pAd O +
- O +
T34A O +
inhibited O +
growth O +
of O +
established O +
tumors O +
and O +
triggered O +
tumor O +
cell O +
apoptosis O +
in O +
vivo O +
. O +

This O +
was O +
associated O +
with O +
a O +
approximately O +
60 O +
% O +
reduction O +
in O +
tumor O +
- O +
derived O +
blood O +
vessels O +
by O +
quantitative O +
morphometry O +
of O +
CD31 O +
- O +
stained O +
tumor O +
areas O +
, O +
and O +
appearance O +
of O +
endothelial O +
cell O +
apoptosis O +
by O +
internucleosomal O +
DNA O +
fragmentation O +
in O +
vivo O +
. O +

CONCLUSIONS O +
: O +
Survivin O +
functions O +
as O +
a O +
novel O +
upstream O +
regulator O +
of O +
mitochondrial O +
- O +
dependent O +
apoptosis O +
, O +
and O +
molecular O +
targeting O +
of O +
this O +
pathway O +
results O +
in O +
anticancer O +
activity O +
via O +
a O +
dual O +
mechanism O +
of O +
induction O +
of O +
tumor O +
cell O +
apoptosis O +
and O +
suppression O +
of O +
angiogenesis O +
. O +

The O +
role O +
of O +
organ O +
vascularization O +
and O +
lipoplex O +
- O +
serum O +
initial O +
contact O +
in O +
intravenous O +
murine O +
lipofection O +
. O +

Following O +
intravenous O +
administration O +
of O +
cationic O +
lipid O +
- O +
DNA O +
complexes O +
( O +
lipoplexes O +
) O +
into O +
mice O +
, O +
transfection O +
( O +
lipofection O +
) O +
occurs O +
predominantly O +
in O +
the O +
lungs O +
. O +

This O +
was O +
attributed O +
to O +
high O +
entrapment O +
of O +
lipoplexes O +
in O +
the O +
extended O +
lung O +
vascular O +
tree O +
. O +

To O +
determine O +
whether O +
lipofection O +
in O +
other O +
organs O +
could O +
be O +
enhanced O +
by O +
increasing O +
the O +
degree O +
of O +
vascularization O +
, O +
we O +
used O +
a O +
transgenic O +
mouse O +
model O +
with O +
tissue O +
- O +
specific O +
angiogenesis O +
in O +
liver O +
. O +

Tail O +
vein O +
injection O +
of O +
N O +
- O +
( O +
1 O +
- O +
( O +
2 O +
, O +
3 O +
- O +
dioleoyloxy O +
) O +
propyl O +
) O +
- O +
N O +
, O +
N O +
, O +
N O +
- O +
trimethylammonium O +
chloride O +
( O +
DOTAP O +
) O +
/ O +
cholesterol O +
lipoplexes O +
resulted O +
in O +
increased O +
lipoplex O +
entrapment O +
in O +
hypervascularized O +
liver O +
but O +
did O +
not O +
boost O +
luciferase O +
expression O +
, O +
suggesting O +
that O +
lipoplex O +
delivery O +
is O +
not O +
a O +
sufficient O +
condition O +
for O +
efficient O +
organ O +
lipofection O +
. O +

Because O +
the O +
intravenously O +
injected O +
lipoplexes O +
migrated O +
within O +
seconds O +
to O +
lungs O +
, O +
we O +
checked O +
whether O +
the O +
effects O +
of O +
immediate O +
contact O +
with O +
serum O +
correlate O +
with O +
lung O +
lipofection O +
efficiency O +
of O +
different O +
DOTAP O +
- O +
based O +
formulations O +
. O +

Under O +
conditions O +
mimicking O +
the O +
injection O +
environment O +
, O +
the O +
lipoplex O +
- O +
serum O +
interaction O +
was O +
strongly O +
dependent O +
on O +
helper O +
lipid O +
and O +
ionic O +
strength O +
: O +
lipoplexes O +
prepared O +
in O +
150 O +
mM O +
NaCl O +
or O +
lipoplexes O +
with O +
high O +
( O +
greater O +
than O +
33 O +
mol O +
% O +
) O +
cholesterol O +
were O +
found O +
to O +
aggregate O +
immediately O +
. O +

This O +
aggregation O +
process O +
was O +
irreversible O +
and O +
was O +
inversely O +
correlated O +
with O +
the O +
percentage O +
of O +
lung O +
cells O +
that O +
took O +
up O +
lipoplexes O +
and O +
with O +
the O +
efficiency O +
of O +
lipofection O +
. O +

No O +
other O +
structural O +
changes O +
in O +
serum O +
were O +
observed O +
for O +
cholesterol O +
- O +
based O +
lipoplexes O +
. O +

Dioleoyl O +
phosphatidylethanolamine O +
- O +
based O +
lipoplexes O +
were O +
found O +
to O +
give O +
low O +
expression O +
, O +
apparently O +
because O +
of O +
an O +
immediate O +
loss O +
of O +
integrity O +
in O +
serum O +
, O +
without O +
lipid O +
- O +
DNA O +
dissociation O +
. O +

Our O +
study O +
suggests O +
that O +
efficient O +
in O +
vivo O +
lipofection O +
is O +
the O +
result O +
of O +
cross O +
- O +
talk O +
between O +
lipoplex O +
composition O +
, O +
interaction O +
with O +
serum O +
, O +
hemodynamics O +
, O +
and O +
target O +
tissue O +
" O +
susceptibility O +
" O +
to O +
transfection O +
. O +

Integration O +
of O +
interferon O +
- O +
alpha O +
/ O +
beta O +
signalling O +
to O +
p53 O +
responses O +
in O +
tumour O +
suppression O +
and O +
antiviral O +
defence O +
. O +

Swift O +
elimination O +
of O +
undesirable O +
cells O +
is O +
an O +
important O +
feature O +
in O +
tumour O +
suppression O +
and O +
immunity O +
. O +

The O +
tumour O +
suppressor O +
p53 O +
and O +
interferon O +
- O +
alpha O +
and O +
- O +
beta O +
( O +
IFN O +
- O +
alpha O +
/ O +
beta O +
) O +
are O +
essential O +
for O +
the O +
induction O +
of O +
apoptosis O +
in O +
cancerous O +
cells O +
and O +
in O +
antiviral O +
immune O +
responses O +
, O +
respectively O +
, O +
but O +
little O +
is O +
known O +
about O +
their O +
interrelationship O +
. O +

Here O +
we O +
show O +
that O +
transcription O +
of O +
the O +
p53 O +
gene O +
is O +
induced O +
by O +
IFN O +
- O +
alpha O +
/ O +
beta O +
, O +
accompanied O +
by O +
an O +
increase O +
in O +
p53 O +
protein O +
level O +
. O +

IFN O +
- O +
alpha O +
/ O +
beta O +
signalling O +
itself O +
does O +
not O +
activate O +
p53 O +
; O +
rather O +
, O +
it O +
contributes O +
to O +
boosting O +
p53 O +
responses O +
to O +
stress O +
signals O +
. O +

We O +
show O +
examples O +
in O +
which O +
p53 O +
gene O +
induction O +
by O +
IFN O +
- O +
alpha O +
/ O +
beta O +
contributes O +
to O +
tumour O +
suppression O +
. O +

Furthermore O +
, O +
we O +
show O +
that O +
p53 O +
is O +
activated O +
in O +
virally O +
infected O +
cells O +
to O +
evoke O +
an O +
apoptotic O +
response O +
and O +
that O +
p53 O +
is O +
critical O +
for O +
antiviral O +
defence O +
of O +
the O +
host O +
. O +

Our O +
study O +
reveals O +
a O +
hitherto O +
unrecognized O +
link O +
between O +
p53 O +
and O +
IFN O +
- O +
alpha O +
/ O +
beta O +
in O +
tumour O +
suppression O +
and O +
antiviral O +
immunity O +
, O +
which O +
may O +
have O +
therapeutic O +
implications O +
. O +

Stereoselective O +
synthesis O +
of O +
1 O +
- O +
aminoalkanephosphonic O +
acids O +
with O +
two O +
chiral O +
centers O +
and O +
their O +
activity O +
towards O +
leucine O +
aminopeptidase O +
. O +

The O +
stereoselective O +
synthesis O +
of O +
1 O +
- O +
amino O +
- O +
2 O +
- O +
alkylalkanephosphonic O +
acids O +
, O +
namely O +
, O +
compounds O +
bearing O +
two O +
chiral O +
centers O +
, O +
was O +
achieved O +
by O +
the O +
condensation O +
of O +
hypophosphorous O +
acid O +
salts O +
of O +
( O +
R O +
) O +
( O +
+ O +
) O +
or O +
( O +
S O +
) O +
( O +
- O +
) O +
- O +
N O +
- O +
alpha O +
- O +
methylbenzylamine O +
with O +
the O +
appropriate O +
aldehydes O +
in O +
isopropanol O +
. O +

Simultaneous O +
deprotection O +
and O +
oxidation O +
by O +
the O +
action O +
of O +
bromine O +
water O +
provided O +
equimolar O +
mixtures O +
of O +
the O +
RS O +
: O +
RR O +
and O +
SR O +
: O +
SS O +
diastereomers O +
of O +
desired O +
acids O +
. O +

They O +
appeared O +
to O +
act O +
as O +
moderate O +
inhibitors O +
of O +
kidney O +
leucine O +
aminopeptidase O +
with O +
potency O +
dependent O +
on O +
the O +
absolute O +
configuration O +
of O +
both O +
centers O +
of O +
chirality O +
. O +

Proliferative O +
diabetic O +
retinopathy O +
is O +
associated O +
with O +
a O +
low O +
level O +
of O +
the O +
natural O +
ocular O +
anti O +
- O +
angiogenic O +
agent O +
pigment O +
epithelium O +
- O +
derived O +
factor O +
( O +
PEDF O +
) O +
in O +
aqueous O +
humor O +
. O +

a O +
pilot O +
study O +
. O +

Retinopathy O +
is O +
the O +
most O +
common O +
microvascular O +
diabetes O +
complication O +
and O +
represents O +
a O +
major O +
threat O +
to O +
the O +
eyesight O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
address O +
the O +
role O +
of O +
pro O +
- O +
and O +
anti O +
- O +
angiogenic O +
molecules O +
in O +
diabetic O +
retinopathy O +
in O +
the O +
aqueous O +
humor O +
of O +
the O +
eye O +
. O +

Aqueous O +
humor O +
was O +
collected O +
at O +
cataract O +
surgery O +
from O +
19 O +
diabetic O +
patients O +
and O +
from O +
13 O +
age O +
- O +
and O +
sex O +
- O +
matched O +
normoglycemic O +
controls O +
. O +

Levels O +
of O +
pro O +
- O +
angiogenic O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
and O +
angiogenic O +
inhibitor O +
pigment O +
epithelium O +
- O +
derived O +
factor O +
( O +
PEDF O +
) O +
were O +
determined O +
. O +

Angiogenic O +
activity O +
of O +
the O +
aqueous O +
humor O +
was O +
quantified O +
by O +
measuring O +
its O +
effect O +
on O +
the O +
migration O +
of O +
capillary O +
endothelial O +
cells O +
. O +

In O +
the O +
aqueous O +
fluid O +
, O +
VEGF O +
levels O +
were O +
increased O +
in O +
diabetics O +
( O +
mean O +
values O +
: O +
501 O +
vs O +
. O +
367 O +
pg O +
/ O +
ml O +
; O +
p O +
= O +
0 O +
. O +
05 O +
) O +
, O +
compared O +
to O +
controls O +
. O +

PEDF O +
was O +
found O +
to O +
be O +
decreased O +
in O +
diabetics O +
( O +
mean O +
values O +
: O +
2080 O +
vs O +
. O +
5780 O +
ng O +
/ O +
ml O +
; O +
p O +
= O +
0 O +
. O +
04 O +
) O +
compared O +
to O +
controls O +
. O +

In O +
seven O +
diabetic O +
patients O +
with O +
proliferative O +
retinopathy O +
, O +
the O +
most O +
profound O +
finding O +
was O +
a O +
significant O +
decrease O +
of O +
the O +
PEDF O +
level O +
( O +
mean O +
value O +
: O +
237 O +
ng O +
/ O +
ml O +
) O +
, O +
whereas O +
VEGF O +
levels O +
were O +
comparable O +
to O +
diabetic O +
patients O +
without O +
proliferation O +
( O +
mean O +
value O +
: O +
3153 O +
; O +
p O +
= O +
0 O +
. O +
003 O +
) O +
. O +

Angiogenic O +
activity O +
in O +
samples O +
of O +
patients O +
from O +
the O +
control O +
group O +
was O +
generally O +
inhibitory O +
due O +
to O +
PEDF O +
, O +
and O +
inhibition O +
was O +
blocked O +
by O +
neutralizing O +
antibodies O +
to O +
PEDF O +
. O +

Likewise O +
, O +
in O +
diabetics O +
without O +
proliferation O +
, O +
angiogenic O +
activity O +
was O +
also O +
blocked O +
by O +
antibodies O +
to O +
PEDF O +
. O +

We O +
will O +
demonstrate O +
here O +
that O +
the O +
level O +
of O +
the O +
natural O +
ocular O +
anti O +
- O +
angiogenic O +
agent O +
PEDF O +
is O +
inversely O +
associated O +
with O +
proliferative O +
retinopathy O +
. O +

PEDF O +
is O +
an O +
important O +
negative O +
regulator O +
of O +
angiogenic O +
activity O +
of O +
aqueous O +
humor O +
. O +

Our O +
data O +
may O +
have O +
implications O +
for O +
the O +
development O +
of O +
novel O +
regimens O +
for O +
diabetic O +
retinopathy O +
. O +

Expression O +
of O +
osteoprotegerin O +
and O +
RANK O +
ligand O +
in O +
breast O +
cancer O +
bone O +
metastasis O +
. O +

Bone O +
destruction O +
is O +
primarily O +
mediated O +
by O +
osteoclastic O +
bone O +
resorption O +
, O +
and O +
cancer O +
cells O +
stimulate O +
the O +
formation O +
and O +
activation O +
of O +
osteoclasts O +
next O +
to O +
metastatic O +
foci O +
. O +

Accumulating O +
evidences O +
indicate O +
that O +
receptor O +
activator O +
of O +
NF O +
- O +
kB O +
ligand O +
( O +
RANKL O +
) O +
is O +
the O +
ultimate O +
extracellular O +
mediator O +
that O +
stimulates O +
osteoclast O +
differentiation O +
into O +
mature O +
osteoclasts O +
. O +

In O +
contrast O +
, O +
osteoprotegerin O +
( O +
OPG O +
) O +
inhibits O +
osteoclast O +
development O +
. O +

In O +
order O +
to O +
elucidate O +
a O +
mechanism O +
for O +
cancer O +
- O +
induced O +
osteoclastogenesis O +
, O +
cells O +
from O +
a O +
human O +
breast O +
cancer O +
line O +
, O +
MDA B-CellLine +
- I-CellLine +
MB I-CellLine +
- I-CellLine +
231 I-CellLine +
, O +
were O +
directly O +
co O +
- O +
cultured O +
with O +
ST2 B-CellLine +
, O +
MC3T3 B-CellLine +
- I-CellLine +
E1 I-CellLine +
, O +
or O +
with O +
primary O +
mouse O +
calvarial O +
cells O +
. O +

Osteoclast O +
- O +
like O +
cells O +
and O +
tartarate O +
resistant O +
acid O +
phosphatase O +
( O +
TRAP O +
) O +
activities O +
were O +
then O +
quantitated O +
. O +

We O +
examined O +
these O +
cell O +
lines O +
and O +
samples O +
from O +
breast O +
cancer O +
by O +
RT O +
- O +
PCR O +
for O +
the O +
expressions O +
of O +
OPG O +
and O +
RANKL O +
mRNA O +
. O +

Compared O +
to O +
controls O +
, O +
co O +
- O +
culture O +
of O +
MDA B-CellLine +
- I-CellLine +
MB I-CellLine +
- I-CellLine +
231 I-CellLine +
cells O +
with O +
stromal O +
or O +
osteoblastic O +
cells O +
induced O +
an O +
increase O +
in O +
number O +
of O +
osteoclasts O +
and O +
TRAP O +
activities O +
. O +

MDA B-CellLine +
- I-CellLine +
MB I-CellLine +
- I-CellLine +
231 I-CellLine +
cells O +
alone O +
or O +
breast O +
cancer O +
samples O +
did O +
not O +
express O +
RANKL O +
mRNA O +
. O +

However O +
, O +
co O +
- O +
culture O +
of O +
these O +
cancer O +
cells O +
with O +
stromal O +
or O +
osteoblastic O +
cells O +
induced O +
RANKL O +
mRNA O +
expression O +
and O +
decreased O +
OPG O +
mRNA O +
expression O +
. O +

These O +
experiments O +
demonstrate O +
that O +
direct O +
interactions O +
between O +
breast O +
cancer O +
and O +
stromal O +
or O +
osteoblastic O +
cells O +
induce O +
osteoclastogenesis O +
in O +
vitro O +
through O +
modulating O +
RANKL O +
expression O +
. O +

T140 O +
analogs O +
as O +
CXCR4 O +
antagonists O +
identified O +
as O +
anti O +
- O +
metastatic O +
agents O +
in O +
the O +
treatment O +
of O +
breast O +
cancer O +
. O +

A O +
chemokine O +
receptor O +
, O +
CXCR4 O +
, O +
and O +
its O +
endogenous O +
ligand O +
, O +
stromal O +
cell O +
- O +
derived O +
factor O +
- O +
1 O +
( O +
SDF O +
- O +
1 O +
) O +
, O +
have O +
been O +
recognized O +
to O +
be O +
involved O +
in O +
the O +
metastasis O +
of O +
several O +
types O +
of O +
cancers O +
. O +

T140 O +
analogs O +
are O +
peptidic O +
CXCR4 O +
antagonists O +
composed O +
of O +
14 O +
amino O +
acid O +
residues O +
that O +
were O +
previously O +
developed O +
as O +
anti O +
- O +
HIV O +
agents O +
having O +
inhibitory O +
activity O +
against O +
HIV O +
- O +
entry O +
through O +
its O +
co O +
- O +
receptor O +
, O +
CXCR4 O +
. O +

Herein O +
, O +
we O +
report O +
that O +
these O +
compounds O +
effectively O +
inhibited O +
SDF O +
- O +
1 O +
- O +
induced O +
migration O +
of O +
human O +
breast O +
cancer O +
cells O +
( O +
MDA B-CellLine +
- I-CellLine +
MB I-CellLine +
- I-CellLine +
231 I-CellLine +
) O +
, O +
human O +
leukemia O +
T O +
cells O +
( O +
Sup B-CellLine +
- I-CellLine +
T1 I-CellLine +
) O +
and O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
at O +
concentrations O +
of O +
10 O +
- O +
100 O +
nM O +
in O +
vitro O +
. O +

Furthermore O +
, O +
slow O +
release O +
administration O +
by O +
subcutaneous O +
injection O +
using O +
an O +
Alzet O +
osmotic O +
pump O +
of O +
a O +
potent O +
and O +
bio O +
- O +
stable O +
T140 O +
analog O +
, O +
4F O +
- O +
benzoyl O +
- O +
TN14003 O +
, O +
gave O +
a O +
partial O +
, O +
but O +
statistically O +
significant O +
( O +
P O +
< O +
/ O +
= O +
0 O +
. O +
05 O +
( O +
t O +
- O +
test O +
) O +
) O +
reduction O +
in O +
pulmonary O +
metastasis O +
of O +
MDA B-CellLine +
- I-CellLine +
MB I-CellLine +
- I-CellLine +
231 I-CellLine +
in O +
SCID O +
mice O +
, O +
even O +
though O +
no O +
attempt O +
was O +
made O +
to O +
inhibit O +
other O +
important O +
targets O +
such O +
as O +
CCR7 O +
. O +

These O +
results O +
suggest O +
that O +
T140 O +
analogs O +
have O +
potential O +
use O +
for O +
cancer O +
therapy O +
, O +
and O +
that O +
small O +
molecular O +
CXCR4 O +
antagonists O +
could O +
potentially O +
replace O +
neutralizing O +
antibodies O +
as O +
anti O +
- O +
metastatic O +
agents O +
for O +
breast O +
cancer O +
. O +

Treatment O +
effects O +
on O +
nigrostriatal O +
projection O +
integrity O +
in O +
partial O +
6 O +
- O +
OHDA O +
lesions O +
: O +
comparison O +
of O +
L O +
- O +
DOPA O +
and O +
pramipexole O +
. O +

There O +
is O +
controversy O +
over O +
potential O +
effects O +
of O +
dopaminergic O +
replacement O +
therapies O +
on O +
the O +
partially O +
lesioned O +
nigrostriatal O +
dopaminergic O +
projection O +
. O +

We O +
evaluated O +
indirect O +
( O +
levodopa O +
, O +
L O +
- O +
DOPA O +
) O +
versus O +
direct O +
( O +
pramipexole O +
, O +
PRA O +
) O +
dopaminergic O +
treatment O +
effects O +
on O +
nigrostriatal O +
lesion O +
severity O +
as O +
measured O +
with O +
vesicular O +
monoamine O +
transporter O +
type O +
- O +
2 O +
( O +
VMAT2 O +
) O +
binding O +
. O +

Prior O +
studies O +
have O +
shown O +
that O +
striatal O +
VMAT2 O +
density O +
provides O +
an O +
objective O +
estimate O +
of O +
dopaminergic O +
neuronal O +
integrity O +
, O +
without O +
confounding O +
effects O +
of O +
compensatory O +
regulation O +
. O +

Partial O +
unilateral O +
median O +
forebrain O +
bundle O +
lesions O +
were O +
made O +
by O +
injection O +
of O +
6 O +
- O +
hydroxydopamine O +
in O +
adult O +
male O +
Sprague O +
- O +
Dawley O +
rats O +
. O +

Lesion O +
severity O +
was O +
estimated O +
using O +
rotational O +
behavior O +
after O +
injections O +
of O +
apomorphine O +
and O +
amphetamine O +
. O +

Rats O +
were O +
ranked O +
and O +
matched O +
in O +
pairs O +
by O +
rotation O +
and O +
assigned O +
to O +
receive O +
either O +
PRA O +
( O +
1 O +
mg O +
/ O +
kg O +
/ O +
day O +
) O +
or O +
L O +
- O +
DOPA O +
/ O +
benserazide O +
( O +
100 O +
/ O +
25 O +
mg O +
/ O +
kg O +
/ O +
day O +
) O +
ip O +
via O +
osmotic O +
pump O +
. O +

After O +
4 O +
weeks O +
of O +
drug O +
treatment O +
, O +
in O +
vitro O +
autoradiography O +
was O +
performed O +
with O +
[ O +
( O +
3 O +
) O +
H O +
] O +
methoxytetrabenazine O +
to O +
measure O +
striatal O +
VMAT2 O +
binding O +
density O +
. O +

Lesion O +
- O +
to O +
- O +
intact O +
VMAT2 O +
density O +
correlated O +
with O +
rotation O +
in O +
both O +
treatment O +
groups O +
. O +

There O +
was O +
no O +
treatment O +
effect O +
on O +
VMAT2 O +
expression O +
in O +
the O +
partially O +
lesioned O +
striatum O +
and O +
thus O +
no O +
differential O +
effect O +
of O +
indirect O +
versus O +
direct O +
dopamimetic O +
treatment O +
on O +
nigrostriatal O +
integrity O +
. O +

CCL16 O +
activates O +
an O +
angiogenic O +
program O +
in O +
vascular O +
endothelial O +
cells O +
. O +

Besides O +
regulating O +
leukocyte O +
trafficking O +
in O +
normal O +
and O +
injured O +
tissues O +
, O +
several O +
chemokines O +
may O +
positively O +
or O +
negatively O +
regulate O +
angiogenesis O +
. O +

Here O +
we O +
report O +
that O +
CCL16 O +
activates O +
an O +
angiogenic O +
program O +
in O +
vascular O +
endothelial O +
cells O +
by O +
activating O +
CCR1 O +
. O +

CCL16 O +
induces O +
dose O +
- O +
dependent O +
random O +
and O +
directional O +
migration O +
of O +
endothelial O +
cells O +
isolated O +
from O +
large O +
vessels O +
and O +
liver O +
capillaries O +
without O +
inducing O +
their O +
proliferation O +
. O +

It O +
also O +
promotes O +
endothelial O +
differentiation O +
into O +
capillary O +
- O +
like O +
structures O +
in O +
an O +
in O +
vitro O +
assay O +
and O +
is O +
angiogenic O +
in O +
the O +
chick O +
chorionallantoic O +
membrane O +
. O +

These O +
angiogenic O +
activities O +
are O +
neutralized O +
by O +
a O +
specific O +
antibody O +
against O +
CCL16 O +
. O +

The O +
direct O +
angiogenic O +
activity O +
of O +
CCL16 O +
is O +
further O +
amplified O +
by O +
its O +
ability O +
to O +
prime O +
endothelium O +
to O +
a O +
mitogen O +
signal O +
induced O +
by O +
vascular O +
endothelial O +
growth O +
factor O +
A O +
and O +
to O +
raise O +
their O +
basal O +
production O +
of O +
CXCL8 O +
and O +
CCL2 O +
, O +
2 O +
other O +
angiogenic O +
chemokines O +
. O +

BX471 O +
( O +
R O +
- O +
N O +
- O +
[ O +
5 O +
- O +
chloro O +
- O +
2 O +
- O +
[ O +
2 O +
- O +
[ O +
4 O +
( O +
4 O +
- O +
fluorophenyl O +
) O +
methyl O +
] O +
- O +
2 O +
- O +
methyl O +
- O +
1 O +
- O +
piperazinyl O +
] O +
- O +
2 O +
- O +
oxoethoxy O +
] O +
phenyl O +
] O +
urea O +
hydrochloric O +
acid O +
salt O +
) O +
, O +
a O +
CCR1 O +
antagonist O +
, O +
inhibits O +
angiogenic O +
properties O +
of O +
CCL16 O +
, O +
whereas O +
blocking O +
of O +
CCR8 O +
or O +
desensitizing O +
CCR2 O +
, O +
which O +
are O +
both O +
well O +
known O +
receptors O +
for O +
CCL16 O +
, O +
did O +
not O +
abolish O +
endothelial O +
activation O +
. O +

CCL16 O +
may O +
be O +
specifically O +
cross O +
- O +
linked O +
to O +
CCR1 O +
expressed O +
on O +
endothelial O +
cells O +
. O +

The O +
largely O +
restricted O +
CCL16 O +
expression O +
in O +
the O +
liver O +
suggests O +
that O +
this O +
chemokine O +
may O +
play O +
a O +
role O +
in O +
hepatic O +
vascular O +
formation O +
during O +
development O +
and O +
in O +
angiogenesis O +
associated O +
to O +
hepatic O +
diseases O +
. O +

Simvastatin O +
induces O +
apoptosis O +
of O +
B O +
- O +
CLL O +
cells O +
by O +
activation O +
of O +
mitochondrial O +
caspase O +
9 O +
. O +

BACKGROUND O +
AND O +
OBJECTIVES O +
: O +
Chronic O +
lymphocytic O +
leukemia O +
( O +
CLL O +
) O +
is O +
the O +
most O +
common O +
leukemia O +
in O +
the O +
western O +
world O +
. O +

Despite O +
several O +
advances O +
in O +
therapeutic O +
options O +
, O +
the O +
disease O +
remains O +
incurable O +
. O +

Recently O +
, O +
it O +
was O +
repeatedly O +
demonstrated O +
that O +
statins O +
, O +
competitive O +
inhibitors O +
of O +
3 O +
- O +
hydroxy O +
- O +
3 O +
- O +
methyl O +
glutaryl O +
coenzyme O +
A O +
( O +
HMG O +
- O +
CoA O +
) O +
reductase O +
, O +
have O +
antineoplastic O +
effects O +
. O +

Therefore O +
we O +
aimed O +
to O +
study O +
the O +
effects O +
of O +
simvastatin O +
( O +
Sim O +
) O +
on O +
malignant O +
B O +
cells O +
derived O +
from O +
patients O +
with O +
CLL O +
and O +
mechanisms O +
of O +
action O +
of O +
the O +
drug O +
. O +

METHODS O +
AND O +
RESULTS O +
: O +
Purified O +
B O +
- O +
CLL O +
cells O +
from O +
15 O +
patients O +
were O +
cultured O +
either O +
alone O +
or O +
with O +
Sim O +
at O +
concentrations O +
of O +
10 O +
, O +
50 O +
, O +
and O +
100 O +
microM O +
. O +

Viability O +
, O +
measured O +
by O +
the O +
activity O +
of O +
mitochondrial O +
dehydrogenases O +
, O +
was O +
reduced O +
significantly O +
in O +
the O +
cells O +
treated O +
with O +
Sim O +
at O +
50 O +
and O +
100 O +
microM O +
for O +
24 O +
hours O +
( O +
p O +
< O +
0 O +
. O +
005 O +
) O +
. O +

The O +
level O +
of O +
apoptosis O +
, O +
as O +
measured O +
by O +
annexin O +
binding O +
to O +
exposed O +
phosphatidylserine O +
moieties O +
, O +
increased O +
significantly O +
in O +
the O +
treated O +
cells O +
at O +
concentrations O +
higher O +
than O +
50 O +
microM O +
for O +
24 O +
hours O +
( O +
p O +
< O +
0 O +
. O +
003 O +
) O +
. O +

The O +
level O +
of O +
necrosis O +
, O +
as O +
measured O +
by O +
propidium O +
iodide O +
internalization O +
, O +
increased O +
significantly O +
after O +
24 O +
hours O +
exposure O +
to O +
Sim O +
at O +
50 O +
microM O +
( O +
p O +
< O +
0 O +
. O +
01 O +
) O +
. O +

The O +
apoptotic O +
cascade O +
was O +
studied O +
by O +
immunoblot O +
analysis O +
of O +
caspases O +
following O +
Sim O +
treatment O +
. O +

These O +
showed O +
cleavage O +
of O +
caspases O +
9 O +
, O +
8 O +
, O +
and O +
3 O +
. O +

Addition O +
of O +
the O +
caspase O +
inhibitor O +
Z O +
- O +
VAD O +
. O +
fmk O +
inhibited O +
caspase O +
8 O +
and O +
3 O +
significantly O +
but O +
did O +
not O +
affect O +
caspase O +
9 O +
. O +

CONCLUSION O +
: O +
Exposure O +
of O +
clonal O +
B O +
lymphocytes O +
from O +
patients O +
with O +
CLL O +
to O +
simvastatin O +
decreases O +
viability O +
significantly O +
by O +
the O +
induction O +
of O +
apoptosis O +
. O +

The O +
apoptosis O +
induced O +
by O +
Sim O +
is O +
probably O +
initiated O +
by O +
the O +
mitochondrial O +
caspase O +
9 O +
, O +
which O +
indirectly O +
leads O +
to O +
activation O +
of O +
caspase O +
3 O +
and O +
8 O +
. O +

[ O +
Community O +
intervention O +
on O +
hypertension O +
and O +
stroke O +
] O +
. O +

OBJECTIVE O +
: O +

To O +
evaluate O +
the O +
community O +
- O +
based O +
intervention O +
on O +
reduction O +
of O +
hypertension O +
and O +
stroke O +
in O +
different O +
age O +
groups O +
and O +
subtypes O +
hypertension O +
. O +

METHODS O +
: O +

In O +
6 O +
cities O +
, O +
2 O +
geographically O +
separated O +
communities O +
with O +
a O +
registered O +
population O +
about O +
10 O +
000 O +
of O +
each O +
were O +
selected O +
as O +
either O +
intervention O +
or O +
control O +
communities O +
. O +

A O +
cohort O +
containing O +
2 O +
700 O +
subjects O +
, O +
35 O +
years O +
or O +
older O +
, O +
and O +
free O +
of O +
stroke O +
were O +
sampled O +
from O +
each O +
community O +
. O +

The O +
baseline O +
survey O +
was O +
conducted O +
to O +
screen O +
the O +
subjects O +
for O +
intervention O +
. O +

In O +
each O +
city O +
, O +
a O +
program O +
for O +
control O +
of O +
hypertension O +
, O +
heart O +
diseases O +
and O +
diabetes O +
was O +
initiated O +
in O +
the O +
intervention O +
cohort O +
and O +
health O +
education O +
was O +
provided O +
to O +
the O +
whole O +
intervention O +
community O +
. O +

A O +
follow O +
- O +
up O +
survey O +
was O +
conducted O +
3 O +
years O +
later O +
. O +

RESULTS O +
: O +

Within O +
3 O +
years O +
, O +
the O +
prevalence O +
of O +
hypertension O +
increased O +
in O +
both O +
intervention O +
and O +
control O +
cohorts O +
, O +
as O +
well O +
as O +
in O +
the O +
middle O +
and O +
elderly O +
cohorts O +
, O +
especially O +
in O +
the O +
middle O +
aged O +
in O +
control O +
group O +
. O +

Among O +
hypertensives O +
in O +
the O +
intervention O +
cohort O +
, O +
the O +
rates O +
of O +
awareness O +
, O +
treatment O +
and O +
control O +
of O +
hypertension O +
got O +
improved O +
. O +

The O +
incidence O +
of O +
stroke O +
was O +
29 O +
% O +
lower O +
( O +
HR O +
= O +
0 O +
. O +
71 O +
, O +
95 O +
% O +
CI O +
: O +
0 O +
. O +
58 O +
- O +
0 O +
. O +
87 O +
) O +
and O +
mortality O +
of O +
stroke O +
was O +
40 O +
% O +
lower O +
( O +
HR O +
= O +
0 O +
. O +
60 O +
, O +
95 O +
% O +
CI O +
: O +
0 O +
. O +
42 O +
- O +
0 O +
. O +
86 O +
) O +
in O +
the O +
intervention O +
cohort O +
than O +
the O +
control O +
cohort O +
. O +

The O +
intervention O +
was O +
most O +
effective O +
in O +
reduction O +
of O +
stroke O +
for O +
those O +
with O +
isolated O +
systolic O +
hypertension O +
and O +
combined O +
systolic O +
and O +
diastolic O +
hypertension O +
( O +
All O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

Meanwhile O +
, O +
all O +
- O +
cause O +
mortality O +
was O +
11 O +
% O +
lower O +
( O +
HR O +
= O +
0 O +
. O +
89 O +
, O +
95 O +
% O +
CI O +
: O +
0 O +
. O +
78 O +
- O +
0 O +
. O +
99 O +
) O +
in O +
the O +
intervention O +
cohort O +
than O +
in O +
the O +
control O +
cohort O +
. O +

CONCLUSION O +
: O +

The O +
community O +
- O +
based O +
intervention O +
was O +
effective O +
in O +
controlling O +
the O +
development O +
of O +
hypertension O +
and O +
stroke O +
, O +
while O +
the O +
elderly O +
people O +
benefit O +
more O +
than O +
the O +
middle O +
aged O +
people O +
from O +
the O +
intervention O +
. O +

Neutrophil O +
function O +
in O +
chronic O +
neutrophilic O +
leukemia O +
: O +
defective O +
respiratory O +
burst O +
in O +
response O +
to O +
phorbol O +
esters O +
. O +

Functional O +
analyses O +
were O +
performed O +
on O +
neutrophils O +
isolated O +
from O +
6 O +
patients O +
from O +
two O +
institutions O +
who O +
displayed O +
features O +
of O +
chronic O +
neutrophilic O +
leukemia O +
( O +
CNL O +
) O +
. O +

These O +
neutrophils O +
demonstrated O +
a O +
consistent O +
deficiency O +
( O +
44 O +
+ O +
/ O +
- O +
8 O +
% O +
of O +
control O +
values O +
) O +
in O +
superoxide O +
anion O +
( O +
O2 O +
- O +
) O +
production O +
in O +
response O +
to O +
the O +
phorbol O +
ester O +
, O +
phorbol O +
myristate O +
acetate O +
( O +
PMA O +
) O +
. O +

O2 O +
- O +
production O +
in O +
response O +
to O +
chemotactic O +
peptides O +
was O +
near O +
normal O +
( O +
82 O +
. O +
3 O +
+ O +
/ O +
- O +
10 O +
. O +
7 O +
% O +
of O +
control O +
values O +
) O +
. O +

Bacterial O +
killing O +
was O +
normal O +
in O +
the O +
two O +
patients O +
studied O +
, O +
and O +
chemotaxis O +
was O +
diminished O +
in O +
response O +
to O +
zymosan O +
- O +
activated O +
plasma O +
and O +
to O +
high O +
concentrations O +
of O +
chemotactic O +
peptides O +
in O +
the O +
patients O +
studied O +
. O +

Cytosolic O +
C O +
kinase O +
activity O +
was O +
decreased O +
in O +
one O +
of O +
the O +
two O +
patients O +
studied O +
. O +

These O +
results O +
suggest O +
that O +
a O +
deficient O +
O2 O +
- O +
release O +
in O +
response O +
to O +
PMA O +
is O +
a O +
hallmark O +
of O +
neutrophils O +
in O +
CNL O +
and O +
may O +
provide O +
a O +
diagnostic O +
indicator O +
of O +
this O +
condition O +
. O +

In O +
situ O +
alkylation O +
of O +
cysteine O +
residues O +
in O +
a O +
hydrophobic O +
membrane O +
protein O +
immobilized O +
on O +
polyvinylidene O +
difluoride O +
membranes O +
by O +
electroblotting O +
prior O +
to O +
microsequence O +
and O +
amino O +
acid O +
analysis O +
. O +

For O +
identification O +
of O +
cysteine O +
residues O +
on O +
microsequence O +
analysis O +
it O +
is O +
crucial O +
to O +
derivatize O +
the O +
sulfhydryl O +
groups O +
. O +

This O +
reaction O +
requires O +
a O +
desalting O +
step O +
which O +
often O +
represents O +
a O +
major O +
obstacle O +
, O +
especially O +
if O +
the O +
sample O +
consists O +
of O +
limited O +
amounts O +
of O +
a O +
hydrophobic O +
membrane O +
protein O +
. O +

An O +
alkylation O +
procedure O +
is O +
described O +
, O +
allowing O +
efficient O +
derivatization O +
( O +
greater O +
than O +
90 O +
% O +
) O +
of O +
cysteines O +
and O +
cystines O +
even O +
in O +
low O +
microgram O +
quantities O +
, O +
as O +
revealed O +
by O +
test O +
analyses O +
with O +
lysozyme O +
and O +
a O +
hydrophobic O +
membrane O +
protein O +
. O +

The O +
modified O +
protein O +
is O +
recovered O +
in O +
high O +
yields O +
in O +
a O +
form O +
suitable O +
for O +
both O +
microsequence O +
analysis O +
and O +
amino O +
acid O +
analysis O +
. O +

The O +
method O +
involves O +
electrophoretic O +
desalting O +
by O +
miniaturized O +
Tricine O +
- O +
sodium O +
dodecyl O +
sulfate O +
- O +
polyacrylamide O +
gel O +
electrophoresis O +
and O +
in O +
situ O +
alkylation O +
after O +
electro O +
- O +
transfer O +
onto O +
polyvinylidene O +
difluoride O +
membranes O +
. O +

Precautions O +
against O +
NH2 O +
- O +
terminal O +
blocking O +
during O +
sample O +
preparations O +
are O +
provided O +
. O +

The O +
general O +
applicability O +
of O +
the O +
method O +
is O +
illustrated O +
by O +
the O +
structural O +
characterization O +
of O +
the O +
low O +
abundance O +
membrane O +
receptor O +
for O +
human O +
urokinase O +
plasminogen O +
activator O +
. O +

Cloning O +
and O +
characterization O +
of O +
the O +
latent O +
membrane O +
protein O +
( O +
LMP O +
) O +
of O +
a O +
specific O +
Epstein O +
- O +
Barr O +
virus O +
variant O +
derived O +
from O +
the O +
nasopharyngeal O +
carcinoma O +
in O +
the O +
Taiwanese O +
population O +
. O +

A O +
DNA O +
fragment O +
containing O +
Epstein O +
- O +
Barr O +
virus O +
( O +
EBV O +
) O +
terminal O +
fragment O +
sequence O +
was O +
obtained O +
from O +
a O +
genomic O +
library O +
of O +
nasopharyngeal O +
carcinoma O +
( O +
NPC O +
) O +
. O +

One O +
of O +
the O +
clones O +
( O +
clone O +
1510 O +
) O +
contained O +
the O +
gene O +
encoding O +
latent O +
membrane O +
protein O +
( O +
LMP O +
) O +
. O +

Sequence O +
analysis O +
revealed O +
that O +
this O +
gene O +
had O +
95 O +
% O +
homology O +
with O +
the O +
LMP O +
sequence O +
of O +
the O +
B95 O +
- O +
8 O +
strain O +
. O +

Among O +
the O +
sequence O +
variations O +
, O +
there O +
was O +
a O +
change O +
from O +
G O +
to O +
T O +
at O +
nucleotide O +
position O +
169 O +
, O +
426 O +
, O +
resulting O +
in O +
the O +
loss O +
of O +
an O +
XhoI O +
site O +
in O +
exon O +
1 O +
of O +
the O +
LMP O +
gene O +
. O +

A O +
pair O +
of O +
primers O +
bracketing O +
the O +
XhoI O +
site O +
were O +
designed O +
to O +
synthesize O +
the O +
EBV O +
DNA O +
fragment O +
from O +
nucleotides O +
169 O +
, O +
081 O +
- O +
169 O +
, O +
577 O +
by O +
using O +
the O +
polymerase O +
chain O +
reaction O +
( O +
PCR O +
) O +
method O +
. O +

The O +
PCR O +
products O +
were O +
then O +
subject O +
to O +
XhoI O +
digestion O +
and O +
to O +
DNA O +
sequencing O +
analysis O +
. O +

This O +
restriction O +
enzyme O +
site O +
polymorphism O +
along O +
with O +
the O +
sequence O +
variations O +
were O +
also O +
observed O +
in O +
50 O +
biopsy O +
tissues O +
as O +
well O +
as O +
in O +
the O +
throat O +
washings O +
of O +
6 O +
out O +
of O +
20 O +
healthy O +
individuals O +
that O +
we O +
examined O +
, O +
indicating O +
that O +
the O +
EBV O +
strain O +
predominantly O +
existing O +
in O +
these O +
biopsy O +
tissues O +
was O +
different O +
from O +
strains O +
of O +
B95 O +
- O +
8 O +
, O +
Jijoye O +
or O +
nude O +
mouse O +
passaged O +
cells O +
( O +
C15 B-CellLine +
) O +
with O +
an O +
African O +
origin O +
, O +
but O +
closely O +
resembled O +
other O +
nude O +
mouse O +
passaged O +
CAO B-CellLine +
cells O +
which O +
were O +
originally O +
derived O +
from O +
China O +
. O +

Balb B-CellLine +
/ I-CellLine +
c I-CellLine +
3T3 I-CellLine +
cells O +
carrying O +
this O +
NPC O +
- O +
LMP O +
gene O +
showed O +
a O +
transformed O +
cell O +
morphology O +
and O +
were O +
tumorigenic O +
in O +
nude O +
mice O +
. O +

The O +
relationship O +
between O +
this O +
unique O +
type O +
of O +
EBV O +
and O +
NPC O +
has O +
yet O +
to O +
be O +
established O +
. O +

The O +
effect O +
of O +
p O +
- O +
chlorophenylalanine O +
on O +
the O +
pethidine O +
- O +
or O +
methadone O +
- O +
induced O +
decrease O +
in O +
locomotor O +
activity O +
of O +
rats O +
. O +

Either O +
pethidine O +
HCl O +
( O +
50 O +
mg O +
/ O +
kg O +
s O +
. O +
c O +
. O +
) O +
or O +
methadone O +
HCl O +
( O +
8 O +
mg O +
/ O +
kg O +
s O +
. O +
c O +
. O +
) O +
produced O +
a O +
prominent O +
decrease O +
in O +
locomotor O +
activity O +
of O +
rats O +
. O +

Pretreatment O +
of O +
rats O +
with O +
p O +
- O +
chlorophenylalanine O +
( O +
p O +
- O +
CPA O +
, O +
320 O +
mg O +
/ O +
kg O +
i O +
. O +
p O +
. O +
) O +
48 O +
h O +
before O +
the O +
narcotic O +
injection O +
significantly O +
antagonized O +
the O +
activity O +
- O +
decreasing O +
effects O +
of O +
narcotics O +
. O +

When O +
rats O +
pretreated O +
with O +
p O +
- O +
CPA O +
were O +
given O +
5 O +
- O +
hydroxytryptophan O +
( O +
75 O +
mg O +
/ O +
kg O +
s O +
. O +
c O +
. O +
) O +
30 O +
min O +
before O +
narcotic O +
administration O +
, O +
the O +
activity O +
- O +
decreasing O +
response O +
to O +
narcotics O +
was O +
restored O +
. O +

Thus O +
, O +
a O +
decrease O +
in O +
locomotor O +
activity O +
induced O +
in O +
rats O +
by O +
either O +
pethidine O +
or O +
methadone O +
is O +
probably O +
mediated O +
by O +
serotonergic O +
mechanisms O +
. O +

Autocrine O +
angiotensin O +
system O +
regulation O +
of O +
bovine O +
aortic O +
endothelial O +
cell O +
migration O +
and O +
plasminogen O +
activator O +
involves O +
modulation O +
of O +
proto O +
- O +
oncogene O +
pp60c O +
- O +
src O +
expression O +
. O +

Rapid O +
endothelial O +
cell O +
migration O +
and O +
inhibition O +
of O +
thrombosis O +
are O +
critical O +
for O +
the O +
resolution O +
of O +
denudation O +
injuries O +
to O +
the O +
vessel O +
wall O +
. O +

Inhibition O +
of O +
the O +
endothelial O +
cell O +
autocrine O +
angiotensin O +
system O +
, O +
with O +
either O +
the O +
angiotensin O +
- O +
converting O +
enzyme O +
inhibitor O +
lisinopril O +
or O +
the O +
angiotensin O +
II O +
receptor O +
antagonist O +
sar1 O +
, O +
ile8 O +
- O +
angiotensin O +
II O +
, O +
leads O +
to O +
increased O +
endothelial O +
cell O +
migration O +
and O +
urokinase O +
- O +
like O +
plasminogen O +
activator O +
( O +
u O +
- O +
PA O +
) O +
activity O +
( O +
Bell O +
, O +
L O +
. O +
, O +
and O +
J O +
. O +
A O +
. O +
Madri O +
. O +
1990 O +
. O +
Am O +
. O +
J O +
. O +
Pathol O +
. O +
137 O +
: O +
7 O +
- O +
12 O +
) O +
. O +

Inhibition O +
of O +
the O +
autocrine O +
angiotensin O +
system O +
with O +
the O +
converting O +
- O +
enzyme O +
inhibitor O +
or O +
the O +
receptor O +
antagonist O +
also O +
leads O +
to O +
increased O +
expression O +
of O +
the O +
proto O +
- O +
oncogene O +
c O +
- O +
src O +
: O +
pp60c O +
- O +
src O +
mRNA O +
increased O +
7 O +
- O +
11 O +
- O +
fold O +
, O +
c O +
- O +
src O +
protein O +
3 O +
- O +
fold O +
, O +
and O +
c O +
- O +
src O +
kinase O +
activity O +
2 O +
- O +
3 O +
- O +
fold O +
. O +

Endothelial O +
cell O +
expression O +
of O +
c O +
- O +
src O +
was O +
constitutively O +
elevated O +
after O +
stable O +
infection O +
with O +
a O +
retroviral O +
vector O +
containing O +
the O +
c O +
- O +
src O +
coding O +
sequence O +
. O +

Constitutively O +
increased O +
c O +
- O +
src O +
kinase O +
activity O +
reconstituted O +
the O +
increases O +
in O +
migration O +
and O +
u O +
- O +
PA O +
observed O +
with O +
angiotensin O +
system O +
interruption O +
. O +

Antisera O +
to O +
bovine O +
u O +
- O +
PA O +
blocked O +
the O +
increase O +
in O +
migration O +
associated O +
with O +
increased O +
c O +
- O +
src O +
expression O +
. O +

These O +
data O +
suggest O +
that O +
increases O +
in O +
endothelial O +
cell O +
migration O +
and O +
plasminogen O +
activator O +
after O +
angiotensin O +
system O +
inhibition O +
are O +
at O +
least O +
partially O +
pp60c O +
- O +
src O +
mediated O +
. O +

Elevated O +
c O +
- O +
src O +
expression O +
with O +
angiotensin O +
system O +
inhibition O +
may O +
act O +
to O +
enhance O +
intimal O +
wound O +
closure O +
and O +
to O +
reduce O +
luminal O +
thrombogenicity O +
in O +
vivo O +
. O +

Angiogenesis O +
- O +
- O +
biomedical O +
technology O +
. O +

All O +
of O +
these O +
studies O +
show O +
that O +
angiogenesis O +
research O +
can O +
benefit O +
from O +
new O +
biomedical O +
technology O +
tools O +
currently O +
being O +
developed O +
, O +
as O +
well O +
as O +
contribute O +
by O +
providing O +
new O +
technologies O +
that O +
can O +
be O +
used O +
in O +
other O +
areas O +
of O +
medicine O +
. O +

It O +
is O +
hoped O +
that O +
the O +
chapters O +
in O +
this O +
book O +
in O +
this O +
area O +
will O +
provide O +
the O +
reader O +
with O +
an O +
up O +
- O +
to O +
- O +
date O +
appreciation O +
of O +
some O +
of O +
the O +
exciting O +
research O +
that O +
is O +
currently O +
being O +
pursued O +
. O +

Interleukin O +
- O +
1 O +
receptor O +
antagonist O +
inhibits O +
ischaemic O +
and O +
excitotoxic O +
neuronal O +
damage O +
in O +
the O +
rat O +
. O +

Interleukin O +
- O +
1 O +
( O +
IL O +
- O +
1 O +
) O +
synthesis O +
in O +
the O +
brain O +
is O +
stimulated O +
by O +
mechanical O +
injury O +
and O +
IL O +
- O +
1 O +
mimics O +
some O +
effects O +
of O +
injury O +
, O +
such O +
as O +
gliosis O +
and O +
neovascularization O +
. O +

We O +
report O +
that O +
neuronal O +
death O +
resulting O +
from O +
focal O +
cerebral O +
ischaemia O +
( O +
middle O +
cerebral O +
artery O +
occlusion O +
, O +
24 O +
h O +
) O +
is O +
significantly O +
inhibited O +
( O +
by O +
50 O +
% O +
) O +
in O +
rats O +
injected O +
with O +
a O +
recombinant O +
IL O +
- O +
1 O +
receptor O +
antagonist O +
( O +
IL O +
- O +
1ra O +
, O +
10 O +
micrograms O +
, O +
icv O +
30 O +
min O +
before O +
and O +
10 O +
min O +
after O +
ischaemia O +
) O +
. O +

Excitotoxic O +
damage O +
due O +
to O +
striatal O +
infusion O +
of O +
an O +
NMDA O +
- O +
receptor O +
agonist O +
( O +
cis O +
- O +
2 O +
, O +
4 O +
- O +
methanoglutamate O +
) O +
was O +
also O +
markedly O +
inhibited O +
( O +
71 O +
% O +
) O +
by O +
injection O +
of O +
the O +
IL O +
- O +
1ra O +
. O +

These O +
data O +
indicate O +
that O +
endogenous O +
IL O +
- O +
1 O +
is O +
a O +
mediator O +
of O +
ischaemic O +
and O +
excitotoxic O +
brain O +
damage O +
, O +
and O +
that O +
inhibitors O +
of O +
IL O +
- O +
1 O +
action O +
may O +
be O +
of O +
therapeutic O +
value O +
in O +
the O +
treatment O +
of O +
acute O +
or O +
chronic O +
neuronal O +
death O +
. O +

Laser O +
treatment O +
of O +
eccentric O +
leaks O +
in O +
central O +
serous O +
chorioretinopathy O +
resulting O +
in O +
disappearance O +
of O +
untreated O +
juxtafoveal O +
leaks O +
. O +

In O +
central O +
serous O +
chorioretinopathy O +
( O +
CSCR O +
) O +
laser O +
treatment O +
of O +
leaking O +
points O +
close O +
to O +
the O +
macular O +
center O +
should O +
be O +
avoided O +
because O +
of O +
the O +
possibility O +
of O +
producing O +
juxtafoveal O +
scotoma O +
and O +
stimulating O +
choroidal O +
neovascularization O +
. O +

Nine O +
eyes O +
of O +
nine O +
consecutive O +
patients O +
with O +
CSCR O +
had O +
two O +
or O +
more O +
leaking O +
points O +
within O +
a O +
macular O +
detachment O +
, O +
one O +
of O +
which O +
was O +
foveal O +
or O +
near O +
to O +
the O +
fovea O +
. O +

Photocoagulation O +
with O +
green O +
argon O +
laser O +
was O +
performed O +
in O +
all O +
eyes O +
, O +
treating O +
all O +
the O +
leaking O +
points O +
except O +
for O +
the O +
central O +
one O +
. O +

Visual O +
symptoms O +
regressed O +
after O +
treatment O +
, O +
and O +
the O +
serous O +
detachment O +
was O +
resolved O +
10 O +
days O +
to O +
4 O +
weeks O +
after O +
photocoagulation O +
in O +
all O +
cases O +
. O +

Fluorescein O +
angiography O +
showed O +
no O +
leakage O +
at O +
either O +
the O +
central O +
leakage O +
point O +
or O +
the O +
leakage O +
point O +
that O +
had O +
been O +
treated O +
. O +

These O +
results O +
led O +
us O +
to O +
believe O +
that O +
the O +
central O +
or O +
dependent O +
leak O +
in O +
our O +
cases O +
was O +
not O +
sufficient O +
to O +
maintain O +
the O +
serous O +
detachment O +
by O +
itself O +
. O +

An O +
alternative O +
hypothesis O +
is O +
that O +
the O +
untreated O +
leak O +
did O +
not O +
represent O +
real O +
fluid O +
movement O +
but O +
only O +
diffusion O +
of O +
fluorescein O +
molecules O +
, O +
or O +
a O +
false O +
leak O +
. O +

In O +
cases O +
of O +
CSCR O +
with O +
multiple O +
leaks O +
within O +
a O +
single O +
macular O +
detachment O +
, O +
we O +
believe O +
that O +
a O +
foveal O +
leak O +
may O +
be O +
a O +
dependent O +
or O +
false O +
leak O +
and O +
that O +
direct O +
treatment O +
is O +
not O +
necessary O +
. O +

Transcriptional O +
and O +
post O +
- O +
translation O +
regulation O +
of O +
the O +
Tie1 O +
receptor O +
by O +
fluid O +
shear O +
stress O +
changes O +
in O +
vascular O +
endothelial O +
cells O +
. O +

The O +
interaction O +
between O +
the O +
vascular O +
endothelium O +
and O +
hemodynamic O +
forces O +
( O +
and O +
more O +
specifically O +
, O +
fluid O +
shear O +
stress O +
) O +
, O +
induced O +
by O +
the O +
flow O +
of O +
blood O +
, O +
plays O +
a O +
major O +
role O +
in O +
vascular O +
remodeling O +
and O +
in O +
new O +
blood O +
vessels O +
formation O +
via O +
a O +
process O +
termed O +
arteriogenesis O +
. O +

Tie1 O +
is O +
an O +
orphan O +
tyrosine O +
kinase O +
receptor O +
expressed O +
almost O +
exclusively O +
in O +
endothelial O +
cells O +
and O +
is O +
required O +
for O +
normal O +
vascular O +
development O +
and O +
maintenance O +
. O +

The O +
present O +
study O +
demonstrates O +
that O +
Tie1 O +
expression O +
is O +
rapidly O +
down O +
- O +
regulated O +
in O +
endothelial O +
cells O +
exposed O +
to O +
shear O +
stress O +
, O +
and O +
more O +
so O +
to O +
shear O +
stress O +
changes O +
. O +

This O +
down O +
- O +
regulation O +
is O +
accompanied O +
by O +
a O +
rapid O +
cleavage O +
of O +
Tie1 O +
and O +
binding O +
of O +
the O +
cleaved O +
Tie1 O +
45 O +
kDa O +
endodomain O +
to O +
Tie2 O +
. O +

The O +
rapid O +
cleavage O +
of O +
Tie1 O +
is O +
followed O +
by O +
a O +
transcriptional O +
down O +
- O +
regulation O +
in O +
response O +
to O +
shear O +
stress O +
. O +

The O +
activity O +
of O +
the O +
Tie1 O +
promoter O +
is O +
suppressed O +
by O +
shear O +
stress O +
and O +
by O +
tumor O +
necrosis O +
factor O +
alpha O +
. O +

Shear O +
stress O +
- O +
induced O +
transcriptional O +
suppression O +
of O +
Tie1 O +
is O +
mediated O +
by O +
a O +
negative O +
shear O +
stress O +
response O +
element O +
, O +
localized O +
in O +
a O +
region O +
of O +
250 O +
bp O +
within O +
the O +
promoter O +
. O +

The O +
rapid O +
down O +
- O +
regulation O +
of O +
Tie1 O +
by O +
shear O +
stress O +
changes O +
and O +
its O +
rapid O +
binding O +
to O +
Tie2 O +
may O +
be O +
required O +
for O +
destabilization O +
of O +
endothelial O +
cells O +
in O +
order O +
to O +
initiate O +
the O +
process O +
of O +
vascular O +
restructuring O +
. O +

The O +
presence O +
of O +
nitrite O +
during O +
UVA O +
irradiation O +
protects O +
from O +
apoptosis O +
. O +

Nitrite O +
occurs O +
ubiquitously O +
in O +
biological O +
fluids O +
such O +
as O +
blood O +
and O +
sweat O +
, O +
representing O +
an O +
oxidation O +
product O +
of O +
nitric O +
oxide O +
. O +

Nitrite O +
has O +
been O +
associated O +
with O +
a O +
variety O +
of O +
adverse O +
effects O +
such O +
as O +
mutagenicity O +
, O +
carcinogenesis O +
, O +
and O +
toxicity O +
. O +

In O +
contrast O +
, O +
here O +
we O +
demonstrate O +
that O +
the O +
presence O +
of O +
nitrite O +
, O +
but O +
not O +
nitrate O +
, O +
during O +
irradiation O +
of O +
endothelial O +
cells O +
in O +
culture O +
exerts O +
a O +
potent O +
and O +
concentration O +
- O +
dependent O +
protection O +
against O +
UVA O +
- O +
induced O +
apoptotic O +
cell O +
death O +
. O +

Protection O +
is O +
half O +
- O +
maximal O +
at O +
a O +
concentration O +
of O +
3 O +
mM O +
, O +
and O +
complete O +
rescue O +
is O +
observed O +
at O +
10 O +
mM O +
. O +

Nitrite O +
- O +
mediated O +
protection O +
is O +
mediated O +
via O +
inhibition O +
of O +
lipid O +
peroxidation O +
in O +
a O +
similar O +
manner O +
as O +
seen O +
with O +
butylated O +
hydroxytoluene O +
, O +
a O +
known O +
inhibitor O +
of O +
lipid O +
peroxidation O +
. O +

Interestingly O +
, O +
nitrite O +
- O +
mediated O +
protection O +
is O +
completely O +
abolished O +
by O +
coincubation O +
with O +
the O +
NO O +
scavenger O +
cPTIO O +
. O +

Using O +
electron O +
paramagnetic O +
resonance O +
( O +
EPR O +
) O +
spectroscopy O +
or O +
Faraday O +
modulation O +
spectroscopy O +
, O +
we O +
directly O +
prove O +
UVA O +
- O +
induced O +
NO O +
formation O +
in O +
solutions O +
containing O +
nitrite O +
. O +

In O +
conclusion O +
, O +
evidence O +
is O +
presented O +
that O +
nitrite O +
represents O +
a O +
protective O +
agent O +
against O +
UVA O +
- O +
induced O +
apoptosis O +
due O +
to O +
photodecomposition O +
of O +
nitrite O +
and O +
subsequent O +
formation O +
of O +
NO O +
. O +

Maternal O +
antenatal O +
anxiety O +
and O +
behavioural O +
/ O +
emotional O +
problems O +
in O +
children O +
: O +
a O +
test O +
of O +
a O +
programming O +
hypothesis O +
. O +

BACKGROUND O +
: O +

Previous O +
animal O +
investigations O +
link O +
antenatal O +
stress O +
with O +
a O +
range O +
of O +
persistent O +
behavioural O +
abnormalities O +
in O +
the O +
offspring O +
. O +

The O +
current O +
study O +
examined O +
if O +
the O +
effect O +
was O +
also O +
found O +
in O +
humans O +
through O +
middle O +
childhood O +
. O +

METHODS O +
: O +

The O +
current O +
study O +
is O +
based O +
on O +
the O +
Avon O +
Longitudinal O +
Study O +
of O +
Parents O +
and O +
Children O +
( O +
ALSPAC O +
) O +
, O +
a O +
prospective O +
, O +
community O +
- O +
based O +
study O +
that O +
has O +
followed O +
a O +
cohort O +
of O +
women O +
from O +
pregnancy O +
. O +

Self O +
- O +
report O +
measures O +
of O +
maternal O +
anxiety O +
and O +
depression O +
were O +
assessed O +
at O +
repeated O +
intervals O +
in O +
pregnancy O +
and O +
the O +
postnatal O +
period O +
. O +

Children O +
' O +
s O +
behavioural O +
/ O +
emotional O +
problems O +
were O +
assessed O +
by O +
parent O +
report O +
at O +
age O +
47 O +
and O +
81 O +
months O +
. O +

Information O +
on O +
obstetric O +
and O +
psychosocial O +
factors O +
was O +
obtained O +
at O +
several O +
points O +
in O +
pregnancy O +
and O +
the O +
postnatal O +
period O +
. O +

RESULTS O +
: O +

Children O +
whose O +
mothers O +
experienced O +
high O +
levels O +
of O +
anxiety O +
in O +
late O +
pregnancy O +
exhibited O +
higher O +
rates O +
of O +
behavioural O +
/ O +
emotional O +
problems O +
at O +
81 O +
months O +
of O +
age O +
after O +
controlling O +
for O +
obstetric O +
risks O +
, O +
psychosocial O +
disadvantage O +
, O +
and O +
postnatal O +
anxiety O +
and O +
depression O +
( O +
for O +
girls O +
, O +
OR O +
= O +
1 O +
. O +
91 O +
, O +
95 O +
% O +
CI O +
= O +
1 O +
. O +
26 O +
- O +
2 O +
. O +
89 O +
; O +
for O +
boys O +
, O +
OR O +
= O +
2 O +
. O +
16 O +
, O +
95 O +
% O +
CI O +
= O +
1 O +
. O +
41 O +
- O +
3 O +
. O +
30 O +
) O +
. O +

Furthermore O +
, O +
the O +
effect O +
at O +
81 O +
months O +
was O +
comparable O +
to O +
what O +
was O +
previously O +
obtained O +
at O +
47 O +
months O +
, O +
suggesting O +
the O +
kind O +
of O +
persistent O +
effect O +
proposed O +
in O +
the O +
animal O +
literature O +
. O +

CONCLUSIONS O +
: O +

There O +
is O +
evidence O +
that O +
antenatal O +
stress O +
/ O +
anxiety O +
has O +
a O +
programming O +
effect O +
on O +
the O +
fetus O +
which O +
lasts O +
at O +
least O +
until O +
middle O +
childhood O +
. O +

Therapeutic O +
angiogenesis O +
: O +
a O +
complex O +
problem O +
requiring O +
a O +
sophisticated O +
approach O +
. O +

Blood O +
and O +
vascular O +
disorders O +
underlie O +
a O +
plethora O +
of O +
pathologic O +
conditions O +
and O +
are O +
the O +
single O +
most O +
frequent O +
cause O +
of O +
human O +
disease O +
. O +

Ischemia O +
, O +
involving O +
restricted O +
blood O +
flow O +
to O +
tissues O +
is O +
the O +
most O +
common O +
consequence O +
of O +
vessel O +
dysfunction O +
resulting O +
in O +
the O +
disruption O +
of O +
oxygen O +
and O +
nutrient O +
delivery O +
and O +
the O +
accumulation O +
of O +
waste O +
metabolites O +
. O +

Cells O +
can O -
not O +
survive O +
extended O +
severe O +
ischemia O +
but O +
may O +
be O +
able O +
to O +
adapt O +
to O +
a O +
moderate O +
condition O +
where O +
diffusion O +
to O +
and O +
from O +
bordering O +
nonischemic O +
regions O +
sustains O +
vital O +
functions O +
. O +

Under O +
this O +
condition O +
, O +
the O +
secondary O +
functions O +
of O +
effected O +
cells O +
are O +
likely O +
to O +
be O +
impaired O +
, O +
and O +
a O +
new O +
metabolic O +
equilibrium O +
is O +
established O +
, O +
determined O +
by O +
the O +
level O +
of O +
cross O +
- O +
diffusion O +
and O +
degree O +
of O +
hypoxia O +
. O +

In O +
tissues O +
with O +
a O +
normally O +
high O +
metabolic O +
turnover O +
such O +
as O +
skeletal O +
and O +
cardiac O +
muscle O +
, O +
even O +
mild O +
ischemia O +
causes O +
hypoxia O +
, O +
acidosis O +
, O +
and O +
depressed O +
function O +
( O +
contractility O +
) O +
and O +
eventually O +
threatens O +
myocyte O +
viability O +
and O +
organ O +
function O +
. O +

Ischemic O +
cardiac O +
muscle O +
is O +
additionally O +
vulnerable O +
because O +
reperfusion O +
is O +
essential O +
for O +
survival O +
but O +
reperfusion O +
itself O +
poses O +
additional O +
stress O +
principally O +
from O +
increased O +
production O +
of O +
free O +
radicals O +
during O +
reoxygenation O +
. O +

The O +
latter O +
effect O +
is O +
called O +
reperfusion O +
injury O +
and O +
can O +
cause O +
as O +
much O +
damage O +
as O +
the O +
ischemia O +
. O +

The O +
treatment O +
possibilities O +
for O +
ischemia O +
- O +
related O +
vascular O +
disease O +
are O +
limited O +
. O +

Lipid O +
/ O +
cholesterol O +
- O +
lowering O +
agents O +
, O +
diet O +
and O +
antiplatelet O +
adherence O +
( O +
aspirin O +
) O +
therapy O +
may O +
help O +
slow O +
the O +
progression O +
of O +
vessel O +
disease O +
in O +
some O +
instances O +
; O +
but O +
surgical O +
reconstruction O +
may O +
be O +
the O +
only O +
option O +
in O +
advanced O +
stages O +
, O +
and O +
even O +
this O +
is O +
not O +
always O +
an O +
option O +
. O +

An O +
alternative O +
and O +
rather O +
obvious O +
strategy O +
to O +
treat O +
ischemia O +
is O +
to O +
activate O +
endogenous O +
angiogenic O +
or O +
arteriogenic O +
pathways O +
to O +
stimulate O +
revascularization O +
of O +
the O +
tissue O +
. O +

The O +
feasibility O +
of O +
such O +
a O +
strategy O +
has O +
now O +
been O +
established O +
through O +
the O +
results O +
of O +
studies O +
over O +
the O +
past O +
decade O +
, O +
and O +
a O +
new O +
discipline O +
called O +
therapeutic O +
angiogenesis O +
has O +
emerged O +
. O +

This O +
review O +
focuses O +
on O +
the O +
application O +
of O +
therapeutic O +
angiogenesis O +
for O +
treating O +
ischemic O +
muscle O +
disease O +
and O +
includes O +
a O +
critical O +
evaluation O +
of O +
the O +
parameters O +
and O +
limitations O +
of O +
current O +
procedures O +
. O +

The O +
development O +
of O +
this O +
technology O +
has O +
benefited O +
from O +
its O +
application O +
to O +
both O +
peripheral O +
and O +
coronary O +
artery O +
disease O +
and O +
results O +
from O +
both O +
are O +
reviewed O +
here O +
. O +

Induction O +
of O +
apoptosis O +
in O +
skeletal O +
tissues O +
: O +
phosphate O +
- O +
mediated O +
chick O +
chondrocyte O +
apoptosis O +
is O +
calcium O +
dependent O +
. O +

In O +
an O +
earlier O +
study O +
, O +
we O +
have O +
shown O +
that O +
Pi O +
induced O +
apoptosis O +
of O +
terminally O +
differentiated O +
hypertrophic O +
chondrocytes O +
. O +

To O +
ascertain O +
whether O +
Ca2 O +
+ O +
modulates O +
Pi O +
- O +
induced O +
cell O +
death O +
, O +
we O +
asked O +
the O +
following O +
two O +
questions O +
: O +
First O +
, O +
can O +
we O +
prevent O +
Pi O +
- O +
induced O +
apoptosis O +
by O +
removing O +
Ca2 O +
+ O +
from O +
the O +
culture O +
medium O +
; O +
alternatively O +
, O +
can O +
we O +
potentiate O +
cell O +
death O +
by O +
increasing O +
the O +
Ca2 O +
+ O +
concentration O +
? O +

Second O +
, O +
can O +
we O +
inhibit O +
chondrocyte O +
apoptosis O +
by O +
blocking O +
Pi O +
transport O +
? O +

We O +
also O +
explored O +
the O +
mechanism O +
of O +
apoptosis O +
by O +
evaluating O +
mitochondrial O +
activity O +
and O +
reactive O +
oxygen O +
species O +
( O +
ROS O +
) O +
generation O +
in O +
cells O +
treated O +
with O +
the O +
ion O +
pair O +
. O +

We O +
noted O +
that O +
EDTA O +
and O +
EGTA O +
blocked O +
Pi O +
- O +
induced O +
apoptosis O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
. O +

While O +
high O +
levels O +
of O +
Ca2 O +
+ O +
alone O +
had O +
little O +
effect O +
on O +
chondrocyte O +
viability O +
, O +
the O +
cation O +
enhanced O +
Pi O +
- O +
dependent O +
cell O +
death O +
and O +
greatly O +
increased O +
Pi O +
uptake O +
. O +

When O +
Pi O +
transport O +
was O +
blocked O +
, O +
there O +
was O +
complete O +
inhibition O +
of O +
cell O +
killing O +
. O +

The O +
process O +
of O +
cell O +
death O +
was O +
characterized O +
by O +
mitochondrial O +
hyperpolarization O +
; O +
two O +
hours O +
following O +
apoptogen O +
treatment O +
, O +
there O +
was O +
a O +
significant O +
decrease O +
in O +
the O +
mitochondrial O +
membrane O +
potential O +
. O +

Coincident O +
with O +
the O +
changes O +
in O +
mitochondrial O +
function O +
, O +
there O +
was O +
an O +
increase O +
in O +
intracellular O +
Ca2 O +
+ O +
that O +
was O +
maintained O +
throughout O +
the O +
experimental O +
period O +
. O +

A O +
raised O +
Ca2 O +
+ O +
signal O +
was O +
observed O +
in O +
blebs O +
at O +
the O +
cell O +
membrane O +
. O +

Finally O +
, O +
we O +
noted O +
that O +
, O +
75 O +
minutes O +
after O +
treatment O +
with O +
the O +
ion O +
pair O +
, O +
there O +
was O +
a O +
six O +
- O +
fold O +
elevation O +
in O +
ROS O +
levels O +
. O +

This O +
increase O +
declined O +
to O +
baseline O +
values O +
after O +
three O +
hours O +
. O +

Based O +
on O +
these O +
observations O +
, O +
we O +
suggest O +
that O +
, O +
at O +
the O +
cartilage O +
mineralization O +
front O +
, O +
an O +
elevation O +
in O +
local O +
environmental O +
Ca2 O +
+ O +
and O +
Pi O +
concentrations O +
modulates O +
oxidative O +
metabolism O +
, O +
and O +
triggers O +
apoptosis O +
of O +
terminally O +
differentiated O +
chondrocytes O +
. O +

Cell O +
type O +
- O +
specific O +
regulation O +
of O +
angiogenic O +
growth O +
factor O +
gene O +
expression O +
and O +
induction O +
of O +
angiogenesis O +
in O +
nonischemic O +
tissue O +
by O +
a O +
constitutively O +
active O +
form O +
of O +
hypoxia O +
- O +
inducible O +
factor O +
1 O +
. O +

Understanding O +
molecular O +
mechanisms O +
regulating O +
angiogenesis O +
may O +
lead O +
to O +
novel O +
therapies O +
for O +
ischemic O +
disorders O +
. O +

Hypoxia O +
- O +
inducible O +
factor O +
1 O +
( O +
HIF O +
- O +
1 O +
) O +
activates O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
gene O +
expression O +
in O +
hypoxic O +
/ O +
ischemic O +
tissue O +
. O +

In O +
this O +
study O +
we O +
demonstrate O +
that O +
exposure O +
of O +
primary O +
cultures O +
of O +
cardiac O +
and O +
vascular O +
cells O +
to O +
hypoxia O +
or O +
AdCA5 O +
, O +
an O +
adenovirus O +
encoding O +
a O +
constitutively O +
active O +
form O +
of O +
HIF O +
- O +
1alpha O +
, O +
modulates O +
the O +
expression O +
of O +
genes O +
encoding O +
the O +
angiogenic O +
factors O +
angiopoietin O +
- O +
1 O +
( O +
ANGPT1 O +
) O +
, O +
ANGPT2 O +
, O +
placental O +
growth O +
factor O +
, O +
and O +
platelet O +
- O +
derived O +
growth O +
factor O +
- O +
B O +
. O +

Loss O +
- O +
of O +
- O +
function O +
effects O +
were O +
also O +
observed O +
in O +
HIF O +
- O +
1alpha O +
- O +
null O +
embryonic O +
stem O +
cells O +
. O +

Depending O +
on O +
the O +
cell O +
type O +
, O +
expression O +
of O +
ANGPT1 O +
and O +
ANGPT2 O +
was O +
either O +
activated O +
or O +
repressed O +
in O +
response O +
to O +
hypoxia O +
or O +
AdCA5 O +
. O +

In O +
all O +
cases O +
, O +
there O +
was O +
complete O +
concordance O +
between O +
the O +
effects O +
of O +
hypoxia O +
and O +
AdCA5 O +
. O +

Injection O +
of O +
AdCA5 O +
into O +
mouse O +
eyes O +
induced O +
neovascularization O +
in O +
multiple O +
capillary O +
beds O +
, O +
including O +
those O +
not O +
responsive O +
to O +
VEGF O +
alone O +
. O +

Analysis O +
of O +
gene O +
expression O +
revealed O +
increased O +
expression O +
of O +
ANGPT1 O +
, O +
ANGPT2 O +
, O +
platelet O +
- O +
derived O +
growth O +
factor O +
- O +
B O +
, O +
placental O +
growth O +
factor O +
, O +
and O +
VEGF O +
mRNA O +
in O +
AdCA5 O +
- O +
injected O +
eyes O +
. O +

These O +
results O +
indicate O +
that O +
HIF O +
- O +
1 O +
functions O +
as O +
a O +
master O +
regulator O +
of O +
angiogenesis O +
by O +
controlling O +
the O +
expression O +
of O +
multiple O +
angiogenic O +
growth O +
factors O +
and O +
that O +
adenovirus O +
- O +
mediated O +
expression O +
of O +
a O +
constitutively O +
active O +
form O +
of O +
HIF O +
- O +
1alpha O +
is O +
sufficient O +
to O +
induce O +
angiogenesis O +
in O +
nonischemic O +
tissue O +
of O +
an O +
adult O +
animal O +
. O +

Differential O +
regulation O +
of O +
in O +
vivo O +
angiogenesis O +
by O +
angiotensin O +
II O +
receptors O +
. O +

Angiotensin O +
II O +
( O +
ANG O +
II O +
) O +
, O +
a O +
key O +
regulator O +
of O +
blood O +
pressure O +
and O +
body O +
fluid O +
homeostasis O +
, O +
exerts O +
mitogenic O +
effects O +
on O +
endothelial O +
cells O +
. O +

We O +
therefore O +
hypothesized O +
that O +
ANG O +
II O +
could O +
be O +
a O +
mediator O +
between O +
homeostatic O +
changes O +
within O +
the O +
vascular O +
perfusion O +
bed O +
and O +
growth O +
factor O +
- O +
driven O +
angiogenesis O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
applied O +
the O +
alginate O +
implant O +
angiogenesis O +
model O +
in O +
mice O +
with O +
normal O +
ANG O +
II O +
levels O +
, O +
elevated O +
ANG O +
II O +
levels O +
by O +
transgenic O +
overexpression O +
of O +
angiotensinogen O +
( O +
AOGEN O +
) O +
, O +
or O +
in O +
AT2 O +
receptor O +
- O +
deficient O +
mice O +
. O +

We O +
demonstrate O +
that O +
a O +
decrease O +
in O +
the O +
amount O +
of O +
circulating O +
ANG O +
II O +
by O +
the O +
angiotensin O +
- O +
converting O +
enzyme O +
( O +
ACE O +
) O +
inhibitor O +
enalapril O +
or O +
the O +
AT1 O +
receptor O +
antagonist O +
losartan O +
induced O +
a O +
stimulation O +
of O +
in O +
vivo O +
angiogenesis O +
implying O +
an O +
inhibitory O +
function O +
of O +
ANG O +
II O +
through O +
the O +
AT1 O +
receptor O +
. O +

However O +
, O +
the O +
strong O +
increase O +
of O +
angiogenesis O +
in O +
AOGEN O +
- O +
transgenic O +
mice O +
compared O +
with O +
mice O +
with O +
normal O +
ANG O +
II O +
levels O +
suggests O +
additional O +
stimulatory O +
activity O +
. O +

We O +
showed O +
that O +
the O +
ANG O +
II O +
- O +
induced O +
stimulation O +
of O +
angiogenesis O +
is O +
linked O +
to O +
the O +
AT2 O +
receptor O +
as O +
an O +
impaired O +
induction O +
of O +
angiogenesis O +
was O +
obtained O +
in O +
AT2 O +
receptor O +
knockout O +
mice O +
. O +

These O +
findings O +
provide O +
the O +
first O +
evidence O +
that O +
the O +
AT2 O +
receptor O +
mediates O +
a O +
stimulation O +
of O +
in O +
vivo O +
angiogenesis O +
and O +
indicate O +
that O +
ANG O +
II O +
is O +
a O +
humoral O +
regulator O +
of O +
peripheral O +
angiogenesis O +
involving O +
two O +
receptor O +
subtypes O +
with O +
opposing O +
actions O +
. O +

Expression O +
, O +
regulation O +
, O +
and O +
function O +
of O +
IGF O +
- O +
1 O +
, O +
IGF O +
- O +
1R O +
, O +
and O +
IGF O +
- O +
1 O +
binding O +
proteins O +
in O +
blood O +
vessels O +
. O +

The O +
vascular O +
insulin O +
- O +
like O +
growth O +
factor O +
( O +
IGF O +
) O +
- O +
1 O +
system O +
includes O +
the O +
IGFs O +
, O +
the O +
IGF O +
- O +
1 O +
receptor O +
( O +
IGF O +
- O +
1R O +
) O +
, O +
and O +
multiple O +
binding O +
proteins O +
. O +

This O +
growth O +
factor O +
system O +
exerts O +
multiple O +
physiologic O +
effects O +
on O +
the O +
vasculature O +
through O +
both O +
endocrine O +
and O +
autocrine O +
/ O +
paracrine O +
mechanisms O +
. O +

The O +
effects O +
of O +
IGF O +
- O +
1 O +
are O +
mediated O +
principally O +
through O +
the O +
IGF O +
- O +
1R O +
but O +
are O +
modulated O +
by O +
complex O +
interactions O +
with O +
multiple O +
IGF O +
binding O +
proteins O +
that O +
themselves O +
are O +
regulated O +
by O +
phosphorylation O +
, O +
proteolysis O +
, O +
polymerization O +
, O +
and O +
cell O +
or O +
matrix O +
association O +
. O +

During O +
the O +
last O +
decade O +
, O +
a O +
significant O +
body O +
of O +
evidence O +
has O +
accumulated O +
, O +
indicating O +
that O +
expression O +
of O +
the O +
components O +
of O +
the O +
IGF O +
system O +
are O +
regulated O +
by O +
multiple O +
factors O +
, O +
including O +
growth O +
factors O +
, O +
cytokines O +
, O +
lipoproteins O +
, O +
reactive O +
oxygen O +
species O +
, O +
and O +
hemodynamic O +
forces O +
. O +

In O +
addition O +
, O +
cross O +
- O +
talk O +
between O +
the O +
IGF O +
system O +
and O +
other O +
growth O +
factors O +
and O +
integrin O +
receptors O +
has O +
been O +
demonstrated O +
. O +

There O +
is O +
accumulating O +
evidence O +
of O +
a O +
role O +
for O +
IGF O +
- O +
1 O +
in O +
multiple O +
vascular O +
pathologies O +
, O +
including O +
atherosclerosis O +
, O +
hypertension O +
, O +
restenosis O +
, O +
angiogenesis O +
, O +
and O +
diabetic O +
vascular O +
disease O +
. O +

This O +
review O +
will O +
discuss O +
the O +
regulation O +
of O +
expression O +
of O +
IGF O +
- O +
1 O +
, O +
IGF O +
- O +
1R O +
, O +
and O +
IGF O +
binding O +
proteins O +
in O +
the O +
vasculature O +
and O +
summarize O +
evidence O +
implicating O +
involvement O +
of O +
this O +
system O +
in O +
vascular O +
diseases O +
. O +

Microvascular O +
density O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
immunoreactivity O +
as O +
predictors O +
of O +
regional O +
lymph O +
node O +
metastasis O +
from O +
betel O +
- O +
associated O +
oral O +
squamous O +
cell O +
carcinoma O +
. O +

PURPOSE O +
: O +
Neovascularization O +
has O +
profound O +
effects O +
on O +
tumor O +
growth O +
and O +
metastasis O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
is O +
a O +
mitogen O +
that O +
acts O +
exclusively O +
on O +
endothelial O +
cells O +
. O +

The O +
roles O +
of O +
miscrovascularity O +
density O +
( O +
MVD O +
) O +
and O +
VEGF O +
expression O +
in O +
the O +
progression O +
of O +
oral O +
squamous O +
cell O +
carcinoma O +
( O +
OSCC O +
) O +
have O +
been O +
controversial O +
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
measure O +
the O +
MVD O +
and O +
VEGF O +
expression O +
in O +
a O +
cohort O +
of O +
patients O +
with O +
betel O +
- O +
associated O +
OSCC O +
and O +
to O +
evaluate O +
for O +
possible O +
clinicopathologic O +
correlations O +
. O +

PATIENTS O +
AND O +
METHODS O +
: O +
The O +
paraffin O +
sections O +
from O +
49 O +
subjects O +
with O +
OSCC O +
were O +
subjected O +
to O +
immunohistochemical O +
studies O +
to O +
measure O +
the O +
highest O +
MVD O +
( O +
h O +
- O +
MVD O +
) O +
and O +
cytoplasmic O +
immunoreactivity O +
of O +
VEGF O +
. O +

The O +
findings O +
in O +
the O +
tissue O +
samples O +
were O +
analyzed O +
with O +
regard O +
to O +
the O +
patients O +
' O +
risk O +
factors O +
and O +
clinical O +
course O +
. O +

RESULTS O +
: O +
The O +
OSCC O +
samples O +
had O +
an O +
average O +
h O +
- O +
MVD O +
score O +
of O +
27 O +
. O +
7 O +
/ O +
mm O +
( O +
2 O +
) O +
. O +

VEGF O +
immunoreactivity O +
was O +
positive O +
in O +
75 O +
. O +
5 O +
% O +
of O +
samples O +
. O +

Both O +
h O +
- O +
MVD O +
and O +
VEGF O +
immunoreactivity O +
were O +
statistically O +
associated O +
with O +
lymph O +
node O +
metastasis O +
( O +
P O +
= O +
. O +
012 O +
and O +
. O +
037 O +
, O +
respectively O +
) O +
. O +

A O +
marginally O +
significant O +
association O +
was O +
also O +
noted O +
between O +
the O +
h O +
- O +
MVD O +
and O +
patient O +
survival O +
( O +
P O +
= O +
. O +
056 O +
) O +
. O +

The O +
age O +
and O +
oral O +
habits O +
of O +
patients O +
, O +
as O +
well O +
as O +
the O +
tumor O +
site O +
and O +
size O +
, O +
did O +
not O +
appear O +
to O +
be O +
correlated O +
with O +
h O +
- O +
MVD O +
or O +
VEGF O +
immunoreactivity O +
. O +

CONCLUSION O +
: O +
The O +
data O +
suggest O +
that O +
both O +
h O +
- O +
MVD O +
and O +
VEGF O +
immunoreactivity O +
may O +
be O +
useful O +
predictors O +
for O +
the O +
progression O +
of O +
a O +
subset O +
of O +
OSCC O +
associated O +
mostly O +
with O +
betel O +
use O +
. O +

Antiangiogenesis O +
therapy O +
might O +
have O +
a O +
role O +
in O +
reducing O +
regional O +
metastasis O +
. O +

Insulin O +
- O +
like O +
growth O +
factor O +
1 O +
receptor O +
enhances O +
invasion O +
and O +
induces O +
resistance O +
to O +
apoptosis O +
of O +
colon O +
cancer O +
cells O +
through O +
the O +
Akt O +
/ O +
Bcl O +
- O +
x O +
( O +
L O +
) O +
pathway O +
. O +

Colon O +
cancer O +
overexpresses O +
insulin O +
- O +
like O +
growth O +
factor O +
1 O +
( O +
IGF1 O +
) O +
and O +
insulin O +
- O +
like O +
growth O +
factor O +
1 O +
receptor O +
( O +
IGF1 O +
- O +
R O +
) O +
, O +
as O +
compared O +
with O +
normal O +
or O +
adenomatous O +
mucosa O +
, O +
and O +
it O +
has O +
been O +
postulated O +
that O +
colorectal O +
cancer O +
cells O +
depend O +
on O +
the O +
IGF1 O +
/ O +
IGF1 O +
- O +
R O +
pathway O +
for O +
their O +
growth O +
and O +
progression O +
. O +

In O +
this O +
study O +
, O +
using O +
the O +
human O +
colon O +
cancer O +
cell O +
line O +
HCT116 B-CellLine +
, O +
we O +
find O +
that O +
established O +
HCT116 B-CellLine +
/ O +
IGF1 O +
- O +
R O +
transfectants O +
exhibit O +
a O +
more O +
aggressive O +
transformed O +
phenotype O +
than O +
the O +
parental O +
cell O +
line O +
, O +
as O +
demonstrated O +
by O +
their O +
higher O +
proliferation O +
rate O +
in O +
response O +
to O +
IGF1 O +
, O +
higher O +
degree O +
of O +
anchorage O +
- O +
independent O +
growth O +
, O +
resistance O +
to O +
serum O +
deprivation O +
- O +
induced O +
apoptosis O +
, O +
and O +
higher O +
migratory O +
capability O +
in O +
a O +
monolayer O +
" O +
wounding O +
assay O +
. O +
" O +
When O +
injected O +
into O +
nude O +
mice O +
, O +
HCT116 B-CellLine +
/ O +
IGF1 O +
- O +
R O +
transfectants O +
were O +
highly O +
invasive O +
and O +
produced O +
distant O +
metastases O +
, O +
whereas O +
the O +
parental O +
cell O +
did O +
not O +
. O +

Moreover O +
, O +
the O +
overexpression O +
of O +
IGF1 O +
- O +
R O +
in O +
these O +
cells O +
was O +
associated O +
with O +
IGF1 O +
- O +
R O +
- O +
induced O +
activation O +
of O +
Akt O +
and O +
up O +
- O +
regulation O +
of O +
the O +
antiapoptotic O +
protein O +
Bcl O +
- O +
x O +
( O +
L O +
) O +
. O +

We O +
also O +
show O +
that O +
Akt O +
pathway O +
mediates O +
IGF1 O +
- O +
R O +
- O +
induced O +
Bcl O +
- O +
x O +
( O +
L O +
) O +
expression O +
at O +
transcriptional O +
level O +
. O +

Our O +
data O +
demonstrate O +
, O +
for O +
the O +
first O +
time O +
, O +
that O +
IGF1 O +
- O +
R O +
/ O +
Akt O +
/ O +
Bcl O +
- O +
x O +
( O +
L O +
) O +
pathway O +
may O +
contribute O +
to O +
a O +
more O +
aggressive O +
malignant O +
phenotype O +
, O +
in O +
a O +
subset O +
of O +
colorectal O +
cancers O +
. O +

Promotion O +
of O +
tumorigenesis O +
by O +
heterozygous O +
disruption O +
of O +
the O +
beclin O +
1 O +
autophagy O +
gene O +
. O +

Malignant O +
cells O +
often O +
display O +
defects O +
in O +
autophagy O +
, O +
an O +
evolutionarily O +
conserved O +
pathway O +
for O +
degrading O +
long O +
- O +
lived O +
proteins O +
and O +
cytoplasmic O +
organelles O +
. O +

However O +
, O +
as O +
yet O +
, O +
there O +
is O +
no O +
genetic O +
evidence O +
for O +
a O +
role O +
of O +
autophagy O +
genes O +
in O +
tumor O +
suppression O +
. O +

The O +
beclin O +
1 O +
autophagy O +
gene O +
is O +
monoallelically O +
deleted O +
in O +
40 O +
- O +
75 O +
% O +
of O +
cases O +
of O +
human O +
sporadic O +
breast O +
, O +
ovarian O +
, O +
and O +
prostate O +
cancer O +
. O +

Therefore O +
, O +
we O +
used O +
a O +
targeted O +
mutant O +
mouse O +
model O +
to O +
test O +
the O +
hypothesis O +
that O +
monoallelic O +
deletion O +
of O +
beclin O +
1 O +
promotes O +
tumorigenesis O +
. O +

Here O +
we O +
show O +
that O +
heterozygous O +
disruption O +
of O +
beclin O +
1 O +
increases O +
the O +
frequency O +
of O +
spontaneous O +
malignancies O +
and O +
accelerates O +
the O +
development O +
of O +
hepatitis O +
B O +
virus O +
- O +
induced O +
premalignant O +
lesions O +
. O +

Molecular O +
analyses O +
of O +
tumors O +
in O +
beclin O +
1 O +
heterozygous O +
mice O +
show O +
that O +
the O +
remaining O +
wild O +
- O +
type O +
allele O +
is O +
neither O +
mutated O +
nor O +
silenced O +
. O +

Furthermore O +
, O +
beclin O +
1 O +
heterozygous O +
disruption O +
results O +
in O +
increased O +
cellular O +
proliferation O +
and O +
reduced O +
autophagy O +
in O +
vivo O +
. O +

These O +
findings O +
demonstrate O +
that O +
beclin O +
1 O +
is O +
a O +
haplo O +
- O +
insufficient O +
tumor O +
- O +
suppressor O +
gene O +
and O +
provide O +
genetic O +
evidence O +
that O +
autophagy O +
is O +
a O +
novel O +
mechanism O +
of O +
cell O +
- O +
growth O +
control O +
and O +
tumor O +
suppression O +
. O +

Thus O +
, O +
mutation O +
of O +
beclin O +
1 O +
or O +
other O +
autophagy O +
genes O +
may O +
contribute O +
to O +
the O +
pathogenesis O +
of O +
human O +
cancers O +
. O +

Effects O +
of O +
dietary O +
folate O +
on O +
ulcerative O +
colitis O +
- O +
associated O +
colorectal O +
carcinogenesis O +
in O +
the O +
interleukin O +
2 O +
- O +
and O +
beta O +
( O +
2 O +
) O +
- O +
microglobulin O +
- O +
deficient O +
mice O +
. O +

Folate O +
supplementation O +
may O +
reduce O +
the O +
risk O +
of O +
colorectal O +
dysplasia O +
and O +
cancer O +
in O +
subjects O +
with O +
chronic O +
ulcerative O +
colitis O +
( O +
UC O +
) O +
. O +

The O +
interleukin O +
( O +
IL O +
) O +
2 O +
- O +
and O +
beta O +
( O +
2 O +
) O +
- O +
microglobulin O +
( O +
beta O +
( O +
2 O +
) O +
m O +
) O +
- O +
deficient O +
( O +
IL O +
- O +
2 O +
( O +
null O +
) O +
x O +
beta O +
( O +
2 O +
) O +
m O +
( O +
null O +
) O +
) O +
mice O +
spontaneously O +
develop O +
colon O +
cancer O +
in O +
the O +
setting O +
of O +
chronic O +
UC O +
. O +

This O +
study O +
investigated O +
the O +
effects O +
of O +
dietary O +
folate O +
on O +
the O +
development O +
of O +
UC O +
- O +
associated O +
colon O +
cancer O +
in O +
the O +
IL O +
- O +
2 O +
( O +
null O +
) O +
x O +
beta O +
( O +
2 O +
) O +
m O +
( O +
null O +
) O +
mice O +
. O +

Weaning O +
IL O +
- O +
2 O +
( O +
null O +
) O +
x O +
beta O +
( O +
2 O +
) O +
m O +
( O +
null O +
) O +
mice O +
were O +
randomized O +
to O +
receive O +
0 O +
( O +
deficient O +
; O +
n O +
= O +
40 O +
) O +
, O +
2 O +
( O +
basal O +
requirement O +
; O +
control O +
; O +
n O +
= O +
46 O +
) O +
, O +
or O +
8 O +
( O +
supplemented O +
; O +
n O +
= O +
36 O +
) O +
mg O +
folate O +
/ O +
kg O +
diet O +
for O +
32 O +
weeks O +
. O +

At O +
necropsy O +
, O +
all O +
macroscopic O +
colonic O +
tumors O +
were O +
identified O +
and O +
histologically O +
classified O +
as O +
dysplasia O +
or O +
adenocarcinoma O +
. O +

The O +
incidence O +
of O +
high O +
- O +
grade O +
lesions O +
( O +
high O +
- O +
grade O +
dysplasia O +
/ O +
carcinoma O +
in O +
situ O +
and O +
invasive O +
adenocarcinoma O +
) O +
in O +
the O +
folate O +
- O +
supplemented O +
group O +
was O +
46 O +
% O +
lower O +
than O +
that O +
in O +
the O +
control O +
group O +
( O +
35 O +
. O +
3 O +
% O +
versus O +
65 O +
. O +
1 O +
% O +
, O +
P O +
= O +
0 O +
. O +
009 O +
) O +
. O +

The O +
incidence O +
of O +
high O +
- O +
grade O +
lesions O +
in O +
the O +
folate O +
- O +
deficient O +
group O +
was O +
also O +
49 O +
% O +
lower O +
than O +
that O +
in O +
the O +
control O +
group O +
( O +
33 O +
. O +
3 O +
% O +
versus O +
65 O +
. O +
1 O +
% O +
, O +
P O +
= O +
0 O +
. O +
007 O +
) O +
. O +

The O +
higher O +
mortality O +
rate O +
in O +
the O +
folate O +
- O +
deficient O +
group O +
compared O +
with O +
the O +
other O +
two O +
groups O +
( O +
25 O +
% O +
versus O +
6 O +
. O +
5 O +
% O +
and O +
5 O +
. O +
6 O +
% O +
, O +
P O +
< O +
0 O +
. O +
02 O +
) O +
partially O +
accounted O +
for O +
the O +
low O +
incidence O +
of O +
high O +
- O +
grade O +
lesions O +
in O +
this O +
group O +
. O +

These O +
data O +
indicate O +
that O +
dietary O +
folate O +
supplementation O +
at O +
4x O +
the O +
basal O +
dietary O +
requirement O +
significantly O +
suppresses O +
UC O +
- O +
associated O +
colorectal O +
carcinogenesis O +
in O +
the O +
IL O +
- O +
2 O +
( O +
null O +
) O +
x O +
beta O +
( O +
2 O +
) O +
m O +
( O +
null O +
) O +
mice O +
. O +

These O +
data O +
also O +
suggest O +
that O +
folate O +
deficiency O +
may O +
inhibit O +
colorectal O +
carcinogenesis O +
in O +
chronic O +
UC O +
. O +

However O +
, O +
the O +
high O +
mortality O +
observed O +
in O +
the O +
folate O +
- O +
deficient O +
group O +
precludes O +
a O +
definitive O +
conclusion O +
concerning O +
the O +
effect O +
of O +
folate O +
deficiency O +
on O +
UC O +
- O +
associated O +
colorectal O +
carcinogenesis O +
in O +
this O +
model O +
. O +

[ O +
Laboratory O +
diagnostics O +
of O +
Crimean O +
hemorrhagic O +
fever O +
by O +
polymerase O +
chain O +
reaction O +
] O +
. O +

Our O +
group O +
developed O +
, O +
within O +
the O +
present O +
case O +
study O +
, O +
two O +
techniques O +
' O +
variations O +
, O +
i O +
. O +
e O +
. O +
a O +
single O +
- O +
step O +
RT O +
- O +
PCR O +
and O +
nested O +
RT O +
- O +
PCR O +
assays O +
, O +
for O +
the O +
purpose O +
of O +
detecting O +
the O +
Crimean O +
- O +
Congo O +
hemorrhagic O +
fever O +
RNA O +
virus O +
in O +
human O +
samples O +
. O +

The O +
above O +
assays O +
as O +
well O +
as O +
those O +
previously O +
recommended O +
by O +
the O +
Ministry O +
of O +
Health O +
of O +
the O +
Russian O +
Federation O +
were O +
simultaneously O +
used O +
in O +
14 O +
clinical O +
samples O +
obtained O +
from O +
patients O +
with O +
Crimean O +
hemorrhagic O +
fever O +
. O +

After O +
assessing O +
the O +
detection O +
accuracy O +
, O +
it O +
was O +
found O +
that O +
the O +
developed O +
- O +
by O +
- O +
us O +
test O +
system O +
displayed O +
the O +
same O +
or O +
even O +
better O +
diagnostic O +
values O +
versus O +
the O +
previously O +
recommended O +
nested O +
RT O +
- O +
PCR O +
and O +
a O +
1000 O +
- O +
fold O +
advantage O +
over O +
the O +
previously O +
recommended O +
single O +
- O +
step O +
RT O +
- O +
PCA O +
. O +

The O +
single O +
- O +
step O +
RT O +
- O +
PCR O +
assay O +
variation O +
is O +
always O +
more O +
preferable O +
in O +
sense O +
of O +
technical O +
and O +
economic O +
motivations O +
. O +

Finally O +
, O +
the O +
test O +
system O +
developed O +
by O +
us O +
has O +
every O +
reason O +
to O +
become O +
the O +
method O +
of O +
choice O +
in O +
routine O +
PCR O +
diagnosis O +
of O +
Crimean O +
hemorrhagic O +
fever O +
after O +
all O +
official O +
trials O +
and O +
approvals O +
are O +
duly O +
complied O +
with O +
. O +

Endogenous O +
thyroid O +
hormones O +
modulate O +
pituitary O +
somatotroph O +
differentiation O +
during O +
chicken O +
embryonic O +
development O +
. O +

Growth O +
hormone O +
cell O +
differentiation O +
normally O +
occurs O +
between O +
day O +
14 O +
and O +
day O +
16 O +
of O +
chicken O +
embryonic O +
development O +
. O +

We O +
reported O +
previously O +
that O +
corticosterone O +
( O +
CORT O +
) O +
could O +
induce O +
somatotroph O +
differentiation O +
in O +
vitro O +
and O +
in O +
vivo O +
and O +
that O +
thyroid O +
hormones O +
could O +
act O +
in O +
combination O +
with O +
CORT O +
to O +
further O +
augment O +
the O +
abundance O +
of O +
somatotrophs O +
in O +
vitro O +
. O +

The O +
objective O +
of O +
the O +
present O +
study O +
was O +
to O +
test O +
our O +
hypothesis O +
that O +
endogenous O +
thyroid O +
hormones O +
regulate O +
the O +
abundance O +
of O +
somatotrophs O +
during O +
chicken O +
embryonic O +
development O +
. O +

Plasma O +
samples O +
were O +
collected O +
on O +
embryonic O +
day O +
( O +
e O +
) O +
9 O +
- O +
14 O +
. O +

We O +
found O +
that O +
plasma O +
CORT O +
and O +
thyroid O +
hormone O +
levels O +
increased O +
progressively O +
in O +
mid O +
- O +
embryogenesis O +
to O +
e O +
13 O +
or O +
e O +
14 O +
, O +
immediately O +
before O +
normal O +
somatotroph O +
differentiation O +
. O +

Administration O +
of O +
thyroxine O +
( O +
T4 O +
) O +
and O +
triiodothyronine O +
( O +
T3 O +
) O +
into O +
the O +
albumen O +
of O +
fertile O +
eggs O +
on O +
e O +
11 O +
increased O +
somatotroph O +
proportions O +
prematurely O +
on O +
e O +
13 O +
in O +
the O +
developing O +
chick O +
embryos O +
in O +
vivo O +
. O +

Furthermore O +
, O +
administration O +
of O +
methimazole O +
, O +
the O +
thyroid O +
hormone O +
synthesis O +
inhibitor O +
, O +
on O +
e O +
9 O +
inhibited O +
somatotroph O +
differentiation O +
in O +
vivo O +
, O +
as O +
assessed O +
on O +
e O +
14 O +
; O +
this O +
suppression O +
was O +
completely O +
reversed O +
by O +
T3 O +
replacement O +
on O +
e O +
11 O +
. O +

Since O +
we O +
reported O +
that O +
T3 O +
alone O +
was O +
ineffective O +
in O +
vitro O +
, O +
we O +
interpret O +
these O +
findings O +
to O +
indicate O +
that O +
the O +
effects O +
of O +
treatments O +
in O +
vivo O +
were O +
due O +
to O +
interactions O +
with O +
endogenous O +
glucocorticoids O +
. O +

These O +
results O +
indicate O +
that O +
treatment O +
with O +
exogenous O +
thyroid O +
hormones O +
can O +
modulate O +
somatotroph O +
abundance O +
and O +
that O +
endogenous O +
thyroid O +
hormone O +
synthesis O +
likely O +
contributes O +
to O +
normal O +
somatotroph O +
differentiation O +
. O +

Prognostic O +
significance O +
and O +
correlation O +
with O +
survival O +
of O +
bcl O +
- O +
2 O +
and O +
TGF O +
- O +
beta O +
RII O +
in O +
colon O +
cancer O +
. O +

Bcl O +
- O +
2 O +
and O +
TGF O +
- O +
beta O +
receptors O +
type O +
II O +
( O +
RII O +
) O +
in O +
colon O +
carcinomas O +
were O +
studied O +
in O +
a O +
series O +
of O +
113 O +
patients O +
, O +
to O +
determine O +
their O +
prognostic O +
significance O +
and O +
to O +
correlate O +
their O +
expression O +
with O +
other O +
prognostic O +
indicators O +
. O +

Bcl O +
- O +
2 O +
expression O +
in O +
the O +
tumor O +
cells O +
showed O +
a O +
reverse O +
relation O +
with O +
tumor O +
size O +
( O +
P O +
= O +
0 O +
. O +
018 O +
) O +
, O +
histological O +
grade O +
( O +
P O +
= O +
0 O +
. O +
04 O +
) O +
, O +
and O +
stage O +
( O +
P O +
= O +
0 O +
. O +
013 O +
) O +
. O +

Univariate O +
survival O +
analysis O +
using O +
the O +
log O +
rank O +
test O +
showed O +
that O +
the O +
survival O +
of O +
patients O +
with O +
bcl O +
- O +
2 O +
- O +
positive O +
tumors O +
was O +
significantly O +
better O +
than O +
the O +
survival O +
of O +
patients O +
with O +
bcl O +
- O +
2 O +
- O +
negative O +
tumors O +
( O +
P O +
= O +
0 O +
. O +
02 O +
) O +
. O +

However O +
, O +
when O +
entered O +
into O +
a O +
multivariate O +
analysis O +
model O +
, O +
it O +
was O +
not O +
found O +
to O +
be O +
of O +
independent O +
prognostic O +
significance O +
. O +

TGF O +
- O +
beta O +
RII O +
expression O +
was O +
correlated O +
with O +
stage O +
( O +
P O +
= O +
0 O +
. O +
03 O +
) O +
, O +
while O +
no O +
statistically O +
significant O +
correlation O +
was O +
found O +
between O +
TGF O +
- O +
beta O +
RII O +
expression O +
and O +
histological O +
grade O +
or O +
survival O +
. O +

In O +
conclusion O +
, O +
these O +
results O +
provide O +
additional O +
evidence O +
for O +
the O +
role O +
of O +
bcl O +
- O +
2 O +
and O +
TGF O +
- O +
beta O +
RII O +
in O +
carcinogenesis O +
of O +
the O +
colon O +
, O +
while O +
they O +
do O +
not O +
support O +
the O +
use O +
of O +
these O +
factors O +
as O +
prognostic O +
markers O +
in O +
patients O +
with O +
colon O +
cancer O +
. O +

Antibiotic O +
- O +
induced O +
persistence O +
of O +
cytotoxic O +
Staphylococcus O +
aureus O +
in O +
non O +
- O +
phagocytic O +
cells O +
. O +

OBJECTIVES O +
: O +

After O +
infection O +
of O +
non O +
- O +
phagocytic O +
cells O +
, O +
some O +
Staphylococcus O +
aureus O +
strains O +
are O +
able O +
to O +
survive O +
and O +
kill O +
their O +
host O +
cells O +
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
action O +
of O +
various O +
antibiotics O +
on O +
the O +
survival O +
of O +
host O +
cells O +
and O +
/ O +
or O +
intracellular O +
S O +
. O +
aureus O +
. O +

METHODS O +
: O +

Murine O +
keratinocyte O +
( O +
PAM212 B-CellLine +
) O +
and O +
fibroblast O +
( O +
mKSA B-CellLine +
) O +
cell O +
lines O +
were O +
infected O +
with O +
cytotoxic O +
S O +
. O +
aureus O +
and O +
cultured O +
in O +
the O +
presence O +
of O +
various O +
antibiotics O +
at O +
graded O +
concentrations O +
. O +

The O +
viability O +
of O +
host O +
cells O +
was O +
measured O +
24 O +
h O +
after O +
infection O +
. O +

To O +
determine O +
the O +
bacterial O +
viability O +
within O +
host O +
cells O +
, O +
cellular O +
lysates O +
were O +
prepared O +
and O +
colony O +
forming O +
units O +
were O +
quantified O +
using O +
a O +
spiral O +
plater O +
. O +

Host O +
cells O +
infected O +
with O +
fluorescein O +
isothiocyanate O +
( O +
FITC O +
) O +
- O +
labelled O +
S O +
. O +
aureus O +
were O +
analysed O +
by O +
flow O +
cytometry O +
and O +
microscopy O +
to O +
determine O +
the O +
subcellular O +
localization O +
S O +
. O +
aureus O +
. O +

RESULTS O +
: O +

Oxacillin O +
, O +
vancomycin O +
, O +
gentamicin O +
, O +
ciprofloxacin O +
and O +
trimethoprim O +
/ O +
sulfamethoxazole O +
did O +
not O +
rescue O +
host O +
cells O +
from O +
cell O +
death O +
induced O +
by O +
intracellular O +
S O +
. O +
aureus O +
. O +

In O +
contrast O +
, O +
linezolid O +
, O +
rifampicin O +
, O +
azithromycin O +
, O +
clindamycin O +
, O +
erythromycin O +
and O +
quinupristin O +
/ O +
dalfopristin O +
suppressed O +
the O +
cytotoxic O +
action O +
of O +
S O +
. O +
aureus O +
. O +

After O +
withdrawal O +
of O +
antibiotics O +
, O +
intracellular O +
S O +
. O +
aureus O +
regained O +
cytotoxic O +
activity O +
and O +
killed O +
their O +
host O +
cells O +
. O +

Only O +
rifampicin O +
was O +
able O +
to O +
eliminate O +
intracellular O +
S O +
. O +
aureus O +
completely O +
within O +
72 O +
h O +
. O +

In O +
contrast O +
, O +
clindamycin O +
, O +
azithromycin O +
and O +
linezolid O +
induced O +
a O +
state O +
of O +
intracellular O +
persistence O +
of O +
viable O +
S O +
. O +
aureus O +
. O +

CONCLUSIONS O +
: O +

Antibiotics O +
commonly O +
used O +
for O +
the O +
management O +
of O +
S O +
. O +
aureus O +
infections O +
appear O +
to O +
create O +
a O +
niche O +
for O +
invasive O +
intracellular O +
S O +
. O +
aureus O +
, O +
which O +
may O +
play O +
an O +
important O +
role O +
for O +
persistence O +
and O +
recurrence O +
of O +
infection O +
. O +

Because O +
of O +
its O +
unique O +
ability O +
to O +
eliminate O +
intracellular O +
S O +
. O +
aureus O +
, O +
rifampicin O +
appears O +
to O +
be O +
valuable O +
for O +
the O +
treatment O +
of O +
invasive O +
S O +
. O +
aureus O +
infections O +
. O +

Expression O +
of O +
EphA2 O +
and O +
E O +
- O +
cadherin O +
in O +
colorectal O +
cancer O +
: O +
correlation O +
with O +
cancer O +
metastasis O +
. O +

Recently O +
, O +
overexpression O +
of O +
EphA2 O +
, O +
a O +
member O +
of O +
the O +
Eph O +
family O +
of O +
receptor O +
tyrosine O +
kinases O +
, O +
has O +
been O +
reported O +
in O +
several O +
cancers O +
. O +

Reduced O +
expression O +
of O +
E O +
- O +
cadherin O +
, O +
an O +
intercellular O +
adhesion O +
molecule O +
of O +
epithelial O +
cells O +
, O +
has O +
been O +
reported O +
to O +
be O +
associated O +
with O +
aggressive O +
clinicopathological O +
phenotypes O +
in O +
various O +
cancers O +
. O +

In O +
epithelial O +
cells O +
, O +
EphA2 O +
and O +
E O +
- O +
cadherin O +
co O +
- O +
localize O +
to O +
sites O +
of O +
cell O +
- O +
cell O +
contact O +
, O +
and O +
it O +
has O +
been O +
shown O +
that O +
E O +
- O +
cadherin O +
regulates O +
EphA2 O +
. O +

This O +
study O +
aimed O +
to O +
clarify O +
the O +
relationship O +
between O +
the O +
expression O +
of O +
the O +
EphA2 O +
and O +
E O +
- O +
cadherin O +
proteins O +
and O +
clinicopathological O +
characteristics O +
, O +
with O +
reference O +
to O +
the O +
expression O +
levels O +
of O +
both O +
EphA2 O +
and O +
E O +
- O +
cadherin O +
, O +
in O +
patients O +
with O +
colorectal O +
cancer O +
. O +

We O +
performed O +
immunohistochemical O +
staining O +
of O +
EphA2 O +
and O +
E O +
- O +
cadherin O +
with O +
EphA2 O +
and O +
E O +
- O +
cadherin O +
monoclonal O +
antibodies O +
in O +
samples O +
from O +
194 O +
primary O +
lesions O +
of O +
colorectal O +
cancer O +
. O +

The O +
expression O +
level O +
of O +
EphA2 O +
had O +
a O +
statistically O +
significant O +
relationship O +
with O +
liver O +
metastasis O +
, O +
lymphatic O +
vessel O +
invasion O +
and O +
clinical O +
stage O +
( O +
p O +
= O +
0 O +
. O +
0477 O +
, O +
0 O +
. O +
0316 O +
and O +
0 O +
. O +
0467 O +
, O +
respectively O +
) O +
. O +

In O +
addition O +
, O +
the O +
positivity O +
rate O +
of O +
EphA2 O +
was O +
significantly O +
higher O +
in O +
primary O +
lesions O +
with O +
lymph O +
node O +
metastasis O +
than O +
in O +
those O +
without O +
metastasis O +
( O +
p O +
= O +
0 O +
. O +
0014 O +
) O +
. O +

However O +
, O +
the O +
expression O +
level O +
of O +
E O +
- O +
cadherin O +
had O +
an O +
inverse O +
relationship O +
with O +
both O +
differentiation O +
level O +
of O +
the O +
tumor O +
and O +
lymphatic O +
vessel O +
invasion O +
( O +
p O +
= O +
0 O +
. O +
0430 O +
and O +
0 O +
. O +
0320 O +
, O +
respectively O +
) O +
. O +

Furthermore O +
, O +
a O +
significant O +
relationship O +
between O +
the O +
expression O +
of O +
EphA2 O +
and O +
E O +
- O +
cadherin O +
was O +
observed O +
. O +

In O +
conclusion O +
, O +
our O +
study O +
revealed O +
that O +
the O +
overexpression O +
of O +
EphA2 O +
protein O +
in O +
colorectal O +
carcinoma O +
tissue O +
correlates O +
closely O +
with O +
cancer O +
progression O +
and O +
hematogenous O +
and O +
lymphogenous O +
metastasis O +
, O +
suggesting O +
that O +
both O +
EphA2 O +
and O +
E O +
- O +
cadherin O +
may O +
play O +
an O +
important O +
role O +
in O +
tumor O +
metastasis O +
in O +
colorectal O +
cancer O +
. O +

Outcomes O +
of O +
cefazolin O +
versus O +
ceftriaxone O +
therapy O +
in O +
treating O +
lower O +
respiratory O +
tract O +
infections O +
in O +
adults O +
. O +

OBJECTIVE O +
: O +

To O +
determine O +
whether O +
choice O +
of O +
a O +
first O +
- O +
versus O +
third O +
- O +
generation O +
cephalosporin O +
as O +
initial O +
therapy O +
for O +
lower O +
respiratory O +
tract O +
infections O +
in O +
hospitalized O +
adults O +
affects O +
the O +
course O +
and O +
duration O +
of O +
care O +
, O +
both O +
of O +
which O +
may O +
influence O +
antimicrobial O +
treatment O +
cost O +
. O +

DESIGN O +
: O +

Retrospective O +
analysis O +
of O +
discharge O +
abstracts O +
and O +
hospital O +
pharmacy O +
records O +
. O +

SETTING O +
: O +

Forty O +
- O +
eight O +
US O +
acute O +
- O +
care O +
hospitals O +
. O +

PATIENTS O +
: O +

One O +
thousand O +
ninety O +
- O +
two O +
hospitalized O +
adults O +
( O +
aged O +
> O +
17 O +
y O +
) O +
with O +
principal O +
diagnoses O +
of O +
lower O +
respiratory O +
tract O +
infections O +
( O +
DRGs O +
79 O +
- O +
80 O +
, O +
89 O +
- O +
90 O +
) O +
. O +

INTERVENTIONS O +
: O +

Cefazolin O +
or O +
ceftriaxone O +
, O +
given O +
as O +
sole O +
antimicrobial O +
therapy O +
for O +
at O +
least O +
one O +
day O +
. O +

MAIN O +
OUTCOME O +
MEASURES O +
: O +

( O +
1 O +
) O +
The O +
number O +
of O +
patients O +
who O +
received O +
another O +
parenteral O +
antibiotic O +
anytime O +
prior O +
to O +
hospital O +
discharge O +
; O +
( O +
2 O +
) O +
the O +
number O +
of O +
days O +
during O +
which O +
patients O +
received O +
any O +
parenteral O +
antibiotic O +
while O +
in O +
the O +
hospital O +
; O +
and O +
( O +
3 O +
) O +
the O +
number O +
of O +
days O +
patients O +
remained O +
hospitalized O +
following O +
the O +
start O +
of O +
antibiotic O +
therapy O +
. O +

RESULTS O +
: O +

Patients O +
treated O +
with O +
cefazolin O +
( O +
n O +
= O +
763 O +
) O +
were O +
more O +
likely O +
to O +
receive O +
another O +
parenteral O +
antibiotic O +
while O +
in O +
the O +
hospital O +
( O +
30 O +
. O +
3 O +
vs O +
. O +
20 O +
. O +
7 O +
percent O +
; O +
p O +
< O +
0 O +
. O +
001 O +
) O +
and O +
received O +
more O +
total O +
days O +
of O +
therapy O +
( O +
7 O +
. O +
2 O +
vs O +
. O +
6 O +
. O +
7 O +
d O +
; O +
p O +
< O +
0 O +
. O +
05 O +
) O +
than O +
those O +
treated O +
with O +
ceftriaxone O +
( O +
n O +
= O +
329 O +
) O +
. O +

Although O +
the O +
time O +
to O +
hospital O +
discharge O +
did O +
not O +
differ O +
in O +
the O +
full O +
sample O +
( O +
9 O +
. O +
2 O +
d O +
for O +
both O +
groups O +
) O +
, O +
it O +
was O +
greater O +
among O +
those O +
receiving O +
cefazolin O +
( O +
8 O +
. O +
6 O +
vs O +
. O +
8 O +
. O +
0 O +
d O +
; O +
p O +
< O +
0 O +
. O +
05 O +
) O +
when O +
patients O +
with O +
lengths O +
of O +
stay O +
exceeding O +
24 O +
days O +
were O +
excluded O +
from O +
both O +
groups O +
. O +

CONCLUSIONS O +
: O +

In O +
addition O +
to O +
acquisition O +
cost O +
, O +
differences O +
in O +
course O +
and O +
duration O +
of O +
care O +
should O +
be O +
considered O +
when O +
determining O +
the O +
most O +
cost O +
- O +
effective O +
choice O +
for O +
antimicrobial O +
therapy O +
. O +

Full O +
sequencing O +
analysis O +
of O +
estrogen O +
receptor O +
- O +
alpha O +
gene O +
polymorphism O +
and O +
its O +
association O +
with O +
breast O +
cancer O +
risk O +
. O +

BACKGROUND O +
: O +

The O +
estrogen O +
receptor O +
plays O +
a O +
critical O +
role O +
in O +
breast O +
cancer O +
development O +
and O +
progression O +
. O +

So O +
the O +
genetic O +
polymorphism O +
of O +
ER O +
- O +
alpha O +
gene O +
could O +
affect O +
cancer O +
risk O +
and O +
phenotype O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +

We O +
fully O +
sequenced O +
the O +
ER O +
- O +
alpha O +
gene O +
to O +
investigate O +
its O +
single O +
nucleotide O +
polymorphisms O +
( O +
SNPs O +
) O +
in O +
100 O +
breast O +
cancer O +
patients O +
and O +
100 O +
controls O +
. O +

RESULTS O +
: O +

Six O +
novel O +
polymorphism O +
in O +
the O +
control O +
and O +
11 O +
in O +
cancer O +
patients O +
were O +
found O +
. O +

The O +
G O +
/ O +
G O +
genotype O +
at O +
C975 O +
G O +
and O +
A O +
/ O +
A O +
genotype O +
at O +
G1782 O +
A O +
had O +
a O +
protective O +
effect O +
against O +
breast O +
cancer O +
when O +
compared O +
to O +
other O +
genotypes O +
( O +
OR O +
= O +
0 O +
. O +
3 O +
and O +
0 O +
. O +
3 O +
, O +
respectively O +
) O +
. O +

975 O -
G O +
allele O +
was O +
associated O +
inversely O +
with O +
the O +
p53 O +
expression O +
and O +
positively O +
with O +
the O +
bcl O +
- O +
2 O +
expression O +
in O +
cancer O +
with O +
borderline O +
significance O +
. O +

Combining O +
this O +
result O +
with O +
our O +
previous O +
study O +
, O +
these O +
associations O +
became O +
more O +
significant O +
( O +
p O +
= O +
0 O +
. O +
005 O +
and O +
0 O +
. O +
019 O +
, O +
respectively O +
) O +
. O +

CONCLUSION O +
: O +

Polymorphisms O +
in O +
ER O +
- O +
alpha O +
gene O +
can O +
affect O +
the O +
breast O +
cancer O +
susceptibility O +
and O +
may O +
be O +
related O +
to O +
other O +
protein O +
expression O +
, O +
such O +
as O +
p53 O +
and O +
bcl O +
- O +
2 O +
. O +

Effect O +
of O +
antitumor O +
agents O +
on O +
cytotoxicity O +
induction O +
by O +
sodium O +
fluoride O +
. O +

We O +
have O +
recently O +
found O +
that O +
sodium O +
fluoride O +
( O +
NaF O +
) O +
induced O +
apoptotic O +
cell O +
death O +
in O +
tumor O +
cell O +
lines O +
. O +

We O +
investigated O +
here O +
whether O +
6 O +
popular O +
antitumor O +
compounds O +
modify O +
the O +
cytotoxic O +
activity O +
of O +
NaF O +
against O +
human O +
squamous O +
cell O +
carcinoma O +
( O +
HSC B-CellLine +
- I-CellLine +
2 I-CellLine +
) O +
and O +
human O +
promyelocytic O +
leukemia O +
( O +
HL B-CellLine +
- I-CellLine +
60 I-CellLine +
) O +
cell O +
lines O +
. O +

Cytotoxic O +
concentrations O +
of O +
cisplatin O +
, O +
etoposide O +
, O +
doxorubicin O +
or O +
peplomycin O +
( O +
tentatively O +
termed O +
as O +
Group O +
I O +
compounds O +
) O +
, O +
but O +
not O +
methotrexate O +
and O +
5 O +
- O +
FU O +
( O +
tentatively O +
termed O +
as O +
Group O +
II O +
compounds O +
) O +
, O +
enhanced O +
the O +
cytotoxic O +
activity O +
of O +
NaF O +
. O +

NaF O +
and O +
Group O +
I O +
compounds O +
induced O +
internucleosomal O +
DNA O +
fragmentation O +
in O +
HL B-CellLine +
- I-CellLine +
60 I-CellLine +
cells O +
, O +
whereas O +
Group O +
II O +
compounds O +
were O +
inactive O +
even O +
in O +
the O +
presence O +
of O +
NaF O +
. O +

Most O +
Group O +
I O +
compounds O +
except O +
doxorubicin O +
( O +
which O +
induced O +
DNA O +
fragmentation O +
less O +
effectively O +
than O +
others O +
) O +
activated O +
caspase O +
3 O +
more O +
efficiently O +
than O +
Group O +
II O +
compounds O +
. O +

Caspase O +
8 O +
( O +
involved O +
in O +
non O +
- O +
mitochondrial O +
extrinsic O +
pathway O +
) O +
and O +
caspase O +
9 O +
( O +
involved O +
in O +
mitochondrial O +
intrinsic O +
pathway O +
) O +
were O +
also O +
activated O +
, O +
but O +
to O +
a O +
much O +
lesser O +
extent O +
. O +

NaF O +
reduced O +
the O +
glucose O +
consumption O +
at O +
early O +
stage O +
, O +
possibly O +
by O +
inhibition O +
of O +
glycolysis O +
, O +
whereas O +
cisplatin O +
and O +
etoposide O +
reduced O +
the O +
glucose O +
consumption O +
at O +
later O +
stage O +
, O +
suggesting O +
that O +
early O +
decline O +
of O +
glucose O +
consumption O +
is O +
rather O +
specific O +
to O +
NaF O +
. O +

Angiopoietin O +
/ O +
tie O +
- O +
2 O +
as O +
mediators O +
of O +
angiogenesis O +
: O +
a O +
role O +
in O +
congestive O +
heart O +
failure O +
? O +

Angiogenic O +
factors O +
, O +
in O +
particular O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
and O +
the O +
angiopoietins O +
, O +
Ang O +
- O +
1 O +
and O +
- O +
2 O +
, O +
have O +
recently O +
generated O +
significant O +
interest O +
, O +
especially O +
in O +
oncology O +
. O +

The O +
process O +
of O +
angiogenesis O +
is O +
also O +
thought O +
to O +
occur O +
in O +
response O +
to O +
ischaemic O +
conditions O +
, O +
which O +
lie O +
at O +
the O +
core O +
of O +
cardiovascular O +
disease O +
states O +
such O +
as O +
coronary O +
artery O +
disease O +
and O +
congestive O +
heart O +
failure O +
. O +

However O +
, O +
current O +
data O +
do O +
not O +
conclusively O +
show O +
evidence O +
of O +
angiogenesis O +
per O +
se O +
in O +
these O +
conditions O +
, O +
despite O +
( O +
for O +
example O +
) O +
the O +
presence O +
of O +
high O +
levels O +
of O +
VEGF O +
and O +
Ang O +
- O +
2 O +
. O +

High O +
levels O +
of O +
these O +
angiogenic O +
factors O +
in O +
heart O +
disease O +
also O +
have O +
not O +
translated O +
into O +
clinically O +
significant O +
new O +
vessel O +
formation O +
, O +
as O +
in O +
accelerated O +
cancer O +
growth O +
or O +
proliferative O +
retinopathy O +
. O +

Indeed O +
, O +
we O +
would O +
hypothesize O +
that O +
these O +
angiogenic O +
markers O +
- O +
- O +
especially O +
the O +
angiopoietins O +
- O +
- O +
do O +
not O +
necessarily O +
translate O +
into O +
new O +
vessel O +
formation O +
in O +
congestive O +
heart O +
failure O +
( O +
CHF O +
) O +
, O +
but O +
may O +
well O +
reflect O +
disturbances O +
of O +
endothelial O +
integrity O +
in O +
CHF O +
. O +

Covariance O +
structure O +
analysis O +
: O +
statistical O +
practice O +
, O +
theory O +
, O +
and O +
directions O +
. O +

Although O +
covariance O +
structure O +
analysis O +
is O +
used O +
increasingly O +
to O +
analyze O +
nonexperimental O +
data O +
, O +
important O +
statistical O +
requirements O +
for O +
its O +
proper O +
use O +
are O +
frequently O +
ignored O +
. O +

Valid O +
conclusions O +
about O +
the O +
adequacy O +
of O +
a O +
model O +
as O +
an O +
acceptable O +
representation O +
of O +
data O +
, O +
which O +
are O +
based O +
on O +
goodness O +
- O +
of O +
- O +
fit O +
test O +
statistics O +
and O +
standard O +
errors O +
of O +
parameter O +
estimates O +
, O +
rely O +
on O +
the O +
model O +
estimation O +
procedure O +
being O +
appropriate O +
for O +
the O +
data O +
. O +

Using O +
analogies O +
to O +
linear O +
regression O +
and O +
anova O +
, O +
this O +
review O +
examines O +
conditions O +
under O +
which O +
conclusions O +
drawn O +
from O +
various O +
estimation O +
methods O +
will O +
be O +
correct O +
and O +
the O +
consequences O +
of O +
ignoring O +
these O +
conditions O +
. O +

A O +
distinction O +
is O +
made O +
between O +
estimation O +
methods O +
that O +
are O +
either O +
correctly O +
or O +
incorrectly O +
specified O +
for O +
the O +
distribution O +
of O +
data O +
being O +
analyzed O +
, O +
and O +
it O +
is O +
shown O +
that O +
valid O +
conclusions O +
are O +
possible O +
even O +
under O +
misspecification O +
. O +

A O +
brief O +
example O +
illustrates O +
the O +
ideas O +
. O +

Internet O +
access O +
is O +
given O +
to O +
a O +
computer O +
code O +
for O +
several O +
methods O +
that O +
are O +
not O +
available O +
in O +
programs O +
such O +
as O +
EQS O +
or O +
LISREL O +
. O +

Morphogenesis O +
of O +
embryonic O +
CNS O +
vessels O +
. O +

This O +
chapter O +
focuses O +
on O +
the O +
morphology O +
of O +
blood O +
vessel O +
formation O +
in O +
and O +
around O +
the O +
early O +
central O +
nervous O +
system O +
( O +
CNS O +
, O +
i O +
. O +
e O +
. O +
, O +
brain O +
and O +
spinal O +
cord O +
) O +
of O +
avian O +
embryos O +
. O +

We O +
discuss O +
cell O +
lineages O +
, O +
proliferation O +
and O +
interactions O +
of O +
endothelial O +
cells O +
, O +
pericytes O +
and O +
smooth O +
muscle O +
cells O +
, O +
and O +
macrophages O +
. O +

Due O +
to O +
space O +
limitations O +
, O +
we O +
can O +
not O +
review O +
the O +
molecular O +
control O +
of O +
CNS O +
angiogenesis O +
, O +
but O +
refer O +
the O +
reader O +
to O +
other O +
chapters O +
in O +
this O +
book O +
and O +
to O +
recent O +
publications O +
on O +
the O +
assembly O +
of O +
the O +
vasculature O +
( O +
1 O +
, O +
2 O +
) O +
. O +

[ O +
Correlation O +
between O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
- O +
C O +
in O +
tumor O +
- O +
associated O +
macrophages O +
and O +
lymphatic O +
metastasis O +
in O +
oral O +
cancer O +
] O +
. O +

BACKGROUND O +
& O +
# O +
38 O +
; O +
OBJECTIVE O +
: O +
Previous O +
study O +
shows O +
that O +
both O +
vascular O +
endothelial O +
growth O +
- O +
C O +
( O +
VEGF O +
- O +
C O +
) O +
and O +
tumor O +
- O +
associated O +
macrophages O +
( O +
TAMs O +
) O +
are O +
related O +
to O +
lymphatic O +
metastasis O +
. O +

This O +
study O +
aimed O +
to O +
explore O +
the O +
correlation O +
between O +
the O +
expression O +
of O +
VEGF O +
- O +
C O +
in O +
TAMs O +
and O +
lymphatic O +
metastasis O +
in O +
human O +
oral O +
squamous O +
- O +
cell O +
carcinoma O +
( O +
OSCC O +
) O +
. O +

METHODS O +
: O +
After O +
immunohistochemical O +
staining O +
, O +
light O +
microscope O +
was O +
used O +
for O +
counting O +
macrophages O +
and O +
automated O +
image O +
analysis O +
quantification O +
was O +
used O +
to O +
determine O +
VEGF O +
- O +
C O +
expression O +
, O +
which O +
was O +
reflected O +
by O +
positive O +
index O +
( O +
PI O +
) O +
. O +

In O +
addition O +
, O +
the O +
double O +
staining O +
was O +
also O +
used O +
to O +
determine O +
VEGF O +
- O +
C O +
expression O +
in O +
TAMs O +
. O +

RESULTS O +
: O +
VEGF O +
- O +
C O +
expression O +
was O +
higher O +
in O +
lymphatic O +
metastasis O +
group O +
( O +
PI O +
= O +
12 O +
. O +
169 O +
+ O +
/ O +
- O +
2 O +
. O +
778 O +
) O +
than O +
in O +
no O +
- O +
metastasis O +
group O +
( O +
PI O +
= O +
8 O +
. O +
498 O +
+ O +
/ O +
- O +
2 O +
. O +
674 O +
, O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

TAMs O +
counts O +
was O +
related O +
to O +
VEGF O +
- O +
C O +
expression O +
in O +
OSCC O +
( O +
r O +
= O +
0 O +
. O +
370 O +
, O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

The O +
result O +
of O +
double O +
staining O +
indicated O +
that O +
macrophage O +
with O +
positive O +
VEGF O +
- O +
C O +
expression O +
accounted O +
for O +
about O +
22 O +
. O +
8 O +
% O +
of O +
the O +
total O +
. O +

CONCLUSION O +
: O +
Not O +
only O +
tumor O +
cells O +
but O +
also O +
TAMs O +
secrete O +
the O +
VEGF O +
- O +
C O +
in O +
OSCC O +
, O +
and O +
TAMs O +
may O +
play O +
a O +
major O +
role O +
in O +
peritumoral O +
lymphatic O +
neoangiogenesis O +
and O +
lymphatic O +
metastasis O +
. O +

The O +
candidate O +
tumour O +
suppressor O +
protein O +
ING4 O +
regulates O +
brain O +
tumour O +
growth O +
and O +
angiogenesis O +
. O +

Gliomas O +
are O +
the O +
most O +
common O +
primary O +
tumours O +
of O +
the O +
central O +
nervous O +
system O +
, O +
with O +
nearly O +
15 O +
, O +
000 O +
diagnosed O +
annually O +
in O +
the O +
United O +
States O +
and O +
a O +
lethality O +
approaching O +
80 O +
% O +
within O +
the O +
first O +
year O +
of O +
glioblastoma O +
diagnosis O +
. O +

The O +
marked O +
induction O +
of O +
angiogenesis O +
in O +
glioblastomas O +
suggests O +
that O +
it O +
is O +
a O +
necessary O +
part O +
of O +
malignant O +
progression O +
; O +
however O +
, O +
the O +
precise O +
molecular O +
mechanisms O +
underlying O +
the O +
regulation O +
of O +
brain O +
tumour O +
growth O +
and O +
angiogenesis O +
remain O +
unresolved O +
. O +

Here O +
we O +
report O +
that O +
a O +
candidate O +
tumour O +
suppressor O +
gene O +
, O +
ING4 O +
, O +
is O +
involved O +
in O +
regulating O +
brain O +
tumour O +
growth O +
and O +
angiogenesis O +
. O +

Expression O +
of O +
ING4 O +
is O +
significantly O +
reduced O +
in O +
gliomas O +
as O +
compared O +
with O +
normal O +
human O +
brain O +
tissue O +
, O +
and O +
the O +
extent O +
of O +
reduction O +
correlates O +
with O +
the O +
progression O +
from O +
lower O +
to O +
higher O +
grades O +
of O +
tumours O +
. O +

In O +
mice O +
, O +
xenografts O +
of O +
human O +
glioblastoma O +
U87MG O +
, O +
which O +
has O +
decreased O +
expression O +
of O +
ING4 O +
, O +
grow O +
significantly O +
faster O +
and O +
have O +
higher O +
vascular O +
volume O +
fractions O +
than O +
control O +
tumours O +
. O +

We O +
show O +
that O +
ING4 O +
physically O +
interacts O +
with O +
p65 O +
( O +
RelA O +
) O +
subunit O +
of O +
nuclear O +
factor O +
NF O +
- O +
kappaB O +
, O +
and O +
that O +
ING4 O +
regulates O +
brain O +
tumour O +
angiogenesis O +
through O +
transcriptional O +
repression O +
of O +
NF O +
- O +
kappaB O +
- O +
responsive O +
genes O +
. O +

These O +
results O +
indicate O +
that O +
ING4 O +
has O +
an O +
important O +
role O +
in O +
brain O +
tumour O +
pathogenesis O +
. O +

Deletion O +
of O +
guanine O +
nucleotide O +
binding O +
protein O +
alpha O +
z O +
subunit O +
in O +
mice O +
induces O +
a O +
gene O +
dose O +
dependent O +
tolerance O +
to O +
morphine O +
. O +

The O +
mechanism O +
underlying O +
the O +
development O +
of O +
tolerance O +
to O +
morphine O +
is O +
still O +
incompletely O +
understood O +
. O +

Morphine O +
binds O +
to O +
opioid O +
receptors O +
, O +
which O +
in O +
turn O +
activates O +
downstream O +
second O +
messenger O +
cascades O +
through O +
heterotrimeric O +
guanine O +
nucleotide O +
binding O +
proteins O +
( O +
G O +
proteins O +
) O +
. O +

In O +
this O +
paper O +
, O +
we O +
show O +
that O +
G O +
( O +
z O +
) O +
, O +
a O +
member O +
of O +
the O +
inhibitory O +
G O +
protein O +
family O +
, O +
plays O +
an O +
important O +
role O +
in O +
mediating O +
the O +
analgesic O +
and O +
lethality O +
effects O +
of O +
morphine O +
after O +
tolerance O +
development O +
. O +

We O +
blocked O +
signaling O +
through O +
the O +
G O +
( O +
z O +
) O +
second O +
messenger O +
cascade O +
by O +
genetic O +
ablation O +
of O +
the O +
alpha O +
subunit O +
of O +
the O +
G O +
protein O +
in O +
mice O +
. O +

The O +
Galpha O +
( O +
z O +
) O +
knockout O +
mouse O +
develops O +
significantly O +
increased O +
tolerance O +
to O +
morphine O +
, O +
which O +
depends O +
on O +
Galpha O +
( O +
z O +
) O +
gene O +
dosage O +
. O +

Further O +
experiments O +
demonstrate O +
that O +
the O +
enhanced O +
morphine O +
tolerance O +
is O +
not O +
caused O +
by O +
pharmacokinetic O +
and O +
behavioural O +
learning O +
mechanisms O +
. O +

The O +
results O +
suggest O +
that O +
G O +
( O +
z O +
) O +
signaling O +
pathways O +
are O +
involved O +
in O +
transducing O +
the O +
analgesic O +
and O +
lethality O +
effects O +
of O +
morphine O +
following O +
chronic O +
morphine O +
treatment O +
. O +

Nuclear O +
translocation O +
of O +
a O +
clusterin O +
isoform O +
is O +
associated O +
with O +
induction O +
of O +
anoikis O +
in O +
SV40 O +
- O +
immortalized O +
human O +
prostate O +
epithelial O +
cells O +
. O +

Clusterin O +
gene O +
expression O +
is O +
potently O +
induced O +
in O +
experimental O +
models O +
in O +
which O +
apoptosis O +
is O +
activated O +
, O +
such O +
as O +
rat O +
prostate O +
involution O +
following O +
castration O +
. O +

Nevertheless O +
, O +
its O +
precise O +
physiological O +
role O +
has O +
not O +
yet O +
been O +
established O +
, O +
and O +
both O +
anti O +
- O +
apoptotic O +
and O +
pro O +
- O +
apoptotic O +
functions O +
have O +
been O +
suggested O +
for O +
this O +
gene O +
. O +

Clusterin O +
expression O +
level O +
depends O +
on O +
cell O +
proliferation O +
state O +
, O +
and O +
we O +
recently O +
showed O +
that O +
its O +
over O +
- O +
expression O +
inhibited O +
cell O +
cycle O +
progression O +
of O +
SV40 O +
- O +
immortalized O +
human O +
prostate O +
epithelial O +
cells O +
PNT2 B-CellLine +
and O +
PNT1a B-CellLine +
. O +

Here O +
we O +
studied O +
clusterin O +
expression O +
in O +
PNT1a B-CellLine +
cells O +
subjected O +
to O +
serum O +
- O +
starvation O +
with O +
the O +
aim O +
of O +
defining O +
clusterin O +
early O +
molecular O +
changes O +
following O +
apoptosis O +
induction O +
. O +

Under O +
serum O +
- O +
starvation O +
conditions O +
, O +
decreased O +
growth O +
rate O +
, O +
slow O +
rounding O +
- O +
up O +
of O +
cells O +
, O +
cell O +
detachment O +
, O +
and O +
formation O +
of O +
apoptotic O +
bodies O +
indicative O +
of O +
anoikis O +
( O +
detachment O +
- O +
induced O +
apoptosis O +
) O +
were O +
preceded O +
by O +
significant O +
downregulation O +
of O +
70 O +
kDa O +
clusterin O +
precursor O +
and O +
upregulation O +
of O +
45 O +
- O +
40 O +
kDa O +
isoforms O +
. O +

On O +
the O +
8th O +
day O +
of O +
serum O +
- O +
free O +
culturing O +
, O +
only O +
the O +
higher O +
molecular O +
weight O +
protein O +
- O +
band O +
of O +
about O +
45 O +
kDa O +
was O +
clearly O +
induced O +
and O +
accumulated O +
in O +
detached O +
cells O +
and O +
apoptotic O +
bodies O +
in O +
which O +
PARP O +
was O +
activated O +
. O +

Anoikis O +
was O +
preceded O +
by O +
induction O +
and O +
transloction O +
of O +
a O +
45 O +
- O +
kDa O +
clusterin O +
isoform O +
to O +
the O +
nucleus O +
. O +

Thus O +
, O +
nuclear O +
targeting O +
of O +
a O +
specific O +
45 O +
- O +
kDa O +
isoform O +
of O +
clusterin O +
appeared O +
to O +
be O +
an O +
early O +
and O +
specific O +
molecular O +
signal O +
triggering O +
anoikis O +
- O +
death O +
. O +

Considering O +
also O +
that O +
clusterin O +
is O +
downregulated O +
during O +
prostate O +
cancer O +
onset O +
and O +
progression O +
, O +
and O +
that O +
its O +
upregulation O +
has O +
inhibited O +
DNA O +
synthesis O +
and O +
cell O +
cycle O +
progression O +
of O +
immortalized O +
human O +
prostate O +
epithelial O +
cells O +
, O +
we O +
suggest O +
that O +
clusterin O +
might O +
be O +
a O +
new O +
anti O +
- O +
oncogene O +
in O +
the O +
prostate O +
. O +

TGFbeta1 O +
, O +
back O +
to O +
the O +
future O +
: O +
revisiting O +
its O +
role O +
as O +
a O +
transforming O +
growth O +
factor O +
. O +

TGFbeta1 O +
was O +
initially O +
identified O +
in O +
culture O +
media O +
from O +
transformed O +
cells O +
as O +
part O +
of O +
a O +
factor O +
that O +
could O +
produce O +
a O +
transformed O +
phenotype O +
in O +
a O +
nontransformed O +
cell O +
line O +
. O +

Subsequently O +
this O +
activity O +
was O +
separated O +
into O +
TGFbeta O +
and O +
TGFalpha O +
an O +
EGF O +
receptor O +
ligand O +
. O +

With O +
the O +
discovery O +
that O +
TGFbeta1 O +
was O +
a O +
potent O +
growth O +
inhibitor O +
of O +
epithelial O +
cells O +
, O +
and O +
the O +
identification O +
of O +
inactivating O +
mutations O +
within O +
the O +
TGFbeta1 O +
signaling O +
pathway O +
in O +
cancers O +
it O +
became O +
clear O +
that O +
TGFbeta1 O +
signaling O +
is O +
a O +
tumor O +
suppressor O +
pathway O +
for O +
early O +
stages O +
of O +
cancer O +
. O +

However O +
many O +
human O +
carcinomas O +
overexpress O +
TGFbeta1 O +
and O +
this O +
is O +
associated O +
with O +
poor O +
patient O +
prognosis O +
and O +
increased O +
frequency O +
of O +
metastasis O +
. O +

Similar O +
results O +
have O +
been O +
obtained O +
with O +
tumor O +
cell O +
lines O +
and O +
experimental O +
animal O +
models O +
. O +

Thus O +
stage O +
specific O +
duality O +
of O +
function O +
is O +
the O +
emerging O +
paradigm O +
for O +
the O +
role O +
of O +
TGFbeta1 O +
in O +
cancer O +
. O +

This O +
review O +
will O +
focus O +
on O +
the O +
evidence O +
for O +
TGFbeta1 O +
as O +
a O +
tumor O +
promoting O +
and O +
metastasis O +
factor O +
and O +
examine O +
the O +
biological O +
and O +
molecular O +
basis O +
for O +
these O +
effects O +
. O +

It O +
is O +
proposed O +
that O +
the O +
switch O +
from O +
tumor O +
suppressor O +
to O +
oncogene O +
reflects O +
genetic O +
or O +
epigenetic O +
alterations O +
in O +
signaling O +
pathways O +
in O +
tumor O +
cells O +
that O +
alter O +
the O +
readout O +
from O +
the O +
TGFbeta1 O +
pathway O +
. O +

Role O +
of O +
thrombin O +
in O +
angiogenesis O +
and O +
tumor O +
progression O +
. O +

Clinical O +
, O +
laboratory O +
, O +
histopathological O +
, O +
and O +
pharmacological O +
evidence O +
support O +
the O +
notion O +
that O +
the O +
coagulation O +
system O +
, O +
which O +
is O +
activated O +
in O +
most O +
cancer O +
patients O +
, O +
plays O +
an O +
important O +
role O +
in O +
tumor O +
biology O +
. O +

Our O +
laboratory O +
has O +
provided O +
evidence O +
that O +
thrombin O +
activates O +
angiogenesis O +
, O +
a O +
process O +
which O +
is O +
essential O +
in O +
tumor O +
growth O +
and O +
metastasis O +
. O +

This O +
event O +
is O +
independent O +
of O +
fibrin O +
formation O +
. O +

At O +
the O +
cellular O +
level O +
many O +
actions O +
of O +
thrombin O +
can O +
contribute O +
to O +
activation O +
of O +
angiogenesis O +
: O +
( O +
1 O +
) O +
. O +

Thrombin O +
decreases O +
the O +
ability O +
of O +
endothelial O +
cells O +
to O +
attach O +
to O +
basement O +
membrane O +
proteins O +
. O +

( O +
2 O +
) O +
. O +

Thrombin O +
greatly O +
potentiates O +
vascular O +
endothelial O +
growth O +
factor O +
- O +
( O +
VEGF O +
- O +
) O +
induced O +
endothelial O +
cell O +
proliferation O +
. O +

This O +
potentiation O +
is O +
accompanied O +
by O +
up O +
- O +
regulation O +
of O +
the O +
expression O +
of O +
VEGF O +
receptors O +
( O +
kinase O +
insert O +
domain O +
- O +
containing O +
receptor O +
[ O +
KDR O +
] O +
and O +
fms O +
- O +
like O +
tyrosine O +
kinase O +
[ O +
Flt O +
- O +
1 O +
] O +
) O +
. O +

( O +
3 O +
) O +
. O +

Thrombin O +
increases O +
the O +
mRNA O +
and O +
protein O +
levels O +
of O +
alpha O +
( O +
v O +
) O +
beta O +
( O +
3 O +
) O +
integrin O +
and O +
serves O +
as O +
a O +
ligand O +
to O +
this O +
receptor O +
. O +

Furthermore O +
, O +
thrombin O +
increases O +
the O +
secretion O +
of O +
VEGF O +
and O +
enhances O +
the O +
expression O +
and O +
protein O +
synthesis O +
of O +
matrix O +
metalloprotease O +
- O +
9 O +
and O +
alpha O +
( O +
v O +
) O +
beta O +
( O +
3 O +
) O +
integrin O +
in O +
human O +
prostate O +
cancer O +
PC B-CellLine +
- I-CellLine +
3 I-CellLine +
cells O +
. O +

These O +
results O +
could O +
explain O +
the O +
angiogenic O +
and O +
tumor O +
- O +
promoting O +
effect O +
of O +
thrombin O +
and O +
provide O +
the O +
basis O +
for O +
development O +
of O +
thrombin O +
receptor O +
mimetics O +
or O +
antagonists O +
for O +
therapeutic O +
application O +
. O +

Levels O +
of O +
expression O +
of O +
CYR61 O +
and O +
CTGF O +
are O +
prognostic O +
for O +
tumor O +
progression O +
and O +
survival O +
of O +
individuals O +
with O +
gliomas O +
. O +

The O +
biological O +
properties O +
of O +
CCN O +
proteins O +
include O +
stimulation O +
of O +
cell O +
proliferation O +
, O +
migration O +
, O +
and O +
adhesion O +
, O +
as O +
well O +
as O +
angiogenesis O +
and O +
tumorigenesis O +
. O +

We O +
quantified O +
CYR61 O +
, O +
CTGF O +
, O +
WISP O +
- O +
1 O +
, O +
and O +
NOV O +
mRNA O +
expression O +
levels O +
in O +
samples O +
from O +
sixty O +
- O +
six O +
primary O +
gliomas O +
and O +
five O +
normal O +
brain O +
samples O +
using O +
quantitative O +
real O +
- O +
time O +
PCR O +
assay O +
. O +

Statistical O +
analysis O +
was O +
performed O +
to O +
explore O +
the O +
links O +
between O +
expression O +
of O +
the O +
CCN O +
genes O +
and O +
clinical O +
and O +
pathological O +
parameters O +
. O +

Overexpression O +
of O +
CYR61 O +
, O +
CTGF O +
, O +
WISP O +
- O +
1 O +
, O +
and O +
NOV O +
occurred O +
in O +
48 O +
% O +
( O +
32 O +
of O +
66 O +
) O +
, O +
58 O +
% O +
( O +
38 O +
of O +
66 O +
) O +
, O +
36 O +
% O +
( O +
24 O +
of O +
66 O +
) O +
, O +
and O +
15 O +
% O +
( O +
10 O +
of O +
66 O +
) O +
of O +
primary O +
gliomas O +
, O +
respectively O +
. O +

Interestingly O +
, O +
significant O +
associations O +
were O +
found O +
between O +
CYR61 O +
expression O +
versus O +
tumor O +
grade O +
, O +
pathology O +
, O +
gender O +
, O +
and O +
age O +
at O +
diagnosis O +
. O +

Also O +
, O +
a O +
significant O +
correlation O +
existed O +
between O +
CTGF O +
mRNA O +
levels O +
versus O +
tumor O +
grade O +
, O +
gender O +
, O +
and O +
pathology O +
. O +

In O +
contrast O +
to O +
CYR61 O +
and O +
CTGF O +
, O +
no O +
significant O +
association O +
was O +
found O +
between O +
expression O +
of O +
either O +
WISP O +
- O +
1 O +
or O +
NOV O +
versus O +
any O +
of O +
the O +
pathological O +
features O +
. O +

Furthermore O +
, O +
Cox O +
regression O +
analysis O +
showed O +
that O +
CYR61 O +
and O +
CTGF O +
expression O +
had O +
a O +
significant O +
correlation O +
with O +
patient O +
survival O +
. O +

These O +
results O +
suggest O +
that O +
CYR61 O +
and O +
CTGF O +
may O +
play O +
a O +
role O +
in O +
the O +
progression O +
of O +
gliomas O +
; O +
their O +
levels O +
at O +
diagnosis O +
may O +
have O +
prognostic O +
significance O +
; O +
and O +
these O +
proteins O +
might O +
serve O +
as O +
valuable O +
targets O +
for O +
therapeutic O +
intervention O +
. O +

NIH3T3 B-CellLine +
transfectant O +
containing O +
human O +
K O +
- O +
ras O +
oncogene O +
shows O +
enhanced O +
metastatic O +
activity O +
after O +
in O +
vivo O +
tumor O +
growth O +
or O +
co O +
- O +
culture O +
with O +
fibroblasts O +
. O +

A O +
clone O +
of O +
NIH3T3 B-CellLine +
transformant O +
( O +
H B-CellLine +
- I-CellLine +
3 I-CellLine +
) O +
, O +
obtained O +
by O +
transfecting O +
genomic O +
DNA O +
of O +
a O +
human O +
colon O +
carcinoma O +
cell O +
line O +
, O +
contains O +
human O +
K O +
- O +
ras O +
oncogene O +
and O +
yields O +
metastatic O +
pulmonary O +
nodules O +
after O +
intravenous O +
injection O +
of O +
the O +
cells O +
into O +
nude O +
mice O +
. O +

This O +
metastatic O +
ability O +
was O +
enhanced O +
remarkably O +
after O +
in O +
vivo O +
tumor O +
growth O +
( O +
subcutaneous O +
tumor O +
formation O +
in O +
nude O +
mice O +
) O +
accompanied O +
by O +
increased O +
mRNA O +
expression O +
and O +
gene O +
amplification O +
of O +
the O +
human O +
- O +
derived O +
K O +
- O +
ras O +
oncogene O +
, O +
while O +
it O +
declined O +
gradually O +
as O +
the O +
passage O +
number O +
increased O +
in O +
vitro O +
, O +
with O +
corresponding O +
decreases O +
of O +
gene O +
amplification O +
and O +
mRNA O +
expression O +
. O +

Six O +
subclones O +
were O +
randomly O +
selected O +
from O +
H B-CellLine +
- I-CellLine +
3 I-CellLine +
cells O +
which O +
had O +
been O +
subcultured O +
to O +
passage O +
22 O +
. O +

All O +
of O +
the O +
clones O +
in O +
culture O +
showed O +
almost O +
the O +
same O +
low O +
level O +
of O +
metastatic O +
ability O +
and O +
exhibited O +
little O +
K O +
- O +
ras O +
oncogene O +
amplification O +
with O +
correspondingly O +
low O +
mRNA O +
expression O +
. O +

However O +
, O +
after O +
they O +
formed O +
tumors O +
in O +
nude O +
mice O +
, O +
every O +
clone O +
acquired O +
high O +
metastatic O +
ability O +
and O +
the O +
gene O +
amplification O +
increased O +
, O +
with O +
elevated O +
mRNA O +
expression O +
. O +

These O +
experimental O +
facts O +
indicated O +
that O +
acquisition O +
of O +
metastatic O +
ability O +
coupled O +
with O +
the O +
function O +
of O +
K O +
- O +
ras O +
oncogene O +
was O +
conditional O +
in O +
nature O +
, O +
being O +
strongly O +
affected O +
by O +
in O +
vivo O +
tumor O +
circumstances O +
. O +

The O +
low O +
metastatic O +
and O +
G O +
- O +
418 O +
- O +
resistant O +
H B-CellLine +
- I-CellLine +
3 I-CellLine +
cells O +
were O +
co O +
- O +
cultured O +
with O +
BALB B-CellLine +
/ I-CellLine +
c3T3 I-CellLine +
fibroblasts O +
for O +
2 O +
- O +
4 O +
weeks O +
. O +

After O +
removal O +
of O +
fibroblasts O +
by O +
exposure O +
to O +
G O +
- O +
418 O +
, O +
the O +
tumor O +
cells O +
exhibited O +
increased O +
metastatic O +
ability O +
and O +
human O +
K O +
- O +
ras O +
oncogene O +
mRNA O +
, O +
suggesting O +
an O +
intimate O +
interaction O +
between O +
H B-CellLine +
- I-CellLine +
3 I-CellLine +
cells O +
and O +
fibroblasts O +
influencing O +
the O +
function O +
of O +
transfected O +
human O +
K O +
- O +
ras O +
oncogene O +
. O +

Fibroblasts O +
of O +
the O +
host O +
animal O +
may O +
thus O +
have O +
an O +
important O +
role O +
in O +
generating O +
enhanced O +
metastatic O +
activity O +
of O +
H B-CellLine +
- I-CellLine +
3 I-CellLine +
cells O +
. O +

Potent O +
antibacterial O +
activity O +
of O +
Y O +
- O +
754 O +
, O +
a O +
novel O +
benzimidazole O +
compound O +
with O +
selective O +
action O +
against O +
Helicobacter O +
pylori O +
. O +

Y O +
- O +
754 O +
, O +
a O +
novel O +
benzimidazole O +
compound O +
, O +
was O +
investigated O +
for O +
in O +
vitro O +
and O +
in O +
vivo O +
antibacterial O +
activity O +
. O +

Unlike O +
amoxicillin O +
, O +
clarithromycin O +
, O +
and O +
metronidazole O +
, O +
the O +
compound O +
had O +
no O +
activity O +
against O +
common O +
aerobic O +
and O +
anaerobic O +
bacteria O +
other O +
than O +
Helicobacter O +
pylori O +
. O +

The O +
minimum O +
inhibitory O +
concentration O +
of O +
Y O +
- O +
754 O +
against O +
H O +
. O +
pylori O +
, O +
at O +
0 O +
. O +
025 O +
microg O +
/ O +
ml O +
, O +
was O +
nearly O +
equal O +
to O +
that O +
of O +
amoxicillin O +
and O +
clarithromycin O +
. O +

The O +
respective O +
concentrations O +
of O +
Y O +
- O +
754 O +
, O +
amoxicillin O +
, O +
clarithromycin O +
, O +
and O +
metronidazole O +
required O +
to O +
inhibit O +
90 O +
% O +
of O +
39 O +
isolates O +
of O +
H O +
. O +
pylori O +
were O +
0 O +
. O +
05 O +
, O +
0 O +
. O +
39 O +
, O +
6 O +
. O +
25 O +
, O +
and O +
25 O +
microg O +
/ O +
ml O +
, O +
indicating O +
the O +
potent O +
activity O +
of O +
Y O +
- O +
754 O +
, O +
including O +
activity O +
against O +
clarithromycin O +
- O +
and O +
metronidazole O +
- O +
resistant O +
strains O +
. O +

The O +
anti O +
- O +
H O +
. O +
pylori O +
activity O +
of O +
Y O +
- O +
754 O +
was O +
potent O +
even O +
at O +
pH O +
5 O +
. O +
5 O +
and O +
was O +
bactericidal O +
at O +
concentrations O +
of O +
0 O +
. O +
1 O +
microg O +
/ O +
ml O +
and O +
above O +
. O +

Exposure O +
of O +
H O +
. O +
pylori O +
to O +
Y O +
- O +
754 O +
did O +
not O +
result O +
in O +
the O +
induction O +
of O +
drug O +
- O +
resistant O +
mutation O +
. O +

Oral O +
administration O +
( O +
10 O +
mg O +
/ O +
kg O +
twice O +
a O +
day O +
for O +
7 O +
days O +
) O +
to O +
Mongolian O +
gerbils O +
infected O +
with O +
strain O +
ATCC O +
43504 O +
demonstrated O +
that O +
Y O +
- O +
754 O +
was O +
effective O +
in O +
H O +
. O +
pylori O +
eradication O +
and O +
that O +
its O +
eradication O +
efficacy O +
increased O +
in O +
line O +
with O +
the O +
progress O +
of O +
damage O +
to O +
the O +
gastric O +
mucosa O +
caused O +
by O +
H O +
. O +
pylori O +
infection O +
. O +

Y O +
- O +
754 O +
was O +
also O +
efficacious O +
in O +
the O +
treatment O +
of O +
infection O +
by O +
the O +
clarithromycin O +
- O +
resistant O +
strain O +
OIT O +
- O +
36 O +
. O +

The O +
results O +
obtained O +
lead O +
to O +
the O +
expectation O +
that O +
the O +
new O +
benzimidazole O +
Y O +
- O +
754 O +
will O +
, O +
in O +
the O +
near O +
future O +
, O +
be O +
used O +
for O +
H O +
. O +
pylori O +
eradication O +
therapy O +
in O +
peptic O +
ulcer O +
patients O +
. O +

Active O +
respiratory O +
syncytial O +
virus O +
purified O +
by O +
ion O +
- O +
exchange O +
chromatography O +
: O +
characterization O +
of O +
binding O +
and O +
elution O +
requirements O +
. O +

Two O +
viruses O +
, O +
respiratory O +
syncytial O +
virus O +
( O +
RSV O +
) O +
and O +
vesicular O +
stomatitis O +
virus O +
( O +
VSV O +
) O +
were O +
used O +
to O +
evaluate O +
viral O +
purification O +
by O +
an O +
affinity O +
resin O +
column O +
( O +
Matrex O +
Cellufine O +
Sulfate O +
( O +
MCS O +
) O +
; O +
Amicon O +
Division O +
, O +
WR O +
Grace O +
& O +
Co O +
. O +
) O +
. O +

Viable O +
RSV O +
was O +
purified O +
significantly O +
from O +
crude O +
cell O +
lysate O +
by O +
a O +
single O +
pass O +
through O +
a O +
column O +
containing O +
the O +
anionic O +
MCS O +
resin O +
. O +

Most O +
cell O +
protein O +
and O +
albumin O +
eluted O +
from O +
the O +
MCS O +
resin O +
with O +
phosphate O +
buffered O +
saline O +
( O +
PBS O +
) O +
but O +
RSV O +
eluted O +
at O +
high O +
ionic O +
strength O +
, O +
i O +
. O +
e O +
. O +
, O +
greater O +
than O +
or O +
equal O +
to O +
0 O +
. O +
6 O +
M O +
NaCl O +
. O +

Further O +
purification O +
was O +
possible O +
by O +
sucrose O +
step O +
gradient O +
centrifugation O +
. O +

The O +
RSV O +
prepared O +
by O +
column O +
purification O +
or O +
by O +
column O +
plus O +
sucrose O +
gradient O +
separation O +
was O +
both O +
intact O +
and O +
infective O +
. O +

RSV O +
and O +
pure O +
samples O +
of O +
VSV O +
were O +
used O +
to O +
optimize O +
ionic O +
strength O +
and O +
salts O +
for O +
elution O +
from O +
the O +
MCS O +
column O +
: O +
0 O +
. O +
8 O +
M O +
NaCl O +
removed O +
most O +
of O +
the O +
viral O +
protein O +
. O +

The O +
capacity O +
of O +
the O +
MCS O +
gel O +
for O +
RSV O +
or O +
VSV O +
was O +
found O +
to O +
be O +
about O +
0 O +
. O +
6 O +
- O +
0 O +
. O +
8 O +
mg O +
viral O +
protein O +
per O +
ml O +
of O +
hydrated O +
resin O +
. O +

Detergent O +
- O +
solubilized O +
viral O +
membrane O +
proteins O +
bound O +
to O +
the O +
MCS O +
resin O +
in O +
0 O +
. O +
145 O +
M O +
NaCl O +
and O +
eluted O +
with O +
higher O +
salt O +
concentrations O +
. O +

Thus O +
, O +
this O +
resin O +
also O +
may O +
be O +
a O +
useful O +
aid O +
for O +
relatively O +
gentle O +
purification O +
of O +
these O +
proteins O +
. O +

Lactoferrin O +
enhances O +
Fas O +
expression O +
and O +
apoptosis O +
in O +
the O +
colon O +
mucosa O +
of O +
azoxymethane O +
- O +
treated O +
rats O +
. O +

Bovine O +
lactoferrin O +
, O +
a O +
multifunctional O +
glycoprotein O +
, O +
has O +
been O +
shown O +
to O +
strongly O +
inhibit O +
development O +
of O +
azoxymethane O +
( O +
AOM O +
) O +
- O +
induced O +
rat O +
colon O +
tumors O +
. O +

Little O +
, O +
however O +
, O +
is O +
known O +
about O +
the O +
inhibitory O +
mechanisms O +
. O +

We O +
have O +
demonstrated O +
recently O +
that O +
lactoferrin O +
enhances O +
the O +
expression O +
of O +
a O +
member O +
of O +
the O +
tumor O +
necrosis O +
factor O +
receptor O +
family O +
, O +
Fas O +
, O +
in O +
the O +
colon O +
mucosa O +
during O +
both O +
early O +
and O +
late O +
stages O +
of O +
carcinogenesis O +
. O +

Thus O +
, O +
Fas O +
could O +
be O +
involved O +
in O +
bovine O +
lactoferrin O +
- O +
mediated O +
inhibition O +
of O +
tumor O +
development O +
. O +

To O +
investigate O +
this O +
possibility O +
, O +
we O +
studied O +
the O +
influence O +
of O +
bovine O +
lactoferrin O +
on O +
Fas O +
- O +
mediated O +
apoptosis O +
with O +
regard O +
to O +
expression O +
of O +
Fas O +
, O +
activation O +
of O +
caspase O +
- O +
8 O +
and O +
caspase O +
- O +
3 O +
, O +
and O +
DNA O +
fragmentation O +
in O +
the O +
colon O +
mucosa O +
of O +
AOM O +
- O +
treated O +
rats O +
. O +

Western O +
blot O +
analysis O +
demonstrated O +
a O +
> O +
2 O +
. O +
5 O +
- O +
fold O +
increase O +
in O +
Fas O +
protein O +
expression O +
, O +
as O +
well O +
as O +
elevation O +
of O +
the O +
active O +
forms O +
of O +
both O +
caspase O +
- O +
8 O +
and O +
caspase O +
- O +
3 O +
. O +

Immunohistochemical O +
analysis O +
revealed O +
Fas O +
- O +
positive O +
cells O +
and O +
apoptotic O +
cells O +
preferentially O +
within O +
the O +
proximal O +
colon O +
region O +
, O +
clearly O +
at O +
the O +
site O +
of O +
bovine O +
lactoferrin O +
- O +
mediated O +
tumor O +
inhibition O +
. O +

These O +
results O +
suggest O +
that O +
apoptosis O +
caused O +
by O +
elevated O +
expression O +
of O +
Fas O +
is O +
involved O +
in O +
chemoprevention O +
by O +
lactoferrin O +
of O +
colon O +
carcinogenesis O +
. O +

Dynein O +
light O +
chain O +
1 O +
, O +
a O +
p21 O +
- O +
activated O +
kinase O +
1 O +
- O +
interacting O +
substrate O +
, O +
promotes O +
cancerous O +
phenotypes O +
. O +

We O +
identified O +
dynein O +
light O +
chain O +
1 O +
( O +
DLC1 O +
) O +
as O +
a O +
physiologic O +
substrate O +
of O +
p21 O +
- O +
activated O +
kinase O +
1 O +
( O +
Pak1 O +
) O +
. O +

Pak1 O +
- O +
DLC1 O +
interaction O +
plays O +
an O +
essential O +
role O +
in O +
cell O +
survival O +
, O +
which O +
depends O +
on O +
Pak1 O +
' O +
s O +
phosphorylation O +
of O +
DLC1 O +
on O +
Ser88 O +
. O +

Pak1 O +
associates O +
with O +
the O +
complex O +
of O +
DLC1 O +
and O +
BimL O +
, O +
a O +
proapoptotic O +
BH3 O +
- O +
only O +
protein O +
, O +
and O +
phosphorylates O +
both O +
proteins O +
. O +

Phosphorylation O +
of O +
BimL O +
by O +
Pak1 O +
prevents O +
it O +
from O +
interacting O +
with O +
and O +
inactivation O +
of O +
Bcl O +
- O +
2 O +
, O +
an O +
antiapoptotic O +
protein O +
. O +

Overexpression O +
of O +
DLC1 O +
but O +
not O +
DLC1 O +
- O +
Ser88Ala O +
mutant O +
promotes O +
cancerous O +
properties O +
of O +
breast O +
cancer O +
cells O +
. O +

DLC1 O +
protein O +
level O +
is O +
elevated O +
in O +
more O +
than O +
90 O +
% O +
of O +
human O +
breast O +
tumors O +
. O +

The O +
regulation O +
of O +
cell O +
survival O +
functions O +
by O +
Pak1 O +
- O +
DLC1 O +
interaction O +
represents O +
a O +
novel O +
mechanism O +
by O +
which O +
a O +
signaling O +
kinase O +
might O +
regulate O +
the O +
cancerous O +
phenotypes O +
. O +

Novel O +
insights O +
into O +
the O +
pathogenesis O +
of O +
uric O +
acid O +
nephrolithiasis O +
. O +

PURPOSE O +
OF O +
REVIEW O +
: O +

The O +
factors O +
involved O +
in O +
the O +
pathogenesis O +
of O +
uric O +
acid O +
nephrolithiasis O +
are O +
well O +
known O +
. O +

A O +
low O +
urinary O +
pH O +
is O +
the O +
most O +
significant O +
element O +
in O +
the O +
generation O +
of O +
stones O +
, O +
with O +
hyperuricosuria O +
being O +
a O +
less O +
common O +
finding O +
. O +

The O +
underlying O +
mechanism O +
( O +
s O +
) O +
responsible O +
for O +
these O +
disturbances O +
remain O +
poorly O +
characterized O +
. O +

This O +
review O +
summarizes O +
previous O +
knowledge O +
and O +
highlights O +
some O +
recent O +
developments O +
in O +
the O +
pathophysiology O +
of O +
low O +
urine O +
pH O +
and O +
hyperuricosuria O +
. O +

RECENT O +
FINDINGS O +
: O +

Epidemiological O +
and O +
metabolic O +
studies O +
have O +
indicated O +
an O +
association O +
between O +
uric O +
acid O +
nephrolithiasis O +
and O +
insulin O +
resistance O +
. O +

Some O +
potential O +
mechanisms O +
include O +
impaired O +
ammoniagenesis O +
caused O +
by O +
resistance O +
to O +
insulin O +
action O +
in O +
the O +
renal O +
proximal O +
tubule O +
, O +
or O +
substrate O +
competition O +
by O +
free O +
fatty O +
acids O +
. O +

The O +
evaluation O +
of O +
a O +
large O +
Sicilian O +
kindred O +
recently O +
revealed O +
a O +
putative O +
genetic O +
locus O +
linked O +
to O +
uric O +
acid O +
stone O +
disease O +
. O +

The O +
identification O +
of O +
novel O +
complementary O +
DNA O +
has O +
provided O +
an O +
interesting O +
insight O +
into O +
the O +
renal O +
handling O +
of O +
uric O +
acid O +
, O +
including O +
one O +
genetic O +
cause O +
of O +
renal O +
uric O +
acid O +
wasting O +
. O +

SUMMARY O +
: O +

The O +
recognition O +
of O +
metabolic O +
, O +
molecular O +
, O +
and O +
genetic O +
factors O +
that O +
influence O +
urinary O +
pH O +
, O +
and O +
uric O +
acid O +
metabolism O +
and O +
excretion O +
, O +
will O +
provide O +
novel O +
insights O +
into O +
the O +
pathogenesis O +
of O +
uric O +
acid O +
stones O +
, O +
and O +
open O +
the O +
way O +
for O +
new O +
therapeutic O +
strategies O +
. O +

Effects O +
of O +
buffer O +
properties O +
on O +
cyclodextrin O +
glucanotransferase O +
reactions O +
and O +
cyclodextrin O +
production O +
from O +
raw O +
sago O +
( O +
Cycas O +
revoluta O +
) O +
starch O +
. O +

Results O +
from O +
the O +
present O +
study O +
have O +
shown O +
that O +
the O +
ionic O +
species O +
of O +
buffers O +
, O +
pH O +
values O +
and O +
reaction O +
temperature O +
can O +
affect O +
the O +
enzyme O +
unit O +
activities O +
and O +
product O +
specificity O +
of O +
Toruzyme O +
( O +
Novo O +
Nordisk O +
A O +
/ O +
S O +
Bagsvaerd O +
, O +
Denmark O +
) O +
CGTase O +
( O +
cyclodextrin O +
glucanotransferase O +
) O +
. O +

Applying O +
a O +
similar O +
reaction O +
environment O +
( O +
acetate O +
buffer O +
, O +
pH O +
6 O +
. O +
0 O +
; O +
temperature O +
, O +
60 O +
degrees O +
C O +
) O +
, O +
the O +
CGTase O +
was O +
found O +
to O +
be O +
capable O +
of O +
producing O +
pre O +
dominantly O +
beta O +
- O +
cyclodextrin O +
from O +
either O +
raw O +
or O +
gelatinized O +
sago O +
( O +
Cycas O +
revoluta O +
) O +
starch O +
. O +

Changing O +
the O +
buffer O +
from O +
acetate O +
to O +
phosphate O +
reduced O +
the O +
yield O +
of O +
beta O +
- O +
cyclodextrin O +
from O +
2 O +
. O +
48 O +
to O +
1 O +
. O +
42 O +
mg O +
/ O +
ml O +
and O +
also O +
affected O +
the O +
product O +
specificity O +
, O +
where O +
production O +
of O +
both O +
alpha O +
- O +
and O +
beta O +
- O +
cyclodextrins O +
were O +
more O +
pronounced O +
. O +

The O +
decrease O +
in O +
the O +
production O +
of O +
cyclodextrins O +
in O +
phosphate O +
buffer O +
was O +
significant O +
at O +
both O +
pH O +
6 O +
. O +
0 O +
and O +
7 O +
. O +
0 O +
. O +

However O +
, O +
changing O +
the O +
buffer O +
to O +
Tris O +
/ O +
HCl O +
( O +
pH O +
7 O +
. O +
0 O +
) O +
showed O +
a O +
significant O +
increase O +
in O +
beta O +
- O +
cyclodextrin O +
production O +
. O +

Increasing O +
the O +
ionic O +
strength O +
of O +
sodium O +
acetate O +
and O +
Tris O +
/ O +
HCl O +
buffers O +
at O +
pH O +
6 O +
. O +
0 O +
and O +
7 O +
. O +
0 O +
to O +
equivalent O +
ionic O +
strength O +
of O +
phosphate O +
buffers O +
showed O +
no O +
significant O +
effects O +
on O +
cyclodextrin O +
production O +
. O +

Higher O +
yield O +
of O +
cyclodextrins O +
at O +
pH O +
7 O +
. O +
0 O +
when O +
Tris O +
/ O +
HCl O +
was O +
used O +
might O +
be O +
due O +
to O +
the O +
binding O +
of O +
chloride O +
ions O +
at O +
the O +
calcium O +
- O +
binding O +
sites O +
of O +
the O +
CGTase O +
, O +
resulting O +
in O +
the O +
shift O +
of O +
the O +
optimum O +
pH O +
close O +
to O +
physiological O +
environment O +
, O +
leading O +
to O +
an O +
increase O +
in O +
the O +
activities O +
and O +
specificity O +
. O +

Hypothesis O +
: O +
Induced O +
angiogenesis O +
after O +
surgery O +
in O +
premenopausal O +
node O +
- O +
positive O +
breast O +
cancer O +
patients O +
is O +
a O +
major O +
underlying O +
reason O +
why O +
adjuvant O +
chemotherapy O +
works O +
particularly O +
well O +
for O +
those O +
patients O +
. O +

BACKGROUND O +
: O +
We O +
suggest O +
that O +
surgical O +
extirpation O +
of O +
primary O +
breast O +
cancer O +
among O +
other O +
effects O +
accelerates O +
relapse O +
for O +
some O +
premenopausal O +
node O +
- O +
positive O +
patients O +
. O +

These O +
accelerated O +
relapses O +
occur O +
within O +
10 O +
months O +
of O +
surgery O +
for O +
untreated O +
patients O +
. O +

The O +
mechanism O +
proposed O +
is O +
a O +
stimulation O +
of O +
angiogenesis O +
for O +
distant O +
dormant O +
micrometastases O +
. O +

This O +
has O +
been O +
suggested O +
as O +
one O +
of O +
the O +
mechanisms O +
to O +
explain O +
the O +
mammography O +
paradox O +
for O +
women O +
aged O +
40 O +
- O +
49 O +
years O +
. O +

We O +
could O +
imagine O +
that O +
it O +
also O +
plays O +
a O +
role O +
in O +
adjuvant O +
chemotherapy O +
effectiveness O +
since O +
, O +
perhaps O +
not O +
coincidentally O +
, O +
this O +
is O +
most O +
beneficial O +
for O +
premenopausal O +
node O +
- O +
positive O +
patients O +
. O +

HYPOTHESIS O +
: O +
We O +
speculate O +
that O +
there O +
is O +
a O +
burst O +
of O +
angiogenesis O +
of O +
distant O +
dormant O +
micrometastases O +
after O +
surgery O +
in O +
approximately O +
20 O +
% O +
of O +
premenopausal O +
node O +
- O +
positive O +
patients O +
. O +

We O +
also O +
speculate O +
that O +
this O +
synchronizes O +
them O +
into O +
a O +
temporal O +
highly O +
chemosensitive O +
state O +
and O +
is O +
the O +
underlying O +
reason O +
why O +
adjuvant O +
chemotherapy O +
works O +
particularly O +
well O +
for O +
that O +
patient O +
category O +
. O +

Furthermore O +
, O +
this O +
may O +
explain O +
why O +
cancer O +
in O +
younger O +
patients O +
is O +
more O +
often O +
' O +
aggressive O +
' O +
. O +

TESTING O +
THE O +
HYPOTHESIS O +
: O +
Stimulation O +
of O +
dormant O +
micrometastases O +
by O +
primary O +
tumor O +
removal O +
is O +
known O +
to O +
occur O +
in O +
animal O +
models O +
. O +

However O +
, O +
we O +
need O +
to O +
determine O +
whether O +
it O +
happens O +
in O +
breast O +
cancer O +
. O +

Transient O +
circulating O +
levels O +
of O +
angioactive O +
molecules O +
and O +
serial O +
high O +
- O +
resolution O +
imaging O +
studies O +
of O +
focal O +
angiogenesis O +
might O +
help O +
. O +

IMPLICATIONS O +
: O +
Short O +
- O +
course O +
cytotoxic O +
chemotherapy O +
after O +
surgery O +
has O +
probably O +
reached O +
its O +
zenith O +
, O +
and O +
other O +
strategies O +
, O +
perhaps O +
antiangiogenic O +
methods O +
, O +
are O +
needed O +
to O +
successfully O +
treat O +
more O +
patients O +
. O +

In O +
addition O +
, O +
the O +
hypothesis O +
predicts O +
that O +
early O +
detection O +
, O +
which O +
is O +
designed O +
to O +
find O +
more O +
patients O +
without O +
involved O +
lymph O +
nodes O +
, O +
may O +
not O +
be O +
a O +
synergistic O +
strategy O +
with O +
adjuvant O +
chemotherapy O +
, O +
which O +
works O +
best O +
with O +
positive O +
lymph O +
node O +
patients O +
. O +

Targeting O +
wide O +
- O +
range O +
oncogenic O +
transformation O +
via O +
PU24FCl O +
, O +
a O +
specific O +
inhibitor O +
of O +
tumor O +
Hsp90 O +
. O +

Agents O +
that O +
inhibit O +
Hsp90 O +
function O +
hold O +
significant O +
promise O +
in O +
cancer O +
therapy O +
. O +

Here O +
we O +
present O +
PU24FCl O +
, O +
a O +
representative O +
of O +
the O +
first O +
class O +
of O +
designed O +
Hsp90 O +
inhibitors O +
. O +

By O +
specifically O +
and O +
potently O +
inhibiting O +
tumor O +
Hsp90 O +
, O +
PU24FCl O +
exhibits O +
wide O +
- O +
ranging O +
anti O +
- O +
cancer O +
activities O +
that O +
occur O +
at O +
similar O +
doses O +
in O +
all O +
tested O +
tumor O +
types O +
. O +

Normal O +
cells O +
are O +
10 O +
- O +
to O +
50 O +
- O +
fold O +
more O +
resistant O +
to O +
these O +
effects O +
. O +

Its O +
Hsp90 O +
inhibition O +
results O +
in O +
multiple O +
anti O +
- O +
tumor O +
- O +
specific O +
effects O +
, O +
such O +
as O +
degradation O +
of O +
Hsp90 O +
- O +
client O +
proteins O +
involved O +
in O +
cell O +
growth O +
, O +
survival O +
, O +
and O +
specific O +
transformation O +
, O +
inhibition O +
of O +
cancer O +
cell O +
growth O +
, O +
delay O +
of O +
cell O +
cycle O +
progression O +
, O +
induction O +
of O +
morphological O +
and O +
functional O +
changes O +
, O +
and O +
apoptosis O +
. O +

In O +
concordance O +
with O +
its O +
higher O +
affinity O +
for O +
tumor O +
Hsp90 O +
, O +
in O +
vivo O +
PU24FCl O +
accumulates O +
in O +
tumors O +
while O +
being O +
rapidly O +
cleared O +
from O +
normal O +
tissue O +
. O +

Concentrations O +
achieved O +
in O +
vivo O +
in O +
tumors O +
lead O +
to O +
single O +
- O +
agent O +
anti O +
- O +
tumor O +
activity O +
at O +
non O +
- O +
toxic O +
doses O +
. O +

Multicriteria O +
evaluation O +
of O +
simulated O +
logging O +
scenarios O +
in O +
a O +
tropical O +
rain O +
forest O +
. O +

Forest O +
growth O +
models O +
are O +
useful O +
tools O +
for O +
investigating O +
the O +
long O +
- O +
term O +
impacts O +
of O +
logging O +
. O +

In O +
this O +
paper O +
, O +
the O +
results O +
of O +
the O +
rain O +
forest O +
growth O +
model O +
FORMIND O +
were O +
assessed O +
by O +
a O +
multicriteria O +
decision O +
analysis O +
. O +

The O +
main O +
processes O +
covered O +
by O +
FORMIND O +
include O +
tree O +
growth O +
, O +
mortality O +
, O +
regeneration O +
and O +
competition O +
. O +

Tree O +
growth O +
is O +
calculated O +
based O +
on O +
a O +
carbon O +
balance O +
approach O +
. O +

Trees O +
compete O +
for O +
light O +
and O +
space O +
; O +
dying O +
large O +
trees O +
fall O +
down O +
and O +
create O +
gaps O +
in O +
the O +
forest O +
. O +

Sixty O +
- O +
four O +
different O +
logging O +
scenarios O +
for O +
an O +
initially O +
undisturbed O +
forest O +
stand O +
at O +
Deramakot O +
( O +
Malaysia O +
) O +
were O +
simulated O +
. O +

The O +
scenarios O +
differ O +
regarding O +
the O +
logging O +
cycle O +
, O +
logging O +
method O +
, O +
cutting O +
limit O +
and O +
logging O +
intensity O +
. O +

We O +
characterise O +
the O +
impacts O +
with O +
four O +
criteria O +
describing O +
the O +
yield O +
, O +
canopy O +
opening O +
and O +
changes O +
in O +
species O +
composition O +
. O +

Multicriteria O +
decision O +
analysis O +
was O +
used O +
for O +
the O +
first O +
time O +
to O +
evaluate O +
the O +
scenarios O +
and O +
identify O +
the O +
efficient O +
ones O +
. O +

Our O +
results O +
plainly O +
show O +
that O +
reduced O +
- O +
impact O +
logging O +
scenarios O +
are O +
more O +
' O +
efficient O +
' O +
than O +
the O +
others O +
, O +
since O +
in O +
these O +
scenarios O +
forest O +
damage O +
is O +
minimised O +
without O +
significantly O +
reducing O +
yield O +
. O +

Nevertheless O +
, O +
there O +
is O +
a O +
trade O +
- O +
off O +
between O +
yield O +
and O +
achieving O +
a O +
desired O +
ecological O +
state O +
of O +
logged O +
forest O +
; O +
the O +
ecological O +
state O +
of O +
the O +
logged O +
forests O +
can O +
only O +
be O +
improved O +
by O +
reducing O +
yields O +
and O +
enlarging O +
the O +
logging O +
cycles O +
. O +

Our O +
study O +
also O +
demonstrates O +
that O +
high O +
cutting O +
limits O +
or O +
low O +
logging O +
intensities O +
can O -
not O +
compensate O +
for O +
the O +
high O +
level O +
of O +
damage O +
caused O +
by O +
conventional O +
logging O +
techniques O +
. O +

Rational O +
synthesis O +
of O +
multicyclic O +
bis O +
[ O +
2 O +
] O +
catenanes O +
. O +

Bis O +
- O +
loop O +
tetraurea O +
calix O +
[ O +
4 O +
] O +
arene O +
6 O +
has O +
been O +
prepared O +
by O +
acylation O +
of O +
the O +
wide O +
- O +
rim O +
calix O +
[ O +
4 O +
] O +
arene O +
tetraamine O +
1 O +
with O +
the O +
activated O +
bis O +
( O +
urethane O +
) O +
8 O +
under O +
dilution O +
conditions O +
. O +

Similarly O +
the O +
bis O +
( O +
Boc O +
- O +
protected O +
) O +
tetraamine O +
2 O +
is O +
converted O +
into O +
the O +
mono O +
- O +
loop O +
derivative O +
3 O +
which O +
after O +
deprotection O +
and O +
acylation O +
gives O +
the O +
bisalkenyl O +
derivative O +
5 O +
. O +

In O +
apolar O +
solvents O +
this O +
tetraurea O +
calix O +
[ O +
4 O +
] O +
arene O +
5 O +
forms O +
regioselectively O +
a O +
single O +
hydrogen O +
- O +
bonded O +
homodimer O +
, O +
from O +
which O +
the O +
bis O +
[ O +
2 O +
] O +
catenane O +
10a O +
is O +
formed O +
in O +
49 O +
% O +
by O +
a O +
metathesis O +
reaction O +
followed O +
by O +
hydrogenation O +
. O +

Bis O +
- O +
loop O +
derivative O +
6 O +
forms O +
no O +
homodimers O +
for O +
steric O +
reasons O +
, O +
but O +
a O +
stoichiometric O +
mixture O +
with O +
the O +
open O +
- O +
chain O +
tetraalkenyl O +
derivative O +
7a O +
contains O +
exclusively O +
the O +
heterodimer O +
. O +

Metathesis O +
and O +
subsequent O +
hydrogenation O +
now O +
yields O +
65 O +
% O +
of O +
the O +
pure O +
bis O +
[ O +
2 O +
] O +
catenane O +
10a O +
which O +
could O +
not O +
be O +
isolated O +
from O +
the O +
complex O +
reaction O +
mixture O +
obtained O +
from O +
the O +
homodimer O +
7a O +
. O +
7a O +
. O +

The O +
chirality O +
of O +
10a O +
( O +
D O +
( O +
2 O +
) O +
symmetry O +
) O +
has O +
been O +
verified O +
by O +
optical O +
resolution O +
using O +
HPLC O +
on O +
a O +
chiral O +
stationary O +
phase O +
. O +

Matrix O +
metalloproteinase O +
activity O +
and O +
immunohistochemical O +
profile O +
of O +
matrix O +
metalloproteinase O +
- O +
2 O +
and O +
- O +
9 O +
and O +
tissue O +
inhibitor O +
of O +
metalloproteinase O +
- O +
1 O +
during O +
human O +
dermal O +
wound O +
healing O +
. O +

Proteolytic O +
activity O +
is O +
required O +
for O +
the O +
turnover O +
of O +
the O +
extracellular O +
matrix O +
during O +
wound O +
healing O +
. O +

Matrix O +
metalloproteinases O +
can O +
collectively O +
cleave O +
all O +
components O +
of O +
the O +
extracellular O +
matrix O +
, O +
with O +
the O +
endogenous O +
tissue O +
inhibitor O +
of O +
metalloproteinase O +
- O +
1 O +
regulating O +
their O +
activity O +
. O +

Breast O +
tissue O +
taken O +
at O +
varying O +
postoperative O +
times O +
( O +
n O +
= O +
92 O +
) O +
or O +
during O +
surgery O +
( O +
controls O +
, O +
n O +
= O +
17 O +
) O +
, O +
was O +
used O +
to O +
investigate O +
the O +
temporal O +
and O +
spatial O +
activity O +
of O +
matrix O +
metalloproteinase O +
- O +
2 O +
and O +
- O +
9 O +
and O +
tissue O +
inhibitor O +
of O +
metalloproteinase O +
- O +
1 O +
during O +
human O +
wound O +
healing O +
. O +

Matrix O +
metalloproteinase O +
activity O +
, O +
determined O +
using O +
a O +
quenched O +
fluorescence O +
substrate O +
assay O +
, O +
increased O +
during O +
early O +
healing O +
( O +
3 O +
- O +
8 O +
weeks O +
) O +
compared O +
to O +
controls O +
, O +
and O +
then O +
decreased O +
between O +
24 O +
and O +
36 O +
weeks O +
after O +
surgery O +
( O +
p O +
less O +
than O +
0 O +
. O +
05 O +
until O +
24 O +
weeks O +
, O +
Mann O +
- O +
Whitney O +
U O +
- O +
test O +
) O +
. O +

Immunohistochemistry O +
scores O +
for O +
matrix O +
metalloproteinase O +
- O +
9 O +
expression O +
were O +
significantly O +
elevated O +
compared O +
to O +
controls O +
in O +
scar O +
endothelial O +
cells O +
and O +
fibroblasts O +
from O +
2 O +
until O +
12 O +
and O +
20 O +
weeks O +
, O +
respectively O +
. O +

Matrix O +
metalloproteinase O +
- O +
2 O +
staining O +
was O +
observed O +
exclusively O +
in O +
fibroblasts O +
, O +
reaching O +
maximum O +
levels O +
8 O +
- O +
12 O +
weeks O +
after O +
surgery O +
, O +
decreasing O +
by O +
1 O +
. O +
5 O +
years O +
but O +
remaining O +
significantly O +
increased O +
. O +

Tissue O +
inhibitor O +
of O +
metalloproteinase O +
- O +
1 O +
staining O +
was O +
relatively O +
sparse O +
but O +
was O +
significantly O +
increased O +
until O +
8 O +
weeks O +
after O +
surgery O +
. O +

These O +
results O +
show O +
that O +
matrix O +
metalloproteinases O +
are O +
present O +
at O +
elevated O +
levels O +
during O +
early O +
wound O +
healing O +
, O +
when O +
angiogenesis O +
occurs O +
, O +
and O +
suggest O +
that O +
matrix O +
metalloproteinase O +
- O +
9 O +
may O +
play O +
a O +
significant O +
role O +
. O +

The O +
later O +
expression O +
of O +
matrix O +
metalloproteinase O +
- O +
2 O +
and O +
- O +
9 O +
in O +
fibroblasts O +
suggests O +
a O +
role O +
in O +
extracellular O +
matrix O +
remodeling O +
. O +

The O +
learning O +
curve O +
: O +
the O +
advantages O +
and O +
disadvantages O +
in O +
the O +
use O +
of O +
focus O +
groups O +
as O +
a O +
method O +
of O +
data O +
collection O +
. O +

Focus O +
groups O +
are O +
not O +
simply O +
a O +
discussion O +
between O +
people O +
, O +
but O +
are O +
focused O +
interviews O +
exploring O +
interactions O +
between O +
participants O +
. O +

In O +
this O +
paper O +
, O +
Ian O +
Mansell O +
, O +
Glynis O +
Bennett O +
, O +
Ruth O +
Northway O +
, O +
Donna O +
Mead O +
and O +
Laurie O +
Moseley O +
explore O +
the O +
complexities O +
and O +
practicalities O +
of O +
using O +
focus O +
groups O +
in O +
research O +
, O +
with O +
reference O +
to O +
a O +
study O +
of O +
palliative O +
care O +
services O +
. O +

Differential O +
proteomic O +
analysis O +
of O +
human O +
hepatocellular O +
carcinoma O +
cell O +
line O +
metastasis O +
- O +
associated O +
proteins O +
. O +

PURPOSE O +
: O +
The O +
comparative O +
study O +
of O +
differentially O +
expression O +
of O +
protein O +
profiles O +
of O +
hepatocellular O +
carcinoma O +
cell O +
lines O +
with O +
various O +
metastasic O +
potential O +
and O +
screening O +
key O +
molecules O +
related O +
to O +
hepatocellular O +
carcinoma O +
metastasis O +
and O +
recurrence O +
. O +

METHODS O +
: O +
Using O +
two O +
- O +
dimensional O +
electrophoresis O +
and O +
liquid O +
chromatography O +
- O +
electrospray O +
ionization O +
- O +
tandem O +
mass O +
spectrometry O +
( O +
LC O +
- O +
ESI O +
- O +
MS O +
/ O +
MS O +
) O +
, O +
we O +
analyzed O +
differentially O +
displayed O +
proteomics O +
of O +
human O +
hepatocellular O +
carcinoma O +
cell O +
lines O +
Hep3B B-CellLine +
, O +
MHCC97L B-CellLine +
, O +
MHCC97H B-CellLine +
with O +
different O +
metastasic O +
potential O +
. O +

RESULTS O +
: O +
Approximate O +
1 O +
, O +
000 O +
protein O +
spots O +
were O +
detected O +
on O +
silver O +
- O +
stained O +
gel O +
by O +
ImageMaster O +
( O +
977 O +
+ O +
/ O +
- O +
113 O +
spots O +
in O +
Hep3B B-CellLine +
, O +
1092 O +
+ O +
/ O +
- O +
40 O +
in O +
MHCC97L B-CellLine +
, O +
and O +
889 O +
+ O +
/ O +
- O +
14 O +
in O +
MHCC97H B-CellLine +
) O +
. O +

Fifty O +
distinct O +
different O +
protein O +
spots O +
were O +
analyzed O +
with O +
online O +
LC O +
- O +
ESI O +
- O +
MS O +
/ O +
MS O +
. O +

Only O +
26 O +
protein O +
spots O +
had O +
a O +
positive O +
result O +
, O +
including O +
annexin1 O +
, O +
S100A4 O +
, O +
and O +
so O +
on O +
. O +

In O +
comparison O +
with O +
nonmetastasis O +
Hep3B B-CellLine +
cell O +
lines O +
, O +
there O +
were O +
16 O +
proteins O +
overexpressed O +
in O +
MHCC97H B-CellLine +
and O +
MHCC97L B-CellLine +
, O +
10 O +
proteins O +
underexpressed O +
in O +
MHCC97H B-CellLine +
and O +
MHCC97L B-CellLine +
. O +

Applying O +
cell O +
immunohistochemistry O +
and O +
RT O +
- O +
PCR O +
, O +
we O +
further O +
validated O +
two O +
interesting O +
and O +
different O +
proteins O +
, O +
annexin1 O +
and O +
S100A4 O +
. O +

CONCLUSION O +
: O +
The O +
protein O +
profile O +
of O +
metastatic O +
hepatocellular O +
carcinoma O +
cell O +
lines O +
displayed O +
obvious O +
differences O +
compared O +
with O +
non O +
- O +
metastatic O +
liver O +
cancer O +
cell O +
lines O +
. O +

The O +
results O +
imply O +
that O +
various O +
different O +
proteins O +
may O +
lead O +
to O +
HCC O +
metastasis O +
together O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
in O +
seizures O +
: O +
a O +
double O +
- O +
edged O +
sword O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
is O +
a O +
vascular O +
growth O +
factor O +
which O +
induces O +
angiogenesis O +
( O +
the O +
development O +
of O +
new O +
blood O +
vessels O +
) O +
, O +
vascular O +
permeability O +
, O +
and O +
inflammation O +
. O +

In O +
brain O +
, O +
receptors O +
for O +
VEGF O +
have O +
been O +
localized O +
to O +
vascular O +
endothelium O +
, O +
neurons O +
, O +
and O +
glia O +
. O +

VEGF O +
is O +
upregulated O +
after O +
hypoxic O +
injury O +
to O +
the O +
brain O +
, O +
which O +
can O +
occur O +
during O +
cerebral O +
ischemia O +
or O +
high O +
- O +
altitude O +
edema O +
, O +
and O +
has O +
been O +
implicated O +
in O +
the O +
blood O +
- O +
brain O +
barrier O +
breakdown O +
associated O +
with O +
these O +
conditions O +
. O +

Given O +
its O +
recently O +
- O +
described O +
role O +
as O +
an O +
inflammatory O +
mediator O +
, O +
VEGF O +
could O +
also O +
contribute O +
to O +
the O +
inflammatory O +
responses O +
observed O +
in O +
cerebral O +
ischemia O +
. O +

After O +
seizures O +
, O +
blood O +
- O +
brain O +
barrier O +
breakdown O +
and O +
inflammation O +
is O +
also O +
observed O +
in O +
brain O +
, O +
albeit O +
on O +
a O +
lower O +
scale O +
than O +
that O +
observed O +
after O +
stroke O +
. O +

Recent O +
evidence O +
has O +
suggested O +
a O +
role O +
for O +
inflammation O +
in O +
seizure O +
disorders O +
. O +

We O +
have O +
described O +
striking O +
increases O +
in O +
VEGF O +
protein O +
in O +
both O +
neurons O +
and O +
glia O +
after O +
pilocarpine O +
- O +
induced O +
status O +
epilepticus O +
in O +
the O +
brain O +
. O +

Increases O +
in O +
VEGF O +
could O +
contribute O +
to O +
the O +
blood O +
- O +
brain O +
barrier O +
breakdown O +
and O +
inflammation O +
observed O +
after O +
seizures O +
. O +

However O +
, O +
VEGF O +
has O +
also O +
been O +
shown O +
to O +
be O +
neuroprotective O +
across O +
several O +
experimental O +
paradigms O +
, O +
and O +
hence O +
could O +
potentially O +
protect O +
vulnerable O +
cells O +
from O +
damage O +
associated O +
with O +
seizures O +
. O +

Therefore O +
, O +
the O +
role O +
of O +
VEGF O +
after O +
seizures O +
could O +
be O +
either O +
protective O +
or O +
destructive O +
. O +

Although O +
only O +
further O +
research O +
will O +
determine O +
the O +
exact O +
nature O +
of O +
VEGF O +
' O +
s O +
role O +
after O +
seizures O +
, O +
preliminary O +
data O +
indicate O +
that O +
VEGF O +
plays O +
a O +
protective O +
role O +
after O +
seizures O +
. O +

Clinical O +
implication O +
of O +
expression O +
of O +
cyclooxygenase O +
- O +
2 O +
and O +
peroxisome O +
proliferator O +
activated O +
- O +
receptor O +
gamma O +
in O +
epithelial O +
ovarian O +
tumours O +
. O +

Expression O +
of O +
cyclooxygenase O +
( O +
COX O +
) O +
- O +
2 O +
plays O +
a O +
key O +
role O +
in O +
tumorigenesis O +
and O +
development O +
and O +
peroxisome O +
proliferator O +
- O +
activated O +
receptor O +
gamma O +
( O +
PPARgamma O +
) O +
has O +
been O +
implicated O +
in O +
the O +
control O +
of O +
COX O +
- O +
2 O +
expression O +
in O +
some O +
tissues O +
. O +

The O +
aim O +
of O +
this O +
study O +
is O +
to O +
investigate O +
( O +
1 O +
) O +
whether O +
expression O +
of O +
COX O +
- O +
2 O +
and O +
PPARgamma O +
is O +
associated O +
with O +
ovarian O +
carcinogenesis O +
and O +
progression O +
of O +
ovarian O +
tumours O +
and O +
( O +
2 O +
) O +
whether O +
COX O +
- O +
2 O +
expression O +
is O +
controlled O +
through O +
ligand O +
- O +
mediated O +
activation O +
of O +
PPARgamma O +
in O +
ovarian O +
carcinoma O +
cells O +
. O +

For O +
this O +
purpose O +
, O +
the O +
presence O +
of O +
COX O +
- O +
2 O +
and O +
PPARgamma O +
was O +
immunohistochemically O +
examined O +
in O +
71 O +
epithelial O +
ovarian O +
carcinomas O +
, O +
18 O +
borderline O +
tumours O +
and O +
23 O +
benign O +
tumours O +
and O +
the O +
levels O +
of O +
COX O +
- O +
2 O +
and O +
PPARgamma O +
proteins O +
were O +
determined O +
by O +
enzyme O +
immunoassay O +
in O +
four O +
benign O +
tumours O +
, O +
three O +
borderline O +
tumours O +
and O +
12 O +
carcinomas O +
. O +

The O +
frequency O +
of O +
COX O +
- O +
2 O +
and O +
PPARgamma O +
detection O +
was O +
significantly O +
increased O +
and O +
decreased O +
as O +
lesions O +
progressed O +
to O +
carcinoma O +
, O +
respectively O +
. O +

The O +
COX O +
- O +
2 O +
protein O +
was O +
not O +
detected O +
in O +
the O +
three O +
borderline O +
tumours O +
, O +
whereas O +
PPARgamma O +
protein O +
was O +
detected O +
in O +
all O +
of O +
them O +
. O +

COX O +
- O +
2 O +
protein O +
was O +
detected O +
in O +
eight O +
of O +
the O +
12 O +
carcinomas O +
, O +
whereas O +
PPARgamma O +
protein O +
was O +
detected O +
in O +
only O +
two O +
cases O +
. O +

In O +
addition O +
, O +
PPARgamma O +
protein O +
was O +
not O +
detected O +
in O +
all O +
of O +
the O +
eight O +
carcinomas O +
in O +
which O +
COX O +
- O +
2 O +
protein O +
was O +
detected O +
, O +
suggesting O +
that O +
expression O +
of O +
PPARgamma O +
and O +
COX O +
- O +
2 O +
was O +
in O +
a O +
reciprocal O +
relationship O +
. O +

Furthermore O +
, O +
in O +
cultured O +
ovarian O +
carcinoma O +
cells O +
, O +
Western O +
blot O +
revealed O +
that O +
PPARgamma O +
and O +
COX O +
- O +
2 O +
expression O +
was O +
regulated O +
conversely O +
as O +
a O +
result O +
of O +
stimulation O +
by O +
15 O +
- O +
deoxy O +
- O +
Delta O +
( O +
12 O +
, O +
14 O +
) O +
PGJ O +
( O +
2 O +
) O +
( O +
15 O +
- O +
PGJ O +
( O +
2 O +
) O +
) O +
, O +
a O +
PPARgamma O +
activator O +
. O +

In O +
addition O +
, O +
15d O +
- O +
PGJ O +
( O +
2 O +
) O +
suppressed O +
tumour O +
necrosis O +
factor O +
- O +
alpha O +
- O +
induced O +
- O +
COX O +
- O +
2 O +
expression O +
, O +
confirming O +
the O +
reciprocal O +
correlation O +
between O +
COX O +
- O +
2 O +
and O +
PPARgamma O +
. O +

From O +
these O +
results O +
, O +
it O +
was O +
suggested O +
that O +
PPARgamma O +
activation O +
might O +
suppress O +
COX O +
- O +
2 O +
expression O +
via O +
the O +
nuclear O +
factor O +
- O +
kappaB O +
pathway O +
in O +
the O +
ovarian O +
carcinoma O +
cells O +
and O +
that O +
low O +
expression O +
of O +
PPARgamma O +
and O +
high O +
expression O +
of O +
COX O +
- O +
2 O +
might O +
be O +
involved O +
in O +
carcinogenesis O +
and O +
progression O +
of O +
ovarian O +
tumours O +
. O +

Safety O +
of O +
verteporfin O +
for O +
treatment O +
of O +
subfoveal O +
choroidal O +
neovascular O +
membranes O +
associated O +
with O +
age O +
- O +
related O +
macular O +
degeneration O +
. O +

Photodynamic O +
therapy O +
( O +
PDT O +
) O +
is O +
a O +
novel O +
treatment O +
entity O +
that O +
exploits O +
the O +
photophysical O +
properties O +
of O +
various O +
photosensitive O +
chemical O +
entities O +
which O +
, O +
upon O +
light O +
activation O +
, O +
results O +
in O +
targeted O +
photooxidation O +
and O +
subsequent O +
tissue O +
destruction O +
. O +

The O +
antiangiogenic O +
properties O +
of O +
PDT O +
have O +
been O +
adapted O +
for O +
treatment O +
of O +
subfoveal O +
choroidal O +
neovascular O +
membranes O +
due O +
to O +
disease O +
states O +
such O +
as O +
age O +
- O +
related O +
macular O +
degeneration O +
( O +
AMD O +
) O +
. O +

Historically O +
, O +
PDT O +
has O +
been O +
limited O +
by O +
a O +
lack O +
of O +
suitable O +
photosensitive O +
dyes O +
. O +

However O +
, O +
agents O +
such O +
as O +
verteporfin O +
, O +
a O +
second O +
- O +
generation O +
benzoporphyrin O +
derivative O +
, O +
appear O +
to O +
be O +
free O +
from O +
the O +
extensive O +
phototoxicity O +
that O +
limited O +
the O +
success O +
of O +
previous O +
agents O +
. O +

Verteporfin O +
has O +
a O +
high O +
affinity O +
for O +
choroidal O +
neovascular O +
membranes O +
, O +
typically O +
found O +
with O +
exudative O +
AMD O +
, O +
and O +
upon O +
photoactivation O +
results O +
in O +
targeted O +
microvascular O +
damage O +
and O +
thrombus O +
formation O +
with O +
resultant O +
vessel O +
occlusion O +
. O +

Scrutiny O +
of O +
diagnostic O +
indicators O +
for O +
verteporfin O +
administration O +
, O +
including O +
critical O +
angiographic O +
evaluation O +
of O +
lesion O +
size O +
and O +
visual O +
acuity O +
, O +
is O +
essential O +
to O +
treatment O +
success O +
. O +

Large O +
lesions O +
with O +
relatively O +
good O +
visual O +
acuity O +
( O +
20 O +
/ O +
50 O +
or O +
better O +
) O +
may O +
be O +
at O +
particular O +
risk O +
for O +
marked O +
vision O +
loss O +
following O +
verteporfin O +
administration O +
. O +

Lesion O +
composition O +
also O +
appears O +
to O +
influence O +
visual O +
outcome O +
with O +
verteporfin O +
use O +
. O +

The O +
safety O +
of O +
verteporfin O +
is O +
directly O +
dependent O +
upon O +
the O +
appropriate O +
integration O +
of O +
dosage O +
, O +
infusion O +
and O +
light O +
activation O +
required O +
for O +
a O +
suitable O +
pharmacotherapeutic O +
outcome O +
. O +

When O +
used O +
appropriately O +
, O +
and O +
with O +
adequate O +
patient O +
education O +
regarding O +
photosensitivity O +
, O +
the O +
risk O +
- O +
benefit O +
of O +
verteporfin O +
for O +
the O +
medical O +
treatment O +
of O +
neovascular O +
AMD O +
is O +
favourable O +
. O +

Retrospective O +
case O +
series O +
of O +
juxtafoveal O +
choroidal O +
neovascularization O +
treated O +
with O +
photodynamic O +
therapy O +
with O +
verteporfin O +
. O +

PURPOSE O +
: O +
To O +
describe O +
visual O +
acuity O +
and O +
angiographic O +
outcomes O +
of O +
juxtafoveal O +
choroidal O +
neovascularization O +
( O +
CNV O +
) O +
treated O +
with O +
photodynamic O +
therapy O +
and O +
verteporfin O +
( O +
PDT O +
) O +
. O +

METHODS O +
: O +
Four O +
hundred O +
eighty O +
- O +
four O +
consecutive O +
eyes O +
of O +
446 O +
patients O +
treated O +
with O +
PDT O +
from O +
January O +
1 O +
, O +
2001 O +
, O +
to O +
June O +
30 O +
, O +
2002 O +
, O +
were O +
identified O +
from O +
billing O +
records O +
. O +

Fluorescein O +
angiograms O +
were O +
reviewed O +
retrospectively O +
to O +
identify O +
juxtafoveal O +
CNV O +
. O +

Eligible O +
patients O +
had O +
CNV O +
in O +
which O +
the O +
central O +
boundary O +
of O +
the O +
lesion O +
was O +
between O +
1 O +
and O +
199 O +
microm O +
from O +
the O +
geometric O +
center O +
of O +
the O +
foveal O +
avascular O +
zone O +
( O +
FAZ O +
) O +
. O +

Patient O +
charts O +
were O +
reviewed O +
for O +
visual O +
acuity O +
of O +
the O +
treated O +
eye O +
before O +
PDT O +
and O +
at O +
6 O +
- O +
and O +
12 O +
- O +
month O +
follow O +
- O +
up O +
examinations O +
. O +

Presence O +
of O +
subfoveal O +
CNV O +
at O +
6 O +
and O +
12 O +
months O +
of O +
follow O +
- O +
up O +
was O +
determined O +
by O +
review O +
of O +
fluorescein O +
angiograms O +
. O +

A O +
lesion O +
was O +
considered O +
subfoveal O +
if O +
it O +
extended O +
underneath O +
the O +
geometric O +
center O +
of O +
the O +
FAZ O +
. O +

RESULTS O +
: O +
Twenty O +
- O +
one O +
eyes O +
had O +
juxtafoveal O +
CNV O +
. O +

Median O +
change O +
in O +
visual O +
acuity O +
both O +
6 O +
and O +
12 O +
months O +
after O +
the O +
initial O +
PDT O +
was O +
0 O +
lines O +
( O +
n O +
= O +
18 O +
at O +
6 O +
months O +
, O +
range O +
- O +
14 O +
to O +
+ O +
8 O +
lines O +
; O +
n O +
= O +
17 O +
at O +
12 O +
months O +
, O +
range O +
- O +
18 O +
to O +
+ O +
7 O +
lines O +
) O +
. O +

Eleven O +
lesions O +
progressed O +
to O +
a O +
subfoveal O +
location O +
by O +
12 O +
months O +
. O +

Visual O +
acuity O +
in O +
eyes O +
with O +
progressive O +
lesions O +
decreased O +
a O +
median O +
of O +
4 O +
lines O +
of O +
vision O +
. O +

CONCLUSIONS O +
: O +
Despite O +
a O +
small O +
sample O +
size O +
and O +
limited O +
length O +
of O +
follow O +
- O +
up O +
, O +
this O +
study O +
shows O +
that O +
visual O +
acuity O +
on O +
average O +
can O +
remain O +
stable O +
for O +
at O +
least O +
12 O +
months O +
after O +
PDT O +
of O +
juxtafoveal O +
lesions O +
. O +

Growth O +
through O +
the O +
foveal O +
center O +
still O +
can O +
occur O +
, O +
however O +
, O +
and O +
this O +
can O +
be O +
associated O +
with O +
substantial O +
visual O +
loss O +
. O +

Is O +
there O +
an O +
upper O +
limit O +
of O +
intracranial O +
pressure O +
in O +
patients O +
with O +
severe O +
head O +
injury O +
if O +
cerebral O +
perfusion O +
pressure O +
is O +
maintained O +
? O +

Authors O +
of O +
recent O +
studies O +
have O +
championed O +
the O +
importance O +
of O +
maintaining O +
cerebral O +
perfusion O +
pressure O +
( O +
CPP O +
) O +
to O +
prevent O +
secondary O +
brain O +
injury O +
following O +
traumatic O +
head O +
injury O +
. O +

Data O +
from O +
these O +
studies O +
have O +
provided O +
little O +
information O +
regarding O +
outcome O +
following O +
severe O +
head O +
injury O +
in O +
patients O +
with O +
an O +
intracranial O +
pressure O +
( O +
ICP O +
) O +
greater O +
than O +
40 O +
mm O +
Hg O +
, O +
however O +
, O +
in O +
July O +
1997 O +
the O +
authors O +
instituted O +
a O +
protocol O +
for O +
the O +
management O +
of O +
severe O +
head O +
injury O +
in O +
patients O +
with O +
a O +
Glasgow O +
Coma O +
Scale O +
score O +
lower O +
than O +
9 O +
. O +

The O +
protocol O +
was O +
focused O +
on O +
resuscitation O +
from O +
acidosis O +
, O +
maintenance O +
of O +
a O +
CPP O +
greater O +
than O +
60 O +
mm O +
Hg O +
through O +
whatever O +
means O +
necessary O +
as O +
well O +
as O +
elevation O +
of O +
the O +
head O +
of O +
the O +
bed O +
, O +
mannitol O +
infusion O +
, O +
and O +
ventriculostomy O +
with O +
cerebrospinal O +
fluid O +
drainage O +
for O +
control O +
of O +
ICP O +
. O +

Since O +
the O +
institution O +
of O +
this O +
protocol O +
, O +
nine O +
patients O +
had O +
a O +
sustained O +
ICP O +
greater O +
than O +
40 O +
mm O +
Hg O +
for O +
2 O +
or O +
more O +
hours O +
, O +
and O +
five O +
of O +
these O +
had O +
an O +
ICP O +
greater O +
than O +
75 O +
mm O +
Hg O +
on O +
insertion O +
of O +
the O +
ICP O +
monitor O +
and O +
later O +
experienced O +
herniation O +
and O +
expired O +
within O +
24 O +
hours O +
. O +

Because O +
of O +
the O +
severe O +
nature O +
of O +
the O +
injuries O +
demonstrated O +
on O +
computerized O +
tomography O +
scans O +
and O +
their O +
physical O +
examinations O +
, O +
these O +
patients O +
were O +
not O +
aggressively O +
treated O +
under O +
this O +
protocol O +
. O +

The O +
authors O +
vigorously O +
attempted O +
to O +
maintain O +
a O +
CPP O +
greater O +
than O +
60 O +
mm O +
Hg O +
with O +
intensive O +
fluid O +
resuscitation O +
and O +
the O +
administration O +
of O +
pressor O +
agents O +
in O +
the O +
four O +
remaining O +
patients O +
who O +
had O +
developed O +
an O +
ICP O +
higher O +
than O +
40 O +
mm O +
Hg O +
after O +
placement O +
of O +
the O +
ICP O +
monitor O +
. O +

Two O +
patients O +
had O +
an O +
episodic O +
ICP O +
greater O +
than O +
40 O +
mm O +
Hg O +
for O +
more O +
than O +
36 O +
hours O +
, O +
the O +
third O +
patient O +
had O +
an O +
episodic O +
ICP O +
greater O +
than O +
of O +
50 O +
mm O +
Hg O +
for O +
more O +
than O +
36 O +
hours O +
, O +
and O +
the O +
fourth O +
patient O +
had O +
an O +
episodic O +
ICP O +
greater O +
than O +
50 O +
mm O +
Hg O +
for O +
more O +
than O +
48 O +
hours O +
. O +

On O +
discharge O +
, O +
all O +
four O +
patients O +
were O +
able O +
to O +
perform O +
normal O +
activities O +
of O +
daily O +
living O +
with O +
minimal O +
assistance O +
and O +
experience O +
ongoing O +
improvement O +
. O +

Data O +
from O +
this O +
preliminary O +
study O +
indicate O +
that O +
intense O +
, O +
aggressive O +
management O +
of O +
CPP O +
can O +
lead O +
to O +
good O +
neurological O +
outcomes O +
despite O +
extremely O +
high O +
ICP O +
. O +

Aggressive O +
CPP O +
therapy O +
should O +
be O +
performed O +
and O +
maintained O +
even O +
though O +
apparently O +
lethal O +
ICP O +
levels O +
may O +
be O +
present O +
. O +

Further O +
study O +
is O +
needed O +
to O +
support O +
these O +
encouraging O +
results O +
. O +

[ O +
Epidemiology O +
of O +
fractures O +
of O +
the O +
proximal O +
femur O +
] O +
. O +

Fractures O +
of O +
the O +
upper O +
end O +
of O +
the O +
femur O +
constitute O +
a O +
major O +
public O +
health O +
problem O +
which O +
, O +
for O +
demographic O +
reasons O +
, O +
will O +
become O +
worse O +
during O +
the O +
next O +
decades O +
. O +

The O +
clinical O +
determination O +
of O +
femoral O +
neck O +
fractures O +
is O +
imperfectly O +
known O +
. O +

Two O +
factors O +
seem O +
to O +
be O +
determinant O +
: O +
bone O +
fragility O +
and O +
fall O +
, O +
but O +
these O +
factors O +
are O +
frequent O +
in O +
the O +
elderly O +
and O +
other O +
factors O +
seem O +
to O +
intervene O +
, O +
notably O +
the O +
modality O +
of O +
the O +
impact O +
and O +
the O +
protection O +
reflexes O +
during O +
the O +
fall O +
. O +

The O +
epidemiology O +
of O +
proximal O +
femur O +
fractures O +
therefore O +
can O -
not O +
be O +
restricted O +
to O +
the O +
diminution O +
of O +
bone O +
mass O +
. O +

Beside O +
age O +
and O +
female O +
sex O +
, O +
the O +
confirmed O +
risk O +
factors O +
for O +
these O +
fractures O +
are O +
: O +
ethnic O +
origin O +
, O +
absence O +
of O +
replacement O +
hormonal O +
therapy O +
in O +
menopausal O +
women O +
, O +
slight O +
build O +
and O +
absorption O +
of O +
certain O +
psychotropic O +
drugs O +
. O +

To O +
be O +
efficient O +
, O +
preventive O +
measures O +
must O +
rest O +
on O +
a O +
better O +
knowledge O +
of O +
the O +
determinant O +
factors O +
. O +

Epidemiological O +
research O +
should O +
develop O +
rationally O +
and O +
aim O +
at O +
identifying O +
more O +
accurate O +
risk O +
factors O +
, O +
taking O +
into O +
account O +
the O +
mechanisms O +
responsible O +
for O +
proximal O +
femur O +
fractures O +
: O +
fall O +
, O +
lack O +
of O +
cushioning O +
and O +
protection O +
during O +
the O +
fall O +
, O +
and O +
bone O +
fragility O +
. O +

Newly O +
recognized O +
syndrome O +
with O +
heminasal O +
aplasia O +
and O +
ocular O +
anomalies O +
or O +
wider O +
spectrum O +
of O +
heminasal O +
aplasia O +
/ O +
atypical O +
clefting O +
syndrome O +
? O +

We O +
report O +
on O +
five O +
unrelated O +
Brazilian O +
patients O +
with O +
heminasal O +
aplasia O +
associated O +
with O +
diverses O +
anomalies O +
, O +
including O +
lateral O +
proboscis O +
, O +
and O +
anomalies O +
of O +
the O +
eye O +
and O +
first O +
branchial O +
arch O +
. O +

We O +
suggest O +
that O +
these O +
patients O +
represent O +
different O +
conditions O +
within O +
the O +
spectrum O +
of O +
the O +
heminasal O +
aplasia O +
malformation O +
. O +

Clinical O +
, O +
genetic O +
, O +
and O +
differential O +
diagnosis O +
are O +
discussed O +
. O +

Convergence O +
of O +
p53 O +
and O +
TGF O +
- O +
beta O +
signaling O +
networks O +
. O +

p53 O +
is O +
a O +
protein O +
with O +
many O +
talents O +
. O +

One O +
of O +
the O +
most O +
fundamental O +
is O +
the O +
ability O +
to O +
act O +
as O +
essential O +
growth O +
checkpoint O +
that O +
protects O +
cells O +
against O +
cellular O +
transformation O +
. O +

p53 O +
does O +
so O +
through O +
the O +
induction O +
of O +
genes O +
leading O +
to O +
growth O +
arrest O +
or O +
apoptosis O +
. O +

Most O +
of O +
the O +
studies O +
focusing O +
on O +
the O +
mechanisms O +
of O +
p53 O +
activity O +
have O +
been O +
performed O +
in O +
cultured O +
cells O +
upon O +
treatment O +
with O +
well O +
- O +
established O +
p53 O +
- O +
activating O +
inputs O +
, O +
such O +
as O +
high O +
doses O +
of O +
radiations O +
, O +
DNA O +
- O +
damaging O +
drugs O +
and O +
activated O +
oncogenes O +
. O +

However O +
, O +
how O +
the O +
tumor O +
suppressive O +
functions O +
of O +
p53 O +
become O +
concerted O +
with O +
the O +
extracellular O +
cues O +
arriving O +
at O +
the O +
cell O +
surface O +
during O +
tissue O +
homeostasis O +
, O +
remains O +
largely O +
unknown O +
. O +

Intriguingly O +
, O +
two O +
recent O +
papers O +
have O +
shed O +
new O +
light O +
into O +
this O +
unexplored O +
field O +
, O +
indicating O +
that O +
p53 O +
plays O +
a O +
key O +
role O +
in O +
TGF O +
- O +
beta O +
- O +
induced O +
growth O +
arrest O +
and O +
, O +
unexpectedly O +
, O +
in O +
the O +
developmental O +
effects O +
of O +
TGF O +
- O +
beta O +
in O +
early O +
embryos O +
. O +

Here O +
we O +
review O +
and O +
comment O +
on O +
these O +
findings O +
and O +
on O +
their O +
implications O +
for O +
cancer O +
biology O +
. O +

Enhanced O +
IGF O +
- O +
1 O +
expression O +
improves O +
smooth O +
muscle O +
cell O +
engraftment O +
after O +
cell O +
transplantation O +
. O +

The O +
functional O +
benefit O +
of O +
cell O +
transplantation O +
after O +
a O +
myocardial O +
infarction O +
is O +
diminished O +
by O +
early O +
cell O +
losses O +
. O +

IGF O +
- O +
1 O +
enhances O +
cell O +
proliferation O +
and O +
survival O +
. O +

We O +
hypothesized O +
that O +
IGF O +
- O +
1 O +
- O +
transfected O +
smooth O +
muscle O +
cells O +
( O +
SMCs O +
) O +
would O +
enhance O +
cell O +
survival O +
and O +
improve O +
engraftment O +
after O +
cell O +
transplantation O +
. O +

The O +
IGF O +
- O +
1 O +
gene O +
was O +
transfected O +
into O +
male O +
SMCs O +
and O +
compared O +
with O +
SMCs O +
transfected O +
with O +
a O +
plasmid O +
vector O +
( O +
vector O +
control O +
) O +
and O +
nontransfected O +
SMCs O +
( O +
cell O +
control O +
) O +
. O +

IGF O +
- O +
1 O +
mRNA O +
( O +
n O +
= O +
10 O +
/ O +
group O +
) O +
and O +
protein O +
levels O +
( O +
n O +
= O +
6 O +
/ O +
group O +
) O +
were O +
higher O +
( O +
P O +
less O +
than O +
0 O +
. O +
05 O +
for O +
all O +
groups O +
) O +
at O +
3 O +
, O +
7 O +
, O +
and O +
14 O +
days O +
compared O +
with O +
controls O +
. O +

VEGF O +
was O +
also O +
increased O +
in O +
parallel O +
to O +
enhanced O +
IGF O +
- O +
1 O +
expression O +
. O +

IGF O +
- O +
1 O +
- O +
transfected O +
cells O +
demonstrated O +
greater O +
cell O +
proliferation O +
, O +
stimulated O +
angiogenesis O +
, O +
and O +
decreased O +
caspase O +
- O +
3 O +
activity O +
after O +
simulated O +
ischemia O +
and O +
reperfusion O +
( O +
P O +
less O +
than O +
0 O +
. O +
05 O +
for O +
all O +
groups O +
compared O +
with O +
vector O +
or O +
cell O +
controls O +
) O +
. O +

A O +
uniform O +
left O +
ventricular O +
injury O +
was O +
produced O +
in O +
female O +
rats O +
using O +
a O +
cryoprobe O +
. O +

Three O +
weeks O +
later O +
, O +
2 O +
x O +
10 O +
( O +
6 O +
) O +
cells O +
from O +
three O +
groups O +
were O +
implanted O +
into O +
the O +
scar O +
. O +

One O +
week O +
later O +
, O +
IGF O +
- O +
1 O +
- O +
transfected O +
SMCs O +
had O +
increased O +
myocardial O +
IGF O +
- O +
1 O +
and O +
VEGF O +
levels O +
, O +
increased O +
Bcl2 O +
expression O +
, O +
limited O +
cell O +
apoptosis O +
, O +
and O +
enhanced O +
vessel O +
formation O +
in O +
the O +
myocardial O +
scar O +
compared O +
with O +
the O +
two O +
control O +
groups O +
( O +
P O +
less O +
than O +
0 O +
. O +
05 O +
for O +
all O +
groups O +
) O +
. O +

The O +
proportion O +
of O +
SMCs O +
surviving O +
in O +
the O +
implanted O +
region O +
was O +
greater O +
( O +
P O +
less O +
than O +
0 O +
. O +
05 O +
) O +
in O +
the O +
IGF O +
- O +
1 O +
- O +
transfected O +
group O +
than O +
in O +
the O +
vector O +
or O +
cell O +
controls O +
. O +

Gene O +
enhancement O +
with O +
IGF O +
- O +
1 O +
improved O +
donor O +
cell O +
proliferation O +
, O +
survival O +
, O +
and O +
engraftment O +
after O +
cell O +
transplantation O +
, O +
perhaps O +
mediated O +
by O +
enhanced O +
angiogenesis O +
and O +
reduced O +
apoptosis O +
. O +

[ O +
Altered O +
expression O +
of O +
PTEN O +
gene O +
and O +
LOH O +
of O +
its O +
epigenetic O +
microsatellite O +
in O +
gastric O +
carcinoma O +
] O +
. O +

OBJECTIVE O +
: O +
To O +
investigate O +
the O +
expression O +
of O +
PTEN O +
and O +
loss O +
of O +
heterozygosity O +
( O +
LOH O +
) O +
of O +
its O +
epigenetic O +
microsatellite O +
in O +
gastric O +
carcinoma O +
and O +
explore O +
their O +
roles O +
in O +
progression O +
of O +
gastric O +
carcinoma O +
. O +

METHODS O +
: O +
LOH O +
of O +
epigenetic O +
microsatellites O +
of O +
PTEN O +
( O +
D10S541 O +
, O +
D10S583 O +
and O +
D10S1687 O +
) O +
in O +
advanced O +
gastric O +
cancer O +
was O +
detected O +
by O +
PCR O +
- O +
SSCP O +
. O +

Expression O +
of O +
PTEN O +
mRNA O +
and O +
protein O +
in O +
normal O +
gastric O +
mucosa O +
and O +
gastric O +
cancer O +
was O +
evaluated O +
by O +
RT O +
- O +
PCR O +
and O +
SABC O +
immunohistochemistry O +
, O +
respectively O +
. O +

The O +
relationship O +
between O +
expression O +
of O +
PTEN O +
mRNA O +
and O +
protein O +
and O +
lymph O +
node O +
metastasis O +
or O +
LOH O +
of O +
microsatellites O +
was O +
discussed O +
. O +

RESULTS O +
: O +
LOH O +
of O +
D10S541 O +
, O +
D10S583 O +
and O +
D10S1687 O +
was O +
found O +
in O +
37 O +
. O +
5 O +
% O +
( O +
21 O +
/ O +
56 O +
) O +
of O +
advanced O +
gastric O +
cancers O +
. O +

The O +
positive O +
rates O +
of O +
PTEN O +
mRNA O +
expression O +
were O +
80 O +
. O +
4 O +
% O +
( O +
45 O +
/ O +
56 O +
) O +
, O +
45 O +
. O +
5 O +
% O +
( O +
5 O +
/ O +
11 O +
) O +
and O +
32 O +
. O +
1 O +
% O +
( O +
18 O +
/ O +
56 O +
) O +
in O +
normal O +
mucosa O +
, O +
early O +
and O +
advanced O +
gastric O +
carcinomas O +
, O +
respectively O +
, O +
while O +
78 O +
. O +
6 O +
% O +
( O +
44 O +
/ O +
56 O +
) O +
, O +
44 O +
. O +
5 O +
% O +
( O +
5 O +
/ O +
11 O +
) O +
and O +
28 O +
. O +
6 O +
% O +
( O +
16 O +
/ O +
56 O +
) O +
at O +
the O +
protein O +
level O +
. O +

PTEN O +
mRNA O +
and O +
protein O +
were O +
less O +
frequently O +
expressed O +
in O +
early O +
and O +
advanced O +
gastric O +
carcinomas O +
than O +
that O +
in O +
normal O +
gastric O +
mucosa O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

There O +
was O +
positive O +
correlation O +
between O +
PTEN O +
mRNA O +
expression O +
and O +
LOH O +
of O +
microsatellites O +
in O +
advanced O +
gastric O +
carcinomas O +
. O +

PTEN O +
protein O +
expression O +
paralleled O +
with O +
its O +
mRNA O +
expression O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

The O +
expression O +
of O +
PTEN O +
mRNA O +
and O +
protein O +
was O +
negatively O +
correlated O +
with O +
lymph O +
node O +
metastasis O +
of O +
advanced O +
gastric O +
carcinomas O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

CONCLUSION O +
: O +
Down O +
- O +
regulated O +
expression O +
of O +
PTEN O +
gene O +
is O +
found O +
in O +
different O +
stages O +
of O +
gastric O +
carcinoma O +
, O +
and O +
is O +
closely O +
correlated O +
with O +
LOH O +
of O +
its O +
epigenetic O +
microsatellites O +
, O +
which O +
probably O +
is O +
its O +
underlying O +
molecular O +
mechanisms O +
. O +

It O +
suggests O +
that O +
altered O +
PTEN O +
gene O +
contributes O +
to O +
tumorigenesis O +
and O +
progression O +
of O +
gastric O +
carcinomas O +
. O +

Flow O +
dynamics O +
of O +
the O +
internal O +
thoracic O +
and O +
radial O +
artery O +
T O +
- O +
graft O +
. O +

BACKGROUND O +
: O +

Complex O +
use O +
of O +
arterial O +
conduits O +
has O +
resurrected O +
concerns O +
about O +
the O +
adequacy O +
of O +
conduit O +
flow O +
. O +

The O +
T O +
- O +
graft O +
is O +
the O +
extreme O +
example O +
of O +
this O +
trend O +
. O +

Our O +
purpose O +
was O +
to O +
identify O +
the O +
limitation O +
of O +
single O +
source O +
inflow O +
and O +
to O +
compare O +
flow O +
capacity O +
with O +
completion O +
coronary O +
flow O +
. O +

METHODS O +
: O +

Between O +
February O +
1999 O +
and O +
November O +
2001 O +
, O +
372 O +
patients O +
underwent O +
total O +
arterial O +
revascularization O +
with O +
the O +
T O +
- O +
graft O +
alone O +
. O +

Intraoperative O +
flows O +
were O +
recorded O +
for O +
each O +
limb O +
of O +
the O +
T O +
- O +
graft O +
before O +
and O +
after O +
distal O +
anastomoses O +
in O +
204 O +
patients O +
. O +

Independent O +
predictors O +
of O +
T O +
- O +
graft O +
flow O +
were O +
identified O +
by O +
multivariate O +
analysis O +
. O +

RESULTS O +
: O +

Free O +
flow O +
for O +
the O +
radial O +
arterial O +
( O +
RA O +
) O +
limb O +
was O +
161 O +
+ O +
/ O +
- O +
81 O +
mL O +
/ O +
min O +
, O +
the O +
internal O +
thoracic O +
artery O +
( O +
ITA O +
) O +
limb O +
137 O +
+ O +
/ O +
- O +
57 O +
mL O +
/ O +
min O +
( O +
combined O +
298 O +
+ O +
/ O +
- O +
101 O +
mL O +
/ O +
min O +
) O +
versus O +
simultaneous O +
limb O +
flow O +
of O +
226 O +
+ O +
/ O +
- O +
84 O +
mL O +
/ O +
min O +
giving O +
a O +
flow O +
restriction O +
of O +
24 O +
% O +
+ O +
/ O +
- O +
14 O +
% O +
. O +

Completion O +
coronary O +
flow O +
was O +
88 O +
+ O +
/ O +
- O +
49 O +
mL O +
/ O +
min O +
for O +
the O +
RA O +
, O +
60 O +
+ O +
/ O +
- O +
45 O +
mL O +
/ O +
min O +
for O +
the O +
ITA O +
, O +
and O +
140 O +
+ O +
/ O +
- O +
70 O +
mL O +
/ O +
min O +
for O +
both O +
limbs O +
simultaneously O +
to O +
give O +
a O +
flow O +
reserve O +
( O +
vs O +
simultaneous O +
free O +
flow O +
) O +
of O +
160 O +
% O +
or O +
1 O +
. O +
6 O +
. O +

Independent O +
predictors O +
of O +
completion O +
RA O +
limb O +
flow O +
are O +
RA O +
proximal O +
diameter O +
( O +
p O +
= O +
0 O +
. O +
005 O +
) O +
, O +
number O +
of O +
anastomoses O +
( O +
p O +
= O +
0 O +
. O +
018 O +
) O +
, O +
and O +
target O +
stenosis O +
( O +
p O +
= O +
0 O +
. O +
005 O +
) O +
. O +

CONCLUSIONS O +
: O +

A O +
flow O +
reserve O +
of O +
1 O +
. O +
6 O +
compares O +
favorably O +
with O +
an O +
ITA O +
flow O +
reserve O +
of O +
1 O +
. O +
8 O +
at O +
1 O +
- O +
month O +
postoperatively O +
and O +
1 O +
. O +
8 O +
for O +
both O +
the O +
ITA O +
T O +
- O +
graft O +
and O +
the O +
ITA O +
/ O +
RA O +
T O +
- O +
graft O +
at O +
1 O +
- O +
week O +
postoperatively O +
as O +
reported O +
by O +
others O +
. O +

Proximal O +
RA O +
diameter O +
and O +
competitive O +
coronary O +
flow O +
influence O +
completion O +
T O +
- O +
graft O +
flow O +
. O +

These O +
data O +
quantitate O +
the O +
limitation O +
of O +
single O +
source O +
inflow O +
of O +
the O +
T O +
- O +
graft O +
configuration O +
and O +
support O +
its O +
continued O +
use O +
. O +

Expression O +
of O +
DCC O +
and O +
netrin O +
- O +
1 O +
in O +
normal O +
human O +
endometrium O +
and O +
its O +
implication O +
in O +
endometrial O +
carcinogenesis O +
. O +

OBJECTIVE O +
: O +
Although O +
DCC O +
has O +
been O +
considered O +
as O +
a O +
candidate O +
tumor O +
suppressor O +
, O +
the O +
roles O +
it O +
plays O +
in O +
the O +
uterine O +
endometrium O +
and O +
in O +
the O +
carcinogenic O +
process O +
remains O +
unclear O +
. O +

To O +
define O +
these O +
roles O +
more O +
clearly O +
, O +
we O +
examined O +
the O +
expression O +
of O +
DCC O +
and O +
its O +
ligand O +
, O +
netrin O +
- O +
1 O +
, O +
in O +
the O +
normal O +
endometrium O +
and O +
in O +
endometrial O +
cancer O +
. O +

METHODS O +
: O +
The O +
expression O +
of O +
DCC O +
and O +
netrin O +
- O +
1 O +
in O +
normal O +
endometrial O +
glands O +
and O +
in O +
cancer O +
cell O +
lines O +
was O +
examined O +
by O +
RT O +
- O +
PCR O +
and O +
immunohistochemistry O +
. O +

The O +
effects O +
of O +
exogenous O +
DCC O +
and O +
netrin O +
- O +
1 O +
expression O +
were O +
observed O +
together O +
with O +
the O +
respective O +
expression O +
vector O +
transfection O +
. O +

RESULTS O +
: O +
Endometrial O +
glands O +
in O +
the O +
proliferative O +
and O +
early O +
secretory O +
phase O +
expressed O +
both O +
DCC O +
and O +
netrin O +
- O +
1 O +
, O +
but O +
glands O +
in O +
the O +
late O +
- O +
secretory O +
phase O +
tended O +
to O +
silence O +
DCC O +
expression O +
. O +

In O +
addition O +
, O +
all O +
of O +
the O +
endometrial O +
cancer O +
cell O +
lines O +
lost O +
normal O +
DCC O +
expression O +
. O +

Restored O +
DCC O +
expression O +
in O +
the O +
cancer O +
cell O +
lines O +
in O +
the O +
absence O +
of O +
netrin O +
- O +
1 O +
induced O +
apoptosis O +
. O +

However O +
, O +
no O +
changes O +
were O +
observed O +
in O +
the O +
presence O +
of O +
netrin O +
- O +
1 O +
. O +

CONCLUSION O +
: O +
Our O +
observations O +
suggest O +
that O +
DCC O +
/ O +
netrin O +
- O +
1 O +
signaling O +
may O +
commit O +
cells O +
to O +
the O +
transition O +
of O +
endometrial O +
gland O +
architecture O +
or O +
function O +
from O +
a O +
proliferating O +
to O +
a O +
secretory O +
phase O +
. O +

In O +
addition O +
, O +
the O +
silencing O +
of O +
DCC O +
expression O +
may O +
contribute O +
to O +
the O +
escape O +
of O +
endometrial O +
cancer O +
cells O +
from O +
a O +
DCC O +
- O +
regulated O +
apoptotic O +
program O +
, O +
thereby O +
promoting O +
malignant O +
phenotypes O +
. O +

Role O +
of O +
osteopontin O +
in O +
adhesion O +
, O +
migration O +
, O +
cell O +
survival O +
and O +
bone O +
remodeling O +
. O +

Osteopontin O +
( O +
OPN O +
) O +
is O +
a O +
secreted O +
adhesive O +
glycophosphoprotein O +
expressed O +
by O +
several O +
cell O +
types O +
. O +

It O +
is O +
normally O +
produced O +
in O +
bone O +
, O +
teeth O +
, O +
kidney O +
and O +
epithelial O +
lining O +
tissues O +
and O +
is O +
found O +
in O +
plasma O +
and O +
breast O +
milk O +
. O +

It O +
is O +
involved O +
in O +
a O +
number O +
of O +
physiologic O +
and O +
pathologic O +
events O +
including O +
angiogenesis O +
, O +
apoptosis O +
, O +
inflammation O +
, O +
wound O +
healing O +
and O +
tumor O +
metastasis O +
. O +

In O +
this O +
review O +
focus O +
will O +
be O +
on O +
OPN O +
in O +
bone O +
and O +
its O +
role O +
in O +
adhesion O +
, O +
migration O +
and O +
cell O +
survival O +
. O +

These O +
aspects O +
of O +
OPN O +
biology O +
are O +
important O +
in O +
tumorigenesis O +
. O +

Neurologic O +
diagnosis O +
and O +
treatment O +
in O +
patients O +
with O +
computed O +
tomography O +
and O +
nasal O +
endoscopy O +
negative O +
facial O +
pain O +
. O +

OBJECTIVE O +
: O +

To O +
determine O +
the O +
helpfulness O +
of O +
specialist O +
neurology O +
referral O +
for O +
patients O +
with O +
facial O +
pain O +
, O +
a O +
normal O +
sinus O +
computed O +
tomography O +
( O +
CT O +
) O +
scan O +
, O +
and O +
normal O +
nasal O +
endoscopy O +
findings O +
. O +

STUDY O +
DESIGN O +
: O +

Prospective O +
identification O +
of O +
patients O +
and O +
analysis O +
of O +
data O +
approved O +
by O +
the O +
Institutional O +
Review O +
Board O +
. O +

METHODS O +
: O +

The O +
data O +
of O +
104 O +
consecutive O +
patients O +
presenting O +
with O +
facial O +
pain O +
, O +
a O +
normal O +
sinus O +
CT O +
scan O +
, O +
and O +
normal O +
nasal O +
endoscopy O +
findings O +
were O +
reviewed O +
. O +

The O +
patients O +
presented O +
to O +
a O +
single O +
rhinologist O +
in O +
a O +
tertiary O +
care O +
institution O +
. O +

All O +
patients O +
were O +
referred O +
for O +
specialist O +
neurologic O +
evaluation O +
and O +
potential O +
treatment O +
. O +

Further O +
information O +
was O +
obtained O +
from O +
a O +
patient O +
survey O +
. O +

RESULTS O +
: O +

Of O +
the O +
104 O +
patients O +
, O +
81 O +
were O +
women O +
and O +
23 O +
were O +
men O +
. O +

The O +
average O +
age O +
was O +
46 O +
years O +
( O +
range O +
, O +
22 O +
- O +
85 O +
) O +
. O +

Fifty O +
- O +
six O +
had O +
clear O +
CT O +
scans O +
, O +
48 O +
had O +
minimal O +
change O +
, O +
and O +
all O +
had O +
negative O +
endoscopies O +
. O +

Twenty O +
- O +
nine O +
had O +
previous O +
unsuccessful O +
sinus O +
surgery O +
. O +

The O +
average O +
follow O +
- O +
up O +
period O +
was O +
10 O +
. O +
5 O +
months O +
. O +

Forty O +
of O +
75 O +
patients O +
seeing O +
a O +
neurologist O +
were O +
seen O +
on O +
multiple O +
occasions O +
. O +

Four O +
percent O +
of O +
patients O +
seen O +
by O +
a O +
neurologist O +
had O +
an O +
unsuspected O +
serious O +
intracranial O +
diagnosis O +
. O +

The O +
most O +
common O +
diagnoses O +
were O +
migraine O +
( O +
37 O +
% O +
) O +
, O +
rebound O +
headache O +
( O +
17 O +
% O +
) O +
, O +
chronic O +
daily O +
headache O +
( O +
17 O +
% O +
) O +
, O +
and O +
obstructive O +
sleep O +
apnea O +
( O +
16 O +
% O +
) O +
. O +

Overall O +
, O +
58 O +
% O +
improved O +
on O +
medical O +
therapy O +
; O +
60 O +
% O +
of O +
those O +
with O +
a O +
clear O +
CT O +
scan O +
improved O +
, O +
and O +
53 O +
% O +
of O +
those O +
with O +
minimal O +
change O +
on O +
CT O +
scan O +
improved O +
( O +
P O +
= O +
. O +
749 O +
) O +
. O +

CONCLUSIONS O +
: O +

Facial O +
pain O +
remains O +
a O +
difficult O +
symptom O +
to O +
diagnose O +
and O +
treat O +
in O +
rhinologic O +
practice O +
. O +

Patients O +
often O +
undergo O +
surgery O +
without O +
help O +
. O +

Most O +
patients O +
with O +
facial O +
pain O +
, O +
a O +
normal O +
sinus O +
CT O +
scan O +
, O +
and O +
normal O +
endoscopy O +
findings O +
benefit O +
from O +
neurologic O +
consultation O +
. O +

Serious O +
intracranial O +
pathologic O +
conditions O +
can O +
be O +
excluded O +
and O +
diagnosis O +
- O +
specific O +
pharmacogenetic O +
therapy O +
instituted O +
with O +
improvement O +
in O +
more O +
than O +
50 O +
% O +
. O +

[ O +
Glaucoma O +
and O +
ocular O +
ischemic O +
syndrome O +
- O +
- O +
case O +
report O +
] O +

PURPOSE O +
: O +
Ocular O +
ischemic O +
syndrome O +
( O +
OIS O +
) O +
is O +
often O +
poorly O +
diagnosed O +
and O +
treated O +
as O +
primary O +
open O +
angle O +
glaucoma O +
or O +
later O +
on O +
, O +
as O +
neovascular O +
glaucoma O +
. O +

We O +
present O +
a O +
54 O +
year O +
old O +
male O +
, O +
treated O +
topical O +
since O +
23 O +
years O +
for O +
glaucoma O +
and O +
sent O +
to O +
our O +
clinic O +
for O +
trabeculectomy O +
because O +
of O +
rapid O +
worsening O +
of O +
vision O +
on O +
right O +
eye O +
with O +
bilateral O +
total O +
excavation O +
of O +
optic O +
disc O +
. O +

MATERIAL O +
AND O +
METHODS O +
: O +
Observational O +
case O +
report O +
. O +

RESULTS O +
: O +
Because O +
of O +
typical O +
signs O +
of O +
IOS O +
( O +
iris O +
neovascularization O +
, O +
mid O +
- O +
peripheral O +
dot O +
and O +
blot O +
hemorrhages O +
in O +
both O +
eyes O +
, O +
narrowed O +
arterioles O +
in O +
right O +
eye O +
, O +
following O +
examinations O +
were O +
performed O +
: O +
Doppler O +
ultrasonography O +
of O +
carotid O +
arteries O +
, O +
digital O +
subtractional O +
angiography O +
of O +
the O +
carotid O +
vessels O +
and O +
magnetic O +
resonance O +
angiography O +
. O +

The O +
examinations O +
showed O +
occlusion O +
of O +
the O +
right O +
common O +
carotid O +
artery O +
and O +
with O +
80 O +
% O +
stenosis O +
of O +
the O +
left O +
common O +
carotid O +
artery O +
, O +
occlusion O +
of O +
abdominal O +
aorta O +
. O +

After O +
phacoemulsification O +
with O +
implantation O +
of O +
intraocular O +
lens O +
because O +
of O +
rapid O +
intumescence O +
cataract O +
in O +
the O +
right O +
eye O +
, O +
and O +
endarterectomy O +
of O +
left O +
external O +
carotid O +
artery O +
, O +
the O +
neovascularization O +
of O +
the O +
iris O +
regressed O +
in O +
both O +
eyes O +
. O +

CONCLUSION O +
: O +
In O +
case O +
of O +
iris O +
neovascularization O +
or O +
mid O +
- O +
peripheral O +
hemorrhages O +
the O +
Doppler O +
sonography O +
of O +
carotid O +
arteries O +
should O +
be O +
performed O +
. O +

Quick O +
cooperation O +
between O +
ophthalmologist O +
, O +
radiologist O +
and O +
vascular O +
surgeon O +
following O +
endarterectomy O +
seems O +
to O +
stop O +
progressing O +
changes O +
of O +
ocular O +
ischemic O +
syndrome O +
. O +

Structural O +
evolution O +
in O +
cationic O +
micelles O +
upon O +
incorporation O +
of O +
a O +
polar O +
organic O +
dopant O +
. O +

Micelles O +
of O +
cetyltrimethylammonium O +
bromide O +
( O +
CTAB O +
) O +
, O +
when O +
doped O +
with O +
increasing O +
levels O +
of O +
4 O +
- O +
ethylphenol O +
, O +
show O +
microstructural O +
transitions O +
from O +
spherical O +
micelles O +
to O +
elongated O +
wormlike O +
micelles O +
, O +
disks O +
, O +
and O +
subsequently O +
to O +
globular O +
and O +
then O +
to O +
tubular O +
vesicles O +
. O +

Wormlike O +
micelles O +
are O +
observed O +
at O +
a O +
dopant O +
- O +
to O +
- O +
CTAB O +
molar O +
ratio O +
of O +
1 O +
: O +
3 O +
. O +

At O +
higher O +
dopant O +
ratios O +
( O +
1 O +
: O +
1 O +
) O +
, O +
globular O +
vesicles O +
are O +
observed O +
which O +
transition O +
to O +
tubular O +
vesicles O +
when O +
the O +
dopant O +
becomes O +
the O +
predominant O +
species O +
at O +
a O +
ratio O +
of O +
3 O +
: O +
1 O +
. O +

These O +
transitions O +
are O +
reflected O +
in O +
small O +
- O +
angle O +
neutron O +
scattering O +
analysis O +
and O +
, O +
interestingly O +
, O +
can O +
be O +
directly O +
observed O +
through O +
cryo O +
- O +
transmission O +
electron O +
microscopy O +
. O +

The O +
para O +
- O +
substituted O +
phenol O +
is O +
interfacially O +
active O +
and O +
modulates O +
interfacial O +
curvature O +
of O +
the O +
micelles O +
. O +

The O +
observations O +
of O +
microstructure O +
modifications O +
have O +
relevance O +
to O +
the O +
synthesis O +
of O +
mesoporous O +
materials O +
using O +
CTAB O +
as O +
the O +
template O +
. O +

Thiazole O +
orange O +
positive O +
platelets O +
in O +
a O +
dog O +
with O +
Evans O +
' O +
syndrome O +
. O +

We O +
examined O +
transition O +
for O +
the O +
percentage O +
of O +
reticulated O +
platelets O +
( O +
RP O +
% O +
) O +
and O +
platelet O +
count O +
in O +
a O +
canine O +
case O +
of O +
Evans O +
' O +
syndrome O +
. O +

The O +
result O +
demonstrated O +
that O +
measurement O +
of O +
the O +
RP O +
% O +
can O +
be O +
useful O +
in O +
evaluating O +
platelet O +
production O +
in O +
the O +
bone O +
marrow O +
and O +
response O +
to O +
treatment O +
. O +

Granulocyte O +
- O +
macrophage O +
colony O +
- O +
stimulating O +
factor O +
and O +
interleukin O +
- O +
3 O +
enhance O +
the O +
incorporation O +
of O +
cytosine O +
arabinoside O +
into O +
the O +
DNA O +
of O +
leukemic O +
blasts O +
and O +
the O +
cytotoxic O +
effect O +
on O +
clonogenic O +
cells O +
from O +
patients O +
with O +
acute O +
myeloid O +
leukemia O +
. O +

In O +
the O +
present O +
study O +
the O +
effects O +
of O +
the O +
48 O +
- O +
hour O +
administration O +
of O +
granulocyte O +
- O +
macrophage O +
colony O +
- O +
stimulating O +
factor O +
( O +
GM O +
- O +
CSF O +
) O +
( O +
100 O +
U O +
/ O +
mL O +
) O +
or O +
interleukin O +
- O +
3 O +
( O +
IL O +
- O +
3 O +
) O +
( O +
100 O +
U O +
/ O +
mL O +
) O +
on O +
the O +
proliferative O +
activity O +
of O +
leukemic O +
cells O +
and O +
on O +
the O +
intracellular O +
metabolism O +
and O +
cytotoxic O +
efficacy O +
of O +
a O +
subsequent O +
12 O +
- O +
hour O +
application O +
of O +
cytosine O +
arabinoside O +
( O +
ara O +
- O +
C O +
) O +
at O +
doses O +
of O +
0 O +
. O +
1 O +
, O +
1 O +
. O +
0 O +
, O +
10 O +
. O +
0 O +
, O +
and O +
100 O +
. O +
0 O +
mumol O +
/ O +
L O +
were O +
evaluated O +
on O +
bone O +
marrow O +
cells O +
from O +
17 O +
patients O +
with O +
acute O +
myeloid O +
leukemia O +
. O +

After O +
GM O +
- O +
CSF O +
or O +
IL O +
- O +
3 O +
, O +
a O +
1 O +
. O +
2 O +
- O +
to O +
2 O +
. O +
4 O +
- O +
fold O +
increase O +
in O +
S O +
- O +
phase O +
cells O +
was O +
observed O +
in O +
nine O +
of O +
14 O +
GM O +
- O +
CSF O +
and O +
seven O +
of O +
11 O +
IL O +
- O +
3 O +
cases O +
. O +

3H O +
- O +
Cytosine O +
arabinoside O +
incorporation O +
into O +
the O +
DNA O +
was O +
enhanced O +
1 O +
. O +
33 O +
- O +
to O +
18 O +
. O +
3 O +
- O +
fold O +
over O +
respective O +
controls O +
in O +
14 O +
of O +
17 O +
patients O +
. O +

While O +
in O +
control O +
specimens O +
are O +
ara O +
- O +
C O +
dose O +
- O +
dependent O +
increase O +
in O +
3H O +
- O +
ara O +
- O +
C O +
uptake O +
was O +
accompanied O +
by O +
a O +
corresponding O +
rise O +
in O +
intracellular O +
ara O +
- O +
C O +
- O +
5 O +
' O +
triphosphate O +
( O +
ara O +
- O +
CTP O +
) O +
levels O +
, O +
ara O +
- O +
CTP O +
concentrations O +
were O +
not O +
increased O +
after O +
GM O +
- O +
CSF O +
or O +
IL O +
- O +
3 O +
exposure O +
, O +
resulting O +
in O +
a O +
higher O +
ara O +
- O +
C O +
to O +
ara O +
- O +
CTP O +
ratio O +
over O +
controls O +
. O +

This O +
finding O +
may O +
be O +
explained O +
by O +
a O +
stimulatory O +
effect O +
of O +
GM O +
- O +
CSF O +
and O +
IL O +
- O +
3 O +
on O +
ara O +
- O +
C O +
phosphorylating O +
enzymes O +
and O +
a O +
more O +
rapid O +
incorporation O +
of O +
ara O +
- O +
CTP O +
into O +
the O +
DNA O +
of O +
leukemic O +
blasts O +
. O +

These O +
effects O +
translated O +
into O +
a O +
2 O +
. O +
2 O +
- O +
to O +
229 O +
. O +
0 O +
- O +
fold O +
increase O +
in O +
the O +
cytotoxic O +
activity O +
of O +
ara O +
- O +
C O +
against O +
clonogenic O +
leukemic O +
cells O +
after O +
GM O +
- O +
CSF O +
or O +
IL O +
- O +
3 O +
pretreatment O +
. O +

Hence O +
, O +
GM O +
- O +
CSF O +
and O +
IL O +
- O +
3 O +
enhance O +
the O +
intracellular O +
metabolism O +
of O +
ara O +
- O +
C O +
and O +
its O +
incorporation O +
into O +
the O +
DNA O +
of O +
leukemic O +
cells O +
leading O +
to O +
a O +
higher O +
antileukemic O +
activity O +
of O +
ara O +
- O +
C O +
on O +
clonogenic O +
leukemic O +
cells O +
( O +
CFU O +
- O +
L O +
) O +
. O +

Oxidation O +
in O +
rheumatoid O +
arthritis O +
. O +

Oxygen O +
metabolism O +
has O +
an O +
important O +
role O +
in O +
the O +
pathogenesis O +
of O +
rheumatoid O +
arthritis O +
. O +

Reactive O +
oxygen O +
species O +
( O +
ROS O +
) O +
produced O +
in O +
the O +
course O +
of O +
cellular O +
oxidative O +
phosphorylation O +
, O +
and O +
by O +
activated O +
phagocytic O +
cells O +
during O +
oxidative O +
bursts O +
, O +
exceed O +
the O +
physiological O +
buffering O +
capacity O +
and O +
result O +
in O +
oxidative O +
stress O +
. O +

The O +
excessive O +
production O +
of O +
ROS O +
can O +
damage O +
protein O +
, O +
lipids O +
, O +
nucleic O +
acids O +
, O +
and O +
matrix O +
components O +
. O +

They O +
also O +
serve O +
as O +
important O +
intracellular O +
signaling O +
molecules O +
that O +
amplify O +
the O +
synovial O +
inflammatory O +
- O +
proliferative O +
response O +
. O +

Repetitive O +
cycles O +
of O +
hypoxia O +
and O +
reoxygenation O +
associated O +
with O +
changes O +
in O +
synovial O +
perfusion O +
are O +
postulated O +
to O +
activate O +
hypoxia O +
- O +
inducible O +
factor O +
- O +
1alpha O +
and O +
nuclear O +
factor O +
- O +
kappaB O +
, O +
two O +
key O +
transcription O +
factors O +
that O +
are O +
regulated O +
by O +
changes O +
in O +
cellular O +
oxygenation O +
and O +
cytokine O +
stimulation O +
, O +
and O +
that O +
in O +
turn O +
orchestrate O +
the O +
expression O +
of O +
a O +
spectrum O +
of O +
genes O +
critical O +
to O +
the O +
persistence O +
of O +
synovitis O +
. O +

An O +
understanding O +
of O +
the O +
complex O +
interactions O +
involved O +
in O +
these O +
pathways O +
might O +
allow O +
the O +
development O +
of O +
novel O +
therapeutic O +
strategies O +
for O +
rheumatoid O +
arthritis O +
. O +

Human O +
cytomegalovirus O +
5 O +
- O +
kilobase O +
immediate O +
- O +
early O +
RNA O +
is O +
a O +
stable O +
intron O +
. O +

Immediate O +
- O +
early O +
viral O +
gene O +
products O +
of O +
human O +
cytomegalovirus O +
( O +
HCMV O +
) O +
are O +
derived O +
from O +
several O +
genomic O +
loci O +
and O +
largely O +
serve O +
to O +
establish O +
a O +
cellular O +
environment O +
conducive O +
to O +
viral O +
replication O +
. O +

We O +
have O +
further O +
examined O +
an O +
unusual O +
immediate O +
- O +
early O +
transcript O +
known O +
as O +
the O +
5 O +
- O +
kb O +
RNA O +
, O +
concluding O +
that O +
it O +
is O +
a O +
stable O +
intron O +
encoded O +
by O +
HCMV O +
. O +

The O +
5 O +
- O +
kb O +
RNA O +
is O +
highly O +
AT O +
rich O +
in O +
sequence O +
and O +
lacks O +
open O +
reading O +
frames O +
likely O +
to O +
be O +
translated O +
into O +
protein O +
. O +

We O +
confirmed O +
the O +
absence O +
of O +
polyadenylation O +
of O +
the O +
transcript O +
and O +
showed O +
that O +
it O +
is O +
primarily O +
nuclear O +
localized O +
during O +
viral O +
infection O +
. O +

We O +
mapped O +
the O +
5 O +
' O +
end O +
of O +
the O +
5 O +
- O +
kb O +
RNA O +
to O +
a O +
consensus O +
splice O +
donor O +
site O +
and O +
localized O +
the O +
3 O +
' O +
end O +
in O +
the O +
vicinity O +
of O +
a O +
splice O +
acceptor O +
site O +
. O +

In O +
transfection O +
studies O +
, O +
we O +
showed O +
that O +
the O +
5 O +
- O +
kb O +
RNA O +
can O +
be O +
spliced O +
from O +
a O +
heterologous O +
primary O +
transcript O +
. O +

Using O +
bacterial O +
artificial O +
chromosome O +
technology O +
, O +
we O +
constructed O +
a O +
viral O +
recombinant O +
containing O +
a O +
mutation O +
in O +
the O +
5 O +
' O +
splice O +
donor O +
site O +
that O +
defines O +
the O +
5 O +
' O +
end O +
of O +
the O +
RNA O +
and O +
found O +
that O +
this O +
mutation O +
eliminates O +
expression O +
of O +
the O +
5 O +
- O +
kb O +
RNA O +
during O +
viral O +
infection O +
. O +

This O +
mutant O +
grows O +
in O +
human O +
fibroblasts O +
without O +
complementation O +
. O +

Taken O +
together O +
, O +
these O +
data O +
support O +
the O +
conclusion O +
that O +
the O +
5 O +
- O +
kb O +
RNA O +
is O +
a O +
stable O +
intron O +
expressed O +
by O +
HCMV O +
. O +

Silencing O +
of O +
monocarboxylate O +
transporters O +
via O +
small O +
interfering O +
ribonucleic O +
acid O +
inhibits O +
glycolysis O +
and O +
induces O +
cell O +
death O +
in O +
malignant O +
glioma O +
: O +
an O +
in O +
vitro O +
study O +
. O +

OBJECTIVE O +
: O +
Dependence O +
on O +
glycolysis O +
is O +
a O +
hallmark O +
of O +
malignant O +
tumors O +
. O +

As O +
a O +
consequence O +
, O +
these O +
tumors O +
generate O +
more O +
lactate O +
, O +
which O +
is O +
effluxed O +
from O +
cells O +
by O +
monocarboxylate O +
transporters O +
( O +
MCTs O +
) O +
. O +

We O +
hypothesized O +
that O +
1 O +
) O +
MCT O +
expression O +
in O +
malignant O +
tumors O +
may O +
differ O +
from O +
normal O +
tissue O +
in O +
quantity O +
, O +
isoform O +
, O +
or O +
both O +
; O +
and O +
2 O +
) O +
silencing O +
MCT O +
expression O +
would O +
induce O +
intracellular O +
acidification O +
, O +
resulting O +
in O +
decreased O +
proliferation O +
and O +
/ O +
or O +
increased O +
cell O +
death O +
. O +

METHODS O +
: O +
We O +
quantified O +
expression O +
of O +
MCT O +
isoforms O +
in O +
human O +
glioblastoma O +
multiforme O +
and O +
glioma O +
- O +
derived O +
cells O +
lines O +
by O +
Western O +
blot O +
analysis O +
. O +

MCTs O +
that O +
were O +
abundant O +
or O +
specific O +
to O +
glioma O +
then O +
were O +
targeted O +
in O +
the O +
model O +
U B-CellLine +
- I-CellLine +
87 I-CellLine +
MG O +
glioma O +
cell O +
line O +
via O +
small O +
interfering O +
ribonucleic O +
acid O +
- O +
mediated O +
gene O +
silencing O +
and O +
tested O +
for O +
inhibition O +
of O +
lactate O +
efflux O +
, O +
intracellular O +
pH O +
changes O +
, O +
reduced O +
proliferation O +
, O +
and O +
/ O +
or O +
induction O +
of O +
cell O +
death O +
. O +

RESULTS O +
: O +
MCT O +
1 O +
and O +
2 O +
were O +
the O +
primary O +
isoforms O +
expressed O +
in O +
human O +
glioblastoma O +
multiforme O +
and O +
glioma O +
- O +
derived O +
cell O +
lines O +
. O +

In O +
contrast O +
, O +
MCT O +
3 O +
was O +
the O +
predominantly O +
expressed O +
isoform O +
in O +
normal O +
brain O +
. O +

Small O +
interfering O +
ribonucleic O +
acid O +
specific O +
for O +
MCT O +
1 O +
and O +
2 O +
reduced O +
expression O +
of O +
these O +
isoforms O +
in O +
U B-CellLine +
- I-CellLine +
87 I-CellLine +
MG I-CellLine +
cells O +
to O +
barely O +
detectable O +
levels O +
and O +
reduced O +
lactate O +
efflux O +
by O +
30 O +
% O +
individually O +
and O +
85 O +
% O +
in O +
combination O +
, O +
with O +
a O +
concomitant O +
decrease O +
of O +
intracellular O +
pH O +
by O +
0 O +
. O +
6 O +
units O +
( O +
a O +
fourfold O +
increase O +
in O +
intracellular O +
H O +
( O +
+ O +
) O +
) O +
. O +

Prolonged O +
silencing O +
of O +
both O +
MCTs O +
reduced O +
viability O +
by O +
75 O +
% O +
individually O +
and O +
92 O +
% O +
in O +
combination O +
, O +
as O +
measured O +
by O +
both O +
phenotypic O +
and O +
flow O +
cytometric O +
analyses O +
. O +

CONCLUSION O +
: O +
MCT O +
targeting O +
significantly O +
reduced O +
the O +
viability O +
of O +
U B-CellLine +
- I-CellLine +
87 I-CellLine +
MG I-CellLine +
cells O +
mediated O +
by O +
both O +
apoptosis O +
and O +
necrosis O +
. O +

This O +
indicates O +
that O +
the O +
strategy O +
may O +
be O +
a O +
useful O +
therapeutic O +
avenue O +
for O +
treatment O +
of O +
patients O +
with O +
malignant O +
glioma O +
. O +

Hypoxia O +
- O +
responsive O +
element O +
- O +
mediated O +
soluble O +
Tie2 O +
vector O +
exhibits O +
an O +
anti O +
- O +
angiogenic O +
activity O +
in O +
vitro O +
under O +
hypoxic O +
condition O +
. O +

Hypoxia O +
- O +
inducible O +
factor O +
- O +
1 O +
( O +
HIF O +
- O +
1 O +
) O +
is O +
one O +
of O +
the O +
key O +
mammalian O +
transcription O +
factors O +
and O +
shows O +
increased O +
levels O +
in O +
both O +
protein O +
stability O +
and O +
intrinsic O +
transcriptional O +
activity O +
during O +
low O +
oxygen O +
tension O +
. O +

Hypoxia O +
- O +
activated O +
functional O +
HIF O +
- O +
1 O +
protein O +
binds O +
to O +
hypoxia O +
- O +
responsive O +
elements O +
( O +
HRE O +
) O +
in O +
the O +
enhancers O +
of O +
several O +
genes O +
including O +
VEGF O +
, O +
the O +
major O +
player O +
in O +
angiogenesis O +
, O +
and O +
initiates O +
their O +
mRNA O +
expression O +
. O +

The O +
molecular O +
mechanisms O +
regulating O +
the O +
gene O +
expression O +
under O +
hypoxic O +
conditions O +
could O +
increase O +
the O +
therapeutic O +
window O +
of O +
tumor O +
- O +
specific O +
delivery O +
systems O +
. O +

In O +
this O +
study O +
, O +
to O +
examine O +
hypoxia O +
- O +
specific O +
production O +
of O +
anti O +
- O +
angiogenic O +
therapeutic O +
gene O +
, O +
we O +
constructed O +
5 O +
copies O +
of O +
HRE O +
( O +
5xHRE O +
) O +
of O +
human O +
VEGF O +
linked O +
to O +
soluble O +
Tie2 O +
( O +
sTie2 O +
) O +
driven O +
by O +
minimal O +
SV40 O +
promoter O +
( O +
5xHRE O +
/ O +
SV40 O +
/ O +
sTie2 O +
) O +
. O +

Our O +
data O +
showed O +
that O +
under O +
hypoxia O +
the O +
secreted O +
sTie2 O +
selectively O +
inhibited O +
tube O +
formation O +
and O +
migration O +
capacities O +
of O +
endothelial O +
cells O +
in O +
vitro O +
. O +

Hence O +
, O +
we O +
propose O +
that O +
the O +
vector O +
system O +
, O +
5xHRE O +
/ O +
SV40 O +
/ O +
sTie2 O +
, O +
might O +
be O +
a O +
useful O +
tool O +
for O +
down O +
- O +
regulating O +
tumor O +
angiogenesis O +
under O +
hypoxic O +
condition O +
. O +

Glucocorticoid O +
receptor O +
- O +
induced O +
MAPK O +
phosphatase O +
- O +
1 O +
( O +
MPK O +
- O +
1 O +
) O +
expression O +
inhibits O +
paclitaxel O +
- O +
associated O +
MAPK O +
activation O +
and O +
contributes O +
to O +
breast O +
cancer O +
cell O +
survival O +
. O +

Glucocorticoid O +
receptor O +
( O +
GR O +
) O +
activation O +
has O +
recently O +
been O +
shown O +
to O +
inhibit O +
apoptosis O +
in O +
breast O +
epithelial O +
cells O +
. O +

We O +
have O +
previously O +
described O +
a O +
group O +
of O +
genes O +
that O +
is O +
rapidly O +
up O +
- O +
regulated O +
in O +
these O +
cells O +
following O +
dexamethasone O +
( O +
Dex O +
) O +
treatment O +
. O +

In O +
an O +
effort O +
to O +
dissect O +
the O +
mechanisms O +
of O +
GR O +
- O +
mediated O +
breast O +
epithelial O +
cell O +
survival O +
, O +
we O +
now O +
examine O +
the O +
molecular O +
events O +
downstream O +
of O +
GR O +
activation O +
. O +

Here O +
we O +
show O +
that O +
GR O +
activation O +
leads O +
to O +
both O +
the O +
rapid O +
induction O +
of O +
MAPK O +
phosphatase O +
- O +
1 O +
( O +
MKP O +
- O +
1 O +
) O +
mRNA O +
and O +
its O +
sustained O +
expression O +
. O +

Induction O +
of O +
the O +
MKP O +
- O +
1 O +
protein O +
in O +
the O +
MCF10A B-CellLine +
- O +
Myc O +
and O +
MDA B-CellLine +
- I-CellLine +
MB I-CellLine +
- I-CellLine +
231 I-CellLine +
breast O +
epithelial O +
cell O +
lines O +
was O +
also O +
seen O +
. O +

Paclitaxel O +
treatment O +
resulted O +
in O +
MAPK O +
activation O +
and O +
apoptosis O +
of O +
MDA B-CellLine +
- I-CellLine +
MB I-CellLine +
- I-CellLine +
231 I-CellLine +
breast O +
cancer O +
cells O +
, O +
and O +
both O +
processes O +
were O +
inhibited O +
by O +
Dex O +
pretreatment O +
. O +

Furthermore O +
, O +
induction O +
of O +
MKP O +
- O +
1 O +
correlated O +
with O +
the O +
inhibition O +
of O +
extracellular O +
signal O +
- O +
regulated O +
kinase O +
( O +
ERK1 O +
/ O +
2 O +
) O +
and O +
c O +
- O +
Jun O +
N O +
- O +
terminal O +
kinase O +
( O +
JNK O +
) O +
activity O +
, O +
whereas O +
p38 O +
activity O +
was O +
minimally O +
affected O +
. O +

Blocking O +
Dex O +
- O +
induced O +
MKP O +
- O +
1 O +
induction O +
using O +
small O +
interfering O +
RNA O +
increased O +
ERK1 O +
/ O +
2 O +
and O +
JNK O +
phosphorylation O +
and O +
decreased O +
cell O +
survival O +
. O +

ERK1 O +
/ O +
2 O +
and O +
JNK O +
inactivation O +
was O +
associated O +
with O +
Ets O +
- O +
like O +
transcription O +
factor O +
- O +
1 O +
( O +
ELK O +
- O +
1 O +
) O +
dephosphorylation O +
. O +

To O +
explore O +
the O +
gene O +
expression O +
changes O +
that O +
occur O +
downstream O +
of O +
ELK O +
- O +
1 O +
dephosphorylation O +
, O +
we O +
used O +
a O +
combination O +
of O +
temporal O +
gene O +
expression O +
data O +
and O +
promoter O +
element O +
analyses O +
. O +

This O +
approach O +
revealed O +
a O +
previously O +
unrecognized O +
transcriptional O +
target O +
of O +
ELK O +
- O +
1 O +
, O +
the O +
human O +
tissue O +
plasminogen O +
activator O +
( O +
tPA O +
) O +
. O +

We O +
verified O +
the O +
predicted O +
ELK O +
- O +
1 O +
- O +
- O +
> O +
tPA O +
transcriptional O +
regulatory O +
relationship O +
using O +
a O +
luciferase O +
reporter O +
assay O +
. O +

We O +
conclude O +
that O +
GR O +
- O +
mediated O +
MAPK O +
inactivation O +
contributes O +
to O +
cell O +
survival O +
and O +
that O +
the O +
potential O +
transcriptional O +
targets O +
of O +
this O +
inhibition O +
can O +
be O +
identified O +
from O +
large O +
scale O +
gene O +
array O +
analysis O +
. O +

Proteome O +
analysis O +
of O +
NIH3T3 B-CellLine +
cells O +
transformed O +
by O +
activated O +
Galpha12 O +
: O +
regulation O +
of O +
leukemia O +
- O +
associated O +
protein O +
SET O +
. O +

Galpha O +
( O +
12 O +
) O +
, O +
the O +
alpha O +
- O +
subunit O +
of O +
the O +
G12 O +
family O +
of O +
heterotrimeric O +
G O +
proteins O +
is O +
involved O +
in O +
the O +
regulation O +
of O +
cell O +
proliferation O +
and O +
neoplastic O +
transformation O +
. O +

GTPase O +
- O +
deficient O +
, O +
constitutively O +
activated O +
mutant O +
of O +
Galpha O +
( O +
12 O +
) O +
( O +
Galpha O +
( O +
12 O +
) O +
Q229L O +
or O +
Galpha O +
( O +
12 O +
) O +
QL O +
) O +
has O +
been O +
previously O +
shown O +
to O +
induce O +
oncogenic O +
transformation O +
of O +
NIH3T3 B-CellLine +
cells O +
promoting O +
serum O +
- O +
and O +
anchorage O +
- O +
independent O +
growth O +
. O +

Reduced O +
growth O +
- O +
factor O +
dependent O +
, O +
autonomous O +
cell O +
growth O +
forms O +
a O +
critical O +
defining O +
point O +
at O +
which O +
a O +
normal O +
cell O +
turns O +
into O +
an O +
oncogenic O +
one O +
. O +

To O +
identify O +
the O +
underlying O +
mechanism O +
involved O +
in O +
such O +
growth O +
- O +
factor O +
/ O +
serum O +
independent O +
growth O +
of O +
Galpha O +
( O +
12 O +
) O +
QL O +
- O +
transformed O +
NIH3T3 B-CellLine +
, O +
we O +
carried O +
out O +
a O +
two O +
- O +
dimensional O +
differential O +
proteome O +
analysis O +
of O +
Galpha O +
( O +
12 O +
) O +
QL O +
- O +
transformed O +
NIH3T3 B-CellLine +
cells O +
and O +
cells O +
expressing O +
vector O +
control O +
. O +

This O +
analysis O +
revealed O +
a O +
total O +
of O +
22 O +
protein O +
- O +
spots O +
whose O +
expression O +
was O +
altered O +
by O +
more O +
than O +
3 O +
- O +
folds O +
. O +

Two O +
of O +
these O +
spots O +
were O +
identified O +
by O +
MALDI O +
- O +
MS O +
analysis O +
as O +
proliferating O +
cell O +
nuclear O +
antigen O +
( O +
PCNA O +
) O +
and O +
myeloid O +
- O +
leukemia O +
- O +
associated O +
SET O +
protein O +
. O +

The O +
increased O +
expressions O +
of O +
these O +
proteins O +
in O +
Galpha O +
( O +
12 O +
) O +
QL O +
cells O +
were O +
validated O +
by O +
immunoblot O +
analysis O +
. O +

Furthermore O +
, O +
transient O +
transfection O +
studies O +
with O +
NIH3T3 B-CellLine +
cells O +
indicated O +
that O +
the O +
expression O +
of O +
activated O +
Galpha O +
( O +
12 O +
) O +
readily O +
increased O +
the O +
expression O +
of O +
SET O +
protein O +
by O +
24 O +
h O +
. O +

As O +
SET O +
has O +
been O +
previously O +
reported O +
to O +
be O +
an O +
inhibitor O +
of O +
phosphatase O +
PP2A O +
, O +
the O +
nuclear O +
phosphatase O +
activity O +
was O +
monitored O +
in O +
cells O +
expressing O +
activated O +
Galpha O +
( O +
12 O +
) O +
. O +

Our O +
results O +
indicate O +
that O +
the O +
nuclear O +
phosphatase O +
activity O +
is O +
inhibited O +
by O +
greater O +
than O +
50 O +
% O +
in O +
Galpha O +
( O +
12 O +
) O +
QL O +
cells O +
compared O +
to O +
vector O +
control O +
cells O +
. O +

Thus O +
, O +
our O +
results O +
from O +
differential O +
proteome O +
analysis O +
presented O +
here O +
report O +
for O +
the O +
first O +
time O +
a O +
role O +
for O +
SET O +
in O +
Galpha O +
( O +
12 O +
) O +
- O +
mediated O +
signaling O +
pathways O +
and O +
a O +
role O +
for O +
Galpha O +
( O +
12 O +
) O +
in O +
the O +
regulation O +
of O +
the O +
leukemia O +
- O +
associated O +
SET O +
- O +
protein O +
expression O +
. O +

TBX21 O +
: O +
a O +
functional O +
variant O +
predicts O +
improvement O +
in O +
asthma O +
with O +
the O +
use O +
of O +
inhaled O +
corticosteroids O +
. O +

TBX21 O +
encodes O +
for O +
the O +
transcription O +
factor O +
T O +
- O +
bet O +
( O +
T O +
- O +
box O +
expressed O +
in O +
T O +
cells O +
) O +
, O +
which O +
influences O +
naive O +
T O +
lymphocyte O +
development O +
and O +
has O +
been O +
implicated O +
in O +
asthma O +
pathogenesis O +
. O +

Specifically O +
, O +
the O +
T O +
- O +
bet O +
knockout O +
mouse O +
spontaneously O +
develops O +
airway O +
hyperresponsiveness O +
and O +
other O +
changes O +
consistent O +
with O +
asthma O +
. O +

Because O +
airway O +
responsiveness O +
is O +
moderated O +
by O +
the O +
use O +
of O +
inhaled O +
corticosteroids O +
in O +
asthma O +
, O +
it O +
is O +
conceivable O +
that O +
genetic O +
variation O +
in O +
TBX21 O +
may O +
alter O +
asthma O +
phenotypes O +
in O +
a O +
treatment O +
- O +
specific O +
fashion O +
. O +

Here O +
we O +
demonstrate O +
that O +
the O +
nonsynonymous O +
variation O +
in O +
TBX21 O +
coding O +
for O +
replacement O +
of O +
histidine O +
33 O +
with O +
glutamine O +
is O +
associated O +
with O +
significant O +
improvement O +
in O +
the O +
PC O +
( O +
20 O +
) O +
( O +
a O +
measure O +
of O +
airway O +
responsiveness O +
) O +
of O +
asthmatic O +
children O +
in O +
a O +
large O +
clinical O +
trial O +
spanning O +
4 O +
years O +
. O +

We O +
note O +
that O +
this O +
increase O +
occurs O +
only O +
in O +
the O +
children O +
randomized O +
to O +
inhaled O +
corticosteroids O +
and O +
that O +
it O +
dramatically O +
enhances O +
the O +
overall O +
improvement O +
in O +
PC O +
( O +
20 O +
) O +
associated O +
with O +
inhaled O +
corticosteroid O +
usage O +
. O +

The O +
average O +
PC O +
( O +
20 O +
) O +
at O +
trial O +
end O +
for O +
subjects O +
on O +
inhaled O +
corticosteroids O +
possessing O +
a O +
variant O +
allele O +
was O +
in O +
the O +
normal O +
range O +
for O +
nonasthmatics O +
. O +

In O +
cellular O +
models O +
, O +
we O +
show O +
that O +
the O +
TBX21 O +
variant O +
increases O +
T O +
helper O +
1 O +
and O +
decreases O +
T O +
helper O +
2 O +
cytokine O +
expression O +
comparably O +
with O +
wild O +
type O +
. O +

TBX21 O +
may O +
thus O +
be O +
an O +
important O +
determinant O +
pharmacogenetic O +
response O +
to O +
the O +
therapy O +
of O +
asthma O +
with O +
inhaled O +
corticosteroids O +
. O +

Matrix O +
metalloproteinase O +
/ O +
tissue O +
inhibitors O +
of O +
matrix O +
metalloproteinase O +
phenotype O +
identifies O +
poor O +
prognosis O +
colorectal O +
cancers O +
. O +

PURPOSE O +
: O +
The O +
matrix O +
metalloproteinases O +
( O +
MMPs O +
) O +
are O +
a O +
family O +
of O +
proteolytic O +
enzymes O +
involved O +
in O +
tumor O +
invasion O +
; O +
several O +
individual O +
members O +
of O +
which O +
have O +
been O +
implicated O +
in O +
tumor O +
prognosis O +
. O +

These O +
enzymes O +
and O +
their O +
physiologic O +
inhibitors O +
, O +
the O +
tissue O +
inhibitors O +
of O +
matrix O +
metalloproteinases O +
( O +
TIMPs O +
) O +
, O +
act O +
in O +
a O +
coordinated O +
manner O +
to O +
form O +
an O +
integrated O +
system O +
. O +

Therefore O +
, O +
to O +
understand O +
their O +
role O +
in O +
tumor O +
invasion O +
, O +
it O +
is O +
necessary O +
to O +
evaluate O +
them O +
collectively O +
. O +

EXPERIMENTAL O +
DESIGN O +
: O +
In O +
this O +
study O +
all O +
of O +
the O +
major O +
members O +
of O +
the O +
matrix O +
metalloproteinase O +
( O +
MMP O +
- O +
1 O +
, O +
MMP O +
- O +
2 O +
, O +
MMP O +
- O +
3 O +
, O +
MMP O +
- O +
7 O +
, O +
MMP O +
- O +
9 O +
, O +
MMP O +
- O +
13 O +
, O +
MT1 O +
- O +
MMP O +
and O +
MT2 O +
- O +
MMP O +
) O +
/ O +
tissue O +
inhibitor O +
of O +
matrix O +
metalloproteinase O +
( O +
TIMP O +
- O +
1 O +
, O +
TIMP O +
- O +
2 O +
, O +
and O +
TIMP O +
- O +
3 O +
) O +
system O +
have O +
been O +
investigated O +
by O +
immunohistochemistry O +
in O +
a O +
series O +
( O +
n O +
= O +
90 O +
) O +
of O +
stage O +
III O +
( O +
Dukes O +
' O +
C O +
) O +
colorectal O +
cancers O +
. O +

An O +
immunohistochemical O +
score O +
based O +
on O +
the O +
intensity O +
of O +
immunoreactivity O +
and O +
proportion O +
of O +
immunoreactive O +
cells O +
was O +
established O +
for O +
each O +
MMP O +
and O +
TIMP O +
. O +

RESULTS O +
: O +
The O +
MMP O +
/ O +
TIMP O +
profile O +
defined O +
by O +
hierarchical O +
cluster O +
analysis O +
of O +
the O +
immunohistochemical O +
score O +
identifies O +
a O +
distinct O +
group O +
of O +
colorectal O +
cancers O +
with O +
poor O +
prognosis O +
( O +
log O +
- O +
rank O +
test O +
, O +
12 O +
. O +
22 O +
, O +
P O +
= O +
0 O +
. O +
0005 O +
) O +
. O +

The O +
median O +
survival O +
time O +
of O +
patients O +
in O +
this O +
survival O +
group O +
was O +
18 O +
months O +
compared O +
with O +
a O +
median O +
survival O +
of O +
49 O +
months O +
in O +
the O +
" O +
good O +
" O +
survival O +
group O +
. O +

Multivariate O +
analysis O +
showed O +
that O +
this O +
profile O +
was O +
independently O +
the O +
most O +
significant O +
prognostic O +
factor O +
( O +
P O +
= O +
0 O +
. O +
001 O +
) O +
. O +

CONCLUSIONS O +
: O +
This O +
study O +
has O +
identified O +
that O +
the O +
MMP O +
/ O +
TIMP O +
profile O +
is O +
an O +
independent O +
indicator O +
of O +
poor O +
prognosis O +
in O +
colorectal O +
cancer O +
. O +

2 O +
- O +
methoxyestradiol O +
inhibits O +
hypoxia O +
- O +
inducible O +
factor O +
1alpha O +
, O +
tumor O +
growth O +
, O +
and O +
angiogenesis O +
and O +
augments O +
paclitaxel O +
efficacy O +
in O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O +
. O +

PURPOSE O +
: O +
Head O +
and O +
neck O +
squamous O +
cell O +
carcinomas O +
have O +
been O +
reported O +
to O +
overexpress O +
hypoxia O +
- O +
inducible O +
factor O +
( O +
HIF O +
) O +
- O +
1alpha O +
, O +
a O +
transcription O +
factor O +
that O +
promotes O +
expression O +
of O +
angiogenesis O +
factors O +
and O +
resistance O +
to O +
programmed O +
and O +
therapy O +
- O +
induced O +
cell O +
death O +
. O +

2 O +
- O +
Methoxyestradiol O +
( O +
2ME2 O +
) O +
is O +
a O +
natural O +
compound O +
with O +
HIF O +
- O +
1alpha O +
inhibitory O +
activity O +
that O +
is O +
currently O +
being O +
evaluated O +
in O +
phase O +
1 O +
and O +
2 O +
clinical O +
trials O +
for O +
advanced O +
solid O +
tumors O +
and O +
multiple O +
myeloma O +
. O +

To O +
our O +
knowledge O +
, O +
this O +
is O +
the O +
first O +
study O +
to O +
evaluate O +
the O +
effects O +
of O +
2ME2 O +
in O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O +
. O +

EXPERIMENTAL O +
DESIGN O +
: O +
In O +
the O +
present O +
study O +
, O +
we O +
investigated O +
the O +
effects O +
of O +
2ME2 O +
alone O +
and O +
in O +
combination O +
with O +
paclitaxel O +
, O +
an O +
active O +
agent O +
in O +
recurrent O +
or O +
advanced O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O +
. O +

RESULTS O +
: O +
2ME2 O +
exhibited O +
antiproliferative O +
and O +
cytotoxic O +
effects O +
in O +
a O +
panel O +
of O +
five O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O +
cell O +
lines O +
in O +
the O +
0 O +
. O +
5 O +
to O +
10 O +
micromol O +
/ O +
L O +
range O +
, O +
including O +
induction O +
of O +
G2 O +
- O +
M O +
blockade O +
, O +
caspase O +
- O +
3 O +
/ O +
7 O +
activation O +
, O +
and O +
apoptosis O +
at O +
48 O +
hours O +
. O +

2ME2 O +
resulted O +
in O +
decreased O +
nuclear O +
HIF O +
- O +
1alpha O +
- O +
binding O +
activity O +
and O +
affected O +
the O +
expression O +
of O +
downstream O +
genes O +
, O +
such O +
as O +
bid O +
, O +
a O +
proapoptotic O +
bcl O +
- O +
2 O +
family O +
member O +
, O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
, O +
a O +
proangiogenic O +
cytokine O +
. O +

The O +
up O +
- O +
regulation O +
of O +
Bid O +
( O +
57 O +
. O +
5 O +
% O +
at O +
12 O +
hours O +
, O +
P O +
less O +
than O +
0 O +
. O +
0006 O +
) O +
and O +
inhibition O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
secretion O +
( O +
57 O +
. O +
7 O +
% O +
at O +
24 O +
hours O +
, O +
P O +
less O +
than O +
0 O +
. O +
015 O +
; O +
and O +
50 O +
. O +
3 O +
% O +
at O +
48 O +
hours O +
, O +
P O +
less O +
than O +
0 O +
. O +
0006 O +
) O +
could O +
be O +
partially O +
attributed O +
to O +
the O +
effects O +
on O +
HIF O +
- O +
1alpha O +
, O +
because O +
HIF O +
- O +
1alpha O +
small O +
interfering O +
RNAs O +
produced O +
similar O +
effects O +
. O +

Finally O +
, O +
in O +
vivo O +
, O +
in O +
a O +
xenograft O +
model O +
of O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O +
using O +
UM B-CellLine +
- I-CellLine +
SCC I-CellLine +
- I-CellLine +
11A I-CellLine +
cells O +
, O +
2ME2 O +
exhibited O +
antitumor O +
and O +
antiangiogenic O +
activity O +
, O +
as O +
measured O +
by O +
CD31 O +
immunostaining O +
. O +

CONCLUSIONS O +
: O +
These O +
results O +
provide O +
support O +
for O +
the O +
use O +
of O +
2ME2 O +
in O +
combination O +
with O +
paclitaxel O +
for O +
the O +
treatment O +
of O +
recurrent O +
or O +
advanced O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O +
. O +

HIF O +
- O +
2alpha O +
expression O +
in O +
human O +
fetal O +
paraganglia O +
and O +
neuroblastoma O +
: O +
relation O +
to O +
sympathetic O +
differentiation O +
, O +
glucose O +
deficiency O +
, O +
and O +
hypoxia O +
. O +

Solid O +
tumors O +
are O +
frequently O +
necrotic O +
and O +
hypoxic O +
due O +
to O +
poor O +
vascularization O +
. O +

Tumor O +
cells O +
adapt O +
to O +
hypoxia O +
by O +
modulating O +
their O +
phenotype O +
. O +

Key O +
players O +
in O +
this O +
process O +
are O +
the O +
hypoxia O +
- O +
inducible O +
factors O +
( O +
HIF O +
- O +
1alpha O +
to O +
3alpha O +
) O +
. O +

HIFs O +
are O +
also O +
expressed O +
during O +
normal O +
development O +
; O +
for O +
example O +
, O +
HIF O +
- O +
2alpha O +
is O +
specifically O +
expressed O +
and O +
appears O +
to O +
be O +
involved O +
in O +
the O +
development O +
of O +
the O +
murine O +
sympathetic O +
nervous O +
system O +
( O +
SNS O +
) O +
. O +

Here O +
, O +
we O +
demonstrate O +
that O +
HIF O +
- O +
2alpha O +
protein O +
is O +
selectively O +
present O +
in O +
human O +
fetal O +
week O +
8 O +
. O +
5 O +
SNS O +
paraganglia O +
. O +

Neuroblastoma O +
is O +
derived O +
from O +
SNS O +
precursors O +
. O +

In O +
a O +
subset O +
of O +
neuroblastomas O +
, O +
a O +
spontaneous O +
neuronal O +
to O +
neuroendocrine O +
differentiation O +
occurs O +
in O +
areas O +
adjacent O +
to O +
necrotic O +
zones O +
. O +

As O +
HIF O +
- O +
2alpha O +
activity O +
has O +
been O +
associated O +
not O +
only O +
with O +
hypoxic O +
but O +
also O +
with O +
hypoglycemic O +
conditions O +
, O +
we O +
have O +
investigated O +
putative O +
effects O +
of O +
hypoxia O +
, O +
glucose O +
depletion O +
, O +
and O +
HIF O +
- O +
2alpha O +
on O +
the O +
neuroblastoma O +
phenotype O +
. O +

HIF O +
- O +
2alpha O +
was O +
detected O +
in O +
hypoxic O +
and O +
in O +
well O +
- O +
oxygenized O +
neuroblastoma O +
cells O +
and O +
tissue O +
, O +
presumably O +
reflecting O +
their O +
embryonic O +
features O +
. O +

With O +
regard O +
to O +
differentiation O +
, O +
hypoxic O +
cells O +
lost O +
their O +
neuronal O +
/ O +
neuroendocrine O +
features O +
and O +
gained O +
marker O +
gene O +
expression O +
associated O +
with O +
an O +
immature O +
, O +
neural O +
crest O +
- O +
like O +
phenotype O +
. O +

Low O +
glucose O +
potentiated O +
the O +
effect O +
of O +
hypoxia O +
. O +

These O +
findings O +
suggest O +
that O +
poorly O +
vascularized O +
neuroblastomas O +
become O +
immature O +
and O +
maintain O +
a O +
more O +
aggressive O +
phenotype O +
, O +
which O +
possibly O +
could O +
involve O +
a O +
sustained O +
stabilization O +
and O +
activation O +
of O +
HIF O +
- O +
2alpha O +
. O +

Reduced O +
prognostic O +
power O +
of O +
ventricular O +
late O +
potentials O +
in O +
post O +
- O +
infarction O +
patients O +
of O +
the O +
reperfusion O +
era O +
. O +

AIMS O +
: O +

To O +
test O +
the O +
prognostic O +
value O +
of O +
ventricular O +
late O +
potentials O +
( O +
LPs O +
) O +
in O +
a O +
large O +
cohort O +
of O +
post O +
- O +
infarction O +
patients O +
in O +
the O +
modern O +
reperfusion O +
era O +
. O +

METHODS O +
AND O +
RESULTS O +
: O +

1800 O +
consecutive O +
survivors O +
of O +
acute O +
myocardial O +
infarction O +
in O +
sinus O +
rhythm O +
and O +
under O +
76 O +
years O +
of O +
age O +
were O +
enrolled O +
. O +

Many O +
( O +
99 O +
% O +
) O +
of O +
the O +
patients O +
received O +
reperfusion O +
/ O +
revascularization O +
therapy O +
( O +
91 O +
% O +
percutaneous O +
coronary O +
intervention O +
) O +
and O +
up O +
- O +
to O +
- O +
date O +
pharmacological O +
treatment O +
( O +
99 O +
% O +
aspirin O +
, O +
93 O +
% O +
beta O +
- O +
blockers O +
, O +
90 O +
% O +
ACE O +
- O +
inhibitors O +
, O +
and O +
85 O +
% O +
statins O +
) O +
. O +

LPs O +
were O +
calculated O +
in O +
968 O +
patients O +
and O +
found O +
to O +
be O +
present O +
in O +
90 O +
( O +
9 O +
. O +
3 O +
% O +
) O +
. O +

The O +
primary O +
endpoint O +
was O +
the O +
composite O +
of O +
cardiac O +
death O +
and O +
serious O +
arrhythmic O +
events O +
. O +

The O +
secondary O +
endpoint O +
was O +
the O +
composite O +
of O +
sudden O +
cardiac O +
death O +
and O +
serious O +
arrhythmic O +
events O +
. O +

During O +
follow O +
- O +
up O +
( O +
median O +
34 O +
months O +
) O +
, O +
26 O +
patients O +
reached O +
the O +
primary O +
endpoint O +
. O +

The O +
presence O +
of O +
LPs O +
was O +
not O +
significantly O +
associated O +
with O +
the O +
primary O +
endpoint O +
in O +
univariable O +
or O +
multivariable O +
analysis O +
. O +

In O +
contrast O +
, O +
low O +
( O +
< O +
or O +
= O +
30 O +
% O +
) O +
left O +
ventricular O +
ejection O +
fraction O +
( O +
hazard O +
ratio O +
9 O +
. O +
6 O +
, O +
95 O +
% O +
confidence O +
interval O +
4 O +
. O +
1 O +
- O +
22 O +
. O +
4 O +
) O +
, O +
heart O +
rate O +
turbulence O +
category O +
2 O +
( O +
7 O +
. O +
5 O +
, O +
2 O +
. O +
4 O +
- O +
23 O +
. O +
9 O +
) O +
and O +
category O +
1 O +
( O +
5 O +
. O +
3 O +
, O +
1 O +
. O +
9 O +
- O +
14 O +
. O +
9 O +
) O +
were O +
significant O +
predictors O +
in O +
both O +
univariable O +
and O +
multivariable O +
analysis O +
. O +

CONCLUSION O +
: O +

Ventricular O +
LPs O +
are O +
of O +
limited O +
use O +
for O +
risk O +
stratification O +
in O +
unselected O +
post O +
- O +
infarction O +
patients O +
in O +
the O +
modern O +
reperfusion O +
era O +
. O +

Expression O +
and O +
purification O +
of O +
the O +
catalytic O +
domain O +
of O +
human O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
2 O +
for O +
inhibitor O +
screening O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
, O +
an O +
endothelial O +
cell O +
- O +
specific O +
mitogen O +
, O +
can O +
act O +
in O +
tumor O +
- O +
induced O +
angiogenesis O +
by O +
binding O +
to O +
specific O +
receptors O +
on O +
the O +
surface O +
of O +
endothelial O +
cells O +
. O +

One O +
such O +
receptor O +
, O +
VEGFR O +
- O +
2 O +
/ O +
KDR O +
, O +
plays O +
a O +
key O +
role O +
in O +
VEGF O +
- O +
induced O +
angiogenesis O +
. O +

Here O +
, O +
we O +
expressed O +
the O +
catalytic O +
domain O +
of O +
VEGFR O +
- O +
2 O +
as O +
a O +
soluble O +
active O +
kinase O +
using O +
Bac O +
- O +
to O +
- O +
Bac O +
expression O +
system O +
, O +
and O +
investigated O +
correlations O +
between O +
VEGFR O +
- O +
2 O +
activity O +
and O +
enzyme O +
concentration O +
, O +
ATP O +
concentration O +
, O +
substrate O +
concentration O +
and O +
divalent O +
cation O +
type O +
. O +

We O +
used O +
these O +
data O +
to O +
establish O +
a O +
convenient O +
, O +
effective O +
and O +
non O +
- O +
radioactive O +
ELISA O +
screening O +
technique O +
for O +
the O +
identification O +
and O +
evaluation O +
of O +
potential O +
inhibitors O +
for O +
VEGFR O +
- O +
2 O +
kinase O +
. O +

We O +
screened O +
200 O +
RTK O +
target O +
- O +
based O +
compounds O +
and O +
identified O +
one O +
( O +
TKI O +
- O +
31 O +
) O +
that O +
potently O +
inhibited O +
VEGFR O +
- O +
2 O +
kinase O +
activity O +
( O +
IC50 O +
= O +
0 O +
. O +
596 O +
microM O +
) O +
. O +

Treatment O +
of O +
NIH3T3 B-CellLine +
/ O +
KDR O +
cells O +
with O +
TKI O +
- O +
31 O +
blocked O +
VEGF O +
- O +
induced O +
phosphorylation O +
of O +
KDR O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
. O +

Moreover O +
, O +
TKI O +
- O +
31 O +
dose O +
- O +
dependently O +
suppressed O +
HUVEC O +
tube O +
formation O +
. O +

Thus O +
, O +
we O +
herein O +
report O +
a O +
novel O +
, O +
efficient O +
method O +
for O +
identifying O +
VEGFR O +
- O +
2 O +
kinase O +
inhibitors O +
and O +
introduce O +
one O +
, O +
TKI O +
- O +
31 O +
, O +
that O +
may O +
prove O +
to O +
be O +
a O +
useful O +
new O +
angiogenesis O +
inhibitor O +
. O +

An O +
evaluation O +
of O +
low O +
molecular O +
weight O +
heparin O +
and O +
hyperbaric O +
oxygen O +
treatment O +
in O +
the O +
prevention O +
of O +
intra O +
- O +
abdominal O +
adhesions O +
and O +
wound O +
healing O +
. O +

BACKGROUND O +
: O +
Abdominal O +
surgery O +
can O +
lead O +
to O +
intra O +
- O +
abdominal O +
adhesions O +
with O +
significant O +
morbidity O +
and O +
mortality O +
. O +

To O +
prevent O +
adhesions O +
, O +
an O +
experimental O +
study O +
was O +
planned O +
to O +
designate O +
the O +
effects O +
of O +
low O +
molecular O +
weight O +
( O +
LMW O +
) O +
heparins O +
and O +
hyperbaric O +
oxygen O +
( O +
HBO O +
) O +
therapy O +
both O +
on O +
the O +
formation O +
of O +
adhesions O +
and O +
wound O +
healing O +
. O +

METHODS O +
: O +
Thirty O +
- O +
eight O +
Wistar O +
albino O +
rats O +
underwent O +
laparotomy O +
to O +
cause O +
intra O +
- O +
abdominal O +
adhesions O +
by O +
mechanical O +
abrasion O +
of O +
the O +
cecum O +
and O +
ethanol O +
application O +
. O +

The O +
rats O +
were O +
divided O +
into O +
4 O +
groups O +
. O +

In O +
the O +
control O +
group O +
( O +
group O +
1 O +
) O +
no O +
further O +
management O +
was O +
undertaken O +
. O +

Group O +
2 O +
was O +
treated O +
by O +
Enoxaparine O +
Na O +
, O +
group O +
3 O +
received O +
HBO O +
therapy O +
, O +
and O +
group O +
4 O +
was O +
given O +
both O +
enoxaparine O +
Na O +
and O +
HBO O +
treatment O +
. O +

RESULTS O +
: O +
There O +
was O +
a O +
statistically O +
significant O +
difference O +
between O +
the O +
control O +
and O +
enoxaparine O +
Na O +
groups O +
regarding O +
adhesions O +
. O +

Statistically O +
significant O +
differences O +
were O +
observed O +
between O +
groups O +
1 O +
and O +
4 O +
and O +
between O +
groups O +
1 O +
and O +
3 O +
regarding O +
the O +
hydroxyproline O +
content O +
of O +
the O +
abdominal O +
wounds O +
. O +

In O +
the O +
pathologic O +
analysis O +
of O +
the O +
abdominal O +
wounds O +
, O +
there O +
was O +
no O +
statistically O +
significant O +
difference O +
between O +
any O +
of O +
the O +
groups O +
, O +
including O +
the O +
control O +
group O +
, O +
regarding O +
inflammation O +
. O +

Statistically O +
significant O +
differences O +
were O +
observed O +
regarding O +
angiogenesis O +
between O +
the O +
control O +
group O +
and O +
groups O +
3 O +
and O +
4 O +
. O +

There O +
was O +
also O +
a O +
statistically O +
significant O +
difference O +
regarding O +
fibrosis O +
between O +
groups O +
1 O +
and O +
4 O +
. O +

CONCLUSIONS O +
: O +
Enoxaparine O +
Na O +
decreased O +
intra O +
- O +
abdominal O +
adhesions O +
, O +
and O +
HBO O +
therapy O +
had O +
no O +
beneficial O +
effect O +
on O +
adhesions O +
. O +

Enoxaparine O +
Na O +
had O +
no O +
harmful O +
effects O +
on O +
wound O +
healing O +
, O +
and O +
HBO O +
therapy O +
increased O +
the O +
process O +
of O +
wound O +
healing O +
. O +

Novel O +
biological O +
agents O +
for O +
the O +
treatment O +
of O +
hormone O +
- O +
refractory O +
prostate O +
cancer O +
( O +
HRPC O +
) O +
. O +

Hormone O +
- O +
refractory O +
prostate O +
cancer O +
( O +
HRPC O +
) O +
is O +
an O +
inevitable O +
evolution O +
of O +
prostate O +
carcinogenesis O +
, O +
through O +
which O +
the O +
normal O +
dependence O +
on O +
hormones O +
for O +
growth O +
and O +
survival O +
is O +
bypassed O +
. O +

Although O +
advances O +
in O +
terms O +
of O +
symptoms O +
palliation O +
and O +
quality O +
of O +
life O +
improvement O +
have O +
been O +
addressed O +
with O +
current O +
treatment O +
options O +
, O +
innovative O +
approaches O +
are O +
needed O +
to O +
improve O +
survival O +
rates O +
. O +

A O +
thorough O +
understanding O +
of O +
HRPC O +
- O +
associated O +
molecular O +
pathways O +
and O +
mechanisms O +
of O +
resistance O +
are O +
a O +
prerequisite O +
for O +
novel O +
potential O +
therapeutic O +
interventions O +
. O +

Preclinical O +
and O +
early O +
clinical O +
studies O +
are O +
ongoing O +
to O +
evaluate O +
new O +
therapies O +
that O +
target O +
specific O +
molecular O +
entities O +
. O +

Agents O +
under O +
development O +
include O +
growth O +
factor O +
receptor O +
inhibitors O +
, O +
small O +
molecules O +
targeting O +
signal O +
transduction O +
pathways O +
, O +
apoptosis O +
and O +
cell O +
- O +
cycle O +
regulators O +
, O +
angiogenesis O +
and O +
metastasis O +
inhibitors O +
, O +
differentiation O +
agents O +
, O +
telomerase O +
inactivators O +
, O +
and O +
epigenetic O +
therapeutics O +
. O +

Incorporation O +
of O +
these O +
agents O +
into O +
existing O +
treatment O +
regimens O +
will O +
guide O +
us O +
in O +
the O +
development O +
of O +
a O +
multidisciplinary O +
treatment O +
strategy O +
of O +
HRPC O +
. O +

This O +
article O +
critically O +
reviews O +
published O +
data O +
on O +
new O +
biological O +
agents O +
that O +
are O +
being O +
tested O +
in O +
HRPC O +
clinical O +
trials O +
, O +
highlights O +
ongoing O +
research O +
and O +
considers O +
the O +
future O +
perspectives O +
of O +
this O +
new O +
class O +
of O +
agents O +
. O +

Role O +
of O +
thrombogenic O +
factors O +
in O +
the O +
development O +
of O +
atherosclerosis O +
. O +

Hemostatic O +
factors O +
play O +
a O +
crucial O +
role O +
in O +
generating O +
thrombotic O +
plugs O +
at O +
sites O +
of O +
vascular O +
damage O +
( O +
atherothrombosis O +
) O +
. O +

However O +
, O +
whether O +
hemostatic O +
factors O +
contribute O +
directly O +
or O +
indirectly O +
to O +
the O +
pathogenesis O +
of O +
atherosclerosis O +
remains O +
uncertain O +
. O +

Autopsy O +
studies O +
have O +
revealed O +
that O +
intimal O +
thickening O +
represents O +
the O +
first O +
stage O +
of O +
atherosclerosis O +
and O +
that O +
lipid O +
- O +
rich O +
plaque O +
arises O +
from O +
such O +
lesions O +
. O +

Several O +
factors O +
contribute O +
to O +
the O +
start O +
of O +
intimal O +
thickening O +
. O +

Platelets O +
release O +
several O +
growth O +
factors O +
and O +
bioactive O +
agents O +
that O +
play O +
a O +
central O +
role O +
in O +
development O +
of O +
not O +
only O +
thrombus O +
but O +
also O +
of O +
intimal O +
thickening O +
. O +

We O +
have O +
been O +
investigating O +
which O +
coagulation O +
factors O +
simultaneously O +
, O +
or O +
subsequently O +
with O +
platelet O +
aggregation O +
, O +
participate O +
in O +
thrombus O +
formation O +
. O +

Tissue O +
factor O +
( O +
TF O +
) O +
is O +
an O +
essential O +
initiator O +
of O +
blood O +
coagulation O +
that O +
is O +
expressed O +
in O +
various O +
stages O +
of O +
atherosclerotic O +
lesions O +
in O +
humans O +
and O +
other O +
animals O +
. O +

Factors O +
including O +
thrombin O +
and O +
fibrin O +
, O +
which O +
are O +
downstream O +
of O +
the O +
coagulation O +
cascade O +
activated O +
by O +
TF O +
, O +
also O +
contribute O +
to O +
atherosclerosis O +
. O +

TF O +
is O +
involved O +
in O +
cell O +
migration O +
, O +
embryogenesis O +
and O +
angiogenesis O +
. O +

Thus O +
TF O +
, O +
in O +
addition O +
to O +
factors O +
downstream O +
of O +
the O +
coagulation O +
cascade O +
and O +
the O +
protease O +
- O +
activated O +
receptor O +
2 O +
activation O +
system O +
, O +
would O +
be O +
a O +
multifactorial O +
regulator O +
of O +
atherogenesis O +
. O +

Investigating O +
the O +
causes O +
of O +
low O +
birth O +
weight O +
in O +
contrasting O +
ovine O +
paradigms O +
. O +

Intrauterine O +
growth O +
restriction O +
( O +
IUGR O +
) O +
still O +
accounts O +
for O +
a O +
large O +
incidence O +
of O +
infant O +
mortality O +
and O +
morbidity O +
worldwide O +
. O +

Many O +
of O +
the O +
circulatory O +
and O +
transport O +
properties O +
of O +
the O +
sheep O +
placenta O +
are O +
similar O +
to O +
those O +
of O +
the O +
human O +
placenta O +
and O +
as O +
such O +
, O +
the O +
pregnant O +
sheep O +
offers O +
an O +
excellent O +
model O +
in O +
which O +
to O +
study O +
the O +
development O +
of O +
IUGR O +
. O +

Two O +
natural O +
models O +
of O +
ovine O +
IUGR O +
are O +
those O +
of O +
hyperthermic O +
exposure O +
during O +
pregnancy O +
, O +
and O +
adolescent O +
overfeeding O +
, O +
also O +
during O +
pregnancy O +
. O +

Both O +
models O +
yield O +
significantly O +
reduced O +
placental O +
weights O +
and O +
an O +
asymmetrically O +
growth O +
- O +
restricted O +
fetus O +
, O +
and O +
display O +
altered O +
maternal O +
hormone O +
concentrations O +
, O +
indicative O +
of O +
an O +
impaired O +
trophoblast O +
capacity O +
. O +

Additionally O +
, O +
impaired O +
placental O +
angiogenesis O +
and O +
uteroplacental O +
blood O +
flow O +
appears O +
to O +
be O +
an O +
early O +
defect O +
in O +
both O +
the O +
hyperthermic O +
and O +
adolescent O +
paradigms O +
. O +

The O +
effects O +
of O +
these O +
alterations O +
in O +
placental O +
functional O +
development O +
appear O +
to O +
be O +
irreversible O +
. O +

IUGR O +
fetuses O +
are O +
both O +
hypoxic O +
and O +
hypoglycaemic O +
, O +
and O +
have O +
reduced O +
insulin O +
and O +
insulin O +
- O +
like O +
growth O +
factor O +
- O +
1 O +
( O +
IGF O +
- O +
1 O +
) O +
, O +
and O +
elevated O +
concentrations O +
of O +
lactate O +
. O +

However O +
, O +
fetal O +
utilization O +
of O +
oxygen O +
and O +
glucose O +
, O +
on O +
a O +
weight O +
basis O +
, O +
remain O +
constant O +
compared O +
with O +
control O +
pregnancies O +
. O +

Maintained O +
utilization O +
of O +
these O +
substrates O +
, O +
in O +
a O +
substrate O +
- O +
deficient O +
environment O +
, O +
suggests O +
increased O +
sensitivities O +
to O +
metabolic O +
signals O +
, O +
which O +
may O +
play O +
a O +
role O +
in O +
the O +
development O +
of O +
metabolic O +
diseases O +
in O +
later O +
adult O +
life O +
. O +

Angiogenin O +
is O +
up O +
- O +
regulated O +
in O +
the O +
nucleus O +
and O +
cytoplasm O +
in O +
human O +
primary O +
breast O +
carcinoma O +
and O +
is O +
associated O +
with O +
markers O +
of O +
hypoxia O +
but O +
not O +
survival O +
. O +

Angiogenin O +
, O +
a O +
14 O +
. O +
2 O +
kD O +
polypeptide O +
that O +
was O +
originally O +
noted O +
for O +
its O +
angiogenic O +
activity O +
, O +
is O +
now O +
increasingly O +
recognized O +
to O +
have O +
a O +
multiplicity O +
of O +
biological O +
roles O +
in O +
both O +
physiological O +
and O +
pathological O +
conditions O +
. O +

In O +
breast O +
cancer O +
, O +
there O +
are O +
conflicting O +
studies O +
questioning O +
the O +
role O +
of O +
angiogenin O +
. O +

Here O +
, O +
the O +
pattern O +
of O +
expression O +
of O +
angiogenin O +
during O +
the O +
transition O +
from O +
normal O +
breast O +
tissue O +
to O +
ductal O +
carcinoma O +
in O +
situ O +
and O +
invasive O +
carcinoma O +
is O +
reported O +
together O +
with O +
the O +
correlates O +
between O +
the O +
level O +
of O +
angiogenin O +
in O +
239 O +
invasive O +
carcinomas O +
and O +
standard O +
clinicopathological O +
parameters O +
, O +
hypoxia O +
- O +
inducible O +
factor O +
( O +
HIF O +
) O +
- O +
1 O +
alpha O +
and O +
the O +
HIF O +
- O +
1 O +
alpha O +
target O +
gene O +
DEC O +
- O +
1 O +
. O +

This O +
study O +
shows O +
that O +
angiogenin O +
expression O +
is O +
up O +
- O +
regulated O +
in O +
the O +
cytoplasmic O +
and O +
nuclear O +
compartments O +
in O +
in O +
situ O +
carcinoma O +
and O +
invasive O +
carcinoma O +
compared O +
with O +
normal O +
breast O +
tissue O +
and O +
that O +
angiogenin O +
expression O +
in O +
invasive O +
carcinomas O +
is O +
significantly O +
positively O +
associated O +
with O +
high O +
tumour O +
grade O +
( O +
p O +
= O +
0 O +
. O +
03 O +
) O +
, O +
positive O +
oestrogen O +
receptor O +
( O +
ER O +
) O +
status O +
( O +
p O +
= O +
0 O +
. O +
01 O +
) O +
, O +
HIF O +
- O +
1 O +
alpha O +
( O +
p O +
= O +
0 O +
. O +
001 O +
) O +
and O +
DEC O +
1 O +
( O +
p O +
= O +
0 O +
. O +
001 O +
) O +
, O +
but O +
not O +
with O +
patient O +
age O +
( O +
p O +
= O +
0 O +
. O +
8 O +
) O +
, O +
tumour O +
size O +
( O +
p O +
= O +
0 O +
. O +
25 O +
) O +
, O +
lymph O +
node O +
status O +
( O +
p O +
= O +
0 O +
. O +
69 O +
) O +
, O +
epidermal O +
growth O +
factor O +
receptor O +
( O +
p O +
= O +
0 O +
. O +
56 O +
) O +
or O +
microvessel O +
density O +
( O +
p O +
= O +
0 O +
. O +
32 O +
) O +
. O +

No O +
difference O +
in O +
relapse O +
- O +
free O +
( O +
p O +
= O +
0 O +
. O +
26 O +
) O +
or O +
overall O +
( O +
p O +
= O +
0 O +
. O +
63 O +
) O +
survival O +
was O +
observed O +
in O +
patients O +
stratified O +
by O +
angiogenin O +
expression O +
. O +

This O +
study O +
suggests O +
that O +
angiogenin O +
may O +
be O +
important O +
in O +
breast O +
cancer O +
progression O +
and O +
that O +
, O +
through O +
its O +
relationship O +
with O +
ER O +
, O +
it O +
may O +
be O +
a O +
target O +
for O +
tamoxifen O +
. O +

Hereditary O +
paraganglioma O +
/ O +
pheochromocytoma O +
and O +
inherited O +
succinate O +
dehydrogenase O +
deficiency O +
. O +

Mitochondrial O +
complex O +
II O +
, O +
or O +
succinate O +
dehydrogenase O +
, O +
is O +
a O +
key O +
enzymatic O +
complex O +
involved O +
in O +
both O +
the O +
tricarboxylic O +
acid O +
( O +
TCA O +
) O +
cycle O +
and O +
oxidative O +
phosphorylation O +
as O +
part O +
of O +
the O +
mitochondrial O +
respiratory O +
chain O +
. O +

Germline O +
succinate O +
dehydrogenase O +
subunit O +
A O +
( O +
SDHA O +
) O +
mutations O +
have O +
been O +
reported O +
in O +
a O +
few O +
patients O +
with O +
a O +
classical O +
mitochondrial O +
neurodegenerative O +
disease O +
. O +

Mutations O +
in O +
the O +
genes O +
encoding O +
the O +
three O +
other O +
succinate O +
dehydrogenase O +
subunits O +
( O +
SDHB O +
, O +
SDHC O +
and O +
SDHD O +
) O +
have O +
been O +
identified O +
in O +
patients O +
affected O +
by O +
familial O +
or O +
' O +
apparently O +
sporadic O +
' O +
paraganglioma O +
and O +
/ O +
or O +
pheochromocytoma O +
, O +
an O +
autosomal O +
inherited O +
cancer O +
- O +
susceptibility O +
syndrome O +
. O +

These O +
discoveries O +
have O +
dramatically O +
changed O +
the O +
work O +
- O +
up O +
and O +
genetic O +
counseling O +
of O +
patients O +
and O +
families O +
with O +
paragangliomas O +
and O +
/ O +
or O +
pheochromocytomas O +
. O +

The O +
subsequent O +
identification O +
of O +
germline O +
mutations O +
in O +
the O +
gene O +
encoding O +
fumarase O +
- O +
- O +
another O +
TCA O +
cycle O +
enzyme O +
- O +
- O +
in O +
a O +
new O +
hereditary O +
form O +
of O +
susceptibility O +
to O +
renal O +
, O +
uterine O +
and O +
cutaneous O +
tumors O +
has O +
highlighted O +
the O +
potential O +
role O +
of O +
the O +
TCA O +
cycle O +
and O +
, O +
more O +
generally O +
, O +
of O +
the O +
mitochondria O +
in O +
cancer O +
. O +

[ O +
Uncommon O +
etiology O +
of O +
gastrointestinal O +
bleeding O +
: O +
duodenal O +
metastases O +
from O +
renal O +
cell O +
carcinoma O +
] O +
. O +

Because O +
of O +
its O +
unpredictable O +
behavior O +
, O +
renal O +
cell O +
carcinoma O +
is O +
one O +
of O +
the O +
most O +
controversial O +
neoplasms O +
. O +

On O +
the O +
one O +
hand O +
, O +
patients O +
frequently O +
show O +
metastases O +
at O +
diagnosis O +
because O +
of O +
its O +
slight O +
manifestations O +
, O +
while O +
on O +
the O +
other O +
, O +
the O +
neoplasm O +
can O +
remain O +
stable O +
after O +
nephrectomy O +
and O +
can O +
then O +
metastasize O +
many O +
years O +
later O +
. O +

When O +
this O +
happens O +
, O +
the O +
metastases O +
usually O +
involve O +
more O +
than O +
2 O +
organs O +
. O +

The O +
most O +
frequent O +
sites O +
of O +
metastases O +
are O +
the O +
lung O +
and O +
lymph O +
nodes O +
, O +
followed O +
by O +
the O +
bones O +
and O +
liver O +
, O +
while O +
duodenal O +
involvement O +
is O +
rare O +
. O +

Indeed O +
, O +
intestinal O +
metastases O +
are O +
found O +
in O +
only O +
2 O +
% O +
of O +
autopsies O +
and O +
of O +
these O +
, O +
renal O +
cell O +
carcinoma O +
metastases O +
account O +
for O +
7 O +
. O +
1 O +
% O +
. O +

We O +
present O +
a O +
case O +
of O +
a O +
solitary O +
late O +
recurrence O +
presenting O +
as O +
upper O +
gastrointestinal O +
bleeding O +
19 O +
years O +
after O +
nephrectomy O +
for O +
clear O +
cell O +
renal O +
carcinoma O +
. O +

Mouse O +
p10 O +
, O +
an O +
alternative O +
spliced O +
form O +
of O +
p15INK4b O +
, O +
inhibits O +
cell O +
cycle O +
progression O +
and O +
malignant O +
transformation O +
. O +

The O +
INK4 O +
family O +
of O +
proteins O +
negatively O +
regulates O +
cell O +
cycle O +
progression O +
at O +
the O +
G O +
( O +
1 O +
) O +
- O +
S O +
transition O +
by O +
inhibiting O +
cyclin O +
- O +
dependent O +
kinases O +
. O +

Two O +
of O +
these O +
cell O +
cycle O +
inhibitors O +
, O +
p16 O +
( O +
INK4A O +
) O +
and O +
p15 O +
( O +
INK4B O +
) O +
, O +
have O +
tumor O +
suppressor O +
activities O +
and O +
are O +
inactivated O +
in O +
human O +
cancer O +
. O +

Interestingly O +
, O +
both O +
INK4 O +
genes O +
express O +
alternative O +
splicing O +
variants O +
. O +

In O +
addition O +
to O +
p16 O +
( O +
INK4A O +
) O +
, O +
the O +
INK4A O +
locus O +
encodes O +
a O +
splice O +
variant O +
, O +
termed O +
p12 O +
- O +
- O +
specifically O +
expressed O +
in O +
human O +
pancreas O +
- O +
- O +
and O +
ARF O +
, O +
a O +
protein O +
encoded O +
by O +
an O +
alternative O +
reading O +
frame O +
that O +
acts O +
as O +
a O +
tumor O +
suppressor O +
through O +
the O +
p53 O +
pathway O +
. O +

Similarly O +
, O +
the O +
human O +
INK4B O +
locus O +
encodes O +
the O +
p15 O +
( O +
INK4B O +
) O +
tumor O +
suppressor O +
and O +
one O +
alternatively O +
spliced O +
form O +
, O +
termed O +
as O +
p10 O +
. O +

We O +
show O +
here O +
that O +
p10 O +
, O +
which O +
arises O +
from O +
the O +
use O +
of O +
an O +
alternative O +
splice O +
donor O +
site O +
within O +
intron O +
1 O +
, O +
is O +
conserved O +
in O +
the O +
mouse O +
genome O +
and O +
is O +
widely O +
expressed O +
in O +
mouse O +
tissues O +
. O +

Similarly O +
to O +
mouse O +
p15 O +
( O +
INK4B O +
) O +
, O +
p10 O +
expression O +
is O +
also O +
induced O +
by O +
oncogenic O +
insults O +
and O +
transforming O +
growth O +
factor O +
- O +
beta O +
treatment O +
and O +
acts O +
as O +
a O +
cell O +
cycle O +
inhibitor O +
. O +

Importantly O +
, O +
we O +
show O +
that O +
mouse O +
p10 O +
is O +
able O +
to O +
induce O +
cell O +
cycle O +
arrest O +
in O +
a O +
p53 O +
- O +
dependent O +
manner O +
. O +

We O +
also O +
show O +
that O +
mouse O +
p10 O +
is O +
able O +
to O +
inhibit O +
foci O +
formation O +
and O +
anchorage O +
- O +
independent O +
growth O +
in O +
wild O +
- O +
type O +
mouse O +
embryonic O +
fibroblasts O +
, O +
and O +
that O +
these O +
antitransforming O +
properties O +
of O +
mouse O +
p10 O +
are O +
also O +
p53 O +
- O +
dependent O +
. O +

These O +
results O +
indicate O +
that O +
the O +
INK4B O +
locus O +
, O +
similarly O +
to O +
INK4A O +
- O +
ARF O +
, O +
harbors O +
two O +
different O +
splicing O +
variants O +
that O +
can O +
be O +
involved O +
in O +
the O +
regulation O +
of O +
both O +
the O +
p53 O +
and O +
retinoblastoma O +
pathways O +
, O +
the O +
two O +
major O +
molecular O +
pathways O +
in O +
tumor O +
suppression O +
. O +

p53 O +
mutation O +
heterogeneity O +
in O +
cancer O +
. O +

The O +
p53 O +
gene O +
is O +
inactivated O +
in O +
about O +
50 O +
% O +
of O +
human O +
cancers O +
and O +
the O +
p53 O +
protein O +
is O +
an O +
essential O +
component O +
of O +
the O +
cell O +
response O +
induced O +
by O +
genotoxic O +
stresses O +
such O +
as O +
those O +
generated O +
by O +
radiotherapy O +
or O +
chemotherapy O +
. O +

It O +
is O +
therefore O +
highly O +
likely O +
that O +
these O +
alterations O +
are O +
an O +
important O +
component O +
in O +
tumor O +
resistance O +
to O +
therapy O +
. O +

The O +
particular O +
characteristics O +
of O +
these O +
alterations O +
, O +
80 O +
% O +
of O +
which O +
are O +
missense O +
mutations O +
leading O +
to O +
functionally O +
heterogeneous O +
proteins O +
, O +
make O +
p53 O +
a O +
unique O +
gene O +
in O +
the O +
class O +
of O +
tumor O +
suppressor O +
genes O +
. O +

A O +
considerable O +
number O +
of O +
mutant O +
p53 O +
proteins O +
probably O +
have O +
an O +
oncogenic O +
activity O +
per O +
se O +
and O +
therefore O +
actively O +
participate O +
in O +
cell O +
transformation O +
. O +

The O +
fact O +
that O +
the O +
apoptotic O +
and O +
antiproliferative O +
functions O +
of O +
p53 O +
can O +
be O +
dissociated O +
in O +
certain O +
mutants O +
also O +
suggests O +
another O +
level O +
of O +
complexity O +
in O +
the O +
relationships O +
between O +
p53 O +
inactivation O +
and O +
neoplasia O +
. O +

Rofecoxib O +
as O +
adjunctive O +
therapy O +
for O +
haemophilic O +
arthropathy O +
. O +

Joint O +
haemorrhage O +
and O +
subsequent O +
haemophilic O +
arthropathy O +
are O +
significant O +
complications O +
in O +
haemophilia O +
. O +

The O +
pathophysiology O +
involves O +
inflammation O +
and O +
angiogenesis O +
. O +

Cyclooxygenase O +
- O +
2 O +
( O +
COX O +
- O +
2 O +
) O +
inhibitors O +
are O +
anti O +
- O +
inflammatory O +
agents O +
, O +
which O +
have O +
potent O +
anti O +
- O +
inflammatory O +
, O +
anti O +
- O +
angiogenic O +
and O +
analgesic O +
properties O +
yet O +
do O +
not O +
affect O +
platelet O +
function O +
in O +
the O +
manner O +
of O +
traditional O +
non O +
- O +
steroidal O +
anti O +
- O +
inflammatory O +
drugs O +
. O +

These O +
properties O +
make O +
such O +
agents O +
potentially O +
useful O +
as O +
adjunctive O +
therapy O +
in O +
haemophilia O +
. O +

There O +
is O +
only O +
one O +
prior O +
report O +
describing O +
rofecoxib O +
treatment O +
in O +
a O +
single O +
haemophilia O +
patient O +
. O +

Our O +
objectives O +
were O +
to O +
determine O +
the O +
safety O +
and O +
efficacy O +
of O +
rofecoxib O +
in O +
treating O +
acute O +
haemarthrosis O +
, O +
chronic O +
synovitis O +
, O +
target O +
joints O +
and O +
pain O +
. O +

We O +
conducted O +
a O +
retrospective O +
medical O +
record O +
review O +
of O +
patients O +
treated O +
with O +
rofecoxib O +
for O +
acute O +
haemarthrosis O +
, O +
chronic O +
synovitis O +
, O +
target O +
joint O +
or O +
pain O +
. O +

The O +
safety O +
and O +
efficacy O +
of O +
rofecoxib O +
treatment O +
were O +
determined O +
based O +
on O +
subjective O +
patient O +
reports O +
and O +
physical O +
examinations O +
during O +
follow O +
- O +
up O +
clinic O +
visits O +
. O +

A O +
total O +
of O +
28 O +
patients O +
between O +
3 O +
and O +
37 O +
years O +
of O +
age O +
were O +
treated O +
for O +
a O +
total O +
of O +
42 O +
courses O +
of O +
rofecoxib O +
treatment O +
. O +

All O +
courses O +
were O +
evaluated O +
for O +
safety O +
and O +
31 O +
for O +
efficacy O +
. O +

Rofecoxib O +
was O +
used O +
for O +
eight O +
acute O +
haemarthrosis O +
, O +
four O +
target O +
joints O +
, O +
seven O +
cases O +
of O +
synovitis O +
and O +
12 O +
episodes O +
of O +
pain O +
. O +

Efficacy O +
was O +
demonstrated O +
particularly O +
for O +
chronic O +
synovitis O +
and O +
pain O +
and O +
no O +
serious O +
adverse O +
events O +
occurred O +
. O +

This O +
is O +
the O +
largest O +
study O +
to O +
date O +
evaluating O +
COX O +
- O +
2 O +
inhibitors O +
as O +
adjunctive O +
therapy O +
in O +
haemophilia O +
and O +
suggests O +
that O +
these O +
agents O +
may O +
be O +
an O +
important O +
adjunctive O +
therapy O +
in O +
the O +
management O +
of O +
haemophilia O +
. O +

Sox9 O +
neural O +
crest O +
determinant O +
gene O +
controls O +
patterning O +
and O +
closure O +
of O +
the O +
posterior O +
frontal O +
cranial O +
suture O +
. O +

Cranial O +
suture O +
development O +
involves O +
a O +
complex O +
interaction O +
of O +
genes O +
and O +
tissues O +
derived O +
from O +
neural O +
crest O +
cells O +
( O +
NCC O +
) O +
and O +
paraxial O +
mesoderm O +
. O +

In O +
mice O +
, O +
the O +
posterior O +
frontal O +
( O +
PF O +
) O +
suture O +
closes O +
during O +
the O +
first O +
month O +
of O +
life O +
while O +
other O +
sutures O +
remain O +
patent O +
throughout O +
the O +
life O +
of O +
the O +
animal O +
. O +

Given O +
the O +
unique O +
NCC O +
origin O +
of O +
PF O +
suture O +
complex O +
( O +
analogous O +
to O +
metopic O +
suture O +
in O +
humans O +
) O +
, O +
we O +
performed O +
quantitative O +
real O +
- O +
time O +
PCR O +
and O +
immunohistochemistry O +
to O +
study O +
the O +
expression O +
pattern O +
of O +
the O +
NCC O +
determinant O +
gene O +
Sox9 O +
and O +
select O +
markers O +
of O +
extracellular O +
matrix O +
. O +

Our O +
results O +
indicated O +
a O +
unique O +
up O +
- O +
regulated O +
expression O +
of O +
Sox9 O +
, O +
a O +
regulator O +
of O +
chondrogenesis O +
, O +
during O +
initiation O +
of O +
PF O +
suture O +
closure O +
, O +
along O +
with O +
the O +
expression O +
of O +
specific O +
cartilage O +
markers O +
( O +
Type O +
II O +
Collagen O +
and O +
Type O +
X O +
Collagen O +
) O +
, O +
as O +
well O +
as O +
cartilage O +
tissue O +
formation O +
in O +
the O +
PF O +
suture O +
. O +

This O +
process O +
was O +
followed O +
by O +
expression O +
of O +
bone O +
markers O +
( O +
Type O +
I O +
Collagen O +
and O +
Osteocalcin O +
) O +
, O +
suggesting O +
endochondral O +
ossification O +
. O +

Moreover O +
, O +
we O +
studied O +
the O +
effect O +
of O +
haploinsufficiency O +
of O +
the O +
NCC O +
determinant O +
gene O +
Sox9 O +
in O +
the O +
NCC O +
derived O +
PF O +
suture O +
complex O +
. O +

A O +
decrease O +
in O +
dosage O +
of O +
Sox9 O +
by O +
haploinsufficiency O +
in O +
NCC O +
- O +
derived O +
tissues O +
resulted O +
in O +
delayed O +
PF O +
suture O +
closure O +
. O +

These O +
results O +
demonstrate O +
a O +
unique O +
development O +
of O +
the O +
PF O +
suture O +
complex O +
and O +
the O +
role O +
of O +
Sox9 O +
as O +
an O +
important O +
contributor O +
to O +
timely O +
and O +
proper O +
closure O +
of O +
the O +
PF O +
suture O +
through O +
endochondral O +
ossification O +
. O +

Bcl O +
- O +
2 O +
decreases O +
cell O +
proliferation O +
and O +
promotes O +
accumulation O +
of O +
cells O +
in O +
S O +
phase O +
without O +
affecting O +
the O +
rate O +
of O +
apoptosis O +
in O +
human O +
ovarian O +
carcinoma O +
cells O +
. O +

OBJECTIVES O +
: O +

The O +
Bcl O +
- O +
2 O +
protein O +
is O +
an O +
important O +
regulator O +
of O +
the O +
apoptotic O +
cascade O +
and O +
promotes O +
cell O +
survival O +
. O +

Bcl O +
- O +
2 O +
can O +
also O +
delay O +
entry O +
into O +
the O +
cell O +
cycle O +
from O +
quiescence O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
used O +
two O +
isogenic O +
human O +
ovarian O +
carcinoma O +
cell O +
lines O +
, O +
which O +
expressed O +
differential O +
levels O +
of O +
Bcl O +
- O +
2 O +
proteins O +
, O +
to O +
demonstrate O +
that O +
Bcl O +
- O +
2 O +
may O +
regulate O +
the O +
growth O +
rates O +
of O +
adenocarcinoma O +
cells O +
. O +

METHODS O +
: O +

The O +
growth O +
rates O +
of O +
two O +
isogenic O +
ovarian O +
cancer O +
cell O +
lines O +
were O +
determined O +
by O +
XTT O +
assays O +
and O +
flow O +
cytometry O +
combined O +
with O +
PI O +
staining O +
. O +

Bcl O +
- O +
2 O +
- O +
overexpressing O +
SKOV3 B-CellLine +
cells O +
were O +
modified O +
to O +
express O +
a O +
doxycycline O +
- O +
inducible O +
anti O +
- O +
Bcl O +
- O +
2 O +
single O +
- O +
chain O +
antibody O +
and O +
the O +
effects O +
of O +
Bcl O +
- O +
2 O +
protein O +
inhibition O +
on O +
cell O +
proliferation O +
and O +
apoptosis O +
were O +
assessed O +
. O +

RESULTS O +
: O +

We O +
demonstrate O +
that O +
Bcl O +
- O +
2 O +
promotes O +
the O +
accumulation O +
of O +
proliferating O +
carcinoma O +
cells O +
in O +
S O +
phase O +
. O +

The O +
Bcl O +
- O +
2 O +
- O +
overexpressing O +
SKOV3 B-CellLine +
cell O +
line O +
proliferates O +
markedly O +
faster O +
and O +
shows O +
delayed O +
progression O +
to O +
G2 O -
M O +
phase O +
compared O +
to O +
its O +
low O +
Bcl O +
- O +
2 O +
- O +
expressing O +
counterpart O +
SKOV3 B-CellLine +
. I-CellLine +
ip1 I-CellLine +
cell O +
line O +
. O +

Single O +
- O +
chain O +
antibody O +
- O +
mediated O +
inhibition O +
of O +
Bcl O +
- O +
2 O +
in O +
SKOV3 B-CellLine +
cells O +
was O +
associated O +
with O +
increased O +
growth O +
rates O +
and O +
more O +
rapid O +
cell O +
cycle O +
progression O +
. O +

Treatment O +
with O +
cisplatin O +
resulted O +
in O +
more O +
cells O +
accumulating O +
in O +
S O +
phase O +
in O +
Bcl O +
- O +
2 O +
- O +
overexpressing O +
SKOV3 B-CellLine +
cells O +
, O +
while O +
the O +
inhibition O +
of O +
Bcl O +
- O +
2 O +
abolished O +
delayed O +
entry O +
into O +
G2 O -
M O +
phase O +
without O +
affecting O +
cisplatin O +
- O +
induced O +
apoptosis O +
. O +

CONCLUSIONS O +
: O +

Our O +
results O +
suggest O +
that O +
, O +
in O +
ovarian O +
cancer O +
cells O +
, O +
Bcl O +
- O +
2 O +
delays O +
cell O +
cycle O +
progression O +
by O +
promoting O +
accumulation O +
of O +
cells O +
in O +
S O +
phase O +
without O +
affecting O +
the O +
rate O +
of O +
apoptosis O +
. O +

Thus O +
, O +
in O +
addition O +
to O +
its O +
known O +
role O +
at O +
the O +
G0 O +
/ O +
G1 O +
checkpoint O +
, O +
we O +
demonstrate O +
for O +
the O +
first O +
time O +
that O +
Bcl O +
- O +
2 O +
also O +
regulates O +
the O +
S O +
phase O +
. O +

Treatment O +
of O +
transplanted O +
CT26 B-CellLine +
tumour O +
with O +
dendritic O +
cell O +
vaccine O +
in O +
combination O +
with O +
blockade O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
2 O +
and O +
CTLA O +
- O +
4 O +
. O +

We O +
investigated O +
the O +
anti O +
CT26 B-CellLine +
tumour O +
effect O +
of O +
dendritic O +
cell O +
based O +
vaccination O +
with O +
the O +
MuLV O +
gp70 O +
envelope O +
protein O +
- O +
derived O +
peptides O +
AH1 O +
and O +
p320 O +
- O +
333 O +
. O +

Vaccination O +
lead O +
to O +
generation O +
of O +
AH1 O +
specific O +
cytotoxic O +
lymphocytes O +
( O +
CTL O +
) O +
and O +
some O +
decrease O +
in O +
tumour O +
growth O +
of O +
simultaneously O +
inoculated O +
CT26 B-CellLine +
cells O +
. O +

After O +
combination O +
with O +
an O +
antibody O +
against O +
VEGF O +
receptor O +
2 O +
( O +
DC101 O +
) O +
, O +
a O +
significant O +
increase O +
in O +
survival O +
of O +
the O +
tumour O +
cell O +
recipients O +
was O +
observed O +
. O +

Also O +
, O +
monotherapy O +
with O +
an O +
antibody O +
against O +
CTLA O +
- O +
4 O +
( O +
9H10 O +
) O +
, O +
led O +
to O +
approximately O +
100 O +
% O +
survival O +
of O +
tumour O +
cell O +
recipients O +
. O +

However O +
, O +
effective O +
treatment O +
of O +
mice O +
with O +
already O +
established O +
tumours O +
was O +
only O +
obtained O +
after O +
combination O +
of O +
vaccination O +
, O +
DC101 O +
and O +
9H10 O +
treatment O +
in O +
which O +
setting O +
80 O +
% O +
of O +
the O +
mice O +
rejected O +
their O +
tumours O +
. O +

Randomized O +
, O +
open O +
label O +
, O +
prospective O +
study O +
on O +
the O +
effect O +
of O +
zoledronic O +
acid O +
on O +
the O +
prevention O +
of O +
bone O +
metastases O +
in O +
patients O +
with O +
recurrent O +
solid O +
tumors O +
that O +
did O +
not O +
present O +
with O +
bone O +
metastases O +
at O +
baseline O +
. O +

OBJECTIVES O +
: O +
Bisphosphonates O +
have O +
been O +
used O +
successfully O +
in O +
the O +
treatment O +
of O +
hypercalcemia O +
and O +
to O +
reduce O +
skeletal O +
- O +
related O +
complications O +
of O +
bone O +
metastases O +
. O +

Recent O +
in O +
vitro O +
and O +
in O +
vivo O +
evidence O +
suggest O +
that O +
they O +
may O +
also O +
have O +
direct O +
antitumor O +
effects O +
via O +
induction O +
of O +
apoptosis O +
, O +
inhibition O +
of O +
the O +
invasive O +
potential O +
of O +
tumor O +
cell O +
lines O +
in O +
vitro O +
, O +
inhibition O +
of O +
angiogenesis O +
, O +
and O +
reduction O +
in O +
tumor O +
growth O +
indirectly O +
via O +
effects O +
on O +
accessory O +
cells O +
. O +

This O +
is O +
a O +
randomized O +
, O +
open O +
label O +
, O +
prospective O +
study O +
that O +
examined O +
the O +
effect O +
of O +
preventive O +
zoledronic O +
acid O +
treatment O +
on O +
the O +
development O +
of O +
bone O +
metastases O +
in O +
patients O +
with O +
recurrent O +
solid O +
tumors O +
, O +
without O +
bone O +
metastases O +
at O +
the O +
time O +
of O +
randomization O +
. O +

METHODS O +
: O +
Forty O +
patients O +
with O +
recurrent O +
or O +
metastatic O +
advanced O +
cancer O +
, O +
without O +
bone O +
metastases O +
, O +
were O +
randomized O +
into O +
the O +
trial O +
to O +
either O +
receive O +
zoledronic O +
acid O +
or O +
no O +
treatment O +
. O +

Patients O +
were O +
followed O +
up O +
until O +
bone O +
metastases O +
were O +
established O +
. O +

RESULTS O +
: O +
The O +
percentage O +
of O +
patients O +
being O +
bone O +
metastases O +
free O +
at O +
12 O +
mo O +
was O +
60 O +
% O +
in O +
the O +
zoledronic O +
acid O +
and O +
10 O +
% O +
in O +
the O +
control O +
group O +
( O +
p O +
less O +
than O +
0 O +
. O +
0005 O +
) O +
, O +
while O +
the O +
percentages O +
at O +
18 O +
mo O +
were O +
20 O +
% O +
and O +
5 O +
% O +
respectively O +
( O +
p O +
= O +
0 O +
. O +
0002 O +
) O +
. O +

CONCLUSIONS O +
: O +
The O +
results O +
have O +
shown O +
that O +
bisphosphonates O +
as O +
adjuvant O +
treatment O +
might O +
be O +
useful O +
for O +
the O +
prevention O +
of O +
bone O +
metastases O +
; O +
however O +
, O +
there O +
is O +
need O +
for O +
blinded O +
randomized O +
data O +
before O +
such O +
an O +
approach O +
would O +
be O +
confirmed O +
. O +

In O +
the O +
meantime O +
preventive O +
use O +
of O +
bisphosphonates O +
in O +
patients O +
without O +
any O +
bone O +
metastases O +
should O +
not O +
be O +
used O +
outside O +
the O +
scope O +
of O +
a O +
clinical O +
trial O +
. O +

VEGF O +
- O +
targeted O +
therapy O +
: O +
therapeutic O +
potential O +
and O +
recent O +
advances O +
. O +

After O +
over O +
30 O +
years O +
of O +
theorizing O +
, O +
the O +
use O +
of O +
angiogenesis O +
inhibitors O +
as O +
anticancer O +
therapy O +
has O +
finally O +
moved O +
from O +
the O +
realm O +
of O +
research O +
to O +
reality O +
. O +

Normal O +
adult O +
vasculature O +
is O +
generally O +
quiescent O +
in O +
nature O +
, O +
with O +
endothelial O +
cells O +
dividing O +
approximately O +
every O +
10 O +
years O +
. O +

In O +
contrast O +
, O +
the O +
growth O +
of O +
tumors O +
requires O +
constant O +
vascular O +
growth O +
and O +
remodeling O +
in O +
order O +
for O +
solid O +
tumors O +
to O +
grow O +
beyond O +
1 O +
- O +
2 O +
mm O +
( O +
3 O +
) O +
in O +
size O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
and O +
its O +
receptors O +
are O +
key O +
regulators O +
of O +
the O +
process O +
of O +
angiogenesis O +
, O +
which O +
makes O +
them O +
attractive O +
therapeutic O +
targets O +
. O +

A O +
multitude O +
of O +
VEGF O +
- O +
targeted O +
inhibitory O +
agents O +
are O +
currently O +
being O +
investigated O +
for O +
the O +
treatment O +
of O +
cancer O +
. O +

This O +
review O +
article O +
focuses O +
on O +
recent O +
developments O +
in O +
the O +
use O +
of O +
angiogenesis O +
inhibitors O +
for O +
the O +
treatment O +
of O +
breast O +
, O +
lung O +
, O +
and O +
colorectal O +
cancers O +
. O +

Thalidomide O +
and O +
angiostatin O +
inhibit O +
tumor O +
growth O +
in O +
a O +
murine O +
xenograft O +
model O +
of O +
human O +
cervical O +
cancer O +
. O +

OBJECTIVE O +
: O +
To O +
determine O +
the O +
impact O +
of O +
thalidomide O +
and O +
angiostatin O +
on O +
tumor O +
growth O +
, O +
angiogenesis O +
, O +
and O +
apoptosis O +
in O +
a O +
xenograft O +
model O +
of O +
cervical O +
cancer O +
. O +

METHODS O +
: O +
Human O +
umbilical O +
endothelial O +
cells O +
were O +
treated O +
with O +
angiostatin O +
or O +
thalidomide O +
and O +
bFGF O +
- O +
induced O +
proliferation O +
was O +
assessed O +
with O +
the O +
MTT O +
assay O +
. O +

Human O +
cervical O +
cancer O +
cells O +
( O +
CaSki B-CellLine +
and O +
SiHa B-CellLine +
) O +
were O +
injected O +
into O +
the O +
flanks O +
of O +
nude O +
mice O +
. O +

After O +
tumors O +
developed O +
, O +
mice O +
were O +
treated O +
with O +
angiostatin O +
20 O +
mg O +
/ O +
kg O +
/ O +
day O +
or O +
thalidomide O +
200 O +
mg O +
/ O +
kg O +
/ O +
day O +
for O +
30 O +
days O +
. O +

Fractional O +
tumor O +
growth O +
was O +
determined O +
and O +
immunohistochemical O +
analysis O +
of O +
tumors O +
was O +
used O +
to O +
determine O +
degree O +
of O +
angiogenesis O +
. O +

TUNEL O +
assay O +
was O +
used O +
to O +
assess O +
apoptosis O +
. O +

RESULTS O +
: O +
Angiostatin O +
inhibited O +
endothelial O +
cell O +
proliferation O +
by O +
50 O +
- O +
60 O +
% O +
. O +

Thalidomide O +
had O +
no O +
direct O +
effect O +
on O +
endothelial O +
cells O +
. O +

Angiostatin O +
and O +
thalidomide O +
both O +
inhibited O +
tumor O +
growth O +
by O +
about O +
55 O +
% O +
. O +

We O +
found O +
no O +
additive O +
or O +
synergistic O +
effect O +
when O +
the O +
two O +
agents O +
were O +
combined O +
. O +

Both O +
agents O +
inhibited O +
angiogenesis O +
and O +
induced O +
apoptosis O +
when O +
compared O +
to O +
tumors O +
from O +
control O +
animals O +
. O +

CONCLUSIONS O +
: O +
Angiostatin O +
and O +
thalidomide O +
inhibit O +
tumor O +
growth O +
, O +
angiogenesis O +
, O +
and O +
induce O +
apoptosis O +
in O +
this O +
xenograft O +
model O +
of O +
cervical O +
cancer O +
. O +

MDM2 O +
as O +
a O +
predictor O +
of O +
prostate O +
carcinoma O +
outcome O +
: O +
an O +
analysis O +
of O +
Radiation O +
Therapy O +
Oncology O +
Group O +
Protocol O +
8610 O +
. O +

BACKGROUND O +
: O +
The O +
MDM2 O +
oncoprotein O +
promotes O +
p53 O +
degradation O +
via O +
ubiquitin O +
, O +
establishing O +
negative O +
feedback O +
control O +
of O +
p53 O +
and O +
consequently O +
affecting O +
cell O +
cycle O +
arrest O +
and O +
apoptosis O +
. O +

The O +
authors O +
evaluated O +
the O +
association O +
between O +
MDM2 O +
expression O +
and O +
local O +
failure O +
, O +
distant O +
metastasis O +
( O +
DM O +
) O +
, O +
cause O +
- O +
specific O +
mortality O +
, O +
and O +
overall O +
mortality O +
in O +
men O +
treated O +
in O +
Radiation O +
Therapy O +
Oncology O +
Group O +
8610 O +
with O +
radiotherapy O +
, O +
with O +
or O +
without O +
androgen O +
deprivation O +
. O +

METHODS O +
: O +
Of O +
the O +
456 O +
eligible O +
and O +
analyzable O +
patients O +
( O +
parent O +
cohort O +
) O +
, O +
adequate O +
archival O +
diagnostic O +
tissue O +
specimens O +
from O +
108 O +
patients O +
were O +
available O +
for O +
MDM2 O +
analysis O +
( O +
MDM2 O +
cohort O +
) O +
. O +

Cox O +
proportional O +
hazards O +
multivariate O +
analysis O +
( O +
MVA O +
) O +
was O +
used O +
to O +
determine O +
the O +
relation O +
of O +
MDM2 O +
to O +
the O +
endpoints O +
. O +

MDM2 O +
overexpression O +
was O +
manually O +
classified O +
as O +
> O +
5 O +
% O +
nuclear O +
staining O +
. O +

An O +
image O +
analysis O +
system O +
was O +
also O +
used O +
to O +
quantify O +
the O +
proportion O +
of O +
tumor O +
nuclei O +
with O +
MDM2 O +
staining O +
( O +
ACIS O +
index O +
) O +
and O +
staining O +
intensity O +
. O +

RESULTS O +
: O +
Overexpression O +
of O +
MDM2 O +
by O +
manual O +
counts O +
was O +
seen O +
in O +
44 O +
% O +
( O +
n O +
= O +
47 O +
) O +
of O +
the O +
patients O +
. O +

In O +
the O +
manual O +
count O +
analysis O +
, O +
there O +
was O +
no O +
significant O +
relation O +
between O +
MDM2 O +
overexpression O +
and O +
outcome O +
. O +

The O +
ACIS O +
index O +
, O +
using O +
a O +
cutoff O +
point O +
defined O +
by O +
the O +
median O +
value O +
, O +
< O +
or O +
= O +
3 O +
% O +
versus O +
> O +
3 O +
% O +
, O +
was O +
related O +
to O +
5 O +
- O +
year O +
DM O +
rates O +
in O +
univariate O +
analyses O +
( O +
32 O +
. O +
6 O +
% O +
vs O +
. O +
45 O +
. O +
8 O +
% O +
; O +
P O +
= O +
0 O +
. O +
057 O +
) O +
and O +
MVA O +
( O +
P O +
= O +
0 O +
. O +
06 O +
) O +
. O +

The O +
intensity O +
of O +
MDM2 O +
staining O +
was O +
not O +
significant O +
. O +

CONCLUSIONS O +
: O +
MDM2 O +
expression O +
quantified O +
by O +
image O +
analysis O +
was O +
weakly O +
associated O +
with O +
DM O +
. O +

The O +
cohort O +
examined O +
was O +
relatively O +
small O +
and O +
with O +
larger O +
patient O +
numbers O +
, O +
MDM2 O +
overexpression O +
may O +
emerge O +
as O +
a O +
more O +
significant O +
covariate O +
. O +

Therapeutic O +
Electromagnetic O +
Field O +
( O +
TEMF O +
) O +
and O +
gamma O +
irradiation O +
on O +
human O +
breast O +
cancer O +
xenograft O +
growth O +
, O +
angiogenesis O +
and O +
metastasis O +
. O +

BACKGROUND O +
: O +
The O +
effects O +
of O +
a O +
rectified O +
semi O +
- O +
sinewave O +
signal O +
( O +
15 O +
mT O +
amplitude O +
, O +
120 O +
pulses O +
per O +
second O +
, O +
EMF O +
Therapeutics O +
, O +
Inc O +
. O +
) O +
( O +
TEMF O +
) O +
alone O +
and O +
in O +
combination O +
with O +
gamma O +
irradiation O +
( O +
IR O +
) O +
therapy O +
in O +
nude O +
mice O +
bearing O +
a O +
human O +
MDA B-CellLine +
MB231 I-CellLine +
breast O +
cancer O +
xenograft O +
were O +
tested O +
. O +

Green O +
fluorescence O +
protein O +
transfected O +
cancer O +
cells O +
were O +
injected O +
into O +
the O +
mammary O +
fat O +
pad O +
of O +
young O +
female O +
mice O +
. O +

Six O +
weeks O +
later O +
, O +
mice O +
were O +
randomly O +
divided O +
into O +
four O +
treatment O +
groups O +
: O +
untreated O +
controls O +
; O +
10 O +
minute O +
daily O +
TEMF O +
; O +
200 O +
cGy O +
of O +
IR O +
every O +
other O +
day O +
( O +
total O +
800 O +
cGy O +
) O +
; O +
IR O +
plus O +
daily O +
TEMF O +
. O +

Some O +
mice O +
in O +
each O +
group O +
were O +
euthanized O +
24 O +
hours O +
after O +
the O +
end O +
of O +
IR O +
. O +

TEMF O +
treatment O +
continued O +
for O +
3 O +
additional O +
weeks O +
. O +

Tumor O +
sections O +
were O +
stained O +
for O +
: O +
endothelial O +
cells O +
with O +
CD31 O +
and O +
PAS O +
or O +
hypoxia O +
inducible O +
factor O +
1alpha O +
( O +
HIF O +
) O +
. O +

RESULTS O +
: O +
Most O +
tumors O +
less O +
than O +
35 O +
mm3 O +
were O +
white O +
but O +
tumors O +
greater O +
than O +
35 O +
mm3 O +
were O +
pink O +
and O +
had O +
a O +
vascularized O +
capsule O +
. O +

The O +
cortex O +
within O +
100 O +
microns O +
of O +
the O +
capsule O +
had O +
little O +
vascularization O +
. O +

Blood O +
vessels O +
, O +
capillaries O +
, O +
and O +
endothelial O +
pseudopods O +
were O +
found O +
at O +
greater O +
than O +
100 O +
microns O +
from O +
the O +
capsule O +
( O +
subcortex O +
) O +
. O +

Tumors O +
greater O +
than O +
35 O +
mm3 O +
treated O +
with O +
IR O +
24 O +
hours O +
previously O +
or O +
with O +
TEMF O +
had O +
decreased O +
blood O +
vessels O +
in O +
the O +
subcortex O +
and O +
more O +
endothelial O +
pseudopods O +
projecting O +
into O +
hypoxic O +
, O +
HIF O +
positive O +
areas O +
than O +
tumors O +
from O +
the O +
control O +
group O +
. O +

Mice O +
that O +
received O +
either O +
IR O +
or O +
TEMF O +
had O +
significantly O +
fewer O +
lung O +
metastatic O +
sites O +
and O +
slower O +
tumor O +
growth O +
than O +
did O +
untreated O +
mice O +
. O +

No O +
harmful O +
side O +
effects O +
were O +
attributed O +
to O +
TEMF O +
. O +

CONCLUSION O +
: O +
TEMF O +
therapy O +
provided O +
a O +
safe O +
means O +
for O +
retarding O +
tumor O +
vascularization O +
, O +
growth O +
and O +
metastasis O +
. O +

Thrombospondins O +
, O +
metallo O +
proteases O +
and O +
thrombospondin O +
receptors O +
messenger O +
RNA O +
and O +
protein O +
expression O +
in O +
different O +
tumour O +
sublines O +
of O +
the O +
Dunning O +
prostate O +
cancer O +
model O +
. O +

Thrombospondin O +
is O +
a O +
potent O +
inhibitor O +
of O +
angiogenesis O +
and O +
might O +
therefore O +
be O +
important O +
in O +
controlling O +
tumour O +
growth O +
. O +

TSP O +
interacts O +
with O +
a O +
number O +
of O +
proteases O +
and O +
receptors O +
and O +
in O +
this O +
way O +
inhibits O +
stimulation O +
of O +
angiogenesis O +
. O +

An O +
earlier O +
study O +
showed O +
that O +
thrombospondin O +
is O +
expressed O +
in O +
benign O +
prostatic O +
hyperplasia O +
( O +
BPH O +
) O +
and O +
high O +
- O +
grade O +
prostatic O +
intraepithelial O +
neoplasia O +
( O +
PIN O +
) O +
but O +
is O +
absent O +
in O +
prostate O +
cancer O +
. O +

The O +
present O +
study O +
was O +
therefore O +
designed O +
to O +
evaluate O +
the O +
expression O +
of O +
thrombospondin O +
1 O +
and O +
2 O +
( O +
TSP O +
- O +
1 O +
, O +
TSP O +
- O +
2 O +
) O +
, O +
TSP O +
receptors O +
CD36 O +
and O +
CD47 O +
, O +
and O +
matrix O +
- O +
metalloproteases O +
2 O +
and O +
9 O +
( O +
MMP O +
- O +
, O +
MMP O +
- O +
9 O +
) O +
in O +
a O +
rat O +
prostate O +
cancer O +
model O +
. O +

By O +
using O +
immunohistochemistry O +
, O +
Western O +
blot O +
, O +
and O +
real O +
- O +
time O +
PCR O +
the O +
expression O +
patterns O +
of O +
TSP O +
- O +
1 O +
, O +
TSP O +
- O +
2 O +
, O +
CD36 O +
, O +
CD47 O +
, O +
MMP O +
- O +
2 O +
, O +
and O +
MMP O +
- O +
9 O +
were O +
investigated O +
in O +
normal O +
rat O +
prostate O +
tissue O +
and O +
five O +
malignant O +
Dunning O +
sublines O +
tissue O +
. O +

TSP O +
- O +
1 O +
mRNA O +
levels O +
were O +
decreased O +
in O +
all O +
tumours O +
compared O +
with O +
normal O +
prostate O +
. O +

However O +
, O +
there O +
was O +
no O +
difference O +
in O +
expression O +
of O +
TSP O +
- O +
2 O +
and O +
CD36 O +
mRNA O +
in O +
these O +
samples O +
. O +

MMP O +
- O +
2 O +
was O +
increased O +
with O +
malignancy O +
, O +
but O +
no O +
expression O +
of O +
MMP O +
- O +
9 O +
was O +
seen O +
. O +

The O +
CD47 O +
receptor O +
did O +
slightly O +
increase O +
with O +
malignancy O +
except O +
for O +
H3327 O +
. O +

The O +
results O +
showed O +
that O +
thrombospondin O +
is O +
expressed O +
in O +
normal O +
prostate O +
but O +
not O +
in O +
prostate O +
tumours O +
in O +
a O +
rat O +
model O +
. O +

Simultaneously O +
, O +
MMP O +
- O +
2 O +
expression O +
increases O +
with O +
malignancy O +
. O +

Bovine O +
papillomavirus O +
E7 O +
transformation O +
function O +
correlates O +
with O +
cellular O +
p600 O +
protein O +
binding O +
. O +

The O +
E7 O +
oncoprotein O +
of O +
bovine O +
papillomavirus O +
type O +
1 O +
( O +
BPV O +
- O +
1 O +
) O +
is O +
required O +
for O +
the O +
full O +
transformation O +
activity O +
of O +
the O +
virus O +
. O +

However O +
, O +
the O +
mechanism O +
by O +
which O +
E7 O +
contributes O +
to O +
cellular O +
transformation O +
is O +
unknown O +
. O +

To O +
address O +
this O +
question O +
, O +
we O +
used O +
the O +
proteomic O +
approach O +
of O +
tandem O +
affinity O +
purification O +
to O +
identify O +
cellular O +
proteins O +
that O +
are O +
in O +
complex O +
with O +
E7 O +
, O +
and O +
identified O +
the O +
600 O +
- O +
kDa O +
protein O +
, O +
p600 O +
, O +
as O +
a O +
binding O +
partner O +
of O +
E7 O +
. O +

The O +
ability O +
of O +
E7 O +
to O +
complex O +
with O +
p600 O +
correlated O +
with O +
its O +
ability O +
to O +
enhance O +
anchorage O +
independence O +
of O +
BPV O +
- O +
1 O +
E6 O +
- O +
expressing O +
cells O +
. O +

Furthermore O +
, O +
E7 O +
mutant O +
proteins O +
impaired O +
in O +
their O +
ability O +
to O +
bind O +
p600 O +
were O +
transformation O +
defective O +
. O +

Additionally O +
, O +
knockdown O +
of O +
p600 O +
reduced O +
transformation O +
of O +
cells O +
expressing O +
both O +
BPV O +
- O +
1 O +
E6 O +
and O +
E7 O +
, O +
as O +
well O +
as O +
E6 O +
alone O +
, O +
suggesting O +
that O +
the O +
ability O +
of O +
E7 O +
to O +
transformed O +
cells O +
is O +
mediated O +
, O +
at O +
least O +
in O +
part O +
, O +
through O +
its O +
ability O +
to O +
bind O +
p600 O +
. O +

These O +
data O +
complement O +
work O +
that O +
shows O +
that O +
HPV16 O +
E7 O +
also O +
interacts O +
with O +
p600 O +
, O +
and O +
that O +
this O +
interaction O +
correlates O +
with O +
the O +
ability O +
of O +
HPV16 O +
E7 O +
to O +
transform O +
cells O +
. O +

These O +
studies O +
thus O +
identify O +
p600 O +
as O +
a O +
shared O +
target O +
of O +
the O +
E7 O +
proteins O +
of O +
multiple O +
papillomaviruses O +
. O +

Experimental O +
investigation O +
of O +
equibiaxial O +
extension O +
and O +
breakup O +
of O +
drops O +
in O +
a O +
molten O +
two O +
- O +
phase O +
polymer O +
blend O +
. O +

We O +
experimentally O +
investigate O +
the O +
breakup O +
of O +
an O +
equibiaxially O +
elongated O +
polystyrene O +
( O +
PS O +
) O +
drop O +
in O +
a O +
poly O +
( O +
methyl O +
methacrylate O +
) O +
( O +
PMMA O +
) O +
matrix O +
during O +
relaxation O +
after O +
melt O +
elongation O +
. O +

In O +
equibiaxial O +
elongation O +
, O +
the O +
initially O +
spherical O +
PS O +
drop O +
is O +
deformed O +
into O +
an O +
ellipsoidal O +
disclike O +
shape O +
for O +
our O +
test O +
parameters O +
. O +

Using O +
a O +
hotstage O +
in O +
combination O +
with O +
a O +
light O +
microscope O +
, O +
we O +
observe O +
the O +
evolution O +
of O +
the O +
drop O +
shape O +
during O +
relaxation O +
. O +

In O +
the O +
initial O +
stage O +
of O +
relaxation O +
, O +
fingers O +
and O +
holes O +
are O +
formed O +
. O +

The O +
holes O +
are O +
located O +
preferentially O +
near O +
the O +
rim O +
of O +
the O +
drop O +
. O +

The O +
number O +
and O +
the O +
size O +
of O +
the O +
holes O +
increase O +
with O +
time O +
such O +
that O +
the O +
elongated O +
PS O +
drop O +
attains O +
a O +
complex O +
shape O +
during O +
relaxation O +
. O +

The O +
fingers O +
form O +
bulbous O +
ends O +
which O +
separate O +
from O +
the O +
fingers O +
. O +

We O +
discuss O +
the O +
dynamics O +
of O +
this O +
breakup O +
process O +
by O +
taking O +
into O +
account O +
the O +
interfacial O +
energy O +
between O +
PS O +
and O +
PMMA O +
. O +

Our O +
analysis O +
shows O +
that O +
a O +
very O +
large O +
number O +
of O +
small O +
PS O +
droplets O +
can O +
be O +
generated O +
by O +
the O +
sequential O +
breakup O +
of O +
the O +
elongated O +
PS O +
drop O +
. O +

Molecular O +
requirements O +
for O +
epithelial O +
- O +
mesenchymal O +
transition O +
during O +
tumor O +
progression O +
. O +

Epithelial O +
- O +
mesenchymal O +
transitions O +
( O +
EMTs O +
) O +
occur O +
as O +
key O +
steps O +
during O +
embryonic O +
morphogenesis O +
, O +
and O +
are O +
now O +
implicated O +
in O +
the O +
progression O +
of O +
primary O +
tumors O +
towards O +
metastases O +
. O +

Recent O +
advances O +
have O +
fostered O +
a O +
more O +
detailed O +
understanding O +
of O +
molecular O +
mechanisms O +
and O +
networks O +
governing O +
EMT O +
in O +
tumor O +
progression O +
. O +

Besides O +
TGFbeta O +
and O +
RTK O +
/ O +
Ras O +
signaling O +
, O +
autocrine O +
factors O +
and O +
Wnt O +
- O +
, O +
Notch O +
- O +
, O +
Hedgehog O +
- O +
and O +
NF O +
- O +
kappaB O +
- O +
dependent O +
pathways O +
were O +
found O +
to O +
contribute O +
to O +
EMT O +
. O +

Repression O +
of O +
E O +
- O +
cadherin O +
by O +
transcriptional O +
regulators O +
such O +
as O +
Snail O +
or O +
Twist O +
emerges O +
as O +
one O +
critical O +
step O +
driving O +
EMT O +
, O +
and O +
this O +
stage O +
is O +
currently O +
being O +
molecularly O +
linked O +
with O +
many O +
of O +
the O +
new O +
players O +
. O +

Increasing O +
evidence O +
suggests O +
that O +
EMT O +
plays O +
a O +
specific O +
role O +
in O +
the O +
migration O +
of O +
cells O +
from O +
a O +
primary O +
tumor O +
into O +
the O +
circulation O +
and O +
may O +
provide O +
a O +
rationale O +
for O +
developing O +
more O +
effective O +
cancer O +
therapies O +
. O +

A O +
novel O +
conotoxin O +
from O +
Conus O +
delessertii O +
with O +
posttranslationally O +
modified O +
lysine O +
residues O +
. O +

A O +
major O +
peptide O +
, O +
de13a O +
from O +
the O +
crude O +
venom O +
of O +
Conus O +
delessertii O +
collected O +
in O +
the O +
Yucatan O +
Channel O +
, O +
Mexico O +
, O +
was O +
purified O +
. O +

The O +
peptide O +
had O +
a O +
high O +
content O +
of O +
posttranslationally O +
modified O +
amino O +
acids O +
, O +
including O +
6 O +
- O +
bromotryptophan O +
and O +
a O +
nonstandard O +
amino O +
acid O +
that O +
proved O +
to O +
be O +
5 O +
- O +
hydroxylysine O +
. O +

This O +
is O +
the O +
first O +
report O +
of O +
5 O +
- O +
hydroxylysine O +
residues O +
in O +
conotoxins O +
. O +

The O +
sequence O +
analysis O +
, O +
together O +
with O +
cDNA O +
cloning O +
and O +
a O +
mass O +
determination O +
( O +
monoisotopic O +
mass O +
of O +
3486 O +
. O +
76 O +
Da O +
) O +
, O +
established O +
that O +
the O +
mature O +
toxin O +
has O +
the O +
sequence O +
DCOTSCOTTCANGWECCKGYOCVNKACSGCTH O +
, O +
where O +
O O +
is O +
4 O +
- O +
hydroxyproline O +
, O +
W O +
6 O +
- O +
bromotryptophan O +
, O +
and O +
K O +
5 O +
- O +
hydroxylysine O +
, O +
the O +
asterisk O +
represents O +
the O +
amidated O +
C O +
- O +
terminus O +
, O +
and O +
the O +
calculated O +
monoisotopic O +
mass O +
is O +
3487 O +
. O +
09 O +
Da O +
. O +

The O +
eight O +
Cys O +
residues O +
are O +
arranged O +
in O +
a O +
pattern O +
( O +
C O +
- O +
C O +
- O +
C O +
- O +
CC O +
- O +
C O +
- O +
C O +
- O +
C O +
) O +
not O +
described O +
previously O +
in O +
conotoxins O +
. O +

This O +
arrangement O +
, O +
for O +
which O +
we O +
propose O +
the O +
designation O +
of O +
framework O +
# O +
13 O +
or O +
XIII O +
, O +
differs O +
from O +
the O +
ones O +
( O +
C O +
- O +
C O +
- O +
CC O +
- O +
CC O +
- O +
C O +
- O +
C O +
and O +
C O +
- O +
C O +
- O +
C O +
- O +
C O +
- O +
CC O +
- O +
C O +
- O +
C O +
) O +
present O +
in O +
other O +
conotoxins O +
which O +
also O +
contain O +
eight O +
Cys O +
residues O +
. O +

This O +
peptide O +
thus O +
defines O +
a O +
novel O +
class O +
of O +
conotoxins O +
, O +
with O +
a O +
new O +
posttranslational O +
modification O +
not O +
previously O +
found O +
in O +
other O +
Conus O +
peptide O +
families O +
. O +

Management O +
of O +
extremity O +
trauma O +
and O +
related O +
infections O +
occurring O +
in O +
the O +
aquatic O +
environment O +
. O +

Wounds O +
sustained O +
in O +
oceans O +
, O +
lakes O +
, O +
and O +
streams O +
are O +
exposed O +
to O +
a O +
milieu O +
of O +
bacteria O +
rarely O +
encountered O +
in O +
typical O +
land O +
- O +
based O +
injuries O +
. O +

These O +
include O +
Vibrio O +
species O +
, O +
Aeromonas O +
hydrophila O +
, O +
Pseudomonas O +
and O +
Plesiomonas O +
species O +
, O +
Erysipelothrix O +
rhusiopathiae O +
, O +
Mycobacterium O +
marinum O +
, O +
and O +
other O +
microbes O +
. O +

Failure O +
to O +
recognize O +
and O +
treat O +
these O +
less O +
common O +
pathogens O +
in O +
a O +
timely O +
manner O +
may O +
result O +
in O +
significant O +
morbidity O +
or O +
death O +
. O +

Initial O +
antibiotic O +
therapy O +
should O +
address O +
common O +
gram O +
- O +
positive O +
and O +
gram O +
- O +
negative O +
aquatic O +
bacteria O +
, O +
depending O +
on O +
the O +
environment O +
. O +

Trauma O +
occurring O +
in O +
brackish O +
or O +
salt O +
water O +
should O +
be O +
treated O +
with O +
doxycycline O +
and O +
ceftazidime O +
, O +
or O +
a O +
fluoroquinolone O +
( O +
eg O +
, O +
ciprofloxacin O +
or O +
levofloxacin O +
) O +
. O +

Freshwater O +
wounds O +
should O +
be O +
managed O +
with O +
ciprofloxacin O +
, O +
levofloxacin O +
, O +
or O +
a O +
third O +
- O +
or O +
fourth O +
- O +
generation O +
cephalosporin O +
( O +
eg O +
, O +
ceftazidime O +
) O +
. O +

Injuries O +
sustained O +
in O +
a O +
marine O +
or O +
freshwater O +
environment O +
may O +
result O +
from O +
bites O +
or O +
venomous O +
stings O +
of O +
aquatic O +
organisms O +
as O +
well O +
as O +
from O +
accidental O +
trauma O +
. O +

Musculoskeletal O +
trauma O +
caused O +
by O +
venomous O +
underwater O +
species O +
( O +
eg O +
, O +
stingrays O +
, O +
stinging O +
fish O +
, O +
sea O +
urchins O +
, O +
and O +
coral O +
) O +
requires O +
immediate O +
neutralization O +
of O +
the O +
heat O +
- O +
labile O +
toxin O +
with O +
immersion O +
in O +
nonscalding O +
water O +
for O +
30 O +
to O +
90 O +
minutes O +
. O +

Appropriate O +
management O +
of O +
aquatic O +
wounds O +
requires O +
recognition O +
of O +
the O +
mechanism O +
of O +
injury O +
, O +
neutralization O +
of O +
venom O +
, O +
antibiotic O +
administration O +
, O +
radiographic O +
assessment O +
, O +
surgical O +
debridement O +
with O +
irrigation O +
, O +
wound O +
cultures O +
, O +
and O +
structural O +
repair O +
or O +
amputation O +
as O +
indicated O +
by O +
the O +
severity O +
of O +
the O +
injury O +
. O +

Minimal O +
contribution O +
of O +
marrow O +
- O +
derived O +
endothelial O +
precursors O +
to O +
tumor O +
vasculature O +
. O +

During O +
embryogenesis O +
, O +
vascular O +
and O +
hemopoietic O +
cells O +
originate O +
from O +
a O +
common O +
precursor O +
, O +
the O +
hemangioblast O +
. O +

Recent O +
evidence O +
suggests O +
the O +
existence O +
of O +
endothelial O +
precursors O +
in O +
adult O +
bone O +
marrow O +
cells O +
, O +
but O +
it O +
is O +
unclear O +
whether O +
those O +
precursors O +
have O +
a O +
role O +
in O +
tumor O +
neovascularization O +
. O +

In O +
this O +
report O +
, O +
we O +
demonstrate O +
that O +
murine O +
bone O +
marrow O +
contains O +
endothelial O +
progenitors O +
, O +
which O +
arise O +
from O +
a O +
cell O +
with O +
self O +
- O +
renewing O +
capacity O +
, O +
and O +
can O +
integrate O +
into O +
tumor O +
microvasculature O +
, O +
albeit O +
at O +
a O +
very O +
low O +
frequency O +
. O +

A O +
transgenic O +
double O +
- O +
reporter O +
strategy O +
allowed O +
us O +
to O +
demonstrate O +
definitively O +
that O +
tumor O +
bone O +
marrow O +
- O +
derived O +
endothelial O +
cells O +
arise O +
by O +
transdifferentiation O +
of O +
marrow O +
progenitors O +
rather O +
than O +
by O +
cell O +
fusion O +
. O +

Single O +
cell O +
transplants O +
showed O +
that O +
a O +
common O +
precursor O +
contributes O +
to O +
both O +
the O +
hemopoietic O +
and O +
endothelial O +
lineages O +
, O +
thus O +
demonstrating O +
the O +
presence O +
of O +
an O +
adult O +
hemangioblast O +
. O +

Furthermore O +
, O +
we O +
demonstrate O +
that O +
increased O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
- O +
A O +
secretion O +
by O +
tumor O +
cells O +
, O +
as O +
well O +
as O +
activation O +
of O +
VEGF O +
receptor O +
- O +
2 O +
in O +
bone O +
marrow O +
cells O +
does O +
not O +
alter O +
the O +
mobilization O +
and O +
incorporation O +
of O +
marrow O +
- O +
derived O +
endothelial O +
progenitors O +
into O +
tumor O +
vasculature O +
. O +

Finally O +
, O +
in O +
human O +
umbilical O +
cord O +
blood O +
cells O +
, O +
we O +
show O +
that O +
endothelial O +
precursors O +
make O +
up O +
only O +
approximately O +
1 O +
in O +
10 O +
( O +
7 O +
) O +
mononuclear O +
cells O +
but O +
are O +
highly O +
enriched O +
in O +
the O +
CD133 O +
+ O +
cell O +
population O +
. O +

By O +
ruling O +
out O +
cell O +
fusion O +
, O +
we O +
clearly O +
demonstrate O +
the O +
existence O +
of O +
an O +
adult O +
hemangioblast O +
, O +
but O +
the O +
differentiation O +
of O +
marrow O +
stem O +
cells O +
toward O +
the O +
endothelial O +
lineage O +
is O +
an O +
extremely O +
rare O +
event O +
. O +

Furthermore O +
, O +
we O +
show O +
that O +
VEGF O +
- O +
A O +
stimulation O +
of O +
hemopoietic O +
cells O +
does O +
not O +
significantly O +
alter O +
this O +
process O +
. O +

Impaired O +
coronary O +
collateral O +
vessel O +
development O +
in O +
patients O +
with O +
proliferative O +
diabetic O +
retinopathy O +
. O +

BACKGROUND O +
: O +
Diabetic O +
patients O +
have O +
been O +
reported O +
to O +
have O +
impaired O +
coronary O +
collateral O +
vessel O +
growth O +
, O +
although O +
they O +
have O +
excessive O +
neovascularization O +
in O +
the O +
retina O +
. O +

HYPOTHESIS O +
: O +
This O +
study O +
was O +
designed O +
to O +
compare O +
coronary O +
collateral O +
circulation O +
( O +
CCC O +
) O +
in O +
patients O +
with O +
proliferative O +
diabetic O +
retinopathy O +
( O +
PDR O +
) O +
with O +
that O +
in O +
patients O +
without O +
DR O +
. O +

METHODS O +
: O +
Ninety O +
diabetic O +
patients O +
with O +
chronic O +
total O +
occlusion O +
in O +
at O +
least O +
one O +
major O +
epicardial O +
coronary O +
artery O +
were O +
enrolled O +
in O +
the O +
study O +
. O +

Groups O +
1 O +
and O +
2 O +
consisted O +
of O +
48 O +
patients O +
without O +
DR O +
and O +
42 O +
patients O +
with O +
PDR O +
, O +
respectively O +
. O +

Coronary O +
collateral O +
circulation O +
( O +
CCC O +
) O +
was O +
analyzed O +
according O +
to O +
the O +
Rentrop O +
system O +
. O +

Each O +
group O +
was O +
also O +
divided O +
into O +
two O +
subgroups O +
according O +
to O +
poor O +
and O +
good O +
CCC O +
. O +

Serum O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
levels O +
were O +
measured O +
using O +
the O +
enzyme O +
- O +
linked O +
immunosorbent O +
assay O +
( O +
ELISA O +
) O +
kit O +
. O +

RESULTS O +
: O +
The O +
mean O +
Rentrop O +
collateral O +
score O +
was O +
higher O +
in O +
Group O +
1 O +
than O +
in O +
Group O +
2 O +
( O +
2 O +
. O +
39 O +
+ O +
/ O +
- O +
1 O +
. O +
07 O +
vs O +
. O +
1 O +
. O +
76 O +
+ O +
/ O +
- O +
0 O +
. O +
76 O +
, O +
respectively O +
, O +
p O +
less O +
than O +
0 O +
. O +
001 O +
) O +
. O +

When O +
the O +
two O +
groups O +
were O +
compared O +
with O +
respect O +
to O +
poor O +
and O +
good O +
CCC O +
, O +
poor O +
CCC O +
was O +
higher O +
in O +
patients O +
with O +
PDR O +
( O +
64 O +
vs O +
. O +
36 O +
% O +
, O +
respectively O +
, O +
p O +
= O +
0 O +
. O +
01 O +
) O +
. O +

Serum O +
VEGF O +
levels O +
were O +
higher O +
in O +
patients O +
with O +
PDR O +
than O +
in O +
those O +
without O +
DR O +
( O +
219 O +
+ O +
/ O +
- O +
99 O +
vs O +
. O +
139 O +
+ O +
/ O +
- O +
98 O +
pg O +
/ O +
ml O +
, O +
p O +
less O +
than O +
0 O +
. O +
001 O +
) O +
; O +
however O +
, O +
patients O +
with O +
poor O +
and O +
good O +
CCC O +
had O +
similar O +
VEGF O +
levels O +
. O +

CONCLUSIONS O +
: O +
We O +
have O +
shown O +
that O +
patients O +
with O +
PDR O +
have O +
a O +
lower O +
coronary O +
collateral O +
score O +
than O +
patients O +
without O +
DR O +
. O +

Also O +
, O +
serum O +
VEGF O +
was O +
significantly O +
higher O +
in O +
patients O +
with O +
PDR O +
than O +
in O +
those O +
without O +
DR O +
. O +

These O +
findings O +
have O +
suggested O +
that O +
diabetes O +
mellitus O +
may O +
have O +
a O +
different O +
action O +
on O +
retinal O +
and O +
coronary O +
circulation O +
. O +

Enhancement O +
of O +
skin O +
permeation O +
of O +
ketotifen O +
by O +
supersaturation O +
generated O +
by O +
amorphous O +
form O +
of O +
the O +
drug O +
. O +

Pressure O +
sensitive O +
adhesive O +
( O +
PSA O +
) O +
matrices O +
containing O +
amorphous O +
ketotifen O +
were O +
prepared O +
and O +
evaluated O +
for O +
enhanced O +
skin O +
permeability O +
of O +
the O +
drug O +
. O +

A O +
solvent O +
casting O +
method O +
using O +
silicone O +
- O +
typed O +
PSA O +
was O +
employed O +
, O +
and O +
n O +
- O +
hexane O +
, O +
an O +
original O +
solvent O +
for O +
the O +
PSA O +
and O +
one O +
more O +
solvent O +
, O +
dichloromethane O +
, O +
tetrahydrofuran O +
, O +
acetone O +
, O +
ethyl O +
acetate O +
or O +
toluene O +
, O +
were O +
used O +
for O +
complete O +
dissolution O +
of O +
ketotifen O +
and O +
high O +
dispersion O +
in O +
an O +
amorphous O +
state O +
of O +
the O +
drug O +
. O +

Presence O +
of O +
the O +
amorphous O +
form O +
was O +
judged O +
based O +
on O +
the O +
in O +
vitro O +
drug O +
release O +
rate O +
from O +
the O +
matrix O +
. O +

As O +
a O +
result O +
, O +
dichloromethane O +
and O +
tetrahudrofuran O +
were O +
selected O +
as O +
appropriate O +
dilution O +
solvents O +
. O +

In O +
vitro O +
permeation O +
experiments O +
through O +
excised O +
hairless O +
mouse O +
skin O +
revealed O +
that O +
the O +
steady O +
- O +
state O +
flux O +
from O +
the O +
amorphous O +
ketotifen O +
- O +
dispersed O +
matrices O +
was O +
about O +
five O +
times O +
greater O +
than O +
that O +
of O +
the O +
crystalline O +
ketotifen O +
- O +
dispersed O +
matrices O +
, O +
and O +
that O +
the O +
enhancement O +
ratio O +
was O +
in O +
good O +
agreement O +
with O +
the O +
solubility O +
ratio O +
of O +
the O +
amorphous O +
to O +
crystalline O +
form O +
of O +
the O +
drug O +
. O +

Comparison O +
of O +
the O +
skin O +
permeation O +
profiles O +
of O +
amorphous O +
ketotifen O +
- O +
dispersed O +
matrices O +
between O +
two O +
different O +
drug O +
contents O +
suggested O +
that O +
the O +
steady O +
- O +
state O +
flux O +
was O +
not O +
influenced O +
by O +
the O +
drug O +
content O +
. O +

In O +
addition O +
, O +
at O +
both O +
drug O +
contents O +
, O +
the O +
period O +
of O +
the O +
steady O +
- O +
state O +
permeation O +
coincided O +
with O +
the O +
time O +
until O +
the O +
amorphous O +
drug O +
was O +
depleted O +
from O +
the O +
matrix O +
. O +

These O +
results O +
suggest O +
that O +
the O +
increase O +
in O +
skin O +
permeation O +
of O +
ketotifen O +
from O +
PSA O +
matrix O +
was O +
due O +
to O +
the O +
supersaturation O +
generated O +
by O +
amorphous O +
form O +
, O +
and O +
that O +
the O +
amorphous O +
form O +
was O +
stable O +
during O +
the O +
application O +
period O +
. O +

Polybrominated O +
diphenyl O +
ethers O +
in O +
indoor O +
dust O +
in O +
Ottawa O +
, O +
Canada O +
: O +
implications O +
for O +
sources O +
and O +
exposure O +
. O +

Polybrominated O +
diphenyl O +
ethers O +
( O +
PBDEs O +
) O +
are O +
widely O +
used O +
as O +
additive O +
flame O +
retardants O +
in O +
plastics O +
, O +
soft O +
furnishings O +
, O +
electrical O +
and O +
electronic O +
equipment O +
, O +
and O +
insulation O +
in O +
the O +
indoor O +
environment O +
, O +
and O +
may O +
be O +
released O +
indoors O +
via O +
volatilization O +
or O +
as O +
dusts O +
. O +

The O +
penta O +
- O +
and O +
octa O +
- O +
brominated O +
mixes O +
are O +
now O +
banned O +
in O +
most O +
parts O +
of O +
Europe O +
, O +
and O +
phasing O +
out O +
of O +
their O +
use O +
has O +
recently O +
begun O +
in O +
North O +
America O +
. O +

This O +
study O +
follows O +
a O +
previous O +
investigation O +
into O +
indoor O +
air O +
levels O +
of O +
PBDEs O +
. O +

House O +
dust O +
was O +
analyzed O +
from O +
the O +
family O +
vacuum O +
cleaners O +
of O +
68 O +
of O +
the O +
same O +
74 O +
randomly O +
selected O +
homes O +
, O +
in O +
Ottawa O +
, O +
Canada O +
during O +
the O +
winter O +
of O +
2002 O +
- O +
2003 O +
. O +

PBDEs O +
, O +
comprising O +
on O +
average O +
42 O +
% O +
BDE O +
- O +
209 O +
, O +
were O +
found O +
in O +
all O +
samples O +
. O +

The O +
levels O +
were O +
log O +
- O +
normally O +
distributed O +
with O +
a O +
geometric O +
mean O +
sigmaPBDE O +
of O +
2000 O +
ng O +
g O +
( O +
- O +
1 O +
) O +
, O +
and O +
a O +
median O +
of O +
1800 O +
ng O +
g O +
( O +
- O +
1 O +
) O +
dust O +
. O +

The O +
levels O +
in O +
dust O +
did O +
not O +
correlate O +
with O +
questionnaire O +
information O +
on O +
house O +
characteristics O +
. O +

Correlations O +
were O +
found O +
between O +
pentamix O +
congener O +
levels O +
in O +
dust O +
and O +
in O +
air O +
from O +
the O +
same O +
homes O +
, O +
but O +
not O +
for O +
congeners O +
of O +
the O +
more O +
highly O +
brominated O +
mixes O +
. O +

Exposure O +
scenarios O +
are O +
presented O +
for O +
mean O +
and O +
high O +
dust O +
ingestion O +
rates O +
, O +
and O +
compared O +
against O +
exposures O +
from O +
other O +
pathways O +
, O +
for O +
both O +
adults O +
and O +
toddlers O +
( O +
6 O +
months O +
- O +
2 O +
years O +
) O +
. O +

Assuming O +
a O +
mean O +
dust O +
ingestion O +
rate O +
and O +
median O +
dust O +
and O +
air O +
concentrations O +
, O +
adults O +
would O +
be O +
exposed O +
to O +
ca O +
. O +

7 O +
. O +
5 O +
ng O +
sigmaPBDE O +
d O +
( O +
- O +
1 O +
) O +
via O +
the O +
dust O +
ingestion O +
pathway O +
, O +
which O +
represents O +
approximately O +
14 O +
% O +
of O +
total O +
daily O +
exposure O +
when O +
compared O +
to O +
diet O +
( O +
82 O +
% O +
) O +
and O +
inhalation O +
( O +
4 O +
% O +
) O +
. O +

However O +
, O +
for O +
toddlers O +
the O +
equivalent O +
intakes O +
would O +
be O +
99 O +
ng O +
d O +
( O +
- O +
1 O +
) O +
, O +
representing O +
80 O +
% O +
of O +
their O +
daily O +
PBDE O +
exposure O +
. O +

At O +
high O +
dust O +
ingestion O +
rates O +
these O +
values O +
increase O +
to O +
180 O +
ng O +
d O +
( O +
- O +
1 O +
) O +
( O +
80 O +
% O +
daily O +
intake O +
) O +
for O +
adults O +
and O +
360 O +
ng O +
d O +
( O +
- O +
1 O +
) O +
( O +
89 O +
% O +
daily O +
intake O +
) O +
for O +
toddlers O +
. O +

The O +
data O +
give O +
a O +
clearer O +
picture O +
of O +
sources O +
of O +
PBDE O +
exposure O +
in O +
the O +
home O +
environment O +
and O +
suggest O +
that O +
dust O +
could O +
be O +
a O +
significant O +
exposure O +
pathway O +
for O +
some O +
individuals O +
, O +
particularly O +
children O +
. O +

The O +
threshold O +
level O +
of O +
adenomatous O +
polyposis O +
coli O +
protein O +
for O +
mouse O +
intestinal O +
tumorigenesis O +
. O +

The O +
adenomatous O +
polyposis O +
coli O +
( O +
APC O +
) O +
gene O +
, O +
whose O +
mutations O +
are O +
responsible O +
for O +
familial O +
adenomatous O +
polyposis O +
, O +
is O +
a O +
major O +
negative O +
controller O +
of O +
the O +
Wnt O +
/ O +
beta O +
- O +
catenin O +
pathway O +
. O +

To O +
investigate O +
the O +
dose O +
- O +
dependent O +
effects O +
of O +
APC O +
protein O +
in O +
suppressing O +
intestinal O +
tumorigenesis O +
, O +
we O +
constructed O +
mutant O +
mice O +
carrying O +
hypomorphic O +
Apc O +
alleles O +
Apc O +
( O +
neoR O +
) O +
and O +
Apc O +
( O +
neoF O +
) O +
whose O +
expression O +
levels O +
were O +
reduced O +
to O +
20 O +
% O +
and O +
10 O +
% O +
of O +
the O +
wild O +
type O +
, O +
respectively O +
. O +

Although O +
both O +
hypomorphic O +
heterozygotes O +
developed O +
intestinal O +
polyps O +
, O +
tumor O +
multiplicities O +
were O +
much O +
lower O +
than O +
that O +
in O +
Apc O +
( O +
Delta716 O +
) O +
mice O +
, O +
heterozygotes O +
of O +
an O +
Apc O +
null O +
allele O +
. O +

Like O +
in O +
Apc O +
( O +
Delta716 O +
) O +
mice O +
, O +
loss O +
of O +
the O +
wild O +
- O +
type O +
Apc O +
allele O +
was O +
confirmed O +
for O +
all O +
polyps O +
examined O +
in O +
the O +
Apc O +
( O +
neoR O +
) O +
and O +
Apc O +
( O +
neoF O +
) O +
mice O +
. O +

In O +
the O +
embryonic O +
stem O +
cells O +
homozygous O +
for O +
these O +
hypomorphic O +
Apc O +
alleles O +
, O +
the O +
level O +
of O +
the O +
APC O +
protein O +
was O +
inversely O +
correlated O +
with O +
both O +
the O +
beta O +
- O +
catenin O +
accumulation O +
and O +
beta O +
- O +
catenin O +
/ O +
T O +
- O +
cell O +
factor O +
transcriptional O +
activity O +
. O +

These O +
results O +
suggest O +
that O +
the O +
reduced O +
APC O +
protein O +
level O +
increases O +
intestinal O +
polyp O +
multiplicity O +
through O +
quantitative O +
stimulation O +
of O +
the O +
beta O +
- O +
catenin O +
/ O +
T O +
- O +
cell O +
factor O +
transcription O +
. O +

We O +
further O +
estimated O +
the O +
threshold O +
of O +
APC O +
protein O +
level O +
that O +
forms O +
one O +
polyp O +
per O +
mouse O +
as O +
approximately O +
15 O +
% O +
of O +
the O +
wild O +
type O +
. O +

These O +
results O +
also O +
suggest O +
therapeutic O +
implications O +
concerning O +
Wnt O +
signaling O +
inhibitors O +
. O +

Pathogenesis O +
of O +
thrombosis O +
in O +
essential O +
thrombocythemia O +
and O +
polycythemia O +
vera O +
: O +
the O +
role O +
of O +
neutrophils O +
. O +

Thrombotic O +
complications O +
are O +
frequently O +
observed O +
in O +
patients O +
with O +
polycythemia O +
vera O +
( O +
PV O +
) O +
and O +
essential O +
thrombocythemia O +
( O +
ET O +
) O +
. O +

Abnormalities O +
of O +
red O +
blood O +
cells O +
and O +
platelets O +
arising O +
from O +
the O +
clonal O +
rearrangement O +
of O +
hematopoietic O +
cells O +
have O +
been O +
considered O +
, O +
although O +
causal O +
relationships O +
between O +
any O +
of O +
these O +
specific O +
abnormalities O +
and O +
thrombosis O +
have O +
not O +
been O +
clearly O +
established O +
. O +

The O +
involvement O +
of O +
neutrophils O +
and O +
macrophages O +
, O +
which O +
participate O +
in O +
thrombosis O +
and O +
hemostasis O +
, O +
has O +
been O +
insufficiently O +
explored O +
in O +
PV O +
and O +
ET O +
. O +

Persistent O +
activation O +
of O +
circulating O +
neutrophils O +
was O +
recently O +
demonstrated O +
in O +
ET O +
and O +
PV O +
patients O +
, O +
in O +
parallel O +
with O +
an O +
increase O +
in O +
plasma O +
concentrations O +
of O +
endothelial O +
damage O +
- O +
derived O +
and O +
prothrombotic O +
substances O +
. O +

Other O +
studies O +
have O +
explored O +
whether O +
the O +
augmentation O +
of O +
adhesion O +
of O +
neutrophils O +
may O +
affect O +
neutrophil O +
/ O +
platelet O +
interaction O +
since O +
a O +
significant O +
increase O +
in O +
circulating O +
neutrophil O +
/ O +
platelet O +
aggregates O +
is O +
found O +
in O +
ET O +
and O +
PV O +
. O +

This O +
review O +
summarizes O +
the O +
current O +
knowledge O +
of O +
the O +
pathogenesis O +
of O +
thrombosis O +
in O +
PV O +
and O +
ET O +
, O +
with O +
emphasis O +
on O +
the O +
role O +
of O +
neutrophils O +
in O +
hemostasis O +
and O +
their O +
possible O +
involvement O +
in O +
the O +
mechanisms O +
of O +
the O +
acquired O +
thrombophilia O +
of O +
these O +
patients O +
. O +

Available O +
data O +
suggest O +
that O +
these O +
hemostatic O +
markers O +
deserve O +
to O +
be O +
included O +
in O +
prospective O +
clinical O +
studies O +
aimed O +
at O +
identifying O +
their O +
predictive O +
role O +
in O +
the O +
vascular O +
complications O +
of O +
patients O +
with O +
ET O +
and O +
PV O +
. O +

The O +
merits O +
of O +
vascular O +
targeting O +
for O +
gynecologic O +
malignancies O +
. O +

Neovascularization O +
is O +
an O +
early O +
and O +
critical O +
step O +
in O +
tumor O +
development O +
and O +
progression O +
. O +

Tumor O +
vessels O +
are O +
distinct O +
from O +
their O +
normal O +
counterparts O +
morphologically O +
as O +
well O +
as O +
at O +
a O +
molecular O +
level O +
. O +

Recent O +
studies O +
on O +
factors O +
involved O +
in O +
tumor O +
vascular O +
development O +
have O +
identified O +
new O +
therapeutic O +
targets O +
for O +
inhibiting O +
tumor O +
neovascularization O +
and O +
thus O +
tumor O +
progression O +
. O +

However O +
, O +
the O +
process O +
of O +
tumor O +
blood O +
vessel O +
formation O +
is O +
complex O +
, O +
and O +
each O +
tumor O +
exhibits O +
unique O +
features O +
in O +
its O +
vasculature O +
. O +

An O +
understanding O +
of O +
the O +
relative O +
contribution O +
of O +
various O +
pathways O +
in O +
the O +
development O +
of O +
tumor O +
vasculature O +
is O +
critical O +
for O +
developing O +
effective O +
and O +
selective O +
therapeutic O +
approaches O +
. O +

Several O +
such O +
agents O +
are O +
currently O +
in O +
clinical O +
trials O +
, O +
and O +
many O +
others O +
are O +
under O +
development O +
. O +

In O +
this O +
review O +
, O +
the O +
mechanisms O +
and O +
factors O +
involved O +
in O +
tumor O +
blood O +
vessel O +
formation O +
are O +
discussed O +
. O +

In O +
addition O +
, O +
selected O +
novel O +
classes O +
of O +
antivascular O +
therapies O +
, O +
including O +
those O +
targeting O +
tumor O +
endothelial O +
cells O +
and O +
other O +
components O +
of O +
the O +
tumor O +
vasculature O +
, O +
are O +
summarized O +
. O +

Normal O +
and O +
transforming O +
functions O +
of O +
RUNX1 O +
: O +
a O +
perspective O +
. O +

Converging O +
studies O +
from O +
many O +
investigators O +
indicate O +
that O +
RUNX1 O +
has O +
a O +
critical O +
role O +
in O +
the O +
correct O +
maintenance O +
of O +
essential O +
cellular O +
functions O +
during O +
embryonic O +
development O +
and O +
after O +
birth O +
. O +

The O +
discovery O +
that O +
this O +
gene O +
is O +
also O +
frequently O +
mutated O +
in O +
human O +
leukemia O +
has O +
increased O +
the O +
interest O +
in O +
the O +
role O +
that O +
RUNX1 O +
plays O +
in O +
both O +
normal O +
and O +
transforming O +
pathways O +
. O +

Here O +
, O +
we O +
provide O +
an O +
overview O +
of O +
the O +
many O +
roles O +
of O +
RUNX1 O +
in O +
hematopoietic O +
self O +
- O +
renewal O +
and O +
differentiation O +
and O +
summarize O +
the O +
information O +
that O +
is O +
currently O +
available O +
on O +
the O +
many O +
mechanisms O +
of O +
RUNX1 O +
deregulation O +
in O +
human O +
leukemia O +
. O +

Sensitivity O +
variation O +
in O +
two O +
- O +
center O +
holographic O +
recording O +
. O +

An O +
experimental O +
study O +
of O +
variation O +
of O +
sensitivity O +
with O +
recording O +
and O +
sensitizing O +
intensities O +
in O +
two O +
- O +
center O +
recording O +
is O +
presented O +
. O +

The O +
experimental O +
results O +
are O +
in O +
good O +
agreement O +
with O +
the O +
theoretical O +
predictions O +
. O +

It O +
is O +
shown O +
experimentally O +
, O +
for O +
what O +
is O +
to O +
our O +
knowledge O +
the O +
first O +
time O +
, O +
that O +
the O +
sensitivity O +
is O +
a O +
function O +
of O +
the O +
ratio O +
of O +
recording O +
to O +
sensitizing O +
intensities O +
and O +
not O +
the O +
absolute O +
intensities O +
. O +

Also O +
, O +
the O +
ratio O +
of O +
recording O +
to O +
sensitizing O +
intensities O +
should O +
be O +
small O +
to O +
obtain O +
high O +
sensitivity O +
values O +
. O +

We O +
also O +
report O +
the O +
highest O +
sensitivity O +
( O +
S O +
= O +
0 O +
. O +
15 O +
cm O +
/ O +
J O +
) O +
that O +
has O +
been O +
achieved O +
to O +
date O +
for O +
a O +
LiNbO3 O +
: O +
Fe O +
: O +
Mn O +
crystal O +
. O +

Domain O +
5 O +
of O +
cleaved O +
high O +
molecular O +
weight O +
kininogen O +
inhibits O +
endothelial O +
cell O +
migration O +
through O +
Akt O +
. O +

Domain O +
5 O +
( O +
D5 O +
) O +
of O +
cleaved O +
high O +
molecular O +
weight O +
kininogen O +
( O +
HKa O +
) O +
inhibits O +
angiogenesis O +
in O +
vivo O +
and O +
endothelial O +
cell O +
migration O +
in O +
vitro O +
, O +
but O +
the O +
cell O +
signaling O +
pathways O +
involved O +
in O +
HKa O +
and O +
D5 O +
inhibition O +
of O +
endothelial O +
cell O +
migration O +
are O +
incompletely O +
delineated O +
. O +

This O +
study O +
examines O +
the O +
mechanism O +
of O +
HKa O +
and O +
D5 O +
inhibition O +
of O +
two O +
potent O +
stimulators O +
of O +
endothelial O +
cell O +
migration O +
, O +
sphingosine O +
1 O +
- O +
phosphate O +
( O +
S1P O +
) O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
, O +
that O +
act O +
through O +
the O +
P13 O +
- O +
kinase O +
- O +
Akt O +
signaling O +
pathway O +
. O +

HKa O +
and O +
D5 O +
inhibit O +
bovine O +
pulmonary O +
artery O +
endothelial O +
cell O +
( O +
BPAE O +
) O +
or O +
human O +
umbilical O +
vein O +
endothelial O +
cell O +
chemotaxis O +
in O +
the O +
modified O +
- O +
Boyden O +
chamber O +
in O +
response O +
toVEGF O +
or O +
S1P O +
. O +

The O +
inhibition O +
of O +
migration O +
by O +
HKa O +
is O +
reversed O +
by O +
antibodies O +
to O +
urokinase O +
- O +
type O +
plasminogen O +
activator O +
receptor O +
. O +

Both O +
HKa O +
and O +
D5 O +
decrease O +
the O +
speed O +
of O +
BPAE O +
cell O +
migration O +
and O +
alter O +
the O +
morphology O +
in O +
live O +
, O +
time O +
- O +
lapse O +
microscopy O +
after O +
stimulation O +
with O +
S1P O +
or O +
VEGF O +
. O +

HKa O +
and O +
D5 O +
reduce O +
the O +
localization O +
of O +
paxillin O +
to O +
the O +
focal O +
adhesions O +
after O +
S1P O +
and O +
VEGF O +
stimulation O +
. O +

To O +
better O +
understand O +
the O +
intracellular O +
signaling O +
pathways O +
, O +
we O +
examined O +
the O +
effect O +
of O +
HKa O +
on O +
the O +
phosphorylation O +
of O +
Akt O +
and O +
its O +
downstream O +
effector O +
, O +
GSK O +
- O +
3alpha O +
HKa O +
and O +
D5 O +
inhibit O +
phosphorylation O +
of O +
Akt O +
and O +
GSK O +
- O +
3alpha O +
after O +
stimulation O +
withVEGF O +
and O +
S1P O +
. O +

Inhibitors O +
of O +
Akt O +
and O +
P13 O +
- O +
kinase O +
, O +
the O +
upstream O +
activator O +
of O +
Akt O +
, O +
block O +
endothelial O +
cell O +
migration O +
and O +
disrupt O +
paxillin O +
localization O +
to O +
the O +
focal O +
adhesions O +
after O +
stimulation O +
with O +
VEGF O +
and O +
S1P O +
. O +

Therefore O +
we O +
suggest O +
that O +
HKa O +
through O +
its O +
D5 O +
domain O +
alters O +
P13 O +
- O +
kinase O +
- O +
Akt O +
signaling O +
to O +
inhibit O +
endothelial O +
cell O +
migration O +
through O +
alterations O +
in O +
the O +
focal O +
adhesions O +
. O +

Histopathological O +
development O +
of O +
gastric O +
tumors O +
induced O +
by O +
N O +
- O +
methyl O +
- O +
N O +
' O +
- O +
nitro O +
- O +
N O +
- O +
nitrosoguanidine O +
in O +
rats O +
. O +

The O +
development O +
of O +
carcinoma O +
was O +
examined O +
in O +
male O +
Wistar O +
rats O +
( O +
n O +
= O +
120 O +
) O +
exposed O +
to O +
N O +
- O +
methyl O +
- O +
N O +
' O +
- O +
nitro O +
- O +
N O +
- O +
nitrosoguanidine O +
( O +
MNNG O +
) O +
in O +
the O +
drinking O +
water O +
( O +
83 O +
micrograms O +
/ O +
ml O +
) O +
for O +
16 O +
weeks O +
. O +

After O +
MNNG O +
administration O +
, O +
rats O +
were O +
investigated O +
by O +
endoscopic O +
observation O +
, O +
visualization O +
of O +
microvascular O +
structure O +
, O +
and O +
estimation O +
of O +
lectin O +
binding O +
sites O +
. O +

Changes O +
of O +
bile O +
reflux O +
to O +
the O +
stomach O +
was O +
observed O +
endoscopically O +
at O +
24 O +
weeks O +
as O +
well O +
as O +
the O +
development O +
of O +
gastric O +
mucosal O +
erosions O +
. O +

Protruding O +
and O +
expansive O +
ulcerating O +
carcinomas O +
developed O +
at O +
36 O +
weeks O +
and O +
had O +
a O +
microvascular O +
pattern O +
similar O +
to O +
that O +
of O +
human O +
adenocarcinoma O +
. O +

Estimation O +
of O +
lectin O +
binding O +
site O +
and O +
pattern O +
was O +
useful O +
to O +
evaluate O +
the O +
malignant O +
potential O +
of O +
cell O +
proliferation O +
. O +

We O +
postulate O +
that O +
endoscopic O +
observation O +
is O +
valuable O +
in O +
investigating O +
the O +
development O +
of O +
gastric O +
carcinoma O +
, O +
and O +
microvascular O +
structure O +
and O +
lectin O +
binding O +
pattern O +
may O +
be O +
useful O +
to O +
demonstrate O +
the O +
mechanism O +
of O +
growth O +
of O +
gastric O +
carcinoma O +
. O +

Effect O +
of O +
thalidomide O +
affecting O +
VEGF O +
secretion O +
, O +
cell O +
migration O +
, O +
adhesion O +
and O +
capillary O +
tube O +
formation O +
of O +
human O +
endothelial O +
EA B-CellLine +
. I-CellLine +
hy I-CellLine +
926 I-CellLine +
cells O +
. O +

Angiogenesis O +
, O +
new O +
blood O +
vessel O +
formation O +
, O +
is O +
a O +
multistep O +
process O +
, O +
precisely O +
regulated O +
by O +
pro O +
- O +
angiogenic O +
cytokines O +
, O +
which O +
stimulate O +
endothelial O +
cells O +
to O +
migrate O +
, O +
proliferate O +
and O +
differentiate O +
to O +
form O +
new O +
capillary O +
microvessels O +
. O +

Excessive O +
vascular O +
development O +
and O +
blood O +
vessel O +
remodeling O +
appears O +
in O +
psoriasis O +
, O +
rheumatoid O +
arthritis O +
, O +
diabetic O +
retinopathy O +
and O +
solid O +
tumors O +
formation O +
. O +

Thalidomide O +
[ O +
alpha O +
- O +
( O +
N O +
- O +
phthalimido O +
) O +
- O +
glutarimide O +
] O +
is O +
known O +
to O +
be O +
a O +
potent O +
inhibitor O +
of O +
angiogenesis O +
, O +
but O +
the O +
mechanism O +
of O +
its O +
inhibitory O +
action O +
remains O +
unclear O +
. O +

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
investigate O +
the O +
potential O +
influence O +
of O +
thalidomide O +
on O +
the O +
several O +
steps O +
of O +
angiogenesis O +
, O +
using O +
in O +
vitro O +
models O +
. O +

We O +
have O +
evaluated O +
the O +
effect O +
of O +
thalidomide O +
on O +
VEGF O +
secretion O +
, O +
cell O +
migration O +
, O +
adhesion O +
as O +
well O +
as O +
in O +
capillary O +
formation O +
of O +
human O +
endothelial O +
cell O +
line O +
EA B-CellLine +
. I-CellLine +
hy I-CellLine +
926 I-CellLine +
. O +

Thalidomide O +
at O +
the O +
concentrations O +
of O +
0 O +
. O +
01 O +
microM O +
and O +
10 O +
microM O +
inhibited O +
VEGF O +
secretion O +
into O +
supernatants O +
, O +
decreased O +
the O +
number O +
of O +
formed O +
capillary O +
tubes O +
and O +
increased O +
cell O +
adhesion O +
to O +
collagen O +
. O +

Administration O +
of O +
thalidomide O +
at O +
the O +
concentration O +
of O +
0 O +
. O +
01 O +
microM O +
increased O +
cell O +
migration O +
, O +
while O +
at O +
10 O +
microM O +
, O +
it O +
decreased O +
cell O +
migration O +
. O +

Thalidomide O +
in O +
concentrations O +
from O +
0 O +
. O +
1 O +
microM O +
to O +
10 O +
microM O +
did O +
not O +
change O +
cell O +
proliferation O +
of O +
72 O +
- O +
h O +
cell O +
cultures O +
. O +

We O +
conclude O +
that O +
anti O +
- O +
angiogenic O +
action O +
of O +
thalidomide O +
is O +
due O +
to O +
direct O +
inhibitory O +
action O +
on O +
VEGF O +
secretion O +
and O +
capillary O +
microvessel O +
formation O +
as O +
well O +
as O +
immunomodulatory O +
influence O +
on O +
EA O +
. O +
hy O +
926 O +
cells O +
migration O +
and O +
adhesion O +
. O +

VEGFR1 O +
- O +
positive O +
haematopoietic O +
bone O +
marrow O +
progenitors O +
initiate O +
the O +
pre O +
- O +
metastatic O +
niche O +
. O +

The O +
cellular O +
and O +
molecular O +
mechanisms O +
by O +
which O +
a O +
tumour O +
cell O +
undergoes O +
metastasis O +
to O +
a O +
predetermined O +
location O +
are O +
largely O +
unknown O +
. O +

Here O +
we O +
demonstrate O +
that O +
bone O +
marrow O +
- O +
derived O +
haematopoietic O +
progenitor O +
cells O +
that O +
express O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
1 O +
( O +
VEGFR1 O +
; O +
also O +
known O +
as O +
Flt1 O +
) O +
home O +
to O +
tumour O +
- O +
specific O +
pre O +
- O +
metastatic O +
sites O +
and O +
form O +
cellular O +
clusters O +
before O +
the O +
arrival O +
of O +
tumour O +
cells O +
. O +

Preventing O +
VEGFR1 O +
function O +
using O +
antibodies O +
or O +
by O +
the O +
removal O +
of O +
VEGFR1 O +
( O +
+ O +
) O +
cells O +
from O +
the O +
bone O +
marrow O +
of O +
wild O +
- O +
type O +
mice O +
abrogates O +
the O +
formation O +
of O +
these O +
pre O +
- O +
metastatic O +
clusters O +
and O +
prevents O +
tumour O +
metastasis O +
, O +
whereas O +
reconstitution O +
with O +
selected O +
Id3 O +
( O +
inhibitor O +
of O +
differentiation O +
3 O +
) O +
- O +
competent O +
VEGFR1 O +
+ O +
cells O +
establishes O +
cluster O +
formation O +
and O +
tumour O +
metastasis O +
in O +
Id3 O +
knockout O +
mice O +
. O +

We O +
also O +
show O +
that O +
VEGFR1 O +
+ O +
cells O +
express O +
VLA O +
- O +
4 O +
( O +
also O +
known O +
as O +
integrin O +
alpha4beta1 O +
) O +
, O +
and O +
that O +
tumour O +
- O +
specific O +
growth O +
factors O +
upregulate O +
fibronectin O +
- O +
- O +
a O +
VLA O +
- O +
4 O +
ligand O +
- O +
- O +
in O +
resident O +
fibroblasts O +
, O +
providing O +
a O +
permissive O +
niche O +
for O +
incoming O +
tumour O +
cells O +
. O +

Conditioned O +
media O +
obtained O +
from O +
distinct O +
tumour O +
types O +
with O +
unique O +
patterns O +
of O +
metastatic O +
spread O +
redirected O +
fibronectin O +
expression O +
and O +
cluster O +
formation O +
, O +
thereby O +
transforming O +
the O +
metastatic O +
profile O +
. O +

These O +
findings O +
demonstrate O +
a O +
requirement O +
for O +
VEGFR1 O +
+ O +
haematopoietic O +
progenitors O +
in O +
the O +
regulation O +
of O +
metastasis O +
, O +
and O +
suggest O +
that O +
expression O +
patterns O +
of O +
fibronectin O +
and O +
VEGFR1 O +
+ O +
VLA O +
- O +
4 O +
+ O +
clusters O +
dictate O +
organ O +
- O +
specific O +
tumour O +
spread O +
. O +

Regulation O +
of O +
skin O +
microvasculature O +
angiogenesis O +
, O +
cell O +
migration O +
, O +
and O +
permeability O +
by O +
a O +
specific O +
inhibitor O +
of O +
PKCalpha O +
. O +

Activation O +
of O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
induces O +
phenotypic O +
changes O +
in O +
the O +
morphology O +
of O +
microvascular O +
endothelial O +
cells O +
that O +
affect O +
major O +
functions O +
of O +
the O +
microvasculature O +
. O +

These O +
functions O +
include O +
the O +
first O +
stages O +
of O +
sprouting O +
in O +
angiogenesis O +
, O +
cell O +
migration O +
following O +
wounding O +
, O +
and O +
vascular O +
permeability O +
. O +

The O +
specific O +
isoform O +
( O +
s O +
) O +
of O +
PKC O +
responsible O +
for O +
each O +
of O +
these O +
changes O +
has O +
not O +
been O +
previously O +
identified O +
. O +

In O +
this O +
study O +
, O +
we O +
used O +
two O +
inflammatory O +
agents O +
, O +
IL O +
- O +
1beta O +
and O +
phorbol O +
myristic O +
acetate O +
, O +
to O +
activate O +
PKC O +
isozymes O +
and O +
specific O +
inhibitors O +
of O +
PKCalpha O +
( O +
Go6976 O +
) O +
and O +
PKCbeta O +
( O +
hispidin O +
) O +
to O +
distinguish O +
how O +
each O +
of O +
these O +
isoform O +
( O +
s O +
) O +
controls O +
angiogenesis O +
, O +
wound O +
healing O +
, O +
and O +
permeability O +
. O +

In O +
all O +
cases O +
, O +
only O +
inhibition O +
of O +
PKCalpha O +
inhibited O +
each O +
of O +
these O +
functions O +
when O +
compared O +
to O +
the O +
inhibition O +
of O +
PKCbeta O +
. O +

Additional O +
analysis O +
of O +
the O +
mechanism O +
of O +
action O +
of O +
Go6976 O +
( O +
RT O +
- O +
PCR O +
, O +
Western O +
blots O +
, O +
and O +
immunohistochemistry O +
) O +
of O +
the O +
changes O +
in O +
the O +
phosphorylated O +
and O +
nonphosphorylated O +
forms O +
of O +
PKCalpha O +
in O +
the O +
cell O +
membrane O +
and O +
cytoplasm O +
confirmed O +
the O +
specificity O +
of O +
PKCalpha O +
inhibition O +
by O +
Go6976 O +
. O +

These O +
studies O +
therefore O +
indicate O +
a O +
specific O +
and O +
a O +
regulatory O +
role O +
of O +
the O +
PKCalpha O +
isoform O +
in O +
three O +
major O +
endothelial O +
cell O +
functions O +
that O +
are O +
important O +
in O +
the O +
maintenance O +
of O +
microvascular O +
homeostasis O +
. O +

Recent O +
advances O +
in O +
minisatellite O +
biology O +
. O +

Highly O +
polymorphic O +
tandemly O +
repeated O +
' O +
minisatellite O +
' O +
loci O +
are O +
very O +
abundant O +
in O +
the O +
human O +
genome O +
, O +
and O +
of O +
considerable O +
utility O +
in O +
human O +
genetic O +
analysis O +
. O +

This O +
review O +
describes O +
the O +
use O +
of O +
an O +
ordered O +
- O +
array O +
Charomid O +
library O +
in O +
the O +
systematic O +
and O +
efficient O +
cloning O +
of O +
these O +
regions O +
, O +
and O +
in O +
the O +
analysis O +
of O +
the O +
relative O +
overlap O +
between O +
the O +
different O +
probes O +
used O +
to O +
screen O +
for O +
hypervariable O +
loci O +
. O +

Recent O +
work O +
on O +
the O +
process O +
of O +
mutation O +
leading O +
to O +
the O +
generation O +
of O +
new O +
- O +
length O +
alleles O +
is O +
also O +
discussed O +
, O +
including O +
the O +
observation O +
that O +
at O +
least O +
some O +
mutations O +
may O +
be O +
due O +
to O +
unequal O +
exchanges O +
. O +

The O +
Kaposi O +
' O +
s O +
sarcoma O +
- O +
associated O +
herpesvirus O +
G O +
protein O +
- O +
coupled O +
receptor O +
as O +
a O +
therapeutic O +
target O +
for O +
the O +
treatment O +
of O +
Kaposi O +
' O +
s O +
sarcoma O +
. O +

The O +
Kaposi O +
' O +
s O +
sarcoma O +
- O +
associated O +
herpesvirus O +
( O +
KSHV O +
) O +
encodes O +
a O +
G O +
protein O +
- O +
coupled O +
receptor O +
( O +
vGPCR O +
) O +
that O +
has O +
been O +
implicated O +
in O +
the O +
initiation O +
of O +
Kaposi O +
' O +
s O +
sarcoma O +
, O +
identifying O +
vGPCR O +
as O +
an O +
attractive O +
target O +
for O +
preventing O +
Kaposi O +
' O +
s O +
sarcoma O +
. O +

However O +
, O +
as O +
only O +
a O +
fraction O +
of O +
cells O +
in O +
advanced O +
Kaposi O +
' O +
s O +
sarcoma O +
lesions O +
express O +
vGPCR O +
, O +
it O +
is O +
unclear O +
whether O +
this O +
unique O +
viral O +
oncogene O +
contributes O +
to O +
Kaposi O +
' O +
s O +
sarcoma O +
progression O +
. O +

We O +
therefore O +
set O +
out O +
to O +
determine O +
whether O +
the O +
few O +
cells O +
that O +
express O +
vGPCR O +
in O +
established O +
tumors O +
represent O +
an O +
appropriate O +
therapeutic O +
target O +
for O +
the O +
treatment O +
of O +
patients O +
with O +
preexisting O +
Kaposi O +
' O +
s O +
sarcoma O +
. O +

To O +
this O +
end O +
, O +
we O +
generated O +
endothelial O +
cell O +
lines O +
stably O +
expressing O +
vGPCR O +
or O +
key O +
KSHV O +
latently O +
expressed O +
proteins O +
( O +
vCyclin O +
, O +
vFlip O +
, O +
and O +
LANA1 O +
) O +
. O +

The O +
endothelial O +
cell O +
line O +
expressing O +
vGPCR O +
was O +
rendered O +
sensitive O +
to O +
treatment O +
with O +
the O +
nucleoside O +
analogue O +
ganciclovir O +
by O +
using O +
a O +
bicistronic O +
construct O +
coexpressing O +
the O +
herpes O +
simplex O +
virus O +
1 O +
thymidine O +
kinase O +
. O +

S O +
. O +
c O +
. O +
injection O +
into O +
nude O +
mice O +
with O +
mixed O +
- O +
cell O +
populations O +
formed O +
tumors O +
that O +
approximate O +
the O +
ratio O +
of O +
vGPCR O +
- O +
expressing O +
and O +
KSHV O +
latent O +
gene O +
- O +
expressing O +
cells O +
. O +

These O +
mice O +
were O +
then O +
treated O +
with O +
ganciclovir O +
to O +
specifically O +
target O +
only O +
the O +
vGPCR O +
- O +
expressing O +
cells O +
. O +

Surprisingly O +
, O +
despite O +
the O +
expression O +
of O +
KSHV O +
latent O +
genes O +
in O +
the O +
vast O +
majority O +
of O +
tumor O +
cells O +
, O +
specifically O +
targeting O +
only O +
the O +
few O +
vGPCR O +
- O +
expressing O +
cells O +
in O +
established O +
tumors O +
resulted O +
in O +
tumor O +
regression O +
. O +

Moreover O +
, O +
we O +
observed O +
an O +
increase O +
in O +
apoptosis O +
of O +
latent O +
gene O +
- O +
expressing O +
cells O +
after O +
the O +
pharmacologic O +
deletion O +
of O +
the O +
vGPCR O +
- O +
expressing O +
cells O +
. O +

These O +
findings O +
indicate O +
that O +
vGPCR O +
may O +
play O +
a O +
key O +
role O +
in O +
Kaposi O +
' O +
s O +
sarcoma O +
progression O +
and O +
provide O +
experimental O +
justification O +
for O +
developing O +
molecular O +
- O +
based O +
therapies O +
specifically O +
targeting O +
vGPCR O +
and O +
its O +
effectors O +
for O +
the O +
treatment O +
of O +
Kaposi O +
' O +
s O +
sarcoma O +
patients O +
. O +

The O +
differential O +
regulation O +
of O +
human O +
telomerase O +
reverse O +
transcriptase O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
may O +
contribute O +
to O +
the O +
clinically O +
more O +
aggressive O +
behavior O +
of O +
p63 O +
- O +
positive O +
breast O +
carcinomas O +
. O +

p63 O +
, O +
a O +
p53 O +
homologue O +
, O +
is O +
a O +
myoepithelial O +
cell O +
marker O +
in O +
the O +
normal O +
mammary O +
gland O +
but O +
p63 O +
- O +
positive O +
neoplastic O +
cells O +
may O +
be O +
found O +
in O +
up O +
to O +
11 O +
% O +
of O +
invasive O +
breast O +
carcinomas O +
. O +

This O +
study O +
aims O +
to O +
verify O +
the O +
relationship O +
between O +
p63 O +
expression O +
and O +
several O +
clinicopathological O +
features O +
and O +
tumor O +
markers O +
of O +
clinical O +
significance O +
in O +
breast O +
pathology O +
including O +
key O +
regulators O +
of O +
the O +
cell O +
cycle O +
, O +
oncogenes O +
, O +
apoptosis O +
- O +
related O +
proteins O +
, O +
metalloproteinases O +
and O +
their O +
inhibitors O +
. O +

Immunohistochemistry O +
with O +
27 O +
primary O +
antibodies O +
was O +
performed O +
in O +
100 O +
formalin O +
- O +
fixed O +
paraffin O +
- O +
embedded O +
samples O +
of O +
invasive O +
ductal O +
carcinomas O +
. O +

p63 O +
- O +
positive O +
cells O +
were O +
found O +
in O +
16 O +
% O +
of O +
carcinomas O +
. O +

p63 O +
- O +
positive O +
carcinomas O +
were O +
poorly O +
differentiated O +
, O +
hormone O +
receptor O +
- O +
negative O +
neoplasms O +
with O +
a O +
high O +
proliferation O +
rate O +
. O +

p63 O +
also O +
correlated O +
with O +
advanced O +
pathological O +
stage O +
, O +
tumor O +
size O +
, O +
and O +
the O +
expression O +
of O +
human O +
telomerase O +
reverse O +
transcriptase O +
( O +
hTERT O +
) O +
, O +
tissue O +
inhibitor O +
of O +
matrix O +
metalloproteinase O +
1 O +
( O +
TIMP1 O +
) O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
. O +

The O +
expression O +
of O +
TIMP1 O +
suggests O +
that O +
the O +
anti O +
- O +
proteolytic O +
stimuli O +
may O +
be O +
preponderant O +
in O +
p63 O +
- O +
positive O +
carcinomas O +
. O +

hTERT O +
activity O +
is O +
associated O +
with O +
nodal O +
metastases O +
and O +
cellular O +
proliferation O +
. O +

VEGF O +
regulates O +
angiogenesis O +
, O +
which O +
is O +
also O +
a O +
fundamental O +
event O +
in O +
the O +
process O +
of O +
tumor O +
growth O +
and O +
metastatic O +
dissemination O +
. O +

Thus O +
, O +
the O +
differential O +
regulation O +
of O +
hTERT O +
and O +
VEGF O +
in O +
p63 O +
- O +
positive O +
breast O +
carcinomas O +
may O +
contribute O +
to O +
the O +
clinically O +
more O +
aggressive O +
behavior O +
of O +
these O +
neoplasms O +
. O +

Mechanisms O +
of O +
pericyte O +
recruitment O +
in O +
tumour O +
angiogenesis O +
: O +
a O +
new O +
role O +
for O +
metalloproteinases O +
. O +

Pericytes O +
occur O +
in O +
tumour O +
blood O +
vessels O +
and O +
are O +
critical O +
for O +
the O +
development O +
of O +
a O +
functional O +
vascular O +
network O +
. O +

Targeting O +
tumour O +
pericytes O +
is O +
a O +
promising O +
anti O +
- O +
angiogenic O +
therapy O +
but O +
requires O +
identifying O +
the O +
mechanisms O +
of O +
their O +
recruitment O +
in O +
tumour O +
and O +
addressing O +
whether O +
these O +
mechanisms O +
can O +
be O +
selectively O +
harnessed O +
. O +

Among O +
the O +
pathways O +
involved O +
in O +
pericyte O +
recruitment O +
during O +
embryonic O +
development O +
, O +
the O +
contribution O +
of O +
platelet O +
- O +
derived O +
growth O +
factor O +
B O +
and O +
sphingosine O +
1 O +
- O +
phosphate O +
is O +
confirmed O +
in O +
tumour O +
angiogenesis O +
. O +

The O +
effect O +
of O +
angiopoietin O +
1 O +
depends O +
on O +
the O +
tumour O +
model O +
. O +

Transforming O +
growth O +
factor O +
- O +
beta1 O +
enhances O +
tumour O +
vascularization O +
and O +
microvessel O +
maturation O +
. O +

Recent O +
reports O +
suggest O +
a O +
participation O +
of O +
matrix O +
metalloproteinases O +
( O +
MMP O +
) O +
in O +
tumour O +
pericyte O +
recruitment O +
that O +
is O +
consistent O +
with O +
the O +
effect O +
of O +
certain O +
MMPs O +
in O +
the O +
development O +
of O +
microvasculature O +
in O +
embryonic O +
development O +
and O +
in O +
in O +
vitro O +
models O +
of O +
vascular O +
remodelling O +
. O +

Here O +
, O +
we O +
discuss O +
the O +
possibility O +
for O +
MMPs O +
to O +
contribute O +
to O +
pericyte O +
recruitment O +
at O +
six O +
levels O +
: O +
( O +
1 O +
) O +
direct O +
promotion O +
of O +
pericyte O +
invasion O +
by O +
extracellular O +
matrix O +
degradation O +
; O +
( O +
2 O +
) O +
stimulation O +
of O +
pericyte O +
proliferation O +
and O +
protection O +
against O +
apoptosis O +
by O +
modification O +
of O +
the O +
ECM O +
; O +
( O +
3 O +
) O +
activation O +
of O +
pericytes O +
through O +
the O +
release O +
of O +
growth O +
factor O +
bound O +
to O +
the O +
ECM O +
; O +
( O +
4 O +
) O +
transactivation O +
of O +
angiogenic O +
cell O +
surface O +
receptor O +
; O +
( O +
5 O +
) O +
propagation O +
of O +
angiogenic O +
signalling O +
as O +
cofactor O +
; O +
and O +
( O +
6 O +
) O +
recruitment O +
of O +
bone O +
marrow O +
- O +
derived O +
stem O +
cells O +
. O +

Regulation O +
of O +
tumor O +
angiogenesis O +
by O +
thrombospondin O +
- O +
1 O +
. O +

Angiogenesis O +
plays O +
a O +
critical O +
role O +
in O +
the O +
growth O +
and O +
metastasis O +
of O +
tumors O +
. O +

Thrombospondin O +
- O +
1 O +
( O +
TSP O +
- O +
1 O +
) O +
is O +
a O +
potent O +
angiogenesis O +
inhibitor O +
, O +
and O +
down O +
- O +
regulation O +
of O +
TSP O +
- O +
1 O +
has O +
been O +
suggested O +
to O +
alter O +
tumor O +
growth O +
by O +
modulating O +
angiogenesis O +
in O +
a O +
variety O +
of O +
tumor O +
types O +
. O +

Expression O +
of O +
TSP O +
- O +
1 O +
is O +
up O +
- O +
regulated O +
by O +
the O +
tumor O +
suppressor O +
gene O +
, O +
p53 O +
, O +
and O +
down O +
- O +
regulated O +
by O +
oncogenes O +
such O +
as O +
Myc O +
and O +
Ras O +
. O +

TSP O +
- O +
1 O +
inhibits O +
angiogenesis O +
by O +
inhibiting O +
endothelial O +
cell O +
migration O +
and O +
proliferation O +
and O +
by O +
inducing O +
apoptosis O +
. O +

In O +
addition O +
, O +
activation O +
of O +
transforming O +
growth O +
factor O +
beta O +
( O +
TGF O +
- O +
beta O +
) O +
by O +
TSP O +
- O +
1 O +
plays O +
a O +
crucial O +
role O +
in O +
the O +
regulation O +
of O +
tumor O +
progression O +
. O +

An O +
understanding O +
of O +
the O +
molecular O +
basis O +
of O +
TSP O +
- O +
1 O +
- O +
mediated O +
inhibition O +
of O +
angiogenesis O +
and O +
tumor O +
progression O +
will O +
aid O +
in O +
the O +
development O +
of O +
novel O +
therapeutics O +
for O +
the O +
treatment O +
of O +
cancer O +
. O +

Regulation O +
of O +
the O +
composition O +
of O +
the O +
extracellular O +
matrix O +
by O +
low O +
density O +
lipoprotein O +
receptor O +
- O +
related O +
protein O +
- O +
1 O +
: O +
activities O +
based O +
on O +
regulation O +
of O +
mRNA O +
expression O +
. O +

Low O +
density O +
lipoprotein O +
receptor O +
- O +
related O +
protein O +
- O +
1 O +
( O +
LRP O +
- O +
1 O +
) O +
is O +
a O +
catabolic O +
receptor O +
for O +
extracellular O +
matrix O +
( O +
ECM O +
) O +
structural O +
proteins O +
and O +
for O +
proteins O +
that O +
bind O +
to O +
ECM O +
. O +

LRP O +
- O +
1 O +
also O +
is O +
implicated O +
in O +
integrin O +
maturation O +
. O +

In O +
this O +
study O +
, O +
we O +
applied O +
a O +
proteomics O +
strategy O +
to O +
identify O +
novel O +
proteins O +
involved O +
in O +
ECM O +
modeling O +
that O +
are O +
regulated O +
by O +
LRP O +
- O +
1 O +
. O +

We O +
show O +
that O +
LRP O +
- O +
1 O +
deficiency O +
in O +
murine O +
embryonic O +
fibroblasts O +
( O +
MEFs O +
) O +
is O +
associated O +
with O +
increased O +
levels O +
of O +
type O +
III O +
collagen O +
and O +
pigment O +
epithelium O +
- O +
derived O +
factor O +
, O +
which O +
accumulate O +
in O +
the O +
substratum O +
surrounding O +
cells O +
. O +

The O +
collagen O +
receptor O +
, O +
uPAR O +
- O +
AP O +
/ O +
Endo O +
- O +
180 O +
, O +
is O +
also O +
increased O +
in O +
LRP O +
- O +
1 O +
- O +
deficient O +
MEFs O +
. O +

Human O +
LRP O +
- O +
1 O +
reversed O +
the O +
changes O +
in O +
protein O +
expression O +
associated O +
with O +
LRP O +
- O +
1 O +
deficiency O +
; O +
however O +
, O +
the O +
endocytic O +
activity O +
of O +
LRP O +
- O +
1 O +
was O +
not O +
involved O +
. O +

Instead O +
, O +
regulation O +
occurred O +
at O +
the O +
mRNA O +
level O +
. O +

Inhibition O +
of O +
c O +
- O +
Jun O +
amino O +
- O +
terminal O +
kinase O +
( O +
JNK O +
) O +
blocked O +
type O +
III O +
collagen O +
expression O +
in O +
LRP O +
- O +
1 O +
- O +
deficient O +
MEFs O +
, O +
suggesting O +
regulation O +
of O +
JNK O +
activity O +
as O +
a O +
mechanism O +
by O +
which O +
LRP O +
- O +
1 O +
controls O +
mRNA O +
expression O +
. O +

The O +
ability O +
of O +
LRP O +
- O +
1 O +
to O +
regulate O +
expression O +
of O +
the O +
factors O +
identified O +
here O +
suggests O +
a O +
role O +
for O +
LRP O +
- O +
1 O +
in O +
determining O +
blood O +
vessel O +
structure O +
and O +
in O +
angiogenesis O +
. O +

Involvement O +
of O +
de O +
novo O +
ceramide O +
synthesis O +
in O +
radiocontrast O +
- O +
induced O +
renal O +
tubular O +
cell O +
injury O +
. O +

We O +
reported O +
previously O +
that O +
various O +
radiocontrast O +
media O +
cause O +
apoptosis O +
in O +
porcine O +
proximal O +
tubular O +
( O +
LLC O +
- O +
PK O +
( O +
1 O +
) O +
) O +
cells O +
, O +
in O +
which O +
reduction O +
in O +
B O +
- O +
cell O +
lymphoma O +
( O +
Bcl O +
) O +
- O +
2 O +
expression O +
and O +
caspase O +
- O +
3 O +
activation O +
are O +
implicated O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
investigated O +
a O +
role O +
for O +
ceramide O +
in O +
radiocontrast O +
media O +
- O +
induced O +
apoptosis O +
in O +
renal O +
tubular O +
cells O +
. O +

LLC O +
- O +
PK O +
( O +
1 O +
) O +
cells O +
were O +
exposed O +
to O +
radiocontrast O +
media O +
for O +
30 O +
min O +
, O +
followed O +
by O +
incubation O +
for O +
24 O +
h O +
in O +
normal O +
medium O +
. O +

Cell O +
viability O +
was O +
assessed O +
by O +
2 O +
- O +
( O +
2 O +
- O +
methoxy O +
- O +
4 O +
- O +
nitrophenyl O +
) O +
- O +
3 O +
- O +
( O +
4 O +
- O +
nitrophenyl O +
) O +
- O +
5 O +
- O +
( O +
2 O +
, O +
4 O +
- O +
disulfophenyl O +
) O +
- O +
2H O +
- O +
tetrazolium O +
monosodium O +
salt O +
assay O +
, O +
while O +
apoptosis O +
was O +
determined O +
by O +
terminal O +
deoxynucleotidyl O +
transferase O +
- O +
mediated O +
dUTP O +
nick O +
end O +
labeling O +
stain O +
. O +

Immunofluorescent O +
stains O +
were O +
performed O +
using O +
antibodies O +
against O +
phosphorylated O +
Akt O +
( O +
pAkt O +
) O +
and O +
cAMP O +
response O +
element O +
binding O +
protein O +
( O +
CREB O +
) O +
( O +
pCREB O +
) O +
, O +
and O +
ceramide O +
. O +

The O +
mRNA O +
expression O +
and O +
protein O +
content O +
of O +
Bcl O +
- O +
2 O +
were O +
determined O +
by O +
reverse O +
transcriptase O +
- O +
polymerase O +
chain O +
reaction O +
and O +
enzyme O +
immunoassay O +
, O +
respectively O +
. O +

In O +
vivo O +
model O +
of O +
contrast O +
- O +
induced O +
renal O +
injury O +
was O +
induced O +
in O +
mice O +
with O +
unilateral O +
renal O +
occlusion O +
. O +

The O +
cell O +
injury O +
induced O +
by O +
the O +
nonionic O +
radiocontrast O +
medium O +
ioversol O +
was O +
reversed O +
by O +
inhibiting O +
de O +
novo O +
ceramide O +
synthesis O +
with O +
fumonisin O +
B O +
( O +
1 O +
) O +
( O +
FB O +
( O +
1 O +
) O +
) O +
and O +
L O +
- O +
cycloserine O +
, O +
but O +
not O +
by O +
suppressing O +
sphingomyelin O +
breakdown O +
with O +
D609 O +
. O +

FB O +
( O +
1 O +
) O +
reversed O +
ioversol O +
- O +
induced O +
decrease O +
in O +
the O +
immunoreactivities O +
of O +
pAkt O +
and O +
pCREB O +
, O +
reduction O +
in O +
Bcl O +
- O +
2 O +
expression O +
and O +
caspase O +
- O +
3 O +
activation O +
. O +

Like O +
ioversol O +
, O +
C2 O +
ceramide O +
and O +
the O +
Akt O +
inhibitor O +
Src O +
homology O +
- O +
6 O +
induced O +
apoptosis O +
by O +
reducing O +
pAkt O +
and O +
pCREB O +
- O +
like O +
immunoreactivities O +
, O +
lowering O +
Bcl O +
- O +
2 O +
expression O +
and O +
enhancing O +
caspase O +
- O +
3 O +
activity O +
. O +

Indeed O +
, O +
various O +
radiocontrast O +
media O +
, O +
excluding O +
iodixanol O +
which O +
showed O +
the O +
least O +
nephrotoxicity O +
, O +
enhanced O +
ceramide O +
- O +
like O +
immunoreactivity O +
. O +

The O +
role O +
for O +
de O +
novo O +
ceramide O +
synthesis O +
was O +
also O +
shown O +
in O +
the O +
in O +
vivo O +
model O +
of O +
radiocontrast O +
nephropathy O +
. O +

We O +
demonstrated O +
here O +
for O +
the O +
first O +
time O +
that O +
the O +
enhancement O +
of O +
de O +
novo O +
ceramide O +
synthesis O +
contributes O +
to O +
radiocontrast O +
nephropathy O +
. O +

Decrease O +
in O +
c O +
- O +
Myc O +
activity O +
enhances O +
cancer O +
cell O +
sensitivity O +
to O +
vinblastine O +
. O +

The O +
c O +
- O +
myc O +
oncogene O +
encodes O +
for O +
a O +
transcriptional O +
factor O +
involved O +
in O +
many O +
cellular O +
processes O +
such O +
as O +
proliferation O +
, O +
differentiation O +
and O +
apoptosis O +
. O +

According O +
to O +
these O +
different O +
functions O +
, O +
the O +
role O +
of O +
c O +
- O +
Myc O +
protein O +
in O +
cellular O +
sensitivity O +
to O +
anti O +
- O +
cancer O +
drugs O +
is O +
controversial O +
. O +

We O +
defined O +
the O +
role O +
of O +
c O +
- O +
Myc O +
in O +
cancer O +
cell O +
sensitivity O +
to O +
vinblastine O +
( O +
VLB O +
) O +
using O +
human O +
colon O +
cancer O +
cells O +
: O +
LoVo B-CellLine +
wild O +
- O +
type O +
or O +
transfected O +
with O +
a O +
plasmid O +
containing O +
the O +
human O +
c O +
- O +
myc O +
gene O +
in O +
antisense O +
orientation O +
( O +
LoVo B-CellLine +
- O +
mycANS O +
) O +
. O +

Analysis O +
of O +
VLB O +
cytotoxicity O +
demonstrated O +
a O +
3 O +
- O +
fold O +
increase O +
in O +
VLB O +
sensitivity O +
in O +
LoVo B-CellLine +
- O +
mycANS O +
cells O +
. O +

Comparison O +
between O +
cells O +
revealed O +
different O +
apoptosis O +
kinetics O +
: O +
accumulation O +
of O +
cells O +
in O +
sub O +
- O +
G1 O +
phase O +
and O +
poly O +
( O +
ADP O +
- O +
ribose O +
) O +
polymerase O +
cleavage O +
occurred O +
earlier O +
in O +
LoVo B-CellLine +
- O +
mycANS O +
. O +

Then O +
, O +
we O +
demonstrated O +
a O +
mitochondrial O +
membrane O +
potential O +
disruption O +
followed O +
by O +
cytochrome O +
c O +
release O +
that O +
indicates O +
the O +
involvement O +
of O +
mitochondria O +
in O +
this O +
apoptotic O +
signaling O +
pathway O +
. O +

This O +
earlier O +
apoptosis O +
was O +
accompanied O +
by O +
a O +
Bcl O +
- O +
2 O +
decrease O +
and O +
a O +
p53 O +
increase O +
. O +

In O +
conclusion O +
, O +
the O +
decrease O +
in O +
c O +
- O +
Myc O +
expression O +
enhanced O +
the O +
VLB O +
sensitivity O +
, O +
triggering O +
earlier O +
apoptosis O +
through O +
induction O +
of O +
the O +
intrinsic O +
pathway O +
. O +

Thus O +
, O +
c O +
- O +
myc O +
induction O +
is O +
a O +
resistance O +
factor O +
and O +
our O +
findings O +
suggest O +
that O +
tumors O +
carrying O +
low O +
levels O +
of O +
c O +
- O +
Myc O +
protein O +
could O +
be O +
more O +
responsive O +
to O +
vinca O +
alkaloids O +
treatment O +
. O +

Moreover O +
, O +
the O +
downregulation O +
of O +
c O +
- O +
myc O +
oncogene O +
by O +
an O +
antisense O +
strategy O +
might O +
represent O +
a O +
useful O +
goal O +
for O +
improving O +
the O +
efficacy O +
of O +
this O +
anti O +
- O +
neoplastic O +
drug O +
family O +
. O +

Sensitization O +
to O +
gimatecan O +
- O +
induced O +
apoptosis O +
by O +
tumor O +
necrosis O +
factor O +
- O +
related O +
apoptosis O +
inducing O +
ligand O +
in O +
prostate O +
carcinoma O +
cells O +
. O +

Since O +
the O +
intrinsic O +
resistance O +
of O +
prostate O +
carcinoma O +
likely O +
reflects O +
a O +
low O +
susceptibility O +
to O +
drug O +
- O +
induced O +
apoptosis O +
, O +
in O +
this O +
study O +
we O +
explored O +
the O +
possibility O +
of O +
sensitizing O +
prostate O +
carcinoma O +
cells O +
to O +
apoptosis O +
by O +
combination O +
of O +
TRAIL O +
with O +
camptothecins O +
. O +

Indeed O +
, O +
these O +
agents O +
are O +
known O +
to O +
activate O +
different O +
pathways O +
of O +
apoptosis O +
. O +

Topotecan O +
- O +
and O +
gimatecan O +
induced O +
moderate O +
up O +
- O +
regulation O +
of O +
TRAIL O +
- O +
R1 O +
and O +
- O +
R2 O +
which O +
resulted O +
in O +
a O +
different O +
cell O +
response O +
to O +
the O +
combination O +
in O +
androgen O +
- O +
independent O +
cells O +
( O +
DU B-CellLine +
- I-CellLine +
145 I-CellLine +
and O +
PC B-CellLine +
- I-CellLine +
3 I-CellLine +
) O +
. O +

In O +
DU B-CellLine +
- I-CellLine +
145 I-CellLine +
cells O +
apoptosis O +
was O +
increased O +
by O +
lower O +
TRAIL O +
concentrations O +
and O +
was O +
earlier O +
than O +
in O +
PC B-CellLine +
- I-CellLine +
3 I-CellLine +
cells O +
, O +
as O +
shown O +
using O +
Annexin O +
V O +
- O +
binding O +
assay O +
. O +

The O +
relative O +
resistance O +
of O +
PC B-CellLine +
- I-CellLine +
3 I-CellLine +
cells O +
to O +
drug O +
- O +
induced O +
apoptosis O +
was O +
associated O +
with O +
constitutive O +
Akt O +
activation O +
, O +
higher O +
levels O +
of O +
cFLIP O +
- O +
L O +
and O +
Bcl O +
- O +
2 O +
, O +
and O +
lower O +
levels O +
of O +
Bax O +
. O +

The O +
different O +
expression O +
/ O +
activation O +
of O +
apoptosis O +
- O +
related O +
factors O +
appears O +
to O +
influence O +
the O +
sensitization O +
of O +
prostate O +
carcinoma O +
cells O +
by O +
TRAIL O +
. O +

Potentiation O +
of O +
camptothecin O +
- O +
induced O +
apoptosis O +
by O +
TRAIL O +
appears O +
dependent O +
on O +
cooperation O +
between O +
extrinsic O +
and O +
intrinsic O +
pathways O +
, O +
as O +
documented O +
by O +
loss O +
of O +
the O +
sensitization O +
to O +
apoptosis O +
following O +
reduction O +
of O +
caspase O +
8 O +
after O +
small O +
interfering O +
RNA O +
transfection O +
. O +

The O +
efficacy O +
of O +
the O +
approach O +
may O +
be O +
critically O +
dependent O +
on O +
the O +
intrinsic O +
susceptibility O +
to O +
apoptosis O +
of O +
different O +
tumors O +
. O +

These O +
observations O +
support O +
that O +
the O +
activation O +
of O +
multiple O +
signals O +
could O +
enhance O +
apoptotic O +
response O +
and O +
suggest O +
the O +
therapeutic O +
interest O +
of O +
the O +
TRAIL O +
/ O +
camptothecin O +
combination O +
. O +

c O +
- O +
Met O +
expression O +
is O +
regulated O +
by O +
Mitf O +
in O +
the O +
melanocyte O +
lineage O +
. O +

Hepatocyte O +
growth O +
factor O +
( O +
HGF O +
) O +
/ O +
c O +
- O +
Met O +
signaling O +
is O +
thought O +
to O +
be O +
a O +
key O +
pathway O +
in O +
both O +
melanocyte O +
development O +
and O +
melanoma O +
metastasis O +
. O +

Here O +
, O +
HGF O +
stimulation O +
of O +
melanocytes O +
was O +
seen O +
to O +
up O +
- O +
regulate O +
c O +
- O +
Met O +
expression O +
. O +

In O +
an O +
effort O +
to O +
decipher O +
the O +
mechanism O +
by O +
which O +
HGF O +
up O +
- O +
regulates O +
its O +
receptor O +
, O +
we O +
found O +
that O +
c O +
- O +
Met O +
is O +
a O +
direct O +
transcriptional O +
target O +
of O +
Mitf O +
. O +

This O +
was O +
confirmed O +
with O +
chromatin O +
immunoprecipitation O +
experiments O +
of O +
the O +
human O +
c O +
- O +
Met O +
promoter O +
, O +
as O +
well O +
as O +
by O +
the O +
ability O +
of O +
adenovirally O +
expressed O +
Mitf O +
to O +
modulate O +
endogenous O +
c O +
- O +
Met O +
protein O +
levels O +
in O +
melanocytes O +
. O +

Disruption O +
of O +
Mitf O +
blocked O +
HGF O +
- O +
dependent O +
increases O +
in O +
endogenous O +
c O +
- O +
Met O +
message O +
and O +
protein O +
levels O +
, O +
indicating O +
that O +
HGF O +
regulates O +
its O +
own O +
receptor O +
levels O +
via O +
Mitf O +
. O +

Finally O +
, O +
dominant O +
- O +
negative O +
inhibition O +
of O +
Mitf O +
resulted O +
in O +
profound O +
resistance O +
of O +
melanocytes O +
and O +
melanoma O +
cells O +
to O +
HGF O +
- O +
dependent O +
matrix O +
invasion O +
, O +
suggesting O +
a O +
physiologic O +
role O +
for O +
this O +
pathway O +
in O +
melanocytic O +
development O +
and O +
melanoma O +
. O +

L O +
- O +
Carnitine O +
ameliorates O +
methotrexate O +
- O +
induced O +
oxidative O +
organ O +
injury O +
and O +
inhibits O +
leukocyte O +
death O +
. O +

Methotrexate O +
( O +
MTX O +
) O +
, O +
a O +
folic O +
acid O +
antagonist O +
widely O +
used O +
for O +
the O +
treatment O +
of O +
a O +
variety O +
of O +
tumors O +
and O +
inflammatory O +
diseases O +
, O +
affects O +
normal O +
tissues O +
that O +
have O +
a O +
high O +
rate O +
of O +
proliferation O +
, O +
including O +
the O +
hematopoietic O +
cells O +
of O +
the O +
bone O +
marrow O +
and O +
the O +
gastrointestinal O +
mucosal O +
cells O +
. O +

To O +
elucidate O +
the O +
role O +
of O +
free O +
radicals O +
and O +
leukocytes O +
in O +
MTX O +
- O +
induced O +
oxidative O +
organ O +
damage O +
and O +
the O +
putative O +
protective O +
effect O +
of O +
L O +
- O +
carnitine O +
( O +
L O +
- O +
Car O +
) O +
, O +
Wistar O +
albino O +
rats O +
were O +
administered O +
a O +
single O +
dose O +
of O +
MTX O +
( O +
20 O +
mg O +
/ O +
kg O +
) O +
followed O +
by O +
either O +
saline O +
or O +
L O +
- O +
Car O +
( O +
500 O +
mg O +
/ O +
kg O +
) O +
for O +
5 O +
days O +
. O +

After O +
decapitation O +
of O +
the O +
rats O +
, O +
trunk O +
blood O +
was O +
obtained O +
, O +
and O +
the O +
ileum O +
, O +
liver O +
, O +
and O +
kidney O +
were O +
removed O +
for O +
histological O +
examination O +
and O +
for O +
the O +
measurement O +
of O +
malondialdehyde O +
( O +
MDA O +
) O +
and O +
glutathione O +
( O +
GSH O +
) O +
levels O +
, O +
myeloperoxidase O +
( O +
MPO O +
) O +
activity O +
, O +
and O +
collagen O +
content O +
. O +

Our O +
results O +
showed O +
that O +
MTX O +
administration O +
increased O +
the O +
MDA O +
and O +
MPO O +
activities O +
and O +
collagen O +
content O +
and O +
decreased O +
GSH O +
levels O +
in O +
all O +
tissues O +
, O +
while O +
these O +
alterations O +
were O +
reversed O +
in O +
L O +
- O +
Car O +
- O +
treated O +
group O +
. O +

The O +
elevated O +
serum O +
TNF O +
- O +
alpha O +
level O +
observed O +
following O +
MTX O +
treatment O +
was O +
depressed O +
with O +
L O +
- O +
Car O +
. O +

The O +
oxidative O +
burst O +
of O +
neutrophils O +
stimulated O +
by O +
Annexin O +
V O +
was O +
reduced O +
in O +
the O +
saline O +
- O +
treated O +
MTX O +
group O +
, O +
while O +
L O +
- O +
Car O +
abolished O +
this O +
inhibition O +
. O +

Similarly O +
, O +
flow O +
cytometric O +
measurements O +
revealed O +
that O +
leukocyte O +
apoptosis O +
was O +
increased O +
in O +
MTX O +
- O +
treated O +
animals O +
, O +
while O +
L O +
- O +
Car O +
reversed O +
these O +
effects O +
. O +

Severe O +
degeneration O +
of O +
the O +
intestinal O +
mucosa O +
, O +
liver O +
parenchyma O +
, O +
and O +
glomerular O +
and O +
tubular O +
epithelium O +
observed O +
in O +
the O +
saline O +
- O +
treated O +
MTX O +
group O +
was O +
improved O +
by O +
L O +
- O +
Car O +
treatment O +
. O +

These O +
results O +
suggest O +
that O +
L O +
- O +
Car O +
, O +
possibly O +
via O +
its O +
free O +
radical O +
scavenging O +
and O +
antioxidant O +
properties O +
, O +
ameliorates O +
MTX O +
- O +
induced O +
oxidative O +
organ O +
injury O +
and O +
inhibits O +
leukocyte O +
apoptosis O +
. O +

Thus O +
, O +
supplementation O +
with O +
L O +
- O +
Carnitine O +
as O +
an O +
adjuvant O +
therapy O +
may O +
be O +
promising O +
in O +
alleviating O +
the O +
systemic O +
side O +
- O +
effects O +
of O +
chemotherapeutics O +
. O +

Pericytes O +
limit O +
tumor O +
cell O +
metastasis O +
. O +

Previously O +
we O +
observed O +
that O +
neural O +
cell O +
adhesion O +
molecule O +
( O +
NCAM O +
) O +
deficiency O +
in O +
beta O +
tumor O +
cells O +
facilitates O +
metastasis O +
into O +
distant O +
organs O +
and O +
local O +
lymph O +
nodes O +
. O +

Here O +
, O +
we O +
show O +
that O +
NCAM O +
- O +
deficient O +
beta O +
cell O +
tumors O +
grew O +
leaky O +
blood O +
vessels O +
with O +
perturbed O +
pericyte O +
- O +
endothelial O +
cell O +
- O +
cell O +
interactions O +
and O +
deficient O +
perivascular O +
deposition O +
of O +
ECM O +
components O +
. O +

Conversely O +
, O +
tumor O +
cell O +
expression O +
of O +
NCAM O +
in O +
a O +
fibrosarcoma O +
model O +
( O +
T241 O +
) O +
improved O +
pericyte O +
recruitment O +
and O +
increased O +
perivascular O +
deposition O +
of O +
ECM O +
molecules O +
. O +

Together O +
, O +
these O +
findings O +
suggest O +
that O +
NCAM O +
may O +
limit O +
tumor O +
cell O +
metastasis O +
by O +
stabilizing O +
the O +
microvessel O +
wall O +
. O +

To O +
directly O +
address O +
whether O +
pericyte O +
dysfunction O +
increases O +
the O +
metastatic O +
potential O +
of O +
solid O +
tumors O +
, O +
we O +
studied O +
beta O +
cell O +
tumorigenesis O +
in O +
primary O +
pericyte O +
- O +
deficient O +
Pdgfb O +
( O +
ret O +
/ O +
ret O +
) O +
mice O +
. O +

This O +
resulted O +
in O +
beta O +
tumor O +
cell O +
metastases O +
in O +
distant O +
organs O +
and O +
local O +
lymph O +
nodes O +
, O +
demonstrating O +
a O +
role O +
for O +
pericytes O +
in O +
limiting O +
tumor O +
cell O +
metastasis O +
. O +

These O +
data O +
support O +
a O +
new O +
model O +
for O +
how O +
tumor O +
cells O +
trigger O +
metastasis O +
by O +
perturbing O +
pericyte O +
- O +
endothelial O +
cell O +
- O +
cell O +
interactions O +
. O +

NF O +
- O +
kappaB O +
and O +
IKK O +
as O +
therapeutic O +
targets O +
in O +
cancer O +
. O +

The O +
transcription O +
factor O +
NF O +
- O +
kappaB O +
and O +
associated O +
regulatory O +
factors O +
( O +
including O +
IkappaB O +
kinase O +
subunits O +
and O +
the O +
IkappaB O +
family O +
member O +
Bcl O +
- O +
3 O +
) O +
are O +
strongly O +
implicated O +
in O +
a O +
variety O +
of O +
hematologic O +
and O +
solid O +
tumor O +
malignancies O +
. O +

A O +
role O +
for O +
NF O +
- O +
kappaB O +
in O +
cancer O +
cells O +
appears O +
to O +
involve O +
regulation O +
of O +
cell O +
proliferation O +
, O +
control O +
of O +
apoptosis O +
, O +
promotion O +
of O +
angiogenesis O +
, O +
and O +
stimulation O +
of O +
invasion O +
/ O +
metastasis O +
. O +

Consistent O +
with O +
a O +
role O +
for O +
NF O +
- O +
kappaB O +
in O +
oncogenesis O +
are O +
observations O +
that O +
inhibition O +
of O +
NF O +
- O +
kappaB O +
alone O +
or O +
in O +
combination O +
with O +
cancer O +
therapies O +
leads O +
to O +
tumor O +
cell O +
death O +
or O +
growth O +
inhibition O +
. O +

However O +
, O +
other O +
experimental O +
data O +
indicate O +
that O +
NF O +
- O +
kappaB O +
can O +
play O +
a O +
tumor O +
suppressor O +
role O +
in O +
certain O +
settings O +
and O +
that O +
it O +
can O +
be O +
important O +
in O +
promoting O +
an O +
apoptotic O +
signal O +
downstream O +
of O +
certain O +
cancer O +
therapy O +
regimens O +
. O +

In O +
order O +
to O +
appropriately O +
move O +
NF O +
- O +
kappaB O +
inhibitors O +
in O +
the O +
clinic O +
, O +
thorough O +
approaches O +
must O +
be O +
initiated O +
to O +
determine O +
the O +
molecular O +
mechanisms O +
that O +
dictate O +
the O +
complexity O +
of O +
oncologic O +
and O +
therapeutic O +
outcomes O +
that O +
are O +
controlled O +
by O +
NF O +
- O +
kappaB O +
. O +

Runx2 O +
and O +
MYC O +
collaborate O +
in O +
lymphoma O +
development O +
by O +
suppressing O +
apoptotic O +
and O +
growth O +
arrest O +
pathways O +
in O +
vivo O +
. O +

Members O +
of O +
the O +
Runx O +
and O +
MYC O +
families O +
have O +
been O +
implicated O +
as O +
collaborating O +
oncogenes O +
. O +

The O +
mechanism O +
of O +
this O +
potent O +
collaboration O +
is O +
elucidated O +
in O +
this O +
study O +
of O +
Runx2 O +
/ O +
MYC O +
mice O +
. O +

As O +
shown O +
previously O +
, O +
ectopic O +
expression O +
of O +
Runx2 O +
in O +
the O +
thymus O +
leads O +
to O +
a O +
preneoplastic O +
state O +
defined O +
by O +
an O +
accumulation O +
of O +
cells O +
with O +
an O +
immature O +
phenotype O +
and O +
a O +
low O +
proliferative O +
rate O +
. O +

We O +
now O +
show O +
that O +
c O +
- O +
MYC O +
overexpression O +
is O +
sufficient O +
to O +
rescue O +
proliferation O +
and O +
to O +
release O +
the O +
differentiation O +
block O +
imposed O +
by O +
Runx2 O +
. O +

Analysis O +
of O +
Runx2 O +
- O +
expressing O +
lymphomas O +
reveals O +
a O +
consistently O +
low O +
rate O +
of O +
apoptosis O +
, O +
in O +
contrast O +
to O +
lymphomas O +
of O +
MYC O +
mice O +
which O +
are O +
often O +
highly O +
apoptotic O +
. O +

The O +
low O +
apoptosis O +
phenotype O +
is O +
dominant O +
in O +
Runx2 O +
/ O +
MYC O +
tumors O +
, O +
indicating O +
that O +
Runx2 O +
confers O +
a O +
potent O +
survival O +
advantage O +
to O +
MYC O +
- O +
expressing O +
tumor O +
cells O +
. O +

The O +
role O +
of O +
the O +
p53 O +
pathway O +
in O +
Runx2 O +
/ O +
MYC O +
tumors O +
was O +
explored O +
on O +
a O +
p53 O +
heterozygote O +
background O +
. O +

Surprisingly O +
, O +
functional O +
p53 O +
was O +
retained O +
in O +
vivo O +
, O +
even O +
after O +
transplantation O +
, O +
whereas O +
explanted O +
tumor O +
cells O +
displayed O +
rapid O +
allele O +
loss O +
in O +
vitro O +
. O +

Our O +
results O +
show O +
that O +
Runx2 O +
and O +
MYC O +
overcome O +
distinct O +
" O +
fail O +
- O +
safe O +
" O +
responses O +
and O +
that O +
their O +
selection O +
as O +
collaborating O +
genes O +
is O +
due O +
to O +
their O +
ability O +
to O +
neutralize O +
each O +
other O +
' O +
s O +
negative O +
growth O +
effect O +
. O +

Furthermore O +
, O +
the O +
Runx2 O +
/ O +
MYC O +
combination O +
overcomes O +
the O +
requirement O +
for O +
genetic O +
inactivation O +
of O +
the O +
p53 O +
pathway O +
in O +
vivo O +
. O +

Inhibition O +
of O +
the O +
mammalian O +
target O +
of O +
rapamycin O +
( O +
mTOR O +
) O +
by O +
rapamycin O +
increases O +
chemosensitivity O +
of O +
CaSki B-CellLine +
cells O +
to O +
paclitaxel O +
. O +

Paclitaxel O +
, O +
a O +
potent O +
anti O +
- O +
neoplastic O +
agent O +
, O +
has O +
been O +
found O +
to O +
be O +
effective O +
against O +
several O +
tumours O +
, O +
including O +
cervical O +
cancer O +
. O +

However O +
, O +
the O +
exact O +
mechanism O +
underlying O +
the O +
cytotoxic O +
effects O +
of O +
pacitaxel O +
, O +
especially O +
in O +
the O +
survival O +
- O +
signalling O +
pathway O +
, O +
is O +
poorly O +
understood O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
molecular O +
pathway O +
of O +
the O +
cytotoxic O +
effect O +
of O +
paclitaxel O +
in O +
human O +
cervical O +
cancer O +
cell O +
lines O +
. O +

Four O +
human O +
cervical O +
cancer O +
cell O +
lines O +
were O +
treated O +
for O +
24 O +
h O +
with O +
various O +
concentration O +
of O +
paclitaxel O +
, O +
and O +
the O +
sensitivity O +
was O +
analysed O +
by O +
an O +
MTT O +
assay O +
. O +

The O +
cell O +
cycle O +
progression O +
and O +
sub O +
- O +
G1 O +
population O +
were O +
analysed O +
by O +
flow O +
cytometry O +
. O +

Apoptosis O +
was O +
further O +
measured O +
by O +
DNA O +
fragmentation O +
and O +
microscope O +
examination O +
. O +

The O +
protein O +
expression O +
was O +
determined O +
by O +
Western O +
blot O +
analysis O +
. O +

Our O +
results O +
showed O +
that O +
HeLa B-CellLine +
cells O +
demonstrated O +
the O +
highest O +
sensitivity O +
to O +
paclitaxel O +
, O +
whereas O +
CaSki B-CellLine +
cells O +
showed O +
the O +
lowest O +
. O +

In O +
cervical O +
cancer O +
cells O +
, O +
paclitaxel O +
induced O +
apoptosis O +
through O +
an O +
intrinsic O +
pathway O +
with O +
prior O +
G2 O +
/ O +
M O +
arrest O +
. O +

In O +
addition O +
, O +
we O +
showed O +
that O +
paclitaxel O +
downregulated O +
the O +
phosphorylation O +
of O +
Akt O +
in O +
both O +
HeLa B-CellLine +
and O +
CaSki B-CellLine +
cells O +
. O +

Interestingly O +
, O +
in O +
CaSki B-CellLine +
cells O +
, O +
which O +
were O +
more O +
suggestive O +
of O +
a O +
resistant O +
phenotype O +
, O +
paclitaxel O +
induced O +
the O +
activation O +
of O +
mTOR O +
as O +
a O +
downstream O +
target O +
of O +
Akt O +
. O +

Pre O +
- O +
treatment O +
with O +
rapamycin O +
inhibited O +
activation O +
of O +
mTOR O +
signalling O +
and O +
significantly O +
enhanced O +
the O +
sensitivity O +
of O +
CaSki B-CellLine +
cells O +
to O +
paclitaxel O +
by O +
increasing O +
apoptotic O +
cell O +
death O +
. O +

This O +
effect O +
was O +
mediated O +
, O +
at O +
least O +
partly O +
, O +
through O +
caspase O +
activation O +
. O +

Overall O +
, O +
paclitaxel O +
exerts O +
its O +
anti O +
- O +
tumour O +
effects O +
on O +
cervical O +
cancer O +
cells O +
by O +
inducing O +
apoptosis O +
through O +
intrinsic O +
pathway O +
, O +
and O +
rapamycin O +
targeted O +
to O +
mTOR O +
can O +
sensitise O +
paclitaxel O +
- O +
resistant O +
cervical O +
cancer O +
cells O +
. O +

Circulating O +
endothelial O +
cells O +
in O +
malignant O +
disease O +
. O +

Cancer O +
is O +
a O +
disease O +
largely O +
dependent O +
on O +
neoangiogenesis O +
. O +

Cancer O +
neoangiogenesis O +
is O +
often O +
disordered O +
and O +
abnormal O +
, O +
with O +
evidence O +
of O +
coexisting O +
vascular O +
endothelial O +
dysfunction O +
. O +

A O +
novel O +
method O +
of O +
assessing O +
vascular O +
endothelial O +
function O +
in O +
cancer O +
is O +
via O +
the O +
quantification O +
of O +
circulating O +
endothelial O +
cells O +
( O +
CEC O +
) O +
. O +

Unusual O +
in O +
healthy O +
individuals O +
, O +
their O +
presence O +
in O +
elevated O +
numbers O +
often O +
indicates O +
substantial O +
vascular O +
endothelial O +
perturbation O +
. O +

Another O +
interesting O +
cell O +
type O +
is O +
the O +
endothelial O +
progenitor O +
cell O +
( O +
EPC O +
) O +
, O +
whose O +
numbers O +
increase O +
in O +
the O +
presence O +
of O +
vascular O +
damage O +
. O +

Recent O +
research O +
suggests O +
that O +
EPCs O +
have O +
an O +
important O +
role O +
in O +
tumor O +
vasculogenesis O +
. O +

Another O +
marker O +
being O +
investigated O +
in O +
the O +
context O +
of O +
vascular O +
dysfunction O +
and O +
coagulopathy O +
is O +
the O +
endothelial O +
microparticle O +
( O +
EMP O +
) O +
. O +

Thus O +
, O +
CECs O +
, O +
EPCs O +
and O +
EMPs O +
may O +
represent O +
potentially O +
novel O +
methods O +
for O +
evaluating O +
the O +
vascular O +
status O +
of O +
cancer O +
patients O +
. O +

This O +
review O +
will O +
summarize O +
the O +
current O +
position O +
of O +
CECs O +
, O +
EPCs O +
and O +
EMPs O +
in O +
cell O +
biology O +
terms O +
, O +
with O +
particular O +
emphasis O +
on O +
their O +
relationship O +
to O +
malignant O +
disease O +
. O +

Targeting O +
PIM O +
kinases O +
impairs O +
survival O +
of O +
hematopoietic O +
cells O +
transformed O +
by O +
kinase O +
inhibitor O +
- O +
sensitive O +
and O +
kinase O +
inhibitor O +
- O +
resistant O +
forms O +
of O +
Fms O +
- O +
like O +
tyrosine O +
kinase O +
3 O +
and O +
BCR O +
/ O +
ABL O +
. O +

Previous O +
studies O +
have O +
shown O +
that O +
activation O +
of O +
the O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
5 O +
( O +
STAT5 O +
) O +
plays O +
an O +
essential O +
role O +
in O +
leukemogenesis O +
mediated O +
through O +
constitutive O +
activated O +
protein O +
tyrosine O +
kinases O +
( O +
PTK O +
) O +
. O +

Because O +
PIM O +
- O +
1 O +
is O +
a O +
STAT5 O +
target O +
gene O +
, O +
we O +
analyzed O +
the O +
role O +
of O +
the O +
family O +
of O +
PIM O +
serine O +
/ O +
threonine O +
kinases O +
( O +
PIM O +
- O +
1 O +
to O +
PIM O +
- O +
3 O +
) O +
in O +
PTK O +
- O +
mediated O +
transformation O +
of O +
hematopoietic O +
cells O +
. O +

Ba B-CellLine +
/ I-CellLine +
F3 I-CellLine +
cells O +
transformed O +
to O +
growth O +
factor O +
independence O +
by O +
various O +
oncogenic O +
PTKs O +
( O +
TEL O +
/ O +
JAK2 O +
, O +
TEL O +
/ O +
TRKC O +
, O +
TEL O +
/ O +
ABL O +
, O +
BCR O +
/ O +
ABL O +
, O +
FLT3 O +
- O +
ITD O +
, O +
and O +
H4 O +
/ O +
PDGFbetaR O +
) O +
show O +
abundant O +
expression O +
of O +
PIM O +
- O +
1 O +
and O +
PIM O +
- O +
2 O +
. O +

Suppression O +
of O +
PIM O +
- O +
1 O +
activity O +
had O +
a O +
negligible O +
effect O +
on O +
transformation O +
. O +

In O +
contrast O +
, O +
expression O +
of O +
kinase O +
- O +
dead O +
PIM O +
- O +
2 O +
mutant O +
( O +
PIM O +
- O +
2KD O +
) O +
led O +
to O +
a O +
rapid O +
decline O +
of O +
survival O +
in O +
Ba B-CellLine +
/ I-CellLine +
F3 I-CellLine +
cells O +
transformed O +
by O +
FLT3 O +
- O +
ITD O +
but O +
not O +
by O +
other O +
oncogenic O +
PTKs O +
tested O +
. O +

Coexpression O +
of O +
PIM O +
- O +
1KD O +
and O +
PIM O +
- O +
2KD O +
abrogated O +
growth O +
factor O +
- O +
independent O +
growth O +
of O +
Ba B-CellLine +
/ I-CellLine +
F3 I-CellLine +
transformed O +
by O +
several O +
PTKs O +
, O +
including O +
BCR O +
/ O +
ABL O +
. O +

Targeted O +
down O +
- O +
regulation O +
of O +
PIM O +
- O +
2 O +
by O +
RNA O +
interference O +
( O +
RNAi O +
) O +
selectively O +
abrogated O +
survival O +
of O +
Ba B-CellLine +
/ I-CellLine +
F3 I-CellLine +
cells O +
transformed O +
by O +
various O +
Fms O +
- O +
like O +
tyrosine O +
kinase O +
3 O +
( O +
FLT3 O +
) O +
- O +
activating O +
mutants O +
[ O +
internal O +
tandem O +
duplication O +
( O +
ITD O +
) O +
and O +
kinase O +
domain O +
] O +
and O +
attenuated O +
growth O +
of O +
human O +
cell O +
lines O +
containing O +
FLT3 O +
mutations O +
. O +

Interestingly O +
, O +
cells O +
transformed O +
by O +
FLT3 O +
and O +
BCR O +
/ O +
ABL O +
mutations O +
that O +
confer O +
resistance O +
to O +
small O +
- O +
molecule O +
tyrosine O +
kinase O +
inhibitors O +
were O +
still O +
sensitive O +
to O +
knockdown O +
of O +
PIM O +
- O +
2 O +
, O +
or O +
PIM O +
- O +
1 O +
and O +
PIM O +
- O +
2 O +
by O +
RNAi O +
. O +

Our O +
observations O +
indicate O +
that O +
combined O +
inactivation O +
of O +
PIM O +
- O +
1 O +
and O +
PIM O +
- O +
2 O +
interferes O +
with O +
oncogenic O +
PTKs O +
and O +
suggest O +
that O +
PIMs O +
are O +
alternative O +
therapeutic O +
targets O +
in O +
PTK O +
- O +
mediated O +
leukemia O +
. O +

Targeting O +
the O +
PIM O +
kinase O +
family O +
could O +
provide O +
a O +
new O +
avenue O +
to O +
overcome O +
resistance O +
against O +
small O +
- O +
molecule O +
tyrosine O +
kinase O +
inhibitors O +
. O +

Complications O +
after O +
plate O +
fixation O +
of O +
phalangeal O +
fractures O +
. O +

PURPOSE O +
: O +

To O +
assess O +
the O +
complications O +
after O +
plate O +
fixation O +
of O +
phalangeal O +
fractures O +
, O +
their O +
correlation O +
with O +
the O +
type O +
of O +
injury O +
, O +
and O +
the O +
outcome O +
. O +

METHODS O +
: O +

We O +
retrospectively O +
reviewed O +
the O +
clinical O +
records O +
and O +
the O +
x O +
- O +
rays O +
of O +
54 O +
consecutive O +
patients O +
with O +
64 O +
phalangeal O +
fractures O +
treated O +
by O +
open O +
reduction O +
and O +
plate O +
fixation O +
with O +
regard O +
to O +
fracture O +
healing O +
, O +
plate O +
loosening O +
or O +
failure O +
, O +
infection O +
, O +
complex O +
regional O +
pain O +
syndrome O +
, O +
pain O +
, O +
return O +
to O +
work O +
, O +
and O +
range O +
of O +
motion O +
. O +

RESULTS O +
: O +

In O +
31 O +
out O +
of O +
54 O +
patients O +
( O +
57 O +
% O +
) O +
and O +
33 O +
out O +
of O +
64 O +
fractures O +
( O +
52 O +
% O +
) O +
, O +
one O +
or O +
more O +
major O +
complications O +
occurred O +
. O +

Stiffness O +
( O +
definition O +
is O +
composite O +
range O +
of O +
motion O +
of O +
metaphalangeal O +
, O +
proximal O +
interphalangeal O +
, O +
and O +
distal O +
interphalangeal O +
joints O +
added O +
together O +
equaling O +
< O +
180 O +
degrees O +
) O +
contributed O +
the O +
highest O +
number O +
( O +
22 O +
patients O +
, O +
24 O +
fractures O +
) O +
. O +

The O +
complication O +
rates O +
were O +
not O +
different O +
whether O +
the O +
fracture O +
was O +
open O +
or O +
closed O +
, O +
if O +
it O +
was O +
located O +
in O +
the O +
proximal O +
or O +
middle O +
phalanx O +
, O +
the O +
presence O +
or O +
absence O +
of O +
an O +
associated O +
soft O +
tissue O +
lesion O +
, O +
and O +
the O +
patient O +
' O +
s O +
occupation O +
. O +

CONCLUSIONS O +
: O +

In O +
spite O +
of O +
early O +
mobilization O +
, O +
stiffness O +
is O +
the O +
most O +
frequent O +
complication O +
after O +
open O +
reduction O +
and O +
plate O +
fixation O +
of O +
phalangeal O +
fractures O +
. O +

The O +
undue O +
amount O +
of O +
scarring O +
and O +
adhesion O +
may O +
arise O +
from O +
the O +
implant O +
itself O +
or O +
the O +
difficulty O +
in O +
finding O +
the O +
perfect O +
mixture O +
between O +
the O +
minimal O +
surgical O +
invasiveness O +
and O +
a O +
sufficient O +
restoration O +
of O +
skeletal O +
stability O +
. O +

Otherwise O +
, O +
plate O +
fixation O +
of O +
unstable O +
and O +
complex O +
phalangeal O +
fractures O +
proved O +
efficient O +
and O +
reliable O +
, O +
although O +
not O +
free O +
of O +
potential O +
problems O +
. O +

A O +
potential O +
role O +
for O +
the O +
Src O +
- O +
like O +
adapter O +
protein O +
SLAP O +
- O +
2 O +
in O +
signaling O +
by O +
the O +
colony O +
stimulating O +
factor O +
- O +
1 O +
receptor O +
. O +

The O +
development O +
of O +
macrophages O +
from O +
myeloid O +
progenitor O +
cells O +
is O +
primarily O +
controlled O +
by O +
the O +
growth O +
factor O +
colony O +
stimulating O +
factor O +
- O +
1 O +
( O +
CSF O +
- O +
1 O +
) O +
and O +
its O +
cognate O +
receptor O +
, O +
a O +
transmembrane O +
tyrosine O +
kinase O +
encoded O +
by O +
the O +
c O +
- O +
Fms O +
proto O +
- O +
oncogene O +
. O +

The O +
CSF O +
- O +
1 O +
receptor O +
exerts O +
its O +
biological O +
effects O +
on O +
cells O +
via O +
a O +
range O +
of O +
signaling O +
proteins O +
including O +
Erk1 O +
/ O +
2 O +
and O +
Akt O +
. O +

Here O +
we O +
have O +
investigated O +
the O +
potential O +
involvement O +
of O +
the O +
Src O +
- O +
like O +
adapter O +
protein O +
( O +
SLAP O +
- O +
2 O +
) O +
in O +
signaling O +
by O +
the O +
CSF O +
- O +
1 O +
receptor O +
in O +
mouse O +
bone O +
marrow O +
- O +
derived O +
macrophages O +
. O +

RT O +
- O +
PCR O +
analysis O +
revealed O +
constitutive O +
expression O +
of O +
the O +
SLAP O +
- O +
2 O +
gene O +
in O +
bone O +
marrow O +
macrophages O +
. O +

Surprisingly O +
, O +
co O +
- O +
immunoprecipitation O +
and O +
GST O +
binding O +
experiments O +
demonstrated O +
that O +
the O +
CSF O +
- O +
1 O +
receptor O +
could O +
bind O +
to O +
SLAP O +
- O +
2 O +
in O +
a O +
ligand O +
- O +
independent O +
manner O +
. O +

Furthermore O +
, O +
the O +
binding O +
of O +
SLAP O +
- O +
2 O +
to O +
the O +
CSF O +
- O +
1 O +
receptor O +
involved O +
multiple O +
domains O +
of O +
SLAP O +
- O +
2 O +
. O +

SLAP O +
- O +
2 O +
also O +
bound O +
c O +
- O +
Cbl O +
, O +
with O +
the O +
interaction O +
being O +
mediated O +
, O +
at O +
least O +
in O +
part O +
, O +
by O +
the O +
unique O +
C O +
- O +
terminal O +
domain O +
of O +
SLAP O +
- O +
2 O +
. O +

Overexpression O +
of O +
SLAP O +
- O +
2 O +
in O +
bone O +
marrow O +
macrophages O +
partially O +
suppressed O +
the O +
CSF O +
- O +
1 O +
- O +
induced O +
tyrosine O +
phosphorylation O +
and O +
/ O +
or O +
expression O +
level O +
of O +
a O +
approximately O +
80 O +
kDa O +
protein O +
without O +
affecting O +
CSF O +
- O +
1 O +
- O +
induced O +
global O +
tyrosine O +
phosphorylation O +
, O +
or O +
activation O +
of O +
Akt O +
or O +
Erk1 O +
/ O +
2 O +
. O +

Significantly O +
, O +
CSF O +
- O +
1 O +
stimulation O +
induced O +
serine O +
phosphorylation O +
of O +
SLAP O +
- O +
2 O +
. O +

Pharmacologic O +
inhibition O +
of O +
specific O +
protein O +
kinases O +
revealed O +
that O +
CSF O +
- O +
1 O +
- O +
induced O +
phosphorylation O +
of O +
SLAP O +
- O +
2 O +
was O +
dependent O +
on O +
JNK O +
activity O +
. O +

Taken O +
together O +
, O +
our O +
results O +
suggest O +
that O +
SLAP O +
- O +
2 O +
could O +
potentially O +
be O +
involved O +
in O +
signaling O +
by O +
the O +
CSF O +
- O +
1 O +
receptor O +
. O +

The O +
ictal O +
bradycardia O +
syndrome O +
: O +
localization O +
and O +
lateralization O +
. O +

PURPOSE O +
: O +

Previous O +
studies O +
have O +
established O +
the O +
importance O +
of O +
the O +
insular O +
cortex O +
and O +
temporal O +
lobe O +
in O +
cardiovascular O +
autonomic O +
modulation O +
. O +

Some O +
investigators O +
, O +
based O +
on O +
the O +
results O +
of O +
cortical O +
stimulation O +
response O +
, O +
functional O +
imaging O +
, O +
EEG O +
recordings O +
of O +
seizures O +
, O +
and O +
lesional O +
studies O +
, O +
have O +
suggested O +
that O +
cardiac O +
sympathetic O +
and O +
parasympathetic O +
function O +
may O +
be O +
lateralized O +
, O +
with O +
sympathetic O +
representation O +
lateralized O +
to O +
the O +
right O +
insula O +
, O +
and O +
parasympathetic O +
, O +
to O +
the O +
left O +
. O +

These O +
studies O +
have O +
suggested O +
that O +
ictal O +
bradycardia O +
is O +
most O +
commonly O +
a O +
manifestation O +
of O +
activation O +
of O +
the O +
left O +
temporal O +
and O +
insular O +
cortex O +
. O +

However O +
, O +
the O +
evidence O +
for O +
this O +
is O +
inconsistent O +
. O +

We O +
sought O +
to O +
assess O +
critically O +
the O +
predictable O +
value O +
of O +
ictal O +
bradycardia O +
for O +
seizure O +
localization O +
and O +
lateralization O +
. O +

METHODS O +
: O +

In O +
this O +
study O +
, O +
we O +
reviewed O +
the O +
localization O +
of O +
seizure O +
activity O +
in O +
13 O +
consecutive O +
patients O +
with O +
ictal O +
bradycardia O +
diagnosed O +
during O +
prolonged O +
video O +
- O +
EEG O +
monitoring O +
at O +
Mayo O +
Clinic O +
Rochester O +
. O +

The O +
localization O +
of O +
electrographic O +
seizure O +
activity O +
at O +
seizure O +
onset O +
and O +
bradycardia O +
onset O +
was O +
identified O +
in O +
all O +
patients O +
. O +

In O +
addition O +
, O +
we O +
performed O +
a O +
comprehensive O +
review O +
of O +
the O +
ictal O +
bradycardia O +
literature O +
focusing O +
on O +
localization O +
of O +
seizure O +
activity O +
in O +
ictal O +
bradycardia O +
cases O +
. O +

RESULTS O +
: O +

All O +
occurrences O +
of O +
ictal O +
bradycardia O +
in O +
the O +
13 O +
identified O +
patients O +
were O +
associated O +
with O +
temporal O +
lobe O +
- O +
onset O +
seizures O +
. O +

However O +
, O +
no O +
consistent O +
lateralization O +
of O +
seizure O +
activity O +
was O +
found O +
at O +
onset O +
of O +
seizure O +
activity O +
or O +
at O +
onset O +
of O +
bradycardia O +
in O +
this O +
population O +
. O +

Seizure O +
activity O +
was O +
bilateral O +
at O +
bradycardia O +
onset O +
in O +
nine O +
of O +
13 O +
patients O +
. O +

The O +
results O +
from O +
the O +
literature O +
review O +
also O +
showed O +
that O +
a O +
predominance O +
of O +
patients O +
had O +
bilateral O +
activity O +
at O +
bradycardia O +
onset O +
; O +
however O +
, O +
more O +
of O +
the O +
ictal O +
bradycardia O +
cases O +
from O +
the O +
literature O +
had O +
left O +
hemispheric O +
localization O +
of O +
seizure O +
onset O +
. O +

CONCLUSIONS O +
: O +

Ictal O +
bradycardia O +
most O +
often O +
occurs O +
in O +
association O +
with O +
bilateral O +
hemispheric O +
seizure O +
activity O +
and O +
is O +
not O +
a O +
consistent O +
lateralizing O +
sign O +
in O +
localizing O +
seizure O +
onset O +
. O +

Our O +
data O +
do O +
not O +
support O +
the O +
existence O +
of O +
a O +
strictly O +
unilateral O +
parasympathetic O +
cardiomotor O +
representation O +
in O +
the O +
left O +
hemisphere O +
, O +
as O +
has O +
been O +
suggested O +
. O +

Ectopic O +
localization O +
of O +
mitochondrial O +
ATP O +
synthase O +
: O +
a O +
target O +
for O +
anti O +
- O +
angiogenesis O +
intervention O +
? O +

A O +
receptor O +
for O +
angiostatin O +
was O +
identified O +
on O +
the O +
surface O +
of O +
endothelial O +
cells O +
as O +
F O +
( O +
1 O +
) O +
- O +
F O +
( O +
0 O +
) O +
ATP O +
synthase O +
( O +
Moser O +
et O +
al O +
. O +
, O +
1999 O +
) O +
. O +

Proc O +
. O +

Natl O +
. O +

Acad O +
. O +

Sci O +
. O +

U O +
. O +
S O +
. O +
A O +
. O +

96 O +
, O +
2811 O +
- O +
2816 O +
. O +

This O +
ectopic O +
ATP O +
synthase O +
catalyzes O +
ATP O +
synthesis O +
and O +
is O +
inhibited O +
by O +
angiostatin O +
over O +
a O +
wide O +
pH O +
range O +
. O +

Endothelial O +
cells O +
grown O +
at O +
normal O +
pH O +
suffer O +
no O +
ill O +
effects O +
from O +
this O +
angiostatin O +
- O +
mediated O +
inhibition O +
of O +
ATP O +
synthase O +
, O +
whereas O +
endothelial O +
cells O +
grown O +
at O +
low O +
, O +
tumor O +
- O +
like O +
extracellular O +
pH O +
can O -
not O +
maintain O +
a O +
normal O +
intracellular O +
pH O +
and O +
die O +
. O +

Angiostatin O +
inhibits O +
both O +
ATP O +
synthesis O +
and O +
ATP O +
hydrolysis O +
( O +
Moser O +
et O +
al O +
. O +
, O +
2001 O +
) O +
and O +
interferes O +
with O +
intracellular O +
pH O +
regulation O +
( O +
Wahl O +
and O +
Grant O +
, O +
2002 O +
; O +
Wahl O +
et O +
al O +
. O +
, O +
2002 O +
) O +
. O +

Although O +
angiostatin O +
administered O +
intravenously O +
is O +
cleared O +
from O +
the O +
circulation O +
in O +
a O +
matter O +
of O +
minutes O +
, O +
angiostatin O +
- O +
mimetics O +
that O +
are O +
more O +
stable O +
have O +
potential O +
for O +
clinical O +
application O +
. O +

An O +
angiostatin O +
- O +
mimetic O +
activity O +
has O +
recently O +
been O +
observed O +
using O +
a O +
polyclonal O +
antibody O +
against O +
the O +
beta O +
catalytic O +
subunit O +
of O +
ATP O +
synthase O +
. O +

In O +
order O +
to O +
explore O +
the O +
mechanism O +
of O +
action O +
of O +
angiostatin O +
and O +
its O +
mimetics O +
, O +
further O +
work O +
needs O +
to O +
be O +
done O +
to O +
evaluate O +
clinical O +
applicability O +
, O +
specificity O +
, O +
and O +
contraindications O +
for O +
this O +
class O +
of O +
therapeutics O +
. O +

Hepatitis O +
B O +
virus O +
integration O +
event O +
in O +
human O +
chromosome O +
17p O +
near O +
the O +
p53 O +
gene O +
identifies O +
the O +
region O +
of O +
the O +
chromosome O +
commonly O +
deleted O +
in O +
virus O +
- O +
positive O +
hepatocellular O +
carcinomas O +
. O +

The O +
development O +
of O +
hepatocellular O +
carcinoma O +
( O +
HCC O +
) O +
presumably O +
occurs O +
in O +
multiple O +
steps O +
and O +
is O +
influenced O +
by O +
numerous O +
factors O +
. O +

Hepatitis O +
B O +
virus O +
( O +
HBV O +
) O +
is O +
strongly O +
associated O +
with O +
the O +
development O +
of O +
HCC O +
in O +
people O +
chronically O +
infected O +
with O +
the O +
virus O +
, O +
but O +
the O +
mechanism O +
of O +
viral O +
involvement O +
remains O +
unclear O +
. O +

One O +
possibility O +
is O +
that O +
the O +
gross O +
chromosomal O +
alterations O +
frequently O +
observed O +
in O +
HCC O +
DNA O +
at O +
the O +
site O +
of O +
HBV O +
integration O +
may O +
alter O +
the O +
expression O +
of O +
important O +
nearby O +
cellular O +
genes O +
. O +

We O +
previously O +
reported O +
the O +
cloning O +
and O +
characterization O +
of O +
a O +
HBV O +
insert O +
from O +
a O +
Chinese O +
HCC O +
. O +

The O +
viral O +
insert O +
mapped O +
to O +
chromosome O +
17p11 O +
. O +
2 O +
- O +
12 O +
, O +
and O +
cellular O +
sequences O +
were O +
duplicated O +
at O +
the O +
site O +
of O +
viral O +
integration O +
. O +

In O +
the O +
present O +
study O +
a O +
DNA O +
probe O +
derived O +
from O +
cellular O +
DNA O +
sequences O +
adjacent O +
to O +
the O +
previously O +
characterized O +
HBV O +
insert O +
was O +
used O +
to O +
analyze O +
a O +
set O +
of O +
19 O +
matched O +
normal O +
liver O +
and O +
HBV O +
- O +
positive O +
hepatoma O +
samples O +
obtained O +
from O +
the O +
same O +
region O +
of O +
China O +
, O +
near O +
Shanghai O +
. O +

Tumor O +
- O +
specific O +
DNA O +
changes O +
were O +
detected O +
in O +
two O +
additional O +
HCCs O +
, O +
suggesting O +
that O +
the O +
small O +
region O +
of O +
chromosome O +
17p O +
defined O +
by O +
the O +
flanking O +
cell O +
DNA O +
probe O +
is O +
commonly O +
altered O +
in O +
hepatomas O +
. O +

Restriction O +
fragment O +
length O +
polymorphism O +
studies O +
demonstrated O +
that O +
the O +
loss O +
of O +
one O +
copy O +
of O +
portions O +
of O +
chromosome O +
17 O +
occurred O +
in O +
10 O +
( O +
53 O +
% O +
) O +
of O +
the O +
19 O +
patients O +
. O +

The O +
loss O +
of O +
one O +
allele O +
of O +
the O +
p53 O +
gene O +
( O +
located O +
on O +
chromosome O +
17p13 O +
) O +
occurred O +
in O +
at O +
least O +
6 O +
( O +
60 O +
% O +
) O +
of O +
the O +
10 O +
patients O +
who O +
were O +
heterozygous O +
at O +
the O +
p53 O +
locus O +
. O +

As O +
the O +
p53 O +
gene O +
is O +
known O +
to O +
possess O +
tumor O +
suppressor O +
activity O +
, O +
the O +
functional O +
loss O +
of O +
this O +
gene O +
may O +
be O +
a O +
significant O +
step O +
in O +
the O +
development O +
of O +
a O +
subset O +
of O +
HCCs O +
. O +

High O +
levels O +
of O +
allele O +
loss O +
also O +
were O +
detected O +
for O +
chromosomes O +
8q O +
( O +
4 O +
of O +
9 O +
; O +
44 O +
% O +
) O +
and O +
16p O +
( O +
5 O +
of O +
6 O +
; O +
83 O +
% O +
) O +
and O +
may O +
indicate O +
the O +
presence O +
of O +
additional O +
cellular O +
genes O +
whose O +
functional O +
loss O +
is O +
important O +
in O +
the O +
development O +
of O +
HCCs O +
. O +

GDP O +
and O +
AGE O +
receptors O +
: O +
mechanisms O +
of O +
peritoneal O +
damage O +
. O +

Long O +
- O +
term O +
peritoneal O +
dialysis O +
( O +
PD O +
) O +
is O +
limited O +
by O +
morphological O +
changes O +
of O +
the O +
peritoneal O +
membrane O +
. O +

Structural O +
changes O +
were O +
promoted O +
by O +
toxicity O +
of O +
glucose O +
degradation O +
products O +
( O +
GDPs O +
) O +
which O +
are O +
generated O +
during O +
heat O +
sterilization O +
in O +
peritoneal O +
dialysis O +
fluids O +
( O +
PDFs O +
) O +
. O +

Besides O +
their O +
direct O +
toxicity O +
GDPs O +
promote O +
formation O +
of O +
advanced O +
glycation O +
endproducts O +
( O +
AGEs O +
) O +
. O +

RAGE O +
( O +
receptor O +
for O +
AGE O +
) O +
is O +
the O +
best O +
characterized O +
signal O +
transduction O +
receptor O +
for O +
AGEs O +
and O +
is O +
expressed O +
on O +
mesothelial O +
cells O +
. O +

The O +
effects O +
of O +
PDFs O +
with O +
different O +
amounts O +
of O +
GDPs O +
were O +
compared O +
on O +
morphological O +
changes O +
in O +
the O +
peritoneal O +
membrane O +
in O +
a O +
RAGE O +
- O +
/ O +
- O +
mouse O +
model O +
. O +

It O +
could O +
be O +
demonstrated O +
that O +
RAGE O +
plays O +
a O +
pivotal O +
role O +
in O +
structural O +
damage O +
( O +
e O +
. O +
g O +
. O +
inflammation O +
, O +
neoangiogenesis O +
and O +
fibrosis O +
) O +
of O +
the O +
peritoneal O +
membrane O +
. O +

Further O +
investigations O +
of O +
this O +
pathway O +
with O +
regard O +
to O +
preventing O +
peritoneal O +
fibrosis O +
should O +
be O +
performed O +
to O +
maintain O +
the O +
integrity O +
of O +
the O +
peritoneal O +
membrane O +
in O +
peritoneal O +
dialysis O +
patients O +
. O +

Hyperfibrinogenemia O +
is O +
associated O +
with O +
lymphatic O +
as O +
well O +
as O +
hematogenous O +
metastasis O +
and O +
worse O +
clinical O +
outcome O +
in O +
T2 O +
gastric O +
cancer O +
. O +

BACKGROUND O +
: O +
Abnormal O +
hemostasis O +
in O +
cancer O +
patients O +
has O +
previously O +
been O +
described O +
, O +
however O +
the O +
correlation O +
between O +
the O +
plasma O +
fibrinogen O +
level O +
and O +
cancer O +
metastasis O +
and O +
prognosis O +
has O +
not O +
been O +
reported O +
in O +
a O +
large O +
- O +
scale O +
clinical O +
study O +
. O +

METHODS O +
: O +
Preoperative O +
plasma O +
fibrinogen O +
levels O +
were O +
retrospectively O +
examined O +
in O +
405 O +
patients O +
who O +
underwent O +
surgery O +
for O +
advanced O +
gastric O +
cancer O +
. O +

The O +
association O +
of O +
fibrinogen O +
levels O +
with O +
clinical O +
/ O +
pathological O +
findings O +
and O +
clinical O +
outcome O +
was O +
evaluated O +
. O +

RESULTS O +
: O +
There O +
was O +
a O +
positive O +
correlation O +
between O +
plasma O +
fibrinogen O +
levels O +
and O +
the O +
depth O +
of O +
invasion O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
. O +

Hyperfibrinogenemia O +
( O +
> O +
310 O +
mg O +
/ O +
dl O +
) O +
was O +
independently O +
associated O +
with O +
lymph O +
node O +
( O +
Odds O +
Ratio O +
; O +
2 O +
. O +
342 O +
, O +
P O +
= O +
0 O +
. O +
0032 O +
) O +
and O +
liver O +
( O +
Odds O +
Ratio O +
; O +
2 O +
. O +
933 O +
, O +
P O +
= O +
0 O +
. O +
0147 O +
) O +
metastasis O +
, O +
not O +
with O +
peritoneal O +
metastasis O +
in O +
this O +
series O +
. O +

Patients O +
with O +
hyperfibrinogenemia O +
showed O +
worse O +
clinical O +
outcome O +
in O +
T2 O +
gastric O +
cancer O +
, O +
however O +
, O +
there O +
was O +
no O +
correlation O +
of O +
plasma O +
fibrinogen O +
level O +
with O +
prognosis O +
in O +
T3 O +
/ O +
T4 O +
gastric O +
cancer O +
. O +

CONCLUSION O +
: O +
Our O +
results O +
might O +
support O +
the O +
idea O +
that O +
hyperfibrinogenemia O +
can O +
augment O +
lymphatic O +
and O +
hematogeneous O +
metastasis O +
of O +
advanced O +
gastric O +
cancer O +
, O +
which O +
is O +
major O +
determinant O +
of O +
the O +
prognosis O +
in O +
T2 O +
gastric O +
cancer O +
. O +

Therefore O +
, O +
in O +
the O +
situation O +
without O +
peritoneal O +
involvement O +
, O +
hyperfibrinogenemia O +
is O +
a O +
useful O +
biomarker O +
to O +
predict O +
the O +
possible O +
metastasis O +
and O +
worse O +
clinical O +
outcome O +
in O +
T2 O +
gastric O +
cancer O +
. O +

Alteration O +
of O +
homeobox O +
gene O +
expression O +
by O +
N O +
- O +
ras O +
transformation O +
of O +
PA B-CellLine +
- I-CellLine +
1 I-CellLine +
human O +
teratocarcinoma O +
cells O +
. O +

We O +
used O +
a O +
series O +
of O +
cell O +
clones O +
from O +
a O +
human O +
teratocarcinoma O +
cell O +
line O +
, O +
PA B-CellLine +
- I-CellLine +
1 I-CellLine +
, O +
to O +
study O +
the O +
effect O +
of O +
transformation O +
by O +
an O +
activated O +
N O +
- O +
ras O +
oncogene O +
on O +
the O +
expression O +
of O +
genes O +
involved O +
in O +
retinoic O +
acid O +
( O +
RA O +
) O +
- O +
induced O +
differentiation O +
and O +
growth O +
regulation O +
. O +

Recently O +
, O +
it O +
has O +
been O +
shown O +
that O +
expression O +
of O +
human O +
HOX O +
2 O +
genes O +
is O +
sequentially O +
activated O +
by O +
RA O +
beginning O +
from O +
Hox O +
2 O +
. O +
9 O +
at O +
the O +
3 O +
' O +
end O +
of O +
the O +
HOX O +
2 O +
cluster O +
( O +
A O +
. O +
Simeone O +
, O +
D O +
. O +
Acampora O +
, O +
L O +
. O +
Arcioni O +
, O +
P O +
. O +
W O +
. O +
Andrews O +
, O +
E O +
. O +
Boncinelli O +
, O +
and O +
F O +
. O +
Mavilio O +
, O +
Nature O +
[ O +
London O +
] O +
346 O +
: O +
763 O +
- O +
766 O +
, O +
1990 O +
) O +
. O +

We O +
now O +
report O +
that O +
six O +
different O +
genes O +
of O +
the O +
cluster O +
HOX O +
1 O +
are O +
sequentially O +
induced O +
by O +
RA O +
in O +
a O +
similar O +
temporal O +
pattern O +
, O +
beginning O +
with O +
genes O +
at O +
the O +
3 O +
' O +
end O +
of O +
the O +
cluster O +
. O +

However O +
, O +
in O +
N O +
- O +
ras O +
- O +
transformed O +
cell O +
clones O +
, O +
RA O +
- O +
induced O +
expression O +
of O +
these O +
homeobox O +
genes O +
is O +
delayed O +
. O +

Hox O +
1 O +
. O +
4 O +
and O +
Hox O +
1 O +
. O +
3 O +
, O +
genes O +
abundantly O +
induced O +
in O +
nontransformed O +
clones O +
after O +
3 O +
days O +
of O +
RA O +
treatment O +
, O +
are O +
expressed O +
in O +
N O +
- O +
ras O +
- O +
transformed O +
cells O +
only O +
after O +
10 O +
days O +
of O +
RA O +
treatment O +
. O +

At O +
this O +
time O +
, O +
the O +
cells O +
' O +
growth O +
is O +
arrested O +
at O +
very O +
high O +
density O +
, O +
and O +
no O +
differentiated O +
morphologic O +
characteristics O +
are O +
observed O +
. O +

Constitutive O +
expression O +
of O +
a O +
transfected O +
Hox O +
1 O +
. O +
4 O +
gene O +
under O +
the O +
control O +
of O +
a O +
simian O +
virus O +
40 O +
promotor O +
leads O +
to O +
differentiated O +
cell O +
morphology O +
similar O +
to O +
that O +
of O +
the O +
RA O +
- O +
induced O +
phenotype O +
and O +
restores O +
the O +
growth O +
- O +
inhibitory O +
effects O +
of O +
RA O +
in O +
N O +
- O +
ras O +
- O +
transformed O +
cells O +
. O +

These O +
observations O +
provide O +
evidence O +
that O +
enhanced O +
proliferation O +
in O +
N O +
- O +
ras O +
- O +
transformed O +
cells O +
compromises O +
teratocarcinoma O +
cell O +
differentiation O +
by O +
a O +
mechanism O +
that O +
transiently O +
suppresses O +
homeobox O +
gene O +
induction O +
and O +
implies O +
a O +
central O +
role O +
for O +
homeobox O +
genes O +
in O +
RA O +
- O +
induced O +
cell O +
differentiation O +
. O +

We O +
conclude O +
that O +
stimulation O +
of O +
a O +
putative O +
growth O +
factor O +
signal O +
pathway O +
, O +
associated O +
with O +
ras O +
- O +
induced O +
proliferation O +
, O +
transiently O +
suppresses O +
the O +
induction O +
of O +
transcription O +
factors O +
functionally O +
involved O +
in O +
cell O +
growth O +
and O +
differentiation O +
. O +

Dendrimer O +
- O +
templated O +
Fe O +
nanoparticles O +
for O +
the O +
growth O +
of O +
single O +
- O +
wall O +
carbon O +
nanotubes O +
by O +
plasma O +
- O +
enhanced O +
CVD O +
. O +

A O +
fourth O +
- O +
generation O +
( O +
G4 O +
) O +
poly O +
( O +
amidoamine O +
) O +
( O +
PAMAM O +
) O +
dendrimer O +
( O +
G4 O +
- O +
NH2 O +
) O +
has O +
been O +
used O +
as O +
a O +
template O +
to O +
deliver O +
nearly O +
monodispersed O +
catalyst O +
nanoparticles O +
to O +
SiO2 O +
/ O +
Si O +
, O +
Ti O +
/ O +
Si O +
, O +
sapphire O +
, O +
and O +
porous O +
anodic O +
alumina O +
( O +
PAA O +
) O +
substrates O +
. O +

Fe2O3 O +
nanoparticles O +
obtained O +
after O +
calcination O +
of O +
the O +
immobilized O +
Fe3 O +
+ O +
/ O +
G4 O +
- O +
NH2 O +
composite O +
served O +
as O +
catalytic O +
" O +
seeds O +
" O +
for O +
the O +
growth O +
of O +
single O +
- O +
wall O +
carbon O +
nanotubes O +
( O +
SWNTs O +
) O +
by O +
microwave O +
plasma O +
- O +
enhanced O +
CVD O +
( O +
PECVD O +
) O +
. O +

To O +
surmount O +
the O +
difficulty O +
associated O +
with O +
SWNT O +
growth O +
via O +
PECVD O +
, O +
reaction O +
conditions O +
that O +
promote O +
the O +
stabilization O +
of O +
Fe O +
nanoparticles O +
, O +
resulting O +
in O +
enhanced O +
SWNT O +
selectivity O +
and O +
quality O +
, O +
have O +
been O +
identified O +
. O +

In O +
particular O +
, O +
in O +
situ O +
annealing O +
of O +
Fe O +
catalyst O +
in O +
an O +
N2 O +
atmosphere O +
was O +
found O +
to O +
improve O +
SWNT O +
selectivity O +
and O +
quality O +
. O +

H2 O +
prereduction O +
at O +
900 O +
degrees O +
C O +
for O +
5 O +
min O +
was O +
also O +
found O +
to O +
enhance O +
SWNT O +
selectivity O +
and O +
quality O +
for O +
SiO2 O +
/ O +
Si O +
supported O +
catalyst O +
, O +
albeit O +
of O +
lower O +
quality O +
for O +
sapphire O +
supported O +
catalyst O +
. O +

The O +
application O +
of O +
positive O +
dc O +
bias O +
voltage O +
( O +
+ O +
200 O +
V O +
) O +
during O +
SWNT O +
growth O +
was O +
shown O +
to O +
be O +
very O +
effective O +
in O +
removing O +
amorphous O +
carbon O +
impurities O +
while O +
enhancing O +
graphitization O +
, O +
SWNT O +
selectivity O +
, O +
and O +
vertical O +
alignment O +
. O +

The O +
results O +
of O +
this O +
study O +
should O +
promote O +
the O +
use O +
of O +
exposed O +
Fe O +
nanoparticles O +
supported O +
on O +
different O +
substrates O +
for O +
the O +
growth O +
of O +
high O +
- O +
quality O +
SWNTs O +
by O +
PECVD O +
. O +

Fluoro O +
- O +
Jade O +
B O +
staining O +
following O +
zymosan O +
microinjection O +
into O +
the O +
spinal O +
cord O +
white O +
matter O +
. O +

1 O +
. O +

The O +
fluorescein O +
derivate O +
Fluoro O +
- O +
Jade O +
B O +
( O +
FJB O +
) O +
, O +
which O +
primarily O +
labels O +
dead O +
or O +
dying O +
neurons O +
, O +
was O +
used O +
to O +
study O +
the O +
acute O +
focal O +
inflammation O +
in O +
the O +
spinal O +
cord O +
white O +
matter O +
. O +

Inflammation O +
was O +
induced O +
by O +
microinjection O +
of O +
the O +
yeast O +
particulate O +
zymosan O +
to O +
evaluate O +
the O +
biological O +
effects O +
of O +
intraspinal O +
macrophages O +
activation O +
without O +
the O +
confounding O +
effects O +
of O +
physical O +
trauma O +
. O +

2 O +
. O +

A O +
single O +
bolus O +
of O +
zymosan O +
( O +
Sigma O +
, O +
75 O +
nL O +
) O +
was O +
stereotaxically O +
injected O +
at O +
the O +
thoracic O +
level O +
into O +
the O +
lateral O +
white O +
matter O +
of O +
rat O +
spinal O +
cord O +
. O +

A O +
standard O +
Fluoro O +
- O +
Jade O +
B O +
staining O +
protocol O +
was O +
applied O +
to O +
spinal O +
cord O +
sections O +
at O +
6 O +
, O +
12 O +
, O +
24 O +
h O +
and O +
2 O +
, O +
4 O +
days O +
postinjection O +
. O +

Neutral O +
Red O +
, O +
NADPH O +
- O +
diaphorase O +
, O +
Iba1 O +
- O +
IR O +
, O +
and O +
DAPI O +
staining O +
protocols O +
accomplished O +
examination O +
of O +
the O +
cells O +
participating O +
in O +
the O +
acute O +
inflammatory O +
response O +
. O +

3 O +
. O +

Zymosan O +
caused O +
formation O +
of O +
clearly O +
delineated O +
inflammation O +
lesions O +
localized O +
in O +
the O +
lateral O +
white O +
matter O +
of O +
the O +
spinal O +
cord O +
. O +

Fluoro O +
- O +
Jade O +
B O +
stained O +
cells O +
in O +
the O +
area O +
of O +
inflammation O +
were O +
not O +
observed O +
at O +
12 O +
h O +
postinjection O +
while O +
mild O +
FJB O +
staining O +
appeared O +
at O +
24 O +
h O +
and O +
intense O +
staining O +
was O +
observed O +
at O +
2 O +
and O +
4 O +
days O +
postinjection O +
. O +

4 O +
. O +

This O +
study O +
shows O +
that O +
the O +
acute O +
response O +
to O +
zymosan O +
- O +
induced O +
inflammation O +
in O +
the O +
rat O +
spinal O +
cord O +
white O +
matter O +
causes O +
a O +
gradual O +
appearance O +
of O +
phagocytic O +
microglia O +
/ O +
macrophages O +
and O +
delayed O +
FJB O +
staining O +
of O +
the O +
inflammatory O +
cells O +
. O +

5 O +
. O +

FJB O +
, O +
a O +
reliable O +
marker O +
of O +
dying O +
neurons O +
, O +
is O +
a O +
more O +
universal O +
agent O +
than O +
formerly O +
believed O +
. O +

One O +
possible O +
explanation O +
for O +
the O +
gradual O +
appearance O +
of O +
FJB O +
- O +
stained O +
cells O +
in O +
the O +
area O +
of O +
inflammation O +
is O +
that O +
specific O +
time O +
is O +
required O +
for O +
sufficient O +
levels O +
of O +
proteins O +
and O +
/ O +
or O +
myelin O +
debris O +
of O +
axonal O +
origin O +
to O +
appear O +
in O +
the O +
cytoplasm O +
of O +
phagocytic O +
microglia O +
/ O +
macrophages O +
. O +

Prostate O +
- O +
specific O +
membrane O +
antigen O +
regulates O +
angiogenesis O +
by O +
modulating O +
integrin O +
signal O +
transduction O +
. O +

The O +
transmembrane O +
peptidase O +
prostate O +
- O +
specific O +
membrane O +
antigen O +
( O +
PSMA O +
) O +
is O +
universally O +
upregulated O +
in O +
the O +
vasculature O +
of O +
solid O +
tumors O +
, O +
but O +
its O +
functional O +
role O +
in O +
tumor O +
angiogenesis O +
has O +
not O +
been O +
investigated O +
. O +

Here O +
we O +
show O +
that O +
angiogenesis O +
is O +
severely O +
impaired O +
in O +
PSMA O +
- O +
null O +
animals O +
and O +
that O +
this O +
angiogenic O +
defect O +
occurs O +
at O +
the O +
level O +
of O +
endothelial O +
cell O +
invasion O +
through O +
the O +
extracellular O +
matrix O +
barrier O +
. O +

Because O +
proteolytic O +
degradation O +
of O +
the O +
extracellular O +
matrix O +
is O +
a O +
critical O +
component O +
of O +
endothelial O +
invasion O +
in O +
angiogenesis O +
, O +
it O +
is O +
logical O +
to O +
assume O +
that O +
PSMA O +
participates O +
in O +
matrix O +
degradation O +
. O +

However O +
, O +
we O +
demonstrate O +
a O +
novel O +
and O +
more O +
complex O +
role O +
for O +
PSMA O +
in O +
angiogenesis O +
, O +
where O +
it O +
is O +
a O +
principal O +
component O +
of O +
a O +
regulatory O +
loop O +
that O +
is O +
tightly O +
modulating O +
laminin O +
- O +
specific O +
integrin O +
signaling O +
and O +
GTPase O +
- O +
dependent O +
, O +
p21 O +
- O +
activated O +
kinase O +
1 O +
( O +
PAK O +
- O +
1 O +
) O +
activity O +
. O +

We O +
show O +
that O +
PSMA O +
inhibition O +
, O +
knockdown O +
, O +
or O +
deficiency O +
decreases O +
endothelial O +
cell O +
invasion O +
in O +
vitro O +
via O +
integrin O +
and O +
PAK O +
, O +
thus O +
abrogating O +
angiogenesis O +
. O +

Interestingly O +
, O +
the O +
neutralization O +
of O +
beta O +
( O +
1 O +
) O +
or O +
the O +
inactivation O +
of O +
PAK O +
increases O +
PSMA O +
activity O +
, O +
suggesting O +
that O +
they O +
negatively O +
regulate O +
PSMA O +
. O +

This O +
negative O +
regulation O +
is O +
mediated O +
by O +
the O +
cytoskeleton O +
as O +
the O +
disruption O +
of O +
interactions O +
between O +
the O +
PSMA O +
cytoplasmic O +
tail O +
and O +
the O +
anchor O +
protein O +
filamin O +
A O +
decreases O +
PSMA O +
activity O +
, O +
integrin O +
function O +
, O +
and O +
PAK O +
activation O +
. O +

Finally O +
, O +
the O +
inhibition O +
of O +
PAK O +
activation O +
enhances O +
the O +
PSMA O +
/ O +
filamin O +
A O +
interaction O +
and O +
, O +
thus O +
, O +
boosts O +
PSMA O +
activity O +
. O +

These O +
data O +
imply O +
that O +
PSMA O +
participates O +
in O +
an O +
autoregulatory O +
loop O +
, O +
wherein O +
active O +
PSMA O +
facilitates O +
integrin O +
signaling O +
and O +
PAK O +
activation O +
, O +
leading O +
to O +
both O +
productive O +
invasion O +
and O +
downregulation O +
of O +
integrin O +
beta O +
( O +
1 O +
) O +
signaling O +
via O +
reduced O +
PSMA O +
activity O +
. O +

Therefore O +
, O +
we O +
have O +
identified O +
a O +
novel O +
role O +
for O +
PSMA O +
as O +
a O +
true O +
molecular O +
interface O +
, O +
integrating O +
both O +
extracellular O +
and O +
intracellular O +
signals O +
during O +
angiogenesis O +
. O +

Defective O +
expression O +
of O +
HRK O +
is O +
associated O +
with O +
promoter O +
methylation O +
in O +
primary O +
central O +
nervous O +
system O +
lymphomas O +
. O +

OBJECTIVES O +
: O +
Recently O +
, O +
it O +
has O +
been O +
reported O +
that O +
expression O +
of O +
the O +
HRK O +
gene O +
was O +
significantly O +
reduced O +
by O +
hypermethylation O +
in O +
astrocytic O +
tumors O +
. O +

Our O +
aim O +
is O +
to O +
verify O +
the O +
alterations O +
in O +
the O +
HRK O +
gene O +
in O +
primary O +
central O +
nervous O +
system O +
lymphomas O +
( O +
PCNSLs O +
) O +
. O +

METHODS O +
: O +
We O +
analyzed O +
the O +
hypermethylation O +
status O +
and O +
expression O +
of O +
the O +
gene O +
and O +
12q13 O +
. O +
1 O +
loss O +
of O +
heterozygosity O +
in O +
31 O +
PCNSLs O +
. O +

RESULTS O +
: O +
A O +
total O +
of O +
13 O +
PCNSLs O +
( O +
31 O +
% O +
) O +
demonstrated O +
hypermethylation O +
in O +
either O +
the O +
promoter O +
or O +
exon O +
1 O +
; O +
loss O +
of O +
HRK O +
expression O +
was O +
immunohistochemically O +
observed O +
in O +
9 O +
tumors O +
and O +
was O +
significantly O +
associated O +
with O +
promoter O +
methylation O +
. O +

In O +
addition O +
, O +
higher O +
apoptotic O +
counts O +
were O +
associated O +
with O +
HRK O +
positivity O +
. O +

PCNSLs O +
with O +
HRK O +
methylation O +
also O +
showed O +
methylation O +
of O +
multiple O +
genes O +
, O +
such O +
as O +
p14ARF O +
, O +
p16INK4a O +
, O +
RB1 O +
, O +
p27Kip1 O +
and O +
O6 O +
- O +
MGMT O +
. O +

Patients O +
with O +
tumors O +
demonstrating O +
concurrent O +
methylation O +
of O +
more O +
than O +
half O +
of O +
their O +
genes O +
demonstrated O +
significantly O +
poorer O +
survival O +
and O +
earlier O +
recurrence O +
. O +

Hypermethylation O +
of O +
the O +
HRK O +
promoter O +
alone O +
was O +
not O +
associated O +
with O +
overall O +
outcome O +
, O +
but O +
relapse O +
- O +
free O +
survival O +
was O +
significantly O +
shorter O +
. O +

CONCLUSIONS O +
: O +
Our O +
findings O +
suggest O +
that O +
transcriptional O +
repression O +
of O +
HRK O +
is O +
caused O +
by O +
promoter O +
hypermethylation O +
in O +
PCNSL O +
, O +
and O +
that O +
the O +
loss O +
of O +
HRK O +
associated O +
with O +
the O +
methylation O +
profile O +
of O +
other O +
genes O +
is O +
a O +
potential O +
step O +
in O +
the O +
modulation O +
of O +
cellular O +
death O +
by O +
apoptosis O +
during O +
PCNSL O +
tumorigenesis O +
. O +

Changes O +
of O +
lymphocyte O +
subsets O +
in O +
leukemia O +
patients O +
who O +
received O +
allogenic O +
bone O +
marrow O +
transplantation O +
. O +

Proportional O +
changes O +
of O +
lymphocyte O +
subsets O +
in O +
the O +
peripheral O +
blood O +
were O +
monitored O +
by O +
two O +
- O +
color O +
flow O +
- O +
cytometry O +
in O +
seven O +
leukemia O +
patients O +
who O +
had O +
received O +
allogenic O +
bone O +
marrow O +
transplantation O +
( O +
BMT O +
) O +
. O +

Lymphocyte O +
counts O +
, O +
and O +
proportions O +
of O +
T O +
and O +
B O +
- O +
cells O +
returned O +
to O +
normal O +
ranges O +
between O +
the O +
2nd O +
and O +
12th O +
months O +
after O +
BMT O +
. O +

Activated O +
T O +
- O +
cells O +
prominently O +
increased O +
after O +
BMT O +
, O +
and O +
the O +
values O +
gradually O +
returned O +
toward O +
normal O +
. O +

As O +
to O +
lymphocyte O +
subsets O +
, O +
the O +
proportions O +
of O +
CD O +
4 O +
+ O +
cells O +
had O +
remained O +
low O +
, O +
while O +
those O +
of O +
CD O +
8 O +
+ O +
cells O +
high O +
for O +
a O +
whole O +
observation O +
period O +
after O +
BMT O +
. O +

The O +
changes O +
of O +
CD O +
4 O +
+ O +
cells O +
were O +
caused O +
by O +
the O +
decrease O +
of O +
suppressor O +
- O +
inducer O +
T O +
- O +
cells O +
( O +
CD O +
4 O +
+ O +
Leu O +
8 O +
+ O +
) O +
. O +

High O +
proportion O +
of O +
CD O +
8 O +
+ O +
cells O +
was O +
mainly O +
associated O +
with O +
increased O +
suppressor O +
T O +
- O +
cells O +
( O +
CD O +
8 O +
+ O +
CD O +
11 O +
+ O +
) O +
. O +

Among O +
natural O +
killer O +
( O +
NK O +
) O +
cells O +
, O +
highly O +
active O +
NK O +
cells O +
( O +
CD O +
16 O +
+ O +
CD O +
57 O +
- O +
) O +
markedly O +
increased O +
shortly O +
after O +
BMT O +
, O +
and O +
gradually O +
returned O +
to O +
normal O +
. O +

CD O +
16 O +
- O +
CD O +
57 O +
+ O +
NK O +
cells O +
increased O +
beyond O +
normal O +
ranges O +
after O +
the O +
2nd O +
month O +
. O +

The O +
incidence O +
or O +
degree O +
of O +
acute O +
and O +
chronic O +
graft O +
- O +
versus O +
- O +
host O +
diseases O +
( O +
GVHD O +
) O +
did O +
not O +
correlate O +
with O +
the O +
changes O +
of O +
any O +
lymphocyte O +
subsets O +
. O +

The O +
present O +
results O +
suggest O +
that O +
the O +
increase O +
of O +
activated O +
T O +
- O +
cells O +
shortly O +
after O +
BMT O +
reflects O +
lymphocyte O +
reconstitution O +
. O +

The O +
prolonged O +
immune O +
deficiency O +
after O +
BMT O +
might O +
be O +
related O +
to O +
either O +
deficient O +
expression O +
of O +
homing O +
receptor O +
( O +
Leu O +
8 O +
antigen O +
) O +
on O +
CD O +
4 O +
+ O +
cells O +
or O +
increased O +
suppressor O +
T O +
- O +
cells O +
( O +
CD O +
8 O +
+ O +
CD O +
11 O +
+ O +
) O +
. O +

In O +
addition O +
, O +
the O +
early O +
increase O +
of O +
NK O +
cells O +
after O +
BMT O +
may O +
compensate O +
for O +
the O +
immune O +
deficiency O +
in O +
BMT O +
patients O +
. O +

Fluoroscopically O +
guided O +
cervical O +
prolotherapy O +
for O +
instability O +
with O +
blinded O +
pre O +
and O +
post O +
radiographic O +
reading O +
. O +

BACKGROUND O +
: O +

Several O +
authors O +
have O +
postulated O +
that O +
cervical O +
instability O +
is O +
a O +
major O +
cause O +
of O +
traumatic O +
spinal O +
pain O +
. O +

OBJECTIVE O +
: O +

The O +
purpose O +
of O +
this O +
prospective O +
case O +
series O +
study O +
( O +
n O +
= O +
6 O +
) O +
was O +
to O +
determine O +
if O +
proliferant O +
injections O +
have O +
an O +
effect O +
on O +
cervical O +
translation O +
as O +
measured O +
by O +
a O +
blinded O +
reader O +
. O +

DESIGN O +
: O +

This O +
study O +
was O +
a O +
prospective O +
case O +
series O +
. O +

Study O +
participants O +
were O +
selected O +
from O +
patients O +
seen O +
for O +
the O +
primary O +
complaint O +
of O +
Motor O +
Vehicle O +
Collision O +
related O +
neck O +
pain O +
in O +
a O +
private O +
sub O +
- O +
specialty O +
pain O +
clinic O +
. O +

METHODS O +
: O +

Flexion O +
and O +
extension O +
views O +
were O +
obtained O +
by O +
standard O +
radiographs O +
taken O +
with O +
a O +
C O +
- O +
Arm O +
fluoroscope O +
under O +
Valium O +
sedation O +
. O +

Patients O +
with O +
more O +
than O +
2 O +
. O +
7 O +
mm O +
of O +
absolute O +
cervical O +
translation O +
and O +
at O +
least O +
50 O +
% O +
reduction O +
of O +
cervical O +
and O +
referred O +
pain O +
with O +
a O +
two O +
day O +
rigid O +
cervical O +
immobilization O +
test O +
were O +
admitted O +
into O +
the O +
study O +
. O +

Participants O +
underwent O +
3 O +
prolotherapy O +
injections O +
at O +
all O +
sites O +
that O +
demonstrated O +
translation O +
. O +

The O +
difference O +
in O +
means O +
between O +
pre O +
- O +
test O +
and O +
post O +
- O +
test O +
measurements O +
( O +
flexion O +
translation O +
, O +
extension O +
translation O +
, O +
and O +
pain O +
VAS O +
scores O +
) O +
were O +
assessed O +
by O +
a O +
Wilcoxon O +
signed O +
ranks O +
test O +
( O +
alpha O +
= O +
0 O +
. O +
05 O +
) O +
. O +

RESULTS O +
: O +

The O +
mean O +
post O +
- O +
test O +
VAS O +
score O +
( O +
M O +
= O +
3 O +
. O +
83 O +
, O +
SD O +
= O +
2 O +
. O +
3 O +
, O +
t O +
= O +
2 O +
. O +
889 O +
) O +
was O +
significantly O +
less O +
( O +
p O +
= O +
0 O +
. O +
04 O +
) O +
than O +
the O +
mean O +
pre O +
- O +
test O +
VAS O +
score O +
( O +
M O +
= O +
5 O +
. O +
75 O +
, O +
SD O +
= O +
1 O +
. O +
94 O +
) O +
. O +

The O +
correlation O +
between O +
difference O +
in O +
mean O +
extension O +
at O +
C2 O +
- O +
3 O +
and O +
C5 O +
- O +
6 O +
and O +
difference O +
in O +
mean O +
extension O +
was O +
significant O +
( O +
rho O +
= O +
0 O +
. O +
89 O +
, O +
p O +
= O +
0 O +
. O +
02 O +
and O +
rho O +
= O +
0 O +
. O +
85 O +
, O +
p O +
= O +
0 O +
. O +
03 O +
respectively O +
) O +
. O +

Difference O +
in O +
mean O +
flexion O +
at O +
C3 O +
- O +
4 O +
and O +
C4 O +
- O +
5 O +
was O +
significantly O +
correlated O +
with O +
difference O +
in O +
mean O +
flexion O +
( O +
rho O +
= O +
0 O +
. O +
88 O +
, O +
p O +
= O +
0 O +
. O +
02 O +
and O +
rho O +
= O +
0 O +
. O +
941 O +
, O +
p O +
< O +
0 O +
. O +
01 O +
respectively O +
) O +
. O +

CONCLUSIONS O +
: O +

The O +
results O +
of O +
this O +
study O +
demonstrate O +
statistically O +
significant O +
correlations O +
between O +
proliferant O +
injections O +
, O +
a O +
reduction O +
of O +
both O +
cervical O +
flexion O +
and O +
extension O +
translation O +
, O +
as O +
well O +
as O +
a O +
reduction O +
in O +
pain O +
VAS O +
score O +
. O +

Since O +
patients O +
with O +
traumatic O +
cervical O +
instability O +
have O +
few O +
viable O +
treatment O +
options O +
other O +
than O +
surgical O +
fusion O +
, O +
cervical O +
proliferant O +
injections O +
under O +
C O +
- O +
Arm O +
fluoroscope O +
may O +
be O +
a O +
viable O +
treatment O +
option O +
. O +

Differential O +
mechanisms O +
of O +
radiosensitization O +
by O +
2 O +
- O +
deoxy O +
- O +
D O +
- O +
glucose O +
in O +
the O +
monolayers O +
and O +
multicellular O +
spheroids O +
of O +
a O +
human O +
glioma O +
cell O +
line O +
. O +

In O +
vitro O +
studies O +
using O +
monolayer O +
cultures O +
of O +
human O +
tumor O +
cell O +
lines O +
have O +
shown O +
that O +
2 O +
- O +
DG O +
selectively O +
inhibits O +
energy O +
- O +
dependent O +
DNA O +
repair O +
and O +
cellular O +
recovery O +
processes O +
in O +
cancer O +
cells O +
. O +

However O +
, O +
monolayer O +
cultures O +
differ O +
greatly O +
from O +
the O +
complex O +
environmental O +
conditions O +
generated O +
in O +
solid O +
tumors O +
that O +
develop O +
inhomogeneous O +
hypoxic O +
and O +
necrotic O +
regions O +
. O +

In O +
contrast O +
, O +
multicellular O +
spheroids O +
mimic O +
heterogeneous O +
cellular O +
behavior O +
and O +
the O +
consequent O +
functional O +
characteristics O +
of O +
in O +
vivo O +
solid O +
tumors O +
, O +
and O +
serve O +
as O +
important O +
in O +
vitro O +
model O +
to O +
investigate O +
tumor O +
biology O +
and O +
responses O +
to O +
potential O +
therapeutic O +
agents O +
. O +

The O +
present O +
study O +
compares O +
the O +
radiomodification O +
by O +
2 O +
- O +
DG O +
in O +
monolayer O +
cultures O +
and O +
spheroids O +
of O +
a O +
human O +
glioma O +
cell O +
line O +
( O +
BMG B-CellLine +
- I-CellLine +
1 I-CellLine +
) O +
to O +
gain O +
insight O +
into O +
the O +
effects O +
in O +
solid O +
tumors O +
. O +

In O +
spheroids O +
, O +
the O +
glucose O +
consumption O +
( O +
2 O +
. O +
1 O +
p O +
mole O +
/ O +
cell O +
/ O +
h O +
) O +
and O +
lactate O +
production O +
( O +
3 O +
. O +
67 O +
p O +
mole O +
/ O +
cell O +
/ O +
h O +
) O +
was O +
nearly O +
2 O +
- O +
3 O +
fold O +
higher O +
than O +
in O +
monolayer O +
cells O +
( O +
0 O +
. O +
83 O +
and O +
1 O +
. O +
43 O +
p O +
mole O +
/ O +
cell O +
/ O +
h O +
respectively O +
) O +
. O +

Presence O +
of O +
2 O +
- O +
DG O +
( O +
5 O +
mM O +
) O +
for O +
2 O +
- O +
4 O +
h O +
inhibited O +
the O +
glucose O +
usage O +
and O +
lactate O +
production O +
by O +
70 O +
% O +
in O +
spheroids O +
, O +
while O +
a O +
35 O +
% O +
reduction O +
was O +
observed O +
in O +
monolayer O +
cells O +
. O +

Under O +
these O +
conditions O +
, O +
2 O +
- O +
DG O +
drastically O +
enhanced O +
the O +
radiation O +
- O +
induced O +
cell O +
death O +
of O +
spheroids O +
( O +
by O +
2 O +
- O +
3 O +
folds O +
) O +
; O +
while O +
a O +
40 O +
% O +
increase O +
was O +
observed O +
in O +
monolayer O +
cells O +
. O +

Radiosensitization O +
by O +
2 O +
- O +
DG O +
in O +
monolayer O +
cells O +
was O +
primarily O +
due O +
to O +
an O +
increase O +
in O +
mitotic O +
death O +
( O +
23 O +
% O +
) O +
linked O +
to O +
cytogenetic O +
damage O +
( O +
micronuclei O +
) O +
, O +
whereas O +
a O +
profound O +
induction O +
of O +
apoptosis O +
( O +
40 O +
% O +
) O +
accounted O +
for O +
the O +
sensitization O +
in O +
spheroids O +
. O +

Although O +
the O +
Bcl O +
- O +
2 O +
and O +
Bax O +
levels O +
were O +
significantly O +
higher O +
in O +
spheroids O +
, O +
Bcl O +
- O +
2 O +
/ O +
Bax O +
ratio O +
was O +
similar O +
in O +
monolayers O +
and O +
spheroids O +
. O +

Comet O +
assay O +
revealed O +
a O +
late O +
onset O +
of O +
DNA O +
breaks O +
in O +
the O +
presence O +
of O +
2 O +
- O +
DG O +
following O +
irradiation O +
only O +
in O +
spheroids O +
, O +
which O +
corroborated O +
well O +
with O +
the O +
late O +
onset O +
of O +
oxidative O +
stress O +
. O +

2 O +
- O +
DG O +
did O +
not O +
induce O +
a O +
significant O +
cell O +
cycle O +
delay O +
in O +
monolayers O +
, O +
while O +
a O +
transient O +
G O +
( O +
2 O +
) O +
delay O +
was O +
apparent O +
in O +
spheroids O +
. O +

Heparin O +
immobilized O +
porous O +
PLGA O +
microspheres O +
for O +
angiogenic O +
growth O +
factor O +
delivery O +
. O +

PURPOSE O +
: O +
Heparin O +
immobilized O +
porous O +
poly O +
( O +
D O +
, O +
L O +
- O +
lactic O +
- O +
co O +
- O +
glycolic O +
acid O +
) O +
( O +
PLGA O +
) O +
microspheres O +
were O +
prepared O +
for O +
sustained O +
release O +
of O +
basic O +
fibroblast O +
growth O +
factor O +
( O +
bFGF O +
) O +
to O +
induce O +
angiogenesis O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +
Porous O +
PLGA O +
microspheres O +
having O +
primary O +
amine O +
groups O +
on O +
the O +
surface O +
were O +
prepared O +
using O +
an O +
oil O +
- O +
in O +
- O +
water O +
( O +
O O +
/ O +
W O +
) O +
single O +
emulsion O +
method O +
using O +
Pluronic O +
F O +
- O +
127 O +
as O +
an O +
extractable O +
porogen O +
. O +

Heparin O +
was O +
surface O +
immobilized O +
via O +
covalent O +
conjugation O +
. O +

bFGF O +
was O +
loaded O +
into O +
the O +
heparin O +
functionalized O +
( O +
PLGA O +
- O +
heparin O +
) O +
microspheres O +
by O +
a O +
simple O +
dipping O +
method O +
. O +

The O +
bFGF O +
loaded O +
PLGA O +
- O +
heparin O +
microspheres O +
were O +
tested O +
for O +
in O +
vitro O +
release O +
and O +
in O +
vivo O +
angiogenic O +
activity O +
. O +

RESULTS O +
: O +
PLGA O +
microspheres O +
with O +
an O +
open O +
- O +
porous O +
structure O +
were O +
formed O +
. O +

The O +
amount O +
of O +
conjugated O +
amine O +
group O +
onto O +
the O +
microspheres O +
was O +
1 O +
. O +
93 O +
+ O +
/ O +
- O +
0 O +
. O +
01 O +
nmol O +
/ O +
mg O +
- O +
microspheres O +
, O +
while O +
the O +
amount O +
of O +
heparin O +
was O +
95 O +
. O +
8 O +
pmol O +
/ O +
mg O +
- O +
microspheres O +
. O +

PLGA O +
- O +
heparin O +
microspheres O +
released O +
out O +
bFGF O +
in O +
a O +
more O +
sustained O +
manner O +
with O +
a O +
smaller O +
extent O +
of O +
initial O +
burst O +
than O +
PLGA O +
microspheres O +
, O +
indicating O +
that O +
surface O +
immobilized O +
heparin O +
controlled O +
the O +
release O +
rate O +
of O +
bFGF O +
. O +

Subcutaneous O +
implantation O +
of O +
bFGF O +
loaded O +
PLGA O +
- O +
heparin O +
microspheres O +
in O +
mice O +
significantly O +
induced O +
the O +
formation O +
of O +
new O +
vascular O +
microvessels O +
. O +

CONCLUSIONS O +
: O +
PLGA O +
microspheres O +
with O +
an O +
open O +
porous O +
structure O +
allowed O +
significant O +
amount O +
of O +
heparin O +
immobilization O +
and O +
bFGF O +
loading O +
. O +

bFGF O +
loaded O +
PLGA O +
- O +
HP O +
microspheres O +
showed O +
sustained O +
release O +
profiles O +
of O +
bFGF O +
in O +
vitro O +
, O +
demonstrating O +
reversible O +
and O +
specific O +
binding O +
of O +
bFGF O +
to O +
immobilized O +
heparin O +
. O +

They O +
also O +
induced O +
local O +
angiogenesis O +
in O +
vivo O +
in O +
an O +
animal O +
model O +
. O +

[ O +
Autologous O +
bone O +
marrow O +
stem O +
cell O +
or O +
peripheral O +
blood O +
endothelial O +
progenitor O +
cell O +
therapy O +
in O +
patients O +
with O +
peripheral O +
limb O +
ischaemia O +
] O +

No O +
effective O +
medical O +
therapies O +
have O +
been O +
developed O +
sofar O +
to O +
enhance O +
blood O +
flow O +
in O +
the O +
legs O +
of O +
patients O +
with O +
peripheral O +
arterial O +
disease O +
( O +
PAD O +
) O +
. O +

For O +
patients O +
with O +
limb O +
threatening O +
ischaemia O +
the O +
only O +
option O +
for O +
relief O +
of O +
rest O +
pain O +
or O +
gangraena O +
is O +
amputation O +
. O +

There O +
is O +
evidence O +
in O +
experimental O +
and O +
clinical O +
studies O +
that O +
adult O +
bone O +
marrow O +
- O +
derived O +
stem O +
cells O +
and O +
endothelial O +
progenitor O +
cells O +
participate O +
in O +
the O +
development O +
of O +
new O +
blood O +
vessels O +
, O +
called O +
neoangiogenesis O +
or O +
neovascularization O +
. O +

Clinical O +
results O +
induced O +
by O +
autologous O +
bone O +
marrow O +
stem O +
cells O +
or O +
angiogenic O +
growth O +
/ O +
differentiation O +
factors O +
in O +
end O +
- O +
stage O +
patients O +
with O +
PAD O +
are O +
summarized O +
. O +

Considering O +
the O +
relatively O +
few O +
number O +
of O +
patients O +
treated O +
by O +
angiogenic O +
therapy O +
, O +
the O +
interpretation O +
of O +
clinical O +
results O +
needs O +
cautiousness O +
. O +

Formation O +
of O +
new O +
bone O +
during O +
vertical O +
distraction O +
osteogenesis O +
of O +
the O +
human O +
mandible O +
is O +
related O +
to O +
the O +
presence O +
of O +
blood O +
vessels O +
. O +

We O +
examined O +
the O +
effect O +
of O +
distraction O +
rate O +
on O +
blood O +
vessel O +
growth O +
in O +
intramembraneous O +
ossification O +
after O +
vertical O +
distraction O +
osteogenesis O +
in O +
the O +
human O +
mandible O +
. O +

Six O +
edentulous O +
patients O +
( O +
aged O +
60 O +
+ O +
/ O +
- O +
9 O +
years O +
) O +
with O +
a O +
severely O +
atrophic O +
mandible O +
underwent O +
bone O +
augmentation O +
with O +
distraction O +
osteogenesis O +
. O +

Two O +
distraction O +
rates O +
( O +
0 O +
. O +
5 O +
and O +
1 O +
mm O +
/ O +
day O +
) O +
were O +
compared O +
and O +
for O +
each O +
group O +
three O +
patients O +
were O +
analyzed O +
. O +

Vascular O +
histomorphometry O +
was O +
carried O +
out O +
in O +
two O +
different O +
areas O +
in O +
the O +
distraction O +
gap O +
: O +
( O +
1 O +
) O +
in O +
the O +
first O +
and O +
( O +
2 O +
) O +
in O +
the O +
second O +
1 O +
mm O +
area O +
from O +
the O +
osteotomy O +
line O +
, O +
representing O +
the O +
oldest O +
and O +
younger O +
new O +
- O +
bone O +
area O +
, O +
respectively O +
. O +

Correlation O +
analysis O +
was O +
performed O +
between O +
blood O +
vessel O +
parameters O +
and O +
the O +
amount O +
of O +
new O +
bone O +
formed O +
during O +
distraction O +
. O +

Histological O +
analysis O +
demonstrated O +
the O +
presence O +
of O +
blood O +
vessels O +
throughout O +
the O +
soft O +
connective O +
tissue O +
in O +
the O +
distraction O +
gap O +
. O +

The O +
volume O +
density O +
of O +
blood O +
vessels O +
between O +
the O +
two O +
investigated O +
areas O +
was O +
significantly O +
lower O +
in O +
the O +
1 O +
mm O +
/ O +
day O +
groups O +
, O +
suggesting O +
a O +
delay O +
in O +
angiogenesis O +
in O +
this O +
group O +
of O +
patients O +
. O +

A O +
positive O +
correlation O +
between O +
blood O +
vessel O +
volume O +
and O +
bone O +
volume O +
density O +
was O +
found O +
in O +
the O +
younger O +
new O +
- O +
bone O +
area O +
but O +
not O +
in O +
the O +
oldest O +
new O +
- O +
bone O +
area O +
. O +

This O +
correlation O +
was O +
due O +
to O +
a O +
higher O +
number O +
of O +
blood O +
vessels O +
rather O +
than O +
to O +
a O +
larger O +
size O +
of O +
the O +
blood O +
vessels O +
. O +

Our O +
data O +
suggest O +
that O +
the O +
lower O +
blood O +
vessel O +
density O +
found O +
in O +
the O +
patients O +
with O +
1 O +
mm O +
/ O +
day O +
distraction O +
rate O +
may O +
be O +
related O +
to O +
disruption O +
of O +
angiogenesis O +
in O +
the O +
soft O +
connective O +
tissue O +
of O +
the O +
gap O +
or O +
to O +
a O +
less O +
optimal O +
mechanical O +
stimulation O +
of O +
cells O +
involved O +
in O +
angiogenesis O +
. O +

This O +
probably O +
results O +
in O +
the O +
slower O +
rate O +
of O +
osteogenesis O +
seen O +
at O +
the O +
1 O +
mm O +
/ O +
day O +
distraction O +
rate O +
compared O +
with O +
the O +
0 O +
. O +
5 O +
mm O +
/ O +
day O +
distraction O +
rate O +
. O +

The O +
data O +
support O +
the O +
concept O +
that O +
a O +
positive O +
relationship O +
exists O +
between O +
the O +
density O +
of O +
blood O +
vessels O +
and O +
the O +
formation O +
of O +
bone O +
. O +

For O +
distraction O +
of O +
the O +
human O +
mandible O +
in O +
elderly O +
patients O +
, O +
a O +
distraction O +
rate O +
of O +
0 O +
. O +
5 O +
mm O +
/ O +
day O +
seems O +
beneficial O +
. O +

[ O +
The O +
prevalence O +
of O +
ADHD O +
and O +
attention O +
problems O +
in O +
preschool O +
- O +
aged O +
children O +
. O +
A O +
comparison O +
of O +
two O +
diagnostic O +
instruments O +
] O +
. O +

OBJECTIVES O +
: O +

In O +
order O +
to O +
analyse O +
the O +
prevalence O +
of O +
ADHD O +
and O +
attention O +
problems O +
in O +
preschool O +
- O +
aged O +
children O +
, O +
mothers O +
were O +
asked O +
to O +
rate O +
their O +
children O +
using O +
two O +
measuring O +
instruments O +
. O +

METHODS O +
: O +

The O +
analysis O +
is O +
part O +
of O +
a O +
prospective O +
, O +
randomised O +
control O +
study O +
of O +
N O +
= O +
280 O +
children O +
aged O +
three O +
to O +
six O +
years O +
, O +
whose O +
mothers O +
rated O +
them O +
using O +
the O +
Child O +
Behaviour O +
Checklist O +
/ O +
CBCL O +
1 O +
1 O +
/ O +
2 O +
- O +
5 O +
and O +
the O +
Parent O +
Rating O +
Scale O +
for O +
Attention O +
- O +
Deficit O +
Hyperactivity O +
Disorder O +
( O +
ADHD O +
) O +
. O +

RESULTS O +
: O +

The O +
prevalence O +
rates O +
ranged O +
from O +
2 O +
. O +
7 O +
% O +
to O +
9 O +
. O +
9 O +
% O +
. O +

There O +
was O +
no O +
significant O +
gender O +
effect O +
in O +
this O +
age O +
group O +
. O +

CONCLUSIONS O +
: O +

The O +
study O +
delivers O +
initial O +
findings O +
and O +
provides O +
support O +
for O +
decisions O +
to O +
implement O +
in O +
Germany O +
new O +
assessment O +
methods O +
for O +
preschool O +
- O +
aged O +
children O +
with O +
ADHD O +
or O +
hyperkinetic O +
syndrome O +
. O +

Finally O +
, O +
the O +
different O +
rates O +
of O +
prevalence O +
and O +
the O +
implications O +
of O +
the O +
findings O +
for O +
epidemiology O +
and O +
the O +
prevention O +
of O +
ADHD O +
and O +
attention O +
problems O +
among O +
preschool O +
- O +
aged O +
children O +
are O +
discussed O +
. O +

The O +
role O +
of O +
syndecans O +
in O +
disease O +
and O +
wound O +
healing O +
. O +

Syndecans O +
are O +
a O +
family O +
of O +
transmembrane O +
heparan O +
sulfate O +
proteoglycans O +
widely O +
expressed O +
in O +
both O +
developing O +
and O +
adult O +
tissues O +
. O +

Until O +
recently O +
, O +
their O +
role O +
in O +
pathogenesis O +
was O +
largely O +
unexplored O +
. O +

In O +
this O +
review O +
, O +
we O +
discuss O +
the O +
reported O +
involvement O +
of O +
syndecans O +
in O +
human O +
cancers O +
, O +
infectious O +
diseases O +
, O +
obesity O +
, O +
wound O +
healing O +
and O +
angiogenesis O +
. O +

In O +
some O +
cancers O +
, O +
syndecan O +
expression O +
has O +
been O +
shown O +
to O +
regulate O +
tumor O +
cell O +
function O +
( O +
e O +
. O +
g O +
. O +
proliferation O +
, O +
adhesion O +
, O +
and O +
motility O +
) O +
and O +
serve O +
as O +
a O +
prognostic O +
marker O +
for O +
tumor O +
progression O +
and O +
patient O +
survival O +
. O +

The O +
ectodomains O +
and O +
heparan O +
sulfate O +
glycosaminoglycan O +
chains O +
of O +
syndecans O +
can O +
also O +
act O +
as O +
receptors O +
/ O +
co O +
- O +
receptors O +
for O +
some O +
bacterial O +
and O +
viral O +
pathogens O +
, O +
mediating O +
infection O +
. O +

In O +
addition O +
, O +
syndecans O +
bind O +
to O +
obesity O +
- O +
related O +
factors O +
and O +
regulate O +
their O +
signaling O +
, O +
in O +
turn O +
modulating O +
food O +
consumption O +
and O +
weight O +
balance O +
. O +

In O +
vivo O +
animal O +
models O +
of O +
tissue O +
injury O +
and O +
in O +
vitro O +
data O +
also O +
implicate O +
syndecans O +
in O +
processes O +
necessary O +
for O +
wound O +
healing O +
, O +
including O +
fibroblast O +
and O +
endothelial O +
proliferation O +
, O +
cell O +
motility O +
, O +
angiogenesis O +
, O +
and O +
extracellular O +
matrix O +
organization O +
. O +

These O +
new O +
insights O +
into O +
the O +
involvement O +
of O +
syndecans O +
in O +
disease O +
and O +
tissue O +
repair O +
coupled O +
with O +
the O +
emergence O +
of O +
syndecan O +
- O +
specific O +
molecular O +
tools O +
may O +
lead O +
to O +
novel O +
therapies O +
for O +
a O +
variety O +
of O +
human O +
diseases O +
. O +

High O +
- O +
Dose O +
celecoxib O +
and O +
metronomic O +
" O +
low O +
- O +
dose O +
" O +
cyclophosphamide O +
is O +
an O +
effective O +
and O +
safe O +
therapy O +
in O +
patients O +
with O +
relapsed O +
and O +
refractory O +
aggressive O +
histology O +
non O +
- O +
Hodgkin O +
' O +
s O +
lymphoma O +
. O +

PURPOSE O +
: O +
Angiogenesis O +
is O +
increased O +
in O +
aggressive O +
histology O +
non O +
- O +
Hodgkin O +
' O +
s O +
lymphoma O +
and O +
may O +
be O +
a O +
target O +
with O +
selective O +
cyclooxygenase O +
- O +
2 O +
inhibition O +
and O +
metronomic O +
chemotherapy O +
. O +

EXPERIMENTAL O +
DESIGN O +
: O +
We O +
assessed O +
response O +
, O +
toxicity O +
, O +
and O +
biomarkers O +
of O +
angiogenesis O +
to O +
low O +
- O +
dose O +
cyclophosphamide O +
( O +
50 O +
mg O +
p O +
. O +
o O +
. O +
o O +
. O +
d O +
. O +
) O +
and O +
high O +
- O +
dose O +
celecoxib O +
( O +
400 O +
mg O +
p O +
. O +
o O +
. O +
b O +
. O +
i O +
. O +
d O +
. O +
) O +
in O +
adult O +
patients O +
with O +
relapsed O +
or O +
refractory O +
aggressive O +
non O +
- O +
Hodgkin O +
' O +
s O +
lymphoma O +
in O +
a O +
multicenter O +
phase O +
II O +
prospective O +
study O +
. O +

RESULTS O +
: O +
Thirty O +
- O +
two O +
of O +
35 O +
patients O +
( O +
median O +
age O +
, O +
62 O +
years O +
) O +
are O +
evaluable O +
for O +
response O +
. O +

Patients O +
had O +
primarily O +
relapsed O +
diffuse O +
large O +
B O +
- O +
cell O +
lymphoma O +
( O +
63 O +
% O +
) O +
were O +
heavily O +
pretreated O +
( O +
median O +
of O +
three O +
regimens O +
) O +
and O +
high O +
risk O +
( O +
79 O +
% O +
international O +
prognostic O +
index O +
, O +
greater O +
than O +
or O +
= O +
2 O +
) O +
and O +
34 O +
% O +
were O +
relapsed O +
after O +
autologous O +
stem O +
cell O +
transplant O +
. O +

With O +
a O +
median O +
follow O +
- O +
up O +
of O +
8 O +
. O +
4 O +
months O +
, O +
the O +
overall O +
best O +
response O +
rate O +
is O +
37 O +
% O +
( O +
2 O +
complete O +
clinical O +
response O +
/ O +
complete O +
clinical O +
response O +
unconfirmed O +
and O +
9 O +
partial O +
response O +
) O +
, O +
with O +
22 O +
% O +
achieving O +
stable O +
disease O +
. O +

Median O +
overall O +
and O +
progression O +
- O +
free O +
survivals O +
are O +
14 O +
. O +
4 O +
and O +
4 O +
. O +
7 O +
months O +
, O +
respectively O +
. O +

The O +
median O +
response O +
duration O +
was O +
8 O +
. O +
2 O +
months O +
. O +

The O +
most O +
common O +
toxicity O +
was O +
skin O +
rash O +
( O +
40 O +
% O +
) O +
; O +
myelosuppression O +
and O +
gastrointestinal O +
side O +
effects O +
were O +
uncommon O +
. O +

Three O +
patients O +
developed O +
deep O +
vein O +
thromboses O +
and O +
two O +
heavily O +
pretreated O +
patients O +
developed O +
treatment O +
- O +
related O +
acute O +
myelogenous O +
leukemia O +
or O +
myelodysplasia O +
after O +
3 O +
. O +
7 O +
and O +
12 O +
months O +
of O +
therapy O +
. O +

Circulating O +
endothelial O +
cells O +
and O +
their O +
precursors O +
declined O +
and O +
remained O +
low O +
in O +
responders O +
, O +
whereas O +
plasma O +
vascular O +
endothelial O +
growth O +
factor O +
trended O +
to O +
decline O +
in O +
responding O +
patients O +
but O +
increase O +
in O +
nonresponders O +
. O +

Trough O +
celecoxib O +
levels O +
achieved O +
targeted O +
" O +
antiangiogenic O +
" O +
levels O +
. O +

CONCLUSIONS O +
: O +
Low O +
- O +
dose O +
cyclophosphamide O +
and O +
high O +
- O +
dose O +
celecoxib O +
is O +
well O +
tolerated O +
and O +
active O +
in O +
pretreated O +
aggressive O +
non O +
- O +
Hodgkin O +
' O +
s O +
lymphoma O +
. O +

Close O +
surveillance O +
for O +
arterial O +
and O +
venous O +
thrombotic O +
events O +
is O +
recommended O +
. O +

The O +
decline O +
in O +
circulating O +
endothelial O +
cells O +
and O +
their O +
precursors O +
suggests O +
that O +
this O +
combination O +
may O +
be O +
working O +
by O +
inhibiting O +
angiogenesis O +
but O +
should O +
be O +
validated O +
in O +
a O +
larger O +
patient O +
sample O +
. O +

Structure O +
of O +
the O +
genetic O +
code O +
suggested O +
by O +
the O +
hydropathy O +
correlation O +
between O +
anticodons O +
and O +
amino O +
acid O +
residues O +
. O +

The O +
correlation O +
between O +
hydropathies O +
of O +
anticodons O +
and O +
amino O +
acids O +
, O +
detected O +
by O +
other O +
authors O +
utilizing O +
scales O +
of O +
amino O +
acid O +
molecules O +
in O +
solution O +
, O +
was O +
improved O +
with O +
the O +
utilization O +
of O +
scales O +
of O +
amino O +
acid O +
residues O +
in O +
proteins O +
. O +

Three O +
partitions O +
were O +
discerned O +
in O +
the O +
correlation O +
plot O +
with O +
the O +
principal O +
dinucleotides O +
of O +
anticodons O +
( O +
pDiN O +
, O +
excluding O +
the O +
wobble O +
position O +
) O +
. O +

( O +
a O +
) O +
The O +
set O +
of O +
outliers O +
of O +
the O +
correlation O +
: O +
Gly O +
- O +
CC O +
, O +
Pro O +
- O +
GG O +
, O +
Ser O +
- O +
GA O +
and O +
Ser O +
- O +
CU O +
. O +

The O +
amino O +
acids O +
are O +
consistently O +
small O +
, O +
hydro O +
- O +
apathetic O +
, O +
stabilizers O +
of O +
protein O +
N O +
- O +
ends O +
, O +
preferred O +
in O +
aperiodic O +
protein O +
conformations O +
and O +
belong O +
to O +
synthetases O +
class O +
II O +
. O +

The O +
pDiN O +
sequences O +
are O +
representative O +
of O +
the O +
homogeneous O +
sector O +
( O +
triplets O +
NRR O +
and O +
NYY O +
) O +
, O +
distinguished O +
from O +
the O +
mixed O +
sector O +
( O +
triplets O +
NRY O +
and O +
NYR O +
) O +
, O +
that O +
depict O +
a O +
70 O +
% O +
correspondence O +
to O +
the O +
synthetases O +
class O +
II O +
and O +
I O +
, O +
respectively O +
. O +

The O +
triplet O +
pairs O +
proposed O +
to O +
be O +
responsible O +
for O +
the O +
coherence O +
in O +
the O +
set O +
of O +
outliers O +
are O +
of O +
the O +
palindromic O +
kind O +
, O +
where O +
the O +
lateral O +
bases O +
are O +
the O +
same O +
, O +
CCC O +
: O +
GGG O +
and O +
AGA O +
: O +
UCU O +
. O +

This O +
suggests O +
that O +
UCU O +
previously O +
belonged O +
to O +
Ser O +
, O +
adding O +
to O +
other O +
indications O +
that O +
the O +
attribution O +
of O +
Arg O +
to O +
YCU O +
was O +
due O +
to O +
an O +
expansion O +
of O +
the O +
Arg O +
- O +
tRNA O +
synthetase O +
specificity O +
. O +

The O +
other O +
attributions O +
produced O +
two O +
correlation O +
sets O +
. O +

( O +
b O +
) O +
One O +
corresponds O +
to O +
the O +
remaining O +
pDiN O +
of O +
the O +
homogeneous O +
sector O +
, O +
containing O +
both O +
synthetase O +
classes O +
; O +
its O +
regression O +
line O +
overlapped O +
the O +
one O +
formed O +
by O +
the O +
remaining O +
attributions O +
to O +
class O +
II O +
. O +

( O +
c O +
) O +
The O +
other O +
contains O +
the O +
pDiN O +
of O +
the O +
mixed O +
sector O +
and O +
produced O +
steeper O +
slopes O +
, O +
especially O +
with O +
the O +
class O +
I O +
attributions O +
. O +

It O +
is O +
suggested O +
that O +
the O +
correlation O +
was O +
established O +
when O +
the O +
amino O +
acid O +
composition O +
of O +
the O +
protein O +
synthetases O +
became O +
progressively O +
enriched O +
and O +
that O +
the O +
set O +
of O +
outliers O +
were O +
the O +
earliest O +
to O +
have O +
been O +
fixed O +
. O +

Photodynamic O +
therapy O +
with O +
verteporfin O +
for O +
subfoveal O +
choroidal O +
neovascularization O +
secondary O +
to O +
pathologic O +
myopia O +
: O +
long O +
- O +
term O +
study O +
. O +

PURPOSE O +
: O +
To O +
assess O +
the O +
safety O +
and O +
effectiveness O +
of O +
photodynamic O +
therapy O +
( O +
PDT O +
) O +
with O +
verteporfin O +
for O +
subfoveal O +
choroidal O +
neovascularization O +
( O +
CNV O +
) O +
secondary O +
to O +
pathologic O +
myopia O +
( O +
PM O +
) O +
. O +

METHODS O +
: O +
Sixty O +
- O +
two O +
patients O +
( O +
62 O +
eyes O +
) O +
with O +
PM O +
underwent O +
PDT O +
according O +
to O +
the O +
guidelines O +
of O +
the O +
Verteporfin O +
in O +
Photodynamic O +
Therapy O +
Study O +
. O +

Clinical O +
evaluations O +
performed O +
at O +
all O +
study O +
visits O +
included O +
measurement O +
of O +
best O +
- O +
corrected O +
Snellen O +
visual O +
acuity O +
, O +
slit O +
- O +
lamp O +
biomicroscopy O +
, O +
and O +
fundus O +
fluorescein O +
angiography O +
. O +

Patients O +
were O +
followed O +
up O +
at O +
1 O +
month O +
and O +
3 O +
months O +
after O +
treatment O +
and O +
thereafter O +
at O +
3 O +
- O +
month O +
intervals O +
. O +

RESULTS O +
: O +
The O +
final O +
visual O +
acuity O +
of O +
the O +
study O +
patients O +
, O +
after O +
a O +
median O +
follow O +
- O +
up O +
of O +
31 O +
months O +
, O +
improved O +
by O +
greater O +
than O +
or O +
= O +
1 O +
Snellen O +
lines O +
in O +
8 O +
patients O +
( O +
13 O +
% O +
) O +
, O +
deteriorated O +
in O +
20 O +
( O +
32 O +
% O +
) O +
, O +
and O +
remained O +
stable O +
in O +
34 O +
( O +
55 O +
% O +
) O +
. O +

The O +
baseline O +
visual O +
acuity O +
was O +
similar O +
in O +
the O +
various O +
study O +
groups O +
. O +

The O +
final O +
mean O +
visual O +
acuity O +
in O +
group O +
A O +
( O +
55 O +
years O +
of O +
age O +
or O +
younger O +
) O +
was O +
20 O +
/ O +
80 O +
and O +
significantly O +
( O +
P O +
= O +
0 O +
. O +
006 O +
) O +
better O +
than O +
that O +
( O +
20 O +
/ O +
138 O +
) O +
in O +
group O +
B O +
( O +
older O +
than O +
55 O +
years O +
of O +
age O +
) O +
. O +

The O +
mean O +
final O +
visual O +
acuity O +
in O +
eyes O +
with O +
higher O +
refractive O +
error O +
at O +
baseline O +
( O +
greater O +
than O +
- O +
17 O +
diopters O +
) O +
was O +
significantly O +
better O +
( O +
P O +
= O +
0 O +
. O +
014 O +
) O +
than O +
that O +
in O +
eyes O +
with O +
lower O +
refractive O +
error O +
( O +
- O +
6 O +
to O +
- O +
10 O +
diopters O +
) O +
. O +

CNV O +
size O +
did O +
not O +
affect O +
visual O +
outcomes O +
. O +

CONCLUSION O +
: O +
PDT O +
preserves O +
vision O +
in O +
patients O +
with O +
CNV O +
associated O +
with O +
PM O +
. O +

Younger O +
patients O +
and O +
eyes O +
with O +
higher O +
refractive O +
error O +
appear O +
more O +
likely O +
to O +
benefit O +
from O +
PDT O +
with O +
verteporfin O +
. O +

Medical O +
adherence O +
and O +
childhood O +
chronic O +
illness O +
: O +
family O +
daily O +
management O +
skills O +
and O +
emotional O +
climate O +
as O +
emerging O +
contributors O +
. O +

PURPOSE O +
OF O +
REVIEW O +
: O +

To O +
describe O +
recent O +
research O +
that O +
examines O +
family O +
factors O +
that O +
promote O +
or O +
derail O +
adherence O +
to O +
medical O +
regimens O +
for O +
children O +
with O +
chronic O +
health O +
conditions O +
, O +
primarily O +
asthma O +
, O +
diabetes O +
, O +
and O +
cystic O +
fibrosis O +
. O +

From O +
the O +
past O +
2 O +
years O +
, O +
eight O +
correlational O +
studies O +
were O +
identified O +
which O +
specifically O +
examined O +
the O +
links O +
between O +
family O +
management O +
strategies O +
, O +
family O +
climate O +
and O +
medical O +
adherence O +
. O +

RECENT O +
FINDINGS O +
: O +

Findings O +
from O +
the O +
studies O +
suggest O +
that O +
team O +
- O +
based O +
management O +
strategies O +
and O +
cohesive O +
family O +
climate O +
promote O +
adherence O +
to O +
medical O +
treatments O +
over O +
time O +
. O +

Family O +
interactions O +
that O +
are O +
characterized O +
by O +
conflict O +
and O +
disengagement O +
tend O +
to O +
disrupt O +
adherence O +
and O +
inevitably O +
cause O +
a O +
decline O +
in O +
child O +
health O +
. O +

Moreover O +
, O +
these O +
findings O +
seem O +
to O +
be O +
moderated O +
by O +
child O +
age O +
in O +
that O +
poorer O +
adherence O +
often O +
occurs O +
when O +
a O +
child O +
reaches O +
adolescence O +
and O +
is O +
searching O +
for O +
greater O +
autonomy O +
. O +

SUMMARY O +
: O +

Future O +
research O +
should O +
consider O +
the O +
challenges O +
in O +
measuring O +
medical O +
adherence O +
in O +
the O +
family O +
context O +
as O +
well O +
as O +
incorporating O +
more O +
naturalistic O +
studies O +
of O +
family O +
interactions O +
. O +

Randomized O +
controlled O +
trials O +
using O +
family O +
- O +
based O +
interventions O +
may O +
consider O +
focusing O +
on O +
medical O +
adherence O +
as O +
an O +
important O +
mediator O +
between O +
family O +
process O +
and O +
child O +
health O +
outcomes O +
. O +

C O +
/ O +
EBPbeta O +
is O +
over O +
- O +
expressed O +
in O +
gastric O +
carcinogenesis O +
and O +
is O +
associated O +
with O +
COX O +
- O +
2 O +
expression O +
. O +

The O +
CCAAT O +
/ O +
enhancer O +
- O +
binding O +
protein O +
beta O +
( O +
C O +
/ O +
EBPbeta O +
) O +
transcription O +
factor O +
has O +
been O +
associated O +
with O +
several O +
cancer O +
models O +
. O +

In O +
this O +
study O +
, O +
the O +
expression O +
of O +
C O +
/ O +
EBPbeta O +
was O +
analysed O +
in O +
a O +
series O +
of O +
90 O +
gastric O +
carcinomas O +
( O +
GCs O +
) O +
. O +

We O +
also O +
assessed O +
the O +
effect O +
of O +
C O +
/ O +
EBPbeta O +
on O +
COX O +
- O +
2 O +
expression O +
. O +

In O +
normal O +
gastric O +
mucosa O +
, O +
C O +
/ O +
EBPbeta O +
expression O +
was O +
restricted O +
to O +
cells O +
in O +
the O +
proliferative O +
zone O +
. O +

In O +
intestinal O +
metaplasia O +
, O +
dysplasia O +
, O +
and O +
GC O +
of O +
the O +
intestinal O +
and O +
atypical O +
subtypes O +
, O +
C O +
/ O +
EBPbeta O +
was O +
over O +
- O +
expressed O +
( O +
p O +
< O +
0 O +
. O +
0001 O +
, O +
for O +
the O +
association O +
with O +
histological O +
type O +
) O +
. O +

C O +
/ O +
EBPbeta O +
and O +
Ki67 O +
, O +
a O +
marker O +
of O +
cell O +
proliferation O +
, O +
were O +
also O +
co O +
- O +
expressed O +
in O +
primary O +
GC O +
. O +

We O +
also O +
observed O +
an O +
overlap O +
between O +
C O +
/ O +
EBPbeta O +
and O +
COX O +
- O +
2 O +
expression O +
in O +
GC O +
. O +

Using O +
GC O +
cell O +
lines O +
we O +
show O +
that O +
C O +
/ O +
EBPbeta O +
can O +
regulate O +
the O +
expression O +
of O +
endogenous O +
COX O +
- O +
2 O +
and O +
transactivate O +
the O +
promoter O +
of O +
the O +
COX O +
- O +
2 O +
gene O +
, O +
depending O +
on O +
its O +
methylation O +
status O +
. O +

These O +
results O +
suggest O +
that O +
C O +
/ O +
EBPbeta O +
may O +
be O +
a O +
marker O +
of O +
neoplastic O +
transformation O +
and O +
also O +
play O +
an O +
active O +
role O +
in O +
gastric O +
tumourigenesis O +
by O +
regulating O +
COX O +
- O +
2 O +
expression O +
. O +

Neoplastic O +
transformation O +
of O +
ciliary O +
body O +
epithelium O +
is O +
associated O +
with O +
loss O +
of O +
opticin O +
expression O +
. O +

BACKGROUND O +
: O +
Opticin O +
is O +
a O +
recently O +
discovered O +
glycoprotein O +
present O +
predominantly O +
in O +
the O +
vitreous O +
humour O +
. O +

It O +
is O +
synthesised O +
and O +
secreted O +
by O +
the O +
ciliary O +
body O +
epithelium O +
( O +
CBE O +
) O +
from O +
the O +
initiation O +
of O +
CBE O +
development O +
in O +
the O +
embryo O +
, O +
and O +
production O +
continues O +
throughout O +
life O +
. O +

AIM O +
: O +
To O +
determine O +
whether O +
a O +
variety O +
of O +
ciliary O +
body O +
tumours O +
synthesise O +
opticin O +
to O +
characterise O +
further O +
its O +
role O +
in O +
ciliary O +
body O +
health O +
and O +
disease O +
. O +

METHODS O +
: O +
Immunohistochemistry O +
was O +
used O +
to O +
determine O +
the O +
distribution O +
of O +
opticin O +
in O +
normal O +
human O +
CBE O +
, O +
and O +
in O +
hyperplastic O +
and O +
neoplastic O +
CBE O +
lesions O +
. O +

RESULTS O +
: O +
Opticin O +
was O +
immunolocalised O +
to O +
the O +
basal O +
cell O +
surface O +
and O +
basement O +
membrane O +
material O +
of O +
the O +
non O +
- O +
pigmented O +
CBE O +
in O +
nine O +
donor O +
eyes O +
as O +
well O +
as O +
four O +
hyperplastic O +
lesions O +
of O +
the O +
CBE O +
( O +
Fuchs O +
' O +
s O +
adenoma O +
) O +
. O +

By O +
contrast O +
, O +
none O +
of O +
eight O +
neoplastic O +
lesions O +
( O +
two O +
adenoma O +
and O +
six O +
adenocarcinoma O +
) O +
of O +
CBE O +
stained O +
for O +
opticin O +
. O +

CONCLUSION O +
: O +
The O +
present O +
series O +
supports O +
the O +
theory O +
that O +
opticin O +
is O +
produced O +
by O +
the O +
non O +
- O +
pigmented O +
CBE O +
throughout O +
adult O +
life O +
. O +

Loss O +
of O +
opticin O +
expression O +
by O +
this O +
tissue O +
is O +
associated O +
with O +
and O +
could O +
contribute O +
towards O +
neoplastic O +
transformation O +
. O +

Imaging O +
tumor O +
angiogenesis O +
. O +

Since O +
the O +
discovery O +
of O +
vascular O +
- O +
specific O +
growth O +
factors O +
with O +
angiogenic O +
activity O +
, O +
there O +
has O +
been O +
a O +
significant O +
effort O +
to O +
develop O +
cancer O +
drugs O +
that O +
restrict O +
tumorigenesis O +
by O +
targeting O +
the O +
blood O +
supply O +
. O +

In O +
this O +
issue O +
of O +
the O +
JCI O +
, O +
Mancuso O +
et O +
al O +
. O +
use O +
mouse O +
models O +
to O +
better O +
understand O +
the O +
plasticity O +
of O +
the O +
tumor O +
vasculature O +
in O +
the O +
face O +
of O +
antiangiogenic O +
therapy O +
( O +
see O +
the O +
related O +
article O +
beginning O +
on O +
page O +
2610 O +
) O +
. O +

They O +
describe O +
a O +
rapid O +
regrowth O +
of O +
the O +
tumor O +
vasculature O +
following O +
withdrawal O +
of O +
VEGFR O +
inhibitors O +
, O +
emphasizing O +
the O +
importance O +
of O +
fully O +
understanding O +
the O +
function O +
of O +
these O +
and O +
similar O +
treatments O +
used O +
in O +
the O +
clinic O +
at O +
the O +
cellular O +
and O +
molecular O +
level O +
. O +

Collagen O +
- O +
poly O +
glycolic O +
acid O +
hybrid O +
matrix O +
with O +
basic O +
fibroblast O +
growth O +
factor O +
accelerated O +
angiogenesis O +
and O +
granulation O +
tissue O +
formation O +
in O +
diabetic O +
mice O +
. O +

Because O +
poor O +
skin O +
wound O +
healing O +
associated O +
with O +
diabetes O +
is O +
thought O +
to O +
be O +
partly O +
a O +
result O +
from O +
impaired O +
angiogenesis O +
, O +
treatments O +
that O +
improve O +
angiogenesis O +
could O +
have O +
important O +
clinical O +
applications O +
. O +

We O +
herein O +
report O +
the O +
effects O +
of O +
novel O +
developed O +
material O +
, O +
collagen O +
- O +
poly O +
glycolic O +
acid O +
fiber O +
hybrid O +
matrix O +
, O +
being O +
used O +
together O +
with O +
basic O +
fibroblast O +
growth O +
factor O +
to O +
promote O +
wound O +
healing O +
of O +
full O +
- O +
thickness O +
skin O +
defects O +
on O +
the O +
back O +
of O +
type O +
2 O +
diabetic O +
Lepr O +
( O +
db O +
) O +
mice O +
. O +

Our O +
data O +
indicates O +
that O +
this O +
therapeutic O +
approach O +
markedly O +
promotes O +
angiogenesis O +
and O +
granulation O +
tissue O +
formation O +
in O +
comparison O +
with O +
other O +
conditions O +
14 O +
days O +
after O +
wounding O +
. O +

Hypocholesterolaemic O +
and O +
antioxidant O +
effects O +
of O +
Glycyrrhiza O +
glabra O +
( O +
Linn O +
) O +
in O +
rats O +
. O +

The O +
hypocholesterolaemic O +
and O +
antioxidant O +
effects O +
of O +
Glycyrrhiza O +
glabra O +
( O +
GG O +
) O +
root O +
powder O +
were O +
examined O +
in O +
hypercholesterolaemic O +
male O +
albino O +
rats O +
. O +

A O +
4 O +
- O +
week O +
administration O +
of O +
GG O +
root O +
powder O +
( O +
5 O +
and O +
10 O +
gm O +
% O +
in O +
diet O +
) O +
to O +
hypercholesterolaemic O +
rats O +
resulted O +
in O +
significant O +
reduction O +
in O +
plasma O +
, O +
hepatic O +
total O +
lipids O +
, O +
cholesterol O +
, O +
triglycerides O +
and O +
plasma O +
low O +
- O +
density O +
lipoprotein O +
and O +
VLDL O +
- O +
cholesterol O +
accompanied O +
by O +
significant O +
increases O +
in O +
HDL O +
- O +
cholesterol O +
levels O +
. O +

Furthermore O +
, O +
significant O +
increases O +
in O +
fecal O +
cholesterol O +
, O +
neutral O +
sterols O +
and O +
bile O +
acid O +
excretion O +
along O +
with O +
an O +
increase O +
in O +
hepatic O +
HMG O +
- O +
CoA O +
reductase O +
activity O +
and O +
bile O +
acid O +
production O +
were O +
observed O +
in O +
these O +
animals O +
. O +

The O +
root O +
powder O +
administration O +
to O +
hypercholesterolaemic O +
rats O +
also O +
decreased O +
hepatic O +
lipid O +
peroxidation O +
with O +
a O +
concomitant O +
increase O +
in O +
superoxide O +
dismutase O +
( O +
SOD O +
) O +
and O +
catalase O +
activities O +
and O +
total O +
ascorbic O +
acid O +
content O +
. O +

Thus O +
, O +
the O +
hypocholesterolaemic O +
and O +
antioxidant O +
effects O +
of O +
GG O +
root O +
appeared O +
to O +
be O +
mediated O +
via O +
( O +
i O +
) O +
accelerated O +
cholesterol O +
, O +
neutral O +
sterol O +
and O +
bile O +
acid O +
elimination O +
through O +
fecal O +
matter O +
with O +
an O +
increased O +
hepatic O +
bile O +
acid O +
production O +
and O +
( O +
ii O +
) O +
improving O +
the O +
activities O +
of O +
hepatic O +
SOD O +
, O +
catalase O +
and O +
increasing O +
the O +
ascorbic O +
acid O +
content O +
. O +

The O +
normo O +
- O +
cholesterolaemic O +
animals O +
when O +
fed O +
with O +
GG O +
root O +
powder O +
at O +
10 O +
gm O +
% O +
level O +
, O +
registered O +
a O +
significant O +
decline O +
in O +
plasma O +
lipid O +
profiles O +
and O +
an O +
increase O +
in O +
HDL O +
- O +
cholesterol O +
content O +
. O +

The O +
antioxidant O +
status O +
of O +
these O +
animals O +
also O +
was O +
improved O +
upon O +
treatment O +
. O +

Multicentre O +
study O +
on O +
peri O +
- O +
and O +
postoperative O +
central O +
venous O +
oxygen O +
saturation O +
in O +
high O +
- O +
risk O +
surgical O +
patients O +
. O +

INTRODUCTION O +
: O +

Low O +
central O +
venous O +
oxygen O +
saturation O +
( O +
ScvO2 O +
) O +
has O +
been O +
associated O +
with O +
increased O +
risk O +
of O +
postoperative O +
complications O +
in O +
high O +
- O +
risk O +
surgery O +
. O +

Whether O +
this O +
association O +
is O +
centre O +
- O +
specific O +
or O +
more O +
generalisable O +
is O +
not O +
known O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
assess O +
the O +
association O +
between O +
peri O +
- O +
and O +
postoperative O +
ScvO2 O +
and O +
outcome O +
in O +
high O +
- O +
risk O +
surgical O +
patients O +
in O +
a O +
multicentre O +
setting O +
. O +

METHODS O +
: O +

Three O +
large O +
European O +
university O +
hospitals O +
( O +
two O +
in O +
Finland O +
, O +
one O +
in O +
Switzerland O +
) O +
participated O +
. O +

In O +
60 O +
patients O +
with O +
intra O +
- O +
abdominal O +
surgery O +
lasting O +
more O +
than O +
90 O +
minutes O +
, O +
the O +
presence O +
of O +
at O +
least O +
two O +
of O +
Shoemaker O +
' O +
s O +
criteria O +
, O +
and O +
ASA O +
( O +
American O +
Society O +
of O +
Anesthesiologists O +
) O +
class O +
greater O +
than O +
2 O +
, O +
ScvO2 O +
was O +
determined O +
preoperatively O +
and O +
at O +
two O +
hour O +
intervals O +
during O +
the O +
operation O +
until O +
12 O +
hours O +
postoperatively O +
. O +

Hospital O +
length O +
of O +
stay O +
( O +
LOS O +
) O +
mortality O +
, O +
and O +
predefined O +
postoperative O +
complications O +
were O +
recorded O +
. O +

RESULTS O +
: O +

The O +
age O +
of O +
the O +
patients O +
was O +
72 O +
+ O +
/ O +
- O +
10 O +
years O +
( O +
mean O +
+ O +
/ O +
- O +
standard O +
deviation O +
) O +
, O +
and O +
simplified O +
acute O +
physiology O +
score O +
( O +
SAPS O +
II O +
) O +
was O +
32 O +
+ O +
/ O +
- O +
12 O +
. O +

Hospital O +
LOS O +
was O +
10 O +
. O +
5 O +
( O +
8 O +
to O +
14 O +
) O +
days O +
, O +
and O +
28 O +
- O +
day O +
hospital O +
mortality O +
was O +
10 O +
. O +
0 O +
% O +
. O +

Preoperative O +
ScvO2 O +
decreased O +
from O +
77 O +
% O +
+ O +
/ O +
- O +
10 O +
% O +
to O +
70 O +
% O +
+ O +
/ O +
- O +
11 O +
% O +
( O +
p O +
< O +
0 O +
. O +
001 O +
) O +
immediately O +
after O +
surgery O +
and O +
remained O +
unchanged O +
12 O +
hours O +
later O +
. O +

A O +
total O +
of O +
67 O +
postoperative O +
complications O +
were O +
recorded O +
in O +
32 O +
patients O +
. O +

After O +
multivariate O +
analysis O +
, O +
mean O +
ScvO2 O +
value O +
( O +
odds O +
ratio O +
[ O +
OR O +
] O +
1 O +
. O +
23 O +
[ O +
95 O +
% O +
confidence O +
interval O +
( O +
CI O +
) O +
1 O +
. O +
01 O +
to O +
1 O +
. O +
50 O +
] O +
, O +
p O +
= O +
0 O +
. O +
037 O +
) O +
, O +
hospital O +
LOS O +
( O +
OR O +
0 O +
. O +
75 O +
[ O +
95 O +
% O +
CI O +
0 O +
. O +
59 O +
to O +
0 O +
. O +
94 O +
] O +
, O +
p O +
= O +
0 O +
. O +
012 O +
) O +
, O +
and O +
SAPS O +
II O +
( O +
OR O +
0 O +
. O +
90 O +
[ O +
95 O +
% O +
CI O +
0 O +
. O +
82 O +
to O +
0 O +
. O +
99 O +
] O +
, O +
p O +
= O +
0 O +
. O +
029 O +
) O +
were O +
independently O +
associated O +
with O +
postoperative O +
complications O +
. O +

The O +
optimal O +
value O +
of O +
mean O +
ScvO2 O +
to O +
discriminate O +
between O +
patients O +
who O +
did O +
or O +
did O +
not O +
develop O +
complications O +
was O +
73 O +
% O +
( O +
sensitivity O +
72 O +
% O +
, O +
specificity O +
61 O +
% O +
) O +
. O +

CONCLUSION O +
: O +

Low O +
ScvO2 O +
perioperatively O +
is O +
related O +
to O +
increased O +
risk O +
of O +
postoperative O +
complications O +
in O +
high O +
- O +
risk O +
surgery O +
. O +

This O +
warrants O +
trials O +
with O +
goal O +
- O +
directed O +
therapy O +
using O +
ScvO2 O +
as O +
a O +
target O +
in O +
high O +
- O +
risk O +
surgery O +
patients O +
. O +

Carcinogenesis O +
and O +
transcriptional O +
regulation O +
through O +
Maf O +
recognition O +
elements O +
. O +

Many O +
studies O +
on O +
carcinogenesis O +
carried O +
out O +
early O +
in O +
the O +
last O +
century O +
are O +
united O +
on O +
the O +
consensus O +
that O +
cancer O +
is O +
a O +
genetic O +
disease O +
. O +

Cancer O +
cells O +
typically O +
display O +
gene O +
dysfunction O +
and O +
endogenous O +
or O +
exogenous O +
insults O +
resulting O +
in O +
gene O +
dysfunction O +
are O +
often O +
carcinogenic O +
. O +

Recent O +
advances O +
in O +
stem O +
cell O +
biology O +
added O +
the O +
new O +
concept O +
that O +
cancer O +
originates O +
from O +
a O +
single O +
cancer O +
- O +
initiating O +
cell O +
. O +

To O +
understand O +
the O +
molecular O +
basis O +
of O +
carcinogenesis O +
from O +
the O +
beginning O +
to O +
the O +
full O +
acquirement O +
of O +
malignancy O +
, O +
factors O +
concerned O +
with O +
carcinogenesis O +
were O +
categorized O +
into O +
three O +
groups O +
: O +
those O +
guarding O +
and O +
stabilizing O +
genomes O +
, O +
those O +
regulating O +
cell O +
proliferation O +
, O +
and O +
those O +
conferring O +
resistance O +
to O +
various O +
micro O +
- O +
environmental O +
stresses O +
. O +

One O +
example O +
of O +
particular O +
interest O +
is O +
the O +
Keap1 O +
- O +
Nrf2 O +
system O +
since O +
, O +
according O +
to O +
recent O +
studies O +
, O +
it O +
has O +
turned O +
out O +
to O +
be O +
ambivalent O +
. O +

Nrf2 O +
heterodimerizes O +
with O +
small O +
Maf O +
protein O +
to O +
strongly O +
activate O +
transcription O +
through O +
the O +
Maf O +
recognition O +
element O +
( O +
MARE O +
) O +
and O +
Keap1 O +
is O +
an O +
inhibitory O +
regulator O +
of O +
Nrf2 O +
. O +

The O +
genes O +
regulated O +
by O +
Nrf2 O +
are O +
very O +
important O +
for O +
cellular O +
protection O +
of O +
the O +
genome O +
from O +
xenobiotic O +
and O +
oxidative O +
stresses O +
and O +
, O +
consequently O +
, O +
for O +
preventing O +
carcinogenesis O +
. O +

This O +
implies O +
that O +
enhancing O +
Nrf2 O +
activity O +
is O +
a O +
promising O +
method O +
for O +
thwarting O +
cancer O +
. O +

On O +
the O +
contrary O +
, O +
the O +
constitutive O +
activation O +
of O +
Nrf2 O +
due O +
to O +
mutations O +
in O +
the O +
keap1 O +
gene O +
is O +
characteristically O +
observed O +
in O +
lung O +
cancer O +
cells O +
, O +
suggesting O +
that O +
induced O +
expression O +
of O +
Nrf2 O +
target O +
genes O +
favors O +
the O +
prevalence O +
of O +
cancer O +
cells O +
. O +

Lysophosphatidic O +
acid O +
downregulates O +
tissue O +
inhibitor O +
of O +
metalloproteinases O +
, O +
which O +
are O +
negatively O +
involved O +
in O +
lysophosphatidic O +
acid O +
- O +
induced O +
cell O +
invasion O +
. O +

Ovarian O +
cancer O +
is O +
a O +
highly O +
metastatic O +
disease O +
. O +

Lysophosphatidic O +
acid O +
( O +
LPA O +
) O +
levels O +
are O +
elevated O +
in O +
ascites O +
from O +
ovarian O +
cancer O +
patients O +
, O +
but O +
its O +
potential O +
role O +
in O +
ovarian O +
cancer O +
metastasis O +
has O +
just O +
begun O +
to O +
be O +
revealed O +
. O +

In O +
this O +
work O +
, O +
we O +
show O +
that O +
LPA O +
stimulates O +
invasion O +
of O +
primary O +
ovarian O +
cancer O +
cells O +
, O +
but O +
not O +
ovarian O +
epithelial O +
or O +
borderline O +
ovarian O +
tumor O +
cells O +
, O +
although O +
these O +
benign O +
cells O +
indeed O +
respond O +
to O +
LPA O +
in O +
cell O +
migration O +
. O +

We O +
have O +
found O +
that O +
LPA O +
downregulates O +
tissue O +
inhibitor O +
of O +
metalloproteinases O +
( O +
TIMPs O +
) O +
. O +

TIMP2 O +
and O +
TIMP3 O +
play O +
functional O +
role O +
in O +
LPA O +
- O +
induced O +
invasion O +
as O +
negative O +
regulators O +
. O +

G O +
( O +
i O +
) O +
protein O +
, O +
phosphatidylinositol O +
- O +
3 O +
kinase O +
( O +
PI3 O -
K O +
) O +
, O +
p38 O +
mitogen O +
- O +
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
, O +
cytosolic O +
phospholipase O +
A O +
( O +
2 O +
) O +
and O +
urokinase O +
type O +
plasminogen O +
activator O +
( O +
uPA O +
) O +
are O +
required O +
for O +
LPA O +
- O +
induced O +
cells O +
invasion O +
. O +

TIMP3 O +
may O +
affect O +
two O +
independent O +
downstream O +
targets O +
, O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
and O +
p38 O +
MAPK O +
. O +

In O +
vivo O +
, O +
LPA O +
stimulates O +
tumor O +
metastasis O +
in O +
an O +
orthotopic O +
ovarian O +
tumor O +
model O +
, O +
which O +
can O +
be O +
inhibited O +
by O +
a O +
PI3 O -
K O +
inhibitor O +
, O +
LY294002 O +
. O +

In O +
summary O +
, O +
LPA O +
is O +
likely O +
a O +
key O +
component O +
for O +
promoting O +
ovarian O +
metastasis O +
in O +
vivo O +
. O +

LPA O +
downregulates O +
TIMP3 O +
, O +
which O +
may O +
have O +
targets O +
other O +
than O +
metalloproteinases O +
. O +

Our O +
in O +
vivo O +
metastasis O +
mouse O +
model O +
is O +
useful O +
for O +
studying O +
the O +
efficacy O +
of O +
therapeutic O +
regimes O +
of O +
ovarian O +
cancer O +
. O +

p18Ink4c O +
, O +
but O +
not O +
p27Kip1 O +
, O +
collaborates O +
with O +
Men1 O +
to O +
suppress O +
neuroendocrine O +
organ O +
tumors O +
. O +

Mutant O +
mice O +
lacking O +
both O +
cyclin O +
- O +
dependent O +
kinase O +
( O +
CDK O +
) O +
inhibitors O +
p18 O +
( O +
Ink4c O +
) O +
and O +
p27 O +
( O +
Kip1 O +
) O +
develop O +
a O +
tumor O +
spectrum O +
reminiscent O +
of O +
human O +
multiple O +
endocrine O +
neoplasia O +
( O +
MEN O +
) O +
syndromes O +
. O +

To O +
determine O +
how O +
p18 O +
and O +
p27 O +
genetically O +
interact O +
with O +
Men1 O +
, O +
the O +
tumor O +
suppressor O +
gene O +
mutated O +
in O +
familial O +
MEN1 O +
, O +
we O +
characterized O +
p18 O +
- O +
Men1 O +
and O +
p27 O +
- O +
Men1 O +
double O +
mutant O +
mice O +
. O +

Compared O +
with O +
their O +
corresponding O +
single O +
mutant O +
littermates O +
, O +
the O +
p18 O +
( O +
- O +
/ O +
- O +
) O +
; O +
Men1 O +
( O +
+ O +
/ O +
- O +
) O +
mice O +
develop O +
tumors O +
at O +
an O +
accelerated O +
rate O +
and O +
with O +
an O +
increased O +
incidence O +
in O +
the O +
pituitary O +
, O +
thyroid O +
, O +
parathyroid O +
, O +
and O +
pancreas O +
. O +

In O +
the O +
pituitary O +
and O +
pancreatic O +
islets O +
, O +
phosphorylation O +
of O +
the O +
retinoblastoma O +
( O +
Rb O +
) O +
protein O +
at O +
both O +
CDK2 O +
and O +
CDK4 O +
/ O +
6 O +
sites O +
was O +
increased O +
in O +
p18 O +
( O +
- O +
/ O +
- O +
) O +
and O +
Men1 O +
( O +
+ O +
/ O +
- O +
) O +
cells O +
and O +
was O +
further O +
increased O +
in O +
p18 O +
( O +
- O +
/ O +
- O +
) O +
; O +
Men1 O +
( O +
+ O +
/ O +
- O +
) O +
cells O +
. O +

The O +
remaining O +
wild O +
- O +
type O +
Men1 O +
allele O +
was O +
lost O +
in O +
most O +
tumors O +
from O +
Men1 O +
( O +
+ O +
/ O +
- O +
) O +
mice O +
but O +
was O +
retained O +
in O +
most O +
tumors O +
from O +
p18 O +
( O +
- O +
/ O +
- O +
) O +
; O +
Men1 O +
( O +
+ O +
/ O +
- O +
) O +
mice O +
. O +

Combined O +
mutations O +
of O +
p27 O +
( O +
- O +
/ O +
- O +
) O +
and O +
Men1 O +
( O +
+ O +
/ O +
- O +
) O +
, O +
in O +
contrast O +
, O +
did O +
not O +
exhibit O +
noticeable O +
synergistic O +
stimulation O +
of O +
Rb O +
kinase O +
activity O +
, O +
cell O +
proliferation O +
, O +
and O +
tumor O +
growth O +
. O +

These O +
results O +
demonstrate O +
that O +
functional O +
collaboration O +
exists O +
between O +
p18 O +
and O +
Men1 O +
and O +
suggest O +
that O +
Men1 O +
may O +
regulate O +
additional O +
factor O +
( O +
s O +
) O +
that O +
interact O +
with O +
p18 O +
and O +
p27 O +
differently O +
. O +

[ O +
Treatment O +
of O +
squamous O +
intraepithelial O +
lesion O +
of O +
type O +
CIN2 O +
et O +
CIN3 O +
with O +
laser O +
CO2 O +
vaporization O +
: O +
retrospective O +
study O +
of O +
52 O +
cases O +
] O +
. O +

OBJECTIVES O +
: O +

This O +
study O +
was O +
carried O +
out O +
over O +
an O +
8 O +
- O +
year O +
period O +
in O +
order O +
to O +
evaluate O +
the O +
long O +
- O +
term O +
effectiveness O +
of O +
laser O +
CO2 O +
vaporization O +
in O +
the O +
treatment O +
of O +
squamous O +
intraepithelial O +
lesion O +
of O +
type O +
CIN2 O +
and O +
CIN3 O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +

A O +
retrospective O +
study O +
of O +
52 O +
cases O +
of O +
cervical O +
lesions O +
of O +
type O +
CIN2 O +
and O +
CIN3 O +
treated O +
in O +
first O +
intention O +
by O +
laser O +
CO2 O +
vaporization O +
was O +
carried O +
out O +
at O +
the O +
hospital O +
Jeanne O +
- O +
de O +
- O +
Flandre O +
in O +
CHRU O +
of O +
Lille O +
from O +
1996 O +
to O +
2003 O +
. O +

This O +
treatment O +
was O +
performed O +
on O +
only O +
high O +
- O +
grade O +
exo O +
- O +
cervical O +
lesions O +
, O +
of O +
small O +
size O +
( O +
< O +
2cm2 O +
) O +
, O +
after O +
a O +
complete O +
colposcopic O +
examination O +
. O +

RESULTS O +
: O +

Fifty O +
- O +
two O +
patients O +
were O +
treated O +
by O +
first O +
- O +
intention O +
laser O +
vaporization O +
only O +
. O +

Mean O +
age O +
was O +
29 O +
. O +
4 O +
years O +
and O +
51 O +
. O +
9 O +
% O +
were O +
nulliparous O +
. O +

At O +
the O +
first O +
cyto O +
- O +
colposcopic O +
control O +
, O +
there O +
were O +
17 O +
persistent O +
lesions O +
( O +
32 O +
. O +
7 O +
% O +
) O +
. O +

Among O +
the O +
35 O +
patients O +
without O +
persistent O +
lesion O +
, O +
29 O +
achieved O +
cure O +
( O +
absence O +
of O +
recurrence O +
) O +
, O +
4 O +
presented O +
a O +
recurrence O +
and O +
2 O +
were O +
lost O +
to O +
follow O +
- O +
up O +
. O +

CONCLUSION O +
: O +

The O +
current O +
data O +
of O +
the O +
literature O +
concerning O +
the O +
treatment O +
by O +
laser O +
CO2 O +
vaporization O +
authorize O +
application O +
of O +
this O +
method O +
for O +
certain O +
high O +
- O +
grade O +
exocervical O +
lesions O +
after O +
a O +
complete O +
colposcopic O +
examination O +
. O +

This O +
type O +
of O +
treatment O +
remains O +
less O +
aggressive O +
than O +
a O +
surgical O +
treatment O +
. O +

The O +
high O +
rate O +
of O +
residual O +
lesions O +
in O +
particular O +
in O +
the O +
event O +
of O +
CIN3 O +
can O +
be O +
due O +
to O +
an O +
incomplete O +
destruction O +
of O +
the O +
lesion O +
. O +

Patients O +
should O +
thus O +
be O +
advised O +
that O +
monitoring O +
is O +
an O +
integral O +
part O +
of O +
the O +
treatment O +
. O +

Laser O +
vaporization O +
could O +
be O +
limited O +
to O +
CIN1 O +
and O +
CIN2 O +
lesions O +
. O +

Punica O +
granatum O +
( O +
pomegranate O +
) O +
and O +
its O +
potential O +
for O +
prevention O +
and O +
treatment O +
of O +
inflammation O +
and O +
cancer O +
. O +

The O +
last O +
7 O +
years O +
have O +
seen O +
over O +
seven O +
times O +
as O +
many O +
publications O +
indexed O +
by O +
Medline O +
dealing O +
with O +
pomegranate O +
and O +
Punica O +
granatum O +
than O +
in O +
all O +
the O +
years O +
preceding O +
them O +
. O +

Because O +
of O +
this O +
, O +
and O +
the O +
virtual O +
explosion O +
of O +
interest O +
in O +
pomegranate O +
as O +
a O +
medicinal O +
and O +
nutritional O +
product O +
that O +
has O +
followed O +
, O +
this O +
review O +
is O +
accordingly O +
launched O +
. O +

The O +
pomegranate O +
tree O +
, O +
Punica O +
granatum O +
, O +
especially O +
its O +
fruit O +
, O +
possesses O +
a O +
vast O +
ethnomedical O +
history O +
and O +
represents O +
a O +
phytochemical O +
reservoir O +
of O +
heuristic O +
medicinal O +
value O +
. O +

The O +
tree O +
/ O +
fruit O +
can O +
be O +
divided O +
into O +
several O +
anatomical O +
compartments O +
: O +
( O +
1 O +
) O +
seed O +
, O +
( O +
2 O +
) O +
juice O +
, O +
( O +
3 O +
) O +
peel O +
, O +
( O +
4 O +
) O +
leaf O +
, O +
( O +
5 O +
) O +
flower O +
, O +
( O +
6 O +
) O +
bark O +
, O +
and O +
( O +
7 O +
) O +
roots O +
, O +
each O +
of O +
which O +
has O +
interesting O +
pharmacologic O +
activity O +
. O +

Juice O +
and O +
peels O +
, O +
for O +
example O +
, O +
possess O +
potent O +
antioxidant O +
properties O +
, O +
while O +
juice O +
, O +
peel O +
and O +
oil O +
are O +
all O +
weakly O +
estrogenic O +
and O +
heuristically O +
of O +
interest O +
for O +
the O +
treatment O +
of O +
menopausal O +
symptoms O +
and O +
sequellae O +
. O +

The O +
use O +
of O +
juice O +
, O +
peel O +
and O +
oil O +
have O +
also O +
been O +
shown O +
to O +
possess O +
anticancer O +
activities O +
, O +
including O +
interference O +
with O +
tumor O +
cell O +
proliferation O +
, O +
cell O +
cycle O +
, O +
invasion O +
and O +
angiogenesis O +
. O +

These O +
may O +
be O +
associated O +
with O +
plant O +
based O +
anti O +
- O +
inflammatory O +
effects O +
, O +
The O +
phytochemistry O +
and O +
pharmacological O +
actions O +
of O +
all O +
Punica O +
granatum O +
components O +
suggest O +
a O +
wide O +
range O +
of O +
clinical O +
applications O +
for O +
the O +
treatment O +
and O +
prevention O +
of O +
cancer O +
, O +
as O +
well O +
as O +
other O +
diseases O +
where O +
chronic O +
inflammation O +
is O +
believed O +
to O +
play O +
an O +
essential O +
etiologic O +
role O +
. O +

Angiotensin O +
II O +
induces O +
soluble O +
fms O +
- O +
Like O +
tyrosine O +
kinase O +
- O +
1 O +
release O +
via O +
calcineurin O +
signaling O +
pathway O +
in O +
pregnancy O +
. O +

Maternal O +
endothelial O +
dysfunction O +
in O +
preeclampsia O +
is O +
associated O +
with O +
increased O +
soluble O +
fms O +
- O +
like O +
tyrosine O +
kinase O +
- O +
1 O +
( O +
sFlt O +
- O +
1 O +
) O +
, O +
a O +
circulating O +
antagonist O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
placental O +
growth O +
factor O +
. O +

Angiotensin O +
II O +
( O +
Ang O +
II O +
) O +
is O +
a O +
potent O +
vasoconstrictor O +
that O +
increases O +
concomitant O +
with O +
sFlt O +
- O +
1 O +
during O +
pregnancy O +
. O +

Therefore O +
, O +
we O +
speculated O +
that O +
Ang O +
II O +
may O +
promote O +
the O +
expression O +
of O +
sFlt O +
- O +
1 O +
in O +
pregnancy O +
. O +

Here O +
we O +
report O +
that O +
infusion O +
of O +
Ang O +
II O +
significantly O +
increases O +
circulating O +
levels O +
of O +
sFlt O +
- O +
1 O +
in O +
pregnant O +
mice O +
, O +
thereby O +
demonstrating O +
that O +
Ang O +
II O +
is O +
a O +
regulator O +
of O +
sFlt O +
- O +
1 O +
secretion O +
in O +
vivo O +
. O +

Furthermore O +
, O +
Ang O +
II O +
stimulated O +
sFlt O +
- O +
1 O +
production O +
in O +
a O +
dose O +
- O +
and O +
time O +
- O +
dependent O +
manner O +
from O +
human O +
villous O +
explants O +
and O +
cultured O +
trophoblasts O +
but O +
not O +
from O +
endothelial O +
cells O +
, O +
suggesting O +
that O +
trophoblasts O +
are O +
the O +
primary O +
source O +
of O +
sFlt O +
- O +
1 O +
during O +
pregnancy O +
. O +

As O +
expected O +
, O +
Ang O +
II O +
- O +
induced O +
sFlt O +
- O +
1 O +
secretion O +
resulted O +
in O +
the O +
inhibition O +
of O +
endothelial O +
cell O +
migration O +
and O +
in O +
vitro O +
tube O +
formation O +
. O +

In O +
vitro O +
and O +
in O +
vivo O +
studies O +
with O +
losartan O +
, O +
small O +
interfering O +
RNA O +
specific O +
for O +
calcineurin O +
and O +
FK506 O +
demonstrated O +
that O +
Ang O +
II O +
- O +
mediated O +
sFlt O +
- O +
1 O +
release O +
was O +
via O +
Ang O +
II O +
type O +
1 O +
receptor O +
activation O +
and O +
calcineurin O +
signaling O +
, O +
respectively O +
. O +

These O +
findings O +
reveal O +
a O +
previously O +
unrecognized O +
regulatory O +
role O +
for O +
Ang O +
II O +
on O +
sFlt O +
- O +
1 O +
expression O +
in O +
murine O +
and O +
human O +
pregnancy O +
and O +
suggest O +
that O +
elevated O +
sFlt O +
- O +
1 O +
levels O +
in O +
preeclampsia O +
may O +
be O +
caused O +
by O +
a O +
dysregulation O +
of O +
the O +
local O +
renin O +
/ O +
angiotensin O +
system O +
. O +

p21 O +
delays O +
tumor O +
onset O +
by O +
preservation O +
of O +
chromosomal O +
stability O +
. O +

The O +
p53 O +
protein O +
suppresses O +
tumorigenesis O +
by O +
initiating O +
cellular O +
functions O +
such O +
as O +
cell O +
cycle O +
arrest O +
and O +
apoptosis O +
in O +
response O +
to O +
DNA O +
damage O +
. O +

A O +
p53 O +
mutant O +
, O +
p53R172P O +
, O +
which O +
is O +
deficient O +
for O +
apoptosis O +
but O +
retains O +
a O +
partial O +
cell O +
cycle O +
arrest O +
function O +
, O +
delays O +
tumor O +
onset O +
in O +
mice O +
. O +

Remarkably O +
, O +
lymphomas O +
arising O +
in O +
Trp53 O +
( O +
515C O +
/ O +
515C O +
) O +
mice O +
( O +
encoding O +
p53R172P O +
) O +
retain O +
stable O +
genomes O +
. O +

Given O +
the O +
dominant O +
role O +
of O +
p21 O +
in O +
p53 O +
cell O +
cycle O +
control O +
, O +
we O +
crossed O +
Trp53 O +
( O +
515C O +
/ O +
515C O +
) O +
mice O +
onto O +
a O +
p21 O +
- O +
null O +
background O +
to O +
determine O +
whether O +
p21 O +
was O +
required O +
for O +
maintaining O +
chromosomal O +
stability O +
and O +
delaying O +
tumor O +
onset O +
. O +

Loss O +
of O +
p21 O +
completely O +
abolished O +
the O +
cell O +
cycle O +
arrest O +
function O +
of O +
p53R172P O +
and O +
accelerated O +
tumor O +
onset O +
in O +
Trp53 O +
( O +
515C O +
/ O +
515C O +
) O +
mice O +
. O +

Cytogenetic O +
examination O +
of O +
Trp53 O +
( O +
515C O +
/ O +
515C O +
) O +
p21 O +
( O +
- O +
/ O +
- O +
) O +
sarcomas O +
and O +
lymphomas O +
revealed O +
aneuploidy O +
and O +
chromosomal O +
aberrations O +
that O +
were O +
absent O +
in O +
Trp53 O +
( O +
515C O +
/ O +
515C O +
) O +
malignancies O +
. O +

Thus O +
, O +
p21 O +
coupled O +
p53 O +
- O +
dependent O +
checkpoint O +
control O +
and O +
preservation O +
of O +
chromosomal O +
stability O +
, O +
and O +
cooperated O +
with O +
apoptosis O +
in O +
suppressing O +
tumor O +
onset O +
in O +
mice O +
. O +

Role O +
of O +
the O +
fibrinolytic O +
and O +
matrix O +
metalloproteinase O +
systems O +
in O +
development O +
of O +
adipose O +
tissue O +
. O +

Obesity O +
is O +
a O +
common O +
disorder O +
and O +
related O +
diseases O +
such O +
as O +
diabetes O +
, O +
atherosclerosis O +
, O +
hypertension O +
, O +
cardiovascular O +
disease O +
and O +
cancer O +
are O +
a O +
major O +
cause O +
of O +
mortality O +
and O +
morbidity O +
in O +
Western O +
- O +
type O +
societies O +
. O +

Development O +
of O +
obesity O +
is O +
associated O +
with O +
extensive O +
modifications O +
in O +
adipose O +
tissue O +
involving O +
adipogenesis O +
, O +
angiogenesis O +
and O +
extracellular O +
matrix O +
proteolysis O +
. O +

The O +
fibrinolytic O +
( O +
plasminogen O +
/ O +
plasmin O +
) O +
and O +
matrix O +
metalloproteinase O +
( O +
MMP O +
) O +
systems O +
cooperate O +
in O +
these O +
processes O +
. O +

A O +
nutritionally O +
induced O +
obesity O +
model O +
in O +
transgenic O +
mice O +
has O +
been O +
used O +
extensively O +
to O +
study O +
the O +
role O +
of O +
the O +
fibrinolytic O +
and O +
MMP O +
systems O +
in O +
the O +
development O +
of O +
obesity O +
. O +

These O +
studies O +
support O +
a O +
role O +
of O +
both O +
systems O +
in O +
adipogenesis O +
and O +
obesity O +
; O +
the O +
role O +
of O +
specific O +
members O +
of O +
these O +
families O +
, O +
however O +
, O +
remains O +
to O +
be O +
determined O +
. O +

Recombinant O +
human O +
prothrombin O +
kringle O +
- O +
2 O +
inhibits O +
B16F10 B-CellLine +
melanoma O +
metastasis O +
through O +
inhibition O +
of O +
neovascularization O +
and O +
reduction O +
of O +
matrix O +
metalloproteinase O +
expression O +
. O +

Angiogenesis O +
, O +
a O +
multi O +
- O +
step O +
process O +
which O +
involves O +
endothelial O +
cell O +
proliferation O +
, O +
adhesion O +
, O +
migration O +
, O +
and O +
basement O +
membrane O +
( O +
BM O +
) O +
degradation O +
, O +
is O +
essential O +
for O +
tumor O +
metastasis O +
. O +

Here O +
we O +
show O +
that O +
recombinant O +
human O +
prothrombin O +
kringle O +
- O +
2 O +
( O +
rk O +
- O +
2 O +
) O +
inhibited O +
bovine O +
capillary O +
endothelial O +
cell O +
migration O +
with O +
an O +
IC O +
( O +
50 O +
) O +
( O +
concentration O +
for O +
half O +
maximal O +
inhibition O +
) O +
of O +
38 O +
nM O +
and O +
inhibited O +
adhesion O +
to O +
extracellular O +
matrix O +
( O +
ECM O +
) O +
proteins O +
. O +

Because O +
tumor O +
metastasis O +
requires O +
angiogenesis O +
, O +
we O +
examined O +
whether O +
rk O +
- O +
2 O +
could O +
inhibit O +
metastases O +
induced O +
by O +
injection O +
of O +
B16F10 B-CellLine +
melanoma O +
cells O +
into O +
mice O +
. O +

The O +
results O +
revealed O +
that O +
the O +
metastatic O +
tumors O +
in O +
mouse O +
lung O +
were O +
markedly O +
decreased O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
and O +
acute O +
lung O +
injury O +
induced O +
by O +
B16F10 B-CellLine +
melanoma O +
metastasis O +
was O +
diminished O +
by O +
systemic O +
rk O +
- O +
2 O +
treatment O +
. O +

In O +
immunohistochemical O +
analysis O +
, O +
rk O +
- O +
2 O +
reduced O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
, O +
which O +
is O +
a O +
potent O +
angiogenic O +
activator O +
and O +
neovascularization O +
in O +
the O +
mouse O +
lung O +
. O +

Also O +
, O +
rk O +
- O +
2 O +
diminished O +
the O +
expression O +
of O +
matrix O +
metalloproteinase O +
- O +
2 O +
and O +
- O +
9 O +
in O +
the O +
mouse O +
lung O +
which O +
induces O +
tumor O +
metastasis O +
and O +
angiogenesis O +
. O +

These O +
data O +
suggest O +
that O +
inhibition O +
of O +
B16F10 B-CellLine +
melanoma O +
metastasis O +
by O +
rk O +
- O +
2 O +
was O +
caused O +
by O +
inhibition O +
of O +
neovascularization O +
and O +
reduction O +
of O +
matrix O +
metalloproteinase O +
expression O +
. O +

Extracellular O +
matrix O +
as O +
a O +
bioactive O +
material O +
for O +
soft O +
tissue O +
reconstruction O +
. O +

The O +
extracellular O +
matrix O +
( O +
ECM O +
) O +
directs O +
all O +
phases O +
of O +
healing O +
following O +
trauma O +
or O +
disease O +
and O +
is O +
therefore O +
a O +
natural O +
source O +
of O +
prosthetic O +
mesh O +
material O +
that O +
can O +
be O +
used O +
strategically O +
to O +
induce O +
the O +
repair O +
and O +
restoration O +
of O +
soft O +
tissues O +
following O +
surgery O +
. O +

Biomaterials O +
such O +
as O +
Surgisis O +
( O +
Cook O +
Biotech O +
Incorporated O +
, O +
West O +
Lafayette O +
, O +
IN O +
, O +
USA O +
) O +
, O +
which O +
are O +
derived O +
from O +
natural O +
ECM O +
, O +
provide O +
the O +
extracellular O +
components O +
necessary O +
to O +
direct O +
the O +
healing O +
response O +
, O +
allow O +
for O +
the O +
proliferation O +
of O +
new O +
, O +
healthy O +
tissue O +
and O +
restore O +
tissue O +
integrity O +
to O +
the O +
damaged O +
site O +
. O +

The O +
3 O +
- O +
D O +
organization O +
of O +
these O +
extracellular O +
components O +
distinguishes O +
the O +
Surgisis O +
mesh O +
from O +
synthetic O +
materials O +
and O +
is O +
associated O +
with O +
constructive O +
tissue O +
remodelling O +
instead O +
of O +
scar O +
tissue O +
. O +

Common O +
features O +
of O +
this O +
ECM O +
- O +
assisted O +
tissue O +
remodelling O +
include O +
angiogenesis O +
, O +
recruitment O +
of O +
circulating O +
progenitor O +
cells O +
and O +
constructive O +
remodelling O +
of O +
damaged O +
tissue O +
structures O +
. O +

The O +
tissue O +
response O +
to O +
this O +
biologic O +
mesh O +
is O +
discussed O +
in O +
the O +
context O +
of O +
recent O +
reports O +
on O +
clinical O +
hernia O +
repair O +
. O +

Activation O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
through O +
reactive O +
oxygen O +
species O +
mediates O +
20 O +
- O +
hydroxyeicosatetraenoic O +
acid O +
- O +
induced O +
endothelial O +
cell O +
proliferation O +
. O +

20 O +
- O +
Hydroxyeicosatetraenoic O +
acid O +
( O +
20 O +
- O +
HETE O +
) O +
is O +
formed O +
by O +
the O +
omega O +
- O +
hydroxylation O +
of O +
arachidonic O +
acid O +
by O +
cytochrome O +
P450 O +
4A O +
and O +
4F O +
enzymes O +
, O +
and O +
it O +
induces O +
angiogenic O +
responses O +
in O +
vivo O +
. O +

To O +
test O +
the O +
hypothesis O +
that O +
20 O +
- O +
HETE O +
increases O +
endothelial O +
cell O +
( O +
EC O +
) O +
proliferation O +
via O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
, O +
we O +
studied O +
the O +
effects O +
of O +
WIT003 O +
[ O +
20 O +
- O +
hydroxyeicosa O +
- O +
5 O +
( O +
Z O +
) O +
, O +
14 O +
( O +
Z O +
) O +
- O +
dienoic O +
acid O +
] O +
, O +
a O +
20 O +
- O +
HETE O +
analog O +
on O +
human O +
macrovascular O +
or O +
microvascular O +
EC O +
. O +

WIT003 O +
, O +
as O +
well O +
as O +
pure O +
20 O +
- O +
HETE O +
, O +
stimulated O +
EC O +
proliferation O +
by O +
approximately O +
40 O +
% O +
. O +

These O +
proliferative O +
effects O +
were O +
accompanied O +
by O +
increased O +
VEGF O +
expression O +
and O +
release O +
that O +
were O +
observed O +
as O +
early O +
as O +
4 O +
h O +
after O +
20 O +
- O +
HETE O +
agonist O +
addition O +
. O +

This O +
was O +
accompanied O +
by O +
increased O +
phosphorylation O +
of O +
the O +
VEGF O +
receptor O +
2 O +
. O +

The O +
proliferative O +
effects O +
of O +
20 O +
- O +
HETE O +
were O +
markedly O +
inhibited O +
by O +
a O +
VEGF O +
- O +
neutralizing O +
antibody O +
. O +

Polyethylene O +
glycol O +
- O +
superoxide O +
dismutase O +
( O +
PEG O +
- O +
SOD O +
) O +
markedly O +
inhibited O +
both O +
the O +
increases O +
in O +
VEGF O +
expression O +
and O +
the O +
proliferative O +
effects O +
of O +
20 O +
- O +
HETE O +
. O +

In O +
contrast O +
, O +
administration O +
of O +
the O +
NAD O +
( O +
P O +
) O +
H O +
oxidase O +
inhibitor O +
apocynin O +
had O +
no O +
effect O +
to O +
the O +
proliferative O +
response O +
to O +
20 O +
- O +
HETE O +
. O +

The O +
20 O +
- O +
HETE O +
agonist O +
markedly O +
increased O +
superoxide O +
formation O +
as O +
reflected O +
by O +
an O +
increase O +
in O +
dihydroethidium O +
staining O +
of O +
EC O +
, O +
and O +
this O +
increase O +
was O +
inhibited O +
by O +
PEG O +
- O +
SOD O +
but O +
not O +
by O +
apocynin O +
. O +

20 O +
- O +
HETE O +
also O +
increased O +
the O +
phosphorylation O +
of O +
p42 O +
/ O +
p44 O +
mitogen O +
- O +
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
in O +
EC O +
, O +
whereas O +
an O +
inhibitor O +
of O +
MAPK O +
[ O +
U0126 O +
, O +
1 O +
, O +
4 O +
- O +
diamino O +
- O +
2 O +
, O +
3 O +
- O +
dicyano O +
- O +
1 O +
, O +
4 O +
- O +
bis O +
( O +
2 O +
- O +
aminophenylthio O +
) O +
butadiene O +
] O +
suppressed O +
the O +
proliferative O +
and O +
the O +
VEGF O +
changes O +
but O +
not O +
the O +
pro O +
- O +
oxidant O +
effects O +
of O +
20 O +
- O +
HETE O +
. O +

These O +
data O +
suggest O +
that O +
20 O +
- O +
HETE O +
stimulates O +
superoxide O +
formation O +
by O +
pathways O +
other O +
than O +
apocynin O +
- O +
sensitive O +
NAD O +
( O +
P O +
) O +
H O +
oxidase O +
, O +
thereby O +
activating O +
MAPK O +
and O +
then O +
enhancing O +
VEGF O +
synthesis O +
that O +
drives O +
EC O +
proliferation O +
. O +

Thus O +
, O +
20 O +
- O +
HETE O +
may O +
be O +
involved O +
in O +
the O +
regulation O +
of O +
EC O +
functions O +
, O +
such O +
as O +
angiogenesis O +
. O +

Relationship O +
of O +
cellular O +
immunity O +
, O +
cytokines O +
and O +
CRP O +
with O +
clinical O +
course O +
in O +
breast O +
cancer O +
patients O +
with O +
endocrine O +
- O +
dependent O +
distant O +
metastases O +
treated O +
with O +
immunotherapy O +
. O +

We O +
have O +
reported O +
important O +
benefits O +
and O +
survival O +
with O +
an O +
immunotherapy O +
schedule O +
in O +
patients O +
with O +
endocrine O +
- O +
dependent O +
breast O +
cancer O +
and O +
distant O +
metastases O +
. O +

Here O +
clinical O +
outcome O +
is O +
updated O +
and O +
its O +
correlation O +
with O +
new O +
immunological O +
data O +
is O +
shown O +
. O +

In O +
32 O +
evaluated O +
breast O +
cancer O +
patients O +
with O +
endocrine O +
- O +
dependent O +
distant O +
metastases O +
treated O +
with O +
a O +
new O +
immunotherapy O +
schedule O +
( O +
cyclic O +
administration O +
of O +
beta O +
- O +
interferon O +
and O +
interleukin O +
- O +
2 O +
) O +
, O +
cellular O +
immunity O +
, O +
cytokines O +
and O +
CRP O +
were O +
related O +
to O +
the O +
clinical O +
course O +
. O +

Estimated O +
and O +
true O +
5 O +
- O +
10 O +
year O +
overall O +
survival O +
rates O +
from O +
first O +
line O +
antiestrogen O +
and O +
distant O +
metastases O +
were O +
higher O +
than O +
previously O +
reported O +
in O +
a O +
similar O +
population O +
. O +

Interleukin O +
- O +
2 O +
administration O +
was O +
followed O +
by O +
a O +
significant O +
increase O +
in O +
total O +
lymphocytes O +
, O +
CD4 O +
+ O +
, O +
CD8 O +
+ O +
, O +
CD16 O +
+ O +
56 O +
+ O +
( O +
NK O +
) O +
cells O +
, O +
IL O +
- O +
6 O +
, O +
IL O +
- O +
12 O +
, O +
and O +
CRP O +
( O +
from O +
P O +
< O +
0 O +
. O +
04 O +
to O +
P O +
< O +
0 O +
. O +
000 O +
) O +
but O +
no O +
change O +
in O +
IL O +
- O +
10 O +
and O +
TGFbeta1 O +
during O +
clinical O +
benefit O +
. O +

During O +
progressive O +
disease O +
no O +
change O +
was O +
observed O +
in O +
the O +
former O +
parameters O +
, O +
concomitant O +
with O +
a O +
significant O +
increase O +
in O +
IL O +
- O +
10 O +
( O +
P O +
= O +
0 O +
. O +
020 O +
) O +
and O +
a O +
significant O +
decrease O +
in O +
TGFbeta1 O +
( O +
P O +
= O +
0 O +
. O +
023 O +
) O +
. O +

These O +
findings O +
confirm O +
that O +
cellular O +
immunity O +
is O +
significantly O +
stimulated O +
by O +
IL O +
- O +
2 O +
only O +
during O +
clinical O +
benefit O +
. O +

Furthermore O +
, O +
these O +
results O +
demonstrate O +
that O +
different O +
changes O +
of O +
proinflammatory O +
cytokines O +
, O +
CRP O +
and O +
inhibiting O +
factors O +
are O +
consistent O +
with O +
associated O +
clinical O +
benefit O +
or O +
with O +
disease O +
progression O +
, O +
respectively O +
. O +

Trib1 O +
and O +
Evi1 O +
cooperate O +
with O +
Hoxa O +
and O +
Meis1 O +
in O +
myeloid O +
leukemogenesis O +
. O +

Cooperative O +
activation O +
of O +
Meis1 O +
and O +
Hoxa9 O +
perturbs O +
myeloid O +
differentiation O +
and O +
eventually O +
leads O +
myeloid O +
progenitors O +
to O +
leukemia O +
, O +
yet O +
it O +
remains O +
to O +
be O +
clarified O +
what O +
kinds O +
of O +
subsequent O +
molecular O +
processes O +
are O +
required O +
for O +
development O +
of O +
overt O +
leukemia O +
. O +

To O +
understand O +
the O +
molecular O +
pathway O +
in O +
Hoxa9 O +
/ O +
Meis1 O +
- O +
induced O +
leukemogenesis O +
, O +
retroviral O +
insertional O +
mutagenesis O +
was O +
applied O +
using O +
retrovirus O +
- O +
mediated O +
gene O +
transfer O +
. O +

The O +
mice O +
that O +
received O +
Hoxa9 O +
/ O +
Meis1 O +
- O +
transduced O +
bone O +
marrow O +
cells O +
developed O +
acute O +
myeloid O +
leukemia O +
( O +
AML O +
) O +
, O +
and O +
Trib1 O +
, O +
Evi1 O +
, O +
Ahi1 O +
, O +
Raralpha O +
, O +
Pitpnb O +
, O +
and O +
AK039950 O +
were O +
identified O +
as O +
candidate O +
cooperative O +
genes O +
located O +
near O +
common O +
retroviral O +
integration O +
sites O +
. O +

Trib1 O +
and O +
Evi1 O +
were O +
up O +
- O +
regulated O +
due O +
to O +
retroviral O +
insertions O +
, O +
and O +
coexpression O +
of O +
these O +
genes O +
significantly O +
accelerated O +
the O +
onset O +
of O +
Hoxa9 O +
/ O +
Meis1 O +
- O +
induced O +
AML O +
, O +
suggesting O +
that O +
Trib1 O +
and O +
Evi1 O +
are O +
the O +
key O +
collaborators O +
. O +

Furthermore O +
, O +
Trib1 O +
by O +
itself O +
is O +
a O +
novel O +
myeloid O +
oncogene O +
, O +
enhancing O +
phosphorylation O +
of O +
ERK O +
, O +
resulting O +
in O +
inhibition O +
of O +
apoptosis O +
. O +

These O +
results O +
demonstrate O +
the O +
importance O +
of O +
specific O +
oncogene O +
interaction O +
in O +
myeloid O +
leukemogenesis O +
. O +

Pro O +
/ O +
antioxidant O +
status O +
and O +
AP O +
- O +
1 O +
transcription O +
factor O +
in O +
murine O +
skin O +
following O +
topical O +
exposure O +
to O +
cumene O +
hydroperoxide O +
. O +

Organic O +
peroxides O +
, O +
widely O +
used O +
in O +
the O +
chemical O +
and O +
pharmaceutical O +
industries O +
, O +
can O +
act O +
as O +
skin O +
tumor O +
promoters O +
and O +
cause O +
epidermal O +
hyperplasia O +
. O +

They O +
are O +
also O +
known O +
to O +
trigger O +
free O +
radical O +
generation O +
. O +

The O +
present O +
study O +
evaluated O +
the O +
effect O +
of O +
cumene O +
hydroperoxide O +
( O +
Cum O +
- O +
OOH O +
) O +
on O +
the O +
induction O +
of O +
activator O +
protein O +
- O +
1 O +
( O +
AP O +
- O +
1 O +
) O +
, O +
which O +
is O +
linked O +
to O +
the O +
expression O +
of O +
genes O +
regulating O +
cell O +
proliferation O +
, O +
growth O +
and O +
transformation O +
. O +

Previously O +
, O +
we O +
reported O +
that O +
topical O +
exposure O +
to O +
Cum O +
- O +
OOH O +
caused O +
formation O +
of O +
free O +
radicals O +
and O +
oxidative O +
stress O +
in O +
the O +
skin O +
of O +
vitamin O +
E O +
- O +
deficient O +
mice O +
. O +

The O +
present O +
study O +
used O +
JB6 O +
P O +
+ O +
mouse O +
epidermal O +
cells O +
and O +
AP O +
- O +
1 O +
- O +
luciferase O +
reporter O +
transgenic O +
mice O +
to O +
identify O +
whether O +
exposure O +
to O +
Cum O +
- O +
OOH O +
caused O +
activation O +
of O +
AP O +
- O +
1 O +
, O +
oxidative O +
stress O +
, O +
depletion O +
of O +
antioxidants O +
and O +
tumor O +
formation O +
during O +
two O +
- O +
stage O +
carcinogenesis O +
. O +

In O +
vitro O +
studies O +
found O +
that O +
exposure O +
to O +
Cum O +
- O +
OOH O +
reduced O +
the O +
level O +
of O +
glutathione O +
( O +
GSH O +
) O +
in O +
mouse O +
epidermal O +
cells O +
( O +
JB6 O +
P O +
+ O +
) O +
and O +
caused O +
the O +
induction O +
of O +
AP O +
- O +
1 O +
. O +

Mice O +
primed O +
with O +
dimethyl O +
- O +
benz O +
[ O +
a O +
] O +
anthracene O +
( O +
DMBA O +
) O +
were O +
topically O +
exposed O +
to O +
Cum O +
- O +
OOH O +
( O +
82 O +
. O +
6 O +
micromol O +
) O +
or O +
the O +
positive O +
control O +
, O +
12 O +
- O +
O O +
- O +
tetradecanoylphorbol O +
- O +
13 O +
- O +
acetate O +
( O +
TPA O +
, O +
17 O +
nmol O +
) O +
, O +
twice O +
weekly O +
for O +
29 O +
weeks O +
. O +

Activation O +
of O +
AP O +
- O +
1 O +
in O +
skin O +
was O +
detected O +
as O +
early O +
as O +
2 O +
weeks O +
following O +
Cum O +
- O +
OOH O +
or O +
TPA O +
exposure O +
. O +

No O +
AP O +
- O +
1 O +
expression O +
was O +
found O +
19 O +
weeks O +
after O +
initiation O +
. O +

Papilloma O +
formation O +
was O +
observed O +
in O +
both O +
the O +
DMBA O +
- O +
TPA O +
- O +
and O +
DMBA O +
- O +
Cum O +
- O +
OOH O +
- O +
exposed O +
animals O +
, O +
whereas O +
skin O +
carcinomas O +
were O +
found O +
only O +
in O +
the O +
DMBA O +
- O +
Cum O +
- O +
OOH O +
- O +
treated O +
mice O +
. O +

A O +
greater O +
accumulation O +
of O +
peroxidative O +
products O +
( O +
thiobarbituric O +
acid O +
- O +
reactive O +
substances O +
) O +
, O +
inflammation O +
and O +
decreased O +
levels O +
of O +
GSH O +
and O +
total O +
antioxidant O +
reserves O +
were O +
also O +
observed O +
in O +
the O +
skin O +
of O +
DMBA O +
- O +
Cum O +
- O +
OOH O +
- O +
exposed O +
mice O +
. O +

These O +
results O +
suggest O +
that O +
Cum O +
- O +
OOH O +
- O +
induced O +
carcinogenesis O +
is O +
accompanied O +
by O +
increased O +
AP O +
- O +
1 O +
activation O +
and O +
changes O +
in O +
antioxidant O +
status O +
. O +

Segmental O +
atrial O +
contraction O +
in O +
patients O +
restored O +
to O +
sinus O +
rhythm O +
after O +
cardioversion O +
for O +
chronic O +
atrial O +
fibrillation O +
: O +
a O +
colour O +
Doppler O +
tissue O +
imaging O +
study O +
. O +

AIMS O +
: O +

There O +
is O +
little O +
known O +
about O +
segmental O +
atrial O +
function O +
in O +
patients O +
with O +
atrial O +
arrhythmias O +
. O +

We O +
evaluated O +
segmental O +
atrial O +
contractility O +
using O +
colour O +
Doppler O +
tissue O +
imaging O +
( O +
CDTI O +
) O +
in O +
patients O +
with O +
chronic O +
atrial O +
fibrillation O +
( O +
CAF O +
) O +
who O +
were O +
successfully O +
restored O +
and O +
maintained O +
in O +
sinus O +
rhythm O +
( O +
SR O +
) O +
. O +

METHODS O +
AND O +
RESULTS O +
: O +

We O +
compared O +
the O +
segmental O +
atrial O +
contractility O +
in O +
39 O +
CAF O +
patients O +
who O +
were O +
successfully O +
cardioverted O +
and O +
maintained O +
in O +
SR O +
for O +
6 O +
months O +
. O +

Follow O +
up O +
echocardiograms O +
were O +
performed O +
at O +
baseline O +
, O +
1 O +
week O +
, O +
1 O +
month O +
and O +
6 O +
months O +
and O +
compared O +
to O +
a O +
normal O +
age O +
matched O +
cohort O +
( O +
n O +
= O +
34 O +
) O +
. O +

Using O +
CDTI O +
, O +
mean O +
peak O +
velocities O +
of O +
atrial O +
contraction O +
were O +
measured O +
from O +
annular O +
, O +
mid O +
and O +
superior O +
segments O +
of O +
lateral O +
and O +
septal O +
walls O +
of O +
the O +
left O +
atrium O +
and O +
right O +
atrium O +
in O +
the O +
apical O +
four O +
- O +
chamber O +
view O +
. O +

Segmental O +
velocities O +
from O +
the O +
posterior O +
and O +
anterior O +
walls O +
of O +
the O +
left O +
atrium O +
were O +
measured O +
from O +
the O +
apical O +
two O +
- O +
chamber O +
view O +
. O +

Segmental O +
left O +
atrial O +
velocities O +
improved O +
over O +
time O +
in O +
the O +
CAF O +
group O +
, O +
with O +
the O +
majority O +
of O +
the O +
recovery O +
occurring O +
in O +
the O +
first O +
month O +
, O +
but O +
failed O +
to O +
normalise O +
even O +
at O +
6 O +
months O +
. O +

In O +
comparison O +
, O +
the O +
right O +
atrial O +
velocities O +
in O +
the O +
AF O +
group O +
had O +
normalised O +
at O +
1 O +
month O +
. O +

CONCLUSION O +
: O +

Patients O +
with O +
CAF O +
have O +
persistent O +
segmental O +
left O +
atrial O +
dysfunction O +
even O +
6 O +
months O +
after O +
restoration O +
and O +
maintenance O +
of O +
SR O +
, O +
though O +
right O +
atrial O +
velocities O +
appear O +
to O +
normalise O +
. O +

This O +
differential O +
recovery O +
indicates O +
that O +
left O +
atrial O +
function O +
remains O +
subnormal O +
in O +
patients O +
with O +
CAF O +
despite O +
maintenance O +
of O +
SR O +
, O +
suggesting O +
underlying O +
atrial O +
myopathy O +
or O +
fibrosis O +
as O +
a O +
consequence O +
of O +
CAF O +
. O +

[ O +
Study O +
on O +
the O +
expression O +
of O +
angiogenesis O +
and O +
spontaneous O +
apoptosis O +
and O +
their O +
relevance O +
in O +
laryngeal O +
squamous O +
cell O +
carcinoma O +
] O +

OBJECTIVE O +
: O +
To O +
investigate O +
the O +
relationship O +
among O +
angiogenesis O +
, O +
spontaneous O +
apoptosis O +
and O +
clinicopathological O +
parameters O +
in O +
laryngeal O +
squamous O +
cell O +
carcinoma O +
( O +
LSCC O +
) O +
. O +

METHOD O +
: O +
The O +
intratumor O +
microvessel O +
density O +
( O +
IMVD O +
) O +
, O +
apoptotic O +
index O +
( O +
AI O +
) O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
expression O +
were O +
detected O +
by O +
immunohistochemistry O +
SABC O +
and O +
terminal O +
uridine O +
deoxynucleotidyl O +
transferase O +
mediated O +
nick O +
end O +
labeling O +
( O +
TUNEL O +
) O +
methods O +
in34 O +
LSCC O +
patients O +
. O +

RESULT O +
: O +
The O +
average O +
IMVD O +
was O +
( O +
21 O +
. O +
50 O +
+ O +
/ O +
- O +
8 O +
. O +
87 O +
) O +
, O +
and O +
median O +
of O +
AI O +
was O +
1 O +
. O +
15 O +
% O +
. O +

The O +
average O +
IMVD O +
in O +
positive O +
and O +
negative O +
cervical O +
lymphatic O +
metastasis O +
was O +
( O +
26 O +
. O +
33 O +
+ O +
/ O +
- O +
9 O +
. O +
70 O +
) O +
and O +
( O +
17 O +
. O +
68 O +
+ O +
/ O +
- O +
6 O +
. O +
06 O +
) O +
respectively O +
, O +
and O +
the O +
IMVD O +
with O +
positive O +
lymphatic O +
metastasis O +
tumors O +
was O +
statistical O +
significantly O +
higher O +
than O +
those O +
with O +
negative O +
cervical O +
lymphatic O +
metastasis O +
tumors O +
( O +
P O +
less O +
than O +
0 O +
. O +
01 O +
) O +
. O +

The O +
average O +
IMVD O +
had O +
statistical O +
difference O +
in O +
histological O +
grading O +
( O +
P O +
less O +
than O +
0 O +
. O +
01 O +
) O +
, O +
and O +
analysis O +
by O +
one O +
to O +
one O +
, O +
the O +
average O +
IMVD O +
had O +
statistical O +
difference O +
between O +
high O +
and O +
median O +
grading O +
. O +

Expression O +
of O +
VEGF O +
had O +
a O +
significantly O +
positive O +
correlation O +
with O +
IMVD O +
( O +
r O +
= O +
0 O +
. O +
51 O +
, O +
P O +
less O +
than O +
0 O +
. O +
01 O +
) O +
. O +

Statistical O +
analysis O +
revealed O +
a O +
significantly O +
inverse O +
correlation O +
between O +
AI O +
and O +
IMVD O +
( O +
r O +
= O +
- O +
0 O +
. O +
53 O +
, O +
P O +
less O +
than O +
0 O +
. O +
01 O +
) O +
. O +

We O +
failed O +
to O +
find O +
the O +
statistical O +
difference O +
between O +
IMVD O +
and O +
tumor O +
T O +
- O +
stage O +
in O +
LSCC O +
. O +

CONCLUSION O +
: O +
IMVD O +
may O +
be O +
an O +
important O +
indicator O +
to O +
predict O +
cervical O +
lymphatic O +
metastasis O +
in O +
LSCC O +
. O +

VEGF O +
might O +
be O +
an O +
important O +
angiogenic O +
factor O +
, O +
and O +
could O +
promote O +
tumor O +
angiogenesis O +
in O +
LSCC O +
. O +

Tumor O +
angiogenesis O +
might O +
contribute O +
to O +
tumor O +
malignant O +
progression O +
by O +
inhibiting O +
spontaneous O +
apoptosis O +
in O +
LSCC O +
. O +

Hyperforin O +
blocks O +
neutrophil O +
activation O +
of O +
matrix O +
metalloproteinase O +
- O +
9 O +
, O +
motility O +
and O +
recruitment O +
, O +
and O +
restrains O +
inflammation O +
- O +
triggered O +
angiogenesis O +
and O +
lung O +
fibrosis O +
. O +

Hyperforin O +
( O +
Hyp O +
) O +
, O +
a O +
polyphenol O +
- O +
derivative O +
of O +
St O +
. O +

John O +
' O +
s O +
wort O +
( O +
Hypericum O +
perforatum O +
) O +
, O +
has O +
emerged O +
as O +
key O +
player O +
not O +
only O +
in O +
the O +
antidepressant O +
activity O +
of O +
the O +
plant O +
but O +
also O +
as O +
an O +
inhibitor O +
of O +
bacteria O +
lymphocyte O +
and O +
tumor O +
cell O +
proliferation O +
, O +
and O +
matrix O +
proteinases O +
. O +

We O +
tested O +
whether O +
as O +
well O +
as O +
inhibiting O +
leukocyte O +
elastase O +
( O +
LE O +
) O +
activity O +
, O +
Hyp O +
might O +
be O +
effective O +
in O +
containing O +
both O +
polymorphonuclear O +
neutrophil O +
( O +
PMN O +
) O +
leukocyte O +
recruitment O +
and O +
unfavorable O +
eventual O +
tissue O +
responses O +
. O +

The O +
results O +
show O +
that O +
, O +
without O +
affecting O +
in O +
vitro O +
human O +
PMN O +
viability O +
and O +
chemokine O +
- O +
receptor O +
expression O +
, O +
Hyp O +
( O +
as O +
stable O +
dicyclohexylammonium O +
salt O +
) O +
was O +
able O +
to O +
inhibit O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
their O +
chemotaxis O +
and O +
chemoinvasion O +
( O +
IC50 O +
= O +
1 O +
microM O +
for O +
both O +
) O +
; O +
this O +
effect O +
was O +
associated O +
with O +
a O +
reduced O +
expression O +
of O +
the O +
adhesion O +
molecule O +
CD11b O +
by O +
formyl O +
- O +
Met O +
- O +
Leu O +
- O +
Phe O +
- O +
stimulated O +
neutrophils O +
and O +
block O +
of O +
LE O +
- O +
triggered O +
activation O +
of O +
the O +
gelatinase O +
matrix O +
metalloproteinase O +
- O +
9 O +
. O +

PMN O +
- O +
triggered O +
angiogenesis O +
is O +
also O +
blocked O +
by O +
both O +
local O +
injection O +
and O +
daily O +
i O +
. O +
p O +
. O +
administration O +
of O +
the O +
Hyp O +
salt O +
in O +
an O +
interleukin O +
- O +
8 O +
- O +
induced O +
murine O +
model O +
. O +

Furthermore O +
, O +
i O +
. O +
p O +
. O +
treatment O +
with O +
Hyp O +
reduces O +
acute O +
PMN O +
recruitment O +
and O +
enhances O +
resolution O +
in O +
a O +
pulmonary O +
bleomycin O +
- O +
induced O +
inflammation O +
model O +
, O +
significantly O +
reducing O +
consequent O +
fibrosis O +
. O +

These O +
results O +
indicate O +
that O +
Hyp O +
is O +
a O +
powerful O +
anti O +
- O +
inflammatory O +
compound O +
with O +
therapeutic O +
potential O +
, O +
and O +
they O +
elucidate O +
mechanistic O +
keys O +
. O +

New O +
vectors O +
and O +
strategies O +
for O +
cardiovascular O +
gene O +
therapy O +
. O +

Cardiovascular O +
diseases O +
are O +
the O +
major O +
cause O +
of O +
morbidity O +
and O +
mortality O +
in O +
both O +
men O +
and O +
women O +
in O +
industrially O +
developed O +
countries O +
. O +

These O +
disorders O +
may O +
result O +
from O +
impaired O +
angiogenesis O +
, O +
particularly O +
in O +
response O +
to O +
hypoxia O +
. O +

Despite O +
many O +
limitations O +
, O +
gene O +
therapy O +
is O +
still O +
emerging O +
as O +
a O +
potential O +
alternative O +
for O +
patients O +
who O +
are O +
not O +
candidates O +
for O +
traditional O +
revascularization O +
procedures O +
, O +
like O +
angioplasty O +
or O +
vein O +
grafts O +
. O +

This O +
review O +
focuses O +
on O +
recent O +
approaches O +
in O +
the O +
development O +
of O +
new O +
gene O +
delivery O +
vectors O +
, O +
with O +
great O +
respect O +
to O +
newly O +
discovered O +
AAV O +
serotypes O +
and O +
their O +
modified O +
forms O +
. O +

Moreover O +
, O +
some O +
new O +
cardiovascular O +
gene O +
therapy O +
strategies O +
have O +
been O +
highlighted O +
, O +
such O +
as O +
combination O +
of O +
different O +
angiogenic O +
growth O +
factors O +
or O +
simultaneous O +
application O +
of O +
genes O +
and O +
progenitor O +
cells O +
in O +
order O +
to O +
obtain O +
stable O +
and O +
functional O +
blood O +
vessels O +
in O +
ischemic O +
tissue O +
. O +

Impaired O +
apoptosis O +
of O +
pulmonary O +
endothelial O +
cells O +
is O +
associated O +
with O +
intimal O +
proliferation O +
and O +
irreversibility O +
of O +
pulmonary O +
hypertension O +
in O +
congenital O +
heart O +
disease O +
. O +

OBJECTIVES O +
: O +
This O +
study O +
sought O +
to O +
assess O +
the O +
cellular O +
and O +
histologic O +
basis O +
of O +
irreversible O +
pulmonary O +
hypertension O +
( O +
PHT O +
) O +
in O +
the O +
clinical O +
setting O +
of O +
congenital O +
heart O +
disease O +
( O +
CHD O +
) O +
. O +

BACKGROUND O +
: O +
Although O +
many O +
children O +
with O +
CHD O +
develop O +
pulmonary O +
vascular O +
disease O +
, O +
it O +
is O +
unclear O +
why O +
this O +
complication O +
is O +
reversible O +
after O +
complete O +
repair O +
in O +
some O +
cases O +
but O +
irreversible O +
in O +
others O +
. O +

Because O +
failure O +
of O +
endothelial O +
cell O +
apoptosis O +
might O +
lead O +
to O +
intimal O +
proliferation O +
and O +
lack O +
of O +
reversibility O +
of O +
PHT O +
, O +
we O +
investigated O +
this O +
and O +
other O +
key O +
markers O +
of O +
vasoactivity O +
and O +
angiogenesis O +
in O +
subjects O +
with O +
PHT O +
and O +
CHD O +
. O +

METHODS O +
: O +
We O +
assessed O +
antiapoptotic O +
and O +
proapoptotic O +
markers O +
in O +
vascular O +
and O +
perivascular O +
cells O +
in O +
lung O +
biopsy O +
samples O +
from O +
18 O +
patients O +
with O +
CHD O +
, O +
7 O +
with O +
reversible O +
and O +
11 O +
with O +
irreversible O +
PHT O +
, O +
and O +
6 O +
control O +
patients O +
. O +

Immunostaining O +
for O +
endothelial O +
nitric O +
oxide O +
synthase O +
, O +
vascular O +
endothelial O +
growth O +
factor O +
, O +
and O +
CD34 O +
( O +
markers O +
of O +
vasoactivity O +
and O +
neoangiogenesis O +
) O +
was O +
also O +
performed O +
. O +

RESULTS O +
: O +
The O +
antiapoptotic O +
protein O +
Bcl O +
- O +
2 O +
was O +
highly O +
expressed O +
by O +
pulmonary O +
endothelial O +
cells O +
in O +
all O +
cases O +
of O +
irreversible O +
PHT O +
but O +
in O +
no O +
cases O +
of O +
reversible O +
PHT O +
, O +
nor O +
in O +
control O +
patients O +
( O +
p O +
less O +
than O +
0 O +
. O +
001 O +
) O +
. O +

Intimal O +
proliferation O +
was O +
present O +
in O +
10 O +
of O +
11 O +
irreversible O +
PHT O +
cases O +
, O +
but O +
never O +
observed O +
in O +
reversible O +
PHT O +
( O +
p O +
less O +
than O +
0 O +
. O +
001 O +
) O +
. O +

Similarly O +
, O +
perivascular O +
inflammatory O +
T O +
- O +
cells O +
expressed O +
more O +
antiapoptotic O +
proteins O +
in O +
irreversible O +
PHT O +
( O +
p O +
less O +
than O +
0 O +
. O +
01 O +
) O +
. O +

Irreversible O +
PHT O +
cases O +
were O +
also O +
more O +
likely O +
to O +
show O +
compensatory O +
upregulation O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
new O +
small O +
vessel O +
formation O +
at O +
the O +
sites O +
of O +
native O +
vessel O +
stenosis O +
or O +
occlusion O +
( O +
p O +
less O +
than O +
0 O +
. O +
001 O +
) O +
. O +

CONCLUSIONS O +
: O +
Irreversible O +
PHT O +
is O +
strongly O +
associated O +
with O +
impaired O +
endothelial O +
cell O +
apoptosis O +
and O +
antiapoptotic O +
signaling O +
from O +
perivascular O +
inflammatory O +
cells O +
. O +

These O +
changes O +
are O +
associated O +
with O +
intimal O +
proliferation O +
and O +
vessel O +
narrowing O +
, O +
and O +
thereby O +
may O +
contribute O +
to O +
clinical O +
outcomes O +
associated O +
with O +
pulmonary O +
hypertension O +
. O +

Inhibition O +
of O +
Dll4 O +
- O +
mediated O +
signaling O +
induces O +
proliferation O +
of O +
immature O +
vessels O +
and O +
results O +
in O +
poor O +
tissue O +
perfusion O +
. O +

Vascular O +
development O +
is O +
dependent O +
on O +
various O +
growth O +
factors O +
and O +
certain O +
modifiers O +
critical O +
for O +
providing O +
arterial O +
or O +
venous O +
identity O +
, O +
interaction O +
with O +
the O +
surrounding O +
stroma O +
and O +
tissues O +
, O +
hierarchic O +
network O +
formation O +
, O +
and O +
recruitment O +
of O +
pericytes O +
. O +

Notch O +
receptors O +
and O +
ligands O +
( O +
Jagged O +
and O +
Delta O +
- O +
like O +
) O +
play O +
a O +
critical O +
role O +
in O +
this O +
process O +
in O +
addition O +
to O +
VEGF O +
. O +

Dll4 O +
is O +
one O +
of O +
the O +
Notch O +
ligands O +
that O +
regulates O +
arterial O +
specification O +
and O +
maturation O +
events O +
. O +

In O +
the O +
current O +
study O +
, O +
we O +
have O +
shown O +
that O +
loss O +
of O +
function O +
by O +
either O +
targeted O +
allele O +
deletion O +
or O +
use O +
of O +
a O +
soluble O +
form O +
of O +
Dll4 O +
extracellular O +
domain O +
leads O +
to O +
inhibition O +
of O +
Notch O +
signaling O +
, O +
resulting O +
in O +
increased O +
vascular O +
proliferation O +
but O +
defective O +
maturation O +
. O +

Newly O +
forming O +
vessels O +
have O +
thin O +
caliber O +
, O +
a O +
markedly O +
reduced O +
vessel O +
lumen O +
, O +
markedly O +
reduced O +
pericyte O +
recruitment O +
, O +
and O +
deficient O +
vascular O +
perfusion O +
. O +

sDll4 O +
similarly O +
induced O +
defective O +
vascular O +
response O +
in O +
tumor O +
implants O +
leading O +
to O +
reduced O +
tumor O +
growth O +
. O +

Interference O +
with O +
Dll4 O +
- O +
Notch O +
signaling O +
may O +
be O +
particularly O +
desirable O +
in O +
tumors O +
that O +
have O +
highly O +
induced O +
Dll4 O +
- O +
Notch O +
pathway O +
. O +

[ O +
Diagnostic O +
value O +
of O +
DNA O +
, O +
RNA O +
and O +
proliferating O +
cell O +
nuclear O +
antigen O +
examination O +
in O +
malignant O +
pleural O +
effusions O +
by O +
flow O +
cytometry O +
] O +
. O +

OBJECTIVE O +
: O +

To O +
study O +
the O +
diagnostic O +
value O +
of O +
DNA O +
, O +
RNA O +
and O +
proliferating O +
cell O +
nuclear O +
antigen O +
( O +
PCNA O +
) O +
examination O +
in O +
malignant O +
effusion O +
by O +
multiparametric O +
flow O +
cytometry O +
, O +
and O +
therefore O +
to O +
provide O +
proof O +
for O +
clinical O +
application O +
. O +

METHODS O +
: O +

Forty O +
seven O +
patients O +
with O +
pleural O +
effusions O +
in O +
our O +
hospital O +
from O +
August O +
2003 O +
to O +
February O +
2004 O +
were O +
divided O +
into O +
two O +
groups O +
: O +
19 O +
suffering O +
from O +
benign O +
pleural O +
effusions O +
and O +
28 O +
from O +
malignant O +
effusions O +
confirmed O +
by O +
pathologic O +
examination O +
. O +

The O +
cells O +
for O +
diagnosis O +
were O +
divided O +
into O +
four O +
groups O +
stained O +
by O +
PI O +
( O +
Propidium O +
- O +
iodide O +
) O +
, O +
PY O +
( O +
Pyronin O +
) O +
, O +
PCNA O +
- O +
FITC O +
and O +
PCNA O +
- O +
mouse O +
- O +
alpha O +
- O +
2a O +
. O +

The O +
specimens O +
were O +
analyzed O +
by O +
a O +
flow O +
cytometer O +
( O +
FacS O +
Caliber O +
, O +
Becton O +
Dickinson O +
) O +
. O +

The O +
sensitivity O +
and O +
the O +
specificity O +
of O +
each O +
examination O +
and O +
combined O +
examination O +
were O +
calculated O +
by O +
statistic O +
software O +
SPSS O +
13 O +
. O +
0 O +
. O +

RESULTS O +
: O +

( O +
1 O +
) O +
The O +
expression O +
of O +
DI O +
, O +
RI O +
, O +
and O +
PI O +
in O +
benign O +
pleural O +
effusion O +
was O +
1 O +
. O +
03 O +
+ O +
/ O +
- O +
0 O +
. O +
06 O +
, O +
10 O +
. O +
03 O +
+ O +
/ O +
- O +
0 O +
. O +
54 O +
, O +
and O +
( O +
4 O +
. O +
86 O +
+ O +
/ O +
- O +
0 O +
. O +
72 O +
) O +
% O +
, O +
respectively O +
, O +
and O +
those O +
in O +
malignant O +
ones O +
was O +
1 O +
. O +
26 O +
+ O +
/ O +
- O +
0 O +
. O +
17 O +
, O +
11 O +
. O +
65 O +
+ O +
/ O +
- O +
1 O +
. O +
45 O +
, O +
and O +
( O +
11 O +
. O +
97 O +
+ O +
/ O +
- O +
1 O +
. O +
50 O +
) O +
% O +
, O +
respectively O +
, O +
the O +
difference O +
being O +
statistically O +
significant O +
. O +

The O +
cutoff O +
value O +
of O +
DI O +
, O +
RI O +
and O +
PI O +
was O +
1 O +
. O +
10 O +
% O +
, O +
10 O +
. O +
75 O +
% O +
and O +
4 O +
. O +
56 O +
% O +
, O +
and O +
the O +
sensitivity O +
of O +
DI O +
examination O +
was O +
89 O +
. O +
3 O +
% O +
, O +
78 O +
. O +
6 O +
% O +
, O +
75 O +
. O +
0 O +
% O +
, O +
and O +
the O +
specificity O +
was O +
89 O +
. O +
5 O +
% O +
, O +
98 O +
. O +
5 O +
% O +
, O +
84 O +
. O +
2 O +
% O +
, O +
respectively O +
. O +

( O +
2 O +
) O +
In O +
6 O +
cases O +
suffering O +
from O +
malignant O +
pleural O +
effusions O +
, O +
RI O +
was O +
positive O +
but O +
DI O +
was O +
negative O +
, O +
indicating O +
that O +
DI O +
combined O +
with O +
RI O +
examination O +
was O +
better O +
than O +
DI O +
examination O +
alone O +
. O +

( O +
3 O +
) O +
In O +
5 O +
cases O +
suffering O +
from O +
malignant O +
pleural O +
effusions O +
confirmed O +
by O +
tissue O +
examination O +
, O +
the O +
cytology O +
was O +
negative O +
, O +
but O +
the O +
result O +
of O +
DI O +
and O +
RI O +
was O +
abnormal O +
, O +
indicating O +
that O +
flow O +
cytometry O +
was O +
complementary O +
to O +
pathologic O +
examination O +
. O +

( O +
4 O +
) O +
The O +
sensitivity O +
of O +
DI O +
+ O +
RI O +
, O +
DI O +
+ O +
PI O +
, O +
RI O +
+ O +
PI O +
and O +
DI O +
+ O +
RI O +
+ O +
PI O +
combined O +
examination O +
was O +
98 O +
. O +
2 O +
% O +
, O +
89 O +
. O +
3 O +
% O +
, O +
89 O +
. O +
3 O +
% O +
, O +
92 O +
. O +
9 O +
% O +
; O +
the O +
specificity O +
was O +
84 O +
. O +
2 O +
% O +
, O +
89 O +
. O +
5 O +
% O +
, O +
84 O +
. O +
2 O +
% O +
, O +
94 O +
. O +
2 O +
% O +
respectively O +
. O +

The O +
results O +
demonstrated O +
that O +
DI O +
+ O +
RI O +
+ O +
PI O +
combined O +
examination O +
was O +
the O +
best O +
, O +
which O +
showed O +
the O +
least O +
false O +
negative O +
and O +
false O +
positive O +
results O +
. O +

The O +
sensitivity O +
of O +
DI O +
+ O +
RI O +
combined O +
examination O +
was O +
98 O +
. O +
2 O +
% O +
, O +
but O +
the O +
specificity O +
was O +
84 O +
. O +
2 O +
% O +
, O +
the O +
false O +
positive O +
rate O +
being O +
higher O +
than O +
DI O +
+ O +
RI O +
+ O +
PI O +
combined O +
examination O +
. O +

In O +
none O +
of O +
the O +
benign O +
pleural O +
effusions O +
was O +
the O +
DI O +
+ O +
RI O +
+ O +
PI O +
higher O +
than O +
the O +
cutoff O +
value O +
, O +
suggesting O +
that O +
combined O +
examination O +
can O +
exclude O +
benign O +
pleural O +
effusions O +
. O +

CONCLUSIONS O +
: O +

DNA O +
, O +
RNA O +
and O +
PCNA O +
examinations O +
by O +
flow O +
cytometry O +
are O +
of O +
value O +
in O +
the O +
diagnosis O +
of O +
malignant O +
effusion O +
, O +
especially O +
for O +
cases O +
which O +
can O +
not O +
be O +
diagnosed O +
by O +
cytological O +
examination O +
. O +

DI O +
+ O +
RI O +
+ O +
PI O +
combined O +
examination O +
showed O +
better O +
results O +
with O +
the O +
lowest O +
false O +
negative O +
and O +
false O +
positive O +
rates O +
. O +

Schizophrenia O +
: O +
a O +
common O +
disease O +
caused O +
by O +
multiple O +
rare O +
alleles O +
. O +

Schizophrenia O +
is O +
widely O +
held O +
to O +
stem O +
from O +
the O +
combined O +
effects O +
of O +
multiple O +
common O +
polymorphisms O +
, O +
each O +
with O +
a O +
small O +
impact O +
on O +
disease O +
risk O +
. O +

We O +
suggest O +
an O +
alternative O +
view O +
: O +
that O +
schizophrenia O +
is O +
highly O +
heterogeneous O +
genetically O +
and O +
that O +
many O +
predisposing O +
mutations O +
are O +
highly O +
penetrant O +
and O +
individually O +
rare O +
, O +
even O +
specific O +
to O +
single O +
cases O +
or O +
families O +
. O +

This O +
" O +
common O +
disease O +
- O +
- O +
rare O +
alleles O +
" O +
hypothesis O +
is O +
supported O +
by O +
recent O +
findings O +
in O +
human O +
genomics O +
and O +
by O +
allelic O +
and O +
locus O +
heterogeneity O +
for O +
other O +
complex O +
traits O +
. O +

We O +
review O +
the O +
implications O +
of O +
this O +
model O +
for O +
gene O +
discovery O +
research O +
in O +
schizophrenia O +
. O +

SWAP O +
- O +
70 O +
is O +
required O +
for O +
oncogenic O +
transformation O +
by O +
v O +
- O +
Src O +
in O +
mouse O +
embryo O +
fibroblasts O +
. O +

SWAP O +
- O +
70 O +
is O +
a O +
phosphatidylinositol O +
trisphosphate O +
( O +
PtdIns O +
( O +
3 O +
, O +
4 O +
, O +
5 O +
) O +
P O +
( O +
3 O +
) O +
) O +
binding O +
protein O +
, O +
which O +
acts O +
in O +
F O +
- O +
actin O +
rearrangement O +
. O +

The O +
role O +
of O +
SWAP O +
- O +
70 O +
in O +
oncogenic O +
transformation O +
of O +
mouse O +
embryo O +
fibroblasts O +
( O +
MEFs O +
) O +
by O +
v O +
- O +
Src O +
was O +
examined O +
by O +
use O +
of O +
MEFs O +
defective O +
in O +
SWAP O +
- O +
70 O +
. O +

v O +
- O +
Src O +
morphologically O +
transformed O +
MEFs O +
lacking O +
SWAP O +
- O +
70 O +
, O +
but O +
growth O +
of O +
the O +
transformed O +
cells O +
in O +
culture O +
was O +
slower O +
than O +
that O +
of O +
cells O +
supplemented O +
with O +
exogenous O +
SWAP O +
- O +
70 O +
. O +

The O +
v O +
- O +
Src O +
- O +
transformed O +
MEFs O +
deficient O +
in O +
SWAP O +
- O +
70 O +
were O +
unable O +
to O +
grow O +
in O +
soft O +
agar O +
while O +
those O +
expressing O +
SWAP70 O +
readily O +
formed O +
colonies O +
, O +
suggesting O +
that O +
SWAP O +
- O +
70 O +
is O +
required O +
for O +
anchorage O +
independent O +
growth O +
of O +
v O +
- O +
Src O +
transformed O +
MEFs O +
. O +

When O +
transplanted O +
in O +
nude O +
mice O +
, O +
tumors O +
formed O +
by O +
the O +
v O +
- O +
Src O +
transformed O +
SWAP O +
- O +
70 O +
( O +
- O +
/ O +
- O +
) O +
MEFs O +
were O +
smaller O +
than O +
those O +
formed O +
by O +
cells O +
expressing O +
exogenous O +
SWAP O +
- O +
70 O +
. O +

These O +
results O +
suggest O +
that O +
SWAP O +
- O +
70 O +
may O +
be O +
required O +
for O +
oncogenic O +
transformation O +
and O +
contributes O +
to O +
cell O +
growth O +
in O +
MEFs O +
transformed O +
by O +
v O +
- O +
Src O +
. O +

Tsg101 O +
is O +
upregulated O +
in O +
a O +
subset O +
of O +
invasive O +
human O +
breast O +
cancers O +
and O +
its O +
targeted O +
overexpression O +
in O +
transgenic O +
mice O +
reveals O +
weak O +
oncogenic O +
properties O +
for O +
mammary O +
cancer O +
initiation O +
. O +

Previous O +
studies O +
reported O +
that O +
the O +
Tumor O +
Susceptibility O +
Gene O +
101 O +
( O +
TSG101 O +
) O +
is O +
upregulated O +
in O +
selected O +
human O +
malignancies O +
, O +
and O +
the O +
expression O +
of O +
exogenous O +
Tsg101 O +
was O +
suggested O +
to O +
transform O +
immortalized O +
fibroblasts O +
in O +
culture O +
. O +

To O +
date O +
, O +
the O +
potential O +
oncogenic O +
properties O +
of O +
Tsg101 O +
have O +
not O +
been O +
examined O +
in O +
vivo O +
owing O +
to O +
the O +
lack O +
of O +
appropriate O +
model O +
systems O +
. O +

In O +
this O +
study O +
, O +
we O +
show O +
that O +
Tsg101 O +
is O +
highly O +
expressed O +
in O +
a O +
subset O +
of O +
invasive O +
human O +
breast O +
cancers O +
. O +

Based O +
on O +
this O +
observation O +
, O +
we O +
generated O +
the O +
first O +
transgenic O +
mouse O +
model O +
with O +
a O +
targeted O +
overexpression O +
of O +
Tsg101 O +
in O +
the O +
developing O +
mammary O +
gland O +
to O +
test O +
whether O +
exogenous O +
Tsg101 O +
is O +
capable O +
of O +
initiating O +
tumorigenesis O +
. O +

Normal O +
functionality O +
of O +
exogenous O +
Tsg101 O +
was O +
tested O +
by O +
rescuing O +
the O +
survival O +
of O +
Tsg101 O +
- O +
deficient O +
mammary O +
epithelial O +
cells O +
in O +
conditional O +
knockout O +
mice O +
. O +

The O +
overexpression O +
of O +
Tsg101 O +
resulted O +
in O +
increased O +
phosphorylation O +
of O +
the O +
epidermal O +
growth O +
factor O +
receptor O +
and O +
downstream O +
activation O +
of O +
MAP O +
kinases O +
. O +

Despite O +
an O +
increase O +
in O +
the O +
activation O +
of O +
these O +
signal O +
transducers O +
, O +
the O +
mammary O +
gland O +
of O +
females O +
expressing O +
exogenous O +
Tsg101 O +
developed O +
normally O +
throughout O +
the O +
reproductive O +
cycle O +
. O +

In O +
aging O +
females O +
, O +
the O +
overexpression O +
of O +
Tsg101 O +
seemed O +
to O +
increase O +
the O +
susceptibility O +
of O +
mammary O +
epithelia O +
toward O +
malignant O +
transformation O +
. O +

However O +
, O +
owing O +
to O +
the O +
long O +
latency O +
of O +
tumor O +
formation O +
and O +
the O +
sporadic O +
occurrence O +
of O +
bona O +
fide O +
mammary O +
cancers O +
, O +
we O +
conclude O +
that O +
the O +
Tsg101 O +
protein O +
has O +
only O +
weak O +
oncogenic O +
properties O +
. O +

Instead O +
of O +
cancer O +
initiation O +
, O +
it O +
is O +
therefore O +
likely O +
that O +
Tsg101 O +
plays O +
a O +
more O +
predominant O +
role O +
in O +
the O +
progression O +
of O +
a O +
subset O +
of O +
spontaneously O +
arising O +
breast O +
cancers O +
. O +

Expression O +
of O +
Bcl O +
- O +
xL O +
, O +
Bax O +
, O +
and O +
p53 O +
in O +
primary O +
tumors O +
and O +
lymph O +
node O +
metastases O +
in O +
oral O +
squamous O +
cell O +
carcinoma O +
. O +

Disturbances O +
in O +
expression O +
of O +
apoptosis O +
- O +
associated O +
proteins O +
take O +
part O +
in O +
the O +
development O +
and O +
progression O +
of O +
many O +
human O +
malignancies O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
the O +
assessment O +
of O +
correlations O +
among O +
proteins O +
involved O +
in O +
apoptosis O +
- O +
Bcl O +
- O +
xL O +
, O +
Bax O +
, O +
and O +
p53 O +
- O +
as O +
well O +
as O +
relationships O +
of O +
these O +
proteins O +
with O +
selected O +
clinicopathological O +
features O +
in O +
oral O +
squamous O +
cell O +
carcinoma O +
. O +

Consequently O +
, O +
we O +
examined O +
by O +
immunohistochemistry O +
, O +
using O +
the O +
avidin O +
- O +
biotin O +
- O +
peroxidase O +
method O +
, O +
Bcl O +
- O +
xL O +
, O +
Bax O +
, O +
and O +
p53 O +
expression O +
in O +
56 O +
samples O +
of O +
primary O +
oral O +
squamous O +
cell O +
carcinoma O +
and O +
in O +
22 O +
matched O +
pairs O +
of O +
primary O +
and O +
metastatic O +
tumors O +
. O +

The O +
evaluation O +
of O +
immunostaining O +
of O +
Bcl O +
- O +
xL O +
, O +
Bax O +
, O +
and O +
p53 O +
was O +
analyzed O +
in O +
10 O +
different O +
tumor O +
fields O +
, O +
and O +
the O +
mean O +
percentage O +
of O +
tumor O +
cells O +
with O +
positive O +
staining O +
was O +
evaluated O +
. O +

The O +
significance O +
of O +
the O +
associations O +
was O +
determined O +
using O +
Spearman O +
correlation O +
analysis O +
and O +
the O +
chi O +
- O +
square O +
test O +
. O +

We O +
found O +
positive O +
Bcl O +
- O +
xL O +
, O +
Bax O +
, O +
and O +
p53 O +
immunostaining O +
in O +
44 O +
. O +
6 O +
% O +
, O +
28 O +
. O +
6 O +
% O +
, O +
and O +
58 O +
. O +
9 O +
% O +
of O +
the O +
studied O +
primary O +
tumors O +
and O +
in O +
63 O +
. O +
6 O +
% O +
, O +
45 O +
. O +
5 O +
% O +
, O +
and O +
72 O +
. O +
7 O +
% O +
of O +
lymph O +
node O +
metastases O +
, O +
respectively O +
. O +

Analysis O +
of O +
associations O +
among O +
studied O +
proteins O +
revealed O +
positive O +
correlation O +
between O +
Bcl O +
- O +
xL O +
and O +
Bax O +
in O +
primary O +
tumors O +
( O +
P O +
< O +
0 O +
. O +
03 O +
, O +
r O +
= O +
0 O +
. O +
307 O +
) O +
. O +

Statistically O +
significant O +
relationship O +
between O +
p53 O +
expression O +
in O +
primary O +
oral O +
cancers O +
and O +
its O +
expression O +
in O +
lymph O +
node O +
metastases O +
( O +
P O +
< O +
0 O +
. O +
02 O +
) O +
as O +
well O +
as O +
increased O +
expression O +
of O +
Bcl O +
- O +
xL O +
, O +
Bax O +
, O +
and O +
p53 O +
in O +
metastatic O +
sites O +
compared O +
with O +
primary O +
tumors O +
could O +
indicate O +
an O +
association O +
of O +
these O +
proteins O +
with O +
oral O +
cancer O +
progression O +
and O +
development O +
of O +
metastases O +
. O +

Moreover O +
, O +
we O +
suppose O +
that O +
knowledge O +
about O +
heterogeneity O +
between O +
primary O +
and O +
metastatic O +
tumor O +
might O +
help O +
to O +
understand O +
mechanisms O +
of O +
oral O +
cancer O +
progression O +
. O +

Mechanisms O +
for O +
the O +
magnolol O +
- O +
induced O +
cell O +
death O +
of O +
CGTH O +
W O +
- O +
2 O +
thyroid O +
carcinoma O +
cells O +
. O +

Magnolol O +
, O +
a O +
substance O +
purified O +
from O +
the O +
bark O +
of O +
Magnolia O +
officialis O +
, O +
inhibits O +
cell O +
proliferation O +
and O +
induces O +
apoptosis O +
in O +
a O +
variety O +
of O +
cancer O +
cells O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
study O +
the O +
effects O +
of O +
magnolol O +
on O +
CGTH O +
W O +
- O +
2 O +
thyroid O +
carcinoma O +
cells O +
. O +

After O +
24 O +
h O +
treatment O +
with O +
80 O +
microM O +
magnolol O +
in O +
serum O +
- O +
containing O +
medium O +
, O +
about O +
50 O +
% O +
of O +
the O +
cells O +
exhibited O +
apoptotic O +
features O +
and O +
20 O +
% O +
necrotic O +
features O +
. O +

Cytochrome O +
- O +
c O +
staining O +
was O +
diffused O +
in O +
the O +
cytoplasm O +
of O +
the O +
apoptotic O +
cells O +
, O +
but O +
restricted O +
to O +
the O +
mitochondria O +
in O +
control O +
cells O +
. O +

Western O +
blot O +
analyses O +
showed O +
an O +
increase O +
in O +
levels O +
of O +
activated O +
caspases O +
( O +
caspase O +
- O +
3 O +
and O +
- O +
7 O +
) O +
and O +
of O +
cleaved O +
poly O +
( O +
ADP O +
- O +
ribose O +
) O +
polymerase O +
( O +
PARP O +
) O +
by O +
magnolol O +
. O +

Concomitantly O +
, O +
immunostaining O +
for O +
apoptosis O +
inducing O +
factor O +
( O +
AIF O +
) O +
showed O +
a O +
time O +
- O +
dependent O +
translocation O +
from O +
the O +
mitochondria O +
to O +
the O +
nucleus O +
. O +

Inhibition O +
of O +
either O +
PARP O +
or O +
caspase O +
activity O +
blocked O +
magnolol O +
- O +
induced O +
apoptosis O +
, O +
supporting O +
the O +
involvement O +
of O +
the O +
caspases O +
and O +
PARP O +
. O +

In O +
addition O +
, O +
magnolol O +
activated O +
phosphatase O +
and O +
tensin O +
homolog O +
deleted O +
on O +
chromosome O +
10 O +
( O +
PTEN O +
) O +
and O +
inactivated O +
Akt O +
by O +
decreasing O +
levels O +
of O +
phosphorylated O +
PTEN O +
and O +
phosphorylated O +
Akt O +
. O +

These O +
data O +
suggest O +
that O +
magnolol O +
promoted O +
apoptosis O +
probably O +
by O +
alleviating O +
the O +
inhibitory O +
effect O +
of O +
Akt O +
on O +
caspase O +
9 O +
. O +

Furthermore O +
, O +
inhibition O +
of O +
PARP O +
activity O +
, O +
but O +
not O +
of O +
caspase O +
activity O +
, O +
completely O +
prevented O +
magnolol O +
- O +
induced O +
necrosis O +
, O +
suggesting O +
the O +
notion O +
that O +
it O +
might O +
be O +
caused O +
by O +
depletion O +
of O +
intracellular O +
ATP O +
levels O +
due O +
to O +
PARP O +
activation O +
. O +

These O +
results O +
show O +
that O +
magnolol O +
initiates O +
apoptosis O +
via O +
the O +
cytochrome O +
- O +
c O +
/ O +
caspase O +
3 O +
/ O +
PARP O +
/ O +
AIF O +
and O +
PTEN O +
/ O +
Akt O +
/ O +
caspase O +
9 O +
/ O +
PARP O +
pathways O +
and O +
necrosis O +
via O +
PARP O +
activation O +
. O +

[ O +
Anomalous O +
origin O +
of O +
the O +
right O +
coronary O +
artery O +
from O +
the O +
left O +
sinus O +
of O +
Valsalva O +
: O +
case O +
report O +
and O +
literature O +
review O +
] O +
. O +

We O +
describe O +
the O +
case O +
of O +
a O +
patient O +
in O +
whom O +
evaluation O +
of O +
effort O +
angina O +
revealed O +
a O +
tight O +
stenosis O +
of O +
a O +
right O +
coronary O +
artery O +
anomalously O +
arising O +
from O +
the O +
left O +
sinus O +
of O +
Valsalva O +
, O +
which O +
was O +
successfully O +
treated O +
by O +
stent O +
implantation O +
. O +

The O +
abnormal O +
origin O +
of O +
the O +
right O +
coronary O +
artery O +
from O +
the O +
left O +
aortic O +
sinus O +
coursing O +
between O +
the O +
aorta O +
and O +
the O +
pulmonary O +
trunk O +
is O +
a O +
rare O +
congenital O +
anomaly O +
. O +

It O +
may O +
remain O +
asymptomatic O +
, O +
but O +
can O +
also O +
cause O +
major O +
cardiac O +
events O +
, O +
even O +
in O +
the O +
absence O +
of O +
coronary O +
atherosclerosis O +
. O +

We O +
discuss O +
the O +
clinical O +
importance O +
of O +
this O +
anomaly O +
and O +
review O +
the O +
literature O +
concerning O +
current O +
views O +
and O +
therapy O +
. O +

The O +
cancer O +
cell O +
' O +
s O +
" O +
power O +
plants O +
" O +
as O +
promising O +
therapeutic O +
targets O +
: O +
an O +
overview O +
. O +

This O +
introductory O +
article O +
to O +
the O +
review O +
series O +
entitled O +
" O +
The O +
Cancer O +
Cell O +
' O +
s O +
Power O +
Plants O +
as O +
Promising O +
Therapeutic O +
Targets O +
" O +
is O +
written O +
while O +
more O +
than O +
20 O +
million O +
people O +
suffer O +
from O +
cancer O +
. O +

It O +
summarizes O +
strategies O +
to O +
destroy O +
or O +
prevent O +
cancers O +
by O +
targeting O +
their O +
energy O +
production O +
factories O +
, O +
i O +
. O +
e O +
. O +
, O +
" O +
power O +
plants O +
. O +
" O +
All O +
nucleated O +
animal O +
/ O +
human O +
cells O +
have O +
two O +
types O +
of O +
power O +
plants O +
, O +
i O +
. O +
e O +
. O +
, O +
systems O +
that O +
make O +
the O +
" O +
high O +
energy O +
" O +
compound O +
ATP O +
from O +
ADP O +
and O +
P O +
( O +
i O +
) O +
. O +

One O +
type O +
is O +
" O +
glycolysis O +
, O +
" O +
the O +
other O +
the O +
" O +
mitochondria O +
. O +
" O +
In O +
contrast O +
to O +
most O +
normal O +
cells O +
where O +
the O +
mitochondria O +
are O +
the O +
major O +
ATP O +
producers O +
( O +
> O +
90 O +
% O +
) O +
in O +
fueling O +
growth O +
, O +
human O +
cancers O +
detected O +
via O +
Positron O +
Emission O +
Tomography O +
( O +
PET O +
) O +
rely O +
on O +
both O +
types O +
of O +
power O +
plants O +
. O +

In O +
such O +
cancers O +
, O +
glycolysis O +
may O +
contribute O +
nearly O +
half O +
the O +
ATP O +
even O +
in O +
the O +
presence O +
of O +
oxygen O +
( O +
" O +
Warburg O +
effect O +
" O +
) O +
. O +

Based O +
solely O +
on O +
cell O +
energetics O +
, O +
this O +
presents O +
a O +
challenge O +
to O +
identify O +
curative O +
agents O +
that O +
destroy O +
only O +
cancer O +
cells O +
as O +
they O +
must O +
destroy O +
both O +
of O +
their O +
power O +
plants O +
causing O +
" O +
necrotic O +
cell O +
death O +
" O +
and O +
leave O +
normal O +
cells O +
alone O +
. O +

One O +
such O +
agent O +
, O +
3 O +
- O +
bromopyruvate O +
( O +
3 O +
- O +
BrPA O +
) O +
, O +
a O +
lactic O +
acid O +
analog O +
, O +
has O +
been O +
shown O +
to O +
inhibit O +
both O +
glycolytic O +
and O +
mitochondrial O +
ATP O +
production O +
in O +
rapidly O +
growing O +
cancers O +
( O +
Ko O +
et O +
al O +
. O +
, O +
Cancer O +
Letts O +
. O +
, O +
173 O +
, O +
83 O +
- O +
91 O +
, O +
2001 O +
) O +
, O +
leave O +
normal O +
cells O +
alone O +
, O +
and O +
eradicate O +
advanced O +
cancers O +
( O +
19 O +
of O +
19 O +
) O +
in O +
a O +
rodent O +
model O +
( O +
Ko O +
et O +
al O +
. O +
, O +
Biochem O +
. O +
Biophys O +
. O +
Res O +
. O +
Commun O +
. O +
, O +
324 O +
, O +
269 O +
- O +
275 O +
, O +
2004 O +
) O +
. O +

A O +
second O +
approach O +
is O +
to O +
induce O +
only O +
cancer O +
cells O +
to O +
undergo O +
" O +
apoptotic O +
cell O +
death O +
. O +
" O +
Here O +
, O +
mitochondria O +
release O +
cell O +
death O +
inducing O +
factors O +
( O +
e O +
. O +
g O +
. O +
, O +
cytochrome O +
c O +
) O +
. O +

In O +
a O +
third O +
approach O +
, O +
cancer O +
cells O +
are O +
induced O +
to O +
die O +
by O +
both O +
apoptotic O +
and O +
necrotic O +
events O +
. O +

In O +
summary O +
, O +
much O +
effort O +
is O +
being O +
focused O +
on O +
identifying O +
agents O +
that O +
induce O +
" O +
necrotic O +
, O +
" O +
" O +
apoptotic O +
" O +
or O +
apoptotic O +
plus O +
necrotic O +
cell O +
death O +
only O +
in O +
cancer O +
cells O +
. O +

Regardless O +
how O +
death O +
is O +
inflicted O +
, O +
every O +
cancer O +
cell O +
must O +
die O +
, O +
be O +
it O +
fast O +
or O +
slow O +
. O +

Determination O +
of O +
eprosartan O +
in O +
human O +
plasma O +
and O +
urine O +
by O +
LC O +
/ O +
MS O +
/ O +
MS O +
. O +

A O +
protein O +
precipitation O +
, O +
liquid O +
chromatography O +
/ O +
tandem O +
mass O +
spectrometry O +
( O +
LC O +
/ O +
MS O +
/ O +
MS O +
) O +
method O +
has O +
been O +
developed O +
and O +
validated O +
for O +
the O +
determination O +
of O +
eprosartan O +
in O +
human O +
plasma O +
and O +
urine O +
. O +

The O +
solvent O +
system O +
also O +
served O +
as O +
a O +
protein O +
precipitation O +
reagent O +
. O +

The O +
chromatographic O +
separation O +
was O +
achieved O +
on O +
a O +
CAPCELL O +
PAK O +
C18 O +
column O +
( O +
50 O +
mmx2 O +
. O +
0 O +
mm O +
, O +
5 O +
microm O +
, O +
Shiseido O +
) O +
. O +

A O +
mobile O +
phase O +
was O +
consisted O +
of O +
0 O +
. O +
5 O +
% O +
formic O +
acid O +
in O +
water O +
and O +
0 O +
. O +
5 O +
% O +
formic O +
acid O +
in O +
acetonitrile O +
( O +
72 O +
: O +
28 O +
) O +
. O +

Detection O +
was O +
by O +
positive O +
ion O +
electrospray O +
tandem O +
mass O +
spectrometry O +
on O +
a O +
Sciex O +
API3000 O +
. O +

The O +
standard O +
curves O +
, O +
which O +
ranged O +
from O +
5 O +
to O +
2000 O +
ng O +
/ O +
mL O +
in O +
human O +
plasma O +
and O +
from O +
0 O +
. O +
25 O +
to O +
50 O +
microg O +
/ O +
mL O +
in O +
urine O +
, O +
were O +
fitted O +
to O +
a O +
1 O +
/ O +
x O +
weighted O +
quadratic O +
regression O +
model O +
. O +

The O +
method O +
proved O +
to O +
be O +
accurate O +
, O +
specific O +
and O +
sensitive O +
enough O +
to O +
be O +
successfully O +
applied O +
to O +
a O +
pharmacokinetic O +
study O +
. O +

The O +
relationship O +
between O +
brain O +
activity O +
and O +
peak O +
grip O +
force O +
is O +
modulated O +
by O +
corticospinal O +
system O +
integrity O +
after O +
subcortical O +
stroke O +
. O +

In O +
healthy O +
human O +
subjects O +
, O +
the O +
relative O +
contribution O +
of O +
cortical O +
regions O +
to O +
motor O +
performance O +
varies O +
with O +
the O +
task O +
parameters O +
. O +

Additionally O +
, O +
after O +
stroke O +
, O +
recruitment O +
of O +
cortical O +
areas O +
during O +
a O +
simple O +
motor O +
task O +
varies O +
with O +
corticospinal O +
system O +
integrity O +
. O +

We O +
investigated O +
whether O +
the O +
pattern O +
of O +
motor O +
system O +
recruitment O +
in O +
a O +
task O +
involving O +
increasingly O +
forceful O +
hand O +
grips O +
is O +
influenced O +
by O +
the O +
degree O +
of O +
corticospinal O +
system O +
damage O +
. O +

Nine O +
chronic O +
subcortical O +
stroke O +
patients O +
and O +
nine O +
age O +
- O +
matched O +
controls O +
underwent O +
functional O +
magnetic O +
brain O +
imaging O +
whilst O +
performing O +
repetitive O +
isometric O +
hand O +
grips O +
. O +

Target O +
grip O +
forces O +
were O +
varied O +
between O +
15 O +
% O +
and O +
45 O +
% O +
of O +
individual O +
maximum O +
grip O +
force O +
. O +

Corticospinal O +
system O +
functional O +
integrity O +
was O +
assessed O +
with O +
transcranial O +
magnetic O +
stimulation O +
. O +

Averaged O +
across O +
all O +
forces O +
, O +
there O +
was O +
more O +
task O +
- O +
related O +
activation O +
compared O +
with O +
rest O +
in O +
the O +
secondary O +
motor O +
areas O +
of O +
patients O +
with O +
greater O +
corticospinal O +
system O +
damage O +
, O +
confirming O +
previous O +
reports O +
. O +

However O +
, O +
here O +
we O +
were O +
primarily O +
interested O +
in O +
regional O +
brain O +
activation O +
, O +
which O +
covaried O +
with O +
the O +
amount O +
of O +
force O +
generated O +
, O +
implying O +
a O +
prominent O +
executive O +
role O +
in O +
force O +
production O +
. O +

We O +
found O +
that O +
in O +
control O +
subjects O +
and O +
patients O +
with O +
lesser O +
corticospinal O +
system O +
damage O +
, O +
signal O +
change O +
increased O +
linearly O +
with O +
increasing O +
force O +
output O +
in O +
contralateral O +
primary O +
motor O +
cortex O +
, O +
supplementary O +
motor O +
area O +
and O +
ipsilateral O +
cerebellum O +
. O +

In O +
contrast O +
, O +
in O +
patients O +
with O +
greater O +
corticospinal O +
system O +
damage O +
, O +
force O +
- O +
related O +
signal O +
changes O +
were O +
seen O +
mainly O +
in O +
contralesional O +
dorsolateral O +
premotor O +
cortex O +
, O +
bilateral O +
ventrolateral O +
premotor O +
cortices O +
and O +
contralesional O +
cerebellum O +
, O +
but O +
not O +
ipsilesional O +
primary O +
motor O +
cortex O +
. O +

These O +
findings O +
suggest O +
that O +
the O +
premotor O +
cortices O +
might O +
play O +
a O +
new O +
and O +
functionally O +
relevant O +
role O +
in O +
controlling O +
force O +
production O +
in O +
patients O +
with O +
more O +
severe O +
corticospinal O +
system O +
disruption O +
. O +

Antimicrobial O +
prophylaxis O +
in O +
vaginal O +
gynecologic O +
surgery O +
: O +
a O +
prospective O +
randomized O +
study O +
comparing O +
amoxicillin O +
- O +
clavulanic O +
acid O +
with O +
cefazolin O +
. O +

The O +
aim O +
of O +
this O +
prospective O +
, O +
randomized O +
study O +
was O +
to O +
compare O +
amoxicillin O +
- O +
clavulanic O +
acid O +
with O +
cefazolin O +
as O +
ultra O +
- O +
short O +
term O +
prophylaxis O +
in O +
vaginal O +
gynecologic O +
surgery O +
. O +

It O +
was O +
conducted O +
at O +
the O +
Department O +
of O +
Obstetrics O +
and O +
Gynecology O +
, O +
University O +
of O +
Bari O +
. O +

Patients O +
were O +
randomly O +
allocated O +
to O +
receive O +
amoxicillin O +
- O +
clavulanic O +
acid O +
( O +
2 O +
. O +
2 O +
g O +
) O +
[ O +
Group O +
A O +
] O +
or O +
cefazolin O +
( O +
2 O +
g O +
) O +
[ O +
Group O +
B O +
] O +
as O +
a O +
single O +
dose O +
30 O +
minutes O +
before O +
surgery O +
. O +

Each O +
patient O +
was O +
assessed O +
daily O +
until O +
discharge O +
to O +
evidence O +
febrile O +
status O +
and O +
the O +
presence O +
of O +
infections O +
at O +
the O +
operative O +
site O +
, O +
urinary O +
tract O +
and O +
respiratory O +
tract O +
. O +

In O +
the O +
amoxicillin O +
- O +
clavulanic O +
acid O +
( O +
Group O +
A O +
) O +
and O +
cefazolin O +
( O +
Group O +
B O +
) O +
groups O +
, O +
overall O +
88 O +
and O +
90 O +
patients O +
, O +
respectively O +
, O +
were O +
evaluable O +
for O +
prophylactic O +
efficacy O +
at O +
hospital O +
discharge O +
. O +

Infectious O +
complications O +
were O +
infrequent O +
in O +
both O +
arms O +
, O +
with O +
febrile O +
morbidity O +
occurring O +
in O +
4 O +
( O +
4 O +
. O +
5 O +
% O +
) O +
and O +
16 O +
( O +
8 O +
. O +
9 O +
% O +
) O +
patients O +
respectively O +
in O +
the O +
amoxicillin O +
- O +
clavulanic O +
acid O +
and O +
cefazolin O +
groups O +
( O +
p O +
= O +
0 O +
. O +
016 O +
) O +
. O +

Urinary O +
tract O +
infections O +
were O +
higher O +
but O +
not O +
significantly O +
in O +
the O +
amoxicillin O +
- O +
clavulanic O +
acid O +
group O +
( O +
6 O +
. O +
8 O +
% O +
versus O +
4 O +
. O +
4 O +
% O +
) O +
, O +
whereas O +
asymptomatic O +
bacteriuria O +
was O +
detected O +
in O +
2 O +
. O +
2 O +
% O +
of O +
the O +
patients O +
in O +
both O +
groups O +
. O +

There O +
was O +
no O +
respiratory O +
tract O +
infection O +
or O +
septic O +
death O +
in O +
either O +
group O +
. O +

It O +
is O +
concluded O +
that O +
ultra O +
- O +
short O +
term O +
prophylaxis O +
with O +
both O +
amoxicillin O +
- O +
clavulanic O +
acid O +
and O +
cefazolin O +
is O +
safe O +
and O +
effective O +
in O +
elective O +
vaginal O +
gynecologic O +
surgery O +
. O +

Pathological O +
animal O +
models O +
in O +
the O +
experimental O +
evaluation O +
of O +
tumour O +
microvasculature O +
with O +
magnetic O +
resonance O +
imaging O +
. O +

PURPOSE O +
: O +
The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
the O +
applications O +
of O +
magnetic O +
resonance O +
imaging O +
( O +
MRI O +
) O +
, O +
and O +
in O +
particular O +
, O +
dynamic O +
contrast O +
- O +
enhanced O +
MRI O +
( O +
DCE O +
- O +
MRI O +
) O +
, O +
in O +
the O +
assessment O +
of O +
tumour O +
microvasculature O +
by O +
means O +
of O +
animal O +
tumour O +
models O +
evaluated O +
before O +
and O +
after O +
antiangiogenic O +
treatment O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +
Forty O +
- O +
two O +
MRI O +
exams O +
were O +
performed O +
with O +
intravascular O +
contrast O +
media O +
in O +
21 O +
rats O +
: O +
tumours O +
were O +
induced O +
by O +
subcutaneous O +
injection O +
of O +
colon O +
carcinoma O +
cells O +
in O +
7 O +
rats O +
and O +
mammary O +
adenocarcinoma O +
cells O +
in O +
14 O +
rats O +
. O +

Perfusion O +
and O +
permeability O +
parameters O +
of O +
the O +
implanted O +
tumours O +
were O +
evaluated O +
by O +
using O +
two O +
contrast O +
media O +
( O +
B22956 O +
/ O +
1 O +
and O +
Gd O +
- O +
DTPA37 O +
- O +
albumin O +
) O +
to O +
establish O +
response O +
to O +
treatment O +
with O +
two O +
different O +
antiangiogenic O +
drugs O +
( O +
tamoxifen O +
and O +
SU6668 O +
) O +
. O +

These O +
parameters O +
were O +
correlated O +
with O +
histology O +
to O +
obtain O +
a O +
radiological O +
- O +
histological O +
map O +
of O +
tumour O +
microvasculature O +
. O +

RESULTS O +
: O +
DCE O +
- O +
MRI O +
revealed O +
greater O +
enhancement O +
in O +
the O +
peripheral O +
area O +
than O +
in O +
the O +
central O +
area O +
in O +
all O +
the O +
examined O +
animal O +
models O +
. O +

In O +
the O +
mammary O +
carcinoma O +
experiment O +
, O +
vascular O +
permeability O +
measured O +
by O +
means O +
of O +
B22956 O +
/ O +
1 O +
in O +
the O +
animals O +
treated O +
with O +
the O +
antiangiogenic O +
drug O +
( O +
0 O +
. O +
0043317 O +
+ O +
/ O +
- O +
0 O +
. O +
0040418 O +
ml O +
/ O +
min O +
( O +
- O +
1 O +
) O +
/ O +
ml O +
( O +
- O +
1 O +
) O +
) O +
was O +
significantly O +
less O +
than O +
in O +
untreated O +
animals O +
( O +
0 O +
. O +
0090460 O +
+ O +
/ O +
- O +
0 O +
. O +
0043680 O +
ml O +
/ O +
min O +
( O +
- O +
1 O +
) O +
/ O +
ml O +
( O +
- O +
1 O +
) O +
) O +
, O +
whereas O +
no O +
significant O +
difference O +
was O +
observed O +
with O +
Gd O +
- O +
DTPA O +
- O +
albumin O +
( O +
13 O +
. O +
14 O +
+ O +
/ O +
- O +
13 O +
. O +
94 O +
ml O +
/ O +
min O +
( O +
- O +
1 O +
) O +
/ O +
ml O +
( O +
- O +
1 O +
) O +
in O +
treated O +
animals O +
and O +
18 O +
. O +
07 O +
+ O +
/ O +
- O +
11 O +
. O +
92 O +
ml O +
/ O +
min O +
( O +
- O +
1 O +
) O +
/ O +
ml O +
( O +
- O +
1 O +
) O +
in O +
untreated O +
animals O +
) O +
. O +

In O +
the O +
colon O +
carcinoma O +
experiment O +
, O +
mean O +
permeability O +
and O +
perfusion O +
decreased O +
by O +
51 O +
% O +
( O +
from O +
5 O +
. O +
2 O +
+ O +
/ O +
- O +
1 O +
. O +
1 O +
to O +
2 O +
. O +
5 O +
+ O +
/ O +
- O +
0 O +
. O +
8 O +
ml O +
/ O +
100 O +
ml O +
) O +
and O +
59 O +
% O +
( O +
from O +
0 O +
. O +
00165 O +
+ O +
/ O +
- O +
5 O +
. O +
1 O +
to O +
0 O +
. O +
0067 O +
+ O +
/ O +
- O +
4 O +
. O +
8 O +
ml O +
/ O +
min O +
( O +
- O +
1 O +
) O +
/ O +
ml O +
( O +
- O +
1 O +
) O +
of O +
tissue O +
) O +
, O +
respectively O +
, O +
in O +
all O +
animals O +
after O +
antiangiogenic O +
drug O +
administration O +
. O +

CONCLUSIONS O +
: O +
DCE O +
- O +
MRI O +
permits O +
a O +
noninvasive O +
evaluation O +
of O +
tumour O +
microcirculation O +
and O +
in O +
particular O +
of O +
its O +
dynamic O +
characteristics O +
and O +
vascularity O +
before O +
and O +
after O +
antiangiogenic O +
treatment O +
. O +

An O +
antibody O +
directed O +
against O +
PDGF O +
receptor O +
beta O +
enhances O +
the O +
antitumor O +
and O +
the O +
anti O +
- O +
angiogenic O +
activities O +
of O +
an O +
anti O +
- O +
VEGF O +
receptor O +
2 O +
antibody O +
. O +

Platelet O +
- O +
derived O +
growth O +
factor O +
( O +
PDGF O +
) O +
and O +
its O +
receptors O +
( O +
PDGFR O +
) O +
play O +
important O +
roles O +
in O +
tumorigenesis O +
through O +
stimulating O +
tumor O +
growth O +
and O +
promoting O +
angiogenesis O +
via O +
enhancing O +
pericyte O +
recruitment O +
and O +
vessel O +
maturation O +
. O +

Here O +
we O +
produced O +
a O +
neutralizing O +
antibody O +
, O +
1B3 O +
, O +
directed O +
against O +
mouse O +
PDGFRbeta O +
. O +

1B3 O +
binds O +
to O +
PDGFRbeta O +
with O +
high O +
affinity O +
( O +
9x10 O +
( O +
- O +
11 O +
) O +
M O +
) O +
and O +
blocks O +
PDGF O +
- O +
BB O +
from O +
binding O +
to O +
the O +
receptor O +
with O +
an O +
IC O +
( O +
50 O +
) O +
of O +
approximately O +
1 O +
. O +
2 O +
nM O +
. O +

The O +
antibody O +
also O +
blocks O +
ligand O +
- O +
stimulated O +
activation O +
of O +
PDGFRbeta O +
and O +
downstream O +
signaling O +
molecules O +
, O +
including O +
Akt O +
and O +
MAPK O +
p42 O +
/ O +
44 O +
, O +
in O +
tumor O +
cells O +
. O +

In O +
animal O +
studies O +
, O +
1B3 O +
significantly O +
enhanced O +
the O +
antitumor O +
and O +
the O +
anti O +
- O +
angiogenic O +
activities O +
of O +
DC101 O +
, O +
an O +
antibody O +
directed O +
against O +
mouse O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
2 O +
, O +
in O +
a O +
pancreatic O +
( O +
BxPC B-CellLine +
- I-CellLine +
3 I-CellLine +
) O +
and O +
a O +
non O +
- O +
small O +
cell O +
lung O +
( O +
NCI B-CellLine +
- I-CellLine +
H460 I-CellLine +
) O +
tumor O +
xenograft O +
models O +
. O +

Treatment O +
with O +
the O +
combination O +
of O +
1B3 O +
and O +
DC101 O +
in O +
BxPC B-CellLine +
- I-CellLine +
3 I-CellLine +
xenograft O +
- O +
bearing O +
mice O +
resulted O +
in O +
tumor O +
regression O +
in O +
58 O +
% O +
of O +
mice O +
compared O +
to O +
that O +
in O +
18 O +
% O +
of O +
mice O +
treated O +
with O +
DC101 O +
alone O +
. O +

Taken O +
together O +
, O +
these O +
results O +
lend O +
great O +
support O +
to O +
use O +
PDGFRbeta O +
antagonists O +
in O +
combinations O +
with O +
other O +
antitumor O +
and O +
/ O +
or O +
anti O +
- O +
angiogenic O +
agents O +
in O +
the O +
treatment O +
of O +
a O +
variety O +
of O +
cancers O +
. O +

[ O +
Synthetic O +
fragments O +
of O +
the O +
NS1 O +
protein O +
of O +
the O +
tick O +
- O +
borne O +
encephalitis O +
virus O +
exhibiting O +
a O +
protective O +
effect O +
] O +
. O +

Potentially O +
immunoactive O +
regions O +
of O +
the O +
NS1 O +
nonstructural O +
protein O +
of O +
the O +
tick O +
- O +
borne O +
encephalitis O +
virus O +
that O +
can O +
stimulate O +
the O +
antibody O +
formation O +
in O +
vivo O +
and O +
protect O +
animals O +
from O +
this O +
disease O +
were O +
chosen O +
on O +
the O +
basis O +
of O +
theoretical O +
calculations O +
. O +

Eleven O +
16 O +
- O +
to O +
27 O +
- O +
aa O +
peptides O +
containing O +
the O +
chosen O +
regions O +
were O +
synthesized O +
. O +

The O +
ability O +
of O +
the O +
free O +
peptides O +
( O +
without O +
any O +
high O +
- O +
molecular O +
- O +
mass O +
carrier O +
) O +
to O +
stimulate O +
the O +
production O +
of O +
antipeptide O +
antibodies O +
in O +
mice O +
of O +
three O +
lines O +
and O +
ensure O +
the O +
formation O +
of O +
protective O +
immunity O +
was O +
studied O +
. O +

Most O +
of O +
these O +
peptides O +
were O +
shown O +
to O +
exhibit O +
the O +
immunogenic O +
activity O +
in O +
a O +
free O +
state O +
. O +

Five O +
fragments O +
that O +
can O +
protect O +
mice O +
from O +
the O +
infection O +
by O +
a O +
lethal O +
dose O +
of O +
tick O +
- O +
borne O +
encephalitis O +
virus O +
were O +
found O +
. O +

In O +
vivo O +
p53 O +
response O +
and O +
immune O +
reaction O +
underlie O +
highly O +
effective O +
low O +
- O +
dose O +
radiotherapy O +
in O +
follicular O +
lymphoma O +
. O +

Very O +
low O +
- O +
dose O +
irradiation O +
( O +
2 O +
x O +
2 O +
Gy O +
) O +
is O +
a O +
new O +
, O +
effective O +
, O +
and O +
safe O +
local O +
treatment O +
for O +
follicular O +
lymphoma O +
. O +

To O +
understand O +
the O +
biologic O +
mechanisms O +
of O +
this O +
extremely O +
effective O +
response O +
, O +
we O +
compared O +
by O +
microarray O +
the O +
gene O +
- O +
expression O +
profile O +
of O +
patients O +
' O +
biopsies O +
taken O +
before O +
and O +
after O +
radiation O +
. O +

In O +
all O +
patients O +
, O +
a O +
major O +
and O +
consistent O +
induction O +
of O +
p53 O +
target O +
genes O +
was O +
seen O +
. O +

p53 O +
targets O +
involved O +
in O +
cell O +
- O +
cycle O +
arrest O +
and O +
apoptosis O +
showed O +
the O +
same O +
mode O +
of O +
regulation O +
, O +
indicating O +
that O +
, O +
in O +
vivo O +
, O +
both O +
are O +
activated O +
simultaneously O +
. O +

p53 O +
up O +
- O +
regulation O +
and O +
p53 O +
- O +
mediated O +
proliferation O +
arrest O +
and O +
apoptosis O +
were O +
substantiated O +
using O +
immunohistochemistry O +
, O +
with O +
activation O +
of O +
both O +
the O +
intrinsic O +
and O +
the O +
extrinsic O +
apoptotic O +
pathways O +
. O +

The O +
other O +
induced O +
genes O +
revealed O +
a O +
whole O +
set O +
of O +
biologically O +
meaningful O +
genes O +
related O +
to O +
macrophage O +
activation O +
and O +
TH1 O +
immune O +
response O +
. O +

Immunohistochemical O +
analysis O +
suggested O +
a O +
specific O +
activation O +
or O +
differentiation O +
of O +
resident O +
macrophages O +
by O +
apoptotic O +
cells O +
. O +

These O +
biologic O +
insights O +
are O +
important O +
arguments O +
to O +
advocate O +
the O +
use O +
of O +
low O +
- O +
dose O +
radiotherapy O +
as O +
an O +
effective O +
palliative O +
treatment O +
for O +
follicular O +
lymphoma O +
. O +

Moreover O +
, O +
this O +
study O +
is O +
the O +
first O +
in O +
vivo O +
report O +
of O +
the O +
radiation O +
- O +
induced O +
p53 O +
apoptotic O +
response O +
in O +
patients O +
and O +
suggests O +
that O +
this O +
apoptotic O +
response O +
is O +
not O +
immunologically O +
silent O +
. O +

Caffeine O +
inhibits O +
adenosine O +
- O +
induced O +
accumulation O +
of O +
hypoxia O +
- O +
inducible O +
factor O +
- O +
1alpha O +
, O +
vascular O +
endothelial O +
growth O +
factor O +
, O +
and O +
interleukin O +
- O +
8 O +
expression O +
in O +
hypoxic O +
human O +
colon O +
cancer O +
cells O +
. O +

Frequent O +
coffee O +
consumption O +
has O +
been O +
associated O +
with O +
a O +
reduced O +
risk O +
of O +
colorectal O +
cancer O +
in O +
a O +
number O +
of O +
case O +
- O +
control O +
studies O +
. O +

Coffee O +
is O +
a O +
leading O +
source O +
of O +
methylxanthines O +
, O +
such O +
as O +
caffeine O +
. O +

The O +
induction O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
and O +
interleukin O +
- O +
8 O +
( O +
IL O +
- O +
8 O +
) O +
is O +
an O +
essential O +
feature O +
of O +
tumor O +
angiogenesis O +
, O +
and O +
the O +
hypoxia O +
- O +
inducible O +
factor O +
- O +
1 O +
( O +
HIF O +
- O +
1 O +
) O +
transcription O +
factor O +
is O +
known O +
to O +
be O +
a O +
key O +
regulator O +
of O +
this O +
process O +
. O +

In O +
this O +
study O +
, O +
we O +
investigated O +
the O +
effects O +
of O +
caffeine O +
on O +
HIF O +
- O +
1 O +
protein O +
accumulation O +
and O +
on O +
VEGF O +
and O +
IL O +
- O +
8 O +
expression O +
in O +
the O +
human O +
colon O +
cancer O +
cell O +
line O +
HT29 B-CellLine +
under O +
hypoxic O +
conditions O +
. O +

Our O +
results O +
show O +
that O +
caffeine O +
significantly O +
inhibits O +
adenosine O +
- O +
induced O +
HIF O +
- O +
1alpha O +
protein O +
accumulation O +
in O +
cancer O +
cells O +
. O +

We O +
show O +
that O +
HIF O +
- O +
1alpha O +
and O +
VEGF O +
are O +
increased O +
through O +
A3 O +
adenosine O +
receptor O +
stimulation O +
, O +
whereas O +
the O +
effects O +
on O +
IL O +
- O +
8 O +
are O +
mediated O +
via O +
the O +
A2B O +
subtype O +
. O +

Pretreatment O +
of O +
cells O +
with O +
caffeine O +
significantly O +
reduces O +
adenosine O +
- O +
induced O +
VEGF O +
promoter O +
activity O +
and O +
VEGF O +
and O +
IL O +
- O +
8 O +
expression O +
. O +

The O +
mechanism O +
of O +
caffeine O +
seems O +
to O +
involve O +
the O +
inhibition O +
of O +
the O +
extracellular O +
signal O +
- O +
regulated O +
kinase O +
1 O +
/ O +
2 O +
( O +
ERK1 O +
/ O +
2 O +
) O +
, O +
p38 O +
, O +
and O +
Akt O +
, O +
leading O +
to O +
a O +
marked O +
decrease O +
in O +
adenosine O +
- O +
induced O +
HIF O +
- O +
1alpha O +
accumulation O +
, O +
VEGF O +
transcriptional O +
activation O +
, O +
and O +
VEGF O +
and O +
IL O +
- O +
8 O +
protein O +
accumulation O +
. O +

From O +
a O +
functional O +
perspective O +
, O +
we O +
observe O +
that O +
caffeine O +
also O +
significantly O +
inhibits O +
the O +
A3 O +
receptor O +
- O +
stimulated O +
cell O +
migration O +
of O +
colon O +
cancer O +
cells O +
. O +

Conditioned O +
media O +
prepared O +
from O +
colon O +
cells O +
treated O +
with O +
an O +
adenosine O +
analog O +
increased O +
human O +
umbilical O +
vein O +
endothelial O +
cell O +
migration O +
. O +

These O +
data O +
provide O +
evidence O +
that O +
adenosine O +
could O +
modulate O +
the O +
migration O +
of O +
colon O +
cancer O +
cells O +
by O +
an O +
HIF O +
- O +
1alpha O +
/ O +
VEGF O +
/ O +
IL O +
- O +
8 O +
- O +
dependent O +
mechanism O +
and O +
that O +
caffeine O +
has O +
the O +
potential O +
to O +
inhibit O +
colon O +
cancer O +
cell O +
growth O +
. O +

Angiogenesis O +
in O +
the O +
caprine O +
caruncles O +
in O +
non O +
- O +
pregnant O +
and O +
pregnant O +
normal O +
and O +
swainsonine O +
- O +
treated O +
does O +
. O +

Microvascular O +
corrosion O +
casts O +
of O +
caruncles O +
from O +
non O +
- O +
pregnant O +
and O +
pregnant O +
doe O +
goats O +
at O +
4 O +
, O +
7 O +
, O +
10 O +
, O +
13 O +
, O +
16 O +
, O +
and O +
18 O +
weeks O +
were O +
examined O +
with O +
scanning O +
electron O +
microscopy O +
. O +

The O +
internal O +
convex O +
surface O +
of O +
the O +
caruncles O +
of O +
non O +
- O +
pregnant O +
does O +
was O +
covered O +
with O +
capillary O +
meshes O +
of O +
regular O +
diameter O +
and O +
form O +
, O +
without O +
crypts O +
. O +

As O +
pregnancy O +
advanced O +
the O +
complexity O +
of O +
the O +
vasculature O +
increased O +
: O +
at O +
4 O +
weeks O +
the O +
surface O +
showed O +
a O +
pattern O +
of O +
ridges O +
separated O +
by O +
troughs O +
. O +

At O +
later O +
stages O +
, O +
branches O +
of O +
radial O +
arteries O +
penetrated O +
the O +
periphery O +
forming O +
an O +
extensive O +
mesh O +
of O +
capillaries O +
on O +
the O +
concave O +
surface O +
. O +

Capillary O +
diameters O +
increased O +
significantly O +
during O +
pregnancy O +
, O +
especially O +
after O +
4 O +
weeks O +
, O +
when O +
large O +
flattened O +
sinusoids O +
formed O +
. O +

These O +
sinusoids O +
had O +
a O +
great O +
deal O +
of O +
surface O +
area O +
for O +
potential O +
contact O +
with O +
the O +
fetal O +
component O +
. O +

The O +
caprine O +
placenta O +
is O +
usually O +
considered O +
to O +
have O +
increased O +
interhemal O +
distance O +
compared O +
with O +
endotheliochorial O +
and O +
hemochorial O +
types O +
: O +
our O +
results O +
suggest O +
that O +
the O +
very O +
extensive O +
development O +
of O +
sinusoids O +
and O +
crypts O +
may O +
compensate O +
for O +
any O +
negative O +
consequences O +
of O +
the O +
placental O +
architecture O +
. O +

Placental O +
angiogenesis O +
, O +
which O +
is O +
physiologically O +
normal O +
, O +
may O +
serve O +
as O +
a O +
general O +
model O +
of O +
this O +
process O +
in O +
other O +
circumstances O +
, O +
such O +
as O +
tumor O +
. O +

The O +
effect O +
of O +
swainsonine O +
( O +
active O +
compound O +
of O +
locoweed O +
and O +
a O +
potential O +
anticancer O +
drug O +
) O +
on O +
vascular O +
development O +
showed O +
no O +
differences O +
in O +
sinusoidal O +
diameters O +
at O +
7 O +
weeks O +
, O +
but O +
a O +
decrease O +
in O +
capillary O +
density O +
was O +
noted O +
. O +

Swainsonine O +
caused O +
a O +
great O +
distortion O +
to O +
the O +
vasculature O +
at O +
18 O +
weeks O +
. O +

The O +
effects O +
of O +
this O +
compound O +
on O +
the O +
vascular O +
development O +
lend O +
credibility O +
to O +
its O +
potential O +
as O +
an O +
anticancer O +
agent O +
. O +

Stress O +
and O +
psychological O +
distress O +
among O +
SARS O +
survivors O +
1 O +
year O +
after O +
the O +
outbreak O +
. O +

OBJECTIVE O +
: O +

Our O +
study O +
examined O +
the O +
stress O +
level O +
and O +
psychological O +
distress O +
of O +
severe O +
acute O +
respiratory O +
syndrome O +
( O +
SARS O +
) O +
survivors O +
1 O +
year O +
after O +
the O +
outbreak O +
. O +

METHOD O +
: O +

During O +
the O +
SARS O +
outbreak O +
in O +
2003 O +
, O +
we O +
used O +
the O +
10 O +
- O +
item O +
Perceived O +
Stress O +
Scale O +
( O +
PSS O +
- O +
10 O +
) O +
to O +
assess O +
SARS O +
survivors O +
treated O +
in O +
2 O +
major O +
hospitals O +
( O +
non O +
- O +
health O +
care O +
workers O +
, O +
n O +
= O +
49 O +
; O +
health O +
care O +
workers O +
, O +
n O +
= O +
30 O +
) O +
. O +

We O +
invited O +
SARS O +
survivors O +
from O +
the O +
same O +
hospitals O +
( O +
non O +
- O +
health O +
care O +
workers O +
, O +
n O +
= O +
63 O +
; O +
health O +
care O +
workers O +
, O +
n O +
= O +
33 O +
) O +
to O +
complete O +
the O +
PSS O +
- O +
10 O +
again O +
in O +
2004 O +
. O +

At O +
that O +
time O +
, O +
they O +
were O +
also O +
asked O +
to O +
complete O +
the O +
General O +
Health O +
Questionnaire O +
( O +
GHQ O +
- O +
12 O +
) O +
and O +
measures O +
of O +
depression O +
, O +
anxiety O +
, O +
and O +
posttraumatic O +
symptoms O +
. O +

PSS O +
- O +
10 O +
scores O +
were O +
also O +
obtained O +
from O +
matched O +
community O +
control O +
subjects O +
during O +
the O +
outbreak O +
( O +
n O +
= O +
145 O +
) O +
and O +
again O +
in O +
2004 O +
( O +
n O +
= O +
112 O +
) O +
. O +

RESULTS O +
: O +

SARS O +
survivors O +
had O +
higher O +
stress O +
levels O +
during O +
the O +
outbreak O +
, O +
compared O +
with O +
control O +
subjects O +
( O +
PSS O +
- O +
10 O +
scores O +
= O +
19 O +
. O +
8 O +
and O +
17 O +
. O +
9 O +
, O +
respectively O +
; O +
P O +
< O +
0 O +
. O +
01 O +
) O +
, O +
and O +
this O +
persisted O +
1 O +
year O +
later O +
( O +
PSS O +
- O +
10 O +
scores O +
= O +
19 O +
. O +
9 O +
and O +
17 O +
. O +
3 O +
, O +
respectively O +
; O +
P O +
< O +
0 O +
. O +
01 O +
) O +
without O +
signs O +
of O +
decrease O +
. O +

In O +
2004 O +
, O +
SARS O +
survivors O +
also O +
showed O +
worrying O +
levels O +
of O +
depression O +
, O +
anxiety O +
, O +
and O +
posttraumatic O +
symptoms O +
. O +

An O +
alarming O +
proportion O +
( O +
64 O +
% O +
) O +
scored O +
above O +
the O +
GHQ O +
- O +
12 O +
cut O +
- O +
off O +
that O +
suggests O +
psychiatric O +
morbidity O +
. O +

During O +
the O +
outbreak O +
, O +
health O +
care O +
worker O +
SARS O +
survivors O +
had O +
stress O +
levels O +
similar O +
to O +
those O +
of O +
non O +
- O +
health O +
care O +
workers O +
, O +
but O +
health O +
care O +
workers O +
showed O +
significantly O +
higher O +
stress O +
levels O +
in O +
2004 O +
( O +
PSS O +
- O +
10 O +
score O +
= O +
22 O +
. O +
8 O +
, O +
compared O +
with O +
PSS O +
- O +
10 O +
score O +
= O +
18 O +
. O +
4 O +
; O +
P O +
< O +
0 O +
. O +
05 O +
) O +
and O +
had O +
higher O +
depression O +
, O +
anxiety O +
, O +
posttraumatic O +
symptoms O +
, O +
and O +
GHQ O +
- O +
12 O +
scores O +
. O +

CONCLUSIONS O +
: O +

One O +
year O +
after O +
the O +
outbreak O +
, O +
SARS O +
survivors O +
still O +
had O +
elevated O +
stress O +
levels O +
and O +
worrying O +
levels O +
of O +
psychological O +
distress O +
. O +

The O +
situation O +
of O +
health O +
care O +
worker O +
SARS O +
survivors O +
is O +
particularly O +
worrying O +
. O +

The O +
long O +
- O +
term O +
psychological O +
implications O +
of O +
infectious O +
diseases O +
should O +
not O +
be O +
ignored O +
. O +

Mental O +
health O +
services O +
could O +
play O +
an O +
important O +
role O +
in O +
rehabilitation O +
. O +

High O +
- O +
grade O +
clear O +
cell O +
renal O +
cell O +
carcinoma O +
has O +
a O +
higher O +
angiogenic O +
activity O +
than O +
low O +
- O +
grade O +
renal O +
cell O +
carcinoma O +
based O +
on O +
histomorphological O +
quantification O +
and O +
qRT O +
- O +
PCR O +
mRNA O +
expression O +
profile O +
. O +

Clear O +
cell O +
renal O +
cell O +
carcinoma O +
( O +
CC O +
- O +
RCC O +
) O +
is O +
a O +
highly O +
vascularised O +
tumour O +
and O +
is O +
therefore O +
an O +
attractive O +
disease O +
to O +
study O +
angiogenesis O +
and O +
to O +
test O +
novel O +
angiogenesis O +
inhibitors O +
in O +
early O +
clinical O +
development O +
. O +

Endothelial O +
cell O +
proliferation O +
plays O +
a O +
pivotal O +
role O +
in O +
the O +
process O +
of O +
angiogenesis O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
compare O +
angiogenesis O +
parameters O +
in O +
low O +
nuclear O +
grade O +
( O +
n O +
= O +
87 O +
) O +
vs O +
high O +
nuclear O +
grade O +
CC O +
- O +
RCC O +
( O +
n O +
= O +
63 O +
) O +
. O +

A O +
panel O +
of O +
antibodies O +
was O +
used O +
for O +
immunohistochemistry O +
: O +
CD34 O +
/ O +
Ki O +
- O +
67 O +
, O +
carbonic O +
anhydrase O +
IX O +
, O +
hypoxia O +
- O +
inducible O +
factor O +
- O +
1alpha O +
( O +
HIF O +
- O +
1alpha O +
) O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
. O +

Vessel O +
density O +
( O +
MVD O +
- O +
microvessel O +
density O +
) O +
, O +
endothelial O +
cell O +
proliferation O +
fraction O +
( O +
ECP O +
% O +
) O +
and O +
tumour O +
cell O +
proliferation O +
fraction O +
( O +
TCP O +
% O +
) O +
were O +
assessed O +
. O +

mRNA O +
expression O +
levels O +
of O +
angiogenesis O +
stimulators O +
and O +
inhibitors O +
were O +
determined O +
by O +
quantitative O +
RT O +
- O +
PCR O +
. O +

High O +
- O +
grade O +
CC O +
- O +
RCC O +
showed O +
a O +
higher O +
ECP O +
% O +
( O +
P O +
= O +
0 O +
. O +
049 O +
) O +
, O +
a O +
higher O +
TCP O +
% O +
( O +
P O +
= O +
0 O +
. O +
009 O +
) O +
, O +
a O +
higher O +
VEGF O +
protein O +
expression O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
, O +
a O +
lower O +
MVD O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
and O +
a O +
lower O +
HIF O +
- O +
1alpha O +
protein O +
expression O +
( O +
P O +
= O +
0 O +
. O +
002 O +
) O +
than O +
low O +
- O +
grade O +
CC O +
- O +
RCC O +
. O +

Growth O +
factor O +
mRNA O +
expression O +
analyses O +
revealed O +
a O +
higher O +
expression O +
of O +
angiopoietin O +
2 O +
in O +
low O +
- O +
grade O +
CC O +
- O +
RCC O +
. O +

Microvessel O +
density O +
and O +
ECP O +
% O +
were O +
inversely O +
correlated O +
( O +
Rho O +
= O +
- O +
0 O +
. O +
26 O +
, O +
P O +
= O +
0 O +
. O +
001 O +
) O +
. O +

Because O +
of O +
the O +
imperfect O +
association O +
of O +
nuclear O +
grade O +
and O +
ECP O +
% O +
or O +
MVD O +
, O +
CC O +
- O +
RCC O +
was O +
also O +
grouped O +
based O +
on O +
low O +
/ O +
high O +
MVD O +
and O +
ECP O +
% O +
. O +

This O +
analysis O +
revealed O +
a O +
higher O +
expression O +
of O +
vessel O +
maturation O +
and O +
stabilisation O +
factors O +
( O +
placental O +
growth O +
factor O +
, O +
PDGFB1 O +
, O +
angiopoietin O +
1 O +
) O +
in O +
CC O +
- O +
RCC O +
with O +
high O +
MVD O +
, O +
a O +
group O +
of O +
CC O +
- O +
RCC O +
highly O +
enriched O +
in O +
low O +
nuclear O +
grade O +
CC O +
- O +
RCC O +
, O +
with O +
low O +
ECP O +
% O +
. O +

Our O +
results O +
suggest O +
heterogeneity O +
in O +
angiogenic O +
activity O +
and O +
vessel O +
maturation O +
of O +
CC O +
- O +
RCC O +
, O +
to O +
a O +
large O +
extent O +
linked O +
to O +
nuclear O +
grade O +
, O +
and O +
, O +
with O +
probable O +
therapeutic O +
implications O +
. O +

Characterization O +
of O +
transferrin O +
glycoforms O +
in O +
human O +
serum O +
by O +
CE O +
- O +
UV O +
and O +
CE O +
- O +
ESI O +
- O +
MS O +
. O +

Human O +
transferrin O +
( O +
Tf O +
) O +
is O +
a O +
model O +
glycoprotein O +
for O +
congenital O +
disorders O +
of O +
glycosylation O +
( O +
CDG O +
) O +
diagnosis O +
. O +

In O +
the O +
last O +
few O +
years O +
, O +
new O +
CE O +
- O +
UV O +
methods O +
for O +
intact O +
Tf O +
glycoforms O +
analysis O +
have O +
been O +
developed O +
using O +
nonvolatile O +
BGEs O +
and O +
organic O +
modifiers O +
. O +

However O +
, O +
the O +
use O +
of O +
these O +
BGEs O +
does O +
not O +
allow O +
the O +
coupling O +
of O +
these O +
procedures O +
with O +
electrospray O +
MS O +
( O +
ESI O +
- O +
MS O +
) O +
. O +

In O +
this O +
study O +
, O +
a O +
new O +
CE O +
- O +
UV O +
separation O +
method O +
of O +
Tf O +
glycoforms O +
is O +
developed O +
, O +
using O +
a O +
double O +
- O +
layer O +
stable O +
coating O +
and O +
a O +
volatile O +
BGE O +
based O +
on O +
ammonium O +
acetate O +
. O +

The O +
separation O +
method O +
is O +
optimized O +
using O +
standard O +
Tf O +
and O +
their O +
potential O +
is O +
demonstrated O +
applying O +
the O +
method O +
to O +
the O +
analysis O +
of O +
sera O +
Tf O +
from O +
healthy O +
individuals O +
and O +
CDG O +
patients O +
. O +

The O +
CE O +
- O +
UV O +
separation O +
method O +
has O +
been O +
coupled O +
to O +
ESI O +
- O +
MS O +
detection O +
. O +

Main O +
parameters O +
such O +
as O +
sheath O +
liquid O +
composition O +
are O +
optimized O +
in O +
order O +
to O +
obtain O +
a O +
good O +
sensitivity O +
. O +

The O +
CE O +
- O +
ESI O +
- O +
MS O +
method O +
has O +
also O +
been O +
used O +
in O +
serum O +
samples O +
obtaining O +
the O +
separation O +
of O +
the O +
different O +
proteins O +
present O +
in O +
serum O +
and O +
partial O +
separation O +
of O +
Tf O +
glycoforms O +
. O +

Different O +
mass O +
spectra O +
and O +
deconvoluted O +
molecular O +
masses O +
were O +
obtained O +
for O +
each O +
sialoform O +
, O +
allowing O +
unequivocal O +
glycoform O +
identification O +
. O +

Medical O +
therapy O +
for O +
intermittent O +
claudication O +
. O +

Medical O +
therapy O +
to O +
improve O +
symptoms O +
, O +
stabilise O +
the O +
underlying O +
vascular O +
disease O +
and O +
improve O +
lower O +
limb O +
outcomes O +
is O +
an O +
important O +
and O +
effective O +
adjunct O +
to O +
lifestyle O +
modification O +
and O +
surgical O +
or O +
endovascular O +
interventions O +
in O +
patients O +
with O +
IC O +
. O +

Randomised O +
placebo O +
controlled O +
trials O +
have O +
shown O +
that O +
the O +
phosphodiesterase O +
III O +
inhibitor O +
cilostazol O +
100 O -
mg O +
bid O +
improves O +
pain O +
- O +
free O +
and O +
maximum O +
walking O +
distance O +
, O +
as O +
well O +
as O +
quality O +
of O +
life O +
, O +
in O +
a O +
range O +
of O +
patients O +
with O +
intermittent O +
claudication O +
in O +
whom O +
there O +
is O +
no O +
evidence O +
of O +
tissue O +
necrosis O +
or O +
rest O +
pain O +
. O +

This O +
review O +
summarises O +
the O +
evidence O +
from O +
8 O +
pivotal O +
trials O +
of O +
cilostazol O +
involving O +
over O +
2000 O +
patients O +
with O +
intermittent O +
claudication O +
treated O +
for O +
up O +
to O +
6 O +
months O +
. O +

There O +
is O +
comparatively O +
less O +
evidence O +
to O +
support O +
the O +
use O +
of O +
other O +
treatment O +
modalities O +
for O +
relief O +
of O +
symptoms O +
in O +
intermittent O +
claudication O +
, O +
but O +
there O +
is O +
considerable O +
interest O +
in O +
therapeutic O +
angiogenesis O +
to O +
promote O +
new O +
vessel O +
formation O +
and O +
enhance O +
collateralisation O +
of O +
the O +
lower O +
limb O +
using O +
recombinant O +
growth O +
factor O +
proteins O +
or O +
gene O +
transfer O +
strategies O +
. O +

The O +
rationale O +
for O +
therapeutic O +
angiogenesis O +
is O +
discussed O +
, O +
together O +
with O +
the O +
most O +
recent O +
results O +
from O +
randomised O +
trials O +
in O +
patients O +
with O +
peripheral O +
arterial O +
disease O +
. O +

Deletion O +
of O +
Tip30 O +
leads O +
to O +
rapid O +
immortalization O +
of O +
murine O +
mammary O +
epithelial O +
cells O +
and O +
ductal O +
hyperplasia O +
in O +
the O +
mammary O +
gland O +
. O +

Transformation O +
of O +
mammary O +
epithelial O +
cells O +
( O +
MECs O +
) O +
from O +
the O +
normal O +
to O +
the O +
neoplastic O +
stage O +
requires O +
the O +
dysregulation O +
of O +
tumor O +
suppressor O +
genes O +
and O +
proto O +
- O +
oncogenes O +
. O +

Tip30 O +
is O +
a O +
tumor O +
suppressor O +
that O +
can O +
inhibit O +
estrogen O +
receptor O +
- O +
mediated O +
transcription O +
in O +
MECs O +
, O +
but O +
its O +
role O +
in O +
MEC O +
proliferation O +
remains O +
unknown O +
. O +

Here O +
, O +
we O +
show O +
that O +
deleting O +
the O +
Tip30 O +
gene O +
leads O +
to O +
ductal O +
hyperplasia O +
in O +
mouse O +
mammary O +
glands O +
early O +
in O +
life O +
and O +
extensive O +
mammary O +
hyperplasia O +
with O +
age O +
. O +

Tip30 O +
( O +
- O +
/ O +
- O +
) O +
mammary O +
glands O +
transplanted O +
into O +
wild O +
- O +
type O +
mammary O +
fat O +
pads O +
also O +
display O +
mammary O +
trees O +
with O +
extensive O +
ductal O +
hyperplasia O +
. O +

Strikingly O +
, O +
Tip30 O +
deletion O +
promotes O +
proliferation O +
of O +
primary O +
MECs O +
and O +
results O +
in O +
rapid O +
immortalization O +
of O +
MECs O +
in O +
vitro O +
relative O +
to O +
wild O +
- O +
type O +
cells O +
. O +

Gene O +
array O +
analysis O +
identified O +
significant O +
increases O +
in O +
the O +
expression O +
of O +
mammary O +
epithelial O +
growth O +
factors O +
Wisp2 O +
and O +
Igf O +
- O +
1 O +
in O +
Tip30 O +
( O +
- O +
/ O +
- O +
) O +
cells O +
. O +

Knockdown O +
of O +
either O +
Wisp2 O +
or O +
Igf O +
- O +
1 O +
using O +
short O +
interfering O +
RNA O +
dramatically O +
inhibited O +
proliferation O +
of O +
Tip30 O +
( O +
- O +
/ O +
- O +
) O +
cells O +
. O +

Together O +
, O +
these O +
results O +
suggest O +
that O +
Tip30 O +
is O +
an O +
intrinsic O +
and O +
negative O +
regulator O +
of O +
MEC O +
proliferation O +
partly O +
through O +
the O +
inhibition O +
of O +
Wisp2 O +
and O +
Igf O +
- O +
1 O +
expression O +
, O +
and O +
its O +
absence O +
in O +
the O +
mammary O +
gland O +
may O +
predispose O +
MECs O +
to O +
neoplastic O +
transformation O +
. O +

Long O +
- O +
term O +
immunosuppression O +
in O +
burned O +
patients O +
assessed O +
by O +
in O +
vitro O +
neutrophil O +
oxidative O +
burst O +
( O +
Phagoburst O +
) O +
. O +

OBJECTIVE O +
: O +

To O +
assess O +
the O +
duration O +
and O +
magnitude O +
of O +
immunosuppression O +
induced O +
by O +
burns O +
as O +
measured O +
by O +
the O +
neutrophil O +
oxidative O +
burst O +
in O +
vitro O +
. O +

DESIGN O +
: O +

Prospective O +
exploratory O +
cohort O +
study O +
. O +

SETTING O +
: O +

Tertiary O +
referral O +
unit O +
, O +
University O +
Hospital O +
, O +
Linkoping O +
, O +
Sweden O +
( O +
National O +
Burn O +
Unit O +
) O +
. O +

PATIENTS O +
AND O +
HEALTHY O +
VOLUNTEERS O +
( O +
CONTROLS O +
) O +
: O +
Twenty O +
- O +
eight O +
subjects O +
consecutively O +
admitted O +
to O +
the O +
Burn O +
Unit O +
. O +

The O +
mean O +
total O +
burn O +
surface O +
area O +
( O +
TBSA O +
% O +
) O +
was O +
36 O +
( O +
range O +
13 O +
- O +
87 O +
) O +
and O +
mean O +
age O +
44 O +
years O +
( O +
range O +
14 O +
- O +
89 O +
) O +
. O +

Patients O +
' O +
data O +
were O +
collected O +
prospectively O +
in O +
the O +
burn O +
unit O +
, O +
which O +
also O +
included O +
sequential O +
organ O +
failure O +
assessment O +
( O +
SOFA O +
) O +
score O +
. O +

INTERVENTIONS O +
: O +

None O +
. O +

MEASUREMENTS O +
AND O +
RESULTS O +
: O +

To O +
assess O +
the O +
changes O +
in O +
the O +
oxidative O +
capacity O +
of O +
neutrophils O +
after O +
the O +
burn O +
, O +
blood O +
samples O +
for O +
the O +
Phagoburst O +
analysis O +
were O +
taken O +
on O +
admission O +
and O +
at O +
least O +
once O +
every O +
second O +
week O +
for O +
the O +
duration O +
of O +
stay O +
in O +
hospital O +
and O +
thereafter O +
monthly O +
up O +
to O +
12 O +
months O +
after O +
the O +
burn O +
. O +

Neutrophils O +
were O +
stimulated O +
in O +
vitro O +
by O +
Escherichia O +
coli O +
, O +
phorbol O +
12 O +
- O +
phorbol O +
myristate O +
13 O +
- O +
acetate O +
( O +
PMA O +
) O +
, O +
and O +
peptide O +
N O +
- O +
formyl O +
- O +
Met O +
- O +
Leu O +
- O +
Phe O +
( O +
fMLP O +
) O +
. O +

Oxidative O +
burst O +
was O +
measured O +
by O +
flow O +
cytometry O +
. O +

Oxidative O +
capacity O +
of O +
the O +
neutrophils O +
decreased O +
similarly O +
for O +
all O +
three O +
stimulants O +
: O +
there O +
was O +
a O +
pathological O +
decrease O +
shortly O +
after O +
admission O +
, O +
with O +
the O +
lowest O +
value O +
occurring O +
between O +
days O +
7 O +
and O +
10 O +
, O +
followed O +
by O +
a O +
gradual O +
recovery O +
during O +
the O +
ensuing O +
months O +
. O +

Full O +
recovery O +
( O +
to O +
the O +
values O +
of O +
the O +
controls O +
) O +
was O +
seen O +
first O +
3 O +
. O +
5 O +
months O +
after O +
the O +
burn O +
. O +

Using O +
multiple O +
regression O +
, O +
we O +
found O +
that O +
only O +
age O +
and O +
time O +
since O +
the O +
burn O +
significantly O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
affected O +
the O +
oxidative O +
burst O +
. O +

White O +
cell O +
count O +
( O +
WCC O +
) O +
and O +
C O +
- O +
reactive O +
protein O +
( O +
CRP O +
) O +
values O +
returned O +
to O +
reference O +
ranges O +
long O +
before O +
the O +
oxidative O +
burst O +
. O +

CONCLUSIONS O +
: O +

This O +
study O +
provides O +
evidence O +
that O +
immunosuppression O +
in O +
those O +
injured O +
by O +
burns O +
, O +
as O +
assessed O +
by O +
the O +
in O +
vitro O +
oxidative O +
burst O +
of O +
neutrophils O +
, O +
remains O +
long O +
after O +
the O +
event O +
of O +
the O +
burn O +
( O +
up O +
to O +
3 O +
. O +
5 O +
months O +
after O +
burn O +
) O +
. O +

Absence O +
of O +
correlations O +
to O +
TBSA O +
% O +
, O +
FTB O +
% O +
, O +
blood O +
transfusion O +
, O +
opiates O +
provided O +
, O +
and O +
multiple O +
organ O +
failure O +
score O +
and O +
laboratory O +
infection O +
variables O +
together O +
with O +
the O +
finding O +
that O +
decreased O +
oxidative O +
burst O +
was O +
uniform O +
after O +
the O +
injury O +
, O +
suggesting O +
that O +
this O +
immunosuppression O +
is O +
primarily O +
due O +
to O +
the O +
general O +
metabolic O +
response O +
rather O +
than O +
recurring O +
infections O +
. O +

A O +
pivotal O +
role O +
for O +
p53 O +
: O +
balancing O +
aerobic O +
respiration O +
and O +
glycolysis O +
. O +

The O +
genetic O +
basis O +
of O +
increased O +
glycolytic O +
activity O +
observed O +
in O +
cancer O +
cells O +
is O +
likely O +
to O +
be O +
the O +
result O +
of O +
complex O +
interactions O +
of O +
multiple O +
regulatory O +
pathways O +
. O +

Here O +
we O +
review O +
the O +
recent O +
evidence O +
of O +
a O +
simple O +
genetic O +
mechanism O +
by O +
which O +
tumor O +
suppressor O +
p53 O +
regulates O +
mitochondrial O +
respiration O +
with O +
secondary O +
changes O +
in O +
glycolysis O +
that O +
are O +
reminiscent O +
of O +
the O +
Warburg O +
effect O +
. O +

The O +
biological O +
significance O +
of O +
this O +
regulation O +
of O +
the O +
two O +
major O +
pathways O +
of O +
energy O +
generation O +
by O +
p53 O +
remains O +
to O +
be O +
seen O +
. O +

The O +
contribution O +
of O +
Harold O +
F O +
. O +
Dvorak O +
to O +
the O +
study O +
of O +
tumor O +
angiogenesis O +
and O +
stroma O +
generation O +
mechanisms O +
. O +

In O +
1983 O +
, O +
Harold O +
Dvorak O +
and O +
his O +
colleagues O +
were O +
the O +
first O +
to O +
show O +
that O +
tumor O +
cells O +
secreted O +
vascular O +
permeability O +
factor O +
( O +
VPF O +
) O +
and O +
that O +
a O +
blocking O +
antibody O +
to O +
VPF O +
could O +
prevent O +
the O +
edema O +
and O +
fluid O +
accumulation O +
that O +
is O +
characteristic O +
of O +
human O +
cancers O +
. O +

In O +
1986 O +
, O +
Dvorak O +
went O +
on O +
to O +
demonstrate O +
that O +
VPF O +
was O +
secreted O +
by O +
a O +
variety O +
of O +
human O +
tumor O +
cell O +
lines O +
and O +
proposed O +
that O +
VPF O +
was O +
in O +
part O +
responsible O +
for O +
the O +
abnormal O +
vasculature O +
seen O +
in O +
human O +
tumors O +
. O +

As O +
a O +
result O +
, O +
he O +
and O +
other O +
investigators O +
demonstrated O +
that O +
VPF O +
was O +
capable O +
of O +
stimulating O +
endothelial O +
cell O +
growth O +
and O +
angiogenesis O +
. O +

These O +
fundamental O +
discoveries O +
led O +
to O +
additional O +
research O +
conducted O +
by O +
Napoleone O +
Ferrara O +
and O +
his O +
laboratory O +
, O +
confirming O +
the O +
cloning O +
of O +
VPF O +
and O +
renaming O +
the O +
protein O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
. O +

In O +
1986 O +
, O +
Dvorak O +
proposed O +
that O +
by O +
secreting O +
VPF O +
, O +
tumors O +
induce O +
angiogenesis O +
by O +
turning O +
on O +
the O +
wound O +
healing O +
response O +
. O +

He O +
noted O +
that O +
wounds O +
, O +
like O +
tumors O +
, O +
secrete O +
VPF O +
, O +
causing O +
blood O +
vessels O +
to O +
leak O +
plasma O +
fibrinogen O +
, O +
which O +
stimulates O +
blood O +
vessel O +
growth O +
and O +
provides O +
a O +
matrix O +
on O +
which O +
they O +
can O +
spread O +
. O +

Unlike O +
wounds O +
, O +
however O +
, O +
that O +
turn O +
off O +
VPF O +
production O +
after O +
healing O +
, O +
tumors O +
did O +
not O +
turn O +
off O +
their O +
VPF O +
production O +
and O +
instead O +
continued O +
to O +
make O +
large O +
amounts O +
of O +
VPF O +
, O +
allowing O +
malignant O +
cells O +
to O +
continue O +
to O +
induce O +
new O +
blood O +
vessels O +
and O +
so O +
to O +
grow O +
and O +
spread O +
. O +

Thus O +
, O +
tumors O +
behave O +
like O +
wounds O +
that O +
fail O +
to O +
heal O +
. O +

This O +
work O +
is O +
again O +
extremely O +
significant O +
for O +
patients O +
worldwide O +
, O +
as O +
Dvorak O +
' O +
s O +
scientific O +
research O +
is O +
leading O +
his O +
colleagues O +
all O +
over O +
the O +
world O +
to O +
examine O +
how O +
to O +
treat O +
a O +
tumor O +
through O +
its O +
blood O +
supply O +
. O +

Modulating O +
metastasis O +
by O +
a O +
lymphangiogenic O +
switch O +
in O +
prostate O +
cancer O +
. O +

Prostate O +
cancer O +
dissemination O +
is O +
difficult O +
to O +
detect O +
in O +
the O +
clinic O +
, O +
and O +
few O +
treatment O +
options O +
exist O +
for O +
patients O +
with O +
advanced O +
- O +
stage O +
disease O +
. O +

Our O +
aim O +
was O +
to O +
investigate O +
the O +
role O +
of O +
tumor O +
lymphangiogenesis O +
during O +
metastasis O +
. O +

Further O +
, O +
we O +
implemented O +
a O +
noninvasive O +
molecular O +
imaging O +
technique O +
to O +
facilitate O +
the O +
assessment O +
of O +
the O +
metastatic O +
process O +
. O +

The O +
metastatic O +
potentials O +
of O +
several O +
human O +
prostate O +
cancer O +
xenograft O +
models O +
, O +
LAPC B-CellLine +
- I-CellLine +
4 I-CellLine +
, O +
LAPC B-CellLine +
- I-CellLine +
9 I-CellLine +
, O +
PC3 B-CellLine +
and O +
CWR22Rv B-CellLine +
- I-CellLine +
1 I-CellLine +
were O +
compared O +
. O +

The O +
cells O +
were O +
labeled O +
with O +
luciferase O +
, O +
a O +
bioluminescence O +
imaging O +
reporter O +
gene O +
, O +
to O +
enable O +
optical O +
imaging O +
. O +

After O +
tumor O +
implantation O +
the O +
animals O +
were O +
examined O +
weekly O +
during O +
several O +
months O +
for O +
the O +
appearance O +
of O +
metastases O +
. O +

Metastatic O +
lesions O +
were O +
confirmed O +
by O +
immunohistochemistry O +
. O +

Additionally O +
, O +
the O +
angiogenic O +
and O +
lymphangiogenic O +
profiles O +
of O +
the O +
tumors O +
were O +
characterized O +
. O +

To O +
confirm O +
the O +
role O +
of O +
lymphangiogenesis O +
in O +
mediating O +
metastasis O +
, O +
the O +
low O +
- O +
metastatic O +
LAPC B-CellLine +
- I-CellLine +
9 I-CellLine +
tumor O +
cells O +
were O +
engineered O +
to O +
overexpress O +
VEGF O +
- O +
C O +
, O +
and O +
the O +
development O +
of O +
metastases O +
was O +
evaluated O +
. O +

Our O +
results O +
show O +
CWR22Rv B-CellLine +
- I-CellLine +
1 I-CellLine +
and O +
PC3 B-CellLine +
tumor O +
cell O +
lines O +
to O +
be O +
more O +
metastatic O +
than O +
LAPC B-CellLine +
- I-CellLine +
4 I-CellLine +
, O +
which O +
in O +
turn O +
disseminates O +
more O +
readily O +
than O +
LAPC B-CellLine +
- I-CellLine +
9 I-CellLine +
. O +

The O +
difference O +
in O +
metastatic O +
potential O +
correlated O +
with O +
the O +
endogenous O +
production O +
levels O +
of O +
lymphangiogenic O +
growth O +
factor O +
VEGF O +
- O +
C O +
and O +
the O +
presence O +
of O +
tumor O +
lymphatics O +
. O +

In O +
agreement O +
, O +
induced O +
overexpression O +
of O +
VEGF O +
- O +
C O +
in O +
LAPC B-CellLine +
- I-CellLine +
9 I-CellLine +
enhanced O +
tumor O +
lymphangiogenesis O +
leading O +
to O +
the O +
development O +
of O +
metastatic O +
lesions O +
. O +

Taken O +
together O +
, O +
our O +
studies O +
, O +
based O +
on O +
a O +
molecular O +
imaging O +
approach O +
for O +
semiquantitative O +
detection O +
of O +
micrometastases O +
, O +
point O +
to O +
an O +
important O +
role O +
of O +
tumor O +
lymphatics O +
in O +
the O +
metastatic O +
process O +
of O +
human O +
prostate O +
cancer O +
. O +

In O +
particular O +
, O +
VEGF O +
- O +
C O +
seems O +
to O +
play O +
a O +
key O +
role O +
in O +
prostate O +
cancer O +
metastasis O +
. O +

Quantitative O +
sequencing O +
of O +
complex O +
mixtures O +
of O +
heterochitooligosaccharides O +
by O +
vMALDI O +
- O +
linear O +
ion O +
trap O +
mass O +
spectrometry O +
. O +

Heterochitooligosaccharides O +
possess O +
interesting O +
biological O +
properties O +
. O +

Isobaric O +
mixtures O +
of O +
such O +
linear O +
heterochitooligosaccharides O +
can O +
be O +
obtained O +
by O +
chemical O +
or O +
enzymatic O +
degradation O +
of O +
chitosan O +
. O +

However O +
, O +
the O +
separation O +
of O +
such O +
mixtures O +
is O +
a O +
challenging O +
analytical O +
problem O +
which O +
is O +
so O +
far O +
unresolved O +
. O +

It O +
is O +
shown O +
that O +
these O +
isobaric O +
mixtures O +
can O +
be O +
sequenced O +
and O +
quantified O +
simultaneously O +
using O +
standard O +
derivatization O +
and O +
multistage O +
tandem O +
mass O +
spectrometric O +
techniques O +
. O +

A O +
linear O +
ion O +
trap O +
mass O +
spectrometer O +
equipped O +
with O +
a O +
vacuum O +
matrix O +
- O +
assisted O +
laser O +
desorption O +
ionization O +
( O +
vMALDI O +
) O +
source O +
is O +
used O +
to O +
perform O +
MS2 O +
as O +
well O +
as O +
MS3 O +
experiments O +
. O +

Selective O +
activation O +
of O +
mast O +
cells O +
in O +
rheumatoid O +
synovial O +
tissue O +
results O +
in O +
production O +
of O +
TNF O +
- O +
alpha O +
, O +
IL O +
- O +
1beta O +
and O +
IL O +
- O +
1Ra O +
. O +

OBJECTIVES O +
AND O +
DESIGN O +
: O +

To O +
study O +
the O +
consequences O +
of O +
mast O +
cell O +
activation O +
in O +
human O +
synovial O +
tissue O +
. O +

METHODS O +
: O +

Synovial O +
tissue O +
was O +
obtained O +
from O +
18 O +
RA O +
patients O +
and O +
mast O +
cells O +
was O +
selectively O +
activated O +
in O +
synovial O +
tissue O +
explant O +
cultures O +
. O +

Expression O +
of O +
TNF O +
- O +
alpha O +
, O +
IL O +
- O +
1beta O +
and O +
IL O +
- O +
1Ra O +
were O +
determined O +
and O +
tissue O +
distribution O +
of O +
IL O +
- O +
1beta O +
was O +
studied O +
. O +

RESULTS O +
: O +

Compared O +
to O +
untreated O +
synovia O +
, O +
selective O +
activation O +
of O +
synovial O +
mast O +
cells O +
increased O +
significantly O +
the O +
production O +
of O +
TNF O +
- O +
alpha O +
( O +
0 O +
. O +
49 O +
+ O +
/ O +
- O +
0 O +
. O +
88 O +
vs O +
. O +
4 O +
. O +
56 O +
+ O +
/ O +
- O +
3 O +
. O +
18 O +
pg O +
/ O +
mg O +
wet O +
tissue O +
, O +
p O +
< O +
0 O +
. O +
001 O +
) O +
and O +
IL O +
- O +
1beta O +
( O +
0 O +
. O +
058 O +
+ O +
/ O +
- O +
0 O +
. O +
032 O +
vs O +
. O +
2 O +
. O +
55 O +
+ O +
/ O +
- O +
1 O +
. O +
98 O +
pg O +
/ O +
mg O +
wet O +
tissue O +
, O +
p O +
= O +
0 O +
. O +
013 O +
) O +
. O +

The O +
expression O +
of O +
TNF O +
- O +
alpha O +
and O +
IL O +
- O +
1beta O +
mRNA O +
increased O +
significantly O +
( O +
19 O +
- O +
fold O +
( O +
p O +
= O +
0 O +
. O +
009 O +
) O +
and O +
13 O +
- O +
fold O +
( O +
p O +
= O +
0 O +
. O +
031 O +
) O +
, O +
respectively O +
) O +
. O +

Mast O +
cell O +
activation O +
induced O +
IL O +
- O +
1beta O +
expression O +
in O +
particular O +
in O +
nearby O +
CD68 O +
positive O +
synovial O +
macrophages O +
. O +

Secretion O +
of O +
IL O +
- O +
1Ra O +
was O +
also O +
increased O +
but O +
to O +
a O +
lesser O +
degree O +
than O +
that O +
of O +
IL O +
- O +
1beta O +
. O +

CONCLUSIONS O +
: O +

Synovial O +
mast O +
cells O +
produce O +
proinflammmatory O +
cytokines O +
and O +
may O +
thus O +
contribute O +
to O +
the O +
inflammation O +
in O +
RA O +
. O +

An O +
assay O +
to O +
measure O +
angiogenesis O +
in O +
human O +
fat O +
tissue O +
. O +

BACKGROUND O +
: O +
Inhibition O +
of O +
angiogenesis O +
reverses O +
rodent O +
obesity O +
. O +

A O +
validated O +
assay O +
in O +
human O +
fat O +
tissue O +
is O +
needed O +
to O +
study O +
the O +
role O +
of O +
angiogenesis O +
in O +
human O +
obesity O +
. O +

METHODS O +
: O +
Human O +
fat O +
tissue O +
fragments O +
from O +
surgery O +
were O +
placed O +
in O +
96 O +
- O +
well O +
plates O +
, O +
embedded O +
in O +
fibrin O +
thrombin O +
clot O +
and O +
overlaid O +
with O +
cell O +
culture O +
media O +
containing O +
20 O +
% O +
fetal O +
bovine O +
serum O +
. O +

After O +
15 O +
days O +
, O +
the O +
clots O +
were O +
examined O +
by O +
histology O +
and O +
electron O +
microscopy O +
. O +

The O +
effect O +
of O +
taxol O +
, O +
cobalt O +
chloride O +
and O +
a O +
heparin O +
- O +
steroid O +
combination O +
was O +
tested O +
in O +
the O +
fat O +
tissue O +
assay O +
and O +
compared O +
to O +
the O +
validated O +
human O +
placental O +
vein O +
angiogenesis O +
model O +
( O +
HPVAM O +
) O +
. O +

RESULTS O +
: O +
Blood O +
vessels O +
initiated O +
growth O +
and O +
elongated O +
from O +
the O +
fat O +
tissue O +
fragments O +
over O +
15 O +
days O +
. O +

Presence O +
of O +
blood O +
vessels O +
was O +
confirmed O +
with O +
histology O +
and O +
electron O +
microscopy O +
. O +

Taxol O +
at O +
10 O +
( O +
- O +
6 O +
) O +
and O +
10 O +
( O +
- O +
7 O +
) O +
M O +
completely O +
inhibited O +
angiogenesis O +
, O +
while O +
Taxol O +
10 O +
( O +
- O +
8 O +
) O +
and O +
10 O +
( O +
- O +
9 O +
) O +
M O +
and O +
the O +
heparin O +
- O +
steroid O +
partially O +
inhibited O +
angiogenesis O +
. O +

The O +
response O +
to O +
taxol O +
and O +
heparin O +
- O +
steroid O +
was O +
similar O +
to O +
that O +
of O +
the O +
HPVAM O +
, O +
a O +
validated O +
angiogenesis O +
assay O +
. O +

Cobalt O +
chloride O +
, O +
a O +
stimulator O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
stimulated O +
angiogenesis O +
initiation O +
at O +
10 O +
( O +
- O +
9 O +
) O +
M O +
in O +
fat O +
tissue O +
and O +
the O +
HPVAM O +
, O +
but O +
at O +
10 O +
( O +
- O +
10 O +
) O +
M O +
blood O +
vessel O +
growth O +
was O +
stimulated O +
only O +
in O +
the O +
fat O +
assay O +
. O +

CONCLUSION O +
: O +
This O +
angiogenesis O +
assay O +
based O +
on O +
human O +
fat O +
tissue O +
uses O +
three O +
- O +
dimensionally O +
intact O +
human O +
tissue O +
. O +

The O +
vessels O +
are O +
derived O +
from O +
quiescient O +
vessels O +
within O +
the O +
fat O +
. O +

These O +
properties O +
allow O +
the O +
angiogenic O +
switch O +
to O +
be O +
evaluated O +
in O +
an O +
in O +
vitro O +
setting O +
. O +

The O +
angiogenic O +
response O +
of O +
fat O +
tissue O +
is O +
not O +
identical O +
to O +
placental O +
tissue O +
. O +

This O +
assay O +
allows O +
exploration O +
of O +
angiogenesis O +
in O +
fat O +
tissue O +
. O +

Rapid O +
mixing O +
between O +
old O +
and O +
new O +
C O +
pools O +
in O +
the O +
canopy O +
of O +
mature O +
forest O +
trees O +
. O +

Stable O +
C O +
isotope O +
signals O +
in O +
plant O +
tissues O +
became O +
a O +
key O +
tool O +
in O +
explaining O +
growth O +
responses O +
to O +
the O +
environment O +
. O +

The O +
technique O +
is O +
based O +
on O +
the O +
fundamental O +
assumption O +
that O +
the O +
isotopic O +
composition O +
of O +
a O +
given O +
unit O +
of O +
tissue O +
( O +
e O +
. O +
g O +
. O +
a O +
tree O +
ring O +
) O +
reflects O +
the O +
specific O +
C O +
uptake O +
conditions O +
in O +
the O +
leaf O +
at O +
a O +
given O +
time O +
. O +

Beyond O +
the O +
methodological O +
implications O +
of O +
any O +
deviation O +
from O +
this O +
assumption O +
, O +
it O +
is O +
of O +
physiological O +
interest O +
whether O +
new O +
C O +
is O +
transferred O +
directly O +
from O +
sources O +
( O +
a O +
photosynthesizing O +
leaf O +
) O +
to O +
structural O +
sinks O +
( O +
e O +
. O +
g O +
. O +
adjacent O +
stem O +
tissue O +
) O +
, O +
or O +
inherently O +
passes O +
through O +
existing O +
( O +
mobile O +
) O +
C O +
pools O +
, O +
which O +
may O +
be O +
of O +
variable O +
( O +
older O +
) O +
age O +
. O +

Here O +
, O +
we O +
explore O +
the O +
fate O +
of O +
( O +
13 O +
) O +
C O +
- O +
labelled O +
photosynthates O +
in O +
the O +
crowns O +
of O +
a O +
30 O +
- O +
35 O +
m O +
tall O +
, O +
mixed O +
forest O +
using O +
a O +
canopy O +
crane O +
. O +

In O +
all O +
nine O +
study O +
species O +
labelled O +
C O +
reached O +
woody O +
tissue O +
within O +
2 O +
- O +
9 O +
h O +
after O +
labelling O +
. O +

Four O +
months O +
later O +
, O +
very O +
small O +
signals O +
were O +
left O +
in O +
branch O +
wood O +
of O +
Tilia O +
suggesting O +
that O +
low O +
mixing O +
of O +
new O +
, O +
labelled O +
C O +
with O +
old O +
C O +
had O +
taken O +
place O +
. O +

In O +
contrast O +
, O +
signals O +
in O +
Fagus O +
and O +
Quercus O +
had O +
increased O +
, O +
indicating O +
more O +
intense O +
mixing O +
. O +

This O +
species O +
- O +
specific O +
mixing O +
of O +
new O +
with O +
old O +
C O +
pools O +
is O +
likely O +
to O +
mask O +
year O +
- O +
or O +
season O +
- O +
specific O +
linkages O +
between O +
tree O +
ring O +
formation O +
and O +
climate O +
and O +
has O +
considerable O +
implications O +
for O +
climate O +
reconstruction O +
using O +
stable O +
isotopes O +
as O +
proxies O +
for O +
past O +
climatic O +
conditions O +
. O +

Adaptive O +
landscapes O +
and O +
emergent O +
phenotypes O +
: O +
why O +
do O +
cancers O +
have O +
high O +
glycolysis O +
? O +

Investigating O +
the O +
causes O +
of O +
increased O +
aerobic O +
glycolysis O +
in O +
tumors O +
( O +
Warburg O +
Effect O +
) O +
has O +
gone O +
in O +
and O +
out O +
of O +
fashion O +
many O +
times O +
since O +
it O +
was O +
first O +
described O +
almost O +
a O +
century O +
ago O +
. O +

The O +
field O +
is O +
currently O +
in O +
ascendance O +
due O +
to O +
two O +
factors O +
. O +

Over O +
a O +
million O +
FDG O +
- O +
PET O +
studies O +
have O +
unequivocally O +
identified O +
increased O +
glucose O +
uptake O +
as O +
a O +
hallmark O +
of O +
metastatic O +
cancer O +
in O +
humans O +
. O +

These O +
observations O +
, O +
combined O +
with O +
new O +
molecular O +
insights O +
with O +
HIF O +
- O +
1alpha O +
and O +
c O +
- O +
myc O +
, O +
have O +
rekindled O +
an O +
interest O +
in O +
this O +
important O +
phenotype O +
. O +

A O +
preponderance O +
of O +
work O +
has O +
been O +
focused O +
on O +
the O +
molecular O +
mechanisms O +
underlying O +
this O +
effect O +
, O +
with O +
the O +
expectation O +
that O +
a O +
mechanistic O +
understanding O +
may O +
lead O +
to O +
novel O +
therapeutic O +
approaches O +
. O +

There O +
is O +
also O +
an O +
implicit O +
assumption O +
that O +
a O +
mechanistic O +
understanding O +
, O +
although O +
fundamentally O +
reductionist O +
, O +
will O +
nonetheless O +
lead O +
to O +
a O +
more O +
profound O +
teleological O +
understanding O +
of O +
the O +
need O +
for O +
altered O +
metabolism O +
in O +
invasive O +
cancers O +
. O +

In O +
this O +
communication O +
, O +
we O +
describe O +
an O +
alternative O +
approach O +
that O +
begins O +
with O +
teleology O +
; O +
i O +
. O +
e O +
. O +
adaptive O +
landscapes O +
and O +
selection O +
pressures O +
that O +
promote O +
emergence O +
of O +
aerobic O +
glycolysis O +
during O +
the O +
somatic O +
evolution O +
of O +
invasive O +
cancer O +
. O +

Mathematical O +
models O +
and O +
empirical O +
observations O +
are O +
used O +
to O +
define O +
the O +
adaptive O +
advantage O +
of O +
aerobic O +
glycolysis O +
that O +
would O +
explain O +
its O +
remarkable O +
prevalence O +
in O +
human O +
cancers O +
. O +

These O +
studies O +
have O +
led O +
to O +
the O +
hypothesis O +
that O +
increased O +
consumption O +
of O +
glucose O +
in O +
metastatic O +
lesions O +
is O +
not O +
used O +
for O +
substantial O +
energy O +
production O +
via O +
Embden O +
- O +
Meyerhoff O +
glycolysis O +
, O +
but O +
rather O +
for O +
production O +
of O +
acid O +
, O +
which O +
gives O +
the O +
cancer O +
cells O +
a O +
competitive O +
advantage O +
for O +
invasion O +
. O +

Alternative O +
hypotheses O +
, O +
wherein O +
the O +
glucose O +
is O +
used O +
for O +
generation O +
of O +
reducing O +
equivalents O +
( O +
NADPH O +
) O +
or O +
anabolic O +
precursors O +
( O +
ribose O +
) O +
are O +
also O +
discussed O +
. O +

Neurohypophyseal O +
granulomatous O +
germinoma O +
invading O +
the O +
right O +
cavernous O +
sinus O +
: O +
case O +
report O +
and O +
review O +
of O +
the O +
literature O +
. O +

We O +
encountered O +
a O +
rare O +
case O +
of O +
neurohypophyseal O +
germinoma O +
with O +
a O +
prominent O +
granulomatous O +
reaction O +
, O +
which O +
invaded O +
the O +
right O +
cavernous O +
sinus O +
. O +

The O +
neuroimaging O +
and O +
histopathology O +
features O +
in O +
this O +
case O +
were O +
unique O +
, O +
distinguishing O +
it O +
from O +
other O +
types O +
of O +
suprasellar O +
lesions O +
. O +

A O +
13 O +
- O +
year O +
- O +
old O +
boy O +
presented O +
with O +
loss O +
of O +
appetite O +
and O +
polyuria O +
; O +
both O +
symptoms O +
were O +
present O +
for O +
1 O +
year O +
, O +
and O +
headache O +
, O +
general O +
fatigue O +
and O +
blurred O +
vision O +
present O +
for O +
the O +
prior O +
2 O +
months O +
. O +

On O +
admission O +
, O +
neurological O +
examination O +
indicated O +
bitemporal O +
hemianopsia O +
and O +
optic O +
atrophy O +
. O +

Endocrinological O +
exam O +
showed O +
panhypopituitarism O +
. O +

Tumor O +
markers O +
such O +
as O +
alpha O +
- O +
fetoprotein O +
, O +
human O +
growth O +
hormone O +
, O +
carcinoembryonic O +
antigen O +
, O +
and O +
placental O +
alkaline O +
phosphatase O +
were O +
negative O +
. O +

Brain O +
CT O +
revealed O +
a O +
suprasellar O +
tumor O +
with O +
calcification O +
. O +

MR O +
T O +
( O +
1 O +
) O +
- O +
weighted O +
and O +
T O +
( O +
2 O +
) O +
- O +
weighted O +
images O +
showed O +
the O +
tumor O +
to O +
be O +
isointense O +
to O +
normal O +
brain O +
parenchyma O +
and O +
to O +
be O +
enhanced O +
densely O +
. O +

The O +
tumor O +
also O +
involved O +
the O +
right O +
cavernous O +
sinus O +
, O +
so O +
that O +
a O +
biopsy O +
was O +
performed O +
by O +
the O +
transsphenoidal O +
approach O +
. O +

On O +
pathologic O +
examination O +
of O +
the O +
specimen O +
, O +
typical O +
large O +
tumor O +
cells O +
with O +
lymphocytic O +
cell O +
infiltration O +
and O +
prominent O +
granulomatous O +
reaction O +
were O +
observed O +
. O +

Neurohypophyseal O +
granulomatous O +
germinoma O +
was O +
diagnosed O +
. O +

Radiotherapy O +
was O +
performed O +
with O +
a O +
total O +
dose O +
of O +
51 O +
Gy O +
and O +
the O +
tumor O +
shrank O +
remarkably O +
. O +

The O +
patient O +
returned O +
to O +
school O +
under O +
hormone O +
replacement O +
therapy O +
. O +

Melissoidesin O +
G O +
, O +
a O +
diterpenoid O +
purified O +
from O +
Isodon O +
melissoides O +
, O +
induces O +
leukemic O +
- O +
cell O +
apoptosis O +
through O +
induction O +
of O +
redox O +
imbalance O +
and O +
exhibits O +
synergy O +
with O +
other O +
anticancer O +
agents O +
. O +

Melissoidesin O +
G O +
( O +
MOG O +
) O +
is O +
a O +
new O +
diterpenoid O +
purified O +
from O +
Isodon O +
melissoides O +
, O +
a O +
plant O +
used O +
in O +
Chinese O +
traditional O +
medicine O +
as O +
antitumor O +
and O +
anti O +
- O +
inflammatory O +
agents O +
. O +

In O +
our O +
study O +
, O +
MOG O +
was O +
shown O +
to O +
specifically O +
inhibit O +
the O +
growth O +
of O +
human O +
leukemia O +
cell O +
lines O +
and O +
primary O +
acute O +
myeloid O +
leukemia O +
( O +
AML O +
) O +
blasts O +
via O +
induction O +
of O +
apoptosis O +
, O +
with O +
the O +
evidence O +
of O +
mitochondrial O +
DeltaPsim O +
loss O +
, O +
reactive O +
oxygen O +
species O +
production O +
, O +
caspases O +
activation O +
and O +
nuclear O +
fragmentation O +
. O +

Furthermore O +
, O +
it O +
was O +
shown O +
that O +
thiol O +
- O +
containing O +
antioxidants O +
completely O +
blocked O +
MOG O +
- O +
induced O +
mitochondrial O +
DeltaPsim O +
loss O +
and O +
subsequent O +
cell O +
apoptosis O +
, O +
while O +
the O +
inhibition O +
of O +
apoptosis O +
by O +
benzyloxy O +
- O +
carbonyl O +
- O +
Val O +
- O +
Ala O +
- O +
Asp O +
- O +
fluoromethylketone O +
only O +
partially O +
attenuated O +
mitochondrial O +
DeltaPsim O +
loss O +
, O +
indicating O +
that O +
MOG O +
- O +
induced O +
redox O +
imbalance O +
is O +
an O +
early O +
event O +
upstream O +
to O +
mitochondrial O +
DeltaPsim O +
loss O +
and O +
caspase O +
- O +
3 O +
activation O +
. O +

Consistently O +
, O +
it O +
was O +
found O +
that O +
MOG O +
rapidly O +
decreased O +
the O +
intracellular O +
glutathione O +
( O +
GSH O +
) O +
content O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
and O +
the O +
significance O +
of O +
GSH O +
depletion O +
in O +
MOG O +
- O +
induced O +
apoptosis O +
was O +
further O +
supported O +
by O +
the O +
protective O +
effects O +
of O +
tert O +
- O +
butylhydroquinone O +
( O +
tBHQ O +
) O +
and O +
the O +
facilitative O +
effects O +
of O +
DL O +
- O +
buthionine O +
( O +
S O +
, O +
R O +
) O +
- O +
sulfoximine O +
( O +
BSO O +
) O +
. O +

Furthermore O +
, O +
it O +
was O +
showed O +
that O +
GSH O +
depletion O +
induced O +
by O +
MOG O +
rendered O +
some O +
leukemia O +
cell O +
lines O +
more O +
sensitive O +
to O +
arsenic O +
trioxide O +
( O +
As2O3 O +
) O +
, O +
doxorubicin O +
or O +
cisplatin O +
. O +

Additionally O +
, O +
the O +
synergistic O +
apoptotic O +
effects O +
of O +
MOG O +
with O +
As2O3 O +
were O +
detected O +
in O +
HL B-CellLine +
- I-CellLine +
60 I-CellLine +
and O +
primary O +
AML O +
cells O +
, O +
but O +
not O +
in O +
normal O +
cells O +
, O +
suggesting O +
the O +
selective O +
toxicity O +
of O +
their O +
combination O +
to O +
the O +
malignant O +
cells O +
. O +

Together O +
, O +
we O +
proposed O +
that O +
MOG O +
alone O +
or O +
administered O +
with O +
other O +
anticancer O +
agents O +
may O +
provide O +
a O +
novel O +
therapeutic O +
strategy O +
for O +
leukemia O +
. O +

Subcellular O +
localisation O +
of O +
BAG O +
- O +
1 O +
and O +
its O +
regulation O +
of O +
vitamin O +
D O +
receptor O +
- O +
mediated O +
transactivation O +
and O +
involucrin O +
expression O +
in O +
oral O +
keratinocytes O +
: O +
implications O +
for O +
oral O +
carcinogenesis O +
. O +

In O +
oral O +
cancers O +
, O +
cytoplasmic O +
BAG O +
- O +
1 O +
overexpression O +
is O +
a O +
marker O +
of O +
poor O +
prognosis O +
. O +

BAG O +
- O +
1 O +
regulates O +
cellular O +
growth O +
, O +
differentiation O +
and O +
survival O +
through O +
interactions O +
with O +
diverse O +
proteins O +
, O +
including O +
the O +
vitamin O +
D O +
receptor O +
( O +
VDR O +
) O +
, O +
a O +
key O +
regulator O +
of O +
keratinocyte O +
growth O +
and O +
differentiation O +
. O +

BAG O +
- O +
1 O +
is O +
expressed O +
ubiquitously O +
in O +
human O +
cells O +
as O +
three O +
major O +
isoforms O +
of O +
50 O +
kDa O +
( O +
BAG O +
- O +
1L O +
) O +
, O +
46 O +
kDa O +
( O +
BAG O +
- O +
1 O -
M O +
) O +
and O +
36 O +
kDa O +
( O +
BAG O +
- O +
1S O +
) O +
from O +
a O +
single O +
mRNA O +
. O +

In O +
oral O +
keratinocytes O +
BAG O +
- O +
1L O +
, O +
but O +
not O +
BAG O +
- O +
1 O -
M O +
and O +
BAG O +
- O +
1S O +
, O +
enhanced O +
VDR O +
transactivation O +
in O +
response O +
to O +
1alpha O +
, O +
25 O +
- O +
dihydroxyvitamin O +
D3 O +
. O +

BAG O +
- O +
1L O +
was O +
nucleoplasmic O +
and O +
nucleolar O +
, O +
whereas O +
BAG O +
- O +
1S O +
and O +
BAG O +
- O +
1 O -
M O +
were O +
cytoplasmic O +
and O +
nucleoplasmic O +
in O +
localisation O +
. O +

Having O +
identified O +
the O +
nucleolar O +
localisation O +
sequence O +
in O +
BAG O +
- O +
1L O +
, O +
we O +
showed O +
that O +
mutation O +
of O +
this O +
sequence O +
did O +
not O +
prevent O +
BAG O +
- O +
1L O +
from O +
potentiating O +
VDR O +
activity O +
. O +

BAG O +
- O +
1L O +
also O +
potentiated O +
transactivation O +
of O +
known O +
vitamin O +
- O +
D O +
- O +
responsive O +
gene O +
promoters O +
, O +
osteocalcin O +
and O +
24 O +
- O +
hydroxylase O +
, O +
and O +
enhanced O +
VDR O +
- O +
dependent O +
transcription O +
and O +
protein O +
expression O +
of O +
the O +
keratinocyte O +
differentiation O +
marker O +
, O +
involucrin O +
. O +

These O +
results O +
demonstrate O +
endogenous O +
gene O +
regulation O +
by O +
BAG O +
- O +
1L O +
by O +
potentiating O +
nuclear O +
hormone O +
receptor O +
function O +
and O +
suggest O +
a O +
role O +
for O +
BAG O +
- O +
1L O +
in O +
24 O +
- O +
hydroxylase O +
regulation O +
of O +
vitamin O +
D O +
metabolism O +
and O +
the O +
cellular O +
response O +
of O +
oral O +
keratinocytes O +
to O +
1alpha O +
, O +
25 O +
- O +
dihydroxyvitamin O +
D3 O +
. O +

By O +
contrast O +
to O +
the O +
cytoplasmic O +
BAG O +
- O +
1 O +
isoforms O +
, O +
BAG O +
- O +
1L O +
may O +
act O +
to O +
suppress O +
tumorigenesis O +
. O +

Hedgehog O +
signaling O +
in O +
the O +
murine O +
melanoma O +
microenvironment O +
. O +

The O +
Hedgehog O +
intercellular O +
signaling O +
pathway O +
regulates O +
cell O +
proliferation O +
and O +
differentiation O +
. O +

This O +
pathway O +
has O +
been O +
implicated O +
to O +
play O +
a O +
role O +
in O +
the O +
pathogenesis O +
of O +
cancer O +
and O +
in O +
embryonic O +
blood O +
vessel O +
development O +
. O +

In O +
the O +
current O +
study O +
, O +
Hedgehog O +
signaling O +
in O +
tumor O +
related O +
vasculature O +
and O +
microenvironment O +
was O +
examined O +
using O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
and O +
B16F0 B-CellLine +
( O +
murine O +
melanoma O +
) O +
tumors O +
models O +
. O +

Use O +
of O +
exogenous O +
Sonic O +
hedgehog O +
( O +
Shh O +
) O +
peptide O +
significantly O +
increased O +
BrdU O +
incorporation O +
in O +
endothelial O +
cells O +
in O +
vitro O +
by O +
a O +
factor O +
of O +
2 O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
. O +

The O +
Hedgehog O +
pathway O +
antagonist O +
cyclopamine O +
effectively O +
reduced O +
Shh O +
- O +
induced O +
proliferation O +
to O +
control O +
levels O +
. O +

To O +
study O +
Hedgehog O +
signaling O +
in O +
vivo O +
a O +
hind O +
limb O +
tumor O +
model O +
with O +
the O +
B16F0 B-CellLine +
cell O +
line O +
was O +
used O +
. O +

Treatment O +
with O +
25 O +
mg O +
/ O +
kg O +
cyclopamine O +
significantly O +
attenuated O +
BrdU O +
incorporation O +
in O +
tumor O +
cells O +
threefold O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
, O +
in O +
tumor O +
related O +
endothelial O +
cells O +
threefold O +
( O +
P O +
= O +
0 O +
. O +
004 O +
) O +
, O +
and O +
delayed O +
tumor O +
growth O +
by O +
4 O +
days O +
. O +

Immunohistochemistry O +
revealed O +
that O +
the O +
Hedgehog O +
receptor O +
Patched O +
was O +
localized O +
to O +
the O +
tumor O +
stroma O +
and O +
that O +
B16F0 B-CellLine +
cells O +
expressed O +
Shh O +
peptide O +
. O +

Furthermore O +
, O +
mouse O +
embryonic O +
fibroblasts O +
required O +
the O +
presence O +
of O +
B16F0 B-CellLine +
cells O +
to O +
express O +
Patched O +
in O +
a O +
co O +
- O +
culture O +
assay O +
system O +
. O +

These O +
studies O +
indicate O +
that O +
Shh O +
peptide O +
produced O +
by O +
melanoma O +
cells O +
induces O +
Patched O +
expression O +
in O +
fibroblasts O +
. O +

To O +
study O +
tumor O +
related O +
angiogenesis O +
a O +
vascular O +
window O +
model O +
was O +
used O +
to O +
monitor O +
tumor O +
vascularity O +
. O +

Treatment O +
with O +
cyclopamine O +
significantly O +
attenuated O +
vascular O +
formation O +
by O +
a O +
factor O +
of O +
2 O +
. O +
5 O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
and O +
altered O +
vascular O +
morphology O +
. O +

Furthermore O +
, O +
cyclopamine O +
reduced O +
tumor O +
blood O +
vessel O +
permeability O +
to O +
FITC O +
labeled O +
dextran O +
while O +
having O +
no O +
effect O +
on O +
normal O +
blood O +
vessels O +
. O +

These O +
studies O +
suggest O +
that O +
Hedgehog O +
signaling O +
regulates O +
melanoma O +
related O +
vascular O +
formation O +
and O +
function O +
. O +

Expression O +
of O +
epidermal O +
growth O +
factor O +
receptor O +
, O +
transforming O +
growth O +
factor O +
- O +
alpha O +
and O +
Ki O +
- O +
67 O +
in O +
relationship O +
to O +
malignant O +
transformation O +
of O +
pleomorphic O +
adenoma O +
. O +

CONCLUSION O +
: O +
Quantitative O +
assessment O +
is O +
more O +
sensitive O +
as O +
a O +
measure O +
of O +
cellular O +
protein O +
content O +
as O +
compared O +
with O +
standard O +
optical O +
density O +
measurements O +
. O +

The O +
data O +
support O +
the O +
hypothesis O +
that O +
increased O +
epidermal O +
growth O +
factor O +
receptor O +
( O +
EGFR O +
) O +
and O +
transforming O +
growth O +
factor O +
( O +
TGF O +
) O +
- O +
alpha O +
expression O +
is O +
associated O +
with O +
early O +
events O +
in O +
malignant O +
transformation O +
of O +
pleomorphic O +
adenoma O +
( O +
PA O +
) O +
. O +

OBJECTIVE O +
: O +
In O +
the O +
present O +
study O +
, O +
we O +
attempted O +
to O +
identify O +
EGFR O +
and O +
TGF O +
- O +
alpha O +
expression O +
and O +
Ki O +
- O +
67 O +
index O +
in O +
carcinoma O +
ex O +
- O +
pleomorphic O +
adenoma O +
( O +
Ca O +
ex O +
- O +
PA O +
) O +
and O +
PA O +
. O +

We O +
also O +
compared O +
the O +
presence O +
of O +
EGFR O +
and O +
TGF O +
- O +
alpha O +
and O +
Ki O +
- O +
67 O +
index O +
with O +
clinical O +
data O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +
The O +
tissues O +
were O +
stained O +
with O +
monoclonal O +
antibodies O +
to O +
EGFR O +
, O +
TGF O +
- O +
alpha O +
and O +
Ki O +
- O +
67 O +
. O +

The O +
results O +
were O +
analysed O +
using O +
quantitative O +
immunohistochemical O +
analysis O +
. O +

We O +
also O +
analysed O +
the O +
association O +
of O +
patients O +
' O +
prognosis O +
with O +
clinical O +
parameters O +
and O +
the O +
histological O +
classification O +
of O +
the O +
carcinomatous O +
component O +
. O +

RESULTS O +
: O +
As O +
regards O +
the O +
association O +
of O +
patients O +
' O +
prognosis O +
with O +
EGFR O +
staining O +
and O +
Ki O +
- O +
67 O +
index O +
, O +
a O +
significant O +
increase O +
was O +
observed O +
in O +
patients O +
who O +
died O +
or O +
had O +
residual O +
disease O +
compared O +
with O +
patients O +
who O +
were O +
alive O +
without O +
disease O +
. O +

In O +
the O +
immunohistochemical O +
analysis O +
of O +
EGFR O +
and O +
TGF O +
- O +
alpha O +
and O +
Ki67 O +
index O +
, O +
a O +
significant O +
increase O +
was O +
observed O +
in O +
Ca O +
ex O +
- O +
PA O +
, O +
especially O +
with O +
adenocarcinoma O +
, O +
compared O +
with O +
PA O +
and O +
sialadenitis O +
. O +

Transporters O +
, O +
enzymes O +
, O +
and O +
enalapril O +
removal O +
in O +
a O +
rat O +
( O +
CC531 B-CellLine +
- O +
induced O +
) O +
liver O +
metastatic O +
model O +
. O +

Temporal O +
changes O +
in O +
physiological O +
spaces O +
, O +
protein O +
expression O +
of O +
transporters O +
and O +
enzymes O +
, O +
and O +
enalapril O +
removal O +
were O +
appraised O +
in O +
the O +
metastatic O +
liver O +
tumor O +
model O +
developed O +
from O +
male O +
Wag O +
/ O +
Rij O +
rats O +
after O +
the O +
intraportal O +
injection O +
of O +
CC531 B-CellLine +
colon O +
adenocarcinoma O +
cells O +
; O +
sham O +
- O +
operated O +
preparations O +
received O +
PBS O +
. O +

Liver O +
tissue O +
spaces O +
, O +
investigated O +
with O +
multiple O +
indicator O +
dilution O +
technique O +
in O +
liver O +
perfusion O +
studies O +
, O +
were O +
unchanged O +
at O +
week O +
3 O +
after O +
tumor O +
induction O +
. O +

At O +
week O +
4 O +
, O +
however O +
, O +
the O +
sinusoidal O +
blood O +
volume O +
and O +
albumin O +
Disse O +
space O +
in O +
tumor O +
- O +
bearing O +
livers O +
were O +
slightly O +
lower O +
compared O +
with O +
those O +
of O +
shams O +
. O +

Increased O +
levels O +
of O +
the O +
canalicular O +
ATP O +
transporters O +
, O +
P O +
- O +
glycoprotein O +
, O +
multidrug O +
resistance O +
- O +
associated O +
protein O +
2 O +
( O +
Mrp2 O +
) O +
, O +
and O +
bile O +
salt O +
export O +
pump O +
( O +
Bsep O +
) O +
at O +
week O +
2 O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
, O +
unchanged O +
levels O +
of O +
Ntcp O +
, O +
Oatp1a1 O +
, O +
Oatp1a4 O +
, O +
and O +
Mct2 O +
, O +
but O +
decreased O +
levels O +
of O +
cytochrome O +
P450 O +
3a2 O +
( O +
Cyp3a2 O +
) O +
and O +
glutathione O +
S O +
- O +
transferase O +
( O +
Gst4 O +
- O +
4 O +
) O +
at O +
week O +
4 O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
were O +
observed O +
in O +
peritumor O +
vs O +
. O +
sham O +
- O +
operated O +
liver O +
tissues O +
with O +
Western O +
blotting O +
. O +

The O +
steady O +
- O +
state O +
extraction O +
ratio O +
of O +
enalapril O +
, O +
a O +
substrate O +
that O +
enters O +
the O +
liver O +
rapidly O +
via O +
Oatp1a1 O +
and O +
primarily O +
undergoes O +
metabolism O +
by O +
the O +
carboxylesterases O +
, O +
was O +
unaffected O +
by O +
liver O +
metastasis O +
at O +
week O +
4 O +
regardless O +
of O +
its O +
delivery O +
via O +
the O +
portal O +
vein O +
or O +
hepatic O +
artery O +
into O +
the O +
perfused O +
liver O +
preparations O +
. O +

Wnt O +
signaling O +
, O +
stem O +
cells O +
, O +
and O +
the O +
cellular O +
origin O +
of O +
breast O +
cancer O +
. O +

The O +
breast O +
epithelium O +
comprises O +
cells O +
at O +
different O +
stages O +
of O +
differentiation O +
, O +
including O +
stem O +
cells O +
, O +
progenitor O +
cells O +
, O +
and O +
more O +
differentiated O +
epithelial O +
and O +
myoepithelial O +
cells O +
. O +

Wnt O +
signaling O +
plays O +
a O +
critical O +
role O +
in O +
regulating O +
stem O +
/ O +
progenitor O +
cells O +
in O +
the O +
mammary O +
gland O +
as O +
well O +
as O +
other O +
tissue O +
compartments O +
. O +

Furthermore O +
, O +
there O +
is O +
strong O +
evidence O +
suggesting O +
that O +
aberrant O +
activation O +
of O +
Wnt O +
signaling O +
induces O +
mammary O +
tumors O +
from O +
stem O +
/ O +
progenitor O +
cells O +
, O +
and O +
that O +
Wnt O +
exerts O +
its O +
oncogenic O +
effects O +
through O +
LRP5 O +
/ O +
6 O +
- O +
mediated O +
activation O +
of O +
beta O +
- O +
catenin O +
and O +
mTOR O +
pathways O +
. O +

Recent O +
studies O +
using O +
avian O +
retrovirus O +
- O +
mediated O +
introduction O +
of O +
oncogenes O +
into O +
a O +
small O +
subset O +
of O +
somatic O +
mammary O +
cells O +
suggest O +
that O +
polyoma O +
middle O +
T O +
antigen O +
( O +
PyMT O +
) O +
may O +
also O +
preferentially O +
transform O +
stem O +
/ O +
progenitor O +
cells O +
. O +

These O +
observations O +
suggest O +
that O +
stem O +
/ O +
progenitor O +
cells O +
in O +
the O +
mammary O +
gland O +
may O +
be O +
especially O +
susceptible O +
to O +
oncogenic O +
transformation O +
. O +

Whether O +
more O +
differentiated O +
cells O +
may O +
also O +
be O +
transformed O +
by O +
particular O +
oncogenes O +
is O +
actively O +
debated O +
; O +
it O +
is O +
presently O +
unclear O +
whether O +
stem O +
cells O +
or O +
differentiated O +
mammary O +
cells O +
are O +
more O +
susceptible O +
to O +
transformation O +
by O +
individual O +
oncogenes O +
. O +

Better O +
stem O +
cell O +
and O +
progenitor O +
cell O +
markers O +
as O +
well O +
as O +
the O +
ability O +
to O +
specifically O +
target O +
oncogenes O +
into O +
different O +
mammary O +
cell O +
types O +
will O +
be O +
needed O +
to O +
determine O +
the O +
spectrum O +
of O +
oncogene O +
transformation O +
for O +
stem O +
cells O +
versus O +
more O +
differentiated O +
cells O +
. O +

CX3CR1 O +
- O +
dependent O +
subretinal O +
microglia O +
cell O +
accumulation O +
is O +
associated O +
with O +
cardinal O +
features O +
of O +
age O +
- O +
related O +
macular O +
degeneration O +
. O +

The O +
role O +
of O +
retinal O +
microglial O +
cells O +
( O +
MCs O +
) O +
in O +
age O +
- O +
related O +
macular O +
degeneration O +
( O +
AMD O +
) O +
is O +
unclear O +
. O +

Here O +
we O +
demonstrated O +
that O +
all O +
retinal O +
MCs O +
express O +
CX3C O +
chemokine O +
receptor O +
1 O +
( O +
CX3CR1 O +
) O +
and O +
that O +
homozygosity O +
for O +
the O +
CX3CR1 O +
M280 O +
allele O +
, O +
which O +
is O +
associated O +
with O +
impaired O +
cell O +
migration O +
, O +
increases O +
the O +
risk O +
of O +
AMD O +
. O +

In O +
humans O +
with O +
AMD O +
, O +
MCs O +
accumulated O +
in O +
the O +
subretinal O +
space O +
at O +
sites O +
of O +
retinal O +
degeneration O +
and O +
choroidal O +
neovascularization O +
( O +
CNV O +
) O +
. O +

In O +
CX3CR1 O +
- O +
deficient O +
mice O +
, O +
MCs O +
accumulated O +
subretinally O +
with O +
age O +
and O +
albino O +
background O +
and O +
after O +
laser O +
impact O +
preceding O +
retinal O +
degeneration O +
. O +

Raising O +
the O +
albino O +
mice O +
in O +
the O +
dark O +
prevented O +
both O +
events O +
. O +

The O +
appearance O +
of O +
lipid O +
- O +
bloated O +
subretinal O +
MCs O +
was O +
drusen O +
- O +
like O +
on O +
funduscopy O +
of O +
senescent O +
mice O +
, O +
and O +
CX3CR1 O +
- O +
dependent O +
MC O +
accumulation O +
was O +
associated O +
with O +
an O +
exacerbation O +
of O +
experimental O +
CNV O +
. O +

These O +
results O +
show O +
that O +
CX3CR1 O +
- O +
dependent O +
accumulation O +
of O +
subretinal O +
MCs O +
evokes O +
cardinal O +
features O +
of O +
AMD O +
. O +

These O +
findings O +
reveal O +
what O +
we O +
believe O +
to O +
be O +
a O +
novel O +
pathogenic O +
process O +
with O +
important O +
implications O +
for O +
the O +
development O +
of O +
new O +
therapies O +
for O +
AMD O +
. O +

Ovarian O +
cancers O +
overexpress O +
the O +
antimicrobial O +
protein O +
hCAP O +
- O +
18 O +
and O +
its O +
derivative O +
LL O +
- O +
37 O +
increases O +
ovarian O +
cancer O +
cell O +
proliferation O +
and O +
invasion O +
. O +

The O +
role O +
of O +
the O +
pro O +
- O +
inflammatory O +
peptide O +
, O +
LL O +
- O +
37 O +
, O +
and O +
its O +
pro O +
- O +
form O +
, O +
human O +
cationic O +
antimicrobial O +
protein O +
18 O +
( O +
hCAP O +
- O +
18 O +
) O +
, O +
in O +
cancer O +
development O +
and O +
progression O +
is O +
poorly O +
understood O +
. O +

In O +
damaged O +
and O +
inflamed O +
tissue O +
, O +
LL O +
- O +
37 O +
functions O +
as O +
a O +
chemoattractant O +
, O +
mitogen O +
and O +
pro O +
- O +
angiogenic O +
factor O +
suggesting O +
that O +
the O +
peptide O +
may O +
potentiate O +
tumor O +
progression O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
characterize O +
the O +
distribution O +
of O +
hCAP O +
- O +
18 O +
/ O +
LL O +
- O +
37 O +
in O +
normal O +
and O +
cancerous O +
ovarian O +
tissue O +
and O +
to O +
examine O +
the O +
effects O +
of O +
LL O +
- O +
37 O +
on O +
ovarian O +
cancer O +
cells O +
. O +

Expression O +
of O +
hCAP O +
- O +
18 O +
/ O +
LL O +
- O +
37 O +
was O +
localized O +
to O +
immune O +
and O +
granulosa O +
cells O +
of O +
normal O +
ovarian O +
tissue O +
. O +

By O +
contrast O +
, O +
ovarian O +
tumors O +
displayed O +
significantly O +
higher O +
levels O +
of O +
hCAP O +
- O +
18 O +
/ O +
LL O +
- O +
37 O +
where O +
expression O +
was O +
observed O +
in O +
tumor O +
and O +
stromal O +
cells O +
. O +

Protein O +
expression O +
was O +
statistically O +
compared O +
to O +
the O +
degree O +
of O +
immune O +
cell O +
infiltration O +
and O +
microvessel O +
density O +
in O +
epithelial O +
- O +
derived O +
ovarian O +
tumors O +
and O +
a O +
significant O +
correlation O +
was O +
observed O +
for O +
both O +
. O +

It O +
was O +
demonstrated O +
that O +
ovarian O +
tumor O +
tissue O +
lysates O +
and O +
ovarian O +
cancer O +
cell O +
lines O +
express O +
hCAP O +
- O +
18 O +
/ O +
LL O +
- O +
37 O +
. O +

Treatment O +
of O +
ovarian O +
cancer O +
cell O +
lines O +
with O +
recombinant O +
LL O +
- O +
37 O +
stimulated O +
proliferation O +
, O +
chemotaxis O +
, O +
invasion O +
and O +
matrix O +
metalloproteinase O +
expression O +
. O +

These O +
data O +
demonstrate O +
for O +
the O +
first O +
time O +
that O +
hCAP O +
- O +
18 O +
/ O +
LL O +
- O +
37 O +
is O +
significantly O +
overexpressed O +
in O +
ovarian O +
tumors O +
and O +
suggest O +
LL O +
- O +
37 O +
may O +
contribute O +
to O +
ovarian O +
tumorigenesis O +
through O +
direct O +
stimulation O +
of O +
tumor O +
cells O +
, O +
initiation O +
of O +
angiogenesis O +
and O +
recruitment O +
of O +
immune O +
cells O +
. O +

These O +
data O +
provide O +
further O +
evidence O +
of O +
the O +
existing O +
relationship O +
between O +
pro O +
- O +
inflammatory O +
molecules O +
and O +
ovarian O +
cancer O +
progression O +
. O +

Conditional O +
deletion O +
of O +
Smad1 O +
and O +
Smad5 O +
in O +
somatic O +
cells O +
of O +
male O +
and O +
female O +
gonads O +
leads O +
to O +
metastatic O +
tumor O +
development O +
in O +
mice O +
. O +

The O +
transforming O +
growth O +
factor O +
beta O +
( O +
TGFbeta O +
) O +
family O +
has O +
critical O +
roles O +
in O +
the O +
regulation O +
of O +
fertility O +
. O +

In O +
addition O +
, O +
the O +
pathogenesis O +
of O +
some O +
human O +
cancers O +
is O +
attributed O +
to O +
misregulation O +
of O +
TGFbeta O +
function O +
and O +
SMAD2 O +
or O +
SMAD4 O +
mutations O +
. O +

There O +
are O +
limited O +
mouse O +
models O +
for O +
the O +
BMP O +
signaling O +
SMADs O +
( O +
BR O +
- O +
SMADs O +
) O +
1 O +
, O +
5 O +
, O +
and O +
8 O +
because O +
of O +
embryonic O +
lethality O +
and O +
suspected O +
genetic O +
redundancy O +
. O +

Using O +
tissue O +
- O +
specific O +
ablation O +
in O +
mice O +
, O +
we O +
deleted O +
the O +
BR O +
- O +
SMADs O +
from O +
somatic O +
cells O +
of O +
ovaries O +
and O +
testes O +
. O +

Single O +
conditional O +
knockouts O +
for O +
Smad1 O +
or O +
Smad5 O +
or O +
mice O +
homozygous O +
null O +
for O +
Smad8 O +
are O +
viable O +
and O +
fertile O +
. O +

Female O +
double O +
Smad1 O +
Smad5 O +
and O +
triple O +
Smad1 O +
Smad5 O +
Smad8 O +
conditional O +
knockout O +
mice O +
become O +
infertile O +
and O +
develop O +
metastatic O +
granulosa O +
cell O +
tumors O +
. O +

Male O +
double O +
Smad1 O +
Smad5 O +
conditional O +
knockout O +
mice O +
are O +
fertile O +
but O +
demonstrate O +
metastatic O +
testicular O +
tumor O +
development O +
. O +

Microarray O +
analysis O +
indicated O +
significant O +
alterations O +
in O +
expression O +
of O +
genes O +
related O +
to O +
the O +
TGFbeta O +
pathway O +
, O +
as O +
well O +
as O +
genes O +
involved O +
in O +
infertility O +
and O +
extracellular O +
matrix O +
production O +
. O +

These O +
data O +
strongly O +
implicate O +
the O +
BR O +
- O +
SMADs O +
as O +
part O +
of O +
a O +
critical O +
developmental O +
pathway O +
in O +
ovaries O +
and O +
testis O +
that O +
, O +
when O +
disrupted O +
, O +
leads O +
to O +
malignant O +
transformation O +
. O +

Role O +
of O +
telomeres O +
in O +
vascular O +
senescence O +
. O +

Telomeres O +
are O +
DNA O +
regions O +
composed O +
of O +
TTAGGG O +
repeats O +
that O +
are O +
located O +
at O +
the O +
ends O +
of O +
chromosomes O +
. O +

Specific O +
proteins O +
associate O +
with O +
the O +
telomeres O +
and O +
form O +
non O +
- O +
nucleosomal O +
DNA O +
- O +
protein O +
complexes O +
that O +
serve O +
as O +
protective O +
caps O +
for O +
the O +
chromosome O +
ends O +
. O +

There O +
is O +
accumulating O +
evidence O +
that O +
progressive O +
telomere O +
shortening O +
is O +
closely O +
related O +
to O +
cardiovascular O +
disease O +
. O +

For O +
example O +
, O +
vascular O +
cell O +
senescence O +
has O +
been O +
reported O +
to O +
occur O +
in O +
human O +
atherosclerotic O +
lesions O +
and O +
this O +
change O +
is O +
associated O +
with O +
telomere O +
shortening O +
. O +

Impairment O +
of O +
telomere O +
integrity O +
causes O +
vascular O +
dysfunction O +
, O +
which O +
is O +
prevented O +
by O +
the O +
activation O +
of O +
telomerase O +
. O +

Mice O +
with O +
short O +
telomeres O +
develop O +
hypertension O +
and O +
exhibit O +
impaired O +
neovascularization O +
. O +

Short O +
telomeres O +
have O +
also O +
been O +
reported O +
in O +
the O +
leukocytes O +
of O +
patients O +
with O +
cardiovascular O +
disease O +
or O +
various O +
cardiovascular O +
risk O +
factors O +
. O +

Although O +
it O +
remains O +
unclear O +
whether O +
short O +
telomeres O +
directly O +
cause O +
cardiovascular O +
disease O +
, O +
manipulation O +
of O +
telomere O +
function O +
is O +
potentially O +
an O +
attractive O +
strategy O +
for O +
the O +
treatment O +
of O +
vascular O +
senescence O +
. O +

Ectopic O +
decorin O +
expression O +
up O +
- O +
regulates O +
VEGF O +
expression O +
in O +
mouse O +
cerebral O +
endothelial O +
cells O +
via O +
activation O +
of O +
the O +
transcription O +
factors O +
Sp1 O +
, O +
HIF1alpha O +
, O +
and O +
Stat3 O +
. O +

We O +
demonstrate O +
that O +
a O +
proteoglycan O +
decorin O +
( O +
DCN O +
) O +
up O +
- O +
regulates O +
the O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
expression O +
with O +
activation O +
of O +
VEGF O +
regulating O +
transcription O +
factors O +
Sp1 O +
, O +
hypoxia O +
- O +
inducible O +
factor O +
1alpha O +
( O +
HIF1alpha O +
) O +
, O +
and O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
3 O +
( O +
Stat3 O +
) O +
via O +
epidermal O +
growth O +
factor O +
receptor O +
( O +
EGFR O +
) O +
, O +
mitogen O +
- O +
activated O +
protein O +
kinase O +
extracellular O +
signal O +
- O +
regulated O +
kinase O +
1 O +
/ O +
2 O +
( O +
ERK1 O +
/ O +
2 O +
) O +
, O +
and O +
protein O +
kinase O +
B O +
( O +
AKT O +
) O +
pathways O +
in O +
DCN O +
transfected O +
mouse O +
cerebral O +
endothelial O +
( O +
MCE O +
) O +
cells O +
. O +

Treatment O +
with O +
pharmacological O +
inhibitors O +
and O +
small O +
interfering O +
RNAs O +
reveal O +
that O +
induction O +
and O +
activation O +
of O +
Sp1 O +
, O +
HIF1alpha O +
, O +
and O +
Stat3 O +
facilitate O +
their O +
nuclear O +
localization O +
and O +
binding O +
to O +
their O +
specific O +
motifs O +
of O +
the O +
VEGF O +
promoter O +
and O +
induce O +
VEGF O +
expression O +
via O +
two O +
independent O +
pathways O +
, O +
DCN O +
/ O +
EGFR O +
/ O +
phosphoinositide O +
- O +
3 O +
kinase O +
/ O +
AKT O +
and O +
DCN O +
/ O +
EGFR O +
/ O +
ERK1 O +
/ O +
2 O +
, O +
respectively O +
, O +
in O +
DCN O +
synthesizing O +
MCE O +
cells O +
. O +

The O +
cell O +
type O +
specific O +
glycosylation O +
protects O +
Sp1 O +
and O +
HIF1alpha O +
from O +
proteosome O +
degradation O +
and O +
plays O +
an O +
important O +
and O +
novel O +
role O +
in O +
the O +
regulation O +
of O +
VEGF O +
in O +
DCN O +
transfected O +
MCE O +
cells O +
. O +

Induction O +
of O +
gelatinases O +
( O +
matrix O +
metalloproteinase O +
2 O +
and O +
9 O +
) O +
, O +
the O +
serine O +
protease O +
tissue O +
plasminogen O +
activator O +
and O +
plasmin O +
by O +
DCN O +
transfection O +
in O +
MCE O +
cells O +
leads O +
to O +
extracellular O +
proteolysis O +
and O +
to O +
release O +
of O +
matrix O +
- O +
bound O +
VEGF O +
and O +
activation O +
of O +
angiogenesis O +
. O +

In O +
this O +
study O +
, O +
we O +
demonstrate O +
that O +
two O +
independent O +
downstream O +
signal O +
pathways O +
, O +
DCN O +
/ O +
EGFR O +
/ O +
ERK1 O +
/ O +
2 O +
and O +
DCN O +
/ O +
EGFR O +
/ O +
phosphoinositide O +
- O +
3 O +
kinase O +
/ O +
AKT O +
, O +
mediate O +
up O +
- O +
regulation O +
and O +
activation O +
of O +
transcription O +
factors O +
of O +
VEGF O +
such O +
as O +
HIF1alpha O +
, O +
Stat3 O +
, O +
and O +
Sp1 O +
and O +
increase O +
VEGF O +
transcription O +
and O +
angiogenesis O +
in O +
MCE O +
cells O +
. O +

Melanoma O +
/ O +
skin O +
cancer O +
screening O +
clinics O +
: O +
experiences O +
in O +
The O +
Netherlands O +
. O +

In O +
1989 O +
and O +
1990 O +
we O +
conducted O +
two O +
free O +
melanoma O +
/ O +
skin O +
screening O +
clinics O +
in O +
Oss O +
and O +
Arnhem O +
in O +
the O +
Netherlands O +
. O +

The O +
study O +
was O +
carried O +
out O +
along O +
the O +
lines O +
of O +
the O +
recent O +
campaigns O +
supported O +
by O +
the O +
American O +
Academy O +
of O +
Dermatology O +
. O +

Of O +
2564 O +
persons O +
screened O +
, O +
53 O +
had O +
melanoma O +
or O +
nonmelanoma O +
skin O +
cancer O +
( O +
2 O +
. O +
1 O +
% O +
) O +
. O +

Compliance O +
with O +
follow O +
- O +
up O +
for O +
persons O +
with O +
suspected O +
melanoma O +
/ O +
skin O +
cancer O +
was O +
adequate O +
( O +
93 O +
of O +
103 O +
; O +
90 O +
. O +
3 O +
% O +
) O +
. O +

M O +
. O +
leprae O +
- O +
and O +
BCG O +
- O +
induced O +
chemiluminescence O +
response O +
of O +
monocytes O +
from O +
leprosy O +
patients O +
and O +
healthy O +
subjects O +
: O +
effects O +
of O +
gamma O +
- O +
interferon O +
and O +
GM O +
- O +
CSF O +
. O +

Mycobacterium O +
leprae O +
, O +
in O +
contrast O +
to O +
BCG O +
, O +
failed O +
to O +
trigger O +
any O +
chemiluminescence O +
( O +
CL O +
) O +
response O +
in O +
mononuclear O +
cells O +
from O +
either O +
leprosy O +
patients O +
or O +
healthy O +
subjects O +
, O +
a O +
deficit O +
not O +
reversed O +
by O +
either O +
interferon O +
- O +
gamma O +
or O +
GM O +
- O +
CSF O +
. O +

Chemiluminescence O +
responses O +
induced O +
without O +
mycobacteria O +
or O +
with O +
BCG O +
were O +
found O +
to O +
be O +
lower O +
in O +
leprosy O +
patients O +
than O +
in O +
controls O +
. O +

M O +
. O +
leprae O +
were O +
also O +
less O +
well O +
phagocytosed O +
than O +
BCG O +
. O +

However O +
, O +
there O +
was O +
a O +
significant O +
difference O +
in O +
phagocytosis O +
between O +
healthy O +
and O +
tuberculoid O +
leprosy O +
subjects O +
. O +

Phagocytosis O +
was O +
not O +
altered O +
by O +
the O +
addition O +
of O +
either O +
lymphokine O +
, O +
and O +
no O +
major O +
differences O +
between O +
healthy O +
subjects O +
and O +
patients O +
were O +
observed O +
. O +

Preincubating O +
mononuclear O +
cells O +
with O +
anti O +
- O +
mycobacteria O +
antibodies O +
( O +
lepromatous O +
patients O +
' O +
sera O +
) O +
did O +
not O +
increase O +
the O +
CL O +
response O +
nor O +
the O +
phagocytosis O +
of O +
M O +
. O +
leprae O +
or O +
BCG O +
. O +

[ O +
Clinical O +
significance O +
of O +
interleukin O +
- O +
6 O +
( O +
IL O +
- O +
6 O +
) O +
as O +
a O +
prognostic O +
factor O +
of O +
cancer O +
disease O +
] O +

Interleukin O +
- O +
6 O +
( O +
IL O +
- O +
6 O +
) O +
is O +
proinflammatory O +
cytokine O +
that O +
produces O +
multifunctional O +
effects O +
. O +

It O +
is O +
also O +
involved O +
in O +
the O +
regulation O +
of O +
immune O +
reactions O +
, O +
hematopoiesis O +
and O +
inflammatory O +
state O +
. O +

Interleukin O +
- O +
6 O +
has O +
been O +
shown O +
to O +
be O +
associated O +
with O +
tumor O +
progression O +
including O +
inhibition O +
of O +
cancer O +
cells O +
apoptosis O +
and O +
stimulation O +
of O +
angiogenesis O +
. O +

Anti O +
- O +
IL O +
- O +
6 O +
therapy O +
is O +
a O +
new O +
strategy O +
in O +
the O +
inflammatory O +
autoimmune O +
diseases O +
and O +
cancer O +
. O +

Clinical O +
studies O +
have O +
shown O +
elevated O +
serum O +
IL O +
- O +
6 O +
concentrations O +
in O +
patients O +
with O +
endometrial O +
cancer O +
, O +
non O +
- O +
small O +
cell O +
lung O +
carcinoma O +
, O +
colorectal O +
cancer O +
, O +
renal O +
cell O +
carcinoma O +
, O +
breast O +
and O +
ovarian O +
cancer O +
. O +

Serum O +
IL O +
- O +
6 O +
levels O +
correlate O +
with O +
tumor O +
stage O +
, O +
and O +
survival O +
of O +
patients O +
. O +

In O +
this O +
article O +
we O +
have O +
focused O +
on O +
a O +
role O +
of O +
IL O +
- O +
6 O +
as O +
a O +
prognostic O +
factor O +
in O +
several O +
malignancies O +
such O +
as O +
colorectal O +
cancer O +
, O +
breast O +
cancer O +
, O +
gastric O +
cancer O +
and O +
pancreatic O +
cancer O +
. O +

Tumor O +
microenvironment O +
, O +
a O +
dangerous O +
society O +
leading O +
to O +
cancer O +
metastasis O +
. O +

From O +
mechanisms O +
to O +
therapy O +
and O +
prevention O +
. O +

Cancer O +
is O +
no O +
longer O +
considered O +
by O +
scientists O +
just O +
a O +
jumble O +
of O +
mutated O +
cells O +
. O +

To O +
grow O +
, O +
invade O +
and O +
metastasize O +
, O +
a O +
treacherous O +
society O +
between O +
cancer O +
and O +
host O +
cells O +
must O +
be O +
formed O +
, O +
and O +
this O +
association O +
provides O +
novel O +
and O +
effective O +
clinical O +
targets O +
for O +
cancer O +
control O +
and O +
prevention O +
. O +

This O +
collection O +
of O +
reviews O +
at O +
the O +
front O +
- O +
edge O +
of O +
scientific O +
knowledge O +
focuses O +
on O +
host O +
- O +
tumor O +
cell O +
interactions O +
, O +
the O +
disastrous O +
consequences O +
they O +
can O +
produce O +
and O +
approaches O +
the O +
ways O +
to O +
break O +
up O +
these O +
cellular O +
conspiracies O +
, O +
to O +
leave O +
the O +
tumor O +
cells O +
unattended O +
and O +
vulnerable O +
. O +

Effects O +
of O +
spironolactone O +
on O +
corneal O +
allograft O +
survival O +
in O +
the O +
rat O +
. O +

PURPOSE O +
: O +
Spironolactone O +
has O +
recently O +
been O +
shown O +
to O +
have O +
suppressive O +
effects O +
on O +
several O +
immunoactive O +
and O +
proinflammatory O +
cytokines O +
. O +

In O +
this O +
study O +
, O +
we O +
investigated O +
the O +
effects O +
of O +
spironolactone O +
on O +
the O +
prevention O +
of O +
corneal O +
allograft O +
rejection O +
in O +
a O +
MHC O +
class O +
I O +
/ O +
II O +
mismatch O +
rat O +
corneal O +
transplant O +
model O +
. O +

METHODS O +
: O +
Grafted O +
animals O +
for O +
corneal O +
survival O +
analysis O +
were O +
assigned O +
to O +
receive O +
either O +
spironolactone O +
suspension O +
( O +
orally O +
, O +
100 O +
mg O +
/ O +
kg O +
/ O +
day O +
, O +
n O +
= O +
7 O +
) O +
, O +
phosphate O +
- O +
buffered O +
saline O +
( O +
PBS O +
, O +
orally O +
, O +
same O +
volume O +
as O +
spironolactone O +
, O +
n O +
= O +
9 O +
) O +
or O +
remained O +
untreated O +
( O +
n O +
= O +
16 O +
) O +
. O +

Additional O +
grafted O +
rats O +
treated O +
with O +
spironolactone O +
( O +
n O +
= O +
6 O +
) O +
or O +
PBS O +
( O +
n O +
= O +
8 O +
) O +
were O +
sacrificed O +
on O +
day O +
12 O +
for O +
quantitative O +
RT O +
- O +
PCR O +
analysis O +
for O +
mechanistic O +
studies O +
. O +

RESULTS O +
: O +
Mean O +
( O +
+ O +
/ O +
- O +
SEM O +
) O +
graft O +
survival O +
was O +
significantly O +
prolonged O +
in O +
animals O +
receiving O +
spironolactone O +
( O +
14 O +
. O +
9 O +
+ O +
/ O +
- O +
2 O +
. O +
0 O +
days O +
) O +
compared O +
with O +
both O +
PBS O +
- O +
treated O +
( O +
12 O +
. O +
3 O +
+ O +
/ O +
- O +
1 O +
. O +
2 O +
days O +
, O +
p O +
= O +
0 O +
. O +
007 O +
) O +
and O +
untreated O +
controls O +
( O +
13 O +
. O +
0 O +
+ O +
/ O +
- O +
1 O +
. O +
0 O +
days O +
, O +
p O +
= O +
0 O +
. O +
01 O +
) O +
. O +

We O +
found O +
a O +
decrease O +
in O +
corneal O +
neovascularization O +
in O +
spironolactone O +
- O +
treated O +
rats O +
compared O +
with O +
the O +
PBS O +
- O +
treated O +
group O +
, O +
although O +
the O +
difference O +
was O +
not O +
statistically O +
significant O +
. O +

Spironolactone O +
affected O +
both O +
systemic O +
( O +
down O +
- O +
regulation O +
of O +
CD25 O +
+ O +
cells O +
in O +
spleen O +
) O +
and O +
local O +
immune O +
response O +
( O +
up O +
- O +
regulation O +
of O +
IL O +
- O +
10 O +
in O +
cornea O +
) O +
. O +

CONCLUSION O +
: O +
We O +
present O +
initial O +
results O +
demonstrating O +
anti O +
- O +
inflammatory O +
effects O +
of O +
spironolactone O +
. O +

FAS O +
- O +
1377 O +
G O +
/ O +
A O +
polymorphism O +
and O +
the O +
risk O +
of O +
lymph O +
node O +
metastasis O +
in O +
cervical O +
cancer O +
. O +

Single O +
- O +
nucleotide O +
polymorphisms O +
of O +
the O +
FAS O +
- O +
1377 O -
G O +
/ O +
A O +
, O +
FAS O +
- O +
670A O +
/ O +
G O +
, O +
and O +
FASL O +
- O +
844 O -
T O +
/ O +
C O +
genes O +
may O +
alter O +
transcriptional O +
activity O +
of O +
these O +
genes O +
. O +

Recent O +
evidence O +
suggests O +
an O +
association O +
of O +
these O +
polymorphisms O +
with O +
an O +
increased O +
risk O +
of O +
cervical O +
cancer O +
, O +
so O +
we O +
explored O +
this O +
relationship O +
. O +

Genotypes O +
of O +
155 O +
patients O +
with O +
cervical O +
cancer O +
and O +
160 O +
healthy O +
control O +
subjects O +
were O +
determined O +
using O +
polymerase O +
chain O +
reaction O +
- O +
based O +
restriction O +
fragment O +
length O +
polymorphism O +
( O +
PCR O +
- O +
RFLP O +
) O +
. O +

Associations O +
with O +
cancer O +
risk O +
were O +
estimated O +
using O +
two O +
- O +
sided O +
logistic O +
regression O +
. O +

We O +
observed O +
a O +
significantly O +
increased O +
risk O +
of O +
lymph O +
node O +
metastasis O +
associated O +
with O +
the O +
FAS O +
- O +
1377 O +
GA O +
or O +
AA O +
polymorphism O +
[ O +
odds O +
ratio O +
( O +
OR O +
) O +
= O +
4 O +
. O +
16 O +
, O +
95 O +
% O +
confidence O +
interval O +
( O +
CI O +
) O +
= O +
1 O +
. O +
10 O +
to O +
15 O +
. O +
74 O +
; O +
P O +
= O +
0 O +
. O +
036 O +
] O +
. O +

In O +
addition O +
, O +
the O +
FAS O +
- O +
670AG O +
or O +
GG O +
genotype O +
showed O +
an O +
increased O +
incidence O +
of O +
node O +
metastasis O +
, O +
but O +
these O +
findings O +
were O +
not O +
statistically O +
significant O +
( O +
OR O +
= O +
3 O +
. O +
67 O +
, O +
95 O +
% O +
CI O +
= O +
0 O +
. O +
96 O +
- O +
14 O +
. O +
00 O +
, O +
P O +
= O +
0 O +
. O +
059 O +
) O +
. O +

There O +
was O +
no O +
significant O +
association O +
between O +
an O +
increased O +
risk O +
of O +
cervical O +
cancer O +
and O +
polymorphisms O +
of O +
the O +
death O +
pathway O +
genes O +
FAS O +
and O +
FASL O +
. O +

None O +
of O +
the O +
polymorphisms O +
were O +
associated O +
with O +
risk O +
of O +
advanced O +
stage O +
or O +
histologic O +
subtype O +
of O +
cervical O +
cancer O +
. O +

In O +
conclusion O +
, O +
FAS O +
- O +
1377 O +
G O +
- O +
- O +
> O +
A O +
polymorphism O +
may O +
be O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
lymph O +
node O +
metastasis O +
in O +
Korean O +
cervical O +
cancer O +
patients O +
. O +

Detection O +
of O +
lymphovascular O +
invasion O +
in O +
early O +
breast O +
cancer O +
by O +
D2 O +
- O +
40 O +
( O +
podoplanin O +
) O +
: O +
a O +
clinically O +
useful O +
predictor O +
for O +
axillary O +
lymph O +
node O +
metastases O +
. O +

PURPOSE O +
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
use O +
of O +
D2 O +
- O +
40 O +
for O +
the O +
detection O +
of O +
lymphovascular O +
invasion O +
( O +
LVI O +
) O +
in O +
node O +
positive O +
and O +
negative O +
early O +
breast O +
cancer O +
. O +

LVI O +
is O +
associated O +
with O +
axillary O +
lymph O +
node O +
metastases O +
( O +
ALNM O +
) O +
and O +
a O +
long O +
- O +
term O +
prognostic O +
factor O +
. O +

A O +
precise O +
identification O +
of O +
LVI O +
would O +
have O +
a O +
strong O +
clinical O +
impact O +
for O +
breast O +
cancer O +
patients O +
. O +

METHODS O +
: O +
Immunohistochemical O +
staining O +
with O +
D2 O +
- O +
40 O +
and O +
CD34 O +
was O +
performed O +
on O +
formalin O +
- O +
fixed O +
, O +
paraffin O +
- O +
embedded O +
tissue O +
sections O +
of O +
254 O +
invasive O +
breast O +
tumors O +
of O +
247 O +
patients O +
with O +
node O +
negative O +
and O +
node O +
positive O +
early O +
breast O +
cancer O +
. O +

All O +
slides O +
were O +
screened O +
for O +
the O +
presence O +
of O +
LVI O +
. O +

Correlation O +
with O +
clinico O +
- O +
pathological O +
factors O +
including O +
LVI O +
as O +
retrieved O +
by O +
routine O +
haematoxylin O +
and O +
eosin O +
( O +
H O +
. O +
E O +
. O +
) O +
stained O +
sections O +
and O +
the O +
eligibility O +
for O +
the O +
prediction O +
of O +
ALNM O +
was O +
assessed O +
. O +

RESULTS O +
: O +
Using O +
the O +
D2 O +
- O +
40 O +
antibody O +
for O +
immunostaining O +
, O +
our O +
results O +
demonstrate O +
a O +
significant O +
higher O +
detection O +
( O +
P O +
< O +
0 O +
. O +
001 O +
) O +
of O +
LVI O +
as O +
compared O +
with O +
routine O +
H O +
. O +
E O +
. O +
- O +
staining O +
in O +
early O +
breast O +
cancer O +
. O +

LVI O +
was O +
correctly O +
identified O +
by O +
D2 O +
- O +
40 O +
( O +
D2 O +
- O +
40 O +
+ O +
) O +
in O +
70 O +
out O +
of O +
254 O +
tumors O +
( O +
28 O +
% O +
) O +
as O +
compared O +
to O +
40 O +
tumors O +
( O +
16 O +
% O +
) O +
by O +
routine O +
HE O +
staining O +
( O +
HE O +
+ O +
) O +
. O +

There O +
was O +
a O +
significant O +
correlation O +
between O +
D2 O +
- O +
40 O +
+ O +
LVI O +
and O +
age O +
, O +
t O +
- O +
stage O +
, O +
nodal O +
status O +
, O +
grading O +
and O +
hormonreceptor O +
- O +
status O +
. O +

Correlation O +
between O +
D2 O +
- O +
40 O +
+ O +
LVI O +
and O +
menopausal O +
- O +
status O +
, O +
HER2 O +
- O +
status O +
and O +
histological O +
type O +
was O +
not O +
significant O +
, O +
while O +
there O +
was O +
a O +
significant O +
correlation O +
of O +
D2 O +
- O +
40 O +
and O +
so O +
called O +
" O +
triple O +
negative O +
" O +
tumors O +
( O +
ER O +
/ O +
PR O +
and O +
HER2neu O +
- O +
negative O +
) O +
. O +

In O +
a O +
multivariate O +
analysis O +
D2 O +
- O +
40 O +
+ O +
was O +
the O +
strongest O +
predictor O +
for O +
ALNM O +
with O +
an O +
odds O +
ratio O +
of O +
3 O +
. O +
489 O +
and O +
a O +
P O +
- O +
value O +
of O +
P O +
= O +
0 O +
. O +
0003 O +
, O +
followed O +
only O +
by O +
T O +
- O +
stage O +
and O +
grading O +
with O +
odds O +
ratios O +
of O +
3 O +
. O +
167 O +
and O +
1 O +
. O +
953 O +
and O +
P O +
- O +
values O +
P O +
= O +
0 O +
. O +
0003 O +
and O +
P O +
= O +
0 O +
. O +
0352 O +
. O +

CONCLUSION O +
: O +
Immunostaining O +
with O +
D2 O +
- O +
40 O +
significantly O +
increased O +
the O +
frequency O +
of O +
detection O +
of O +
lymphatic O +
invasion O +
compared O +
to O +
conventional O +
H O +
. O +
E O +
. O +
- O +
staining O +
in O +
early O +
breast O +
cancer O +
. O +

As O +
LVI O +
is O +
a O +
strong O +
predictive O +
and O +
prognostic O +
marker O +
, O +
the O +
monoclonal O +
antibody O +
D2 O +
- O +
40 O +
has O +
the O +
potential O +
to O +
play O +
a O +
significant O +
role O +
in O +
pathological O +
routine O +
workup O +
of O +
breast O +
tumors O +
. O +

Further O +
prospective O +
studies O +
are O +
needed O +
to O +
prove O +
the O +
clinical O +
impact O +
of O +
D2 O +
- O +
40 O +
. O +

Expression O +
of O +
CDK4 O +
or O +
CDK2 O +
in O +
mouse O +
oral O +
cavity O +
is O +
retained O +
in O +
adult O +
pituitary O +
with O +
distinct O +
effects O +
on O +
tumorigenesis O +
. O +

The O +
keratin O +
5 O +
( O +
K5 O +
) O +
promoter O +
drives O +
transgenic O +
expression O +
to O +
the O +
basal O +
cell O +
layer O +
of O +
stratified O +
epithelia O +
. O +

Surprisingly O +
, O +
analysis O +
of O +
K5CDK4 O +
and O +
K5CDK2 O +
transgenic O +
mouse O +
embryos O +
showed O +
CDK4 O +
and O +
CDK2 O +
expression O +
not O +
only O +
in O +
the O +
expected O +
tissues O +
, O +
but O +
also O +
in O +
the O +
adenohypophysis O +
. O +

This O +
organ O +
is O +
derived O +
from O +
an O +
upwards O +
growth O +
of O +
the O +
primitive O +
oropharynx O +
, O +
a O +
K5 O +
- O +
expressing O +
tissue O +
. O +

We O +
show O +
that O +
transgenic O +
expression O +
of O +
CDKs O +
in O +
the O +
embryonic O +
oral O +
ectoderm O +
is O +
specifically O +
retained O +
in O +
undifferentiated O +
cells O +
from O +
the O +
pars O +
intermedia O +
of O +
the O +
adenohypophysis O +
. O +

Interestingly O +
, O +
we O +
found O +
that O +
K5CDK4 O +
mice O +
show O +
a O +
decreased O +
number O +
of O +
pituitary O +
stem O +
cells O +
, O +
even O +
though O +
CDK4 O +
is O +
not O +
expressed O +
in O +
the O +
stem O +
cells O +
but O +
in O +
transit O +
- O +
amplifying O +
( O +
TA O +
) O +
- O +
like O +
cells O +
. O +

Interestingly O +
, O +
CDK4 O +
- O +
expressing O +
cells O +
, O +
but O +
not O +
CDK2 O +
- O +
expressing O +
cells O +
, O +
strongly O +
synergize O +
with O +
lack O +
of O +
p27 O +
( O +
Kip1 O +
) O +
to O +
generate O +
pituitary O +
carcinomas O +
that O +
appear O +
with O +
shortened O +
latency O +
and O +
are O +
drastically O +
more O +
aggressive O +
than O +
those O +
arising O +
in O +
p27 O +
( O +
- O +
/ O +
- O +
) O +
mice O +
. O +

Thus O +
, O +
we O +
show O +
that O +
deregulation O +
of O +
CDK O +
expression O +
in O +
the O +
primitive O +
oral O +
epithelium O +
plays O +
a O +
unique O +
function O +
, O +
providing O +
a O +
selective O +
advantage O +
that O +
gives O +
rise O +
to O +
transgene O +
- O +
positive O +
TA O +
- O +
like O +
pituitary O +
cells O +
. O +

Furthermore O +
, O +
retention O +
of O +
CDK4 O +
in O +
these O +
TA O +
- O +
like O +
pituitary O +
cells O +
synergizes O +
with O +
loss O +
of O +
p27 O +
( O +
Kip1 O +
) O +
to O +
induce O +
pituitary O +
adenocarcinomas O +
. O +

This O +
model O +
suggests O +
that O +
forced O +
expression O +
of O +
CDK4 O +
sensitizes O +
cells O +
and O +
synergizes O +
with O +
a O +
second O +
change O +
resulting O +
in O +
tumor O +
development O +
. O +

[ O +
Photodynamic O +
therapy O +
in O +
severe O +
chronic O +
central O +
serous O +
chorioretinopaty O +
] O +

OBJECTIVE O +
: O +
To O +
determine O +
the O +
efficacy O +
of O +
Photodynamic O +
Therapy O +
( O +
PDT O +
) O +
in O +
chronic O +
Central O +
Serous O +
Chorioretinopathy O +
( O +
CSC O +
) O +
. O +

METHODS O +
: O +
Patients O +
diagnosed O +
with O +
chronic O +
CSC O +
, O +
with O +
clinical O +
evidence O +
of O +
activity O +
and O +
treated O +
with O +
Photodynamic O +
Therapy O +
, O +
are O +
included O +
in O +
this O +
report O +
. O +

All O +
were O +
assessed O +
by O +
a O +
complete O +
ophthalmological O +
examination O +
, O +
including O +
assessment O +
of O +
the O +
best O +
corrected O +
visual O +
acuity O +
( O +
BCVA O +
) O +
using O +
an O +
ETDRS O +
chart O +
, O +
fluorescein O +
and O +
indocyanine O +
angiography O +
and O +
optical O +
coherence O +
tomography O +
( O +
OCT O +
) O +
. O +

The O +
main O +
objective O +
of O +
the O +
study O +
was O +
to O +
determine O +
the O +
mean O +
visual O +
acuity O +
change O +
. O +

RESULTS O +
: O +
11 O +
eyes O +
of O +
11 O +
patients O +
were O +
included O +
in O +
the O +
study O +
, O +
which O +
had O +
a O +
mean O +
follow O +
- O +
up O +
period O +
of O +
11 O +
months O +
. O +

The O +
mean O +
BCVA O +
increased O +
from O +
20 O +
/ O +
76 O +
to O +
20 O +
/ O +
64 O +
. O +

35 O +
% O +
of O +
eyes O +
improved O +
their O +
BCVA O +
by O +
2 O +
lines O +
or O +
more O +
, O +
45 O +
% O +
remained O +
stable O +
and O +
18 O +
% O +
lost O +
2 O +
lines O +
or O +
more O +
. O +

Choroidal O +
hyperpermeability O +
was O +
reduced O +
in O +
every O +
case O +
. O +

Neurosensorial O +
retinal O +
detachment O +
decreased O +
in O +
80 O +
% O +
of O +
cases O +
. O +

Only O +
one O +
eye O +
received O +
a O +
second O +
PDT O +
treatment O +
due O +
to O +
choroidal O +
neovascularization O +
. O +

An O +
increase O +
of O +
atrophy O +
over O +
the O +
Retinal O +
Pigment O +
Epithelium O +
( O +
RPE O +
) O +
was O +
observed O +
in O +
another O +
patient O +
. O +

CONCLUSIONS O +
: O +
PDT O +
can O +
reduce O +
the O +
clinical O +
signs O +
of O +
activity O +
, O +
such O +
as O +
choroidal O +
hyperpermeability O +
or O +
neurosensorial O +
retinal O +
detachment O +
, O +
in O +
patients O +
affected O +
by O +
chronic O +
CSC O +
. O +

However O +
, O +
the O +
increase O +
in O +
visual O +
acuity O +
is O +
variable O +
, O +
probably O +
due O +
to O +
the O +
extent O +
of O +
RPE O +
damage O +
. O +

N O +
- O +
myc O +
augments O +
death O +
and O +
attenuates O +
protective O +
effects O +
of O +
Bcl O +
- O +
2 O +
in O +
trophically O +
stressed O +
neuroblastoma O +
cells O +
. O +

N O +
- O +
myc O +
has O +
proapoptotic O +
functions O +
, O +
yet O +
it O +
acts O +
as O +
an O +
oncogene O +
in O +
neuroblastoma O +
. O +

Thus O +
, O +
antiapoptotic O +
mechanisms O +
have O +
to O +
be O +
operative O +
in O +
neuroblastoma O +
cells O +
that O +
antagonize O +
the O +
proapoptotic O +
effects O +
of O +
N O +
- O +
myc O +
. O +

We O +
conditionally O +
activated O +
N O +
- O +
myc O +
in O +
SH B-CellLine +
- I-CellLine +
EP I-CellLine +
neuroblastoma O +
cells O +
subjected O +
to O +
the O +
trophic O +
stress O +
of O +
serum O +
or O +
nutrient O +
deprivation O +
while O +
changing O +
the O +
expression O +
of O +
Bcl O +
- O +
2 O +
, O +
survivin O +
and O +
FLIP O +
( O +
L O +
) O +
, O +
antiapoptotic O +
molecules O +
often O +
overexpressed O +
in O +
poor O +
prognosis O +
neuroblastomas O +
. O +

Bcl O +
- O +
2 O +
protected O +
SH B-CellLine +
- I-CellLine +
EP I-CellLine +
cells O +
from O +
death O +
during O +
nutritional O +
deprivation O +
by O +
activating O +
energetically O +
advantageous O +
oxidative O +
phosphorylation O +
. O +

N O +
- O +
myc O +
overrode O +
the O +
metabolic O +
protection O +
provided O +
by O +
Bcl O +
- O +
2 O +
- O +
induced O +
oxidative O +
phosphorylation O +
by O +
reestablishing O +
the O +
glycolytic O +
phenotype O +
and O +
attenuated O +
the O +
antiapoptotic O +
effect O +
of O +
Bcl O +
- O +
2 O +
during O +
metabolic O +
stress O +
. O +

Survivin O +
partially O +
antagonized O +
the O +
growth O +
suppressive O +
function O +
of O +
N O +
- O +
myc O +
in O +
SH B-CellLine +
- I-CellLine +
EP I-CellLine +
neuroblastoma O +
cells O +
during O +
serum O +
deprivation O +
whereas O +
FLIP O +
( O +
L O +
) O +
did O +
not O +
. O +

These O +
findings O +
advance O +
our O +
understanding O +
of O +
the O +
functions O +
of O +
N O +
- O +
myc O +
in O +
neuroblastoma O +
cells O +
. O +

Angiopoietin O +
- O +
1 O +
prevents O +
VEGF O +
- O +
induced O +
endothelial O +
permeability O +
by O +
sequestering O +
Src O +
through O +
mDia O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
and O +
Angiopoietin O +
1 O +
( O +
Ang1 O +
) O +
are O +
both O +
potent O +
proangiogenic O +
factors O +
, O +
but O +
, O +
whereas O +
VEGF O +
causes O +
vascular O +
permeability O +
, O +
Ang1 O +
stabilizes O +
blood O +
vessels O +
and O +
protects O +
them O +
from O +
VEGF O +
- O +
induced O +
plasma O +
leakage O +
. O +

The O +
antivascular O +
permeability O +
mechanisms O +
deployed O +
by O +
Ang1 O +
are O +
still O +
undefined O +
. O +

Here O +
, O +
we O +
demonstrate O +
that O +
Ang1 O +
halts O +
the O +
ability O +
of O +
VEGF O +
to O +
induce O +
the O +
phosphorylation O +
- O +
dependent O +
redistribution O +
of O +
the O +
adhesion O +
molecule O +
VE O +
- O +
cadherin O +
, O +
thereby O +
rescuing O +
the O +
endothelial O +
barrier O +
function O +
. O +

Ang1 O +
inhibits O +
the O +
activation O +
of O +
Src O +
by O +
VEGF O +
, O +
the O +
most O +
upstream O +
component O +
of O +
the O +
pathway O +
linking O +
VEGF O +
receptors O +
to O +
VE O +
- O +
cadherin O +
internalization O +
. O +

Indeed O +
, O +
Ang1 O +
promotes O +
the O +
activation O +
of O +
mDia O +
through O +
RhoA O +
, O +
resulting O +
in O +
the O +
association O +
of O +
mDia O +
with O +
Src O +
. O +

This O +
ultimately O +
deprives O +
VEGF O +
receptors O +
of O +
an O +
essential O +
molecule O +
required O +
for O +
promoting O +
the O +
disruption O +
of O +
endothelial O +
cell O +
- O +
cell O +
contacts O +
and O +
paracellular O +
permeability O +
. O +

RUNX1 O +
DNA O +
- O +
binding O +
mutations O +
and O +
RUNX1 O +
- O +
PRDM16 O +
cryptic O +
fusions O +
in O +
BCR O +
- O +
ABL O +
+ O +
leukemias O +
are O +
frequently O +
associated O +
with O +
secondary O +
trisomy O +
21 O +
and O +
may O +
contribute O +
to O +
clonal O +
evolution O +
and O +
imatinib O +
resistance O +
. O +

Acquired O +
molecular O +
abnormalities O +
( O +
mutations O +
or O +
chromosomal O +
translocations O +
) O +
of O +
the O +
RUNX1 O +
transcription O +
factor O +
gene O +
are O +
frequent O +
in O +
acute O +
myeloblastic O +
leukemias O +
( O +
AMLs O +
) O +
and O +
in O +
therapy O +
- O +
related O +
myelodysplastic O +
syndromes O +
, O +
but O +
rarely O +
in O +
acute O +
lymphoblastic O +
leukemias O +
( O +
ALLs O +
) O +
and O +
chronic O +
myelogenous O +
leukemias O +
( O +
CMLs O +
) O +
. O +

Among O +
18 O +
BCR O +
- O +
ABL O +
+ O +
leukemias O +
presenting O +
acquired O +
trisomy O +
of O +
chromosome O +
21 O +
, O +
we O +
report O +
a O +
high O +
frequency O +
( O +
33 O +
% O +
) O +
of O +
recurrent O +
point O +
mutations O +
( O +
4 O +
in O +
myeloid O +
blast O +
crisis O +
[ O +
BC O +
] O +
CML O +
and O +
one O +
in O +
chronic O +
phase O +
CML O +
) O +
within O +
the O +
DNA O +
- O +
binding O +
region O +
of O +
RUNX1 O +
. O +

We O +
did O +
not O +
found O +
any O +
mutation O +
in O +
de O +
novo O +
BCR O +
- O +
ABL O +
+ O +
ALLs O +
or O +
lymphoid O +
BC O +
CML O +
. O +

Emergence O +
of O +
the O +
RUNX1 O +
mutations O +
was O +
detected O +
at O +
diagnosis O +
or O +
before O +
the O +
acquisition O +
of O +
trisomy O +
21 O +
during O +
disease O +
progression O +
. O +

In O +
addition O +
, O +
we O +
also O +
report O +
a O +
high O +
frequency O +
of O +
cryptic O +
chromosomal O +
RUNX1 O +
translocation O +
to O +
a O +
novel O +
recently O +
described O +
gene O +
partner O +
, O +
PRDM16 O +
on O +
chromosome O +
1p36 O +
, O +
for O +
3 O +
( O +
21 O +
. O +
4 O +
% O +
) O +
of O +
14 O +
investigated O +
patients O +
: O +
2 O +
myeloid O +
BC O +
CMLs O +
and O +
, O +
for O +
the O +
first O +
time O +
, O +
1 O +
therapy O +
- O +
related O +
BCR O +
- O +
ABL O +
+ O +
ALL O +
. O +

Two O +
patients O +
presented O +
both O +
RUNX1 O +
mutations O +
and O +
RUNX1 O +
- O +
PRDM16 O +
fusion O +
. O +

These O +
events O +
are O +
associated O +
with O +
a O +
short O +
survival O +
and O +
support O +
the O +
concept O +
of O +
a O +
cooperative O +
effect O +
of O +
BCR O +
- O +
ABL O +
with O +
molecular O +
RUNX1 O +
abnormalities O +
on O +
the O +
differentiation O +
arrest O +
phenotype O +
observed O +
during O +
progression O +
of O +
CML O +
and O +
in O +
BCR O +
- O +
ABL O +
+ O +
ALL O +
. O +

A O +
new O +
autosomal O +
dominant O +
vascular O +
retinopathy O +
syndrome O +
. O +

We O +
describe O +
a O +
new O +
syndrome O +
with O +
autosomal O +
dominant O +
transmission O +
whose O +
most O +
striking O +
feature O +
is O +
vascular O +
retinopathy O +
. O +

The O +
retinopathy O +
is O +
often O +
associated O +
with O +
migraine O +
, O +
Raynaud O +
' O +
s O +
phenomenon O +
and O +
mental O +
changes O +
, O +
mainly O +
forgetfulness O +
, O +
aggression O +
and O +
depression O +
. O +

To O +
define O +
this O +
syndrome O +
we O +
collected O +
medical O +
data O +
on O +
110 O +
family O +
members O +
. O +

General O +
ophthalmological O +
examination O +
and O +
fluorescein O +
angiography O +
were O +
performed O +
in O +
61 O +
persons O +
. O +

The O +
retinopathy O +
, O +
as O +
diagnosed O +
in O +
22 O +
persons O +
, O +
is O +
characterized O +
by O +
central O +
and O +
peripheral O +
microangiopathy O +
, O +
areas O +
of O +
capillary O +
non O +
- O +
perfusion O +
, O +
haemorrhages O +
, O +
cotton O +
wool O +
spots O +
and O +
, O +
in O +
a O +
more O +
advanced O +
stage O +
, O +
occlusion O +
of O +
large O +
retinal O +
vessels O +
, O +
which O +
can O +
induce O +
a O +
neovascular O +
response O +
. O +

A O +
vascular O +
occlusive O +
disorder O +
may O +
be O +
the O +
common O +
aetiological O +
factor O +
of O +
the O +
various O +
manifestation O +
of O +
this O +
syndrome O +
. O +

The O +
element O +
effect O +
and O +
nucleophilicity O +
in O +
nucleophilic O +
aromatic O +
photosubstitution O +
( O +
SN2Ar O +
* O +
) O +
. O +

Local O +
atom O +
effects O +
as O +
mechanistic O +
probes O +
of O +
very O +
fast O +
reactions O +
. O +

Photoreactions O +
of O +
4 O +
- O +
nitroanisole O +
and O +
the O +
2 O +
- O +
halo O +
- O +
4 O +
- O +
nitroanisoles O +
( O +
halogen O +
= O +
F O +
, O +
Cl O +
, O +
Br O +
, O +
and O +
I O +
) O +
with O +
the O +
nucleophiles O +
hydroxide O +
ion O +
and O +
pyridine O +
have O +
been O +
investigated O +
quantitatively O +
to O +
extend O +
the O +
findings O +
recently O +
communicated O +
for O +
cyanide O +
ion O +
. O +

The O +
halonitroanisoles O +
on O +
excitation O +
form O +
triplet O +
pi O +
, O +
pi O +
* O +
states O +
, O +
which O +
undergo O +
substitution O +
of O +
the O +
halogen O +
by O +
nucleophiles O +
. O +

Chemical O +
yields O +
of O +
photoproducts O +
, O +
Stern O +
- O +
Volmer O +
kinetic O +
plots O +
, O +
triplet O +
lifetimes O +
, O +
and O +
triplet O +
yields O +
are O +
reported O +
for O +
the O +
five O +
compounds O +
with O +
the O +
three O +
nucleophiles O +
. O +

Following O +
a O +
standard O +
kinetic O +
treatment O +
, O +
73 O +
rate O +
constants O +
are O +
determined O +
for O +
elementary O +
reactions O +
of O +
the O +
triplets O +
including O +
quenching O +
and O +
various O +
nucleophilic O +
addition O +
processes O +
. O +

The O +
photoadditions O +
are O +
roughly O +
14 O +
orders O +
of O +
magnitude O +
faster O +
than O +
thermal O +
counterparts O +
. O +

Rate O +
constants O +
for O +
attack O +
at O +
the O +
fluorine O +
- O +
bearing O +
carbon O +
of O +
triplet O +
2 O +
- O +
fluoro O +
- O +
4 O +
- O +
nitroanisole O +
are O +
2 O +
. O +
9 O +
x O +
10 O +
( O +
9 O +
) O +
, O +
1 O +
. O +
3 O +
x O +
10 O +
( O +
9 O +
) O +
, O +
and O +
6 O +
. O +
3 O +
x O +
10 O +
( O +
8 O +
) O +
M O +
( O +
- O +
1 O +
) O +
s O +
( O +
- O +
1 O +
) O +
for O +
cyanide O +
ion O +
, O +
hydroxide O +
ion O +
, O +
and O +
pyridine O +
, O +
respectively O +
. O +

The O +
relative O +
rates O +
for O +
attack O +
at O +
the O +
halogen O +
- O +
bearing O +
carbons O +
for O +
F O +
/ O +
Cl O +
/ O +
Br O +
/ O +
I O +
are O +
27 O +
: O +
1 O +
. O +
9 O +
: O +
1 O +
. O +
9 O +
: O +
1 O +
( O +
cyanide O +
ion O +
) O +
, O +
29 O +
: O +
2 O +
. O +
6 O +
: O +
2 O +
. O +
4 O +
: O +
1 O +
( O +
hydroxide O +
ion O +
) O +
, O +
and O +
39 O +
: O +
3 O +
. O +
9 O +
: O +
3 O +
. O +
5 O +
: O +
1 O +
( O +
pyridine O +
) O +
, O +
respectively O +
. O +

The O +
relative O +
nucleophilicities O +
vary O +
somewhat O +
with O +
the O +
attack O +
site O +
; O +
they O +
are O +
about O +
5 O +
: O +
2 O +
: O +
1 O +
for O +
cyanide O +
ion O +
, O +
hydroxide O +
ion O +
, O +
and O +
pyridine O +
for O +
attack O +
at O +
the O +
halogen O +
- O +
bearing O +
carbons O +
. O +

The O +
trend O +
of O +
the O +
element O +
effect O +
opposes O +
that O +
of O +
aliphatic O +
substitution O +
and O +
elimination O +
but O +
is O +
similar O +
in O +
size O +
and O +
parallel O +
to O +
that O +
of O +
thermal O +
nucleophilic O +
aromatic O +
substitution O +
. O +

Relative O +
nucleophilicities O +
in O +
the O +
photoreactions O +
are O +
also O +
similar O +
to O +
those O +
of O +
comparable O +
but O +
vastly O +
slower O +
thermal O +
reactions O +
. O +

The O +
findings O +
imply O +
that O +
the O +
efficiency O +
- O +
determining O +
step O +
of O +
the O +
halogen O +
photosubstitution O +
is O +
simple O +
formation O +
of O +
a O +
sigma O +
- O +
complex O +
through O +
electron O +
- O +
paired O +
bonding O +
within O +
the O +
triplet O +
manifold O +
. O +

Suppression O +
of O +
lung O +
tumor O +
growth O +
and O +
metastasis O +
in O +
mice O +
by O +
adeno O +
- O +
associated O +
virus O +
- O +
mediated O +
expression O +
of O +
vasostatin O +
. O +

PURPOSE O +
: O +
Angiogenesis O +
inhibitors O +
have O +
strong O +
therapeutic O +
potential O +
as O +
antitumor O +
agents O +
in O +
suppressing O +
tumor O +
growth O +
and O +
metastatic O +
progression O +
. O +

Vasostatin O +
, O +
the O +
N O +
- O +
terminal O +
domain O +
of O +
calreticulin O +
, O +
is O +
a O +
potent O +
angiogenesis O +
inhibitor O +
. O +

In O +
this O +
study O +
, O +
we O +
determined O +
the O +
effectiveness O +
of O +
vasostatin O +
delivered O +
by O +
recombinant O +
pseudotype O +
adeno O +
- O +
associated O +
virus O +
2 O +
/ O +
5 O +
( O +
rAAV2 O +
/ O +
5 O +
- O +
VAS O +
) O +
as O +
a O +
gene O +
therapy O +
approach O +
for O +
lung O +
cancer O +
treatment O +
. O +

EXPERIMENTAL O +
DESIGN O +
: O +
We O +
used O +
rAAV2 O +
/ O +
5 O +
to O +
deliver O +
vasostatin O +
intratumorally O +
or O +
systemically O +
in O +
different O +
mouse O +
lung O +
tumor O +
models O +
- O +
- O +
subcutaneous O +
, O +
orthotopic O +
xenograft O +
, O +
and O +
spontaneous O +
metastasis O +
lung O +
tumor O +
models O +
. O +

The O +
therapeutic O +
efficacy O +
of O +
rAAV2 O +
/ O +
5 O +
- O +
VAS O +
was O +
determined O +
by O +
monitoring O +
tumor O +
volume O +
, O +
survival O +
rate O +
, O +
and O +
degree O +
of O +
neovascularization O +
after O +
treatment O +
in O +
these O +
models O +
. O +

RESULTS O +
: O +
Mice O +
bearing O +
subcutaneous O +
tumor O +
of O +
rAAV2 O +
/ O +
5 O +
- O +
VAS O +
pretreated O +
Lewis O +
lung O +
carcinoma O +
cells O +
showed O +
> O +
50 O +
% O +
reduction O +
in O +
primary O +
tumor O +
volume O +
and O +
reduced O +
spontaneous O +
pulmonary O +
metastases O +
. O +

The O +
tumor O +
- O +
suppressive O +
action O +
of O +
rAAV2 O +
/ O +
5 O +
- O +
VAS O +
in O +
subcutaneous O +
human O +
lung O +
tumor O +
A549 B-CellLine +
xenograft O +
correlated O +
with O +
a O +
reduced O +
number O +
of O +
capillary O +
vessels O +
in O +
tumors O +
. O +

In O +
the O +
orthotopic O +
xenograft O +
model O +
, O +
rAAV2 O +
/ O +
5 O +
- O +
VAS O +
suppressed O +
metastasis O +
of O +
A549 B-CellLine +
tumors O +
to O +
mediastinal O +
lymph O +
nodes O +
and O +
contralateral O +
lung O +
. O +

Furthermore O +
, O +
treatment O +
of O +
immunocompetent O +
mice O +
in O +
the O +
spontaneous O +
lung O +
metastases O +
model O +
with O +
rAAV2 O +
/ O +
5 O +
- O +
VAS O +
after O +
primary O +
tumor O +
excision O +
prolonged O +
their O +
median O +
survival O +
from O +
21 O +
to O +
51 O +
. O +
5 O +
days O +
. O +

CONCLUSION O +
: O +
Our O +
results O +
show O +
the O +
effectiveness O +
of O +
rAAV2 O +
/ O +
5 O +
- O +
VAS O +
as O +
an O +
angiogenesis O +
inhibitor O +
in O +
suppressing O +
tumor O +
growth O +
during O +
different O +
stages O +
of O +
tumor O +
progression O +
, O +
validating O +
the O +
application O +
of O +
rAAV2 O +
/ O +
5 O +
- O +
VAS O +
gene O +
therapy O +
in O +
treatment O +
against O +
lung O +
cancer O +
. O +

Survivin O +
expression O +
in O +
breast O +
carcinoma O +
: O +
correlation O +
with O +
apoptosis O +
and O +
prognosis O +
. O +

BACKGROUND O +
: O +
Survivin O +
is O +
a O +
novel O +
inhibitor O +
of O +
apoptosis O +
commonly O +
detected O +
in O +
tissues O +
during O +
fetal O +
development O +
and O +
in O +
cancer O +
, O +
but O +
not O +
usually O +
in O +
normal O +
tissues O +
. O +

It O +
has O +
been O +
suggested O +
that O +
the O +
expression O +
of O +
this O +
protein O +
may O +
be O +
of O +
prognostic O +
significance O +
in O +
gastric O +
, O +
colorectal O +
, O +
and O +
bladder O +
carcinomas O +
. O +

We O +
assessed O +
survivin O +
expression O +
in O +
breast O +
carcinomas O +
correlating O +
results O +
with O +
expression O +
of O +
other O +
antiapoptotic O +
( O +
bcl O +
- O +
2 O +
, O +
bcl O +
- O +
x O +
) O +
and O +
proapoptotic O +
( O +
bax O +
) O +
markers O +
, O +
with O +
prognostic O +
parameters O +
, O +
and O +
with O +
prognosis O +
. O +

DESIGN O +
: O +
Paraffin O +
- O +
embedded O +
sections O +
of O +
37 O +
breast O +
carcinomas O +
were O +
immunostained O +
for O +
survivin O +
, O +
bcl O +
- O +
2 O +
, O +
bcl O +
- O +
x O +
, O +
and O +
bax O +
. O +

Expression O +
was O +
evaluated O +
in O +
normal O +
breast O +
tissue O +
and O +
carcinoma O +
, O +
nuclei O +
and O +
cytoplasm O +
, O +
as O +
intensity O +
( O +
0 O +
to O +
3 O +
+ O +
) O +
, O +
and O +
percentage O +
of O +
positive O +
cells O +
. O +

RESULTS O +
: O +
Survivin O +
expression O +
was O +
noted O +
in O +
30 O +
( O +
81 O +
% O +
) O +
of O +
breast O +
carcinomas O +
, O +
and O +
in O +
normal O +
breast O +
tissue O +
, O +
in O +
nuclei O +
, O +
and O +
cytoplasm O +
. O +

There O +
was O +
a O +
significant O +
correlation O +
( O +
P O +
= O +
0 O +
. O +
022 O +
) O +
between O +
survivin O +
and O +
bcl O +
- O +
x O +
expression O +
; O +
survivin O +
and O +
bcl O +
- O +
x O +
tended O +
to O +
correlate O +
with O +
overall O +
survival O +
( O +
P O +
= O +
0 O +
. O +
072 O +
and O +
0 O +
. O +
075 O +
, O +
respectively O +
) O +
, O +
but O +
not O +
with O +
disease O +
- O +
free O +
survival O +
( O +
P O +
= O +
0 O +
. O +
19 O +
and O +
0 O +
. O +
18 O +
, O +
respectively O +
) O +
. O +

There O +
was O +
no O +
correlation O +
of O +
survivin O +
with O +
bcl O +
- O +
2 O +
or O +
bax O +
expression O +
, O +
or O +
with O +
other O +
prognostic O +
parameters O +
( O +
age O +
, O +
tumor O +
size O +
, O +
histologic O +
type O +
, O +
histologic O +
grade O +
, O +
nodal O +
status O +
, O +
and O +
tumor O +
stage O +
) O +
( O +
P O +
> O +
0 O +
. O +
05 O +
) O +
. O +

CONCLUSION O +
: O +
The O +
majority O +
( O +
81 O +
% O +
) O +
of O +
breast O +
carcinomas O +
show O +
survivin O +
expression O +
which O +
correlates O +
with O +
bcl O +
- O +
x O +
, O +
another O +
antiapoptotic O +
marker O +
, O +
and O +
both O +
markers O +
tend O +
to O +
correlate O +
with O +
prognosis O +
. O +

Radiation O +
retinopathy O +
is O +
treatable O +
with O +
anti O +
- O +
vascular O +
endothelial O +
growth O +
factor O +
bevacizumab O +
( O +
Avastin O +
) O +
. O +

PURPOSE O +
: O +
To O +
report O +
on O +
bevacizumab O +
treatment O +
for O +
radiation O +
retinopathy O +
affecting O +
the O +
macula O +
. O +

PATIENTS O +
AND O +
METHODS O +
: O +
Twenty O +
- O +
one O +
patients O +
with O +
radiation O +
retinopathy O +
( O +
edema O +
, O +
hemorrhages O +
, O +
capillary O +
dropout O +
, O +
and O +
neovascularization O +
) O +
and O +
a O +
subjective O +
or O +
objective O +
loss O +
of O +
vision O +
were O +
treated O +
. O +

Treatment O +
involved O +
intravitreal O +
injection O +
of O +
bevacizumab O +
( O +
1 O +
. O +
25 O +
mg O +
in O +
0 O +
. O +
05 O +
mL O +
) O +
every O +
6 O +
- O +
12 O +
weeks O +
. O +

Treatment O +
was O +
discontinued O +
at O +
patient O +
request O +
or O +
if O +
there O +
was O +
no O +
measurable O +
response O +
to O +
therapy O +
. O +

Main O +
outcome O +
measures O +
included O +
best O +
corrected O +
visual O +
acuity O +
, O +
ophthalmic O +
examination O +
, O +
retinal O +
photography O +
, O +
and O +
angiography O +
. O +

RESULTS O +
: O +
Bevacizumab O +
treatment O +
was O +
followed O +
by O +
reductions O +
in O +
retinal O +
hemorrhage O +
, O +
exudation O +
, O +
and O +
edema O +
. O +

Visual O +
acuities O +
were O +
stable O +
or O +
improved O +
in O +
86 O +
% O +
( O +
n O +
= O +
18 O +
) O +
. O +

Three O +
patients O +
discontinued O +
therapy O +
. O +

Each O +
was O +
legally O +
blind O +
before O +
treatment O +
( O +
n O +
= O +
1 O +
) O +
, O +
experienced O +
little O +
to O +
no O +
subjective O +
improvement O +
( O +
n O +
= O +
2 O +
) O +
, O +
or O +
was O +
poorly O +
compliant O +
( O +
n O +
= O +
2 O +
) O +
. O +

Three O +
patients O +
( O +
14 O +
% O +
) O +
regained O +
2 O +
or O +
more O +
lines O +
of O +
visual O +
acuity O +
. O +

No O +
ocular O +
or O +
systemic O +
bevacizumab O +
- O +
related O +
side O +
effects O +
were O +
observed O +
. O +

CONCLUSIONS O +
: O +
Intravitreal O +
bevacizumab O +
can O +
be O +
used O +
to O +
treat O +
radiation O +
retinopathy O +
. O +

In O +
most O +
cases O +
treatment O +
was O +
associated O +
with O +
decreased O +
vascular O +
leakage O +
, O +
stabilization O +
, O +
or O +
improved O +
vision O +
. O +

An O +
anti O +
- O +
vascular O +
endothelial O +
growth O +
factor O +
strategy O +
may O +
reduce O +
tissue O +
damage O +
associated O +
with O +
radiation O +
vasculopathy O +
and O +
neuropathy O +
. O +

Mitogen O +
- O +
activated O +
protein O +
kinase O +
kinase O +
signaling O +
promotes O +
growth O +
and O +
vascularization O +
of O +
fibrosarcoma O +
. O +

We O +
hypothesized O +
that O +
signaling O +
through O +
multiple O +
mitogen O +
- O +
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
kinase O +
( O +
MKK O +
) O +
pathways O +
is O +
essential O +
for O +
the O +
growth O +
and O +
vascularization O +
of O +
soft O +
- O +
tissue O +
sarcomas O +
, O +
which O +
are O +
malignant O +
tumors O +
derived O +
from O +
mesenchymal O +
tissues O +
. O +

We O +
tested O +
this O +
using O +
HT B-CellLine +
- I-CellLine +
1080 I-CellLine +
, O +
NCI B-CellLine +
, O +
and O +
Shac B-CellLine +
fibrosarcoma O +
- O +
derived O +
cell O +
lines O +
and O +
anthrax O +
lethal O +
toxin O +
( O +
LeTx O +
) O +
, O +
a O +
bacterial O +
toxin O +
that O +
inactivates O +
MKKs O +
. O +

Western O +
blots O +
confirmed O +
that O +
LeTx O +
treatment O +
reduced O +
the O +
levels O +
of O +
phosphorylated O +
extracellular O +
signal O +
- O +
regulated O +
kinase O +
and O +
p38 O +
MAPK O +
in O +
vitro O +
. O +

Although O +
short O +
treatments O +
with O +
LeTx O +
only O +
modestly O +
affected O +
cell O +
proliferation O +
, O +
sustained O +
treatment O +
markedly O +
reduced O +
cell O +
numbers O +
. O +

LeTx O +
also O +
substantially O +
inhibited O +
the O +
extracellular O +
release O +
of O +
angioproliferative O +
factors O +
including O +
vascular O +
endothelial O +
growth O +
factor O +
, O +
interleukin O +
- O +
8 O +
, O +
and O +
basic O +
fibroblast O +
growth O +
factor O +
. O +

Similar O +
results O +
were O +
obtained O +
with O +
cell O +
lines O +
derived O +
from O +
malignant O +
fibrous O +
histiocytomas O +
, O +
leiomyosarcomas O +
, O +
and O +
liposarcomas O +
. O +

In O +
vivo O +
, O +
LeTx O +
decreased O +
MAPK O +
activity O +
and O +
blocked O +
fibrosarcoma O +
growth O +
. O +

Growth O +
inhibition O +
correlated O +
with O +
decreased O +
cellular O +
proliferation O +
and O +
extensive O +
necrosis O +
, O +
and O +
it O +
was O +
accompanied O +
by O +
a O +
decrease O +
in O +
tumor O +
mean O +
vessel O +
density O +
as O +
well O +
as O +
a O +
reduction O +
in O +
serum O +
expression O +
of O +
angioproliferative O +
cytokines O +
. O +

Vital O +
imaging O +
using O +
high O +
- O +
resolution O +
ultrasound O +
enhanced O +
with O +
contrast O +
microbubbles O +
revealed O +
that O +
the O +
effects O +
of O +
LeTx O +
on O +
tumor O +
perfusion O +
were O +
remarkably O +
rapid O +
( O +
less O +
than O +
24 O +
h O +
) O +
and O +
resulted O +
in O +
a O +
marked O +
reduction O +
of O +
perfusion O +
within O +
the O +
tumor O +
but O +
not O +
in O +
nontumor O +
tissues O +
. O +

These O +
results O +
are O +
consistent O +
with O +
our O +
initial O +
hypothesis O +
and O +
lead O +
us O +
to O +
propose O +
that O +
MKK O +
inhibition O +
by O +
LeTx O +
is O +
a O +
broadly O +
effective O +
strategy O +
for O +
targeting O +
neovascularization O +
in O +
fibrosarcomas O +
and O +
other O +
similar O +
proliferative O +
lesions O +
. O +

Impact O +
of O +
dexamethasone O +
- O +
induced O +
immunosuppression O +
on O +
the O +
duration O +
and O +
level O +
of O +
shedding O +
of O +
Escherichia O +
coli O +
O157 O +
: O +
H7 O +
in O +
calves O +
. O +

The O +
goal O +
of O +
this O +
study O +
was O +
to O +
determine O +
whether O +
immunosuppression O +
plays O +
a O +
role O +
in O +
the O +
level O +
and O +
duration O +
of O +
fecal O +
shedding O +
of O +
Escherichia O +
coli O +
O157 O +
. O +

Immunosuppression O +
was O +
induced O +
in O +
calves O +
by O +
administering O +
dexamethasone O +
. O +

Six O +
1 O +
- O +
week O +
- O +
old O +
Holstein O +
bull O +
calves O +
were O +
injected O +
intramuscularly O +
with O +
dexamethasone O +
and O +
orally O +
inoculated O +
with O +
10 O +
( O +
9 O +
) O +
CFU O +
of O +
a O +
mixture O +
of O +
three O +
nalidixic O +
- O +
acid O +
resistant O +
strains O +
of O +
E O +
. O +
coli O +
O157 O +
: O +
H7 O +
. O +

Five O +
1 O +
- O +
week O +
- O +
old O +
Holstein O +
bull O +
calves O +
that O +
were O +
given O +
the O +
same O +
oral O +
inoculation O +
of O +
E O +
. O +
coli O +
O157 O +
: O +
H7 O +
, O +
but O +
not O +
the O +
dexamethasone O +
injections O +
, O +
served O +
as O +
controls O +
. O +

All O +
calves O +
were O +
examined O +
daily O +
and O +
fecal O +
samples O +
were O +
collected O +
three O +
times O +
a O +
week O +
for O +
detection O +
and O +
enumeration O +
of O +
the O +
nalidixic O +
- O +
acid O +
resistant O +
E O +
. O +
coli O +
O157 O +
. O +

Four O +
weeks O +
after O +
the O +
last O +
calf O +
stopped O +
shedding O +
, O +
all O +
calves O +
were O +
necropsied O +
and O +
samples O +
from O +
the O +
gastrointestinal O +
tract O +
were O +
taken O +
for O +
the O +
detection O +
of O +
the O +
nalidixic O +
- O +
acid O +
resistant O +
E O +
. O +
coli O +
O157 O +
. O +

Dexamethasone O +
- O +
injected O +
calves O +
shed O +
at O +
higher O +
levels O +
( O +
P O +
= O +
0 O +
. O +
04 O +
) O +
on O +
days O +
4 O +
and O +
7 O +
postinoculation O +
, O +
but O +
not O +
thereafter O +
. O +

None O +
of O +
the O +
samples O +
collected O +
at O +
necropsy O +
were O +
positive O +
for O +
E O +
. O +
coli O +
O157 O +
. O +

Data O +
from O +
this O +
study O +
suggest O +
that O +
there O +
may O +
be O +
a O +
time O +
- O +
dependent O +
relationship O +
between O +
dexamethasone O +
immunosuppression O +
and O +
the O +
fecal O +
concentration O +
of O +
E O +
. O +
coli O +
O157 O +
but O +
that O +
transient O +
immunosuppression O +
does O +
not O +
appear O +
to O +
prolong O +
shedding O +
of O +
E O +
. O +
coli O +
O157 O +
. O +

A O +
novel O +
putative O +
tyrosine O +
kinase O +
receptor O +
with O +
oncogenic O +
potential O +
. O +

We O +
have O +
detected O +
transforming O +
activity O +
by O +
a O +
tumorigenicity O +
assay O +
using O +
NIH3T3 B-CellLine +
cells O +
transfected O +
with O +
DNA O +
from O +
a O +
chronic O +
myeloproliferative O +
disorder O +
patient O +
. O +

Here O +
, O +
we O +
report O +
the O +
cDNA O +
cloning O +
of O +
the O +
corresponding O +
oncogene O +
, O +
designated O +
UFO O +
, O +
in O +
allusion O +
to O +
the O +
as O +
yet O +
unidentified O +
function O +
of O +
its O +
protein O +
. O +

Nucleotide O +
sequence O +
analysis O +
of O +
a O +
3116bp O +
cDNA O +
clone O +
revealed O +
a O +
2682 O +
- O +
bp O +
- O +
long O +
open O +
reading O +
frame O +
capable O +
of O +
directing O +
the O +
synthesis O +
of O +
a O +
894 O +
amino O +
acid O +
polypeptide O +
. O +

The O +
predicted O +
UFO O +
protein O +
exhibits O +
characteristic O +
features O +
of O +
a O +
transmembrane O +
receptor O +
with O +
associated O +
tyrosine O +
kinase O +
activity O +
. O +

The O +
UFO O +
proto O +
- O +
oncogene O +
maps O +
to O +
human O +
chromosome O +
19q13 O +
. O +
1 O +
and O +
is O +
transcribed O +
into O +
two O +
5 O +
. O +
0 O +
kb O +
and O +
3 O +
. O +
2 O +
kb O +
mRNAs O +
in O +
human O +
bone O +
marrow O +
and O +
human O +
tumor O +
cell O +
lines O +
. O +

The O +
UFO O +
locus O +
is O +
evolutionarily O +
conserved O +
between O +
vertebrate O +
species O +
. O +

A O +
4 O +
. O +
0 O +
kb O +
mRNA O +
of O +
the O +
murine O +
UFO O +
homolog O +
is O +
expressed O +
in O +
a O +
variety O +
of O +
different O +
mouse O +
tissues O +
. O +

We O +
thus O +
have O +
identified O +
a O +
novel O +
element O +
of O +
the O +
complex O +
signaling O +
network O +
involved O +
in O +
the O +
control O +
of O +
cell O +
proliferation O +
and O +
differentiation O +
. O +

Functional O +
significance O +
of O +
VEGF O +
- O +
a O +
in O +
human O +
ovarian O +
carcinoma O +
: O +
role O +
in O +
vasculogenic O +
mimicry O +
. O +

Ovarian O +
cancer O +
is O +
a O +
silent O +
killer O +
, O +
and O +
shows O +
early O +
extensive O +
tumor O +
invasion O +
and O +
peritoneal O +
metastasis O +
. O +

The O +
microcirculation O +
of O +
most O +
tumors O +
includes O +
cooperation O +
of O +
pre O +
- O +
existing O +
vessels O +
, O +
intussusceptive O +
microvascular O +
growth O +
, O +
postnatal O +
vasculogenesis O +
, O +
glomeruloid O +
angiogenesis O +
and O +
vasculogenic O +
mimicry O +
( O +
VM O +
) O +
. O +

VM O +
is O +
critical O +
for O +
a O +
tumor O +
blood O +
supply O +
and O +
is O +
asscociated O +
with O +
aggressive O +
features O +
and O +
metastasis O +
. O +

Our O +
studies O +
highlight O +
the O +
plasticity O +
of O +
aggressive O +
human O +
ovarian O +
carcinoma O +
cells O +
and O +
call O +
into O +
question O +
the O +
underlying O +
significance O +
of O +
their O +
ability O +
to O +
form O +
VM O +
in O +
vitro O +
induced O +
by O +
VEGF O +
- O +
a O +
. O +

These O +
studies O +
also O +
show O +
their O +
clinicalpathological O +
features O +
of O +
the O +
cancers O +
with O +
human O +
Paraffin O +
- O +
embedded O +
tumor O +
tissue O +
samples O +
. O +

Results O +
show O +
that O +
the O +
process O +
: O +
VEGF O +
- O +
a O +
- O +
- O +
greater O +
than O +
EphA2 O +
- O +
- O +
greater O +
than O +
MMPs O +
- O +
- O +
greater O +
than O +
VM O +
is O +
the O +
main O +
pathway O +
for O +
VM O +
formation O +
and O +
VEGF O +
- O +
a O +
appears O +
to O +
play O +
an O +
important O +
role O +
in O +
the O +
formation O +
of O +
VM O +
based O +
on O +
our O +
in O +
vitro O +
assays O +
and O +
clinical O +
immunohistochemical O +
analyses O +
. O +

VM O +
- O +
targeting O +
strategies O +
for O +
ovarian O +
cancer O +
include O +
anti O +
- O +
VEGF O +
- O +
a O +
treatment O +
, O +
knocking O +
down O +
the O +
EphA2 O +
gene O +
and O +
using O +
antibodies O +
against O +
human O +
MMPs O +
if O +
the O +
tumor O +
is O +
VM O +
positive O +
. O +

This O +
strategy O +
may O +
be O +
of O +
significant O +
value O +
in O +
laying O +
the O +
foundation O +
for O +
a O +
more O +
explicit O +
anti O +
- O +
tumor O +
angiogenesis O +
therapy O +
. O +

Proteomic O +
comparison O +
of O +
nasopharyngeal O +
cancer O +
cell O +
lines O +
C666 B-CellLine +
- I-CellLine +
1 I-CellLine +
and O +
NP69 B-CellLine +
identifies O +
down O +
- O +
regulation O +
of O +
annexin O +
II O +
and O +
beta2 O +
- O +
tubulin O +
for O +
nasopharyngeal O +
carcinoma O +
. O +

CONTEXT O +
: O +
Nasopharyngeal O +
carcinoma O +
( O +
NPC O +
) O +
, O +
common O +
in O +
southern O +
China O +
and O +
North O +
Africa O +
, O +
has O +
a O +
complex O +
etiology O +
involving O +
interplay O +
between O +
viral O +
, O +
environmental O +
, O +
and O +
hereditary O +
factors O +
and O +
is O +
almost O +
constantly O +
associated O +
with O +
the O +
Epstein O +
- O +
Barr O +
virus O +
. O +

Since O +
the O +
prognosis O +
of O +
locally O +
advanced O +
and O +
metastatic O +
diseases O +
is O +
poor O +
, O +
increased O +
understanding O +
of O +
the O +
pathogenesis O +
of O +
NPC O +
would O +
be O +
important O +
for O +
discovering O +
novel O +
markers O +
for O +
patients O +
' O +
management O +
. O +

OBJECTIVES O +
: O +
To O +
compare O +
the O +
proteomic O +
expression O +
profile O +
between O +
an O +
Epstein O +
- O +
Barr O +
virus O +
- O +
associated O +
NPC O +
cell O +
line O +
( O +
C666 B-CellLine +
- I-CellLine +
1 I-CellLine +
) O +
and O +
a O +
normal O +
NP O +
cell O +
line O +
( O +
NP69 B-CellLine +
) O +
. O +

The O +
proteins O +
with O +
differential O +
expression O +
were O +
analyzed O +
in O +
40 O +
undifferentiated O +
NPC O +
paraffin O +
- O +
embedded O +
specimens O +
. O +

DESIGN O +
: O +
Differentially O +
expressed O +
proteins O +
discovered O +
between O +
the O +
two O +
cell O +
lines O +
were O +
identified O +
by O +
mass O +
spectrometry O +
. O +

After O +
confirmation O +
by O +
immunocytochemical O +
staining O +
, O +
their O +
expression O +
in O +
patient O +
samples O +
was O +
measured O +
using O +
40 O +
pairs O +
of O +
undifferentiated O +
NPCs O +
together O +
with O +
their O +
adjacent O +
normal O +
epithelia O +
. O +

RESULTS O +
: O +
Proteomic O +
findings O +
indicated O +
that O +
adenosine O +
triphosphate O +
synthase O +
alpha O +
chain O +
was O +
up O +
- O +
regulated O +
, O +
whereas O +
annexin O +
II O +
, O +
annexin O +
V O +
, O +
beta O +
( O +
2 O +
) O +
- O +
tubulin O +
, O +
and O +
profilin O +
1 O +
were O +
down O +
- O +
regulated O +
. O +

After O +
confirming O +
the O +
results O +
in O +
agar O +
- O +
processed O +
cell O +
lines O +
, O +
annexin O +
II O +
and O +
beta O +
( O +
2 O +
) O +
- O +
tubulin O +
expression O +
were O +
found O +
to O +
be O +
lower O +
in O +
tumor O +
cells O +
than O +
in O +
adjacent O +
normal O +
epithelial O +
cells O +
in O +
100 O +
% O +
and O +
90 O +
% O +
of O +
the O +
patients O +
' O +
specimens O +
, O +
respectively O +
. O +

Finally O +
, O +
annexin O +
II O +
down O +
- O +
regulation O +
was O +
positively O +
associated O +
with O +
lymph O +
node O +
metastasis O +
, O +
suggesting O +
that O +
it O +
may O +
be O +
a O +
prognostic O +
factor O +
in O +
NPC O +
. O +

CONCLUSIONS O +
: O +
The O +
results O +
suggest O +
that O +
annexin O +
II O +
and O +
beta O +
( O +
2 O +
) O +
- O +
tubulin O +
down O +
- O +
regulation O +
is O +
important O +
in O +
NPC O +
formation O +
and O +
may O +
represent O +
potential O +
targets O +
for O +
further O +
investigations O +
. O +

A O +
practical O +
interface O +
for O +
microfluidics O +
and O +
nanoelectrospray O +
mass O +
spectrometry O +
. O +

We O +
report O +
a O +
new O +
method O +
for O +
fabricating O +
nanospray O +
ionization O +
tips O +
for O +
MS O +
, O +
formed O +
from O +
glass O +
substrates O +
and O +
the O +
inert O +
polymer O +
, O +
parylene O +
- O +
C O +
. O +

Using O +
a O +
single O +
photolithography O +
step O +
, O +
the O +
emitters O +
are O +
formed O +
contiguously O +
with O +
microchannels O +
, O +
such O +
that O +
no O +
dead O +
volumes O +
are O +
observed O +
. O +

In O +
addition O +
, O +
because O +
the O +
devices O +
are O +
very O +
thin O +
( O +
approximately O +
0 O +
. O +
3 O +
mm O +
) O +
and O +
the O +
tips O +
are O +
formed O +
at O +
rectangular O +
corners O +
, O +
the O +
Taylor O +
cone O +
volumes O +
are O +
small O +
, O +
which O +
makes O +
the O +
method O +
attractive O +
for O +
future O +
integration O +
with O +
microfluidic O +
separations O +
. O +

Device O +
performance O +
was O +
demonstrated O +
by O +
evaluating O +
diverse O +
analytes O +
, O +
ranging O +
from O +
synthetic O +
polymers O +
, O +
to O +
peptides O +
, O +
to O +
nucleic O +
acids O +
. O +

For O +
all O +
analytes O +
, O +
performance O +
was O +
similar O +
to O +
that O +
of O +
conventional O +
emitters O +
( O +
pulled O +
- O +
glass O +
capillaries O +
and O +
the O +
Agilent O +
HPLC O +
Chip O +
) O +
with O +
the O +
advantage O +
of O +
rapid O +
, O +
batch O +
fabrication O +
of O +
identical O +
devices O +
. O +

A O +
novel O +
role O +
of O +
thrombospondin O +
- O +
1 O +
in O +
cervical O +
carcinogenesis O +
: O +
inhibit O +
stroma O +
reaction O +
by O +
inhibiting O +
activated O +
fibroblasts O +
from O +
invading O +
cancer O +
. O +

Thrombospondin O +
( O +
TSP O +
) O +
- O +
1 O +
, O +
a O +
potent O +
angiogenesis O +
inhibitor O +
, O +
has O +
been O +
shown O +
to O +
exert O +
different O +
biological O +
functions O +
on O +
various O +
cell O +
types O +
. O +

Here O +
, O +
we O +
investigate O +
the O +
role O +
of O +
TSP O +
- O +
1 O +
in O +
tumor O +
- O +
stroma O +
reaction O +
, O +
which O +
is O +
mainly O +
characterized O +
by O +
fibroblast O +
activation O +
to O +
create O +
a O +
permissive O +
microenvironment O +
for O +
tumor O +
progression O +
. O +

Immunohistochemistry O +
examinations O +
in O +
the O +
human O +
surgical O +
specimens O +
have O +
shown O +
that O +
a O +
downregulation O +
of O +
TSP O +
- O +
1 O +
during O +
the O +
progression O +
of O +
cervical O +
carcinogenesis O +
was O +
accompanied O +
by O +
an O +
emergence O +
in O +
the O +
upregulation O +
of O +
stroma O +
markers O +
, O +
alpha O +
- O +
smooth O +
muscle O +
actin O +
( O +
alpha O +
- O +
SMA O +
) O +
and O +
desmin O +
. O +

Transfection O +
of O +
SiHa B-CellLine +
cervical O +
cancer O +
cells O +
with O +
a O +
plasmid O +
expressing O +
the O +
TSP O +
- O +
1 O +
protein O +
exhibited O +
antiangiogenic O +
activity O +
in O +
vitro O +
and O +
resulted O +
in O +
reduced O +
tumor O +
growth O +
in O +
severe O +
combined O +
immunodeficiency O +
( O +
SCID O +
) O +
mice O +
, O +
which O +
was O +
accompanied O +
by O +
a O +
decrease O +
in O +
tumor O +
vascularization O +
and O +
lower O +
expressions O +
of O +
alpha O +
- O +
SMA O +
and O +
desmin O +
than O +
those O +
in O +
the O +
vector O +
controls O +
. O +

Transfection O +
with O +
TSP O +
- O +
1 O +
and O +
purified O +
TSP O +
- O +
1 O +
added O +
to O +
NIH3T3 B-CellLine +
cells O +
did O +
not O +
alter O +
the O +
protein O +
levels O +
of O +
alpha O +
- O +
SMA O +
and O +
desmin O +
but O +
significantly O +
inhibited O +
matrix O +
metalloprotease O +
- O +
2 O +
activity O +
. O +

Transforming O +
growth O +
factor O +
- O +
beta O +
( O +
TGF O +
- O +
beta O +
) O +
, O +
a O +
major O +
factor O +
in O +
the O +
activation O +
of O +
fibroblasts O +
, O +
increased O +
alpha O +
- O +
SMA O +
and O +
desmin O +
expression O +
and O +
the O +
ability O +
of O +
cell O +
migration O +
and O +
invasion O +
in O +
NIH3T3 B-CellLine +
cells O +
. O +

The O +
increased O +
migration O +
ability O +
and O +
the O +
invasive O +
ability O +
into O +
tumor O +
cluster O +
of O +
TGF O +
- O +
beta O +
- O +
treated O +
NIH3T3 B-CellLine +
cells O +
were O +
dose O +
dependently O +
inhibited O +
by O +
TSP O +
- O +
1 O +
. O +

In O +
contrast O +
, O +
ectopic O +
TSP O +
- O +
1 O +
expression O +
in O +
SiHa B-CellLine +
cells O +
has O +
little O +
effect O +
on O +
the O +
invasive O +
ability O +
of O +
the O +
NIH3T3 B-CellLine +
cells O +
. O +

Together O +
, O +
our O +
findings O +
demonstrate O +
a O +
novel O +
role O +
of O +
TSP O +
- O +
1 O +
to O +
inhibit O +
tumor O +
- O +
stroma O +
reaction O +
that O +
could O +
be O +
attributed O +
to O +
the O +
blockage O +
of O +
activated O +
fibroblasts O +
from O +
invading O +
cancer O +
cells O +
. O +

Targeting O +
a O +
tumor O +
- O +
specific O +
laminin O +
domain O +
critical O +
for O +
human O +
carcinogenesis O +
. O +

Laminin O +
- O +
332 O +
is O +
critical O +
for O +
squamous O +
cell O +
carcinoma O +
( O +
SCC O +
) O +
tumorigenesis O +
, O +
but O +
targeting O +
it O +
for O +
cancer O +
therapy O +
has O +
been O +
unachievable O +
due O +
to O +
key O +
role O +
of O +
laminin O +
- O +
332 O +
in O +
promoting O +
tissue O +
integrity O +
. O +

Here O +
, O +
we O +
show O +
that O +
a O +
portion O +
of O +
laminin O +
- O +
332 O +
, O +
termed O +
G45 O +
, O +
which O +
is O +
proteolytically O +
removed O +
and O +
absent O +
in O +
normal O +
tissues O +
, O +
is O +
prominently O +
expressed O +
in O +
most O +
human O +
SCC B-CellLine +
tumors O +
and O +
plays O +
an O +
important O +
role O +
in O +
human O +
SCC O +
tumorigenesis O +
. O +

Primary O +
human O +
keratinocytes O +
lacking O +
G45 O +
( O +
DeltaG45 O +
) O +
showed O +
alterations O +
of O +
basal O +
receptor O +
organization O +
, O +
impaired O +
matrix O +
deposition O +
, O +
and O +
increased O +
migration O +
. O +

After O +
SCC O +
transformation O +
, O +
the O +
absence O +
of O +
G45 O +
domain O +
in O +
DeltaG45 O +
cells O +
was O +
associated O +
with O +
deficient O +
extracellular O +
signal O +
- O +
regulated O +
kinase O +
and O +
phosphotidylinositol O +
3 O +
- O +
kinase O +
( O +
PI3 O -
K O +
) O +
pathway O +
activation O +
, O +
impaired O +
invasion O +
, O +
deficient O +
metalloproteinase O +
activity O +
, O +
and O +
absent O +
tumorgenicity O +
in O +
vivo O +
. O +

Expression O +
of O +
G45 O +
or O +
activated O +
PI3 O -
K O +
subunit O +
in O +
DeltaG45 O +
cells O +
reversed O +
these O +
abnormalities O +
. O +

G45 O +
antibody O +
treatment O +
induced O +
SCC O +
tumor O +
apoptosis O +
, O +
decreased O +
SCC O +
tumor O +
proliferation O +
, O +
and O +
markedly O +
impaired O +
human O +
SCC O +
tumorigenesis O +
in O +
vivo O +
without O +
affecting O +
normal O +
tissue O +
adhesion O +
. O +

These O +
results O +
show O +
a O +
remarkable O +
selectivity O +
of O +
expression O +
and O +
function O +
for O +
laminin O +
- O +
332 O +
G45 O +
in O +
human O +
SCC O +
tumorigenesis O +
and O +
implicate O +
it O +
as O +
a O +
specific O +
target O +
for O +
anticancer O +
therapy O +
. O +

MMTV O +
- O +
cre O +
- O +
mediated O +
fur O +
inactivation O +
concomitant O +
with O +
PLAG1 O +
proto O +
- O +
oncogene O +
activation O +
delays O +
salivary O +
gland O +
tumorigenesis O +
in O +
mice O +
. O +

Proprotein O +
convertases O +
are O +
serine O +
endoproteases O +
implicated O +
in O +
the O +
proteolytic O +
processing O +
of O +
a O +
large O +
variety O +
of O +
regulatory O +
proteins O +
. O +

An O +
important O +
role O +
of O +
proprotein O +
convertases O +
in O +
tumorigenic O +
processes O +
has O +
been O +
suggested O +
by O +
various O +
studies O +
. O +

In O +
this O +
study O +
, O +
the O +
role O +
of O +
the O +
proprotein O +
convertase O +
furin O +
in O +
PLAG1 O +
proto O +
- O +
oncogene O +
- O +
induced O +
salivary O +
gland O +
tumorigenesis O +
was O +
investigated O +
. O +

PLAG1 O +
overexpression O +
in O +
salivary O +
glands O +
has O +
previously O +
been O +
shown O +
to O +
result O +
in O +
salivary O +
gland O +
tumors O +
in O +
100 O +
% O +
of O +
mice O +
within O +
5 O +
weeks O +
after O +
birth O +
. O +

MMTV O +
- O +
cre O +
- O +
mediated O +
inactivation O +
of O +
fur O +
without O +
over O +
- O +
expression O +
of O +
PLAG1 O +
caused O +
smaller O +
but O +
histologically O +
normal O +
salivary O +
glands O +
. O +

Moreover O +
, O +
the O +
lymph O +
nodes O +
close O +
to O +
the O +
salivary O +
glands O +
were O +
enlarged O +
, O +
and O +
histology O +
showed O +
that O +
they O +
had O +
activated O +
follicles O +
. O +

When O +
genetic O +
ablation O +
of O +
1 O +
or O +
2 O +
alleles O +
of O +
fur O +
and O +
overexpression O +
of O +
the O +
PLAG1 O +
transgene O +
were O +
simultaneously O +
achieved O +
, O +
a O +
significant O +
delay O +
in O +
tumorigenesis O +
was O +
observed O +
. O +

Collectively O +
, O +
these O +
results O +
suggest O +
an O +
important O +
role O +
for O +
furin O +
in O +
PLAG1 O +
- O +
induced O +
salivary O +
gland O +
tumorigenesis O +
in O +
mice O +
. O +

Isotype O +
- O +
specific O +
inhibitors O +
of O +
the O +
glycolytic O +
key O +
regulator O +
pyruvate O +
kinase O +
subtype O +
M2 O +
moderately O +
decelerate O +
tumor O +
cell O +
proliferation O +
. O +

Tumor O +
cells O +
express O +
the O +
glycolytic O +
regulator O +
pyruvate O +
kinase O +
subtype O +
M2 O +
( O +
M2 O +
- O +
PK O +
) O +
, O +
which O +
can O +
occur O +
in O +
a O +
tetrameric O +
form O +
with O +
high O +
affinity O +
to O +
its O +
substrate O +
phosphoenolpyruvate O +
( O +
PEP O +
) O +
and O +
a O +
dimeric O +
form O +
with O +
a O +
low O +
PEP O +
affinity O +
. O +

The O +
transition O +
between O +
both O +
conformations O +
contributes O +
to O +
the O +
control O +
of O +
glycolysis O +
and O +
is O +
important O +
for O +
tumor O +
cell O +
proliferation O +
and O +
survival O +
. O +

Here O +
we O +
targeted O +
M2 O +
- O +
PK O +
by O +
synthetic O +
peptide O +
aptamers O +
, O +
which O +
specifically O +
bind O +
to O +
M2 O +
- O +
PK O +
and O +
shift O +
the O +
isoenzyme O +
into O +
its O +
low O +
affinity O +
dimeric O +
conformation O +
. O +

The O +
aptamer O +
- O +
induced O +
dimerization O +
and O +
inactivation O +
of O +
M2 O +
- O +
PK O +
led O +
to O +
a O +
significant O +
decrease O +
in O +
the O +
PK O +
mass O +
- O +
action O +
ratio O +
as O +
well O +
as O +
ATP O +
: O +
ADP O +
ratio O +
in O +
the O +
target O +
cells O +
. O +

Furthermore O +
, O +
the O +
expression O +
of O +
M2 O +
- O +
PK O +
- O +
binding O +
peptide O +
aptamers O +
moderately O +
reduced O +
the O +
growth O +
of O +
immortalized O +
NIH3T3 B-CellLine +
cell O +
populations O +
by O +
decelerating O +
cell O +
proliferation O +
, O +
but O +
without O +
affecting O +
apoptotic O +
cell O +
death O +
. O +

Moreover O +
, O +
the O +
M2 O +
- O +
PK O +
- O +
binding O +
peptide O +
aptamers O +
also O +
reduced O +
the O +
proliferation O +
rate O +
of O +
human O +
U B-CellLine +
- I-CellLine +
2 I-CellLine +
OS O +
osteosarcoma O +
cells O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
developed O +
the O +
first O +
specific O +
inhibitors O +
of O +
the O +
pyruvate O +
kinase O +
isoenzyme O +
type O +
M2 O +
and O +
present O +
evidence O +
that O +
these O +
inhibitors O +
moderately O +
decelerate O +
tumor O +
cell O +
proliferation O +
. O +

Sciatic O +
nerve O +
repair O +
by O +
microgrooved O +
nerve O +
conduits O +
made O +
of O +
chitosan O +
- O +
gold O +
nanocomposites O +
. O +

BACKGROUND O +
: O +

To O +
better O +
direct O +
the O +
repair O +
of O +
peripheral O +
nerve O +
after O +
injury O +
, O +
an O +
implant O +
consisting O +
of O +
a O +
multicomponent O +
micropatterned O +
conduit O +
seeded O +
with O +
NSC B-CellLine +
was O +
designed O +
. O +

METHODS O +
: O +

The O +
mechanical O +
properties O +
of O +
the O +
chi O +
- O +
Au O +
nanocomposites O +
were O +
tested O +
. O +

In O +
vitro O +
, O +
the O +
effect O +
of O +
chi O +
- O +
Au O +
on O +
cell O +
behavior O +
( O +
NSC B-CellLine +
and O +
glial O +
cell O +
line O +
C6 B-CellLine +
) O +
and O +
the O +
influence O +
of O +
micropattern O +
on O +
cell O +
alignment O +
were O +
evaluated O +
. O +

In O +
vivo O +
, O +
the O +
micropatterned O +
conduits O +
with O +
/ O +
without O +
the O +
preseeded O +
NSC B-CellLine +
were O +
implanted O +
to O +
bridge O +
a O +
10 O +
- O +
mm O +
- O +
long O +
defect O +
of O +
the O +
sciatic O +
nerve O +
in O +
9 O +
male O +
Sprague O +
- O +
Dawley O +
rats O +
. O +

The O +
repair O +
outcome O +
was O +
investigated O +
6 O +
weeks O +
after O +
the O +
surgery O +
. O +

RESULTS O +
: O +

Based O +
on O +
the O +
dynamic O +
modulus O +
, O +
chitosan O +
with O +
50 O +
ppm O +
or O +
more O +
gold O +
was O +
a O +
stronger O +
material O +
than O +
others O +
. O +

In O +
vitro O +
, O +
gold O +
at O +
25 O +
or O +
50 O +
ppm O +
led O +
to O +
better O +
cell O +
performance O +
for O +
NSC B-CellLine +
; O +
and O +
gold O +
at O +
50 O +
ppm O +
gave O +
better O +
cell O +
performance O +
for O +
C6 B-CellLine +
. O +

On O +
the O +
microgrooved O +
substrate O +
, O +
the O +
NSC B-CellLine +
had O +
elongated O +
processes O +
oriented O +
parallel O +
to O +
the O +
grooves O +
, O +
whereas O +
the O +
NSC B-CellLine +
on O +
the O +
nonpatterned O +
surfaces O +
did O +
not O +
exhibit O +
a O +
particular O +
bias O +
in O +
alignment O +
. O +

In O +
vivo O +
, O +
the O +
number O +
of O +
regenerated O +
axons O +
, O +
the O +
regenerated O +
area O +
, O +
and O +
the O +
number O +
of O +
blood O +
vessels O +
were O +
significantly O +
higher O +
in O +
the O +
NSC B-CellLine +
- O +
preseeded O +
conduit O +
. O +

CONCLUSION O +
: O +

Modification O +
of O +
the O +
chitosan O +
matrix O +
by O +
gold O +
nanoparticles O +
not O +
only O +
provides O +
the O +
mechanical O +
strength O +
but O +
also O +
affects O +
the O +
cellular O +
response O +
. O +

The O +
preliminary O +
in O +
vivo O +
data O +
demonstrated O +
that O +
the O +
biodegradable O +
micropatterned O +
conduits O +
preseeded O +
with O +
NSC B-CellLine +
provided O +
a O +
combination O +
of O +
physical O +
and O +
biological O +
guidance O +
cues O +
for O +
regenerating O +
axons O +
at O +
the O +
cellular O +
level O +
and O +
offered O +
a O +
better O +
alternative O +
for O +
repairing O +
sciatic O +
nerve O +
transactions O +
. O +

[ O +
Parotid O +
gland O +
' O +
s O +
tumors O +
in O +
children O +
] O +
. O +

The O +
tumors O +
of O +
the O +
salivary O +
glands O +
are O +
infrequent O +
in O +
children O +
, O +
and O +
parotid O +
gland O +
is O +
involved O +
in O +
80 O +
% O +
of O +
them O +
. O +

When O +
a O +
salivary O +
gland O +
tumor O +
is O +
present O +
, O +
the O +
chance O +
of O +
malignancy O +
is O +
greater O +
in O +
the O +
child O +
than O +
in O +
the O +
adult O +
. O +

We O +
reviewed O +
8 O +
cases O +
identified O +
in O +
patients O +
aged O +
14 O +
years O +
and O +
younger O +
in O +
our O +
hospital O +
, O +
analyzing O +
its O +
antecedents O +
, O +
signs O +
and O +
symptoms O +
, O +
histological O +
features O +
, O +
diagnosis O +
, O +
treatment O +
and O +
evolution O +
. O +

All O +
the O +
patients O +
displayed O +
preauricular O +
painless O +
, O +
non O +
- O +
inflammatory O +
and O +
slow O +
- O +
growing O +
masses O +
to O +
an O +
age O +
between O +
10 O +
months O +
and O +
14 O +
years O +
. O +

Four O +
or O +
them O +
were O +
pleomorphic O +
adenomas O +
, O +
two O +
haemangiomas O +
, O +
one O +
epidermal O +
cysts O +
and O +
one O +
myoepithelial O +
carcinoma O +
. O +

We O +
emphasize O +
the O +
exceptional O +
nature O +
of O +
the O +
carcinoma O +
for O +
its O +
rareness O +
and O +
for O +
the O +
high O +
degree O +
of O +
malignancy O +
expressed O +
. O +

We O +
made O +
a O +
fine O +
needle O +
aspiration O +
biopsy O +
in O +
four O +
cases O +
but O +
they O +
were O +
conclusive O +
only O +
in O +
three O +
. O +

All O +
were O +
treated O +
by O +
surgical O +
resection O +
of O +
the O +
tumour O +
except O +
for O +
the O +
myoepithelial O +
carcinoma O +
and O +
the O +
recurrent O +
pleomorphic O +
adenoma O +
that O +
were O +
treated O +
by O +
total O +
parotidectomy O +
. O +

The O +
malignant O +
tumours O +
of O +
the O +
parotid O +
gland O +
are O +
clinically O +
indistinguishable O +
of O +
the O +
benign O +
ones O +
, O +
thus O +
when O +
any O +
palpable O +
mass O +
appears O +
in O +
the O +
zone O +
of O +
the O +
parotid O +
gland O +
, O +
an O +
accurate O +
diagnosis O +
should O +
be O +
made O +
without O +
delay O +
. O +

The O +
treatment O +
of O +
choice O +
is O +
the O +
surgical O +
excision O +
with O +
wide O +
margins O +
, O +
being O +
other O +
adjuvant O +
treatments O +
less O +
useful O +
to O +
this O +
age O +
than O +
in O +
the O +
adult O +
age O +
. O +

